
PMID- 38490135
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 76
DP  - 2024 Apr
TI  - Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, 
      CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease 
      modelling and therapeutic research.
PG  - 103375
LID - S1873-5061(24)00073-4 [pii]
LID - 10.1016/j.scr.2024.103375 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is the most prevalent adult-onset muscular 
      dystrophy affecting 1 in 8,000 individuals. It is characterized by multisystemic 
      symptoms, primarily myopathy. The root cause of DM1 is a heterozygous CTG triplet 
      expansion beyond the normal size threshold in the non-coding region of the DM1 
      protein kinase gene (DMPK). In our study, we generated and characterized three 
      distinct DM1 induced pluripotent stem cell (iPSC) lines with CTG repeat 
      expansions ranging from 900 to 2000 in the DMPK gene. These iPSC lines maintained 
      normal karyotypes, exhibited distinctive colony morphology, robustly expressed 
      pluripotency markers, differentiated into the three primary germ layers, and 
      lacked residual viral vectors.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Pierre, Marion
AU  - Pierre M
AD  - CERVO Brain Research Centre, Institut Universitaire en Sante Mentale de Quebec, 
      Quebec City, QC G1J 2G3, Canada.
FAU - Jauvin, Dominic
AU  - Jauvin D
AD  - CERVO Brain Research Centre, Institut Universitaire en Sante Mentale de Quebec, 
      Quebec City, QC G1J 2G3, Canada.
FAU - Puymirat, Jack
AU  - Puymirat J
AD  - Department of Medicine, Faculty of Medicine, Universite Laval, Quebec City, QC 
      G1V 0A6, Canada; LOEX, CHU de Quebec-Universite Laval Research Centre, Quebec 
      City QC G1J 1Z4, Canada.
FAU - Boutjdir, Mohamed
AU  - Boutjdir M
AD  - Cardiovascular Research Program, VA New York Harbor Healthcare System, New York 
      City, NY 11209, USA; Department of Medicine, Cell Biology and Pharmacology, SUNY 
      Downstate Health Sciences University, New York, NY 11203, USA; Department of 
      Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
FAU - Chahine, Mohamed
AU  - Chahine M
AD  - CERVO Brain Research Centre, Institut Universitaire en Sante Mentale de Quebec, 
      Quebec City, QC G1J 2G3, Canada; Department of Medicine, Faculty of Medicine, 
      Universite Laval, Quebec City, QC G1V 0A6, Canada. Electronic address: 
      mohamed.chahine@phc.ulaval.ca.
LA  - eng
PT  - Journal Article
DEP - 20240303
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Myotonic Dystrophy/genetics/metabolism
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Trinucleotide Repeat Expansion
MH  - Therapeutic Human Experimentation
MH  - Cell Line
MH  - Myotonin-Protein Kinase/genetics
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/16 05:42
MHDA- 2024/03/25 06:43
CRDT- 2024/03/15 19:13
PHST- 2024/02/08 00:00 [received]
PHST- 2024/03/01 00:00 [revised]
PHST- 2024/03/02 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/03/16 05:42 [pubmed]
PHST- 2024/03/15 19:13 [entrez]
AID - S1873-5061(24)00073-4 [pii]
AID - 10.1016/j.scr.2024.103375 [doi]
PST - ppublish
SO  - Stem Cell Res. 2024 Apr;76:103375. doi: 10.1016/j.scr.2024.103375. Epub 2024 Mar 
      3.

PMID- 38314057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 2589-5370 (Electronic)
IS  - 2589-5370 (Linking)
VI  - 67
DP  - 2024 Jan
TI  - Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, 
      double-blind, placebo-controlled, phase 2 trial.
PG  - 102390
LID - 10.1016/j.eclinm.2023.102390 [doi]
LID - 102390
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a devastating multisystemic 
      disorder caused by a CTG repeat expansion in the DMPK gene, which subsequently 
      triggers toxic RNA expression and dysregulated splicing. In a preclinical study, 
      we demonstrated that erythromycin reduces the toxicity of abnormal RNA and 
      ameliorates the aberrant splicing and motor phenotype in DM1 model mice. METHODS: 
      This multicentre, randomised, double-blind, placebo-controlled, phase 2 trial was 
      conducted at three centres in Japan to translate preclinical findings into 
      practical applications in patients with DM1 by evaluating the safety and efficacy 
      of erythromycin. Between Nov 29, 2019, and Jan 20, 2022, a total of 30 adult 
      patients with DM1 were enrolled and randomly assigned in a 1:2:2 ratio to receive 
      either placebo or erythromycin at two daily doses (500 mg or 800 mg) for 24 
      weeks. The primary outcome included the safety and tolerability of erythromycin. 
      The secondary efficacy measures included splicing biomarkers, 6-min walk test 
      results, muscle strength, and serum creatinine kinase (CK) values. This trial is 
      registered with the Japan Registry of Clinical Trials, jRCT2051190069. FINDINGS: 
      Treatment-related gastrointestinal symptoms occurred more frequently in the 
      erythromycin group, but all adverse events were mild to moderate and resolved 
      spontaneously. No serious safety concerns were identified. The CK levels from 
      baseline to week 24 decreased in the overall erythromycin group compared with the 
      placebo group (mean change of -6.4 U/L [SD 149] vs +182.8 [SD 228]), although 
      this difference was not statistically significant (p = 0.070). Statistically 
      significant improvements in the overall erythromycin treated groups compared to 
      placebo were seen for two of the eleven splicing biomarkers that were each 
      evaluated in half of the trial sample. These were MBNL1 (p = 0.048) and CACNA1S 
      (p = 0.042). INTERPRETATION: Erythromycin demonstrated favourable safety and 
      tolerability profiles in patients with DM1. A well-powered phase 3 trial is 
      needed to evaluate efficacy, building on the preliminary findings from this 
      study. FUNDING: Japan Agency for Medical Research and Development.
CI  - (c) 2023 The Author(s).
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka, 565-0871, Japan.
AD  - Department of Neurology, Yamaguchi University Graduate School of Medicine, 1-1-1 
      Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
FAU - Nakatani, Daisaku
AU  - Nakatani D
AD  - Medical Centre for Translational Research, Department of Medical Innovation, 
      Osaka University Hospital, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Sato, Tomoharu
AU  - Sato T
AD  - Department of Biostatistics & Data Science, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Hasuike, Yuhei
AU  - Hasuike Y
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Kon, Seiko
AU  - Kon S
AD  - Department of Neurology, NHO Aomori National Hospital, 155-1 Hirano, Namioka, 
      Aomori, 038-1331, Japan.
FAU - Saito, Toshio
AU  - Saito T
AD  - Department of Neurology, NHO Osaka Toneyama Medical Centre, 5-1-1 Toneyama, 
      Toyonaka, Osaka, 560-8552, Japan.
FAU - Nakamura, Harumasa
AU  - Nakamura H
AD  - Translational Medical Centre, National Centre of Neurology and Psychiatry, 4-1-1 
      Ogawahigashimachi, Kodaira, Tokyo, 187-8502, Japan.
FAU - Takahashi, Masanori P
AU  - Takahashi MP
AD  - Department of Clinical Laboratory and Biomedical Sciences, Osaka University 
      Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Hida, Eisuke
AU  - Hida E
AD  - Department of Biostatistics & Data Science, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Komaki, Hirofumi
AU  - Komaki H
AD  - Translational Medical Centre, National Centre of Neurology and Psychiatry, 4-1-1 
      Ogawahigashimachi, Kodaira, Tokyo, 187-8502, Japan.
FAU - Matsumura, Tsuyoshi
AU  - Matsumura T
AD  - Department of Neurology, NHO Osaka Toneyama Medical Centre, 5-1-1 Toneyama, 
      Toyonaka, Osaka, 560-8552, Japan.
FAU - Takada, Hiroto
AU  - Takada H
AD  - Department of Neurology, NHO Aomori National Hospital, 155-1 Hirano, Namioka, 
      Aomori, 038-1331, Japan.
FAU - Mochizuki, Hideki
AU  - Mochizuki H
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka, 565-0871, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231226
PL  - England
TA  - EClinicalMedicine
JT  - EClinicalMedicine
JID - 101733727
PMC - PMC10837534
OTO - NOTNLM
OT  - Erythromycin
OT  - Myotonic dystrophy
OT  - RNA toxicity
OT  - Splicing
COIS- M.N. and H.M. are coinventors on a patent (no. JP6460552B2, US10500223B2, 
      EP3323419B1) for MYD-0124 owned by Osaka University. EH belongs to a joint 
      research chair with Shionogi Pharma Co., Ltd.
EDAT- 2024/02/05 06:42
MHDA- 2024/02/05 06:43
PMCR- 2023/12/26
CRDT- 2024/02/05 04:56
PHST- 2023/09/18 00:00 [received]
PHST- 2023/12/06 00:00 [revised]
PHST- 2023/12/06 00:00 [accepted]
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/05 06:42 [pubmed]
PHST- 2024/02/05 04:56 [entrez]
PHST- 2023/12/26 00:00 [pmc-release]
AID - S2589-5370(23)00567-9 [pii]
AID - 102390 [pii]
AID - 10.1016/j.eclinm.2023.102390 [doi]
PST - epublish
SO  - EClinicalMedicine. 2023 Dec 26;67:102390. doi: 10.1016/j.eclinm.2023.102390. 
      eCollection 2024 Jan.

PMID- 38153165
OWN - NLM
STAT- MEDLINE
DCOM- 20240318
LR  - 20240318
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 42
IP  - 2
DP  - 2024 Feb
TI  - Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal 
      infection risk in anti-melanoma differentiation associated gene 5 
      dermatomyositis.
PG  - 237-245
LID - 10.55563/clinexprheumatol/e51d3m [doi]
AB  - OBJECTIVES: Anti-MDA5+ dermatomyositis was associated with poor prognosis due to 
      the high incidence of rapid progressive interstitial lung disease, pulmonary 
      infection. The aim of this study is to investigate the abundance and clinical 
      relevance of exhaustion markers on peripheral CD8 T cells from patients with 
      idiopathic inflammatory myopathy (IIM). METHODS: Twenty-nine healthy controls 
      (HCs) and 71 patients with IIM were enrolled, including 42 with anti-MDA5+ and 18 
      with anti-MDA5- dermatomyositis (DM) and 11 with anti-synthetase syndrome (ASS). 
      Flow cytometry was applied to detect PD-1, TIM-3 and LAG-3 in CD8 T cells. The 
      clinical associations of the CD8 T cell exhaustion phenotype in patients with 
      anti-MDA5+ DM were analysed. RESULTS: CD8 T cells from patients with anti-MDA5+ 
      DM showed significantly increased LAG-3, TIM-3 and PD-1 compared to those from 
      patients with anti-MDA5- IIM (18 with anti-MDA5- DM and 11 with ASS) or HCs 
      (adjusted p all < 0.05). CD8 T cells with distinct exhaustion levels were all 
      significantly increased in anti-MDA5+ DM patients compared with HCs (p all < 
      0.05). Patients with high level of PD-1+ TIM-3+LAG-3+ CD8+ T cells had a 
      significant higher incidence of pulmonary fungal infections but lower counts of 
      CD4+ and CD8+ T cells. ROC analysis revealed that the frequency of 
      PD-1+TIM-3+LAG-3+CD8+ T cell significantly predicted pulmonary fungal infections 
      (area under the curve: 0.828). CONCLUSIONS: CD8 T cells from patients with 
      anti-MDA5+ DM show significant exhausted phenotype, and increased exhausted CD8 T 
      cells were associated with high risk of pulmonary fungal infection.
FAU - Xu, Yue-Tong
AU  - Xu YT
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing; Graduate School of Peking Union Medical College, Chinese 
      Academy of Medical Sciences, Peking Union Medical College, Beijing; and Beijing 
      Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Cao, Zheng-Yi
AU  - Cao ZY
AD  - Department of Haematology, China-Japan Friendship Hospital, Beijing, China.
FAU - Lin, Sang
AU  - Lin S
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing; Graduate School of Peking Union Medical College, Chinese 
      Academy of Medical Sciences, Peking Union Medical College, Beijing; and Beijing 
      Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Shu, Xiao-Ming
AU  - Shu XM
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Lu, Xin
AU  - Lu X
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Wang, Guo-Chun
AU  - Wang GC
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing; Graduate School of Peking Union Medical College, Chinese 
      Academy of Medical Sciences, Peking Union Medical College, Beijing; and Beijing 
      Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China.
FAU - Peng, Qing-Lin
AU  - Peng QL
AD  - Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship 
      Hospital, Beijing; Graduate School of Peking Union Medical College, Chinese 
      Academy of Medical Sciences, Peking Union Medical College, Beijing; and Beijing 
      Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship 
      Hospital, Beijing, China. pqinglin@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231227
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Hepatitis A Virus Cellular Receptor 2)
RN  - EC 3.6.4.13 (Interferon-Induced Helicase, IFIH1)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Humans
MH  - *Dermatomyositis/complications
MH  - Hepatitis A Virus Cellular Receptor 2
MH  - Interferon-Induced Helicase, IFIH1
MH  - Programmed Cell Death 1 Receptor
MH  - Autoantibodies
MH  - CD8-Positive T-Lymphocytes
MH  - T-Lymphocytes
MH  - Retrospective Studies
MH  - Prognosis
EDAT- 2023/12/28 12:42
MHDA- 2024/03/18 06:43
CRDT- 2023/12/28 08:02
PHST- 2023/04/11 00:00 [received]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2024/03/18 06:43 [medline]
PHST- 2023/12/28 12:42 [pubmed]
PHST- 2023/12/28 08:02 [entrez]
AID - 19862 [pii]
AID - 10.55563/clinexprheumatol/e51d3m [doi]
PST - ppublish
SO  - Clin Exp Rheumatol. 2024 Feb;42(2):237-245. doi: 
      10.55563/clinexprheumatol/e51d3m. Epub 2023 Dec 27.

PMID- 38088012
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1532-2130 (Electronic)
IS  - 1090-3798 (Linking)
VI  - 48
DP  - 2024 Jan
TI  - Myotonic dystrophy type 1 (Steinert disease): 29 years of experience at a 
      tertiary pediatric hospital.
PG  - 85-90
LID - S1090-3798(23)00185-X [pii]
LID - 10.1016/j.ejpn.2023.12.001 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by 
      the expansion of a noncoding triplet repeat. METHODS: A cross-sectional study was 
      performed to characterize pediatric patients with DM1 followed in a tertiary 
      hospital over the last 29 years, comparing the congenital and the 
      childhood/juvenile-onset forms. RESULTS: Thirty-seven patients (59.5 % male) were 
      included, with a median age at the latest assessment of 16.8 years and a median 
      follow-up of 7.7 years. Eleven patients were lost to follow-up, and two died. 
      Twenty-five had congenital DM1 (CDM1), and this form had significantly higher 
      triplet repeat length, history of polyhydramnios, lower median age at diagnosis, 
      and first and last assessment. Common symptoms included distal skeletal muscle 
      weakness (75.7 %) and facial involvement (94.6 %), along with 
      dysphonia/dysarthria (73.0 %) and myotonia (73.0 %). Delayed independent 
      ambulation frequency was significantly higher for CDM1 cases. Skeletal 
      deformities affected 54.1 %, with talipes equinovarus and scoliosis occurring 
      exclusively in CDM1 patients. Cognitive deficit was present in 75.7 % of cases. 
      Polysomnograms revealed seven cases of obstructive sleep apnea and two of 
      hypoventilation. Noninvasive ventilation was used in nine cases, and three had 
      recurrent respiratory infections. The cardiovascular system was affected in 
      21.6 % of cases. Gastrointestinal issues included constipation (24.3 %), feeding 
      difficulties (16.2 %), and cholelithiasis (5.4 %). Cataracts, epilepsy, and 
      diabetes mellitus were reported in two cases each. CONCLUSION: Our study 
      highlights the diverse spectrum of severity and multiorgan involvement of DM1 in 
      pediatric patients. It underscores the importance of establishing a 
      pediatric-specific standard of care to enhance health outcomes through 
      comprehensive multidisciplinary management.
CI  - (c) 2023 Published by Elsevier Ltd on behalf of European Paediatric Neurology 
      Society.
FAU - Cascais, Ines
AU  - Cascais I
AD  - Department of Pediatrics, Centro Materno Infantil Do Norte (CMIN), Centro 
      Hospitalar Universitario de Santo Antonio (CHUdSA), Porto, Portugal. Electronic 
      address: cascais.ines@gmail.com.
FAU - Garrido, Cristina
AU  - Garrido C
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Morais, Lurdes
AU  - Morais L
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Amorim, Rosa
AU  - Amorim R
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Lima, Rosa
AU  - Lima R
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Mansilha, Helena Ferreira
AU  - Mansilha HF
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Correia, Teresa
AU  - Correia T
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Oliveira, Antonio
AU  - Oliveira A
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
FAU - Santos, Manuela
AU  - Santos M
AD  - Multidisciplinary Pediatric Neuromuscular Diseases Team, CMIN, CHUdSA, European 
      Reference Network for Rare Neuromuscular Diseases (EURO-NMD) Center, Porto, 
      Portugal.
LA  - eng
PT  - Journal Article
DEP - 20231206
PL  - England
TA  - Eur J Paediatr Neurol
JT  - European journal of paediatric neurology : EJPN : official journal of the 
      European Paediatric Neurology Society
JID - 9715169
SB  - IM
MH  - Pregnancy
MH  - Female
MH  - Humans
MH  - Child
MH  - Male
MH  - *Myotonic Dystrophy/complications/epidemiology/diagnosis
MH  - Cross-Sectional Studies
MH  - Hospitals, Pediatric
MH  - Tertiary Care Centers
MH  - *Cognitive Dysfunction
OTO - NOTNLM
OT  - Myotonic dystrophy type 1
OT  - Pediatrics
OT  - Steinert disease
COIS- Declaration of competing interest The authors declare no conflict of interest 
      relevant to this study.
EDAT- 2023/12/13 06:42
MHDA- 2024/03/25 06:44
CRDT- 2023/12/13 03:44
PHST- 2023/09/01 00:00 [received]
PHST- 2023/11/19 00:00 [revised]
PHST- 2023/12/03 00:00 [accepted]
PHST- 2024/03/25 06:44 [medline]
PHST- 2023/12/13 06:42 [pubmed]
PHST- 2023/12/13 03:44 [entrez]
AID - S1090-3798(23)00185-X [pii]
AID - 10.1016/j.ejpn.2023.12.001 [doi]
PST - ppublish
SO  - Eur J Paediatr Neurol. 2024 Jan;48:85-90. doi: 10.1016/j.ejpn.2023.12.001. Epub 
      2023 Dec 6.

PMID- 37829280
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 14
DP  - 2023
TI  - Clinical interpretation of cell-based non-invasive prenatal testing for monogenic 
      disorders including repeat expansion disorders: potentials and pitfalls.
PG  - 1188472
LID - 10.3389/fgene.2023.1188472 [doi]
LID - 1188472
AB  - Introduction: Circulating fetal cells isolated from maternal blood can be used 
      for prenatal testing, representing a safe alternative to invasive testing. The 
      present study investigated the potential of cell-based noninvasive prenatal 
      testing (NIPT) for diagnosing monogenic disorders dependent on the mode of 
      inheritance. Methods: Maternal blood samples were collected from women opting for 
      prenatal diagnostics for specific monogenic disorders (N = 7). Fetal trophoblasts 
      were enriched and stained using magnetic activated cell sorting and isolated by 
      fluorescens activated single-cell sorting. Individual cells were subject to whole 
      genome amplification, and cells of fetal origin were identified by DNA-profiling 
      using short tandem repeat markers. The amplified fetal DNA was input for genetic 
      testing for autosomal dominant-, autosomal recessive-, X-linked and repeat 
      expansion disorders by direct variant analysis and haplotyping. The cell-based 
      NIPT results were compared with those of invasive testing. Results: In two cases 
      at risk of skeletal dysplasia, caused by variants in the FGFR3 gene (autosomal 
      dominant disorders), cell-based NIPT correctly stated an affected fetus, but 
      allelic dropout of the normal alleles were observed in both cases. Cell-based 
      NIPT gave an accurate result in two cases at risk of autosomal recessive 
      disorders, where the parents carried either different diastrophic dysplasia 
      causing variants in the SLC26A2 gene or the same cystic fibrosis disease-causing 
      variant in the CFTR gene. Cell-based NIPT accurately identified an affected male 
      fetus in a pregnancy at risk of Duchenne muscular dystrophy (DMD gene, X-linked 
      recessive disorders). In two cases at risk of the myotonic dystrophy type 1 (DMPK 
      gene, repeat expansion disorder), cell-based NIPT correctly detected an affected 
      and an unaffected fetus, respectively. Discussion: Circulating fetal cells can be 
      used to detect both maternally- and paternally inherited monogenic disorders 
      irrespective of the type of variant, however, the risk of allelic dropout must be 
      considered. We conclude that the clinical interpretation of the cell-based NIPT 
      result thus varies depending on the disorders' mode of inheritance.
CI  - Copyright (c) 2023 Jeppesen, Hatt, Singh, Schelde, Ravn, Toft, Laursen, Hedegaard, 
      Christensen, Nicolaisen, Andreasen, Pedersen, Vogel and Lildballe.
FAU - Jeppesen, Line Dahl
AU  - Jeppesen LD
AD  - ARCEDI Biotech, Vejle, Denmark.
AD  - Center for Fetal Diagnostics, Aarhus University, Aarhus, Denmark.
FAU - Hatt, Lotte
AU  - Hatt L
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Singh, Ripudaman
AU  - Singh R
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Schelde, Palle
AU  - Schelde P
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Ravn, Katarina
AU  - Ravn K
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Toft, Christian Liebst
AU  - Toft CL
AD  - Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, 
      Denmark.
AD  - Center for Preimplantation Genetic Testing, Aalborg University Hospital, Aalborg, 
      Denmark.
FAU - Laursen, Maria Bach
AU  - Laursen MB
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Hedegaard, Jakob
AU  - Hedegaard J
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Christensen, Inga Baasch
AU  - Christensen IB
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Nicolaisen, Bolette Hestbek
AU  - Nicolaisen BH
AD  - ARCEDI Biotech, Vejle, Denmark.
FAU - Andreasen, Lotte
AU  - Andreasen L
AD  - Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
FAU - Pedersen, Lars Henning
AU  - Pedersen LH
AD  - Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, 
      Denmark.
AD  - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark.
FAU - Vogel, Ida
AU  - Vogel I
AD  - Center for Fetal Diagnostics, Aarhus University, Aarhus, Denmark.
AD  - Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, 
      Denmark.
FAU - Lildballe, Dorte Launholt
AU  - Lildballe DL
AD  - Center for Fetal Diagnostics, Aarhus University, Aarhus, Denmark.
AD  - Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20230927
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC10565008
OTO - NOTNLM
OT  - clinical interpretation
OT  - extravillous trophoblasts
OT  - fetal cells
OT  - monogenic disorders
OT  - noninvasive prenatal testing
OT  - repeat expansion disorders
COIS- Authors LJ, LH, RS, PS, KR, ML, JH, IC, and BN are employed by ARCEDI, a Danish 
      biotech company that holds the proprietary technology for enrichment of fetal 
      cells from maternal blood used in this study. The remaining authors declare that 
      the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2023/10/13 06:45
MHDA- 2023/10/13 06:46
PMCR- 2023/09/27
CRDT- 2023/10/13 04:01
PHST- 2023/03/17 00:00 [received]
PHST- 2023/09/12 00:00 [accepted]
PHST- 2023/10/13 06:46 [medline]
PHST- 2023/10/13 06:45 [pubmed]
PHST- 2023/10/13 04:01 [entrez]
PHST- 2023/09/27 00:00 [pmc-release]
AID - 1188472 [pii]
AID - 10.3389/fgene.2023.1188472 [doi]
PST - epublish
SO  - Front Genet. 2023 Sep 27;14:1188472. doi: 10.3389/fgene.2023.1188472. eCollection 
      2023.

PMID- 37806497
OWN - NLM
STAT- MEDLINE
DCOM- 20240227
LR  - 20240227
IS  - 1872-8111 (Electronic)
IS  - 0168-0102 (Linking)
VI  - 200
DP  - 2024 Mar
TI  - Analysis of splicing abnormalities in the white matter of myotonic dystrophy type 
      1 brain using RNA sequencing.
PG  - 48-56
LID - S0168-0102(23)00192-X [pii]
LID - 10.1016/j.neures.2023.10.002 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by the genomic 
      expansion of CTG repeats, in which RNA-binding proteins, such as muscleblind-like 
      protein, are sequestered in the nucleus, and abnormal splicing is observed in 
      various genes. Although abnormal splicing occurs in the brains of patients with 
      DM1, its relation to central nervous system symptoms is unknown. Several imaging 
      studies have indicated substantial white matter defects in patients with DM1. 
      Here, we performed RNA sequencing and analysis of CTG repeat lengths in the 
      frontal lobe of patients with DM1, separating the gray matter and white matter, 
      to investigate splicing abnormalities in the DM1 brain, especially in the white 
      matter. Several genes showed similar levels of splicing abnormalities in both 
      gray and white matter, with an observable trend toward an increased number of 
      repeats in the gray matter. These findings suggest that white matter defects in 
      DM1 stem from aberrant RNA splicing in both gray and white matter. Notably, 
      several of the genes displaying abnormal splicing are recognized as being 
      dominantly expressed in astrocytes and oligodendrocytes, leading us to 
      hypothesize that splicing defects in the white matter may be attributed to 
      abnormal RNA splicing in glial cells.
CI  - Copyright (c) 2023 Elsevier Ltd and Japan Neuroscience Society. All rights 
      reserved.
FAU - Yoshizumi, Kazuki
AU  - Yoshizumi K
AD  - Department of Neurology, Hyogo Medical University, Nishinomiya, 663-8501 Hyogo, 
      Japan.
FAU - Nishi, Masamitsu
AU  - Nishi M
AD  - Department of Neurology, Hyogo Medical University, Nishinomiya, 663-8501 Hyogo, 
      Japan.
FAU - Igeta, Masataka
AU  - Igeta M
AD  - Department of Biostatistics, Hyogo Medical University, Nishinomiya, 663-8501 
      Hyogo, Japan.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Yamaguchi University Graduate School of Medicine, 
      Yamaguchi, 755-8505 Yamaguchi, Japan.
FAU - Inoue, Kimiko
AU  - Inoue K
AD  - Department of Neurology, National Hospital Organization Osaka Toneyama Medical 
      Center, Toyonaka, 560-8552 Osaka, Japan.
FAU - Matsumura, Tsuyoshi
AU  - Matsumura T
AD  - Department of Neurology, National Hospital Organization Osaka Toneyama Medical 
      Center, Toyonaka, 560-8552 Osaka, Japan.
FAU - Fujimura, Harutoshi
AU  - Fujimura H
AD  - Department of Neurology, National Hospital Organization Osaka Toneyama Medical 
      Center, Toyonaka, 560-8552 Osaka, Japan.
FAU - Jinnai, Kenji
AU  - Jinnai K
AD  - Department of Neurology, National Hospital Organization Hyogo-Chuo Hospital, 
      Sanda, 669-1515 Hyogo, Japan.
FAU - Kimura, Takashi
AU  - Kimura T
AD  - Department of Neurology, Hyogo Medical University, Nishinomiya, 663-8501 Hyogo, 
      Japan. Electronic address: kimura@hyo-med.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20231006
PL  - Ireland
TA  - Neurosci Res
JT  - Neuroscience research
JID - 8500749
SB  - IM
MH  - Humans
MH  - *Myotonic Dystrophy/genetics/metabolism
MH  - *White Matter
MH  - RNA Splicing/genetics
MH  - Brain/metabolism
MH  - Sequence Analysis, RNA
MH  - Alternative Splicing
OTO - NOTNLM
OT  - Aberrant splicing
OT  - CTG repeats
OT  - Glial cell RNAs
OT  - Gray matter
OT  - Muscleblind-like protein
OT  - RNA-binding proteins
COIS- Declarations of interest None.
EDAT- 2023/10/09 00:41
MHDA- 2024/02/27 06:45
CRDT- 2023/10/08 19:29
PHST- 2023/02/24 00:00 [received]
PHST- 2023/10/03 00:00 [revised]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2024/02/27 06:45 [medline]
PHST- 2023/10/09 00:41 [pubmed]
PHST- 2023/10/08 19:29 [entrez]
AID - S0168-0102(23)00192-X [pii]
AID - 10.1016/j.neures.2023.10.002 [doi]
PST - ppublish
SO  - Neurosci Res. 2024 Mar;200:48-56. doi: 10.1016/j.neures.2023.10.002. Epub 2023 
      Oct 6.

PMID- 37797921
OWN - NLM
STAT- Publisher
LR  - 20231005
IS  - 2320-2890 (Electronic)
IS  - 2319-4170 (Linking)
DP  - 2023 Oct 3
TI  - Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model.
PG  - 100667
LID - S2319-4170(23)00104-X [pii]
LID - 10.1016/j.bj.2023.100667 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease 
      caused by a CTG repeat expansion in the 3' untranslated region of the DM1 protein 
      kinase gene. Characteristic degenerative muscle symptoms include myotonia, 
      atrophy, and weakness. We previously proposed an MSI2>miR-7>autophagy axis 
      whereby MSI2 overexpression repressed miR-7 biogenesis that subsequently 
      de-repressed muscle catabolism through excessive autophagy. Because the DM1 
      HSA(LR) mouse model expressing expanded CUG repeats shows weak muscle-wasting 
      phenotypes, we hypothesized that MSI2 overexpression was sufficient to promote 
      muscle dysfunction in vivo. METHODS: By means of recombinant AAV murine Msi2 was 
      overexpressed in neonates HSA(LR) mice skeletal muscle to induce DM1-like 
      phenotypes RESULTS: Sustained overexpression of the murine Msi2 protein in 
      HSA(LR) neonates induced autophagic flux and expression of critical autophagy 
      proteins, increased central nuclei and reduced myofibers area, and weakened 
      muscle strength. Importantly, these changes were independent of Mbnl1, Mbnl2, and 
      Celf1 protein levels, which remained unchanged upon Msi2 overexpression. 
      CONCLUSIONS: Globally, molecular, histological, and functional data from these 
      experiments in the HSA(LR) mouse model confirms the pathological role of Msi2 
      expression levels as an atrophy-associated component that impacts the 
      characteristic muscle dysfunction symptoms in DM1 patients.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Sabater-Arcis, Maria
AU  - Sabater-Arcis M
AD  - Human Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), Dr. Moliner 50, Burjasot, Valencia, 46100, Spain; 
      INCLIVA Biomedical Research Institute, Avda. Menendez Pelayo 4, Valencia, 46010, 
      Spain. Electronic address: maria.sabater@uv.es.
FAU - Moreno, Nerea
AU  - Moreno N
AD  - Human Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), Dr. Moliner 50, Burjasot, Valencia, 46100, Spain; 
      INCLIVA Biomedical Research Institute, Avda. Menendez Pelayo 4, Valencia, 46010, 
      Spain. Electronic address: Nerea.moreno@uv.es.
FAU - Sevilla, Teresa
AU  - Sevilla T
AD  - Neuromuscular and Ataxias Research Group, Health Research Institute Hospital La 
      Fe (IIS La Fe). Av. de Fernando Abril Martorell, 106, 46026 Valencia, Spain; 
      Centre for Biomedical Network Research on Rare Diseases (CIBERER); U763, 
      CB06/05/0091, Valencia, Spain; Department of Medicine, University of Valencia. 
      Av. Blasco Ibanez 15, Valencia, 46010, Spain. Electronic address: 
      sevilla_ter@gva.es.
FAU - Perez Alonso, Manuel
AU  - Perez Alonso M
AD  - Human Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), Dr. Moliner 50, Burjasot, Valencia, 46100, Spain; 
      INCLIVA Biomedical Research Institute, Avda. Menendez Pelayo 4, Valencia, 46010, 
      Spain. Electronic address: manuel.perez@uv.es.
FAU - Bargiela, Ariadna
AU  - Bargiela A
AD  - Neuromuscular and Ataxias Research Group, Health Research Institute Hospital La 
      Fe (IIS La Fe). Av. de Fernando Abril Martorell, 106, 46026 Valencia, Spain. 
      Electronic address: ariadna_bargiela@iislafe.es.
FAU - Artero, Ruben
AU  - Artero R
AD  - Human Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), Dr. Moliner 50, Burjasot, Valencia, 46100, Spain; 
      INCLIVA Biomedical Research Institute, Avda. Menendez Pelayo 4, Valencia, 46010, 
      Spain. Electronic address: ruben.artero@uv.es.
LA  - eng
PT  - Journal Article
DEP - 20231003
PL  - United States
TA  - Biomed J
JT  - Biomedical journal
JID - 101599820
SB  - IM
OTO - NOTNLM
OT  - HSA(LR)
OT  - Msi2
OT  - adeno-associated virus
OT  - muscle atrophy
OT  - myotonic dystrophy
COIS- Declaration of Competing Interest M.S-A., R.A., and A.B. are inventors in patent 
      PCT/EP2022/054129.
EDAT- 2023/10/06 00:43
MHDA- 2023/10/06 00:43
CRDT- 2023/10/05 19:35
PHST- 2023/03/23 00:00 [received]
PHST- 2023/09/19 00:00 [revised]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2023/10/06 00:43 [medline]
PHST- 2023/10/06 00:43 [pubmed]
PHST- 2023/10/05 19:35 [entrez]
AID - S2319-4170(23)00104-X [pii]
AID - 10.1016/j.bj.2023.100667 [doi]
PST - aheadofprint
SO  - Biomed J. 2023 Oct 3:100667. doi: 10.1016/j.bj.2023.100667.

PMID- 37744174
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230926
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 34
DP  - 2023 Dec 12
TI  - Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by 
      promoting endogenous MBNL1 expression.
PG  - 102024
LID - 10.1016/j.omtn.2023.09.001 [doi]
LID - 102024
AB  - Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease caused by a CTG 
      repeat expansion in the DMPK gene that generates toxic RNA with a myriad of 
      downstream alterations in RNA metabolism. A key consequence is the sequestration 
      of alternative splicing regulatory proteins MBNL1/2 by expanded transcripts in 
      the affected tissues. MBNL1/2 depletion interferes with a developmental 
      alternative splicing switch that causes the expression of fetal isoforms in 
      adults. Boosting the endogenous expression of MBNL proteins by inhibiting the 
      natural translational repressors miR-23b and miR-218 has previously been shown to 
      be a promising therapeutic approach. We designed antimiRs against both miRNAs 
      with a phosphorodiamidate morpholino oligonucleotide (PMO) chemistry conjugated 
      to cell-penetrating peptides (CPPs) to improve delivery to affected tissues. In 
      DM1 cells, CPP-PMOs significantly increased MBNL1 levels. In some candidates, 
      this was achieved using concentrations less than two orders of magnitude below 
      the median toxic concentration, with up to 5.38-fold better therapeutic window 
      than previous antagomiRs. In HSA(LR) mice, intravenous injections of CPP-PMOs 
      improve molecular, histopathological, and functional phenotypes, without signs of 
      toxicity. Our findings place CPP-PMOs as promising antimiR candidates to overcome 
      the treatment delivery challenge in DM1 therapy.
CI  - (c) 2023 The Authors.
FAU - Gonzalez-Martinez, Irene
AU  - Gonzalez-Martinez I
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
FAU - Cerro-Herreros, Estefania
AU  - Cerro-Herreros E
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
FAU - Moreno, Nerea
AU  - Moreno N
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
FAU - Garcia-Rey, Andrea
AU  - Garcia-Rey A
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
FAU - Espinosa-Espinosa, Jorge
AU  - Espinosa-Espinosa J
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
AD  - Group of Emerging and Neglected Diseases, Ecoepidemiology and Biodiversity, 
      Health Sciences Faculty, Universidad Internacional SEK, Quito 170521, Ecuador.
FAU - Carrascosa-Saez, Marc
AU  - Carrascosa-Saez M
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
FAU - Piqueras-Losilla, Diego
AU  - Piqueras-Losilla D
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
FAU - Arzumanov, Andrey
AU  - Arzumanov A
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Seoane-Miraz, David
AU  - Seoane-Miraz D
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Jad, Yahya
AU  - Jad Y
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Raz, Richard
AU  - Raz R
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Wood, Matthew J
AU  - Wood MJ
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Varela, Miguel A
AU  - Varela MA
AD  - Department of Paediatrics, Institute of Developmental and Regenerative Medicine 
      (IDRM), University of Oxford, Roosevelt Dr, Oxford OX3 7TY, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Avenue 
      Menendez Pelayo 4 acc, 46010 Valencia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20230905
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC10514136
OTO - NOTNLM
OT  - MBNL proteins
OT  - MT: Oligonucleotides: Therapies and Applications
OT  - PMO chemistry
OT  - alternative splicing
OT  - antisense oligonucleotides
OT  - biodistribution
OT  - cell-penetrating peptides
OT  - microRNAs
OT  - muscle dysfunction
OT  - myotonic dystrophy
COIS- B.L. and R.A. are founders, and CEO and scientific consultant of Arthex Biotech, 
      respectively. Arthex Biotech is developing antimiRs for use in the treatment of 
      DM1.
EDAT- 2023/09/25 06:42
MHDA- 2023/09/25 06:43
PMCR- 2023/09/05
CRDT- 2023/09/25 04:39
PHST- 2022/07/12 00:00 [received]
PHST- 2023/09/01 00:00 [accepted]
PHST- 2023/09/25 06:43 [medline]
PHST- 2023/09/25 06:42 [pubmed]
PHST- 2023/09/25 04:39 [entrez]
PHST- 2023/09/05 00:00 [pmc-release]
AID - S2162-2531(23)00237-8 [pii]
AID - 102024 [pii]
AID - 10.1016/j.omtn.2023.09.001 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2023 Sep 5;34:102024. doi: 10.1016/j.omtn.2023.09.001. 
      eCollection 2023 Dec 12.

PMID- 37742438
OWN - NLM
STAT- Publisher
LR  - 20231022
IS  - 1973-8102 (Electronic)
IS  - 0010-9452 (Linking)
VI  - 168
DP  - 2023 Nov
TI  - Characterization of theory of mind performance in patients with myotonic 
      dystrophy type 1.
PG  - 181-192
LID - S0010-9452(23)00209-5 [pii]
LID - 10.1016/j.cortex.2023.07.008 [doi]
AB  - INTRODUCTION: Myotonic dystrophy type 1 (DM1) is associated with motor 
      dysfunction as well as psychological and cognitive impairments, including altered 
      social cognition. Theory of mind (ToM) impairments have been reported in this 
      disease but their nature and their cognitive/cerebral correlates have yet to be 
      determined. METHODS: Fifty DM1 patients and 50 healthy controls were assessed 
      using the Movie for the Assessment of Social Cognition, which quantifies 
      impairments in affective and cognitive components of ToM through the depiction of 
      everyday situations. We also measured the study participants' cognitive, 
      behavioral and social abilities, quality of life, and brain MRI characteristics. 
      RESULTS: DM1 patients presented a significant impairment in ToM performance 
      compared to controls (p < .001). The patients' errors were related to 
      hypomentalizations (p < .001 vs controls) but not to hypermentalizations 
      (p = .95). The affective component was affected (p < .001 vs controls) but not 
      the cognitive component (p = .09). The ToM impairment was associated with 
      demographic variables (older age and a lower educational level), genetic findings 
      (a larger CTG triplets repeat expansion) and cognitive scores (slower information 
      processing speed). Associations were also found with brain MRI variables (lower 
      white matter and supratentorial volumes) but not with behavioral or social 
      variables. DISCUSSION: DM1 patients display a ToM impairment, characterized by 
      predominant hypomentalizations concerning the affective component. This 
      impairment might result from structural brain abnormalities observed in DM1.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Davion, Jean-Baptiste
AU  - Davion JB
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Neurology, CHU Lille, Lille, France; Reference 
      Centre for Neuromuscular Diseases Nord/Est/Ile-de-France, CHU Lille, Lille, 
      France; Department of Pediatric Neurology, CHU Lille, Lille, France. Electronic 
      address: jeanbaptiste.davion@chu-lille.fr.
FAU - Tard, Celine
AU  - Tard C
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Neurology, CHU Lille, Lille, France; Reference 
      Centre for Neuromuscular Diseases Nord/Est/Ile-de-France, CHU Lille, Lille, 
      France.
FAU - Kuchcinski, Gregory
AU  - Kuchcinski G
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Neuroradiology, CHU Lille, Lille, France.
FAU - Fragoso, Loren
AU  - Fragoso L
AD  - Reference Centre for Neuromuscular Diseases Nord/Est/Ile-de-France, CHU Lille, 
      Lille, France.
FAU - Wilu-Wilu, Amina
AU  - Wilu-Wilu A
AD  - Reference Centre for Neuromuscular Diseases Nord/Est/Ile-de-France, CHU Lille, 
      Lille, France.
FAU - Maurage, Pierre
AU  - Maurage P
AD  - Laboratory for Experimental Psychopathology, Psychological Sciences Research 
      Institute, Catholic University of Louvain, Louvain-la-Neuve, Belgium.
FAU - Nguyen The Tich, Sylvie
AU  - Nguyen The Tich S
AD  - Reference Centre for Neuromuscular Diseases Nord/Est/Ile-de-France, CHU Lille, 
      Lille, France; Department of Pediatric Neurology, CHU Lille, Lille, France.
FAU - Defebvre, Luc
AU  - Defebvre L
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Neurology, CHU Lille, Lille, France.
FAU - D'Hondt, Fabien
AU  - D'Hondt F
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Psychiatry, CHU Lille, Lille, France; Lille-Paris 
      National Resource and Resilience Center (CN2R), Lille, France.
FAU - Delbeuck, Xavier
AU  - Delbeuck X
AD  - U1172 - LilNCog - Lille Neuroscience & Cognition, Univ. Lille, Inserm, CHU Lille, 
      Lille, France; Department of Neurology, CHU Lille, Lille, France.
LA  - eng
PT  - Journal Article
DEP - 20230909
PL  - Italy
TA  - Cortex
JT  - Cortex; a journal devoted to the study of the nervous system and behavior
JID - 0100725
SB  - IM
OTO - NOTNLM
OT  - Movie for the assessment of social cognition
OT  - Myotonic dystrophy
OT  - Neuromuscular disorders
OT  - Social cognition
OT  - Theory of mind
COIS- Declaration of competing interest The authors have no disclosures to report.
EDAT- 2023/09/25 00:42
MHDA- 2023/09/25 00:42
CRDT- 2023/09/24 18:04
PHST- 2023/04/25 00:00 [received]
PHST- 2023/06/30 00:00 [revised]
PHST- 2023/07/25 00:00 [accepted]
PHST- 2023/09/25 00:42 [pubmed]
PHST- 2023/09/25 00:42 [medline]
PHST- 2023/09/24 18:04 [entrez]
AID - S0010-9452(23)00209-5 [pii]
AID - 10.1016/j.cortex.2023.07.008 [doi]
PST - ppublish
SO  - Cortex. 2023 Nov;168:181-192. doi: 10.1016/j.cortex.2023.07.008. Epub 2023 Sep 9.

PMID- 37638448
OWN - NLM
STAT- MEDLINE
DCOM- 20231114
LR  - 20231129
IS  - 2214-3602 (Electronic)
IS  - 2214-3599 (Print)
IS  - 2214-3599 (Linking)
VI  - 10
IP  - 6
DP  - 2023
TI  - Resistance Exercise Training Rescues Mitochondrial Dysfunction in Skeletal Muscle 
      of Patients with Myotonic Dystrophy Type 1.
PG  - 1111-1126
LID - 10.3233/JND-230099 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a dominant autosomal neuromuscular 
      disorder caused by the inheritance of a CTG triplet repeat expansion in the 
      Dystrophia Myotonica Protein Kinase (DMPK) gene. At present, no cure currently 
      exists for DM1 disease. OBJECTIVE: This study investigates the effects of 12-week 
      resistance exercise training on mitochondrial oxidative phosphorylation in 
      skeletal muscle in a cohort of DM1 patients (n = 11, men) in comparison to 
      control muscle with normal oxidative phosphorylation. METHODS: Immunofluorescence 
      was used to assess protein levels of key respiratory chain subunits of complex I 
      (CI) and complex IV (CIV), and markers of mitochondrial mass and cell membrane in 
      individual myofibres sampled from muscle biopsies. Using control's skeletal 
      muscle fibers population, we classified each patient's fibers as having normal, 
      low or high levels of CI and CIV and compared the proportions of fibers before 
      and after exercise training. The significance of changes observed between pre- 
      and post-exercise within patients was estimated using a permutation test. 
      RESULTS: At baseline, DM1 patients present with significantly decreased 
      mitochondrial mass, and isolated or combined CI and CIV deficiency. After 
      resistance exercise training, in most patients a significant increase in 
      mitochondrial mass was observed, and all patients showed a significant increase 
      in CI and/or CIV protein levels. Moreover, improvements in mitochondrial mass 
      were correlated with the one-repetition maximum strength evaluation. CONCLUSIONS: 
      Remarkably, 12-week resistance exercise training is sufficient to partially 
      rescue mitochondrial dysfunction in DM1 patients, suggesting that the response to 
      exercise is in part be due to changes in mitochondria.
FAU - Di Leo, Valeria
AU  - Di Leo V
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust and Newcastle University, Newcastle upon Tyne, England.
FAU - Lawless, Conor
AU  - Lawless C
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
FAU - Roussel, Marie-Pier
AU  - Roussel MP
AD  - Department of Fundamental Sciences, Universite du Quebec a Chicoutimi, Quebec, 
      Canada.
FAU - Gomes, Tiago B
AU  - Gomes TB
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
AD  - NHS Highly Specialised Service for Rare Mitochondrial Disorders, Royal Victoria 
      Infirmary, Newcastle Upon Tyne, UK.
FAU - Gorman, Grainne S
AU  - Gorman GS
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust and Newcastle University, Newcastle upon Tyne, England.
AD  - NHS Highly Specialised Service for Rare Mitochondrial Disorders, Royal Victoria 
      Infirmary, Newcastle Upon Tyne, UK.
FAU - Russell, Oliver M
AU  - Russell OM
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust and Newcastle University, Newcastle upon Tyne, England.
FAU - Tuppen, Helen A L
AU  - Tuppen HAL
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
FAU - Duchesne, Elise
AU  - Duchesne E
AD  - Department of Health Sciences, Universite du Quebec a Chicoutimi, Quebec, Canada.
AD  - Neuromuscular Diseases Interdisciplinary Research Group (GRIMN), 
      Saguenay-Lac-St-Jean Integrated University Health and Social Services Center, 
      Saguenay, QC, Canada.
FAU - Vincent, Amy E
AU  - Vincent AE
AD  - Wellcome Centre for Mitochondrial Research, Translational and Clinical Research 
      Institute, Faculty of Medical Sciences, Newcastle University, UK.
AD  - NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS 
      Foundation Trust and Newcastle University, Newcastle upon Tyne, England.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
SB  - IM
MH  - Male
MH  - Humans
MH  - *Myotonic Dystrophy/genetics
MH  - *Resistance Training
MH  - Muscle, Skeletal/pathology
MH  - Exercise/physiology
MH  - Mitochondria/metabolism
PMC - PMC10657683
OTO - NOTNLM
OT  - Myotonic dystrophy type 1
OT  - mitochondrial dysfunction
OT  - myotonic dystrophy type 1 therapy
OT  - oxidative phosphorylation deficiency
OT  - resistance exercise training
OT  - skeletal muscle
OT  - strength training
COIS- The authors have no conflict of interest to report.
EDAT- 2023/08/28 06:42
MHDA- 2023/11/14 06:43
PMCR- 2023/11/19
CRDT- 2023/08/28 05:27
PHST- 2023/11/14 06:43 [medline]
PHST- 2023/08/28 06:42 [pubmed]
PHST- 2023/08/28 05:27 [entrez]
PHST- 2023/11/19 00:00 [pmc-release]
AID - JND230099 [pii]
AID - 10.3233/JND-230099 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2023;10(6):1111-1126. doi: 10.3233/JND-230099.

PMID- 37635015
OWN - NLM
STAT- MEDLINE
DCOM- 20230918
LR  - 20231003
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 33
IP  - 9
DP  - 2023 Sep
TI  - Role of respiratory characteristics in treatment adherence with noninvasive home 
      mechanical ventilation in myotonic dystrophy type 1, a retrospective study.
PG  - 57-62
LID - S0960-8966(23)00684-3 [pii]
LID - 10.1016/j.nmd.2023.08.004 [doi]
AB  - Chronic respiratory insufficiency is common in patients with myotonic dystrophy 
      type 1 (DM1) and can be treated with noninvasive home mechanical ventilation 
      (HMV). HMV is not always tolerated well resulting in low treatment adherence. We 
      aimed to analyze if baseline respiratory characteristics such as pulmonary 
      function, level of pCO(2) and presence of sleep apnea are associated with HMV 
      treatment adherence in DM1 patients. Pulmonary function testing, polysomnography 
      and blood gas measurement data of DM1 patients were retrospectively collected. 
      Initiation of HMV and treatment adherence after one year was documented. Patients 
      with low treatment adherence (average daily use of HMV <5 h) were grouped with 
      patients that discontinued HMV and compared with patients with high treatment 
      adherence (average daily use of HMV >5 h). HMV was initiated in 101 patients. 
      After one year, 58 patients had low treatment adherence. There were no 
      differences between the low and high treatment adherence group regarding the 
      respiratory characteristics. None of the included predictors (gender, age, body 
      mass index, cytosine-thymine-guanine repeat length, FVC, daytime pCO(2), 
      bicarbonate, nighttime pCO(2), nighttime base excess, apnea-hypopnea index and 
      mean saturation during sleep) was able to significantly predict high treatment 
      adherence. In conclusion, the respiratory characteristics are not associated with 
      treatment adherence with HMV in DM1 patients and cannot be used to identify 
      patients at risk for low HMV treatment adherence.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Vosse, Bettine Anna Hildegard
AU  - Vosse BAH
AD  - Department of Pulmonary Diseases and Home Mechanical Ventilation, Maastricht 
      University Medical Centre+, P.O. Box 5800 6202 AZ Maastricht, the Netherlands. 
      Electronic address: bettine.vosse@mumc.nl.
FAU - Horlings, Corinne Gosewina Cornelia
AU  - Horlings CGC
AD  - Department of Neurology, Medical University Innsbruck, Austria.
FAU - Joosten, Isis Bep Theodora
AU  - Joosten IBT
AD  - Department of Neurology and School for Mental Health and Neuroscience, Maastricht 
      University Medical Centre+, P.O. Box 5800 6202 AZ Maastricht, the Netherlands.
FAU - Cobben, Nicolle Andree Marie
AU  - Cobben NAM
AD  - Department of Pulmonary Diseases and Home Mechanical Ventilation, Maastricht 
      University Medical Centre+, P.O. Box 5800 6202 AZ Maastricht, the Netherlands.
FAU - van Kuijk, Sander Martijn Job
AU  - van Kuijk SMJ
AD  - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht 
      University Medical Centre+, P.O. Box 5800 6202 AZ Maastricht, the Netherlands.
FAU - Wijkstra, Peter Jan
AU  - Wijkstra PJ
AD  - Department of Pulmonary Diseases and Home Mechanical Ventilation, University 
      Medical Centre Groningen, P.O. Box 30.001 Groningen, the Netherlands.
FAU - Faber, Catharina Gerritdina
AU  - Faber CG
AD  - Department of Neurology and School for Mental Health and Neuroscience, Maastricht 
      University Medical Centre+, P.O. Box 5800 6202 AZ Maastricht, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20230809
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Myotonic Dystrophy/complications/therapy
MH  - Respiration, Artificial
MH  - Blood Gas Analysis
MH  - Body Mass Index
OTO - NOTNLM
OT  - Myotonic dystrophy
OT  - Noninvasive ventilation
OT  - Patient adherence
OT  - Respiration, artificial
OT  - Respiratory insufficiency
OT  - Ventilators, Mechanical
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests of personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/08/28 00:41
MHDA- 2023/09/18 12:43
CRDT- 2023/08/27 21:58
PHST- 2023/04/23 00:00 [received]
PHST- 2023/07/12 00:00 [revised]
PHST- 2023/08/08 00:00 [accepted]
PHST- 2023/09/18 12:43 [medline]
PHST- 2023/08/28 00:41 [pubmed]
PHST- 2023/08/27 21:58 [entrez]
AID - S0960-8966(23)00684-3 [pii]
AID - 10.1016/j.nmd.2023.08.004 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2023 Sep;33(9):57-62. doi: 10.1016/j.nmd.2023.08.004. Epub 
      2023 Aug 9.

PMID- 37521782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240104
IS  - 2374-7943 (Print)
IS  - 2374-7951 (Electronic)
IS  - 2374-7943 (Linking)
VI  - 9
IP  - 7
DP  - 2023 Jul 26
TI  - Transcriptome-Wide Studies of RNA-Targeted Small Molecules Provide a Simple and 
      Selective r(CUG)(exp) Degrader in Myotonic Dystrophy.
PG  - 1342-1353
LID - 10.1021/acscentsci.2c01223 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by a highly structured RNA repeat 
      expansion, r(CUG)(exp), harbored in the 3' untranslated region (3' UTR) of 
      dystrophia myotonica protein kinase (DMPK) mRNA and drives disease through a 
      gain-of-function mechanism. A panel of low-molecular-weight fragments capable of 
      reacting with RNA upon UV irradiation was studied for cross-linking to 
      r(CUG)(exp)in vitro, affording perimidin-2-amine diazirine (1) that bound to 
      r(CUG)(exp). The interactions between the small molecule and RNA were further 
      studied by nuclear magnetic resonance (NMR) spectroscopy and molecular modeling. 
      Binding of 1 in DM1 myotubes was profiled transcriptome-wide, identifying 12 
      transcripts including DMPK that were bound by 1. Augmenting the functionality of 
      1 with cleaving capability created a chimeric degrader that specifically targets 
      r(CUG)(exp) for elimination. The degrader broadly improved DM1-associated defects 
      as assessed by RNA-seq, while having limited effects on healthy myotubes. This 
      study (i) provides a platform to investigate molecular recognition of ligands 
      directly in disease-affected cells; (ii) illustrates that RNA degraders can be 
      more specific than the binders from which they are derived; and (iii) suggests 
      that repeating transcripts can be selectively degraded due to the presence of 
      multiple ligand binding sites.
CI  - (c) 2023 The Authors. Published by American Chemical Society.
FAU - Gibaut, Quentin M R
AU  - Gibaut QMR
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Bush, Jessica A
AU  - Bush JA
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Tong, Yuquan
AU  - Tong Y
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Baisden, Jared T
AU  - Baisden JT
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Taghavi, Amirhossein
AU  - Taghavi A
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Olafson, Hailey
AU  - Olafson H
AD  - Center for NeuroGenetics, University of Florida, Gainesville, Florida 32610, 
      United States.
AD  - Department of Molecular Genetics & Microbiology, College of Medicine, University 
      of Florida, Gainesville, Florida 32610, United States.
FAU - Yao, Xiyuan
AU  - Yao X
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Childs-Disney, Jessica L
AU  - Childs-Disney JL
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Center for NeuroGenetics, University of Florida, Gainesville, Florida 32610, 
      United States.
AD  - Department of Molecular Genetics & Microbiology, College of Medicine, University 
      of Florida, Gainesville, Florida 32610, United States.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - The Department of Chemistry, UF Scripps Biomedical Research and The Scripps 
      Research Institute, Jupiter, Florida 33458, United States.
LA  - eng
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20230626
PL  - United States
TA  - ACS Cent Sci
JT  - ACS central science
JID - 101660035
PMC - PMC10375898
COIS- The authors declare the following competing financial interest(s): M.D.D. is a 
      founder of Expansion Therapeutics.
EDAT- 2023/07/31 06:42
MHDA- 2023/07/31 06:43
PMCR- 2023/06/26
CRDT- 2023/07/31 05:13
PHST- 2022/10/14 00:00 [received]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/31 06:42 [pubmed]
PHST- 2023/07/31 05:13 [entrez]
PHST- 2023/06/26 00:00 [pmc-release]
AID - 10.1021/acscentsci.2c01223 [doi]
PST - epublish
SO  - ACS Cent Sci. 2023 Jun 26;9(7):1342-1353. doi: 10.1021/acscentsci.2c01223. 
      eCollection 2023 Jul 26.

PMID- 37397246
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230704
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 11
DP  - 2023
TI  - Promising AAV.U7snRNAs vectors targeting DMPK improve DM1 hallmarks in 
      patient-derived cell lines.
PG  - 1181040
LID - 10.3389/fcell.2023.1181040 [doi]
LID - 1181040
AB  - Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in 
      adults and affects mainly the skeletal muscle, heart, and brain. DM1 is caused by 
      a CTG repeat expansion in the 3'UTR region of the DMPK gene that sequesters 
      muscleblind-like proteins, blocking their splicing activity and forming nuclear 
      RNA foci. Consequently, many genes have their splicing reversed to a fetal 
      pattern. There is no treatment for DM1, but several approaches have been 
      explored, including antisense oligonucleotides (ASOs) aiming to knock down DMPK 
      expression or bind to the CTGs expansion. ASOs were shown to reduce RNA foci and 
      restore the splicing pattern. However, ASOs have several limitations and although 
      being safe treated DM1 patients did not demonstrate improvement in a human 
      clinical trial. AAV-based gene therapies have the potential to overcome such 
      limitations, providing longer and more stable expression of antisense sequences. 
      In the present study, we designed different antisense sequences targeting exons 5 
      or 8 of DMPK and the CTG repeat tract aiming to knock down DMPK expression or 
      promote steric hindrance, respectively. The antisense sequences were inserted in 
      U7snRNAs, which were then vectorized in AAV8 particles. Patient-derived myoblasts 
      treated with AAV8. U7snRNAs showed a significant reduction in the number of RNA 
      foci and re-localization of muscle-blind protein. RNA-seq analysis revealed a 
      global splicing correction in different patient-cell lines, without alteration in 
      DMPK expression.
CI  - Copyright (c) 2023 Almeida, Robriquet, Vetter, Huang, Neinast, Hernandez-Rosario, 
      Rajakumar, Arnold, McBride, Flanigan, Weiss and Wein.
FAU - Almeida, Camila F
AU  - Almeida CF
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
FAU - Robriquet, Florence
AU  - Robriquet F
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
FAU - Vetter, Tatyana A
AU  - Vetter TA
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
FAU - Huang, Nianyuan
AU  - Huang N
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
FAU - Neinast, Reid
AU  - Neinast R
AD  - Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH, 
      United States.
FAU - Hernandez-Rosario, Lumariz
AU  - Hernandez-Rosario L
AD  - Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH, 
      United States.
FAU - Rajakumar, Dhanarajan
AU  - Rajakumar D
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
FAU - Arnold, W David
AU  - Arnold WD
AD  - Department of Neurology, The Ohio State University, Columbus, OH, United States.
AD  - Department of Physical Medicine and Rehabilitation, University of Missouri School 
      of Medicine, Columbia, MO, United States.
FAU - McBride, Kim L
AU  - McBride KL
AD  - Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH, 
      United States.
AD  - Department of Medical Genetics, University of Calgary, Calgary, AB, Canada.
FAU - Flanigan, Kevin M
AU  - Flanigan KM
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
AD  - Department of Neurology, The Ohio State University, Columbus, OH, United States.
AD  - Department of Pediatrics, The Ohio State University, Columbus, OH, United States.
FAU - Weiss, Robert B
AU  - Weiss RB
AD  - Department of Human Genetics, The University of Utah School of Medicine, Salt 
      Lake City, UT, United States.
FAU - Wein, Nicolas
AU  - Wein N
AD  - Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United 
      States.
AD  - Department of Pediatrics, The Ohio State University, Columbus, OH, United States.
LA  - eng
PT  - Journal Article
DEP - 20230615
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC10309041
OTO - NOTNLM
OT  - U7snRNA
OT  - aav
OT  - gene therapy
OT  - myotonic dystrophy
OT  - spliceopathy
COIS- Since the performance of this work, Nationwide Children's Hospital licensed the 
      vector described herein to Audentes/Astellas Therapeutics. NW and KF have 
      received royalty payments as a result of this license. NW is a Scientific Advisor 
      for Alcyone Therapeutics. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2023/07/03 13:05
MHDA- 2023/07/03 13:06
PMCR- 2023/01/01
CRDT- 2023/07/03 11:31
PHST- 2023/03/06 00:00 [received]
PHST- 2023/05/18 00:00 [accepted]
PHST- 2023/07/03 13:06 [medline]
PHST- 2023/07/03 13:05 [pubmed]
PHST- 2023/07/03 11:31 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 1181040 [pii]
AID - 10.3389/fcell.2023.1181040 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2023 Jun 15;11:1181040. doi: 10.3389/fcell.2023.1181040. 
      eCollection 2023.

PMID- 37373276
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230701
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 12
DP  - 2023 Jun 14
TI  - In Cis Effect of DMPK Expanded Alleles in Myotonic Dystrophy Type 1 Patients 
      Carrying Variant Repeats at 5' and 3' Ends of the CTG Array.
LID - 10.3390/ijms241210129 [doi]
LID - 10129
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disease 
      caused by a CTG repeat expansion in the 3'-untranslated region (UTR) of DMPK 
      gene. DM1 alleles containing non-CTG variant repeats (VRs) have been described, 
      with uncertain molecular and clinical consequences. The expanded trinucleotide 
      array is flanked by two CpG islands, and the presence of VRs could confer an 
      additional level of epigenetic variability. This study aims to investigate the 
      association between VR-containing DMPK alleles, parental inheritance and 
      methylation pattern of the DM1 locus. The DM1 mutation has been characterized in 
      20 patients using a combination of SR-PCR, TP-PCR, modified TP-PCR and LR-PCR. 
      Non-CTG motifs have been confirmed by Sanger sequencing. The methylation pattern 
      of the DM1 locus was determined by bisulfite pyrosequencing. We characterized 7 
      patients with VRs within the CTG tract at 5' end and 13 patients carrying non-CTG 
      sequences at 3' end of the DM1 expansion. DMPK alleles with VRs at 5' end or 3' 
      end were invariably unmethylated upstream of the CTG expansion. Interestingly, 
      DM1 patients with VRs at the 3' end showed higher methylation levels in the 
      downstream island of the CTG repeat tract, preferentially when the disease allele 
      was maternally inherited. Our results suggest a potential correlation between 
      VRs, parental origin of the mutation and methylation pattern of the DMPK expanded 
      alleles. A differential CpG methylation status could play a role in the 
      phenotypic variability of DM1 patients, representing a potentially useful 
      diagnostic tool.
FAU - Visconti, Virginia Veronica
AU  - Visconti VV
AUID- ORCID: 0000-0002-4543-7770
AD  - Department of Biomedicine and Prevention, Genetics Unit, University of Rome "Tor 
      Vergata", Via Montpellier 1, 00133 Rome, Italy.
FAU - Macri, Elisa
AU  - Macri E
AUID- ORCID: 0000-0001-9232-0578
AD  - Department of Biomedicine and Prevention, Genetics Unit, University of Rome "Tor 
      Vergata", Via Montpellier 1, 00133 Rome, Italy.
FAU - D'Apice, Maria Rosaria
AU  - D'Apice MR
AD  - Laboratory of Medical Genetics, Tor Vergata Hospital, Viale Oxford 81, 00133 
      Rome, Italy.
FAU - Centofanti, Federica
AU  - Centofanti F
AD  - Department of Biomedicine and Prevention, Genetics Unit, University of Rome "Tor 
      Vergata", Via Montpellier 1, 00133 Rome, Italy.
FAU - Massa, Roberto
AU  - Massa R
AD  - Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 
      1, 00133 Rome, Italy.
FAU - Novelli, Giuseppe
AU  - Novelli G
AUID- ORCID: 0000-0002-7781-602X
AD  - Department of Biomedicine and Prevention, Genetics Unit, University of Rome "Tor 
      Vergata", Via Montpellier 1, 00133 Rome, Italy.
AD  - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Via 
      Atinense 18, 86077 Pozzilli, Italy.
AD  - Department of Pharmacology, School of Medicine, University of Nevada, Reno, NV 
      89557, USA.
FAU - Botta, Annalisa
AU  - Botta A
AUID- ORCID: 0000-0003-4031-5624
AD  - Department of Biomedicine and Prevention, Genetics Unit, University of Rome "Tor 
      Vergata", Via Montpellier 1, 00133 Rome, Italy.
LA  - eng
GR  - Italian DiMio onlus association/Italian DiMio onlus association/
GR  - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of 
      biomedical research in the NHS/European Union/
PT  - Journal Article
DEP - 20230614
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - 0 (DMPK protein, human)
SB  - IM
MH  - Humans
MH  - *Myotonic Dystrophy/genetics
MH  - Alleles
MH  - Myotonin-Protein Kinase/genetics
MH  - Trinucleotide Repeat Expansion
MH  - CpG Islands
PMC - PMC10299395
OTO - NOTNLM
OT  - DMPK gene
OT  - Myotonic dystrophy type 1 (DM1)
OT  - inheritance
OT  - methylation
OT  - variant repeats (VRs)
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/28 06:43
MHDA- 2023/06/29 06:42
PMCR- 2023/06/14
CRDT- 2023/06/28 01:18
PHST- 2023/04/17 00:00 [received]
PHST- 2023/06/07 00:00 [revised]
PHST- 2023/06/12 00:00 [accepted]
PHST- 2023/06/29 06:42 [medline]
PHST- 2023/06/28 06:43 [pubmed]
PHST- 2023/06/28 01:18 [entrez]
PHST- 2023/06/14 00:00 [pmc-release]
AID - ijms241210129 [pii]
AID - ijms-24-10129 [pii]
AID - 10.3390/ijms241210129 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jun 14;24(12):10129. doi: 10.3390/ijms241210129.

PMID- 37352653
OWN - NLM
STAT- MEDLINE
DCOM- 20230908
LR  - 20230913
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 71
DP  - 2023 Sep
TI  - Lymphoblastoid cell lines derived from iPSCs of a myotonic dystrophy type 1 
      patient carrying 700 CTG repeats (CBRCULi007-A) and a control (CBRCULi006-A).
PG  - 103148
LID - S1873-5061(23)00134-4 [pii]
LID - 10.1016/j.scr.2023.103148 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a genetic neuromuscular disorder that affects 
      many organs, including the heart. DM1 is caused by a heterozygous CTG triplet 
      expansion exceeding the normal size threshold in the non-coding region of the DM1 
      protein kinase gene (DMPK). We generated and characterized a DM1 iPSC line 
      carrying a 700 CTG repeat expansion as well as a control iPSC line from a healthy 
      individual. The two iPSC lines expressed several pluripotency markers, had the 
      capacity to differentiate into the three primary germ layers, had no residual 
      viral vectors, had normal karyotypes, and had a typical colony morphology.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Chahine, Mohamed
AU  - Chahine M
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada; Department of Medicine, Faculty of Medicine, Universite 
      Laval, Quebec City, QC G1V 0A6, Canada. Electronic address: 
      Mohamed.Chahine@phc.ulaval.ca.
FAU - Jauvin, Dominic
AU  - Jauvin D
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada.
FAU - Pierre, Marion
AU  - Pierre M
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada.
FAU - Puymirat, Jack
AU  - Puymirat J
AD  - Department of Medicine, Faculty of Medicine, Universite Laval, Quebec City, QC 
      G1V 0A6, Canada; LOEX, CHU de Quebec-Universite Laval Research Centre, Quebec 
      City, QC G1J 1Z4, Canada.
FAU - Boutjdir, Mohamed
AU  - Boutjdir M
AD  - Cardiovascular Research Program, VA New York Harbor Healthcare System, New York 
      City, NY 11209, USA; Department of Medicine, Cell Biology and Pharmacology, SUNY 
      Downstate Health Science University, New York City, NY 11203, USA; Department of 
      Medicine, NYU School of Medicine, New York City, NY 10016, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20230617
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Humans
MH  - *Myotonic Dystrophy/genetics/metabolism
MH  - Trinucleotide Repeat Expansion/genetics
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Cell Line
MH  - Myotonin-Protein Kinase/genetics
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/23 19:11
MHDA- 2023/09/08 06:42
CRDT- 2023/06/23 18:05
PHST- 2023/04/27 00:00 [received]
PHST- 2023/06/15 00:00 [revised]
PHST- 2023/06/16 00:00 [accepted]
PHST- 2023/09/08 06:42 [medline]
PHST- 2023/06/23 19:11 [pubmed]
PHST- 2023/06/23 18:05 [entrez]
AID - S1873-5061(23)00134-4 [pii]
AID - 10.1016/j.scr.2023.103148 [doi]
PST - ppublish
SO  - Stem Cell Res. 2023 Sep;71:103148. doi: 10.1016/j.scr.2023.103148. Epub 2023 Jun 
      17.

PMID- 37200862
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230521
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 32
DP  - 2023 Jun 13
TI  - Block or degrade? Balancing on- and off-target effects of antisense strategies 
      against transcripts with expanded triplet repeats in DM1.
PG  - 622-636
LID - 10.1016/j.omtn.2023.04.010 [doi]
AB  - Antisense oligonucleotide (ASO) therapies for myotonic dystrophy type 1 (DM1) are 
      based on elimination of transcripts containing an expanded repeat or inhibition 
      of sequestration of RNA-binding proteins. This activity is achievable by both 
      degradation of expanded transcripts and steric hindrance, although it is unknown 
      which approach is superior. We compared blocking ASOs with RNase H-recruiting 
      gapmers of equivalent chemistries. Two DMPK target sequences were selected: the 
      triplet repeat and a unique sequence upstream thereof. We assessed ASO effects on 
      transcript levels, ribonucleoprotein foci and disease-associated missplicing, and 
      performed RNA sequencing to investigate on- and off-target effects. Both gapmers 
      and the repeat blocker led to significant DMPK knockdown and a reduction in 
      (CUG)(exp) foci. However, the repeat blocker was more effective in MBNL1 protein 
      displacement and had superior efficiency in splicing correction at the tested 
      dose of 100 nM. By comparison, on a transcriptome level, the blocking ASO had the 
      fewest off-target effects. In particular, the off-target profile of the repeat 
      gapmer asks for cautious consideration in further therapeutic development. 
      Altogether, our study demonstrates the importance of evaluating both on-target 
      and downstream effects of ASOs in a DM1 context, and provides guiding principles 
      for safe and effective targeting of toxic transcripts.
CI  - (c) 2023 The Author(s).
FAU - El Boujnouni, Najoua
AU  - El Boujnouni N
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
FAU - van der Bent, M Leontien
AU  - van der Bent ML
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
FAU - Willemse, Marieke
AU  - Willemse M
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
FAU - 't Hoen, Peter A C
AU  - 't Hoen PAC
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
FAU - Brock, Roland
AU  - Brock R
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
AD  - Department of Medical Biochemistry, College of Medicine and Medical Sciences, 
      Arabian Gulf University, Manama 293, Bahrain.
FAU - Wansink, Derick G
AU  - Wansink DG
AD  - Department of Medical BioSciences, Research Institute for Medical Innovation, 
      Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20230420
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC10185704
OTO - NOTNLM
OT  - DMPK
OT  - MBNL1
OT  - MT: Oligonucleotides: Therapies and Applications
OT  - antisense oligonucleotide
OT  - gapmer
OT  - myotonic dystrophy type 1
OT  - off-target
OT  - steric hindrance
OT  - triplet repeat
COIS- D.G.W. is inventor on patents related to ASOs for treatment of myotonic dystrophy 
      type 1.
EDAT- 2023/05/18 19:12
MHDA- 2023/05/18 19:13
PMCR- 2023/04/20
CRDT- 2023/05/18 16:49
PHST- 2022/10/26 00:00 [received]
PHST- 2023/04/13 00:00 [accepted]
PHST- 2023/05/18 19:13 [medline]
PHST- 2023/05/18 19:12 [pubmed]
PHST- 2023/05/18 16:49 [entrez]
PHST- 2023/04/20 00:00 [pmc-release]
AID - S2162-2531(23)00096-3 [pii]
AID - 10.1016/j.omtn.2023.04.010 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2023 Apr 20;32:622-636. doi: 10.1016/j.omtn.2023.04.010. 
      eCollection 2023 Jun 13.

PMID- 37169279
OWN - NLM
STAT- MEDLINE
DCOM- 20230523
LR  - 20230608
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Print)
IS  - 0014-4835 (Linking)
VI  - 231
DP  - 2023 Jun
TI  - Dysregulation of DNA repair genes in Fuchs endothelial corneal dystrophy.
PG  - 109499
LID - S0014-4835(23)00120-3 [pii]
LID - 10.1016/j.exer.2023.109499 [doi]
AB  - Fuchs Endothelial Corneal Dystrophy (FECD), a late-onset oxidative stress 
      disorder, is the most common cause of corneal endothelial degeneration and is 
      genetically associated with CTG repeat expansion in Transcription Factor 4 
      (TCF4). We previously reported accumulation of nuclear (nDNA) and mitochondrial 
      (mtDNA) damage in FECD. Specifically, mtDNA damage was a prominent finding in 
      development of disease in the ultraviolet-A (UVA) induced FECD mouse model. We 
      hypothesize that an aberrant DNA repair may contribute to the increased DNA 
      damage seen in FECD. We analyzed differential expression profiles of 84 DNA 
      repair genes by real-time PCR arrays using Human DNA Repair RT-Profiler plates 
      using cDNA extracted from Descemet's membrane-corneal endothelium (DM-CE) 
      obtained from FECD patients with expanded (>40) or non-expanded (<40) intronic 
      CTG repeats in TCF4 gene and from age-matched normal donors. Change in mRNA 
      expression of <0.5- or >2.0-fold in FECD relative to normal was set as cutoff for 
      down- or upregulation. Downregulated mitochondrial genes were further validated 
      using the UVA-based mouse model of FECD. FECD specimens exhibited downregulation 
      of 9 genes and upregulation of 8 genes belonging to the four major DNA repair 
      pathways, namely, base excision repair (BER), nucleotide excision repair (NER), 
      mismatch repair (MMR), and double strand break (DSB) repair, compared to normal 
      donors. MMR gene MSH2 and BER gene POLB were preferentially upregulated in 
      expanded FECD. BER genes LIG3 and NEIL2, DSB repair genes PARP3 and TOP3A, NER 
      gene XPC, and unclassified pathway gene TREX1, were downregulated in both 
      expanded and non-expanded FECD. MtDNA repair genes, Lig3, Neil2, and Top3a, were 
      also downregulated in the UVA-based mouse model of FECD. Our findings identify 
      impaired DNA repair pathways that may play an important role in DNA damage due to 
      oxidative stress as well as genetic predisposition noted in FECD.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Ashraf, Shazia
AU  - Ashraf S
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States.
FAU - Deshpande, Neha
AU  - Deshpande N
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States.
FAU - Vasanth, Shivakumar
AU  - Vasanth S
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States.
FAU - Melangath, Geetha
AU  - Melangath G
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States.
FAU - Wong, Raymond J
AU  - Wong RJ
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, 02114, United 
      States; Department of Ophthalmology, Harvard Medical School, Boston, MA, 02115, 
      United States.
FAU - Price, Marianne O
AU  - Price MO
AD  - Price Vision Group and Cornea Research Foundation of America, Indianapolis, IN, 
      46260, United States.
FAU - Price, Francis W Jr
AU  - Price FW Jr
AD  - Price Vision Group and Cornea Research Foundation of America, Indianapolis, IN, 
      46260, United States.
FAU - Jurkunas, Ula V
AU  - Jurkunas UV
AD  - Schepens Eye Research Institute, Boston, MA, 02114, United States; Massachusetts 
      Eye and Ear, Harvard Medical School, Boston, MA, 02114, United States; Department 
      of Ophthalmology, Harvard Medical School, Boston, MA, 02115, United States. 
      Electronic address: ula_jurkunas@meei.harvard.edu.
LA  - eng
GR  - R01 EY020581/EY/NEI NIH HHS/United States
GR  - P30 EY003790/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230509
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (DNA, Mitochondrial)
RN  - EC 3.2.2.- (Neil2 protein, mouse)
RN  - EC 3.2.2.- (DNA Glycosylases)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Humans
MH  - *Fuchs' Endothelial Dystrophy/genetics/metabolism
MH  - Endothelium, Corneal/metabolism
MH  - Genetic Predisposition to Disease
MH  - DNA Repair/genetics
MH  - DNA, Mitochondrial/genetics
MH  - *DNA Glycosylases/genetics/metabolism
PMC - PMC10246500
MID - NIHMS1900859
OTO - NOTNLM
OT  - CTG repeat Expansion
OT  - DNA repair
OT  - Fuchs endothelial corneal dystrophy
OT  - Mitochondrial DNA damage
OT  - Oxidative stress
OT  - TCF4
COIS- Declaration of competing interest The authors declare no competing interest.
EDAT- 2023/05/12 01:07
MHDA- 2023/05/23 06:42
PMCR- 2024/06/01
CRDT- 2023/05/11 19:37
PHST- 2022/12/01 00:00 [received]
PHST- 2023/03/27 00:00 [revised]
PHST- 2023/05/08 00:00 [accepted]
PHST- 2024/06/01 00:00 [pmc-release]
PHST- 2023/05/23 06:42 [medline]
PHST- 2023/05/12 01:07 [pubmed]
PHST- 2023/05/11 19:37 [entrez]
AID - S0014-4835(23)00120-3 [pii]
AID - 10.1016/j.exer.2023.109499 [doi]
PST - ppublish
SO  - Exp Eye Res. 2023 Jun;231:109499. doi: 10.1016/j.exer.2023.109499. Epub 2023 May 
      9.

PMID- 37146135
OWN - NLM
STAT- MEDLINE
DCOM- 20230508
LR  - 20230517
IS  - 2375-2548 (Electronic)
IS  - 2375-2548 (Linking)
VI  - 9
IP  - 18
DP  - 2023 May 5
TI  - Short tandem repeat expansions in sporadic amyotrophic lateral sclerosis and 
      frontotemporal dementia.
PG  - eade2044
LID - 10.1126/sciadv.ade2044 [doi]
LID - eade2044
AB  - Pathogenic short tandem repeat (STR) expansions cause over 20 neurodegenerative 
      diseases. To determine the contribution of STRs in sporadic amyotrophic lateral 
      sclerosis (ALS) and frontotemporal dementia (FTD), we used ExpansionHunter, 
      REviewer, and polymerase chain reaction validation to assess 21 neurodegenerative 
      disease-associated STRs in whole-genome sequencing data from 608 patients with 
      sporadic ALS, 68 patients with sporadic FTD, and 4703 matched controls. We also 
      propose a data-derived outlier detection method for defining allele thresholds in 
      rare STRs. Excluding C9orf72 repeat expansions, 17.6% of clinically diagnosed ALS 
      and FTD cases had at least one expanded STR allele reported to be pathogenic or 
      intermediate for another neurodegenerative disease. We identified and validated 
      162 disease-relevant STR expansions in C9orf72 (ALS/FTD), ATXN1 [spinal 
      cerebellar ataxia type 1 (SCA1)], ATXN2 (SCA2), ATXN8 (SCA8), TBP (SCA17), HTT 
      (Huntington's disease), DMPK [myotonic dystrophy type 1 (DM1)], CNBP (DM2), and 
      FMR1 (fragile-X disorders). Our findings suggest clinical and pathological 
      pleiotropy of neurodegenerative disease genes and highlight their importance in 
      ALS and FTD.
FAU - Henden, Lyndal
AU  - Henden L
AUID- ORCID: 0000-0001-5541-7637
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - Fearnley, Liam G
AU  - Fearnley LG
AUID- ORCID: 0000-0003-2198-5411
AD  - Population Health and Immunity Division, The Walter and Eliza Hall Institute of 
      Medical Research, Parkville, VIC 3052, Australia.
AD  - Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, 
      Australia.
FAU - Grima, Natalie
AU  - Grima N
AUID- ORCID: 0000-0001-6434-7706
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - McCann, Emily P
AU  - McCann EP
AUID- ORCID: 0000-0002-8200-3525
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - Dobson-Stone, Carol
AU  - Dobson-Stone C
AUID- ORCID: 0000-0002-2211-0257
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - School of Medical Sciences, Faculty of Medicine and Health, The University of 
      Sydney, Sydney, NSW 2006, Australia.
FAU - Fitzpatrick, Lauren
AU  - Fitzpatrick L
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
FAU - Friend, Kathryn
AU  - Friend K
AD  - SA Pathology, Women's and Children's Hospital, North Adelaide, SA 5006, 
      Australia.
FAU - Hobson, Lynne
AU  - Hobson L
AD  - SA Pathology, Women's and Children's Hospital, North Adelaide, SA 5006, 
      Australia.
FAU - Chan Moi Fat, Sandrine
AU  - Chan Moi Fat S
AUID- ORCID: 0000-0002-6304-0283
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - Rowe, Dominic B
AU  - Rowe DB
AUID- ORCID: 0000-0003-0912-2146
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
AD  - Department of Clinical Medicine, Faculty of Medicine and Health Sciences, 
      Macquarie University, Macquarie Park, NSW 2109, Australia.
FAU - D'Silva, Susan
AU  - D'Silva S
AUID- ORCID: 0000-0002-6893-6716
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
AD  - Department of Clinical Medicine, Faculty of Medicine and Health Sciences, 
      Macquarie University, Macquarie Park, NSW 2109, Australia.
FAU - Kwok, John B
AU  - Kwok JB
AUID- ORCID: 0000-0001-9574-6195
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - School of Medical Sciences, Faculty of Medicine and Health, The University of 
      Sydney, Sydney, NSW 2006, Australia.
FAU - Halliday, Glenda M
AU  - Halliday GM
AUID- ORCID: 0000-0003-0422-8398
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - School of Medical Sciences, Faculty of Medicine and Health, The University of 
      Sydney, Sydney, NSW 2006, Australia.
FAU - Kiernan, Matthew C
AU  - Kiernan MC
AUID- ORCID: 0000-0001-9054-026X
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW 2050, 
      Australia.
FAU - Mazumder, Srestha
AU  - Mazumder S
AUID- ORCID: 0000-0001-5322-5543
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
FAU - Timmins, Hannah C
AU  - Timmins HC
AUID- ORCID: 0000-0001-5504-1625
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
FAU - Zoing, Margaret
AU  - Zoing M
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
FAU - Pamphlett, Roger
AU  - Pamphlett R
AUID- ORCID: 0000-0003-3326-7273
AD  - Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - Discipline of Pathology, The University of Sydney, Sydney, NSW 2050, Australia.
AD  - Department of Neuropathology, Royal Prince Alfred Hospital, Sydney, NSW 2050, 
      Australia.
FAU - Adams, Lorel
AU  - Adams L
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - Bahlo, Melanie
AU  - Bahlo M
AUID- ORCID: 0000-0001-5132-0774
AD  - Population Health and Immunity Division, The Walter and Eliza Hall Institute of 
      Medical Research, Parkville, VIC 3052, Australia.
AD  - Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, 
      Australia.
FAU - Blair, Ian P
AU  - Blair IP
AUID- ORCID: 0000-0003-3083-0075
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
FAU - Williams, Kelly L
AU  - Williams KL
AUID- ORCID: 0000-0001-6319-9473
AD  - Macquarie University Centre for Motor Neuron Disease Research, Faculty of 
      Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, 
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20230505
PL  - United States
TA  - Sci Adv
JT  - Science advances
JID - 101653440
RN  - 0 (C9orf72 Protein)
RN  - 0 (FMR1 protein, human)
RN  - 139135-51-6 (Fragile X Mental Retardation Protein)
RN  - Amyotrophic lateral sclerosis 1
SB  - IM
MH  - Humans
MH  - *Frontotemporal Dementia/genetics
MH  - *Amyotrophic Lateral Sclerosis/genetics
MH  - C9orf72 Protein/genetics
MH  - DNA Repeat Expansion/genetics
MH  - *Spinocerebellar Ataxias/genetics
MH  - Fragile X Mental Retardation Protein/genetics
PMC - PMC10162670
EDAT- 2023/05/05 18:42
MHDA- 2023/05/08 10:17
PMCR- 2023/05/05
CRDT- 2023/05/05 14:03
PHST- 2023/05/08 10:17 [medline]
PHST- 2023/05/05 18:42 [pubmed]
PHST- 2023/05/05 14:03 [entrez]
PHST- 2023/05/05 00:00 [pmc-release]
AID - ade2044 [pii]
AID - 10.1126/sciadv.ade2044 [doi]
PST - ppublish
SO  - Sci Adv. 2023 May 5;9(18):eade2044. doi: 10.1126/sciadv.ade2044. Epub 2023 May 5.

PMID- 37143315
OWN - NLM
STAT- MEDLINE
DCOM- 20231004
LR  - 20240210
IS  - 1460-2156 (Electronic)
IS  - 0006-8950 (Print)
IS  - 0006-8950 (Linking)
VI  - 146
IP  - 10
DP  - 2023 Oct 3
TI  - Choroid plexus mis-splicing and altered cerebrospinal fluid composition in 
      myotonic dystrophy type 1.
PG  - 4217-4232
LID - 10.1093/brain/awad148 [doi]
AB  - Myotonic dystrophy type 1 is a dominantly inherited multisystemic disease caused 
      by CTG tandem repeat expansions in the DMPK 3' untranslated region. These 
      expanded repeats are transcribed and produce toxic CUG RNAs that sequester and 
      inhibit activities of the MBNL family of developmental RNA processing factors. 
      Although myotonic dystrophy is classified as a muscular dystrophy, the brain is 
      also severely affected by an unusual cohort of symptoms, including hypersomnia, 
      executive dysfunction, as well as early onsets of tau/MAPT pathology and cerebral 
      atrophy. To address the molecular and cellular events that lead to these 
      pathological outcomes, we recently generated a mouse Dmpk CTG expansion knock-in 
      model and identified choroid plexus epithelial cells as particularly affected by 
      the expression of toxic CUG expansion RNAs. To determine if toxic CUG RNAs 
      perturb choroid plexus functions, alternative splicing analysis was performed on 
      lateral and hindbrain choroid plexi from Dmpk CTG knock-in mice. Choroid plexus 
      transcriptome-wide changes were evaluated in Mbnl2 knockout mice, a 
      developmental-onset model of myotonic dystrophy brain dysfunction. To determine 
      if transcriptome changes also occurred in the human disease, we obtained 
      post-mortem choroid plexus for RNA-seq from neurologically unaffected (two 
      females, three males; ages 50-70 years) and myotonic dystrophy type 1 (one 
      female, three males; ages 50-70 years) donors. To test that choroid plexus 
      transcriptome alterations resulted in altered CSF composition, we obtained CSF 
      via lumbar puncture from patients with myotonic dystrophy type 1 (five females, 
      five males; ages 35-55 years) and non-myotonic dystrophy patients (three females, 
      four males; ages 26-51 years), and western blot and osmolarity analyses were used 
      to test CSF alterations predicted by choroid plexus transcriptome analysis. We 
      determined that CUG RNA induced toxicity was more robust in the lateral choroid 
      plexus of Dmpk CTG knock-in mice due to comparatively higher Dmpk and lower Mbnl 
      RNA levels. Impaired transitions to adult splicing patterns during choroid plexus 
      development were identified in Mbnl2 knockout mice, including mis-splicing 
      previously found in Dmpk CTG knock-in mice. Whole transcriptome analysis of 
      myotonic dystrophy type 1 choroid plexus revealed disease-associated RNA 
      expression and mis-splicing events. Based on these RNA changes, predicted 
      alterations in ion homeostasis, secretory output and CSF composition were 
      confirmed by analysis of myotonic dystrophy type 1 CSF. Our results implicate 
      choroid plexus spliceopathy and concomitant alterations in CSF homeostasis as an 
      unappreciated contributor to myotonic dystrophy type 1 CNS pathogenesis.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      Guarantors of Brain. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Nutter, Curtis A
AU  - Nutter CA
AUID- ORCID: 0000-0001-5593-6197
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Kidd, Benjamin M
AU  - Kidd BM
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Carter, Helmut A
AU  - Carter HA
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Hamel, Johanna I
AU  - Hamel JI
AD  - Department of Neurology, University of Rochester, Rochester, NY 14642, USA.
FAU - Mackie, Philip M
AU  - Mackie PM
AD  - Department of Neuroscience, McKnight Brain Institute, College of Medicine, 
      University of Florida, Gainesville, FL 32610, USA.
FAU - Kumbkarni, Nayha
AU  - Kumbkarni N
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Davenport, Mackenzie L
AU  - Davenport ML
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Tuyn, Dana M
AU  - Tuyn DM
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Gopinath, Adithya
AU  - Gopinath A
AD  - Department of Neuroscience, McKnight Brain Institute, College of Medicine, 
      University of Florida, Gainesville, FL 32610, USA.
FAU - Creigh, Peter D
AU  - Creigh PD
AD  - Department of Neurology, University of Rochester, Rochester, NY 14642, USA.
FAU - Sznajder, Lukasz J
AU  - Sznajder LJ
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Ranum, Laura P W
AU  - Ranum LPW
AUID- ORCID: 0000-0001-9808-9661
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, McKnight Brain Institute and the Fixel Institute for 
      Neurological Diseases, College of Medicine, University of Florida, Gainesville, 
      FL 32610, USA.
FAU - Khoshbouei, Habibeh
AU  - Khoshbouei H
AD  - Department of Neuroscience, McKnight Brain Institute, College of Medicine, 
      University of Florida, Gainesville, FL 32610, USA.
FAU - Day, John W
AU  - Day JW
AD  - Department of Neurology and Neurological Sciences, Stanford University School of 
      Medicine, Stanford, CA 94304, USA.
FAU - Sampson, Jacinda B
AU  - Sampson JB
AD  - Department of Neurology and Neurological Sciences, Stanford University School of 
      Medicine, Stanford, CA 94304, USA.
FAU - Prokop, Stefan
AU  - Prokop S
AD  - Department of Pathology, Immunology, and Laboratory Medicine, Center for 
      Translational Research in Neurodegenerative Disease, McKnight Brain Institute and 
      the Fixel Institute for Neurological Diseases, College of Medicine, University of 
      Florida, Gainesville, FL 32610, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
LA  - eng
GR  - R01 NS103172/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Brain
JT  - Brain : a journal of neurology
JID - 0372537
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Humans
MH  - Female
MH  - Mice
MH  - Animals
MH  - *Myotonic Dystrophy/genetics
MH  - Choroid Plexus/metabolism/pathology
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Alternative Splicing
MH  - RNA/genetics
MH  - Mice, Knockout
MH  - Trinucleotide Repeat Expansion
PMC - PMC10545633
OTO - NOTNLM
OT  - RNA disease
OT  - alternative splicing
OT  - development
OT  - neurodegeneration
OT  - short tandem repeat expansion
COIS- M.S.S. is a Scientific Advisory Board member for Kate Therapeutics, Skyhawk 
      Therapeutics and Tacit Therapeutics.
EDAT- 2023/05/05 06:42
MHDA- 2023/10/04 06:44
PMCR- 2024/05/05
CRDT- 2023/05/05 01:23
PHST- 2023/01/23 00:00 [received]
PHST- 2023/04/08 00:00 [revised]
PHST- 2023/04/18 00:00 [accepted]
PHST- 2024/05/05 00:00 [pmc-release]
PHST- 2023/10/04 06:44 [medline]
PHST- 2023/05/05 06:42 [pubmed]
PHST- 2023/05/05 01:23 [entrez]
AID - 7152692 [pii]
AID - awad148 [pii]
AID - 10.1093/brain/awad148 [doi]
PST - ppublish
SO  - Brain. 2023 Oct 3;146(10):4217-4232. doi: 10.1093/brain/awad148.

PMID- 36892629
OWN - NLM
STAT- MEDLINE
DCOM- 20230518
LR  - 20230518
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 270
IP  - 6
DP  - 2023 Jun
TI  - Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and 
      disease severity in myotonic dystrophy type 1.
PG  - 3138-3158
LID - 10.1007/s00415-023-11633-1 [doi]
AB  - BACKGROUND AND PURPOSE: Myotonic dystrophy type 1 (DM1) is the most common form 
      of adult-onset muscular dystrophy and is caused by an repeat expansion 
      [r(CUG)(exp)] located in the 3' untranslated region of the DMPK gene. Symptoms 
      include skeletal and cardiac muscle dysfunction and fibrosis. In DM1, there is a 
      lack of established biomarkers in routine clinical practice. Thus, we aimed to 
      identify a blood biomarker with relevance for DM1-pathophysiology and clinical 
      presentation. METHODS: We collected fibroblasts from 11, skeletal muscles from 
      27, and blood samples from 158 DM1 patients. Moreover, serum, cardiac, and 
      skeletal muscle samples from DMSXL mice were included. We employed proteomics, 
      immunostaining, qPCR and ELISA. Periostin level were correlated with CMRI-data 
      available for some patients. RESULTS: Our studies identified Periostin, a 
      modulator of fibrosis, as a novel biomarker candidate for DM1: proteomic 
      profiling of human fibroblasts and murine skeletal muscles showed significant 
      dysregulation of Periostin. Immunostaining on skeletal and cardiac muscles from 
      DM1 patients and DMSXL mice showed an extracellular increase of Periostin, 
      indicating fibrosis. qPCR studies indicated increased POSTN expression in 
      fibroblasts and muscle. Quantification of Periostin in blood samples from DMSXL 
      mice and two large validation cohorts of DM1 patients showed decreased levels in 
      animals and diseased individuals correlating with repeat expansion and disease 
      severity and presence of cardiac symptoms identified by MRI. Analyses of 
      longitudinal blood samples revealed no correlation with disease progression. 
      CONCLUSIONS: Periostin might serve as a novel stratification biomarker for DM1 
      correlating with disease severity, presence of cardiac malfunction and fibrosis.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
FAU - Nguyen, Chi D L
AU  - Nguyen CDL
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
FAU - Jimenez-Moreno, Aura Cecilia
AU  - Jimenez-Moreno AC
AD  - Newcastle University, Newcastle upon Tyne, NE1 3BZ, United Kingdom.
FAU - Merker, Monika
AU  - Merker M
AD  - Department of Neurology, University Hospital Duesseldorf, 40225, Duesseldorf, 
      Germany.
FAU - Bowers, Charles Joseph
AU  - Bowers CJ
AD  - Newcastle University, Newcastle upon Tyne, NE1 3BZ, United Kingdom.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - Newcastle University, Newcastle upon Tyne, NE1 3BZ, United Kingdom.
FAU - Hentschel, Andreas
AU  - Hentschel A
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
FAU - Muntefering, Thomas
AU  - Muntefering T
AD  - Department of Neurology, University Hospital Duesseldorf, 40225, Duesseldorf, 
      Germany.
FAU - Isham, Angus
AU  - Isham A
AD  - Newcastle University, Newcastle upon Tyne, NE1 3BZ, United Kingdom.
FAU - Ruck, Tobias
AU  - Ruck T
AD  - Department of Neurology, University Hospital Duesseldorf, 40225, Duesseldorf, 
      Germany.
FAU - Vorgerd, Matthias
AU  - Vorgerd M
AD  - Department of Neurology, University Hospital Bergmannsheil, Heimer Institute for 
      Muscle Research, 44789, Bochum, Germany.
FAU - Dobelmann, Vera
AU  - Dobelmann V
AD  - Department of Neurology, University Hospital Duesseldorf, 40225, Duesseldorf, 
      Germany.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Institut National de la Sante et de la Recherche Medicale UMR 1163, Paris, 
      France.
AD  - Laboratory CTGDM, Institut Imagine, Universite Paris Descartes-Sorbonne Paris 
      Cite, Paris, France.
FAU - Schara-Schmidt, Ulrike
AU  - Schara-Schmidt U
AD  - Department of Neuropediatrics and Neuromuscular Centre for Children and 
      Adolescents, Center for Translational Neuro- and Behavioral Sciences, University 
      Duisburg-Essen, 45147, Essen, Germany.
FAU - Gangfuss, Andrea
AU  - Gangfuss A
AD  - Department of Neuropediatrics and Neuromuscular Centre for Children and 
      Adolescents, Center for Translational Neuro- and Behavioral Sciences, University 
      Duisburg-Essen, 45147, Essen, Germany.
FAU - Schroder, Charlotte
AU  - Schroder C
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
FAU - Sickmann, Albert
AU  - Sickmann A
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
FAU - Gross, Claudia
AU  - Gross C
AD  - Institute of Clinical Genetics and Tumor Genetics Bonn, Maximilianstrasse 28D, 
      53111, Bonn, Germany.
FAU - Gorman, Grainne
AU  - Gorman G
AD  - Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle 
      University, Newcastle upon Tyne, NE2 4HH, United Kingdom.
FAU - Stenzel, Werner
AU  - Stenzel W
AD  - Department of Neuropathology, Charite-Universitatsmedizin Berlin, Corporate 
      Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
FAU - Kollipara, Laxmikanth
AU  - Kollipara L
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
FAU - Hathazi, Denisa
AU  - Hathazi D
AD  - Leibniz-Institut fur Analytische Wissenschaften-ISAS-e.V., 44227, Dortmund, 
      Germany.
AD  - Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
FAU - Spendiff, Sally
AU  - Spendiff S
AD  - Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, 
      Department of Medicine, The Ottawa Hospital, and Brain and Mind Research 
      Institute, University of Ottawa, Ottawa, Canada.
FAU - Gagnon, Cynthia
AU  - Gagnon C
AD  - Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, 
      Department of Medicine, The Ottawa Hospital, and Brain and Mind Research 
      Institute, University of Ottawa, Ottawa, Canada.
AD  - School of Rehabilitation, Faculty of Medicine and Health Sciences, Universite de 
      Sherbrooke, Quebec, Canada.
FAU - Preusse, Corinna
AU  - Preusse C
AD  - Department of Neuropathology, Charite-Universitatsmedizin Berlin, Corporate 
      Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
FAU - Duchesne, Elise
AU  - Duchesne E
AD  - Department of Health Sciences, Universite du Quebec a Chicoutimi, Quebec, Canada.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, 
      Department of Medicine, The Ottawa Hospital, and Brain and Mind Research 
      Institute, University of Ottawa, Ottawa, Canada.
AD  - Department of Neuropediatrics and Muscle Disorders, Medical Center-University of 
      Freiburg, Faculty of Medicine, Freiburg, Germany.
AD  - Centro Nacional de Analisis Genomico, Center for Genomic Regulation (CNAG-CRG), 
      Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, 
      Spain.
FAU - Roos, Andreas
AU  - Roos A
AD  - Department of Neurology, University Hospital Bergmannsheil, Heimer Institute for 
      Muscle Research, 44789, Bochum, Germany. roos@andreas-roos.de.
AD  - Department of Neuropediatrics and Neuromuscular Centre for Children and 
      Adolescents, Center for Translational Neuro- and Behavioral Sciences, University 
      Duisburg-Essen, 45147, Essen, Germany. roos@andreas-roos.de.
AD  - Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, 
      Department of Medicine, The Ottawa Hospital, and Brain and Mind Research 
      Institute, University of Ottawa, Ottawa, Canada. roos@andreas-roos.de.
LA  - eng
GR  - FDN-167281/CAPMC/CIHR/Canada
GR  - FDN-167281/CAPMC/CIHR/Canada
PT  - Journal Article
DEP - 20230309
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Mice
MH  - Animals
MH  - *Myotonic Dystrophy/genetics
MH  - Trinucleotide Repeat Expansion
MH  - Proteomics
MH  - Muscle, Skeletal
MH  - Muscle Cells/metabolism
MH  - *Cardiomyopathies/genetics/metabolism
MH  - Patient Acuity
MH  - Myotonin-Protein Kinase/genetics
OTO - NOTNLM
OT  - CTG-trinucleotide expansion
OT  - Clinical proteomics
OT  - DM1 biomarker
OT  - DMPK
OT  - DMSXL
OT  - Steinert's disease
EDAT- 2023/03/10 06:00
MHDA- 2023/05/18 06:42
CRDT- 2023/03/09 11:15
PHST- 2022/10/03 00:00 [received]
PHST- 2023/02/19 00:00 [accepted]
PHST- 2023/02/15 00:00 [revised]
PHST- 2023/05/18 06:42 [medline]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/09 11:15 [entrez]
AID - 10.1007/s00415-023-11633-1 [pii]
AID - 10.1007/s00415-023-11633-1 [doi]
PST - ppublish
SO  - J Neurol. 2023 Jun;270(6):3138-3158. doi: 10.1007/s00415-023-11633-1. Epub 2023 
      Mar 9.

PMID- 36790141
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20231002
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 68
IP  - 2
DP  - 2023 Aug
TI  - Frequency and type of cancers in myotonic dystrophy: A retrospective 
      cross-sectional study.
PG  - 142-148
LID - 10.1002/mus.27801 [doi]
AB  - INTRODUCTION/AIMS: Myotonic dystrophies (DMs) are autosomal dominant diseases in 
      which expression of a mutant expanded repeat mRNA leads to abnormal splicing of 
      downstream effector genes thought to be responsible for their multisystem 
      involvement. Cancer risk and cancer-related deaths are increased in DM patients 
      relative to the general population. We aimed at determining the frequency and 
      type of cancers in both DM1 and DM2 vs a non-DM muscular dystrophy cohort. 
      METHODS: A retrospective, cross-sectional study was carried out on patients with 
      genetically confirmed DM1, DM2, facioscapulohumeral muscular dystrophy (FSHD), 
      and oculopharyngeal muscular dystrophy (OPMD) at our institutions from 2000 to 
      2020. RESULTS: One hundred eighty-five DM1, 67 DM2, 187 FSHD, and 109 OPMD 
      patients were included. Relative to non-DM, DM patients had an increased cancer 
      risk that was independent of age and sex. Specifically, an increased risk of 
      sex-related (ovarian) and non-sex-related (non-melanoma skin, urological, and 
      hematological) cancers was observed in DM1 and DM2, respectively. The length of 
      CTG repeat expansion was not associated with cancer occurrence in the DM1 group. 
      DISCUSSION: In addition to current consensus-based care recommendations, our 
      findings prompt consideration of screening for skin, urological, and 
      hematological cancers in DM2 patients, and screening of ovarian malignancies in 
      DM1 female patients.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - D'Ambrosio, Eleonora S
AU  - D'Ambrosio ES
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
AD  - Department of Neurology, Brigham Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Chuang, Kathy
AU  - Chuang K
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - David, William S
AU  - David WS
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Amato, Anthony A
AU  - Amato AA
AD  - Department of Neurology, Brigham Women's Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Gonzalez-Perez, Paloma
AU  - Gonzalez-Perez P
AUID- ORCID: 0000-0002-3980-8555
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
LA  - eng
SI  - ClinicalTrials.gov/NCT04886518
GR  - K23 NS118048/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230327
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
SB  - IM
CIN - Muscle Nerve. 2023 Aug;68(2):101-102. PMID: 37222138
MH  - Humans
MH  - Female
MH  - *Myotonic Dystrophy/complications/epidemiology/genetics
MH  - Cross-Sectional Studies
MH  - *Muscular Dystrophy, Facioscapulohumeral
MH  - Retrospective Studies
MH  - *Melanoma
OTO - NOTNLM
OT  - frequency
OT  - guidelines
OT  - muscular dystrophy
OT  - myotonic dystrophy
OT  - phenotype
EDAT- 2023/02/16 06:00
MHDA- 2023/07/21 06:43
CRDT- 2023/02/15 08:43
PHST- 2023/02/05 00:00 [revised]
PHST- 2022/05/29 00:00 [received]
PHST- 2023/02/07 00:00 [accepted]
PHST- 2023/07/21 06:43 [medline]
PHST- 2023/02/16 06:00 [pubmed]
PHST- 2023/02/15 08:43 [entrez]
AID - 10.1002/mus.27801 [doi]
PST - ppublish
SO  - Muscle Nerve. 2023 Aug;68(2):142-148. doi: 10.1002/mus.27801. Epub 2023 Mar 27.

PMID- 36739767
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230328
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 67
DP  - 2023 Mar
TI  - Generation of four myotonic dystrophy type 1 patient iPSC lines (CBRCULi002-A, 
      CBRCULi003-A, CBRCULi004-A, CBRCULi005-A) and a control (CBRCULi001-A) derived 
      from lymphoblastoids cell lines.
PG  - 103037
LID - S1873-5061(23)00023-5 [pii]
LID - 10.1016/j.scr.2023.103037 [doi]
AB  - Myotonic dystrophy Type 1 (DM1) is a severe inherited neuromuscular disease and 
      is the most prevalent form of muscular dystrophy in adults. DM1 involves not only 
      the striated muscles including skeletal, and cardiac but also other organs such 
      as the eye, brain and gonads. We have generated and characterized 4 adult 
      heterozygous DM1 iPSC lines carrying between 1300 and 1600 CTG repeat expansion 
      in the DM1 protein kinase gene, and a control from an apparently healthy 
      individual. They all show strong pluripotency markers, differentiation capacity, 
      the absence of residual viral vectors as well as normal karyotypes and colony 
      morphologies.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Jauvin, Dominic
AU  - Jauvin D
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada.
FAU - Pierre, Marion
AU  - Pierre M
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada.
FAU - Boutjdir, Mohamed
AU  - Boutjdir M
AD  - Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, 
      NY 11209, USA; Department of Medicine, Cell Biology and Pharmacology, State 
      University of New York Downstate Health, Science University, New York, NY 11203, 
      USA; Department of Medicine, NYU School of Medicine, New York, NY 10016, USA.
FAU - Puymirat, Jack
AU  - Puymirat J
AD  - LOEX, CHU de Quebec-Universite Laval Research Center, Quebec City, QC G1J 1Z4, 
      Canada; Department of Medicine, Faculty of Medicine, Universite Laval, Quebec 
      City, QC G1V 0A6, Canada.
FAU - Chahine, Mohamed
AU  - Chahine M
AD  - CERVO Research Centre, Institut Universitaire en Sante Mentale de Quebec, Quebec 
      City, QC G1J 2G3, Canada; Department of Medicine, Faculty of Medicine, Universite 
      Laval, Quebec City, QC G1V 0A6, Canada. Electronic address: 
      Mohamed.Chahine@phc.ulaval.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20230131
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Myotonic Dystrophy/metabolism
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Trinucleotide Repeat Expansion
MH  - Cell Line
MH  - Muscle, Skeletal/metabolism
MH  - Myotonin-Protein Kinase/genetics
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/02/06 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/05 18:12
PHST- 2023/01/16 00:00 [received]
PHST- 2023/01/27 00:00 [revised]
PHST- 2023/01/28 00:00 [accepted]
PHST- 2023/02/06 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/02/05 18:12 [entrez]
AID - S1873-5061(23)00023-5 [pii]
AID - 10.1016/j.scr.2023.103037 [doi]
PST - ppublish
SO  - Stem Cell Res. 2023 Mar;67:103037. doi: 10.1016/j.scr.2023.103037. Epub 2023 Jan 
      31.

PMID- 36701310
OWN - NLM
STAT- MEDLINE
DCOM- 20230130
LR  - 20230317
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 18
IP  - 1
DP  - 2023
TI  - The Genomic landscape of short tandem repeats across multiple ancestries.
PG  - e0279430
LID - 10.1371/journal.pone.0279430 [doi]
LID - e0279430
AB  - Short Tandem Repeats (STRs) have been found to play a role in a myriad of complex 
      traits and genetic diseases. We examined the variability in the lengths of over 
      850,000 STR loci in 996 children with suspected genetic disorders and 1,178 
      parents across six separate ancestral groups: Africans, Europeans, East Asians, 
      Admixed Americans, Non-admixed Americans, and Pacific Islanders. For each STR 
      locus we compared allele length between and within each ancestry group. In 
      relation to Europeans, admixed Americans had the most similar STR lengths with 
      only 623 positions either significantly expanded or contracted, while the 
      divergence was highest in Africans, with 4,933 chromosomal positions contracted 
      or expanded. We also examined probands to identify STR expansions at known 
      pathogenic loci. The genes TCF4, AR, and DMPK showed significant expansions with 
      lengths 250% greater than their various average allele lengths in 49, 162, and 11 
      individuals respectively. All 49 individuals containing an expansion in TCF4 and 
      six individuals containing an expansion in DMPK presented with allele lengths 
      longer than the known pathogenic length for these genes. Next, we identified 
      individuals with significant expansions in highly conserved loci across all 
      ancestries. Eighty loci in conserved regions met criteria for divergence. Two of 
      these individuals were found to have exonic STR expansions: one in ZBTB4 and the 
      other in SLC9A7, which is associated with X-linked mental retardation. Finally, 
      we used parent-child trios to detect and analyze de novo mutations. In total, we 
      observed 3,219 de novo expansions, where proband allele lengths are greater than 
      twice the longest parental allele length. This work helps lay the foundation for 
      understanding STR lengths genome-wide across ancestries and may help identify new 
      disease genes and novel mechanisms of pathogenicity in known disease genes.
CI  - Copyright: (c) 2023 Vijayaraghavan et al. This is an open access article 
      distributed under the terms of the Creative Commons Attribution License, which 
      permits unrestricted use, distribution, and reproduction in any medium, provided 
      the original author and source are credited.
FAU - Vijayaraghavan, Prashanth
AU  - Vijayaraghavan P
AUID- ORCID: 0000-0001-7661-236X
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Batalov, Sergey
AU  - Batalov S
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Ding, Yan
AU  - Ding Y
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Sanford, Erica
AU  - Sanford E
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
AD  - Cedars-Sinai Medical Center, Los Angeles, CA, United States of America.
FAU - Kingsmore, Stephen F
AU  - Kingsmore SF
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Dimmock, David
AU  - Dimmock D
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Hobbs, Charlotte
AU  - Hobbs C
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
FAU - Bainbridge, Matthew
AU  - Bainbridge M
AD  - Rady Children's Institute for Genomic Medicine, San Diego, CA, United States of 
      America.
LA  - eng
GR  - R01 HL145175/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230126
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - Humans
MH  - *Genomics
MH  - Exons
MH  - Alleles
MH  - *Microsatellite Repeats/genetics
MH  - High-Throughput Nucleotide Sequencing
PMC - PMC9879404
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/01/27 06:00
MHDA- 2023/01/31 06:00
PMCR- 2023/01/26
CRDT- 2023/01/26 13:42
PHST- 2022/08/10 00:00 [received]
PHST- 2022/12/07 00:00 [accepted]
PHST- 2023/01/26 13:42 [entrez]
PHST- 2023/01/27 06:00 [pubmed]
PHST- 2023/01/31 06:00 [medline]
PHST- 2023/01/26 00:00 [pmc-release]
AID - PONE-D-22-22440 [pii]
AID - 10.1371/journal.pone.0279430 [doi]
PST - epublish
SO  - PLoS One. 2023 Jan 26;18(1):e0279430. doi: 10.1371/journal.pone.0279430. 
      eCollection 2023.

PMID- 36648920
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230702
IS  - 2326-5205 (Electronic)
IS  - 2326-5191 (Linking)
VI  - 75
IP  - 7
DP  - 2023 Jul
TI  - Association of Juvenile Dermatomyositis Disease Activity With the Expansion of 
      Blood Memory B and T Cell Subsets Lacking Follicular Markers.
PG  - 1246-1261
LID - 10.1002/art.42446 [doi]
AB  - OBJECTIVE: This study was undertaken to identify blood markers of juvenile 
      dermatomyositis (DM) disease activity (DA), which are needed to improve disease 
      management. METHODS: The study comprised a total of 123 juvenile DM patients and 
      53 healthy controls. Results of laboratory tests (aldolase, creatinine kinase, 
      lactate dehydrogenase [LDH], aspartate aminotransferase) and clinical measures of 
      DA in patients with juvenile DM, including the Manual Muscle Testing in 8 muscles 
      (MMT-8), Childhood Myositis Assessment Scale (CMAS), and disease activity scores 
      (DAS) (total DAS for juvenile DM, the muscle DAS, and the skin DAS), were 
      recorded when available. Surface phenotype of peripheral blood mononuclear cells 
      was assessed using flow cytometry. Whole blood transcriptional profiles were 
      studied using either RNA-sequencing or microarrays. Differential gene expression 
      was determined using DESeq and compared by pathway and gene ontology analyses. 
      RESULTS: Conventional memory (CD27+IgD-) B cells expressing low CXCR5 levels 
      (CXCR5(low/-) CM B cells) were significantly increased in frequency and absolute 
      numbers in 2 independent cohorts of juvenile DM patients compared with healthy 
      controls. The frequency of CD4+ Th2 memory cells (CD45RA-CXCR5-CCR6-CXCR3-) was 
      also increased in juvenile DM, especially in patients who were within <1 year 
      from diagnosis. The frequency of CXCR5(low/-) CM B cells correlated with serum 
      aldolase levels and with a blood interferon-stimulated gene transcriptional 
      signature. Furthermore, both the frequency and absolute numbers of CXCR5(low/-) 
      CM B cells correlated with clinical and laboratory measures of muscle DA (MMT-8, 
      CMAS, aldolase, and LDH). CONCLUSION: These findings suggest that both CM B cells 
      lacking the CXCR5 follicular marker and CXCR5- Th2 cells represent potential 
      biomarkers of DA in juvenile DM and may contribute to its pathogenesis.
CI  - (c) 2023 American College of Rheumatology.
FAU - Gofshteyn, Jacqueline S
AU  - Gofshteyn JS
AUID- ORCID: 0000-0003-3354-6176
AD  - Department of Pediatrics, Weill Cornell Medical College, New York.
FAU - Mansfield, Leanne
AU  - Mansfield L
AD  - Department of Pediatrics, Weill Cornell Medical College, and Department of 
      Pediatrics, Hospital for Special Surgery, New York.
FAU - Spitznagle, Jacob
AU  - Spitznagle J
AD  - Department of Pediatrics, University of Washington School of Medicine, Seattle, 
      Washington.
FAU - Balasubramanian, Preetha
AU  - Balasubramanian P
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Cardenas, Jacob
AU  - Cardenas J
AD  - Baylor Scott & White Health, Dallas, Texas.
FAU - Miller, Thomas
AU  - Miller T
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Gu, Jinghua
AU  - Gu J
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Wang, Xuan
AU  - Wang X
AD  - Baylor Scott & White Health, Dallas, Texas.
FAU - Punaro, Marilynn
AU  - Punaro M
AD  - University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital 
      for Children, Dallas, Texas.
FAU - Fuller, Julie
AU  - Fuller J
AD  - University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital 
      for Children, Dallas, Texas.
FAU - Nassi, Lorien
AU  - Nassi L
AD  - University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital 
      for Children, Dallas, Texas.
FAU - Stewart, Katie
AU  - Stewart K
AD  - University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital 
      for Children, Dallas, Texas.
FAU - Ohouo, Marina
AU  - Ohouo M
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Stagnar, Cristy
AU  - Stagnar C
AD  - Clemson University College of Behavioral Social and Health Sciences, Clemson, 
      South Carolina.
FAU - Baisch, Jeanine
AU  - Baisch J
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Walters, Lynnette
AU  - Walters L
AD  - Texas Scottish Rite Hospital for Children, Dallas, Texas.
FAU - Wang, Yuanyuan
AU  - Wang Y
AD  - Baylor Scott & White Health, Dallas, Texas.
FAU - Yan, Helena
AU  - Yan H
AD  - Department of Pediatrics, Weill Cornell Medical College, New York.
FAU - Rinchai, Darawan
AU  - Rinchai D
AD  - The Rockefeller University, New York.
FAU - Chaussabel, Damien
AU  - Chaussabel D
AD  - Sidra Medical and Research Center, Doha, Ad Dawhah, Qatar.
FAU - Caielli, Simone
AU  - Caielli S
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
FAU - Hong, Seunghee
AU  - Hong S
AD  - Yonsei University Department of Biochemistry, College of Life Science and 
      Biotechnology, Seodaemun-gu, Seoul, South Korea.
FAU - Onel, Karen
AU  - Onel K
AD  - Department of Pediatrics, Hospital for Special Surgery, New York.
FAU - Wright, Tracey
AU  - Wright T
AD  - University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital 
      for Children, Dallas, Texas.
FAU - Pascual, Virginia
AU  - Pascual V
AD  - Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medical 
      College, New York.
LA  - eng
GR  - NS066274-10/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230518
PL  - United States
TA  - Arthritis Rheumatol
JT  - Arthritis & rheumatology (Hoboken, N.J.)
JID - 101623795
RN  - EC 4.1.2.- (Aldehyde-Lyases)
SB  - IM
MH  - Humans
MH  - *Dermatomyositis/metabolism
MH  - Leukocytes, Mononuclear
MH  - T-Lymphocytes, Helper-Inducer/metabolism
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - Aldehyde-Lyases/metabolism
EDAT- 2023/01/18 06:00
MHDA- 2023/06/29 06:43
CRDT- 2023/01/17 11:34
PHST- 2022/12/23 00:00 [revised]
PHST- 2021/03/09 00:00 [received]
PHST- 2023/01/12 00:00 [accepted]
PHST- 2023/06/29 06:43 [medline]
PHST- 2023/01/18 06:00 [pubmed]
PHST- 2023/01/17 11:34 [entrez]
AID - 10.1002/art.42446 [doi]
PST - ppublish
SO  - Arthritis Rheumatol. 2023 Jul;75(7):1246-1261. doi: 10.1002/art.42446. Epub 2023 
      May 18.

PMID- 36627397
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20230228
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Jan 10
TI  - Quantitative magnetic resonance imaging assessment of muscle composition in 
      myotonic dystrophy mice.
PG  - 503
LID - 10.1038/s41598-023-27661-w [doi]
LID - 503
AB  - Myotonic dystrophy type 1 (DM1) is a severe autosomal dominant neuromuscular 
      disease in which the musculoskeletal system contributes substantially to overall 
      mortality and morbidity. DM1 stems from a noncoding CTG trinucleotide repeat 
      expansion in the DMPK gene. The human skeletal actin long repeat (HSA(LR)) mouse 
      model reproduces several aspects of the disease, but the muscle-wasting phenotype 
      of this model has never been characterized in vivo. Herein, we used quantitative 
      MRI to measure the fat and muscle volumes in the leg compartment (LC) of mice. 
      These acquired data were processed to extract relevant parameters such as fat 
      fraction and fat infiltration (fat LC/LC) in HSA(LR) and control (FBV) muscles. 
      These results showed increased fat volume (fat LC) and fat infiltration within 
      the muscle tissue of the leg compartment (muscle LC), in agreement with 
      necropsies, in which fatty clumps were observed, and consistent with previous 
      findings in DM1 patients. Model mice did not reproduce the characteristic 
      impaired fat fraction, widespread fat replacement through the muscles, or reduced 
      muscle volume reported in patients. Taken together, the observed abnormal 
      replacement of skeletal muscle by fat in the HSA(LR) mice indicates that these 
      mice partially reproduced the muscle phenotype observed in humans.
CI  - (c) 2023. The Author(s).
FAU - Bargiela, Ariadna
AU  - Bargiela A
AD  - Neurology Department, La Fe Health Research Institute (IISLAFE), Neuromuscular 
      Research Unit, Valencia, Spain. ariadna_bargiela@iislafe.es.
FAU - Ten-Esteve, Amadeo
AU  - Ten-Esteve A
AD  - Biomedical Imaging Research Group (GIBI230) and "La Fe" Imaging Node of the 
      Distributed Biomedical Imaging Network (ReDIB), Singular Scientific and Technical 
      Infrastructures (ICTS), Valencia, Spain.
AD  - Medical Imaging Department, La Fe University and Polytechnic Hospital, Valencia, 
      Spain.
FAU - Marti-Bonmati, Luis
AU  - Marti-Bonmati L
AD  - Biomedical Imaging Research Group (GIBI230) and "La Fe" Imaging Node of the 
      Distributed Biomedical Imaging Network (ReDIB), Singular Scientific and Technical 
      Infrastructures (ICTS), Valencia, Spain.
AD  - Medical Imaging Department, La Fe University and Polytechnic Hospital, Valencia, 
      Spain.
FAU - Sevilla, Teresa
AU  - Sevilla T
AD  - Neurology Department, La Fe Health Research Institute (IISLAFE), Neuromuscular 
      Research Unit, Valencia, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), 
      Valencia, Spain.
AD  - Department of Medicine, Universitat de Valencia, Valencia, Spain.
FAU - Perez Alonso, Manuel
AU  - Perez Alonso M
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      University of Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Valencia, 
      Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      University of Valencia, Valencia, Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, Valencia, 
      Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230110
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Humans
MH  - Mice
MH  - Animals
MH  - *Myotonic Dystrophy/diagnostic imaging/genetics/pathology
MH  - Muscle, Skeletal/diagnostic imaging/pathology
MH  - Trinucleotide Repeat Expansion
MH  - Phenotype
MH  - Magnetic Resonance Imaging
PMC - PMC9831979
COIS- The authors declare no competing interests.
EDAT- 2023/01/11 06:00
MHDA- 2023/01/13 06:00
PMCR- 2023/01/10
CRDT- 2023/01/10 23:22
PHST- 2022/06/07 00:00 [received]
PHST- 2023/01/05 00:00 [accepted]
PHST- 2023/01/10 23:22 [entrez]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/01/13 06:00 [medline]
PHST- 2023/01/10 00:00 [pmc-release]
AID - 10.1038/s41598-023-27661-w [pii]
AID - 27661 [pii]
AID - 10.1038/s41598-023-27661-w [doi]
PST - epublish
SO  - Sci Rep. 2023 Jan 10;13(1):503. doi: 10.1038/s41598-023-27661-w.

PMID- 36399603
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20231212
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Print)
IS  - 0002-7863 (Linking)
VI  - 144
IP  - 48
DP  - 2022 Dec 7
TI  - Study of an RNA-Focused DNA-Encoded Library Informs Design of a Degrader of a 
      r(CUG) Repeat Expansion.
PG  - 21972-21979
LID - 10.1021/jacs.2c08883 [doi]
AB  - A solid-phase DNA-encoded library (DEL) was studied for binding the RNA repeat 
      expansion r(CUG)(exp), the causative agent of the most common form of adult-onset 
      muscular dystrophy, myotonic dystrophy type 1 (DM1). A variety of uncharged and 
      novel RNA binders were identified to selectively bind r(CUG)(exp) by using a 
      two-color flow cytometry screen. The cellular activity of one binder was 
      augmented by attaching it with a module that directly cleaves r(CUG)(exp). In DM1 
      patient-derived muscle cells, the compound specifically bound r(CUG)(exp) and 
      allele-specifically eliminated r(CUG)(exp), improving disease-associated defects. 
      The approaches herein can be used to identify and optimize ligands and bind RNA 
      that can be further augmented for functionality including degradation.
FAU - Gibaut, Quentin M R
AU  - Gibaut QMR
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Akahori, Yoshihiro
AU  - Akahori Y
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Bush, Jessica A
AU  - Bush JA
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Taghavi, Amirhossein
AU  - Taghavi A
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Tanaka, Toru
AU  - Tanaka T
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Aikawa, Haruo
AU  - Aikawa H
AUID- ORCID: 0000-0003-2536-900X
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Ryan, Lucas S
AU  - Ryan LS
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
FAU - Paegel, Brian M
AU  - Paegel BM
AUID- ORCID: 0000-0002-6531-6693
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
AD  - Department of Chemistry and Pharmaceutical Sciences, University of California, 
      Irvine, California 92617, United States.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - Department of Chemistry, UF Scripps Biomedical Research and The Scripps Research 
      Institute, Jupiter, Florida 33458, United States.
LA  - eng
GR  - R35 GM140890/GM/NIGMS NIH HHS/United States
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20221118
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
RN  - 9007-49-2 (DNA)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Humans
MH  - *DNA/chemistry/genetics
MH  - *RNA/chemistry/genetics
MH  - *RNA Stability
MH  - *Trinucleotide Repeat Expansion
MH  - *Myotonic Dystrophy/genetics/therapy
MH  - *Gene Library
MH  - Muscle Cells
PMC - PMC9878440
MID - NIHMS1861720
COIS- The authors declare the following competing financial interest(s): MDD is a 
      founder of Expansion Therapeutics.
EDAT- 2022/11/19 06:00
MHDA- 2022/12/15 06:00
PMCR- 2023/12/07
CRDT- 2022/11/18 14:12
PHST- 2022/11/19 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/11/18 14:12 [entrez]
PHST- 2023/12/07 00:00 [pmc-release]
AID - 10.1021/jacs.2c08883 [doi]
PST - ppublish
SO  - J Am Chem Soc. 2022 Dec 7;144(48):21972-21979. doi: 10.1021/jacs.2c08883. Epub 
      2022 Nov 18.

PMID- 36352383
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221116
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Nov 10
TI  - Clinical improvement of DM1 patients reflected by reversal of disease-induced 
      gene expression in blood.
PG  - 395
LID - 10.1186/s12916-022-02591-y [doi]
LID - 395
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is an incurable multisystem disease 
      caused by a CTG-repeat expansion in the DM1 protein kinase (DMPK) gene. The 
      OPTIMISTIC clinical trial demonstrated positive and heterogenous effects of 
      cognitive behavioral therapy (CBT) on the capacity for activity and social 
      participations in DM1 patients. Through a process of reverse engineering, this 
      study aims to identify druggable molecular biomarkers associated with the 
      clinical improvement in the OPTIMISTIC cohort. METHODS: Based on full blood 
      samples collected during OPTIMISTIC, we performed paired mRNA sequencing for 27 
      patients before and after the CBT intervention. Linear mixed effect models were 
      used to identify biomarkers associated with the disease-causing CTG expansion and 
      the mean clinical improvement across all clinical outcome measures. RESULTS: We 
      identified 608 genes for which their expression was significantly associated with 
      the CTG-repeat expansion, as well as 1176 genes significantly associated with the 
      average clinical response towards the intervention. Remarkably, all 97 genes 
      associated with both returned to more normal levels in patients who benefited the 
      most from CBT. This main finding has been replicated based on an external dataset 
      of mRNA data of DM1 patients and controls, singling these genes out as candidate 
      biomarkers for therapy response. Among these candidate genes were DNAJB12, HDAC5, 
      and TRIM8, each belonging to a protein family that is being studied in the 
      context of neurological disorders or muscular dystrophies. Across the different 
      gene sets, gene pathway enrichment analysis revealed disease-relevant impaired 
      signaling in, among others, insulin-, metabolism-, and immune-related pathways. 
      Furthermore, evidence for shared dysregulations with another neuromuscular 
      disease, Duchenne muscular dystrophy, was found, suggesting a partial overlap in 
      blood-based gene dysregulation. CONCLUSIONS: DM1-relevant disease signatures can 
      be identified on a molecular level in peripheral blood, opening new avenues for 
      drug discovery and therapy efficacy assessments.
CI  - (c) 2022. The Author(s).
FAU - van Cruchten, Remco T P
AU  - van Cruchten RTP
AD  - Center for Molecular and Biomolecular Informatics, Radboud Institute for 
      Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
FAU - van As, Daniel
AU  - van As D
AD  - Center for Molecular and Biomolecular Informatics, Radboud Institute for 
      Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The 
      Netherlands.
AD  - Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, 
      Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - Glennon, Jeffrey C
AU  - Glennon JC
AD  - Conway Institute of Biomolecular and Biomedical Research, School of Medicine, 
      University College Dublin, Dublin, Ireland.
FAU - van Engelen, Baziel G M
AU  - van Engelen BGM
AD  - Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, 
      Radboud University Medical Center, Nijmegen, The Netherlands.
FAU - 't Hoen, Peter A C
AU  - 't Hoen PAC
AUID- ORCID: 0000-0003-4450-3112
AD  - Center for Molecular and Biomolecular Informatics, Radboud Institute for 
      Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The 
      Netherlands. Peter-Bram.tHoen@radboudumc.nl.
CN  - OPTIMISTIC consortium
CN  - ReCognitION consortium
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221110
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
RN  - 0 (Carrier Proteins)
RN  - 0 (DNAJB12 protein, human)
RN  - 0 (HSP40 Heat-Shock Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (TRIM8 protein, human)
SB  - IM
MH  - Humans
MH  - Carrier Proteins/genetics/metabolism
MH  - Gene Expression
MH  - HSP40 Heat-Shock Proteins/genetics/metabolism
MH  - *Myotonic Dystrophy/genetics/metabolism/therapy
MH  - Nerve Tissue Proteins/genetics
MH  - RNA, Messenger/genetics
MH  - Trinucleotide Repeat Expansion
PMC - PMC9646470
OTO - NOTNLM
OT  - Biomarker
OT  - Lifestyle intervention
OT  - Myotonic dystrophy type 1
OT  - Peripheral blood
OT  - RNA-seq
OT  - Therapeutic Response
COIS- R. van Cruchten reports no disclosures relevant to the manuscript; D. van As 
      reports no disclosures relevant to the manuscript; J.C. Glennon reports no 
      disclosures relevant to the manuscript; B. G. M. van Engelen received fees (to 
      the institution) and non-financial support from Fulcrum Therapeutics, Facio 
      Therapies, and Arrowhead Pharmaceuticals during the conduct of the study. In 
      addition, he received grant support from the FP7 European Union grand OPTIMISTIC, 
      Marigold Foundation Canada, Prinses Beartrix Spierfonds, Spieren voor Spieren, 
      FSHD Stichting, and FSHD Society. He also has an unpaid function as the head of 
      the scientific advisory board for Euro-DyMA. P. A. C. 't Hoen reports no 
      disclosures relevant to the manuscript.
FIR - Okkersen, K
IR  - Okkersen K
FIR - Jimenez-Moreno, C
IR  - Jimenez-Moreno C
FIR - Wenninger, S
IR  - Wenninger S
FIR - Daidj, F
IR  - Daidj F
FIR - Cumming, S
IR  - Cumming S
FIR - Littleford, R
IR  - Littleford R
FIR - Monckton, D G
IR  - Monckton DG
FIR - Lochmuller, H
IR  - Lochmuller H
FIR - Catt, M
IR  - Catt M
FIR - Faber, C G
IR  - Faber CG
FIR - Hapca, A
IR  - Hapca A
FIR - Donnan, P T
IR  - Donnan PT
FIR - Gorman, G
IR  - Gorman G
FIR - Bassez, G
IR  - Bassez G
FIR - Schoser, B
IR  - Schoser B
FIR - Knoop, H
IR  - Knoop H
FIR - Treweek, S
IR  - Treweek S
FIR - Wansink, Derick G
IR  - Wansink DG
FIR - Impens, Francis
IR  - Impens F
FIR - Gabriels, Ralf
IR  - Gabriels R
FIR - Claeys, Tine
IR  - Claeys T
FIR - Ravel-Chapuis, Aymeric
IR  - Ravel-Chapuis A
FIR - Jasmin, Bernard J
IR  - Jasmin BJ
FIR - Mahon, Niamh
IR  - Mahon N
FIR - Nieuwenhuis, Sylvia
IR  - Nieuwenhuis S
FIR - Martens, Lennart
IR  - Martens L
FIR - Novak, Petr
IR  - Novak P
FIR - Furling, Denis
IR  - Furling D
FIR - Baak, Arie
IR  - Baak A
FIR - Gourdon, Genevieve
IR  - Gourdon G
FIR - MacKenzie, Alex
IR  - MacKenzie A
FIR - Martinat, Cecile
IR  - Martinat C
FIR - Neault, Nafisa
IR  - Neault N
FIR - Roos, Andreas
IR  - Roos A
FIR - Duchesne, Elise
IR  - Duchesne E
FIR - Salz, Renee
IR  - Salz R
FIR - Thompson, Rachel
IR  - Thompson R
FIR - Baghdoyan, Sandrine
IR  - Baghdoyan S
FIR - Varghese, Anu Mary
IR  - Varghese AM
FIR - Blom, Paul
IR  - Blom P
FIR - Spendiff, Sally
IR  - Spendiff S
FIR - Manta, Alexander
IR  - Manta A
EDAT- 2022/11/11 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/11/10
CRDT- 2022/11/10 00:05
PHST- 2022/04/14 00:00 [received]
PHST- 2022/09/30 00:00 [accepted]
PHST- 2022/11/10 00:05 [entrez]
PHST- 2022/11/11 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/11/10 00:00 [pmc-release]
AID - 10.1186/s12916-022-02591-y [pii]
AID - 2591 [pii]
AID - 10.1186/s12916-022-02591-y [doi]
PST - epublish
SO  - BMC Med. 2022 Nov 10;20(1):395. doi: 10.1186/s12916-022-02591-y.

PMID- 36338967
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221108
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - Identification of DAPK1 as an autophagy-related biomarker for myotonic dystrophy 
      type 1.
PG  - 1022640
LID - 10.3389/fgene.2022.1022640 [doi]
LID - 1022640
AB  - Myotonic dystrophy type I (DM1), a CTG repeat expansion hereditary disorder, is 
      primarily characterized by myotonia. Several studies have reported that abnormal 
      autophagy pathway has a close relationship with DM1. However, the underlying key 
      regulatory molecules dictating autophagy disturbance still remains elusive. 
      Previous studies mainly focused on finding targeted therapies for DM1, but the 
      clinical heterogeneity of the DM1 is rarely addressed. Herein, to identify 
      potential regulator genes related to autophagy and cross-correlation among 
      clinical symptoms, we performed weighted gene co-expression network analysis 
      (WGCNA) to construct the co-expression network and screened out 7 core 
      autophagy-related genes (DAPK1, KLHL4, ERBB3, SESN3, ATF4, MEG3, and COL1A1) by 
      overlapping within differentially expressed genes (DEG), cytoHubba, gene 
      significance (GS) and module membership (MM) score. Meanwhile, we here analyzed 
      autophagy-related molecular subtypes of DM1 in relation to the clinical 
      phenotype. Our results show that three genes (DAPK1, SESN3, and MEG3) contribute 
      to distinguish these two molecular subtypes of DM1. We then develop an analysis 
      of RNA-seq data from six human skin fibroblasts (3 DM1, 3 healthy donors). 
      Intriguingly, of the 7 hallmark genes obtained, DAPK1 is the only confirmed gene, 
      and finally identified in vitro by RT-PCR. Furthermore, we assessed the DAPK1 
      accuracy diagnosis of DM1 by plotting a receiver operating characteristic curve 
      (ROC) (AUC = 0.965). In this study, we first validated autophagy status of DM1 
      individuals exhibits a clearly heterogeneity. Our study identified and validated 
      DAPK1 serve as a novel autophagy-related biomarker that correlate with the 
      progression of DM1.
CI  - Copyright (c) 2022 Hu, Ge, Li, Zhang and Li.
FAU - Hu, Min
AU  - Hu M
AD  - Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji 
      University, Shanghai, China.
FAU - Ge, Meng-Ru
AU  - Ge MR
AD  - Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji 
      University, Shanghai, China.
FAU - Li, Hong-Xia
AU  - Li HX
AD  - Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji 
      University, Shanghai, China.
FAU - Zhang, Bei
AU  - Zhang B
AD  - Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji 
      University, Shanghai, China.
FAU - Li, Gang
AU  - Li G
AD  - Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji 
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20221020
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9634726
OTO - NOTNLM
OT  - DAPK1
OT  - autophagy-related gene
OT  - biomarker
OT  - myotonic dystrophy type 1
OT  - weighted gene co-expression network analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/08 06:00
MHDA- 2022/11/08 06:01
PMCR- 2022/10/20
CRDT- 2022/11/07 04:38
PHST- 2022/08/22 00:00 [received]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/11/07 04:38 [entrez]
PHST- 2022/11/08 06:00 [pubmed]
PHST- 2022/11/08 06:01 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - 1022640 [pii]
AID - 10.3389/fgene.2022.1022640 [doi]
PST - epublish
SO  - Front Genet. 2022 Oct 20;13:1022640. doi: 10.3389/fgene.2022.1022640. eCollection 
      2022.

PMID- 36230978
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221202
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 19
DP  - 2022 Sep 27
TI  - Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1).
LID - 10.3390/cells11193018 [doi]
LID - 3018
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease caused by a CTG 
      repeat expansion in the 3' untranslated region of the dystrophia myotonica 
      protein kinase gene. AKT dephosphorylation and autophagy are associated with DM1. 
      Autophagy has been widely studied in DM1, although the endocytic pathway has not. 
      AKT has a critical role in endocytosis, and its phosphorylation is mediated by 
      the activation of tyrosine kinase receptors, such as epidermal growth factor 
      receptor (EGFR). EGF-activated EGFR triggers the internalization and degradation 
      of ligand-receptor complexes that serve as a PI3K/AKT signaling platform. Here, 
      we used primary fibroblasts from healthy subjects and DM1 patients. DM1-derived 
      fibroblasts showed increased autophagy flux, with enlarged endosomes and 
      lysosomes. Thereafter, cells were stimulated with a high concentration of EGF to 
      promote EGFR internalization and degradation. Interestingly, EGF binding to EGFR 
      was reduced in DM1 cells and EGFR internalization was also slowed during the 
      early steps of endocytosis. However, EGF-activated EGFR enhanced AKT and ERK1/2 
      phosphorylation levels in the DM1-derived fibroblasts. Therefore, there was a 
      delay in EGF-stimulated EGFR endocytosis in DM1 cells; this alteration might be 
      due to the decrease in the binding of EGF to EGFR, and not to a decrease in AKT 
      phosphorylation.
FAU - Alegre-Cortes, Eva
AU  - Alegre-Cortes E
AUID- ORCID: 0000-0002-0733-229X
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
FAU - Gimenez-Bejarano, Alberto
AU  - Gimenez-Bejarano A
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
FAU - Uribe-Carretero, Elisabet
AU  - Uribe-Carretero E
AUID- ORCID: 0000-0001-6477-5268
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
FAU - Paredes-Barquero, Marta
AU  - Paredes-Barquero M
AUID- ORCID: 0000-0002-5698-8180
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
FAU - Marques, Andre R A
AU  - Marques ARA
AUID- ORCID: 0000-0001-9674-3017
AD  - iNOVA4Health, NOVA Medical School|Faculdade de Ciencias Medicas, NMS|FCM, 
      Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.
FAU - Lopes-da-Silva, Mafalda
AU  - Lopes-da-Silva M
AD  - iNOVA4Health, NOVA Medical School|Faculdade de Ciencias Medicas, NMS|FCM, 
      Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.
FAU - Vieira, Otilia V
AU  - Vieira OV
AUID- ORCID: 0000-0003-4924-1780
AD  - iNOVA4Health, NOVA Medical School|Faculdade de Ciencias Medicas, NMS|FCM, 
      Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.
FAU - Canales-Cortes, Saray
AU  - Canales-Cortes S
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
FAU - Camello, Pedro J
AU  - Camello PJ
AUID- ORCID: 0000-0001-5026-7166
AD  - Departamento de Fisiologia, Facultad de Veterinaria, Universidad de Extremadura, 
      10003 Caceres, Spain.
AD  - Instituto Universitario de Biomarcadores de Patologias Metabolicas, 10003 
      Caceres, Spain.
FAU - Martinez-Chacon, Guadalupe
AU  - Martinez-Chacon G
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
FAU - Aiastui, Ana
AU  - Aiastui A
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
AD  - Cell Culture Platform, Biodonostia Health Research Institute, 20014 San 
      Sebastian, Spain.
AD  - Neuroscience Area of Biodonostia Health Research Institute, Donostia University 
      Hospital, 20014 San Sebastian, Spain.
FAU - Fernandez-Torron, Roberto
AU  - Fernandez-Torron R
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
AD  - Neuroscience Area of Biodonostia Health Research Institute, Donostia University 
      Hospital, 20014 San Sebastian, Spain.
AD  - Department of Neurology, Donostia University Hospital, 20014 Osakidetza, Spain.
AD  - Ilundain Foundation, 20014 San Sebastian, Spain.
AD  - Department of Neurosciences, University of the Basque Country UPV-EHU, 48940 San 
      Sebastian, Spain.
FAU - Lopez de Munain, Adolfo
AU  - Lopez de Munain A
AUID- ORCID: 0000-0002-9509-4032
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
AD  - Neuroscience Area of Biodonostia Health Research Institute, Donostia University 
      Hospital, 20014 San Sebastian, Spain.
AD  - Department of Neurology, Donostia University Hospital, 20014 Osakidetza, Spain.
AD  - Ilundain Foundation, 20014 San Sebastian, Spain.
AD  - Department of Neurosciences, University of the Basque Country UPV-EHU, 48940 San 
      Sebastian, Spain.
FAU - Gomez-Suaga, Patricia
AU  - Gomez-Suaga P
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
FAU - Niso-Santano, Mireia
AU  - Niso-Santano M
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
FAU - Gonzalez-Polo, Rosa A
AU  - Gonzalez-Polo RA
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
FAU - Fuentes, Jose M
AU  - Fuentes JM
AUID- ORCID: 0000-0001-6910-2089
AD  - Departamento de Bioquimica y Biologia Molecular y Genetica, Facultad de 
      Enfermeria y Terapia Ocupacional, Universidad de Extremadura, Avda de la 
      universidad s/n, 10003 Caceres, Spain.
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
FAU - Yakhine-Diop, Sokhna M S
AU  - Yakhine-Diop SMS
AD  - Instituto de Investigacion Biosanitaria de Extremadura (INUBE), 06071 Caceres, 
      Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades (CIBERNED), 28031 
      Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220927
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Ligands)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - 3' Untranslated Regions
MH  - *Epidermal Growth Factor/genetics/pharmacology
MH  - ErbB Receptors/metabolism
MH  - Humans
MH  - Ligands
MH  - *Myotonic Dystrophy/genetics
MH  - Phosphatidylinositol 3-Kinases/genetics
MH  - Proto-Oncogene Proteins c-akt/metabolism
PMC - PMC9562898
OTO - NOTNLM
OT  - AKT
OT  - DMPK
OT  - LBPA
OT  - autophagy
OT  - endosomes
OT  - lysosomes
OT  - muscle atrophy
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
PMCR- 2022/09/27
CRDT- 2022/10/14 01:54
PHST- 2022/07/09 00:00 [received]
PHST- 2022/09/02 00:00 [revised]
PHST- 2022/09/22 00:00 [accepted]
PHST- 2022/10/14 01:54 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/09/27 00:00 [pmc-release]
AID - cells11193018 [pii]
AID - cells-11-03018 [pii]
AID - 10.3390/cells11193018 [doi]
PST - epublish
SO  - Cells. 2022 Sep 27;11(19):3018. doi: 10.3390/cells11193018.

PMID- 36222125
OWN - NLM
STAT- MEDLINE
DCOM- 20230424
LR  - 20230425
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 32
IP  - 9
DP  - 2023 Apr 20
TI  - Dynamics and variability of transcriptomic dysregulation in congenital myotonic 
      dystrophy during pediatric development.
PG  - 1413-1428
LID - 10.1093/hmg/ddac254 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multi-systemic disorder caused by expansion 
      of CTG microsatellite repeats within DMPK. The most severe form, congenital 
      myotonic dystrophy (CDM), has symptom onset at birth due to large 
      intergenerational repeat expansions. Despite a common mutation, CDM individuals 
      present with a distinct clinical phenotype and absence of common DM1 symptoms. 
      Given the clinical divergence, it is unknown if the hallmark of DM1 pathology, 
      dysregulation of alternative splicing (AS) due to sequestration of MBNL proteins 
      within toxic CUG repeat RNAs, contributes to disease throughout pediatric 
      development. To evaluate global transcriptomic dysregulation, RNA-seq was 
      performed on 36 CDM skeletal muscle biopsies ages 2 weeks to 16 years, including 
      two longitudinal samples. Fifty DM1 and adult/pediatric controls were also 
      sequenced as comparative groups. Despite a large CTG expansion and shared age of 
      onset, CDM individuals presented with a heterogenous, MBNL-dependent mis-splicing 
      signature. Estimation of intracellular MBNL concentrations from splicing 
      responses of select events correlated with total spliceopathy and revealed a 
      distinct, triphasic pattern of AS dysregulation across pediatric development. CDM 
      infants (< 2 years) possess severe mis-splicing that significantly improves in 
      early childhood (2-8 years) independent of sex or CTG repeat load. Adolescent 
      individuals (8-16 years) stratified into two populations with a full range of 
      global splicing dysregulation. DMPK expression changes correlated with 
      alterations in splicing severity during development. This study reveals the 
      complex dynamics of the CDM muscle transcriptome and provides insights into new 
      therapeutic strategies, timing of therapeutic intervention, and biomarker 
      development.
CI  - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Hale, Melissa A
AU  - Hale MA
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, 
      USA.
FAU - Bates, Kameron
AU  - Bates K
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, 
      USA.
FAU - Provenzano, Marina
AU  - Provenzano M
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, 
      USA.
FAU - Johnson, Nicholas E
AU  - Johnson NE
AUID- ORCID: 0000-0002-3917-4257
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, 
      USA.
LA  - eng
GR  - R01FD006071/FD/FDA HHS/United States
GR  - U01DD001242/CC/CDC HHS/United States
GR  - R21TR003184/NH/NIH HHS/United States
GR  - R01 NS104010/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Child, Preschool
MH  - Humans
MH  - *Myotonic Dystrophy/pathology
MH  - Transcriptome/genetics
MH  - Myotonin-Protein Kinase/genetics/metabolism
MH  - Muscle, Skeletal/metabolism
MH  - RNA Splicing/genetics
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC10117163
EDAT- 2022/10/13 06:00
MHDA- 2023/04/24 06:41
PMCR- 2022/10/11
CRDT- 2022/10/12 04:43
PHST- 2022/05/02 00:00 [received]
PHST- 2022/10/04 00:00 [revised]
PHST- 2022/10/09 00:00 [accepted]
PHST- 2023/04/24 06:41 [medline]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/12 04:43 [entrez]
PHST- 2022/10/11 00:00 [pmc-release]
AID - 6759135 [pii]
AID - ddac254 [pii]
AID - 10.1093/hmg/ddac254 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2023 Apr 20;32(9):1413-1428. doi: 10.1093/hmg/ddac254.

PMID- 36099320
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20221009
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 65
IP  - 18
DP  - 2022 Sep 22
TI  - Dynamic Covalent Template-Guided Screen for Nucleic Acid-Targeting Agents.
PG  - 12417-12426
LID - 10.1021/acs.jmedchem.2c01086 [doi]
AB  - Trinucleotide repeat diseases such as myotonic dystrophy type 1 (DM1) and 
      Huntington's disease (HD) are caused by expanded DNA repeats that can be used as 
      templates to synthesize their own inhibitors. Because it would be particularly 
      advantageous to reversibly assemble multivalent nucleic acid-targeting agents in 
      situ, we sought to develop a target-guided screen that uses dynamic covalent 
      chemistry to identify multitarget inhibitors. We report the synthesis of a 
      library of amine- or aldehyde-containing fragments. The assembly of these 
      fragments led to a diverse set of hit combinations that was confirmed by 
      matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) in the 
      presence of DM1 and HD repeat sequences. Of interest for both diseases, the 
      resulting hit combinations inhibited transcription selectively and in a 
      cooperative manner in vitro, with inhibitory concentration (IC(50)) values in the 
      micromolar range. This dynamic covalent library and screening approach could be 
      applied to identify compounds that reversibly assemble on other nucleic acid 
      targets.
FAU - Krueger, Sarah B
AU  - Krueger SB
AUID- ORCID: 0000-0003-4167-3730
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, 
      Illinois 61801, United States.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, 
      Illinois 61801, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220913
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Aldehydes)
RN  - 0 (Amines)
RN  - 0 (Nucleic Acids)
SB  - IM
MH  - *Aldehydes/chemical synthesis/pharmacology
MH  - *Amines/chemical synthesis/pharmacology
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Huntington Disease/genetics
MH  - Myotonic Dystrophy/genetics
MH  - *Nucleic Acids/antagonists & inhibitors/chemistry
MH  - Repetitive Sequences, Nucleic Acid
MH  - Transcription, Genetic/drug effects
EDAT- 2022/09/14 06:00
MHDA- 2022/09/24 06:00
CRDT- 2022/09/13 13:44
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/09/13 13:44 [entrez]
AID - 10.1021/acs.jmedchem.2c01086 [doi]
PST - ppublish
SO  - J Med Chem. 2022 Sep 22;65(18):12417-12426. doi: 10.1021/acs.jmedchem.2c01086. 
      Epub 2022 Sep 13.

PMID- 36099027
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230223
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 32
IP  - 4
DP  - 2023 Jan 27
TI  - Individual-specific levels of CTG*CAG somatic instability are shared across 
      multiple tissues in myotonic dystrophy type 1.
PG  - 621-631
LID - 10.1093/hmg/ddac231 [doi]
AB  - Myotonic dystrophy type 1 is a complex disease caused by a genetically unstable 
      CTG repeat expansion in the 3'-untranslated region of the DMPK gene. 
      Age-dependent, tissue-specific somatic instability has confounded 
      genotype-phenotype associations, but growing evidence suggests that it also 
      contributes directly toward disease progression. Using a well-characterized 
      clinical cohort of DM1 patients from Costa Rica, we quantified somatic 
      instability in blood, buccal cells, skin and skeletal muscle. Whilst skeletal 
      muscle showed the largest expansions, modal allele lengths in skin were also very 
      large and frequently exceeded 2000 CTG repeats. Similarly, the degree of somatic 
      expansion in blood, muscle and skin were associated with each other. Notably, we 
      found that the degree of somatic expansion in skin was highly predictive of that 
      in skeletal muscle. More importantly, we established that individuals whose 
      repeat expanded more rapidly than expected in one tissue (after correction for 
      progenitor allele length and age) also expanded more rapidly than expected in 
      other tissues. We also provide evidence suggesting that individuals in whom the 
      repeat expanded more rapidly than expected in skeletal muscle have an earlier age 
      at onset than expected (after correction for the progenitor allele length). 
      Pyrosequencing analyses of the genomic DNA flanking the CTG repeat revealed that 
      the degree of methylation in muscle was well predicted by the muscle modal allele 
      length and age, but that neither methylation of the flanking DNA nor levels of 
      DMPK sense and anti-sense transcripts could obviously explain individual- or 
      tissue-specific patterns of somatic instability.
CI  - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Morales, Fernando
AU  - Morales F
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Corrales, Eyleen
AU  - Corrales E
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Vasquez, Melissa
AU  - Vasquez M
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Zhang, Baili
AU  - Zhang B
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030-4009, USA.
FAU - Fernandez, Huberth
AU  - Fernandez H
AD  - Hospital Calderon Guardia/Escuela de Medicina, Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Alvarado, Fernando
AU  - Alvarado F
AD  - Hospital Calderon Guardia/Escuela de Medicina, Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Cortes, Sergio
AU  - Cortes S
AD  - Hospital Calderon Guardia/Escuela de Medicina, Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Santamaria-Ulloa, Carolina
AU  - Santamaria-Ulloa C
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Initiative-Mmdbdi, Marigold Myotonic Dystrophy Biomarkers Discovery
AU  - Initiative-Mmdbdi MMDBD
AD  - Marigold Myotonic Dystrophy Biomarkers Discovery Initiative (MMDBDI). See 
      Supplementary Material, Table S3 for the full list of investigators.
FAU - Krahe, Ralf
AU  - Krahe R
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030-4009, USA.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Humans
MH  - *Myotonic Dystrophy/genetics
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Mouth Mucosa
MH  - Alleles
MH  - DNA/genetics
MH  - Myotonin-Protein Kinase/genetics
EDAT- 2022/09/14 06:00
MHDA- 2023/02/07 06:00
CRDT- 2022/09/13 12:03
PHST- 2022/04/08 00:00 [received]
PHST- 2022/08/16 00:00 [revised]
PHST- 2022/09/09 00:00 [accepted]
PHST- 2022/09/14 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
PHST- 2022/09/13 12:03 [entrez]
AID - 6696698 [pii]
AID - 10.1093/hmg/ddac231 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2023 Jan 27;32(4):621-631. doi: 10.1093/hmg/ddac231.

PMID- 36084803
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20221222
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Linking)
VI  - 24
IP  - 11
DP  - 2022 Nov
TI  - Identification of a CCG-Enriched Expanded Allele in Patients with Myotonic 
      Dystrophy Type 1 Using Amplification-Free Long-Read Sequencing.
PG  - 1143-1154
LID - S1525-1578(22)00222-7 [pii]
LID - 10.1016/j.jmoldx.2022.08.003 [doi]
AB  - Myotonic dystrophy type 1 (DM1) exhibits highly heterogeneous clinical 
      manifestations caused by an unstable CTG repeat expansion reaching up to 4000 
      CTG. The clinical variability depends on CTG repeat number, CNG repeat 
      interruptions, and somatic mosaicism. Currently, none of these factors are 
      simultaneously and accurately determined due to the limitations of gold standard 
      methods used in clinical and research laboratories. An amplicon method for 
      targeting the DMPK locus using single-molecule real-time sequencing was recently 
      developed to accurately analyze expanded alleles. However, amplicon-based 
      sequencing still depends on PCR, and the inherent bias toward preferential 
      amplification of smaller repeats can be problematic in DM1. Thus, an 
      amplification-free long-read sequencing method was developed by using CRISPR/Cas9 
      technology in DM1. This method was used to sequence the DMPK locus in patients 
      with CTG repeat expansion ranging from 130 to >1000 CTG. We showed that 
      elimination of PCR amplification improves the accuracy of measurement of 
      inherited repeat number and somatic repeat variations, two key factors in DM1 
      severity and age at onset. For the first time, an expansion composed of >85% CCG 
      repeats was identified by using this innovative method in a DM1 family with an 
      atypical clinical profile. No-amplification targeted sequencing represents a 
      promising method that can overcome research and diagnosis shortcomings, with 
      translational implications for clinical and genetic counseling in DM1.
CI  - Copyright (c) 2022 Association for Molecular Pathology and American Society for 
      Investigative Pathology. Published by Elsevier Inc. All rights reserved.
FAU - Tsai, Yu-Chih
AU  - Tsai YC
AD  - Pacific Biosciences, Menlo Park, California.
FAU - de Pontual, Laure
AU  - de Pontual L
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Heiner, Cheryl
AU  - Heiner C
AD  - Pacific Biosciences, Menlo Park, California.
FAU - Stojkovic, Tanya
AU  - Stojkovic T
AD  - Centre de Reference des Maladies Neuromusculaires Nord-Est/Ile-de-France, 
      Institut de Myologie, GHU Pitie-Salpetriere, Assistance Publique-Hopitaux de 
      Paris, Paris, France.
FAU - Furling, Denis
AU  - Furling D
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Bassez, Guillaume
AU  - Bassez G
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France; Centre de Reference des Maladies Neuromusculaires 
      Nord-Est/Ile-de-France, Institut de Myologie, GHU Pitie-Salpetriere, Assistance 
      Publique-Hopitaux de Paris, Paris, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Tome, Stephanie
AU  - Tome S
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France. Electronic address: stephanie.tome@inserm.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220907
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Humans
MH  - *Myotonic Dystrophy/diagnosis/genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Alleles
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Genetic Counseling
EDAT- 2022/09/10 06:00
MHDA- 2022/11/08 06:00
CRDT- 2022/09/09 19:25
PHST- 2022/04/05 00:00 [received]
PHST- 2022/07/27 00:00 [revised]
PHST- 2022/08/11 00:00 [accepted]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2022/11/08 06:00 [medline]
PHST- 2022/09/09 19:25 [entrez]
AID - S1525-1578(22)00222-7 [pii]
AID - 10.1016/j.jmoldx.2022.08.003 [doi]
PST - ppublish
SO  - J Mol Diagn. 2022 Nov;24(11):1143-1154. doi: 10.1016/j.jmoldx.2022.08.003. Epub 
      2022 Sep 7.

PMID- 36011377
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20221207
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 13
IP  - 8
DP  - 2022 Aug 17
TI  - Intergenerational Influence of Gender and the DM1 Phenotype of the Transmitting 
      Parent in Korean Myotonic Dystrophy Type 1.
LID - 10.3390/genes13081465 [doi]
LID - 1465
AB  - Myotonic dystrophy type 1 (DM1) is the most common autosomal-dominant disorder 
      caused by the CTG repeat expansion of the DMPK, and it has been categorized into 
      three phenotypes: mild, classic, and congenital DM1. Here, we reviewed the 
      intergenerational influence of gender and phenotype of the transmitting parent on 
      the occurrence of Korean DM1. A total of 44 parent-child pairs matched for the 
      gender of the transmitting parent and the affected child and 29 parent-child 
      pairs matched for the gender and DM1 phenotype of the transmitting parent were 
      reviewed. The CTG repeat size of the DMPK in the affected child was found to be 
      significantly greater when transmitted by a female parent to a female child 
      (DM1-FF) (median, 1309 repeats; range, 400-2083) than when transmitted by a male 
      parent to a male child (650; 160-1030; p = 0.038 and 0.048 using the Tukey HSD 
      and the Bonferroni test) or by a male parent to a female child (480; 94-1140; p = 
      0.003). The difference in the CTG repeat size of the DMPK between the 
      transmitting parent and the affected child was also lower when transmitted from a 
      male parent with classic DM1 (-235; -280 to 0) compared to when it was 
      transmitted from a female parent with mild DM1 (866; 612-905; p = 0.015 and 
      0.019) or from a female parent with classic DM1 (DM1-FC) (605; 10-1393; p = 
      0.005). This study highlights that gender and the DM1 phenotype of the 
      transmitting parent had an impact on the CTG repeat size of the DMPK in the 
      affected child, with greater increases being inherited from the DM1-FF or DM1-FC 
      situations in Korean DM1.
FAU - Han, Ji Yoon
AU  - Han JY
AUID- ORCID: 0000-0002-4174-5266
AD  - Department of Pediatrics, College of Medicine, The Catholic University of Korea, 
      Seoul 06591, Korea.
FAU - Jang, Woori
AU  - Jang W
AUID- ORCID: 0000-0001-8376-0133
AD  - Department of Laboratory Medicine, Inha University School of Medicine, Incheon 
      22332, Korea.
FAU - Park, Joonhong
AU  - Park J
AUID- ORCID: 0000-0001-7354-4234
AD  - Department of Laboratory Medicine, Jeonbuk National University Medical School and 
      Hospital, Jeonju 54907, Korea.
AD  - Research Institute of Clinical Medicine of Jeonbuk National University, 
      Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju 
      54907, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220817
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
SB  - IM
MH  - Asian People
MH  - Female
MH  - Humans
MH  - Male
MH  - *Myotonic Dystrophy/genetics
MH  - Parents
MH  - Phenotype
MH  - Republic of Korea
PMC - PMC9408469
OTO - NOTNLM
OT  - CTG repeat
OT  - DM1 phenotype
OT  - DMPK gene
OT  - gender
OT  - intergenerational influence
OT  - myotonic dystrophy type 1
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/08/17
CRDT- 2022/08/26 01:16
PHST- 2022/07/25 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/08/15 00:00 [accepted]
PHST- 2022/08/26 01:16 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/08/17 00:00 [pmc-release]
AID - genes13081465 [pii]
AID - genes-13-01465 [pii]
AID - 10.3390/genes13081465 [doi]
PST - epublish
SO  - Genes (Basel). 2022 Aug 17;13(8):1465. doi: 10.3390/genes13081465.

PMID- 35977479
OWN - NLM
STAT- MEDLINE
DCOM- 20220819
LR  - 20240104
IS  - 2211-1247 (Electronic)
VI  - 40
IP  - 7
DP  - 2022 Aug 16
TI  - Negative autoregulation mitigates collateral RNase activity of repeat-targeting 
      CRISPR-Cas13d in mammalian cells.
PG  - 111226
LID - S2211-1247(22)01043-9 [pii]
LID - 10.1016/j.celrep.2022.111226 [doi]
AB  - CRISPR-Cas13 RNA endonucleases show promise for programmable RNA knockdown. 
      However, sequence-specific binding of Cas13 unleashes non-specific bystander RNA 
      cleavage, or collateral activity, raising concerns for experiments and 
      therapeutic applications. Although robust in cell-free and bacterial 
      environments, collateral activity in mammalian cells remains disputed. We 
      investigate Cas13d collateral activity in a therapeutic context for myotonic 
      dystrophy type 1, caused by a transcribed CTG repeat expansion. We find that, 
      when targeting CUG(n) RNA in mammalian cells, Cas13d depletes endogenous and 
      transgenic RNAs, interferes with critical cellular processes, and activates 
      stress response and apoptosis. Collateral effects also occur when targeting 
      abundant endogenous transcripts. To minimize collateral activity for 
      repeat-targeting approaches, we introduce GENO, an adeno-associated 
      virus-compatible strategy that leverages guide RNA processing to control Cas13d 
      expression. We argue that thorough assessment of collateral activity is necessary 
      when applying Cas13 in mammalian cells and that GENO illustrates advantages of 
      compact regulatory systems for Cas-based gene therapies.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Kelley, Chase P
AU  - Kelley CP
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL 32608, USA; Genetics 
      and Genomics Graduate Program, University of Florida, Gainesville, FL 32608, USA.
FAU - Haerle, Maja C
AU  - Haerle MC
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL 32608, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL 32608, USA; Myology 
      Institute, University of Florida, Gainesville, FL 32608, USA. Electronic address: 
      eric.t.wang@ufl.edu.
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - R01 AG058636/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
RN  - 0 (RNA, Guide, CRISPR-Cas Systems)
RN  - 63231-63-0 (RNA)
RN  - EC 3.1.- (Ribonucleases)
SB  - IM
MH  - Animals
MH  - CRISPR-Cas Systems/genetics
MH  - *Gene Editing
MH  - Homeostasis
MH  - Humans
MH  - Mammals/genetics
MH  - *Myotonic Dystrophy/genetics
MH  - RNA/genetics
MH  - RNA, Guide, CRISPR-Cas Systems/genetics
MH  - Ribonucleases/genetics
PMC - PMC9809062
MID - NIHMS1830646
OTO - NOTNLM
OT  - CP: Molecular biology
OT  - CRISPR
OT  - Cas13d
OT  - DM1
OT  - GENO
OT  - collateral activity
OT  - gRNA excision
OT  - gene therapy
OT  - myotonic dystrophy
OT  - negative autoregulation
OT  - repeat expansion disease
COIS- Declaration of interests E.T.W. has consulted for Expansion Therapeutics, Entrada 
      Therapeutics, Design Therapeutics, Triplet Therapeutics, and Faze Medicines. 
      E.T.W. is a co-founder of, shareholder in, and adviser to Kate Therapeutics. 
      Financial support for research has been provided to the lab of E.T.W. at the 
      University of Florida by Expansion Therapeutics, Entrada Therapeutics, and Kate 
      Therapeutics. E.T.W. and C.P.K. are inventors on a patent application filed by 
      the University of Florida related to this work.
EDAT- 2022/08/18 06:00
MHDA- 2022/08/20 06:00
PMCR- 2023/01/03
CRDT- 2022/08/17 18:23
PHST- 2021/12/20 00:00 [received]
PHST- 2022/04/29 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/08/17 18:23 [entrez]
PHST- 2022/08/18 06:00 [pubmed]
PHST- 2022/08/20 06:00 [medline]
PHST- 2023/01/03 00:00 [pmc-release]
AID - S2211-1247(22)01043-9 [pii]
AID - 10.1016/j.celrep.2022.111226 [doi]
PST - ppublish
SO  - Cell Rep. 2022 Aug 16;40(7):111226. doi: 10.1016/j.celrep.2022.111226.

PMID- 35790065
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20230918
IS  - 1439-7633 (Electronic)
IS  - 1439-4227 (Print)
IS  - 1439-4227 (Linking)
VI  - 23
IP  - 17
DP  - 2022 Sep 5
TI  - Selective and Reversible Ligand Assembly on the DNA and RNA Repeat Sequences in 
      Myotonic Dystrophy.
PG  - e202200260
LID - 10.1002/cbic.202200260 [doi]
AB  - Small molecule targeting of DNA and RNA sequences has come into focus as a 
      therapeutic strategy for diseases such as myotonic dystrophy type 1 (DM1), a 
      trinucleotide repeat disease characterized by RNA gain-of-function. Herein, we 
      report a novel template-selected, reversible assembly of therapeutic agents 
      in situ via aldehyde-amine condensation. Rationally designed small molecule 
      targeting agents functionalized with either an aldehyde or an amine were 
      synthesized and screened against the target nucleic acid sequence. The assembly 
      of fragments was confirmed by MALDI-MS in the presence of DM1-relevant nucleic 
      acid sequences. The resulting hit combinations of aldehyde and amine inhibited 
      the formation of r(CUG)(exp) in vitro in a cooperative manner at low micromolar 
      levels and rescued mis-splicing defects in DM1 model cells. This reversible 
      template-selected assembly is a promising approach to achieve cell permeable and 
      multivalent targeting via in situ synthesis and could be applied to other nucleic 
      acid targets.
CI  - (c) 2022 Wiley-VCH GmbH.
FAU - Krueger, Sarah B
AU  - Krueger SB
AUID- ORCID: 0000-0003-4167-3730
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Ave, Urbana, IL 61801, USA.
FAU - Lanzendorf, Amie N
AU  - Lanzendorf AN
AUID- ORCID: 0000-0001-9125-9840
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Ave, Urbana, IL 61801, USA.
FAU - Jeon, Hyoeun Heather
AU  - Jeon HH
AUID- ORCID: 0000-0003-3283-3819
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Ave, Urbana, IL 61801, USA.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Ave, Urbana, IL 61801, USA.
LA  - eng
GR  - R01 AR069645/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220719
PL  - Germany
TA  - Chembiochem
JT  - Chembiochem : a European journal of chemical biology
JID - 100937360
RN  - 0 (Aldehydes)
RN  - 0 (Amines)
RN  - 0 (Ligands)
RN  - 63231-63-0 (RNA)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Aldehydes
MH  - Amines
MH  - Base Sequence
MH  - DNA
MH  - Humans
MH  - Ligands
MH  - *Myotonic Dystrophy/drug therapy/genetics
MH  - RNA/genetics
MH  - Trinucleotide Repeat Expansion
PMC - PMC9733911
MID - NIHMS1837803
OTO - NOTNLM
OT  - drug design
OT  - myotonic dystrophy type 1
OT  - nucleic acids
OT  - small molecules
OT  - transcription inhibition
COIS- Conflict of Interest The authors declare no conflict of interest.
EDAT- 2022/07/06 06:00
MHDA- 2022/09/09 06:00
PMCR- 2023/09/05
CRDT- 2022/07/05 20:12
PHST- 2022/07/03 00:00 [revised]
PHST- 2022/05/04 00:00 [received]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2022/07/05 20:12 [entrez]
PHST- 2023/09/05 00:00 [pmc-release]
AID - 10.1002/cbic.202200260 [doi]
PST - ppublish
SO  - Chembiochem. 2022 Sep 5;23(17):e202200260. doi: 10.1002/cbic.202200260. Epub 2022 
      Jul 19.

PMID- 35770133
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2632-1297 (Electronic)
IS  - 2632-1297 (Linking)
VI  - 4
IP  - 3
DP  - 2022
TI  - Cell type-specific abnormalities of central nervous system in myotonic dystrophy 
      type 1.
PG  - fcac154
LID - 10.1093/braincomms/fcac154 [doi]
LID - fcac154
AB  - Myotonic dystrophy type 1 is a multisystem genetic disorder involving the muscle, 
      heart and CNS. It is caused by toxic RNA transcription from expanded CTG repeats 
      in the 3'-untranslated region of DMPK, leading to dysregulated splicing of 
      various genes and multisystemic symptoms. Although aberrant splicing of several 
      genes has been identified as the cause of some muscular symptoms, the 
      pathogenesis of CNS symptoms prevalent in patients with myotonic dystrophy type 1 
      remains unelucidated, possibly due to a limitation in studying a diverse mixture 
      of different cell types, including neuronal cells and glial cells. Previous 
      studies revealed neuronal loss in the cortex, myelin loss in the white matter and 
      the presence of axonal neuropathy in patients with myotonic dystrophy type 1. To 
      elucidate the CNS pathogenesis, we investigated cell type-specific abnormalities 
      in cortical neurons, white matter glial cells and spinal motor neurons via 
      laser-capture microdissection. We observed that the CTG repeat instability and 
      cytosine-phosphate-guanine (CpG) methylation status varied among the CNS cell 
      lineages; cortical neurons had more unstable and longer repeats with higher CpG 
      methylation than white matter glial cells, and spinal motor neurons had more 
      stable repeats with lower methylation status. We also identified splicing 
      abnormalities in each CNS cell lineage, such as DLGAP1 in white matter glial 
      cells and CAMKK2 in spinal motor neurons. Furthermore, we demonstrated that 
      aberrant splicing of CAMKK2 is associated with abnormal neurite morphology in 
      myotonic dystrophy type 1 motor neurons. Our laser-capture microdissection-based 
      study revealed cell type-dependent genetic, epigenetic and splicing abnormalities 
      in myotonic dystrophy type 1 CNS, indicating the significant potential of cell 
      type-specific analysis in elucidating the CNS pathogenesis.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      Guarantors of Brain.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Shimizu, Hiroshi
AU  - Shimizu H
AD  - Department of Pathology, Brain Research Institute, Niigata University, 1-757 
      Asahimachi, Chuo-ku, Niigata 951-8585, Japan.
FAU - Ogawa, Kotaro
AU  - Ogawa K
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Hasuike, Yuhei
AU  - Hasuike Y
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Nakajima, Takashi
AU  - Nakajima T
AD  - Department of Neurology, National Hospital Organization Niigata National 
      Hospital, 3-52 Akasakamachi, Kashiwazaki, Niigata 945-8585, Japan.
FAU - Sakurai, Hidetoshi
AU  - Sakurai H
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Shogoin 
      Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Araki, Toshiyuki
AU  - Araki T
AUID- ORCID: 0000-0003-3625-2042
AD  - Department of Peripheral Nervous System Research, National Institute of 
      Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 
      Ogawahigashimachi, Kodaira, Tokyo 187-8502, Japan.
FAU - Okada, Yukinori
AU  - Okada Y
AD  - Department of Statistical Genetics, Osaka University Graduate School of Medicine, 
      2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Kakita, Akiyoshi
AU  - Kakita A
AD  - Department of Pathology, Brain Research Institute, Niigata University, 1-757 
      Asahimachi, Chuo-ku, Niigata 951-8585, Japan.
FAU - Mochizuki, Hideki
AU  - Mochizuki H
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220610
PL  - England
TA  - Brain Commun
JT  - Brain communications
JID - 101755125
PMC - PMC9218787
OTO - NOTNLM
OT  - CAMKK2
OT  - CpG methylation
OT  - laser-capture microdissection
OT  - myotonic dystrophy
OT  - repeat expansion
EDAT- 2022/07/01 06:00
MHDA- 2022/07/01 06:01
PMCR- 2022/06/10
CRDT- 2022/06/30 02:51
PHST- 2021/12/19 00:00 [received]
PHST- 2022/03/13 00:00 [revised]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/06/30 02:51 [entrez]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/07/01 06:01 [medline]
PHST- 2022/06/10 00:00 [pmc-release]
AID - fcac154 [pii]
AID - 10.1093/braincomms/fcac154 [doi]
PST - epublish
SO  - Brain Commun. 2022 Jun 10;4(3):fcac154. doi: 10.1093/braincomms/fcac154. 
      eCollection 2022.

PMID- 35767654
OWN - NLM
STAT- MEDLINE
DCOM- 20220701
LR  - 20240214
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Print)
IS  - 1946-6234 (Linking)
VI  - 14
IP  - 651
DP  - 2022 Jun 29
TI  - MECP2-related pathways are dysregulated in a cortical organoid model of myotonic 
      dystrophy.
PG  - eabn2375
LID - 10.1126/scitranslmed.abn2375 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystem, autosomal-dominant inherited 
      disorder caused by CTG microsatellite repeat expansions (MREs) in the 3' 
      untranslated region of the dystrophia myotonica-protein kinase (DMPK) gene. 
      Despite its prominence as the most common adult-onset muscular dystrophy, 
      patients with congenital to juvenile-onset forms of DM1 can present with 
      debilitating neurocognitive symptoms along the autism spectrum, characteristic of 
      possible in utero cortical defects. However, the molecular mechanism by which CTG 
      MREs lead to these developmental central nervous system (CNS) manifestations is 
      unknown. Here, we showed that CUG foci found early in the maturation of 
      three-dimensional (3D) cortical organoids from DM1 patient-derived induced 
      pluripotent stem cells (iPSCs) cause hyperphosphorylation of CUGBP Elav-like 
      family member 2 (CELF2) protein. Integrative single-cell RNA sequencing and 
      enhanced cross-linking and immunoprecipitation (eCLIP) analysis revealed that 
      reduced CELF2 protein-RNA substrate interactions results in misregulation of 
      genes critical for excitatory synaptic signaling in glutamatergic neurons, 
      including key components of the methyl-CpG binding protein 2 (MECP2) pathway. 
      Comparisons to MECP2((y/-)) cortical organoids revealed convergent molecular and 
      cellular defects such as glutamate toxicity and neuronal loss. Our findings 
      provide evidence suggesting that early-onset DM1 might involve neurodevelopmental 
      disorder-associated pathways and identify N-methyl-d-aspartic acid (NMDA) 
      antagonists as potential treatment avenues for neuronal defects in DM1.
FAU - Morelli, Kathryn H
AU  - Morelli KH
AUID- ORCID: 0000-0002-3123-5369
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Jin, Wenhao
AU  - Jin W
AUID- ORCID: 0000-0002-7885-3527
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Shathe, Shashank
AU  - Shathe S
AUID- ORCID: 0000-0003-3013-4459
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Madrigal, Assael A
AU  - Madrigal AA
AUID- ORCID: 0000-0002-3311-5256
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Jones, Krysten L
AU  - Jones KL
AUID- ORCID: 0000-0001-9194-6245
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Schwartz, Joshua L
AU  - Schwartz JL
AUID- ORCID: 0000-0002-4263-2829
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Bridges, Tristan
AU  - Bridges T
AUID- ORCID: 0000-0002-4252-7965
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Mueller, Jasmine R
AU  - Mueller JR
AUID- ORCID: 0000-0001-6236-8001
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Shankar, Archana
AU  - Shankar A
AUID- ORCID: 0000-0003-3499-4309
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Chaim, Isaac A
AU  - Chaim IA
AUID- ORCID: 0000-0003-1787-046X
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
FAU - Day, John W
AU  - Day JW
AUID- ORCID: 0000-0002-0086-9529
AD  - Stanford University School of Medicine, Palo Alto, CA 94375, USA.
FAU - Yeo, Gene W
AU  - Yeo GW
AUID- ORCID: 0000-0002-0799-6037
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA 92093, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA 92093, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 
      92039, USA.
LA  - eng
GR  - R01 AI123202/AI/NIAID NIH HHS/United States
GR  - K12 GM068524/GM/NIGMS NIH HHS/United States
GR  - U41 HG009889/HG/NHGRI NIH HHS/United States
GR  - U24 HG009889/HG/NHGRI NIH HHS/United States
GR  - R01 HG004659/HG/NHGRI NIH HHS/United States
GR  - U19 MH107367/MH/NIMH NIH HHS/United States
GR  - R01 NS103172/NS/NINDS NIH HHS/United States
GR  - P01 AI132122/AI/NIAID NIH HHS/United States
GR  - R01 EY029166/EY/NEI NIH HHS/United States
GR  - S10 OD025052/OD/NIH HHS/United States
GR  - F32 NS112654/NS/NINDS NIH HHS/United States
GR  - S10 OD026929/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220629
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
RN  - 0 (CELF Proteins)
RN  - 0 (CELF2 protein, human)
RN  - 0 (MECP2 protein, human)
RN  - 0 (Methyl-CpG-Binding Protein 2)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adult
MH  - CELF Proteins/genetics/metabolism
MH  - Humans
MH  - *Methyl-CpG-Binding Protein 2/genetics/metabolism
MH  - *Myotonic Dystrophy/genetics/metabolism
MH  - Nerve Tissue Proteins/genetics/metabolism
MH  - Organoids/metabolism
MH  - RNA Splicing
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Trinucleotide Repeat Expansion
PMC - PMC9645119
MID - NIHMS1837659
COIS- Competing interests: A.S. is currently affiliated with the Department of 
      Neurology and Neurological Sciences at Stanford University School of Medicine in 
      Stanford, CA, USA, and the Wu Tsai Neuroscience Institute at Stanford University, 
      Stanford, CA, USA. G.W.Y. is a cofounder, member of the board of directors, 
      equity holder, and paid consultant for Locanabio and BioInnovations, and a 
      Scientific Adviser and paid consultant to Jumpcode Genomics. G.W.Y. is a 
      distinguished visiting professor at the National University of Singapore. The 
      terms of these arrangements have been reviewed and approved by the USCD in 
      accordance with its conflict-of-interest policies. The authors declare that they 
      have no other competing interests.
EDAT- 2022/06/30 06:00
MHDA- 2022/07/02 06:00
PMCR- 2022/11/09
CRDT- 2022/06/29 14:02
PHST- 2022/06/29 14:02 [entrez]
PHST- 2022/06/30 06:00 [pubmed]
PHST- 2022/07/02 06:00 [medline]
PHST- 2022/11/09 00:00 [pmc-release]
AID - 10.1126/scitranslmed.abn2375 [doi]
PST - ppublish
SO  - Sci Transl Med. 2022 Jun 29;14(651):eabn2375. doi: 10.1126/scitranslmed.abn2375. 
      Epub 2022 Jun 29.

PMID- 35741732
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20220926
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 13
IP  - 6
DP  - 2022 May 28
TI  - High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in 
      Myotonic Dystrophy Type 1.
LID - 10.3390/genes13060970 [doi]
LID - 970
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder caused 
      by the expansion of a CTG repeat in the 3'-UTR of DMPK, which is transcribed to a 
      toxic gain-of-function RNA that affects splicing of a range of genes. The 
      expanded repeat is unstable in both germline and somatic cells. The variable age 
      at disease onset and severity of symptoms have been linked to the inherited CTG 
      repeat length, non-CTG interruptions, and methylation levels flanking the repeat. 
      In general, the genetic biomarkers are investigated separately with specific 
      methods, making it tedious to obtain an overall characterisation of the repeat 
      for a given individual. In the present study, we employed Oxford nanopore 
      sequencing in a pilot study to simultaneously determine the repeat lengths, 
      investigate the presence and nature of repeat interruptions, and quantify 
      methylation levels in the regions flanking the CTG-repeats in four patients with 
      DM1. We determined the repeat lengths, and in three patients, we observed 
      interruptions which were not detected using repeat-primed PCR. Interruptions may 
      thus be more common than previously anticipated and should be investigated in 
      larger cohorts. Allele-specific analyses enabled characterisation of aberrant 
      methylation levels specific to the expanded allele, which greatly increased the 
      sensitivity and resolved cases where the methylation levels were ambiguous.
FAU - Rasmussen, Astrid
AU  - Rasmussen A
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
FAU - Hildonen, Mathis
AU  - Hildonen M
AUID- ORCID: 0000-0002-2016-3670
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
FAU - Vissing, John
AU  - Vissing J
AD  - Copenhagen Neuromuscular Center, Department of Neurology, Copenhagen University 
      Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences, 
      University of Copenhagen, 2200 Copenhagen, Denmark.
FAU - Duno, Morten
AU  - Duno M
AD  - Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 
      2100 Copenhagen, Denmark.
FAU - Tumer, Zeynep
AU  - Tumer Z
AUID- ORCID: 0000-0002-4777-5802
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences, 
      University of Copenhagen, 2200 Copenhagen, Denmark.
FAU - Birkedal, Ulf
AU  - Birkedal U
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220528
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - DNA Methylation
MH  - Humans
MH  - *Myotonic Dystrophy/diagnosis/genetics
MH  - *Myotonin-Protein Kinase/genetics
MH  - Pilot Projects
MH  - RNA Splicing
MH  - Trinucleotide Repeat Expansion
PMC - PMC9222588
OTO - NOTNLM
OT  - Cas9
OT  - DM1
OT  - Oxford nanopore
OT  - diagnostics
OT  - epigenetics
OT  - long-read sequencing
OT  - methylation
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/05/28
CRDT- 2022/06/24 01:13
PHST- 2022/03/23 00:00 [received]
PHST- 2022/05/19 00:00 [revised]
PHST- 2022/05/26 00:00 [accepted]
PHST- 2022/06/24 01:13 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/05/28 00:00 [pmc-release]
AID - genes13060970 [pii]
AID - genes-13-00970 [pii]
AID - 10.3390/genes13060970 [doi]
PST - epublish
SO  - Genes (Basel). 2022 May 28;13(6):970. doi: 10.3390/genes13060970.

PMID- 35628087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2227-9032 (Print)
IS  - 2227-9032 (Electronic)
IS  - 2227-9032 (Linking)
VI  - 10
IP  - 5
DP  - 2022 May 20
TI  - Diaphragmatic Mobility and Chest Expansion in Patients with Scapulocostal 
      Syndrome: A Cross-Sectional Study.
LID - 10.3390/healthcare10050950 [doi]
LID - 950
AB  - Scapulocostal syndrome (SCS) is a subset of myofascial pain syndrome affecting 
      the posterior shoulder and upper back area. Some of the affected muscles are 
      attached to the rib cage, which may affect diaphragmatic mobility and chest 
      expansion. The purpose of this study was to investigate the characteristics of 
      diaphragmatic mobility and chest expansion in patients with SCS. Twenty-nine 
      patients with SCS and twenty-nine healthy participants of a similar age, gender, 
      weight, and height were included in the study. All participants were evaluated 
      for diaphragmatic mobility (DM) by real-time ultrasound (RTUS) and for chest 
      expansion (CE) using a cloth tape measure. An independent t-test was used to 
      compare the outcome variables between groups. The DM value in the SCS group was 
      46.24 +/- 7.26 mm, whereas in the healthy group it was 54.18 +/- 9.74 mm. The DM 
      value was lower in the SCS group compared to in healthy participants (p < 0.05). 
      Chest expansion at the axilla, the fourth intercostal space (4th ICS), and the 
      xiphoid level in the SCS group was 7.26 +/- 1.13, 6.83 +/- 0.94, and 6.86 +/- 1.25, 
      respectively, while chest expansion at the axilla, 4th ICS, and xiphoid level in 
      the healthy group was 7.92 +/- 1.39, 7.54 +/- 1.43, and 8.13 +/- 1.32, respectively. 
      Chest expansion at the 4th ICS and the xiphoid level in the SCS group was 
      significantly lower than in the healthy group (p < 0.05). Patients with SCS 
      presented a decrease in diaphragmatic mobility and chest expansion. Therefore, 
      SCS treatment programs ought to add breathing exercises to improve lung 
      expansion.
FAU - Srijessadarak, Thanaporn
AU  - Srijessadarak T
AD  - Faculty of Associated Medical Sciences, School of Physical Therapy, Khon Kaen 
      University, Khon Kaen 40002, Thailand.
AD  - Faculty of Medicine, Research Institute for Human High Performance and Health 
      Promotion, Khon Kaen University, Khon Kaen 40002, Thailand.
FAU - Arayawichanon, Preeda
AU  - Arayawichanon P
AD  - Department of Rehabilitation Medicine, Faculty of Medicine, Khon Kaen University, 
      Khon Kaen 40002, Thailand.
FAU - Kanpittaya, Jaturat
AU  - Kanpittaya J
AD  - Department of Radiology, Faculty of Medicine, Srinagarind Hospital, Khon Kaen 
      University, Khon Kaen 40002, Thailand.
FAU - Boonprakob, Yodchai
AU  - Boonprakob Y
AUID- ORCID: 0000-0002-2567-869X
AD  - Faculty of Medicine, Research Institute for Human High Performance and Health 
      Promotion, Khon Kaen University, Khon Kaen 40002, Thailand.
AD  - Department of Physical Therapy, Faculty of Associated Medical Science, Khon Kaen 
      University, Khon Kaen 40002, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20220520
PL  - Switzerland
TA  - Healthcare (Basel)
JT  - Healthcare (Basel, Switzerland)
JID - 101666525
PMC - PMC9141335
OTO - NOTNLM
OT  - chest expansion
OT  - diaphragmatic mobility
OT  - myofascial pain syndrome
OT  - respiratory characteristics
OT  - scapulocostal syndrome
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/05/29 06:01
PMCR- 2022/05/20
CRDT- 2022/05/28 01:20
PHST- 2022/04/04 00:00 [received]
PHST- 2022/05/11 00:00 [revised]
PHST- 2022/05/17 00:00 [accepted]
PHST- 2022/05/28 01:20 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/05/29 06:01 [medline]
PHST- 2022/05/20 00:00 [pmc-release]
AID - healthcare10050950 [pii]
AID - healthcare-10-00950 [pii]
AID - 10.3390/healthcare10050950 [doi]
PST - epublish
SO  - Healthcare (Basel). 2022 May 20;10(5):950. doi: 10.3390/healthcare10050950.

PMID- 35575095
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220729
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 132
IP  - 10
DP  - 2022 May 16
TI  - Benefits of aerobic exercise in myotonic dystrophy type 1.
LID - 10.1172/JCI160229 [doi]
LID - e160229
AB  - Myotonic dystrophy type 1 (DM1) is a multisystem trinucleotide repeat expansion 
      disorder characterized by the misregulated alternative splicing of critical 
      mRNAs. Previous work in a transgenic mouse model indicated that aerobic exercise 
      effectively improves splicing regulation and function in skeletal muscle. In this 
      issue of the JCI, Mikhail et al. describe the safety and benefits of applying 
      this approach in individuals affected by DM1. A 12-week aerobic exercise program 
      improved aerobic capacity and mobility, but not by the mechanism observed in 
      transgenic mice. Here, we consider the possible reasons for this disparity and 
      review other salient findings of the study in the context of evolving DM1 
      research.
FAU - Mackenzie, Samuel J
AU  - Mackenzie SJ
FAU - Hamel, Johanna
AU  - Hamel J
FAU - Thornton, Charles A
AU  - Thornton CA
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - R37 NS094393/NS/NINDS NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - IM
CON - J Clin Invest. 2022 May 16;132(10):. PMID: 35316212
MH  - Alternative Splicing
MH  - Animals
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/metabolism
MH  - *Myotonic Dystrophy/genetics/metabolism/therapy
MH  - RNA Splicing
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC9106338
COIS- Conflict of interest: CAT serves as a board member of the Myotonic Dystrophy 
      Foundation, receives compensation for serving on the scientific advisory boards 
      of Dyne Therapeutics and Pepgen, receives research funding from Ionis 
      Pharmaceuticals and Dyne Therapeutics, and receives licensing royalties through 
      the University of Rochester. CAT is coinventor on the following patents: 
      "Compositions and methods related to protein displacement therapy for myotonic 
      dystrophy" (US9371527B2); "Methods and compositions for treatment of myotonia" 
      (US7964570B2); "Modulation of dystrophia myotonica-protein kinase (DMPK) 
      expression" (US9765338B2).
EDAT- 2022/05/17 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/05/16
CRDT- 2022/05/16 06:49
PHST- 2022/05/16 06:49 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/05/16 00:00 [pmc-release]
AID - 160229 [pii]
AID - 10.1172/JCI160229 [doi]
PST - ppublish
SO  - J Clin Invest. 2022 May 16;132(10):e160229. doi: 10.1172/JCI160229.

PMID- 35567413
OWN - NLM
STAT- MEDLINE
DCOM- 20220919
LR  - 20221013
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 31
IP  - 18
DP  - 2022 Sep 10
TI  - Mice lacking MBNL1 and MBNL2 exhibit sudden cardiac death and molecular 
      signatures recapitulating myotonic dystrophy.
PG  - 3144-3160
LID - 10.1093/hmg/ddac108 [doi]
AB  - Myotonic dystrophy (DM) is caused by expansions of C(C)TG repeats in the 
      non-coding regions of the DMPK and CNBP genes, and DM patients often suffer from 
      sudden cardiac death due to lethal conduction block or arrhythmia. Specific 
      molecular changes that underlie DM cardiac pathology have been linked to 
      repeat-associated depletion of Muscleblind-like (MBNL) 1 and 2 proteins and 
      upregulation of CUGBP, Elav-like family member 1 (CELF1). Hypothesis solely 
      targeting MBNL1 or CELF1 pathways that could address all the consequences of 
      repeat expansion in heart remained inconclusive, particularly when the direct 
      cause of mortality and results of transcriptome analyses remained undetermined in 
      Mbnl compound knockout (KO) mice with cardiac phenotypes. Here, we develop 
      Myh6-Cre double KO (DKO) (Mbnl1-/-; Mbnl2cond/cond; Myh6-Cre+/-) mice to 
      eliminate Mbnl1/2 in cardiomyocytes and observe spontaneous lethal cardiac events 
      under no anesthesia. RNA sequencing recapitulates DM heart spliceopathy and shows 
      gene expression changes that were previously undescribed in DM heart studies. 
      Notably, immunoblotting reveals a nearly 6-fold increase of Calsequestrin 1 and 
      50% reduction of epidermal growth factor proteins. Our findings demonstrate that 
      complete ablation of MBNL1/2 in cardiomyocytes is essential for generating sudden 
      death due to lethal cardiac rhythms and reveal potential mechanisms for DM heart 
      pathogenesis.
CI  - (c) The Author(s) 2022. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Lee, Kuang-Yung
AU  - Lee KY
AUID- ORCID: 0000-0002-2089-4801
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
FAU - Seah, Carol
AU  - Seah C
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
FAU - Li, Ching
AU  - Li C
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
FAU - Chen, Yu-Fu
AU  - Chen YF
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
FAU - Chen, Chwen-Yu
AU  - Chen CY
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
FAU - Wu, Ching-I
AU  - Wu CI
AD  - Department of Neurology, Chang Gung Memorial Hospital, Keelung Branch, Keelung, 
      Taiwan.
FAU - Liao, Po-Cheng
AU  - Liao PC
AD  - Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung Branch, 
      Keelung, Taiwan.
FAU - Shyu, Yu-Chiau
AU  - Shyu YC
AUID- ORCID: 0000-0003-1747-2226
AD  - Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung Branch, 
      Keelung, Taiwan.
AD  - Department of Nursing, Chang Gung University of Science and Technology, Taoyuan 
      City, Taiwan.
FAU - Olafson, Hailey R
AU  - Olafson HR
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics, 
      College of Medicine, University of Florida, Gainesville, FL 32610, USA.
FAU - McKee, Kendra K
AU  - McKee KK
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics, 
      College of Medicine, University of Florida, Gainesville, FL 32610, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics, 
      College of Medicine, University of Florida, Gainesville, FL 32610, USA.
FAU - Yeh, Chi-Hsiao
AU  - Yeh CH
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, 
      Linko Branch, Taoyuan, Taiwan.
FAU - Wang, Chao-Hung
AU  - Wang CH
AD  - Chang Gung University, College of Medicine, Taoyuan, Taiwan.
AD  - Division of Cardiology, Department of Internal Medicine, Heart Failure Research 
      Center, Chang Gung Memorial Hospital, Keelung Branch, Keelung, Taiwan.
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Calsequestrin)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (EGF Family of Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alternative Splicing/genetics
MH  - Animals
MH  - Calsequestrin/genetics
MH  - DNA-Binding Proteins/genetics
MH  - Death, Sudden, Cardiac/etiology/pathology
MH  - EGF Family of Proteins/genetics/metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Muscle, Skeletal/metabolism
MH  - Myocytes, Cardiac/metabolism
MH  - *Myotonic Dystrophy/pathology
MH  - RNA-Binding Proteins/genetics/metabolism
PMC - PMC9476621
EDAT- 2022/05/15 06:00
MHDA- 2022/09/20 06:00
PMCR- 2022/05/14
CRDT- 2022/05/14 06:03
PHST- 2022/01/02 00:00 [received]
PHST- 2022/04/22 00:00 [revised]
PHST- 2022/05/04 00:00 [accepted]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/09/20 06:00 [medline]
PHST- 2022/05/14 06:03 [entrez]
PHST- 2022/05/14 00:00 [pmc-release]
AID - 6585751 [pii]
AID - ddac108 [pii]
AID - 10.1093/hmg/ddac108 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2022 Sep 10;31(18):3144-3160. doi: 10.1093/hmg/ddac108.

PMID- 35483041
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220721
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Linking)
VI  - 17
IP  - 5
DP  - 2022 May 20
TI  - A Selective Alkylating Agent for CTG Repeats in Myotonic Dystrophy Type 1.
PG  - 1103-1110
LID - 10.1021/acschembio.1c00949 [doi]
AB  - Disease intervention at the DNA level generally has been avoided because of 
      off-target effects. Recent advances in genome editing technologies using 
      CRISPR-Cas9 have opened a new era in DNA-targeted therapeutic approaches. 
      However, delivery of such systems remains a major challenge. Here, we report a 
      selective DNA-modifying small molecule that targets a disease-specific structure 
      and mismatches involved in myotonic dystrophy type 1 (DM1). This ligand alkylates 
      T-T mismatch-containing hairpins formed in the expanded CTG repeats (d(CTG)(exp)) 
      in DM1. Ligand alkylation of d(CTG)(exp) inhibits the transcription of 
      d(CAG.CTG)(exp), thereby reducing the level of the toxic r(CUG)(exp) transcript. 
      The bioactivity of the ligand also included a reduction in DM1 pathological 
      features such as disease foci formation and misregulation of pre-mRNA splicing in 
      DM1 model cells. Furthermore, the CTG-alkylating ligand may change the 
      d(CAG.CTG)(exp) repeat length dynamics in DM1 patient cells. Our strategy of 
      linking an alkylating moiety to a DNA mismatch-selective small molecule may be 
      generally applicable to other repeat expansion diseases such as Huntington's 
      disease and amyotrophic lateral sclerosis.
FAU - Lee, JuYeon
AU  - Lee J
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, 
      Illinois 61801, United States.
FAU - Li, Ke
AU  - Li K
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, 
      Illinois 61801, United States.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, 
      Illinois 61801, United States.
LA  - eng
GR  - R01 AR069645/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20220428
PL  - United States
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
RN  - 0 (Alkylating Agents)
RN  - 0 (Ligands)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Alkylating Agents/therapeutic use
MH  - DNA
MH  - Humans
MH  - Ligands
MH  - *Myotonic Dystrophy/drug therapy/genetics/pathology
MH  - Trinucleotide Repeat Expansion
EDAT- 2022/04/29 06:00
MHDA- 2022/05/24 06:00
CRDT- 2022/04/28 16:52
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2022/04/28 16:52 [entrez]
AID - 10.1021/acschembio.1c00949 [doi]
PST - ppublish
SO  - ACS Chem Biol. 2022 May 20;17(5):1103-1110. doi: 10.1021/acschembio.1c00949. Epub 
      2022 Apr 28.

PMID- 35401669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - Expanded CUG Repeat RNA Induces Premature Senescence in Myotonic Dystrophy Model 
      Cells.
PG  - 865811
LID - 10.3389/fgene.2022.865811 [doi]
LID - 865811
AB  - Myotonic dystrophy type 1 (DM1) is a dominantly inherited disorder due to a toxic 
      gain of function of RNA transcripts containing expanded CUG repeats (CUG(exp)). 
      Patients with DM1 present with multisystemic symptoms, such as muscle wasting, 
      cognitive impairment, cataract, frontal baldness, and endocrine defects, which 
      resemble accelerated aging. Although the involvement of cellular senescence, a 
      critical component of aging, was suggested in studies of DM1 patient-derived 
      cells, the detailed mechanism of cellular senescence caused by CUG(exp) RNA 
      remains unelucidated. Here, we developed a DM1 cell model that conditionally 
      expressed CUG(exp) RNA in human primary cells so that we could perform a detailed 
      assessment that eliminated the variability in primary cells from different 
      origins. Our DM1 model cells demonstrated that CUG(exp) RNA expression induced 
      cellular senescence by a telomere-independent mechanism. Furthermore, the toxic 
      RNA expression caused mitochondrial dysfunction, excessive reactive oxygen 
      species production, and DNA damage and response, resulting in the 
      senescence-associated increase of cell cycle inhibitors p21 and p16 and secreted 
      mediators insulin-like growth factor binding protein 3 (IGFBP3) and plasminogen 
      activator inhibitor-1 (PAI-1). This study provides unequivocal evidence of the 
      induction of premature senescence by CUG(exp) RNA in our DM1 model cells.
CI  - Copyright (c) 2022 Hasuike, Mochizuki and Nakamori.
FAU - Hasuike, Yuhei
AU  - Hasuike Y
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Mochizuki, Hideki
AU  - Mochizuki H
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220325
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC8990169
OTO - NOTNLM
OT  - IGFBP3
OT  - PAI-1
OT  - cellular senescence
OT  - myotonic dystrophy
OT  - reactive oxygen species
OT  - repeat expansion
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/03/25
CRDT- 2022/04/11 05:28
PHST- 2022/01/30 00:00 [received]
PHST- 2022/03/11 00:00 [accepted]
PHST- 2022/04/11 05:28 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/03/25 00:00 [pmc-release]
AID - 865811 [pii]
AID - 10.3389/fgene.2022.865811 [doi]
PST - epublish
SO  - Front Genet. 2022 Mar 25;13:865811. doi: 10.3389/fgene.2022.865811. eCollection 
      2022.

PMID- 35328743
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220408
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 6
DP  - 2022 Mar 19
TI  - Fluorescence-Based Binding Characterization of Small Molecule Ligands Targeting 
      CUG RNA Repeats.
LID - 10.3390/ijms23063321 [doi]
LID - 3321
AB  - Pathogenic CUG and CCUG RNA repeats have been associated with myotonic dystrophy 
      type 1 and 2 (DM1 and DM2), respectively. Identifying small molecules that can 
      bind these RNA repeats is of great significance to develop potential therapeutics 
      to treat these neurodegenerative diseases. Some studies have shown that 
      aminoglycosides and their derivatives could work as potential lead compounds 
      targeting these RNA repeats. In this work, sisomicin, previously known to bind 
      HIV-1 TAR, is investigated as a possible ligand for CUG RNA repeats. We designed 
      a novel fluorescence-labeled RNA sequence of r(CUG)(10) to mimic cellular RNA 
      repeats and improve the detecting sensitivity. The interaction of sisomicin with 
      CUG RNA repeats is characterized by the change of fluorescent signal, which is 
      initially minimized by covalently incorporating the fluorescein into the RNA 
      bases and later increased upon ligand binding. The results show that sisomicin 
      can bind and stabilize the folded RNA structure. We demonstrate that this new 
      fluorescence-based binding characterization assay is consistent with the classic 
      UV T(m) technique, indicating its feasibility for high-throughput screening of 
      ligand-RNA binding interactions and wide applications to measure the 
      thermodynamic parameters in addition to binding constants and kinetics when 
      probing such interactions.
FAU - Chang, Zhihua
AU  - Chang Z
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
FAU - Zheng, Ya Ying
AU  - Zheng YY
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
FAU - Mathivanan, Johnsi
AU  - Mathivanan J
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
FAU - Valsangkar, Vibhav A
AU  - Valsangkar VA
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
FAU - Du, Jinxi
AU  - Du J
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
FAU - Abou-Elkhair, Reham A I
AU  - Abou-Elkhair RAI
AD  - Applied Nucleic Acids Research Center & Chemistry Department, Faculty of Science, 
      Zagazig University, Zagazig 44523, Egypt.
FAU - Hassan, Abdalla E A
AU  - Hassan AEA
AD  - Applied Nucleic Acids Research Center & Chemistry Department, Faculty of Science, 
      Zagazig University, Zagazig 44523, Egypt.
FAU - Sheng, Jia
AU  - Sheng J
AUID- ORCID: 0000-0001-6198-390X
AD  - Department of Chemistry and The RNA Institute, University at Albany, State 
      University of New York, 1400 Washington Avenue, Albany, NY 12222, USA.
LA  - eng
GR  - R15 GM124627/GM/NIGMS NIH HHS/United States
GR  - R15GM124627/NH/NIH HHS/United States
GR  - CHE1845486/National Science Foundation/
PT  - Journal Article
DEP - 20220319
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Ligands)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - X55XSL74YQ (Sisomicin)
SB  - IM
MH  - Fluorescence
MH  - Humans
MH  - Ligands
MH  - *Myotonic Dystrophy/genetics
MH  - *RNA/genetics
MH  - RNA-Binding Proteins/metabolism
MH  - Sisomicin
PMC - PMC8955525
OTO - NOTNLM
OT  - CUG repeat
OT  - RNA-ligand binding
OT  - aminoglycosides
OT  - fluorescence spectroscopy
OT  - microsatellite RNA expansions
COIS- The authors declare no competing financial interest.
EDAT- 2022/03/26 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/19
CRDT- 2022/03/25 01:07
PHST- 2022/01/30 00:00 [received]
PHST- 2022/03/11 00:00 [revised]
PHST- 2022/03/15 00:00 [accepted]
PHST- 2022/03/25 01:07 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/03/19 00:00 [pmc-release]
AID - ijms23063321 [pii]
AID - ijms-23-03321 [pii]
AID - 10.3390/ijms23063321 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Mar 19;23(6):3321. doi: 10.3390/ijms23063321.

PMID- 35328504
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220408
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 6
DP  - 2022 Mar 12
TI  - Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic 
      Dystrophy Type 1 (DM1).
LID - 10.3390/ijms23063081 [doi]
LID - 3081
AB  - The blood transcriptome was examined in relation to disease severity in type I 
      myotonic dystrophy (DM1) patients who participated in the Observational Prolonged 
      Trial In DM1 to Improve QoL- Standards (OPTIMISTIC) study. This sought to (a) 
      ascertain if transcriptome changes were associated with increasing disease 
      severity, as measured by the muscle impairment rating scale (MIRS), and (b) 
      establish if these changes in mRNA expression and associated biological pathways 
      were also observed in the Dystrophia Myotonica Biomarker Discovery Initiative 
      (DMBDI) microarray dataset in blood (with equivalent MIRS/DMPK repeat length). 
      The changes in gene expression were compared using a number of complementary 
      pathways, gene ontology and upstream regulator analyses, which suggested that 
      symptom severity in DM1 was linked to transcriptomic alterations in innate and 
      adaptive immunity associated with muscle-wasting. Future studies should explore 
      the role of immunity in DM1 in more detail to assess its relevance to DM1.
FAU - Nieuwenhuis, Sylvia
AU  - Nieuwenhuis S
AUID- ORCID: 0000-0001-8254-7445
AD  - Center for Molecular and Biomolecular Informatics (CMBI), Radboud Institute for 
      Molecular Life Sciences, Radboud University Medical Centre, 6500 HB Nijmegen, The 
      Netherlands.
AD  - Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and 
      Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, The Netherlands.
FAU - Widomska, Joanna
AU  - Widomska J
AD  - Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and 
      Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, The Netherlands.
FAU - Blom, Paul
AU  - Blom P
AD  - VDL Enabling Technologies Group B.V., 5651 GH Eindhoven, The Netherlands.
FAU - 't Hoen, Peter-Bram A C
AU  - 't Hoen PAC
AD  - Center for Molecular and Biomolecular Informatics (CMBI), Radboud Institute for 
      Molecular Life Sciences, Radboud University Medical Centre, 6500 HB Nijmegen, The 
      Netherlands.
FAU - van Engelen, Baziel G M
AU  - van Engelen BGM
AD  - Department of Neurology, Donders Institute for Brain Cognition and Behaviour, 
      Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
FAU - Glennon, Jeffrey C
AU  - Glennon JC
AUID- ORCID: 0000-0002-2371-0422
AD  - Department of Cognitive Neuroscience, Donders Institute for Brain Cognition and 
      Behaviour, Radboud University Medical Centre, 6525 EN Nijmegen, The Netherlands.
AD  - Conway Institute of Biomolecular and Biomedical Research, School of Medicine, 
      University College Dublin, D04 V1W8 Dublin, Ireland.
FAU - On Behalf Of The Optimistic Consortium
AU  - On Behalf Of The Optimistic Consortium
LA  - eng
GR  - 305697/European Commission/
GR  - 18-038/European Community E-RARE programme/
PT  - Journal Article
DEP - 20220312
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Gene Expression Profiling
MH  - Humans
MH  - *Myotonic Dystrophy/genetics/metabolism
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Transcriptome
PMC - PMC8954763
OTO - NOTNLM
OT  - DM1 disease severity
OT  - RNA sequencing
OT  - blood
OT  - immunity
OT  - muscle impairment rating scale (MIRS)
OT  - myotonic dystrophy type 1 (DM1)
OT  - pathway analysis
COIS- The authors declare that they have no conflict of interest except van Engelen. 
      van Engelen reports grants from FP7 European Union grant OPTIMISTIC, grants from 
      Marigold Canada, grants from Spieren voor Spieren, grants from the Prinses 
      Beatrix Spierfonds, grants from the Dutch FSHD foundation, grants from the 
      Netherlands Organisation for Scientific Research (NWO), grants from the 
      Netherlands Organisation for Health Research and Development (ZonMw), grants from 
      Association Francaise contre les Myopathies, and grants and personal fees from 
      Fulcrum and Facio, outside the submitted work.
EDAT- 2022/03/26 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/12
CRDT- 2022/03/25 01:07
PHST- 2021/12/30 00:00 [received]
PHST- 2022/02/01 00:00 [revised]
PHST- 2022/03/03 00:00 [accepted]
PHST- 2022/03/25 01:07 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/03/12 00:00 [pmc-release]
AID - ijms23063081 [pii]
AID - ijms-23-03081 [pii]
AID - 10.3390/ijms23063081 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Mar 12;23(6):3081. doi: 10.3390/ijms23063081.

PMID- 35301072
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20230704
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Print)
IS  - 0168-8227 (Linking)
VI  - 186
DP  - 2022 Apr
TI  - Friedreich's Ataxia related Diabetes: Epidemiology and management practices.
PG  - 109828
LID - S0168-8227(22)00640-4 [pii]
LID - 10.1016/j.diabres.2022.109828 [doi]
AB  - AIMS: Friedreich's Ataxia (FRDA) is a progressive neuromuscular disorder 
      typically caused by GAA triplet repeat expansions in both frataxin gene alleles. 
      FRDA can be complicated by diabetes mellitus (DM). The objective of this study 
      was to describe the prevalence of, risk factors for, and management practices of 
      FRDA-related DM. METHODS: FACOMS, a prospective, multi-site natural history 
      study, includes 1,104 individuals. Extracted data included the presence of DM and 
      other co-morbidities, genetic diagnosis, and markers of disease severity. We 
      performed detailed medical record review and a survey for the subset of 
      individuals with FRDA-related DM followed at one FACOMS site, Children's Hospital 
      of Philadelphia. RESULTS: FRDA-related DM was reported by 8.7% of individuals. 
      Age, severe disease, and FRDA cardiac complications were positively associated 
      with DM risk. FRDA-related DM was generally well-controlled, as reflected by 
      HbA1c, though diabetic ketoacidosis did occur. Insulin is the mainstay of 
      treatment (64-74% overall); in adults, metformin use was common and newer 
      glucose-lowering agents were used rarely. CONCLUSIONS: Clinical factors identify 
      individuals at increased risk for FRDA-related DM. Future studies should test 
      strategies for FRDA-related DM screening and management, in particular the 
      potential role for novel glucose-lowering therapies in preventing or delaying 
      FRDA-related cardiac disease.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Tamaroff, Jaclyn
AU  - Tamaroff J
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA. Electronic address: jaclyn.tamaroff@vumc.org.
FAU - DeDio, Anna
AU  - DeDio A
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA.
FAU - Wade, Kristin
AU  - Wade K
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA.
FAU - Wells, McKenzie
AU  - Wells M
AD  - Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA.
FAU - Park, Courtney
AU  - Park C
AD  - Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA.
FAU - Leavens, Karla
AU  - Leavens K
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Rummey, Christian
AU  - Rummey C
AD  - Clinical Data Science GmbH, Basel, Switzerland.
FAU - Kelly, Andrea
AU  - Kelly A
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Lynch, David R
AU  - Lynch DR
AD  - Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, 
      USA; Department of Neurology, Perelman School of Medicine at the University of 
      Pennsylvania, Philadelphia, PA, USA.
FAU - McCormack, Shana E
AU  - McCormack SE
AD  - Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, 
      Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
LA  - eng
GR  - F32 DK128970/DK/NIDDK NIH HHS/United States
GR  - K08 DK131253/DK/NIDDK NIH HHS/United States
GR  - K12 DK094723/DK/NIDDK NIH HHS/United States
GR  - T32 DK063688/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220314
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Iron-Binding Proteins)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Child
MH  - *Diabetes Mellitus/epidemiology/genetics
MH  - Diabetic Ketoacidosis/complications
MH  - *Friedreich Ataxia/complications/epidemiology
MH  - Glucose
MH  - Humans
MH  - Iron-Binding Proteins/genetics
MH  - Prospective Studies
MH  - Risk Factors
MH  - Trinucleotide Repeat Expansion
PMC - PMC9075677
MID - NIHMS1793942
OTO - NOTNLM
OT  - Friedreich's Ataxia
OT  - Mitochondrial diabetes
COIS- Declarations of interest: None
EDAT- 2022/03/19 06:00
MHDA- 2022/05/06 06:00
PMCR- 2023/04/01
CRDT- 2022/03/18 05:39
PHST- 2021/07/13 00:00 [received]
PHST- 2022/03/04 00:00 [revised]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/03/18 05:39 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - S0168-8227(22)00640-4 [pii]
AID - 10.1016/j.diabres.2022.109828 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2022 Apr;186:109828. doi: 10.1016/j.diabres.2022.109828. 
      Epub 2022 Mar 14.

PMID- 35243403
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220305
IS  - 2666-3287 (Electronic)
IS  - 2666-3287 (Linking)
VI  - 7
DP  - 2022 Jun
TI  - Cutaneous findings in myotonic dystrophy.
PG  - 7-12
LID - 10.1016/j.jdin.2021.09.008 [doi]
AB  - Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders 
      resulting from the expansion of (CTG)(n) nucleotide repeats in the DMPK gene. In 
      addition to the hallmark manifestations of myotonia and skeletal muscle atrophy, 
      myotonic dystrophy also affects a myriad of other organs including the heart, 
      lungs, as well as the skin. The most common cutaneous manifestations of myotonic 
      dystrophy are early male frontal alopecia and adult-onset pilomatricomas. 
      Myotonic dystrophy also increases the risk of developing malignant skin diseases 
      such as basal cell carcinoma and melanoma. To aid in the diagnosis and treatment 
      of myotonic dystrophy related skin conditions, it is important for the 
      dermatologist to become cognizant of the common and rare cutaneous manifestations 
      of this genetic disorder. We performed a PubMed search using the key terms 
      "myotonic dystrophy" AND "cutaneous" OR "skin" OR "dermatologic" AND 
      "manifestation" OR "finding." The resulting publications were manually reviewed 
      for additional relevant publications, and subsequent additional searches were 
      performed as needed, especially regarding the molecular mechanisms of 
      pathogenesis. In this review, we aim to provide an overview of myotonic dystrophy 
      types 1 and 2 and summarize their cutaneous manifestations as well as potential 
      mechanisms of pathogenesis.
CI  - (c) 2021 Published by Elsevier Inc on behalf of the American Academy of 
      Dermatology, Inc.
FAU - Kong, Ha Eun
AU  - Kong HE
AD  - Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
FAU - Pollack, Brian P
AU  - Pollack BP
AD  - Atlanta VA Health System, Decatur, Georgia.
AD  - Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
AD  - Department of Pathology, Emory University School of Medicine, Atlanta, Georgia.
AD  - Winship Cancer Institute of Emory University School of Medicine, Atlanta, 
      Georgia.
LA  - eng
PT  - Journal Article
DEP - 20220222
PL  - United States
TA  - JAAD Int
JT  - JAAD international
JID - 101774762
PMC - PMC8867117
OTO - NOTNLM
OT  - BCC
OT  - BCC, basal cell carcinoma
OT  - DM1
OT  - DM1, myotonic dystrophy type 1
OT  - DM2
OT  - DM2, myotonic dystrophy type 2
OT  - DMPK, myotonic dystrophy protein kinase
OT  - RAN, repeat associated non-ATG
OT  - RNA toxicity
OT  - melanoma
OT  - myotonic dystrophy
OT  - pilomatricoma
OT  - syndrome
OT  - triplet repeat expansion
COIS- None disclosed.
EDAT- 2022/03/05 06:00
MHDA- 2022/03/05 06:01
PMCR- 2022/02/22
CRDT- 2022/03/04 05:44
PHST- 2021/09/23 00:00 [accepted]
PHST- 2022/03/04 05:44 [entrez]
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2022/03/05 06:01 [medline]
PHST- 2022/02/22 00:00 [pmc-release]
AID - S2666-3287(21)00077-8 [pii]
AID - 10.1016/j.jdin.2021.09.008 [doi]
PST - epublish
SO  - JAAD Int. 2022 Feb 22;7:7-12. doi: 10.1016/j.jdin.2021.09.008. eCollection 2022 
      Jun.

PMID- 35212003
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220623
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 65
IP  - 6
DP  - 2022 Jun
TI  - Explanatory factors of dynamic balance impairment in myotonic dystrophy type 1.
PG  - 683-687
LID - 10.1002/mus.27527 [doi]
AB  - INTRODUCTION/AIMS: Myotonic dystrophy type 1 (DM1) is a neuromuscular disease 
      affecting many systems and for which muscle weakness is one of the cardinal 
      symptoms. People with DM1 also present with balance-related impairments and high 
      fall risk. The aim of this study was to explore explanatory factors of dynamic 
      balance impairment in the DM1 population. METHODS: A secondary analysis of data 
      collected as part of a larger study was performed. The Mini Balance Evaluation 
      System Test (Mini-BESTest) was used to assess dynamic balance. Age, sex, and CTG 
      repeat length in blood were retrieved from medical records and research files. 
      The maximal isometric muscle strength of five lower limb muscle groups (hip 
      flexors and extensors, knee flexors and extensors, and ankle dorsiflexors) was 
      quantitatively assessed as well as fatigue. Standard multiple regression analysis 
      was used. RESULTS: Fifty-two individuals (31 men) aged between 24 and 81 years 
      were included. The final model explains 65.9% of the balance score; ankle 
      dorsiflexor muscle strength was the strongest explanatory factor, followed by CTG 
      repeat length, age and fatigue to a lesser extent. DISCUSSION: Dynamic balance is 
      impaired in people with DM1. Results of this study suggest that rehabilitation 
      interventions aimed at improving strength of the ankle dorsiflexors and managing 
      fatigue could help to improve dynamic balance in this specific population.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Belair, Nicolas
AU  - Belair N
AD  - Unite d'enseignement en physiotherapie, Departement des sciences de la sante, 
      Universite du Quebec a Chicoutimi, Chicoutimi, Quebec, Canada.
FAU - Cote, Isabelle
AU  - Cote I
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), 
      Centre integre universitaire de sante et de services sociaux du 
      Saguenay-Lac-Saint-Jean, Hopital de Jonquiere, Jonquiere, Quebec, Canada.
FAU - Gagnon, Cynthia
AU  - Gagnon C
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), 
      Centre integre universitaire de sante et de services sociaux du 
      Saguenay-Lac-Saint-Jean, Hopital de Jonquiere, Jonquiere, Quebec, Canada.
AD  - Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CR-CHUS), 
      Sherbrooke, Quebec, Canada.
AD  - Faculte de medecine et des sciences de la sante, Universite de Sherbrooke, 
      Sherbrooke, Quebec, Canada.
AD  - Centre intersectoriel en sante durable (CISD), Universite du Quebec a Chicoutimi, 
      Chicoutimi, Quebec, Canada.
FAU - Mathieu, Jean
AU  - Mathieu J
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), 
      Centre integre universitaire de sante et de services sociaux du 
      Saguenay-Lac-Saint-Jean, Hopital de Jonquiere, Jonquiere, Quebec, Canada.
AD  - Faculte de medecine et des sciences de la sante, Universite de Sherbrooke, 
      Sherbrooke, Quebec, Canada.
FAU - Duchesne, Elise
AU  - Duchesne E
AUID- ORCID: 0000-0002-9953-8315
AD  - Unite d'enseignement en physiotherapie, Departement des sciences de la sante, 
      Universite du Quebec a Chicoutimi, Chicoutimi, Quebec, Canada.
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), 
      Centre integre universitaire de sante et de services sociaux du 
      Saguenay-Lac-Saint-Jean, Hopital de Jonquiere, Jonquiere, Quebec, Canada.
AD  - Centre intersectoriel en sante durable (CISD), Universite du Quebec a Chicoutimi, 
      Chicoutimi, Quebec, Canada.
AD  - Centre de recherche Charles-Le Moyne (CRCLM), Sherbrooke, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220314
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Fatigue
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength/physiology
MH  - Muscle Weakness/etiology
MH  - Muscle, Skeletal
MH  - *Myotonic Dystrophy/complications/diagnosis/genetics
MH  - Young Adult
OTO - NOTNLM
OT  - balance
OT  - explanatory factors
OT  - physiotherapy
OT  - quantitative muscle testing
OT  - rehabilitation
EDAT- 2022/02/26 06:00
MHDA- 2022/05/24 06:00
CRDT- 2022/02/25 05:42
PHST- 2022/02/15 00:00 [revised]
PHST- 2021/06/11 00:00 [received]
PHST- 2022/02/19 00:00 [accepted]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PHST- 2022/02/25 05:42 [entrez]
AID - 10.1002/mus.27527 [doi]
PST - ppublish
SO  - Muscle Nerve. 2022 Jun;65(6):683-687. doi: 10.1002/mus.27527. Epub 2022 Mar 14.

PMID- 35186190
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220405
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Oral Administration of Bacterial beta Cell Expansion Factor A (BefA) Alleviates 
      Diabetes in Mice with Type 1 and Type 2 Diabetes.
PG  - 9206039
LID - 10.1155/2022/9206039 [doi]
LID - 9206039
AB  - Diabetes mellitus (DM) is a group of metabolic diseases, and there is an urgent 
      need to develop new therapeutic DM oral drugs with fewer side effects and sound 
      therapeutic efficacy. In this study, a beta cell expansion factor A (BefA) 
      production strain of Escherichia coli (BL21-pet 28C-BefA) was constructed, and 
      the antidiabetes effect of BefA was evaluated using type 1 DM (T1DM) and type 2 
      DM (T2DM) mice models. The T1DM mice results indicated that BefA significantly 
      reduced blood glucose levels; exerted a protective effect on islet beta cell 
      morphology; downregulated the expressions of TLR-4, p-NFkappaB/NFkappaB, and Bax/Bcl-2, 
      and the secretion levels of IL-1beta and TNF-alpha; increased the expression of PDX-1 
      protein and insulin secretion in a concentration-dependent manner; and restored 
      the disturbed microbial diversity to normal levels. Similarly with the T1DM mice, 
      BefA obviously increased islet beta cells and reduced the inflammatory reaction and 
      apoptosis in T2DM mice, as well as improved liver lipid metabolism by 
      downregulating the expressions of CEBP-alpha, ACC, and Fasn; inhibited the synthesis 
      of triglycerides; and induced Cpt-1, Hmgcs2, and Pparalpha in a 
      concentration-dependent manner. In conclusion, BefA alleviates diabetes via 
      increasing the number of islet beta cells, reducing the inflammatory reaction and 
      apoptosis, improving liver lipid metabolism, and restoring microbial diversity to 
      normal levels, which provides a new strategy for a DM oral drug.
CI  - Copyright (c) 2022 Huan Wang et al.
FAU - Wang, Huan
AU  - Wang H
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
FAU - Wei, Jing
AU  - Wei J
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
FAU - Hu, Hong
AU  - Hu H
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
FAU - Le, Fuyin
AU  - Le F
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
FAU - Wu, Heng
AU  - Wu H
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
FAU - Wei, Hong
AU  - Wei H
AUID- ORCID: 0000-0001-6069-1067
AD  - Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou 510080, China.
FAU - Luo, Jie
AU  - Luo J
AUID- ORCID: 0000-0002-1501-9922
AD  - School of Public Health and Key Laboratory of Preventive Medicine, Nanchang 
      University, Nanchang 330031, China.
FAU - Chen, Tingtao
AU  - Chen T
AUID- ORCID: 0000-0002-0506-8536
AD  - National Engineering Research Center for Bioengineering Drugs and the 
      Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 
      330031, China.
LA  - eng
PT  - Journal Article
DEP - 20220210
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Bacterial Proteins)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Bacterial Proteins/*administration & dosage
MH  - Diabetes Mellitus, Experimental/*drug therapy
MH  - Insulin-Secreting Cells/*drug effects
MH  - Male
MH  - Mice
PMC - PMC8853770
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/22 06:00
MHDA- 2022/04/06 06:00
PMCR- 2022/02/10
CRDT- 2022/02/21 06:02
PHST- 2021/12/08 00:00 [received]
PHST- 2022/01/04 00:00 [revised]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/02/21 06:02 [entrez]
PHST- 2022/02/22 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2022/02/10 00:00 [pmc-release]
AID - 10.1155/2022/9206039 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Feb 10;2022:9206039. doi: 10.1155/2022/9206039. 
      eCollection 2022.

PMID- 35182509
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20240306
IS  - 1474-4465 (Electronic)
IS  - 1474-4422 (Print)
IS  - 1474-4422 (Linking)
VI  - 21
IP  - 3
DP  - 2022 Mar
TI  - Whole genome sequencing for the diagnosis of neurological repeat expansion 
      disorders in the UK: a retrospective diagnostic accuracy and prospective clinical 
      validation study.
PG  - 234-245
LID - S1474-4422(21)00462-2 [pii]
LID - 10.1016/S1474-4422(21)00462-2 [doi]
AB  - BACKGROUND: Repeat expansion disorders affect about 1 in 3000 individuals and are 
      clinically heterogeneous diseases caused by expansions of short tandem DNA 
      repeats. Genetic testing is often locus-specific, resulting in underdiagnosis of 
      people who have atypical clinical presentations, especially in paediatric 
      patients without a previous positive family history. Whole genome sequencing is 
      increasingly used as a first-line test for other rare genetic disorders, and we 
      aimed to assess its performance in the diagnosis of patients with neurological 
      repeat expansion disorders. METHODS: We retrospectively assessed the diagnostic 
      accuracy of whole genome sequencing to detect the most common repeat expansion 
      loci associated with neurological outcomes (AR, ATN1, ATXN1, ATXN2, ATXN3, ATXN7, 
      C9orf72, CACNA1A, DMPK, FMR1, FXN, HTT, and TBP) using samples obtained within 
      the National Health Service in England from patients who were suspected of having 
      neurological disorders; previous PCR test results were used as the reference 
      standard. The clinical accuracy of whole genome sequencing to detect repeat 
      expansions was prospectively examined in previously genetically tested and 
      undiagnosed patients recruited in 2013-17 to the 100 000 Genomes Project in the 
      UK, who were suspected of having a genetic neurological disorder (familial or 
      early-onset forms of ataxia, neuropathy, spastic paraplegia, dementia, motor 
      neuron disease, parkinsonian movement disorders, intellectual disability, or 
      neuromuscular disorders). If a repeat expansion call was made using whole genome 
      sequencing, PCR was used to confirm the result. FINDINGS: The diagnostic accuracy 
      of whole genome sequencing to detect repeat expansions was evaluated against 793 
      PCR tests previously performed within the NHS from 404 patients. Whole genome 
      sequencing correctly classified 215 of 221 expanded alleles and 1316 of 1321 
      non-expanded alleles, showing 97.3% sensitivity (95% CI 94.2-99.0) and 99.6% 
      specificity (99.1-99.9) across the 13 disease-associated loci when compared with 
      PCR test results. In samples from 11 631 patients in the 100 000 Genomes Project, 
      whole genome sequencing identified 81 repeat expansions, which were also tested 
      by PCR: 68 were confirmed as repeat expansions in the full pathogenic range, 11 
      were non-pathogenic intermediate expansions or premutations, and two were 
      non-expanded repeats (16% false discovery rate). INTERPRETATION: In our study, 
      whole genome sequencing for the detection of repeat expansions showed high 
      sensitivity and specificity, and it led to identification of neurological repeat 
      expansion disorders in previously undiagnosed patients. These findings support 
      implementation of whole genome sequencing in clinical laboratories for diagnosis 
      of patients who have a neurological presentation consistent with a repeat 
      expansion disorder. FUNDING: Medical Research Council, Department of Health and 
      Social Care, National Health Service England, National Institute for Health 
      Research, and Illumina.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access 
      article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights 
      reserved.
FAU - Ibanez, Kristina
AU  - Ibanez K
AD  - Genomics England, Queen Mary University of London, London, UK; William Harvey 
      Research Institute, Queen Mary University of London, London, UK.
FAU - Polke, James
AU  - Polke J
AD  - Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, UK.
FAU - Hagelstrom, R Tanner
AU  - Hagelstrom RT
AD  - Illumina, San Diego, CA, USA.
FAU - Dolzhenko, Egor
AU  - Dolzhenko E
AD  - Illumina, San Diego, CA, USA.
FAU - Pasko, Dorota
AU  - Pasko D
AD  - Genomics England, Queen Mary University of London, London, UK.
FAU - Thomas, Ellen Rachel Amy
AU  - Thomas ERA
AD  - Genomics England, Queen Mary University of London, London, UK.
FAU - Daugherty, Louise C
AU  - Daugherty LC
AD  - Genomics England, Queen Mary University of London, London, UK; Healx, Cambridge, 
      UK.
FAU - Kasperaviciute, Dalia
AU  - Kasperaviciute D
AD  - Genomics England, Queen Mary University of London, London, UK; William Harvey 
      Research Institute, Queen Mary University of London, London, UK.
FAU - Smith, Katherine R
AU  - Smith KR
AD  - Genomics England, Queen Mary University of London, London, UK; William Harvey 
      Research Institute, Queen Mary University of London, London, UK.
CN  - WGS for Neurological Diseases Group
FAU - Deans, Zandra C
AU  - Deans ZC
AD  - Genomics Quality Assessment, Department of Laboratory Medicine, Royal Infirmary 
      of Edinburgh, Edinburgh, UK; NHS England and NHS Improvement, London, UK.
FAU - Hill, Sue
AU  - Hill S
AD  - NHS England and NHS Improvement, London, UK.
FAU - Fowler, Tom
AU  - Fowler T
AD  - Genomics England, Queen Mary University of London, London, UK.
FAU - Scott, Richard H
AU  - Scott RH
AD  - Genomics England, Queen Mary University of London, London, UK; Department of 
      Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, 
      London, UK.
FAU - Hardy, John
AU  - Hardy J
AD  - Department of Neurodegenerative Disorders, Institute of Neurology, University 
      College London, London, UK.
FAU - Chinnery, Patrick F
AU  - Chinnery PF
AD  - MRC Mitochondrial Biology Unit and Department of ClinicalNeurosciences, 
      University of Cambridge, Cambridge, UK.
FAU - Houlden, Henry
AU  - Houlden H
AD  - Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, UK; 
      Department of Neuromuscular Diseases, Institute of Neurology, University College 
      London, London, UK.
FAU - Rendon, Augusto
AU  - Rendon A
AD  - Genomics England, Queen Mary University of London, London, UK.
FAU - Caulfield, Mark J
AU  - Caulfield MJ
AD  - Genomics England, Queen Mary University of London, London, UK; William Harvey 
      Research Institute, Queen Mary University of London, London, UK.
FAU - Eberle, Michael A
AU  - Eberle MA
AD  - Illumina, San Diego, CA, USA.
FAU - Taft, Ryan J
AU  - Taft RJ
AD  - Illumina, San Diego, CA, USA. Electronic address: rtaft@illumina.com.
FAU - Tucci, Arianna
AU  - Tucci A
AD  - Genomics England, Queen Mary University of London, London, UK; William Harvey 
      Research Institute, Queen Mary University of London, London, UK. Electronic 
      address: a.tucci@qmul.ac.uk.
CN  - Genomics England Research Consortium
LA  - eng
GR  - MR/K01417X/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/K000608/1/MRC_/Medical Research Council/United Kingdom
GR  - G1001253/MRC_/Medical Research Council/United Kingdom
GR  - MR/L501542/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_EX_MR/M009203/1/MRC_/Medical Research Council/United Kingdom
GR  - G-1307/PUK_/Parkinson's UK/United Kingdom
GR  - MR/S01165X/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S006753/1/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_00015/9/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - G0701075/MRC_/Medical Research Council/United Kingdom
GR  - G0901254/MRC_/Medical Research Council/United Kingdom
GR  - MC_PC_14089/MRC_/Medical Research Council/United Kingdom
GR  - DH_/Department of Health/United Kingdom
GR  - G-0907/PUK_/Parkinson's UK/United Kingdom
GR  - MR/M009203/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/J004758/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lancet Neurol
JT  - The Lancet. Neurology
JID - 101139309
RN  - 0 (FMR1 protein, human)
RN  - 139135-51-6 (Fragile X Mental Retardation Protein)
SB  - IM
CIN - Lancet Neurol. 2022 Mar;21(3):203. PMID: 35182497
CIN - Lancet Neurol. 2022 Mar;21(3):205-207. PMID: 35182498
CIN - Lancet Neurol. 2022 Mar;21(3):222. PMID: 35182508
MH  - Child
MH  - *DNA Repeat Expansion
MH  - Fragile X Mental Retardation Protein/genetics
MH  - Humans
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *State Medicine
MH  - United Kingdom
MH  - Whole Genome Sequencing/methods
PMC - PMC8850201
COIS- Declaration of interests Genomics England is a company wholly owned by the UK 
      Department of Health and Social Care and was created in 2013 to introduce whole 
      genome sequencing into health care in conjunction with NHS England. All authors 
      affiliated with Genomics England (KI, DP, ERAT, LCD, DK, KRS, TF, RHS, AR, MJC, 
      and AT) are, or were, salaried by or seconded to Genomics England. RJT, MAE, ED, 
      and RTH are employees and shareholders of Illumina. PFC is in receipt of a grant 
      from the Wellcome Trust Medical Research Council (MRC). All other named authors 
      declare no competing interests. Declarations of interests for members of the WGS 
      for Neurological Diseases Group are provided in the appendix (p 14).
FIR - McDonagh, Ellen M
IR  - McDonagh EM
FIR - Rueda, Antonio
IR  - Rueda A
FIR - Polychronopoulos, Dimitris
IR  - Polychronopoulos D
FIR - Chan, Georgia
IR  - Chan G
FIR - Angus-Leppan, Heather
IR  - Angus-Leppan H
FIR - Bhatia, Kailash P
IR  - Bhatia KP
FIR - Davison, James E
IR  - Davison JE
FIR - Festenstein, Richard
IR  - Festenstein R
FIR - Fratta, Pietro
IR  - Fratta P
FIR - Giunti, Paola
IR  - Giunti P
FIR - Howard, Robin
IR  - Howard R
FIR - Venkata, Laxmi
IR  - Venkata L
FIR - Laura, Matilde
IR  - Laura M
FIR - McEntagart, Meriel
IR  - McEntagart M
FIR - Menzies, Lara
IR  - Menzies L
FIR - Morris, Huw
IR  - Morris H
FIR - Reilly, Mary M
IR  - Reilly MM
FIR - Robinson, Robert
IR  - Robinson R
FIR - Rosser, Elisabeth
IR  - Rosser E
FIR - Faravelli, Francesca
IR  - Faravelli F
FIR - Schrag, Anette
IR  - Schrag A
FIR - Schott, Jonathan M
IR  - Schott JM
FIR - Warner, Thomas T
IR  - Warner TT
FIR - Wood, Nicholas W
IR  - Wood NW
FIR - Bourn, David
IR  - Bourn D
FIR - Eggleton, Kelly
IR  - Eggleton K
FIR - Labrum, Robyn
IR  - Labrum R
FIR - Twiss, Philip
IR  - Twiss P
FIR - Abbs, Stephen
IR  - Abbs S
FIR - Santos, Liana
IR  - Santos L
FIR - Almheiri, Ghareesa
IR  - Almheiri G
FIR - Sheikh, Isabella
IR  - Sheikh I
FIR - Vandrovcova, Jana
IR  - Vandrovcova J
FIR - Patch, Christine
IR  - Patch C
FIR - Taylor Tavares, Ana Lisa
IR  - Taylor Tavares AL
FIR - Hyder, Zerin
IR  - Hyder Z
FIR - Need, Anna
IR  - Need A
FIR - Brittain, Helen
IR  - Brittain H
FIR - Baple, Emma
IR  - Baple E
FIR - Moutsianas, Loukas
IR  - Moutsianas L
FIR - Deshpande, Viraj
IR  - Deshpande V
FIR - Perry, Denise L
IR  - Perry DL
FIR - Ajay, Subramanian S
IR  - Ajay SS
FIR - Chawla, Aditi
IR  - Chawla A
FIR - Rajan, Vani
IR  - Rajan V
FIR - Oprych, Kathryn
IR  - Oprych K
FIR - Chinnery, Patrick F
IR  - Chinnery PF
FIR - Douglas, Angela
IR  - Douglas A
FIR - Wilson, Gill
IR  - Wilson G
FIR - Ellard, Sian
IR  - Ellard S
FIR - Temple, I Karen
IR  - Temple IK
FIR - Mumford, Andrew
IR  - Mumford A
FIR - McMullan, Dom
IR  - McMullan D
FIR - Naresh, Kikkeri
IR  - Naresh K
FIR - Flinter, Frances A
IR  - Flinter FA
FIR - Taylor, Jenny C
IR  - Taylor JC
FIR - Greenhalgh, Lynn
IR  - Greenhalgh L
FIR - Newman, William
IR  - Newman W
FIR - Brennan, Paul
IR  - Brennan P
FIR - Sayer, John A
IR  - Sayer JA
FIR - Raymond, F Lucy
IR  - Raymond FL
FIR - Chitty, Lyn S
IR  - Chitty LS
FIR - Ambrose, John C
IR  - Ambrose JC
FIR - Arumugam, Prabhu
IR  - Arumugam P
FIR - Bleda, Marta
IR  - Bleda M
FIR - Boardman-Pretty, Freya
IR  - Boardman-Pretty F
FIR - Boissiere, Jeanne M
IR  - Boissiere JM
FIR - Boustred, Christopher R
IR  - Boustred CR
FIR - Craig, Clare E H
IR  - Craig CEH
FIR - de Burca, Anna
IR  - de Burca A
FIR - Devereau, Andrew
IR  - Devereau A
FIR - Elgar, Greg
IR  - Elgar G
FIR - Foulger, Rebecca E
IR  - Foulger RE
FIR - Furio-Tari, Pedro
IR  - Furio-Tari P
FIR - Hackett, Joanne
IR  - Hackett J
FIR - Halai, Dina
IR  - Halai D
FIR - Hamblin, Angela
IR  - Hamblin A
FIR - Henderson, Shirley
IR  - Henderson S
FIR - Holman, James
IR  - Holman J
FIR - Hubbard, Tim J P
IR  - Hubbard TJP
FIR - Jackson, Rob
IR  - Jackson R
FIR - Jones, Louise J
IR  - Jones LJ
FIR - Kayikci, Melis
IR  - Kayikci M
FIR - Lahnstein, Lea
IR  - Lahnstein L
FIR - Lawson, Kay
IR  - Lawson K
FIR - Leigh, Sarah E A
IR  - Leigh SEA
FIR - Leong, Ivonne U S
IR  - Leong IUS
FIR - Lopez, Javier F
IR  - Lopez JF
FIR - Maleady-Crowe, Fiona
IR  - Maleady-Crowe F
FIR - Mason, Joanne
IR  - Mason J
FIR - Mueller, Michael
IR  - Mueller M
FIR - Murugaesu, Nirupa
IR  - Murugaesu N
FIR - Odhams, Chris A
IR  - Odhams CA
FIR - Perez-Gil, Daniel
IR  - Perez-Gil D
FIR - Polychronopoulos, Dimitris
IR  - Polychronopoulos D
FIR - Pullinger, John
IR  - Pullinger J
FIR - Rahim, Tahrima
IR  - Rahim T
FIR - Riesgo-Ferreiro, Pablo
IR  - Riesgo-Ferreiro P
FIR - Rogers, Tim
IR  - Rogers T
FIR - Ryten, Mina
IR  - Ryten M
FIR - Savage, Kevin
IR  - Savage K
FIR - Sawant, Kushmita
IR  - Sawant K
FIR - Siddiq, Afshan
IR  - Siddiq A
FIR - Sieghart, Alexander
IR  - Sieghart A
FIR - Smedley, Damian
IR  - Smedley D
FIR - Sosinsky, Alona
IR  - Sosinsky A
FIR - Spooner, William
IR  - Spooner W
FIR - Stevens, Helen E
IR  - Stevens HE
FIR - Stuckey, Alexander
IR  - Stuckey A
FIR - Sultana, Razvan
IR  - Sultana R
FIR - Thompson, Simon R
IR  - Thompson SR
FIR - Tregidgo, Carolyn
IR  - Tregidgo C
FIR - Walsh, Emma
IR  - Walsh E
FIR - Watters, Sarah A
IR  - Watters SA
FIR - Welland, Matthew J
IR  - Welland MJ
FIR - Williams, Eleanor
IR  - Williams E
FIR - Witkowska, Katarzyna
IR  - Witkowska K
FIR - Wood, Suzanne M
IR  - Wood SM
FIR - Zarowiecki, Magdalena
IR  - Zarowiecki M
EDAT- 2022/02/20 06:00
MHDA- 2022/03/22 06:00
PMCR- 2022/03/01
CRDT- 2022/02/19 20:09
PHST- 2021/02/16 00:00 [received]
PHST- 2021/11/09 00:00 [revised]
PHST- 2021/12/14 00:00 [accepted]
PHST- 2022/02/20 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2022/02/19 20:09 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - S1474-4422(21)00462-2 [pii]
AID - 10.1016/S1474-4422(21)00462-2 [doi]
PST - ppublish
SO  - Lancet Neurol. 2022 Mar;21(3):234-245. doi: 10.1016/S1474-4422(21)00462-2.

PMID- 35145256
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220419
IS  - 2157-846X (Electronic)
IS  - 2157-846X (Linking)
VI  - 6
IP  - 2
DP  - 2022 Feb
TI  - Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein 
      with high affinity for expanded CUG repeats.
PG  - 207-220
LID - 10.1038/s41551-021-00838-2 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an RNA-dominant disease whose pathogenesis 
      stems from the functional loss of muscleblind-like RNA-binding proteins (RBPs), 
      which causes the formation of alternative-splicing defects. The loss of 
      functional muscleblind-like protein 1 (MBNL1) results from its nuclear 
      sequestration by mutant transcripts containing pathogenic expanded CUG repeats 
      (CUGexp). Here we show that an RBP engineered to act as a decoy for CUGexp 
      reverses the toxicity of the mutant transcripts. In vitro, the binding of the RBP 
      decoy to CUGexp in immortalized muscle cells derived from a patient with DM1 
      released sequestered endogenous MBNL1 from nuclear RNA foci, restored MBNL1 
      activity, and corrected the transcriptomic signature of DM1. In mice with DM1, 
      the local or systemic delivery of the RBP decoy via an adeno-associated virus 
      into the animals' skeletal muscle led to the long-lasting correction of the 
      splicing defects and to ameliorated disease pathology. Our findings support the 
      development of decoy RBPs with high binding affinities for expanded RNA repeats 
      as a therapeutic strategy for myotonic dystrophies.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Arandel, Ludovic
AU  - Arandel L
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Matloka, Magdalena
AU  - Matloka M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Klein, Arnaud F
AU  - Klein AF
AUID- ORCID: 0000-0002-3860-7049
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Rau, Frederique
AU  - Rau F
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Sureau, Alain
AU  - Sureau A
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Ney, Michel
AU  - Ney M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Cordier, Aurelien
AU  - Cordier A
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Kondili, Maria
AU  - Kondili M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Polay-Espinoza, Micaela
AU  - Polay-Espinoza M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Naouar, Naira
AU  - Naouar N
AUID- ORCID: 0000-0003-2161-8603
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Ferry, Arnaud
AU  - Ferry A
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
AD  - Sorbonne Paris Cite, Universite Paris Descartes, Paris, France.
FAU - Lemaitre, Megane
AU  - Lemaitre M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
AD  - Sorbonne Universite, Inserm, Phenotypage du petit animal, Paris, France.
FAU - Begard, Severine
AU  - Begard S
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France.
FAU - Colin, Morvane
AU  - Colin M
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France.
FAU - Lamarre, Chloe
AU  - Lamarre C
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France.
FAU - Tran, Helene
AU  - Tran H
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France.
FAU - Buee, Luc
AU  - Buee L
AUID- ORCID: 0000-0002-6261-4230
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France.
FAU - Marie, Joelle
AU  - Marie J
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Sergeant, Nicolas
AU  - Sergeant N
AUID- ORCID: 0000-0003-1448-124X
AD  - Universite de Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Lille, 
      France. nicolas.sergeant@inserm.fr.
FAU - Furling, Denis
AU  - Furling D
AUID- ORCID: 0000-0001-7912-4409
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France. denis.furling@sorbonne-universite.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220210
PL  - England
TA  - Nat Biomed Eng
JT  - Nature biomedical engineering
JID - 101696896
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Animals
MH  - Cell Nucleus/genetics/metabolism/pathology
MH  - Humans
MH  - Mice
MH  - Muscle, Skeletal/metabolism
MH  - *Myotonic Dystrophy/genetics/metabolism/therapy
MH  - RNA/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
EDAT- 2022/02/12 06:00
MHDA- 2022/03/17 06:00
CRDT- 2022/02/11 05:35
PHST- 2020/07/17 00:00 [received]
PHST- 2021/12/07 00:00 [accepted]
PHST- 2022/02/12 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2022/02/11 05:35 [entrez]
AID - 10.1038/s41551-021-00838-2 [pii]
AID - 10.1038/s41551-021-00838-2 [doi]
PST - ppublish
SO  - Nat Biomed Eng. 2022 Feb;6(2):207-220. doi: 10.1038/s41551-021-00838-2. Epub 2022 
      Feb 10.

PMID- 34976437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220104
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 27
DP  - 2022 Mar 8
TI  - Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat 
      expansion in the DMPK gene.
PG  - 184-199
LID - 10.1016/j.omtn.2021.11.024 [doi]
AB  - CRISPR/Cas9-mediated therapeutic gene editing is a promising technology for 
      durable treatment of incurable monogenic diseases such as myotonic dystrophies. 
      Gene-editing approaches have been recently applied to in vitro and in vivo models 
      of myotonic dystrophy type 1 (DM1) to delete the pathogenic CTG-repeat expansion 
      located in the 3' untranslated region of the DMPK gene. In DM1-patient-derived 
      cells removal of the expanded repeats induced beneficial effects on major 
      hallmarks of the disease with reduction in DMPK transcript-containing ribonuclear 
      foci and reversal of aberrant splicing patterns. Here, we set out to excise the 
      triplet expansion in a time-restricted and cell-specific fashion to minimize the 
      potential occurrence of unintended events in off-target genomic loci and select 
      for the target cell type. To this aim, we employed either a ubiquitous 
      promoter-driven or a muscle-specific promoter-driven Cas9 nuclease and 
      tetracycline repressor-based guide RNAs. A dual-vector approach was used to 
      deliver the CRISPR/Cas9 components into DM1 patient-derived cells and in skeletal 
      muscle of a DM1 mouse model. In this way, we obtained efficient and inducible 
      gene editing both in proliferating cells and differentiated post-mitotic myocytes 
      in vitro as well as in skeletal muscle tissue in vivo.
CI  - (c) 2021 The Authors.
FAU - Cardinali, Beatrice
AU  - Cardinali B
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Provenzano, Claudia
AU  - Provenzano C
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Izzo, Mariapaola
AU  - Izzo M
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Voellenkle, Christine
AU  - Voellenkle C
AD  - Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato 
      Milanese, 20097 Milan, Italy.
FAU - Battistini, Jonathan
AU  - Battistini J
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Strimpakos, Georgios
AU  - Strimpakos G
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Golini, Elisabetta
AU  - Golini E
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Mandillo, Silvia
AU  - Mandillo S
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Scavizzi, Ferdinando
AU  - Scavizzi F
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Raspa, Marcello
AU  - Raspa M
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
FAU - Perfetti, Alessandra
AU  - Perfetti A
AD  - Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato 
      Milanese, 20097 Milan, Italy.
FAU - Baci, Denisa
AU  - Baci D
AD  - Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato 
      Milanese, 20097 Milan, Italy.
FAU - Lazarevic, Dejan
AU  - Lazarevic D
AD  - Center for Omics Sciences, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
FAU - Garcia-Manteiga, Jose Manuel
AU  - Garcia-Manteiga JM
AD  - Center for Omics Sciences, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, 75013 Paris, France.
FAU - Martelli, Fabio
AU  - Martelli F
AD  - Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato 
      Milanese, 20097 Milan, Italy.
FAU - Falcone, Germana
AU  - Falcone G
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, 00015 Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20211129
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC8693309
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - CTG repeats
OT  - DM1
OT  - DMSXL mouse model
OT  - gene editing
OT  - gene therapy
OT  - myotonic dystrophy
OT  - skeletal muscle
COIS- The authors declare no competing interests.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/11/29
CRDT- 2022/01/03 05:44
PHST- 2021/08/18 00:00 [received]
PHST- 2021/11/28 00:00 [accepted]
PHST- 2022/01/03 05:44 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/11/29 00:00 [pmc-release]
AID - S2162-2531(21)00299-7 [pii]
AID - 10.1016/j.omtn.2021.11.024 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2021 Nov 29;27:184-199. doi: 10.1016/j.omtn.2021.11.024. 
      eCollection 2022 Mar 8.

PMID- 34975387
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231108
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 15
DP  - 2021
TI  - Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies.
PG  - 791670
LID - 10.3389/fnins.2021.791670 [doi]
LID - 791670
AB  - Purpose: Neurofilament light chain in serum (sNfL) has been suggested as a 
      biomarker for the assessment of neuroaxonal damage. Since NfL are not expressed 
      in muscle, elevated sNfL in patients with primary myopathies suggest additional 
      nervous system involvement. To verify this hypothesis, we measured sNfL in a 
      series of patients with myopathies. Methods: sNfL were determined in 62 patients 
      with molecular proven primary myopathies in whom some nervous system involvement 
      may be predicted: myotonic dystrophy type I and II (DM I, II) and mitochondrial 
      disease. In addition, sNfL were measured in 8 patients with facioscapulohumeral 
      muscular dystrophy (FSHD) and in a disease control group caused by genetic 
      defects exclusively expressed in muscle. Results: sNfL values were significantly 
      elevated in the DM I, the DM II and the mitochondrial group, with FSHD patients 
      showing the lowest sNfL elevations. sNfL levels in the disease control group were 
      not different from the healthy controls. A significant correlation between repeat 
      length and sNfL levels was found in the DM I patients, but not in the DM II 
      patients. Mitochondrial patients with encephalopathy showed significantly higher 
      sNfL concentrations compared to patients with only muscular symptoms. Conclusion: 
      sNfL levels are elevated in myopathies with, based on the underlying molecular 
      defect or clinical features, established nervous system involvement, i.e., 
      myotonic dystrophies and mitochondrial disorders. sNfL were also raised in FSHD, 
      where involvement of the nervous system is not usually clinically apparent. Thus, 
      sNfL concentrations may serve as a biomarker for additional neuronal damage in 
      primary myopathies.
CI  - Copyright (c) 2021 Saak, Benkert, Akgun, Willemse, Kuhle, Ziemssen, Jackson and 
      Schaefer.
FAU - Saak, Annika
AU  - Saak A
AD  - Department of Neurology, University Hospital Dresden, Dresden, Germany.
FAU - Benkert, Pascal
AU  - Benkert P
AD  - Department Klinische Forschung, University Hospital Basel, Basel, Switzerland.
FAU - Akgun, Katja
AU  - Akgun K
AD  - Department of Neurology, University Hospital Dresden, Dresden, Germany.
FAU - Willemse, Eline
AU  - Willemse E
AD  - Department of Neurology, University Hospital Basel, Basel, Switzerland.
FAU - Kuhle, Jens
AU  - Kuhle J
AD  - Department of Neurology, University Hospital Basel, Basel, Switzerland.
FAU - Ziemssen, Tjalf
AU  - Ziemssen T
AD  - Department of Neurology, University Hospital Dresden, Dresden, Germany.
FAU - Jackson, Sandra
AU  - Jackson S
AD  - Department of Neurology, University Hospital Dresden, Dresden, Germany.
FAU - Schaefer, Jochen
AU  - Schaefer J
AD  - Department of Neurology, University Hospital Dresden, Dresden, Germany.
LA  - eng
PT  - Journal Article
DEP - 20211217
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC8718922
OTO - NOTNLM
OT  - facio scapulo humeral dystrophy
OT  - mitochondriopathies
OT  - myopathy
OT  - myotonic dystrophies (DM1 and DM2)
OT  - nervous system involvement
OT  - serum neurofilament
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/01/01
CRDT- 2022/01/03 05:35
PHST- 2021/10/08 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2022/01/03 05:35 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2021.791670 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Dec 17;15:791670. doi: 10.3389/fnins.2021.791670. 
      eCollection 2021.

PMID- 34941747
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 13
IP  - 12
DP  - 2021 Dec 20
TI  - Aurintricarboxylic Acid Decreases RNA Toxicity in a C. elegans Model of Repeat 
      Expansions.
LID - 10.3390/toxins13120910 [doi]
LID - 910
AB  - Pathologic expansions of DNA nucleotide tandem repeats may generate toxic RNA 
      that triggers disease phenotypes. RNA toxicity is the hallmark of multiple 
      expansion repeat disorders, including myotonic dystrophy type 1 (DM1). To date, 
      there are no available disease-modifying therapies for DM1. Our aim was to use 
      drug repositioning to ameliorate the phenotype of affected individuals in a 
      nematode model of DM1. As the RNA interference pathway plays a key role in 
      mediating RNA toxicity, we investigated the effect of aurintricarboxylic acid. We 
      demonstrated that by perturbing the RNA interference machinery using 
      aurintricarboxylic acid, we could annihilate the RNA toxicity and ameliorate the 
      phenotype. As our approach targets a universal disease mechanism, it is 
      potentially relevant for more expansion repeat disorders.
FAU - Braun, Maya
AU  - Braun M
AD  - Department of Developmental Biology and Cancer Research, Institute for Medical 
      Research Israel-Canada, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
FAU - Shoshani, Shachar
AU  - Shoshani S
AD  - Department of Developmental Biology and Cancer Research, Institute for Medical 
      Research Israel-Canada, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
FAU - Mellul-Shtern, Anna
AU  - Mellul-Shtern A
AD  - Department of Developmental Biology and Cancer Research, Institute for Medical 
      Research Israel-Canada, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
FAU - Tabach, Yuval
AU  - Tabach Y
AD  - Department of Developmental Biology and Cancer Research, Institute for Medical 
      Research Israel-Canada, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211220
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - 4431-00-9 (Aurintricarboxylic Acid)
SB  - IM
MH  - Animals
MH  - Aurintricarboxylic Acid/*pharmacology
MH  - Caenorhabditis elegans
MH  - Drug Repositioning
MH  - Gene Expression Regulation/*drug effects
MH  - Longevity/drug effects
MH  - Motor Activity/drug effects
MH  - Myotonic Dystrophy/drug therapy
MH  - RNA Interference
PMC - PMC8706575
OTO - NOTNLM
OT  - C. elegans
OT  - CUG repeats
OT  - RNA interference
OT  - drug repositioning
OT  - small RNA pathway
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/24 06:00
MHDA- 2022/02/26 06:00
PMCR- 2021/12/20
CRDT- 2021/12/23 17:22
PHST- 2021/11/04 00:00 [received]
PHST- 2021/12/06 00:00 [revised]
PHST- 2021/12/17 00:00 [accepted]
PHST- 2021/12/23 17:22 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - toxins13120910 [pii]
AID - toxins-13-00910 [pii]
AID - 10.3390/toxins13120910 [doi]
PST - epublish
SO  - Toxins (Basel). 2021 Dec 20;13(12):910. doi: 10.3390/toxins13120910.

PMID- 34938155
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 15
DP  - 2021
TI  - Developmental Exposure to a Human-Relevant Polychlorinated Biphenyl Mixture 
      Causes Behavioral Phenotypes That Vary by Sex and Genotype in Juvenile Mice 
      Expressing Human Mutations That Modulate Neuronal Calcium.
PG  - 766826
LID - 10.3389/fnins.2021.766826 [doi]
LID - 766826
AB  - Polychlorinated biphenyls (PCBs) are putative environmental risks for 
      neurodevelopmental disorders. Here, we tested two hypotheses: (1) developmental 
      exposure to a human-relevant PCB mixture causes behavioral phenotypes relevant to 
      neurodevelopmental disorders; and (2) expression of human mutations that 
      dysregulate neuronal Ca(2+) homeostasis influence sensitivity to behavioral 
      effects of developmental PCB exposures. To test these hypotheses, we used mice 
      that expressed a gain-of-function mutation (T4826I) in ryanodine receptor 1 
      (RYR1), the X-linked fragile X mental retardation 1 (FMR1) CGG repeat expansion 
      or both mutations (double mutant; DM). Transgenic mice and wildtype (WT) mice 
      were exposed to the MARBLES PCB mix at 0, 0.1, 1, and 6 mg/kg/day in the maternal 
      diet throughout gestation and lactation. The MARBLES PCB mix simulates the 
      relative proportions of the 12 most abundant PCB congeners found in the serum of 
      pregnant women at increased risk for having a child with a neurodevelopmental 
      disorder. We assessed ultrasonic vocalizations at postnatal day 7 (P7), 
      spontaneous repetitive behaviors at P25-P30, and sociability at P27-P32. 
      Developmental PCB exposure reduced ultrasonic vocalizations in WT litters in all 
      dose groups, but had no effect on ultrasonic vocalizations in transgenic litters. 
      Developmental PCB exposure significantly increased self-grooming and decreased 
      sociability in WT males in the 0.1 mg/kg dose group, but had no effect on WT 
      females in any dose group. Genotype alone influenced ultrasonic vocalizations, 
      self-grooming and to a lesser extent sociability. Genotype alone also influenced 
      effects of PCBs on sociability. PCB levels in the brain tissue of pups increased 
      in a dose-dependent manner, but within any dose group did not differ between 
      genotypes. In summary, developmental PCB exposure phenocopied social behavior 
      phenotypes observed in mice expressing human mutations that modify intracellular 
      Ca(2+) dynamics, and expression of these mutations alleviated PCB effects on 
      ultrasonic vocalizations and repetitive behavior, and modified the dose-response 
      relationships and sex-dependent effects of PCB effects on social behavior. These 
      findings suggest that: (1) developmental PCB exposure causes behavioral 
      phenotypes that vary by sex and genotype; and (2) sex-specific responses to 
      environmental factors may contribute to sex biases in the prevalence and/or 
      severity of neurodevelopmental disorders.
CI  - Copyright (c) 2021 Sethi, Keil Stietz, Valenzuela, Klocke, Silverman, Puschner, 
      Pessah and Lein.
FAU - Sethi, Sunjay
AU  - Sethi S
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Keil Stietz, Kimberly P
AU  - Keil Stietz KP
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Valenzuela, Anthony E
AU  - Valenzuela AE
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Klocke, Carolyn R
AU  - Klocke CR
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Silverman, Jill L
AU  - Silverman JL
AD  - Department of Psychiatry and Behavioral Sciences, School of Medicine, University 
      of California, Davis, Davis, CA, United States.
AD  - The MIND Institute, University of California, Davis, Davis, CA, United States.
FAU - Puschner, Birgit
AU  - Puschner B
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Pessah, Isaac N
AU  - Pessah IN
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
AD  - The MIND Institute, University of California, Davis, Davis, CA, United States.
FAU - Lein, Pamela J
AU  - Lein PJ
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
AD  - The MIND Institute, University of California, Davis, Davis, CA, United States.
LA  - eng
GR  - P30 CA093373/CA/NCI NIH HHS/United States
GR  - T32 ES007059/ES/NIEHS NIH HHS/United States
GR  - P30 ES023513/ES/NIEHS NIH HHS/United States
GR  - P50 HD103526/HD/NICHD NIH HHS/United States
GR  - F32 HD088016/HD/NICHD NIH HHS/United States
GR  - R00 ES029537/ES/NIEHS NIH HHS/United States
GR  - P42 ES013661/ES/NIEHS NIH HHS/United States
GR  - R01 ES014901/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20211206
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC8685320
OTO - NOTNLM
OT  - FMR1 permutation
OT  - T4826I mutation
OT  - gene-environment interaction
OT  - neurodevelopmental disorders
OT  - ryanodine receptor
OT  - sex differences
OT  - social behavior
OT  - ultrasonic vocalization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/24 06:01
PMCR- 2021/01/01
CRDT- 2021/12/23 05:46
PHST- 2021/08/30 00:00 [received]
PHST- 2021/11/17 00:00 [accepted]
PHST- 2021/12/23 05:46 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/24 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2021.766826 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Dec 6;15:766826. doi: 10.3389/fnins.2021.766826. eCollection 
      2021.

PMID- 34924936
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 15
DP  - 2021
TI  - Sex and Genotype Modulate the Dendritic Effects of Developmental Exposure to a 
      Human-Relevant Polychlorinated Biphenyls Mixture in the Juvenile Mouse.
PG  - 766802
LID - 10.3389/fnins.2021.766802 [doi]
LID - 766802
AB  - While many neurodevelopmental disorders (NDDs) are thought to result from 
      interactions between environmental and genetic risk factors, the identification 
      of specific gene-environment interactions that influence NDD risk remains a 
      critical data gap. We tested the hypothesis that polychlorinated biphenyls (PCBs) 
      interact with human mutations that alter the fidelity of neuronal Ca(2+) 
      signaling to confer NDD risk. To test this, we used three transgenic mouse lines 
      that expressed human mutations known to alter Ca(2+) signals in neurons: (1) 
      gain-of-function mutation in ryanodine receptor-1 (T4826I-RYR1); (2) CGG-repeat 
      expansion in the 5' non-coding portion of the fragile X mental retardation gene 1 
      (FMR1); and (3) a double mutant (DM) that expressed both mutations. Transgenic 
      and wildtype (WT) mice were exposed throughout gestation and lactation to the 
      MARBLES PCB mix at 0.1, 1, or 6 mg/kg in the maternal diet. The MARBLES mix 
      simulates the relative proportions of the twelve most abundant PCB congeners 
      found in serum from pregnant women at increased risk for having a child with an 
      NDD. Using Golgi staining, the effect of developmental PCB exposure on dendritic 
      arborization of pyramidal neurons in the CA1 hippocampus and somatosensory cortex 
      of male and female WT mice was compared to pyramidal neurons from transgenic 
      mice. A multilevel linear mixed-effects model identified a main effect of dose 
      driven by increased dendritic arborization of cortical neurons in the 1 mg/kg PCB 
      dose group. Subsequent analyses with genotypes indicated that the MARBLES PCB 
      mixture had no effect on the dendritic arborization of hippocampal neurons in WT 
      mice of either sex, but significantly increased dendritic arborization of 
      cortical neurons of WT males in the 6 mg/kg PCB dose group. Transgene expression 
      increased sensitivity to the impact of developmental PCB exposure on dendritic 
      arborization in a sex-, and brain region-dependent manner. In conclusion, 
      developmental exposure to PCBs present in the gestational environment of at-risk 
      humans interfered with normal dendritic morphogenesis in the developing mouse 
      brain in a sex-, genotype- and brain region-dependent manner. Overall, these 
      observations provide proof-of-principle evidence that PCBs interact with 
      heritable mutations to modulate a neurodevelopmental outcome of relevance to 
      NDDs.
CI  - Copyright (c) 2021 Keil Stietz, Sethi, Klocke, de Ruyter, Wilson, Pessah and Lein.
FAU - Keil Stietz, Kimberly P
AU  - Keil Stietz KP
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Sethi, Sunjay
AU  - Sethi S
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Klocke, Carolyn R
AU  - Klocke CR
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - de Ruyter, Tryssa E
AU  - de Ruyter TE
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Wilson, Machelle D
AU  - Wilson MD
AD  - Clinical and Translational Science Center, Division of Biostatistics, Department 
      of Public Health Sciences, School of Medicine, University of California, Davis, 
      Davis, CA, United States.
FAU - Pessah, Isaac N
AU  - Pessah IN
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
FAU - Lein, Pamela J
AU  - Lein PJ
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, United States.
LA  - eng
GR  - P30 CA093373/CA/NCI NIH HHS/United States
GR  - R01 ES029213/ES/NIEHS NIH HHS/United States
GR  - T32 ES007059/ES/NIEHS NIH HHS/United States
GR  - P50 HD103526/HD/NICHD NIH HHS/United States
GR  - F32 HD088016/HD/NICHD NIH HHS/United States
GR  - R00 ES029537/ES/NIEHS NIH HHS/United States
GR  - UL1 TR001860/TR/NCATS NIH HHS/United States
GR  - P30 ES023513/ES/NIEHS NIH HHS/United States
GR  - P42 ES013661/ES/NIEHS NIH HHS/United States
GR  - R01 ES014901/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20211203
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC8678536
OTO - NOTNLM
OT  - FMR1 premutation
OT  - Golgi stain
OT  - Sholl analysis
OT  - gene-environment interaction
OT  - neurodevelopmental disorders
OT  - ryanodine receptor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/21 06:00
MHDA- 2021/12/21 06:01
PMCR- 2021/01/01
CRDT- 2021/12/20 06:04
PHST- 2021/08/30 00:00 [received]
PHST- 2021/11/04 00:00 [accepted]
PHST- 2021/12/20 06:04 [entrez]
PHST- 2021/12/21 06:00 [pubmed]
PHST- 2021/12/21 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2021.766802 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Dec 3;15:766802. doi: 10.3389/fnins.2021.766802. eCollection 
      2021.

PMID- 34923335
OWN - NLM
STAT- MEDLINE
DCOM- 20220128
LR  - 20220128
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 432
DP  - 2022 Jan 15
TI  - Characteristics of myotonic dystrophy patients in the national registry of Japan.
PG  - 120080
LID - S0022-510X(21)02782-9 [pii]
LID - 10.1016/j.jns.2021.120080 [doi]
AB  - Myotonic dystrophies (DM) are inherited autosomal dominant disorders affecting 
      multiple organs. Currently available therapeutics for DM are limited; therefore, 
      a patient registry is essential for therapeutic development and success of 
      clinical trials targeting the diseases. We have developed a nationwide DM 
      registry in Japan under the Registry of Muscular Dystrophy (Remudy). The 
      registration process was patient-initiated; however, physicians certified the 
      clinical information. The dataset includes all Naarden and TREAT-NMD core 
      datasets and additional items covering major DM clinical features. As of March 
      2020, we enrolled 976 patients with genetically confirmed DM. The majority 
      (99.9%) of these patients had DM1, with 11.4% having the congenital form. 
      However, 1 patient had DM2. Upon classifying 969 symptomatic DM1 patients based 
      on their age at onset, an earlier onset was associated with a longer CTG repeat 
      length. Myotonia was the most frequent symptom, followed by hand disability, 
      fatigue, and daytime sleepiness. The frequency of hand disabilities, 
      constipation, and visual disturbances was higher for patients with congenital DM. 
      According to a multiple regression analysis of objective clinical measurements 
      related to prognosis and activities of daily living, CTG repeat length strongly 
      influenced the grip strength, forced vital capacity, and QRS time in an 
      electrocardiogram. However, the grip strength was only modestly related to 
      disease duration. This report will shed light on the Japanese national DM 
      registry, which has recruited a significant number of patients. The registry will 
      provide invaluable data for planning clinical trials and improving the standard 
      of care for patients.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Sugimoto, Marika
AU  - Sugimoto M
AD  - Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical 
      Sciences, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 
      565-0871, Japan.
FAU - Kuru, Satoshi
AU  - Kuru S
AD  - Department of Neurology, National Hospital Organization Suzuka National Hospital, 
      Kasado, Suzuka, Mie 513-8501, Japan.
FAU - Takada, Hiroto
AU  - Takada H
AD  - Department of Neurology, National Hospital Organization Aomori National Hospital, 
      Namioka, Aomori, Aomori 038-1331, Japan.
FAU - Horie, Riho
AU  - Horie R
AD  - Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical 
      Sciences, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 
      565-0871, Japan.
FAU - Yamauchi, Kosuke
AU  - Yamauchi K
AD  - Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical 
      Sciences, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 
      565-0871, Japan.
FAU - Kubota, Tomoya
AU  - Kubota T
AD  - Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical 
      Sciences, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 
      565-0871, Japan.
FAU - Matsumura, Tsuyoshi
AU  - Matsumura T
AD  - Department of Neurology, National Hospital Organization Osaka Toneyama Medical 
      Center, Toneyama, Toyonaka, Osaka 560-8552, Japan.
FAU - Nakamura, Harumasa
AU  - Nakamura H
AD  - Translational Medical Center, National Center of Neurology and Psychiatry, 
      Ogawa-higashi, Kodaira, Tokyo 187-8551, Japan.
FAU - Kimura, En
AU  - Kimura E
AD  - Translational Medical Center, National Center of Neurology and Psychiatry, 
      Ogawa-higashi, Kodaira, Tokyo 187-8551, Japan.
FAU - Takahashi, Masanori P
AU  - Takahashi MP
AD  - Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical 
      Sciences, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 
      565-0871, Japan. Electronic address: mtakahas@sahs.med.osaka-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20211211
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
SB  - IM
MH  - Activities of Daily Living
MH  - Fatigue
MH  - Humans
MH  - Japan/epidemiology
MH  - *Myotonic Dystrophy/epidemiology/genetics
MH  - Registries
OTO - NOTNLM
OT  - CTG repeat length
OT  - Clinical measurements
OT  - ECG
OT  - Myotonic dystrophy
OT  - Pulmonary function
OT  - Registry
OT  - Subjective symptoms
EDAT- 2021/12/20 06:00
MHDA- 2022/01/29 06:00
CRDT- 2021/12/19 20:58
PHST- 2021/03/18 00:00 [received]
PHST- 2021/11/02 00:00 [revised]
PHST- 2021/11/18 00:00 [accepted]
PHST- 2021/12/20 06:00 [pubmed]
PHST- 2022/01/29 06:00 [medline]
PHST- 2021/12/19 20:58 [entrez]
AID - S0022-510X(21)02782-9 [pii]
AID - 10.1016/j.jns.2021.120080 [doi]
PST - ppublish
SO  - J Neurol Sci. 2022 Jan 15;432:120080. doi: 10.1016/j.jns.2021.120080. Epub 2021 
      Dec 11.

PMID- 34915310
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220415
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 58
DP  - 2022 Jan
TI  - Generation of induced pluripotent stem cell line (ZZUi015-A) from a DM1 patient 
      with cataract.
PG  - 102623
LID - S1873-5061(21)00470-0 [pii]
LID - 10.1016/j.scr.2021.102623 [doi]
AB  - Myotonic dystrophy (DM1) is mainly caused by abnormal number of the CTG repeat 
      sequence of the DMPK gene. DM1 clinically manifests mainly as progressive 
      muscular atrophy and muscle weakness. Cataracts form in the eyes of some 
      patients. We successfully induced skin fibroblasts from a DM1 patient with 
      cataract and in turn induced pluripotent stem cells (iPSCs) using an unintegrated 
      reprogramming approach. This cell line will provide a reliable cell model for 
      further studies on the pathogenesis and potential therapeutic targets of DM1.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Li, Tingting
AU  - Li T
AD  - Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou 450052, China.
FAU - Sun, Huifang
AU  - Sun H
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China; School of Medical Sciences, Zhengzhou University, 
      Zhengzhou, Henan 450001, China.
FAU - Wang, Zhuoya
AU  - Wang Z
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Chen, Na
AU  - Chen N
AD  - First School of Clinical Medicine, Henan University of Chinese Medicine, 
      Zhengzhou, Henan 450046, China.
FAU - Zhang, Ke
AU  - Zhang K
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Wang, Yanlin
AU  - Wang Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China. Electronic address: wyllyh1986@126.com.
FAU - Xu, Yuming
AU  - Xu Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China. Electronic address: xuyuming@zzu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211211
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - *Cataract/genetics/metabolism/pathology
MH  - Cell Line
MH  - Fibroblasts/metabolism
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - *Myotonic Dystrophy/metabolism
MH  - Myotonin-Protein Kinase/genetics
MH  - Trinucleotide Repeat Expansion
EDAT- 2021/12/17 06:00
MHDA- 2022/04/16 06:00
CRDT- 2021/12/16 20:26
PHST- 2021/08/19 00:00 [received]
PHST- 2021/12/01 00:00 [revised]
PHST- 2021/12/10 00:00 [accepted]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2021/12/16 20:26 [entrez]
AID - S1873-5061(21)00470-0 [pii]
AID - 10.1016/j.scr.2021.102623 [doi]
PST - ppublish
SO  - Stem Cell Res. 2022 Jan;58:102623. doi: 10.1016/j.scr.2021.102623. Epub 2021 Dec 
      11.

PMID- 34593893
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20211227
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Sep 30
TI  - Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic 
      dystrophy myotubes in a Drosophila model of the disease.
PG  - 19417
LID - 10.1038/s41598-021-98866-0 [doi]
LID - 19417
AB  - In Myotonic Dystrophy type 1 (DM1), a non-coding CTG repeats rare expansion 
      disease; toxic double-stranded RNA hairpins sequester the RNA-binding proteins 
      Muscleblind-like 1 and 2 (MBNL1 and 2) and trigger other DM1-related pathogenesis 
      pathway defects. In this paper, we characterize four D-amino acid hexapeptides 
      identified together with abp1, a peptide previously shown to stabilize CUG RNA in 
      its single-stranded conformation. With the generalized sequence cpy(a/t)(q/w)e, 
      these related peptides improved three MBNL-regulated exon inclusions in 
      DM1-derived cells. Subsequent experiments showed that these compounds generally 
      increased the relative expression of MBNL1 and its nuclear-cytoplasmic 
      distribution, reduced hyperactivated autophagy, and increased the percentage of 
      differentiated (Desmin-positive) cells in vitro. All peptides rescued atrophy of 
      indirect flight muscles in a Drosophila model of the disease, and partially 
      rescued muscle function according to climbing and flight tests. Investigation of 
      their mechanism of action supports that all four compounds can bind to CUG 
      repeats with slightly different association constant, but binding did not 
      strongly influence the secondary structure of the toxic RNA in contrast to abp1. 
      Finally, molecular modeling suggests a detailed view of the interactions of 
      peptide-CUG RNA complexes useful in the chemical optimization of compounds.
CI  - (c) 2021. The Author(s).
FAU - Rapisarda, Anna
AU  - Rapisarda A
AD  - Department of Genetics, University Institute for Biotechnology and Biomedicine 
      (BIOTECMED), University of Valencia, Dr. Moliner, 50, 46100, Burjasot, Valencia, 
      Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, 46010, 
      Valencia, Spain.
FAU - Bargiela, Ariadna
AU  - Bargiela A
AD  - Department of Genetics, University Institute for Biotechnology and Biomedicine 
      (BIOTECMED), University of Valencia, Dr. Moliner, 50, 46100, Burjasot, Valencia, 
      Spain. ariadna.bargiela@uv.es.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, 46010, 
      Valencia, Spain. ariadna.bargiela@uv.es.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - Department of Genetics, University Institute for Biotechnology and Biomedicine 
      (BIOTECMED), University of Valencia, Dr. Moliner, 50, 46100, Burjasot, Valencia, 
      Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, 46010, 
      Valencia, Spain.
AD  - Arthex Biotech S.L. Catedratico Agustin Escardino 9, Parc Scientific University 
      of Valencia, Paterna, Valencia, Spain.
FAU - Pont, Isabel
AU  - Pont I
AD  - Instituto de Ciencia Molecular (ICMol), Departamento de Quimica Inorganica, C. 
      Catedratico Jose Beltran 2, Universidad de Valencia, 46980, Paterna, Spain.
FAU - Estrada-Tejedor, Roger
AU  - Estrada-Tejedor R
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
FAU - Garcia-Espana, Enrique
AU  - Garcia-Espana E
AD  - Instituto de Ciencia Molecular (ICMol), Departamento de Quimica Inorganica, C. 
      Catedratico Jose Beltran 2, Universidad de Valencia, 46980, Paterna, Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - Department of Genetics, University Institute for Biotechnology and Biomedicine 
      (BIOTECMED), University of Valencia, Dr. Moliner, 50, 46100, Burjasot, Valencia, 
      Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, 46010, 
      Valencia, Spain.
FAU - Perez-Alonso, Manuel
AU  - Perez-Alonso M
AD  - Department of Genetics, University Institute for Biotechnology and Biomedicine 
      (BIOTECMED), University of Valencia, Dr. Moliner, 50, 46100, Burjasot, Valencia, 
      Spain.
AD  - Translational Genomics Group, INCLIVA Biomedical Research Institute, 46010, 
      Valencia, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210930
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (MBNL1 protein, human)
RN  - 0 (Peptides)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Cells, Cultured
MH  - Drosophila
MH  - Female
MH  - Fibroblasts
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*metabolism
MH  - Peptides/*metabolism
MH  - Protein Binding
MH  - RNA/*metabolism
MH  - RNA-Binding Proteins/*metabolism
PMC - PMC8484449
COIS- The authors declare no competing interests.
EDAT- 2021/10/02 06:00
MHDA- 2021/12/28 06:00
PMCR- 2021/09/30
CRDT- 2021/10/01 06:51
PHST- 2020/12/09 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/10/01 06:51 [entrez]
PHST- 2021/10/02 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2021/09/30 00:00 [pmc-release]
AID - 10.1038/s41598-021-98866-0 [pii]
AID - 98866 [pii]
AID - 10.1038/s41598-021-98866-0 [doi]
PST - epublish
SO  - Sci Rep. 2021 Sep 30;11(1):19417. doi: 10.1038/s41598-021-98866-0.

PMID- 34591228
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211009
IS  - 2090-5920 (Electronic)
IS  - 1687-157X (Print)
IS  - 1687-157X (Linking)
VI  - 19
IP  - 1
DP  - 2021 Sep 30
TI  - In silico analysis of promoter region and regulatory elements of glucan 
      endo-1,3-beta-glucosidase encoding genes in Solanum tuberosum: cultivar DM 1-3 
      516 R44.
PG  - 145
LID - 10.1186/s43141-021-00240-0 [doi]
LID - 145
AB  - BACKGROUND: Potato (Solanum tuberosum L.) is one of the most important food crops 
      in the world. Pathogens remain as one of the major constraints limiting potato 
      productivity. Thus, understanding of gene regulation mechanism of 
      pathogenesis-related genes such as glucan endo-1,3-beta-glucosidase is a 
      foundation for genetic engineering of potato for disease resistance and reduces 
      the use of fungicides. In the present study, 19 genes were selected and attempts 
      were made through in silico methods to identify and characterize the promoter 
      regions, regulatory elements, and CpG islands of glucan endo-1,3-beta-glucosidase 
      gene in Solanum tuberosum cultivar DM 1-3 516 R44. RESULTS: The current analysis 
      revealed that single transcription start sites (TSSs) were present in 12/19 
      (63.2%) of promoter regions analyzed. The predictive score at a cutoff value of 
      0.8 for the majority (84.2%) of the promoter regions ranged from 0.90 to 1.00. 
      The locations for 42% of the TSSs were below -500 bp relative to the start codon 
      (ATG). MbetaGII was identified as the common promoter motif for 94.4% of the genes 
      with an E value of 3.5e-001. The CpG analysis showed low CpG density in the 
      promoter regions of most of the genes except for gene ID102593331 and ID: 
      102595860. The number of SSRs per gene ranged from 2 to 9 with repeat lengths of 
      2 to 6 bp. Evolutionary distances ranged from 0.685 to 0.770 (mean = 0.73), 
      demonstrating narrower genetic diversity range. Phylogeny was inferred using the 
      UPGMA method, and gene sequences from different species were found to be 
      clustered together. CONCLUSION: In silico identified regulatory elements in 
      promoter regions will contribute to our understanding of the regulatory mechanism 
      of glucan endo-1,3-beta-glucosidase genes and provide a promising target for 
      genetic engineering to improve disease resistance in potatoes.
CI  - (c) 2021. The Author(s).
FAU - Kebede, Atnafu
AU  - Kebede A
AUID- ORCID: 0000-0002-4561-583X
AD  - Department of Applied Biology, School of Applied Natural Science, Adama Science 
      and Technology University, P.O. Box 1888, Adama, Ethiopia. 
      atnafukebede@yahoo.com.
AD  - Department of Biology, College of Natural and Computational Sciences, Dire Dawa 
      University, P.O. Box 1362, Dire Dawa, Ethiopia. atnafukebede@yahoo.com.
FAU - Kebede, Mulugeta
AU  - Kebede M
AD  - Department of Applied Biology, School of Applied Natural Science, Adama Science 
      and Technology University, P.O. Box 1888, Adama, Ethiopia.
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - Netherlands
TA  - J Genet Eng Biotechnol
JT  - Journal, genetic engineering & biotechnology
JID - 101317150
PMC - PMC8484425
OTO - NOTNLM
OT  - CpG island
OT  - Glucan endo-1,3-beta-glucosidase
OT  - Motif
OT  - Promoter
OT  - Solanum tuberosum
OT  - Transcription factor
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/09/30
CRDT- 2021/09/30 12:32
PHST- 2021/05/18 00:00 [received]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/09/30 12:32 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/09/30 00:00 [pmc-release]
AID - 10.1186/s43141-021-00240-0 [pii]
AID - 240 [pii]
AID - 10.1186/s43141-021-00240-0 [doi]
PST - epublish
SO  - J Genet Eng Biotechnol. 2021 Sep 30;19(1):145. doi: 10.1186/s43141-021-00240-0.

PMID- 34589284
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211001
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 25
DP  - 2021 Sep 3
TI  - Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting 
      excessive autophagy through miR-7 biogenesis repression.
PG  - 652-667
LID - 10.1016/j.omtn.2021.08.010 [doi]
AB  - Skeletal muscle symptoms strongly contribute to mortality of myotonic dystrophy 
      type 1 (DM1) patients. DM1 is a neuromuscular genetic disease caused by CTG 
      repeat expansions that, upon transcription, sequester the Muscleblind-like family 
      of proteins and dysregulate alternative splicing of hundreds of genes. However, 
      mis-splicing does not satisfactorily explain muscle atrophy and wasting, and 
      several other contributing factors have been suggested, including hyperactivated 
      autophagy leading to excessive catabolism. MicroRNA (miR)-7 has been demonstrated 
      to be necessary and sufficient to repress the autophagy pathway in cell models of 
      the disease, but the origin of its low levels in DM1 was unknown. We have found 
      that the RNA-binding protein Musashi-2 (MSI2) is upregulated in patient-derived 
      myoblasts and biopsy samples. Because it has been previously reported that MSI2 
      controls miR-7 biogenesis, we tested the hypothesis that excessive MSI2 was 
      repressing miR-7 maturation. Using gene-silencing strategies (small interfering 
      RNAs [siRNAs] and gapmers) and the small molecule MSI2-inhibitor Ro 08-2750, we 
      demonstrate that reducing MSI2 levels or activity boosts miR-7 expression, 
      represses excessive autophagy, and downregulates atrophy-related genes of the UPS 
      system. We also detect a significant upregulation of MBNL1 upon MSI2 silencing. 
      Taken together, we propose MSI2 as a new therapeutic target to treat muscle 
      dysfunction in DM1.
CI  - (c) 2021 The Authors.
FAU - Sabater-Arcis, Maria
AU  - Sabater-Arcis M
AD  - Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Valencia, Spain.
AD  - INCLIVA Biomedical Research Institute, 46100 Burjasot, Valencia, Spain.
FAU - Bargiela, Ariadna
AU  - Bargiela A
AD  - Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Valencia, Spain.
AD  - INCLIVA Biomedical Research Institute, 46100 Burjasot, Valencia, Spain.
FAU - Moreno, Nerea
AU  - Moreno N
AD  - Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Valencia, Spain.
AD  - INCLIVA Biomedical Research Institute, 46100 Burjasot, Valencia, Spain.
FAU - Poyatos-Garcia, Javier
AU  - Poyatos-Garcia J
AD  - Centro de Investigacion Biomedica en Red en Enfermedades Raras (CIBERER), 
      Valencia, Spain.
AD  - Neuromuscular Research Unit, Neurology Department, Instituto de Investigacion 
      Sanitaria la Fe, Hospital Universitari i Politecnic La Fe, 46026 Valencia, Spain.
FAU - Vilchez, Juan J
AU  - Vilchez JJ
AD  - Centro de Investigacion Biomedica en Red en Enfermedades Raras (CIBERER), 
      Valencia, Spain.
AD  - Neuromuscular Research Unit, Neurology Department, Instituto de Investigacion 
      Sanitaria la Fe, Hospital Universitari i Politecnic La Fe, 46026 Valencia, Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - Translational Genomics Group, University Institute for Biotechnology and 
      Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Valencia, Spain.
AD  - INCLIVA Biomedical Research Institute, 46100 Burjasot, Valencia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20210819
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC8463325
OTO - NOTNLM
OT  - MSI2
OT  - antisense oligonucleotides
OT  - autophagy
OT  - miR-7
OT  - muscle atrophy
OT  - muscle dysfunction
OT  - myotonic dystrophy
OT  - myotubes
COIS- The authors declare no competing interests.
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/08/19
CRDT- 2021/09/30 07:15
PHST- 2021/02/04 00:00 [received]
PHST- 2021/08/10 00:00 [accepted]
PHST- 2021/09/30 07:15 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/08/19 00:00 [pmc-release]
AID - S2162-2531(21)00204-3 [pii]
AID - 10.1016/j.omtn.2021.08.010 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2021 Aug 19;25:652-667. doi: 10.1016/j.omtn.2021.08.010. 
      eCollection 2021 Sep 3.

PMID- 34513303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210914
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 26
DP  - 2021 Dec 3
TI  - Preclinical characterization of antagomiR-218 as a potential treatment for 
      myotonic dystrophy.
PG  - 174-191
LID - 10.1016/j.omtn.2021.07.017 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease caused by 
      expansion of unstable CTG repeats in a non-coding region of the DMPK gene. CUG 
      expansions in mutant DMPK transcripts sequester MBNL1 proteins in ribonuclear 
      foci. Depletion of this protein is a primary contributor to disease symptoms such 
      as muscle weakness and atrophy and myotonia, yet upregulation of endogenous MBNL1 
      levels may compensate for this sequestration. Having previously demonstrated that 
      antisense oligonucleotides against miR-218 boost MBNL1 expression and rescue 
      phenotypes in disease models, here we provide preclinical characterization of an 
      antagomiR-218 molecule using the HSA(LR) mouse model and patient-derived 
      myotubes. In HSA(LR), antagomiR-218 reached 40-60 pM 2 weeks after injection, 
      rescued molecular and functional phenotypes in a dose- and time-dependent manner, 
      and showed a good toxicity profile after a single subcutaneous administration. In 
      muscle tissue, antagomiR rescued the normal subcellular distribution of Mbnl1 and 
      did not alter the proportion of myonuclei containing CUG foci. In patient-derived 
      cells, antagomiR-218 improved defective fusion and differentiation and rescued up 
      to 34% of the gene expression alterations found in the transcriptome of patient 
      cells. Importantly, miR-218 was found to be upregulated in DM1 muscle biopsies, 
      pinpointing this microRNA (miRNA) as a relevant therapeutic target.
CI  - (c) 2021 The Author(s).
FAU - Cerro-Herreros, Estefania
AU  - Cerro-Herreros E
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Gonzalez-Martinez, Irene
AU  - Gonzalez-Martinez I
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Moreno, Nerea
AU  - Moreno N
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Espinosa-Espinosa, Jorge
AU  - Espinosa-Espinosa J
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Fernandez-Costa, Juan M
AU  - Fernandez-Costa JM
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Colom-Rodrigo, Anna
AU  - Colom-Rodrigo A
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Overby, Sarah J
AU  - Overby SJ
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Seoane-Miraz, David
AU  - Seoane-Miraz D
AD  - Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headley 
      Way, OX3 9DU, Oxford, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Poyatos-Garcia, Javier
AU  - Poyatos-Garcia J
AD  - The IISLAFE Health Research Institute, Avenida Fernando Abril Martorell, 106 
      Torre A 7 planta, 46026 Valencia, Spain.
AD  - Neuromuscular Reference Centre ERN EURO-NMD and Neuromuscular Pathology and 
      Ataxia Research Group, Hospital La Fe Health Research Institute, Valencia, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), 
      Instituto de Salud Carlos III, Madrid, Spain.
FAU - Vilchez, Juan J
AU  - Vilchez JJ
AD  - The IISLAFE Health Research Institute, Avenida Fernando Abril Martorell, 106 
      Torre A 7 planta, 46026 Valencia, Spain.
AD  - Neuromuscular Reference Centre ERN EURO-NMD and Neuromuscular Pathology and 
      Ataxia Research Group, Hospital La Fe Health Research Institute, Valencia, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), 
      Instituto de Salud Carlos III, Madrid, Spain.
FAU - Lopez de Munain, Adolfo
AU  - Lopez de Munain A
AD  - Biodonostia Health Research Institute, P degrees  Dr. Beguiristain s/n, 20014 
      Donostia-San Sebastian, Spain.
AD  - Hospital Universitario Donostia-Osakidetza-Departamento de 
      Neurociencias-Universidad del Pais Vasco-CIBERNED.
FAU - Varela, Miguel A
AU  - Varela MA
AD  - Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headley 
      Way, OX3 9DU, Oxford, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Wood, Matthew J
AU  - Wood MJ
AD  - Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headley 
      Way, OX3 9DU, Oxford, UK.
AD  - MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK.
FAU - Perez-Alonso, Manuel
AU  - Perez-Alonso M
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - University Research Institute for Biotechnology and Biomedicine (BIOTECMED), 
      Universidad de Valencia, Dr. Moliner, 50, 46100 Burjasot, Valencia, Spain.
AD  - Incliva Biomedical Research Institute, Avenida Menendez Pelayo 4 acc, 46010 
      Valencia, Spain.
LA  - eng
PT  - Journal Article
DEP - 20210729
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC8413838
OTO - NOTNLM
OT  - CTG repeat expansions
OT  - MBNL1 protein
OT  - alternative splicing
OT  - antisense oligonucleotide
OT  - microRNAs
OT  - myotonic dystrophy
OT  - therapeutic gene modulation
OT  - tissue distribution
OT  - transcriptomics
COIS- B.L., R.A., J.M.F.-C., and E.C.-H. are inventors in patent PCT/EP2017/073685. 
      This patent is currently licensed to Arthex Biotech, of which B.L. and R.A. are 
      founders and CEO and scientific consultant, respectively. B.L. and R.A. each hold 
      more than 5% ownership of Arthex, a company with related interests.
EDAT- 2021/09/14 06:00
MHDA- 2021/09/14 06:01
PMCR- 2021/07/29
CRDT- 2021/09/13 06:51
PHST- 2020/10/18 00:00 [received]
PHST- 2021/07/17 00:00 [accepted]
PHST- 2021/09/13 06:51 [entrez]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/09/14 06:01 [medline]
PHST- 2021/07/29 00:00 [pmc-release]
AID - S2162-2531(21)00185-2 [pii]
AID - 10.1016/j.omtn.2021.07.017 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2021 Jul 29;26:174-191. doi: 10.1016/j.omtn.2021.07.017. 
      eCollection 2021 Dec 3.

PMID- 34472530
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211102
IS  - 0970-2113 (Print)
IS  - 0974-598X (Electronic)
IS  - 0970-2113 (Linking)
VI  - 38
IP  - 5
DP  - 2021 Sep-Oct
TI  - Mediastinal and pleural lipomatosis as a manifestation of myotonic dystrophy type 
      1.
PG  - 486-488
LID - 10.4103/lungindia.lungindia_25_21 [doi]
AB  - Mediastinal and pleural lipomatosis is a rare but usually benign and asymptomatic 
      disease. Mediastinal lipomatosis is associated with steroid use, obesity, 
      hyperlipidemia, diabetes, or Cushing syndrome. In some cases, it becomes 
      symptomatic manifesting with dyspnea, thoracic pain, coughing, dysphonia, 
      dysphagia, supraventricular tachycardia, or persistent pneumonia. Mediastinal 
      lipomatosis has not been reported in association with myotonic dystrophy type 1 
      (MD1). In a 65yo male with a long-term history of progressive muscle weakness, 
      hyper-creatine-kinase-emia, bilateral cataract, sleep apnea syndrome, 
      gynecomastia, hepatic steatosis, arterial hypertension, atrioventricular block 1, 
      QTc prolongation, hyperlipidemia, hyperuricemia, and hepatopathy, MD1 was 
      diagnosed upon the clinical presentation and a heterozygous CTG repeat expansion 
      of 1200-1400 repeats in DMPK. Work-up for dyspnea and leg edema revealed heart 
      failure and mediastinal and pleural lipomatosis. Upon standard treatment, heart 
      failure resolved. In conclusion, mediastinal and pleural lipomatosis can be a 
      rare manifestation of MD1 and can manifest with heart failure. In patients with 
      mediastinal lipomatosis, MD1 should be excluded.
FAU - Finsterer, Josef
AU  - Finsterer J
AD  - Municipial Hospital Landstrasse, Messerli Institute, Vienna, Austria.
FAU - Scorza, Fulvio A
AU  - Scorza FA
AD  - Department of Neuroscience, University of Sao Paolo, Sao Paulo, Brasil.
LA  - eng
PT  - Case Reports
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC8509172
OTO - NOTNLM
OT  - CTG repeats
OT  - Cardiac involvement
OT  - lipomatosis
OT  - multisystem
OT  - myotonic dystrophy
COIS- None
EDAT- 2021/09/03 06:00
MHDA- 2021/09/03 06:01
PMCR- 2021/09/01
CRDT- 2021/09/02 08:48
PHST- 2021/09/02 08:48 [entrez]
PHST- 2021/09/03 06:00 [pubmed]
PHST- 2021/09/03 06:01 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - LungIndia_2021_38_5_486_325420 [pii]
AID - LI-38-486 [pii]
AID - 10.4103/lungindia.lungindia_25_21 [doi]
PST - ppublish
SO  - Lung India. 2021 Sep-Oct;38(5):486-488. doi: 10.4103/lungindia.lungindia_25_21.

PMID- 34445314
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20231107
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 16
DP  - 2021 Aug 10
TI  - Transcriptome Analysis in a Primary Human Muscle Cell Differentiation Model for 
      Myotonic Dystrophy Type 1.
LID - 10.3390/ijms22168607 [doi]
LID - 8607
AB  - Myotonic dystrophy type 1 (DM1) is caused by CTG-repeat expansions leading to a 
      complex pathology with a multisystemic phenotype that primarily affects the 
      muscles and brain. Despite a multitude of information, especially on the 
      alternative splicing of several genes involved in the pathology, information 
      about additional factors contributing to the disease development is still 
      lacking. We performed RNAseq and gene expression analyses on proliferating 
      primary human myoblasts and differentiated myotubes. GO-term analysis indicates 
      that in myoblasts and myotubes, different molecular pathologies are involved in 
      the development of the muscular phenotype. Gene set enrichment for splicing 
      reveals the likelihood of whole, differentiation stage specific, splicing 
      complexes that are misregulated in DM1. These data add complexity to the 
      alternative splicing phenotype and we predict that it will be of high importance 
      for therapeutic interventions to target not only mature muscle, but also 
      satellite cells.
FAU - Todorow, Vanessa
AU  - Todorow V
AD  - Department of Neurology, Friedrich-Baur-Institute, LMU Klinikum, 
      Ludwig-Maximilians-University Munich, 80336 Munich, Germany.
FAU - Hintze, Stefan
AU  - Hintze S
AD  - Department of Neurology, Friedrich-Baur-Institute, LMU Klinikum, 
      Ludwig-Maximilians-University Munich, 80336 Munich, Germany.
FAU - Kerr, Alastair R W
AU  - Kerr ARW
AUID- ORCID: 0000-0001-9207-6050
AD  - Cancer Biomarker Centre, CRUK Manchester Institute, University of Manchester, 
      Manchester SK10 4TG, UK.
FAU - Hehr, Andreas
AU  - Hehr A
AD  - Centre for Human Genetics, 93047 Regensburg, Germany.
FAU - Schoser, Benedikt
AU  - Schoser B
AUID- ORCID: 0000-0002-2757-8131
AD  - Department of Neurology, Friedrich-Baur-Institute, LMU Klinikum, 
      Ludwig-Maximilians-University Munich, 80336 Munich, Germany.
FAU - Meinke, Peter
AU  - Meinke P
AD  - Department of Neurology, Friedrich-Baur-Institute, LMU Klinikum, 
      Ludwig-Maximilians-University Munich, 80336 Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210810
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Adult
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Humans
MH  - Myoblasts/cytology/*metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - *RNA Splicing
MH  - *Transcriptome
PMC - PMC8395314
OTO - NOTNLM
OT  - human primary muscle cell culture
OT  - myotonic dystrophy type 1
OT  - splicing
OT  - transcriptomics
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/28 06:00
MHDA- 2021/09/09 06:00
PMCR- 2021/08/10
CRDT- 2021/08/27 01:23
PHST- 2021/06/28 00:00 [received]
PHST- 2021/07/30 00:00 [revised]
PHST- 2021/08/06 00:00 [accepted]
PHST- 2021/08/27 01:23 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/08/10 00:00 [pmc-release]
AID - ijms22168607 [pii]
AID - ijms-22-08607 [pii]
AID - 10.3390/ijms22168607 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Aug 10;22(16):8607. doi: 10.3390/ijms22168607.

PMID- 34432028
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220826
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 31
IP  - 2
DP  - 2021 Dec 27
TI  - Myotonic dystrophy type 1 (DM1) clinical subtypes and CTCF site methylation 
      status flanking the CTG expansion are mutant allele length-dependent.
PG  - 262-274
LID - 10.1093/hmg/ddab243 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a complex disease with a wide spectrum of 
      symptoms. The exact relationship between mutant CTG repeat expansion size and 
      clinical outcome remains unclear. DM1 congenital patients (CDM) inherit the 
      largest expanded alleles, which are associated with abnormal and increased DNA 
      methylation flanking the CTG repeat. However, DNA methylation at the DMPK locus 
      remains understudied. Its relationship to DM1 clinical subtypes, expansion size 
      and age-at-onset is not yet completely understood. Using pyrosequencing-based 
      methylation analysis on 225 blood DNA samples from Costa Rican DM1 patients, we 
      determined that the size of the estimated progenitor allele length (ePAL) is not 
      only a good discriminator between CDM and non-CDM cases (with an estimated 
      threshold at 653 CTG repeats), but also for all DM1 clinical subtypes. Secondly, 
      increased methylation at both CTCF sites upstream and downstream of the expansion 
      was almost exclusively present in CDM cases. Thirdly, levels of abnormal 
      methylation were associated with clinical subtype, age and ePAL, with strong 
      correlations between these variables. Fourthly, both ePAL and the 
      intergenerational expansion size were significantly associated with methylation 
      status. Finally, methylation status was associated with ePAL and maternal 
      inheritance, with almost exclusively maternal transmission of CDM. In conclusion, 
      increased DNA methylation at the CTCF sites flanking the DM1 expansion could be 
      linked to ePAL, and both increased methylation and the ePAL could be considered 
      biomarkers for the CDM phenotype.
CI  - (c) The Author(s) 2021. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Morales, Fernando
AU  - Morales F
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Corrales, Eyleen
AU  - Corrales E
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Zhang, Baili
AU  - Zhang B
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030-4009, USA.
FAU - Vasquez, Melissa
AU  - Vasquez M
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Santamaria-Ulloa, Carolina
AU  - Santamaria-Ulloa C
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Quesada, Hazel
AU  - Quesada H
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose 2060, Costa Rica.
FAU - Sirito, Mario
AU  - Sirito M
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030-4009, USA.
FAU - Estecio, Marcos R
AU  - Estecio MR
AD  - Department of Epigenetics & Molecular Carcinogenesis, University of Texas MD 
      Anderson Cancer Center, Houston, TX 77030-4009, USA.
AD  - Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030-4009, USA.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - Krahe, Ralf
AU  - Krahe R
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX 77030-4009, USA.
AD  - Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030-4009, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CCCTC-Binding Factor)
RN  - 0 (CTCF protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alleles
MH  - CCCTC-Binding Factor
MH  - DNA Methylation/genetics
MH  - Humans
MH  - *Myotonic Dystrophy/genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC8831269
EDAT- 2021/08/26 06:00
MHDA- 2022/04/08 06:00
PMCR- 2022/08/25
CRDT- 2021/08/25 12:22
PHST- 2021/06/11 00:00 [received]
PHST- 2021/08/17 00:00 [revised]
PHST- 2021/08/18 00:00 [accepted]
PHST- 2021/08/26 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2021/08/25 12:22 [entrez]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 6357689 [pii]
AID - ddab243 [pii]
AID - 10.1093/hmg/ddab243 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2021 Dec 27;31(2):262-274. doi: 10.1093/hmg/ddab243.

PMID- 34386887
OWN - NLM
STAT- MEDLINE
DCOM- 20211207
LR  - 20211214
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 42
IP  - 12
DP  - 2021 Dec
TI  - Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.
PG  - 5365-5368
LID - 10.1007/s10072-021-05538-y [doi]
AB  - INTRODUCTION: Myotonic disorders are a group of diseases affecting the muscle, in 
      different ways. Myotonic dystrophy type 1 (DM1) is related to (CTG)n expansion in 
      the 3-untranslated region of the dystrophia myotonica protein kinase (DMPK) gene 
      and is the most frequent and disabling form, causing muscular, visibility, 
      respiratory, and cardiac impairment. Non-dystrophic myotonias (NDMs) affect the 
      skeletal muscle alone. In particular, mutations in the chloride channel (CLCN1) 
      gene cause myotonia congenita (MC), which can have autosomal dominant or 
      recessive inheritance. CASE REPORT: We describe a patient with a family history 
      of asymptomatic or paucisymptomatic myotonia, who presented handgrip myotonia 
      which sharply reduced after mexiletine administration. Molecular analysis showed 
      both a paternally inherited DMPK expansion and a maternally inherited CLCN1 
      mutation. CONCLUSIONS: Only one other similar case was reported so far; however, 
      the segregation of the two mutations and the characteristics of the muscle were 
      not studied. Since our patient lacked the classical phenotypical and muscle 
      histopathological characteristics of DM1 and showed mild splicing alterations 
      despite a pathogenic DMPK expansion and the nuclear accumulation of toxic RNA, we 
      may speculate that the co-occurrence of a CLCN1 mutation could have attenuated 
      the severity of DM1 phenotype.
CI  - (c) 2021. Fondazione Societa Italiana di Neurologia.
FAU - Locci, Sara
AU  - Locci S
AD  - Department of Medical, Surgical and Neurological Sciences, Unit of Neurology and 
      Neurometabolic Diseases, University of Siena, Siena, Italy.
FAU - Cardani, Rosanna
AU  - Cardani R
AD  - Laboratory of Muscle Histopathology and Molecular Biology, IRCCS Policlinico San 
      Donato, Milan, Italy.
FAU - Brunori, Paola
AU  - Brunori P
AD  - Unit of Neurophysiopathology, Silvestrini Hospital, Perugia, Italy.
FAU - Lucchiari, Sabrina
AU  - Lucchiari S
AD  - Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and 
      Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Fondazione Ca' 
      Granda Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Comi, Giacomo P
AU  - Comi GP
AD  - Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and 
      Transplantation (DEPT), University of Milan, Neurology Unit, IRCCS Fondazione Ca' 
      Granda Ospedale Maggiore Policlinico, Milan, Italy.
FAU - Federico, Antonio
AU  - Federico A
AD  - Department of Medical, Surgical and Neurological Sciences, Unit of Neurology and 
      Neurometabolic Diseases, University of Siena, Siena, Italy.
FAU - De Stefano, Nicola
AU  - De Stefano N
AD  - Department of Medical, Surgical and Neurological Sciences, Unit of Neurology and 
      Neurometabolic Diseases, University of Siena, Siena, Italy.
FAU - Meola, Giovanni
AU  - Meola G
AD  - Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
AD  - Department of Neurorehabilitation Sciences, Casa di Cura del Policlinico, Milan, 
      Italy.
FAU - Mignarri, Andrea
AU  - Mignarri A
AUID- ORCID: 0000-0003-3516-7364
AD  - Department of Medical, Surgical and Neurological Sciences, Unit of Neurology and 
      Neurometabolic Diseases, University of Siena, Siena, Italy. 
      andrea.mignarri@teletu.it.
AD  - Department of Medicine, Surgery and Neurosciences, University of Siena, Viale 
      Bracci 2, 53100, Siena, Italy. andrea.mignarri@teletu.it.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210813
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - 0 (Chloride Channels)
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Chloride Channels/genetics
MH  - Hand Strength
MH  - Humans
MH  - Mutation
MH  - *Myotonia/genetics
MH  - *Myotonia Congenita/complications/genetics
MH  - *Myotonic Dystrophy/complications/genetics
MH  - Myotonin-Protein Kinase
OTO - NOTNLM
OT  - CLCN1
OT  - DMPK
OT  - Myotonia
OT  - Myotonia congenita
OT  - Myotonic dystrophy type 1
EDAT- 2021/08/14 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/08/13 07:19
PHST- 2021/05/30 00:00 [received]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/08/13 07:19 [entrez]
AID - 10.1007/s10072-021-05538-y [pii]
AID - 10.1007/s10072-021-05538-y [doi]
PST - ppublish
SO  - Neurol Sci. 2021 Dec;42(12):5365-5368. doi: 10.1007/s10072-021-05538-y. Epub 2021 
      Aug 13.

PMID- 34372915
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220216
IS  - 1756-994X (Electronic)
IS  - 1756-994X (Linking)
VI  - 13
IP  - 1
DP  - 2021 Aug 9
TI  - Genome-wide sequencing as a first-tier screening test for short tandem repeat 
      expansions.
PG  - 126
LID - 10.1186/s13073-021-00932-9 [doi]
LID - 126
AB  - BACKGROUND: Screening for short tandem repeat (STR) expansions in next-generation 
      sequencing data can enable diagnosis, optimal clinical management/treatment, and 
      accurate genetic counseling of patients with repeat expansion disorders. We aimed 
      to develop an efficient computational workflow for reliable detection of STR 
      expansions in next-generation sequencing data and demonstrate its clinical 
      utility. METHODS: We characterized the performance of eight STR analysis methods 
      (lobSTR, HipSTR, RepeatSeq, ExpansionHunter, TREDPARSE, GangSTR, STRetch, and 
      exSTRa) on next-generation sequencing datasets of samples with known 
      disease-causing full-mutation STR expansions and genomes simulated to harbor 
      repeat expansions at selected loci and optimized their sensitivity. We then used 
      a machine learning decision tree classifier to identify an optimal combination of 
      methods for full-mutation detection. In Burrows-Wheeler Aligner (BWA)-aligned 
      genomes, the ensemble approach of using ExpansionHunter, STRetch, and exSTRa 
      performed the best (precision = 82%, recall = 100%, F1-score = 90%). We applied 
      this pipeline to screen 301 families of children with suspected genetic 
      disorders. RESULTS: We identified 10 individuals with full-mutations in the AR, 
      ATXN1, ATXN8, DMPK, FXN, or HTT disease STR locus in the analyzed families. 
      Additional candidates identified in our analysis include two probands with 
      borderline ATXN2 expansions between the established repeat size range for 
      reduced-penetrance and full-penetrance full-mutation and seven individuals with 
      FMR1 CGG repeats in the intermediate/premutation repeat size range. In 67 
      probands with a prior negative clinical PCR test for the FMR1, FXN, or DMPK 
      disease STR locus, or the spinocerebellar ataxia disease STR panel, our pipeline 
      did not falsely identify aberrant expansion. We performed clinical PCR tests on 
      seven (out of 10) full-mutation samples identified by our pipeline and confirmed 
      the expansion status in all, showing absolute concordance between our 
      bioinformatics and molecular findings. CONCLUSIONS: We have successfully 
      demonstrated the application of a well-optimized bioinformatics pipeline that 
      promotes the utility of genome-wide sequencing as a first-tier screening test to 
      detect expansions of known disease STRs. Interrogating clinical next-generation 
      sequencing data for pathogenic STR expansions using our ensemble pipeline can 
      improve diagnostic yield and enhance clinical outcomes for patients with repeat 
      expansion disorders.
CI  - (c) 2021. The Author(s).
FAU - Rajan-Babu, Indhu-Shree
AU  - Rajan-Babu IS
AD  - Department of Medical Genetics, University of British Columbia and Children's & 
      Women's Hospital, Vancouver, BC, V6H3N1, Canada. indhu.babu@bcchr.ca.
AD  - Department of Medical and Molecular Genetics, King's College London, Strand, 
      London, WC2R 2LS, UK. indhu.babu@bcchr.ca.
FAU - Peng, Junran J
AU  - Peng JJ
AD  - Department of Medical Genetics, University of British Columbia and Children's & 
      Women's Hospital, Vancouver, BC, V6H3N1, Canada.
FAU - Chiu, Readman
AU  - Chiu R
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, 
      V5Z4S6, Canada.
CN  - IMAGINE Study
CN  - CAUSES Study
FAU - Li, Chenkai
AU  - Li C
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, 
      V5Z4S6, Canada.
AD  - Bioinformatics Graduate Program, University of British Columbia, Vancouver, BC, 
      V6T1Z4, Canada.
FAU - Mohajeri, Arezoo
AU  - Mohajeri A
AD  - Department of Medical Genetics, University of British Columbia and Children's & 
      Women's Hospital, Vancouver, BC, V6H3N1, Canada.
FAU - Dolzhenko, Egor
AU  - Dolzhenko E
AD  - Illumina Inc., San Diego, CA, 92121, USA.
FAU - Eberle, Michael A
AU  - Eberle MA
AD  - Illumina Inc., San Diego, CA, 92121, USA.
FAU - Birol, Inanc
AU  - Birol I
AD  - Department of Medical Genetics, University of British Columbia and Children's & 
      Women's Hospital, Vancouver, BC, V6H3N1, Canada.
AD  - Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, 
      V5Z4S6, Canada.
FAU - Friedman, Jan M
AU  - Friedman JM
AD  - Department of Medical Genetics, University of British Columbia and Children's & 
      Women's Hospital, Vancouver, BC, V6H3N1, Canada.
LA  - eng
GR  - CIHR - SCA-145104/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210809
PL  - England
TA  - Genome Med
JT  - Genome medicine
JID - 101475844
SB  - IM
EIN - Genome Med. 2021 Sep 13;13(1):151. PMID: 34517885
MH  - Algorithms
MH  - Alleles
MH  - Clinical Decision-Making
MH  - Computational Biology/methods
MH  - *DNA Repeat Expansion
MH  - Databases, Genetic
MH  - Decision Trees
MH  - Genetic Diseases, Inborn/diagnosis/genetics
MH  - Genetic Loci
MH  - *Genome-Wide Association Study/methods
MH  - *High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Machine Learning
MH  - *Microsatellite Repeats
MH  - Molecular Diagnostic Techniques
MH  - Mutation
MH  - Reproducibility of Results
MH  - *Whole Genome Sequencing
PMC - PMC8351082
OTO - NOTNLM
OT  - Clinical bioinformatics
OT  - Machine learning
OT  - Next-generation sequencing
OT  - Repeat expansion
OT  - Short tandem repeats
COIS- ED and MAE are employees of Illumina, Inc., a public company that develops and 
      markets systems for genetic analysis. The remaining authors declare that they 
      have no competing interests.
FIR - Birch, Patricia
IR  - Birch P
FIR - Couse, Madeline
IR  - Couse M
FIR - Guimond, Colleen
IR  - Guimond C
FIR - Lehman, Anna
IR  - Lehman A
FIR - Mwenifumbo, Jill
IR  - Mwenifumbo J
FIR - van Karnebeek, Clara
IR  - van Karnebeek C
FIR - Friedman, Jan
IR  - Friedman J
FIR - Adam, Shelin
IR  - Adam S
FIR - Souich, Christele Du
IR  - Souich CD
FIR - Elliott, Alison
IR  - Elliott A
FIR - Lehman, Anna
IR  - Lehman A
FIR - Mwenifumbo, Jill
IR  - Mwenifumbo J
FIR - Nelson, Tanya
IR  - Nelson T
FIR - van Karnebeek, Clara
IR  - van Karnebeek C
FIR - Friedman, Jan
IR  - Friedman J
EDAT- 2021/08/11 06:00
MHDA- 2022/02/17 06:00
PMCR- 2021/08/09
CRDT- 2021/08/10 05:38
PHST- 2020/09/03 00:00 [received]
PHST- 2021/07/05 00:00 [accepted]
PHST- 2021/08/10 05:38 [entrez]
PHST- 2021/08/11 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
PHST- 2021/08/09 00:00 [pmc-release]
AID - 10.1186/s13073-021-00932-9 [pii]
AID - 932 [pii]
AID - 10.1186/s13073-021-00932-9 [doi]
PST - epublish
SO  - Genome Med. 2021 Aug 9;13(1):126. doi: 10.1186/s13073-021-00932-9.

PMID- 34371182
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20230106
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 30
IP  - 1
DP  - 2022 Jan 5
TI  - Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic 
      dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes.
PG  - 75-91
LID - S1525-0016(21)00398-1 [pii]
LID - 10.1016/j.ymthe.2021.08.004 [doi]
AB  - CTG repeat expansion (CTG(exp)) is associated with aberrant alternate splicing 
      that contributes to cardiac dysfunction in myotonic dystrophy type 1 (DM1). 
      Excision of this CTG(exp) repeat using CRISPR-Cas resulted in the disappearance 
      of punctate ribonuclear foci in cardiomyocyte-like cells derived from DM1-induced 
      pluripotent stem cells (iPSCs). This was associated with correction of the 
      underlying spliceopathy as determined by RNA sequencing and alternate splicing 
      analysis. Certain genes were of particular interest due to their role in cardiac 
      development, maturation, and function (TPM4, CYP2J2, DMD, MBNL3, CACNA1H, ROCK2, 
      ACTB) or their association with splicing (SMN2, GCFC2, MBNL3). Moreover, while 
      comparing isogenic CRISPR-Cas9-corrected versus non-corrected DM1 cardiomyocytes, 
      a prominent difference in the splicing pattern for a number of candidate genes 
      was apparent pertaining to genes that are associated with cardiac function (TNNT, 
      TNNT2, TTN, TPM1, SYNE1, CACNA1A, MTMR1, NEBL, TPM1), cellular signaling (NCOR2, 
      CLIP1, LRRFIP2, CLASP1, CAMK2G), and other DM1-related genes (i.e., NUMA1, MBNL2, 
      LDB3) in addition to the disease-causing DMPK gene itself. Subsequent validation 
      using a selected gene subset, including MBNL1, MBNL2, INSR, ADD3, and CRTC2, 
      further confirmed correction of the spliceopathy following CTG(exp) repeat 
      excision. To our knowledge, the present study provides the first comprehensive 
      unbiased transcriptome-wide analysis of the differential splicing landscape in 
      DM1 patient-derived cardiac cells after excision of the CTG(exp) repeat using 
      CRISPR-Cas9, showing reversal of the abnormal cardiac spliceopathy in DM1.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Dastidar, Sumitava
AU  - Dastidar S
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium.
FAU - Majumdar, Debanjana
AU  - Majumdar D
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium.
FAU - Tipanee, Jaitip
AU  - Tipanee J
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium.
FAU - Singh, Kshitiz
AU  - Singh K
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium.
FAU - Klein, Arnaud F
AU  - Klein AF
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, F-75013 Paris, France.
FAU - Furling, Denis
AU  - Furling D
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, F-75013 Paris, France.
FAU - Chuah, Marinee K
AU  - Chuah MK
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium; Center for Molecular & Vascular Biology, Department of 
      Cardiovascular Sciences, University of Leuven, 3000 Leuven, Belgium. Electronic 
      address: marinee.chuah@vub.be.
FAU - VandenDriessche, Thierry
AU  - VandenDriessche T
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      1090 Brussels, Belgium; Center for Molecular & Vascular Biology, Department of 
      Cardiovascular Sciences, University of Leuven, 3000 Leuven, Belgium. Electronic 
      address: thierry.vandendriessche@vub.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210808
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (ADD3 protein, human)
RN  - 0 (Calmodulin-Binding Proteins)
RN  - 0 (MBNL3 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alternative Splicing
MH  - CRISPR-Cas Systems
MH  - Calmodulin-Binding Proteins/genetics
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Myocytes, Cardiac/metabolism
MH  - *Myotonic Dystrophy/genetics/therapy
MH  - Myotonin-Protein Kinase/genetics
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Transcriptome
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC8753376
OTO - NOTNLM
OT  - CRISPR ribonucleoprotein
OT  - alternate splicing
OT  - cardiomyogenic differentiation
OT  - gene editing
OT  - induced pluripotent stem cells
OT  - myotonic dystrophy
OT  - ribonuclear foci
OT  - spliceopathy
OT  - transcriptome
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2021/08/10 06:00
MHDA- 2022/04/08 06:00
PMCR- 2023/01/05
CRDT- 2021/08/09 20:13
PHST- 2020/07/30 00:00 [received]
PHST- 2021/07/01 00:00 [revised]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2021/08/09 20:13 [entrez]
PHST- 2023/01/05 00:00 [pmc-release]
AID - S1525-0016(21)00398-1 [pii]
AID - 10.1016/j.ymthe.2021.08.004 [doi]
PST - ppublish
SO  - Mol Ther. 2022 Jan 5;30(1):75-91. doi: 10.1016/j.ymthe.2021.08.004. Epub 2021 Aug 
      8.

PMID- 34296199
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230127
IS  - 2666-027X (Electronic)
IS  - 2666-027X (Linking)
VI  - 1
DP  - 2020 Jun 10
TI  - The influence of sex, genotype, and dose on serum and hippocampal cytokine levels 
      in juvenile mice developmentally exposed to a human-relevant mixture of 
      polychlorinated biphenyls.
PG  - 85-103
LID - 10.1016/j.crtox.2020.09.001 [doi]
AB  - Polychlorinated biphenyls (PCBs) are pervasive environmental contaminants 
      implicated as risk factors for neurodevelopmental disorders (NDDs). Immune 
      dysregulation is another NDD risk factor, and developmental PCB exposures are 
      associated with early life immune dysregulation. Studies of the immunomodulatory 
      effects of PCBs have focused on the higher-chlorinated congeners found in legacy 
      commercial mixtures. Comparatively little is known about the immune effects of 
      contemporary, lower-chlorinated PCBs. This is a critical data gap given recent 
      reports that lower-chlorinated congeners comprise >70% of the total PCB burden in 
      serum of pregnant women enrolled in the MARBLES study who are at increased risk 
      for having a child with an NDD. To examine the influence of PCBs, sex, and 
      genotype on cytokine levels, mice were exposed throughout gestation and lactation 
      to a PCB mixture in the maternal diet, which was based on the 12 most abundant 
      PCBs in sera from MARBLES subjects. Using multiplex array, cytokines were 
      quantified in the serum and hippocampus of weanling mice expressing either a 
      human gain-of-function mutation in ryanodine receptor 1 (T4826I mice), a human 
      CGG premutation repeat expansion in the fragile X mental retardation gene 1 (CGG 
      mice), or both mutations (DM mice). Congenic wildtype (WT) mice were used as 
      controls. There were dose-dependent effects of PCB exposure on cytokine 
      concentrations in the serum but not hippocampus. Differential effects of genotype 
      were observed in the serum and hippocampus. Hippocampal cytokines were 
      consistently elevated in T4826I mice and also in WT animals for some cytokines 
      compared to CGG and DM mice, while serum cytokines were usually elevated in the 
      mutant genotypes compared to the WT group. Males had elevated levels of 19 
      cytokines in the serum and 4 in the hippocampus compared to females, but there 
      were also interactions between sex and genotype for 7 hippocampal cytokines. Only 
      the chemokine CCL5 in the serum showed an interaction between PCB dose, genotype, 
      and sex. Collectively, these findings indicate differential influences of PCB 
      exposure and genotype on cytokine levels in serum and hippocampal tissue of 
      weanling mice. These results suggest that developmental PCB exposure has chronic 
      effects on baseline serum, but not hippocampal, cytokine levels in juvenile mice.
FAU - Matelski, Lauren
AU  - Matelski L
AD  - Department of Molecular Biosciences, University of California, Davis, School of 
      Veterinary Medicine, Davis, CA 95616, USA.
FAU - Keil Stietz, Kimberly P
AU  - Keil Stietz KP
AD  - Department of Molecular Biosciences, University of California, Davis, School of 
      Veterinary Medicine, Davis, CA 95616, USA.
FAU - Sethi, Sunjay
AU  - Sethi S
AD  - Department of Molecular Biosciences, University of California, Davis, School of 
      Veterinary Medicine, Davis, CA 95616, USA.
FAU - Taylor, Sandra L
AU  - Taylor SL
AD  - Division of Biostatistics, Department of Public Health Sciences, University of 
      California, Davis, School of Medicine, Davis, CA 95616, USA.
FAU - Van de Water, Judy
AU  - Van de Water J
AD  - MIND Institute, University of California, Davis, School of Medicine, Sacramento, 
      CA 95817, USA.
AD  - Division of Rheumatology, Allergy, and Clinical Immunology, Department of 
      Internal Medicine, University of California, Davis, School of Medicine, Davis, CA 
      95616, USA.
FAU - Lein, Pamela J
AU  - Lein PJ
AD  - Department of Molecular Biosciences, University of California, Davis, School of 
      Veterinary Medicine, Davis, CA 95616, USA.
AD  - MIND Institute, University of California, Davis, School of Medicine, Sacramento, 
      CA 95817, USA.
LA  - eng
GR  - P01 ES011269/ES/NIEHS NIH HHS/United States
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - U54 HD079125/HD/NICHD NIH HHS/United States
GR  - T32 ES007059/ES/NIEHS NIH HHS/United States
GR  - P50 HD103526/HD/NICHD NIH HHS/United States
GR  - R00 ES029537/ES/NIEHS NIH HHS/United States
GR  - UL1 TR001860/TR/NCATS NIH HHS/United States
GR  - P30 ES023513/ES/NIEHS NIH HHS/United States
GR  - P42 ES013661/ES/NIEHS NIH HHS/United States
GR  - R01 ES014901/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20200910
PL  - Netherlands
TA  - Curr Res Toxicol
JT  - Current research in toxicology
JID - 101771915
PMC - PMC8294704
MID - NIHMS1720424
OTO - NOTNLM
OT  - CGG repeat expansion mutation
OT  - Chemokines
OT  - Neurodevelopmental disorders
OT  - Neuroimmune interactions
OT  - Ryanodine receptor
OT  - fmr1
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2020/09/10
CRDT- 2021/07/23 06:56
PHST- 2021/07/23 06:56 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2020/09/10 00:00 [pmc-release]
AID - S2666-027X(20)30011-6 [pii]
AID - 10.1016/j.crtox.2020.09.001 [doi]
PST - ppublish
SO  - Curr Res Toxicol. 2020 Jun 10;1:85-103. doi: 10.1016/j.crtox.2020.09.001. Epub 
      2020 Sep 10.

PMID- 34262431
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210716
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 15
DP  - 2021
TI  - CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1.
PG  - 686735
LID - 10.3389/fnins.2021.686735 [doi]
LID - 686735
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder 
      caused by unstable CTG-repeat expansions in the DMPK gene. Tissue mosaicism has 
      been described for the length of these repeat expansions. The most obvious 
      affected tissue is skeletal muscle, making it the first target for therapy 
      development. To date there is no approved therapy despite some existing 
      approaches. Thus, there is the demand to further advance therapeutic 
      developments, which will in return require several well-characterized preclinical 
      tools and model systems. Here we describe a modified method to identify the 
      CTG-repeat length in primary human myoblasts isolated from DM1 patients that 
      requires less genomic DNA and avoids radioactive labeling. Using this method, we 
      show that primary human DM1 myoblast cultures represent a population of cells 
      with different CTG-repeat length. Comparing DNA from the identical muscle biopsy 
      specimen, the range of CTG-repeat length in the myoblast culture is within the 
      same range of the muscle biopsy specimen. In conclusion, primary human DM1 
      myoblast cultures are a well-suited model to investigate certain aspects of the 
      DM1 pathology. They are a useful platform to perform first-line investigations of 
      preclinical therapies.
CI  - Copyright (c) 2021 Hintze, Mensel, Knaier, Schoser and Meinke.
FAU - Hintze, Stefan
AU  - Hintze S
AD  - Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Mensel, Raphaela
AU  - Mensel R
AD  - Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Knaier, Lisa
AU  - Knaier L
AD  - Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Schoser, Benedikt
AU  - Schoser B
AD  - Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Meinke, Peter
AU  - Meinke P
AD  - Department of Neurology, LMU Klinikum, Friedrich-Baur-Institute, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210628
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC8274452
OTO - NOTNLM
OT  - CTG-repeats
OT  - DMPK
OT  - myotonic dystrophy type 1
OT  - primary human myoblast cultures
OT  - repeat detection
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/16 06:00
MHDA- 2021/07/16 06:01
PMCR- 2021/01/01
CRDT- 2021/07/15 06:18
PHST- 2021/03/27 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/07/15 06:18 [entrez]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2021/07/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2021.686735 [doi]
PST - epublish
SO  - Front Neurosci. 2021 Jun 28;15:686735. doi: 10.3389/fnins.2021.686735. 
      eCollection 2021.

PMID- 34180419
OWN - NLM
STAT- MEDLINE
DCOM- 20220203
LR  - 20220203
IS  - 2214-3602 (Electronic)
VI  - 8
IP  - 6
DP  - 2021
TI  - Diffusion Tensor Imaging Shows Differences Between Myotonic Dystrophy Type 1 and 
      Type 2.
PG  - 949-962
LID - 10.3233/JND-210660 [doi]
AB  - BACKGROUND: Myotonic Dystrophies type 1 and type 2 are hereditary myopathies with 
      dystrophic muscle degeneration in varying degrees. Differences in muscle 
      diffusion between both diseases have not been evaluated yet. OBJECTIVE: To 
      evaluate the ability of muscle diffusion tensor imaging (mDTI) and Dixon 
      fat-quantification to distinguish between Myotonic Dystrophy (DM) type 1 and type 
      2 and if both diseases show distinct muscle involvement patterns. METHODS: We 
      evaluated 6 thigh and 7 calf muscles (both legs) of 10 DM 1, 13 DM 2 and 28 
      healthy controls (HC) with diffusion tensor imaging, T1w and mDixonquant 
      sequences in a 3T MRI scanner. The quantitative mDTI-values axial diffusivity 
      (lambda1), mean diffusivity (MD), radial diffusivity (RD) and fractional anisotropy 
      (FA) as well as fat-fraction were analysed. CTG-triplet repeat-length of DM 1 
      patients was correlated with diffusion metrics and fat-fraction. RESULTS: mDTI 
      showed significant differences between DM 1 and DM 2 vs. healthy controls in 
      diffusion parameters of the thigh (all p < 0.001) except for FA (p = 0.0521 / 
      0.8337). In calf muscles mDTI showed significant differences between DM 1 and DM 
      2 patients (all p < 0.0001) as well as between DM 1 patients and controls (all 
      p = 0.0001). Thigh muscles had a significant higher fat-fraction in both groups 
      vs. controls (p < 0.05). There was no correlation of CTG triplet length with mDTI 
      values and fat-fraction. DISCUSSION: mDTI reveals specific changes of the 
      diffusion parameters and fat-fraction in muscles of DM 1 and DM 2 patients. Thus, 
      the quantitative MRI methods presented in this study provide a powerful tool in 
      differential diagnosis and follow-up of DM 1 and DM 2, however, the data must be 
      validated in larger studies.
FAU - Rehmann, R
AU  - Rehmann R
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
FAU - Schneider-Gold, C
AU  - Schneider-Gold C
AD  - Department of Neurology, University Hospital St. Josef, Ruhr-University Bochum, 
      Bochum, Germany.
FAU - Froeling, M
AU  - Froeling M
AD  - Department of Radiology, University Medical Centre Utrecht, Utrecht, The 
      Netherlands.
FAU - Guttsches, A K
AU  - Guttsches AK
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
FAU - Rohm, M
AU  - Rohm M
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
FAU - Forsting, J
AU  - Forsting J
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
FAU - Vorgerd, M
AU  - Vorgerd M
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
FAU - Schlaffke, L
AU  - Schlaffke L
AD  - Department of Neurology, Heimer Institute for Muscle Research, BG-University 
      Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - Diffusion Tensor Imaging/*methods
MH  - Female
MH  - Humans
MH  - Leg/diagnostic imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal
MH  - Myotonic Dystrophy/*diagnostic imaging
MH  - Prospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Myotonic Dystrophy type 1
OT  - Myotonic Dystrophy type 2
OT  - diffusion tensor imaging
OT  - magnetic resonance imaging
OT  - muscle
OT  - skeletal
EDAT- 2021/06/29 06:00
MHDA- 2022/02/04 06:00
CRDT- 2021/06/28 09:08
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2022/02/04 06:00 [medline]
PHST- 2021/06/28 09:08 [entrez]
AID - JND210660 [pii]
AID - 10.3233/JND-210660 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2021;8(6):949-962. doi: 10.3233/JND-210660.

PMID- 34141068
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240402
IS  - 1948-5875 (Print)
IS  - 1948-5875 (Electronic)
IS  - 1948-5875 (Linking)
VI  - 12
IP  - 6
DP  - 2021 Jun 10
TI  - Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers 
      Targeting a Toxic r(CUG) Repeat Expansion.
PG  - 907-914
LID - 10.1021/acsmedchemlett.1c00027 [doi]
AB  - RNA contributes to disease pathobiology and is an important therapeutic target. 
      The downstream biology of disease-causing RNAs can be short-circuited with small 
      molecules that recognize structured regions. The discovery and optimization of 
      small molecules interacting with RNA is, however, challenging. Herein, we 
      demonstrate a massively parallel one-bead-one-compound methodology, employed to 
      optimize the linker region of a dimeric compound that binds the toxic r(CUG) 
      repeat expansion [r(CUG)(exp)] causative of myotonic dystrophy type 1 (DM1). 
      Indeed, affinity selection on a 331,776-member library allowed the discovery of a 
      compound with enhanced potency both in vitro (10-fold) and in DM1-patient-derived 
      myotubes (5-fold). Molecular dynamics simulations revealed additional 
      interactions between the optimized linker and the RNA, resulting in ca. 10 
      kcal/mol lower binding free energy. The compound was conjugated to a cleavage 
      module, which directly cleaved the transcript harboring the r(CUG)(exp) and 
      alleviated disease-associated defects.
CI  - (c) 2021 American Chemical Society.
FAU - Vezina-Dawod, Simon
AU  - Vezina-Dawod S
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Angelbello, Alicia J
AU  - Angelbello AJ
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Choudhary, Shruti
AU  - Choudhary S
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Wang, Kye Won
AU  - Wang KW
AD  - Department of Chemistry, Florida Atlantic University, Jupiter, Florida 33458, 
      United States.
FAU - Yildirim, Ilyas
AU  - Yildirim I
AUID- ORCID: 0000-0001-8357-1922
AD  - Department of Chemistry, Florida Atlantic University, Jupiter, Florida 33458, 
      United States.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
LA  - eng
GR  - F31 NS110269/NS/NINDS NIH HHS/United States
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20210302
PL  - United States
TA  - ACS Med Chem Lett
JT  - ACS medicinal chemistry letters
JID - 101521073
PMC - PMC8201483
COIS- The authors declare the following competing financial interest(s): M.D.D. is a 
      founder of Expansion Therapeutics. A.J.A. is a current employee of Expansion 
      Therapeutics.
EDAT- 2021/06/19 06:00
MHDA- 2021/06/19 06:01
PMCR- 2022/06/10
CRDT- 2021/06/18 06:43
PHST- 2021/01/13 00:00 [received]
PHST- 2021/02/23 00:00 [accepted]
PHST- 2021/06/18 06:43 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/06/19 06:01 [medline]
PHST- 2022/06/10 00:00 [pmc-release]
AID - 10.1021/acsmedchemlett.1c00027 [doi]
PST - epublish
SO  - ACS Med Chem Lett. 2021 Mar 2;12(6):907-914. doi: 10.1021/acsmedchemlett.1c00027. 
      eCollection 2021 Jun 10.

PMID- 34114350
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220907
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Print)
IS  - 1860-7179 (Linking)
VI  - 16
IP  - 17
DP  - 2021 Sep 6
TI  - A Novel Minor Groove Binder as a Potential Therapeutic Agent for Myotonic 
      Dystrophy Type 1.
PG  - 2638-2644
LID - 10.1002/cmdc.202100243 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder that is 
      inherited in an autosomal dominant manner. DM1 originates in a (CTG...CAG) repeat 
      expansion in the 3'-UTR of the dystrophia myotonic protein kinase (DMPK) gene on 
      chromosome 19. One of the transcripts, r(CUG)(exp) , is toxic in various ways. 
      Herein we report a rationally designed small molecule with a thiazole 
      peptidomimetic unit that can serve as a minor groove binder for the nucleic acid 
      targets. This peptide unit linked to two triaminotriazine recognition units 
      selectively binds to d(CTG)(exp) to inhibit the transcription process, and also 
      targets r(CUG)(exp) selectively to improve representative DM1 pathological 
      molecular features, including foci formation and pre-mRNA splicing defects in DM1 
      model cells. As such, it represents a new structure type that might serve as a 
      lead compound for future structure-activity optimization.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - Li, Ke
AU  - Li K
AUID- ORCID: 0000-0003-3851-7710
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Avenue, 61801, Urbana, IL, USA.
FAU - Krueger, Sarah B
AU  - Krueger SB
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Avenue, 61801, Urbana, IL, USA.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S 
      Mathews Avenue, 61801, Urbana, IL, USA.
LA  - eng
GR  - DGE01746047/Graduate Research Fellow Program/
GR  - US National Science Foundation/
GR  - R01 AR069645/AR/NIAMS NIH HHS/United States
GR  - R01 AR058361/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20210610
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Ligands)
RN  - 0 (Peptidomimetics)
RN  - 0 (Small Molecule Libraries)
RN  - 0 (Thiazoles)
RN  - 0 (Triazines)
SB  - IM
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Ligands
MH  - Molecular Dynamics Simulation
MH  - Molecular Structure
MH  - Myotonic Dystrophy/*drug therapy/metabolism/pathology
MH  - Peptidomimetics/chemistry/*pharmacology
MH  - Small Molecule Libraries/chemistry/*pharmacology
MH  - Structure-Activity Relationship
MH  - Thiazoles/chemistry/*pharmacology
MH  - Triazines/chemistry/*pharmacology
MH  - Trinucleotide Repeats/*drug effects/genetics
PMC - PMC8429064
MID - NIHMS1715138
OTO - NOTNLM
OT  - DNA/RNA recognition
OT  - minor groove binders
OT  - myotonic dystrophy
OT  - thiazole
OT  - triaminotriazine
EDAT- 2021/06/12 06:00
MHDA- 2022/02/26 06:00
PMCR- 2022/09/06
CRDT- 2021/06/11 07:14
PHST- 2021/04/05 00:00 [received]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2021/06/11 07:14 [entrez]
PHST- 2022/09/06 00:00 [pmc-release]
AID - 10.1002/cmdc.202100243 [doi]
PST - ppublish
SO  - ChemMedChem. 2021 Sep 6;16(17):2638-2644. doi: 10.1002/cmdc.202100243. Epub 2021 
      Jun 10.

PMID- 34025359
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210526
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Electronic)
IS  - 1662-5102 (Linking)
VI  - 15
DP  - 2021
TI  - Integrative Cell Type-Specific Multi-Omics Approaches Reveal Impaired Programs of 
      Glial Cell Differentiation in Mouse Culture Models of DM1.
PG  - 662035
LID - 10.3389/fncel.2021.662035 [doi]
LID - 662035
AB  - Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by a 
      non-coding CTG repeat expansion in the DMPK gene. This mutation generates a toxic 
      CUG RNA that interferes with the RNA processing of target genes in multiple 
      tissues. Despite debilitating neurological impairment, the pathophysiological 
      cascade of molecular and cellular events in the central nervous system (CNS) has 
      been less extensively characterized than the molecular pathogenesis of 
      muscle/cardiac dysfunction. Particularly, the contribution of different cell 
      types to DM1 brain disease is not clearly understood. We first used 
      transcriptomics to compare the impact of expanded CUG RNA on the transcriptome of 
      primary neurons, astrocytes and oligodendrocytes derived from DMSXL mice, a 
      transgenic model of DM1. RNA sequencing revealed more frequent expression and 
      splicing changes in glia than neuronal cells. In particular, primary DMSXL 
      oligodendrocytes showed the highest number of transcripts differentially 
      expressed, while DMSXL astrocytes displayed the most severe splicing 
      dysregulation. Interestingly, the expression and splicing defects of DMSXL glia 
      recreated molecular signatures suggestive of impaired cell differentiation: while 
      DMSXL oligodendrocytes failed to upregulate a subset of genes that are naturally 
      activated during the oligodendroglia differentiation, a significant proportion of 
      missplicing events in DMSXL oligodendrocytes and astrocytes increased the 
      expression of RNA isoforms typical of precursor cell stages. Together these data 
      suggest that expanded CUG RNA in glial cells affects preferentially 
      differentiation-regulated molecular events. This hypothesis was corroborated by 
      gene ontology (GO) analyses, which revealed an enrichment for biological 
      processes and cellular components with critical roles during cell 
      differentiation. Finally, we combined exon ontology with phosphoproteomics and 
      cell imaging to explore the functional impact of CUG-associated spliceopathy on 
      downstream protein metabolism. Changes in phosphorylation, protein isoform 
      expression and intracellular localization in DMSXL astrocytes demonstrate the 
      far-reaching impact of the DM1 repeat expansion on cell metabolism. Our 
      multi-omics approaches provide insight into the mechanisms of CUG RNA toxicity in 
      the CNS with cell type resolution, and support the priority for future research 
      on non-neuronal mechanisms and proteomic changes in DM1 brain disease.
CI  - Copyright (c) 2021 Gonzalez-Barriga, Lallemant, Dinca, Braz, Polveche, Magneron, 
      Pionneau, Huguet-Lachon, Claude, Chhuon, Guerrera, Bourgeois, Auboeuf, Gourdon 
      and Gomes-Pereira.
FAU - Gonzalez-Barriga, Anchel
AU  - Gonzalez-Barriga A
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Lallemant, Louison
AU  - Lallemant L
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Dinca, Diana M
AU  - Dinca DM
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Braz, Sandra O
AU  - Braz SO
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
AD  - Inserm UMR 1163, Institut Imagine, Universite Paris Cite, Paris, France.
FAU - Polveche, Helene
AU  - Polveche H
AD  - Laboratory of Biology and Modeling of the Cell, Universite de Lyon, ENS de Lyon, 
      Universite Claude Bernard, CNRS UMR 5239, Inserm U1210, Lyon, France.
AD  - Inserm/UEVE UMR 861, Universite Paris Saclay I-STEM, Corbeil-Essonnes, France.
FAU - Magneron, Paul
AU  - Magneron P
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Pionneau, Cedric
AU  - Pionneau C
AD  - Sorbonne Universite, Inserm, UMS PASS, Plateforme Post-genomique de la Pitie 
      Salpetriere (P3S), Paris, France.
FAU - Huguet-Lachon, Aline
AU  - Huguet-Lachon A
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Claude, Jean-Baptiste
AU  - Claude JB
AD  - Laboratory of Biology and Modeling of the Cell, Universite de Lyon, ENS de Lyon, 
      Universite Claude Bernard, CNRS UMR 5239, Inserm U1210, Lyon, France.
FAU - Chhuon, Cerina
AU  - Chhuon C
AD  - Proteomics Platform Necker, Universite de Paris - Structure Federative de 
      Recherche Necker, Inserm US24/CNRS UMS 3633, Paris, France.
FAU - Guerrera, Ida Chiara
AU  - Guerrera IC
AD  - Proteomics Platform Necker, Universite de Paris - Structure Federative de 
      Recherche Necker, Inserm US24/CNRS UMS 3633, Paris, France.
FAU - Bourgeois, Cyril F
AU  - Bourgeois CF
AD  - Laboratory of Biology and Modeling of the Cell, Universite de Lyon, ENS de Lyon, 
      Universite Claude Bernard, CNRS UMR 5239, Inserm U1210, Lyon, France.
FAU - Auboeuf, Didier
AU  - Auboeuf D
AD  - Laboratory of Biology and Modeling of the Cell, Universite de Lyon, ENS de Lyon, 
      Universite Claude Bernard, CNRS UMR 5239, Inserm U1210, Lyon, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
FAU - Gomes-Pereira, Mario
AU  - Gomes-Pereira M
AD  - Sorbonne Universite, Inserm, Institut de Myologie, Centre de Recherche en 
      Myologie, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20210505
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC8136287
OTO - NOTNLM
OT  - astrocytes
OT  - myotonic dystrophy
OT  - neurons
OT  - oligodendrocytes
OT  - ontology
OT  - phosphoproteomics
OT  - splicing
OT  - transcriptomics
COIS- AG-B was a former employee of BioMarin Pharmaceutical Inc., and holds shares of 
      the company. The remaining authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2021/05/25 06:00
MHDA- 2021/05/25 06:01
PMCR- 2021/01/01
CRDT- 2021/05/24 08:03
PHST- 2021/01/31 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/05/24 08:03 [entrez]
PHST- 2021/05/25 06:00 [pubmed]
PHST- 2021/05/25 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fncel.2021.662035 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2021 May 5;15:662035. doi: 10.3389/fncel.2021.662035. 
      eCollection 2021.

PMID- 33917301
OWN - NLM
STAT- MEDLINE
DCOM- 20210519
LR  - 20210519
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 18
IP  - 7
DP  - 2021 Apr 6
TI  - Fourier-Transform Infrared Spectroscopy as a Discriminatory Tool for Myotonic 
      Dystrophy Type 1 Metabolism: A Pilot Study.
LID - 10.3390/ijerph18073800 [doi]
LID - 3800
AB  - Myotonic dystrophy type 1 (DM1) is a hereditary disease characterized by 
      progressive distal muscle weakness and myotonia. Patients with DM1 have abnormal 
      lipid metabolism and a high propensity to develop a metabolic syndrome in 
      comparison to the general population. It follows that metabolome evaluation in 
      these patients is crucial and may contribute to a better characterization and 
      discrimination between DM1 disease phenotypes and severities. Several 
      experimental approaches are possible to carry out such an analysis; among them is 
      Fourier-transform infrared spectroscopy (FTIR) which evaluates metabolic profiles 
      by categorizing samples through their biochemical composition. In this study, 
      FTIR spectra were acquired and analyzed using multivariate analysis (Principal 
      Component Analysis) using skin DM1 patient-derived fibroblasts and controls. The 
      results obtained showed a clear discrimination between both DM1-derived 
      fibroblasts with different CTG repeat length and with the age of disease onset; 
      this was evident given the distinct metabolic profiles obtained for the two 
      groups. Discrimination could be attributed mainly to the altered lipid metabolism 
      and proteins in the 1800-1500 cm(-1) region. These results suggest that FTIR 
      spectroscopy is a valuable tool to discriminate both DM1-derived fibroblasts with 
      different CTG length and age of onset and to study the metabolomic profile of 
      patients with DM1.
FAU - Mateus, Tiago
AU  - Mateus T
AUID- ORCID: 0000-0002-9513-8197
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Almeida, Idalia
AU  - Almeida I
AUID- ORCID: 0000-0002-0639-0666
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Costa, Adriana
AU  - Costa A
AUID- ORCID: 0000-0002-2963-845X
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Viegas, Diana
AU  - Viegas D
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Magalhaes, Sandra
AU  - Magalhaes S
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
AD  - Department of Chemistry, Aveiro Institute of Materials (CICECO), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Martins, Filipa
AU  - Martins F
AUID- ORCID: 0000-0002-3277-1809
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Herdeiro, Maria Teresa
AU  - Herdeiro MT
AUID- ORCID: 0000-0002-0500-4049
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - da Cruz E Silva, Odete A B
AU  - da Cruz E Silva OAB
AUID- ORCID: 0000-0003-3718-9874
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Fraga, Carla
AU  - Fraga C
AD  - Neurology Department, Centro Hospitalar Tamega e Sousa (CHTS), 4564-007 Penafiel, 
      Portugal.
FAU - Alves, Ivania
AU  - Alves I
AD  - Neurology Department, Centro Hospitalar Tamega e Sousa (CHTS), 4564-007 Penafiel, 
      Portugal.
FAU - Nunes, Alexandra
AU  - Nunes A
AUID- ORCID: 0000-0002-0595-5821
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
FAU - Rebelo, Sandra
AU  - Rebelo S
AUID- ORCID: 0000-0002-5862-5797
AD  - Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of 
      Aveiro, 3810-193 Aveiro, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210406
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
SB  - IM
MH  - Humans
MH  - Muscle Weakness
MH  - *Myotonic Dystrophy/diagnosis/genetics
MH  - Phenotype
MH  - Pilot Projects
MH  - Spectroscopy, Fourier Transform Infrared
PMC - PMC8038712
OTO - NOTNLM
OT  - Fourier-transform infrared spectroscopy
OT  - Principal Component Analysis
OT  - fibroblasts
OT  - metabolomic profile
OT  - myotonic dystrophy type 1
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/20 06:00
PMCR- 2021/04/06
CRDT- 2021/04/30 01:05
PHST- 2021/03/01 00:00 [received]
PHST- 2021/03/26 00:00 [revised]
PHST- 2021/03/30 00:00 [accepted]
PHST- 2021/04/30 01:05 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/20 06:00 [medline]
PHST- 2021/04/06 00:00 [pmc-release]
AID - ijerph18073800 [pii]
AID - ijerph-18-03800 [pii]
AID - 10.3390/ijerph18073800 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2021 Apr 6;18(7):3800. doi: 
      10.3390/ijerph18073800.

PMID- 33807660
OWN - NLM
STAT- MEDLINE
DCOM- 20210422
LR  - 20240331
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 5
DP  - 2021 Mar 5
TI  - Robust Detection of Somatic Mosaicism and Repeat Interruptions by Long-Read 
      Targeted Sequencing in Myotonic Dystrophy Type 1.
LID - 10.3390/ijms22052616 [doi]
LID - 2616
AB  - Myotonic dystrophy type 1 (DM1) is the most complex and variable trinucleotide 
      repeat disorder caused by an unstable CTG repeat expansion, reaching up to 4000 
      CTG in the most severe cases. The genetic and clinical variability of DM1 depend 
      on the sex and age of the transmitting parent, but also on the CTG repeat number, 
      presence of repeat interruptions and/or on the degree of somatic instability. 
      Currently, it is difficult to simultaneously and accurately determine these 
      contributing factors in DM1 patients due to the limitations of gold standard 
      methods used in molecular diagnostics and research laboratories. Our study showed 
      the efficiency of the latest PacBio long-read sequencing technology to sequence 
      large CTG trinucleotides, detect multiple and single repeat interruptions and 
      estimate the levels of somatic mosaicism in DM1 patients carrying complex CTG 
      repeat expansions inaccessible to most methods. Using this innovative approach, 
      we revealed the existence of de novo CCG interruptions associated with CTG 
      stabilization/contraction across generations in a new DM1 family. We also 
      demonstrated that our method is suitable to sequence the DM1 locus and measure 
      somatic mosaicism in DM1 families carrying more than 1000 pure CTG repeats. 
      Better characterization of expanded alleles in DM1 patients can significantly 
      improve prognosis and genetic counseling, not only in DM1 but also for other 
      tandem DNA repeat disorders.
FAU - Mangin, Antoine
AU  - Mangin A
AD  - Centre de Recherche en Myologie, Inserm, Institut de Myologie, Sorbonne 
      Universite, F-75013 Paris, France.
AD  - Dementia Research Institute, Cardiff University, Cardiff CF10 3AT, UK.
FAU - de Pontual, Laure
AU  - de Pontual L
AD  - Centre de Recherche en Myologie, Inserm, Institut de Myologie, Sorbonne 
      Universite, F-75013 Paris, France.
FAU - Tsai, Yu-Chih
AU  - Tsai YC
AUID- ORCID: 0000-0002-2958-0278
AD  - Pacific Biosciences, Menlo Park, CA 94025, USA.
FAU - Monteil, Laetitia
AU  - Monteil L
AD  - Genetics Department of the Hospital of Toulouse, F-31059 Toulouse, France.
FAU - Nizon, Mathilde
AU  - Nizon M
AUID- ORCID: 0000-0003-2170-4210
AD  - CHU de Nantes, Service de Genetique Medicale, Laboratoire de Genetique 
      Moleculaire, F-44000 Nantes, France.
FAU - Boisseau, Pierre
AU  - Boisseau P
AD  - CHU de Nantes, Service de Genetique Medicale, Laboratoire de Genetique 
      Moleculaire, F-44000 Nantes, France.
FAU - Mercier, Sandra
AU  - Mercier S
AUID- ORCID: 0000-0002-6627-8748
AD  - CHU Nantes, Service de Genetique Medicale, Centre de Reference des Maladies 
      Neuromusculaires AOC, F-44000 Nantes, France.
FAU - Ziegle, Janet
AU  - Ziegle J
AD  - Pacific Biosciences, Menlo Park, CA 94025, USA.
FAU - Harting, John
AU  - Harting J
AD  - Pacific Biosciences, Menlo Park, CA 94025, USA.
FAU - Heiner, Cheryl
AU  - Heiner C
AD  - Pacific Biosciences, Menlo Park, CA 94025, USA.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Centre de Recherche en Myologie, Inserm, Institut de Myologie, Sorbonne 
      Universite, F-75013 Paris, France.
FAU - Tome, Stephanie
AU  - Tome S
AD  - Centre de Recherche en Myologie, Inserm, Institut de Myologie, Sorbonne 
      Universite, F-75013 Paris, France.
LA  - eng
GR  - 16331/AFM-Telethon/
GR  - 19757/AFM-Telethon/
GR  - ANR-10-IAHU-01/Agence Nationale de la Recherche/
GR  - 2019/SMRT grant PacBio/
PT  - Journal Article
DEP - 20210305
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Adult
MH  - Female
MH  - *High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mosaicism
MH  - Myotonic Dystrophy/*genetics
MH  - *Trinucleotide Repeat Expansion
PMC - PMC7962047
OTO - NOTNLM
OT  - interrupted CTG repeat expansion
OT  - long read sequencing
OT  - myotonic dystrophy type 1
OT  - somatic mosaicism
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/04 06:00
MHDA- 2021/04/23 06:00
PMCR- 2021/03/05
CRDT- 2021/04/03 01:27
PHST- 2021/02/12 00:00 [received]
PHST- 2021/02/26 00:00 [revised]
PHST- 2021/02/27 00:00 [accepted]
PHST- 2021/04/03 01:27 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2021/04/23 06:00 [medline]
PHST- 2021/03/05 00:00 [pmc-release]
AID - ijms22052616 [pii]
AID - ijms-22-02616 [pii]
AID - 10.3390/ijms22052616 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Mar 5;22(5):2616. doi: 10.3390/ijms22052616.

PMID- 36246012
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2666-9145 (Electronic)
IS  - 2666-9145 (Linking)
VI  - 1
IP  - 1
DP  - 2021 Mar
TI  - Increased Corneal Endothelial Cell Migration in Fuchs Endothelial Corneal 
      Dystrophy: A Live Cell Imaging Study.
PG  - 100006
LID - 10.1016/j.xops.2021.100006 [doi]
LID - 100006
AB  - PURPOSE: To investigate if corneal endothelial cells (CECs) in Fuchs endothelial 
      corneal dystrophy (FECD) have altered cellular migration compared with normal 
      controls. DESIGN: Comparative analysis. MATERIALS: Descemet's membrane and CECs 
      derived from patients with FECD undergoing endothelial keratoplasty or normal 
      cadaveric donors. METHODS: Ex vivo specimens were used for live cell imaging and 
      generation of immortalized cell lines. Live imaging was performed on FECD and 
      normal CECs and on ex vivo specimens transfected with green fluorescent protein. 
      Migration speeds were determined as a function of cellular density using 
      automated cell tracking. Ex vivo specimens were classified as either FECD or 
      normal low cell density (nonconfluent) or high cell density (confluent). Scratch 
      assay was performed on CECs seeded at high confluence to determine migration 
      speed. Genetic analysis from blood samples or CECs was performed to detect a CTG 
      repeat expansion in the TCF4 gene. MAIN OUTCOME MEASURES: Mean cell migration 
      speed. RESULTS: Fuchs endothelial corneal dystrophy CECs in low cell density 
      areas displayed increased mean speed (0.391 +/- 0.005 mum/minute vs. 0.364 +/- 0.005 
      mum/minute; P < 0.001) and mean maximum speed (0.961 +/- 0.010 mum/minute vs. 0.787 +/- 
      0.011 mum/minute; P < 0.001) compared with normal CECs, and increased mean maximum 
      speed (0.778 +/- 0.014 mum/minute vs. 0.680 +/- 0.011 mum/minute; P < 0.001) in high 
      cell density areas ex vivo. Similarly, FECD CECs displayed increased mean speed 
      compared with normal CECs (1.958 +/- 0.020 mum/minute vs. 2.227 +/- 0.021 mum/minute 
      vs. 1.567 +/- 0.019 mum/minute; P < 0.001) under nonconfluent conditions in vitro. 
      Moreover, FECD CECs also displayed increased mean speed compared with normal CECs 
      under high confluent conditions as detected by scratch assay (37.2 +/- 1.1% vs. 
      44.3 +/- 4.1% vs. 70.7 +/- 5.2%; P < 0.001). Morphologic analysis showed that FECD 
      CECs displayed an increased fibroblastic phenotype as detected by 
      filamentous-actin labeling. CONCLUSIONS: Fuchs endothelial corneal dystrophy CECs 
      demonstrated increased migration speed compared with normal CECs. Further 
      investigation into the mechanisms of heightened cell migration in FECD is needed 
      and may provide insight into its pathogenesis, as well as having implications on 
      descemetorhexis without endothelial keratoplasty.
CI  - (c) 2021 by the American Academy of Ophthalmology.
FAU - Ong Tone, Stephan
AU  - Ong Tone S
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
AD  - Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, 
      Canada.
AD  - Department of Ophthalmology, University of Toronto, Toronto, Canada.
FAU - Wylegala, Adam
AU  - Wylegala A
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
FAU - Bohm, Myriam
AU  - Bohm M
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
FAU - Melangath, Geetha
AU  - Melangath G
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
FAU - Deshpande, Neha
AU  - Deshpande N
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
FAU - Jurkunas, Ula V
AU  - Jurkunas UV
AD  - Cornea Center of Excellence, Schepens Eye Research Institute, Harvard Medical 
      School, Boston, Massachusetts.
AD  - Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 
      Massachusetts.
AD  - Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
LA  - eng
PT  - Journal Article
DEP - 20210309
PL  - Netherlands
TA  - Ophthalmol Sci
JT  - Ophthalmology science
JID - 9918230896206676
PMC - PMC9559113
OTO - NOTNLM
OT  - CE, corneal endothelium
OT  - CEC, corneal endothelial cell
OT  - Cell migration
OT  - Corneal endothelium
OT  - DM, Descemet's membrane
OT  - DMEK, Descemet's membrane endothelial keratoplasty
OT  - DWEK, descemetorhexis without endothelial keratoplasty
OT  - Descemetorhexis without endothelial keratoplasty
OT  - Descemet's stripping only
OT  - ECD, endothelial cell density
OT  - ECM, extracellular matrix
OT  - EMT, endothelial-to-mesenchymal transition
OT  - FECD, Fuchs endothelial corneal dystrophy
OT  - Fuchs endothelial corneal dystrophy
OT  - GFP, green fluorescent protein
OT  - LNP, lipid nanoparticle
OT  - PBS, phosphate-buffered saline
OT  - TCF4, transcription factor 4
EDAT- 2021/03/09 00:00
MHDA- 2021/03/09 00:01
PMCR- 2021/03/09
CRDT- 2022/10/17 04:24
PHST- 2020/11/11 00:00 [received]
PHST- 2021/02/09 00:00 [revised]
PHST- 2021/03/03 00:00 [accepted]
PHST- 2022/10/17 04:24 [entrez]
PHST- 2021/03/09 00:00 [pubmed]
PHST- 2021/03/09 00:01 [medline]
PHST- 2021/03/09 00:00 [pmc-release]
AID - S2666-9145(21)00004-X [pii]
AID - 100006 [pii]
AID - 10.1016/j.xops.2021.100006 [doi]
PST - epublish
SO  - Ophthalmol Sci. 2021 Mar 9;1(1):100006. doi: 10.1016/j.xops.2021.100006. 
      eCollection 2021 Mar.

PMID- 33682722
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 2214-3602 (Electronic)
VI  - 8
IP  - 4
DP  - 2021
TI  - Dysregulation of GSK3beta-Target Proteins in Skin Fibroblasts of Myotonic Dystrophy 
      Type 1 (DM1) Patients.
PG  - 603-619
LID - 10.3233/JND-200558 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is the most common monogenetic muscular disorder 
      of adulthood. This multisystemic disease is caused by CTG repeat expansion in the 
      3'-untranslated region of the DM1 protein kinase gene called DMPK. DMPK encodes a 
      myosin kinase expressed in skeletal muscle cells and other cellular populations 
      such as smooth muscle cells, neurons and fibroblasts. The resultant expanded 
      (CUG)n RNA transcripts sequester RNA binding factors leading to ubiquitous and 
      persistent splicing deregulation. The accumulation of mutant CUG repeats is 
      linked to increased activity of glycogen synthase kinase 3 beta (GSK3beta), a highly 
      conserved and ubiquitous serine/threonine kinase with functions in pathways 
      regulating inflammation, metabolism, oncogenesis, neurogenesis and myogenesis. As 
      GSK3beta-inhibition ameliorates defects in myogenesis, muscle strength and myotonia 
      in a DM1 mouse model, this kinase represents a key player of DM1 
      pathobiochemistry and constitutes a promising therapeutic target. To better 
      characterise DM1 patients, and monitor treatment responses, we aimed to define a 
      set of robust disease and severity markers linked to GSK3betaby unbiased proteomic 
      profiling utilizing fibroblasts derived from DM1 patients with low (80- 150) and 
      high (2600- 3600) CTG-repeats. Apart from GSK3beta increase, we identified 
      dysregulation of nine proteins (CAPN1, CTNNB1, CTPS1, DNMT1, HDAC2, HNRNPH3, 
      MAP2K2, NR3C1, VDAC2) modulated by GSK3beta. In silico-based expression studies 
      confirmed expression in neuronal and skeletal muscle cells and revealed a 
      relatively elevated abundance in fibroblasts. The potential impact of each marker 
      in the myopathology of DM1 is discussed based on respective function to inform 
      potential uses as severity markers or for monitoring GSK3beta inhibitor treatment 
      responses.
FAU - Grande, Valentina
AU  - Grande V
AD  - Department of Neuropediatrics, University Hospital Essen, Duisburg-Essen 
      University, Germany.
FAU - Hathazi, Denisa
AU  - Hathazi D
AD  - Leibniz-Institut fur Analytische Wissenschaften -ISAS- e.V., Dortmund, Germany.
AD  - Department of Clinical Neurosciences, School of Clinical Medicine, University of 
      Cambridge, Cambridge, UK.
FAU - O'Connor, Emily
AU  - O'Connor E
AD  - Childrens Hospital of Eastern Ontario Research Institute, University of Ottawa, 
      Ottawa, ON, Canada.
FAU - Marteau, Theo
AU  - Marteau T
AD  - Department of Neuropediatrics, University Hospital Essen, Duisburg-Essen 
      University, Germany.
FAU - Schara-Schmidt, Ulrike
AU  - Schara-Schmidt U
AD  - Department of Neuropediatrics, University Hospital Essen, Duisburg-Essen 
      University, Germany.
FAU - Hentschel, Andreas
AU  - Hentschel A
AD  - Leibniz-Institut fur Analytische Wissenschaften -ISAS- e.V., Dortmund, Germany.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Centre de Recherche en Myologie, Association Institut de Myologie, Sorbonne 
      Universite, Inserm UMR 974, Paris, France.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - National Hospital for Neurology and Neurosurgery, University College London 
      Hospitals NHS Foundation Trust, London, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Childrens Hospital of Eastern Ontario Research Institute, University of Ottawa, 
      Ottawa, ON, Canada.
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, 
      Canada.
AD  - Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Medical 
      Center - University of Freiburg, Freiburg, Germany.
AD  - Centro Nacional de AnalisisGenomico, Center for Genomic Regulation (CNAG-CRG), 
      Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, 
      Spain.
FAU - Roos, Andreas
AU  - Roos A
AD  - Department of Neuropediatrics, University Hospital Essen, Duisburg-Essen 
      University, Germany.
AD  - Childrens Hospital of Eastern Ontario Research Institute, University of Ottawa, 
      Ottawa, ON, Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
RN  - 0 (Biomarkers)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Biomarkers
MH  - Female
MH  - Fibroblasts/*metabolism
MH  - Gene Expression Profiling
MH  - Glycogen Synthase Kinase 3 beta/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Development
MH  - Muscle Fibers, Skeletal/metabolism
MH  - Muscle Strength
MH  - Myotonic Dystrophy/*metabolism
MH  - Myotonin-Protein Kinase/metabolism
MH  - Protein Serine-Threonine Kinases
MH  - Proteomics
MH  - RNA, Messenger
MH  - Skin/*metabolism
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CAPN1
OT  - CTNNB1
OT  - CTPS1
OT  - GSK3beta
OT  - HDAC2
OT  - fibroblast proteomics
EDAT- 2021/03/09 06:00
MHDA- 2021/12/21 06:00
CRDT- 2021/03/08 08:43
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
PHST- 2021/03/08 08:43 [entrez]
AID - JND200558 [pii]
AID - 10.3233/JND-200558 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2021;8(4):603-619. doi: 10.3233/JND-200558.

PMID- 33624941
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 2324-9269 (Electronic)
IS  - 2324-9269 (Linking)
VI  - 9
IP  - 4
DP  - 2021 Apr
TI  - High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 
      using melt curve analysis.
PG  - e1619
LID - 10.1002/mgg3.1619 [doi]
LID - e1619
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is caused by CTG repeat expansions in 
      the DMPK gene and is the most common form of muscular dystrophy. Patients can 
      have long delays from onset to diagnosis, since clinical signs and symptoms are 
      often nonspecific and overlapping with other disorders. Clinical genetic testing 
      by Southern blot or triplet-primed PCR (TP-PCR) is technically challenging and 
      cost prohibitive for population surveys. METHODS: Here, we present a high 
      throughput, low-cost screening tool for CTG repeat expansions using TP-PCR 
      followed by high resolution melt curve analysis with saturating concentrations of 
      SYBR GreenER dye. RESULTS: We determined that multimodal melt profiles from the 
      TP-PCR assay are a proxy for amplicon length stoichiometry. In a screen of 10,097 
      newborn blood spots, melt profile analysis accurately reflected the tri-modal 
      distribution of common alleles from 5 to 35 CTG repeats, and identified the 
      premutation and full expansion alleles. CONCLUSION: We demonstrate that robust 
      detection of expanded CTG repeats in a single tube can be achieved from samples 
      derived from specimens with minimal template DNA such as dried blood spots (DBS). 
      This technique is readily adaptable to large-scale testing programs such as 
      population studies and newborn screening programs.
CI  - (c) 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley 
      Periodicals LLC.
FAU - Butterfield, Russell J
AU  - Butterfield RJ
AUID- ORCID: 0000-0002-8452-7189
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
AD  - Department of Neurology, University of Utah, Salt Lake City, Utah, USA.
FAU - Imburgia, Carina
AU  - Imburgia C
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
FAU - Mayne, Katie
AU  - Mayne K
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
FAU - Newcomb, Tara
AU  - Newcomb T
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
FAU - Dunn, Diane M
AU  - Dunn DM
AD  - Department of Human Genetics, University of Utah, Salt Lake City, Utah, USA.
FAU - Duval, Brett
AU  - Duval B
AD  - Department of Human Genetics, University of Utah, Salt Lake City, Utah, USA.
FAU - Feldkamp, Marcia L
AU  - Feldkamp ML
AD  - Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
FAU - Johnson, Nicholas E
AU  - Johnson NE
AD  - Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, 
      USA.
FAU - Weiss, Robert B
AU  - Weiss RB
AD  - Department of Human Genetics, University of Utah, Salt Lake City, Utah, USA.
LA  - eng
GR  - K08 NS097631/NS/NINDS NIH HHS/United States
GR  - K23 NS091511/NS/NINDS NIH HHS/United States
GR  - R21 NS100040/NS/NINDS NIH HHS/United States
GR  - R21 TR003184/TR/NCATS NIH HHS/United States
GR  - R01 NS104010/NS/NINDS NIH HHS/United States
GR  - U01 DD001242/DD/NCBDD CDC HHS/United States
GR  - R01 FD006071/FD/FDA HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20210224
PL  - United States
TA  - Mol Genet Genomic Med
JT  - Molecular genetics & genomic medicine
JID - 101603758
SB  - IM
MH  - Costs and Cost Analysis
MH  - High-Throughput Screening Assays/economics/*methods/standards
MH  - Humans
MH  - Molecular Diagnostic Techniques/economics/*methods/standards
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - *Nucleic Acid Denaturation
MH  - Sensitivity and Specificity
MH  - *Trinucleotide Repeat Expansion
PMC - PMC8123750
OTO - NOTNLM
OT  - DMPK gene
OT  - melt curve analysis
OT  - myotonic dystrophy
OT  - population screening
OT  - triplet-repeat expansion
COIS- RJB is receiving funding via contracts for clinical trials from PTC Therapeutics, 
      Sarepta Therapeutics, Pfizer, Biogen, Carpricor, and Catabasis. He serves on 
      scientific advisory boards for Sarepta Therapeutics, Biogen, and Pfizer. NEJ has 
      received grant funding from NINDS (R21TR003184; R01NS104010), CDC (U01DD001242) 
      and the FDA (7R01FD006071). He receives royalties from the CCMDHI and the CMTHI. 
      He receives research funds from Dyne, AveXis, CSL Behring, Vertex 
      Pharmaceuticals, Fulcrum Therapeutics, ML Bio, Sarepta, and Acceleron Pharma. He 
      has provided consultation for AveXis, AMO Pharma, Strongbridge Biopharma, 
      Acceleron Pharma, Fulcrum Therapeutics, Dyne, ML Bio, Avidity, and Vertex 
      Pharmaceuticals. CI, KM, TN, DMD, BD, MKF, and RBW report no conflicts of 
      interest.
EDAT- 2021/02/25 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/02/24
CRDT- 2021/02/24 08:43
PHST- 2020/12/23 00:00 [revised]
PHST- 2020/10/12 00:00 [received]
PHST- 2021/01/29 00:00 [accepted]
PHST- 2021/02/25 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/02/24 08:43 [entrez]
PHST- 2021/02/24 00:00 [pmc-release]
AID - MGG31619 [pii]
AID - 10.1002/mgg3.1619 [doi]
PST - ppublish
SO  - Mol Genet Genomic Med. 2021 Apr;9(4):e1619. doi: 10.1002/mgg3.1619. Epub 2021 Feb 
      24.

PMID- 33595997
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20230902
IS  - 1537-1611 (Electronic)
IS  - 1522-0443 (Linking)
VI  - 22
IP  - 3
DP  - 2021 Mar 1
TI  - Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 
      Patients.
PG  - 135-146
LID - 10.1097/CND.0000000000000340 [doi]
AB  - Myotonic dystrophy type 2 (DM2) is an autosomal dominant disorder due to a 
      (CCTG)n repeat expansion in intron 1 of the CNBP gene. In this article, we report 
      the clinicopathologic findings in 50 patients seen at a single site over a 27 
      year period. DM2 was the fifth most common type of muscular dystrophy seen at our 
      center with a 5-fold lower frequency as compared to DM1. Age of symptom onset 
      ranged from 15 to 72 years, and the mean duration between symptom onset and 
      diagnosis was 7.4 years. Weakness referable to the proximal lower extremities was 
      the presenting symptom in 62% of patients. The degree of generalized weakness 
      varied from severe in 30% to no weakness in 20% of patients. Clinical myotonia 
      was noted in 18% and myotonic discharges on electromyography in 97% of patients. 
      Pain symptoms were uncommon in our cohort. A significant correlation was noted 
      between limb weakness and degree of muscle pathologic changes. There was no 
      correlation between CCTG repeat size and other clinicopathologic findings. Six 
      patients (12%) had cardiac abnormalities including one who developed progressive 
      nonischemic dilated cardiomyopathy ultimately leading to cardiac transplantation. 
      In 21 patients followed for 2 or more years, we noted a mean rate of decline in 
      total Medical Research Council score of about 1% per year.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Roy, Bhaskar
AU  - Roy B
AD  - Department of Neurology, University of Connecticut School of Medicine, 
      Farmington, CT.
FAU - Wu, Qian
AU  - Wu Q
AD  - Department of Pathology and Laboratory Medicine, University of Connecticut School 
      of Medicine, Farmington, CT; and.
FAU - Whitaker, Charles H
AU  - Whitaker CH
AD  - Department of Neuromuscular Medicine, Muscular Dystrophy Association Care Center, 
      Hospital for Special Care, New Britain, CT.
FAU - Felice, Kevin J
AU  - Felice KJ
AD  - Department of Neuromuscular Medicine, Muscular Dystrophy Association Care Center, 
      Hospital for Special Care, New Britain, CT.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Neuromuscul Dis
JT  - Journal of clinical neuromuscular disease
JID - 100887391
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Electromyography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness
MH  - Myotonia/diagnosis
MH  - Myotonic Dystrophy/*diagnosis
MH  - Tomography, X-Ray Computed
MH  - Young Adult
COIS- The authors report no conflicts of interest.
EDAT- 2021/02/18 06:00
MHDA- 2021/11/18 06:00
CRDT- 2021/02/17 14:09
PHST- 2021/02/17 14:09 [entrez]
PHST- 2021/02/18 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
AID - 00131402-202103000-00003 [pii]
AID - 10.1097/CND.0000000000000340 [doi]
PST - ppublish
SO  - J Clin Neuromuscul Dis. 2021 Mar 1;22(3):135-146. doi: 
      10.1097/CND.0000000000000340.

PMID- 33575482
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2376-7839 (Print)
IS  - 2376-7839 (Electronic)
IS  - 2376-7839 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Feb
TI  - DMPK mRNA Expression in Human Brain Tissue Throughout the Lifespan.
PG  - e537
LID - 10.1212/NXG.0000000000000537 [doi]
LID - e537
AB  - OBJECTIVE: Myotonic dystrophy is a multisystem disorder caused by a trinucleotide 
      repeat expansion on the myotonic dystrophy protein kinase (DMPK) gene. To 
      determine whether wildtype DMPK expression patterns vary as a function of age, we 
      analyzed DMPK expression in the brain from 99 donors ranging from 5 
      postconceptional weeks to 80 years old. METHODS: We used the BrainSpan messenger 
      RNA sequencing and the Yale Microarray data sets, which included brain tissue 
      samples from 42 and 57 donors, respectively. Collectively, donors ranged in age 
      from 5 postconceptional weeks to 80 years old. DMPK expression was normalized for 
      each donor across regions available in both data sets. Restricted cubic spline 
      linear regression models were used to analyze the effects of log-transformed age 
      and sex on normalized DMPK expression data. RESULTS: Age was a statistically 
      significant predictor of normalized DMPK expression pattern in the human brain in 
      the BrainSpan (p < 0.005) and Yale data sets (p < 0.005). Sex was not a 
      significant predictor. Across both data sets, normalized wildtype DMPK expression 
      steadily increases during fetal development, peaks around birth, and then 
      declines to reach a nadir around age 10. CONCLUSIONS: Peak expression of DMPK 
      coincides with a time of dynamic brain development. Abnormal brain DMPK 
      expression due to myotonic dystrophy may have implications for early brain 
      development.
CI  - Copyright (c) 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Langbehn, Kathleen E
AU  - Langbehn KE
AUID- ORCID: 0000-0001-6875-6320
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - Carlson-Stadler, Zoe
AU  - Carlson-Stadler Z
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - van der Plas, Ellen
AU  - van der Plas E
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - Hefti, Marco M
AU  - Hefti MM
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - Dawson, Jeffrey D
AU  - Dawson JD
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - Moser, David J
AU  - Moser DJ
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
FAU - Nopoulos, Peggy C
AU  - Nopoulos PC
AUID- ORCID: 0000-0001-8810-1903
AD  - Department of Psychiatry (K.E.L., Z.C.-S., E.v.d.P., D.J.M., and P.C.N.), 
      Department of Pathology (M.M.H.), Department of Pediatrics (P.C.N.), and 
      Department of Neurology (P.C.N.), College of Public Health (J.D.D.), University 
      of Iowa.
LA  - eng
GR  - K23 NS109284/NS/NINDS NIH HHS/United States
GR  - KL2 TR002536/TR/NCATS NIH HHS/United States
GR  - R01 NS094387/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20201221
PL  - United States
TA  - Neurol Genet
JT  - Neurology. Genetics
JID - 101671068
PMC - PMC7862092
EDAT- 2021/02/13 06:00
MHDA- 2021/02/13 06:01
PMCR- 2020/12/21
CRDT- 2021/02/12 06:09
PHST- 2020/04/20 00:00 [received]
PHST- 2020/10/19 00:00 [accepted]
PHST- 2021/02/12 06:09 [entrez]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/02/13 06:01 [medline]
PHST- 2020/12/21 00:00 [pmc-release]
AID - NG2020013847 [pii]
AID - 10.1212/NXG.0000000000000537 [doi]
PST - epublish
SO  - Neurol Genet. 2020 Dec 21;7(1):e537. doi: 10.1212/NXG.0000000000000537. 
      eCollection 2021 Feb.

PMID- 33546847
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 31
IP  - 3
DP  - 2021 Mar
TI  - A DM1 patient with CCG variant repeats: Reaching the diagnosis.
PG  - 232-238
LID - S0960-8966(20)30700-8 [pii]
LID - 10.1016/j.nmd.2020.12.005 [doi]
AB  - We report the case of a male patient presenting in his 50s with ptosis, facial 
      and distal limb muscle weakness, clinical and electrical myotonia, and a prior 
      history of cataract extraction. He had a dominant family history in keeping with 
      a similar phenotype. Myotonic dystrophy type 1 was clinically suspected. 
      Triplet-primed polymerase chain reaction in a diagnostic laboratory did not 
      identify a typical CTG repeat expansion on two separate blood samples. However, 
      subsequent genetic testing on a research basis identified a heterozygous repeat 
      expansion containing CCG variant repeats. Our case highlights the point that 
      variant repeats are not detectable on triplet-primed polymerase chain reaction 
      and result in a milder phenotype of myotonic dystrophy. It is crucial to maintain 
      a high clinical index of suspicion of this common neuromuscular condition.
CI  - Crown Copyright (c) 2020. Published by Elsevier B.V. All rights reserved.
FAU - Cumming, Sarah A
AU  - Cumming SA
AD  - Institute of Molecular Cell and Systems Biology, University of Glasgow, Davidson 
      Building, Glasgow G12 8QQ, United Kingdom.
FAU - Oliwa, Agata
AU  - Oliwa A
AD  - Undergraduate Medical School, University of Glasgow, Glasgow, United Kingdom.
FAU - Stevens, Gillian
AU  - Stevens G
AD  - West of Scotland Regional Genetics Service, Laboratory Medicine Building, Queen 
      Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TF, United Kingdom.
FAU - Ballantyne, Bob
AU  - Ballantyne B
AD  - West of Scotland Regional Genetics Service, Laboratory Medicine Building, Queen 
      Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TF, United Kingdom.
FAU - Mann, Cameron
AU  - Mann C
AD  - Neurophysiology Department, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, 1345, Govan Road, Glasgow G51 4TF, United Kingdom.
FAU - Razvi, Saif
AU  - Razvi S
AD  - Neurology Department, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, 1345, Govan Road, Glasgow G51 4TF, United Kingdom.
FAU - Longman, Cheryl
AU  - Longman C
AD  - West of Scotland Regional Genetics Service, Laboratory Medicine Building, Queen 
      Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TF, United Kingdom.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular Cell and Systems Biology, University of Glasgow, Davidson 
      Building, Glasgow G12 8QQ, United Kingdom.
FAU - Farrugia, Maria Elena
AU  - Farrugia ME
AD  - Neurology Department, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, 1345, Govan Road, Glasgow G51 4TF, United Kingdom. 
      Electronic address: m.e.farrugia@doctors.org.uk.
LA  - eng
PT  - Case Reports
DEP - 20201224
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alleles
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
OTO - NOTNLM
OT  - Multisystem disorder
OT  - Myotonic dystrophy
OT  - Triplet repeats
OT  - Variant repeats
COIS- Declaration of Competing Interest D.G.M. has been a scientific consultant and/or 
      received honoraria or stock options from Biogen Idec, AMO Pharma, Charles River, 
      Vertex Pharmaceuticals, Triplet Therapeutics, LoQus23, and Small Molecule RNA and 
      has had research contracts with AMO Pharma and Vertex Pharmaceuticals.
EDAT- 2021/02/07 06:00
MHDA- 2021/11/16 06:00
CRDT- 2021/02/06 05:31
PHST- 2020/07/10 00:00 [received]
PHST- 2020/12/12 00:00 [revised]
PHST- 2020/12/14 00:00 [accepted]
PHST- 2021/02/07 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2021/02/06 05:31 [entrez]
AID - S0960-8966(20)30700-8 [pii]
AID - 10.1016/j.nmd.2020.12.005 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2021 Mar;31(3):232-238. doi: 10.1016/j.nmd.2020.12.005. Epub 
      2020 Dec 24.

PMID- 33526774
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 2158-3188 (Electronic)
IS  - 2158-3188 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Feb 1
TI  - Genome sequencing broadens the range of contributing variants with clinical 
      implications in schizophrenia.
PG  - 84
LID - 10.1038/s41398-021-01211-2 [doi]
LID - 84
AB  - The range of genetic variation with potential clinical implications in 
      schizophrenia, beyond rare copy number variants (CNVs), remains uncertain. We 
      therefore analyzed genome sequencing data for 259 unrelated adults with 
      schizophrenia from a well-characterized community-based cohort previously 
      examined with chromosomal microarray for CNVs (none with 22q11.2 deletions). We 
      analyzed these genomes for rare high-impact variants considered causal for 
      neurodevelopmental disorders, including single-nucleotide variants (SNVs) and 
      small insertions/deletions (indels), for potential clinical relevance based on 
      findings for neurodevelopmental disorders. Also, we investigated a novel variant 
      type, tandem repeat expansions (TREs), in 45 loci known to be associated with 
      monogenic neurological diseases. We found several of these variants in this 
      schizophrenia population suggesting that these variants have a wider clinical 
      spectrum than previously thought. In addition to known pathogenic CNVs, we 
      identified 11 (4.3%) individuals with clinically relevant SNVs/indels in genes 
      converging on schizophrenia-relevant pathways. Clinical yield was significantly 
      enriched in females and in those with broadly defined learning/intellectual 
      disabilities. Genome analyses also identified variants with potential clinical 
      implications, including TREs (one in DMPK; two in ATXN8OS) and ultra-rare 
      loss-of-function SNVs in ZMYM2 (a novel candidate gene for schizophrenia). Of the 
      233 individuals with no pathogenic CNVs, we identified rare high-impact variants 
      (i.e., clinically relevant or with potential clinical implications) for 14 
      individuals (6.0%); some had multiple rare high-impact variants. Mean 
      schizophrenia polygenic risk score was similar between individuals with and 
      without clinically relevant rare genetic variation; common variants were not 
      sufficient for clinical application. These findings broaden the individual and 
      global picture of clinically relevant genetic risk in schizophrenia, and suggest 
      the potential translational value of genome sequencing as a single genetic 
      technology for schizophrenia.
FAU - Mojarad, Bahareh A
AU  - Mojarad BA
AUID- ORCID: 0000-0003-1943-9163
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Yin, Yue
AU  - Yin Y
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Manshaei, Roozbeh
AU  - Manshaei R
AD  - Ted Rogers Centre for Heart Research, Cardiac Genome Clinic, The Hospital for 
      Sick Children, Toronto, ON, Canada.
FAU - Backstrom, Ian
AU  - Backstrom I
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Costain, Gregory
AU  - Costain G
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
AD  - Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, 
      Toronto, ON, Canada.
FAU - Heung, Tracy
AU  - Heung T
AD  - Clinical Genetics Research Program, Centre for Addiction and Mental Health, 
      Toronto, ON, Canada.
AD  - The Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto 
      General Hospital, University Health Network, Toronto, ON, Canada.
FAU - Merico, Daniele
AU  - Merico D
AUID- ORCID: 0000-0002-3728-4401
AD  - Deep Genomics Inc., Toronto, Ontario and The Centre for Applied Genomics (TCAG), 
      The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Marshall, Christian R
AU  - Marshall CR
AD  - Paediatric Laboratory Medicine, Genome Diagnostics, The Hospital for Sick 
      Children, Department of Laboratory Medicine and Pathobiology, University of 
      Toronto, Toronto, ON, Canada.
FAU - Bassett, Anne S
AU  - Bassett AS
AUID- ORCID: 0000-0002-0681-7279
AD  - Clinical Genetics Research Program, Centre for Addiction and Mental Health, 
      Toronto, ON, Canada. anne.bassett@utoronto.ca.
AD  - The Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto 
      General Hospital, University Health Network, Toronto, ON, Canada. 
      anne.bassett@utoronto.ca.
AD  - Department of Psychiatry, University of Toronto, Toronto General Hospital 
      Research Institute and Campbell Family Mental Health Research Institute, Toronto, 
      ON, Canada. anne.bassett@utoronto.ca.
FAU - Yuen, Ryan K C
AU  - Yuen RKC
AUID- ORCID: 0000-0001-7273-4968
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada. 
      ryan.yuen@sickkids.ca.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. 
      ryan.yuen@sickkids.ca.
LA  - eng
GR  - MOP-89066/Gouvernement du Canada | Canadian Institutes of Health Research 
      (Instituts de Recherche en Sante du Canada)/
GR  - MOP-111238/Gouvernement du Canada | Canadian Institutes of Health Research 
      (Instituts de Recherche en Sante du Canada)/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210201
PL  - United States
TA  - Transl Psychiatry
JT  - Translational psychiatry
JID - 101562664
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - DNA Copy Number Variations
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Intellectual Disability
MH  - *Neurodevelopmental Disorders/genetics
MH  - *Schizophrenia/genetics
PMC - PMC7851385
COIS- Daniele Merico is a full-time employee of Deep Genomics Inc. and is entitled to a 
      stock option. All other authors report no financial relationships with commercial 
      interests.
EDAT- 2021/02/03 06:00
MHDA- 2021/06/29 06:00
PMCR- 2021/02/01
CRDT- 2021/02/02 06:04
PHST- 2020/06/28 00:00 [received]
PHST- 2021/01/12 00:00 [accepted]
PHST- 2020/12/28 00:00 [revised]
PHST- 2021/02/02 06:04 [entrez]
PHST- 2021/02/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - 10.1038/s41398-021-01211-2 [pii]
AID - 1211 [pii]
AID - 10.1038/s41398-021-01211-2 [doi]
PST - epublish
SO  - Transl Psychiatry. 2021 Feb 1;11(1):84. doi: 10.1038/s41398-021-01211-2.

PMID- 33507930
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20231110
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 1
DP  - 2021
TI  - Dysglycemia is associated with Mycobacterium tuberculosis lineages in 
      tuberculosis patients of North Lima-Peru.
PG  - e0243184
LID - 10.1371/journal.pone.0243184 [doi]
LID - e0243184
AB  - This study was performed to investigate the role of dysglycemia on the genetic 
      diversity of Mycobacterium tuberculosis (MTB) among pulmonary tuberculosis (TB) 
      patients to build scientific evidence about the possible mechanisms of TB 
      transmission. MTB isolates obtained of patients affected by pulmonary 
      tuberculosis from health care facilities of North Lima-Peru, were analyzed using 
      whole genome sequencing and 24-locus mycobacterial interspersed repetitive-unit 
      -variable-number tandem repeats (MIRU-VNTR). Subsequently, clinical and 
      epidemiological characteristics were associated with clustering, lineages and 
      comorbid conditions. The analysis carried out 112 pulmonary TB patients from 
      various health centers in North Lima, 17 (15%) had diabetes mellitus (DM) and 33 
      (29%) had pre-diabetes (PDM). Latin American-Mediterranean, Haarlem and Beijing 
      were the most frequent MTB lineages found in those patients. Previous TB 
      (adjusted odds ratio [aOR] = 3.65; 95%CI: 1.32-17.81), age (aOR = 1.12; 95%CI: 
      1.03-1.45) and Beijing lineage (aOR = 3.53; 95%CI: 1.08-13.2) were associated 
      with TB-DM comorbidity. Alcoholism (aOR = 2.92; 95%CI: 1.10-8.28), age (aOR = 
      1.05; 95%CI: 1.03-1.12) and Haarlem lineage (aOR = 2.54; 95%CI: 1.04-6.51) were 
      associated with TB-PDM comorbidity. Beijing and Haarlem lineages were 
      independently associated with TB-DM and TB-PDM comorbidities, respectively. 
      Although these findings may be surprising, we must be cautious to suggest that 
      dysglycemia could be associated with a highly clustering and predisposition of 
      MTB lineages related to a serious impact on the severity of TB disease, which 
      requires further research.
FAU - Lopez, Kattya
AU  - Lopez K
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
AD  - Facultad de Ciencias Biologicas, Universidad Nacional Mayor de San Marcos, Lima, 
      Peru.
AD  - Division of Rheumatology, Immunity and Inflammation, Brigham and Women's 
      Hospital, Harvard Medical School, Boston, Massachusetts, United States of 
      America.
FAU - Arriaga, Maria B
AU  - Arriaga MB
AD  - Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Bahia, Brazil.
AD  - Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
AD  - Instituto Brasileiro para Investigacao da Tuberculose, Fundacao Jose Silveira, 
      Salvador, Bahia, Brazil.
FAU - Aliaga, Juan G
AU  - Aliaga JG
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
FAU - Barreda, Nadia N
AU  - Barreda NN
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
FAU - Sanabria, Oswaldo M
AU  - Sanabria OM
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
FAU - Huang, Chuan-Chin
AU  - Huang CC
AD  - Division of Global Health Equity, Brigham and Women's Hospital, Boston, 
      Massachusetts, United States of America.
FAU - Zhang, Zibiao
AU  - Zhang Z
AD  - Department of Global Health and Social Medicine, Harvard Medical School, Boston, 
      Massachusetts, United States of America.
FAU - Garcia-de-la-Guarda, Ruth
AU  - Garcia-de-la-Guarda R
AUID- ORCID: 0000-0003-4801-5642
AD  - Facultad de Ciencias Biologicas, Universidad Nacional Mayor de San Marcos, Lima, 
      Peru.
FAU - Lecca, Leonid
AU  - Lecca L
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
FAU - Calcada Carvalho, Anna Cristina
AU  - Calcada Carvalho AC
AD  - Laboratorio de Inovacoes em Terapias, Ensino e Bioprodutos, Instituto Oswaldo 
      Cruz, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Kritski, Afranio L
AU  - Kritski AL
AD  - Faculdade de Medicina, Programa Academico de Tuberculose, Universidade Federal do 
      Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Calderon, Roger I
AU  - Calderon RI
AUID- ORCID: 0000-0001-8932-0489
AD  - Socios En Salud Sucursal Peru, Lima, Peru.
AD  - Faculdade de Medicina, Programa Academico de Tuberculose, Universidade Federal do 
      Rio de Janeiro, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210128
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/*metabolism
MH  - Cluster Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium tuberculosis/isolation & purification/*physiology
MH  - Peru
MH  - *Phylogeny
MH  - Tuberculosis/*blood/*microbiology
MH  - Young Adult
PMC - PMC7843012
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/01/29 06:00
MHDA- 2021/04/22 06:00
PMCR- 2021/01/28
CRDT- 2021/01/28 17:16
PHST- 2020/11/13 00:00 [received]
PHST- 2021/01/08 00:00 [accepted]
PHST- 2021/01/28 17:16 [entrez]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
PHST- 2021/01/28 00:00 [pmc-release]
AID - PONE-D-20-35763 [pii]
AID - 10.1371/journal.pone.0243184 [doi]
PST - epublish
SO  - PLoS One. 2021 Jan 28;16(1):e0243184. doi: 10.1371/journal.pone.0243184. 
      eCollection 2021.

PMID- 33497365
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 2379-3708 (Electronic)
IS  - 2379-3708 (Linking)
VI  - 6
IP  - 5
DP  - 2021 Mar 8
TI  - Reversible cardiac disease features in an inducible CUG repeat RNA-expressing 
      mouse model of myotonic dystrophy.
LID - 143465 [pii]
LID - 10.1172/jci.insight.143465 [doi]
LID - e143465
AB  - Myotonic dystrophy type 1 (DM1) is caused by a CTG repeat expansion in the DMPK 
      gene. Expression of pathogenic expanded CUG repeat (CUGexp) RNA causes 
      multisystemic disease by perturbing the functions of RNA-binding proteins, 
      resulting in expression of fetal protein isoforms in adult tissues. Cardiac 
      involvement affects 50% of individuals with DM1 and causes 25% of disease-related 
      deaths. We developed a transgenic mouse model for tetracycline-inducible and 
      heart-specific expression of human DMPK mRNA containing 960 CUG repeats. CUGexp 
      RNA is expressed in atria and ventricles and induced mice exhibit 
      electrophysiological and molecular features of DM1 disease, including cardiac 
      conduction delays, supraventricular arrhythmias, nuclear RNA foci with 
      Muscleblind protein colocalization, and alternative splicing defects. 
      Importantly, these phenotypes were rescued upon loss of CUGexp RNA expression. 
      Transcriptome analysis revealed gene expression and alternative splicing changes 
      in ion transport genes that are associated with inherited cardiac conduction 
      diseases, including a subset of genes involved in calcium handling. Consistent 
      with RNA-Seq results, calcium-handling defects were identified in atrial 
      cardiomyocytes isolated from mice expressing CUGexp RNA. These results identify 
      potential tissue-specific mechanisms contributing to cardiac pathogenesis in DM1 
      and demonstrate the utility of reversible phenotypes in our model to facilitate 
      development of targeted therapeutic approaches.
FAU - Rao, Ashish N
AU  - Rao AN
AD  - Department of Molecular and Cellular Biology.
FAU - Campbell, Hannah M
AU  - Campbell HM
AD  - Department of Molecular Physiology and Biophysics, and.
AD  - Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, 
      USA.
FAU - Guan, Xiangnan
AU  - Guan X
AD  - Computational Biology Program, Oregon Health & Science University, Portland, 
      Oregon, USA.
FAU - Word, Tarah A
AU  - Word TA
AD  - Department of Molecular Physiology and Biophysics, and.
FAU - Wehrens, Xander Ht
AU  - Wehrens XH
AD  - Department of Molecular Physiology and Biophysics, and.
AD  - Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, 
      USA.
FAU - Xia, Zheng
AU  - Xia Z
AD  - Computational Biology Program, Oregon Health & Science University, Portland, 
      Oregon, USA.
AD  - Department of Molecular Microbiology and Immunology, Oregon Health & Science 
      University, Portland, Oregon, USA.
FAU - Cooper, Thomas A
AU  - Cooper TA
AD  - Department of Molecular and Cellular Biology.
AD  - Department of Molecular Physiology and Biophysics, and.
AD  - Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, 
      USA.
AD  - Department of Pathology and Immunology, Baylor College of Medicine, Houston, 
      Texas, USA.
LA  - eng
GR  - F30 HL140782/HL/NHLBI NIH HHS/United States
GR  - T32 HL139430/HL/NHLBI NIH HHS/United States
GR  - R01 AR045653/AR/NIAMS NIH HHS/United States
GR  - R01 HL091947/HL/NHLBI NIH HHS/United States
GR  - R01 HL147108/HL/NHLBI NIH HHS/United States
GR  - R01 DK114356/DK/NIDDK NIH HHS/United States
GR  - R01 HL045565/HL/NHLBI NIH HHS/United States
GR  - R01 AR060733/AR/NIAMS NIH HHS/United States
GR  - P30 CA125123/CA/NCI NIH HHS/United States
GR  - K01 LM012877/LM/NLM NIH HHS/United States
GR  - UM1 HG006348/HG/NHGRI NIH HHS/United States
GR  - R01 HL089598/HL/NHLBI NIH HHS/United States
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
GR  - R01 HL147020/HL/NHLBI NIH HHS/United States
GR  - R01 HL117641/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20210308
PL  - United States
TA  - JCI Insight
JT  - JCI insight
JID - 101676073
RN  - 0 (DMPK protein, human)
RN  - 0 (Protein Isoforms)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Cells, Cultured
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - *Myocytes, Cardiac/metabolism/pathology
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Protein Isoforms/metabolism
MH  - Trinucleotide Repeat Expansion
PMC - PMC8021116
OTO - NOTNLM
OT  - Arrhythmias
OT  - Cardiology
OT  - Cell Biology
OT  - RNA processing
COIS- Conflict of interest: XHTW is a founding partner of Elex Biotech, a start-up 
      company that develops drug molecules that target RyRs for the treatment of 
      cardiac arrhythmia disorders.
EDAT- 2021/01/27 06:00
MHDA- 2022/01/11 06:00
PMCR- 2021/03/08
CRDT- 2021/01/26 17:09
PHST- 2020/08/21 00:00 [received]
PHST- 2021/01/20 00:00 [accepted]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/01/26 17:09 [entrez]
PHST- 2021/03/08 00:00 [pmc-release]
AID - 143465 [pii]
AID - 10.1172/jci.insight.143465 [doi]
PST - epublish
SO  - JCI Insight. 2021 Mar 8;6(5):e143465. doi: 10.1172/jci.insight.143465.

PMID- 33472074
OWN - NLM
STAT- MEDLINE
DCOM- 20220128
LR  - 20220716
IS  - 2211-1247 (Electronic)
VI  - 34
IP  - 3
DP  - 2021 Jan 19
TI  - Transcriptome alterations in myotonic dystrophy frontal cortex.
PG  - 108634
LID - S2211-1247(20)31623-5 [pii]
LID - 10.1016/j.celrep.2020.108634 [doi]
AB  - Myotonic dystrophy (DM) is caused by expanded CTG/CCTG repeats, causing symptoms 
      in skeletal muscle, heart, and central nervous system (CNS). CNS issues are 
      debilitating and include hypersomnolence, executive dysfunction, white matter 
      atrophy, and neurofibrillary tangles. Here, we generate RNA-seq transcriptomes 
      from DM and unaffected frontal cortex and identify 130 high-confidence splicing 
      changes, most occurring only in cortex, not skeletal muscle or heart. Mis-spliced 
      exons occur in neurotransmitter receptors, ion channels, and synaptic scaffolds, 
      and GRIP1 mis-splicing modulates kinesin association. Optical mapping of expanded 
      CTG repeats reveals extreme mosaicism, with some alleles showing >1,000 CTGs. 
      Mis-splicing severity correlates with CTG repeat length across individuals. 
      Upregulated genes tend to be microglial and endothelial, suggesting 
      neuroinflammation, and downregulated genes tend to be neuronal. Many gene 
      expression changes strongly correlate with mis-splicing, suggesting candidate 
      biomarkers of disease. These findings provide a framework for mechanistic and 
      therapeutic studies of the DM CNS.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Otero, Brittney A
AU  - Otero BA
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL, USA.
FAU - Poukalov, Kiril
AU  - Poukalov K
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL, USA.
FAU - Hildebrandt, Ryan P
AU  - Hildebrandt RP
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL, USA.
FAU - Thornton, Charles A
AU  - Thornton CA
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY, 
      USA.
FAU - Jinnai, Kenji
AU  - Jinnai K
AD  - Department of Neurology, National Hospital Organization Hyogo-Chuo Hospital, 
      Sanda, Japan.
FAU - Fujimura, Harutoshi
AU  - Fujimura H
AD  - Department of Neurology, National Hospital Organization Toneyama Hospital, Osaka, 
      Japan.
FAU - Kimura, Takashi
AU  - Kimura T
AD  - Department of Neurology, Hyogo College of Medicine, Nichinomiya, Japan.
FAU - Hagerman, Katharine A
AU  - Hagerman KA
AD  - Department of Neurology, Stanford University, Palo Alto, CA, USA.
FAU - Sampson, Jacinda B
AU  - Sampson JB
AD  - Department of Neurology, Stanford University, Palo Alto, CA, USA.
FAU - Day, John W
AU  - Day JW
AD  - Department of Neurology, Stanford University, Palo Alto, CA, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, 
      Genetics Institute, University of Florida, Gainesville, FL, USA. Electronic 
      address: eric.t.wang@ufl.edu.
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
SB  - IM
MH  - Frontal Lobe/*physiopathology
MH  - Humans
MH  - Myotonic Dystrophy/*genetics
MH  - Transcriptome/*genetics
PMC - PMC9272850
MID - NIHMS1821080
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2021/01/21 06:00
MHDA- 2022/01/29 06:00
PMCR- 2022/07/11
CRDT- 2021/01/20 20:05
PHST- 2020/09/14 00:00 [received]
PHST- 2020/11/16 00:00 [revised]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/20 20:05 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2022/01/29 06:00 [medline]
PHST- 2022/07/11 00:00 [pmc-release]
AID - S2211-1247(20)31623-5 [pii]
AID - 10.1016/j.celrep.2020.108634 [doi]
PST - ppublish
SO  - Cell Rep. 2021 Jan 19;34(3):108634. doi: 10.1016/j.celrep.2020.108634.

PMID- 33413573
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 23
IP  - 1
DP  - 2021 Jan 7
TI  - Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced 
      effector functions in dermatomyositis.
PG  - 15
LID - 10.1186/s13075-020-02397-4 [doi]
LID - 15
AB  - BACKGROUND: T cell Ig and ITIM domain (TIGIT)/CD226 pathway has a critical role 
      in regulating T cell responses and has come to the forefront in cancer as a 
      promising immunotherapeutic target. However, its role in autoimmune diseases is 
      just beginning to be elucidated. Dermatomyositis (DM) is an autoimmune disease, 
      in which T cell dysregulation plays a pivotal role, and importantly, it is a 
      common immune-related adverse event in response to treatment of cancers with 
      immune checkpoint inhibitors, but no studies have implicated the TIGIT/CD226 axis 
      in DM. METHODS: We recruited 30 treatment-naive DM patients and 26 healthy 
      controls. Flow cytometry analysis was used to investigate the co-expression of 
      TIGIT and CD226 on T cells in blood samples. Magnetic bead or FACS-based cell 
      isolation, T cell proliferation assay, and intracellular cytokine staining were 
      performed to analyze the functions of different TIGIT/CD226 phenotypes. 
      Recombinant proteins CD155, CD112, and anti-CD226 antibodies were used to 
      suppress the function of TIGIT/CD226-expressing CD4 T cells. RESULTS: Four 
      distinct subsets of T cells based on TIGIT/CD226 co-expression, TIGIT+CD226-, 
      TIGIT+CD226+, TIGIT-CD226+, and TIGIT-CD226-, were identified and characterized 
      in DM patients. Our data showed that the function of CD4 T cell subset varied by 
      the TIGIT/CD226 phenotype. An elevated TIGIT+CD226+ CD4 subset with enhanced 
      effector function was observed in patients with DM, especially the patients 
      complicated with interstitial lung disease. This subpopulation was closely 
      related to DM activity and decreased significantly in DM remission after 
      treatment. Furthermore, the effector function of TIGIT+CD226+ CD4 subset could be 
      suppressed by blocking CD226. CONCLUSION: Our data revealed that the TIGIT and 
      CD226 expression profiles could be used to identify functionally distinct subsets 
      of CD4 T cells and TIGIT+CD226+ CD4 T cells is a significant subset in DM with 
      enhanced frequency and effector function. This abnormal subset could be 
      suppressed by blocking CD226, providing insight into the therapeutic target of 
      the TIGIT/CD226 axis.
FAU - Li, Wenli
AU  - Li W
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Deng, Chuiwen
AU  - Deng C
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
FAU - Yang, Hanbo
AU  - Yang H
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Lu, Xin
AU  - Lu X
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Li, Shanshan
AU  - Li S
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Liu, Xia
AU  - Liu X
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Chen, Fang
AU  - Chen F
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Chen, Lida
AU  - Chen L
AD  - Department of Blood Transfusion, China-Japan Friendship Hospital, Beijing, 
      People's Republic of China.
FAU - Shu, Xiaoming
AU  - Shu X
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Zhang, Lu
AU  - Zhang L
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Liu, Qingyan
AU  - Liu Q
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Wang, Guochun
AU  - Wang G
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China.
FAU - Peng, Qinglin
AU  - Peng Q
AUID- ORCID: 0000-0002-1271-1729
AD  - Department of Rheumatology, China-Japan Friendship Hospital, Ying Hua East Road, 
      Chao Yang District, Beijing, 100029, People's Republic of China. 
      pqinglin@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210107
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (TIGIT protein, human)
SB  - IM
MH  - Antigens, Differentiation, T-Lymphocyte
MH  - *CD4-Positive T-Lymphocytes
MH  - *Dermatomyositis
MH  - Humans
MH  - Receptors, Immunologic
MH  - T-Lymphocyte Subsets
PMC - PMC7791775
OTO - NOTNLM
OT  - CD226
OT  - Co-inhibitory receptor
OT  - Co-stimulatory receptor
OT  - Dermatomyositis
OT  - T cell Ig and ITIM domain
COIS- The authors declare that they have no competing interests.
EDAT- 2021/01/09 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/01/07
CRDT- 2021/01/08 05:47
PHST- 2020/09/10 00:00 [received]
PHST- 2020/12/13 00:00 [accepted]
PHST- 2021/01/08 05:47 [entrez]
PHST- 2021/01/09 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/01/07 00:00 [pmc-release]
AID - 10.1186/s13075-020-02397-4 [pii]
AID - 2397 [pii]
AID - 10.1186/s13075-020-02397-4 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2021 Jan 7;23(1):15. doi: 10.1186/s13075-020-02397-4.

PMID- 33363709
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2001-0370 (Print)
IS  - 2001-0370 (Electronic)
IS  - 2001-0370 (Linking)
VI  - 19
DP  - 2021
TI  - Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts 
      characteristics of DM1.
PG  - 51-61
LID - 10.1016/j.csbj.2020.11.053 [doi]
AB  - Myotonic Dystrophy type 1 (DM1) is an incurable neuromuscular disorder caused by 
      toxic DMPK transcripts that carry CUG repeat expansions in the 3' untranslated 
      region (3'UTR). The intrinsic complexity and lack of crystallographic data makes 
      noncoding RNA regions challenging targets to study in the field of drug 
      discovery. In DM1, toxic transcripts tend to stall in the nuclei forming complex 
      inclusion bodies called foci and sequester many essential alternative splicing 
      factors such as Muscleblind-like 1 (MBNL1). Most DM1 phenotypic features stem 
      from the reduced availability of free MBNL1 and therefore many therapeutic 
      efforts are focused on recovering its normal activity. For that purpose, herein 
      we present pyrido[2,3-d]pyrimidin-7-(8H)-ones, a privileged scaffold showing 
      remarkable biological activity against many targets involved in human disorders 
      including cancer and viral diseases. Their combination with a flexible linker 
      meets the requirements to stabilise DM1 toxic transcripts, and therefore, 
      enabling the release of MBNL1. Therefore, a set of novel 
      pyrido[2,3-d]pyrimidin-7-(8H)-ones derivatives (1a-e) were obtained using click 
      chemistry. 1a exerted over 20% MBNL1 recovery on DM1 toxic RNA activity in 
      primary cell biology studies using patient-derived myoblasts. 1a promising anti 
      DM1 activity may lead to subsequent generations of ligands, highlighting a new 
      affordable treatment against DM1.
CI  - (c) 2020 The Authors.
FAU - Ondono, Raul
AU  - Ondono R
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
FAU - Lirio, Angel
AU  - Lirio A
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
FAU - Elvira, Carlos
AU  - Elvira C
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
FAU - Alvarez-Marimon, Elena
AU  - Alvarez-Marimon E
AD  - Biophysics Unit, Department of Biochemistry and Molecular Biology, School of 
      Medicine, Universitat Autonoma de Barcelona, Cerdanyola del Valles, Spain.
FAU - Provenzano, Claudia
AU  - Provenzano C
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, Rome, Italy.
FAU - Cardinali, Beatrice
AU  - Cardinali B
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, Rome, Italy.
FAU - Perez-Alonso, Manuel
AU  - Perez-Alonso M
AD  - Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain.
AD  - Department of Genetics and Interdisciplinary Research Structure for Biotechnology 
      and Biomedicine, University of Valencia, Valencia, Spain.
FAU - Peralvarez-Marin, Alex
AU  - Peralvarez-Marin A
AD  - Biophysics Unit, Department of Biochemistry and Molecular Biology, School of 
      Medicine, Universitat Autonoma de Barcelona, Cerdanyola del Valles, Spain.
FAU - Borrell, Jose I
AU  - Borrell JI
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
FAU - Falcone, Germana
AU  - Falcone G
AD  - Institute of Biochemistry and Cell Biology, National Research Council, 
      Monterotondo, Rome, Italy.
FAU - Estrada-Tejedor, Roger
AU  - Estrada-Tejedor R
AD  - IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20201206
PL  - Netherlands
TA  - Comput Struct Biotechnol J
JT  - Computational and structural biotechnology journal
JID - 101585369
PMC - PMC7753043
OTO - NOTNLM
OT  - Base recognition
OT  - Molecular modelling
OT  - Myotonic dystrophy
OT  - RNA targeting
OT  - Small molecule
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
PMCR- 2020/12/06
CRDT- 2020/12/28 12:00
PHST- 2020/09/20 00:00 [received]
PHST- 2020/11/25 00:00 [revised]
PHST- 2020/11/28 00:00 [accepted]
PHST- 2020/12/28 12:00 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PHST- 2020/12/06 00:00 [pmc-release]
AID - S2001-0370(20)30520-1 [pii]
AID - 10.1016/j.csbj.2020.11.053 [doi]
PST - epublish
SO  - Comput Struct Biotechnol J. 2020 Dec 6;19:51-61. doi: 10.1016/j.csbj.2020.11.053. 
      eCollection 2021.

PMID- 33362853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 11
DP  - 2020
TI  - A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic 
      Dystrophy Type 1.
PG  - 594576
LID - 10.3389/fgene.2020.594576 [doi]
LID - 594576
AB  - Cas13a, an effector of type VI CRISPR-Cas systems, is an RNA guided RNase with 
      multiplexing and therapeutic potential. This study employs the Leptotrichia 
      shahii (Lsh) Cas13a and a repeat-based CRISPR RNA (crRNA) to track and eliminate 
      toxic RNA aggregates in myotonic dystrophy type 1 (DM1) - a neuromuscular disease 
      caused by CTG expansion in the DMPK gene. We demonstrate that LshCas13a cleaves 
      CUG repeat RNA in biochemical assays and reduces toxic RNA load in 
      patient-derived myoblasts. As a result, LshCas13a reverses the characteristic 
      adult-to-embryonic missplicing events in several key genes that contribute to DM1 
      phenotype. The deactivated LshCas13a can further be repurposed to track RNA-rich 
      organelles within cells. Our data highlights the reprogrammability of LshCas13a 
      and the possible use of Cas13a to target expanded repeat sequences in 
      microsatellite expansion diseases.
CI  - Copyright (c) 2020 Zhang, Bewick, Xia, Furling and Ashizawa.
FAU - Zhang, Nan
AU  - Zhang N
AD  - Department of Neurology, Houston Methodist Research Institute, Houston, TX, 
      United States.
FAU - Bewick, Brittani
AU  - Bewick B
AD  - Department of Neurology, Houston Methodist Research Institute, Houston, TX, 
      United States.
FAU - Xia, Guangbin
AU  - Xia G
AD  - Indiana University School of Medicine, Fort Wayne, IN, United States.
FAU - Furling, Denis
AU  - Furling D
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), Centre de 
      Recherche en Myologie (CRM), Association Institut de Myologie, Sorbonne 
      Universite, Paris, France.
FAU - Ashizawa, Tetsuo
AU  - Ashizawa T
AD  - Department of Neurology, Houston Methodist Research Institute, Houston, TX, 
      United States.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC7758406
OTO - NOTNLM
OT  - CRISPR-Cas13a
OT  - RNA targeting
OT  - myotonic dystrophy
OT  - neurodegeneration
OT  - stress granule
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2020/12/29 06:00
MHDA- 2020/12/29 06:01
PMCR- 2020/12/10
CRDT- 2020/12/28 11:56
PHST- 2020/09/04 00:00 [received]
PHST- 2020/11/23 00:00 [accepted]
PHST- 2020/12/28 11:56 [entrez]
PHST- 2020/12/29 06:00 [pubmed]
PHST- 2020/12/29 06:01 [medline]
PHST- 2020/12/10 00:00 [pmc-release]
AID - 10.3389/fgene.2020.594576 [doi]
PST - epublish
SO  - Front Genet. 2020 Dec 10;11:594576. doi: 10.3389/fgene.2020.594576. eCollection 
      2020.

PMID- 33235377
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220302
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 29
IP  - 3
DP  - 2021 Mar
TI  - Noninvasive prenatal test of single-gene disorders by linked-read direct 
      haplotyping: application in various diseases.
PG  - 463-470
LID - 10.1038/s41431-020-00759-9 [doi]
AB  - Direct haplotyping enables noninvasive prenatal testing (NIPT) without analyzing 
      proband, which is a promising strategy for pregnancies at risk of an inherited 
      single-gene disorder. Here, we aimed to expand the scope of single-gene disorders 
      that NIPT using linked-read direct haplotyping would be applicable to. Three 
      families at risk of myotonic dystrophy type 1, lipoid congenital adrenal 
      hyperplasia, and Fukuyama congenital muscular dystrophy were recruited. All cases 
      exhibited distinct characteristics that are often encountered as hurdles (i.e., 
      repeat expansion, identical variants in both parents, and novel variants with 
      retrotransposon insertion) in the universal clinical application of NIPT. Direct 
      haplotyping of parental genomes was performed by linked-read sequencing, combined 
      with allele-specific PCR, if necessary. Target DMPK, STAR, and FKTN genes in the 
      maternal plasma DNA were sequenced. Posterior risk calculations and an 
      Anderson-Darling test were performed to deduce the maternal and paternal 
      inheritance, respectively. In all cases, we could predict the inheritance of 
      maternal mutant allele with > 99.9% confidence, while paternal mutant alleles 
      were not predicted to be inherited. Our study indicates that direct haplotyping 
      and posterior risk calculation can be applied with subtle modifications to NIPT 
      for the detection of an expanded range of diseases.
FAU - Lee, Jee-Soo
AU  - Lee JS
AD  - Department of Laboratory Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Kyung Bok
AU  - Lee KB
AUID- ORCID: 0000-0003-4561-3188
AD  - Department of Statistics, Seoul National University, Seoul, Republic of Korea.
FAU - Song, Han
AU  - Song H
AD  - Genome Opinion Inc., 7, Yeonmujang 5ga-gil, Seongdong-gu, Seoul, Republic of 
      Korea.
FAU - Sun, ChoongHyun
AU  - Sun C
AD  - Genome Opinion Inc., 7, Yeonmujang 5ga-gil, Seongdong-gu, Seoul, Republic of 
      Korea.
FAU - Kim, Man Jin
AU  - Kim MJ
AD  - Department of Laboratory Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Cho, Sung Im
AU  - Cho SI
AD  - Department of Laboratory Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Lee, Young Kyung
AU  - Lee YK
AD  - Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, 
      Anyang, Republic of Korea.
FAU - Park, Sung Sup
AU  - Park SS
AD  - Department of Laboratory Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea.
FAU - Seong, Moon-Woo
AU  - Seong MW
AUID- ORCID: 0000-0003-2954-3677
AD  - Department of Laboratory Medicine, Seoul National University Hospital, Seoul 
      National University College of Medicine, Seoul, Republic of Korea. 
      mwseong@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201124
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (DMPK protein, human)
RN  - 0 (FKTN protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (steroidogenic acute regulatory protein)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adrenal Hyperplasia, Congenital/diagnosis/*genetics
MH  - Adult
MH  - Female
MH  - *Haplotypes
MH  - Humans
MH  - Male
MH  - Membrane Proteins/genetics
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Noninvasive Prenatal Testing/*methods/standards
MH  - Phosphoproteins/genetics
MH  - Pregnancy
MH  - Sequence Analysis, DNA/methods
MH  - Walker-Warburg Syndrome/diagnosis/*genetics
PMC - PMC7940412
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/11/26 06:00
MHDA- 2022/01/15 06:00
PMCR- 2022/03/01
CRDT- 2020/11/25 05:45
PHST- 2020/02/04 00:00 [received]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/08/26 00:00 [revised]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2020/11/25 05:45 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - 10.1038/s41431-020-00759-9 [pii]
AID - 759 [pii]
AID - 10.1038/s41431-020-00759-9 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2021 Mar;29(3):463-470. doi: 10.1038/s41431-020-00759-9. Epub 
      2020 Nov 24.

PMID- 33171734
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20211204
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 11
DP  - 2020 Nov 7
TI  - Preliminary Findings on CTG Expansion Determination in Different Tissues from 
      Patients with Myotonic Dystrophy Type 1.
LID - 10.3390/genes11111321 [doi]
LID - 1321
AB  - Myotonic Dystrophy type 1 (DM1) is characterized by a high genetic and clinical 
      variability. Determination of the genetic variability in DM1 might help to 
      determine whether there is an association between CTG (Cytosine-Thymine-Guanine) 
      expansion and the clinical manifestations of this condition. We studied the 
      variability of the CTG expansion (progenitor, mode, and longest allele, 
      respectively, and genetic instability) in three tissues (blood, muscle, and 
      tissue) from eight patients with DM1. We also studied the association of genetic 
      data with the patients' clinical characteristics. Although genetic instability 
      was confirmed in all the tissues that we studied, our results suggest that CTG 
      expansion is larger in muscle and skin cells compared with peripheral blood 
      leukocytes. While keeping in mind that more research is needed in larger cohorts, 
      we have provided preliminary evidence suggesting that the estimated progenitor 
      CTG size in muscle could be potentially used as an indicator of age of disease 
      onset and muscle function impairment.
FAU - Ballester-Lopez, Alfonsina
AU  - Ballester-Lopez A
AUID- ORCID: 0000-0002-8922-1664
AD  - Neuromuscular and Neuropediatric Research Group, Institut d'Investigacio en 
      Ciencies de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autonoma 
      de Barcelona, 08916 Badalona, Barcelona, Spain.
AD  - Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de 
      Salud Carlos III, 28029 Madrid, Spain.
FAU - Koehorst, Emma
AU  - Koehorst E
AD  - Neuromuscular and Neuropediatric Research Group, Institut d'Investigacio en 
      Ciencies de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autonoma 
      de Barcelona, 08916 Badalona, Barcelona, Spain.
FAU - Linares-Pardo, Ian
AU  - Linares-Pardo I
AD  - Neuromuscular and Neuropediatric Research Group, Institut d'Investigacio en 
      Ciencies de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autonoma 
      de Barcelona, 08916 Badalona, Barcelona, Spain.
FAU - Nunez-Manchon, Judit
AU  - Nunez-Manchon J
AD  - Neuromuscular and Neuropediatric Research Group, Institut d'Investigacio en 
      Ciencies de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autonoma 
      de Barcelona, 08916 Badalona, Barcelona, Spain.
FAU - Almendrote, Miriam
AU  - Almendrote M
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Lucente, Giuseppe
AU  - Lucente G
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Arbex, Andrea
AU  - Arbex A
AUID- ORCID: 0000-0002-3741-4755
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Puente, Carles
AU  - Puente C
AD  - Servei de Cirugia Ortopedica i Traumatologia, Unitat de ma i nervi Periferic, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
FAU - Lucia, Alejandro
AU  - Lucia A
AD  - Facultad de Ciencias de la Actividad fisica y el Deporte, Universidad Europea, 
      28670 Madrid, Spain.
AD  - Instituto de Investigacion Hospital 12 de Octubre (i+12), 28041 Madrid, Spain.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G126QQ, UK.
FAU - Cumming, Sarah A
AU  - Cumming SA
AUID- ORCID: 0000-0002-0201-3660
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G126QQ, UK.
FAU - Pintos-Morell, Guillem
AU  - Pintos-Morell G
AUID- ORCID: 0000-0002-9347-2386
AD  - Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de 
      Salud Carlos III, 28029 Madrid, Spain.
AD  - Division of Rare Diseases, Vall d'Hebron University Hospital, 08035 Barcelona, 
      Spain.
FAU - Coll-Canti, Jaume
AU  - Coll-Canti J
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Ramos-Fransi, Alba
AU  - Ramos-Fransi A
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Martinez-Pineiro, Alicia
AU  - Martinez-Pineiro A
AD  - Neuromuscular Pathology Unit, Neurology Service, Neuroscience department, 
      Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
FAU - Nogales-Gadea, Gisela
AU  - Nogales-Gadea G
AUID- ORCID: 0000-0002-7414-212X
AD  - Neuromuscular and Neuropediatric Research Group, Institut d'Investigacio en 
      Ciencies de la Salut Germans Trias i Pujol, Campus Can Ruti, Universitat Autonoma 
      de Barcelona, 08916 Badalona, Barcelona, Spain.
AD  - Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de 
      Salud Carlos III, 28029 Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201107
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 5Z93L87A1R (Guanine)
RN  - 8J337D1HZY (Cytosine)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - QR26YLT7LT (Thymine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Blood/metabolism
MH  - Cytosine/metabolism
MH  - Female
MH  - Genetic Variation/genetics
MH  - Guanine/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Skin/metabolism
MH  - Thymine/metabolism
MH  - Trinucleotide Repeat Expansion/*genetics/physiology
PMC - PMC7695006
OTO - NOTNLM
OT  - CTG expansion
OT  - blood
OT  - muscle
OT  - myotonic dystrophy type 1
OT  - skin
OT  - somatic instability
COIS- G.N.G. declares grants from Instituto de Salud Carlos III (Grant Numbers: 
      PI15/01756; P18/00713), Madrid, Spain and AFM Telethon (Trampoline grant number 
      #21108), France. A.L. declares grants from the Spanish government granting agency 
      Instituto de Salud Carlos III, Madrid, Spain. J.N.M. is funded by AFM Telethon 
      Trampoline Grant #21108. A.B.L. is funded by an FI Agaur fellowship FI_B 01090. 
      E.K. is funded by the "La Caixa" Foundation (ID 100010434), fellowship code 
      LCF/BQ/IN18/11660019, co-funded by the European Union's Horizon 2020 research and 
      innovation program under the Marie Sklodowska-Curie grant agreement n degrees 713673. 
      I.L.P. is funded by CP14/00032. G.N.G. is supported by a Miguel Servet research 
      contract (ISCIII CD14/00032, CPII19/00021, and FEDER). G.L. was supported by a 
      Rio Hortega contract (ISCIII CM16/00016 and FEDER). G.P.-M. reports personal 
      honoraria from Shire-Takeda, Amicus, Kyowa-Kirin, and Sanofi-Genzyme, outside the 
      submitted work. The remaining co-authors declare no competing interests.
EDAT- 2020/11/12 06:00
MHDA- 2021/07/27 06:00
PMCR- 2020/11/01
CRDT- 2020/11/11 01:01
PHST- 2020/09/18 00:00 [received]
PHST- 2020/11/02 00:00 [revised]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/11 01:01 [entrez]
PHST- 2020/11/12 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
AID - genes11111321 [pii]
AID - genes-11-01321 [pii]
AID - 10.3390/genes11111321 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Nov 7;11(11):1321. doi: 10.3390/genes11111321.

PMID- 33157036
OWN - NLM
STAT- MEDLINE
DCOM- 20210826
LR  - 20220122
IS  - 2451-9448 (Electronic)
IS  - 2451-9456 (Print)
IS  - 2451-9448 (Linking)
VI  - 28
IP  - 1
DP  - 2021 Jan 21
TI  - A Small Molecule that Binds an RNA Repeat Expansion Stimulates Its Decay via the 
      Exosome Complex.
PG  - 34-45.e6
LID - S2451-9456(20)30423-2 [pii]
LID - 10.1016/j.chembiol.2020.10.007 [doi]
AB  - Many diseases are caused by toxic RNA repeats. Herein, we designed a lead small 
      molecule that binds the structure of the r(CUG) repeat expansion [r(CUG)(exp)] 
      that causes myotonic dystrophy type 1 (DM1) and Fuchs endothelial corneal 
      dystrophy (FECD) and rescues disease biology in patient-derived cells and 
      in vivo. Interestingly, the compound's downstream effects are different in the 
      two diseases, owing to the location of the repeat expansion. In DM1, r(CUG)(exp) 
      is harbored in the 3' untranslated region, and the compound has no effect on the 
      mRNA's abundance. In FECD, however, r(CUG)(exp) is located in an intron, and the 
      small molecule facilitates excision of the intron, which is then degraded by the 
      RNA exosome complex. Thus, structure-specific, RNA-targeting small molecules can 
      act disease specifically to affect biology, either by disabling the 
      gain-of-function mechanism (DM1) or by stimulating quality control pathways to 
      rid a disease-affected cell of a toxic RNA (FECD).
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Angelbello, Alicia J
AU  - Angelbello AJ
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
FAU - Benhamou, Raphael I
AU  - Benhamou RI
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
FAU - Rzuczek, Suzanne G
AU  - Rzuczek SG
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
FAU - Choudhary, Shruti
AU  - Choudhary S
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
FAU - Tang, Zhenzhi
AU  - Tang Z
AD  - Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, Rochester, NY 14642, USA.
FAU - Chen, Jonathan L
AU  - Chen JL
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
FAU - Roy, Madhuparna
AU  - Roy M
AD  - Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
FAU - Wang, Kye Won
AU  - Wang KW
AD  - Department of Chemistry, Florida Atlantic University, Jupiter, FL 33458, USA.
FAU - Yildirim, Ilyas
AU  - Yildirim I
AD  - Department of Chemistry, Florida Atlantic University, Jupiter, FL 33458, USA.
FAU - Jun, Albert S
AU  - Jun AS
AD  - Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287, 
      USA.
FAU - Thornton, Charles A
AU  - Thornton CA
AD  - Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, Rochester, NY 14642, USA.
FAU - Disney, Matthew D
AU  - Disney MD
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA. 
      Electronic address: disney@scripps.edu.
LA  - eng
GR  - DP1 NS096898/NS/NINDS NIH HHS/United States
GR  - R37 NS094393/NS/NINDS NIH HHS/United States
GR  - F31 NS110269/NS/NINDS NIH HHS/United States
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - S10 OD021489/OD/NIH HHS/United States
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201105
PL  - United States
TA  - Cell Chem Biol
JT  - Cell chemical biology
JID - 101676030
RN  - 0 (Small Molecule Libraries)
SB  - IM
CIN - Nat Rev Drug Discov. 2021 Jan;20(1):20. PMID: 33173228
MH  - Cells, Cultured
MH  - Exosomes/*drug effects/metabolism
MH  - Female
MH  - Fuchs' Endothelial Dystrophy/*drug therapy/metabolism
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*drug therapy/metabolism
MH  - Small Molecule Libraries/*pharmacology
MH  - Trinucleotide Repeat Expansion/*drug effects/genetics
PMC - PMC7855261
MID - NIHMS1646111
OTO - NOTNLM
OT  - RNA
OT  - RNA splicing
OT  - chemical biology
OT  - decay pathways
OT  - drug discovery
OT  - microsatellite disorders
OT  - targeted degradation
COIS- Declaration of Interests M.D.D. is a founder of Expansion Therapeutics, and 
      S.G.R. and A.J.A. are currently employees of Expansion Therapeutics. M.D.D. and 
      S.G.R. also have a patent related to this work (US20190152924A1).
EDAT- 2020/11/07 06:00
MHDA- 2021/08/27 06:00
PMCR- 2022/01/21
CRDT- 2020/11/06 20:10
PHST- 2020/05/28 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/11/07 06:00 [pubmed]
PHST- 2021/08/27 06:00 [medline]
PHST- 2020/11/06 20:10 [entrez]
PHST- 2022/01/21 00:00 [pmc-release]
AID - S2451-9456(20)30423-2 [pii]
AID - 10.1016/j.chembiol.2020.10.007 [doi]
PST - ppublish
SO  - Cell Chem Biol. 2021 Jan 21;28(1):34-45.e6. doi: 10.1016/j.chembiol.2020.10.007. 
      Epub 2020 Nov 5.

PMID- 32929188
OWN - NLM
STAT- MEDLINE
DCOM- 20210312
LR  - 20220317
IS  - 2157-846X (Electronic)
IS  - 2157-846X (Linking)
VI  - 5
IP  - 2
DP  - 2021 Feb
TI  - The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes 
      in mouse models of myotonic dystrophy type 1.
PG  - 157-168
LID - 10.1038/s41551-020-00607-7 [doi]
AB  - Myotonic dystrophy type I (DM1) is a multisystemic autosomal-dominant inherited 
      human disorder that is caused by CTG microsatellite repeat expansions (MREs) in 
      the 3' untranslated region of DMPK. Toxic RNAs expressed from such repetitive 
      sequences can be eliminated using CRISPR-mediated RNA targeting, yet evidence of 
      its in vivo efficacy and durability is lacking. Here, using adult and neonatal 
      mouse models of DM1, we show that intramuscular or systemic injections of 
      adeno-associated virus (AAV) vectors encoding nuclease-dead Cas9 and a 
      single-guide RNA targeting CUG repeats results in the expression of the 
      RNA-targeting Cas9 for up to three months, redistribution of the RNA-splicing 
      protein muscleblind-like splicing regulator 1, elimination of foci of toxic RNA, 
      reversal of splicing biomarkers and amelioration of myotonia. The sustained 
      reversal of DM1 phenotypes provides further support that RNA-targeting Cas9 is a 
      viable strategy for treating DM1 and other MRE-associated diseases.
FAU - Batra, Ranjan
AU  - Batra R
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA.
AD  - Locanabio, La Jolla, CA, USA.
FAU - Nelles, David A
AU  - Nelles DA
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA.
AD  - Locanabio, La Jolla, CA, USA.
FAU - Roth, Daniela M
AU  - Roth DM
AD  - Locanabio, La Jolla, CA, USA.
FAU - Krach, Florian
AU  - Krach F
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Nutter, Curtis A
AU  - Nutter CA
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Tadokoro, Takahiro
AU  - Tadokoro T
AUID- ORCID: 0000-0003-4884-0247
AD  - Department of Anesthesiology, School of Medicine, University of California San 
      Diego, La Jolla, CA, USA.
FAU - Thomas, James D
AU  - Thomas JD
AUID- ORCID: 0000-0002-8893-6350
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Sznajder, Lukasz J
AU  - Sznajder LJ
AUID- ORCID: 0000-0001-6822-6485
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Blue, Steven M
AU  - Blue SM
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Gutierrez, Haydee L
AU  - Gutierrez HL
AD  - Locanabio, La Jolla, CA, USA.
FAU - Liu, Patrick
AU  - Liu P
AD  - Locanabio, La Jolla, CA, USA.
FAU - Aigner, Stefan
AU  - Aigner S
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA.
FAU - Platoshyn, Oleksandr
AU  - Platoshyn O
AUID- ORCID: 0000-0001-6529-6752
AD  - Neuroregeneration Laboratory, Department of Anesthesiology, University of 
      California San Diego, La Jolla, CA, USA.
FAU - Miyanohara, Atsushi
AU  - Miyanohara A
AD  - Neuroregeneration Laboratory, Department of Anesthesiology, University of 
      California San Diego, La Jolla, CA, USA.
FAU - Marsala, Martin
AU  - Marsala M
AUID- ORCID: 0000-0001-5048-6422
AD  - Neuroregeneration Laboratory, Department of Anesthesiology, University of 
      California San Diego, La Jolla, CA, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AUID- ORCID: 0000-0001-6245-5367
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Yeo, Gene W
AU  - Yeo GW
AUID- ORCID: 0000-0002-0799-6037
AD  - Department of Cellular and Molecular Medicine, University of California San 
      Diego, La Jolla, CA, USA. geneyeo@ucsd.edu.
AD  - Stem Cell Program, University of California San Diego, La Jolla, CA, USA. 
      geneyeo@ucsd.edu.
AD  - Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, 
      USA. geneyeo@ucsd.edu.
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - R01 NS103172/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200914
PL  - England
TA  - Nat Biomed Eng
JT  - Nature biomedical engineering
JID - 101696896
RN  - 63231-63-0 (RNA)
RN  - EC 3.1.- (CRISPR-Associated Protein 9)
SB  - IM
CIN - Nat Biomed Eng. 2021 Feb;5(2):130-131. PMID: 33580228
MH  - Adenoviridae/physiology
MH  - Animals
MH  - CRISPR-Associated Protein 9/*metabolism
MH  - *CRISPR-Cas Systems
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Editing/*methods
MH  - Genetic Vectors/physiology
MH  - Male
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/genetics/*metabolism
MH  - Phenotype
MH  - RNA/*metabolism
PMC - PMC8241012
MID - NIHMS1703760
COIS- Competing interests G.W.Y. is a cofounder, member of the board of directors, 
      equity holder and paid consultant of Locanabio. D.A.N. is a cofounder and an 
      equity holder of Locanabio. R.B. is an equity holder and employee of Locanabio. 
      M.S.S. is an equity holder of Locanabio and a Scientific Advisory Board member of 
      Skyhawk Therapeutics. The terms of this arrangement have been reviewed and 
      approved by the University of California San Diego and the University of Florida, 
      Gainesville in accordance with their conflict of interest policies. The other 
      authors declare no other competing interests.
EDAT- 2020/09/16 06:00
MHDA- 2021/03/13 06:00
PMCR- 2021/06/29
CRDT- 2020/09/15 05:45
PHST- 2019/05/13 00:00 [received]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/09/16 06:00 [pubmed]
PHST- 2021/03/13 06:00 [medline]
PHST- 2020/09/15 05:45 [entrez]
PHST- 2021/06/29 00:00 [pmc-release]
AID - 10.1038/s41551-020-00607-7 [pii]
AID - 10.1038/s41551-020-00607-7 [doi]
PST - ppublish
SO  - Nat Biomed Eng. 2021 Feb;5(2):157-168. doi: 10.1038/s41551-020-00607-7. Epub 2020 
      Sep 14.

PMID- 32851192
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2376-7839 (Print)
IS  - 2376-7839 (Electronic)
IS  - 2376-7839 (Linking)
VI  - 6
IP  - 5
DP  - 2020 Oct
TI  - Variant repeats within the DMPK CTG expansion protect function in myotonic 
      dystrophy type 1.
PG  - e504
LID - 10.1212/NXG.0000000000000504 [doi]
LID - e504
AB  - OBJECTIVE: We tested the hypothesis that variant repeat interruptions (RIs) 
      within the DMPK CTG repeat tract lead to milder symptoms compared with pure 
      repeats (PRs) in myotonic dystrophy type 1 (DM1). METHODS: We evaluated motor, 
      neurocognitive, and behavioral outcomes in a group of 6 participants with DM1 
      with RI compared with a case-matched sample of 12 participants with DM1 with PR 
      and a case-matched sample of 12 unaffected healthy comparison participants (UA). 
      RESULTS: In every measure, the RI participants were intermediate between UA and 
      PR participants. For muscle strength, the RI group was significantly less 
      impaired than the PR group. For measures of Full Scale IQ, depression, and 
      sleepiness, all 3 groups were significantly different from each other with UA > 
      RI > PR in order of impairment. The RI group was different from unaffected, but 
      not significantly different from PR (UA > RI = PR) in apathy and working memory. 
      Finally, in finger tapping and processing speed, RI did not differ from UA 
      comparisons, but PR had significantly lower scores than the UA comparisons (UA = 
      RI > PR). CONCLUSIONS: Our results support the notion that patients affected by 
      DM1 with RI demonstrate a milder phenotype with the same pattern of deficits as 
      those with PR indicating a similar disease process.
CI  - Copyright (c) 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Miller, Jacob N
AU  - Miller JN
AUID- ORCID: 0000-0002-8248-1199
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - van der Plas, Ellen
AU  - van der Plas E
AUID- ORCID: 0000-0002-7490-6636
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Hamilton, Mark
AU  - Hamilton M
AUID- ORCID: 0000-0001-9719-243X
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Koscik, Timothy R
AU  - Koscik TR
AUID- ORCID: 0000-0002-2551-8127
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Gutmann, Laurie
AU  - Gutmann L
AUID- ORCID: 0000-0003-3926-4209
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Cumming, Sarah A
AU  - Cumming SA
AUID- ORCID: 0000-0002-0201-3660
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
FAU - Nopoulos, Peggy C
AU  - Nopoulos PC
AUID- ORCID: 0000-0001-8810-1903
AD  - Department of Psychiatry (J.N.M., E.P., T.R.K., P.C.N.), University of Iowa 
      Hospitals and Clinics; West of Scotland Clinical Genetics Service (M.H.), Queen 
      Elizabeth University Hospital; Institute of Molecular, Cell and Systems Biology 
      (M.H., S.A.C., D.G.M.), College of Medical, Veterinary and Life Sciences, 
      University of Glasgow, United Kingdom; and Department of Neurology (L.G.), 
      University of Iowa Hospitals and Clinics.
LA  - eng
GR  - R01 NS094387/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20200812
PL  - United States
TA  - Neurol Genet
JT  - Neurology. Genetics
JID - 101671068
PMC - PMC7428360
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
PMCR- 2020/08/12
CRDT- 2020/08/28 06:00
PHST- 2020/03/19 00:00 [received]
PHST- 2020/07/09 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/08/12 00:00 [pmc-release]
AID - NG2020013532 [pii]
AID - 10.1212/NXG.0000000000000504 [doi]
PST - epublish
SO  - Neurol Genet. 2020 Aug 12;6(5):e504. doi: 10.1212/NXG.0000000000000504. 
      eCollection 2020 Oct.

PMID- 32823742
OWN - NLM
STAT- MEDLINE
DCOM- 20210324
LR  - 20210324
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 11
IP  - 8
DP  - 2020 Aug 13
TI  - Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat 
      of DMPK in Patients with Myotonic Dystrophy Type 1.
LID - 10.3390/genes11080936 [doi]
LID - 936
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder 
      mainly characterized by gradual muscle loss, weakness, and delayed relaxation 
      after muscle contraction. It is caused by an expanded CTG repeat in the 3' UTR of 
      DMPK, which is transcribed into a toxic gain-of-function mRNA that affects the 
      splicing of a range of other genes. The repeat is unstable, with a bias towards 
      expansions both in somatic cells and in the germline, which results in a tendency 
      for earlier onset with each generation, as longer repeat lengths generally 
      correlate with earlier onset. Previous studies have found hypermethylation in the 
      regions flanking the repeat in congenital onset DM1 and in some patients with 
      non-congenital DM1. We used pyrosequencing to investigate blood methylation 
      levels in 68 patients with non-congenital DM1, compare the methylation levels 
      between the blood and muscle, and assess whether methylation levels change over 
      time in the blood. We found higher methylation levels in the blood of DM1 
      patients than in healthy controls and especially in the patients who had 
      inherited the disease allele maternally. The methylation levels remained 
      relatively stable over time and are a strong biomarker of the disease, as well as 
      of the maternal inheritance of the disease.
FAU - Hildonen, Mathis
AU  - Hildonen M
AUID- ORCID: 0000-0002-2016-3670
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
FAU - Knak, Kirsten Lykke
AU  - Knak KL
AD  - Department of Neurology, Copenhagen University Hospital, Rigshospitalet, 2100 
      Copenhagen, Denmark.
FAU - Duno, Morten
AU  - Duno M
AD  - Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 
      2100 Copenhagen, Denmark.
FAU - Vissing, John
AU  - Vissing J
AD  - Department of Neurology, Copenhagen University Hospital, Rigshospitalet, 2100 
      Copenhagen, Denmark.
FAU - Tumer, Zeynep
AU  - Tumer Z
AUID- ORCID: 0000-0002-4777-5802
AD  - Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, 
      Rigshospitalet, 2600 Glostrup, Denmark.
AD  - Department of Clinical Medicine, Faculty of Health and Medical Sciences, 
      University of Copenhagen, 2200 Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200813
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Base Sequence
MH  - Child
MH  - Child, Preschool
MH  - *CpG Islands
MH  - *DNA Methylation
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Inheritance Patterns
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism/physiopathology
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Phenotype
MH  - ROC Curve
MH  - *Trinucleotide Repeat Expansion
MH  - Young Adult
PMC - PMC7465187
OTO - NOTNLM
OT  - biomarker
OT  - blood
OT  - epigenetics
OT  - genetics
OT  - inheritance
OT  - muscle
OT  - repeat
OT  - trinucleotide
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study or in the collection, analyses, or interpretation of data.
EDAT- 2020/08/23 06:00
MHDA- 2021/03/25 06:00
PMCR- 2020/08/01
CRDT- 2020/08/23 06:00
PHST- 2020/06/25 00:00 [received]
PHST- 2020/08/10 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/08/23 06:00 [entrez]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/03/25 06:00 [medline]
PHST- 2020/08/01 00:00 [pmc-release]
AID - genes11080936 [pii]
AID - genes-11-00936 [pii]
AID - 10.3390/genes11080936 [doi]
PST - epublish
SO  - Genes (Basel). 2020 Aug 13;11(8):936. doi: 10.3390/genes11080936.

PMID- 32717741
OWN - NLM
STAT- MEDLINE
DCOM- 20210111
LR  - 20231213
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Print)
IS  - 0028-0836 (Linking)
VI  - 586
IP  - 7827
DP  - 2020 Oct
TI  - Genome-wide detection of tandem DNA repeats that are expanded in autism.
PG  - 80-86
LID - 10.1038/s41586-020-2579-z [doi]
AB  - Tandem DNA repeats vary in the size and sequence of each unit (motif). When 
      expanded, these tandem DNA repeats have been associated with more than 40 
      monogenic disorders(1). Their involvement in disorders with complex genetics is 
      largely unknown, as is the extent of their heterogeneity. Here we investigated 
      the genome-wide characteristics of tandem repeats that had motifs with a length 
      of 2-20 base pairs in 17,231 genomes of families containing individuals with 
      autism spectrum disorder (ASD)(2,3) and population control individuals(4). We 
      found extensive polymorphism in the size and sequence of motifs. Many of the 
      tandem repeat loci that we detected correlated with cytogenetic fragile sites. At 
      2,588 loci, gene-associated expansions of tandem repeats that were rare among 
      population control individuals were significantly more prevalent among 
      individuals with ASD than their siblings without ASD, particularly in exons and 
      near splice junctions, and in genes related to the development of the nervous 
      system and cardiovascular system or muscle. Rare tandem repeat expansions had a 
      prevalence of 23.3% in children with ASD compared with 20.7% in children without 
      ASD, which suggests that tandem repeat expansions make a collective contribution 
      to the risk of ASD of 2.6%. These rare tandem repeat expansions included 
      previously undescribed ASD-linked expansions in DMPK and FXN, which are 
      associated with neuromuscular conditions, and in previously unknown loci such as 
      FGF14 and CACNB1. Rare tandem repeat expansions were associated with lower IQ and 
      adaptive ability. Our results show that tandem DNA repeat expansions contribute 
      strongly to the genetic aetiology and phenotypic complexity of ASD.
FAU - Trost, Brett
AU  - Trost B
AUID- ORCID: 0000-0003-4863-7273
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Engchuan, Worrawat
AU  - Engchuan W
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Nguyen, Charlotte M
AU  - Nguyen CM
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Thiruvahindrapuram, Bhooma
AU  - Thiruvahindrapuram B
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Dolzhenko, Egor
AU  - Dolzhenko E
AD  - Illumina, San Diego, CA, USA.
FAU - Backstrom, Ian
AU  - Backstrom I
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Mirceta, Mila
AU  - Mirceta M
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Mojarad, Bahareh A
AU  - Mojarad BA
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Yin, Yue
AU  - Yin Y
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Dov, Alona
AU  - Dov A
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Chandrakumar, Induja
AU  - Chandrakumar I
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Prasolava, Tanya
AU  - Prasolava T
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Shum, Natalie
AU  - Shum N
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Hamdan, Omar
AU  - Hamdan O
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Pellecchia, Giovanna
AU  - Pellecchia G
AUID- ORCID: 0000-0003-4747-3473
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Howe, Jennifer L
AU  - Howe JL
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Whitney, Joseph
AU  - Whitney J
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Klee, Eric W
AU  - Klee EW
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
AD  - Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Baheti, Saurabh
AU  - Baheti S
AD  - Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
FAU - Amaral, David G
AU  - Amaral DG
AD  - MIND Institute and Department of Psychiatry and Behavioral Sciences, University 
      of California Davis School of Medicine, Sacramento, CA, USA.
FAU - Anagnostou, Evdokia
AU  - Anagnostou E
AD  - Holland Bloorview Kids Rehabilitation Hospital, University of Toronto, Toronto, 
      Ontario, Canada.
FAU - Elsabbagh, Mayada
AU  - Elsabbagh M
AUID- ORCID: 0000-0002-7311-9059
AD  - Montreal Neurological Institute and Azrieli Centre for Autism Research, McGill 
      University, Montreal, Quebec, Canada.
FAU - Fernandez, Bridget A
AU  - Fernandez BA
AD  - Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, 
      St. John's, Newfoundland and Labrador, Canada.
FAU - Hoang, Ny
AU  - Hoang N
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Lewis, M E Suzanne
AU  - Lewis MES
AD  - Medical Genetics, University of British Columbia (UBC), Vancouver, British 
      Columbia, Canada.
AD  - BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
FAU - Liu, Xudong
AU  - Liu X
AD  - Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
FAU - Sjaarda, Calvin
AU  - Sjaarda C
AUID- ORCID: 0000-0002-9787-1915
AD  - Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
FAU - Smith, Isabel M
AU  - Smith IM
AD  - Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - IWK Health Centre, Halifax, Nova Scotia, Canada.
FAU - Szatmari, Peter
AU  - Szatmari P
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Zwaigenbaum, Lonnie
AU  - Zwaigenbaum L
AD  - Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
FAU - Glazer, David
AU  - Glazer D
AUID- ORCID: 0000-0002-6407-8646
AD  - Verily Life Sciences, South San Francisco, CA, USA.
FAU - Hartley, Dean
AU  - Hartley D
AD  - Autism Speaks, New York, NY, USA.
FAU - Stewart, A Keith
AU  - Stewart AK
AD  - Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Eberle, Michael A
AU  - Eberle MA
AUID- ORCID: 0000-0001-8965-1253
AD  - Illumina, San Diego, CA, USA.
FAU - Sato, Nozomu
AU  - Sato N
AUID- ORCID: 0000-0002-8906-2798
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
FAU - Pearson, Christopher E
AU  - Pearson CE
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Scherer, Stephen W
AU  - Scherer SW
AUID- ORCID: 0000-0002-8326-1999
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada.
AD  - McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada.
FAU - Yuen, Ryan K C
AU  - Yuen RKC
AUID- ORCID: 0000-0001-7273-4968
AD  - Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada. ryan.yuen@sickkids.ca.
AD  - The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, 
      Ontario, Canada. ryan.yuen@sickkids.ca.
AD  - Department of Molecular Genetics, University of Toronto, Toronto, Ontario, 
      Canada. ryan.yuen@sickkids.ca.
LA  - eng
GR  - R01 MH103371/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200727
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (DMPK protein, human)
RN  - 0 (Iron-Binding Proteins)
RN  - 0 (fibroblast growth factor 14)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
CIN - Nature. 2021 Jan;589(7841):200-202. PMID: 33442037
MH  - Autism Spectrum Disorder/*genetics
MH  - DNA Repeat Expansion/*genetics
MH  - Female
MH  - Fibroblast Growth Factors/genetics
MH  - Genetic Predisposition to Disease
MH  - Genome, Human/*genetics
MH  - *Genomics
MH  - Humans
MH  - Intelligence/genetics
MH  - Iron-Binding Proteins/genetics
MH  - Male
MH  - Myotonin-Protein Kinase/genetics
MH  - Nucleotide Motifs
MH  - Polymorphism, Genetic
MH  - Tandem Repeat Sequences/*genetics
MH  - Frataxin
PMC - PMC9348607
MID - NIHMS1618714
EDAT- 2020/07/28 06:00
MHDA- 2021/01/12 06:00
PMCR- 2022/08/03
CRDT- 2020/07/28 06:00
PHST- 2019/11/16 00:00 [received]
PHST- 2020/06/05 00:00 [accepted]
PHST- 2020/07/28 06:00 [pubmed]
PHST- 2021/01/12 06:00 [medline]
PHST- 2020/07/28 06:00 [entrez]
PHST- 2022/08/03 00:00 [pmc-release]
AID - 10.1038/s41586-020-2579-z [pii]
AID - 10.1038/s41586-020-2579-z [doi]
PST - ppublish
SO  - Nature. 2020 Oct;586(7827):80-86. doi: 10.1038/s41586-020-2579-z. Epub 2020 Jul 
      27.

PMID- 32657583
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210724
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 63
IP  - 14
DP  - 2020 Jul 23
TI  - Optimization of the Linker Domain in a Dimeric Compound that Degrades an r(CUG) 
      Repeat Expansion in Cells.
PG  - 7827-7839
LID - 10.1021/acs.jmedchem.0c00558 [doi]
AB  - RNA repeat expansions are responsible for more than 30 incurable diseases. Among 
      them is myotonic dystrophy type 1 (DM1), the most common form of adult on-set 
      muscular dystrophy. DM1 is caused by an r(CUG) repeat expansion [r(CUG)(exp)] 
      located in the 3' untranslated region (UTR) of the dystrophia myotonica protein 
      kinase gene. This repeat expansion is highly structured, forming a periodic array 
      of 5'CUG/3'GUC internal loop motifs. We therefore designed dimeric compounds that 
      simultaneously bind two of these motifs by connecting two RNA-binding modules 
      with peptoid linkers of different geometries and lengths. The optimal linker 
      contains two proline residues and enhances compound affinity. Equipping this 
      molecule with a bleomycin A5 cleaving module converts the simple binding compound 
      into a potent allele-selective cleaver of r(CUG)(exp). This study shows that the 
      linker in modularly assembled ligands targeting RNA can be optimized to afford 
      potent biological activity.
FAU - Benhamou, Raphael I
AU  - Benhamou RI
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Abe, Masahito
AU  - Abe M
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Choudhary, Shruti
AU  - Choudhary S
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Meyer, Samantha M
AU  - Meyer SM
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Angelbello, Alicia J
AU  - Angelbello AJ
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
LA  - eng
GR  - DP1 NS096898/NS/NINDS NIH HHS/United States
GR  - F31 NS110269/NS/NINDS NIH HHS/United States
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200713
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Benzimidazoles)
RN  - 0 (Oligopeptides)
RN  - 0 (Small Molecule Libraries)
RN  - 11056-06-7 (Bleomycin)
RN  - 5DY91Y7601 (bleomycetin)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Benzimidazoles/chemical synthesis/*pharmacology
MH  - Bleomycin/analogs & derivatives/chemical synthesis/pharmacology
MH  - DNA Damage/drug effects
MH  - Drug Design
MH  - Humans
MH  - Muscle Fibers, Skeletal/drug effects
MH  - Oligopeptides/chemical synthesis/*pharmacology
MH  - RNA/*chemistry/drug effects/genetics
MH  - Small Molecule Libraries/chemical synthesis/pharmacology
MH  - Tandem Repeat Sequences/drug effects
PMC - PMC7450518
MID - NIHMS1619313
EDAT- 2020/07/14 06:00
MHDA- 2020/12/15 06:00
PMCR- 2021/07/23
CRDT- 2020/07/14 06:00
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2021/07/23 00:00 [pmc-release]
AID - 10.1021/acs.jmedchem.0c00558 [doi]
PST - ppublish
SO  - J Med Chem. 2020 Jul 23;63(14):7827-7839. doi: 10.1021/acs.jmedchem.0c00558. Epub 
      2020 Jul 13.

PMID- 32656337
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230928
IS  - 2375-2548 (Electronic)
IS  - 2375-2548 (Linking)
VI  - 6
IP  - 27
DP  - 2020 Jul
TI  - Three-dimensional chromatin interactions remain stable upon CAG/CTG repeat 
      expansion.
PG  - eaaz4012
LID - 10.1126/sciadv.aaz4012 [doi]
LID - eaaz4012
AB  - Expanded CAG/CTG repeats underlie 13 neurological disorders, including myotonic 
      dystrophy type 1 (DM1) and Huntington's disease (HD). Upon expansion, disease 
      loci acquire heterochromatic characteristics, which may provoke changes to 
      chromatin conformation and thereby affect both gene expression and repeat 
      instability. Here, we tested this hypothesis by performing 4C sequencing at the 
      DMPK and HTT loci from DM1 and HD-derived cells. We find that allele sizes 
      ranging from 15 to 1700 repeats displayed similar chromatin interaction profiles. 
      This was true for both loci and for alleles with different DNA methylation levels 
      and CTCF binding. Moreover, the ectopic insertion of an expanded CAG repeat tract 
      did not change the conformation of the surrounding chromatin. We conclude that 
      CAG/CTG repeat expansions are not enough to alter chromatin conformation in cis. 
      Therefore, it is unlikely that changes in chromatin interactions drive repeat 
      instability or changes in gene expression in these disorders.
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American 
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).
FAU - Ruiz Buendia, Gustavo A
AU  - Ruiz Buendia GA
AUID- ORCID: 0000-0002-4935-1480
AD  - Center for Integrative Genomics, Faculty of Biology and Medicine, University of 
      Lausanne, 1015 Lausanne, Switzerland.
FAU - Leleu, Marion
AU  - Leleu M
AD  - School of Life Sciences, Ecole Polytechnique Federale de Lausanne, 1015 Lausanne, 
      Switzerland.
AD  - Vital-IT Group, Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
FAU - Marzetta, Flavia
AU  - Marzetta F
AUID- ORCID: 0000-0002-6684-6880
AD  - Vital-IT Group, Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
FAU - Vanzan, Ludovica
AU  - Vanzan L
AUID- ORCID: 0000-0003-2182-3607
AD  - Department of Genetic Medicine and Development, University of Geneva Medical 
      School, 1211 Geneva, Switzerland.
FAU - Tan, Jennifer Y
AU  - Tan JY
AUID- ORCID: 0000-0003-1064-1162
AD  - Department of Computational Biology, Faculty of Biology and Medicine, University 
      of Lausanne, 1015 Lausanne, Switzerland.
FAU - Ythier, Victor
AU  - Ythier V
AUID- ORCID: 0000-0003-4389-3200
AD  - Department of Genetic Medicine and Development, University of Geneva Medical 
      School, 1211 Geneva, Switzerland.
FAU - Randall, Emma L
AU  - Randall EL
AUID- ORCID: 0000-0002-2112-7751
AD  - UK Dementia Research Institute at Cardiff University at Cardiff University, Hadyn 
      Ellis Building, Maindy Road, CF24 4HQ Cardiff, UK.
FAU - Marques, Ana C
AU  - Marques AC
AUID- ORCID: 0000-0001-5174-8092
AD  - Department of Computational Biology, Faculty of Biology and Medicine, University 
      of Lausanne, 1015 Lausanne, Switzerland.
FAU - Baubec, Tuncay
AU  - Baubec T
AUID- ORCID: 0000-0001-8474-6587
AD  - Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, 
      Switzerland.
FAU - Murr, Rabih
AU  - Murr R
AUID- ORCID: 0000-0002-3346-6590
AD  - Department of Genetic Medicine and Development, University of Geneva Medical 
      School, 1211 Geneva, Switzerland.
AD  - Institute for Genetics and Genomics in Geneva (iGE3), University of Geneva, 1211 
      Geneva, Switzerland.
FAU - Xenarios, Ioannis
AU  - Xenarios I
AUID- ORCID: 0000-0002-3413-6841
AD  - Center for Integrative Genomics, Faculty of Biology and Medicine, University of 
      Lausanne, 1015 Lausanne, Switzerland.
FAU - Dion, Vincent
AU  - Dion V
AUID- ORCID: 0000-0003-4953-7637
AD  - UK Dementia Research Institute at Cardiff University at Cardiff University, Hadyn 
      Ellis Building, Maindy Road, CF24 4HQ Cardiff, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200703
PL  - United States
TA  - Sci Adv
JT  - Science advances
JID - 101653440
SB  - IM
PMC - PMC7334000
EDAT- 2020/07/14 06:00
MHDA- 2020/07/14 06:01
PMCR- 2020/07/03
CRDT- 2020/07/14 06:00
PHST- 2019/09/05 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/07/14 06:00 [entrez]
PHST- 2020/07/14 06:00 [pubmed]
PHST- 2020/07/14 06:01 [medline]
PHST- 2020/07/03 00:00 [pmc-release]
AID - aaz4012 [pii]
AID - 10.1126/sciadv.aaz4012 [doi]
PST - epublish
SO  - Sci Adv. 2020 Jul 3;6(27):eaaz4012. doi: 10.1126/sciadv.aaz4012. eCollection 2020 
      Jul.

PMID- 32649032
OWN - NLM
STAT- MEDLINE
DCOM- 20210706
LR  - 20211117
IS  - 1439-7633 (Electronic)
IS  - 1439-4227 (Print)
IS  - 1439-4227 (Linking)
VI  - 21
IP  - 22
DP  - 2020 Nov 16
TI  - Macrocyclization of a Ligand Targeting a Toxic RNA Dramatically Improves Potency.
PG  - 3229-3233
LID - 10.1002/cbic.202000445 [doi]
AB  - RNA molecules both contribute to and are causative of many human diseases. One 
      method to perturb RNA function is to target its structure with small molecules. 
      However, discovering bioactive ligands for RNA targets is challenging. Here, we 
      show that the bioactivity of a linear dimeric ligand that inactivates the RNA 
      trinucleotide repeat expansion that causes myotonic dystrophy type 1 [DM1; 
      r(CUG)(exp) ] can be improved by macrocyclization. Indeed, the macrocyclic 
      compound is ten times more potent than the linear compound for improving 
      DM1-associated defects in cells, including in patient-derived myotubes (muscle 
      cells). This enhancement in potency is due to the macrocycle's increased affinity 
      and selectively for the target, which inhibit r(CUG)(exp) 's toxic interaction 
      with muscleblind-like 1 (MBNL1), and its superior cell permeability. 
      Macrocyclization could prove to be an effective way to enhance the bioactivity of 
      modularly assembled ligands targeting RNA.
CI  - (c) 2020 Wiley-VCH GmbH.
FAU - Benhamou, Raphael I
AU  - Benhamou RI
AUID- ORCID: 0000-0003-1743-0886
AD  - Departments of Chemistry and Neuroscience, The Scripps Research Institute, 130 
      Scripps Way, Jupiter, FL 33458, USA.
FAU - Vezina-Dawod, Simon
AU  - Vezina-Dawod S
AD  - Departments of Chemistry and Neuroscience, The Scripps Research Institute, 130 
      Scripps Way, Jupiter, FL 33458, USA.
FAU - Choudhary, Shruti
AU  - Choudhary S
AD  - Departments of Chemistry and Neuroscience, The Scripps Research Institute, 130 
      Scripps Way, Jupiter, FL 33458, USA.
FAU - Won Wang, Kye
AU  - Won Wang K
AD  - Department of Chemistry, Florida Atlantic University, John D. MacArthur Campus, 
      Jupiter, FL 33458, USA.
FAU - Meyer, Samantha M
AU  - Meyer SM
AD  - Departments of Chemistry and Neuroscience, The Scripps Research Institute, 130 
      Scripps Way, Jupiter, FL 33458, USA.
FAU - Yildirim, Ilyas
AU  - Yildirim I
AD  - Department of Chemistry, Florida Atlantic University, John D. MacArthur Campus, 
      Jupiter, FL 33458, USA.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - Departments of Chemistry and Neuroscience, The Scripps Research Institute, 130 
      Scripps Way, Jupiter, FL 33458, USA.
LA  - eng
GR  - DP1 NS096898/NS/NINDS NIH HHS/United States
GR  - R35 NS116846/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200826
PL  - Germany
TA  - Chembiochem
JT  - Chembiochem : a European journal of chemical biology
JID - 100937360
RN  - 0 (Ligands)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Small Molecule Libraries)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Cyclization
MH  - Humans
MH  - Ligands
MH  - Macromolecular Substances/chemical synthesis/chemistry
MH  - Molecular Dynamics Simulation
MH  - Molecular Structure
MH  - RNA/*chemistry
MH  - Small Molecule Libraries/chemical synthesis/*chemistry
MH  - Trinucleotide Repeat Expansion
PMC - PMC7674229
MID - NIHMS1634847
OTO - NOTNLM
OT  - RNA
OT  - chemical biology
OT  - macrocycles
OT  - myotonic dystrophy
OT  - repeat expansion disorder
EDAT- 2020/07/11 06:00
MHDA- 2021/07/07 06:00
PMCR- 2021/11/16
CRDT- 2020/07/11 06:00
PHST- 2020/07/07 00:00 [received]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/07/07 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
PHST- 2021/11/16 00:00 [pmc-release]
AID - 10.1002/cbic.202000445 [doi]
PST - ppublish
SO  - Chembiochem. 2020 Nov 16;21(22):3229-3233. doi: 10.1002/cbic.202000445. Epub 2020 
      Aug 26.

PMID- 32607474
OWN - NLM
STAT- MEDLINE
DCOM- 20210415
LR  - 20210415
IS  - 2532-1900 (Electronic)
IS  - 1128-2460 (Print)
IS  - 1128-2460 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Mar
TI  - Identification, molecular characterization and segregation analysis of a variant 
      DMPK pre-mutation allele in a three-generation Italian family.
PG  - 13-18
LID - 10.36185/2532-1900-002 [doi]
AB  - DM1 is an autosomal dominant multisystemic disease caused by an unstable CTG 
      repeat expansion in the 3'-untranslated region (UTR) of the DMPK gene. The 
      complex variant DMPK expanded the alleles containing CAG, CCG, CTC and/or GGC 
      interruptions repetition sequences have been reported in 3-8% of DM1 patients. To 
      date, very few information is available about the frequency and clinical 
      consequences of pre-mutated DMPK variant allele. In this study, we describe a 
      three-generation Italian family showing the segregation of an interrupted DMPK 
      allele within the premutation range. TP-PCR with primers complementary to CCG 
      repetitions and direct sequencing allow us to identify a hetero-triplet 
      (CTG)(6)(CCGCTG)(15)(CTG)(5) repeat structure. The haplotype analysis 
      demonstrated that this variant allele is associated with the European founder DM1 
      haplotype. The pyrosequencing analysis of the CpG islands contained in the 
      flanking regions of the CTG array, did not show the presence of a cis effect of 
      the CCG interruptions on the methylation profile of the DM1 locus. The analysis 
      of both meiotic transmissions, one maternal and one paternal, revealed the 
      intrafamilial stability of the DM1 premutation among relatives. Our findings 
      further support the hypothesis of a stabilizing effect of CCG interruptions on 
      the mutational dynamics of the DM1 locus, also in intermediate DMPK alleles.
CI  - (c)2020 Gaetano Conte Academy - Mediterranean Society of Myology, Naples, Italy.
FAU - Fontana, Luana
AU  - Fontana L
AD  - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 
      Italy.
FAU - Santoro, Massimo
AU  - Santoro M
AD  - Don Gnocchi Foundation, Milan, Italy.
FAU - D'Apice, Maria Rosaria
AU  - D'Apice MR
AD  - Medical Genetics Section, Tor Vergata Hospital, Rome, Italy.
FAU - Peluso, Francesca
AU  - Peluso F
AD  - Medical Genetics Unit, Department of Biomedical Experimental and Clinical 
      Sciences "Mario Serio", University of Florence, Florence, Italy.
FAU - Gori, Giulia
AU  - Gori G
AD  - Medical Genetics Section, Tor Vergata Hospital, Rome, Italy.
FAU - Morrone, Amelia
AU  - Morrone A
AD  - Neuroscience Department, Meyer Children's Hospital, Florence, Italy.
FAU - Novelli, Giuseppe
AU  - Novelli G
AD  - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 
      Italy.
AD  - Medical Genetics Section, Tor Vergata Hospital, Rome, Italy.
AD  - Neuromed IRCCS Institute, Pozzilli, Isernia, Italy.
FAU - Dosa, Laura
AU  - Dosa L
AD  - Medical Genetics Unit, Anna Meyer Children's University Hospital, Florence, 
      Italy.
FAU - Botta, Annalisa
AU  - Botta A
AD  - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20200301
PL  - Italy
TA  - Acta Myol
JT  - Acta myologica : myopathies and cardiomyopathies : official journal of the 
      Mediterranean Society of Myology
JID - 9811169
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adolescent
MH  - Aged, 80 and over
MH  - CpG Islands/genetics
MH  - DNA Methylation
MH  - Family
MH  - Family Characteristics
MH  - Female
MH  - Genotyping Techniques/methods
MH  - Haplotypes/genetics
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - *Myotonic Dystrophy/diagnosis/genetics/physiopathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - *Pedigree
MH  - Repetitive Sequences, Nucleic Acid/genetics
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC7315898
OTO - NOTNLM
OT  - DMPK variant alleles
OT  - TP-PCR analysis
OT  - methylation
OT  - premutation
EDAT- 2020/07/02 06:00
MHDA- 2021/04/16 06:00
PMCR- 2020/03/01
CRDT- 2020/07/02 06:00
PHST- 2020/01/30 00:00 [received]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/07/02 06:00 [entrez]
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/04/16 06:00 [medline]
PHST- 2020/03/01 00:00 [pmc-release]
AID - 10.36185/2532-1900-002 [doi]
PST - epublish
SO  - Acta Myol. 2020 Mar 1;39(1):13-18. doi: 10.36185/2532-1900-002. eCollection 2020 
      Mar.

PMID- 32601694
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20210830
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 29
IP  - 15
DP  - 2020 Aug 29
TI  - Longitudinal increases in somatic mosaicism of the expanded CTG repeat in 
      myotonic dystrophy type 1 are associated with variation in age-at-onset.
PG  - 2496-2507
LID - 10.1093/hmg/ddaa123 [doi]
AB  - In myotonic dystrophy type 1 (DM1), somatic mosaicism of the (CTG)n repeat 
      expansion is age-dependent, tissue-specific and expansion-biased. These features 
      contribute toward variation in disease severity and confound 
      genotype-to-phenotype analyses. To investigate how the (CTG)n repeat expansion 
      changes over time, we collected three longitudinal blood DNA samples separated by 
      8-15 years and used small pool and single-molecule PCR in 43 DM1 patients. We 
      used the lower boundary of the allele length distribution as the best estimate 
      for the inherited progenitor allele length (ePAL), which is itself the best 
      predictor of disease severity. Although in most patients the lower boundary of 
      the allele length distribution was conserved over time, in many this estimate 
      also increased with age, suggesting samples for research studies and clinical 
      trials should be obtained as early as possible. As expected, the modal allele 
      length increased over time, driven primarily by ePAL, age-at-sampling and the 
      time interval. As expected, small expansions <100 repeats did not expand as 
      rapidly as larger alleles. However, the rate of expansion of very large alleles 
      was not obviously proportionally higher. This may, at least in part, be a result 
      of the allele length-dependent increase in large contractions that we also 
      observed. We also determined that individual-specific variation in the increase 
      of modal allele length over time not accounted for by ePAL, age-at-sampling and 
      time was inversely associated with individual-specific variation in age-at-onset 
      not accounted for by ePAL, further highlighting somatic expansion as a 
      therapeutic target in DM1.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Morales, Fernando
AU  - Morales F
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Vasquez, Melissa
AU  - Vasquez M
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Corrales, Eyleen
AU  - Corrales E
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Vindas-Smith, Rebeca
AU  - Vindas-Smith R
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Santamaria-Ulloa, Carolina
AU  - Santamaria-Ulloa C
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Zhang, Baili
AU  - Zhang B
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Sirito, Mario
AU  - Sirito M
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Estecio, Marcos R
AU  - Estecio MR
AD  - Department of Epigenetics & Molecular Carcinogenesis, University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Krahe, Ralf
AU  - Krahe R
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Age of Onset
MH  - Alleles
MH  - Child
MH  - Child, Preschool
MH  - DNA/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mosaicism
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Phenotype
MH  - Trinucleotide Repeat Expansion
MH  - Trinucleotide Repeats/*genetics
EDAT- 2020/07/01 06:00
MHDA- 2021/08/31 06:00
CRDT- 2020/07/01 06:00
PHST- 2019/12/09 00:00 [received]
PHST- 2020/04/13 00:00 [revised]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 5864792 [pii]
AID - 10.1093/hmg/ddaa123 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2020 Aug 29;29(15):2496-2507. doi: 10.1093/hmg/ddaa123.

PMID- 32542526
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 267
IP  - 11
DP  - 2020 Nov
TI  - Change over time in ability to perform activities of daily living in myotonic 
      dystrophy type 1.
PG  - 3235-3242
LID - 10.1007/s00415-020-09970-6 [doi]
AB  - OBJECTIVE: The objective of this longitudinal, observational study was to 
      investigate change over time in ability to perform activities of daily living in 
      myotonic dystrophy type 1 (DM1). METHODS: Adults with genetically confirmed DM1 
      were recruited as part of the PhenoDM1 study in the UK. Data on activities of 
      daily living were recorded through the DM1-Activ(C) at baseline and a follow-up 
      visit after 12 (+/- 3) months. A subset of patients had advanced genetic testing to 
      determine the size of the progenitor allele. RESULTS: Our sample comprised 150 
      patients with DM1 (mean age: 45 years; 52% female). Mean follow-up was 383 days. 
      Mean DM1-Activ(C) total score at baseline was 71.24 (95% confidence interval 
      67.77-74.71) and at the follow-up visit 69.04 (65.54-72.54). Approximately 43% of 
      patients had a lower score at the follow-up visit (indicating a decreased ability 
      to perform activities of daily living), 24% a higher score (indicating an 
      increased ability), and 33% the same score at baseline and follow-up. The mean 
      annual change in the DM1-Activ(C) total score, estimated at - 2.06 (- 3.54 to 
      - 0.59), was significantly related to patients' baseline score, but not sex, 
      disease duration, timed test results, or cytosine-thymine-guanine repeat length. 
      CONCLUSIONS: Change over time in ability to perform activities of daily living as 
      recorded through the DM1-Activ(C) varies substantially between patients with DM1. 
      Our data contribute to the understanding of the natural evolution of the disease, 
      and should be helpful to inform the design of future trials based on the 
      DM1-Activ(C).
FAU - Landfeldt, Erik
AU  - Landfeldt E
AUID- ORCID: 0000-0002-5758-7151
AD  - Department of Women's and Children's Health, Karolinska Institutet, Karolinska 
      Vagen 37A, 171 76, Stockholm, Sweden. erik.landfeldt@ki.se.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
FAU - Jimenez-Moreno, Cecilia
AU  - Jimenez-Moreno C
AD  - Welcome Center for Mitochondrial Research, Translational and Clinical Research 
      Institute, Newcastle University, Newcastle upon Tyne, UK.
AD  - Patient-Centered Research, Evidera, London, UK.
FAU - Cumming, Sarah
AU  - Cumming S
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Faber, Catharina G
AU  - Faber CG
AD  - Department of Neurology, School of Mental Health and Neuroscience, Maastricht 
      University Medical Center, Maastricht, The Netherlands.
FAU - Merkies, Ingemar S J
AU  - Merkies ISJ
AD  - Department of Neurology, School of Mental Health and Neuroscience, Maastricht 
      University Medical Center, Maastricht, The Netherlands.
AD  - Department of Neurology, Curacao Medical Centre, Willemstad, Curacao.
FAU - Gorman, Grainne
AU  - Gorman G
AD  - Institute of Neuroscience, Wellcome Trust Centre for Mitochondrial Research, 
      University of Newcastle, Newcastle, UK.
FAU - Turner, Chris
AU  - Turner C
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
AD  - Queen Square Department of Neuromuscular Disease, University College London, 
      London, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Department of Neuropediatrics and Muscle Disorders, Medical Centre, Faculty of 
      Medicine, University of Freiburg, Freiburg, Germany.
AD  - Children's Hospital of Eastern Ontario Research Institute; Division of Neurology, 
      Department of Medicine, The Ottawa Hospital; and Brain and Mind Research 
      Institute, University of Ottawa, Ottawa, Canada.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200615
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - *Activities of Daily Living
MH  - Adult
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - *Myotonic Dystrophy/genetics
PMC - PMC7578145
OTO - NOTNLM
OT  - Activities of daily living
OT  - Disability
OT  - Participation
OT  - PhenoDM1
COIS- Dr. Landfeldt is an employee of ICON plc (Stockholm, Sweden), outside the 
      submitted work. Dr. Monckton reports having a research contract with Newcastle 
      University during the conduct of the study; personal fees from AMO Pharma, 
      Vertex, Charles River, BridgeBio, Small molecule RNA, and personal fees for 
      scientific advisory board membership from Triplet Therapeutics and LoQus23, 
      outside the submitted work. Dr. Monckton is on the scientific advisory board of 
      the Myotonic Dystrophy Foundation and is a scientific advisor to the Myotonic 
      Dystrophy Support Group. Dr. Faber reports research support from the European 
      Union's Horizon 2020 research and innovation programme Marie Sklodowska-Curie 
      grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), the European 
      Union 7th Framework Programme (Grant no. 602273) for the PROPANE study, Prinses 
      Beatrix Spierfonds, and Grifols and Lamepro for a trial on IVIg in small fibre 
      neuropathy, outside the submitted work. Dr. Faber has participated in steering 
      committees for studies in small fibre neuropathy of Biogen/Convergence and Vertex 
      outside the submitted work. Dr. Merkies received funding for research from the 
      Talecris Talents program, the GSB CIDP Foundation International, Princes Beatrix 
      foundation, and from the European Union 7th Framework Programme (Grant no. 
      602273) outside the submitted work. Furthermore, a research foundation at the 
      University of Maastricht received honoraria on behalf of Dr. Merkies for 
      participation in steering committees of the Talecris ICE Study, LFB, CSL Behring, 
      Novartis, Grifols, and Octapharma outside the submitted work. Dr. Merkies serves 
      on the editorial board of the Journal of Peripheral Nervous system, is a member 
      of the Inflammatory Neuropathy Consortium (INC), and member of the Peripheral 
      Nerve Society. Dr. Turner reports financial support from the Biomedical Research 
      Council and the National Brain Appeal. Dr. Lochmuller is an investigator of the 
      Medical Research Council UK Centre for Neuromuscular Diseases (reference 
      G1002274, grant ID 98482). The other authors report no conflicts of interest.
EDAT- 2020/06/17 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/06/15
CRDT- 2020/06/17 06:00
PHST- 2020/02/17 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/05/25 00:00 [revised]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/17 06:00 [entrez]
PHST- 2020/06/15 00:00 [pmc-release]
AID - 10.1007/s00415-020-09970-6 [pii]
AID - 9970 [pii]
AID - 10.1007/s00415-020-09970-6 [doi]
PST - ppublish
SO  - J Neurol. 2020 Nov;267(11):3235-3242. doi: 10.1007/s00415-020-09970-6. Epub 2020 
      Jun 15.

PMID- 32350131
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20220824
IS  - 1946-6242 (Electronic)
IS  - 1946-6234 (Linking)
VI  - 12
IP  - 541
DP  - 2020 Apr 29
TI  - CDK12 inhibition reduces abnormalities in cells from patients with myotonic 
      dystrophy and in a mouse model.
LID - eaaz2415 [pii]
LID - 10.1126/scitranslmed.aaz2415 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an RNA-based disease with no current 
      treatment. It is caused by a transcribed CTG repeat expansion within the 3' 
      untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. 
      Mutant repeat expansion transcripts remain in the nuclei of patients' cells, 
      forming distinct microscopically detectable foci that contribute substantially to 
      the pathophysiology of the condition. Here, we report small-molecule inhibitors 
      that remove nuclear foci and have beneficial effects in the HSA(LR) mouse model, 
      reducing transgene expression, leading to improvements in myotonia, splicing, and 
      centralized nuclei. Using chemoproteomics in combination with cell-based assays, 
      we identify cyclin-dependent kinase 12 (CDK12) as a druggable target for this 
      condition. CDK12 is a protein elevated in DM1 cell lines and patient muscle 
      biopsies, and our results showed that its inhibition led to reduced expression of 
      repeat expansion RNA. Some of the inhibitors identified in this study are 
      currently the subject of clinical trials for other indications and provide 
      valuable starting points for a drug development program in DM1.
CI  - Copyright (c) 2020 The Authors, some rights reserved; exclusive licensee American 
      Association for the Advancement of Science. No claim to original U.S. Government 
      Works.
FAU - Ketley, Ami
AU  - Ketley A
AUID- ORCID: 0000-0003-3978-2540
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Wojciechowska, Marzena
AU  - Wojciechowska M
AUID- ORCID: 0000-0001-5025-2407
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Ghidelli-Disse, Sonja
AU  - Ghidelli-Disse S
AUID- ORCID: 0000-0002-7735-9746
AD  - Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 
      61997 Heidelberg, Germany.
FAU - Bamborough, Paul
AU  - Bamborough P
AUID- ORCID: 0000-0001-9479-2894
AD  - Computational and Modelling Sciences, GlaxoSmithKline, Medicines Research Centre, 
      Hertfordshire SG1 2NY, UK.
FAU - Ghosh, Tushar K
AU  - Ghosh TK
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Morato, Marta Lopez
AU  - Morato ML
AUID- ORCID: 0000-0002-2194-7258
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Sedehizadeh, Saam
AU  - Sedehizadeh S
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Malik, Naveed Altaf
AU  - Malik NA
AUID- ORCID: 0000-0002-7392-9449
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Tang, Zhenzhi
AU  - Tang Z
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY 
      14642-0001, USA.
FAU - Powalowska, Paulina
AU  - Powalowska P
AUID- ORCID: 0000-0002-1641-7279
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
AD  - School of Chemistry, University of Nottingham, University Park, Nottingham NG7 
      2RD, UK.
FAU - Tanner, Matthew
AU  - Tanner M
AUID- ORCID: 0000-0003-4013-4321
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY 
      14642-0001, USA.
FAU - Billeter-Clark, Rudolf
AU  - Billeter-Clark R
AUID- ORCID: 0000-0002-1203-6882
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Trueman, Rebecca C
AU  - Trueman RC
AUID- ORCID: 0000-0002-6746-0912
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Geiszler, Philippine C
AU  - Geiszler PC
AUID- ORCID: 0000-0003-2674-6014
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Agostini, Alessandra
AU  - Agostini A
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Othman, Othman
AU  - Othman O
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK.
FAU - Bosche, Markus
AU  - Bosche M
AUID- ORCID: 0000-0003-3111-6885
AD  - Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 
      61997 Heidelberg, Germany.
FAU - Bantscheff, Marcus
AU  - Bantscheff M
AUID- ORCID: 0000-0002-8343-8977
AD  - Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 
      61997 Heidelberg, Germany.
FAU - Rudiger, Martin
AU  - Rudiger M
AUID- ORCID: 0000-0001-9658-5311
AD  - Screening Profiling and Mechanistic Biology, GlaxoSmithKline, Medicines Research 
      Centre, Hertfordshire SG1 2NY, UK.
FAU - Mossakowska, Danuta E
AU  - Mossakowska DE
AUID- ORCID: 0000-0001-8579-5479
AD  - Discovery Partnerships with Academia, GlaxoSmithKline, Medicines Research Centre, 
      Hertfordshire SG1 2NY, UK.
AD  - Malopolska Centre of Biotechnology, Jagiellonian University, 30-348 Krakow, 
      Poland.
FAU - Drewry, David H
AU  - Drewry DH
AUID- ORCID: 0000-0001-5973-5798
AD  - Department of Chemical Biology, GlaxoSmithKline, Research Triangle Park, NC 
      27709-3398, USA.
FAU - Zuercher, William J
AU  - Zuercher WJ
AUID- ORCID: 0000-0002-9836-0068
AD  - Department of Chemical Biology, GlaxoSmithKline, Research Triangle Park, NC 
      27709-3398, USA.
AD  - SGC Center for Chemical Biology, UNC, Eshelman School of Pharmacy, Chapel Hill, 
      NC 27599, USA.
FAU - Thornton, Charles A
AU  - Thornton CA
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY 
      14642-0001, USA.
FAU - Drewes, Gerard
AU  - Drewes G
AUID- ORCID: 0000-0003-0575-6766
AD  - Cellzome GmbH, Molecular Discovery Research, GlaxoSmithKline, Meyerhofstrasse 1, 
      61997 Heidelberg, Germany.
FAU - Uings, Iain
AU  - Uings I
AUID- ORCID: 0000-0001-8313-4685
AD  - Discovery Partnerships with Academia, GlaxoSmithKline, Medicines Research Centre, 
      Hertfordshire SG1 2NY, UK.
FAU - Hayes, Christopher J
AU  - Hayes CJ
AUID- ORCID: 0000-0003-1692-3646
AD  - School of Chemistry, University of Nottingham, University Park, Nottingham NG7 
      2RD, UK.
FAU - Brook, J David
AU  - Brook JD
AUID- ORCID: 0000-0002-5946-6740
AD  - School of Life Sciences, University of Nottingham, Queen's Medical Centre, 
      Nottingham NG7 2UH, UK. david.brook@nottingham.ac.uk.
LA  - eng
GR  - G0802629/MRC_/Medical Research Council/United Kingdom
GR  - RG/13/10/30376/BHF_/British Heart Foundation/United Kingdom
GR  - 107562/Z/15/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Sci Transl Med
JT  - Science translational medicine
JID - 101505086
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.22 (CDK12 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
MH  - Animals
MH  - Cyclin-Dependent Kinases
MH  - Disease Models, Animal
MH  - Humans
MH  - Mice
MH  - *Myotonic Dystrophy/drug therapy/genetics
MH  - RNA
MH  - RNA Splicing/genetics
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 2020/05/01 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/05/01 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/09/16 00:00 [revised]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
AID - 12/541/eaaz2415 [pii]
AID - 10.1126/scitranslmed.aaz2415 [doi]
PST - ppublish
SO  - Sci Transl Med. 2020 Apr 29;12(541):eaaz2415. doi: 10.1126/scitranslmed.aaz2415.

PMID- 32203199
OWN - NLM
STAT- MEDLINE
DCOM- 20210527
LR  - 20210702
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 28
IP  - 7
DP  - 2020 Jul
TI  - Parental repeat length instability in myotonic dystrophy type 1 pre- and 
      protomutations.
PG  - 956-962
LID - 10.1038/s41431-020-0601-4 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide repeat expansion 
      on chromosome 19q13.3. While DM1 premutation (36-50 repeats) and protomutation 
      (51-80 repeats) allele carriers are mostly asymptomatic, offspring is at risk of 
      inheriting expanded, symptom-associated, (CTG)n repeats of n > 80. In this study 
      we aimed to evaluate the intergenerational instability of DM1 pre- and 
      protomutation alleles, focussing on the influence of parental gender. One hundred 
      and forty-six parent-child pairs (34 parental premutations, 112 protomutations) 
      were retrospectively selected from the DM1 patient cohort of the Maastricht 
      University Medical Center+. CTG repeat size of parents and children was 
      determined by (triplet-primed) PCR followed by fragment length analysis and 
      Southern blot analysis. Fifty-eight out of eighty-one (71.6%) paternal 
      transmissions led to a (CTG)n repeat of n > 80 in offspring, compared with 15 out 
      of 65 (23.1%) maternal transmissions (p < 0.001). Repeat length instability 
      occurred for paternal (CTG)n repeats of n >/= 45, while maternal instability did 
      not occur until (CTG)n repeats reached a length of n >/= 71. Transmission of 
      premutations caused (CTG)n repeats of n > 80 in offspring only when paternally 
      transmitted (two cases), while protomutations caused (CTG)n repeats of n > 80 in 
      offspring in 71 cases, of which 56 (78.9%) were paternally transmitted. In 
      conclusion, our data show that paternally transmitted pre- and protomutations 
      were more unstable than maternally transmitted pre- and protomutations. For 
      genetic counseling, this implies that males with a small DMPK mutation have a 
      higher risk of symptomatic offspring compared with females. Consequently, we 
      suggest addressing sex-dependent factors in genetic counseling of small-sized CTG 
      repeat carriers.
FAU - Joosten, Isis B T
AU  - Joosten IBT
AD  - Department of Neurology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
AD  - School for Mental Health and Neuroscience, Maastricht University, Maastricht, The 
      Netherlands.
FAU - Hellebrekers, Debby M E I
AU  - Hellebrekers DMEI
AD  - Department of Clinical Genetics, Maastricht University Medical Center+, 
      Maastricht, The Netherlands.
FAU - de Greef, Bianca T A
AU  - de Greef BTA
AD  - Department of Neurology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
AD  - School for Mental Health and Neuroscience, Maastricht University, Maastricht, The 
      Netherlands.
AD  - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht 
      University Medical Center+, Maastricht, The Netherlands.
FAU - Smeets, Hubert J M
AU  - Smeets HJM
AD  - School for Mental Health and Neuroscience, Maastricht University, Maastricht, The 
      Netherlands.
AD  - Department of Genetics and Cell Biology, Clinical Genomics Unit, Maastricht 
      University, Maastricht, The Netherlands.
AD  - School for Oncology and Developmental Biology, Maastricht University, Maastricht, 
      The Netherlands.
FAU - de Die-Smulders, Christine E M
AU  - de Die-Smulders CEM
AD  - Department of Clinical Genetics, Maastricht University Medical Center+, 
      Maastricht, The Netherlands.
FAU - Faber, Catharina G
AU  - Faber CG
AUID- ORCID: 0000-0002-2467-067X
AD  - Department of Neurology, Maastricht University Medical Center+, Maastricht, The 
      Netherlands.
AD  - School for Mental Health and Neuroscience, Maastricht University, Maastricht, The 
      Netherlands.
FAU - Gerrits, Monique M
AU  - Gerrits MM
AD  - Department of Clinical Genetics, Maastricht University Medical Center+, 
      Maastricht, The Netherlands. monique.gerrits@mumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20200312
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
SB  - IM
MH  - Adult
MH  - Child
MH  - Chromosomes, Human, Pair 19/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - *Paternal Inheritance
MH  - *Trinucleotide Repeat Expansion
PMC - PMC7316980
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/03/24 06:00
MHDA- 2021/05/28 06:00
PMCR- 2021/07/01
CRDT- 2020/03/24 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2020/02/25 00:00 [accepted]
PHST- 2020/02/14 00:00 [revised]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2021/05/28 06:00 [medline]
PHST- 2020/03/24 06:00 [entrez]
PHST- 2021/07/01 00:00 [pmc-release]
AID - 10.1038/s41431-020-0601-4 [pii]
AID - 601 [pii]
AID - 10.1038/s41431-020-0601-4 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2020 Jul;28(7):956-962. doi: 10.1038/s41431-020-0601-4. Epub 
      2020 Mar 12.

PMID- 32186845
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210417
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Print)
IS  - 1554-8929 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Apr 17
TI  - Precise Targeted Cleavage of a r(CUG) Repeat Expansion in Cells by Using a 
      Small-Molecule-Deglycobleomycin Conjugate.
PG  - 849-855
LID - 10.1021/acschembio.0c00036 [doi]
AB  - RNA repeat expansions cause more than 30 neurological and neuromuscular diseases 
      with no known cures. Since repeat expansions operate via diverse pathomechanisms, 
      one potential therapeutic strategy is to rid them from disease-affected cells, 
      using bifunctional small molecules that cleave the aberrant RNA. Such an approach 
      has been previously implemented for the RNA repeat that causes myotonic dystrophy 
      type 1 [DM1, r(CUG)(exp)] with Cugamycin, which is a small molecule that 
      selectively binds r(CUG)(exp) conjugated to a bleomycin A5 cleaving module. 
      Herein, we demonstrate that, by replacing bleomycin A5 with deglycobleomycin, an 
      analogue in which the carbohydrate domain of bleomycin A5 is removed, the 
      selectivity of the resulting small-molecule conjugate (DeglycoCugamycin) was 
      enhanced, while maintaining potent and allele-selective cleavage of r(CUG)(exp) 
      and rescue of DM1-associated defects. In particular, DeglycoCugamycin did not 
      induce the DNA damage that is observed with high concentrations (25 muM) of 
      Cugamycin, while selectively cleaving the disease-causing allele and improving 
      DM1 defects at 1 muM.
FAU - Angelbello, Alicia J
AU  - Angelbello AJ
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - DeFeo, Mary E
AU  - DeFeo ME
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
FAU - Glinkerman, Christopher M
AU  - Glinkerman CM
AD  - Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines 
      Road, La Jolla, California 92037, United States.
FAU - Boger, Dale L
AU  - Boger DL
AD  - Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines 
      Road, La Jolla, California 92037, United States.
FAU - Disney, Matthew D
AU  - Disney MD
AUID- ORCID: 0000-0001-8486-1796
AD  - Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 
      Jupiter, Florida 33458, United States.
LA  - eng
GR  - F31 NS110269/NS/NINDS NIH HHS/United States
GR  - R01 CA042056/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20200318
PL  - United States
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (cugamycin)
RN  - 11056-06-7 (Bleomycin)
RN  - 78314-57-5 (deglycobleomycin)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - Bleomycin/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line
MH  - DNA/*chemistry
MH  - DNA Cleavage/*drug effects
MH  - DNA Damage/drug effects
MH  - DNA-Binding Proteins/genetics
MH  - Mice
MH  - RNA-Binding Proteins/genetics
MH  - Trinucleotide Repeat Expansion/*drug effects
PMC - PMC7360342
MID - NIHMS1606112
COIS- The authors declare the following competing financial interest(s): M.D.D. is a 
      founder of Expansion Therapeutics.
EDAT- 2020/03/19 06:00
MHDA- 2021/01/23 06:00
PMCR- 2021/04/17
CRDT- 2020/03/19 06:00
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
PHST- 2020/03/19 06:00 [entrez]
PHST- 2021/04/17 00:00 [pmc-release]
AID - 10.1021/acschembio.0c00036 [doi]
PST - ppublish
SO  - ACS Chem Biol. 2020 Apr 17;15(4):849-855. doi: 10.1021/acschembio.0c00036. Epub 
      2020 Mar 18.

PMID- 32109384
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20240216
IS  - 1878-1551 (Electronic)
IS  - 1534-5807 (Print)
IS  - 1534-5807 (Linking)
VI  - 52
IP  - 6
DP  - 2020 Mar 23
TI  - Aberrant Expression of a Non-muscle RBFOX2 Isoform Triggers Cardiac Conduction 
      Defects in Myotonic Dystrophy.
PG  - 748-763.e6
LID - S1534-5807(20)30069-1 [pii]
LID - 10.1016/j.devcel.2020.01.037 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic genetic disorder caused by the 
      CTG repeat expansion in the 3'-untranslated region of DMPK gene. Heart 
      dysfunctions occur in  approximately 80% of DM1 patients and are the second leading cause of 
      DM1-related deaths. Herein, we report that upregulation of a non-muscle splice 
      isoform of RNA-binding protein RBFOX2 in DM1 heart tissue-due to altered splicing 
      factor and microRNA activities-induces cardiac conduction defects in DM1 
      individuals. Mice engineered to express the non-muscle RBFOX2(40) isoform in 
      heart via tetracycline-inducible transgenesis, or CRISPR/Cas9-mediated genome 
      editing, reproduced DM1-related cardiac conduction delay and spontaneous episodes 
      of arrhythmia. Further, by integrating RNA binding with cardiac transcriptome 
      datasets from DM1 patients and mice expressing the non-muscle RBFOX2 isoform, we 
      identified RBFOX2(40)-driven splicing defects in voltage-gated sodium and 
      potassium channels, which alter their electrophysiological properties. Thus, our 
      results uncover a trans-dominant role for an aberrantly expressed RBFOX2(40) 
      isoform in DM1 cardiac pathogenesis.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Misra, Chaitali
AU  - Misra C
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA.
FAU - Bangru, Sushant
AU  - Bangru S
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA; Cancer Center at Illinois, University of Illinois, Urbana-Champaign, Urbana, 
      IL, USA.
FAU - Lin, Feikai
AU  - Lin F
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA.
FAU - Lam, Kin
AU  - Lam K
AD  - Department of Physics, University of Illinois, Urbana-Champaign, Urbana, IL, USA; 
      Centers for Macromolecular Modeling, Bioinformatics and Experimental Molecular 
      Imaging at Beckman Institute for Advanced Science and Technology, University of 
      Illinois, Urbana-Champaign, Urbana, IL, USA.
FAU - Koenig, Sara N
AU  - Koenig SN
AD  - Department of Physiology and Cell Biology, Davis Heart and Lung Research 
      Institute, College of Medicine, Wexner Medical Center, The Ohio State University, 
      Columbus, OH, USA.
FAU - Lubbers, Ellen R
AU  - Lubbers ER
AD  - Department of Physiology and Cell Biology, Davis Heart and Lung Research 
      Institute, College of Medicine, Wexner Medical Center, The Ohio State University, 
      Columbus, OH, USA.
FAU - Hedhli, Jamila
AU  - Hedhli J
AD  - Department of Bioengineering, University of Illinois, Urbana-Champaign, Urbana, 
      IL, USA; Centers for Macromolecular Modeling, Bioinformatics and Experimental 
      Molecular Imaging at Beckman Institute for Advanced Science and Technology, 
      University of Illinois, Urbana-Champaign, Urbana, IL, USA.
FAU - Murphy, Nathaniel P
AU  - Murphy NP
AD  - Department of Physiology and Cell Biology, Davis Heart and Lung Research 
      Institute, College of Medicine, Wexner Medical Center, The Ohio State University, 
      Columbus, OH, USA.
FAU - Parker, Darren J
AU  - Parker DJ
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA.
FAU - Dobrucki, Lawrence W
AU  - Dobrucki LW
AD  - Department of Bioengineering, University of Illinois, Urbana-Champaign, Urbana, 
      IL, USA; Centers for Macromolecular Modeling, Bioinformatics and Experimental 
      Molecular Imaging at Beckman Institute for Advanced Science and Technology, 
      University of Illinois, Urbana-Champaign, Urbana, IL, USA; Cancer Center at 
      Illinois, University of Illinois, Urbana-Champaign, Urbana, IL, USA.
FAU - Cooper, Thomas A
AU  - Cooper TA
AD  - Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, 
      USA.
FAU - Tajkhorshid, Emad
AU  - Tajkhorshid E
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA; Department of Physics, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA; Department of Bioengineering, University of Illinois, Urbana-Champaign, 
      Urbana, IL, USA; Centers for Macromolecular Modeling, Bioinformatics and 
      Experimental Molecular Imaging at Beckman Institute for Advanced Science and 
      Technology, University of Illinois, Urbana-Champaign, Urbana, IL, USA; Cancer 
      Center at Illinois, University of Illinois, Urbana-Champaign, Urbana, IL, USA.
FAU - Mohler, Peter J
AU  - Mohler PJ
AD  - Department of Physiology and Cell Biology, Davis Heart and Lung Research 
      Institute, College of Medicine, Wexner Medical Center, The Ohio State University, 
      Columbus, OH, USA.
FAU - Kalsotra, Auinash
AU  - Kalsotra A
AD  - Department of Biochemistry, University of Illinois, Urbana-Champaign, Urbana, IL, 
      USA; Carl R. Woese Institute for Genomic Biology, University of Illinois, 
      Urbana-Champaign, Urbana, IL, USA; Cancer Center at Illinois, University of 
      Illinois, Urbana-Champaign, Urbana, IL, USA. Electronic address: 
      kalsotra@illinois.edu.
LA  - eng
GR  - R35 HL135754/HL/NHLBI NIH HHS/United States
GR  - R01 GM122420/GM/NIGMS NIH HHS/United States
GR  - R01 AR045653/AR/NIAMS NIH HHS/United States
GR  - R01 GM123455/GM/NIGMS NIH HHS/United States
GR  - R01 HL126845/HL/NHLBI NIH HHS/United States
GR  - P41 GM104601/GM/NIGMS NIH HHS/United States
GR  - R01 HL045565/HL/NHLBI NIH HHS/United States
GR  - F30 HL137331/HL/NHLBI NIH HHS/United States
GR  - R01 HL134824/HL/NHLBI NIH HHS/United States
GR  - T32 EB019944/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200227
PL  - United States
TA  - Dev Cell
JT  - Developmental cell
JID - 101120028
RN  - 0 (MicroRNAs)
RN  - 0 (Potassium Channels, Voltage-Gated)
RN  - 0 (Protein Isoforms)
RN  - 0 (RBFOX2 protein, human)
RN  - 0 (RNA Splicing Factors)
RN  - 0 (Repressor Proteins)
RN  - 0 (Voltage-Gated Sodium Channels)
SB  - IM
MH  - *Action Potentials
MH  - Adult
MH  - Animals
MH  - Cells, Cultured
MH  - Female
MH  - *Heart Rate
MH  - Humans
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred ICR
MH  - MicroRNAs/genetics/metabolism
MH  - Middle Aged
MH  - Myocytes, Cardiac/metabolism/physiology
MH  - Myotonic Dystrophy/*genetics/metabolism/physiopathology
MH  - Potassium Channels, Voltage-Gated/genetics/metabolism
MH  - Protein Isoforms/genetics/metabolism
MH  - *RNA Splicing
MH  - RNA Splicing Factors/*genetics/metabolism
MH  - Repressor Proteins/*genetics/metabolism
MH  - Voltage-Gated Sodium Channels/genetics/metabolism
PMC - PMC7098852
MID - NIHMS1568635
OTO - NOTNLM
OT  - alternative splicing
OT  - cardiac arrhythmias
OT  - genome editing
OT  - genomics
OT  - ion channels
OT  - microRNA
OT  - molecular dynamics
OT  - myotonic dystrophy
OT  - protein-RNA interactions
COIS- Declaration of Interests The authors declare no competing interests.
EDAT- 2020/02/29 06:00
MHDA- 2020/10/23 06:00
PMCR- 2021/03/23
CRDT- 2020/02/29 06:00
PHST- 2019/07/08 00:00 [received]
PHST- 2019/11/25 00:00 [revised]
PHST- 2020/01/29 00:00 [accepted]
PHST- 2020/02/29 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2020/02/29 06:00 [entrez]
PHST- 2021/03/23 00:00 [pmc-release]
AID - S1534-5807(20)30069-1 [pii]
AID - 10.1016/j.devcel.2020.01.037 [doi]
PST - ppublish
SO  - Dev Cell. 2020 Mar 23;52(6):748-763.e6. doi: 10.1016/j.devcel.2020.01.037. Epub 
      2020 Feb 27.

PMID- 32063450
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 74
DP  - 2020 Apr
TI  - Idiopathic ventricular fibrillation and the V1764fsX1786 frameshift mutation of 
      the SCN5A gene in a myotonic dystrophy type 1 patient.
PG  - 242-244
LID - S0967-5868(19)32357-4 [pii]
LID - 10.1016/j.jocn.2020.02.007 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited muscular 
      dystrophy caused by an expanded CTG repeat in the dystrophia myotonica protein 
      kinase (DMPK) gene. Cardiac involvements in DM1 are characterized by cardiac 
      conduction delays and atrial or ventricular tachycardia, which increase the risk 
      of sudden cardiac death when compared with general population. Only a few reports 
      have investigated the association between DM1 and inherited arrhythmias, 
      including Brugada syndrome and a splicing abnormality of the SCN5A gene, encodes 
      the alpha-subunit of cardiac voltage-gated Na+ channels. Here we report a 24-year-old 
      male patient with progressive grip myotonia and dysphagia, who was genetically 
      diagnosed with idiopathic ventricular fibrillation (IVF) caused by a novel 
      V1764fsX1786 frameshift mutation in the SCN5A gene at the age of 18 years. Family 
      history was negative for arrhythmia, cardiac sudden death, and neuromuscular 
      disorders. Genetic analysis using the Southern blot technique revealed 350 CTG 
      repeats in the DMPK gene. This is the first case of DM1 with genetically 
      confirmed overlapping CTG repeat expansion and a V1764fsX1786 frameshift mutation 
      in the SCN5A gene. Our case suggests that a loss-of-function in the cardiac 
      sodium channel may contribute to the cardiac complications in DM1 patients.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Shimoyama, Takashi
AU  - Shimoyama T
AD  - Department of Neurology, Graduate School of Medicine, Nippon Medical School, 
      Tokyo, Japan. Electronic address: s-takashi@nms.ac.jp.
FAU - Hayashi, Hiroshi
AU  - Hayashi H
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon 
      Medical School, Tokyo, Japan.
FAU - Suzuki, Fumiaki
AU  - Suzuki F
AD  - Department of Neurology, Graduate School of Medicine, Nippon Medical School, 
      Tokyo, Japan.
FAU - Nishiyama, Yasuhiro
AU  - Nishiyama Y
AD  - Department of Neurology, Graduate School of Medicine, Nippon Medical School, 
      Tokyo, Japan.
FAU - Miyamoto, Yoshihiro
AU  - Miyamoto Y
AD  - Division of Genomic Diagnosis and Healthcare, National Cerebral and 
      Cardiovascular Center, Suita, Japan.
FAU - Aiba, Takeshi
AU  - Aiba T
AD  - Division of Cardiology, Department of Internal Medicine, National Cerebral and 
      Cardiovascular Center, Suita, Japan.
FAU - Shimizu, Wataru
AU  - Shimizu W
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon 
      Medical School, Tokyo, Japan.
FAU - Kimura, Kazumi
AU  - Kimura K
AD  - Department of Neurology, Graduate School of Medicine, Nippon Medical School, 
      Tokyo, Japan.
LA  - eng
PT  - Case Reports
DEP - 20200213
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (NAV1.5 Voltage-Gated Sodium Channel)
RN  - 0 (SCN5A protein, human)
RN  - Paroxysmal ventricular fibrillation
SB  - IM
MH  - Adult
MH  - Arrhythmias, Cardiac
MH  - Brugada Syndrome
MH  - Frameshift Mutation
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - NAV1.5 Voltage-Gated Sodium Channel/*genetics
MH  - RNA Splicing
MH  - Tachycardia, Ventricular/complications
MH  - Trinucleotide Repeat Expansion
MH  - Ventricular Fibrillation/*etiology/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - CTG repeat
OT  - Inherited arrythmia
OT  - Myotonic dystrophy type 1
OT  - SCN5A gene
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/02/18 06:00
MHDA- 2020/08/18 06:00
CRDT- 2020/02/18 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/02/18 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2020/02/18 06:00 [entrez]
AID - S0967-5868(19)32357-4 [pii]
AID - 10.1016/j.jocn.2020.02.007 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Apr;74:242-244. doi: 10.1016/j.jocn.2020.02.007. Epub 2020 
      Feb 13.

PMID- 31996899
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20201109
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 3
DP  - 2020 Mar 1
TI  - CTG Expansion in the DMPK Gene: Semen Quality Assessment and Outcome of 
      Preimplantation Genetic Diagnosis.
LID - dgaa041 [pii]
LID - 10.1210/clinem/dgaa041 [doi]
AB  - CONTEXT: Myotonic dystrophy (DM) is an autosomal dominant disorder characterized 
      mainly by myotonia but also by primary hypogonadism. No study has reported on 
      fertility management of patients affected by DM type 1 (DM1). OBJECTIVE: This 
      study investigates the impact of CTG repeats in the DMPK gene on semen quality 
      and preimplantation genetic diagnosis (PGD) outcome. DESIGN: This is a 
      monocentric retrospective observational study conducted from January 2003 to 
      January 2019. SETTING: Antoine Beclere University Hospital, Clamart, France. 
      PATIENTS: Three groups were compared in this study: male DM1 patients (Group A, n 
      = 18), unaffected partners of DM1 female patients (Group B, n = 30), and proven 
      fertile men (Group C, n = 33). Reproductive outcomes after PGD were compared 
      between groups A and B. RESULTS: Sperm volume was reduced in group A (2.0 mL) 
      when compared with groups B (3.0 mL; P < 0.01) and C (3.5 mL; P < 0.01). 
      Progressive motility in raw sperm was also decreased in group A (30%) as compared 
      to group C (40%; P < 0.01). The median number of progressive spermatozoa 
      retrieved after sperm preparation was 2.7 million (M) in group A, which was 
      significantly less than those of groups B (10.0 M; P < 0.01) and C (62.2 M; P < 
      0.01). Sperm motility was inversely correlated to the number of CTG repeats 
      (Spearman r2 = 0.48, Pearson r2 = 0.35). Cumulative live birth rate per transfer 
      was similar between groups, with 32.2% in group A versus 26.8% in group B. 
      CONCLUSIONS: As a precautionary measure, we advise physicians to perform regular 
      monitoring of semen quality in affected males, which would allow sperm 
      cryopreservation should semen parameters fall. PGD allows good reproductive 
      outcomes without disease transmission.
CI  - (c) Endocrine Society 2020. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Puy, Vincent
AU  - Puy V
AD  - Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Beclere 
      Hospital, APHP Clamart, France.
AD  - Laboratoire de Developpement des Gonades, UMRE008 Stabilite Genetique Cellules 
      Souches et Radiations, Universite de Paris, Universite Paris-Saclay, CEA, 
      Fontenay-aux-Roses, France.
FAU - Mayeur, Anne
AU  - Mayeur A
AD  - Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Beclere 
      Hospital, APHP Clamart, France.
FAU - Levy, Alexandre
AU  - Levy A
AD  - Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Beclere 
      Hospital, APHP Clamart, France.
FAU - Hesters, Laetitia
AU  - Hesters L
AD  - Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Beclere 
      Hospital, APHP Clamart, France.
FAU - Raad, Jade
AU  - Raad J
AD  - Department of Reproductive Medicine and Fertility Preservation, Paris-Saclay 
      University, Antoine Beclere Hospital, APHP Clamart, France.
FAU - Monnot, Sophie
AU  - Monnot S
AD  - Institut Imagine et Service de Genetique Moleculaire, Universite de Paris, 
      Hopital Necker Enfants Malades, Paris, France.
FAU - Steffann, Julie
AU  - Steffann J
AD  - Institut Imagine et Service de Genetique Moleculaire, Universite de Paris, 
      Hopital Necker Enfants Malades, Paris, France.
FAU - Frydman, Nelly
AU  - Frydman N
AD  - Reproductive Biology Unit CECOS, Paris-Saclay University, Antoine Beclere 
      Hospital, APHP Clamart, France.
AD  - Laboratoire de Developpement des Gonades, UMRE008 Stabilite Genetique Cellules 
      Souches et Radiations, Universite de Paris, Universite Paris-Saclay, CEA, 
      Fontenay-aux-Roses, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Ovarian Reserve
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Preimplantation Diagnosis/*methods
MH  - Prognosis
MH  - Retrospective Studies
MH  - Semen Analysis
MH  - *Sperm Motility
MH  - Spermatozoa/*chemistry
MH  - *Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CTG repeat
OT  - DMPK
OT  - PGD
OT  - male fertility
OT  - myotonic dystrophy
OT  - reproductive outcome
EDAT- 2020/01/31 06:00
MHDA- 2020/11/11 06:00
CRDT- 2020/01/31 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/01/31 06:00 [entrez]
AID - 5717685 [pii]
AID - 10.1210/clinem/dgaa041 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa041. doi: 10.1210/clinem/dgaa041.

PMID- 31970692
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Print)
IS  - 2168-4790 (Linking)
VI  - 54
IP  - 5
DP  - 2020 Sep
TI  - Patient Input to Inform the Development of Central Nervous System Outcome 
      Measures in Myotonic Dystrophy.
PG  - 1010-1017
LID - 10.1007/s43441-020-00117-3 [doi]
AB  - Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are 
      multisystem, genetic disorders caused by repeat expansions on chromosome 19 (DM1) 
      and chromosome 3 (DM2). Although the effects of DM on the skeletal, cardiac, and 
      smooth muscles, as well as the endocrine and central nervous systems, can be 
      disabling, there are no disease-modifying therapies for the disorder. Following a 
      process established by the US Food and Drug Administration (FDA) in 2012 known as 
      the Patient-Focused Drug Development (PFDD) Initiative, Myotonic (formerly the 
      Myotonic Dystrophy Foundation) has been conducting patient- and 
      caregiver-inclusive sessions to explore disease burden as defined by patients and 
      caregivers, and what affected individuals want most from potential new therapies. 
      In September 2017, at Myotonic's annual conference, a session titled "Bringing 
      the Patient Voice to CNS-Targeting Drug Development in Myotonic Dystrophy" 
      attracted some 350 members of the DM community. During the session, patients and 
      caregivers described CNS disease symptoms, their impact on quality of life, and 
      potential CNS-related targets that they considered important for drug development 
      consideration. These included fatigue and daytime sleepiness; dysregulated sleep; 
      cognitive deficits such as "brain fog," memory and focus impairment, learning and 
      attention difficulties, and time management challenges; 
      emotional/psychological/behavioral difficulties, including impulsivity, apathy, 
      antisocial behavior, personality changes, and depression; social difficulties, 
      including disconnection, lack of awareness, and feelings of isolation; and 
      general anxieties about the future and potential loss of independence. 
      Improvements in memory and lessening of "brain fog" were considered particularly 
      important.
FAU - White, Molly
AU  - White M
AD  - Myotonic Dystrophy Foundation, 1004A O'Reilly Avenue, San Francisco, CA, USA, 
      94129. molly.white@myotonic.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200122
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
SB  - IM
MH  - Central Nervous System
MH  - Humans
MH  - *Myotonic Dystrophy/genetics
MH  - Outcome Assessment, Health Care
MH  - Quality of Life
MH  - United States
PMC - PMC7458891
OTO - NOTNLM
OT  - CNS
OT  - PFDD
OT  - endpoint
OT  - myotonic dystrophy
COIS- There are no potential conflicts of interest or conference presentations of this 
      work.
EDAT- 2020/01/24 06:00
MHDA- 2021/06/03 06:00
PMCR- 2020/01/22
CRDT- 2020/01/24 06:00
PHST- 2019/10/02 00:00 [received]
PHST- 2019/12/06 00:00 [accepted]
PHST- 2020/01/24 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/01/24 06:00 [entrez]
PHST- 2020/01/22 00:00 [pmc-release]
AID - 10.1007/s43441-020-00117-3 [pii]
AID - 117 [pii]
AID - 10.1007/s43441-020-00117-3 [doi]
PST - ppublish
SO  - Ther Innov Regul Sci. 2020 Sep;54(5):1010-1017. doi: 10.1007/s43441-020-00117-3. 
      Epub 2020 Jan 22.

PMID- 31889295
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20240214
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 141
IP  - 5
DP  - 2020 May
TI  - Activities of daily living in myotonic dystrophy type 1.
PG  - 380-387
LID - 10.1111/ane.13215 [doi]
AB  - OBJECTIVES: The objective of this cross-sectional, observational study was to 
      investigate performance of activities of daily living in patients with myotonic 
      dystrophy type 1 (DM1). MATERIALS AND METHODS: Adults with genetically confirmed 
      DM1 were recruited from Newcastle University (Newcastle upon Tyne, UK) and 
      University College London Hospitals NHS Foundation Trust (London, UK). Data on 
      activities of daily living were recorded through the DM1-Activ(C) (scale scores 
      range between 0 and 100, where a higher/lower score indicates a higher/lower 
      ability). RESULTS: Our sample comprised 192 patients with DM1 (mean age: 
      46 years; 51% female). Patients reported most difficulties with running, carrying 
      and putting down heavy objects, and standing on one leg, and least difficulties 
      with eating soup, washing upper body, and taking a shower. Irrespective of the 
      disease duration (mean: 20 years), most patients were able to perform basic and 
      instrumental activities of daily living (eg personal hygiene and grooming, 
      showering, eating, cleaning and shopping), with the exception of functional 
      mobility/transfer tasks (eg walking uphill and running). The mean DM1-Activ(C) 
      total score was estimated at 71 (95% CI: 68-74). Estimated progenitor 
      cytosine-thymine-guanine repeat length and age explained 27% of the variance in 
      DM1-Activ(C) total scores (P < .001). CONCLUSIONS: We show that DM1 impairs 
      performance of activities of daily living, in particular those requiring a high 
      degree of muscle strength, stability and coordination. Yet, across the evolution 
      of the disease, the majority of patients will still be able to independently 
      perform most basic and instrumental activities of daily living.
CI  - (c) 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Landfeldt, Erik
AU  - Landfeldt E
AUID- ORCID: 0000-0002-5758-7151
AD  - Department of Learning, Informatics, Management and Ethics, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, UK.
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
FAU - Jimenez-Moreno, Cecilia
AU  - Jimenez-Moreno C
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, UK.
FAU - Cumming, Sarah
AU  - Cumming S
AUID- ORCID: 0000-0002-0201-3660
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Faber, Catharina G
AU  - Faber CG
AD  - Department of Neurology, School of Mental Health and Neuroscience, Maastricht 
      University Medical Center, Maastricht, The Netherlands.
FAU - Merkies, Ingemar S J
AU  - Merkies ISJ
AD  - Department of Neurology, School of Mental Health and Neuroscience, Maastricht 
      University Medical Center, Maastricht, The Netherlands.
AD  - Department of Neurology, Curacao Medical Centre, Willemstad, Curacao.
FAU - Gorman, Grainne
AU  - Gorman G
AD  - Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, 
      University of Newcastle, Newcastle, UK.
FAU - Turner, Chris
AU  - Turner C
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
AD  - Queen Square Department of Neuromuscular Disease, University College London, 
      London, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Medical 
      Centre-University of Freiburg, Freiburg, Germany.
AD  - Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
AD  - Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, 
      Canada.
AD  - Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada.
LA  - eng
GR  - G1002274/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
DEP - 20200121
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
SB  - IM
MH  - *Activities of Daily Living
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Disability Evaluation
MH  - Disabled Persons
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myotonic Dystrophy/complications/physiopathology
MH  - Young Adult
OTO - NOTNLM
OT  - activities of daily living
OT  - quality of life
OT  - social participation
EDAT- 2020/01/01 06:00
MHDA- 2020/08/25 06:00
CRDT- 2020/01/01 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/12/11 00:00 [revised]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/01/01 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/01/01 06:00 [entrez]
AID - 10.1111/ane.13215 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2020 May;141(5):380-387. doi: 10.1111/ane.13215. Epub 2020 Jan 
      21.

PMID- 31873063
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 2159-3345 (Electronic)
IS  - 2159-3337 (Print)
IS  - 2159-3337 (Linking)
VI  - 30
IP  - 2
DP  - 2020 Apr
TI  - Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic 
      Dystrophy Type 1 Therapy.
PG  - 80-93
LID - 10.1089/nat.2019.0811 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystemic disorder 
      characterized clinically by delayed muscle relaxation and weakness. The disease 
      is caused by a CTG repeat expansion in the 3' untranslated region (3' UTR) of the 
      DMPK gene, which leads to the expression of a toxic gain-of-function mRNA. The 
      expanded CUG repeat mRNA sequesters the MBNL1 splicing regulator in 
      nuclear-retained foci structures, resulting in loss of protein function and 
      disruption of alternative splicing homeostasis. In this study, we used CAG repeat 
      antisense oligonucleotides (ASOs), composed of locked nucleic acid (LNA)- and 
      2'-O-methyl (2'OMe)-modified bases in a chimeric design, to alleviate 
      CUG(expanded)-mediated toxicity. Chimeric 14-18mer LNA/2'OMe oligonucleotides, 
      exhibiting an LNA incorporation of  approximately 33%, significantly ameliorated the 
      misregulated alternative splicing of Mbnl1-dependent exons in primary DM1 mouse 
      myoblasts and tibialis anterior muscles of DM1 mice. Subcutaneous delivery of 
      14mer and 18mer LNA/2'OMe chimeras in DM1 mice resulted in high levels of 
      accumulation in all tested skeletal muscles, as well as in the diaphragm and 
      heart tissue. Despite the efficient delivery, chimeric LNA/2'OMe oligonucleotides 
      were not able, even at a high-dosage regimen (400 mg/kg/week), to correct the 
      misregulated splicing of Serca1 exon 22 in skeletal muscles. Nevertheless, 
      oligonucleotide doses were well-tolerated as determined by histological and 
      plasma biochemistry analyses. Our results provide proof of concept that 
      inhibition of MBNL1 sequestration by systemic delivery of a steric-blocking ASO 
      is extremely challenging, considering the large number of target sites that need 
      to be occupied per RNA molecule. Although not suitable for DM1 therapy, chimeric 
      LNA/2'OMe oligonucleotides could prove to be highly beneficial for other 
      diseases, such as Duchenne muscular dystrophy, that require inhibition of a 
      single target site per RNA molecule.
FAU - Christou, Melina
AU  - Christou M
AD  - Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of 
      Neurology and Genetics, Nicosia, Cyprus.
AD  - The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and 
      Genetics, Nicosia, Cyprus.
FAU - Wengel, Jesper
AU  - Wengel J
AD  - Department of Physics, Chemistry and Pharmacy, Biomolecular Nanoscale Engineering 
      Center, University of Southern Denmark, Odense M, Denmark.
FAU - Sokratous, Kleitos
AU  - Sokratous K
AD  - Department of Electron Microscopy and Molecular Pathology, The Cyprus Institute 
      of Neurology and Genetics, Nicosia, Cyprus.
AD  - Bioinformatics Group, The Cyprus Institute of Neurology and Genetics, Nicosia, 
      Cyprus.
FAU - Kyriacou, Kyriacos
AU  - Kyriacou K
AD  - The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and 
      Genetics, Nicosia, Cyprus.
AD  - Department of Electron Microscopy and Molecular Pathology, The Cyprus Institute 
      of Neurology and Genetics, Nicosia, Cyprus.
FAU - Nikolaou, Georgios
AU  - Nikolaou G
AD  - Veterinary Diagnostic Laboratory, Vet Ex Machina Ltd, Nicosia, Cyprus.
FAU - Phylactou, Leonidas A
AU  - Phylactou LA
AD  - Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of 
      Neurology and Genetics, Nicosia, Cyprus.
AD  - The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and 
      Genetics, Nicosia, Cyprus.
FAU - Mastroyiannopoulos, Nikolaos P
AU  - Mastroyiannopoulos NP
AD  - Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of 
      Neurology and Genetics, Nicosia, Cyprus.
AD  - The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and 
      Genetics, Nicosia, Cyprus.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191223
PL  - United States
TA  - Nucleic Acid Ther
JT  - Nucleic acid therapeutics
JID - 101562758
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (Oligonucleotides)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (locked nucleic acid)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Alternative Splicing/*drug effects/genetics
MH  - Animals
MH  - DNA-Binding Proteins/antagonists & inhibitors/genetics
MH  - Disease Models, Animal
MH  - Exons/genetics
MH  - Humans
MH  - Mice
MH  - Myotonic Dystrophy/genetics/pathology/*therapy
MH  - Myotonin-Protein Kinase/antagonists & inhibitors/*genetics
MH  - Oligonucleotides/genetics/pharmacology
MH  - RNA Splicing/drug effects/genetics
MH  - RNA-Binding Proteins/antagonists & inhibitors/genetics
MH  - Trinucleotide Repeat Expansion/*drug effects/genetics
PMC - PMC7133450
OTO - NOTNLM
OT  - 2'-O-methyl
OT  - DM1
OT  - LNA
OT  - antisense oligonucleotide
OT  - in vivo
COIS- No competing financial interests exist.
EDAT- 2019/12/25 06:00
MHDA- 2021/07/06 06:00
PMCR- 2020/03/26
CRDT- 2019/12/25 06:00
PHST- 2019/12/25 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2019/12/25 06:00 [entrez]
PHST- 2020/03/26 00:00 [pmc-release]
AID - 10.1089/nat.2019.0811 [pii]
AID - 10.1089/nat.2019.0811 [doi]
PST - ppublish
SO  - Nucleic Acid Ther. 2020 Apr;30(2):80-93. doi: 10.1089/nat.2019.0811. Epub 2019 
      Dec 23.

PMID- 31759551
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20200505
IS  - 1875-6263 (Electronic)
IS  - 1028-4559 (Linking)
VI  - 58
IP  - 6
DP  - 2019 Nov
TI  - Targeting myotonic dystrophy by preimplantation genetic diagnosis-karyomapping.
PG  - 891-894
LID - S1028-4559(19)30237-2 [pii]
LID - 10.1016/j.tjog.2019.04.002 [doi]
AB  - OBJECTIVE: To report a case with Myotonic dystrophy type I with successful 
      preimplantation genetic diagnosis-karyomapping. CASE REPORT: A 34-year-old female 
      carrier of myotonic dystrophy type I was treated at our clinic with a successful 
      pregnancy after preimplantation genetic testing for monogenic disorders using 
      karyomapping of her blastocysts. CONCLUSION: Myotonic dystrophy type I is an 
      inherited autosomal dominant disease producing various neuromuscular 
      disturbances. Offspring of carriers have a 50% chance of carrying CTG repeat 
      sequences in the DMPK gene, and various time-consuming methodologies have been 
      developed for genetic diagnosis. With a novel, efficient, and precise method by 
      karyomapping using single nucleotide polymorphism arrays to diagnose single gene 
      disorders, one could terminate the transmission of single gene disorder. Herein, 
      we reported a 34-year-old female carrier of myotonic dystrophy type I achieve a 
      successful pregnancy after preimplantation genetic testing for monogenic 
      disorders using karyomapping method of her blastocysts.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Wang, Cheng-Wei
AU  - Wang CW
AD  - Division of Reproductive Medicine, Department of Obstetrics and Gynecology, 
      Taipei Medical University Hospital, Taiwan.
FAU - Liu, Yung-Liang
AU  - Liu YL
AD  - Division of Reproductive Medicine, Department of Obstetrics and Gynecology, 
      Taipei Medical University Hospital, Taiwan; Department of Obstetrics and 
      Gynecology, Tri-Service General Hospital, National Defense Medical Center, 
      Taiwan.
FAU - Chen, Chi-Huang
AU  - Chen CH
AD  - Division of Reproductive Medicine, Department of Obstetrics and Gynecology, 
      Taipei Medical University Hospital, Taiwan; Department of Obstetrics and 
      Gynecology, School of Medicine, College of Medicine, Taipei Medical University, 
      Taiwan. Electronic address: d102095012@gmail.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Taiwan J Obstet Gynecol
JT  - Taiwanese journal of obstetrics & gynecology
JID - 101213819
SB  - IM
MH  - Adult
MH  - *Blastocyst
MH  - Female
MH  - Genetic Testing/*methods
MH  - Humans
MH  - Karyotyping
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - Pregnancy
MH  - Preimplantation Diagnosis/*methods
OTO - NOTNLM
OT  - Karyomapping
OT  - Myotonic dystrophy
OT  - Preimplantation genetic testing
EDAT- 2019/11/25 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/11/25 06:00
PHST- 2019/04/11 00:00 [accepted]
PHST- 2019/11/25 06:00 [entrez]
PHST- 2019/11/25 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
AID - S1028-4559(19)30237-2 [pii]
AID - 10.1016/j.tjog.2019.04.002 [doi]
PST - ppublish
SO  - Taiwan J Obstet Gynecol. 2019 Nov;58(6):891-894. doi: 10.1016/j.tjog.2019.04.002.

PMID- 31649961
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2329-0501 (Print)
IS  - 2329-0501 (Electronic)
IS  - 2329-0501 (Linking)
VI  - 15
DP  - 2019 Dec 13
TI  - Intrinsic Myogenic Potential of Skeletal Muscle-Derived Pericytes from Patients 
      with Myotonic Dystrophy Type 1.
PG  - 120-132
LID - 10.1016/j.omtm.2019.09.002 [doi]
AB  - Pericytes are multipotent, vessel-associated progenitors that exhibit high 
      proliferative capacity, can cross the blood-muscle barrier, and have the ability 
      to home to muscle tissue and contribute to myogenesis. Consequently, 
      pericyte-based therapies hold great promise for muscular dystrophies. A complex 
      multi-system disorder exhibiting muscular dystrophy for which pericytes might be 
      a valuable cell source is myotonic dystrophy type 1 (DM1). DM1 is caused by an 
      unstable (CTG)n repeat in the DMPK gene and characterized by skeletal muscle 
      weakness, muscle wasting, and myotonia. We have successfully isolated alkaline 
      phosphatase-positive pericytes from skeletal muscle of DM1 patients and a 
      transgenic mouse model. Intranuclear (CUG)n RNA foci, a pathogenic DM1 hallmark, 
      were identified in human and mouse pericytes. Notably, pericytes from DM1 
      patients maintained similar growth parameters and innate myogenic characteristics 
      in vitro compared to cells from unaffected controls. Our in vitro results thus 
      demonstrate the potential of pericytes to ameliorate muscle features in DM1 in a 
      therapeutic setting.
CI  - (c) 2019 The Author(s).
FAU - Ausems, Cornelia Rosanne Maria
AU  - Ausems CRM
AD  - Department of Human Genetics, Radboud University Medical Center, Donders 
      lnstitute for Brain Cognition and Behavior, 6525 GA Nijmegen, the Netherlands.
AD  - Department of Neurology, Radboud University Medical Center, Donders lnstitute for 
      Brain Cognition and Behavior, 6500 HB Nijmegen, the Netherlands.
AD  - Department of Cell Biology, Radboud University Medical Center, Radboud Institute 
      for Molecular Life Sciences, 6525 GA Nijmegen, the Netherlands.
FAU - Raaijmakers, Renee Henrica Lamberta
AU  - Raaijmakers RHL
AD  - Department of Human Genetics, Radboud University Medical Center, Donders 
      lnstitute for Brain Cognition and Behavior, 6525 GA Nijmegen, the Netherlands.
AD  - Department of Neurology, Radboud University Medical Center, Donders lnstitute for 
      Brain Cognition and Behavior, 6500 HB Nijmegen, the Netherlands.
AD  - Department of Cell Biology, Radboud University Medical Center, Radboud Institute 
      for Molecular Life Sciences, 6525 GA Nijmegen, the Netherlands.
FAU - van den Broek, Walterus Johannes Antonius Adriana
AU  - van den Broek WJAA
AD  - Department of Cell Biology, Radboud University Medical Center, Radboud Institute 
      for Molecular Life Sciences, 6525 GA Nijmegen, the Netherlands.
FAU - Willemse, Marieke
AU  - Willemse M
AD  - Department of Cell Biology, Radboud University Medical Center, Radboud Institute 
      for Molecular Life Sciences, 6525 GA Nijmegen, the Netherlands.
FAU - van Engelen, Baziel Gerardus Maria
AU  - van Engelen BGM
AD  - Department of Neurology, Radboud University Medical Center, Donders lnstitute for 
      Brain Cognition and Behavior, 6500 HB Nijmegen, the Netherlands.
FAU - Wansink, Derick Gert
AU  - Wansink DG
AD  - Department of Cell Biology, Radboud University Medical Center, Radboud Institute 
      for Molecular Life Sciences, 6525 GA Nijmegen, the Netherlands.
FAU - van Bokhoven, Hans
AU  - van Bokhoven H
AD  - Department of Human Genetics, Radboud University Medical Center, Donders 
      lnstitute for Brain Cognition and Behavior, 6525 GA Nijmegen, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190912
PL  - United States
TA  - Mol Ther Methods Clin Dev
JT  - Molecular therapy. Methods & clinical development
JID - 101624857
PMC - PMC6804802
OTO - NOTNLM
OT  - RNA toxicity
OT  - cell therapy
OT  - mesoangioblast
OT  - muscle stem cell
OT  - muscular dystrophy
OT  - myogenic progenitor cell
OT  - myotonic dystrophy
OT  - pericyte
OT  - triplet repeat expansion
EDAT- 2019/10/28 06:00
MHDA- 2019/10/28 06:01
PMCR- 2019/09/12
CRDT- 2019/10/26 06:00
PHST- 2019/06/06 00:00 [received]
PHST- 2019/09/04 00:00 [accepted]
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2019/10/28 06:01 [medline]
PHST- 2019/09/12 00:00 [pmc-release]
AID - S2329-0501(19)30099-3 [pii]
AID - 10.1016/j.omtm.2019.09.002 [doi]
PST - epublish
SO  - Mol Ther Methods Clin Dev. 2019 Sep 12;15:120-132. doi: 
      10.1016/j.omtm.2019.09.002. eCollection 2019 Dec 13.

PMID- 31624084
OWN - NLM
STAT- MEDLINE
DCOM- 20191220
LR  - 20221115
IS  - 1549-5477 (Electronic)
IS  - 0890-9369 (Print)
IS  - 0890-9369 (Linking)
VI  - 33
IP  - 23-24
DP  - 2019 Dec 1
TI  - Cell-type-specific dysregulation of RNA alternative splicing in short tandem 
      repeat mouse knockin models of myotonic dystrophy.
PG  - 1635-1640
LID - 10.1101/gad.328963.119 [doi]
AB  - Short tandem repeats (STRs) are prone to expansion mutations that cause multiple 
      hereditary neurological and neuromuscular diseases. To study pathomechanisms 
      using mouse models that recapitulate the tissue specificity and developmental 
      timing of an STR expansion gene, we used rolling circle amplification and 
      CRISPR/Cas9-mediated genome editing to generate Dmpk CTG expansion (CTG(exp)) 
      knockin models of myotonic dystrophy type 1 (DM1). We demonstrate that skeletal 
      muscle myoblasts and brain choroid plexus epithelial cells are particularly 
      susceptible to Dmpk CTG(exp) mutations and RNA missplicing. Our results implicate 
      dysregulation of muscle regeneration and cerebrospinal fluid homeostasis as early 
      pathogenic events in DM1.
CI  - (c) 2019 Nutter et al.; Published by Cold Spring Harbor Laboratory Press.
FAU - Nutter, Curtis A
AU  - Nutter CA
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Bubenik, Jodi L
AU  - Bubenik JL
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Oliveira, Ruan
AU  - Oliveira R
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Ivankovic, Franjo
AU  - Ivankovic F
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Sznajder, Lukasz J
AU  - Sznajder LJ
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Kidd, Benjamin M
AU  - Kidd BM
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Pinto, Belinda S
AU  - Pinto BS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Otero, Brittney A
AU  - Otero BA
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Carter, Helmut A
AU  - Carter HA
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Vitriol, Eric A
AU  - Vitriol EA
AD  - Department of Anatomy and Cell Biology, University of Florida, Gainesville, 
      Florida 32610, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, Gainesville, Florida 32610, USA.
LA  - eng
GR  - R37 NS040389/NS/NINDS NIH HHS/United States
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - RF1 NS098819/NS/NINDS NIH HHS/United States
GR  - P01 NS058901/NS/NINDS NIH HHS/United States
GR  - R01 NS098819/NS/NINDS NIH HHS/United States
GR  - R01 NS103172/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191017
PL  - United States
TA  - Genes Dev
JT  - Genes & development
JID - 8711660
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Alternative Splicing/*genetics
MH  - Animals
MH  - Choroid Plexus/physiopathology
MH  - DNA-Binding Proteins/genetics
MH  - Disease Models, Animal
MH  - Gene Expression Regulation, Developmental
MH  - Gene Knock-In Techniques
MH  - Mice
MH  - Microsatellite Repeats/*genetics
MH  - Muscle Fibers, Skeletal/cytology/pathology
MH  - Muscle, Skeletal/cytology/*physiopathology
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Myotonin-Protein Kinase/genetics/metabolism
MH  - RNA Splicing/*genetics
MH  - RNA-Binding Proteins/genetics
PMC - PMC6942047
OTO - NOTNLM
OT  - MBNL
OT  - RNA splicing
OT  - myotonic dystrophy
OT  - neuromuscular disease
OT  - short tandem repeat
EDAT- 2019/10/19 06:00
MHDA- 2019/12/21 06:00
PMCR- 2020/06/01
CRDT- 2019/10/19 06:00
PHST- 2019/05/17 00:00 [received]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/10/19 06:00 [pubmed]
PHST- 2019/12/21 06:00 [medline]
PHST- 2019/10/19 06:00 [entrez]
PHST- 2020/06/01 00:00 [pmc-release]
AID - gad.328963.119 [pii]
AID - 10.1101/gad.328963.119 [doi]
PST - ppublish
SO  - Genes Dev. 2019 Dec 1;33(23-24):1635-1640. doi: 10.1101/gad.328963.119. Epub 2019 
      Oct 17.

PMID- 31586340
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2056
DP  - 2020
TI  - Tracking Expansions of Stable and Threshold Length Trinucleotide Repeat Tracts In 
      Vivo and In Vitro Using Saccharomyces cerevisiae.
PG  - 25-68
LID - 10.1007/978-1-4939-9784-8_3 [doi]
AB  - Trinucleotide repeat (TNR) tracts are inherently unstable during DNA replication, 
      leading to repeat expansions and/or contractions. Expanded tracts are the cause 
      of over 40 neurodegenerative and neuromuscular diseases. In this chapter, we 
      focus on the (CAG)(n) and (CTG)(n) repeat sequences that, when expanded, lead to 
      Huntington's disease (HD) and myotonic dystrophy type 1 (DM1), respectively, as 
      well as a number of other neurodegenerative diseases. TNR tracts in most 
      individuals are relatively small and stable in terms of length. However, TNR 
      tracts become increasingly prone to expansion as tract length increases, 
      eventually leading to very long tracts that disrupt coding (e.g. HD) or noncoding 
      (e.g., DM1) regions of the genome. It is important to understand the early stages 
      in TNR expansions, that is, the transition from small, stable lengths to 
      susceptible threshold lengths. We describe PCR-based in vivo assays, using the 
      model system Saccharomyces cerevisiae, to determine and characterize the dynamic 
      behavior of TNR tracts in the stable and threshold ranges. We also describe a 
      simple in vitro system to assess tract dynamics during 5' single-stranded DNA 
      (ssDNA) flap processing and to assess the role of different DNA metabolism 
      proteins in these dynamics. These assays can ultimately be used to determine 
      factors that influence the early stages of TNR tract expansion.
FAU - Williams, Gregory M
AU  - Williams GM
AD  - Centre for Chromosome Biology, National University of Ireland, Galway, Galway, 
      Ireland.
AD  - Galway Neuroscience Centre, National Universityof Ireland, Galway, Galway, 
      Ireland.
FAU - Petrides, Athena K
AU  - Petrides AK
AD  - Department of Pathology, Harvard Medical School, Boston, MA, USA.
FAU - Balakrishnan, Lata
AU  - Balakrishnan L
AD  - Department of Biology, Indiana University Purdue University Indianapolis, 
      Indianapolis, IN, USA.
FAU - Surtees, Jennifer A
AU  - Surtees JA
AD  - Department of Biochemistry, JacobsSchool of Medicine and BiomedicalSciences, 
      State University of New York atBuffalo, Buffalo, NY, USA. jsurtees@buffalo.edu.
AD  - Genetics, Genomics and Bioinformatics Program, Jacobs School of Medicine and 
      Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA. 
      jsurtees@buffalo.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (DNA, Single-Stranded)
RN  - 0 (Saccharomyces cerevisiae Proteins)
SB  - IM
MH  - DNA Replication
MH  - DNA, Single-Stranded/*genetics
MH  - Genomic Instability
MH  - Humans
MH  - Microsatellite Instability
MH  - Polymerase Chain Reaction
MH  - Saccharomyces cerevisiae/*genetics
MH  - Saccharomyces cerevisiae Proteins/*genetics
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
OTO - NOTNLM
OT  - Contraction
OT  - DNA replication
OT  - Expansion
OT  - Microsatellite instability
OT  - Polymerase chain reaction
OT  - Repeat tract dynamics
OT  - Saccharomyces cerevisiae
OT  - Trinucleotide repeat
EDAT- 2019/10/06 06:00
MHDA- 2020/11/18 06:00
CRDT- 2019/10/06 06:00
PHST- 2019/10/06 06:00 [entrez]
PHST- 2019/10/06 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1007/978-1-4939-9784-8_3 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2020;2056:25-68. doi: 10.1007/978-1-4939-9784-8_3.

PMID- 31586339
OWN - NLM
STAT- MEDLINE
DCOM- 20201117
LR  - 20201117
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2056
DP  - 2020
TI  - Fast Assays to Detect Interruptions in CTG.CAG Repeat Expansions.
PG  - 11-23
LID - 10.1007/978-1-4939-9784-8_2 [doi]
AB  - Different interrupted repeat expansions have been found in several trinucleotide 
      repeat (TNR) diseases such as fragile X syndrome (FXS), spinocerebellar ataxias 
      (SCAs), and myotonic dystrophies (DMs). Their origins and roles remain poorly 
      understood, especially in myotonic dystrophy type 1 (DM1). We present here the 
      triplet repeat primed polymerase chain reaction (TP-PCR) and restriction 
      enzyme-digested PCR to detect and identify interrupted triplet repeat alleles in 
      DM1. TP-PCR consists of a PCR amplification using a fluoresceinated (FAM) primer 
      flanking the repeat region and a primer pair in CTG.CAG repeats. A detailed 
      analysis of interrupted triplet repeat tracts is essential to fully understand 
      the role of interruptions in the pathogenesis and molecular mechanisms observed 
      in TNR diseases.
FAU - Tome, Stephanie
AU  - Tome S
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France. stephanie.tome@inserm.fr.
AD  - Institut Imagine, Universite Paris-Descartes-Sorbonne Paris-Cite, Paris, France. 
      stephanie.tome@inserm.fr.
AD  - Centre de Recherche en Myologie, CRM, Association Institut de Myologie, INSERM 
      UMRS 974, Sorbonne Universite, Paris, France. stephanie.tome@inserm.fr.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France.
AD  - Institut Imagine, Universite Paris-Descartes-Sorbonne Paris-Cite, Paris, France.
AD  - Centre de Recherche en Myologie, CRM, Association Institut de Myologie, INSERM 
      UMRS 974, Sorbonne Universite, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Oligonucleotides)
RN  - EC 3.1.21.- (DNA Restriction Enzymes)
RN  - TPY09G7XIR (Fluorescein)
SB  - IM
MH  - DNA Restriction Enzymes/metabolism
MH  - Fluorescein/chemistry
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Myotonic Dystrophy/*genetics
MH  - Oligonucleotides/chemistry
MH  - Polymerase Chain Reaction/*methods
MH  - Time Factors
MH  - *Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - Interrupted repeat expansions
OT  - Myotonic dystrophy type 1
OT  - Polymerase chain reaction
OT  - Restriction enzyme-digested PCR
OT  - Trinucleotide repeats
OT  - Triplet repeat prime PCR (TP-PCR)
EDAT- 2019/10/06 06:00
MHDA- 2020/11/18 06:00
CRDT- 2019/10/06 06:00
PHST- 2019/10/06 06:00 [entrez]
PHST- 2019/10/06 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
AID - 10.1007/978-1-4939-9784-8_2 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2020;2056:11-23. doi: 10.1007/978-1-4939-9784-8_2.

PMID- 31570586
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20200702
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 116
IP  - 42
DP  - 2019 Oct 15
TI  - A CTG repeat-selective chemical screen identifies microtubule inhibitors as 
      selective modulators of toxic CUG RNA levels.
PG  - 20991-21000
LID - 10.1073/pnas.1901893116 [doi]
AB  - A CTG repeat expansion in the DMPK gene is the causative mutation of myotonic 
      dystrophy type 1 (DM1). Transcription of the expanded CTG repeat produces toxic 
      gain-of-function CUG RNA, leading to disease symptoms. A screening platform that 
      targets production or stability of the toxic CUG RNA in a selective manner has 
      the potential to provide new biological and therapeutic insights. A DM1 HeLa cell 
      model was generated that stably expresses a toxic r(CUG)480 and an analogous 
      r(CUG)0 control from DMPK and was used to measure the ratio-metric level of 
      r(CUG)480 versus r(CUG)0. This DM1 HeLa model recapitulates pathogenic hallmarks 
      of DM1, including CUG ribonuclear foci and missplicing of pre-mRNA targets of the 
      muscleblind (MBNL) alternative splicing factors. Repeat-selective screening using 
      this cell line led to the unexpected identification of multiple microtubule 
      inhibitors as hits that selectively reduce r(CUG)480 levels and partially rescue 
      MBNL-dependent missplicing. These results were validated by using the Food and 
      Drug Administration-approved clinical microtubule inhibitor colchicine in DM1 
      mouse and primary patient cell models. The mechanism of action was found to 
      involve selective reduced transcription of the CTG expansion that we hypothesize 
      to involve the LINC (linker of nucleoskeleton and cytoskeleton) complex. The 
      unanticipated identification of microtubule inhibitors as selective modulators of 
      toxic CUG RNA opens research directions for this form of muscular dystrophy and 
      may shed light on the biology of CTG repeat expansion and inform therapeutic 
      avenues. This approach has the potential to identify modulators of expanded 
      repeat-containing gene expression for over 30 microsatellite expansion disorders.
FAU - Reddy, Kaalak
AU  - Reddy K
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
FAU - Jenquin, Jana R
AU  - Jenquin JR
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
FAU - McConnell, Ona L
AU  - McConnell OL
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
FAU - Cleary, John D
AU  - Cleary JD
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
FAU - Richardson, Jared I
AU  - Richardson JI
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
FAU - Pinto, Belinda S
AU  - Pinto BS
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
FAU - Haerle, Maja C
AU  - Haerle MC
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
FAU - Delgado, Elizabeth
AU  - Delgado E
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - Department of Molecular Genetics and Microbiology, University of Florida College 
      of Medicine, Gainesville, FL 32610.
FAU - Planco, Lori
AU  - Planco L
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AUID- ORCID: 0000-0003-4714-3044
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 565-0871 
      Osaka, Japan.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610.
AD  - Department of Molecular Genetics and Microbiology, University of Florida College 
      of Medicine, Gainesville, FL 32610.
FAU - Berglund, J Andrew
AU  - Berglund JA
AD  - Center for NeuroGenetics, University of Florida College of Medicine, Gainesville, 
      FL 32610; aberglund@albany.edu.
AD  - The RNA Institute, University at Albany, State University of New York, Albany, NY 
      12222.
LA  - eng
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20190930
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (DMPK protein, human)
RN  - 0 (Small Molecule Libraries)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Animals
MH  - Drug Evaluation, Preclinical/*methods
MH  - HeLa Cells
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Microtubules/*drug effects/genetics/metabolism
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Myotonin-Protein Kinase/genetics/metabolism
MH  - RNA/chemistry/*genetics/metabolism
MH  - Small Molecule Libraries/*pharmacology
MH  - Trinucleotide Repeat Expansion/*drug effects
PMC - PMC6800345
OTO - NOTNLM
OT  - alternative splicing
OT  - muscleblind
OT  - myotonic dystrophy
OT  - transcription
COIS- The authors declare no competing interest.
EDAT- 2019/10/02 06:00
MHDA- 2020/03/31 06:00
PMCR- 2020/03/30
CRDT- 2019/10/02 06:00
PHST- 2019/10/02 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
PHST- 2019/10/02 06:00 [entrez]
PHST- 2020/03/30 00:00 [pmc-release]
AID - 1901893116 [pii]
AID - 201901893 [pii]
AID - 10.1073/pnas.1901893116 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):20991-21000. doi: 
      10.1073/pnas.1901893116. Epub 2019 Sep 30.

PMID- 31520483
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200113
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 60
IP  - 6
DP  - 2019 Dec
TI  - Clinical and genetic characteristics of childhood-onset myotonic dystrophy.
PG  - 732-738
LID - 10.1002/mus.26716 [doi]
AB  - INTRODUCTION: Myotonic dystrophy type 1 (DM1) is caused by a CTG 
      (cytosine-thymine-guanine) trinucleotide repeat expansion. Congenital DM (CDM) 
      presents in the first month of life, whereas individuals with infantile and 
      juvenile DM1 have later onset of symptoms. METHODS: We performed a retrospective 
      chart review of patients with childhood-onset DM1 seen at one of three locations 
      in Dallas, Texas between 1990 and 2018. Symptoms, disease course, cognitive 
      features, and family history were reviewed. RESULTS: Seventy-four patients were 
      included; CDM was diagnosed in 52 patients. There was maternal inheritance in 74% 
      of patients. CTG repeat number ranged from 143 to 2300. Neuropsychiatric and 
      cognitive deficits were common. Over half of the patients had GI disturbances, 
      and orthopedic complications were common. DISCUSSION: Myotonic dystrophy type 1 
      in children requires a multidisciplinary approach to management. Presenting 
      symptoms vary, and repeat expansion size does not necessarily directly relate to 
      severity of symptoms. A consensus for outcome measures is required.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Stokes, Mathew
AU  - Stokes M
AUID- ORCID: 0000-0001-8655-9814
AD  - Department of Pediatrics & Neurology, Division of Pediatric Neurology, The 
      University of Texas Southwestern Medical Center, Dallas, Texas.
AD  - Children's Medical Center Dallas, Dallas, Texas.
FAU - Varughese, Natasha
AU  - Varughese N
AD  - Department of Pediatrics & Neurology, Division of Pediatric Neurology, The 
      University of Texas Southwestern Medical Center, Dallas, Texas.
AD  - Children's Medical Center Dallas, Dallas, Texas.
FAU - Iannaccone, Susan
AU  - Iannaccone S
AD  - Department of Pediatrics & Neurology, Division of Pediatric Neurology, The 
      University of Texas Southwestern Medical Center, Dallas, Texas.
AD  - Children's Medical Center Dallas, Dallas, Texas.
FAU - Castro, Diana
AU  - Castro D
AD  - Department of Pediatrics & Neurology, Division of Pediatric Neurology, The 
      University of Texas Southwestern Medical Center, Dallas, Texas.
AD  - Children's Medical Center Dallas, Dallas, Texas.
LA  - eng
PT  - Journal Article
DEP - 20191023
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Asthma/etiology/physiopathology
MH  - Attention Deficit Disorder with Hyperactivity/etiology/physiopathology
MH  - Cardiac Conduction System Disease/etiology/physiopathology
MH  - Child
MH  - Child, Preschool
MH  - Cognitive Dysfunction/etiology/physiopathology
MH  - Constipation/etiology/physiopathology
MH  - Deglutition Disorders/etiology/physiopathology
MH  - Developmental Disabilities/etiology/physiopathology
MH  - Female
MH  - Gastroesophageal Reflux/etiology/physiopathology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Maternal Inheritance
MH  - Mitral Valve Insufficiency/etiology/physiopathology
MH  - Mood Disorders/etiology/physiopathology
MH  - Myotonic Dystrophy/complications/genetics/*physiopathology
MH  - Myotonin-Protein Kinase/genetics
MH  - Retrospective Studies
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - congenital myotonic dystrophy
OT  - infantile juvenile myotonic dystrophy
OT  - myotonic dystrophy
OT  - myotonic dystrophy type 1
OT  - trinucleotide repeat
EDAT- 2019/09/15 06:00
MHDA- 2020/01/14 06:00
CRDT- 2019/09/15 06:00
PHST- 2018/12/17 00:00 [received]
PHST- 2019/09/10 00:00 [revised]
PHST- 2019/09/12 00:00 [accepted]
PHST- 2019/09/15 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
PHST- 2019/09/15 06:00 [entrez]
AID - 10.1002/mus.26716 [doi]
PST - ppublish
SO  - Muscle Nerve. 2019 Dec;60(6):732-738. doi: 10.1002/mus.26716. Epub 2019 Oct 23.

PMID- 31395669
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20201118
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 93
IP  - 10
DP  - 2019 Sep 3
TI  - Genetic determinants of disease severity in the myotonic dystrophy type 1 
      OPTIMISTIC cohort.
PG  - e995-e1009
LID - 10.1212/WNL.0000000000008056 [doi]
AB  - OBJECTIVE: To evaluate the role of genetic variation at the DMPK locus on 
      symptomatic diversity in 250 adult, ambulant patients with myotonic dystrophy 
      type 1 (DM1) recruited to the Observational Prolonged Trial in Myotonic Dystrophy 
      Type 1 to Improve Quality of Life-Standards, a Target Identification 
      Collaboration (OPTIMISTIC) clinical trial. METHODS: We used small pool PCR to 
      correct age at sampling biases and estimate the progenitor allele CTG repeat 
      length and somatic mutational dynamics, and AciI digests and repeat primed PCR to 
      test for the presence of variant repeats. RESULTS: We confirmed disease severity 
      is driven by progenitor allele length, is further modified by age, and, in some 
      cases, sex, and that patients in whom the CTG repeat expands more rapidly in the 
      soma develop symptoms earlier than predicted. We revealed a key role for variant 
      repeats in reducing disease severity and quantified their role in delaying age at 
      onset by approximately 13.2 years (95% confidence interval 5.7-20.7, 2-tailed t 
      test t = -3.7, p = 0.0019). CONCLUSIONS: Careful characterization of the DMPK CTG 
      repeat to define progenitor allele length and presence of variant repeats has 
      increased utility in understanding clinical variability in a trial cohort and 
      provides a genetic route for defining disease-specific outcome measures, and the 
      basis of treatment response and stratification in DM1 trials.
CI  - Copyright (c) 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Cumming, Sarah A
AU  - Cumming SA
AUID- ORCID: 0000-0002-0201-3660
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Jimenez-Moreno, Cecilia
AU  - Jimenez-Moreno C
AUID- ORCID: 0000-0002-0488-9631
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Okkersen, Kees
AU  - Okkersen K
AUID- ORCID: 0000-0003-2475-1143
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Wenninger, Stephan
AU  - Wenninger S
AUID- ORCID: 0000-0001-8407-3642
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Daidj, Ferroudja
AU  - Daidj F
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Hogarth, Fiona
AU  - Hogarth F
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Littleford, Roberta
AU  - Littleford R
AUID- ORCID: 0000-0003-4868-0132
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Gorman, Grainne
AU  - Gorman G
AUID- ORCID: 0000-0002-7585-3409
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Bassez, Guillaume
AU  - Bassez G
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Schoser, Benedikt
AU  - Schoser B
AUID- ORCID: 0000-0002-2757-8131
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AUID- ORCID: 0000-0003-2324-8001
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - van Engelen, Baziel G M
AU  - van Engelen BGM
AUID- ORCID: 0000-0001-9867-9047
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - From the Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), 
      University of Glasgow; Institute of Genetic Medicine (C.J.-M., H.L.) and 
      Institute of Neurosciences (G.G.), Newcastle University, Newcastle upon Tyne, UK; 
      Department of Neurology (K.O., B.G.M.v.E.), Donders Institute for Brain Cognition 
      and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands; 
      Department of Neurology (S.W., B.S.), Friedrich-Baur-Institute, 
      Ludwig-Maximilians-Universitat Munchen, Munich, Germany; Neuromuscular Reference 
      Centre (F.D., G.B.), Assistance Publique-Hopitaux de Paris, France; and Tayside 
      Clinical Trials Unit (F.H., R.L.), The University of Dundee, UK. 
      darren.monckton@glasgow.ac.uk.
CN  - OPTIMISTIC Consortium
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190808
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
EIN - Neurology. 2020 Mar 10;94(10):459. PMID: 32047069
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/diagnosis/*genetics/*psychology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Polymerase Chain Reaction/methods
MH  - Quality of Life/*psychology
MH  - *Severity of Illness Index
PMC - PMC6745735
EDAT- 2019/08/10 06:00
MHDA- 2020/01/31 06:00
PMCR- 2019/09/03
CRDT- 2019/08/10 06:00
PHST- 2018/07/02 00:00 [received]
PHST- 2019/04/10 00:00 [accepted]
PHST- 2019/08/10 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
PHST- 2019/08/10 06:00 [entrez]
PHST- 2019/09/03 00:00 [pmc-release]
AID - WNL.0000000000008056 [pii]
AID - NEUROLOGY2018906743 [pii]
AID - 10.1212/WNL.0000000000008056 [doi]
PST - ppublish
SO  - Neurology. 2019 Sep 3;93(10):e995-e1009. doi: 10.1212/WNL.0000000000008056. Epub 
      2019 Aug 8.

PMID- 31336350
OWN - NLM
STAT- MEDLINE
DCOM- 20191101
LR  - 20230127
IS  - 1873-6424 (Electronic)
IS  - 0269-7491 (Print)
IS  - 0269-7491 (Linking)
VI  - 253
DP  - 2019 Oct
TI  - Developmental exposure to polychlorinated biphenyls (PCBs) in the maternal diet 
      causes host-microbe defects in weanling offspring mice.
PG  - 708-721
LID - S0269-7491(19)31992-X [pii]
LID - 10.1016/j.envpol.2019.07.066 [doi]
AB  - The gut microbiota is important for maintaining homeostasis of the host. Gut 
      microbes represent the initial site for toxicant processing following dietary 
      exposures to environmental contaminants. The diet is the primary route of 
      exposure to polychlorinated biphenyls (PCBs), which are absorbed via the gut, and 
      subsequently interfere with neurodevelopment and behavior. Developmental 
      exposures to PCBs have been linked to increased risk of neurodevelopmental 
      disorders (NDD), including autism spectrum disorder (ASD), which are also 
      associated with a high prevalence of gastrointestinal (GI) distress and 
      intestinal dysbiosis. We hypothesized that developmental PCB exposure impacts 
      colonization of the gut microbiota, resulting in GI pathophysiology, in a 
      genetically susceptible host. Mouse dams expressing two heritable human mutations 
      (double mutants [DM]) that result in abnormal Ca(2+) dynamics and produce 
      behavioral deficits (gain of function mutation in the ryanodine receptor 1 
      [T4826I-RYR1] and a human CGG repeat expansion [170-200 CGG repeats] in the 
      fragile X mental retardation gene 1 [FMR1 premutation]). DM and congenic wild 
      type (WT) controls were exposed to PCBs (0-6...mg/kg/d) in the diet starting 2 
      weeks before gestation and continuing through postnatal day 21 (P21). Intestinal 
      physiology (Ussing chambers), inflammation (qPCR) and gut microbiome (16S 
      sequencing) studies were performed in offspring mice (P28-P30). Developmental 
      exposure to PCBs in the maternal diet caused significant mucosal barrier defects 
      in ileum and colon (increased secretory state and tight junction permeability) of 
      juvenile DM mice. Furthermore, PCB exposure increased the intestinal inflammatory 
      profile (Il6, Il1beta, and Il22), and resulted in dysbiosis of the gut microbiota, 
      including altered beta-diversity, in juvenile DM mice developmentally exposed to 
      1...mg/kg/d PCBs when compared to WT controls. Collectively, these findings 
      demonstrate a novel interaction between PCB exposure and the gut microbiota in a 
      genetically susceptible host that provide novel insight into environmental risk 
      factors for neurodevelopmental disorders.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Rude, Kavi M
AU  - Rude KM
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Pusceddu, Matteo M
AU  - Pusceddu MM
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Keogh, Ciara E
AU  - Keogh CE
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Sladek, Jessica A
AU  - Sladek JA
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Rabasa, Gonzalo
AU  - Rabasa G
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Miller, Elaine N
AU  - Miller EN
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States.
FAU - Sethi, Sunjay
AU  - Sethi S
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, 95616, United States.
FAU - Keil, Kimberly P
AU  - Keil KP
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, 95616, United States.
FAU - Pessah, Isaac N
AU  - Pessah IN
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, 95616, United States.
FAU - Lein, Pamela J
AU  - Lein PJ
AD  - Department of Molecular Biosciences, School of Veterinary Medicine, University of 
      California, Davis, Davis, CA, 95616, United States.
FAU - Gareau, Melanie G
AU  - Gareau MG
AD  - Department of Anatomy, Physiology and Cell Biology, School of Veterinary 
      Medicine, University of California, Davis, Davis, CA, 95616, United States. 
      Electronic address: mgareau@ucdavis.edu.
LA  - eng
GR  - U24 DK092993/DK/NIDDK NIH HHS/United States
GR  - R56 ES014901/ES/NIEHS NIH HHS/United States
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - K99 ES029537/ES/NIEHS NIH HHS/United States
GR  - T32 ES007059/ES/NIEHS NIH HHS/United States
GR  - P30 ES023513/ES/NIEHS NIH HHS/United States
GR  - R01 ES014901/ES/NIEHS NIH HHS/United States
GR  - F32 HD088016/HD/NICHD NIH HHS/United States
GR  - U2C DK092993/DK/NIDDK NIH HHS/United States
GR  - R00 ES029537/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20190714
PL  - England
TA  - Environ Pollut
JT  - Environmental pollution (Barking, Essex : 1987)
JID - 8804476
RN  - 0 (Environmental Pollutants)
RN  - 0 (FMR1 protein, human)
RN  - 0 (Fmr1 protein, mouse)
RN  - 139135-51-6 (Fragile X Mental Retardation Protein)
RN  - DFC2HB4I0K (Polychlorinated Biphenyls)
SB  - IM
MH  - Animals
MH  - Autism Spectrum Disorder
MH  - Diet
MH  - Dietary Exposure
MH  - Dysbiosis
MH  - Environmental Pollutants/*toxicity
MH  - Female
MH  - Fragile X Mental Retardation Protein
MH  - Gastrointestinal Microbiome
MH  - Homeostasis
MH  - Humans
MH  - Inflammation
MH  - Intestines
MH  - *Maternal Exposure
MH  - Mice
MH  - Polychlorinated Biphenyls/*toxicity
MH  - Tight Junctions
MH  - Toxicity Tests
PMC - PMC6719698
MID - NIHMS1535345
OTO - NOTNLM
OT  - Inflammation
OT  - Intestinal physiology
OT  - Microbiota
OT  - Neurodevelopmental disorders
OT  - PCB
COIS- The authors have no competing financial interests. The authors declare that they 
      have no known competing financial interests or personal relationships that could 
      have appeared to influence the work reported in this paper.
EDAT- 2019/07/25 06:00
MHDA- 2019/11/02 06:00
PMCR- 2020/10/01
CRDT- 2019/07/24 06:00
PHST- 2019/04/17 00:00 [received]
PHST- 2019/07/12 00:00 [revised]
PHST- 2019/07/12 00:00 [accepted]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2019/11/02 06:00 [medline]
PHST- 2019/07/24 06:00 [entrez]
PHST- 2020/10/01 00:00 [pmc-release]
AID - S0269-7491(19)31992-X [pii]
AID - 10.1016/j.envpol.2019.07.066 [doi]
PST - ppublish
SO  - Environ Pollut. 2019 Oct;253:708-721. doi: 10.1016/j.envpol.2019.07.066. Epub 
      2019 Jul 14.

PMID- 31334355
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2376-7839 (Print)
IS  - 2376-7839 (Electronic)
IS  - 2376-7839 (Linking)
VI  - 5
IP  - 3
DP  - 2019 Jun
TI  - DMPK gene DNA methylation levels are associated with muscular and respiratory 
      profiles in DM1.
PG  - e338
LID - 10.1212/NXG.0000000000000338 [doi]
LID - e338
AB  - OBJECTIVE: To assess the effects of dystrophia myotonica protein kinase (DMPK) 
      DNA methylation (DNAme) epivariation on muscular and respiratory profiles in 
      patients with myotonic dystrophy type 1 (DM1). METHODS: Phenotypes were assessed 
      with standardized measures. Pyrosequencing of bisulfite-treated DNA was used to 
      quantify DNAme levels in blood from 90 patients with DM1 (adult form). Modal CTG 
      repeat length was assessed using small-pool PCR. The presence of Acil-sensitive 
      variant repeats was also tested. RESULTS: DNAme levels upstream of the CTG 
      expansion (exon and intron 11) were correlated with modal CTG repeat length (r(s) 
      = -0.224, p = 0.040; r(s) = -0.317, p = 0.003; and r(s) = -0.241, p = 0.027), 
      whereas correlations were observed with epivariations downstream of the CTG 
      repeats (r(s) = 0.227; p = 0.037). The presence of a variant repeat was 
      associated with higher DNAme levels at multiple CpG sites (up to 10% higher; p = 
      0.001). Stepwise multiple linear regression modeling showed that DNAme 
      contributed significantly and independently to explain phenotypic variability in 
      ankle dorsiflexor (3 CpGs: p = 0.001, 0.013, and 0.001), grip (p = 0.089), and 
      pinch (p = 0.028) strengths and in forced vital capacity (2 CpGs: p = 0.002 and 
      0.021) and maximal inspiratory pressure (p = 0.012). CONCLUSIONS: In addition to 
      the CTG repeat length, DMPK epivariations independently explain phenotypic 
      variability in DM1 and could thus improve prognostic accuracy for patients.
FAU - Legare, Cecilia
AU  - Legare C
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Overend, Gayle
AU  - Overend G
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Guay, Simon-Pierre
AU  - Guay SP
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Mathieu, Jean
AU  - Mathieu J
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Gagnon, Cynthia
AU  - Gagnon C
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
FAU - Bouchard, Luigi
AU  - Bouchard L
AD  - Department of Biochemistry (C.L., S.-P.G., L.B.), Universite de Sherbrooke, 
      Sherbrooke; ECOGENE-21 Biocluster (C.L., S.-P.G., L.B.), Chicoutimi, Quebec, 
      Canada; Groupe de Recherche interdisciplinaire sur les maladies neuromusculaires 
      (C.L., J.M., C.G., L.B.), Saguenay, Canada; Institute of Molecular (G.O., 
      D.G.M.), Cell and Systems Biology, University of Glasgow, United Kingdom; and 
      Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-StJean sur les innovations en 
      sante (J.M., C.G.), Faculte de medecine et des sciences de la sante, Universite 
      de Sherbrooke, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190523
PL  - United States
TA  - Neurol Genet
JT  - Neurology. Genetics
JID - 101671068
PMC - PMC6568328
EDAT- 2019/07/25 06:00
MHDA- 2019/07/25 06:01
PMCR- 2019/05/23
CRDT- 2019/07/24 06:00
PHST- 2019/01/31 00:00 [received]
PHST- 2019/04/03 00:00 [revised]
PHST- 2019/04/04 00:00 [accepted]
PHST- 2019/07/24 06:00 [entrez]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2019/07/25 06:01 [medline]
PHST- 2019/05/23 00:00 [pmc-release]
AID - NG2019010165 [pii]
AID - 10.1212/NXG.0000000000000338 [doi]
PST - epublish
SO  - Neurol Genet. 2019 May 23;5(3):e338. doi: 10.1212/NXG.0000000000000338. 
      eCollection 2019 Jun.

PMID- 31316546
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 10
DP  - 2019
TI  - Robust Preimplantation Genetic Testing Strategy for Myotonic Dystrophy Type 1 by 
      Bidirectional Triplet-Primed Polymerase Chain Reaction Combined With 
      Multi-microsatellite Haplotyping Following Whole-Genome Amplification.
PG  - 589
LID - 10.3389/fgene.2019.00589 [doi]
LID - 589
AB  - Myotonic dystrophy type 1 (DM1) is caused by expansion of the DMPK CTG 
      trinucleotide repeat. Disease transmission to offspring can be avoided through 
      prenatal diagnosis or preimplantation genetic testing for monogenic disorders 
      (PGT-M). We describe a robust strategy for DM1 PGT-M that can be applied to 
      virtually any at-risk couple. This strategy utilizes whole-genome amplification, 
      followed by triplet-primed PCR (TP-PCR) detection of expanded DMPK alleles, in 
      parallel with single-tube haplotype analysis of 12 closely linked and highly 
      polymorphic microsatellite markers. Bidirectional TP-PCR and dodecaplex marker 
      PCR assays were optimized and validated on whole-genome amplified single 
      lymphoblasts isolated from DM1 reference cell lines, and tested on a simulated 
      PGT-M case comprising a parent-offspring trio and three simulated embryos. 
      Bidirectional DMPK TP-PCR reliably detects repeat expansions even in the presence 
      of non-CTG interruptions at either end of the expanded allele. Misdiagnoses, 
      diagnostic ambiguity, and couple-specific assay customization are further 
      minimized by the use of multi-marker haplotyping, preventing the loss of 
      potentially unaffected embryos for transfer.
FAU - Lian, Mulias
AU  - Lian M
AD  - Department of Pediatrics, Khoo Teck Puat - National University Children's Medical 
      Institute, National University Health System, Singapore, Singapore.
FAU - Lee, Caroline G
AU  - Lee CG
AD  - Department of Biochemistry, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
AD  - Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, 
      Singapore, Singapore.
AD  - Division of Medical Sciences, National Cancer Center, Singapore, Singapore.
FAU - Chong, Samuel S
AU  - Chong SS
AD  - Department of Pediatrics, Khoo Teck Puat - National University Children's Medical 
      Institute, National University Health System, Singapore, Singapore.
AD  - Department of Pediatrics, Yong Loo Lin School of Medicine, National University of 
      Singapore, Singapore, Singapore.
AD  - Department of Laboratory Medicine, National University Hospital, National 
      University Health System, Singapore, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20190626
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC6611416
OTO - NOTNLM
OT  - DMPK
OT  - haplotype analysis
OT  - myotonic dystrophy type 1
OT  - preimplantation genetic testing
OT  - triplet-primed polymerase chain reaction
EDAT- 2019/07/19 06:00
MHDA- 2019/07/19 06:01
PMCR- 2019/06/26
CRDT- 2019/07/19 06:00
PHST- 2018/08/24 00:00 [received]
PHST- 2019/06/04 00:00 [accepted]
PHST- 2019/07/19 06:00 [entrez]
PHST- 2019/07/19 06:00 [pubmed]
PHST- 2019/07/19 06:01 [medline]
PHST- 2019/06/26 00:00 [pmc-release]
AID - 10.3389/fgene.2019.00589 [doi]
PST - epublish
SO  - Front Genet. 2019 Jun 26;10:589. doi: 10.3389/fgene.2019.00589. eCollection 2019.

PMID- 31306140
OWN - NLM
STAT- MEDLINE
DCOM- 20200217
LR  - 20210110
IS  - 2214-3602 (Electronic)
IS  - 2214-3599 (Print)
VI  - 6
IP  - 3
DP  - 2019
TI  - Brain Structural Features of Myotonic Dystrophy Type 1 and their Relationship 
      with CTG Repeats.
PG  - 321-332
LID - 10.3233/JND-190397 [doi]
AB  - BACKGROUND: Few adequately-powered studies have systematically evaluated brain 
      morphology in adult-onset myotonic dystrophy type 1 (DM1). OBJECTIVE: The goal of 
      the present study was to determine structural brain differences between 
      individuals with and without adult-onset DM1 in a multi-site, case-controlled 
      cohort. We also explored correlations between brain structure and CTG repeat 
      length. METHODS: Neuroimaging data was acquired in 58 unaffected individuals (29 
      women) and 79 individuals with DM1 (50 women). CTG repeat length, expressed as 
      estimated progenitor allele length (ePAL), was determined by small pool PCR. 
      Statistical models were adjusted for age, sex, site, and intracranial volume 
      (ICV). RESULTS: ICV was reduced in DM1 subjects compared with controls. 
      Accounting for the difference in ICV, the DM1 group exhibited smaller volume in 
      frontal grey and white matter, parietal grey matter as well as smaller volume of 
      the corpus callosum, thalamus, putamen, and accumbens. In contrast, volumes of 
      the hippocampus and amygdala were significantly larger in DM1. Greater ePAL was 
      associated with lower volumes of the putamen, occipital grey matter, and 
      thalamus. A positive ePAL association was observed for amygdala volume and 
      cerebellar white matter. CONCLUSIONS: Smaller ICV may be a marker of aberrant 
      neurodevelopment in adult-onset DM1. Volumetric analysis revealed morphological 
      differences, some associated with CTG repeat length, in structures with plausible 
      links to key DM1 symptoms including cognitive deficits and excessive daytime 
      somnolence. These data offer further insights into the basis of CNS disease in 
      DM1, and highlight avenues for further work to identify therapeutic targets and 
      imaging biomarkers.
FAU - van der Plas, Ellen
AU  - van der Plas E
AD  - Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
FAU - Hamilton, Mark J
AU  - Hamilton MJ
AD  - West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, 
      Glasgow, UK.
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Miller, Jacob N
AU  - Miller JN
AD  - Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
FAU - Koscik, Timothy R
AU  - Koscik TR
AD  - Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
FAU - Long, Jeffrey D
AU  - Long JD
AD  - Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
AD  - Department of Biostatistics, University of Iowa, College of Public Health, Iowa 
      City, IA, USA.
FAU - Cumming, Sarah
AU  - Cumming S
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Povilaikaite, Julija
AU  - Povilaikaite J
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Farrugia, Maria Elena
AU  - Farrugia ME
AD  - Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, Glasgow, UK.
FAU - McLean, John
AU  - McLean J
AD  - Department of Neuroradiology, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, Glasgow, UK.
FAU - Jampana, Ravi
AU  - Jampana R
AD  - Department of Neuroradiology, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, Glasgow, UK.
FAU - Magnotta, Vincent A
AU  - Magnotta VA
AD  - Department of Radiology, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
FAU - Gutmann, Laurie
AU  - Gutmann L
AD  - Department of Neurology, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Nopoulos, Peggy C
AU  - Nopoulos PC
AD  - Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, 
      USA.
LA  - eng
GR  - CAF/MD/15/01/CSO_/Chief Scientist Office/United Kingdom
GR  - R01 NS094387/NS/NINDS NIH HHS/United States
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
SB  - IM
MH  - Adult
MH  - Brain/*pathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Sex Factors
MH  - *Trinucleotide Repeat Expansion
PMC - PMC7480174
MID - NIHMS1623355
OTO - NOTNLM
OT  - Myotonic dystrophy
OT  - magnetic resonance imaging
OT  - neuroanatomy
COIS- CONFLICT OF INTEREST Ellen van der Plas- reports no disclosures Mark J. Hamilton- 
      reports no disclosures Jacob N. Miller- reports no disclosures Timothy R. Koscik- 
      reports no disclosures Jeffrey D. Long- is a paid advisory board member for F. 
      Hoffmann-La Roche Ltd, Wave Life Sciences USA Inc, Huntington Study Group, 
      Mitoconix Bio Limited, a paid consultant for Vaccinex Inc and Azevan 
      Pharmaceuticals Inc, and is funded by CHDI Inc, Michael J. Fox Foundation, and 
      National Institutes of Health (USA). Sarah Cumming- reports no disclosures Julija 
      Povilaikaite- reports no disclosures Maria Elena Farrugia- reports no disclosures 
      John McLean- reports no disclosures Ravi Jampana- reports no disclosures Vincent 
      A. Magnotta- reports no disclosures Laurie Gutmann- reports no disclosures Darren 
      Monckton- has been a scientific consultant and/or received an honoraria or stock 
      options from Biogen Idec, AMO Pharma, Charles River, Vertex Pharmaceuticals, 
      Triplet Therapeutics, LoQus23, BridgeBio, and Small Molecule RNA. Darren Monckton 
      is on the Scientific Advisory Board of the Myotonic Dystrophy Foundation, is a 
      scientific advisor to the Myotonic Dystrophy Support Group and is a vice 
      president of Muscular Dystrophy UK. Peggy C. Nopoulos- reports no disclosures
EDAT- 2019/07/16 06:00
MHDA- 2020/02/18 06:00
PMCR- 2020/09/09
CRDT- 2019/07/16 06:00
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2020/02/18 06:00 [medline]
PHST- 2019/07/16 06:00 [entrez]
PHST- 2020/09/09 00:00 [pmc-release]
AID - JND190397 [pii]
AID - 10.3233/JND-190397 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2019;6(3):321-332. doi: 10.3233/JND-190397.

PMID- 31271118
OWN - NLM
STAT- MEDLINE
DCOM- 20200309
LR  - 20200309
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 58
IP  - 10
DP  - 2019 Oct
TI  - An investigative expansion of a competing risk model for first failure site in 
      locally advanced non-small cell lung cancer.
PG  - 1386-1392
LID - 10.1080/0284186X.2019.1631475 [doi]
AB  - Introduction: We hypothesized that gross tumor volume (GTV) of primary tumor 
      (GTV(T)) and nodal volumes (GTV(N)) were predictors of first failure site in 
      non-small cell lung cancer (NSCLC). We aimed at also comparing the prognostic 
      model's complexity to its ability to generate absolute risk predictions with 
      emphasis on variables available at the time of diagnosis. Materials and methods: 
      Three hundred and forty-two patients treated with definitive chemoradiotherapy 
      (CRT) for adenocarcinoma (AC) or squamous cell carcinoma (SCC) in 2009-2017 were 
      analyzed. Clinical data, standardized uptake values on FDG-PET/CT, GTV(T) and 
      GTV(N) were analyzed using multivariate competing risk models. Results: One 
      hundred and thirty-seven patients had SCC. As first site of failure 49 had 
      locoregional failure (LRF), 40 had distant metastasis (DM) and 24 died with no 
      evidence of disease (NED). In 205 patients with AC, 34 had LRF, 118 had DM as 
      first failure site and 17 died with NED. Performance status predicted LRF 
      (p = .02) and UICC stage risk of DM (p = .05 for stage 3, p < .001 for stage 4). 
      Adding histopathology changed predictions with much reduced risk of LRF in AC 
      compared to SCC (HR = 0.5, 95% CI: (0.3-0.75), p = .001). Conversely, AC had a 
      higher rate of DM than SCC (HR = 2.1, 95% CI: (1.5-3.0], p < .001). Addition of 
      FDG metrics and tumor/nodal volume data predicted DM risk (p = .001), but with 
      smaller impact on absolute risk compared to histopathology. Separation of GTV in 
      nodal and tumor lesions did not improve risk predictions. Conclusions: We 
      quantified the effect of adding volumetric and quantitative imaging to competing 
      risk models of first failure site, but did not find tumor volume components to be 
      important. Histopathology remains the simplest and most important factor in 
      prognosticating failure patterns in NSCLC.
FAU - Lacoppidan, Thomas
AU  - Lacoppidan T
AUID- ORCID: 0000-0002-6705-3153
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
FAU - Vogelius, Ivan R
AU  - Vogelius IR
AUID- ORCID: 0000-0002-8877-1218
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
AD  - Department of Clinical Medicine, Faculty of Health Sciences, Copenhagen 
      University , Denmark.
FAU - Pohl, Mette
AU  - Pohl M
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
FAU - Strange, Malene
AU  - Strange M
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
FAU - Persson, Gitte F
AU  - Persson GF
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
AD  - Department of Clinical Medicine, Faculty of Health Sciences, Copenhagen 
      University , Denmark.
AD  - Department of Oncology, Herlev-Gentofte Hospital, Copenhagen University , Herlev 
      , Denmark.
FAU - Nygard, Lotte
AU  - Nygard L
AUID- ORCID: 0000-0003-0408-1007
AD  - Department of Oncology, Rigshospitalet, Copenhagen University Hospital , 
      Copenhagen , Denmark.
LA  - eng
PT  - Journal Article
DEP - 20190704
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adenocarcinoma of Lung/diagnostic imaging/mortality/pathology/*therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/mortality/pathology/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Female
MH  - Fluorodeoxyglucose F18/administration & dosage
MH  - Follow-Up Studies
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung/diagnostic imaging/pathology/radiation effects
MH  - Lung Neoplasms/diagnostic imaging/mortality/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - *Models, Biological
MH  - Neoplasm Recurrence, Local/*diagnosis/epidemiology/prevention & control
MH  - Positron Emission Tomography Computed Tomography
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Radiotherapy Planning, Computer-Assisted/methods
MH  - Retrospective Studies
MH  - Risk Assessment/methods
MH  - Tumor Burden/radiation effects
EDAT- 2019/07/05 06:00
MHDA- 2020/03/10 06:00
CRDT- 2019/07/05 06:00
PHST- 2019/07/05 06:00 [pubmed]
PHST- 2020/03/10 06:00 [medline]
PHST- 2019/07/05 06:00 [entrez]
AID - 10.1080/0284186X.2019.1631475 [doi]
PST - ppublish
SO  - Acta Oncol. 2019 Oct;58(10):1386-1392. doi: 10.1080/0284186X.2019.1631475. Epub 
      2019 Jul 4.

PMID- 31253581
OWN - NLM
STAT- MEDLINE
DCOM- 20200529
LR  - 20240104
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 27
IP  - 8
DP  - 2019 Aug 7
TI  - Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear 
      RNA Foci in the Muscle of DM1 Mice.
PG  - 1372-1388
LID - S1525-0016(19)30268-0 [pii]
LID - 10.1016/j.ymthe.2019.05.021 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by a CTG repeat expansion located in 
      the 3' UTR of the DMPK gene. Expanded DMPK transcripts aggregate into nuclear 
      foci and alter the function of RNA-binding proteins, leading to defects in the 
      alternative splicing of numerous pre-mRNAs. To date, there is no curative 
      treatment for DM1. Here we investigated a gene-editing strategy using the 
      CRISPR-Cas9 system from Staphylococcus aureus (Sa) to delete the CTG repeats in 
      the human DMPK locus. Co-expression of SaCas9 and selected pairs of single-guide 
      RNAs (sgRNAs) in cultured DM1 patient-derived muscle line cells carrying 2,600 
      CTG repeats resulted in targeted DNA deletion, ribonucleoprotein foci 
      disappearance, and correction of splicing abnormalities in various transcripts. 
      Furthermore, a single intramuscular injection of recombinant AAV vectors 
      expressing CRISPR-SaCas9 components in the tibialis anterior muscle of DMSXL 
      (myotonic dystrophy mouse line carrying the human DMPK gene with >1,000 CTG 
      repeats) mice decreased the number of pathological RNA foci in myonuclei. These 
      results establish the proof of concept that genome editing of a large 
      trinucleotide expansion is feasible in muscle and may represent a useful strategy 
      to be further developed for the treatment of myotonic dystrophy.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Lo Scrudato, Mirella
AU  - Lo Scrudato M
AD  - Genethon, INSERM UMR_S951, Univ Evry, Universite Paris Saclay, 91000 Evry, 
      France.
FAU - Poulard, Karine
AU  - Poulard K
AD  - Genethon, INSERM UMR_S951, Univ Evry, Universite Paris Saclay, 91000 Evry, 
      France.
FAU - Sourd, Celia
AU  - Sourd C
AD  - Genethon, INSERM UMR_S951, Univ Evry, Universite Paris Saclay, 91000 Evry, 
      France.
FAU - Tome, Stephanie
AU  - Tome S
AD  - INSERM UMR 1163, Institut Imagine, Universite Paris Descartes-Sorbonne Paris 
      Cite, 75015 Paris, France.
FAU - Klein, Arnaud F
AU  - Klein AF
AD  - INSERM, Association Institut de Myologie, Centre de Recherche en Myologie, 
      Sorbonne Universite, 75013 Paris, France.
FAU - Corre, Guillaume
AU  - Corre G
AD  - Genethon, INSERM UMR_S951, Univ Evry, Universite Paris Saclay, 91000 Evry, 
      France.
FAU - Huguet, Aline
AU  - Huguet A
AD  - INSERM UMR 1163, Institut Imagine, Universite Paris Descartes-Sorbonne Paris 
      Cite, 75015 Paris, France.
FAU - Furling, Denis
AU  - Furling D
AD  - INSERM, Association Institut de Myologie, Centre de Recherche en Myologie, 
      Sorbonne Universite, 75013 Paris, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - INSERM UMR 1163, Institut Imagine, Universite Paris Descartes-Sorbonne Paris 
      Cite, 75015 Paris, France.
FAU - Buj-Bello, Ana
AU  - Buj-Bello A
AD  - Genethon, INSERM UMR_S951, Univ Evry, Universite Paris Saclay, 91000 Evry, 
      France. Electronic address: abujbello@genethon.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190605
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Guide, CRISPR-Cas Systems)
RN  - 0 (RNA, Nuclear)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Base Sequence
MH  - CRISPR-Cas Systems
MH  - Cell Nucleus
MH  - Disease Models, Animal
MH  - Fluorescent Antibody Technique
MH  - *Gene Editing
MH  - Gene Expression
MH  - Gene Targeting
MH  - Genetic Vectors/genetics
MH  - Humans
MH  - Mice
MH  - Mice, Knockout
MH  - Muscle, Skeletal/metabolism/pathology
MH  - Myotonic Dystrophy/genetics/therapy
MH  - Myotonin-Protein Kinase/*genetics
MH  - RNA, Guide, CRISPR-Cas Systems
MH  - *RNA, Nuclear
MH  - Transduction, Genetic
MH  - *Trinucleotide Repeat Expansion
PMC - PMC6697452
OTO - NOTNLM
OT  - CRISPR-Cas9
OT  - DMPK
OT  - gene therapy
OT  - myotonic dystrophy
OT  - nucleotide repeat disorders
EDAT- 2019/06/30 06:00
MHDA- 2020/05/30 06:00
PMCR- 2020/08/07
CRDT- 2019/06/30 06:00
PHST- 2018/09/24 00:00 [received]
PHST- 2019/05/22 00:00 [revised]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/06/30 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
PHST- 2019/06/30 06:00 [entrez]
PHST- 2020/08/07 00:00 [pmc-release]
AID - S1525-0016(19)30268-0 [pii]
AID - 10.1016/j.ymthe.2019.05.021 [doi]
PST - ppublish
SO  - Mol Ther. 2019 Aug 7;27(8):1372-1388. doi: 10.1016/j.ymthe.2019.05.021. Epub 2019 
      Jun 5.

PMID- 31227653
OWN - NLM
STAT- MEDLINE
DCOM- 20200217
LR  - 20200217
IS  - 2214-3602 (Electronic)
VI  - 6
IP  - 3
DP  - 2019
TI  - A Phenotypic Description of Congenital Myotonic Dystrophy using PhenoStacks.
PG  - 341-347
LID - 10.3233/JND-180345 [doi]
AB  - BACKGROUND: Congenital Myotonic Dystrophy (CDM1) is a rare neuromuscular 
      condition caused by a triplet repeat expansion in the DMPK gene. Despite there 
      being a well-recognized clinical syndrome, there has not been an effort to use a 
      standardized ontology system to describe the disease characteristics in existing 
      literature. Thus, comparing or contrasting different cohorts from the literature 
      can be challenging, and coding disease features for clinical research or for 
      registry data items is not uniform. PhenoStacks is a visualization analytics tool 
      which helps graphically illustrate phenotypes of patients with genetic disorders 
      using Human Phenotype Ontology (HPO) terms and can sort phenotypes by different 
      disease characteristics. OBJECTIVE: To demonstrate the efficacy of PhenoStacks 
      and the HPO system as clinical research tools when describing CDM1 cohorts. 
      METHODS: Health Endpoints and Longitudinal progression in congenital myotonic 
      dystrophy (HELP-CDM) is an ongoing study which longitudinally follows patients 
      with CDM1. Items from the HELP-CDM data sheet were matched to corresponding HPO 
      terms and analyzed using PhenoStacks. RESULTS: In total 40 subjects' phenotypes 
      were visualized through PhenoStacks and 73 HPO terms were used for the analysis. 
      Frequent phenotypic features included "high narrow palate", "facial palsy", 
      "ptosis", "hyporeflexia", and "weak voice". Contractures were associated with 
      higher repeat sizes. Hypoplastic muscles and infantile axial hypotonia were more 
      frequently observed in infants. CONCLUSIONS: PhenoStacks is a valuable clinical 
      and scientific tool as it identifies variability within cohorts and highlights 
      significant phenotypic features.
FAU - Prasad, Madhavi
AU  - Prasad M
AD  - Schulich School of Medicine and Dentistry, London, Canada.
FAU - Glueck, Michael
AU  - Glueck M
AD  - Department of Computer Science, University of Toronto, Toronto, Canada.
FAU - Ceballos-Saenz, Delia
AU  - Ceballos-Saenz D
AD  - Department of Pediatrics, Clinical Neurological Sciences and Epidemiology, 
      Western University, London, Canada.
FAU - Zapata-Aldana, Eugenio
AU  - Zapata-Aldana E
AD  - Department of Pediatrics, Clinical Neurological Sciences and Epidemiology, 
      Western University, London, Canada.
FAU - Johnson, Nicholas
AU  - Johnson N
AD  - University of Utah School of Medicine, Utah, United States.
FAU - Campbell, Craig
AU  - Campbell C
AD  - Department of Pediatrics, Clinical Neurological Sciences and Epidemiology, 
      Western University, London, Canada.
FAU - Nguyen, Cam-Tu Emilie
AU  - Nguyen CE
AD  - Pediatric Neurology, CHU Sainte-Justine, Universite de Montreal, Montreal, 
      Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
SB  - IM
MH  - Adolescent
MH  - *Biological Ontologies
MH  - Child
MH  - Child, Preschool
MH  - Disease Progression
MH  - Humans
MH  - Infant
MH  - Longitudinal Studies
MH  - Myotonic Dystrophy/*genetics
MH  - *Phenotype
OTO - NOTNLM
OT  - Human Phenotype Ontology
OT  - Myotonic dystrophy
OT  - PhenoStacks
OT  - congenital
EDAT- 2019/06/23 06:00
MHDA- 2020/02/18 06:00
CRDT- 2019/06/23 06:00
PHST- 2019/06/23 06:00 [pubmed]
PHST- 2020/02/18 06:00 [medline]
PHST- 2019/06/23 06:00 [entrez]
AID - JND180345 [pii]
AID - 10.3233/JND-180345 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2019;6(3):341-347. doi: 10.3233/JND-180345.

PMID- 31220271
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20200701
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 28
IP  - 13
DP  - 2019 Jul 1
TI  - Allele length of the DMPK CTG repeat is a predictor of progressive myotonic 
      dystrophy type 1 phenotypes.
PG  - 2245-2254
LID - 10.1093/hmg/ddz055 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited disorder 
      caused by expansion of a germline and somatically unstable CTG repeat in the DMPK 
      gene. Previously, CTG repeat length at birth has been correlated to patient age 
      at symptom onset. Attempts to correlate CTG repeat length with progressive DM1 
      phenotypes, such as muscle power, have proven difficult. To better correlate 
      genotype with progressive phenotypes, we have measured CTG repeat tract length 
      and screened for interrupting variant repeats in 192 study participants from a 
      well-characterized Canadian cohort. We have assessed genotype-phenotype 
      correlations with nine progressive measures of skeletal muscle power and 
      respiratory function. We have built statistical models that include confounding 
      factors such as sex, age, height and weight to further explain variation in 
      muscle power. Our analysis reveals a strong correlation between DM1 genotype and 
      respiratory function and skeletal muscle power, as part of a complex model that 
      includes additional modulators such as sex, age, height, weight and the presence 
      or absence of interrupting variant repeats. Distal skeletal muscle measurements, 
      such as hand pinch and grip strength, show the strongest correlation with disease 
      genotype. Detailed analysis of CTG repeat length, and incorporation of 
      confounding factors, greatly improves the predictive ability of these models. 
      They reveal a greater genetic influence on individual progressive phenotypes than 
      on age at symptom onset and for clinical trials will help optimize stratification 
      and explain patient variability. They will also help practitioners prioritize 
      assessment of the muscular power measurements that correlate best with disease 
      severity.
CI  - (c) The Author(s) 2019. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Overend, Gayle
AU  - Overend G
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Legare, Cecilia
AU  - Legare C
AD  - Department of Biochemistry, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
AD  - ECOGENE Biocluster, Chicoutimi, Quebec, Canada.
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires, Centre 
      integre universitaire de sante et de services sociaux du Saguenay-Lac-St-Jean, 
      rue de l'Hopital, Saguenay, Quebec, Canada.
FAU - Mathieu, Jean
AU  - Mathieu J
AD  - Ecole de readaptation, Faculte de medecine et des sciences de la sante, 
      Universite de Sherbrooke, Sherbrooke, Canada.
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires, Centre 
      integre universitaire de sante et de services sociaux du Saguenay-Lac-St-Jean, 
      rue de l'Hopital, Saguenay, Quebec, Canada.
FAU - Bouchard, Luigi
AU  - Bouchard L
AD  - Department of Biochemistry, Universite de Sherbrooke, Sherbrooke, Quebec, Canada.
AD  - ECOGENE Biocluster, Chicoutimi, Quebec, Canada.
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires, Centre 
      integre universitaire de sante et de services sociaux du Saguenay-Lac-St-Jean, 
      rue de l'Hopital, Saguenay, Quebec, Canada.
FAU - Gagnon, Cynthia
AU  - Gagnon C
AD  - Ecole de readaptation, Faculte de medecine et des sciences de la sante, 
      Universite de Sherbrooke, Sherbrooke, Canada.
AD  - Groupe de recherche interdisciplinaire sur les maladies neuromusculaires, Centre 
      integre universitaire de sante et de services sociaux du Saguenay-Lac-St-Jean, 
      rue de l'Hopital, Saguenay, Quebec, Canada.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alleles
MH  - Canada
MH  - Cohort Studies
MH  - Female
MH  - Genetic Association Studies
MH  - Genotype
MH  - Hand Strength/physiology
MH  - Humans
MH  - Male
MH  - Models, Statistical
MH  - Muscle, Skeletal/*physiopathology
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Phenotype
MH  - Respiratory Function Tests
MH  - *Trinucleotide Repeat Expansion
PMC - PMC6586140
EDAT- 2019/06/21 06:00
MHDA- 2020/03/31 06:00
PMCR- 2020/07/01
CRDT- 2019/06/21 06:00
PHST- 2019/01/23 00:00 [received]
PHST- 2019/03/13 00:00 [revised]
PHST- 2019/03/13 00:00 [accepted]
PHST- 2019/06/21 06:00 [entrez]
PHST- 2019/06/21 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
PHST- 2020/07/01 00:00 [pmc-release]
AID - 5382376 [pii]
AID - ddz055 [pii]
AID - 10.1093/hmg/ddz055 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2019 Jul 1;28(13):2245-2254. doi: 10.1093/hmg/ddz055.

PMID- 31164682
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20210109
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Jun 4
TI  - Robust and accurate detection and sizing of repeats within the DMPK gene using a 
      novel TP-PCR test.
PG  - 8280
LID - 10.1038/s41598-019-44588-3 [doi]
LID - 8280
AB  - Myotonic dystrophy type 1 is a multisystem disorder caused by the expansion of a 
      trinucleotide repeat in the DMPK gene. In this study we evaluated the performance 
      of the FastDM1(TM) DMPK sizing kit in myotonic dystrophy type 1 testing. This 
      commercially available triplet repeat-primed PCR based kit was validated using 
      reference and clinical samples. Based on testing with 19 reference samples, the 
      assay yielded repeat sizes within three repeats from the consensus reference 
      length, demonstrating an accuracy of 100%. Additionally, the assay generated 
      consistent repeat size information with a concentration range of template-DNA, 
      and upon repetition and reproduction (CV 0.36% to 0.41%). Clinical performance 
      was established with 235 archived prenatal and postnatal clinical samples, 
      yielding results of 100% sensitivity (95% CI, 97.29% to 100%) and 100% 
      specificity (95% CI, 96.19% to 100%) in classifying the samples into the 
      respective genotype groups of 5-35 (normal), 36-50 (non-pathogenic 
      pre-expansion), 51-150 (unstable intermediate-sized pathogenic) or >150 (unstable 
      pathogenic) CTG repeats, respectively. Furthermore, the assay identified 
      interrupted repeat expansions in all samples known to have interruptions, and 
      also identified interruptions in a subset of the clinical samples.
FAU - Leferink, Maike
AU  - Leferink M
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Center, 
      Nijmegen, The Netherlands.
FAU - Wong, Daphne P W
AU  - Wong DPW
AD  - The BioFactory Pte Ltd, Singapore, Republic of Singapore.
FAU - Cai, Shiwei
AU  - Cai S
AD  - The BioFactory Pte Ltd, Singapore, Republic of Singapore.
FAU - Yeo, Minli
AU  - Yeo M
AD  - The BioFactory Pte Ltd, Singapore, Republic of Singapore.
FAU - Ho, Jocelin
AU  - Ho J
AD  - The BioFactory Pte Ltd, Singapore, Republic of Singapore.
FAU - Lian, Mulias
AU  - Lian M
AD  - Khoo Teck Puat - National University Children's Medical Institute, National 
      University Health System, Singapore, Republic of Singapore.
FAU - Kamsteeg, Erik-Jan
AU  - Kamsteeg EJ
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Center, 
      Nijmegen, The Netherlands.
FAU - Chong, Samuel S
AU  - Chong SS
AD  - Khoo Teck Puat - National University Children's Medical Institute, National 
      University Health System, Singapore, Republic of Singapore.
AD  - Department of Paediatrics, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Republic of Singapore.
AD  - Department of Laboratory Medicine, National University Hospital, Singapore, 
      Republic of Singapore.
FAU - Haer-Wigman, Lonneke
AU  - Haer-Wigman L
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Center, 
      Nijmegen, The Netherlands. Lonneke.Haer-Wigman@radboudumc.nl.
FAU - Guan, Ming
AU  - Guan M
AD  - The BioFactory Pte Ltd, Singapore, Republic of Singapore.
LA  - eng
PT  - Journal Article
DEP - 20190604
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Genotype
MH  - Humans
MH  - Myotonic Dystrophy/diagnosis/*genetics/pathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats/*genetics
PMC - PMC6547747
COIS- The authors declare no competing interests.
EDAT- 2019/06/06 06:00
MHDA- 2020/10/27 06:00
PMCR- 2019/06/04
CRDT- 2019/06/06 06:00
PHST- 2019/01/28 00:00 [received]
PHST- 2019/04/17 00:00 [accepted]
PHST- 2019/06/06 06:00 [entrez]
PHST- 2019/06/06 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2019/06/04 00:00 [pmc-release]
AID - 10.1038/s41598-019-44588-3 [pii]
AID - 44588 [pii]
AID - 10.1038/s41598-019-44588-3 [doi]
PST - epublish
SO  - Sci Rep. 2019 Jun 4;9(1):8280. doi: 10.1038/s41598-019-44588-3.

PMID- 31118244
OWN - NLM
STAT- MEDLINE
DCOM- 20191223
LR  - 20210325
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 92
IP  - 24
DP  - 2019 Jun 11
TI  - Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by 
      quantitative MRI.
PG  - e2803-e2814
LID - 10.1212/WNL.0000000000007648 [doi]
AB  - OBJECTIVE: To determine the value of quantitative MRI in providing imaging 
      biomarkers for disease in 20 different upper and lower leg muscles of patients 
      with myotonic dystrophy type 1 (DM1). METHODS: We acquired images covering these 
      muscles in 33 genetically and clinically well-characterized patients with DM1 and 
      10 unaffected controls. MRIs were recorded with a Dixon method to determine 
      muscle fat fraction, muscle volume, and contractile muscle volume, and a 
      multi-echo spin-echo sequence was used to determine T2 water relaxation time 
      (T2(water)), reflecting putative edema. RESULTS: Muscles in patients with DM1 had 
      higher fat fractions than muscles of controls (15.6 +/- 11.1% vs 3.7 +/- 1.5%). In 
      addition, patients had smaller muscle volumes (902 +/- 232 vs 1,097 +/- 251 cm(3)), 
      smaller contractile muscle volumes (779 +/- 247 vs 1,054 +/- 246 cm(3)), and 
      increased T2(water) (33.4 +/- 1.0 vs 31.9 +/- 0.6 milliseconds), indicating atrophy 
      and edema, respectively. Lower leg muscles were affected most frequently, 
      especially the gastrocnemius medialis and soleus. Distribution of fat content per 
      muscle indicated gradual fat infiltration in DM1. Between-patient variation in 
      fat fraction was explained by age ( approximately 45%), and another  approximately 14% was explained by 
      estimated progenitor CTG repeat length (r (2) = 0.485) and somatic instability (r 
      (2) = 0.590). Fat fraction correlated with the 6-minute walk test (r = -0.553) 
      and muscular impairment rating scale (r = 0.537) and revealed subclinical muscle 
      involvement. CONCLUSION: This cross-sectional quantitative MRI study of 20 
      different lower extremity muscles in patients with DM1 revealed abnormal values 
      for muscle fat fraction, volume, and T2(water), which therefore may serve as 
      objective biomarkers to assess disease state of skeletal muscles in these 
      patients. CLINICALTRIALSGOV IDENTIFIER: NCT02118779.
CI  - Copyright (c) 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Heskamp, Linda
AU  - Heskamp L
AUID- ORCID: 0000-0002-6828-9336
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK. 
      linda.heskamp@radboudumc.nl.
FAU - van Nimwegen, Marlies
AU  - van Nimwegen M
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Ploegmakers, Marieke J
AU  - Ploegmakers MJ
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Bassez, Guillaume
AU  - Bassez G
AUID- ORCID: 0000-0002-2044-1052
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Deux, Jean-Francois
AU  - Deux JF
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Cumming, Sarah A
AU  - Cumming SA
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - van Engelen, Baziel G M
AU  - van Engelen BGM
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
FAU - Heerschap, Arend
AU  - Heerschap A
AD  - From the Department of Radiology and Nuclear Medicine (L.H., M.J.P., A.H.) and 
      Department of Neurology (M.v.N., B.G.M.v.E.), Radboud University Medical Center, 
      Nijmegen, the Netherlands; Neuromuscular Reference Center (G.B.), Sorbonne 
      University, INSERM UMRS 974, AP-HP, Pitie-Salpetriere Hospital; Department of 
      Radiology (J.-F.D.), Henri Mondor University Hospital, Paris, France; and 
      Institute of Molecular, Cell and Systems Biology (S.A.C., D.G.M.), College of 
      Medical, Veterinary and Life Sciences, University of Glasgow, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02118779
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190522
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adipose Tissue/*diagnostic imaging/pathology
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Lower Extremity/diagnostic imaging/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*diagnostic imaging/pathology
MH  - Myotonic Dystrophy/*diagnostic imaging/genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Organ Size
PMC - PMC6598795
EDAT- 2019/05/24 06:00
MHDA- 2019/12/24 06:00
PMCR- 2019/06/11
CRDT- 2019/05/24 06:00
PHST- 2018/09/21 00:00 [received]
PHST- 2019/02/07 00:00 [accepted]
PHST- 2019/05/24 06:00 [pubmed]
PHST- 2019/12/24 06:00 [medline]
PHST- 2019/05/24 06:00 [entrez]
PHST- 2019/06/11 00:00 [pmc-release]
AID - WNL.0000000000007648 [pii]
AID - NEUROLOGY2018939884 [pii]
AID - 10.1212/WNL.0000000000007648 [doi]
PST - ppublish
SO  - Neurology. 2019 Jun 11;92(24):e2803-e2814. doi: 10.1212/WNL.0000000000007648. 
      Epub 2019 May 22.

PMID- 31027145
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 17
DP  - 2019 Apr
TI  - Massive abscess with prolonged respiratory failure due to newly diagnosed 
      myotonic dystrophy: A case report.
PG  - e15427
LID - 10.1097/MD.0000000000015427 [doi]
LID - e15427
AB  - RATIONALE: Myotonic dystrophy is a progressive multisystem genetic heterogeneous 
      disorder. General anesthesia with opioids increases the risk of prolonged 
      postanesthetic respiratory recovery in myotonic dystrophy patients. PATIENT 
      CONCERNS: A 20-year-old previously healthy woman was transferred to our emergency 
      department for further workup of respiratory failure, and massive ascites with 
      abscess caused by endometriosis. Hypercapnic respiratory failure persisted under 
      intensive care unit (ICU) management, but finally improved after cessation of 
      fentanyl as a sedative agent. DIAGNOSIS: Myotonic dystrophy type 1. 
      INTERVENTIONS: Massive ascites with abscess was accordingly managed by drainage, 
      antibiotics, and an antifungal agent. Myotonic dystrophy type 1 was confirmed 
      after molecular genetic testing revealed a cytosine-thymine-guanine repeat length 
      of 400 to 450 in the DMPK gene. OUTCOMES: The patient was discharged without 
      complications on hospital day 69. LESSONS: Myotonic dystrophy should be 
      considered when hypercapnic respiratory failure persists in sedated ICU patients. 
      Opioids should not be used for perioperative management of patients with myotonic 
      dystrophy.
FAU - Ota, Koshi
AU  - Ota K
AD  - Department of Emergency Medicine.
FAU - Nakamura, Yoshitsugu
AU  - Nakamura Y
AD  - Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, 
      Osaka, Japan.
FAU - Nakamura, Eriko
AU  - Nakamura E
AD  - Department of Emergency Medicine.
FAU - Takashima, Shogo
AU  - Takashima S
AD  - Department of Emergency Medicine.
FAU - Oka, Masahiro
AU  - Oka M
AD  - Department of Emergency Medicine.
FAU - Ota, Kanna
AU  - Ota K
AD  - Department of Emergency Medicine.
FAU - Sakaue, Masahide
AU  - Sakaue M
AD  - Department of Emergency Medicine.
FAU - Sano, Yohei
AU  - Sano Y
AD  - Department of Emergency Medicine.
FAU - Takasu, Akira
AU  - Takasu A
AD  - Department of Emergency Medicine.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Abscess/*diagnosis/*etiology/genetics/therapy
MH  - Ascites/diagnosis/etiology/therapy
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Myotonic Dystrophy/*complications/*diagnosis/genetics/therapy
MH  - Myotonin-Protein Kinase/genetics
MH  - Respiratory Insufficiency/*diagnosis/*etiology/genetics/therapy
MH  - Young Adult
PMC - PMC6831368
COIS- The authors have no conflicts of interest relevant to the content of this 
      article.
EDAT- 2019/04/28 06:00
MHDA- 2019/05/21 06:00
PMCR- 2019/04/26
CRDT- 2019/04/28 06:00
PHST- 2019/04/28 06:00 [entrez]
PHST- 2019/04/28 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2019/04/26 00:00 [pmc-release]
AID - 00005792-201904260-00096 [pii]
AID - MD-D-18-09649 [pii]
AID - 10.1097/MD.0000000000015427 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Apr;98(17):e15427. doi: 10.1097/MD.0000000000015427.

PMID- 30977424
OWN - NLM
STAT- MEDLINE
DCOM- 20200211
LR  - 20200211
IS  - 1939-6376 (Electronic)
IS  - 1939-6368 (Linking)
VI  - 65
IP  - 5
DP  - 2019 Oct
TI  - The association of Intron 4 VNTR and Glu298Asp polymorphisms of the nitric oxide 
      synthetase 3 gene and vasculogenic erectile dysfunction in Turkish men.
PG  - 383-389
LID - 10.1080/19396368.2019.1601792 [doi]
AB  - Several studies have focused on the impaired role of endothelial nitric oxide 
      synthase (NOS3) gene polymorphism and its association to erectile dysfunction 
      (ED). However, currently controversial results have been reported due to their 
      significant heterogeneity. The present study aimed to assess the genotypic 
      distribution and the allelic frequency of Intron 4 VNTR and Glu298Asp gene 
      polymorphisms in vasculogenic ED patients compared to healthy controls of a 
      specific region of Turkey. A total of 75 patients with ED (median age: 56, 
      IQR:10.5) and 75 healthy controls (median age: 56, IQR:10.5) were prospectively 
      analyzed. All subjects were equally evaluated by the same physician with detailed 
      history-taking, physical examination, International Index of Erectile Function 
      (IIEF) questionnaire, and blood tests (incl. glucose, testosterone, triglyceride 
      and total cholesterol level). Those with an IIEF score under 26 were considered 
      to have ED, by classifying them according to their scores as mild (22-25), 
      moderate (11-21) and severe (1-10) ED. Color doppler ultrasonography was carried 
      out in patients with an IIEF score <22. Hypertension, diabetes mellitus, coronary 
      artery disease, and smoking status were significantly associated with the ED 
      group compared to control subjects with p values of <0.001, <0.001, 0.002 and 
      <0.001, respectively. Overall genotype frequencies was 47 (31%) a/a, 22 (15%) 
      a/b, 82 (55%) b/b for Intron 4 VNTR and 56 (37%) GG, 78 (52%) GT, 16 (11%) TT for 
      the Glu298Asp polymorphism. The frequencies of Intron 4 VNTR a/a allele and 
      Glu298Asp GT allele were associated with severe ED, while a/b and TT were 
      associated with moderate or mild, and b/b and GG were associated with no ED. In 
      contrast to Glu298Asp, statistically significant differences in genotypic 
      frequencies of Intron 4 VNTR gene polymorphism between ED and control subjects 
      was established. Abbreviations: NO: nitric oxide, NOS: nitric oxide synthase, 
      NOS3: endothelial nitric oxide synthase, NOS2: inducible nitric oxide synthase, 
      NOS1: neuronal nitric oxide synthase, HT: hypertension, DM: diabetes mellitus, 
      CAD: coronary artery disease, ED: erectile dysfunction, IIEF: international index 
      of erectile function, VNTR: variable number of tandem repeats, CDU: color doppler 
      ultrasonography, PCR: polymerase chain reaction.
FAU - Arda, Ersan
AU  - Arda E
AUID- ORCID: 0000-0002-5430-6561
AD  - Department of Urology, Trakya University School of Medicine , Edirne , Turkey.
FAU - Ay, Arzu
AU  - Ay A
AD  - Department of Biophysics, Trakya University School of Medicine , Edirne , Turkey.
FAU - Akdere, Hakan
AU  - Akdere H
AD  - Department of Urology, Trakya University School of Medicine , Edirne , Turkey.
FAU - Akdeniz, Esra
AU  - Akdeniz E
AD  - Department of Bioistatistics, Marmara University School of Medicine , Istanbul , 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20190412
PL  - England
TA  - Syst Biol Reprod Med
JT  - Systems biology in reproductive medicine
JID - 101464963
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Erectile Dysfunction/*genetics
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Humans
MH  - Introns
MH  - Male
MH  - Middle Aged
MH  - *Minisatellite Repeats
MH  - Nitric Oxide Synthase Type III/*genetics
MH  - *Polymorphism, Genetic
OTO - NOTNLM
OT  - Erectile dysfunction
OT  - eNOS
OT  - gene polymorphism
EDAT- 2019/04/13 06:00
MHDA- 2020/02/12 06:00
CRDT- 2019/04/13 06:00
PHST- 2019/04/13 06:00 [pubmed]
PHST- 2020/02/12 06:00 [medline]
PHST- 2019/04/13 06:00 [entrez]
AID - 10.1080/19396368.2019.1601792 [doi]
PST - ppublish
SO  - Syst Biol Reprod Med. 2019 Oct;65(5):383-389. doi: 10.1080/19396368.2019.1601792. 
      Epub 2019 Apr 12.

PMID- 30975744
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20201211
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 116
IP  - 18
DP  - 2019 Apr 30
TI  - Intrinsically cell-penetrating multivalent and multitargeting ligands for 
      myotonic dystrophy type 1.
PG  - 8709-8714
LID - 10.1073/pnas.1820827116 [doi]
AB  - Developing highly active, multivalent ligands as therapeutic agents is 
      challenging because of delivery issues, limited cell permeability, and toxicity. 
      Here, we report intrinsically cell-penetrating multivalent ligands that target 
      the trinucleotide repeat DNA and RNA in myotonic dystrophy type 1 (DM1), 
      interrupting the disease progression in two ways. The oligomeric ligands are 
      designed based on the repetitive structure of the target with recognition 
      moieties alternating with bisamidinium groove binders to provide an amphiphilic 
      and polycationic structure, mimicking cell-penetrating peptides. Multiple 
      biological studies suggested the success of our multivalency strategy. The 
      designed oligomers maintained cell permeability and exhibited no apparent 
      toxicity both in cells and in mice at working concentrations. Furthermore, the 
      oligomers showed important activities in DM1 cells and in a DM1 liver mouse 
      model, reducing or eliminating prominent DM1 features. Phenotypic recovery of the 
      climbing defect in adult DM1 Drosophila was also observed. This design strategy 
      should be applicable to other repeat expansion diseases and more generally to 
      DNA/RNA-targeted therapeutics.
FAU - Lee, JuYeon
AU  - Lee J
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 
      61801.
FAU - Bai, Yugang
AU  - Bai Y
AD  - Institute of Chemical Biology and Nanomedicine, Hunan University, Changsha, 
      410082 Hunan, China.
AD  - State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, 
      Changsha, 410082 Hunan, China.
AD  - Department of Chemistry, Hunan University, Changsha, 410082 Hunan, China.
FAU - Chembazhi, Ullas V
AU  - Chembazhi UV
AD  - Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, 
      IL 61801.
FAU - Peng, Shaohong
AU  - Peng S
AD  - Laboratory of Drosophila Research, School of Life Sciences, The Chinese 
      University of Hong Kong, Shatin N.T., Hong Kong Special Administrative Region, 
      People's Republic of China.
FAU - Yum, Kevin
AU  - Yum K
AD  - Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, 
      IL 61801.
FAU - Luu, Long M
AU  - Luu LM
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 
      61801.
FAU - Hagler, Lauren D
AU  - Hagler LD
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 
      61801.
FAU - Serrano, Julio F
AU  - Serrano JF
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 
      61801.
FAU - Chan, H Y Edwin
AU  - Chan HYE
AUID- ORCID: 0000-0003-4307-474X
AD  - Laboratory of Drosophila Research, School of Life Sciences, The Chinese 
      University of Hong Kong, Shatin N.T., Hong Kong Special Administrative Region, 
      People's Republic of China.
FAU - Kalsotra, Auinash
AU  - Kalsotra A
AD  - Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, 
      IL 61801; sczimmer@illinois.edu kalsotra@illinois.edu.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 
      61801; sczimmer@illinois.edu kalsotra@illinois.edu.
LA  - eng
GR  - T32 GM136629/GM/NIGMS NIH HHS/United States
GR  - R01 AR069645/AR/NIAMS NIH HHS/United States
GR  - T32 GM070421/GM/NIGMS NIH HHS/United States
GR  - R01 HL126845/HL/NHLBI NIH HHS/United States
GR  - R01 AR058361/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190411
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Ligands)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA Recognition Motif Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - DNA
MH  - DNA-Binding Proteins
MH  - Drosophila melanogaster
MH  - HeLa Cells
MH  - Humans
MH  - Ligands
MH  - Liver/metabolism
MH  - Mice
MH  - Myoblasts/physiology
MH  - Myotonic Dystrophy/*drug therapy/genetics
MH  - RNA Recognition Motif Proteins
MH  - RNA-Binding Proteins/chemistry/*metabolism
MH  - *Trinucleotide Repeats
PMC - PMC6500145
OTO - NOTNLM
OT  - DNA/RNA-targeting therapeutics
OT  - cell-penetrating peptide mimic
OT  - multivalent ligand
OT  - myotonic dystrophy type 1
OT  - trinucleotide repeat expansion diseases
COIS- The authors declare no conflict of interest.
EDAT- 2019/04/13 06:00
MHDA- 2020/03/26 06:00
PMCR- 2019/10/11
CRDT- 2019/04/13 06:00
PHST- 2019/04/13 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2019/04/13 06:00 [entrez]
PHST- 2019/10/11 00:00 [pmc-release]
AID - 1820827116 [pii]
AID - 201820827 [pii]
AID - 10.1073/pnas.1820827116 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8709-8714. doi: 
      10.1073/pnas.1820827116. Epub 2019 Apr 11.

PMID- 30926669
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20210609
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 116
IP  - 16
DP  - 2019 Apr 16
TI  - Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic 
      dystrophy mouse model.
PG  - 7799-7804
LID - 10.1073/pnas.1901484116 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an incurable neuromuscular disorder caused by 
      an expanded CTG repeat that is transcribed into r(CUG)(exp) The RNA repeat 
      expansion sequesters regulatory proteins such as Muscleblind-like protein 1 
      (MBNL1), which causes pre-mRNA splicing defects. The disease-causing r(CUG)(exp) 
      has been targeted by antisense oligonucleotides, CRISPR-based approaches, and 
      RNA-targeting small molecules. Herein, we describe a designer small molecule, 
      Cugamycin, that recognizes the structure of r(CUG)(exp) and cleaves it in both 
      DM1 patient-derived myotubes and a DM1 mouse model, leaving short repeats of 
      r(CUG) untouched. In contrast, oligonucleotides that recognize r(CUG) sequence 
      rather than structure cleave both long and short r(CUG)-containing transcripts. 
      Transcriptomic, histological, and phenotypic studies demonstrate that Cugamycin 
      broadly and specifically relieves DM1-associated defects in vivo without 
      detectable off-targets. Thus, small molecules that bind and cleave RNA have 
      utility as lead chemical probes and medicines and can selectively target 
      disease-causing RNA structures to broadly improve defects in preclinical animal 
      models.
CI  - Copyright (c) 2019 the Author(s). Published by PNAS.
FAU - Angelbello, Alicia J
AU  - Angelbello AJ
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458.
FAU - Rzuczek, Suzanne G
AU  - Rzuczek SG
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458.
FAU - Mckee, Kendra K
AU  - Mckee KK
AD  - Department of Molecular Genetics & Microbiology, College of Medicine, University 
      of Florida, Gainesville, FL 32610.
AD  - Center for NeuroGenetics, College of Medicine, University of Florida, 
      Gainesville, FL 32610.
FAU - Chen, Jonathan L
AU  - Chen JL
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458.
FAU - Olafson, Hailey
AU  - Olafson H
AD  - Department of Molecular Genetics & Microbiology, College of Medicine, University 
      of Florida, Gainesville, FL 32610.
AD  - Center for NeuroGenetics, College of Medicine, University of Florida, 
      Gainesville, FL 32610.
FAU - Cameron, Michael D
AU  - Cameron MD
AD  - Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL 
      33458.
FAU - Moss, Walter N
AU  - Moss WN
AD  - The Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, 
      Iowa State University, Ames, IA 50011-1079.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics & Microbiology, College of Medicine, University 
      of Florida, Gainesville, FL 32610.
AD  - Center for NeuroGenetics, College of Medicine, University of Florida, 
      Gainesville, FL 32610.
FAU - Disney, Matthew D
AU  - Disney MD
AD  - Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458; 
      disney@scripps.edu.
LA  - eng
GR  - DP1 NS096898/NS/NINDS NIH HHS/United States
GR  - R00 GM112877/GM/NIGMS NIH HHS/United States
GR  - R01 GM133810/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190329
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Oligonucleotides)
RN  - 0 (cugamycin)
RN  - 11056-06-7 (Bleomycin)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Animals
MH  - Bleomycin/*analogs & derivatives/chemistry
MH  - Disease Models, Animal
MH  - Drug Design
MH  - Humans
MH  - Mice
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - Oligonucleotides/*chemistry/metabolism
MH  - RNA/*genetics/*metabolism
MH  - RNA Splicing/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC6475439
OTO - NOTNLM
OT  - RNA
OT  - RNA splicing
OT  - chemical biology
OT  - genetic disease
OT  - nucleic acids
COIS- Conflict of interest statement: M.D.D. and E.T.W. are consultants for Expansion 
      Therapeutics. S.G.R. is a current employee of Expansion Therapeutics.
EDAT- 2019/03/31 06:00
MHDA- 2020/04/09 06:00
PMCR- 2019/03/29
CRDT- 2019/03/31 06:00
PHST- 2019/03/31 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2019/03/31 06:00 [entrez]
PHST- 2019/03/29 00:00 [pmc-release]
AID - 1901484116 [pii]
AID - 201901484 [pii]
AID - 10.1073/pnas.1901484116 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7799-7804. doi: 
      10.1073/pnas.1901484116. Epub 2019 Mar 29.

PMID- 30895625
OWN - NLM
STAT- MEDLINE
DCOM- 20191023
LR  - 20191023
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 59
IP  - 6
DP  - 2019 Jun
TI  - A model to predict ventilator requirement in myotonic dystrophy type 1.
PG  - 683-687
LID - 10.1002/mus.26471 [doi]
AB  - INTRODUCTION: Respiratory failure is one of the most common causes of mortality 
      in myotonic dystrophy type 1 (DM1). The variation in the DM1 phenotype causes 
      difficulty in clinically predicting the severity of respiratory involvement, and 
      variables such as daytime somnolence are insensitive for identifying patients who 
      require continuous or bilevel nocturnal positive airway pressure (NPAP). METHODS: 
      We retrospectively analyzed a cohort of 126 adult onset patients with DM1 at the 
      point of their first respiratory assessment to identify significant factors in 
      predicting ventilator requirement. RESULTS: Triplet repeat years score and Muscle 
      Impairment Rating Scale were significantly linearly related to NPAP and, thus, 
      formed the model. DISCUSSION: We devised a simple model to aid clinicians in 
      predicting at first visit those patients with DM1 who are likely to require NPAP. 
      We also describe the causes of failure to tolerate NPAP in DM1. Muscle Nerve 
      59:683-687, 2019.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Vivekananda, Umesh
AU  - Vivekananda U
AD  - MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and 
      Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom.
FAU - Turner, Chris
AU  - Turner C
AD  - MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and 
      Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20190402
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
SB  - IM
MH  - Adult
MH  - Aged
MH  - Continuous Positive Airway Pressure/*statistics & numerical data
MH  - Female
MH  - Humans
MH  - Hypoventilation/etiology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/complications/physiopathology/*therapy
MH  - Phenotype
MH  - Respiration, Artificial
MH  - Respiratory Insufficiency/etiology/physiopathology/*therapy
MH  - Retrospective Studies
MH  - Sleep Apnea, Obstructive/etiology/*therapy
MH  - Vital Capacity
MH  - Young Adult
OTO - NOTNLM
OT  - daytime somnolescence
OT  - muscle impairment rating scale
OT  - myotonic dystrophy
OT  - nocturnal positive airway pressure
OT  - obstructive sleep apnea
OT  - repeat expansion
EDAT- 2019/03/22 06:00
MHDA- 2019/10/24 06:00
CRDT- 2019/03/22 06:00
PHST- 2018/08/24 00:00 [received]
PHST- 2019/03/17 00:00 [revised]
PHST- 2019/03/19 00:00 [accepted]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/10/24 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.1002/mus.26471 [doi]
PST - ppublish
SO  - Muscle Nerve. 2019 Jun;59(6):683-687. doi: 10.1002/mus.26471. Epub 2019 Apr 2.

PMID- 30891637
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20200225
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 40
IP  - 6
DP  - 2019 Jun
TI  - Abnormal nuclear aggregation and myotube degeneration in myotonic dystrophy type 
      1.
PG  - 1255-1265
LID - 10.1007/s10072-019-03783-w [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by CTG nucleotide repeat expansions in 
      the 3'-untranslated region (3'-UTR) of the dystrophia myotonica protein kinase 
      (DMPK) gene. The expanded CTG repeats encode toxic CUG RNAs that cause disease, 
      largely through RNA gain-of-function. DM1 is a fatal disease characterized by 
      progressive muscle wasting, which has no cure. Regenerative medicine has emerged 
      as a promising therapeutic modality for DM1, especially with the advancement of 
      induced pluripotent stem (iPS) cell technology and therapeutic genome editing. 
      However, there is an unmet need to identify in vitro outcome measures to 
      demonstrate the therapeutic effects prior to in vivo clinical trials. In this 
      study, we examined the muscle regeneration (myotube formation) in normal and DM1 
      myoblasts in vitro to establish outcome measures for therapeutic monitoring. We 
      found normal proliferation of DM1 myoblasts, but abnormal nuclear aggregation 
      during the early stage myotube formation, as well as myotube degeneration during 
      the late stage of myotube formation. We concluded that early abnormal nuclear 
      aggregation and late myotube degeneration offer easy and sensitive outcome 
      measures to monitor therapeutic effects in vitro.
FAU - Wang, Yanlin
AU  - Wang Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Henan, 450000, China.
FAU - Hao, Lei
AU  - Hao L
AD  - Department of Neurology, The Fifth People's Hospital of Chongqing, Chongqing, 
      400062, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Neurology, University of Florida, Gainesville, FL, USA.
FAU - Cleary, John D
AU  - Cleary JD
AD  - Department of Molecular Genetics and Microbiology, University of Florida, 
      Gainesville, FL, USA.
FAU - Tomac, Michael P
AU  - Tomac MP
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - Thapa, Arjun
AU  - Thapa A
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - Guo, Xiuming
AU  - Guo X
AD  - Department of Neurology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, 400016, China.
FAU - Zeng, Desmond
AU  - Zeng D
AD  - Department of Neurology, University of Florida, Gainesville, FL, USA.
FAU - Wang, Hongcai
AU  - Wang H
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - McRae, MacKezie
AU  - McRae M
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - Jastrzemski, Olivia
AU  - Jastrzemski O
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - Smith-Fassler, Ali Marichen
AU  - Smith-Fassler AM
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA.
FAU - Xu, Yuming
AU  - Xu Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Henan, 450000, China. xuyuming@zzu.edu.cn.
FAU - Xia, Guangbin
AU  - Xia G
AUID- ORCID: 0000-0001-9092-3797
AD  - Department of Neurology and Neuroscience, School of Medicine, University of New 
      Mexico, Albuquerque, NM, 87131, USA. guxia@salud.unm.edu.
LA  - eng
GR  - K08 AR064836/National Institutes of Health/
PT  - Journal Article
DEP - 20190319
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
SB  - IM
MH  - Cell Nucleus/*pathology/*physiology
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Humans
MH  - In Vitro Techniques
MH  - Muscle Fibers, Skeletal/*pathology/*physiology
MH  - Myoblasts/physiology
MH  - Myotonic Dystrophy/*pathology/*physiopathology
MH  - *Regeneration
OTO - NOTNLM
OT  - Aggregation
OT  - Degeneration
OT  - Foci
OT  - Myotonic dystrophy
OT  - Myotube
OT  - Nuclear
EDAT- 2019/03/21 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/03/21 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2019/02/20 00:00 [accepted]
PHST- 2019/03/21 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/03/21 06:00 [entrez]
AID - 10.1007/s10072-019-03783-w [pii]
AID - 10.1007/s10072-019-03783-w [doi]
PST - ppublish
SO  - Neurol Sci. 2019 Jun;40(6):1255-1265. doi: 10.1007/s10072-019-03783-w. Epub 2019 
      Mar 19.

PMID- 30788616
OWN - NLM
STAT- MEDLINE
DCOM- 20190627
LR  - 20240214
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 266
IP  - 4
DP  - 2019 Apr
TI  - Disease burden of myotonic dystrophy type 1.
PG  - 998-1006
LID - 10.1007/s00415-019-09228-w [doi]
AB  - OBJECTIVE: The objective of this cross-sectional, observational study was to 
      investigate the disease burden of myotonic dystrophy type 1 (DM1), a disabling 
      muscle disorder. METHODS: Adults with DM1 were recruited as part of the PhenoDM1 
      study from Newcastle University (Newcastle upon Tyne, UK). Disease burden data 
      were recorded through the Individualized Neuromuscular Quality of Life (INQoL) 
      questionnaire. Results were examined by sex and clinical variables [e.g. the 
      six-minute walk test (6MWT), the Mini Mental State Examination, and estimated 
      progenitor and modal allele CTG repeat length]. RESULTS: Our sample consisted of 
      60 patients with DM1 (mean age: 45 years; 45% female). Muscle weakness and 
      fatigue constituted the two most common disease manifestations, reported by 93% 
      and 90% of patients, respectively, followed by muscle locking (73%). Most 
      patients (> 55%) reported feeling anxious/worried, depressed, frustrated, and/or 
      having low confidence/self-esteem, 23% and 33% indicated substantial impairment 
      of daily and leisure activities, respectively, and 47% did not work as a 
      consequence of the disease. Estimated progenitor CTG length corrected by age 
      correlated surprisingly well with INQoL scores. Differences by sex were generally 
      minor. CONCLUSION: We show that DM1 is associated with a substantial disease 
      burden resulting in impairment across many different domains of patients' lives, 
      emphasizing the need for a holistic approach to medical management. Our results 
      also show that the INQoL records relevant information about patients with DM1, 
      but that further investigation of the psychometric properties of the scale is 
      needed for meaningful interpretation of instrument scores.
FAU - Landfeldt, Erik
AU  - Landfeldt E
AUID- ORCID: 0000-0002-5758-7151
AD  - Institute of Environmental Medicine, Karolinska Institutet, Nobels vag 13, 17177, 
      Stockholm, Sweden. erik.landfeldt@ki.se.
AD  - ICON plc, Stockholm, Sweden. erik.landfeldt@ki.se.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, UK.
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
FAU - Jimenez-Moreno, Cecilia
AU  - Jimenez-Moreno C
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, UK.
FAU - Cumming, Sarah
AU  - Cumming S
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Gorman, Grainne
AU  - Gorman G
AD  - Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, 
      University of Newcastle, Newcastle upon Tyne, UK.
FAU - Turner, Chris
AU  - Turner C
AD  - National Hospital for Neurology and Neurosurgery, Queen Square, University 
      College London Hospitals NHS Foundation Trust, London, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - Department of Neuropediatrics and Muscle Disorders, Medical Centre, Faculty of 
      Medicine, University of Freiburg, Freiburg, Germany.
AD  - Division of Neurology, Department of Medicine, Children's Hospital of Eastern 
      Ontario Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, 
      Canada.
LA  - eng
GR  - G1002274/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Observational Study
DEP - 20190220
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Clinical Trials as Topic
MH  - *Cost of Illness
MH  - Cross-Sectional Studies
MH  - Disability Evaluation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology/physiopathology/psychology
MH  - Prevalence
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Walk Test
MH  - Young Adult
PMC - PMC6420885
OTO - NOTNLM
OT  - DM1
OT  - Disease burden
OT  - Genetics
OT  - INQoL
OT  - Myotonic dystrophy
OT  - Quality of life
COIS- CONFLICTS OF INTEREST: This study has been supported by the National Institute of 
      Health Research (NIHR) under the RD-TRC programme and by the Wyck Foundation. Dr. 
      Hanns Lochmuller is an investigator of the Medical Research Council UK Centre for 
      Neuromuscular Diseases (reference G1002274, grant ID 98482). The other authors 
      report no conflicts of interest. ETHICAL STANDARDS: Study ethical approval was 
      granted by the Newcastle and North Tyneside Ethics Committee (reference: 
      NE/15/0178). The study was performed in accordance with the ethical standards 
      laid down in the 1964 Declaration of Helsinki and its later amendments. All 
      patients gave their informed consent prior to their inclusion in the study.
EDAT- 2019/02/23 06:00
MHDA- 2019/06/30 06:00
PMCR- 2019/02/20
CRDT- 2019/02/22 06:00
PHST- 2018/12/04 00:00 [received]
PHST- 2019/02/03 00:00 [accepted]
PHST- 2019/01/25 00:00 [revised]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/06/30 06:00 [medline]
PHST- 2019/02/22 06:00 [entrez]
PHST- 2019/02/20 00:00 [pmc-release]
AID - 10.1007/s00415-019-09228-w [pii]
AID - 9228 [pii]
AID - 10.1007/s00415-019-09228-w [doi]
PST - ppublish
SO  - J Neurol. 2019 Apr;266(4):998-1006. doi: 10.1007/s00415-019-09228-w. Epub 2019 
      Feb 20.

PMID- 30765255
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20200601
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 29
IP  - 3
DP  - 2019 Mar
TI  - Respiratory dysfunction in myotonic dystrophy type 1: A systematic review.
PG  - 198-212
LID - S0960-8966(18)30449-8 [pii]
LID - 10.1016/j.nmd.2018.12.002 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is one of the most common muscular dystrophies in 
      adults. This review summarises the current literature regarding the natural 
      history of respiratory dysfunction in DM1, the role of central respiratory drive 
      and peripheral respiratory muscle involvement and its significance in respiratory 
      function, and investigates the relationship between genetics (CTG repeat length) 
      and respiratory dysfunction. The review included all articles that reported 
      spirometry on 10 or more myotonic dystrophy patients. The final review included 
      55 articles between 1964 and 2017. The major conclusions of this review were (1) 
      confirmation of the current consensus that respiratory dysfunction, predominantly 
      a restrictive ventilatory pattern, is common in myotonic dystrophy and is 
      associated with alveolar hypoventilation, chronic hypercapnia, and sleep 
      disturbance in the form of sleep apnoea and sleep related disordered breathing; 
      (2) contrary to commonly held belief, there is no consensus in the literature 
      regarding the relationship between CTG repeat length and severity of respiratory 
      dysfunction and a relationship has not been established; (3) the natural history 
      and time-course of respiratory functional decline is very poorly understood in 
      the current literature; (4) there is a consensus that there is a significant 
      involvement of central respiratory drive in this alveolar hypoventilation however 
      the current literature does not identify the mechanism for this.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Hawkins, A M
AU  - Hawkins AM
AD  - School of Medicine, Griffith University, Gold Coast, Queensland, Australia; 
      Department of Medicine, Logan Hospital, Meadowbrook, Queensland, Australia. 
      Electronic address: a.hawkins@griffith.edu.au.
FAU - Hawkins, C L
AU  - Hawkins CL
AD  - School of Medicine, University of Queensland, St Lucia, Queensland, Australia.
FAU - Abdul Razak, K
AU  - Abdul Razak K
AD  - School of Medicine, Griffith University, Gold Coast, Queensland, Australia; 
      Department of Medicine, Logan Hospital, Meadowbrook, Queensland, Australia.
FAU - Khoo, T K
AU  - Khoo TK
AD  - School of Medicine, Griffith University, Gold Coast, Queensland, Australia; 
      School of Medicine, University of Wollongong, New South Wales, Australia.
FAU - Tran, K
AU  - Tran K
AD  - School of Medicine, Griffith University, Gold Coast, Queensland, Australia; 
      School of Medicine, University of Queensland, St Lucia, Queensland, Australia; 
      Department of Respiratory Medicine, Logan Hospital, Meadowbrook, Queensland, 
      Australia.
FAU - Jackson, R V
AU  - Jackson RV
AD  - School of Medicine, Griffith University, Gold Coast, Queensland, Australia; 
      Department of Medicine, Logan Hospital, Meadowbrook, Queensland, Australia.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20181209
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
SB  - IM
MH  - Humans
MH  - Hypercapnia/complications/genetics/*physiopathology
MH  - Myotonic Dystrophy/genetics/*physiopathology
MH  - Respiration Disorders/complications/*physiopathology
MH  - Respiratory Muscles/*physiopathology
MH  - Sleep Wake Disorders/genetics/*physiopathology
MH  - Trinucleotide Repeat Expansion/genetics
OTO - NOTNLM
OT  - Cytosine-Thymine-Guanine (CTG)
OT  - Myotonic dystrophy
OT  - Myotonic dystrophy type 1
OT  - Respiratory dysfunction
OT  - Spirometry
EDAT- 2019/02/16 06:00
MHDA- 2020/06/02 06:00
CRDT- 2019/02/16 06:00
PHST- 2018/06/06 00:00 [received]
PHST- 2018/12/02 00:00 [revised]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2019/02/16 06:00 [entrez]
AID - S0960-8966(18)30449-8 [pii]
AID - 10.1016/j.nmd.2018.12.002 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2019 Mar;29(3):198-212. doi: 10.1016/j.nmd.2018.12.002. Epub 
      2018 Dec 9.

PMID- 30755772
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1687-8728 (Print)
IS  - 1687-8736 (Electronic)
IS  - 1687-8728 (Linking)
VI  - 2019
DP  - 2019
TI  - Interleukin-1 Gene Variability and Plasma Levels in Czech Patients with Chronic 
      Periodontitis and Diabetes Mellitus.
PG  - 6802349
LID - 10.1155/2019/6802349 [doi]
LID - 6802349
AB  - Recent studies have suggested a bidirectional relationship between chronic 
      periodontitis (CP) and diabetes mellitus (DM). Immunoregulatory factors such as 
      cytokines play an important role in etiopathogenesis of both diseases. The aim of 
      this study was to analyze variability in interleukin-1 (IL-1) gene cluster and 
      IL-1beta plasma levels in patients with CP, DM, and a combination of both diseases. 
      A total of 1016 individuals participating in this case-control study-225 healthy 
      controls, 264 patients with CP, 132 with type 1 diabetes (T1DM), and 395 patients 
      with type 2 diabetes (T2DM)-were genotyped using methods based on polymerase 
      chain reaction for IL-1 gene polymorphisms (IL-1A (-889C/T, rs1800587), IL-1B 
      (+3953C/T, rs1143634), and IL-1RN (gene for IL-1 receptor antagonist, IL-1RA, 
      86 bp tandem repeats in intron 2)). Levels of IL-1beta were measured by Luminex 
      methods in subgroups of controls, CP, T1DM + CP, and T2DM + CP subjects. Although 
      no significant associations were found in the genotype and allele frequencies of 
      IL-1A (-889C/T), significant differences in the allele frequencies of IL-1B 
      (+3953C/T) were observed between controls and CP patients (P < 0.05). In T1DM 
      patients, IL-1RN ( *) S "short" allele and IL-1RN 12 genotype were significantly 
      less frequent than those in controls (P < 0.01). In haplotype analysis, TTL 
      haplotype decreased the risk of CP development (P < 0.01), whereas CCS and CTL 
      haplotypes (P < 0.01 and P < 0.05) were associated with T1DM. Although IL-1beta 
      levels were measured significantly higher in mononuclear cells after stimulation 
      by mitogens, HSP70, or selected periodontal bacteria than in unstimulated cells, 
      IL-1 genotypes did not correlate with circulating IL-1beta levels. In the Czech 
      population, significant associations between the IL-1B polymorphism with CP and 
      the IL-1RN variant with T1DM were found. Haplotype analysis suggests that 
      variability in IL-1 gene cluster may be one of the factors in the CP and T1DM 
      pathogenesis, although single variants of these polymorphisms are not substantial 
      for protein production.
FAU - Borilova Linhartova, Petra
AU  - Borilova Linhartova P
AUID- ORCID: 0000-0003-0953-3615
AD  - Clinic of Stomatology, Institutions Shared with St. Anne's Faculty Hospital, 
      Faculty of Medicine, Masaryk University, Brno 60200, Czech Republic.
AD  - Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno 
      62500, Czech Republic.
FAU - Poskerova, Hana
AU  - Poskerova H
AUID- ORCID: 0000-0002-0727-0180
AD  - Clinic of Stomatology, Institutions Shared with St. Anne's Faculty Hospital, 
      Faculty of Medicine, Masaryk University, Brno 60200, Czech Republic.
FAU - Tomandlova, Marie
AU  - Tomandlova M
AD  - Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno 62500, 
      Czech Republic.
FAU - Bartova, Jirina
AU  - Bartova J
AUID- ORCID: 0000-0001-5277-6474
AD  - Institute of Clinical and Experimental Dental Medicine, General University 
      Hospital and First Faculty of Medicine, Charles University, Prague 12000, Czech 
      Republic.
FAU - Kankova, Katerina
AU  - Kankova K
AUID- ORCID: 0000-0001-9548-0630
AD  - Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno 
      62500, Czech Republic.
FAU - Fassmann, Antonin
AU  - Fassmann A
AD  - Clinic of Stomatology, Institutions Shared with St. Anne's Faculty Hospital, 
      Faculty of Medicine, Masaryk University, Brno 60200, Czech Republic.
FAU - Izakovicova Holla, Lydie
AU  - Izakovicova Holla L
AUID- ORCID: 0000-0002-7610-8929
AD  - Clinic of Stomatology, Institutions Shared with St. Anne's Faculty Hospital, 
      Faculty of Medicine, Masaryk University, Brno 60200, Czech Republic.
AD  - Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno 
      62500, Czech Republic.
LA  - eng
PT  - Journal Article
DEP - 20190114
PL  - Egypt
TA  - Int J Dent
JT  - International journal of dentistry
JID - 101524183
PMC - PMC6348895
EDAT- 2019/02/14 06:00
MHDA- 2019/02/14 06:01
PMCR- 2019/01/14
CRDT- 2019/02/14 06:00
PHST- 2018/10/12 00:00 [received]
PHST- 2018/12/19 00:00 [accepted]
PHST- 2019/02/14 06:00 [entrez]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2019/02/14 06:01 [medline]
PHST- 2019/01/14 00:00 [pmc-release]
AID - 10.1155/2019/6802349 [doi]
PST - epublish
SO  - Int J Dent. 2019 Jan 14;2019:6802349. doi: 10.1155/2019/6802349. eCollection 
      2019.

PMID- 30730308
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 2379-3708 (Electronic)
IS  - 2379-3708 (Linking)
VI  - 4
IP  - 6
DP  - 2019 Mar 21
TI  - Distinct pathological signatures in human cellular models of myotonic dystrophy 
      subtypes.
LID - 122686 [pii]
LID - 10.1172/jci.insight.122686 [doi]
LID - e122686
AB  - Myotonic dystrophy (DM) is the most common autosomal dominant muscular dystrophy 
      and encompasses both skeletal muscle and cardiac complications. DM is nucleotide 
      repeat expansion disorder in which type 1 (DM1) is due to a trinucleotide repeat 
      expansion on chromosome 19 and type 2 (DM2) arises from a tetranucleotide repeat 
      expansion on chromosome 3. Developing representative models of DM in animals has 
      been challenging due to instability of nucleotide repeat expansions, especially 
      for DM2, which is characterized by nucleotide repeat expansions often greater 
      than 5,000 copies. To investigate mechanisms of human DM, we generated cellular 
      models of DM1 and DM2. We used regulated MyoD expression to reprogram 
      urine-derived cells into myotubes. In this myogenic cell model, we found impaired 
      dystrophin expression, in the presence of muscleblind-like 1 (MBNL1) foci, and 
      aberrant splicing in DM1 but not in DM2 cells. We generated induced pluripotent 
      stem cells (iPSC) from healthy controls and DM1 and DM2 subjects, and we 
      differentiated these into cardiomyocytes. DM1 and DM2 cells displayed an increase 
      in RNA foci concomitant with cellular differentiation. iPSC-derived 
      cardiomyocytes from DM1 but not DM2 had aberrant splicing of known target genes 
      and MBNL sequestration. High-resolution imaging revealed tight association 
      between MBNL clusters and RNA foci in DM1. Ca2+ transients differed between DM1- 
      and DM2 iPSC-derived cardiomyocytes, and each differed from healthy control 
      cells. RNA-sequencing from DM1- and DM2 iPSC-derived cardiomyocytes revealed 
      distinct misregulation of gene expression, as well as differential aberrant 
      splicing patterns. Together, these data support that DM1 and DM2, despite some 
      shared clinical and molecular features, have distinct pathological signatures.
FAU - Kim, Ellis Y
AU  - Kim EY
AD  - Molecular Pathogenesis and Molecular Medicine, The University of Chicago, 
      Chicago, Illinois, USA.
FAU - Barefield, David Y
AU  - Barefield DY
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Vo, Andy H
AU  - Vo AH
AD  - Committee on Development, Regeneration, and Stem Cell Biology, The University of 
      Chicago, Chicago, Illinois, USA.
FAU - Gacita, Anthony M
AU  - Gacita AM
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Schuster, Emma J
AU  - Schuster EJ
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Wyatt, Eugene J
AU  - Wyatt EJ
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Davis, Janel L
AU  - Davis JL
AD  - Department of Biomedical Engineering and.
FAU - Dong, Biqin
AU  - Dong B
AD  - Department of Biomedical Engineering and.
AD  - Department of Mechanical Engineering, Northwestern University, Evanston, 
      Illinois, USA.
FAU - Sun, Cheng
AU  - Sun C
AD  - Department of Mechanical Engineering, Northwestern University, Evanston, 
      Illinois, USA.
FAU - Page, Patrick
AU  - Page P
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Dellefave-Castillo, Lisa
AU  - Dellefave-Castillo L
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Demonbreun, Alexis
AU  - Demonbreun A
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
FAU - Zhang, Hao F
AU  - Zhang HF
AD  - Department of Biomedical Engineering and.
FAU - McNally, Elizabeth M
AU  - McNally EM
AD  - Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois, USA.
LA  - eng
GR  - T32 HD007009/HD/NICHD NIH HHS/United States
GR  - T32 GM008061/GM/NIGMS NIH HHS/United States
GR  - UL1 TR001422/TR/NCATS NIH HHS/United States
GR  - R01 HL061322/HL/NHLBI NIH HHS/United States
GR  - U54 AR052646/AR/NIAMS NIH HHS/United States
GR  - T32 GM008152/GM/NIGMS NIH HHS/United States
GR  - R01 NS047726/NS/NINDS NIH HHS/United States
GR  - R01 HL128075/HL/NHLBI NIH HHS/United States
GR  - K99 HL141698/HL/NHLBI NIH HHS/United States
GR  - F30 HL142187/HL/NHLBI NIH HHS/United States
GR  - F32 HL131304/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190321
PL  - United States
TA  - JCI Insight
JT  - JCI insight
JID - 101676073
RN  - 0 (CNBP protein, human)
RN  - 0 (Dystrophin)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (MyoD Protein)
RN  - 0 (MyoD1 myogenic differentiation protein)
RN  - 0 (RNA-Binding Proteins)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Calcium/metabolism
MH  - Cell Line
MH  - Dystrophin/metabolism
MH  - Gene Expression
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genetic Variation
MH  - Humans
MH  - Induced Pluripotent Stem Cells/metabolism
MH  - Muscle Development
MH  - Muscle Fibers, Skeletal/metabolism
MH  - MyoD Protein/*metabolism
MH  - Myocytes, Cardiac/metabolism/pathology
MH  - Myotonic Dystrophy/classification/*genetics/*pathology/urine
MH  - RNA Splicing
MH  - RNA-Binding Proteins/genetics/metabolism
PMC - PMC6482996
OTO - NOTNLM
OT  - Cardiology
OT  - Genetic variation
OT  - Muscle
OT  - Stem cells
OT  - iPS cells
COIS- Conflict of interest: The authors declare no competing interests or conflicts of 
      interest.
EDAT- 2019/02/08 06:00
MHDA- 2020/06/23 06:00
PMCR- 2019/03/21
CRDT- 2019/02/08 06:00
PHST- 2018/06/04 00:00 [received]
PHST- 2019/01/31 00:00 [accepted]
PHST- 2019/02/08 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2019/02/08 06:00 [entrez]
PHST- 2019/03/21 00:00 [pmc-release]
AID - 122686 [pii]
AID - 10.1172/jci.insight.122686 [doi]
PST - epublish
SO  - JCI Insight. 2019 Mar 21;4(6):e122686. doi: 10.1172/jci.insight.122686. 
      eCollection 2019 Mar 21.

PMID- 30700578
OWN - NLM
STAT- MEDLINE
DCOM- 20190604
LR  - 20200309
IS  - 1469-9001 (Electronic)
IS  - 1355-8382 (Print)
IS  - 1355-8382 (Linking)
VI  - 25
IP  - 4
DP  - 2019 Apr
TI  - Expanded CUG repeats in DMPK transcripts adopt diverse hairpin conformations 
      without influencing the structure of the flanking sequences.
PG  - 481-495
LID - 10.1261/rna.068940.118 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a complex neuromuscular disorder caused by 
      expansion of a CTG repeat in the 3'-untranslated region (UTR) of the DMPK gene. 
      Mutant DMPK transcripts form aberrant structures and anomalously associate with 
      RNA-binding proteins (RBPs). As a first step toward better understanding of the 
      involvement of abnormal DMPK mRNA folding in DM1 manifestation, we used SHAPE, 
      DMS, CMCT, and RNase T1 structure probing in vitro for modeling of the topology 
      of the DMPK 3'-UTR with normal and pathogenic repeat lengths of up to 197 CUG 
      triplets. The resulting structural information was validated by disruption of 
      base-pairing with LNA antisense oligonucleotides (AONs) and used for prediction 
      of therapeutic AON accessibility and verification of DMPK knockdown efficacy in 
      cells. Our model for DMPK RNA structure demonstrates that the hairpin formed by 
      the CUG repeat has length-dependent conformational plasticity, with a structure 
      that is guided by and embedded in an otherwise rigid architecture of flanking 
      regions in the DMPK 3'-UTR. Evidence is provided that long CUG repeats may form 
      not only single asymmetrical hairpins but also exist as branched structures. 
      These newly identified structures have implications for DM1 pathogenic 
      mechanisms, like sequestration of RBPs and repeat-associated non-AUG (RAN) 
      translation.
CI  - (c) 2019 van Cruchten et al.; Published by Cold Spring Harbor Laboratory Press for 
      the RNA Society.
FAU - van Cruchten, Remco T P
AU  - van Cruchten RTP
AUID- ORCID: 0000-0002-2918-1488
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, 6525 GA, The Netherlands.
FAU - Wieringa, Be
AU  - Wieringa B
AUID- ORCID: 0000-0001-9192-8020
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, 6525 GA, The Netherlands.
FAU - Wansink, Derick G
AU  - Wansink DG
AUID- ORCID: 0000-0002-6773-8662
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, 6525 GA, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190130
PL  - United States
TA  - RNA
JT  - RNA (New York, N.Y.)
JID - 9509184
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (Oligonucleotides)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Recombinant Proteins)
RN  - 0 (locked nucleic acid)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - *3' Untranslated Regions
MH  - Base Pairing
MH  - Gene Expression
MH  - Humans
MH  - *Inverted Repeat Sequences
MH  - Models, Genetic
MH  - Myotonic Dystrophy/genetics/metabolism/pathology
MH  - Myotonin-Protein Kinase/*genetics/metabolism
MH  - Nucleic Acid Conformation
MH  - Oligonucleotides/genetics/metabolism
MH  - Oligonucleotides, Antisense/chemical synthesis/genetics/metabolism
MH  - Recombinant Proteins/genetics/metabolism
MH  - *Trinucleotide Repeats
PMC - PMC6426290
OTO - NOTNLM
OT  - DMPK
OT  - RNA folding
OT  - antisense oligonucleotide
OT  - hairpin
OT  - myotonic dystrophy
OT  - trinucleotide repeat
EDAT- 2019/02/01 06:00
MHDA- 2019/06/05 06:00
PMCR- 2019/04/01
CRDT- 2019/02/01 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2019/01/24 00:00 [accepted]
PHST- 2019/02/01 06:00 [pubmed]
PHST- 2019/06/05 06:00 [medline]
PHST- 2019/02/01 06:00 [entrez]
PHST- 2019/04/01 00:00 [pmc-release]
AID - rna.068940.118 [pii]
AID - RA [pii]
AID - 10.1261/rna.068940.118 [doi]
PST - ppublish
SO  - RNA. 2019 Apr;25(4):481-495. doi: 10.1261/rna.068940.118. Epub 2019 Jan 30.

PMID- 30659139
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20191125
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 92
IP  - 8
DP  - 2019 Feb 19
TI  - A large multicenter study of pediatric myotonic dystrophy type 1 for 
      evidence-based management.
PG  - e852-e865
LID - 10.1212/WNL.0000000000006948 [doi]
AB  - OBJECTIVE: To genotypically and phenotypically characterize a large pediatric 
      myotonic dystrophy type 1 (DM1) cohort to provide a solid frame of data for 
      future evidence-based health management. METHODS: Among the 2,697 patients with 
      genetically confirmed DM1 included in the French DM-Scope registry, children were 
      enrolled between January 2010 and February 2016 from 24 centers. Comprehensive 
      cross-sectional analysis of most relevant qualitative and quantitative variables 
      was performed. RESULTS: We studied 314 children (52% females, with 55% 
      congenital, 31% infantile, 14% juvenile form). The age at inclusion was inversely 
      correlated with the CTG repeat length. The paternal transmission rate was higher 
      than expected, especially in the congenital form (13%). A continuum of highly 
      prevalent neurodevelopmental alterations was observed, including cognitive 
      slowing (83%), attention deficit (64%), written language (64%), and spoken 
      language (63%) disorders. Five percent exhibited autism spectrum disorders. 
      Overall, musculoskeletal impairment was mild. Despite low prevalence, 
      cardiorespiratory impairment could be life-threatening, and frequently occurred 
      early in the first decade (25.9%). Gastrointestinal symptoms (27%) and cataracts 
      (7%) were more frequent than expected, while endocrine or metabolic disorders 
      were scarce. CONCLUSIONS: The pedDM-Scope study details the main genotype and 
      phenotype characteristics of the 3 DM1 pediatric subgroups. It highlights 
      striking profiles that could be useful in health care management (including 
      transition into adulthood) and health policy planning.
CI  - (c) 2019 American Academy of Neurology.
FAU - Lagrue, Emmanuelle
AU  - Lagrue E
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France. emmanuelle.lagrue@univ-tours.fr.
FAU - Dogan, Celine
AU  - Dogan C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - De Antonio, Marie
AU  - De Antonio M
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Audic, Frederique
AU  - Audic F
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Bach, Nathalie
AU  - Bach N
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Barnerias, Christine
AU  - Barnerias C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Bellance, Remi
AU  - Bellance R
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Cances, Claude
AU  - Cances C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Chabrol, Brigitte
AU  - Chabrol B
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Cuisset, Jean-Marie
AU  - Cuisset JM
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Desguerre, Isabelle
AU  - Desguerre I
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Durigneux, Julien
AU  - Durigneux J
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Espil, Caroline
AU  - Espil C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Fradin, Melanie
AU  - Fradin M
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Heron, Delphine
AU  - Heron D
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Isapof, Arnaud
AU  - Isapof A
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Jacquin-Piques, Agnes
AU  - Jacquin-Piques A
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Journel, Hubert
AU  - Journel H
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Laroche-Raynaud, Cecile
AU  - Laroche-Raynaud C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Laugel, Vincent
AU  - Laugel V
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Magot, Armelle
AU  - Magot A
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Manel, Veronique
AU  - Manel V
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Mayer, Michele
AU  - Mayer M
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Pereon, Yann
AU  - Pereon Y
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Perrier-Boeswillald, Julie
AU  - Perrier-Boeswillald J
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Peudenier, Sylviane
AU  - Peudenier S
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Quijano-Roy, Susana
AU  - Quijano-Roy S
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Ragot-Mandry, Sylvie
AU  - Ragot-Mandry S
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Richelme, Christian
AU  - Richelme C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Rivier, Francois
AU  - Rivier F
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Sabouraud, Pascal
AU  - Sabouraud P
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Sarret, Catherine
AU  - Sarret C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Testard, Herve
AU  - Testard H
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Vanhulle, Catherine
AU  - Vanhulle C
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Walther-Louvier, Ulrike
AU  - Walther-Louvier U
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Gherardi, Romain
AU  - Gherardi R
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Hamroun, Dalil
AU  - Hamroun D
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
FAU - Bassez, Guillaume
AU  - Bassez G
AUID- ORCID: 0000-0002-2044-1052
AD  - From CHRU de Tours (E.L.), Universite Francois Rabelais de Tours, INSERM U1253, 
      Tours; Neuromuscular Reference Center (C.D., M.D.A., R.G.), AP-HP, Hopital 
      Pitie-Salpetriere, Paris; Inserm UMRS872 (M.D.A.), team22, Centre de recherche 
      des Cordeliers, Paris; Service de neurologie pediatrique (F.A.), pneumologie 
      pediatrique et medecine infantile, Hopital de La Timone, Marseille; Service de 
      pediatrie medicale (N.B.), pole Femme Enfant, CHU, Caen; Consultation myologie 
      (C.B., I.D.), Cliniques des maladies du developpement, Hopital Necker-Enfants 
      Malades, Paris; Centre hospitalier universitaire de Fort de France (R.B.), unite 
      de neuromyologie, Fort de France; Service de pediatrie-Neurologie Pole enfants 
      (C.C.), Hopital des enfants, CHU Purpan, Toulouse; Service de neurologie 
      pediatrique (B.C.), pneumologie pediatrique et medecine infantile, Hopital de La 
      Timone, Marseille; Service de Neuropediatrie et Centre de Reference Maladies 
      Neuromusculaires (J.-M.C.), Hopital Roger-Salengro, Lille; Pole mere-enfant 
      (J.D.), neuropediatrie et neurochirgurgie de l'enfant, CHU d'Angers; Service de 
      pediatrie medicale (C.E.), Hopital Pellegrin, Bordeaux; Pole de pediatrie 
      medico-chirurgicale et genetique Clinique (M.F.), CHU de Rennes-Hopital Sud, 
      Rennes; Centre de Reference Deficiences Intellectuelles (D. Heron), Departement 
      de Genetique et INSERM U975, Groupe hospitalier Pitie-Salpetriere, Paris; Service 
      de neuropediatrie et pathologie du developpement (A.I., M.M.), Hopital Trousseau, 
      Paris; Service de neurophysiologie enfants et adultes (A.J.-P.), Hopital F. 
      Mitterrand, Dijon; Centre hospitalier Bretagne Atlantique (H.J.), Vannes; Hopital 
      de la mere et de l'enfant (C.L.-R.), Dominique Larrey, Limoges; Service de 
      pediatrie 1 (V.L.), Centre de reference pour les maladies neuromusculaires 
      CENRNEST, Hopital de Hautepierre-Hopitaux Universitaires de Strasbourg; CHU 
      Nantes (A.M., Y.P., J.P.-B.), Centre de Reference Maladies Neuromusculaires 
      Nantes-Angers, Hotel-Dieu, Nantes; Service d'Epileptologie Clinique (V.M.), des 
      Troubles du Sommeil et de Neurologie Fonctionnelle de l'Enfant, Hopital Femme 
      Mere Enfant, Lyon; Departement de pediatrie et departement de genetique medicale 
      (S.P.), Hopital Morvan, Brest; Departement de pediatrie (S.Q.-R.), Hopital 
      Raymond Poincare, Garches; Service d'explorations fonctionnelles pediatriques 
      (S.R.-M.), Hopital de Brabois, Vandoeuvre-Les-Nancy; Service de de pediatrie et de 
      neuropediatrie (C.R.), Hopital l'Archet 2, Pole Femme Mere Enfant, Nice; 
      Departement de neuropediatrie (F.R., U.W.-L.), Hopital Gui de Chauliac, 
      Montpellier; Service de pediatrie A-Unite de neurologie pediatrique (P.S.), 
      American Memorial Hospital, Reims; Centre de reference des neuropathies rares et 
      pathologies neuromusculaires (C.S.), Centre hospitalo-universitaire de 
      Clermont-Ferrand, Clermont-Ferrand; Pole de Psychiatrie (H.T.), Neurologie et 
      Reeducation Neurologique, CHU Grenoble Alpes, Grenoble; Service de neurologie 
      pediatrique (C.V.), Pavillon Femme, mere et enfant, Hopital Charles Nicolle, 
      Rouen; Inserm UMR U955 E10 et Universite Paris-Est Creteil (R.G.); Direction de 
      la Recherche et de l'Innovation (D. Hamroun), CHRU de Montpellier; Sorbonne 
      Universite (G.B.), INSERM, UMRS974, Neuromuscular Reference Center, AP-HP, 
      Hopital Pitie-Salpetriere, Paris; and FILNEMUS (E.L., C.D., M.D.A., F.A., N.B., 
      C.B., R.B., C.C., B.C., J.-M.C., I.D., J.D., C.E., M.F., D. Heron, A.I., A.J.-P., 
      H.J., C.L.-R., V.L., A.M., V.M., M.M., Y.P., J.P.-B., S.P., S.Q.-R., S.R.-M., 
      C.R., F.R., P.S., C.S., H.T., C.V., U.W.-L., R.G., D. Hamroun, G.B.), French 
      Neuromuscular Reference Centers, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190118
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
CIN - Neurology. 2020 Jan 21;94(3):145-146. PMID: 31959687
CIN - Neurology. 2020 Jan 21;94(3):146. PMID: 31959688
EIN - Neurology. 2020 Mar 3;94(9):414. PMID: 32029546
MH  - Adolescent
MH  - Arrhythmias, Cardiac/epidemiology/etiology/*physiopathology
MH  - Child
MH  - Child, Preschool
MH  - Evidence-Based Medicine
MH  - Female
MH  - Foot Deformities/epidemiology/etiology
MH  - France/epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Muscle Weakness/epidemiology/etiology/*physiopathology
MH  - Myotonic Dystrophy/complications/epidemiology/genetics/*physiopathology
MH  - Registries
MH  - Respiratory Insufficiency/epidemiology/etiology/*physiopathology
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion
EDAT- 2019/01/20 06:00
MHDA- 2019/11/26 06:00
CRDT- 2019/01/20 06:00
PHST- 2018/02/22 00:00 [received]
PHST- 2018/10/18 00:00 [accepted]
PHST- 2019/01/20 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
PHST- 2019/01/20 06:00 [entrez]
AID - WNL.0000000000006948 [pii]
AID - 10.1212/WNL.0000000000006948 [doi]
PST - ppublish
SO  - Neurology. 2019 Feb 19;92(8):e852-e865. doi: 10.1212/WNL.0000000000006948. Epub 
      2019 Jan 18.

PMID- 30628727
OWN - NLM
STAT- MEDLINE
DCOM- 20200707
LR  - 20200707
IS  - 1469-7793 (Electronic)
IS  - 0022-3751 (Print)
IS  - 0022-3751 (Linking)
VI  - 597
IP  - 5
DP  - 2019 Mar
TI  - Chronic exercise mitigates disease mechanisms and improves muscle function in 
      myotonic dystrophy type 1 mice.
PG  - 1361-1381
LID - 10.1113/JP277123 [doi]
AB  - KEY POINTS: Myotonic dystrophy type 1 (DM1), the second most common muscular 
      dystrophy and most prevalent adult form of muscular dystrophy, is characterized 
      by muscle weakness, wasting and myotonia. A microsatellite repeat expansion 
      mutation results in RNA toxicity and dysregulation of mRNA processing, which are 
      the primary downstream causes of the disorder. Recent studies with DM1 
      participants demonstrate that exercise is safe, enjoyable and elicits benefits in 
      muscle strength and function; however, the molecular mechanisms of exercise 
      adaptation in DM1 are undefined. Our results demonstrate that 7 weeks of 
      volitional running wheel exercise in a pre-clinical DM1 mouse model resulted in 
      significantly improved motor performance, muscle strength and endurance, as well 
      as reduced myotonia. At the cellular level, chronic physical activity attenuated 
      RNA toxicity, liberated Muscleblind-like 1 protein from myonuclear foci and 
      improved mRNA alternative splicing. ABSTRACT: Myotonic dystrophy type 1 (DM1) is 
      a trinucleotide repeat expansion neuromuscular disorder that is most prominently 
      characterized by skeletal muscle weakness, wasting and myotonia. Chronic physical 
      activity is safe and satisfying, and can elicit functional benefits such as 
      improved strength and endurance in DM1 patients, but the underlying cellular 
      basis of exercise adaptation is undefined. Our purpose was to examine the 
      mechanisms of exercise biology in DM1. Healthy, sedentary wild-type (SED-WT) 
      mice, as well as sedentary human skeletal actin-long repeat animals, a murine 
      model of DM1 myopathy (SED-DM1), and DM1 mice with volitional access to a running 
      wheel for 7 weeks (EX-DM1), were utilized. Chronic exercise augmented strength 
      and endurance in vivo and in situ in DM1 mice. These alterations coincided with 
      normalized measures of myopathy, as well as increased mitochondrial content. 
      Electromyography revealed a 70-85% decrease in the duration of myotonic 
      discharges in muscles from EX-DM1 compared to SED-DM1 animals. The 
      exercise-induced enhancements in muscle function corresponded at the molecular 
      level with mitigated spliceopathy, specifically the processing of bridging 
      integrator 1 and muscle-specific chloride channel (CLC-1) transcripts. CLC-1 
      protein content and sarcolemmal expression were lower in SED-DM1 versus SED-WT 
      animals, but they were similar between SED-WT and EX-DM1 groups. Chronic exercise 
      also attenuated RNA toxicity, as indicated by reduced (CUG)(n) foci-positive 
      myonuclei and sequestered Muscleblind-like 1 (MBNL1). Our data indicate that 
      chronic exercise-induced physiological improvements in DM1 occur in concert with 
      mitigated primary downstream disease mechanisms, including RNA toxicity, MBNL1 
      loss-of-function, and alternative mRNA splicing.
CI  - (c) 2019 The Authors. The Journal of Physiology (c) 2019 The Physiological Society.
FAU - Manta, Alexander
AU  - Manta A
AD  - Department of Kinesiology, McMaster University, Hamilton, ON, Canada, L8S 4K1.
FAU - Stouth, Derek W
AU  - Stouth DW
AD  - Department of Kinesiology, McMaster University, Hamilton, ON, Canada, L8S 4K1.
FAU - Xhuti, Donald
AU  - Xhuti D
AD  - Department of Kinesiology, McMaster University, Hamilton, ON, Canada, L8S 4K1.
FAU - Chi, Leon
AU  - Chi L
AD  - Department of Kinesiology, McMaster University, Hamilton, ON, Canada, L8S 4K1.
FAU - Rebalka, Irena A
AU  - Rebalka IA
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, 
      ON, Canada, L8S 4K1.
FAU - Kalmar, Jayne M
AU  - Kalmar JM
AUID- ORCID: 0000-0003-2830-8720
AD  - Department of Kinesiology & Physical Education, Wilfred Laurier University, 
      Waterloo, ON, Canada, N2L 3C5.
FAU - Hawke, Thomas J
AU  - Hawke TJ
AUID- ORCID: 0000-0003-4974-4820
AD  - Department of Pathology and Molecular Medicine, McMaster University, Hamilton, 
      ON, Canada, L8S 4K1.
FAU - Ljubicic, Vladimir
AU  - Ljubicic V
AUID- ORCID: 0000-0002-4592-4093
AD  - Department of Kinesiology, McMaster University, Hamilton, ON, Canada, L8S 4K1.
LA  - eng
GR  - CMA-151727/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190130
PL  - England
TA  - J Physiol
JT  - The Journal of physiology
JID - 0266262
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Disease Models, Animal
MH  - Female
MH  - Male
MH  - Mice
MH  - Muscle, Skeletal/physiology
MH  - Myotonic Dystrophy/genetics/physiopathology/*therapy
MH  - *Physical Conditioning, Animal
MH  - RNA, Messenger/metabolism
PMC - PMC6395422
OTO - NOTNLM
OT  - Exercise physiology
OT  - Mitochondria
OT  - Muscleblind-like 1
OT  - Myotonic dystrophy type 1
OT  - RNA processing
OT  - RNA toxicity
EDAT- 2019/01/11 06:00
MHDA- 2020/07/08 06:00
PMCR- 2020/03/01
CRDT- 2019/01/11 06:00
PHST- 2018/09/09 00:00 [received]
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/11 06:00 [pubmed]
PHST- 2020/07/08 06:00 [medline]
PHST- 2019/01/11 06:00 [entrez]
PHST- 2020/03/01 00:00 [pmc-release]
AID - TJP13402 [pii]
AID - 10.1113/JP277123 [doi]
PST - ppublish
SO  - J Physiol. 2019 Mar;597(5):1361-1381. doi: 10.1113/JP277123. Epub 2019 Jan 30.

PMID- 30615214
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20221207
IS  - 1531-8249 (Electronic)
IS  - 0364-5134 (Linking)
VI  - 85
IP  - 2
DP  - 2019 Feb
TI  - Large normal alleles of ATXN2 decrease age at onset in transthyretin familial 
      amyloid polyneuropathy Val30Met patients.
PG  - 251-258
LID - 10.1002/ana.25409 [doi]
AB  - OBJECTIVE: Transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) is 
      an autosomal dominant neurological disease, caused most frequently by a Val30Met 
      (now classified as Val50Met) substitution in TTR. Age at onset (AO) ranges from 
      19 to 82 years, and variability exists mostly between generations. Unstable 
      oligonucleotide repeats in various genes are the mechanism behind several 
      neurological diseases, found also to act as modifiers for other disorders. Our 
      aim was to investigate whether large normal repeat alleles of 10 genes had a 
      possible modifier effect in AO in Portuguese TTR-FAP Val30Met families. METHODS: 
      We analyzed 329 Portuguese patients from 123 families. Repeat length (at ATXN1, 
      ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR, and DMPK) was assessed by single 
      and multiplex polymerase chain reaction, using fluorescently labeled primers, 
      followed by capillary electrophoresis. We used a family-centered approach, and 
      generalized estimating equations were used to account for AO correlation between 
      family members. RESULTS: For ATXN2, the presence of at least 1 allele longer than 
      22 CAGs was significantly associated with an earlier onset in TTR-FAP Val30Met, 
      decreasing mean AO by 6 years (95% confidence interval = -8.81 to -2.19, p = 
      0.001). No association was found for the remaining repeat loci. INTERPRETATION: 
      Length of normal repeats at ATXN2 may modify AO in TTR-FAP Val30Met and may 
      function as a risk factor. This can be due to the role of ATXN2 in RNA metabolism 
      and as a modulator of various cellular processes, including mitochondrial stress. 
      This may have relevant implications for prognosis and the follow-up of 
      presymptomatic carriers. ANN NEUROL 2019;85:251-258.
CI  - (c) 2019 American Neurological Association.
FAU - Santos, Diana
AU  - Santos D
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
FAU - Coelho, Teresa
AU  - Coelho T
AD  - UCA, Unidade Corino de Andrade, Centro Hospitalar do Porto (CHP).
FAU - Alves-Ferreira, Miguel
AU  - Alves-Ferreira M
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
FAU - Sequeiros, Jorge
AU  - Sequeiros J
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
FAU - Mendonca, Denisa
AU  - Mendonca D
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
AD  - ISPUP, Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.
FAU - Alonso, Isabel
AU  - Alonso I
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
FAU - Sousa, Alda
AU  - Sousa A
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
FAU - Lemos, Carolina
AU  - Lemos C
AD  - i3S, Instituto de Investigacao e Inovacao em Saude, Universidade do Porto.
AD  - UnIGENe, IBMC, Institute for Molecular and Cell Biology, Universidade do Porto.
AD  - ICBAS, Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto.
LA  - eng
GR  - PTDC/SAU-GMG/100240/2008/Fundacao para a Ciencia e a Tecnologia/International
GR  - SFRH/BD/101352/2014/Fundacao para a Ciencia e a Tecnologia/International
GR  - SFRH/BD/91160/2012/Fundacao para a Ciencia e a Tecnologia/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 0 (ATXN2 protein, human)
RN  - 0 (Ataxin-2)
RN  - 0 (Prealbumin)
RN  - 0 (TTR protein, human)
RN  - Amyloidosis, Hereditary, Transthyretin-Related
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Amyloid Neuropathies, Familial/*genetics
MH  - Asymptomatic Diseases
MH  - Ataxin-2/*genetics
MH  - Female
MH  - Genes, Modifier
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Portugal
MH  - Prealbumin/*genetics
MH  - Prognosis
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - White People/genetics
MH  - Young Adult
EDAT- 2019/01/08 06:00
MHDA- 2020/01/07 06:00
CRDT- 2019/01/08 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2019/01/04 00:00 [revised]
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/08 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/01/08 06:00 [entrez]
AID - 10.1002/ana.25409 [doi]
PST - ppublish
SO  - Ann Neurol. 2019 Feb;85(2):251-258. doi: 10.1002/ana.25409.

PMID- 30561649
OWN - NLM
STAT- MEDLINE
DCOM- 20190701
LR  - 20220129
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 28
IP  - 8
DP  - 2019 Apr 15
TI  - Transcriptome alterations in myotonic dystrophy skeletal muscle and heart.
PG  - 1312-1321
LID - 10.1093/hmg/ddy432 [doi]
AB  - Myotonic dystrophy (dystrophia myotonica, DM) is a multi-systemic disease caused 
      by expanded CTG or CCTG microsatellite repeats. Characterized by symptoms in 
      muscle, heart and central nervous system, among others, it is one of the most 
      variable diseases known. A major pathogenic event in DM is the sequestration of 
      muscleblind-like proteins by CUG or CCUG repeat-containing RNAs transcribed from 
      expanded repeats, and differences in the extent of MBNL sequestration dependent 
      on repeat length and expression level may account for some portion of the 
      variability. However, many other cellular pathways are reported to be perturbed 
      in DM, and the severity of specific disease symptoms varies among individuals. To 
      help understand this variability and facilitate research into DM, we generated 
      120 RNASeq transcriptomes from skeletal and heart muscle derived from healthy and 
      DM1 biopsies and autopsies. A limited number of DM2 and Duchenne muscular 
      dystrophy samples were also sequenced. We analyzed splicing and gene expression, 
      identified tissue-specific changes in RNA processing and uncovered transcriptome 
      changes strongly correlating with muscle strength. We created a web resource at 
      http://DMseq.org that hosts raw and processed transcriptome data and provides a 
      lightweight, responsive interface that enables browsing of processed data across 
      the genome.
CI  - (c) The Author(s) 2018. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL, USA.
AD  - Center for NeuroGenetics, University of Florida, Gainesville, FL, USA.
AD  - University of Florida Genetics Institute, University of Florida, Gainesville, FL, 
      USA.
FAU - Treacy, Daniel
AU  - Treacy D
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
FAU - Eichinger, Katy
AU  - Eichinger K
AD  - Department of Neurology, University of Rochester, Rochester, NY, USA.
FAU - Struck, Adam
AU  - Struck A
AD  - Department of Biochemistry, University of Oregon, Eugene, OR, USA.
FAU - Estabrook, Joseph
AU  - Estabrook J
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL, USA.
AD  - Center for NeuroGenetics, University of Florida, Gainesville, FL, USA.
AD  - University of Florida Genetics Institute, University of Florida, Gainesville, FL, 
      USA.
FAU - Olafson, Hailey
AU  - Olafson H
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL, USA.
AD  - Center for NeuroGenetics, University of Florida, Gainesville, FL, USA.
AD  - University of Florida Genetics Institute, University of Florida, Gainesville, FL, 
      USA.
FAU - Wang, Thomas T
AU  - Wang TT
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
FAU - Bhatt, Kirti
AU  - Bhatt K
AD  - Department of Neurology, University of Rochester, Rochester, NY, USA.
FAU - Westbrook, Tony
AU  - Westbrook T
AD  - School of Life Sciences, Queen's Medical Center, University of Nottingham, 
      Nottingham, UK.
FAU - Sedehizadeh, Sam
AU  - Sedehizadeh S
AD  - School of Life Sciences, Queen's Medical Center, University of Nottingham, 
      Nottingham, UK.
FAU - Ward, Amanda
AU  - Ward A
AD  - Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 
      USA.
FAU - Day, John
AU  - Day J
AD  - Department of Neurology, Stanford University, Palo Alto, CA, USA.
FAU - Brook, David
AU  - Brook D
AD  - School of Life Sciences, Queen's Medical Center, University of Nottingham, 
      Nottingham, UK.
FAU - Berglund, J Andrew
AU  - Berglund JA
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL, USA.
AD  - Center for NeuroGenetics, University of Florida, Gainesville, FL, USA.
AD  - University of Florida Genetics Institute, University of Florida, Gainesville, FL, 
      USA.
AD  - Department of Biochemistry, University of Oregon, Eugene, OR, USA.
FAU - Cooper, Thomas
AU  - Cooper T
AD  - Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, 
      USA.
AD  - Department of Molecular Physiology & Biophysics, Baylor College of Medicine, 
      Houston, TX, USA.
AD  - Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, 
      TX, USA.
FAU - Housman, David
AU  - Housman D
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
FAU - Thornton, Charles
AU  - Thornton C
AD  - Department of Neurology, University of Rochester, Rochester, NY, USA.
FAU - Burge, Christopher
AU  - Burge C
AD  - Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
AD  - Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
LA  - eng
GR  - DP5 OD017865/OD/NIH HHS/United States
GR  - T32 GM007413/GM/NIGMS NIH HHS/United States
GR  - 107562/Z/15/Z/WT_/Wellcome Trust/United Kingdom
GR  - R01 AR060733/AR/NIAMS NIH HHS/United States
GR  - G0802629/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
GR  - R01 HL045565/HL/NHLBI NIH HHS/United States
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - R01 AR045653/AR/NIAMS NIH HHS/United States
GR  - RC2 HG005624/HG/NHGRI NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adult
MH  - Alternative Splicing/genetics
MH  - Base Sequence
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Heart/physiology
MH  - Humans
MH  - Male
MH  - Microsatellite Repeats/genetics
MH  - Muscle, Skeletal/*metabolism/physiology
MH  - Myocardium/*metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - Principal Component Analysis
MH  - RNA/genetics
MH  - RNA Splicing/genetics
MH  - RNA-Binding Proteins/metabolism
MH  - Transcriptome/genetics
PMC - PMC6452195
EDAT- 2018/12/19 06:00
MHDA- 2019/07/02 06:00
PMCR- 2020/04/15
CRDT- 2018/12/19 06:00
PHST- 2018/07/30 00:00 [received]
PHST- 2018/11/30 00:00 [revised]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/07/02 06:00 [medline]
PHST- 2018/12/19 06:00 [entrez]
PHST- 2020/04/15 00:00 [pmc-release]
AID - 5250729 [pii]
AID - ddy432 [pii]
AID - 10.1093/hmg/ddy432 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2019 Apr 15;28(8):1312-1321. doi: 10.1093/hmg/ddy432.

PMID- 30546383
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 9
DP  - 2018
TI  - Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by 
      Stabilizing DMPK Expansions in Somatic Cells.
PG  - 601
LID - 10.3389/fgene.2018.00601 [doi]
LID - 601
AB  - CTG expansions in DMPK gene, causing myotonic dystrophy type 1 (DM1), are 
      characterized by pronounced somatic instability. A large proportion of 
      variability of somatic instability is explained by expansion size and patient's 
      age at sampling, while individual-specific differences are attributed to 
      additional factors. The age at onset is extremely variable in DM1, and inversely 
      correlates with the expansion size and individual-specific differences in somatic 
      instability. Three to five percent of DM1 patients carry repeat interruptions and 
      some appear with later age at onset than expected for corresponding expansion 
      size. Herein, we characterized somatic instability of interrupted DMPK expansions 
      and the effect on age at onset in our previously described patients. 
      Repeat-primed PCR showed stable structures of different types and patterns of 
      repeat interruptions in blood cells over time and buccal cells. Single-molecule 
      small-pool PCR quantification of somatic instability and mathematical modeling 
      showed that interrupted expansions were characterized by lower level of somatic 
      instability accompanied by slower progression over time. Mathematical modeling 
      demonstrated that individual-specific differences in somatic instability had 
      greater influence on age at onset in patients with interrupted expansions. 
      Therefore, repeat interruptions have clinical importance for disease course in 
      DM1 patients due to stabilizing effect on DMPK expansions in somatic cells.
FAU - Pesovic, Jovan
AU  - Pesovic J
AD  - Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 
      Belgrade, Serbia.
FAU - Peric, Stojan
AU  - Peric S
AD  - School of Medicine, University of Belgrade, Belgrade, Serbia.
AD  - Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
FAU - Brkusanin, Milos
AU  - Brkusanin M
AD  - Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 
      Belgrade, Serbia.
FAU - Brajuskovic, Goran
AU  - Brajuskovic G
AD  - Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 
      Belgrade, Serbia.
FAU - Rakocevic-Stojanovic, Vidosava
AU  - Rakocevic-Stojanovic V
AD  - School of Medicine, University of Belgrade, Belgrade, Serbia.
AD  - Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
FAU - Savic-Pavicevic, Dusanka
AU  - Savic-Pavicevic D
AD  - Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, 
      Belgrade, Serbia.
LA  - eng
PT  - Journal Article
DEP - 20181127
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC6278776
OTO - NOTNLM
OT  - CTG expansion
OT  - DMPK
OT  - age at onset
OT  - myotonic dystrophy 1
OT  - repeat interruptions
OT  - somatic instability
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/11/27
CRDT- 2018/12/15 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2018/11/15 00:00 [accepted]
PHST- 2018/12/15 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/11/27 00:00 [pmc-release]
AID - 10.3389/fgene.2018.00601 [doi]
PST - epublish
SO  - Front Genet. 2018 Nov 27;9:601. doi: 10.3389/fgene.2018.00601. eCollection 2018.

PMID- 30508964
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 48
DP  - 2018 Nov
TI  - Hemangiomas of the tongue and the oral cavity in a myotonic dystrophy type 1 
      patient: A case report.
PG  - e13448
LID - 10.1097/MD.0000000000013448 [doi]
LID - e13448
AB  - RATIONALE: Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease 
      caused by a cytosine, guanine, thymine (CTG) trinucleotide repeat expansion in 
      the non-coding region of dystrophia myotonica protein kinase gene, causing a 
      multisystem involvement. To date, few studies have been performed to evaluate 
      skin features in DM1 patients, but none reported on the possible association 
      between the disease and tongue hemangiomas. PATIENTS CONCERNS: We report a case 
      of a 63-year-old woman affected by DM1 and presenting, at the intraoral 
      examination, several swelling and buish lesions occurring on buccal and palatal 
      mucosa, and in the anterior two-thirds and margins of the tongue. DIAGNOSIS: 
      Multiple tongue hemangiomas in DM1 patient. INTERVENTIONS: Color Doppler 
      ultrasound revealed hypoechoic lesions with intermittent color picking suggestive 
      of vascular lesion. Surgical excision was performed under general anesthesia. 
      Histopathological examination was compatible with the diagnosis of cavernous 
      hemangiomas. OUTCOMES: At 6 months follow-up, a part from the cosmetic deformity, 
      patient's hemangiomas did not bleed, but caused functional problems with 
      speaking, mastication, and deglutition, in addition to the same symptoms induced 
      by DM1. LESSONS: This case may add new details to better characterize the DM1 
      phenotype, suggesting that even tongue hemangiomas may be part of the DM1 
      multisystem involvement.
FAU - Portaro, Simona
AU  - Portaro S
AD  - Istituto di Ricovero e Cura a Carattere Scientifico Centro Neurolesi 
      "Bonino-Pulejo".
FAU - Naro, Antonino
AU  - Naro A
AD  - Istituto di Ricovero e Cura a Carattere Scientifico Centro Neurolesi 
      "Bonino-Pulejo".
FAU - Guarneri, Claudio
AU  - Guarneri C
AD  - Department of Clinical and Experimental Medicine - Section of Dermatology, 
      University of Messina, Messina.
FAU - Di Toro, Giuseppe
AU  - Di Toro G
AD  - Private Practitioner, Milazzo, Italy.
FAU - Manuli, Alfredo
AU  - Manuli A
AD  - Istituto di Ricovero e Cura a Carattere Scientifico Centro Neurolesi 
      "Bonino-Pulejo".
FAU - Calabro, Rocco Salvatore
AU  - Calabro RS
AD  - Istituto di Ricovero e Cura a Carattere Scientifico Centro Neurolesi 
      "Bonino-Pulejo".
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Female
MH  - Hemangioma, Cavernous/*etiology/pathology
MH  - Humans
MH  - Middle Aged
MH  - Mouth/pathology
MH  - Mouth Neoplasms/*etiology
MH  - Myotonic Dystrophy/*complications
MH  - Tongue/pathology
MH  - Tongue Neoplasms/*etiology/pathology
PMC - PMC6283126
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/12/05 06:00
MHDA- 2018/12/20 06:00
PMCR- 2018/11/30
CRDT- 2018/12/05 06:00
PHST- 2018/12/05 06:00 [entrez]
PHST- 2018/12/05 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2018/11/30 00:00 [pmc-release]
AID - 00005792-201811300-00084 [pii]
AID - MD-D-18-05560 [pii]
AID - 10.1097/MD.0000000000013448 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(48):e13448. doi: 10.1097/MD.0000000000013448.

PMID- 30425655
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1664-042X (Print)
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 9
DP  - 2018
TI  - Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1.
PG  - 1532
LID - 10.3389/fphys.2018.01532 [doi]
LID - 1532
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic disorder with predominant 
      myotonia and muscular dystrophy which is caused by CTG-repeat expansions in the 
      DMPK gene. These repeat expansions are transcribed and the resulting mRNA 
      accumulates RNA-binding proteins involved in splicing, resulting in a general 
      splicing defect. We observed nuclear envelope (NE) alterations in DM1 primary 
      myoblasts. These included invaginations of the NE as well as an altered 
      composition of the nuclear lamina. Specifically, we investigated NE transmembrane 
      proteins (NETs) in DM1 primary myoblasts, staining to determine if their 
      distribution was altered compared to controls and if this could contribute to 
      these structural defects. We also tested the expression of these NETs in muscle 
      and how localization changes in the DM1 primary myoblasts undergoing 
      differentiation in vitro to myotubes. We found no changes in the localization of 
      the tested NETs, but most tended to exhibit reduced expression with increasing 
      DMPK-repeat length. Nonetheless, the DM1 patient expression range was within the 
      expression range of the controls. Additionally, we found a down-regulation of the 
      possible nesprin 1 giant isoform in DM1 primary myoblasts which could contribute 
      to the increased NE invaginations. Thus, nesprin 1 may be an interesting target 
      for further investigation in DM1 disease pathology.
FAU - Hintze, Stefan
AU  - Hintze S
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Knaier, Lisa
AU  - Knaier L
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Limmer, Sarah
AU  - Limmer S
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Schoser, Benedikt
AU  - Schoser B
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Meinke, Peter
AU  - Meinke P
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20181030
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC6218431
OTO - NOTNLM
OT  - myoblasts
OT  - myotonic dystrophy type 1
OT  - myotubes
OT  - nuclear envelope
OT  - nuclear envelope transmembrane proteins
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:01
PMCR- 2018/10/30
CRDT- 2018/11/15 06:00
PHST- 2018/08/17 00:00 [received]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:01 [medline]
PHST- 2018/10/30 00:00 [pmc-release]
AID - 10.3389/fphys.2018.01532 [doi]
PST - epublish
SO  - Front Physiol. 2018 Oct 30;9:1532. doi: 10.3389/fphys.2018.01532. eCollection 
      2018.

PMID- 30381983
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20200309
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Print)
IS  - 1547-6286 (Linking)
VI  - 15
IP  - 11
DP  - 2018
TI  - A potential role of extended simple sequence repeats in competing endogenous RNA 
      crosstalk.
PG  - 1399-1409
LID - 10.1080/15476286.2018.1536593 [doi]
AB  - MicroRNA (miRNA)-mediated crosstalk between coding and non-coding RNAs of various 
      types is known as the competing endogenous RNA (ceRNA) concept. Here, we propose 
      that there is a specific variant of the ceRNA language that takes advantage of 
      simple sequence repeat (SSR) wording. We applied bioinformatics tools to identify 
      human transcripts that may be regarded as repeat-associated ceRNAs (raceRNAs). 
      Multiple protein-coding transcripts, transcribed pseudogenes, long non-coding 
      RNAs (lncRNAs) and circular RNAs (circRNAs) showing this potential were 
      identified, and numerous miRNAs were predicted to bind to SSRs. We propose that 
      simple repeats expanded in various hereditary neurological diseases may act as 
      sponges for miRNAs containing complementary repeats that would affect raceRNA 
      crosstalk. Based on the representation of specific SSRs in transcripts, 
      expression data for SSR-binding miRNAs and expression profiling data from 
      patients, we determined that raceRNA crosstalk is most likely to be perturbed in 
      the case of myotonic dystrophy type 1 (DM1) and type 2 (DM2).
FAU - Witkos, Tomasz M
AU  - Witkos TM
AUID- ORCID: 0000-0002-6568-4429
AD  - a Department of Molecular Biomedicine , Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences , Poznan , Poland.
FAU - Krzyzosiak, Wlodzimierz J
AU  - Krzyzosiak WJ
AD  - a Department of Molecular Biomedicine , Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences , Poznan , Poland.
FAU - Fiszer, Agnieszka
AU  - Fiszer A
AUID- ORCID: 0000-0001-7829-1926
AD  - a Department of Molecular Biomedicine , Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences , Poznan , Poland.
FAU - Koscianska, Edyta
AU  - Koscianska E
AUID- ORCID: 0000-0002-1665-2500
AD  - a Department of Molecular Biomedicine , Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences , Poznan , Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181105
PL  - United States
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Gene Expression Regulation/genetics
MH  - Gene Regulatory Networks/genetics
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - Microsatellite Repeats/*genetics
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - RNA/genetics
MH  - RNA, Circular
MH  - RNA, Long Noncoding/genetics
MH  - RNA, Messenger/*genetics
PMC - PMC6284579
OTO - NOTNLM
OT  - ceRNA hypothesis
OT  - miRNA cooperativity
OT  - miRNA sponge
OT  - microsatellite repeats
OT  - myotonic dystrophy
OT  - non-coding RNAs
OT  - repeat expansion diseases
EDAT- 2018/11/02 06:00
MHDA- 2019/01/08 06:00
PMCR- 2018/11/05
CRDT- 2018/11/02 06:00
PHST- 2018/11/02 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/11/02 06:00 [entrez]
PHST- 2018/11/05 00:00 [pmc-release]
AID - 1536593 [pii]
AID - 10.1080/15476286.2018.1536593 [doi]
PST - ppublish
SO  - RNA Biol. 2018;15(11):1399-1409. doi: 10.1080/15476286.2018.1536593. Epub 2018 
      Nov 5.

PMID- 30311737
OWN - NLM
STAT- MEDLINE
DCOM- 20190321
LR  - 20231011
IS  - 1601-183X (Electronic)
IS  - 1601-1848 (Print)
IS  - 1601-183X (Linking)
VI  - 18
IP  - 1
DP  - 2019 Jan
TI  - Genetic mutations in Ca(2+) signaling alter dendrite morphology and social 
      approach in juvenile mice.
PG  - e12526
LID - 10.1111/gbb.12526 [doi]
AB  - Dendritic morphology is a critical determinant of neuronal connectivity, and 
      calcium signaling plays a predominant role in shaping dendrites. Altered 
      dendritic morphology and genetic mutations in calcium signaling are both 
      associated with neurodevelopmental disorders (NDDs). In this study we tested the 
      hypothesis that dendritic arborization and NDD-relevant behavioral phenotypes are 
      altered by human mutations that modulate calcium-dependent signaling pathways 
      implicated in NDDs. The dendritic morphology of pyramidal neurons in CA1 
      hippocampus and somatosensory cortex was quantified in Golgi-stained brain 
      sections from juvenile mice of both sexes expressing either a human 
      gain-of-function mutation in ryanodine receptor 1 (T4826I-RYR1), a human CGG 
      repeat expansion (170-200 CGG repeats) in the fragile X mental retardation gene 1 
      (FMR1 premutation), both mutations (double mutation; DM), or wildtype mice. In 
      hippocampal neurons, increased dendritic arborization was observed in male 
      T4826I-RYR1 and, to a lesser extent, male FMR1 premutation neurons. Dendritic 
      morphology of cortical neurons was altered in both sexes of FMR1 premutation and 
      DM animals with the most pronounced differences seen in DM females. Genotype also 
      impaired behavior, as assessed using the three-chambered social approach test. 
      The most striking lack of sociability was observed in DM male and female mice. In 
      conclusion, mutations that alter the fidelity of calcium signaling enhance 
      dendritic arborization in a brain region- and sex-specific manner and impair 
      social behavior in juvenile mice. The phenotypic outcomes of these mutations 
      likely provide a susceptible biological substrate for additional environmental 
      stressors that converge on calcium signaling to determine individual NDD risk.
CI  - (c) 2018 John Wiley & Sons Ltd and International Behavioural and Neural Genetics 
      Society.
FAU - Keil, Kimberly P
AU  - Keil KP
AUID- ORCID: 0000-0002-7006-9420
AD  - Department of Molecular Biosciences, University of California-Davis, School of 
      Veterinary Medicine, Davis, California.
FAU - Sethi, Sunjay
AU  - Sethi S
AD  - Department of Molecular Biosciences, University of California-Davis, School of 
      Veterinary Medicine, Davis, California.
FAU - Wilson, Machelle D
AU  - Wilson MD
AD  - Clinical and Translational Science Center, Department of Public Health Sciences, 
      Division of Biostatistics, University of California-Davis, School of Medicine, 
      Davis, California.
FAU - Silverman, Jill L
AU  - Silverman JL
AD  - Department of Psychiatry and Behavioral Sciences, University of California-Davis 
      School of Medicine, Sacramento, California.
AD  - MIND Institute, University of California-Davis, School of Medicine, Sacramento, 
      California.
FAU - Pessah, Isaac N
AU  - Pessah IN
AD  - Department of Molecular Biosciences, University of California-Davis, School of 
      Veterinary Medicine, Davis, California.
AD  - MIND Institute, University of California-Davis, School of Medicine, Sacramento, 
      California.
FAU - Lein, Pamela J
AU  - Lein PJ
AD  - Department of Molecular Biosciences, University of California-Davis, School of 
      Veterinary Medicine, Davis, California.
AD  - MIND Institute, University of California-Davis, School of Medicine, Sacramento, 
      California.
LA  - eng
GR  - P01 ES011269/ES/NIEHS NIH HHS/United States
GR  - R56 ES014901/ES/NIEHS NIH HHS/United States
GR  - P30 ES005605/ES/NIEHS NIH HHS/United States
GR  - U54 HD079125/HD/NICHD NIH HHS/United States
GR  - T32 ES007059/ES/NIEHS NIH HHS/United States
GR  - R833292/EPA/EPA/United States
GR  - P50 HD103526/HD/NICHD NIH HHS/United States
GR  - R01 ES014901/ES/NIEHS NIH HHS/United States
GR  - UL1 TR000002/TR/NCATS NIH HHS/United States
GR  - F32 HD088016/HD/NICHD NIH HHS/United States
GR  - ES007059ES011269ES014901/ES/NIEHS NIH HHS/United States
GR  - HD079125HD088016/HD/NICHD NIH HHS/United States
GR  - TR000002/TR/NCATS NIH HHS/United States
GR  - UL1 TR001860/TR/NCATS NIH HHS/United States
GR  - P30 ES023513/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20181106
PL  - England
TA  - Genes Brain Behav
JT  - Genes, brain, and behavior
JID - 101129617
RN  - 0 (Fmr1 protein, mouse)
RN  - 0 (Ryanodine Receptor Calcium Release Channel)
RN  - 0 (ryanodine receptor 1, mouse)
RN  - 139135-51-6 (Fragile X Mental Retardation Protein)
SB  - IM
MH  - Animals
MH  - CA1 Region, Hippocampal/cytology/metabolism
MH  - *Calcium Signaling
MH  - Dendrites/*metabolism/physiology
MH  - Female
MH  - Fragile X Mental Retardation Protein/genetics
MH  - *Gain of Function Mutation
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neuronal Outgrowth
MH  - Neuronal Plasticity
MH  - Pyramidal Cells/*cytology/metabolism
MH  - Ryanodine Receptor Calcium Release Channel/genetics/metabolism
MH  - *Social Behavior
MH  - Trinucleotide Repeat Expansion
PMC - PMC6540090
MID - NIHMS1021732
OTO - NOTNLM
OT  - FMR1
OT  - Golgi stain Sholl analysis
OT  - autism
OT  - developmental neurobiology
OT  - ryanodine receptor
COIS- CONFLICTS OF INTEREST All authors declare no potential conflicts of interest.
EDAT- 2018/10/13 06:00
MHDA- 2019/03/22 06:00
PMCR- 2019/05/29
CRDT- 2018/10/13 06:00
PHST- 2018/07/31 00:00 [received]
PHST- 2018/10/05 00:00 [revised]
PHST- 2018/10/09 00:00 [accepted]
PHST- 2018/10/13 06:00 [pubmed]
PHST- 2019/03/22 06:00 [medline]
PHST- 2018/10/13 06:00 [entrez]
PHST- 2019/05/29 00:00 [pmc-release]
AID - 10.1111/gbb.12526 [doi]
PST - ppublish
SO  - Genes Brain Behav. 2019 Jan;18(1):e12526. doi: 10.1111/gbb.12526. Epub 2018 Nov 
      6.

PMID- 30304901
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1738-1061 (Print)
IS  - 2092-7258 (Electronic)
IS  - 1738-1061 (Linking)
VI  - 62
IP  - 2
DP  - 2019 Feb
TI  - Genotype-phenotype correlations in pediatric patients with myotonic dystrophy 
      type 1.
PG  - 55-61
LID - 10.3345/kjp.2018.06919 [doi]
AB  - PURPOSE: Myotonic dystrophy, also known as dystrophia myotonica (DM), is an 
      autosomal dominant disorder with 2 genetically distinct forms. DM type 1 (DM1) is 
      the more common form and is caused by abnormal expansion of 
      cytosine/thymine/guanine (CTG) repeats in the DM protein kinase (DMPK ) gene. Our 
      study aimed to determine whether the age of onset is correlated with CTG repeat 
      length in a population of pediatric patients with DM1. METHODS: We 
      retrospectively identified 30 pediatric patients with DM1 that underwent DMPK 
      testing, of which the clinical data of 17 was sufficient. The cohort was divided 
      into 2 subgroups based on the clinical phenotype (congenital-onset vs. 
      late-onset) and number of CTG repeats (<1,000 vs. >/=1,000). RESULTS: We found no 
      significant difference between the age of onset and CTG repeat length in our 
      pediatric patient population. Based on clinical subgrouping, we found that the 
      congenital-onset subgroup was statistically different with respect to several 
      variables, including prematurity, rate of admission to neonatal intensive care 
      unit, need for respiratory support at birth, hypotonia, dysphagia, ventilator 
      dependence, and functional status on last visit, compared to the late-onset 
      subgroup. Based on genetic subgrouping, we found a single variable (poor feeding 
      in neonate) that was significantly different in the large CTG subgroup than that 
      in the small CTG subgroup. CONCLUSION: Clinical variables exhibiting 
      statistically significant differences between the subgroups should be focused on 
      prognosis and designing tailored management approaches for the patients; our 
      findings will contribute to achieve this important goal for treating patients 
      with DM1.
FAU - Kim, Hyeong Jung
AU  - Kim HJ
AD  - Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
FAU - Na, Ji-Hoon
AU  - Na JH
AD  - Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
FAU - Lee, Young-Mock
AU  - Lee YM
AD  - Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20180923
PL  - Korea (South)
TA  - Korean J Pediatr
JT  - Korean journal of pediatrics
JID - 101215374
PMC - PMC6382962
OTO - NOTNLM
OT  - Age of onset
OT  - CTG repeat
OT  - Genotype
OT  - Myotonic dystrophy type 1
OT  - Phenotype
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2018/10/12 06:00
MHDA- 2018/10/12 06:01
PMCR- 2019/02/01
CRDT- 2018/10/12 06:00
PHST- 2018/08/28 00:00 [received]
PHST- 2018/09/20 00:00 [accepted]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2018/10/12 06:01 [medline]
PHST- 2018/10/12 06:00 [entrez]
PHST- 2019/02/01 00:00 [pmc-release]
AID - kjp.2018.06919 [pii]
AID - kjp-2018-06919 [pii]
AID - 10.3345/kjp.2018.06919 [doi]
PST - ppublish
SO  - Korean J Pediatr. 2019 Feb;62(2):55-61. doi: 10.3345/kjp.2018.06919. Epub 2018 
      Sep 23.

PMID- 30216892
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20211204
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 32
DP  - 2018 Oct
TI  - Generation of induced pluripotent stem cell line(ZZUi006-A)from a patient with 
      myotonic dystrophy type 1.
PG  - 61-64
LID - S1873-5061(18)30205-8 [pii]
LID - 10.1016/j.scr.2018.08.013 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a dominantly inherited neurodegenerative 
      disease caused by a CTG repeat expansion close to the DMPK gene. The fibroblasts 
      from a patient with DM1 were successfully converted to induced pluripotent stem 
      cells (iPSCs), designated ZZUi006-A, by employing episomal plasmids expressing 
      OCT3/4, SOX2, KLF4, LIN28, L-MYC. The ZZUi006-A cell line may provide a robust 
      platform for further study of DM1 pathogenesis as well as drug testing and gene 
      therapy research.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Wang, Yanlin
AU  - Wang Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Wang, Zhilei
AU  - Wang Z
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Sun, Huifang
AU  - Sun H
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Shi, Changhe
AU  - Shi C
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Liu, Yutao
AU  - Liu Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Liu, Han
AU  - Liu H
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, Shoutao
AU  - Zhang S
AD  - School of life sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Center for Stem Cell and Regenerative Medicine, Department of Basic Medical 
      Sciences, The First Affiliated Hospital, College of Medicine, Zhejiang 
      University, Hangzhou, Zhejiang 310058, China; Institute of Hematology, Zhejiang 
      University, Hangzhou, Zhejiang 310058, China.
FAU - Xu, Yuming
AU  - Xu Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China. Electronic address: xuyuming@zzu.edu.cn.
FAU - Zhang, Jin
AU  - Zhang J
AD  - Center for Stem Cell and Regenerative Medicine, Department of Basic Medical 
      Sciences, The First Affiliated Hospital, College of Medicine, Zhejiang 
      University, Hangzhou, Zhejiang 310058, China; Institute of Hematology, Zhejiang 
      University, Hangzhou, Zhejiang 310058, China. Electronic address: 
      zhgene@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180822
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
SB  - IM
MH  - Cell Differentiation/genetics/physiology
MH  - Cell Line
MH  - Cells, Cultured
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology/metabolism
MH  - Karyotype
MH  - Kruppel-Like Factor 4
MH  - Male
MH  - Microsatellite Repeats/genetics
MH  - Middle Aged
MH  - Myotonic Dystrophy/*metabolism
MH  - Polymerase Chain Reaction
EDAT- 2018/09/15 06:00
MHDA- 2019/04/16 06:00
CRDT- 2018/09/15 06:00
PHST- 2018/07/28 00:00 [received]
PHST- 2018/08/10 00:00 [accepted]
PHST- 2018/09/15 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2018/09/15 06:00 [entrez]
AID - S1873-5061(18)30205-8 [pii]
AID - 10.1016/j.scr.2018.08.013 [doi]
PST - ppublish
SO  - Stem Cell Res. 2018 Oct;32:61-64. doi: 10.1016/j.scr.2018.08.013. Epub 2018 Aug 
      22.

PMID- 30140252
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 9
DP  - 2018
TI  - Myotonic Dystrophy-A Progeroid Disease?
PG  - 601
LID - 10.3389/fneur.2018.00601 [doi]
LID - 601
AB  - Myotonic dystrophies (DM) are slowly progressing multisystemic disorders caused 
      by repeat expansions in the DMPK or CNBP genes. The multisystemic involvement in 
      DM patients often reflects the appearance of accelerated aging. This is partly 
      due to visible features such as cataracts, muscle weakness, and frontal baldness, 
      but there are also less obvious features like cardiac arrhythmia, diabetes or 
      hypogammaglobulinemia. These aging features suggest the hypothesis that DM could 
      be a segmental progeroid disease. To identify the molecular cause of this 
      characteristic appearance of accelerated aging we compare clinical features of DM 
      to "typical" segmental progeroid disorders caused by mutations in DNA repair or 
      nuclear envelope proteins. Furthermore, we characterize if this premature aging 
      effect is also reflected on the cellular level in DM and investigate overlaps 
      with "classical" progeroid disorders. To investigate the molecular similarities 
      at the cellular level we use primary DM and control cell lines. This analysis 
      reveals many similarities to progeroid syndromes linked to the nuclear envelope. 
      Our comparison on both clinical and molecular levels argues for qualification of 
      DM as a segmental progeroid disorder.
FAU - Meinke, Peter
AU  - Meinke P
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Hintze, Stefan
AU  - Hintze S
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Limmer, Sarah
AU  - Limmer S
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
FAU - Schoser, Benedikt
AU  - Schoser B
AD  - Friedrich-Baur-Institute at the Department of Neurology, University Hospital, 
      Ludwig-Maximilians-University Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180725
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC6095001
OTO - NOTNLM
OT  - DNA repair
OT  - myotonic dystrophy
OT  - nuclear envelope
OT  - premature aging
OT  - segmental progeroid disorder
EDAT- 2018/08/25 06:00
MHDA- 2018/08/25 06:01
PMCR- 2018/07/25
CRDT- 2018/08/25 06:00
PHST- 2018/03/19 00:00 [received]
PHST- 2018/07/06 00:00 [accepted]
PHST- 2018/08/25 06:00 [entrez]
PHST- 2018/08/25 06:00 [pubmed]
PHST- 2018/08/25 06:01 [medline]
PHST- 2018/07/25 00:00 [pmc-release]
AID - 10.3389/fneur.2018.00601 [doi]
PST - epublish
SO  - Front Neurol. 2018 Jul 25;9:601. doi: 10.3389/fneur.2018.00601. eCollection 2018.

PMID- 30094526
OWN - NLM
STAT- MEDLINE
DCOM- 20181116
LR  - 20181116
IS  - 1590-3478 (Electronic)
IS  - 1590-1874 (Linking)
VI  - 39
IP  - 11
DP  - 2018 Nov
TI  - Diastolic heart dysfunction is correlated with CTG repeat length in myotonic 
      dystrophy type 1.
PG  - 1935-1943
LID - 10.1007/s10072-018-3530-z [doi]
AB  - The aims of this study were to investigate the correlations of tri-nucleotide 
      (CTG) repeat length with detailed echocardiography (ECHO) parameters that 
      represent myocardial function and to find a relationship between heart function 
      and CTG repeat length in adult-onset myotonic dystrophy type 1 (DM1). In this 
      study, clinical data for patients with DM1, including age, onset age, CTG repeat 
      length, Medical Research Council sum score (MRCSS), and 6-min walking test 
      (6MWT), were recorded. In addition, ECHO parameters and cardiac conduction 
      abnormalities were evaluated. Among the cardiac parameters, the EA ratio and left 
      ventricular end-diastolic dimension (LVEDD) were significantly correlated with 
      the CTG repeat length (p < 0.05). Interventricular septal thickness at 
      end-diastole was also significantly correlated with the 6MWT in a multivariate 
      linear regression model (p < 0.05). In conclusion, motor function (MRCSS and 
      6MWT) and CTG repeat length significantly correlated with LV diastolic 
      dysfunction in patients with DM1. More emphasis should be given to diastolic 
      dysfunction, which is currently under-recognized, when evaluating patients with 
      DM1 with no abnormalities in routine electrocardiography studies. Lastly, 
      well-designed and longitudinal studies are warranted to characterize and 
      understand the pathophysiology of diastolic dysfunction in DM1.
FAU - Park, Jin-Sung
AU  - Park JS
AD  - Department of Neurology, School of Medicine, Kyungpook National University 
      Chilgok hospital, Daegu, South Korea.
FAU - Kim, Namkyun
AU  - Kim N
AD  - Department of Internal Medicine, Kyungpook National University, School of 
      Medicine, Daegu, South Korea.
FAU - Park, Donghwi
AU  - Park D
AUID- ORCID: 0000-0002-7724-4682
AD  - Department of Rehabilitation Medicine, Daegu Fatima Hospital, Ayangro 99, Dong 
      gu, Daegu, 41199, Republic of Korea. bdome@hanmail.net.
LA  - eng
GR  - NRF- 2017R1D1A1B03033127/Korea Basic Science Institute/
PT  - Journal Article
DEP - 20180809
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiomyopathies/etiology/genetics
MH  - Echocardiography
MH  - Extremities/physiopathology
MH  - Female
MH  - Gait/physiology
MH  - Heart/physiopathology
MH  - Heart Diseases/*etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/*genetics/physiopathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Reproducibility of Results
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Walking/physiology
MH  - Young Adult
OTO - NOTNLM
OT  - Aerobic exercise
OT  - CTG repeat
OT  - Left ventricle diastolic dysfunction
OT  - Myocardial dysfunction
OT  - Myotonia
OT  - Myotonic dystrophy type 1
EDAT- 2018/08/11 06:00
MHDA- 2018/11/18 06:00
CRDT- 2018/08/11 06:00
PHST- 2018/04/27 00:00 [received]
PHST- 2018/08/07 00:00 [accepted]
PHST- 2018/08/11 06:00 [pubmed]
PHST- 2018/11/18 06:00 [medline]
PHST- 2018/08/11 06:00 [entrez]
AID - 10.1007/s10072-018-3530-z [pii]
AID - 10.1007/s10072-018-3530-z [doi]
PST - ppublish
SO  - Neurol Sci. 2018 Nov;39(11):1935-1943. doi: 10.1007/s10072-018-3530-z. Epub 2018 
      Aug 9.

PMID- 29982462
OWN - NLM
STAT- MEDLINE
DCOM- 20190328
LR  - 20211204
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 27
IP  - 19
DP  - 2018 Oct 1
TI  - Pharmacological and physiological activation of AMPK improves the spliceopathy in 
      DM1 mouse muscles.
PG  - 3361-3376
LID - 10.1093/hmg/ddy245 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a debilitating multisystemic disorder caused 
      by a triplet repeat expansion in the 3' untranslated region of dystrophia 
      myotonica protein kinase mRNAs. Mutant mRNAs accumulate in the nucleus of 
      affected cells and misregulate RNA-binding proteins, thereby promoting 
      characteristic missplicing events. However, little is known about the signaling 
      pathways that may be affected in DM1. Here, we investigated the status of 
      activated protein kinase (AMPK) signaling in DM1 skeletal muscle and found that 
      the AMPK pathway is markedly repressed in a DM1 mouse model (human skeletal 
      actin-long repeat, HSALR) and patient-derived DM1 myoblasts. Chronic 
      pharmacological activation of AMPK signaling in DM1 mice with 
      5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) has multiple 
      beneficial effects on the DM1 phenotype. Indeed, a 6-week AICAR treatment of DM1 
      mice promoted expression of a slower, more oxidative phenotype, improved muscle 
      histology and corrected several events associated with RNA toxicity. Importantly, 
      AICAR also had a dose-dependent positive effect on the spliceopathy in 
      patient-derived DM1 myoblasts. In separate experiments, we also show that chronic 
      treatment of DM1 mice with resveratrol as well as voluntary wheel running also 
      rescued missplicing events in muscle. Collectively, our findings demonstrate the 
      therapeutic potential of chronic AMPK stimulation both physiologically and 
      pharmacologically for DM1 patients.
FAU - Ravel-Chapuis, Aymeric
AU  - Ravel-Chapuis A
AD  - Department of Cellular and Molecular Medicine, Faculty of Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
FAU - Al-Rewashdy, Ali
AU  - Al-Rewashdy A
AD  - Department of Cellular and Molecular Medicine, Faculty of Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
FAU - Belanger, Guy
AU  - Belanger G
AD  - Department of Cellular and Molecular Medicine, Faculty of Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
FAU - Jasmin, Bernard J
AU  - Jasmin BJ
AD  - Department of Cellular and Molecular Medicine, Faculty of Medicine, University of 
      Ottawa, Ottawa, ON, Canada.
LA  - eng
GR  - CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleotides)
RN  - 360-97-4 (Aminoimidazole Carboxamide)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
RN  - F0X88YW0YK (AICA ribonucleotide)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - Aminoimidazole Carboxamide/administration & dosage/*analogs & derivatives
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - Mice
MH  - Motor Activity/drug effects
MH  - Muscle, Skeletal/drug effects/physiopathology
MH  - Myoblasts/drug effects
MH  - Myotonic Dystrophy/*drug therapy/genetics/physiopathology
MH  - Protein Kinases/*genetics
MH  - RNA, Messenger/drug effects/genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Resveratrol/administration & dosage
MH  - Ribonucleotides/*administration & dosage
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC6140770
EDAT- 2018/07/10 06:00
MHDA- 2019/03/29 06:00
PMCR- 2019/10/01
CRDT- 2018/07/09 06:00
PHST- 2018/03/29 00:00 [received]
PHST- 2018/06/28 00:00 [accepted]
PHST- 2018/07/10 06:00 [pubmed]
PHST- 2019/03/29 06:00 [medline]
PHST- 2018/07/09 06:00 [entrez]
PHST- 2019/10/01 00:00 [pmc-release]
AID - 5048220 [pii]
AID - ddy245 [pii]
AID - 10.1093/hmg/ddy245 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2018 Oct 1;27(19):3361-3376. doi: 10.1093/hmg/ddy245.

PMID- 29973908
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 9
DP  - 2018
TI  - Distribution and Structure of DM2 Repeat Tract Alleles in the German Population.
PG  - 463
LID - 10.3389/fneur.2018.00463 [doi]
LID - 463
AB  - Autosomal dominant inherited Myotonic dystrophy type 1 and 2 (DM1 and DM2) are 
      the most frequent muscle dystrophies in the European population and are caused by 
      repeat expansion mutations. For Germany cumulative empiric evidence suggests an 
      estimated prevalence of DM2 of roughly 9 in 100,000, therefore being as prevalent 
      as DM1. In DM2, a (CCTG)(n) repeat tract located in the first intron of the CNBP 
      gene is expanded. The CCTG repeat tract is part of a complex repeat structure 
      comprising not only CCTG tetraplets but also repeated TG dinucleotides and TCTG 
      tetraplet elements as well as NCTG interruptions. Here, we provide the 
      distribution of normal sized alleles in the German population, which was found to 
      be highly similar to the Slovak population. Sequencing of 34 unexpanded healthy 
      range alleles in DM2 positive patients (heterozygous for a full expansion) 
      revealed that the CCTG repeat tract is usually interrupted by at least three 
      tetraplets which according to current opinion is supposed to render it stable 
      against expansion. Interestingly, only the largest analyzed normal allele had 23 
      uninterrupted CCTGs and consequently could represent an instable early 
      premutation allele. In our diagnostic history of DM2 cases, a total of 18 
      premutations were detected in 16 independent cases. Here, we describe two 
      premutation families, one with an expansion from a premutation allele and the 
      other with a contraction of a full expansion down to a premutation allele. Our 
      diagnostic results support the general assumption that the premutation range of 
      unstable CCTG stretches lies obviously between 25 and 75 CCTGs. However, the 
      clinical significance of premutation alleles is still unclear. In the light of 
      the two described families we suggest incomplete penetrance. Thus, as it was 
      proposed for other repeat expansion diseases (e.g., Huntington's disease), a 
      fluid transition of penetrance is more likely rather than a clear cut CCTG number 
      threshold.
FAU - Mahyera, Alexis S
AU  - Mahyera AS
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Schneider, Tamara
AU  - Schneider T
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Halliger-Keller, Birgit
AU  - Halliger-Keller B
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Schrooten, Katja
AU  - Schrooten K
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Horner, Eva-Maria
AU  - Horner EM
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Rost, Simone
AU  - Rost S
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
FAU - Kress, Wolfram
AU  - Kress W
AD  - Institute of Human Genetics, Julius-Maximilians-University of Wurzburg, Wurzburg, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20180619
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC6020772
OTO - NOTNLM
OT  - DM2
OT  - de novo expansion
OT  - intergenerational contraction
OT  - penetrance
OT  - premutation
OT  - prevalence
EDAT- 2018/07/06 06:00
MHDA- 2018/07/06 06:01
PMCR- 2018/06/19
CRDT- 2018/07/06 06:00
PHST- 2018/03/14 00:00 [received]
PHST- 2018/05/30 00:00 [accepted]
PHST- 2018/07/06 06:00 [entrez]
PHST- 2018/07/06 06:00 [pubmed]
PHST- 2018/07/06 06:01 [medline]
PHST- 2018/06/19 00:00 [pmc-release]
AID - 10.3389/fneur.2018.00463 [doi]
PST - epublish
SO  - Front Neurol. 2018 Jun 19;9:463. doi: 10.3389/fneur.2018.00463. eCollection 2018.

PMID- 29967337
OWN - NLM
STAT- MEDLINE
DCOM- 20190315
LR  - 20240211
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 26
IP  - 11
DP  - 2018 Nov
TI  - De novo repeat interruptions are associated with reduced somatic instability and 
      mild or absent clinical features in myotonic dystrophy type 1.
PG  - 1635-1647
LID - 10.1038/s41431-018-0156-9 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystem disorder, caused by expansion of 
      a CTG trinucleotide repeat in the 3'-untranslated region of the DMPK gene. The 
      repeat expansion is somatically unstable and tends to increase in length with 
      time, contributing to disease progression. In some individuals, the repeat array 
      is interrupted by variant repeats such as CCG and CGG, stabilising the expansion 
      and often leading to milder symptoms. We have characterised three families, each 
      including one person with variant repeats that had arisen de novo on paternal 
      transmission of the repeat expansion. Two individuals were identified for 
      screening due to an unusual result in the laboratory diagnostic test, and the 
      third due to exceptionally mild symptoms. The presence of variant repeats in all 
      three expanded alleles was confirmed by restriction digestion of small pool PCR 
      products, and allele structures were determined by PacBio sequencing. Each was 
      different, but all contained CCG repeats close to the 3'-end of the repeat 
      expansion. All other family members had inherited pure CTG repeats. The variant 
      repeat-containing alleles were more stable in the blood than pure alleles of 
      similar length, which may in part account for the mild symptoms observed in all 
      three individuals. This emphasises the importance of somatic instability as a 
      disease mechanism in DM1. Further, since patients with variant repeats may have 
      unusually mild symptoms, identification of these individuals has important 
      implications for genetic counselling and for patient stratification in DM1 
      clinical trials.
FAU - Cumming, Sarah A
AU  - Cumming SA
AUID- ORCID: 0000-0002-0201-3660
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
FAU - Hamilton, Mark J
AU  - Hamilton MJ
AUID- ORCID: 0000-0001-9719-243X
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK. 
      markhamilton1@nhs.net.
AD  - West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, 
      Glasgow, G51 4TF, UK. markhamilton1@nhs.net.
FAU - Robb, Yvonne
AU  - Robb Y
AD  - Clinical Genetics Service, Western General Hospital, Edinburgh, EH4 2XU, UK.
FAU - Gregory, Helen
AU  - Gregory H
AD  - Department of Clinical Genetics, Aberdeen Royal Hospital, Aberdeen, AB25 2ZA, UK.
FAU - McWilliam, Catherine
AU  - McWilliam C
AD  - Human Genetics Unit, Ninewells Hospital, Dundee, DD1 9SY, UK.
FAU - Cooper, Anneli
AU  - Cooper A
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
FAU - Adam, Berit
AU  - Adam B
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
FAU - McGhie, Josephine
AU  - McGhie J
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
FAU - Hamilton, Graham
AU  - Hamilton G
AUID- ORCID: 0000-0001-6702-7724
AD  - Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University 
      of Glasgow, Glasgow, G61 1QH, UK.
FAU - Herzyk, Pawel
AU  - Herzyk P
AD  - Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University 
      of Glasgow, Glasgow, G61 1QH, UK.
FAU - Tschannen, Michael R
AU  - Tschannen MR
AD  - Human and Molecular Genetics Center, Medical College Wisconsin, 8701 Watertown 
      Plank Road, Milwaukee, WI, 53226, USA.
FAU - Worthey, Elizabeth
AU  - Worthey E
AD  - Human and Molecular Genetics Center, Medical College Wisconsin, 8701 Watertown 
      Plank Road, Milwaukee, WI, 53226, USA.
AD  - Hudson Alpha Institute for Biotechnology, 601 Genome Way, NW, Huntsville, AL, 
      35806, USA.
FAU - Petty, Richard
AU  - Petty R
AD  - Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, Glasgow, G51 4TF, UK.
FAU - Ballantyne, Bob
AU  - Ballantyne B
AD  - West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, 
      Glasgow, G51 4TF, UK.
CN  - Scottish Myotonic Dystrophy Consortium
FAU - Warner, Jon
AU  - Warner J
AD  - Molecular Genetics Service, Molecular Medicine Centre, Western General Hospital, 
      Crewe Road, Edinburgh, EH4 2XU, UK.
FAU - Farrugia, Maria Elena
AU  - Farrugia ME
AD  - Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth 
      University Hospital, Glasgow, G51 4TF, UK.
FAU - Longman, Cheryl
AU  - Longman C
AD  - West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, 
      Glasgow, G51 4TF, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AUID- ORCID: 0000-0002-8298-8264
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 097821/Z/11/Z/WT_/Wellcome Trust/United Kingdom
GR  - CAF/MD/15/01/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180702
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase/genetics
MH  - Pedigree
MH  - *Phenotype
MH  - *Trinucleotide Repeat Expansion
PMC - PMC6189127
MID - EMS76980
COIS- Professor Monckton has been a paid scientific consultant of Biogen Idec, AMO 
      Pharma, Charles River and Vertex Pharmaceuticals. Professor Monckton also has a 
      research contract with AMO Pharma.
EDAT- 2018/07/04 06:00
MHDA- 2019/03/16 06:00
PMCR- 2019/11/01
CRDT- 2018/07/04 06:00
PHST- 2018/01/18 00:00 [received]
PHST- 2018/03/30 00:00 [accepted]
PHST- 2018/03/23 00:00 [revised]
PHST- 2018/07/04 06:00 [pubmed]
PHST- 2019/03/16 06:00 [medline]
PHST- 2018/07/04 06:00 [entrez]
PHST- 2019/11/01 00:00 [pmc-release]
AID - 10.1038/s41431-018-0156-9 [pii]
AID - 156 [pii]
AID - 10.1038/s41431-018-0156-9 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2018 Nov;26(11):1635-1647. doi: 10.1038/s41431-018-0156-9. Epub 
      2018 Jul 2.

PMID- 29947794
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20240312
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 46
IP  - 16
DP  - 2018 Sep 19
TI  - Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in 
      myotonic dystrophy patient-derived iPS and myogenic cells.
PG  - 8275-8298
LID - 10.1093/nar/gky548 [doi]
AB  - CRISPR/Cas9 is an attractive platform to potentially correct dominant genetic 
      diseases by gene editing with unprecedented precision. In the current 
      proof-of-principle study, we explored the use of CRISPR/Cas9 for gene-editing in 
      myotonic dystrophy type-1 (DM1), an autosomal-dominant muscle disorder, by 
      excising the CTG-repeat expansion in the 3'-untranslated-region (UTR) of the 
      human myotonic dystrophy protein kinase (DMPK) gene in DM1 patient-specific 
      induced pluripotent stem cells (DM1-iPSC), DM1-iPSC-derived myogenic cells and 
      DM1 patient-specific myoblasts. To eliminate the pathogenic gain-of-function 
      mutant DMPK transcript, we designed a dual guide RNA based strategy that excises 
      the CTG-repeat expansion with high efficiency, as confirmed by Southern blot and 
      single molecule real-time (SMRT) sequencing. Correction efficiencies up to 90% 
      could be attained in DM1-iPSC as confirmed at the clonal level, following 
      ribonucleoprotein (RNP) transfection of CRISPR/Cas9 components without the need 
      for selective enrichment. Expanded CTG repeat excision resulted in the 
      disappearance of ribonuclear foci, a quintessential cellular phenotype of DM1, in 
      the corrected DM1-iPSC, DM1-iPSC-derived myogenic cells and DM1 myoblasts. 
      Consequently, the normal intracellular localization of the muscleblind-like 
      splicing regulator 1 (MBNL1) was restored, resulting in the normalization of 
      splicing pattern of SERCA1. This study validates the use of CRISPR/Cas9 for gene 
      editing of repeat expansions.
FAU - Dastidar, Sumitava
AU  - Dastidar S
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Ardui, Simon
AU  - Ardui S
AD  - Department of Human Genetics, University of Leuven, Leuven 3000, Belgium.
FAU - Singh, Kshitiz
AU  - Singh K
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Majumdar, Debanjana
AU  - Majumdar D
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Nair, Nisha
AU  - Nair N
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Fu, Yanfang
AU  - Fu Y
AD  - Molecular Pathology Unit, Center for Cancer Research and Center for Computational 
      and Integrative Biology, Massachusetts General Hospital, Charlestown, MA02129, 
      USA.
AD  - Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Reyon, Deepak
AU  - Reyon D
AD  - Molecular Pathology Unit, Center for Cancer Research and Center for Computational 
      and Integrative Biology, Massachusetts General Hospital, Charlestown, MA02129, 
      USA.
AD  - Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Samara, Ermira
AU  - Samara E
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Gerli, Mattia F M
AU  - Gerli MFM
AD  - Department of Cell and Developmental Biology, University College London, London 
      WC1E6DE, UK.
FAU - Klein, Arnaud F
AU  - Klein AF
AD  - Sorbonne Universites, INSERM, Association Institute de Myologie, Center de 
      Recherche en Myologie, F-75013 , France.
FAU - De Schrijver, Wito
AU  - De Schrijver W
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Tipanee, Jaitip
AU  - Tipanee J
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Seneca, Sara
AU  - Seneca S
AD  - Research Group Reproduction and Genetics (REGE), Center for Medical Genetics, UZ 
      Brussels, Vrije Universiteit Brussel, Brussels 1090, Belgium.
FAU - Tulalamba, Warut
AU  - Tulalamba W
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - Chai, Yoke Chin
AU  - Chai YC
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
FAU - In't Veld, Peter
AU  - In't Veld P
AD  - Department of Pathology, Vrije Universiteit Brussel, Brussels 1090, Belgium.
FAU - Furling, Denis
AU  - Furling D
AD  - Sorbonne Universites, INSERM, Association Institute de Myologie, Center de 
      Recherche en Myologie, F-75013 , France.
FAU - Tedesco, Francesco Saverio
AU  - Tedesco FS
AD  - Department of Cell and Developmental Biology, University College London, London 
      WC1E6DE, UK.
FAU - Vermeesch, Joris R
AU  - Vermeesch JR
AD  - Department of Human Genetics, University of Leuven, Leuven 3000, Belgium.
FAU - Joung, J Keith
AU  - Joung JK
AD  - Molecular Pathology Unit, Center for Cancer Research and Center for Computational 
      and Integrative Biology, Massachusetts General Hospital, Charlestown, MA02129, 
      USA.
AD  - Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Chuah, Marinee K
AU  - Chuah MK
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
AD  - Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, 
      University of Leuven, Leuven 3000, Belgium.
FAU - VandenDriessche, Thierry
AU  - VandenDriessche T
AD  - Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, 
      Brussels 1090, Belgium.
AD  - Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, 
      University of Leuven, Leuven 3000, Belgium.
LA  - eng
GR  - DP1 GM105378/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
MH  - *CRISPR-Cas Systems
MH  - Cells, Cultured
MH  - Child
MH  - Female
MH  - Gene Editing/*methods
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*metabolism
MH  - Middle Aged
MH  - Muscle Development/genetics
MH  - Myoblasts/*metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC6144820
EDAT- 2018/06/28 06:00
MHDA- 2019/08/14 06:00
PMCR- 2018/06/27
CRDT- 2018/06/28 06:00
PHST- 2016/11/09 00:00 [received]
PHST- 2018/06/05 00:00 [accepted]
PHST- 2018/06/28 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/06/28 06:00 [entrez]
PHST- 2018/06/27 00:00 [pmc-release]
AID - 5045645 [pii]
AID - gky548 [pii]
AID - 10.1093/nar/gky548 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2018 Sep 19;46(16):8275-8298. doi: 10.1093/nar/gky548.

PMID- 29664219
OWN - NLM
STAT- MEDLINE
DCOM- 20190614
LR  - 20190614
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Linking)
VI  - 39
IP  - 7
DP  - 2018 Jul
TI  - Unusual association of a unique CAG interruption in 5' of DM1 CTG repeats with 
      intergenerational contractions and low somatic mosaicism.
PG  - 970-982
LID - 10.1002/humu.23531 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a dominant multisystemic disorder associated 
      with high variability of symptoms and anticipation. DM1 is caused by an unstable 
      CTG repeat expansion that usually increases in successive generations and 
      tissues. DM1 family pedigrees have shown that  approximately 90% and 10% of transmissions 
      result in expansions and contractions of the CTG repeat, respectively. To date, 
      the mechanisms of CTG repeat contraction remain poorly documented in DM1. In this 
      report, we identified two new DM1 families with apparent contractions and no 
      worsening of DM1 symptoms in two and three successive maternal transmissions. A 
      new and unique CAG interruption was found in 5' of the CTG expansion in one 
      family, whereas multiple 5' CCG interruptions were detected in the second family. 
      We showed that these interruptions are associated with maternal intergenerational 
      contractions and low somatic mosaicism in blood. By specific triplet-prime PCR, 
      we observed that CTG repeat changes (contractions/expansions) occur 
      preferentially in 3' of the interruptions for both families.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Tome, Stephanie
AU  - Tome S
AUID- ORCID: 0000-0002-0135-9256
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France; Institut Imagine, Universite 
      Paris-Descartes-Sorbonne Paris-Cite, Paris, France.
FAU - Dandelot, Elodie
AU  - Dandelot E
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France; Institut Imagine, Universite 
      Paris-Descartes-Sorbonne Paris-Cite, Paris, France.
FAU - Dogan, Celine
AU  - Dogan C
AD  - Neuromuscular Reference Center, AP-HP, Hopital Pitie-Salpetriere, F-75013, Paris, 
      France.
FAU - Bertrand, Alexis
AU  - Bertrand A
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France; Institut Imagine, Universite 
      Paris-Descartes-Sorbonne Paris-Cite, Paris, France.
FAU - Genevieve, David
AU  - Genevieve D
AD  - Molecular Genetic Laboratory, Necker Hospital, Paris, France.
AD  - Departement de Genetique Medicale, Maladies Rares et Medecine Personnalisee, CHU 
      Montpellier, Universite Montpellier, Montpellier, France.
FAU - Pereon, Yann
AU  - Pereon Y
AD  - Centre for Neuromuscular Diseases, Hotel-Dieu Hospital, Nantes, France.
CN  - DM contraction study group
AD  - Pauline Arnaud: Department of genetic, Bichat Hospital, Paris, France, Raphaele 
      Chasserieau: Centre for Neuromuscular Diseases, Hotel-Dieu Hospital, Nantes, 
      France, Pascal Cintas: Neuromuscular Reference Center, Purpan Hospital, Toulouse, 
      France, Ana-maria Cobo Esteban: Neuromuscular Reference Center, Marin Hospital, 
      Hendaye, France, Marie-Carmen Cruz: Neuromuscular Reference Center, Purpan 
      Hospital, Toulouse, France, Dalil Hamroun: Centre Hospitalo-Universitaire de 
      Montpellier, Montpellier, France, Armelle Magot: Neuromuscular Reference Center, 
      Hotel-Dieu Hospital, Nantes, France, Alexandra Nadaj-Pakleza Neuromuscular 
      Reference Center, Larrey Hospital, Angers, France, Anne-catherine Aube-Gauthier 
      Neuromuscular Reference Center, Larrey Hospital, Angers, France, Andoni 
      Urtizberea: Neuromuscular Reference Center, Marin Hospital, Hendaye, France.
FAU - Simon, Marie
AU  - Simon M
AD  - Molecular Genetic Laboratory, Necker Hospital, Paris, France.
FAU - Bonnefont, Jean-Paul
AU  - Bonnefont JP
AD  - Molecular Genetic Laboratory, Necker Hospital, Paris, France.
FAU - Bassez, Guillaume
AU  - Bassez G
AD  - Sorbonne Universite, Inserm, UMRS974, Neuromuscular Reference center, AP-HP, 
      Hopital Pitie-Salpetriere, F-75013, Paris, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Laboratory CTGDM, Inserm UMR1163, Paris, France; Institut Imagine, Universite 
      Paris-Descartes-Sorbonne Paris-Cite, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180519
PL  - United States
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alleles
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - *Mosaicism
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Myotonin-Protein Kinase/genetics
MH  - Pedigree
MH  - Trinucleotide Repeat Expansion/*genetics
OTO - NOTNLM
OT  - CTG contractions and 5' single CAG interruption
OT  - myotonic dystrophy type 1
OT  - triplet repeat instability
EDAT- 2018/04/18 06:00
MHDA- 2019/06/15 06:00
CRDT- 2018/04/18 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/03/23 00:00 [revised]
PHST- 2018/04/10 00:00 [accepted]
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2019/06/15 06:00 [medline]
PHST- 2018/04/18 06:00 [entrez]
AID - 10.1002/humu.23531 [doi]
PST - ppublish
SO  - Hum Mutat. 2018 Jul;39(7):970-982. doi: 10.1002/humu.23531. Epub 2018 May 19.

PMID- 29605961
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1439-1902 (Electronic)
IS  - 0171-6425 (Linking)
VI  - 66
IP  - 8
DP  - 2018 Nov
TI  - Factors Affecting Postoperative Lung Expansion in Patients with Pyogenic Empyema.
PG  - 697-700
LID - 10.1055/s-0038-1635085 [doi]
AB  - BACKGROUND: In patients with parapneumonic empyema, decortication is usually 
      preferred to ensure functional lung re-expansion. However, there could be 
      patients exhibiting incomplete postoperative lung expansion and inadequate 
      drainage despite decortication. Therefore, we evaluated factors affecting 
      postoperative lung expansion in patients undergoing decortication. METHODS: A 
      total of 221 patients with pyogenic empyema who underwent video-assisted 
      thoracoscopic surgery (VATS) between January and October 2016 in our hospital 
      were reviewed in terms of surgical success. The following factors were evaluated: 
      age; the time between identification of a localized effusion and surgical 
      referral; chest tube drainage durations; any underlying morbidity preoperative 
      blood culture data; and the thickness of the visceral pleura. RESULTS: Several 
      factors that significantly prolonged the postoperative time to lung expansion 
      were evident in patients with diabetes mellitus (DM) and bacteremia; 
      postoperative chest tube drainage was significantly longer in those with DM 
      (p = 0.009) and bacteremia (p = 0.01); and postoperative hospitalization time was 
      significantly longer in patients with bacteremia (p = 0.01). The thickness of the 
      visceral pleura was strongly correlated with postoperative chest tube drainage 
      duration and postoperative hospitalization time (Pearson correlation coefficient, 
      r = 0.245, p = 0.00). CONCLUSIONS: In patients with DM, bacteremia, or thickened 
      pleura, the time to lung expansion after operation was longer. Therefore, 
      stricter pre- and post-operative control of blood-sugar levels and adequate 
      antibiotics are required to facilitate postoperative lung re-expansion. In 
      patients with thickened pleurae, prolonged chest tube placement is unavoidable.
CI  - Georg Thieme Verlag KG Stuttgart . New York.
FAU - Ahn, Hyo Yeong
AU  - Ahn HY
AD  - Department of Thoracic and Cardiovascular Surgery, Pusan National University 
      Hospital, Medical Research Institution, Busan, the Republic of Korea.
FAU - Cho, Jeong Su
AU  - Cho JS
AD  - Department of Thoracic and Cardiovascular Surgery, Pusan National University 
      Hospital, Medical Research Institution, Busan, the Republic of Korea.
FAU - Kim, Yeong Dae
AU  - Kim YD
AD  - Department of Thoracic and Cardiovascular Surgery, Pusan National University 
      Hospital, Medical Research Institution, Busan, the Republic of Korea.
FAU - I, Hoseok
AU  - I H
AD  - Department of Thoracic and Cardiovascular Surgery, Pusan National University 
      Hospital, Medical Research Institution, Busan, the Republic of Korea.
FAU - Song, Seunghwan
AU  - Song S
AD  - Department of Thoracic and Cardiovascular Surgery, Pusan National University 
      Hospital, Medical Research Institution, Busan, the Republic of Korea.
FAU - Eom, Jung Seop
AU  - Eom JS
AD  - Division of Pulmonology, Allergy and Critical Care Medicine, Department of 
      Internal Medicine, Pusan National University Hospital, Medical Research 
      Institution, Busan, the Republic of Korea.
FAU - Mok, Jeongha
AU  - Mok J
AD  - Division of Pulmonology, Allergy and Critical Care Medicine, Department of 
      Internal Medicine, Pusan National University Hospital, Medical Research 
      Institution, Busan, the Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20180401
PL  - Germany
TA  - Thorac Cardiovasc Surg
JT  - The Thoracic and cardiovascular surgeon
JID - 7903387
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chest Tubes
MH  - Child
MH  - Child, Preschool
MH  - *Drainage/adverse effects/instrumentation
MH  - Empyema, Pleural/diagnostic imaging/microbiology/physiopathology/*surgery
MH  - Female
MH  - Humans
MH  - Length of Stay
MH  - Lung/diagnostic imaging/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Pleura/diagnostic imaging/microbiology/*surgery
MH  - Pleural Effusion/diagnostic imaging/microbiology/physiopathology/*surgery
MH  - Recovery of Function
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - *Thoracic Surgery, Video-Assisted/adverse effects
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Young Adult
COIS- The authors have no conflict of interest.
EDAT- 2018/04/02 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/04/02 06:00
PHST- 2018/04/02 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/04/02 06:00 [entrez]
AID - 10.1055/s-0038-1635085 [doi]
PST - ppublish
SO  - Thorac Cardiovasc Surg. 2018 Nov;66(8):697-700. doi: 10.1055/s-0038-1635085. Epub 
      2018 Apr 1.

PMID- 29592894
OWN - NLM
STAT- MEDLINE
DCOM- 20181001
LR  - 20190605
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Print)
IS  - 1754-8403 (Linking)
VI  - 11
IP  - 4
DP  - 2018 Apr 23
TI  - Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and 
      rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy.
LID - 10.1242/dmm.032557 [doi]
LID - dmm032557
AB  - Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disorder caused 
      by expression of mutant myotonin-protein kinase (DMPK) transcripts containing 
      expanded CUG repeats. Pathogenic DMPK RNA sequesters the muscleblind-like (MBNL) 
      proteins, causing alterations in metabolism of various RNAs. Cardiac dysfunction 
      represents the second most common cause of death in DM type 1 (DM1) patients. 
      However, the contribution of MBNL sequestration in DM1 cardiac dysfunction is 
      unclear. We overexpressed Muscleblind (Mbl), the DrosophilaMBNL orthologue, in 
      cardiomyocytes of DM1 model flies and observed a rescue of heart dysfunctions, 
      which are characteristic of these model flies and resemble cardiac defects 
      observed in patients. We also identified a drug - daunorubicin hydrochloride - 
      that directly binds to CUG repeats and alleviates Mbl sequestration in Drosophila 
      DM1 cardiomyocytes, resulting in mis-splicing rescue and cardiac function 
      recovery. These results demonstrate the relevance of Mbl sequestration caused by 
      expanded-CUG-repeat RNA in cardiac dysfunctions in DM1, and highlight the 
      potential of strategies aimed at inhibiting this protein-RNA interaction to 
      recover normal cardiac function.
CI  - (c) 2018. Published by The Company of Biologists Ltd.
FAU - Chakraborty, Mouli
AU  - Chakraborty M
AD  - Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain.
AD  - Department of Genetics and Interdisciplinary Research Structure for Biotechnology 
      and Biomedicine (ERI BIOTECMED), University of Valencia, Valencia 46100, Spain.
AD  - CIPF-INCLIVA Joint Unit, Valencia 46100, Spain.
FAU - Sellier, Chantal
AU  - Sellier C
AD  - Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie 
      Moleculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, University of 
      Strasbourg, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France.
FAU - Ney, Michel
AU  - Ney M
AD  - Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie 
      Moleculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, University of 
      Strasbourg, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France.
FAU - Pascal, Villa
AU  - Pascal V
AD  - PCBIS Plate-forme de Chimie Biologique Integrative de Strasbourg CNRS UMS 3286, 
      Labex Medalis, ESBS, Universite de Strasbourg, 300 Boulevard Sebastien Brant, 
      67412 Illkirch, France.
FAU - Charlet-Berguerand, Nicolas
AU  - Charlet-Berguerand N
AD  - Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie 
      Moleculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, University of 
      Strasbourg, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France.
FAU - Artero, Ruben
AU  - Artero R
AUID- ORCID: 0000-0003-1596-047X
AD  - Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain 
      ruben.artero@uv.es.
AD  - Department of Genetics and Interdisciplinary Research Structure for Biotechnology 
      and Biomedicine (ERI BIOTECMED), University of Valencia, Valencia 46100, Spain.
AD  - CIPF-INCLIVA Joint Unit, Valencia 46100, Spain.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain.
AD  - Department of Genetics and Interdisciplinary Research Structure for Biotechnology 
      and Biomedicine (ERI BIOTECMED), University of Valencia, Valencia 46100, Spain.
AD  - CIPF-INCLIVA Joint Unit, Valencia 46100, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180423
PL  - England
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
RN  - 0 (Drosophila Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (mbl protein, Drosophila)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - IM
EIN - Dis Model Mech. 2018 May 18;11(5):. PMID: 29784710
MH  - Alternative Splicing/genetics
MH  - Animals
MH  - Daunorubicin/*pharmacology
MH  - Disease Models, Animal
MH  - Drosophila Proteins/genetics/*metabolism
MH  - Drosophila melanogaster/drug effects/*metabolism
MH  - Heart/drug effects/*physiopathology
MH  - Myocytes, Cardiac/drug effects/metabolism
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Nuclear Proteins/genetics/*metabolism
MH  - Protein Binding/drug effects
MH  - RNA Stability/drug effects
MH  - RNA, Messenger/genetics/metabolism
MH  - Reproducibility of Results
MH  - Survival Analysis
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC5963859
OTO - NOTNLM
OT  - Daunorubicin
OT  - Drosophila
OT  - Muscleblind
OT  - Myotonic dystrophy
OT  - Trinucleotide repeat disorder
COIS- Competing interestsThe authors declare no competing or financial interests.
EDAT- 2018/03/30 06:00
MHDA- 2018/10/03 06:00
PMCR- 2018/04/23
CRDT- 2018/03/30 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2018/03/14 00:00 [accepted]
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/03/30 06:00 [entrez]
PHST- 2018/04/23 00:00 [pmc-release]
AID - dmm.032557 [pii]
AID - DMM032557 [pii]
AID - 10.1242/dmm.032557 [doi]
PST - epublish
SO  - Dis Model Mech. 2018 Apr 23;11(4):dmm032557. doi: 10.1242/dmm.032557.

PMID- 29556396
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2051-4190 (Print)
IS  - 2051-4190 (Electronic)
IS  - 2051-4190 (Linking)
VI  - 28
DP  - 2018
TI  - Longer trinucleotide repeats of androgen receptor are associated with higher 
      testosterone and low oxytocin levels in diabetic premature ejaculatory 
      dysfunction patients.
PG  - 3
LID - 10.1186/s12610-018-0068-0 [doi]
LID - 3
AB  - BACKGROUND: Despite its worldwide high occurrence, the obscurity regarding the 
      description, epidemiology and management of premature ejaculation remains 
      provocative. It is well established that male premature ejaculatory dysfunction 
      is an increasing problem due to spontaneous ejaculation across a variety of 
      general and clinical subjects. The main goal of this study was to determine the 
      relationships between trinucleotide repeats of the androgen receptor (AR), sex 
      steroids, and pituitary hormones with sexual function in men with type 2 diabetes 
      mellitus (DM) and reported with acquired premature ejaculation (PE). METHODS: A 
      total of 150 normal and 250 PE + DM subjects were enrolled in this study. Each 
      subject was invited to fill out an elaborative questionnaire to acquire precise 
      selective information regarding BMI, duration of PE + DM, self-reported 
      Intra-Vaginal Ejaculatory Latency Time (IELT), sexual and mental health status by 
      using the premature ejaculation diagnostic tool (PEDT) and Beck Depression 
      Inventory-II (BDI-II). Pearson's correlation analysis was used to analyze the 
      relationship between clinical, hormonal, and genetic variables. Ward's minimum 
      variance cluster analysis and principal component analysis were used for 
      evaluation of dependence between genetic, clinical, and demographic parameters. 
      RESULTS: The patients who have the lowest number of (</=21) (CAG)n repeats have 
      higher serum oxytocin levels (114.2 pg/ml; n = 54, 43.2%) than the controls 
      (69.18 pg/ml; n = 22, 17.6%) and the patients with the highest (>/=26) number of 
      (CAG)n repeats (62.9 pg/ml; n = 108, 43.2%).On the other hand, patients who have 
      the highest numbers of (CAG)n repeats (>/=26) have higher serum testosterone 
      (6.1 ng/ml; n = 108, 43.2% of cohort) lower prolactin (3.01 ng/ml; n = 108, 43.2% 
      of cohort) levels than the controls and patients with the lowest numbers (</=21) of 
      (CAG)n repeats and their TSH (1.53 mIU/L, P < 0.05) levels are lower than those 
      of controls. In the Pearson correlation model, self-estimated IELT demonstrated 
      significantly negative correlation with both (CAG)n and (GCC)n repeats 
      (r = - 0.16, p = 0.0001; r = - 0.19, p = 0.0001) respectively. These repeats have 
      positive correlation with PEDT (r = 0.28, p = 0.0001: r = 0.24, p = 0.0001, whole 
      model) and inversely correlated with BDI-II (r = - 0.25, p = 0.0001). CONCLUSION: 
      This study indicates that androgen receptor polymorphism modulates the endocrine 
      effect on ejaculatory reflex and depends strongly on its "cofactors". Moreover, 
      our results also confirmed an association between long tri-nucleotide repeats of 
      androgen receptor, sex steroids, pituitary, and thyroid hormones in relation to  
      acquired premature ejaculatory dysfunction in diabetic patients. However, 
      endocrine regulation of PE reflex is a complex phenomenon that requires further 
      investigation.
FAU - Khan, Haroon Latif
AU  - Khan HL
AD  - Lahore Institute of fertility and Endocrinology, Hameed Latif Hospital, 14 - Abu 
      Bakar Block, New Garden Town, Lahore, Pakistan.
FAU - Bhatti, Shahzad
AU  - Bhatti S
AD  - Lahore Institute of fertility and Endocrinology, Hameed Latif Hospital, 14 - Abu 
      Bakar Block, New Garden Town, Lahore, Pakistan.
AD  - 2Department of Human Genetics and Molecular biology, University of Health 
      Sciences, Lahore, -54600 Pakistan. GRID: grid.412956.d
AD  - 3Institute of Molecular Biology and Biotechnology, The University of Lahore, 
      Lahore, 54600 Pakistan. GRID: grid.440564.7
AD  - 4Department of Medical Education, Rashid Latif Medical College, Lahore, Pakistan. 
      ISNI: 0000 0004 0445 3162. GRID: grid.459922.1
FAU - Abbas, Sana
AU  - Abbas S
AD  - Lahore Institute of fertility and Endocrinology, Hameed Latif Hospital, 14 - Abu 
      Bakar Block, New Garden Town, Lahore, Pakistan.
FAU - Khan, Yousaf Latif
AU  - Khan YL
AD  - Lahore Institute of fertility and Endocrinology, Hameed Latif Hospital, 14 - Abu 
      Bakar Block, New Garden Town, Lahore, Pakistan.
FAU - Gonzalez, Rosa Maria Marquez
AU  - Gonzalez RMM
AD  - Centro de investigacion Biomedica de Occidente, IMSS, Uiversidad de Guadalajara, 
      Jalisco Maxico, Guadalajara, Mexico.
FAU - Aslamkhan, Muhammad
AU  - Aslamkhan M
AD  - 2Department of Human Genetics and Molecular biology, University of Health 
      Sciences, Lahore, -54600 Pakistan. GRID: grid.412956.d
FAU - Gonzalez, Gerardo Rodriguez
AU  - Gonzalez GR
AD  - 6Universidad De Guadalajara CIBO, IMSS, Sierra Mojada 800 Independencia, 44340 
      Guadalajara, Jalisco Maxicom Mexico. ISNI: 0000 0001 1091 9430. GRID: 
      grid.419157.f
FAU - Aydin, Hikmet Hakan
AU  - Aydin HH
AD  - 7Department of Medical Biochemistry, Ege University School of Medicine, Bornova, 
      Izmir Turkey. ISNI: 0000 0001 1092 2592. GRID: grid.8302.9
LA  - eng
PT  - Journal Article
DEP - 20180306
PL  - England
TA  - Basic Clin Androl
JT  - Basic and clinical andrology
JID - 101640161
PMC - PMC5838858
OTO - NOTNLM
OT  - Androgen receptor
OT  - Diabetes mellitus
OT  - Oxytocin
OT  - Premature ejaculation
OT  - Testosterone
COIS- The authors declare that they have no competing interests.Springer Nature remains 
      neutral with regard to jurisdictional claims in published maps and institutional 
      affiliations.
EDAT- 2018/03/21 06:00
MHDA- 2018/03/21 06:01
PMCR- 2018/03/06
CRDT- 2018/03/21 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2018/02/01 00:00 [accepted]
PHST- 2018/03/21 06:00 [entrez]
PHST- 2018/03/21 06:00 [pubmed]
PHST- 2018/03/21 06:01 [medline]
PHST- 2018/03/06 00:00 [pmc-release]
AID - 68 [pii]
AID - 10.1186/s12610-018-0068-0 [doi]
PST - epublish
SO  - Basic Clin Androl. 2018 Mar 6;28:3. doi: 10.1186/s12610-018-0068-0. eCollection 
      2018.

PMID- 29551391
OWN - NLM
STAT- MEDLINE
DCOM- 20190625
LR  - 20190625
IS  - 1095-8584 (Electronic)
IS  - 0022-2828 (Linking)
VI  - 118
DP  - 2018 May
TI  - Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through 
      human iPSC-derived cardiomyocytes.
PG  - 95-109
LID - S0022-2828(18)30083-X [pii]
LID - 10.1016/j.yjmcc.2018.03.012 [doi]
AB  - Myotonic Dystrophy type 1 (DM1) is a multisystemic disease, autosomal dominant, 
      caused by a CTG repeat expansion in DMPK gene. We assessed the appropriateness of 
      patient-specific induced pluripotent stem cell-derived cardiomyocytes (CMs) as a 
      model to recapitulate some aspects of the pathogenetic mechanism involving 
      cardiac manifestations in DM1 patients. Once obtained in vitro, CMs have been 
      characterized for their morphology and their functionality. CMs DM1 show 
      intranuclear foci and transcript markers abnormally spliced respect to WT ones, 
      as well as several irregularities in nuclear morphology, probably caused by an 
      unbalanced lamin A/C ratio. Electrophysiological characterization evidences an 
      abnormal profile only in CMs DM1 such that the administration of antiarrythmic 
      drugs to these cells highlights even more the functional defect linked to the 
      disease. Finally, Atomic Force Measurements reveal differences in the 
      biomechanical behaviour of CMs DM1, in terms of frequencies and synchronicity of 
      the beats. Altogether the complex phenotype described in this work, strongly 
      reproduces some aspects of the human DM1 cardiac phenotype. Therefore, the 
      present study provides an in vitro model suggesting novel insights into the 
      mechanisms leading to the development of arrhythmogenesis and dilatative 
      cardiomyopathy to consider when approaching to DM1 patients, especially for the 
      risk assessment of sudden cardiac death (SCD). These data could be also useful in 
      identifying novel biomarkers effective in clinical settings and patient-tailored 
      therapies.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Spitalieri, Paola
AU  - Spitalieri P
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Talarico, Rosa V
AU  - Talarico RV
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Caioli, Silvia
AU  - Caioli S
AD  - I.R.C.C.S. S. Lucia, Rome, Italy.
FAU - Murdocca, Michela
AU  - Murdocca M
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Serafino, Annalucia
AU  - Serafino A
AD  - IFT, Italian National Research Council, Rome, Italy.
FAU - Girasole, Marco
AU  - Girasole M
AD  - ISM, Italian National Research Council, Rome, Italy.
FAU - Dinarelli, Simone
AU  - Dinarelli S
AD  - ISM, Italian National Research Council, Rome, Italy.
FAU - Longo, Giovanni
AU  - Longo G
AD  - ISM, Italian National Research Council, Rome, Italy.
FAU - Pucci, Sabina
AU  - Pucci S
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Botta, Annalisa
AU  - Botta A
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Novelli, Giuseppe
AU  - Novelli G
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
FAU - Zona, Cristina
AU  - Zona C
AD  - I.R.C.C.S. S. Lucia, Rome, Italy; Dept of Systems Medicine, University of Rome 
      "Tor Vergata", Rome, Italy.
FAU - Mango, Ruggiero
AU  - Mango R
AD  - Dept of Emergency Polyclinic Tor Vergata, Rome, Italy.
FAU - Sangiuolo, Federica
AU  - Sangiuolo F
AD  - Dept of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy. Electronic address: sangiuolo@med.uniroma2.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180315
PL  - England
TA  - J Mol Cell Cardiol
JT  - Journal of molecular and cellular cardiology
JID - 0262322
RN  - 0 (Lamins)
SB  - IM
MH  - Adult
MH  - Arrhythmias, Cardiac/pathology/physiopathology
MH  - Biomechanical Phenomena
MH  - Cell Differentiation
MH  - Cell Nucleus Shape
MH  - Cellular Reprogramming
MH  - Electrophysiological Phenomena
MH  - Female
MH  - Heart Ventricles/pathology/physiopathology
MH  - Humans
MH  - Induced Pluripotent Stem Cells/metabolism/*pathology
MH  - Lamins/metabolism
MH  - Male
MH  - Middle Aged
MH  - *Models, Biological
MH  - Myocardial Contraction
MH  - Myocardium/*pathology
MH  - Myocytes, Cardiac/metabolism/*pathology
MH  - Myotonic Dystrophy/*pathology/physiopathology
MH  - Phenotype
OTO - NOTNLM
OT  - Antiarrhytmic drugs
OT  - Cardiomyocytes
OT  - Electrophysiological analysis
OT  - Human induced pluripotent stem cells
OT  - Myotonic Dystrophy type 1 (DM1)
EDAT- 2018/03/20 06:00
MHDA- 2019/06/27 06:00
CRDT- 2018/03/20 06:00
PHST- 2018/01/22 00:00 [received]
PHST- 2018/03/12 00:00 [revised]
PHST- 2018/03/14 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2019/06/27 06:00 [medline]
PHST- 2018/03/20 06:00 [entrez]
AID - S0022-2828(18)30083-X [pii]
AID - 10.1016/j.yjmcc.2018.03.012 [doi]
PST - ppublish
SO  - J Mol Cell Cardiol. 2018 May;118:95-109. doi: 10.1016/j.yjmcc.2018.03.012. Epub 
      2018 Mar 15.

PMID- 29381654
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1473-558X (Electronic)
IS  - 0959-4965 (Linking)
VI  - 29
IP  - 3
DP  - 2018 Feb 7
TI  - Macroscopic and microscopic diversity of missplicing in the central nervous 
      system of patients with myotonic dystrophy type 1.
PG  - 235-240
LID - 10.1097/WNR.0000000000000968 [doi]
AB  - Myotonic dystrophy type I (DM1) is a multiorgan disease caused by CTG-repeat 
      expansion in the DMPK gene. Sequestration of the splicing factor MBNL1 results in 
      aberrant splicing in many genes in DM1 skeletal muscle, whereas MBNL2 plays a 
      leading role in missplicing in the central nervous system (CNS) of patients with 
      DM1. Splicing misregulation of most MBNL2-regulated genes occurs in the temporal 
      cortex but not in the cerebellum of autopsied patients with DM1. To understand 
      the diversity at macroscopic and microscopic levels in CNS of patients with DM1. 
      Using autopsied brain tissues, we examined alternative splicing ratios of 
      MBNL2-regulated genes and expression levels of potential splicing factors. We 
      found differences in splicing abnormalities among tested regions of the CNS from 
      patients with DM1. In the frontal and temporal cortices and the hippocampus, many 
      genes were aberrantly spliced, but severity differed among the brain regions. By 
      contrast, there were no significant differences in the ratio of splicing variants 
      for most of the genes in the cerebellar cortex and spinal cord between DM1 and 
      control samples. We failed to find any change in the amount of potential factors 
      (MBNL and CUGBP proteins and DMPK mRNA) which explain the modest missplicing in 
      the cerebellum. LASER capture microdissection demonstrated splicing misregulation 
      in the molecular layer of the cerebellum but not in the granular layer. This is 
      the first study to reveal missplicing in a functional cell layer of DM1 and to 
      compare splicing misregulation in a wide region of the CNS using statistical 
      analysis.
FAU - Furuta, Mitsuru
AU  - Furuta M
AD  - Division of Neurology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya.
AD  - Department of Neurology.
FAU - Kimura, Takashi
AU  - Kimura T
AD  - Division of Neurology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology.
FAU - Matsumura, Tsuyoshi
AU  - Matsumura T
AD  - Department of Neurology, National Hospital Organization Toneyama Hospital, 
      Toyonaka, Japan.
FAU - Fujimura, Harutoshi
AU  - Fujimura H
AD  - Department of Neurology, National Hospital Organization Toneyama Hospital, 
      Toyonaka, Japan.
FAU - Jinnai, Kenji
AU  - Jinnai K
AD  - Department of Neurology, National Hospital Organization Hyogo-Chuo Hospital, 
      Ohara.
FAU - Takahashi, Masanori P
AU  - Takahashi MP
AD  - Department of Neurology.
AD  - Department of Functional Diagnostic Science, Osaka University Graduate School of 
      Medicine, Suita.
FAU - Mochizuki, Hideki
AU  - Mochizuki H
AD  - Department of Neurology.
FAU - Yoshikawa, Hiroo
AU  - Yoshikawa H
AD  - Division of Neurology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuroreport
JT  - Neuroreport
JID - 9100935
SB  - IM
MH  - *Alternative Splicing
MH  - Brain/*metabolism
MH  - Gene Expression
MH  - Genetic Variation
MH  - Humans
MH  - Myotonic Dystrophy/genetics/*metabolism
EDAT- 2018/01/31 06:00
MHDA- 2019/04/05 06:00
CRDT- 2018/01/31 06:00
PHST- 2018/01/31 06:00 [entrez]
PHST- 2018/01/31 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
AID - 00001756-201802010-00014 [pii]
AID - 10.1097/WNR.0000000000000968 [doi]
PST - ppublish
SO  - Neuroreport. 2018 Feb 7;29(3):235-240. doi: 10.1097/WNR.0000000000000968.

PMID- 29334465
OWN - NLM
STAT- MEDLINE
DCOM- 20180605
LR  - 20190921
IS  - 1520-4995 (Electronic)
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 57
IP  - 6
DP  - 2018 Feb 13
TI  - Design of a "Mini" Nucleic Acid Probe for Cooperative Binding of an RNA-Repeated 
      Transcript Associated with Myotonic Dystrophy Type 1.
PG  - 907-911
LID - 10.1021/acs.biochem.7b01239 [doi]
AB  - Toxic RNAs containing expanded trinucleotide repeats are the cause of many 
      neuromuscular disorders, one being myotonic dystrophy type 1 (DM1). DM1 is 
      triggered by CTG-repeat expansion in the 3'-untranslated region of the DMPK gene, 
      resulting in a toxic gain of RNA function through sequestration of MBNL1 protein, 
      among others. Herein, we report the development of a relatively short miniPEG-gamma 
      peptide nucleic acid probe, two triplet repeats in length, containing terminal 
      pyrene moieties, that is capable of binding rCUG repeats in a sequence-specific 
      and selective manner. The newly designed probe can discriminate the pathogenic 
      rCUG(exp) from the wild-type transcript and disrupt the rCUG(exp)-MBNL1 complex. 
      The work provides a proof of concept for the development of relatively short 
      nucleic acid probes for targeting RNA-repeat expansions associated with DM1 and 
      other related neuromuscular disorders.
FAU - Hsieh, Wei-Che
AU  - Hsieh WC
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Bahal, Raman
AU  - Bahal R
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Thadke, Shivaji A
AU  - Thadke SA
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Bhatt, Kirti
AU  - Bhatt K
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Sobczak, Krzysztof
AU  - Sobczak K
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Thornton, Charles
AU  - Thornton C
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
FAU - Ly, Danith H
AU  - Ly DH
AUID- ORCID: 0000-0002-8760-0070
AD  - Department of Chemistry, double daggerInstitute for Biomolecular Design and Discovery (IBD), 
      and  section signCNAST, Carnegie Mellon University , 4400 Fifth Avenue, Pittsburgh, 
      Pennsylvania 15213, United States.
AD  - Department of Neurology, Box 645, University of Rochester Medical Center , 601 
      Elmwood Avenue, Rochester, New York 14642, United States.
LA  - eng
GR  - R21 NS098102/NS/NINDS NIH HHS/United States
GR  - R37 NS094393/NS/NINDS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180119
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 0 (DMPK protein, human)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (Peptide Nucleic Acids)
RN  - 0 (RNA Probes)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Base Sequence
MH  - Binding Sites
MH  - Humans
MH  - Myotonic Dystrophy/genetics/*metabolism
MH  - Myotonin-Protein Kinase/genetics/metabolism
MH  - Peptide Nucleic Acids/chemistry/genetics/*metabolism
MH  - RNA/chemistry/genetics/*metabolism
MH  - RNA Probes/chemistry/genetics/*metabolism
MH  - RNA-Binding Proteins/metabolism
MH  - *Trinucleotide Repeat Expansion
PMC - PMC6091549
MID - NIHMS983791
COIS- Notes The authors declare no competing financial interest.
EDAT- 2018/01/16 06:00
MHDA- 2018/06/06 06:00
PMCR- 2018/08/14
CRDT- 2018/01/16 06:00
PHST- 2018/01/16 06:00 [pubmed]
PHST- 2018/06/06 06:00 [medline]
PHST- 2018/01/16 06:00 [entrez]
PHST- 2018/08/14 00:00 [pmc-release]
AID - 10.1021/acs.biochem.7b01239 [doi]
PST - ppublish
SO  - Biochemistry. 2018 Feb 13;57(6):907-911. doi: 10.1021/acs.biochem.7b01239. Epub 
      2018 Jan 19.

PMID- 29328504
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
DP  - 2018 Jan 12
TI  - Myotonic dystrophy patient preferences in patient-reported outcome measures.
LID - 10.1002/mus.26066 [doi]
AB  - INTRODUCTION: When preparing for clinical trials in myotonic dystrophy type-1 
      (DM1), it is important that researchers develop and identify patient-reported 
      outcome measures with good measurement properties. METHODS: Fifty-two DM1 
      patients enrolled in 2 clinical studies completed the Myotonic Dystrophy Health 
      Index (MDHI), 36-Item Short Form Health Survey (version 2; SF-36v2), 
      Individualized Neuromuscular Quality of Life questionnaire (INQoL), and a 
      questionnaire comparing the relevance, usability, overall preference, and 
      perceived responsiveness of each measure. The associations between instrument 
      scores and physical function, genetic test results, and employment status were 
      examined. RESULTS: The MDHI was preferred over the INQoL in 13 of 13 areas and 
      was preferred over the SF-36v2 in 9 of 13 areas. The MDHI was the only score that 
      was associated with participant employment status, CTG repeat length, and the 3 
      measurements of clinical function. DISCUSSION: The MDHI correlates well with 
      physical function and is viewed favorably by participants in DM1 clinical 
      studies. Muscle Nerve, 2018.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Heatwole, Chad
AU  - Heatwole C
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Johnson, Nicholas
AU  - Johnson N
AUID- ORCID: 0000-0002-3917-4257
AD  - Department of Neurology, University of Utah Medical Center, Salt Lake City, Utah, 
      USA.
FAU - Dekdebrun, Jeanne
AU  - Dekdebrun J
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Dilek, Nuran
AU  - Dilek N
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Eichinger, Kate
AU  - Eichinger K
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Hilbert, James
AU  - Hilbert J
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Luebbe, Elizabeth
AU  - Luebbe E
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Martens, William
AU  - Martens W
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Mcdermott, Michael P
AU  - Mcdermott MP
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
AD  - Department of Biostatistics and Computational Biology, University of Rochester 
      Medical Center, Rochester, New York, USA.
FAU - Thornton, Charles
AU  - Thornton C
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
FAU - Moxley, Richard
AU  - Moxley R
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue Rochester, New York, 14642, USA.
LA  - eng
PT  - Journal Article
DEP - 20180112
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
OTO - NOTNLM
OT  - Myotonic Dystrophy Health Index
OT  - clinical trial
OT  - myotonic dystrophy type-1
OT  - patient relevant
OT  - patient-reported outcome measure
EDAT- 2018/01/13 06:00
MHDA- 2018/01/13 06:00
CRDT- 2018/01/13 06:00
PHST- 2017/04/17 00:00 [received]
PHST- 2018/01/05 00:00 [revised]
PHST- 2018/01/07 00:00 [accepted]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
PHST- 2018/01/13 06:00 [entrez]
AID - 10.1002/mus.26066 [doi]
PST - aheadofprint
SO  - Muscle Nerve. 2018 Jan 12. doi: 10.1002/mus.26066.

PMID- 29296622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2328-9503 (Print)
IS  - 2328-9503 (Electronic)
IS  - 2328-9503 (Linking)
VI  - 4
IP  - 12
DP  - 2017 Dec
TI  - Relationships between grip strength, myotonia, and CTG expansion in myotonic 
      dystrophy type 1.
PG  - 921-925
LID - 10.1002/acn3.496 [doi]
AB  - In myotonic dystrophy type 1, several studies have suggested causal relationships 
      between CTG repeat length and the severity of symptoms, such as weakness or 
      myotonia. We aimed to explore these relationships in a large population of 144 
      DM1 patients. All patients underwent clinical and functional assessments using a 
      standardized test for grip strength and myotonia assessment. Myotonia was 
      assessed using a fully automatic software based on mathematical modeling of 
      relaxation force curve. CTG repeat length was statistically correlated with both 
      myotonia and grip strength, which are two major primary neuromuscular symptoms of 
      DM1 patients. However, these relationships are not clinically meaningful and not 
      predictive at the individual level.
FAU - Hogrel, Jean-Yves
AU  - Hogrel JY
AUID- ORCID: 0000-0003-0045-7505
AD  - Institut de Myologie GH Pitie-Salpetriere Paris France.
FAU - Ollivier, Gwenn
AU  - Ollivier G
AD  - Institut de Myologie GH Pitie-Salpetriere Paris France.
FAU - Ledoux, Isabelle
AU  - Ledoux I
AD  - Institut de Myologie GH Pitie-Salpetriere Paris France.
FAU - Hebert, Luc J
AU  - Hebert LJ
AD  - Universite de Laval Quebec Canada.
FAU - Eymard, Bruno
AU  - Eymard B
AD  - Institut de Myologie GH Pitie-Salpetriere Paris France.
FAU - Puymirat, Jack
AU  - Puymirat J
AD  - Universite de Laval Quebec Canada.
FAU - Bassez, Guillaume
AU  - Bassez G
AD  - Institut de Myologie GH Pitie-Salpetriere Paris France.
LA  - eng
PT  - Journal Article
DEP - 20171107
PL  - United States
TA  - Ann Clin Transl Neurol
JT  - Annals of clinical and translational neurology
JID - 101623278
PMC - PMC5740258
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:01
PMCR- 2017/11/07
CRDT- 2018/01/04 06:00
PHST- 2017/07/20 00:00 [received]
PHST- 2017/10/02 00:00 [revised]
PHST- 2017/10/02 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:01 [medline]
PHST- 2017/11/07 00:00 [pmc-release]
AID - ACN3496 [pii]
AID - 10.1002/acn3.496 [doi]
PST - epublish
SO  - Ann Clin Transl Neurol. 2017 Nov 7;4(12):921-925. doi: 10.1002/acn3.496. 
      eCollection 2017 Dec.

PMID- 29291944
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20180920
IS  - 0925-4439 (Print)
IS  - 0925-4439 (Linking)
VI  - 1864
IP  - 3
DP  - 2018 Mar
TI  - Expanded [CCTG]n repetitions are not associated with abnormal methylation at the 
      CNBP locus in myotonic dystrophy type 2 (DM2) patients.
PG  - 917-924
LID - S0925-4439(17)30494-5 [pii]
LID - 10.1016/j.bbadis.2017.12.037 [doi]
AB  - Myotonic Dystrophy type 2 (DM2) is a multisystemic disorder associated with an 
      expanded [CCTG]n repeat in intron 1 of the CNBP gene. Epigenetic modifications 
      have been reported in many repeat expansion disorders, including myotonic 
      dystrophy type 1 (DM1), either as a mechanism to explain somatic repeat 
      instability or transcriptional alterations in disease genes. The purpose of our 
      work was to determine the effect of DM2 mutation on the methylation status of CpG 
      islands localized in the 5' promoter region and in the 3' end of the [CCTG]n 
      expansion of the CNBP gene. By bisulfite pyrosequencing, we characterized the 
      methylation profile of two different CpG islands within these regions, either in 
      whole blood and skeletal muscle tissues of DM2 patients (n=72 and n=7, 
      respectively) and controls (n=50 and n=7, respectively). Moreover, we compared 
      the relative mRNA transcript levels of CNBP gene in leukocytes and in skeletal 
      muscle tissues from controls and DM2 patients. We found that CpG sites located in 
      the promoter region showed hypomethylation, whereas CpG sites at 3' end of the 
      CCTG array are hypermethylated. Statistical analyses did not demonstrate any 
      significant differences in the methylation profile between DM2 patients and 
      controls in both tissues analyzed. According to the methylation analysis, CNBP 
      gene expression levels are not significantly altered in DM2 patients. These 
      results show that [CCTG]n repeat expansion, differently from the DM1 mutation, 
      does not influence the methylation status of the CNBP gene and suggest that other 
      molecular mechanisms are involved in the pathogenesis of DM2.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Santoro, Massimo
AU  - Santoro M
AD  - Don Gnocchi Foundation, Milan, Italy.
FAU - Fontana, Luana
AU  - Fontana L
AD  - Dept. of Biomedicine and Prevention, Medical Genetics Section, University of Rome 
      Tor Vergata, Italy.
FAU - Maiorca, Francesca
AU  - Maiorca F
AD  - Dept. of Biomedicine and Prevention, Medical Genetics Section, University of Rome 
      Tor Vergata, Italy.
FAU - Centofanti, Federica
AU  - Centofanti F
AD  - Dept. of Biomedicine and Prevention, Medical Genetics Section, University of Rome 
      Tor Vergata, Italy.
FAU - Massa, Roberto
AU  - Massa R
AD  - Department of Systems Medicine (Neurology), University of Rome Tor Vergata, 
      Italy.
FAU - Silvestri, Gabriella
AU  - Silvestri G
AD  - Policlinico Gemelli Foundation, Institute of Neurology, Rome, Italy.
FAU - Novelli, Giuseppe
AU  - Novelli G
AD  - Dept. of Biomedicine and Prevention, Medical Genetics Section, University of Rome 
      Tor Vergata, Italy; Neuromed IRCSS Pozzilli, Italy.
FAU - Botta, Annalisa
AU  - Botta A
AD  - Dept. of Biomedicine and Prevention, Medical Genetics Section, University of Rome 
      Tor Vergata, Italy. Electronic address: botta@med.uniroma2.it.
LA  - eng
PT  - Journal Article
DEP - 20171229
PL  - Netherlands
TA  - Biochim Biophys Acta Mol Basis Dis
JT  - Biochimica et biophysica acta. Molecular basis of disease
JID - 101731730
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Case-Control Studies
MH  - CpG Islands
MH  - DNA Methylation/*genetics
MH  - DNA Repeat Expansion/*genetics
MH  - Female
MH  - Genetic Association Studies
MH  - Genetic Loci
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Sequence Analysis, DNA
OTO - NOTNLM
OT  - Bisulfite pyrosequencing
OT  - CNBP expression
OT  - Methylation
OT  - Myotonic dystrophy type 2
EDAT- 2018/01/03 06:00
MHDA- 2018/04/24 06:00
CRDT- 2018/01/03 06:00
PHST- 2017/08/21 00:00 [received]
PHST- 2017/12/21 00:00 [revised]
PHST- 2017/12/28 00:00 [accepted]
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2018/01/03 06:00 [entrez]
AID - S0925-4439(17)30494-5 [pii]
AID - 10.1016/j.bbadis.2017.12.037 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):917-924. doi: 
      10.1016/j.bbadis.2017.12.037. Epub 2017 Dec 29.

PMID- 29274549
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20211204
IS  - 1876-7753 (Electronic)
IS  - 1873-5061 (Linking)
VI  - 26
DP  - 2018 Jan
TI  - Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic 
      dystrophy type 1 patient carrying (CTG)(200) expansion in the DMPK gene: 
      CHUQi001-A.
PG  - 103-106
LID - S1873-5061(17)30269-6 [pii]
LID - 10.1016/j.scr.2017.12.010 [doi]
AB  - Human immortalized Epstein-Barr virus (EBV) lymphoblastoids cells line (LCLs) 
      from a 26-year- old male affected by an adult form of myotonic dystrophy type 1 
      (DM1) disease and carrying 200 CTG repeats mutation in the blood was used to 
      generate induced pluripotent stem cells (iPSCs) using the Sendai virus expressing 
      KLF4, OCT4, SOX2 and C-MYC. The resulting iPSCs were EBV free, expressed the 
      pluripotency markers, could be differentiated into the three germ layers in 
      vitro, had a normal karyotype, and retained the genetic DM1 mutation. This iPSC 
      line could be useful for the investigation of DM1 mechanisms.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Martineau, Laurie
AU  - Martineau L
AD  - CHU de Quebec-Universite Laval Research Center, Quebec, Canada. Electronic 
      address: laurie.martineau@crchudequebec.ulaval.ca.
FAU - Racine, Veronique
AU  - Racine V
AD  - CHU de Quebec-Universite Laval Research Center, Quebec, Canada.
FAU - Benichou, Siham Ait
AU  - Benichou SA
AD  - CHU de Quebec-Universite Laval Research Center, Quebec, Canada.
FAU - Puymirat, Jack
AU  - Puymirat J
AD  - CHU de Quebec-Universite Laval Research Center, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171216
PL  - England
TA  - Stem Cell Res
JT  - Stem cell research
JID - 101316957
RN  - 0 (Biomarkers)
RN  - 0 (DMPK protein, human)
RN  - 0 (KLF4 protein, human)
RN  - 0 (Kruppel-Like Factor 4)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Biomarkers/metabolism
MH  - *Cell Differentiation
MH  - Cell Line
MH  - Cells, Cultured
MH  - *Cellular Reprogramming
MH  - Humans
MH  - Induced Pluripotent Stem Cells/metabolism/*pathology
MH  - Kruppel-Like Factor 4
MH  - Lymphocytes/metabolism/*pathology
MH  - Male
MH  - Myotonic Dystrophy/metabolism/*pathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2017/12/24 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/12/24 06:00
PHST- 2017/09/08 00:00 [received]
PHST- 2017/12/05 00:00 [revised]
PHST- 2017/12/14 00:00 [accepted]
PHST- 2017/12/24 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/12/24 06:00 [entrez]
AID - S1873-5061(17)30269-6 [pii]
AID - 10.1016/j.scr.2017.12.010 [doi]
PST - ppublish
SO  - Stem Cell Res. 2018 Jan;26:103-106. doi: 10.1016/j.scr.2017.12.010. Epub 2017 Dec 
      16.

PMID- 29246312
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 9
DP  - 2017 Dec 15
TI  - CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in 
      Myogenic Cells Derived from Myotonic Dystrophy 1 Patients.
PG  - 337-348
LID - S2162-2531(17)30267-6 [pii]
LID - 10.1016/j.omtn.2017.10.006 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular 
      dystrophy, characterized by progressive myopathy, myotonia, and multi-organ 
      involvement. This dystrophy is an inherited autosomal dominant disease caused by 
      a (CTG)n expansion within the 3' untranslated region of the DMPK gene. Expression 
      of the mutated gene results in production of toxic transcripts that aggregate as 
      nuclear foci and sequester RNA-binding proteins, resulting in mis-splicing of 
      several transcripts, defective translation, and microRNA dysregulation. No 
      effective therapy is yet available for treatment of the disease. In this study, 
      myogenic cell models were generated from myotonic dystrophy patient-derived 
      fibroblasts. These cells exhibit typical disease-associated ribonuclear 
      aggregates, containing CUG repeats and muscleblind-like 1 protein, and 
      alternative splicing alterations. We exploited these cell models to develop new 
      gene therapy strategies aimed at eliminating the toxic mutant repeats. Using the 
      CRISPR/Cas9 gene-editing system, the repeat expansions were removed, therefore 
      preventing nuclear foci formation and splicing alterations. Compared with the 
      previously reported strategies of inhibition/degradation of CUG expanded 
      transcripts by various techniques, the advantage of this approach is that 
      affected cells can be permanently reverted to a normal phenotype.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Provenzano, Claudia
AU  - Provenzano C
AD  - Institute of Cell Biology and Neurobiology, National Research Council, 
      Monterotondo, Rome, Italy.
FAU - Cappella, Marisa
AU  - Cappella M
AD  - Institute of Cell Biology and Neurobiology, National Research Council, 
      Monterotondo, Rome, Italy; DAHFMO-Unit of Histology and Medical Embryology, 
      Sapienza University of Rome, Rome, Italy.
FAU - Valaperta, Rea
AU  - Valaperta R
AD  - Molecular Biology Laboratory, Policlinico San Donato-IRCCS, San Donato Milanese, 
      Milan, Italy.
FAU - Cardani, Rosanna
AU  - Cardani R
AD  - Muscle Histopathology and Molecular Biology Laboratory, Policlinico San 
      Donato-IRCCS, San Donato Milanese, Milan, Italy.
FAU - Meola, Giovanni
AU  - Meola G
AD  - Department of Neurology, IRCCS Policlinico San Donato, San Donato Milanese, 
      Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, 
      Milan, Italy.
FAU - Martelli, Fabio
AU  - Martelli F
AD  - Molecular Cardiology Laboratory, Policlinico San Donato-IRCCS, San Donato 
      Milanese, Milan, Italy.
FAU - Cardinali, Beatrice
AU  - Cardinali B
AD  - Institute of Cell Biology and Neurobiology, National Research Council, 
      Monterotondo, Rome, Italy. Electronic address: beatrice.cardinali@cnr.it.
FAU - Falcone, Germana
AU  - Falcone G
AD  - Institute of Cell Biology and Neurobiology, National Research Council, 
      Monterotondo, Rome, Italy. Electronic address: germana.falcone@cnr.it.
LA  - eng
PT  - Journal Article
DEP - 20171014
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC5684470
OTO - NOTNLM
OT  - CRISPR/Cas9
OT  - CTG repeats
OT  - DM1 cell models
OT  - DMPK
OT  - muscle disease
OT  - myotonic dystrophy type 1
OT  - phenotypic reversion
OT  - splicing alterations
OT  - trinucleotide expansion
EDAT- 2017/12/17 06:00
MHDA- 2017/12/17 06:01
PMCR- 2017/10/14
CRDT- 2017/12/17 06:00
PHST- 2017/08/07 00:00 [received]
PHST- 2017/10/11 00:00 [revised]
PHST- 2017/10/11 00:00 [accepted]
PHST- 2017/12/17 06:00 [entrez]
PHST- 2017/12/17 06:00 [pubmed]
PHST- 2017/12/17 06:01 [medline]
PHST- 2017/10/14 00:00 [pmc-release]
AID - S2162-2531(17)30267-6 [pii]
AID - 10.1016/j.omtn.2017.10.006 [doi]
PST - ppublish
SO  - Mol Ther Nucleic Acids. 2017 Dec 15;9:337-348. doi: 10.1016/j.omtn.2017.10.006. 
      Epub 2017 Oct 14.

PMID- 29114849
OWN - NLM
STAT- MEDLINE
DCOM- 20181010
LR  - 20240327
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 142
IP  - 6
DP  - 2018 Mar 15
TI  - Risk of skin cancer among patients with myotonic dystrophy type 1 based on 
      primary care physician data from the U.K. Clinical Practice Research Datalink.
PG  - 1174-1181
LID - 10.1002/ijc.31143 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an inherited multisystem neuromuscular 
      disorder caused by a CTG trinucleotide repeat expansion in the DMPK gene. Recent 
      evidence documents that DM1 patients have an increased risk of certain cancers, 
      but whether skin cancer risks are elevated is unclear. Using the U.K. Clinical 
      Practice Research Datalink (CPRD), we identified 1,061 DM1 patients and 15,119 
      DM1-free individuals matched on gender, birth year (+/-2 years), attending practice 
      and registration year (+/-1 year). We calculated the hazard ratios (HRs) and 95% 
      confidence intervals (CIs) for the association of DM1 diagnosis with skin cancer 
      risk using Cox proportional hazards models, for all skin cancers combined and by 
      histological subtype. Follow-up started at the latest of the age at practice 
      registration, DM1 diagnosis/control selection or January 1st 1988, and ended at 
      the earliest of the age at first skin cancer diagnosis, death, transfer out of 
      the practice, last date of data collection or the end of the CPRD record (October 
      31, 2016). During a median follow-up of 3.6 years, 35 DM1 patients and 108 
      matched DM1-free individuals developed a skin cancer. DM1 patients had an 
      increased risk of skin cancer overall (HR = 5.44, 95% CI = 3.33-8.89, 
      p < 0.0001), and basal cell carcinoma (BCC) (HR = 5.78, 95% CI = 3.36-9.92, 
      p < 0.0001). Risks did not differ by gender, or age at DM1 diagnosis 
      (p-heterogeneity > 0.5). Our data confirm suggested associations between DM1 and 
      skin neoplasms with the highest risk seen for BCC. Patients are advised to 
      minimize ultraviolet light exposure and seek medical advice for suspicious 
      lesions.
CI  - (c) 2017 UICC.
FAU - Wang, Youjin
AU  - Wang Y
AUID- ORCID: 0000-0001-5841-4183
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Pfeiffer, Ruth M
AU  - Pfeiffer RM
AD  - Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Alsaggaf, Rotana
AU  - Alsaggaf R
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Meeraus, Wilhelmine
AU  - Meeraus W
AD  - Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory 
      Agency, London, United Kingdom.
FAU - Gage, Julia C
AU  - Gage JC
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Anderson, Lesley A
AU  - Anderson LA
AD  - Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, 
      Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
FAU - Bremer, Renee C
AU  - Bremer RC
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, United Kingdom.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, 
      Newcastle University, Newcastle upon Tyne, United Kingdom.
FAU - Greene, Mark H
AU  - Greene MH
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
FAU - Gadalla, Shahinaz M
AU  - Gadalla SM
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, Bethesda, MD.
LA  - eng
GR  - ZIA CP010144-17/Intramural NIH HHS/United States
GR  - ZIA CP010144-18/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20171120
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Carcinoma, Basal Cell/*epidemiology
MH  - Electronic Health Records/statistics & numerical data
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology/genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Primary Health Care/*statistics & numerical data
MH  - Risk Assessment
MH  - Skin Neoplasms/*epidemiology
MH  - Trinucleotide Repeat Expansion/genetics
MH  - United Kingdom/epidemiology
MH  - Young Adult
PMC - PMC5773358
MID - NIHMS924222
OTO - NOTNLM
OT  - basal cell carcinoma
OT  - cancer
OT  - melanoma
OT  - myotonic dystrophy
OT  - non-melanoma
OT  - skin
COIS- CONFLICT OF INTEREST Dr. Wilhelmine Meeraus is currently employed as a 
      respiratory epidemiologist by GlaxoSmithKline, and holds GlaxoSmithKline shares. 
      Dr. Meeraus was employed by CPRD when the study was designed and conducted. There 
      is no other conflict of interest to disclose.
EDAT- 2017/11/09 06:00
MHDA- 2018/10/12 06:00
PMCR- 2019/03/15
CRDT- 2017/11/09 06:00
PHST- 2017/06/18 00:00 [received]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/10/12 00:00 [accepted]
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2017/11/09 06:00 [entrez]
PHST- 2019/03/15 00:00 [pmc-release]
AID - 10.1002/ijc.31143 [doi]
PST - ppublish
SO  - Int J Cancer. 2018 Mar 15;142(6):1174-1181. doi: 10.1002/ijc.31143. Epub 2017 Nov 
      20.

PMID- 29091763
OWN - NLM
STAT- MEDLINE
DCOM- 20180612
LR  - 20191228
IS  - 2211-1247 (Electronic)
VI  - 21
IP  - 5
DP  - 2017 Oct 31
TI  - Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.
PG  - 1240-1252
LID - S2211-1247(17)31450-X [pii]
LID - 10.1016/j.celrep.2017.10.018 [doi]
AB  - Myotonic dystrophy types 1 (DM1) and 2 (DM2) are dominantly inherited 
      neuromuscular disorders caused by a toxic gain of function of expanded CUG and 
      CCUG repeats, respectively. Although both disorders are clinically similar, 
      congenital myotonic dystrophy (CDM), a severe DM form, is found only in DM1. CDM 
      is also characterized by muscle fiber immaturity not observed in adult DM, 
      suggesting specific pathological mechanisms. Here, we revealed upregulation of 
      the interleukin-6 (IL-6) myokine signaling pathway in CDM muscles. We also found 
      a correlation between muscle immaturity and not only IL-6 expression but also 
      expanded CTG repeat length and CpG methylation status upstream of the repeats. 
      Aberrant CpG methylation was associated with transcriptional dysregulation at the 
      repeat locus, increasing the toxic RNA burden that upregulates IL-6. Because the 
      IL-6 pathway is involved in myocyte maturation and muscle atrophy, our results 
      indicate that enhanced RNA toxicity contributes to severe CDM phenotypes through 
      aberrant IL-6 signaling.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Suita, 
      Osaka 565-0871, Japan. Electronic address: mnakamor@neurol.med.osaka-u.ac.jp.
FAU - Hamanaka, Kohei
AU  - Hamanaka K
AD  - Department of Neuromuscular Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan.
FAU - Thomas, James D
AU  - Thomas JD
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Hayashi, Yukiko K
AU  - Hayashi YK
AD  - Department of Pathophysiology, Tokyo Medical University, Shinjuku, Tokyo 
      160-0022, Japan.
FAU - Takahashi, Masanori P
AU  - Takahashi MP
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Suita, 
      Osaka 565-0871, Japan; Department of Functional Diagnostic Science, Osaka 
      University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Nishino, Ichizo
AU  - Nishino I
AD  - Department of Neuromuscular Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan.
FAU - Mochizuki, Hideki
AU  - Mochizuki H
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Suita, 
      Osaka 565-0871, Japan.
LA  - eng
GR  - DP5 OD017865/OD/NIH HHS/United States
GR  - P01 NS058901/NS/NINDS NIH HHS/United States
GR  - R01 NS098819/NS/NINDS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
RN  - 0 (ATXN7 protein, human)
RN  - 0 (Ataxin-7)
RN  - 0 (CCCTC-Binding Factor)
RN  - 0 (CTCF protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (FXR1 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Muscle Proteins)
RN  - 0 (NRAP protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (STAT3 protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alternative Splicing
MH  - Ataxin-7/genetics/metabolism
MH  - Binding Sites
MH  - CCCTC-Binding Factor/genetics/metabolism
MH  - CpG Islands
MH  - DNA Methylation
MH  - Humans
MH  - Infant
MH  - Interleukin-6/metabolism
MH  - Muscle Proteins/genetics/metabolism
MH  - Muscles/metabolism
MH  - Myotonic Dystrophy/genetics/metabolism/*pathology
MH  - Myotonin-Protein Kinase/genetics
MH  - Protein Binding
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - STAT3 Transcription Factor/metabolism
MH  - Signal Transduction/*physiology
MH  - Transcription, Genetic
MH  - Trinucleotide Repeat Expansion
MH  - Up-Regulation
PMC - PMC5689469
MID - NIHMS915567
OTO - NOTNLM
OT  - CTCF
OT  - ER stress
OT  - IL-6
OT  - NF-kappaB
OT  - cytokine
OT  - muscular dystrophy
OT  - splicing
OT  - trinucleotide
COIS- Conflict of interest The authors have declared that no conflict of interest 
      exists.
EDAT- 2017/11/02 06:00
MHDA- 2018/06/13 06:00
PMCR- 2017/11/16
CRDT- 2017/11/02 06:00
PHST- 2017/06/07 00:00 [received]
PHST- 2017/09/02 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/11/02 06:00 [entrez]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2018/06/13 06:00 [medline]
PHST- 2017/11/16 00:00 [pmc-release]
AID - S2211-1247(17)31450-X [pii]
AID - 10.1016/j.celrep.2017.10.018 [doi]
PST - ppublish
SO  - Cell Rep. 2017 Oct 31;21(5):1240-1252. doi: 10.1016/j.celrep.2017.10.018.

PMID- 29066035
OWN - NLM
STAT- MEDLINE
DCOM- 20191014
LR  - 20220409
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 28
IP  - 1
DP  - 2018 Jan
TI  - Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 
      correlates with the six-minute walk test and CTG repeats.
PG  - 29-37
LID - S0960-8966(17)30350-4 [pii]
LID - 10.1016/j.nmd.2017.08.005 [doi]
AB  - The aim of this study was to elucidate correlations among clinical, genetic, and 
      magnetic resonance imaging (MRI) data of muscles in myotonic dystrophy type 1 
      (DM1). We retrospectively reviewed the medical records and images of nineteen 
      patients with DM1 from different families. We retrieved the genetic data (CTG 
      repeats) and the clinical data, which included disease duration, creatine kinase 
      level, sum score of manual muscle testing, modified Medical Research Council sum 
      score, and the six-minute walk test results (6MWT). The correlation analyses 
      showed a statistically significant correlation between the modified Medical 
      Research Council sum score and CTG repeat numbers. Among the lower extremity 
      muscles, 6MWT correlated most with the sum of the ankle plantar-flexors (the 
      soleus, medial, and lateral gastrocnemius muscles). Compared to the other 
      plantar-flexor muscles, the soleus muscle presented the highest correlation with 
      the 6MWT. Additionally, our results showed that the CTG repeat numbers did not 
      correlate with the 6MWT. However, it correlated with the modified Medical 
      Research Council sum score. The ankle plantar-flexor muscles were the most 
      severely affected muscles revealed in the whole body MRI, and presented 
      statistically significant correlation with the 6MWT. Among the plantar-flexor 
      muscles, the soleus muscle most influenced the 6MWT.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Park, Donghwi
AU  - Park D
AD  - Department of Rehabilitation Medicine, Daegu Fatima Hospital, Daegu, South Korea; 
      Department of Pharmacology, Kyungpook National University, School of medicine, 
      Daegu, South Korea.
FAU - Lee, Sang-Hoon
AU  - Lee SH
AD  - Department of Radiology, Kyungpook National University Medical Center, Daegu, 
      South Korea.
FAU - Shin, Jin-Hong
AU  - Shin JH
AD  - Department of Neurology, Pusan National University Yangsan Hospital, Yangsan, 
      South Korea.
FAU - Park, Jin-Sung
AU  - Park JS
AD  - Department of Neurology, Kyungpook National University, School of medicine, 
      Daegu, South of Korea. Electronic address: jinforeva@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170824
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Lower Extremity/*diagnostic imaging
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*diagnostic imaging
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Retrospective Studies
MH  - *Trinucleotide Repeats
MH  - Walk Test
OTO - NOTNLM
OT  - CTG repeats
OT  - Crural muscles
OT  - Magnetic resonance imaging
OT  - Myotonic dystrophy
OT  - Six-minute walk test
EDAT- 2017/10/27 06:00
MHDA- 2019/10/15 06:00
CRDT- 2017/10/26 06:00
PHST- 2017/03/18 00:00 [received]
PHST- 2017/08/04 00:00 [revised]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2017/10/27 06:00 [pubmed]
PHST- 2019/10/15 06:00 [medline]
PHST- 2017/10/26 06:00 [entrez]
AID - S0960-8966(17)30350-4 [pii]
AID - 10.1016/j.nmd.2017.08.005 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2018 Jan;28(1):29-37. doi: 10.1016/j.nmd.2017.08.005. Epub 
      2017 Aug 24.

PMID- 29056323
OWN - NLM
STAT- MEDLINE
DCOM- 20171121
LR  - 20240104
IS  - 1097-4164 (Electronic)
IS  - 1097-2765 (Print)
IS  - 1097-2765 (Linking)
VI  - 68
IP  - 3
DP  - 2017 Nov 2
TI  - Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.
PG  - 479-490.e5
LID - S1097-2765(17)30711-6 [pii]
LID - 10.1016/j.molcel.2017.09.033 [doi]
AB  - Transcription of expanded microsatellite repeats is associated with multiple 
      human diseases, including myotonic dystrophy, Fuchs endothelial corneal 
      dystrophy, and C9orf72-ALS/FTD. Reducing production of RNA and proteins arising 
      from these expanded loci holds therapeutic benefit. Here, we tested the 
      hypothesis that deactivated Cas9 enzyme impedes transcription across expanded 
      microsatellites. We observed a repeat length-, PAM-, and strand-dependent 
      reduction of repeat-containing RNAs upon targeting dCas9 directly to repeat 
      sequences; targeting the non-template strand was more effective. Aberrant 
      splicing patterns were rescued in DM1 cells, and production of RAN peptides 
      characteristic of DM1, DM2, and C9orf72-ALS/FTD cells was drastically decreased. 
      Systemic delivery of dCas9/gRNA by adeno-associated virus led to reductions in 
      pathological RNA foci, rescue of chloride channel 1 protein expression, and 
      decreased myotonia. These observations suggest that transcription of 
      microsatellite repeat-containing RNAs is more sensitive to perturbation than 
      transcription of other RNAs, indicating potentially viable strategies for 
      therapeutic intervention.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pinto, Belinda S
AU  - Pinto BS
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Saxena, Tanvi
AU  - Saxena T
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Oliveira, Ruan
AU  - Oliveira R
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Mendez-Gomez, Hector R
AU  - Mendez-Gomez HR
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Cleary, John D
AU  - Cleary JD
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Denes, Lance T
AU  - Denes LT
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - McConnell, Ona
AU  - McConnell O
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Arboleda, Juan
AU  - Arboleda J
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Xia, Guangbin
AU  - Xia G
AD  - Department of Neurology, University of Florida, Gainesville, FL 32610, USA; 
      Center for NeuroGenetics, University of Florida, Gainesville, FL 32610, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - Department of Molecular Genetics & Microbiology, University of Florida, 
      Gainesville, FL 32610, USA; Center for NeuroGenetics, University of Florida, 
      Gainesville, FL 32610, USA. Electronic address: eric.t.wang@ufl.edu.
LA  - eng
GR  - DP5 OD017865/OD/NIH HHS/United States
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20171019
PL  - United States
TA  - Mol Cell
JT  - Molecular cell
JID - 9802571
RN  - 0 (C9orf72 Protein)
RN  - 0 (C9orf72 protein, human)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD24 protein, human)
RN  - 0 (CLC-1 channel)
RN  - 0 (CRISPR-Associated Proteins)
RN  - 0 (Chloride Channels)
RN  - 0 (RNA, Guide, CRISPR-Cas Systems)
RN  - EC 3.1.- (Endonucleases)
RN  - EC 3.6.5.2 (ran GTP-Binding Protein)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - C9orf72 Protein/genetics/metabolism
MH  - CD24 Antigen/genetics/metabolism
MH  - CRISPR-Associated Proteins/*metabolism
MH  - *CRISPR-Cas Systems
MH  - Chloride Channels/genetics/metabolism
MH  - Dependovirus/genetics
MH  - Disease Models, Animal
MH  - Down-Regulation
MH  - Endonucleases/*metabolism
MH  - Enzyme Activation
MH  - Female
MH  - Genetic Therapy/*methods
MH  - Genetic Vectors
MH  - HEK293 Cells
MH  - HeLa Cells
MH  - Humans
MH  - Male
MH  - Mice, Transgenic
MH  - *Microsatellite Repeats
MH  - Myoblasts/metabolism/pathology
MH  - Myotonic Dystrophy/genetics/metabolism/pathology/*therapy
MH  - RNA, Guide, CRISPR-Cas Systems/biosynthesis/genetics
MH  - *Transcription, Genetic
MH  - Transduction, Genetic
MH  - ran GTP-Binding Protein/genetics/metabolism
PMC - PMC6013302
MID - NIHMS914855
OTO - NOTNLM
OT  - C9ORF72/ALS/FTD
OT  - CRISPR
OT  - Cas9
OT  - RNA polymerase II
OT  - RNA toxicity
OT  - amyotrophic lateral sclerosis
OT  - microsatellite repeat disease
OT  - myotonic dystrophy
OT  - transcription
EDAT- 2017/10/24 06:00
MHDA- 2017/11/29 06:00
PMCR- 2018/11/02
CRDT- 2017/10/24 06:00
PHST- 2017/04/13 00:00 [received]
PHST- 2017/09/05 00:00 [revised]
PHST- 2017/09/22 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
PHST- 2018/11/02 00:00 [pmc-release]
AID - S1097-2765(17)30711-6 [pii]
AID - 10.1016/j.molcel.2017.09.033 [doi]
PST - ppublish
SO  - Mol Cell. 2017 Nov 2;68(3):479-490.e5. doi: 10.1016/j.molcel.2017.09.033. Epub 
      2017 Oct 19.

PMID- 29043641
OWN - NLM
STAT- MEDLINE
DCOM- 20180606
LR  - 20201209
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1672
DP  - 2018
TI  - Measuring Dynamic Behavior of Trinucleotide Repeat Tracts In Vivo in 
      Saccharomyces cerevisiae.
PG  - 439-470
LID - 10.1007/978-1-4939-7306-4_30 [doi]
AB  - Trinucleotide repeat (TNR) tracts are inherently unstable during DNA replication, 
      leading to repeat expansions and/or contractions. Expanded tracts are the cause 
      of over 40 neurodegenerative and neuromuscular diseases. In this chapter, we 
      focus on the (CNG)(n) repeat sequences that, when expanded, lead to Huntington's 
      disease (HD), myotonic dystrophy type 1 (DM1), and a number of other 
      neurodegenerative diseases. We describe a series of in vivo assays, using the 
      model system Saccharomyces cerevisiae, to determine and characterize the dynamic 
      behavior of TNR tracts that are in the early stages of expansion, i.e., the 
      so-called threshold range. Through a series of time courses and PCR-based assays, 
      dynamic changes in tract length can be observed as a function of time. These 
      assays can ultimately be used to determine how genetic factors influence the 
      process of tract expansion in these early stages.
FAU - Williams, Gregory M
AU  - Williams GM
AD  - Department of Biochemistry, School of Medicine and Biomedical Sciences, State 
      University of New York at Buffalo, Buffalo, NY, 14214, USA.
FAU - Surtees, Jennifer A
AU  - Surtees JA
AD  - Department of Biochemistry, School of Medicine and Biomedical Sciences, State 
      University of New York at Buffalo, Buffalo, NY, 14214, USA. jsurtees@buffalo.edu.
AD  - Genetics, Genomics and Bioinformatics Program, Jacobs School of Medicine and 
      Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, 
      USA. jsurtees@buffalo.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (DNA, Fungal)
SB  - IM
MH  - DNA Replication
MH  - DNA, Fungal/isolation & purification
MH  - Gene Expression
MH  - Genes, Reporter
MH  - Genome, Fungal
MH  - Genomic Instability
MH  - Microsatellite Instability
MH  - Mutation Rate
MH  - Saccharomyces cerevisiae/*genetics
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
OTO - NOTNLM
OT  - Contraction
OT  - DNA replication
OT  - Expansion
OT  - Microsatellite instability
OT  - Polymerase chain reaction
OT  - Repeat tract dynamics
OT  - Saccharomyces cerevisiae
OT  - Trinucleotide repeat
EDAT- 2017/10/19 06:00
MHDA- 2018/06/07 06:00
CRDT- 2017/10/19 06:00
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/06/07 06:00 [medline]
AID - 10.1007/978-1-4939-7306-4_30 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2018;1672:439-470. doi: 10.1007/978-1-4939-7306-4_30.

PMID- 29036654
OWN - NLM
STAT- MEDLINE
DCOM- 20190708
LR  - 20190708
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 46
IP  - 1
DP  - 2018 Jan 9
TI  - Detection of expanded RNA repeats using thermostable group II intron reverse 
      transcriptase.
PG  - e1
LID - 10.1093/nar/gkx867 [doi]
AB  - Cellular accumulation of repetitive RNA occurs in several dominantly-inherited 
      genetic disorders. Expanded CUG, CCUG or GGGGCC repeats are expressed in myotonic 
      dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), or familial amyotrophic 
      lateral sclerosis, respectively. Expanded repeat RNAs (ER-RNAs) exert a toxic 
      gain-of-function and are prime therapeutic targets in these diseases. However, 
      efforts to quantify ER-RNA levels or monitor knockdown are confounded by stable 
      structure and heterogeneity of the ER-RNA tract and background signal from 
      non-expanded repeats. Here, we used a thermostable group II intron reverse 
      transcriptase (TGIRT-III) to convert ER-RNA to cDNA, followed by quantification 
      on slot blots. We found that TGIRT-III was capable of reverse transcription (RTn) 
      on enzymatically synthesized ER-RNAs. By using conditions that limit cDNA 
      synthesis from off-target sequences, we observed hybridization signals on cDNA 
      slot blots from DM1 and DM2 muscle samples but not from healthy controls. In 
      transgenic mouse models of DM1 the cDNA slot blots accurately reflected the 
      differences of ER-RNA expression across different transgenic lines, and showed 
      therapeutic reductions in skeletal and cardiac muscle, accompanied by 
      improvements of the DM1-associated splicing defects. TGIRT-III was also active on 
      CCCCGG- and GGGGCC-repeats, suggesting that ER-RNA analysis is feasible for 
      several repeat expansion disorders.
CI  - (c) The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic 
      Acids Research.
FAU - Carrell, Samuel T
AU  - Carrell ST
AD  - Department of Biomedical Genetics, University of Rochester Medical Center, 
      Rochester, NY 14611, USA.
FAU - Tang, Zhenzhi
AU  - Tang Z
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY 
      14611, USA.
FAU - Mohr, Sabine
AU  - Mohr S
AD  - Department of Molecular Biosciences, Institute for Cellular and Molecular 
      Biology, University of Texas at Austin, Austin, TX 78712, USA.
FAU - Lambowitz, Alan M
AU  - Lambowitz AM
AD  - Department of Molecular Biosciences, Institute for Cellular and Molecular 
      Biology, University of Texas at Austin, Austin, TX 78712, USA.
FAU - Thornton, Charles A
AU  - Thornton CA
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, NY 
      14611, USA.
LA  - eng
GR  - R37 NS094393/NS/NINDS NIH HHS/United States
GR  - R01 GM037949/GM/NIGMS NIH HHS/United States
GR  - S10 OD021489/OD/NIH HHS/United States
GR  - R21 NS093177/NS/NINDS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (RNA-Directed DNA Polymerase)
RN  - Amyotrophic lateral sclerosis 1
SB  - IM
MH  - Amyotrophic Lateral Sclerosis/*genetics/metabolism
MH  - Animals
MH  - Base Sequence
MH  - Electrophoresis, Capillary
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Enzyme Stability
MH  - Humans
MH  - Introns/*genetics
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/metabolism/pathology
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - RNA/*genetics
MH  - RNA Splicing
MH  - RNA-Directed DNA Polymerase/*genetics/metabolism
MH  - Repetitive Sequences, Nucleic Acid/*genetics
MH  - Temperature
PMC - PMC5758912
EDAT- 2017/10/17 06:00
MHDA- 2019/07/10 06:00
PMCR- 2017/10/03
CRDT- 2017/10/17 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/09/27 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2017/10/17 06:00 [entrez]
PHST- 2017/10/03 00:00 [pmc-release]
AID - 4282668 [pii]
AID - gkx867 [pii]
AID - 10.1093/nar/gkx867 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2018 Jan 9;46(1):e1. doi: 10.1093/nar/gkx867.

PMID- 29029879
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180611
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 27
IP  - 11
DP  - 2017 Nov
TI  - Reduced renal function in patients with Myotonic Dystrophy type 1 and the 
      association to CTG expansion and other potential risk factors for chronic kidney 
      disease.
PG  - 1038-1042
LID - S0960-8966(17)30212-2 [pii]
LID - 10.1016/j.nmd.2017.08.002 [doi]
AB  - Myotonic dystrophy type 1 (DM1) affects several organs. Disease severity and age 
      at onset are correlated to the CTG repeat expansion. The aim of this study was to 
      assess renal function and the association to numbers of CTG repeat expansion in 
      patients with DM1. Ninety-eight patients with DM1 were included. Glomerular 
      filtration rate (measured GFR) was measured using iohexol clearance. Data on CTG 
      repeats were available in 83/98 (85%) patients. The overall mGFR was 74 (16) 
      ml/min/1.73 m(2) (range 38-134). Sixty-four patients (69%) had a mild and sixteen 
      patients (17%) a moderate decrease in renal function (mGFR 60-89 and 
      30-59 ml/min/1.73 m(2), respectively). No correlations were found between CTG 
      repeats and mGFR (r = 0.10, p = 0.4) or between CTG repeats and serum cystatin C 
      (r = 0.12, p = 0.29). CTG repeats was positively correlated to creatinine-based 
      estimates of GFR (eGFR) (modified diet in renal disease r = 0.49, p < 0.001, 
      CKD-EPI creatinine equation; r = 0.50, p < 0.001), but analyses using Structural 
      Equation Modeling showed no correlation. The correlation was explained by an 
      indirect effect via serum creatinine and skeletal muscle mass index. In 
      conclusion, patients with DM1 seem to have a slight decrease in renal function 
      but there is no association between renal function and the number of CTG repeats, 
      a marker of disease severity.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Aldenbratt, Annika
AU  - Aldenbratt A
AD  - Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Lindberg, Christopher
AU  - Lindberg C
AD  - Department of Neurology, Neuromuscular Centre, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
FAU - Svensson, Maria K
AU  - Svensson MK
AD  - Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic 
      address: maria.k.svensson@medsci.uu.se.
LA  - eng
PT  - Journal Article
DEP - 20170815
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (Biomarkers)
RN  - 0 (Cystatin C)
RN  - 0 (DMPK protein, human)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Albuminuria/epidemiology/genetics/physiopathology
MH  - Biomarkers/blood
MH  - Cohort Studies
MH  - Creatinine/blood
MH  - Cystatin C/blood
MH  - Female
MH  - Glomerular Filtration Rate/genetics
MH  - Humans
MH  - Kidney/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology/physiopathology
MH  - Myotonic Dystrophy/epidemiology/*genetics/*physiopathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Organ Size
MH  - Renal Insufficiency, Chronic/epidemiology/*genetics/*physiopathology
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CTG repeats
OT  - Myotonic dystrophy type 1
OT  - Neuromuscular disease
OT  - Renal function
EDAT- 2017/10/17 06:00
MHDA- 2018/06/12 06:00
CRDT- 2017/10/15 06:00
PHST- 2017/03/23 00:00 [received]
PHST- 2017/07/04 00:00 [revised]
PHST- 2017/08/07 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2017/10/15 06:00 [entrez]
AID - S0960-8966(17)30212-2 [pii]
AID - 10.1016/j.nmd.2017.08.002 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2017 Nov;27(11):1038-1042. doi: 10.1016/j.nmd.2017.08.002. 
      Epub 2017 Aug 15.

PMID- 28942489
OWN - NLM
STAT- MEDLINE
DCOM- 20180802
LR  - 20181113
IS  - 1364-6753 (Electronic)
IS  - 1364-6745 (Linking)
VI  - 18
IP  - 4
DP  - 2017 Dec
TI  - Molecular genetic and clinical characterization of myotonic dystrophy type 1 
      patients carrying variant repeats within DMPK expansions.
PG  - 207-218
LID - 10.1007/s10048-017-0523-7 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by a highly unstable expansion of CTG 
      repeats in the DMPK gene. Its huge phenotypic variability cannot be explained 
      solely by the repeat number. Recently, variant repeats within the DMPK expansions 
      have emerged as potential disease modifiers. The frequency of variant expanded 
      alleles was estimated in 242 DM1 patients from 174 Serbian families using 
      repeat-primed PCR (RP-PCR). The patterns of variant repeats were determined by 
      direct sequencing of RP-PCR or PCR products. PCR-based southern blot was 
      performed to get insight into the intergenerational mutational dynamics of 
      variant expanded alleles. All patients carrying variant repeats were clinically 
      re-examined. Variant repeats were observed in eight patients from five families 
      (2.9%). They were detected only at the 3' end of DMPK expansions. CCG variant 
      repeats were present in seven patients, either as a part of regular runs of 
      CCGCTG hexamer, individual repeats, or CCG blocks. Analyses of three 
      intergenerational transmissions revealed a considerable stability or likely a 
      contraction of variant expanded alleles. Intriguingly, a decrease in age at onset 
      accompanied these transmissions. Overall, patients were characterized by a milder 
      phenotype and/or some atypical symptoms that could be rather clinically 
      suggestive of myotonic dystrophy type 2. In addition, the first case of de novo 
      CTC variant repeat was observed. Variant repeats might explain a part of the 
      phenotypic variability in a small percent of DM1 patients and likely display a 
      stabilizing effect on the meiotic instability of DMPK expanded alleles.
FAU - Pesovic, Jovan
AU  - Pesovic J
AD  - Faculty of Biology, Center for Human Molecular Genetics, University of Belgrade, 
      Studentski trg 16, PO Box 43, Belgrade, 11000, Serbia. 
      jovan.pesovic@bio.bg.ac.rs.
FAU - Peric, S
AU  - Peric S
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6-8, Belgrade, 11000, Serbia.
FAU - Brkusanin, M
AU  - Brkusanin M
AD  - Faculty of Biology, Center for Human Molecular Genetics, University of Belgrade, 
      Studentski trg 16, PO Box 43, Belgrade, 11000, Serbia.
FAU - Brajuskovic, G
AU  - Brajuskovic G
AD  - Faculty of Biology, Center for Human Molecular Genetics, University of Belgrade, 
      Studentski trg 16, PO Box 43, Belgrade, 11000, Serbia.
FAU - Rakocevic-Stojanovic, V
AU  - Rakocevic-Stojanovic V
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6-8, Belgrade, 11000, Serbia.
FAU - Savic-Pavicevic, Dusanka
AU  - Savic-Pavicevic D
AUID- ORCID: 0000-0002-2079-4077
AD  - Faculty of Biology, Center for Human Molecular Genetics, University of Belgrade, 
      Studentski trg 16, PO Box 43, Belgrade, 11000, Serbia. duska@bio.bg.ac.rs.
LA  - eng
GR  - 173016/Ministry of Education, Science and Technological Development, Republic of 
      Serbia/
GR  - 175083/Ministry of Education, Science and Technological Development, Republic of 
      Serbia/
PT  - Journal Article
DEP - 20170923
PL  - United States
TA  - Neurogenetics
JT  - Neurogenetics
JID - 9709714
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Alleles
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Pedigree
OTO - NOTNLM
OT  - CTG expansion
OT  - DMPK
OT  - Myotonic dystrophy 1
OT  - Trinucleotide repeats
OT  - Variant repeats
EDAT- 2017/09/25 06:00
MHDA- 2018/08/03 06:00
CRDT- 2017/09/25 06:00
PHST- 2017/07/02 00:00 [received]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2018/08/03 06:00 [medline]
PHST- 2017/09/25 06:00 [entrez]
AID - 10.1007/s10048-017-0523-7 [pii]
AID - 10.1007/s10048-017-0523-7 [doi]
PST - ppublish
SO  - Neurogenetics. 2017 Dec;18(4):207-218. doi: 10.1007/s10048-017-0523-7. Epub 2017 
      Sep 23.

PMID- 28904984
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2328-9503 (Print)
IS  - 2328-9503 (Electronic)
IS  - 2328-9503 (Linking)
VI  - 4
IP  - 9
DP  - 2017 Sep
TI  - Impact of diabetes in the Friedreich ataxia clinical outcome measures study.
PG  - 622-631
LID - 10.1002/acn3.439 [doi]
AB  - OBJECTIVE: Friedreich ataxia (FA) is a progressive neuromuscular disorder caused 
      by GAA triplet repeat expansions or point mutations in the FXN gene. FA is 
      associated with increased risk of diabetes mellitus (DM). This study assessed the 
      age-specific prevalence of FA-associated DM and its impact on neurologic 
      outcomes. RESEARCH DESIGN AND METHODS: Participants were 811 individuals with FA 
      from 12 international sites in a prospective natural history study (FA Clinical 
      Outcome Measures Study, FACOMS). Physical function was assessed, using validated 
      instruments. Multivariable regression analyses examined the independent 
      association of DM with outcomes. RESULTS: Mean age of participants was 30.1 years 
      (SD 15.3, range: 7-82), 50% were female, and 94% were non-Hispanic white. 9% 
      (42/459) of adults and 3% (10/352) of children had DM. Individuals with 
      FA-associated DM were older (P < 0.001), had longer GAA repeat length on the 
      least affected FXN allele (P = 0.037), and more severe FA (P = 0.0001). Of 
      individuals with DM, 65% (34/52) were taking insulin. Even after accounting 
      statistically for both age and GAA repeat length, DM was independently associated 
      with greater FA symptom burden (P = 0.010), reduced capacity to perform 
      activities of daily living (P = 0.021), and a decrease of 0.33 SDs on a composite 
      performance measure (95% CI: -0.56-0.11, P = 0.004); the relative impact of DM 
      was most apparent in younger individuals. CONCLUSIONS: DM-associated FA has an 
      independent adverse impact on well-being in affected individuals, particularly at 
      younger ages. In future, evidence-based approaches for identification and 
      management of FA-related DM may improve both health and function.
FAU - McCormick, Ashley
AU  - McCormick A
AD  - Division of Neurology Children's Hospital of Philadelphia Philadelphia 
      Pennsylvania 19104.
FAU - Farmer, Jennifer
AU  - Farmer J
AD  - Division of Neurology Children's Hospital of Philadelphia Philadelphia 
      Pennsylvania 19104.
AD  - Department of Neurology Perelman School of Medicine at the University of 
      Pennsylvania Philadelphia Pennsylvania 19104.
AD  - Department of Pediatrics Perelman School of Medicine at the University of 
      Pennsylvania Philadelphia Pennsylvania 19104.
FAU - Perlman, Susan
AU  - Perlman S
AD  - Department of Neurology University of California Los Angeles Los Angeles 
      California 90095.
FAU - Delatycki, Martin
AU  - Delatycki M
AD  - Department of Genetics Murdoch Children's Research Institute Victoria Australia.
FAU - Wilmot, George
AU  - Wilmot G
AD  - Department of Neurology Emory University School of Medicine Atlanta Georgia 
      30322.
FAU - Matthews, Katherine
AU  - Matthews K
AD  - Department of Neurology University of Iowa Carver College of Medicine Iowa City 
      Iowa 52242.
FAU - Yoon, Grace
AU  - Yoon G
AD  - Clinical and Metabolic Genetics Hospital for Sick Children Toronto Canada.
FAU - Hoyle, Chad
AU  - Hoyle C
AD  - Department of Neurology Ohio State University College of Medicine Columbus Ohio 
      43210.
FAU - Subramony, Sub H
AU  - Subramony SH
AD  - Department of Neurology University of Florida College of Medicine Gainesville 
      Florida 32610.
FAU - Zesiewicz, Theresa
AU  - Zesiewicz T
AD  - Department of Neurology University of South Florida Tampa Florida 33612.
FAU - Lynch, David R
AU  - Lynch DR
AD  - Division of Neurology Children's Hospital of Philadelphia Philadelphia 
      Pennsylvania 19104.
AD  - Department of Neurology Perelman School of Medicine at the University of 
      Pennsylvania Philadelphia Pennsylvania 19104.
AD  - Department of Pediatrics Perelman School of Medicine at the University of 
      Pennsylvania Philadelphia Pennsylvania 19104.
FAU - McCormack, Shana E
AU  - McCormack SE
AUID- ORCID: 0000-0002-1143-4459
AD  - Department of Pediatrics Perelman School of Medicine at the University of 
      Pennsylvania Philadelphia Pennsylvania 19104.
AD  - Division of Endocrinology and Diabetes Children's Hospital of Philadelphia 
      Philadelphia Pennsylvania 19104.
LA  - eng
GR  - K12 DK094723/DK/NIDDK NIH HHS/United States
GR  - K23 DK102659/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20170726
PL  - United States
TA  - Ann Clin Transl Neurol
JT  - Annals of clinical and translational neurology
JID - 101623278
PMC - PMC5590524
EDAT- 2017/09/15 06:00
MHDA- 2017/09/15 06:01
PMCR- 2017/07/26
CRDT- 2017/09/15 06:00
PHST- 2017/02/21 00:00 [received]
PHST- 2017/06/12 00:00 [revised]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2017/09/15 06:01 [medline]
PHST- 2017/07/26 00:00 [pmc-release]
AID - ACN3439 [pii]
AID - 10.1002/acn3.439 [doi]
PST - epublish
SO  - Ann Clin Transl Neurol. 2017 Jul 26;4(9):622-631. doi: 10.1002/acn3.439. 
      eCollection 2017 Sep.

PMID- 28886202
OWN - NLM
STAT- MEDLINE
DCOM- 20170919
LR  - 20181113
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 58
IP  - 11
DP  - 2017 Sep 1
TI  - Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic 
      Dystrophy.
PG  - 4579-4585
LID - 10.1167/iovs.17-22350 [doi]
AB  - PURPOSE: The most common cause of Fuchs' endothelial corneal dystrophy (FECD) is 
      an intronic CTG repeat expansion in TCF4. Expanded CUG repeat RNA colocalize with 
      splicing factor, muscleblind-like 1 (MBNL1), in nuclear foci in endothelium as a 
      molecular hallmark. Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder 
      caused by a CTG repeat expansion in the 3'-untranslated region (UTR) of DMPK. In 
      this study, we examine for RNA-MBNL1 foci in endothelial cells of FECD subjects 
      with DM1, test the hypothesis that DM1 patients are at risk for FECD, and 
      determine prevalence of TCF4 and DMPK expansions in a FECD cohort. METHODS: Using 
      FISH, we examined for nuclear RNA-MBNL1 foci in endothelial cells from FECD 
      subjects with DM1. We examined 13 consecutive unrelated DM1 patients for FECD 
      using slit-lamp and specular microscopy. We genotyped TCF4 and DMPK repeat 
      polymorphisms in a FECD cohort of 317 probands using short-tandem repeat and 
      triplet repeat-primed PCR assays. RESULTS: We detected abundant nuclear RNA foci 
      colocalizing with MBNL1 in endothelial cells of FECD subjects with DM1. Six of 
      thirteen DM1 patients (46%) had slit-lamp and specular microscopic findings of 
      FECD, compared to 4% disease prevalence (P = 5.5 x 10-6). As expected, 222 out of 
      317 (70%) FECD probands harbored TCF4 expansion, while one subject harbored DMPK 
      expansion without prior diagnosis of DM1. CONCLUSIONS: Our work suggests that DM1 
      patients are at risk for FECD. DMPK mutations contribute to the genetic burden of 
      FECD but are uncommon. We establish a connection between two repeat expansion 
      disorders converging upon RNA-MBNL1 foci and FECD.
FAU - Mootha, V Vinod
AU  - Mootha VV
AD  - Department of Ophthalmology, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
AD  - McDermott Center for Human Growth and Development, University of Texas 
      Southwestern Medical Center, Dallas, Texas, United States.
FAU - Hansen, Brock
AU  - Hansen B
AD  - Department of Ophthalmology, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
FAU - Rong, Ziye
AU  - Rong Z
AD  - Department of Ophthalmology, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
FAU - Mammen, Pradeep P
AU  - Mammen PP
AD  - Department of Internal Medicine, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
FAU - Zhou, Zhengyang
AU  - Zhou Z
AD  - McDermott Center for Human Growth and Development, University of Texas 
      Southwestern Medical Center, Dallas, Texas, United States.
FAU - Xing, Chao
AU  - Xing C
AD  - McDermott Center for Human Growth and Development, University of Texas 
      Southwestern Medical Center, Dallas, Texas, United States.
AD  - Department of Bioinformatics, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
AD  - Department of Clinical Sciences, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
FAU - Gong, Xin
AU  - Gong X
AD  - Department of Ophthalmology, University of Texas Southwestern Medical Center, 
      Dallas, Texas, United States.
LA  - eng
GR  - P30 EY020799/EY/NEI NIH HHS/United States
GR  - R01 EY022161/EY/NEI NIH HHS/United States
GR  - U54 AR068791/AR/NIAMS NIH HHS/United States
GR  - UL1 TR001105/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors)
RN  - 0 (DMPK protein, human)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA, Nuclear)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (TCF4 protein, human)
RN  - 0 (Transcription Factor 4)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
CIN - Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5838. PMID: 29136408
MH  - Adult
MH  - Aged
MH  - Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/*genetics
MH  - Endothelium, Corneal/metabolism/pathology
MH  - Female
MH  - Fuchs' Endothelial Dystrophy/*genetics/pathology
MH  - Genotyping Techniques
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase/*genetics
MH  - Polymerase Chain Reaction
MH  - RNA Splicing
MH  - *RNA, Nuclear
MH  - RNA-Binding Proteins/*genetics
MH  - Slit Lamp
MH  - Transcription Factor 4
MH  - Transcription Factors/*genetics
MH  - Trinucleotide Repeat Expansion
PMC - PMC5590687
EDAT- 2017/09/09 06:00
MHDA- 2017/09/20 06:00
PMCR- 2017/09/01
CRDT- 2017/09/09 06:00
PHST- 2017/09/09 06:00 [entrez]
PHST- 2017/09/09 06:00 [pubmed]
PHST- 2017/09/20 06:00 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - 2653896 [pii]
AID - IOVS-17-22350R1 [pii]
AID - 10.1167/iovs.17-22350 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4579-4585. doi: 
      10.1167/iovs.17-22350.

PMID- 28810563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 14
IP  - 2
DP  - 2017 Aug
TI  - Dystrophia myotonica type 1 presenting with dysarthria: A case report and 
      literature review.
PG  - 1104-1108
LID - 10.3892/etm.2017.4579 [doi]
AB  - Dystrophia myotonica (DM) type 1 is an autosomal dominant disorder, caused by a 
      trinucleotide CTG repeat expansion in the 3' untranslated region of the 
      dystrophia myotonica protein kinase (DMPK) gene (chromosome 19q13.3). The 
      disorder affects different organ systems, including the skeletal muscles, ocular 
      lens, lungs, heart and gastrointestinal tract, as well as the endocrine and 
      central nervous systems. The skeletal muscles are most frequently involved, 
      whereby the disorder manifests as myotonia, muscle weakness and amyotrophy. 
      However, DM type 1 presenting with dysarthria is rare. The current study presents 
      a case of a 28-year-old male with DM type 1 presenting with dysarthria and 
      associated multifocal hyperintense lesions in the white matter. Although 
      electromyogram measurements identified myotonic discharges in all extremities, a 
      muscle biopsy failed to detect the characteristic pathological features of DM 
      type 1. A lack of a positive family history for DM type 1 also obscured 
      diagnosis. However, genetic analysis detected a single allele in the P12 segment 
      of the DMPK gene that included a CTG expansion of 13 repeats and a three-base 
      gradient fragment in the P134 segment that included a CTG expansion of >600 
      repeats. According to the characteristics of dysarthria, multifocal hyperintense 
      lesions in the white matter, electromyogram measurement results and genetic 
      testing results, a diagnosis of DM type 1 was confirmed.
FAU - Li, Chunrong
AU  - Li C
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, Jilin 130012, P.R. China.
FAU - Zhang, Xiaoling
AU  - Zhang X
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, Jilin 130012, P.R. China.
FAU - Zhou, Chunkui
AU  - Zhou C
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, Jilin 130012, P.R. China.
FAU - Zhu, Lijun
AU  - Zhu L
AD  - Department of Neurology, The Third Teaching Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Liu, Kangding
AU  - Liu K
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, Jilin 130012, P.R. China.
FAU - Fang, Shaokuan
AU  - Fang S
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, Jilin 130012, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170612
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC5525585
OTO - NOTNLM
OT  - case report
OT  - dysarthria
OT  - dystrophia myotonica
OT  - genetic analysis
EDAT- 2017/08/16 06:00
MHDA- 2017/08/16 06:01
PMCR- 2017/06/12
CRDT- 2017/08/17 06:00
PHST- 2015/10/13 00:00 [received]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/08/17 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/08/16 06:01 [medline]
PHST- 2017/06/12 00:00 [pmc-release]
AID - ETM-0-0-4579 [pii]
AID - 10.3892/etm.2017.4579 [doi]
PST - ppublish
SO  - Exp Ther Med. 2017 Aug;14(2):1104-1108. doi: 10.3892/etm.2017.4579. Epub 2017 Jun 
      12.

PMID- 28803727
OWN - NLM
STAT- MEDLINE
DCOM- 20170901
LR  - 20240104
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Print)
IS  - 0092-8674 (Linking)
VI  - 170
IP  - 5
DP  - 2017 Aug 24
TI  - Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.
PG  - 899-912.e10
LID - S0092-8674(17)30817-6 [pii]
LID - 10.1016/j.cell.2017.07.010 [doi]
AB  - Microsatellite repeat expansions in DNA produce pathogenic RNA species that cause 
      dominantly inherited diseases such as myotonic dystrophy type 1 and 2 (DM1/2), 
      Huntington's disease, and C9orf72-linked amyotrophic lateral sclerosis (C9-ALS). 
      Means to target these repetitive RNAs are required for diagnostic and therapeutic 
      purposes. Here, we describe the development of a programmable CRISPR system 
      capable of specifically visualizing and eliminating these toxic RNAs. We observe 
      specific targeting and efficient elimination of microsatellite repeat expansion 
      RNAs both when exogenously expressed and in patient cells. Importantly, 
      RNA-targeting Cas9 (RCas9) reverses hallmark features of disease including 
      elimination of RNA foci among all conditions studied (DM1, DM2, C9-ALS, 
      polyglutamine diseases), reduction of polyglutamine protein products, 
      relocalization of repeat-bound proteins to resemble healthy controls, and 
      efficient reversal of DM1-associated splicing abnormalities in patient myotubes. 
      Finally, we report a truncated RCas9 system compatible with adeno-associated 
      viral packaging. This effort highlights the potential of RCas9 for human 
      therapeutics.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Batra, Ranjan
AU  - Batra R
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Nelles, David A
AU  - Nelles DA
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Pirie, Elaine
AU  - Pirie E
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Blue, Steven M
AU  - Blue SM
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Marina, Ryan J
AU  - Marina RJ
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Wang, Harrison
AU  - Wang H
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Chaim, Isaac A
AU  - Chaim IA
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Thomas, James D
AU  - Thomas JD
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Zhang, Nigel
AU  - Zhang N
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Nguyen, Vu
AU  - Nguyen V
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Aigner, Stefan
AU  - Aigner S
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Markmiller, Sebastian
AU  - Markmiller S
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA.
FAU - Xia, Guangbin
AU  - Xia G
AD  - Department of Neurology, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Corbett, Kevin D
AU  - Corbett KD
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Ludwig Institute for Cancer Research, San Diego Branch, 
      La Jolla, CA, USA; Department of Chemistry, University of California, San Diego, 
      La Jolla, CA, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL, USA.
FAU - Yeo, Gene W
AU  - Yeo GW
AD  - Department of Cellular and Molecular Medicine, University of California at San 
      Diego, La Jolla, CA, USA; Stem Cell Program, University of California at San 
      Diego, La Jolla, CA, USA; Institute for Genomic Medicine, University of 
      California at San Diego, La Jolla, CA, USA; Molecular Engineering Laboratory, 
      A( *)STAR, Singapore, Singapore; Department of Physiology, Yong Loo Lin School of 
      Medicine, National University of Singapore, Singapore, Singapore. Electronic 
      address: geneyeo@ucsd.edu.
LA  - eng
GR  - K12 GM068524/GM/NIGMS NIH HHS/United States
GR  - R01 HG004659/HG/NHGRI NIH HHS/United States
GR  - T32 GM008666/GM/NIGMS NIH HHS/United States
GR  - R01 NS103172/NS/NINDS NIH HHS/United States
GR  - R01 NS075449/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20170810
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Oligonucleotides, Antisense)
SB  - IM
CIN - Mol Cell. 2017 Nov 2;68(3):473-475. PMID: 29100050
MH  - Animals
MH  - COS Cells
MH  - Cell Line
MH  - Cells, Cultured
MH  - Chlorocebus aethiops
MH  - *Clustered Regularly Interspaced Short Palindromic Repeats
MH  - Genetic Therapy/*methods
MH  - Microsatellite Repeats
MH  - Oligonucleotides, Antisense/*pharmacology
MH  - RNA Splicing
MH  - Trinucleotide Repeat Expansion
PMC - PMC5873302
MID - NIHMS944246
OTO - NOTNLM
OT  - ALS
OT  - CRISPR
OT  - Huntington's disease
OT  - RNA-targeting Cas9
OT  - adeno-associated virus
OT  - gene therapy
OT  - microsatellite repeat expansion
OT  - minimal Cas9
OT  - myotonic dystrophy
EDAT- 2017/08/15 06:00
MHDA- 2017/09/02 06:00
PMCR- 2018/03/28
CRDT- 2017/08/15 06:00
PHST- 2017/04/14 00:00 [received]
PHST- 2017/06/11 00:00 [revised]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/08/15 06:00 [pubmed]
PHST- 2017/09/02 06:00 [medline]
PHST- 2017/08/15 06:00 [entrez]
PHST- 2018/03/28 00:00 [pmc-release]
AID - S0092-8674(17)30817-6 [pii]
AID - 10.1016/j.cell.2017.07.010 [doi]
PST - ppublish
SO  - Cell. 2017 Aug 24;170(5):899-912.e10. doi: 10.1016/j.cell.2017.07.010. Epub 2017 
      Aug 10.

PMID- 28782311
OWN - NLM
STAT- MEDLINE
DCOM- 20180918
LR  - 20180918
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 65
IP  - 6
DP  - 2017 Jun
TI  - Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular 
      Characterization: Experience at Tertiary Care Centre.
PG  - 32-37
AB  - OBJECTIVE: Myotonic dystrophy type 1 (DM1) is the most common myotonic disorder. 
      Molecular genetic testing of the Dystrophia Myotonica-Protein Kinase DMPK gene to 
      detect expansion of CTG repeats is confirmatory. TP-PCR (Triplet 
      Primed-Polymerase Chain Reaction) is rapid and effective screening for the CTG 
      repeat expansions in myotonic dystrophy. Indian data regarding clinical and 
      genetic evaluation of DM1 are sparse. MATERIAL AND METHODS: This was a 
      prospective observational study at a tertiary neurology centre. It included 
      subjects having clinical and electrophysiological evidence of myotonia with CTG 
      repeat expansion of DMPK gene demonstrated by TP-PCR. Diagnostic molecular 
      assessment was done by two-step procedure; conventional PCR and Fragment length 
      analysis followed by TP-PCR. RESULTS: Seventeen patients fulfilled the inclusion 
      criteria. There were fifteen males and two females, with age ranging from 19 to 
      53 years (mean age 33years). In the phenotype, large calves were seen in three 
      patients and ophthalmoparesis and scapular winging were seen in one patient each. 
      Screening of patients by PCR-Fragment analysis identified all 17 cases to be of 
      DM1. Further confirmatory test by TP-PCR also successfully identified the cases 
      to be of DM1. TP-PCR technique using forward combination primers was used 
      successfully in detecting expansion of CTG repeats in 13 cases whereas in 
      remaining 4 cases reverse primer combination was used successfully. CONCLUSIONS: 
      This series establishes that a combination of PCR- Fragment analysis and TP-PCR 
      is simple and cost effective in determining the diagnosis of Myotonic dystrophy 
      type 1. This study also documents a new clinical observation of calf hypertrophy 
      in genetically confirmed patients with DM1.
FAU - Khadilkar, Satish
AU  - Khadilkar S
AD  - Professor.
FAU - Jagiasi, Kamlesh
AU  - Jagiasi K
AD  - Associate Professor.
FAU - Yadav, Jayendra
AU  - Yadav J
AD  - Resident, GGMC and JJ Hospital, Mumbai, Maharashtra.
FAU - Chavan, Sushant V
AU  - Chavan SV
AD  - Genetist, Progenex Lab, Mumbai, Maharashtra.
FAU - Soni, Girish
AU  - Soni G
AD  - Assistant Professor, GGMC and JJ Hospital, Mumbai, Maharashtra.
FAU - Patel, Bhagyadhan
AU  - Patel B
AD  - Resident, GGMC and JJ Hospital, Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - CpG Islands/genetics
MH  - Electromyography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase/genetics
MH  - Polymerase Chain Reaction/methods
MH  - Prospective Studies
MH  - Tertiary Care Centers
MH  - Young Adult
EDAT- 2017/08/07 06:00
MHDA- 2018/09/19 06:00
CRDT- 2017/08/08 06:00
PHST- 2017/08/08 06:00 [entrez]
PHST- 2017/08/07 06:00 [pubmed]
PHST- 2018/09/19 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2017 Jun;65(6):32-37.

PMID- 30227044
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200103
IS  - 2168-4804 (Electronic)
IS  - 2168-4790 (Linking)
VI  - 51
IP  - 4
DP  - 2017 Jul
TI  - Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the 
      Myotonic Dystrophy Foundation-Sponsored Workshop.
PG  - 516-522
LID - 10.1177/2168479016683988 [doi]
AB  - Myotonic dystrophy (DM) is an autosomal dominant, repeat expansion, progressive 
      disorder with no drug therapies. Consequently, to better define a regulatory 
      pathway in anticipation of new treatment strategies under investigation, the 
      Myotonic Dystrophy Foundation convened a workshop entitled "Patient-Centered 
      Therapy Development for Myotonic Dystrophy" in September 2015. Participants 
      included representatives from academia, industry, the patient community, the 
      National Institutes of Health (NIH) and the Food and Drug Administration (FDA). 
      Presenters described the symptom burden of the disease, and existing data on DM 
      biomarkers, endpoints, natural history, and benefit-risk considerations. FDA 
      participants helped clarify the regulatory requirements for new drug treatment 
      approvals and DM-specific issues such as variability, slow progression, and low 
      prevalence. Workshop attendees gained a better understanding of DM and the 
      current status of existing data and tools to support therapeutic drug research 
      and development.
FAU - Hesterlee, Sharon
AU  - Hesterlee S
AD  - 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA.
FAU - Amur, Shashi
AU  - Amur S
AD  - 2 Office of Translational Sciences, CDER, FDA, Silver Spring, MD, USA.
FAU - Bain, Lisa J
AU  - Bain LJ
AD  - 3 Science Writer, Elverson, PA, USA.
FAU - Carulli, John
AU  - Carulli J
AD  - 4 Precision Medicine, Biogen, Cambridge, MA, USA.
FAU - Clarke, Sarah
AU  - Clarke S
AD  - 5 Patient and caregiver, NY, USA.
FAU - Day, John W
AU  - Day JW
AD  - 6 Department of Neurology, School of Medicine, Stanford University, Palo Alto, 
      CA, USA.
FAU - Gagnon, Cynthia
AU  - Gagnon C
AD  - 7 School of Rehabilitation, Universite de Sherbrooke, Quebec, Canada.
FAU - Hagerman, Katharine
AU  - Hagerman K
AD  - 6 Department of Neurology, School of Medicine, Stanford University, Palo Alto, 
      CA, USA.
FAU - Heatwole, Chad
AU  - Heatwole C
AD  - 8 Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, Rochester, NY, USA.
FAU - Johnson, Nicholas E
AU  - Johnson NE
AD  - 9 Department of Neurology, School of Medicine, University of Utah, Salt Lake 
      City, UT, USA.
FAU - Moxley, Richard 3rd
AU  - Moxley R 3rd
AD  - 8 Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, Rochester, NY, USA.
FAU - Patel, Nikunj
AU  - Patel N
AD  - 10 Office of New Drugs, CDER, FDA, Silver Spring, MD, USA.
FAU - Thornton, Charles
AU  - Thornton C
AD  - 8 Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, Rochester, NY, USA.
FAU - Kessel, Woodie
AU  - Kessel W
AD  - 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA.
FAU - White, Molly
AU  - White M
AD  - 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20170209
PL  - Switzerland
TA  - Ther Innov Regul Sci
JT  - Therapeutic innovation & regulatory science
JID - 101597411
OTO - NOTNLM
OT  - MDHI
OT  - PFDD
OT  - biomarker
OT  - endpoint
OT  - myotonic dystrophy
EDAT- 2017/07/01 00:00
MHDA- 2017/07/01 00:01
CRDT- 2018/09/19 06:00
PHST- 2018/09/19 06:00 [entrez]
PHST- 2017/07/01 00:00 [pubmed]
PHST- 2017/07/01 00:01 [medline]
AID - 10.1177/2168479016683988 [doi]
PST - ppublish
SO  - Ther Innov Regul Sci. 2017 Jul;51(4):516-522. doi: 10.1177/2168479016683988. Epub 
      2017 Feb 9.

PMID- 28623239
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20230807
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Print)
IS  - 1754-8403 (Linking)
VI  - 10
IP  - 8
DP  - 2017 Aug 1
TI  - (CCUG)(n) RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) 
      activates apoptosis.
PG  - 993-1003
LID - 10.1242/dmm.026179 [doi]
AB  - The myotonic dystrophies are prototypic toxic RNA gain-of-function diseases. 
      Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are caused by different 
      unstable, noncoding microsatellite repeat expansions - (CTG)(DM1) in DMPK and 
      (CCTG)(DM2) in CNBP Although transcription of mutant repeats into (CUG)(DM1) or 
      (CCUG)(DM2) appears to be necessary and sufficient to cause disease, their 
      pathomechanisms remain incompletely understood. To study the mechanisms of 
      (CCUG)(DM2) toxicity and develop a convenient model for drug screening, we 
      generated a transgenic DM2 model in the fruit fly Drosophila melanogaster with 
      (CCUG)(n) repeats of variable length (n=16 and 106). Expression of noncoding 
      (CCUG)(106), but not (CCUG)(16), in muscle and retinal cells led to the formation 
      of ribonuclear foci and mis-splicing of genes implicated in DM pathology. 
      Mis-splicing could be rescued by co-expression of human MBNL1, but not by CUGBP1 
      (CELF1) complementation. Flies with (CCUG)(106) displayed strong disruption of 
      external eye morphology and of the underlying retina. Furthermore, expression of 
      (CCUG)(106) in developing retinae caused a strong apoptotic response. Inhibition 
      of apoptosis rescued the retinal disruption in (CCUG)(106) flies. Finally, we 
      tested two chemical compounds that have shown therapeutic potential in DM1 
      models. Whereas treatment of (CCUG)(106) flies with pentamidine had no effect, 
      treatment with a PKR inhibitor blocked both the formation of RNA foci and 
      apoptosis in retinae of (CCUG)(106) flies. Our data indicate that expression of 
      expanded (CCUG)(DM2) repeats is toxic, causing inappropriate cell death in 
      affected fly eyes. Our Drosophila DM2 model might provide a convenient tool for 
      in vivo drug screening.
CI  - (c) 2017. Published by The Company of Biologists Ltd.
FAU - Yenigun, Vildan Betul
AU  - Yenigun VB
AD  - Department of Biochemistry & Molecular Biology, University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
AD  - Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
AD  - Graduate Programs in Genes & Development, University of Texas Graduate School in 
      Biomedical Sciences at Houston, Houston, TX, USA.
FAU - Sirito, Mario
AU  - Sirito M
AD  - Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Amcheslavky, Alla
AU  - Amcheslavky A
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts 
      Medical School, Worcester, MA, USA.
FAU - Czernuszewicz, Tomek
AU  - Czernuszewicz T
AD  - Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Colonques-Bellmunt, Jordi
AU  - Colonques-Bellmunt J
AD  - Valentia BioPharma, Paterna, Spain.
FAU - Garcia-Alcover, Irma
AU  - Garcia-Alcover I
AD  - Valentia BioPharma, Paterna, Spain.
FAU - Wojciechowska, Marzena
AU  - Wojciechowska M
AD  - Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Bolduc, Clare
AU  - Bolduc C
AUID- ORCID: 0000-0002-1321-6017
AD  - Department of Biochemistry & Molecular Biology, University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
FAU - Chen, Zhihong
AU  - Chen Z
AD  - Department of Biochemistry & Molecular Biology, University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA.
FAU - Lopez Castel, Arturo
AU  - Lopez Castel A
AD  - Valentia BioPharma, Paterna, Spain.
FAU - Krahe, Ralf
AU  - Krahe R
AD  - Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA andreas.bergmann@umassmed.edu rkrahe@mdanderson.org.
AD  - Graduate Programs in Genes & Development, University of Texas Graduate School in 
      Biomedical Sciences at Houston, Houston, TX, USA.
AD  - Graduate Programs in Human & Molecular Genetics, University of Texas Graduate 
      School in Biomedical Sciences at Houston, Houston, Texas, USA.
FAU - Bergmann, Andreas
AU  - Bergmann A
AUID- ORCID: 0000-0002-9134-871X
AD  - Department of Biochemistry & Molecular Biology, University of Texas MD Anderson 
      Cancer Center, Houston, TX, USA andreas.bergmann@umassmed.edu 
      rkrahe@mdanderson.org.
AD  - Graduate Programs in Genes & Development, University of Texas Graduate School in 
      Biomedical Sciences at Houston, Houston, TX, USA.
AD  - Department of Molecular, Cell and Cancer Biology, University of Massachusetts 
      Medical School, Worcester, MA, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 AR048171/AR/NIAMS NIH HHS/United States
GR  - R01 GM068016/GM/NIGMS NIH HHS/United States
GR  - R35 GM118330/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170616
PL  - England
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
RN  - 0 (Drosophila Proteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 63231-63-0 (RNA)
RN  - 673LC5J4LQ (Pentamidine)
RN  - EC 2.7.11.1 (eIF-2 Kinase)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects/genetics
MH  - DNA Repeat Expansion/*genetics
MH  - Disease Models, Animal
MH  - Drosophila Proteins/genetics/metabolism
MH  - Drosophila melanogaster/drug effects/*genetics
MH  - Humans
MH  - Muscle, Skeletal/drug effects/metabolism/pathology
MH  - Muscular Atrophy/pathology
MH  - Myotonic Dystrophy/*genetics
MH  - Neurons/drug effects/metabolism/pathology
MH  - Pentamidine/pharmacology
MH  - Photoreceptor Cells, Invertebrate/drug effects/metabolism/pathology
MH  - Protein Kinase Inhibitors/pharmacology
MH  - RNA/*toxicity
MH  - RNA Splicing/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Retina/abnormalities/drug effects/pathology
MH  - eIF-2 Kinase/antagonists & inhibitors/metabolism
PMC - PMC5560059
OTO - NOTNLM
OT  - Apoptosis
OT  - DM2
OT  - Drosophila
OT  - Muscleblind
OT  - Myotonic dystrophy
OT  - RNA toxicity
COIS- Competing interestsThe authors declare no competing or financial interests.
EDAT- 2017/06/18 06:00
MHDA- 2018/04/24 06:00
PMCR- 2017/08/01
CRDT- 2017/06/18 06:00
PHST- 2016/05/11 00:00 [received]
PHST- 2017/06/14 00:00 [accepted]
PHST- 2017/06/18 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2017/06/18 06:00 [entrez]
PHST- 2017/08/01 00:00 [pmc-release]
AID - dmm.026179 [pii]
AID - DMM026179 [pii]
AID - 10.1242/dmm.026179 [doi]
PST - ppublish
SO  - Dis Model Mech. 2017 Aug 1;10(8):993-1003. doi: 10.1242/dmm.026179. Epub 2017 Jun 
      16.

PMID- 28540995
OWN - NLM
STAT- MEDLINE
DCOM- 20171020
LR  - 20181202
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 58
IP  - 4
DP  - 2017 Jul
TI  - Cortical Thickness and White Matter Integrity are Associated with CTG Expansion 
      Size in Myotonic Dystrophy Type I.
PG  - 807-815
LID - 10.3349/ymj.2017.58.4.807 [doi]
AB  - PURPOSE: Myotonic dystrophy type 1 (DM1) is characterized by progressive muscular 
      weakness with symptoms caused by involvement of the brain. The aim of this study 
      was to delineate global changes in cortical thickness and white matter integrity 
      in patients with DM1, compared to age-matched healthy controls, and in brain 
      areas highly correlated with CTG repeat size. MATERIALS AND METHODS: Cortical 
      thickness and white matter integrity were compared in nine adult DM1 patients and 
      age matched healthy controls using T1-weighted and diffusion tensor imaging. The 
      patients' intelligence quotient (IQ) and CTG repeat size were measured in each 
      individual. RESULTS: Cortical thickness was significantly reduced in the frontal, 
      temporal, and occipital cortices, while tract-based spatial statistics showed 
      decreased diffusion metrics in widespread areas, including the bilateral 
      orbitofrontal, anterior frontal, insular, external capsule, and occipital 
      cortices in DM1 patients, compared to controls. Additionally, thickness was 
      negatively correlated with the number of CTG repeats in those areas. White matter 
      integrity was negatively correlated with CTG repeats in the left entorhinal, 
      anterior corona radiata, orbitofrontal, and lateral occipital areas. No 
      statistically significant correlation was found between IQ scores and the size of 
      CTG repeats. CONCLUSION: Our results suggest that DM1 is associated with wide 
      distributions of network changes in both gray and white matter. Some of areas 
      related to cognition showed significant correlations with CTG repeats.
CI  - (c) Copyright: Yonsei University College of Medicine 2017
FAU - Yoo, Woo Kyoung
AU  - Yoo WK
AD  - Department of Physical Medicine and Rehabilitation and Hallym Institute of 
      Translational Genomics and Bioinformatics, Hallym Sacred Heart Hospital, Hallym 
      University College of Medicine, Anyang, Korea.
FAU - Park, Yoon Ghil
AU  - Park YG
AD  - Department of Rehabilitation Medicine and Rehabilitation Institute of 
      Neuromuscular Disease, Gangnam Severance Hospital, Yonsei University College of 
      Medicine, Seoul, Korea. drtlc@yuhs.ac.
FAU - Choi, Young Chul
AU  - Choi YC
AD  - Department of Neurology and Rehabilitation Institute of Neuromuscular Disease, 
      Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
FAU - Kim, Sun Mi
AU  - Kim SM
AD  - Department of Rehabilitation Medicine and Rehabilitation Institute of 
      Neuromuscular Disease, Gangnam Severance Hospital, Yonsei University College of 
      Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Cerebral Cortex/*pathology
MH  - Demography
MH  - Diffusion Tensor Imaging
MH  - Female
MH  - Humans
MH  - Intelligence Tests
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - White Matter/*pathology
MH  - Young Adult
PMC - PMC5447113
OTO - NOTNLM
OT  - CTG expansion size
OT  - Myotonia
OT  - cognitive function
OT  - myelinopathy
OT  - orbitofrontal network
OT  - resting network
COIS- The authors have no financial conflicts of interest.
EDAT- 2017/05/26 06:00
MHDA- 2017/10/21 06:00
PMCR- 2017/07/01
CRDT- 2017/05/26 06:00
PHST- 2016/09/09 00:00 [received]
PHST- 2017/02/02 00:00 [revised]
PHST- 2017/02/15 00:00 [accepted]
PHST- 2017/05/26 06:00 [entrez]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2017/10/21 06:00 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - 58.807 [pii]
AID - 10.3349/ymj.2017.58.4.807 [doi]
PST - ppublish
SO  - Yonsei Med J. 2017 Jul;58(4):807-815. doi: 10.3349/ymj.2017.58.4.807.

PMID- 28435090
OWN - NLM
STAT- MEDLINE
DCOM- 20170814
LR  - 20180917
IS  - 1874-9399 (Print)
IS  - 1874-9399 (Linking)
VI  - 1860
IP  - 6
DP  - 2017 Jun
TI  - Trinucleotide-repeat expanded and normal DMPK transcripts contain unusually long 
      poly(A) tails despite differential nuclear residence.
PG  - 740-749
LID - S1874-9399(17)30022-6 [pii]
LID - 10.1016/j.bbagrm.2017.04.002 [doi]
AB  - In yeast and higher eukaryotes nuclear retention of transcripts may serve in 
      control over RNA decay, nucleocytoplasmic transport and premature cytoplasmic 
      appearance of mRNAs. Hyperadenylation of RNA is known to be associated with 
      nuclear retention, but the cause-consequence relationship between 
      hyperadenylation and regulation of RNA nuclear export is still unclear. We 
      compared polyadenylation status between normal and expanded DMPK transcripts in 
      muscle cells and tissues derived from unaffected individuals and patients with 
      myotonic dystrophy type 1 (DM1). DM1 is an autosomal dominant disorder caused by 
      (CTG)n repeat expansion in the DMPK gene. DM1 etiology is characterized by an 
      almost complete block of nuclear export of DMPK transcripts carrying a long 
      (CUG)n repeat, including aberrant sequestration of RNA-binding proteins. We show 
      here by use of cell fractionation, RNA size separation and analysis of poly(A) 
      tail length that a considerable fraction of transcripts from the normal DMPK 
      allele is also retained in the nucleus (~30%). They carry poly(A) tails with an 
      unusually broad length distribution, ranging between a few dozen to >500 
      adenosine residues. Remarkably, expanded DMPK (CUG)n transcripts from the mutant 
      allele, almost exclusively nuclear, carry equally long poly(A) tails. Our 
      findings thus suggest that nuclear retention may be a common feature of 
      regulation of DMPK RNA expression. The typical forced nuclear residence of 
      expanded DMPK transcripts affects this regulation in tissues of DM1 patients, but 
      not through hyperadenylation.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Gudde, Anke E E G
AU  - Gudde AEEG
AD  - Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, 
      Department of Cell Biology, Nijmegen, The Netherlands.
FAU - van Kessel, Ingeborg D G
AU  - van Kessel IDG
AD  - Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, 
      Department of Cell Biology, Nijmegen, The Netherlands.
FAU - Andre, Laurene M
AU  - Andre LM
AD  - Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, 
      Department of Cell Biology, Nijmegen, The Netherlands.
FAU - Wieringa, Be
AU  - Wieringa B
AD  - Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, 
      Department of Cell Biology, Nijmegen, The Netherlands.
FAU - Wansink, Derick G
AU  - Wansink DG
AD  - Radboud University Medical Centre, Radboud Institute for Molecular Life Sciences, 
      Department of Cell Biology, Nijmegen, The Netherlands. Electronic address: 
      rick.wansink@radboudumc.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170418
PL  - Netherlands
TA  - Biochim Biophys Acta Gene Regul Mech
JT  - Biochimica et biophysica acta. Gene regulatory mechanisms
JID - 101731723
RN  - 0 (DMPK protein, human)
RN  - 24937-83-5 (Poly A)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Alleles
MH  - Cell Line, Transformed
MH  - Cell Nucleus/genetics/*metabolism/pathology
MH  - *Gene Expression Regulation, Enzymologic
MH  - Humans
MH  - Myotonic Dystrophy/enzymology/genetics/pathology
MH  - Myotonin-Protein Kinase/*biosynthesis/genetics
MH  - *Poly A
MH  - *Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - DMPK
OT  - Hyperadenylation
OT  - Myotonic dystrophy
OT  - Nuclear retention
OT  - Poly(A) tail
OT  - RNA processing
OT  - Trinucleotide repeat instability
EDAT- 2017/04/25 06:00
MHDA- 2017/08/15 06:00
CRDT- 2017/04/25 06:00
PHST- 2017/01/25 00:00 [received]
PHST- 2017/03/26 00:00 [revised]
PHST- 2017/04/14 00:00 [accepted]
PHST- 2017/04/25 06:00 [pubmed]
PHST- 2017/08/15 06:00 [medline]
PHST- 2017/04/25 06:00 [entrez]
AID - S1874-9399(17)30022-6 [pii]
AID - 10.1016/j.bbagrm.2017.04.002 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Gene Regul Mech. 2017 Jun;1860(6):740-749. doi: 
      10.1016/j.bbagrm.2017.04.002. Epub 2017 Apr 18.

PMID- 28363916
OWN - NLM
STAT- MEDLINE
DCOM- 20171220
LR  - 20221207
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 7
IP  - 3
DP  - 2017 Mar 31
TI  - Analysis of CTG repeat length variation in the DMPK gene in the general 
      population and the molecular diagnosis of myotonic dystrophy type 1 in Malaysia.
PG  - e010711
LID - 10.1136/bmjopen-2015-010711 [doi]
LID - e010711
AB  - OBJECTIVE: The lack of epidemiological data and molecular diagnostic services in 
      Malaysia has hampered the setting-up of a comprehensive management plan for 
      patients with myotonic dystrophy type 1 (DM1), leading to delayed diagnosis, 
      treatment and support for patients and families. The aim of this study was to 
      estimate the prevalence of DM1 in the 3 major ethnic groups in Malaysia and 
      evaluate the feasibility of a single tube triplet-primed PCR (TP-PCR) method for 
      diagnosis of DM1 in Malaysia. DESIGN, SETTING AND PARTICIPANTS: We used PCR to 
      determine the size of CTG repeats in 377 individuals not known to be affected by 
      DM and 11 DM1 suspected patients, recruited from a tertiary hospital in Kuala 
      Lumpur. TP-PCR was performed on selected samples, followed by Southern blot 
      hybridisation of PCR amplified fragments to confirm and estimate the size of CTG 
      expansion. OUTCOME MEASURES: The number of individuals not known to be affected 
      by DM with (CTG)(>18) was determined according to ethnic group and as a whole 
      population. The chi(2) test was performed to compare the distribution of (CTG)(>18) 
      with 12 other populations. Additionally, the accuracy of TP-PCR in detecting CTG 
      expansion in 11 patients with DM1 was determined by comparing the results with 
      that from Southern blot hybridisation. RESULTS: Of the 754 chromosomes studied, 
      (CTG)(>18) frequency of 3.60%, 1.57% and 4.00% in the Malay, Chinese and Indian 
      subpopulations, respectively, was detected, showing similarities to data from 
      Thai, Taiwanese and Kuwaiti populations. We also successfully detected CTG 
      expansions in 9 patients using the TP-PCR method followed by the estimation of 
      CTG expansion size via Southern blot hybridisation. CONCLUSIONS: The results show 
      a low DM1 prevalence in Malaysia with the possibility of underdiagnosis and 
      demonstrates the feasibility of using a clinical and TP-PCR-based approach for 
      rapid and cost-effective DM1 diagnosis in developing countries.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Ambrose, Kathlin K
AU  - Ambrose KK
AD  - Department of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Ishak, Taufik
AU  - Ishak T
AD  - Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Lian, Lay-Hoong
AU  - Lian LH
AD  - Department of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Goh, Khean-Jin
AU  - Goh KJ
AD  - Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Wong, Kum-Thong
AU  - Wong KT
AD  - Department of Pathology, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Ahmad-Annuar, Azlina
AU  - Ahmad-Annuar A
AD  - Department of Biomedical Science, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Thong, Meow-Keong
AU  - Thong MK
AD  - Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20170331
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Asian People/genetics
MH  - Blotting, Southern
MH  - Child, Preschool
MH  - China/ethnology
MH  - Ethnicity
MH  - Female
MH  - Humans
MH  - India/ethnology
MH  - Malaysia/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Molecular Diagnostic Techniques
MH  - Myotonic Dystrophy/epidemiology/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Polymerase Chain Reaction
MH  - Prevalence
MH  - Trinucleotide Repeats/*genetics
MH  - White People/genetics
PMC - PMC5387946
OTO - NOTNLM
OT  - CTG repeats
OT  - TP-PCR
OT  - genetic counselling
OT  - molecular diagnosis
OT  - myotonic dystrophy type 1
OT  - prevalence
COIS- Competing interests: None declared.
EDAT- 2017/04/02 06:00
MHDA- 2017/12/21 06:00
PMCR- 2017/03/31
CRDT- 2017/04/02 06:00
PHST- 2017/04/02 06:00 [entrez]
PHST- 2017/04/02 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
PHST- 2017/03/31 00:00 [pmc-release]
AID - bmjopen-2015-010711 [pii]
AID - 10.1136/bmjopen-2015-010711 [doi]
PST - epublish
SO  - BMJ Open. 2017 Mar 31;7(3):e010711. doi: 10.1136/bmjopen-2015-010711.

PMID- 28317292
OWN - NLM
STAT- MEDLINE
DCOM- 20170605
LR  - 20240213
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Print)
IS  - 1351-5101 (Linking)
VI  - 24
IP  - 5
DP  - 2017 May
TI  - Pigmentation phenotype, photosensitivity and skin neoplasms in patients with 
      myotonic dystrophy.
PG  - 713-718
LID - 10.1111/ene.13276 [doi]
AB  - BACKGROUND AND PURPOSE: Recent studies have suggested a possible excess risk of 
      skin neoplasms in patients with myotonic dystrophy (DM). Risk factors related to 
      this observation have not been defined. METHOD: Information regarding personal 
      history of skin tumors, pigmentation phenotype, and skin reaction to sun exposure 
      were collected from 266 DM patients who were enrolled in the US National 
      Institutes of Health National Registry of Myotonic Dystrophy and 
      Facioscapulohumeral Muscular Dystrophy Patients and Family Members. RESULTS: 
      Seventy-seven subjects reported having skin tumors that were either benign (n = 
      31), malignant (n = 32) or both (n = 14). Female gender [odds ratio (OR) = 2.27, 
      95% confidence interval (CI) 1.02-5.05, P = 0.04], older age (OR = 1.10, 95% CI 
      1.05-1.16, P < 0.001) and DM1 subtype (OR = 3.42, 95% CI 1.27-9.26, P = 0.02) 
      were associated with a malignant skin tumor. The associations between malignant 
      skin tumors and known risk factors [light eye color (OR = 1.62, 95% CI 0.78-3.39, 
      P = 0.20), light skin complexion (OR = 1.31, 95% CI 0.63-2.73, P = 0.48) and 
      moderate/extensive face freckles (OR = 1.47, 95% CI 0.50-4.34, P = 0.49)] were 
      modest. Strong, but not statistically significant, associations were noted with 
      sunburn reactions when exposed to sunlight (OR = 4.28, 95% CI 0.91-19.95, P = 
      0.06, and OR = 2.19, 95% CI 0.67-7.09, P = 0.19, for sunburn with and without 
      blistering, respectively). CONCLUSIONS: Although our study was limited by small 
      sample size, the risk factors for malignant skin tumors in DM strongly resemble 
      the general population. It is recommended that DM patients adhere to sun exposure 
      protective behavior.
CI  - Published 2017. This article is a U.S. Government work and is in the public 
      domain in the USA.
FAU - Gadalla, S M
AU  - Gadalla SM
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, NIH, Bethesda, MD, USA.
FAU - Hilbert, J E
AU  - Hilbert JE
AD  - Department of Neurology, Neuromuscular Disease Center, University of Rochester 
      Medical Center, Rochester, NY, USA.
FAU - Martens, W B
AU  - Martens WB
AD  - Department of Neurology, Neuromuscular Disease Center, University of Rochester 
      Medical Center, Rochester, NY, USA.
FAU - Givens, S
AU  - Givens S
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, NIH, Bethesda, MD, USA.
FAU - Moxley, R T 3rd
AU  - Moxley RT 3rd
AD  - Department of Neurology, Neuromuscular Disease Center, University of Rochester 
      Medical Center, Rochester, NY, USA.
FAU - Greene, M H
AU  - Greene MH
AD  - Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National 
      Cancer Institute, NIH, Bethesda, MD, USA.
LA  - eng
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
GR  - ZIA CP010144-17/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20170320
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanosis/*epidemiology
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology
MH  - Phenotype
MH  - *Registries
MH  - Risk Factors
MH  - Skin Neoplasms/*epidemiology
MH  - Skin Pigmentation/*physiology
MH  - Sunburn/*epidemiology
MH  - Young Adult
PMC - PMC5464410
MID - NIHMS859881
OTO - NOTNLM
OT  - cancer
OT  - myotonic dystrophy
OT  - repeat expansion size
OT  - risk factors
OT  - skin
COIS- CONFLICTS OF INTEREST None of the manuscript authors has conflict of interest to 
      disclose
EDAT- 2017/03/21 06:00
MHDA- 2017/06/06 06:00
PMCR- 2018/05/01
CRDT- 2017/03/21 06:00
PHST- 2016/08/05 00:00 [received]
PHST- 2017/01/04 00:00 [accepted]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2017/06/06 06:00 [medline]
PHST- 2017/03/21 06:00 [entrez]
PHST- 2018/05/01 00:00 [pmc-release]
AID - 10.1111/ene.13276 [doi]
PST - ppublish
SO  - Eur J Neurol. 2017 May;24(5):713-718. doi: 10.1111/ene.13276. Epub 2017 Mar 20.

PMID- 28211918
OWN - NLM
STAT- MEDLINE
DCOM- 20181030
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
DP  - 2017 Feb 13
TI  - Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG 
      repeat instability.
PG  - 42522
LID - 10.1038/srep42522 [doi]
LID - 42522
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal-dominant multi-system disease 
      caused by expanded CTG repeats in dystrophia myotonica protein kinase (DMPK). The 
      expanded CTG repeats are unstable and can increase the length of the gene with 
      age, which worsens the symptoms. In order to establish a human stem cell system 
      suitable for the investigation of repeat instability, DM1 patient-derived iPSCs 
      were generated and differentiated into three cell types commonly affected in DM1, 
      namely cardiomyocytes, neurons and myocytes. Then we precisely analysed the CTG 
      repeat lengths in these cells. Our DM1-iPSCs showed a gradual lengthening of CTG 
      repeats with unchanged repeat distribution in all cell lines depending on the 
      passage numbers of undifferentiated cells. However, the average CTG repeat length 
      did not change significantly after differentiation into different somatic cell 
      types. We also evaluated the chromatin accessibility in DM1-iPSCs using ATAC-seq. 
      The chromatin status in DM1 cardiomyocytes was closed at the DMPK locus as well 
      as at SIX5 and its promoter region, whereas it was open in control, suggesting 
      that the epigenetic modifications may be related to the CTG repeat expansion in 
      DM1. These findings may help clarify the role of repeat instability in the CTG 
      repeat expansion in DM1.
FAU - Ueki, Junko
AU  - Ueki J
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
AD  - Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, 
      Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Nakamura, Masahiro
AU  - Nakamura M
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Nishikawa, Misato
AU  - Nishikawa M
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Yoshida, Yoshinori
AU  - Yoshida Y
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Tanaka, Azusa
AU  - Tanaka A
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Morizane, Asuka
AU  - Morizane A
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Kamon, Masayoshi
AU  - Kamon M
AD  - Department of Peripheral Nervous System Research, National Institute of 
      Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, 
      Kodaira, Tokyo 187-8502, Japan.
FAU - Araki, Toshiyuki
AU  - Araki T
AD  - Department of Peripheral Nervous System Research, National Institute of 
      Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, 
      Kodaira, Tokyo 187-8502, Japan.
FAU - Takahashi, Masanori P
AU  - Takahashi MP
AD  - Department of Neurology, Osaka University Graduate School of Medicine, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
AD  - Department of Functional Diagnostic Science, Osaka University Graduate School of 
      Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Watanabe, Akira
AU  - Watanabe A
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Inagaki, Nobuya
AU  - Inagaki N
AD  - Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, 
      Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
FAU - Sakurai, Hidetoshi
AU  - Sakurai H
AD  - Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 
      Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170213
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Cell Differentiation/genetics
MH  - Chromatin Assembly and Disassembly
MH  - *Genomic Instability
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology/*metabolism
MH  - Karyotype
MH  - Muscle Cells/cytology/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Neurons/cytology/metabolism
MH  - RNA Splicing
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
PMC - PMC5304155
COIS- The authors declare no competing financial interests.
EDAT- 2017/02/18 06:00
MHDA- 2018/10/31 06:00
PMCR- 2017/02/13
CRDT- 2017/02/18 06:00
PHST- 2016/09/28 00:00 [received]
PHST- 2017/01/09 00:00 [accepted]
PHST- 2017/02/18 06:00 [entrez]
PHST- 2017/02/18 06:00 [pubmed]
PHST- 2018/10/31 06:00 [medline]
PHST- 2017/02/13 00:00 [pmc-release]
AID - srep42522 [pii]
AID - 10.1038/srep42522 [doi]
PST - epublish
SO  - Sci Rep. 2017 Feb 13;7:42522. doi: 10.1038/srep42522.

PMID- 28168524
OWN - NLM
STAT- MEDLINE
DCOM- 20170711
LR  - 20191210
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 264
IP  - 4
DP  - 2017 Apr
TI  - Functional impairment in patients with myotonic dystrophy type 1 can be assessed 
      by an ataxia rating scale (SARA).
PG  - 701-708
LID - 10.1007/s00415-017-8399-x [doi]
AB  - Myotonic dystrophy type 1 (DM1) is not characterised by ataxia per se; however, 
      DM1 and ataxia patients show similar disturbances in movement coordination often 
      experiencing walking and balance difficulties, although caused by different 
      underlying pathologies. This study aims to investigate the use of a scale 
      previously described for the assessment and rating of ataxia (SARA) with the 
      hypothesis that it could have utility in DM1 patients as a measure of disease 
      severity and risk of falling. Data from 54 DM1 patients were pulled from the 
      PHENO-DM1 natural history study for analysis. Mean SARA score in the DM1 
      population was 5.45 relative to the maximum score of eight. A flooring effect 
      (score 0) was observed in mild cases within the sample. Inter-rater and 
      test-retest reliability was high with intraclass coefficients (ICC) of 0.983 and 
      1.00, respectively. Internal consistency was acceptable as indicated by a 
      Cronbach's alpha of 0.761. Component analysis revealed two principle components. 
      SARA correlated with: (1) all measures of muscle function tested, including 
      quantitative muscle testing of ankle dorsiflexion (r = -0.584*), the 6 min walk 
      test (r = -0.739*), 10 m walk test (r = 0.741*), and the nine hole peg test 
      (r = 0.602*) and (2) measures of disease severity/burden, such as MIRS 
      (r = 0.718*), MDHI (r = 0.483*), and DM1-Activ (r = -0.749*) (*p < 0.001). The 
      SARA score was predicted by an interaction between modal CTG repeat length and 
      age at sampling (r = 0.678, p = 0.003). A score of eight or above predicted the 
      use of a walking aid with a sensitivity of 100% and a specificity of 85.7%. We 
      suggest that further research is warranted to ascertain whether SARA or 
      components of SARA are useful outcome measures for clinical trials in DM1. As a 
      tool, it can be used for gathering information about disease severity/burden and 
      helping to identify patients in need of a walking aid, and can potentially be 
      applied in both research and healthcare settings.
FAU - DiPaolo, Giovanni
AU  - DiPaolo G
AD  - Keel University School of Medicine, Stoke-on-Trent, UK.
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Jimenez-Moreno, Cecilia
AU  - Jimenez-Moreno C
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK. a.c.jimenez-moreno@newcastle.ac.uk.
FAU - Nikolenko, Nikoletta
AU  - Nikolenko N
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Atalaia, Antonio
AU  - Atalaia A
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK.
AD  - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow, UK.
FAU - Guglieri, Michela
AU  - Guglieri M
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK.
FAU - Lochmuller, Hanns
AU  - Lochmuller H
AD  - John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle 
      upon Tyne, UK.
LA  - eng
PT  - Journal Article
DEP - 20170206
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Accidental Falls
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Ataxia/*diagnosis/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength
MH  - Myotonic Dystrophy/*complications/*diagnosis
MH  - Myotonin-Protein Kinase/genetics
MH  - Outcome Assessment, Health Care
MH  - Postural Balance/physiology
MH  - Reproducibility of Results
MH  - Sensation Disorders/etiology
MH  - *Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Trinucleotide Repeats/genetics
MH  - Young Adult
PMC - PMC5374179
OTO - NOTNLM
OT  - Balance
OT  - DM1
OT  - Falls
OT  - Myotonic dystrophy
COIS- CONFLICTS OF INTEREST: Giovanni Di Paolo: This project was part of Mr. Di Paolo 
      MRes' research project. Cecilia Jimenez Moreno: Mrs Jimenez Moreno PhD 
      studentship is a combined funding from Consejo Nacional de Ciencia y Tecnologia 
      (CONACYT), Mexico (ID 611819) and a university scholarship from the MRC centre 
      for neuromuscular diseases and the Barbour Foundation, UK. Nikoletta Nikolenko: 
      Dr. Nikolenko's contract is part of the PHENO-DM1 study grant. Antonio Atalaia: 
      No conflict of interests. Darren G. Monckton: Prof. Monckton has been supported 
      by awards from the Muscular Dystrophy UK, the Myotonic Dystrophy Support Group, 
      and the European Union. Professor Monckton has also been a paid scientific 
      consultant of Biogen Idec and AMO Pharma. Michela Guglieri: No conflict of 
      interests. Hanns Lochmuller: Prof. Lochmuller has been awarded with the National 
      Institute of Health Research IHR and Wyck grant to perform the PHENO-DM1 study. 
      ETHICAL STANDARDS: The author declares that the research documented in the 
      submitted manuscript has been carried out in accordance with high research and 
      ethical standards.
EDAT- 2017/02/09 06:00
MHDA- 2017/07/14 06:00
PMCR- 2017/02/06
CRDT- 2017/02/08 06:00
PHST- 2016/12/02 00:00 [received]
PHST- 2017/01/17 00:00 [accepted]
PHST- 2017/01/08 00:00 [revised]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2017/02/08 06:00 [entrez]
PHST- 2017/02/06 00:00 [pmc-release]
AID - 10.1007/s00415-017-8399-x [pii]
AID - 8399 [pii]
AID - 10.1007/s00415-017-8399-x [doi]
PST - ppublish
SO  - J Neurol. 2017 Apr;264(4):701-708. doi: 10.1007/s00415-017-8399-x. Epub 2017 Feb 
      6.

PMID- 28129118
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20240104
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 25
IP  - 1
DP  - 2017 Jan 4
TI  - CRISPR/Cas9-Induced (CTG...CAG)(n) Repeat Instability in the Myotonic Dystrophy 
      Type 1 Locus: Implications for Therapeutic Genome Editing.
PG  - 24-43
LID - S1525-0016(16)45369-4 [pii]
LID - 10.1016/j.ymthe.2016.10.014 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by (CTG...CAG)(n)-repeat expansion within 
      the DMPK gene and thought to be mediated by a toxic RNA gain of function. Current 
      attempts to develop therapy for this disease mainly aim at destroying or blocking 
      abnormal properties of mutant DMPK (CUG)n RNA. Here, we explored a DNA-directed 
      strategy and demonstrate that single clustered regularly interspaced short 
      palindromic repeats (CRISPR)/Cas9-cleavage in either its 5' or 3' unique flank 
      promotes uncontrollable deletion of large segments from the expanded 
      trinucleotide repeat, rather than formation of short indels usually seen after 
      double-strand break repair. Complete and precise excision of the repeat tract 
      from normal and large expanded DMPK alleles in myoblasts from unaffected 
      individuals, DM1 patients, and a DM1 mouse model could be achieved at high 
      frequency by dual CRISPR/Cas9-cleavage at either side of the (CTG...CAG)n sequence. 
      Importantly, removal of the repeat appeared to have no detrimental effects on the 
      expression of genes in the DM1 locus. Moreover, myogenic capacity, 
      nucleocytoplasmic distribution, and abnormal RNP-binding behavior of transcripts 
      from the edited DMPK gene were normalized. Dual sgRNA-guided excision of the 
      (CTG...CAG)n tract by CRISPR/Cas9 technology is applicable for developing isogenic 
      cell lines for research and may provide new therapeutic opportunities for 
      patients with DM1.
CI  - Copyright (c) 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - van Agtmaal, Ellen L
AU  - van Agtmaal EL
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands.
FAU - Andre, Laurene M
AU  - Andre LM
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands.
FAU - Willemse, Marieke
AU  - Willemse M
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands.
FAU - Cumming, Sarah A
AU  - Cumming SA
AD  - Institute of Molecular, Cell, and Systems Biology, College of Medical, 
      Veterinary, and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - van Kessel, Ingeborg D G
AU  - van Kessel IDG
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands.
FAU - van den Broek, Walther J A A
AU  - van den Broek WJAA
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Inserm UMR 1163, 75015 Paris, France; Imagine Institute, Paris Descartes-Sorbonne 
      Paris Cite University, 75270 Paris, France.
FAU - Furling, Denis
AU  - Furling D
AD  - UPMC Universite Paris 06, Inserm UMRS974, CNRS FRE3617, Center for Research in 
      Myology, Sorbonne Universites, 75252 Paris, France.
FAU - Mouly, Vincent
AU  - Mouly V
AD  - UPMC Universite Paris 06, Inserm UMRS974, CNRS FRE3617, Center for Research in 
      Myology, Sorbonne Universites, 75252 Paris, France.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell, and Systems Biology, College of Medical, 
      Veterinary, and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - Wansink, Derick G
AU  - Wansink DG
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands. Electronic address: rick.wansink@radboudumc.nl.
FAU - Wieringa, Be
AU  - Wieringa B
AD  - Radboud Institute for Molecular Life Sciences, Department of Cell Biology, 
      Radboud University Medical Center, Geert Grooteplein 28, 6525 GA, Nijmegen, the 
      Netherlands. Electronic address: be.wieringa@radboudumc.nl.
LA  - eng
PT  - Journal Article
DEP - 20170104
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Bacterial Proteins)
RN  - 0 (Codon)
RN  - 0 (RNA, Guide, CRISPR-Cas Systems)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 3.1.- (CRISPR-Associated Protein 9)
RN  - EC 3.1.- (Cas9 endonuclease Streptococcus pyogenes)
RN  - EC 3.1.- (Endonucleases)
SB  - IM
MH  - Animals
MH  - Bacterial Proteins/genetics
MH  - Base Sequence
MH  - CRISPR-Associated Protein 9
MH  - *CRISPR-Cas Systems
MH  - Clustered Regularly Interspaced Short Palindromic Repeats
MH  - Codon
MH  - Disease Models, Animal
MH  - Endonucleases/genetics
MH  - Fibroblasts/metabolism
MH  - *Gene Editing
MH  - Gene Expression
MH  - Gene Order
MH  - Genetic Loci
MH  - *Genomic Instability
MH  - Humans
MH  - Mice
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - RNA, Guide, CRISPR-Cas Systems
MH  - RNA, Messenger/genetics/metabolism
MH  - Sequence Deletion
MH  - *Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
PMC - PMC5363205
OTO - NOTNLM
OT  - (CTG...CAG)n repeat
OT  - CRISPR/Cas9
OT  - DM1 myoblasts
OT  - NHEJ
OT  - dsDNA break repair
OT  - myotonic dystrophy
OT  - somatic cell therapy
OT  - therapeutic genome editing
OT  - trinucleotide instability
EDAT- 2017/01/28 06:00
MHDA- 2017/06/07 06:00
PMCR- 2018/01/04
CRDT- 2017/01/28 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2016/10/10 00:00 [revised]
PHST- 2016/10/11 00:00 [accepted]
PHST- 2017/01/28 06:00 [entrez]
PHST- 2017/01/28 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
PHST- 2018/01/04 00:00 [pmc-release]
AID - S1525-0016(16)45369-4 [pii]
AID - 10.1016/j.ymthe.2016.10.014 [doi]
PST - ppublish
SO  - Mol Ther. 2017 Jan 4;25(1):24-43. doi: 10.1016/j.ymthe.2016.10.014. Epub 2017 Jan 
      4.

PMID- 28102759
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20231105
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Print)
IS  - 1547-6286 (Linking)
VI  - 14
IP  - 10
DP  - 2017 Oct 3
TI  - Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs 
      with and without (CAG)n repeat.
PG  - 1374-1388
LID - 10.1080/15476286.2017.1279787 [doi]
AB  - The unstable (CTG.CAG)n trinucleotide repeat in the myotonic dystrophy type 1 
      (DM1) locus is bidirectionally transcribed from genes with terminal overlap. By 
      transcription in the sense direction, the DMPK gene produces various 
      alternatively spliced mRNAs with a (CUG)n repeat in their 3' UTR. Expression in 
      opposite orientation reportedly yields (CAG)n-repeat containing RNA, but both 
      structure and biologic significance of this antisense gene (DM1-AS) are largely 
      unknown. Via a combinatorial approach of computational and experimental analyses 
      of RNA from unaffected individuals and DM1 patients we discovered that DM1-AS 
      spans >6 kb, contains alternative transcription start sites and uses alternative 
      polyadenylation sites up- and downstream of the (CAG)n repeat. Moreover, its 
      primary transcripts undergo alternative splicing, whereby the (CAG)n segment is 
      removed as part of an intron. Thus, in patients a mixture of DM1-AS RNAs with and 
      without expanded (CAG)n repeat are produced. DM1-AS expression appears 
      upregulated in patients, but transcript abundance remains very low in all tissues 
      analyzed. Our data suggest that DM1-AS transcripts belong to the class of long 
      non-coding RNAs. These and other biologically relevant implications for how 
      (CAG)n-expanded transcripts may contribute to DM1 pathology can now be explored 
      experimentally.
FAU - Gudde, Anke E E G
AU  - Gudde AEEG
AD  - a Radboud University Medical Center , Department of Cell Biology , Nijmegen , The 
      Netherlands.
FAU - van Heeringen, Simon J
AU  - van Heeringen SJ
AUID- ORCID: 0000-0002-0411-3219
AD  - b Radboud University, Faculty of Science , Department of Molecular Developmental 
      Biology, Radboud Institute for Molecular Life Sciences , Nijmegen , The 
      Netherlands.
FAU - de Oude, Amanda I
AU  - de Oude AI
AUID- ORCID: 0000-0001-8315-3982
AD  - a Radboud University Medical Center , Department of Cell Biology , Nijmegen , The 
      Netherlands.
FAU - van Kessel, Ingeborg D G
AU  - van Kessel IDG
AD  - a Radboud University Medical Center , Department of Cell Biology , Nijmegen , The 
      Netherlands.
FAU - Estabrook, Joseph
AU  - Estabrook J
AD  - c Department of Molecular Genetics and Microbiology , Center for Neurogenetics, 
      University of Florida College of Medicine , Gainesville , FL , USA.
FAU - Wang, Eric T
AU  - Wang ET
AD  - c Department of Molecular Genetics and Microbiology , Center for Neurogenetics, 
      University of Florida College of Medicine , Gainesville , FL , USA.
FAU - Wieringa, Be
AU  - Wieringa B
AD  - a Radboud University Medical Center , Department of Cell Biology , Nijmegen , The 
      Netherlands.
FAU - Wansink, Derick G
AU  - Wansink DG
AD  - a Radboud University Medical Center , Department of Cell Biology , Nijmegen , The 
      Netherlands.
LA  - eng
GR  - DP5 OD017865/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170119
PL  - United States
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Antisense)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Adolescent
MH  - Alternative Splicing
MH  - Case-Control Studies
MH  - Cell Line
MH  - Computational Biology/methods
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase/chemistry/*genetics
MH  - Open Reading Frames
MH  - Polyadenylation
MH  - RNA, Antisense/chemistry/*genetics
MH  - RNA, Long Noncoding/genetics
MH  - RNA, Messenger/*chemistry/genetics
MH  - Transcription Initiation Site
MH  - *Trinucleotide Repeat Expansion
MH  - Up-Regulation
PMC - PMC5711456
OTO - NOTNLM
OT  - Antisense RNA
OT  - RAN translation
OT  - bidirectional transcription
OT  - long noncoding RNA
OT  - low-abundant RNA
OT  - microsatellite instability
OT  - myotonic dystrophy
OT  - triplet repeat expansion
EDAT- 2017/01/20 06:00
MHDA- 2018/07/28 06:00
PMCR- 2017/01/19
CRDT- 2017/01/20 06:00
PHST- 2017/01/20 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/01/20 06:00 [entrez]
PHST- 2017/01/19 00:00 [pmc-release]
AID - 1279787 [pii]
AID - 10.1080/15476286.2017.1279787 [doi]
PST - ppublish
SO  - RNA Biol. 2017 Oct 3;14(10):1374-1388. doi: 10.1080/15476286.2017.1279787. Epub 
      2017 Jan 19.

PMID- 27854230
OWN - NLM
STAT- MEDLINE
DCOM- 20180315
LR  - 20180315
IS  - 2214-3599 (Print)
VI  - 3
IP  - 3
DP  - 2016 Aug 30
TI  - Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic 
      Dystrophy Cohort.
PG  - 405-412
AB  - BACKGROUND: Congenital myotonic dystrophy (CDM) is a neuromuscular disorder 
      caused by a CTG triplet repeat expansion in the DMPK gene. In addition to the 
      expected motor delay, affected children often have significant developmental 
      disability in language and cognitive realms, which ultimately impacts on quality 
      of life. OBJECTIVE: In a prospective cohort of children with CDM to 1) present 
      the profile of language and motor developmental milestones, and 2) describe their 
      early childhood health related quality of life (HRQOL). METHODS: A five year 
      cohort study of eligible incident cases of CDM was performed via the Canadian 
      Pediatric Surveillance Program (CPSP). Consenting subjects were then followed 
      from infancy in a prospective cohort study. Caregivers were contacted every 3 
      months for the first year of life, and then twice yearly in order to obtain data 
      concerning language skills, motor development and parent proxy HRQOL from the 
      PedsQL and Infant and Toddler Quality of life (ITQOL) questionnaires. RESULTS: 
      Milestones were achieved at later ages in patients when compared to healthy 
      children. Girls appeared to be more delayed than boys in both language and motor 
      skills. HRQOL scores remained stable in this cohort, for both the PedsQL and 
      ITQOL. CONCLUSIONS: Understanding developmental milestones and quality of life 
      are important parameters when judging a child's overall health. For CDM patients 
      delineating developmental milestones and QOL have important clinical care and 
      research implications.
FAU - Prasad, Madhavi
AU  - Prasad M
FAU - Hicks, Rhiannon
AU  - Hicks R
FAU - MacKay, Melissa
AU  - MacKay M
FAU - Nguyen, Cam-Tu
AU  - Nguyen CT
FAU - Campbell, Craig
AU  - Campbell C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
SB  - IM
MH  - Canada
MH  - *Child Development
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Developmental Disabilities/etiology/*physiopathology
MH  - Female
MH  - Humans
MH  - Infant
MH  - Language Development Disorders/etiology/*physiopathology
MH  - Male
MH  - *Motor Skills
MH  - Motor Skills Disorders/etiology/*physiopathology
MH  - Myotonic Dystrophy/complications/*physiopathology
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Sex Factors
OTO - NOTNLM
OT  - Myotonic dystrophy
OT  - QOL
OT  - congenital
OT  - developmental milestones
EDAT- 2016/11/18 06:00
MHDA- 2018/03/16 06:00
CRDT- 2016/11/18 06:00
PHST- 2016/11/18 06:00 [entrez]
PHST- 2016/11/18 06:00 [pubmed]
PHST- 2018/03/16 06:00 [medline]
AID - JND160165 [pii]
AID - 10.3233/JND-160165 [doi]
PST - ppublish
SO  - J Neuromuscul Dis. 2016 Aug 30;3(3):405-412. doi: 10.3233/JND-160165.

PMID- 27727437
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20210601
IS  - 1934-8258 (Electronic)
IS  - 1934-8258 (Linking)
VI  - 91
DP  - 2016 Oct 11
TI  - Molecular Diagnosis of Myotonic Dystrophy.
PG  - 9.29.1-9.29.19
LID - 10.1002/cphg.22 [doi]
AB  - Myotonic dystrophy types 1 (DM1) and 2 (DM2) are autosomal dominant, 
      microsatellite repeat expansion disorders that affect muscle function. Myotonic 
      dystrophy type 1 is caused by CTG repeat expansion in the 3' UTR region of the 
      DMPK gene. Patients with DM2 have expansion of CCTG repeats in intron 1 of the 
      CNBP gene. In this unit, we review and discuss the clinical phenotypes, genetic 
      mutations causing the diseases, and the molecular diagnostic approaches and tools 
      that are used to determine repeat sizes in DM1/2. In summary, the goal of this 
      chapter is to provide the reader with a basic understanding of the clinical, 
      genetic and diagnostic aspects of these disorders. (c) 2016 by John Wiley & Sons, 
      Inc.
CI  - Copyright (c) 2016 John Wiley & Sons, Inc.
FAU - Chakraborty, Sujata
AU  - Chakraborty S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine, Indianapolis, Indiana.
FAU - Vatta, Matteo
AU  - Vatta M
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine, Indianapolis, Indiana.
FAU - Bachinski, Linda L
AU  - Bachinski LL
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      Texas.
FAU - Krahe, Ralf
AU  - Krahe R
AD  - Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, 
      Texas.
FAU - Dlouhy, Stephen
AU  - Dlouhy S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine, Indianapolis, Indiana.
FAU - Bai, Shaochun
AU  - Bai S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine, Indianapolis, Indiana.
LA  - eng
GR  - R01 AR048171/AR/NIAMS NIH HHS/United States
PT  - Journal Article
DEP - 20161011
PL  - United States
TA  - Curr Protoc Hum Genet
JT  - Current protocols in human genetics
JID - 101287858
SB  - IM
MH  - Humans
MH  - Mutation/*genetics
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Pathology, Molecular/*methods
MH  - Phenotype
MH  - Trinucleotide Repeat Expansion/*genetics
OTO - NOTNLM
OT  - CCTG repeat
OT  - CNBP
OT  - CTG repeat
OT  - DMPK
OT  - Myotonic dystrophy type 2
OT  - Southern Blot
OT  - myotonic dystrophy type 1
OT  - repeat-primed PCR (RP-PCR)
OT  - triplet-repeat primed PCR (TP-PCR)
EDAT- 2016/10/12 06:00
MHDA- 2018/03/13 06:00
CRDT- 2016/10/12 06:00
PHST- 2016/10/12 06:00 [entrez]
PHST- 2016/10/12 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
AID - 10.1002/cphg.22 [doi]
PST - epublish
SO  - Curr Protoc Hum Genet. 2016 Oct 11;91:9.29.1-9.29.19. doi: 10.1002/cphg.22.

PMID- 27695335
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 12
DP  - 2016
TI  - Expanded DMPK repeats in dizygotic twins referred for diagnosis of autism versus 
      absence of expanded DMPK repeats at screening of 330 children with autism.
PG  - 2367-2372
AB  - Myotonic dystrophy type 1 (DM1) belongs to the broad spectrum of genetic 
      disorders associated with autism spectrum disorders (ASD). ASD were reported 
      predominantly in congenital and early childhood forms of DM1. We describe 
      dizygotic twin boys with ASD who were referred for routine laboratory genetic 
      testing and in whom karyotyping, FMR1 gene testing, and single nucleotide 
      polymorphism array analysis yielded negative results. The father of the boys was 
      later diagnosed with suspected DM1, and testing revealed characteristic DMPK gene 
      expansions in his genome as well as in the genomes of both twins and their elder 
      brother, who also suffered from ASD. In accord with previous reports on childhood 
      forms of DM1, our patients showed prominent neuropsychiatric phenotypes 
      characterized especially by hypotonia, developmental and language delay, 
      emotional and affective lability, lowered adaptability, and social withdrawal. 
      The experience with this family and multiple literature reports of ASD in DM1 on 
      the one side but the lack of literature data on the frequency of DMPK gene 
      expansions in ASD patients on the other side prompted us to screen the DMPK gene 
      in a sample of 330 patients with ASD who were first seen by a geneticist before 
      they were 10 years of age, before the muscular weakness, which may signal DM1, 
      usually becomes obvious. The absence of any DMPK gene expansions in this cohort 
      indicates that targeted DMPK gene testing can be recommended only in ASD patients 
      with specific symptoms or family history suggestive of DM1.
FAU - Musova, Zuzana
AU  - Musova Z
AD  - Department of Biology and Medical Genetics.
FAU - Hancarova, Miroslava
AU  - Hancarova M
AD  - Department of Biology and Medical Genetics.
FAU - Havlovicova, Marketa
AU  - Havlovicova M
AD  - Department of Biology and Medical Genetics.
FAU - Pourova, Radka
AU  - Pourova R
AD  - Department of Biology and Medical Genetics.
FAU - Hrdlicka, Michal
AU  - Hrdlicka M
AD  - Department of Child Psychiatry.
FAU - Kraus, Josef
AU  - Kraus J
AD  - Department of Child Neurology, Charles University 2nd Faculty of Medicine and 
      University Hospital Motol.
FAU - Trkova, Marie
AU  - Trkova M
AD  - Gennet, Centre for Fetal Medicine, Prague, Czech Republic.
FAU - Stejskal, David
AU  - Stejskal D
AD  - Gennet, Centre for Fetal Medicine, Prague, Czech Republic.
FAU - Sedlacek, Zdenek
AU  - Sedlacek Z
AD  - Department of Biology and Medical Genetics.
LA  - eng
PT  - Journal Article
DEP - 20160919
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC5034902
OTO - NOTNLM
OT  - DMPK gene
OT  - autism
OT  - comorbidity
OT  - genetic testing
OT  - myotonic dystrophy type 1
EDAT- 2016/10/04 06:00
MHDA- 2016/10/04 06:01
PMCR- 2016/09/19
CRDT- 2016/10/04 06:00
PHST- 2016/10/04 06:00 [entrez]
PHST- 2016/10/04 06:00 [pubmed]
PHST- 2016/10/04 06:01 [medline]
PHST- 2016/09/19 00:00 [pmc-release]
AID - ndt-12-2367 [pii]
AID - 10.2147/NDT.S113917 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2016 Sep 19;12:2367-2372. doi: 10.2147/NDT.S113917. 
      eCollection 2016.

PMID- 27573860
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180611
IS  - 1521-3765 (Electronic)
IS  - 0947-6539 (Linking)
VI  - 22
IP  - 42
DP  - 2016 Oct 10
TI  - A Ligand That Targets CUG Trinucleotide Repeats.
PG  - 14881-14889
LID - 10.1002/chem.201602741 [doi]
AB  - The development of small molecules that can recognize specific RNA secondary and 
      tertiary structures is currently an important research topic for developing tools 
      to modulate gene expression and therapeutic drugs. Expanded CUG trinucleotide 
      repeats, known as toxic RNA, capture the splicing factor MBNL1 and are causative 
      of neurological disorder myotonic dystrophy type 1 (DM1). Herein, the rational 
      molecular design, synthesis, and binding analysis of 2,9-diaminoalkyl-substituted 
      1,10-phenanthroline (DAP), which bound to CUG trinucleotide repeats, is 
      described. The results of melting temperature (T(m) ) analyses, surface plasmon 
      resonance (SPR) assay, and electrospray spray ionization time-of-flight (ESI-TOF) 
      mass spectrometry showed that DAP bound to r(CUG)(9) but not to r(CAG)(9) and 
      r(CGG)(9) . The dual luciferase assay clearly indicated DAP bound to the 
      r(CUG)(n) repeat by affecting the translation in vitro.
CI  - (c) 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Li, Jinxing
AU  - Li J
AD  - Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and 
      Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, 567-0047, Japan.
FAU - Matsumoto, Jun
AU  - Matsumoto J
AD  - Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and 
      Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, 567-0047, Japan.
FAU - Bai, Li-Ping
AU  - Bai LP
AD  - State Key Laboratory of Quality Research in Chinese Medicine and, Macau Institute 
      for Applied Research in Medicine and Health, Macau University of Science and 
      Technology, Avenida Wai Long, Taipa, Macau, China.
FAU - Murata, Asako
AU  - Murata A
AD  - Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and 
      Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, 567-0047, Japan.
FAU - Dohno, Chikara
AU  - Dohno C
AD  - Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and 
      Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, 567-0047, Japan.
FAU - Nakatani, Kazuhiko
AU  - Nakatani K
AD  - Department of Regulatory Bioorganic Chemistry, The Institute of Scientific and 
      Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, 567-0047, Japan. 
      nakatani@sanken.osaka-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20160830
PL  - Germany
TA  - Chemistry
JT  - Chemistry (Weinheim an der Bergstrasse, Germany)
JID - 9513783
RN  - 0 (Ligands)
RN  - 0 (Phenanthrolines)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - W4X6ZO7939 (1,10-phenanthroline)
SB  - IM
MH  - Humans
MH  - Ligands
MH  - Myotonic Dystrophy/*metabolism
MH  - Phenanthrolines/*chemistry
MH  - RNA/chemistry/*metabolism
MH  - RNA Splicing
MH  - RNA-Binding Proteins/chemistry/*metabolism
MH  - Trinucleotide Repeat Expansion/*physiology
MH  - Trinucleotide Repeats/*drug effects
OTO - NOTNLM
OT  - (CUG)n repeats
OT  - RNA
OT  - SPR
OT  - small molecules
OT  - translation
EDAT- 2016/08/31 06:00
MHDA- 2018/06/12 06:00
CRDT- 2016/08/31 06:00
PHST- 2016/06/09 00:00 [received]
PHST- 2016/08/31 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2016/08/31 06:00 [entrez]
AID - 10.1002/chem.201602741 [doi]
PST - ppublish
SO  - Chemistry. 2016 Oct 10;22(42):14881-14889. doi: 10.1002/chem.201602741. Epub 2016 
      Aug 30.

PMID- 27473828
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20220409
IS  - 1878-3252 (Electronic)
IS  - 0946-672X (Linking)
VI  - 37
DP  - 2016 Sep
TI  - Short repeats in the heme oxygenase 1 gene promoter is associated with increased 
      levels of inflammation, ferritin and higher risk of type-2 diabetes mellitus.
PG  - 25-30
LID - S0946-672X(16)30092-X [pii]
LID - 10.1016/j.jtemb.2016.06.001 [doi]
AB  - OBJECTIVE: We evaluated the relationship between the HO1 genotype, ferritin 
      levels and the risk of type-2 diabetes and inflammation. RESEARCH METHODS: Eight 
      hundred thirty-five individuals were evaluated and classified according to their 
      nutritional status and the presence of type-2 diabetes: 153 overweight (OW); 62 
      obese (OB); 55 type-2 diabetes mellitus (DM); 202 OWDM; 239 OBDM and 124 controls 
      (C). We studied biochemical (glycemia, insulin, lipid profile, liver enzyme, 
      creatinine, hsCRP), hematological (hemoglobin, free erythrocyte protoporphyrin, 
      transferrin receptor and serum Fe and ferritin) and oxidative stress (SOD, GHS 
      and TBARS) parameters. We determined heme oxygenase activity and the (GT)n 
      polymorphism in its gene promoter. RESULTS: Individuals with diabetes, 
      independent of nutritional status, showed high levels of ferritin and HO activity 
      compared to control subjects. Allelic frequency was not different between the 
      groups (Chi(2), NS) however, genotypes were different (Chi(2), P<0.001). The SS 
      (short-short) genotype was higher in all DM individuals compared to controls and 
      MM was higher in controls. SM (short-medium) genotype was an independent risk 
      factor for DM in logistic regression analysis. We observed high risk for type-2 
      diabetes mellitus in the presence of SM genotype and high levels of ferritin (OR 
      adjusted: 2.7; 1.9-3.6; p<0.001; compared to control group). It was also 
      significantly related to inflammation. CONCLUSION: The SM genotype in HO1 gene 
      promoter and ferritin levels were associated with higher risk for type-2 diabetes 
      and for having a higher marker of inflammation, which is the main risk factor for 
      the development of chronic diseases.
CI  - Copyright (c) 2016 Elsevier GmbH. All rights reserved.
FAU - Andrews, Monica
AU  - Andrews M
AD  - Micronutrient Laboratory, Institute of Nutrition and Food Technology (INTA), 
      University of Chile, El Libano 5524, Macul, Santiago, Chile.
FAU - Leiva, Elba
AU  - Leiva E
AD  - Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Faculty 
      of Health Science, University of Talca, Talca, Chile.
FAU - Arredondo-Olguin, Miguel
AU  - Arredondo-Olguin M
AD  - Micronutrient Laboratory, Institute of Nutrition and Food Technology (INTA), 
      University of Chile, El Libano 5524, Macul, Santiago, Chile. Electronic address: 
      marredon@inta.uchile.cl.
LA  - eng
PT  - Journal Article
DEP - 20160602
PL  - Germany
TA  - J Trace Elem Med Biol
JT  - Journal of trace elements in medicine and biology : organ of the Society for 
      Minerals and Trace Elements (GMS)
JID - 9508274
RN  - 9007-73-2 (Ferritins)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
SB  - IM
MH  - Adult
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Female
MH  - Ferritins/*metabolism
MH  - Heme Oxygenase-1/*genetics
MH  - Humans
MH  - Inflammation/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic/*genetics
MH  - *Promoter Regions, Genetic
MH  - Risk Factors
OTO - NOTNLM
OT  - Ferritin
OT  - Heme oxygenase
OT  - Inflammation
OT  - Iron
OT  - Polymorphism
OT  - Type-2 diabetes mellitus
EDAT- 2016/07/31 06:00
MHDA- 2017/06/18 06:00
CRDT- 2016/07/31 06:00
PHST- 2016/01/08 00:00 [received]
PHST- 2016/05/18 00:00 [revised]
PHST- 2016/06/01 00:00 [accepted]
PHST- 2016/07/31 06:00 [entrez]
PHST- 2016/07/31 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
AID - S0946-672X(16)30092-X [pii]
AID - 10.1016/j.jtemb.2016.06.001 [doi]
PST - ppublish
SO  - J Trace Elem Med Biol. 2016 Sep;37:25-30. doi: 10.1016/j.jtemb.2016.06.001. Epub 
      2016 Jun 2.

PMID- 27358583
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160630
LR  - 20200930
IS  - 1226-2560 (Print)
IS  - 2093-8144 (Electronic)
IS  - 1226-2560 (Linking)
VI  - 25
IP  - 3
DP  - 2016 Jun
TI  - Bilateral Adduction Palsy in a Patient with Myotonic Dystrophy Type 1.
PG  - 143-5
LID - 10.5607/en.2016.25.3.143 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by CTG repeat expansion in the DMPK 
      gene in chromosome 19q13.3. External ophthalmoplegia is a rare manifestation in 
      DM1. We report a DM1 patient confirmed by the presence of 650 CTG triplet 
      expansions in the DMPK gene and had limitation of adduction gaze bilaterally. 
      Brain MRI showed bilateral medial rectus muscles atrophy. Our patient provides 
      additional evidence of ocular motor muscle involvement in DM1.
FAU - Kim, Hong-Jeon
AU  - Kim HJ
AD  - Department of Neurology, Jeju National University School of Medicine, Jeju 63241, 
      Korea.
FAU - Oh, Jung-Hwan
AU  - Oh JH
AD  - Department of Neurology, Jeju National University School of Medicine, Jeju 63241, 
      Korea.
FAU - Kang, Sa-Yoon
AU  - Kang SY
AD  - Department of Neurology, Jeju National University School of Medicine, Jeju 63241, 
      Korea.
LA  - eng
PT  - Case Reports
DEP - 20160527
PL  - Korea (South)
TA  - Exp Neurobiol
JT  - Experimental neurobiology
JID - 101278187
PMC - PMC4923359
OTO - NOTNLM
OT  - Atrophy
OT  - MRI
OT  - Myotonia
OT  - Myotonic dystrophy
OT  - Ophthalmoplegia
EDAT- 2016/07/01 06:00
MHDA- 2016/07/01 06:01
PMCR- 2016/06/01
CRDT- 2016/07/01 06:00
PHST- 2016/03/24 00:00 [received]
PHST- 2016/05/13 00:00 [revised]
PHST- 2016/05/15 00:00 [accepted]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2016/07/01 06:01 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - 10.5607/en.2016.25.3.143 [doi]
PST - ppublish
SO  - Exp Neurobiol. 2016 Jun;25(3):143-5. doi: 10.5607/en.2016.25.3.143. Epub 2016 May 
      27.

PMID- 27323306
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20181202
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 23
IP  - 9
DP  - 2016 Sep
TI  - Cognition in myotonic dystrophy type 1: a 5-year follow-up study.
PG  - 1471-6
LID - 10.1111/ene.13062 [doi]
AB  - BACKGROUND AND PURPOSE: Studies on cognitive decline in myotonic dystrophy type 1 
      (DM1) are characterized by conflicting results. The purpose of the present study 
      was to analyse possible decline in classical/adult onset DM1 at a 5-year 
      follow-up and to explore the correlation with disease-related and demographic 
      factors. METHODS: Patients with DM1 (n = 37) were examined with a comprehensive 
      neuropsychological test battery yielding measures on memory, attention, verbal, 
      visuospatial and executive functions. Assessment of muscle impairment and CTG 
      repeat expansion size was performed. RESULTS: A majority of the participants 
      (65%) performed worse at follow-up. Compared to normative data, patients scored 
      significantly worse on tests measuring memory, attention, visuospatial 
      construction and verbal ability. Neither CTG repeat size nor muscle impairment 
      related to cognitive decline. However, age at onset and disease duration were 
      correlated with the number of tests in which performance was below 1 SD at both 
      baseline and follow-up examination. CONCLUSIONS: Measurements show that 
      classical/adult onset DM1 is characterized by cognitive decline. Both earlier 
      onset and longer duration of the disease are indicative of more cognitive 
      deficits.
CI  - (c) 2016 EAN.
FAU - Winblad, S
AU  - Winblad S
AD  - Department of Psychology, University of Gothenburg, Gothenburg, Sweden.
AD  - Neuromuscular Centre, Department of Neurology, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
FAU - Samuelsson, L
AU  - Samuelsson L
AD  - Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, 
      Sweden.
FAU - Lindberg, C
AU  - Lindberg C
AD  - Neuromuscular Centre, Department of Neurology, Sahlgrenska University Hospital, 
      Gothenburg, Sweden.
AD  - Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, 
      Sweden.
FAU - Meola, G
AU  - Meola G
AD  - Department of Biomedical Sciences for Health, IRCCS Policlinico San Donato, 
      University of Milan, San Donato Milanese, Italy.
LA  - eng
PT  - Journal Article
DEP - 20160620
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adult
MH  - Attention
MH  - *Cognition
MH  - Cognitive Dysfunction
MH  - Disease Progression
MH  - Executive Function
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Memory
MH  - Mental Status and Dementia Tests
MH  - Middle Aged
MH  - Muscular Diseases/epidemiology/etiology
MH  - Myotonic Dystrophy/epidemiology/genetics/*psychology
MH  - Socioeconomic Factors
MH  - Space Perception
MH  - Trinucleotide Repeat Expansion
MH  - Young Adult
OTO - NOTNLM
OT  - cognition
OT  - cognitive decline
OT  - myotonic dystrophy
OT  - neuromuscular
EDAT- 2016/06/21 06:00
MHDA- 2018/01/05 06:00
CRDT- 2016/06/21 06:00
PHST- 2015/11/02 00:00 [received]
PHST- 2016/05/13 00:00 [accepted]
PHST- 2016/06/21 06:00 [entrez]
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 10.1111/ene.13062 [doi]
PST - ppublish
SO  - Eur J Neurol. 2016 Sep;23(9):1471-6. doi: 10.1111/ene.13062. Epub 2016 Jun 20.

PMID- 27245480
OWN - NLM
STAT- MEDLINE
DCOM- 20170919
LR  - 20181113
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Print)
IS  - 1860-7179 (Linking)
VI  - 11
IP  - 13
DP  - 2016 Jul 5
TI  - A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats 
      that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.
PG  - 1428-35
LID - 10.1002/cmdc.201600081 [doi]
AB  - Myotonic dystrophy is the most common form of adult-onset muscular dystrophy, 
      originating in a CTG repeat expansion in the DMPK gene. The expanded CUG 
      transcript sequesters MBNL1, a key regulator of alternative splicing, leading to 
      the misregulation of numerous pre-mRNAs. We report an RNA-targeted agent as a 
      possible lead compound for the treatment of myotonic dystrophy type 1 (DM1) that 
      reveals both the promise and challenges for this type of small-molecule approach. 
      The agent is a potent inhibitor of the MBNL1-rCUG complex with an inhibition 
      constant (Ki ) of 25+/-8 nm, and is also relatively nontoxic to HeLa cells, able to 
      dissolve nuclear foci, and correct the insulin receptor splicing defect in DM1 
      model cells. Moreover, treatment with this compound improves two separate disease 
      phenotypes in a Drosophila model of DM1: adult external eye degeneration and 
      larval crawling defect. However, the compound has a relatively low maximum 
      tolerated dose in mice, and its cell uptake may be limited, providing insight 
      into directions for future development.
CI  - (c) 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Luu, Long M
AU  - Luu LM
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Nguyen, Lien
AU  - Nguyen L
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Peng, Shaohong
AU  - Peng S
AD  - Laboratory of Drosophila Research and School of Life Sciences, The Chinese 
      University of Hong Kong, Shatin, N.T., Hong Kong SAR, P.R. China.
FAU - Lee, JuYeon
AU  - Lee J
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Lee, Hyang Yeon
AU  - Lee HY
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Wong, Chun-Ho
AU  - Wong CH
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Hergenrother, Paul J
AU  - Hergenrother PJ
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA.
FAU - Chan, H Y Edwin
AU  - Chan HY
AD  - Laboratory of Drosophila Research and School of Life Sciences, The Chinese 
      University of Hong Kong, Shatin, N.T., Hong Kong SAR, P.R. China. 
      hyechan@cuhk.edu.hk.
FAU - Zimmerman, Steven C
AU  - Zimmerman SC
AUID- ORCID: 0000-0002-5333-3437
AD  - Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. 
      Mathews Ave., Urbana, IL, 61801, USA. sczimmer@illinois.edu.
LA  - eng
GR  - R01 AR058361/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160601
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Alexa Fluor 647)
RN  - 0 (Amidines)
RN  - 0 (Carbocyanines)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Ligands)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Triazines)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.10.1 (Receptor, Insulin)
SB  - IM
MH  - Amidines/chemical synthesis/pharmacology/*therapeutic use
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Carbocyanines/chemistry
MH  - Click Chemistry
MH  - Cycloaddition Reaction
MH  - Drosophila
MH  - Fluorescent Dyes/chemistry
MH  - HeLa Cells
MH  - Humans
MH  - Ligands
MH  - Mice
MH  - Myotonic Dystrophy/*drug therapy
MH  - RNA/antagonists & inhibitors
MH  - RNA Splicing/drug effects
MH  - RNA-Binding Proteins/*antagonists & inhibitors
MH  - Receptor, Insulin/genetics
MH  - Triazines/chemical synthesis/pharmacology/*therapeutic use
MH  - *Trinucleotide Repeat Expansion
PMC - PMC5074844
MID - NIHMS821420
OTO - NOTNLM
OT  - Click chemistry
OT  - Drosophila model
OT  - Myotonic dystrophy
OT  - RNA recognition
OT  - RNA-protein inhibitor
EDAT- 2016/06/02 06:00
MHDA- 2017/09/20 06:00
PMCR- 2017/07/05
CRDT- 2016/06/02 06:00
PHST- 2016/02/05 00:00 [received]
PHST- 2016/04/29 00:00 [revised]
PHST- 2016/06/02 06:00 [entrez]
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/09/20 06:00 [medline]
PHST- 2017/07/05 00:00 [pmc-release]
AID - 10.1002/cmdc.201600081 [doi]
PST - ppublish
SO  - ChemMedChem. 2016 Jul 5;11(13):1428-35. doi: 10.1002/cmdc.201600081. Epub 2016 
      Jun 1.

PMID- 27222292
OWN - NLM
STAT- MEDLINE
DCOM- 20170616
LR  - 20181113
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 24
IP  - 10
DP  - 2016 Oct
TI  - Identification of variants in MBNL1 in patients with a myotonic dystrophy-like 
      phenotype.
PG  - 1467-72
LID - 10.1038/ejhg.2016.41 [doi]
AB  - The myotonic dystrophies (DMs) are the most common inherited muscular disorders 
      in adults. In most of the cases, the disease is caused by (CTG)n/(CCTG)n repeat 
      expansions (EXPs) in non-coding regions of the genes DMPK (dystrophia 
      myotonica-protein kinase) and CNBP (CCHC-type zinc-finger nucleic acid-binding 
      protein). The EXP is transcribed into mutant RNAs, which provoke a common 
      pathomechanism that is characterized by misexpression and mis-splicing. In this 
      study, we screened 138 patients with typical clinical features of DM being 
      negative for EXP in the known genes. We sequenced DMPK and CNBP - associated with 
      DM, as well as CELF1 (CUGBP, Elav-like family member 1) and MBNL1 
      (muscleblind-like splicing regulator 1) - associated with the pathomechanism of 
      DM, for pathogenic variants, addressing the question whether defects in other 
      genes could cause a DM-like phenotype. We identified variants in three unrelated 
      patients in the MBNL1 gene, two of them were heterozygous missense mutations and 
      one an in-frame deletion of three amino acids. The variants were located in 
      different conserved regions of the protein. The missense mutations were 
      classified as potentially pathogenic by prediction tools. Analysis of MBNL1 
      splice target genes was carried out for one of the patients using RNA from 
      peripheral blood leukocytes (PBL). Analysis of six genes known to show 
      mis-splicing in the skeletal muscle gave no informative results on the effect of 
      this variant when tested in PBL. The association of these variants with the DM 
      phenotype therefore remains unconfirmed, but we hope that in view of the key role 
      of MBNL1 in DM pathogenesis our observations may foster further studies in this 
      direction.
FAU - Larsen, Mirjam
AU  - Larsen M
AD  - Department of Human Genetics, Julius-Maximilians-University, Wurzburg, Germany.
FAU - Kress, Wolfram
AU  - Kress W
AD  - Department of Human Genetics, Julius-Maximilians-University, Wurzburg, Germany.
FAU - Schoser, Benedikt
AU  - Schoser B
AD  - Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, 
      Munich, Germany.
FAU - Hehr, Ute
AU  - Hehr U
AD  - Center for and Department of Human Genetics, University of Regensburg, 
      Regensburg, Germany.
FAU - Muller, Clemens R
AU  - Muller CR
AD  - Department of Human Genetics, Julius-Maximilians-University, Wurzburg, Germany.
FAU - Rost, Simone
AU  - Rost S
AD  - Department of Human Genetics, Julius-Maximilians-University, Wurzburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20160525
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Female
MH  - Gene Deletion
MH  - Heterozygote
MH  - Humans
MH  - Leukocytes/metabolism
MH  - Male
MH  - Muscle, Skeletal/metabolism
MH  - Mutation, Missense
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - *Phenotype
MH  - RNA Splicing
MH  - RNA-Binding Proteins/*genetics/metabolism
PMC - PMC5027686
EDAT- 2016/05/26 06:00
MHDA- 2017/06/18 06:00
PMCR- 2017/10/01
CRDT- 2016/05/26 06:00
PHST- 2015/06/12 00:00 [received]
PHST- 2016/03/22 00:00 [revised]
PHST- 2016/04/12 00:00 [accepted]
PHST- 2016/05/26 06:00 [entrez]
PHST- 2016/05/26 06:00 [pubmed]
PHST- 2017/06/18 06:00 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
AID - ejhg201641 [pii]
AID - 10.1038/ejhg.2016.41 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2016 Oct;24(10):1467-72. doi: 10.1038/ejhg.2016.41. Epub 2016 
      May 25.

PMID- 26994442
OWN - NLM
STAT- MEDLINE
DCOM- 20170118
LR  - 20171116
IS  - 1568-7856 (Electronic)
IS  - 1568-7856 (Linking)
VI  - 40
DP  - 2016 Apr
TI  - A polymorphism in the MSH3 mismatch repair gene is associated with the levels of 
      somatic instability of the expanded CTG repeat in the blood DNA of myotonic 
      dystrophy type 1 patients.
PG  - 57-66
LID - S1568-7864(15)30063-X [pii]
LID - 10.1016/j.dnarep.2016.01.001 [doi]
AB  - Somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 is 
      age-dependent, tissue-specific and expansion-biased, contributing toward the 
      tissue-specificity and progressive nature of the symptoms. Previously, using 
      regression modelling of repeat instability we showed that variation in the rate 
      of somatic expansion in blood DNA contributes toward variation in age of onset, 
      directly implicating somatic expansion in the disease pathway. Here, we confirm 
      these results using a larger more genetically homogenous Costa Rican DM1 cohort 
      (p<0.001). Interestingly, we also provide evidence that supports subtle 
      sex-dependent differences in repeat length-dependent age at onset and somatic 
      mutational dynamics. Previously, we demonstrated that variation in the rate of 
      somatic expansion was a heritable quantitative trait. Given the important role 
      that DNA mismatch repair genes play in mediating expansions in mouse models, we 
      tested for modifier gene effects with 13 DNA mismatch gene polymorphisms (one 
      each in MSH2, PMS2, MSH6 and MLH1; and nine in MSH3). After correcting for allele 
      length and age effects, we identified three polymorphisms in MSH3 that were 
      associated with variation in somatic instability: Rs26279 (p=0.003); Rs1677658 
      (p=0.009); and Rs10168 (p=0.031). However, only the association with Rs26279 
      remained significant after multiple testing correction. Although we revealed a 
      statistically significant association between Rs26279 and somatic instability, we 
      did not detect an association with the age at onset. Individuals with the A/A 
      genotype for Rs26279 tended to show a greater propensity to expand the CTG repeat 
      than other genotypes. Interestingly, this SNP results in an amino acid change in 
      the critical ATPase domain of MSH3 and is potentially functionally dimorphic. 
      These data suggest that MSH3 is a key player in generating somatic variation in 
      DM1 patients and further highlight MSH3 as a potential therapeutic target.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Morales, Fernando
AU  - Morales F
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica; Escuela de Medicina, Universidad de Costa Rica, San Jose, Costa 
      Rica; Centro de Investigacion en Neurociencias, Universidad de Costa Rica, San 
      Jose, Costa Rica. Electronic address: fernando.moralesmontero@ucr.ac.cr.
FAU - Vasquez, Melissa
AU  - Vasquez M
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica; Centro de Investigacion en Neurociencias, Universidad de Costa 
      Rica, San Jose, Costa Rica.
FAU - Santamaria, Carolina
AU  - Santamaria C
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica; Escuela de Nutricion, Universidad de Costa Rica, San Jose, 
      Costa Rica.
FAU - Cuenca, Patricia
AU  - Cuenca P
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica; Escuela de Medicina, Universidad de Costa Rica, San Jose, Costa 
      Rica; Centro de Investigacion en Neurociencias, Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Corrales, Eyleen
AU  - Corrales E
AD  - Instituto de Investigaciones en Salud (INISA), Universidad de Costa Rica, San 
      Jose, Costa Rica.
FAU - Monckton, Darren G
AU  - Monckton DG
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160308
PL  - Netherlands
TA  - DNA Repair (Amst)
JT  - DNA repair
JID - 101139138
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MSH3 protein, human)
RN  - 0 (MutS Homolog 3 Protein)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - DNA/blood/genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mosaicism
MH  - MutS Homolog 3 Protein
MH  - Myotonic Dystrophy/blood/*genetics
MH  - *Polymorphism, Single Nucleotide
MH  - *Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - DNA mismatch repair
OT  - Modifier gene
OT  - Myotonic dystrophy
OT  - Simple sequence repeat
OT  - Somatic mosaicism
OT  - Trinucleotide repeat
EDAT- 2016/03/20 06:00
MHDA- 2017/01/19 06:00
CRDT- 2016/03/20 06:00
PHST- 2015/08/03 00:00 [received]
PHST- 2016/01/28 00:00 [revised]
PHST- 2016/01/29 00:00 [accepted]
PHST- 2016/03/20 06:00 [entrez]
PHST- 2016/03/20 06:00 [pubmed]
PHST- 2017/01/19 06:00 [medline]
AID - S1568-7864(15)30063-X [pii]
AID - 10.1016/j.dnarep.2016.01.001 [doi]
PST - ppublish
SO  - DNA Repair (Amst). 2016 Apr;40:57-66. doi: 10.1016/j.dnarep.2016.01.001. Epub 
      2016 Mar 8.

PMID- 26921003
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20221207
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Print)
IS  - 0741-5214 (Linking)
VI  - 65
IP  - 3
DP  - 2017 Mar
TI  - Expansion and angiogenic potential of mesenchymal stem cells from patients with 
      critical limb ischemia.
PG  - 826-838.e1
LID - S0741-5214(16)00222-6 [pii]
LID - 10.1016/j.jvs.2015.02.061 [doi]
AB  - BACKGROUND: Critical limb ischemia (CLI) is a life- and limb-threatening 
      condition affecting 1% to 10% of the population with peripheral arterial disease. 
      Traditional revascularization options are not possible for up to 50% of CLI 
      patients, in which case, the use of cellular therapies, such as bone 
      marrow-derived mesenchymal stem cells (MSCs), hold great promise as an 
      alternative revascularization therapy. However, no randomized, controlled phase 3 
      trials to date have demonstrated an improvement in limb salvage with cellular 
      therapies. This may be due to poor cell quality (ie, inability to generate a 
      sufficient number of angiogenic MSCs) or to the inadequate retention and 
      viability of MSCs after delivery, or both. Because concerns remain about the 
      expansion and angiogenic potential of autologous MSCs in the CLI population, the 
      objective of this study was to examine the effect of our novel culture media 
      supplement, pooled human platelet lysate (PL), in lieu of the standard fetal 
      bovine serum (FBS), to improve the expansion potential of MSCs from CLI patients. 
      We also characterized the in vitro angiogenic activity of MSCs from the tibia of 
      amputated CLI limbs compared with MSCs from healthy donors. METHODS: MSCs were 
      obtained from the tibia of four CLI patients (ISC) and four ISC patients with 
      diabetes mellitus (ISC+DM) undergoing major amputation. Healthy MSCs were 
      aspirated from the iliac crest of four young and healthy donors. MSCs were 
      isolated and expanded in culture with PL or FBS. MSCs from passage 3 to 6 were 
      used for phenotypic marker expression and for adipogenic and osteogenic 
      differentiation and were tested for their in vitro angiogenic activity on human 
      microdermal endothelial cells. In parallel MSCs were cultured to passage 11 for 
      population-doubling calculations. RESULTS: MSCs from ISC and ISC+DM patients and 
      from healthy patients exhibited appropriate expression of cell surface markers 
      and differentiation capacity. Population doublings were significantly greater for 
      PL-stimulated compared with FBS-stimulated MSCs in all groups. Biologically 
      active amounts of angiogens were identified in the secretome of all MSCs without 
      consistent trends among groups. PL expansion did not adversely affect the 
      angiogenic activity of MSCs compared with FBS. The ISC and ISC+DM MSCs 
      demonstrated angiogenic effects on endothelial cells similar to those of healthy 
      and ISC MSCs. CONCLUSIONS: PL promotes the rapid expansion of MSCs from CLI and 
      healthy persons. Importantly, MSCs expanded from CLI patients demonstrate the 
      desired angiogenic activity compared with their healthy counterparts. We conclude 
      that autologous MSCs from CLI patients can be sufficiently expanded with PL and 
      be expected to deliver requisite angiogenic effects in vivo. We expect the 
      improved expansion of ISC and ISC+DM with PL to be helpful in improving the 
      successful delivery of autologous MSCs to patients with CLI.
CI  - Published by Elsevier Inc.
FAU - Brewster, Luke
AU  - Brewster L
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, Ga; Surgical 
      and Research Services, Atlanta Veterans Affairs Medical Center, Atlanta, Ga; 
      Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, Atlanta, Ga. Electronic address: lbrewst@emory.edu.
FAU - Robinson, Scott
AU  - Robinson S
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, Ga.
FAU - Wang, Ruoya
AU  - Wang R
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, Ga.
FAU - Griffiths, Sarah
AU  - Griffiths S
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, Atlanta, Ga.
FAU - Li, Haiyan
AU  - Li H
AD  - Department of Surgery, Emory University School of Medicine, Atlanta, Ga.
FAU - Peister, Alexandra
AU  - Peister A
AD  - Department of Biology, Morehouse College, Atlanta, Ga.
FAU - Copland, Ian
AU  - Copland I
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, Atlanta, Ga; Department of Hematology and Medical Oncology, Emory 
      University School of Medicine, Atlanta, Ga.
FAU - McDevitt, Todd
AU  - McDevitt T
AD  - Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of 
      Technology, Atlanta, Ga; Wallace H. Coulter Department of Biomedical Engineering 
      at Georgia Institute of Technology, Atlanta, Ga.
LA  - eng
GR  - K08 HL119592/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000454/TR/NCATS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20160224
PL  - United States
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
RN  - 0 (Angiogenic Proteins)
RN  - 0 (Biomarkers)
SB  - IM
CIN - J Vasc Surg. 2017 Mar;65(3):838. PMID: 28236923
MH  - Adipogenesis
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amputation, Surgical
MH  - Angiogenic Proteins/metabolism
MH  - Biomarkers/metabolism
MH  - Case-Control Studies
MH  - Cell Communication
MH  - Cell Lineage
MH  - *Cell Proliferation
MH  - Cell Separation/methods
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Critical Illness
MH  - Diabetic Angiopathies/diagnosis/*pathology/physiopathology/surgery
MH  - Endothelial Cells/metabolism
MH  - Female
MH  - Humans
MH  - Ischemia/diagnosis/*pathology/physiopathology/surgery
MH  - Lower Extremity/*blood supply
MH  - Male
MH  - Mesenchymal Stem Cells/metabolism/*pathology
MH  - Middle Aged
MH  - *Neovascularization, Physiologic
MH  - Osteogenesis
MH  - Phenotype
MH  - Tibia/metabolism/*pathology/surgery
MH  - Time Factors
MH  - Young Adult
PMC - PMC4996777
MID - NIHMS668047
EDAT- 2016/02/28 06:00
MHDA- 2017/05/18 06:00
PMCR- 2018/03/01
CRDT- 2016/02/28 06:00
PHST- 2014/10/09 00:00 [received]
PHST- 2015/02/18 00:00 [accepted]
PHST- 2016/02/28 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
PHST- 2016/02/28 06:00 [entrez]
PHST- 2018/03/01 00:00 [pmc-release]
AID - S0741-5214(16)00222-6 [pii]
AID - 10.1016/j.jvs.2015.02.061 [doi]
PST - ppublish
SO  - J Vasc Surg. 2017 Mar;65(3):826-838.e1. doi: 10.1016/j.jvs.2015.02.061. Epub 2016 
      Feb 24.

PMID- 26905645
OWN - NLM
STAT- MEDLINE
DCOM- 20160727
LR  - 20160318
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Linking)
VI  - 342
IP  - 1
DP  - 2016 Mar 1
TI  - Reliable and versatile immortal muscle cell models from healthy and myotonic 
      dystrophy type 1 primary human myoblasts.
PG  - 39-51
LID - S0014-4827(16)30033-7 [pii]
LID - 10.1016/j.yexcr.2016.02.013 [doi]
AB  - Primary human skeletal muscle cells (hSkMCs) are invaluable tools for deciphering 
      the basic molecular mechanisms of muscle-related biological processes and 
      pathological alterations. Nevertheless, their use is quite restricted due to poor 
      availability, short life span and variable purity of the cells during in vitro 
      culture. Here, we evaluate a recently published method of hSkMCs immortalization, 
      relying on ectopic expression of cyclin D1 (CCND1), cyclin-dependent kinase 4 
      (CDK4) and telomerase (TERT) in myoblasts from healthy donors (n=3) and myotonic 
      dystrophy type 1 (DM1) patients (n=2). The efficacy to maintain the myogenic and 
      non-transformed phenotype, as well as the main pathogenetic hallmarks of DM1, has 
      been assessed. Combined expression of the three genes i) maintained the 
      CD56(NCAM)-positive myoblast population and differentiation potential; ii) 
      preserved the non-transformed phenotype and iii) maintained the CTG repeat 
      length, amount of nuclear foci and aberrant alternative splicing in immortal 
      muscle cells. Moreover, immortal hSkMCs displayed attractive additional features 
      such as structural maturation of sarcomeres, persistence of Pax7-positive cells 
      during differentiation and complete disappearance of nuclear foci following 
      (CAG)7 antisense oligonucleotide (ASO) treatment. Overall, the CCND1, CDK4 and 
      TERT immortalization yields versatile, reliable and extremely useful human muscle 
      cell models to investigate the basic molecular features of human muscle cell 
      biology, to elucidate the molecular pathogenetic mechanisms and to test new 
      therapeutic approaches for DM1 in vitro.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Pantic, Boris
AU  - Pantic B
AD  - Department of Neurosciences, University of Padua, Italy. Electronic address: 
      boris.pantic@yahoo.it.
FAU - Borgia, Doriana
AU  - Borgia D
AD  - Department of Neurosciences, University of Padua, Italy. Electronic address: 
      doriana89b@hotmail.it.
FAU - Giunco, Silvia
AU  - Giunco S
AD  - Department of Surgery, Oncology and Gastroenterology, Section of Oncology and 
      Immunology, University of Padua, Padua, Italy. Electronic address: 
      silvia.giunco@unipd.it.
FAU - Malena, Adriana
AU  - Malena A
AD  - Department of Neurosciences, University of Padua, Italy. Electronic address: 
      adriana.malena@unipd.it.
FAU - Kiyono, Tohru
AU  - Kiyono T
AD  - Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research 
      Institute, Tokyo, Japan. Electronic address: tkiyono@ncc.go.jp.
FAU - Salvatori, Sergio
AU  - Salvatori S
AD  - Department of Biomedical Sciences, University of Padua, Italy. Electronic 
      address: patgen08@mail.bio.unipd.it.
FAU - De Rossi, Anita
AU  - De Rossi A
AD  - Department of Surgery, Oncology and Gastroenterology, Section of Oncology and 
      Immunology, University of Padua, Padua, Italy; Unit of Viral Oncology, Istituto 
      Oncologico Veneto (IOV)-IRCCS, Padua, Italy. Electronic address: 
      anita.derossi@unipd.it.
FAU - Giardina, Emiliano
AU  - Giardina E
AD  - Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy; 
      Molecular Genetics Laboratory UILDM, Santa Lucia Foundation, Rome, Italy. 
      Electronic address: giardina@med.uniroma2.it.
FAU - Sangiuolo, Federica
AU  - Sangiuolo F
AD  - Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy. 
      Electronic address: sangiuolo@med.uniroma2.it.
FAU - Pegoraro, Elena
AU  - Pegoraro E
AD  - Department of Neurosciences, University of Padua, Italy. Electronic address: 
      elena.pegoraro@unipd.it.
FAU - Vergani, Lodovica
AU  - Vergani L
AD  - Department of Neurosciences, University of Padua, Italy. Electronic address: 
      lodovica.vergani@unipd.it.
FAU - Botta, Annalisa
AU  - Botta A
AD  - Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy. 
      Electronic address: botta@med.uniroma2.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160219
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
SB  - IM
MH  - Alternative Splicing
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Humans
MH  - Muscle Fibers, Skeletal/physiology
MH  - Myoblasts/*physiology
MH  - Myotonic Dystrophy/*pathology
MH  - Primary Cell Culture
MH  - Sarcomeres/metabolism
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - ASOs
OT  - CDK4
OT  - Cyclin D1
OT  - Human muscle cell models
OT  - Immortalization
OT  - Myotonic dystrophy type 1
OT  - TERT
EDAT- 2016/02/26 06:00
MHDA- 2016/07/28 06:00
CRDT- 2016/02/25 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/02/17 00:00 [revised]
PHST- 2016/02/18 00:00 [accepted]
PHST- 2016/02/25 06:00 [entrez]
PHST- 2016/02/26 06:00 [pubmed]
PHST- 2016/07/28 06:00 [medline]
AID - S0014-4827(16)30033-7 [pii]
AID - 10.1016/j.yexcr.2016.02.013 [doi]
PST - ppublish
SO  - Exp Cell Res. 2016 Mar 1;342(1):39-51. doi: 10.1016/j.yexcr.2016.02.013. Epub 
      2016 Feb 19.

PMID- 26882032
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20161230
IS  - 1423-0208 (Electronic)
IS  - 0251-5350 (Linking)
VI  - 46
IP  - 3
DP  - 2016
TI  - An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of 
      Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy.
PG  - 191-7
LID - 10.1159/000444018 [doi]
AB  - BACKGROUND: Prevalence estimates for the 2 forms of myotonic dystrophy types 1 
      and 2 (DM1 and DM2) are not exhaustive or non-available. Our aim was to estimate 
      the minimum prevalence of DM1 and DM2 in Italy in the Rome province, applying 
      standards of descriptive epidemiology. METHODS: All patients with a molecular 
      diagnosis of DM1/DM2 and residents in the Rome province in 2013 have been 
      enrolled, and the age-standardized prevalence has been calculated, assuming a 
      Poisson distribution and adjusting for age. RESULTS: We identified 395 DM1 
      patients: the age-standardized prevalence for total, females and males was 9.65, 
      8.35 and 11.07/100,000, respectively. The mean age of subjects differed 
      considerably according to CTG repeat length (p = 0.001). Forty DM2 patients were 
      identified. The age-standardized prevalence for total, females and males was 
      0.99, 1.07 and 0.90/100,000, respectively. The mean age was 57.05. CONCLUSIONS: 
      We estimated for the first time the age-standardized prevalence and the sex and 
      age distribution of DM1 and DM2 in a general population. A higher prevalence of 
      males in DM1 and females in DM2 and a higher mean age of DM2 patients (+8 years) 
      were ascertained. Prevalence of DM2 was 10% that of DM1. These prevalence values 
      are probably lower than mutational rates due to the incomplete penetrance of DM1 
      mutations and to the clinical elusiveness of DM2. Our findings will be useful in 
      designing cohort studies and for developing a disease registry.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Vanacore, Nicola
AU  - Vanacore N
AD  - National Centre for Epidemiology, Surveillance and Health Promotion, National 
      Institute of Health, Rome, Italy.
FAU - Rastelli, Emanuele
AU  - Rastelli E
FAU - Antonini, Giovanni
AU  - Antonini G
FAU - Bianchi, Maria Laura Ester
AU  - Bianchi ML
FAU - Botta, Annalisa
AU  - Botta A
FAU - Bucci, Elisabetta
AU  - Bucci E
FAU - Casali, Carlo
AU  - Casali C
FAU - Costanzi-Porrini, Sandro
AU  - Costanzi-Porrini S
FAU - Giacanelli, Manlio
AU  - Giacanelli M
FAU - Gibellini, Manuela
AU  - Gibellini M
FAU - Modoni, Anna
AU  - Modoni A
FAU - Novelli, Giuseppe
AU  - Novelli G
FAU - Pennisi, Elena Maria
AU  - Pennisi EM
FAU - Petrucci, Antonio
AU  - Petrucci A
FAU - Piantadosi, Carlo
AU  - Piantadosi C
FAU - Silvestri, Gabriella
AU  - Silvestri G
FAU - Terracciano, Chiara
AU  - Terracciano C
FAU - Massa, Roberto
AU  - Massa R
LA  - eng
PT  - Journal Article
DEP - 20160217
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
SB  - IM
CIN - Neuroepidemiology. 2016;46(3):228. PMID: 26974673
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/*epidemiology
MH  - Prevalence
MH  - Rome/epidemiology
MH  - Sex Distribution
MH  - Young Adult
EDAT- 2016/02/18 06:00
MHDA- 2016/12/20 06:00
CRDT- 2016/02/17 06:00
PHST- 2015/06/26 00:00 [received]
PHST- 2016/01/14 00:00 [accepted]
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - 000444018 [pii]
AID - 10.1159/000444018 [doi]
PST - ppublish
SO  - Neuroepidemiology. 2016;46(3):191-7. doi: 10.1159/000444018. Epub 2016 Feb 17.

PMID- 26708183
OWN - NLM
STAT- MEDLINE
DCOM- 20160930
LR  - 20181113
IS  - 2038-8306 (Electronic)
IS  - 1121-760X (Print)
IS  - 1121-760X (Linking)
VI  - 59
IP  - 4
DP  - 2015 Oct 26
TI  - Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a 
      useful tool in myotonic dystrophy type 1.
PG  - 2562
LID - 10.4081/ejh.2015.2562 [doi]
LID - 2562
AB  - Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by a CTG 
      repeat expansion in 3'UTR of DMPK gene. This mutation causes accumulation of 
      toxic RNA in nuclear foci leading to splicing misregulation of specific genes. In 
      view of future clinical trials with antisense oligonucleotides in DM1 patients, 
      it is important to set up sensitive and minimally-invasive tools to monitor the 
      efficacy of treatments on skeletal muscle. A tibialis anterior (TA) muscle sample 
      of about 60 mg was obtained from 5 DM1 patients and 5 healthy subjects through a 
      needle biopsy. A fragment of about 40 mg was used for histological examination 
      and a fragment of about 20 mg was used for biomolecular analysis. The TA 
      fragments obtained with the minimally-invasive needle biopsy technique is enough 
      to perform all the histopathological and biomolecular evaluations useful to 
      monitor a clinical trial on DM1 patients.
FAU - Iachettini, S
AU  - Iachettini S
AD  - IRCCS-Policlinico San Donato. sara.iachettini@gmail.com.
FAU - Valaperta, R
AU  - Valaperta R
FAU - Marchesi, A
AU  - Marchesi A
FAU - Perfetti, A
AU  - Perfetti A
FAU - Cuomo, G
AU  - Cuomo G
FAU - Fossati, B
AU  - Fossati B
FAU - Vaienti, L
AU  - Vaienti L
FAU - Costa, E
AU  - Costa E
FAU - Meola, G
AU  - Meola G
FAU - Cardani, R
AU  - Cardani R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151026
PL  - Italy
TA  - Eur J Histochem
JT  - European journal of histochemistry : EJH
JID - 9207930
SB  - IM
MH  - Adult
MH  - Biopsy, Fine-Needle
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscle, Skeletal/*metabolism/*pathology
MH  - Myotonic Dystrophy/*genetics/*metabolism/*pathology
PMC - PMC4698615
COIS- Conflict of interest: the authors declare no conflict of interest.
EDAT- 2015/12/29 06:00
MHDA- 2016/10/01 06:00
PMCR- 2015/10/26
CRDT- 2015/12/29 06:00
PHST- 2015/08/17 00:00 [received]
PHST- 2015/10/03 00:00 [accepted]
PHST- 2015/09/25 00:00 [revised]
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2016/10/01 06:00 [medline]
PHST- 2015/10/26 00:00 [pmc-release]
AID - 10.4081/ejh.2015.2562 [doi]
PST - epublish
SO  - Eur J Histochem. 2015 Oct 26;59(4):2562. doi: 10.4081/ejh.2015.2562.

PMID- 26640575
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 10
IP  - 5
DP  - 2015 Nov
TI  - Clinical, pathological and genetic characteristics of a pedigree with myotonic 
      dystrophy type 1.
PG  - 1931-1936
AB  - The aim of the present study was to investigate the clinical, pathological and 
      molecular genetic characteristics of a pedigree with myotonic dystrophy type 1 
      (DM1). A series of clinical data from a pedigree with DM1 were collected. Muscle 
      biopsy revealed a typical nuclear ingression within numerous muscle fibers 
      following hematoxylin and eosin staining. Genomic DNA was extracted from the 
      venous blood of two patients and the triplet-primed polymerase chain reaction 
      method was performed to amplify the dystrophia myotonic protein kinase (DMPK) 
      gene. The amplified products were subjected to gene sequencing by capillary 
      fluorescence electrophoresis, and a pathogenic mutation in the DMPK gene 
      comprising >50 cytosine-thymine-guanine repeat sequences was found. DM1 includes 
      multi-system damage, as well as skeletal muscle involvement, and can affect the 
      central nervous system, endocrine glands, skin and heart. A skeletal muscle 
      biopsy and genetic testing can confirm the diagnosis and clarify the severity of 
      the disease. In addition, it is necessary to distinguish DM1 from DM2.
FAU - Liu, Qing
AU  - Liu Q
AD  - Department of Neurology, Taiyuan Central Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030009, P.R. China.
FAU - Zheng, Yu-Fei
AU  - Zheng YF
AD  - Department of Neurology, Taiyuan Central Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030009, P.R. China.
FAU - Zhu, Yan-Ping
AU  - Zhu YP
AD  - Department of Neurology, Taiyuan Central Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030009, P.R. China.
FAU - Ling, Shi-Qing
AU  - Ling SQ
AD  - Department of Neurology, Taiyuan Central Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030009, P.R. China.
FAU - Li, Wei-Rong
AU  - Li WR
AD  - Department of Neurology, Taiyuan Central Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi 030009, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150909
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC4665748
OTO - NOTNLM
OT  - myotonia
OT  - myotonic dystrophy type 1
OT  - myotonic dystrophy type 2
OT  - nuclear ingression
OT  - skeletal muscle pathology
EDAT- 2015/12/08 06:00
MHDA- 2015/12/08 06:01
PMCR- 2015/09/09
CRDT- 2015/12/08 06:00
PHST- 2014/10/23 00:00 [received]
PHST- 2015/07/23 00:00 [accepted]
PHST- 2015/12/08 06:00 [entrez]
PHST- 2015/12/08 06:00 [pubmed]
PHST- 2015/12/08 06:01 [medline]
PHST- 2015/09/09 00:00 [pmc-release]
AID - ETM-0-0-2738 [pii]
AID - 10.3892/etm.2015.2738 [doi]
PST - ppublish
SO  - Exp Ther Med. 2015 Nov;10(5):1931-1936. doi: 10.3892/etm.2015.2738. Epub 2015 Sep 
      9.

PMID- 26615955
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20170722
IS  - 1095-9130 (Electronic)
IS  - 1046-2023 (Linking)
VI  - 98
DP  - 2016 Apr 1
TI  - RNA FISH for detecting expanded repeats in human diseases.
PG  - 115-123
LID - S1046-2023(15)30156-0 [pii]
LID - 10.1016/j.ymeth.2015.11.017 [doi]
AB  - RNA fluorescence in situ hybridization (FISH) is a widely used technique for 
      detecting transcripts in fixed cells and tissues. Many variants of RNA FISH have 
      been proposed to increase signal strength, resolution and target specificity. The 
      current variants of this technique facilitate the detection of the subcellular 
      localization of transcripts at a single molecule level. Among the applications of 
      RNA FISH are studies on nuclear RNA foci in diseases resulting from the expansion 
      of tri-, tetra-, penta- and hexanucleotide repeats present in different single 
      genes. The partial or complete retention of mutant transcripts forming RNA 
      aggregates within the nucleoplasm has been shown in multiple cellular disease 
      models and in the tissues of patients affected with these atypical mutations. 
      Relevant diseases include, among others, myotonic dystrophy type 1 (DM1) with CUG 
      repeats, Huntington's disease (HD) and spinocerebellar ataxia type 3 (SCA3) with 
      CAG repeats, fragile X-associated tremor/ataxia syndrome (FXTAS) with CGG 
      repeats, myotonic dystrophy type 2 (DM2) with CCUG repeats, amyotrophic lateral 
      sclerosis/frontotemporal dementia (ALS/FTD) with GGGGCC repeats and 
      spinocerebellar ataxia type 32 (SCA32) with GGCCUG. In this article, we summarize 
      the results obtained with FISH to examine RNA nuclear inclusions. We provide a 
      detailed protocol for detecting RNAs containing expanded CAG and CUG repeats in 
      different cellular models, including fibroblasts, lymphoblasts, induced 
      pluripotent stem cells and murine and human neuronal progenitors. We also present 
      the results of the first single-molecule FISH application in a cellular model of 
      polyglutamine disease.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Urbanek, Martyna O
AU  - Urbanek MO
AD  - Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences, Noskowskiego 12/14 Str., 61-704 Poznan, Poland.
FAU - Krzyzosiak, Wlodzimierz J
AU  - Krzyzosiak WJ
AD  - Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish 
      Academy of Sciences, Noskowskiego 12/14 Str., 61-704 Poznan, Poland. Electronic 
      address: wlodkrzy@ibch.poznan.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151123
PL  - United States
TA  - Methods
JT  - Methods (San Diego, Calif.)
JID - 9426302
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Peptides)
RN  - 26700-71-0 (polyglutamine)
RN  - 63231-63-0 (RNA)
RN  - Fragile X Tremor Ataxia Syndrome
SB  - IM
MH  - *Alternative Splicing
MH  - Amyotrophic Lateral Sclerosis/diagnosis/genetics/pathology
MH  - Animals
MH  - Ataxia/diagnosis/genetics/pathology
MH  - Cell Line
MH  - Fibroblasts/metabolism/pathology
MH  - Fluorescent Dyes/chemistry
MH  - Fragile X Syndrome/diagnosis/genetics/pathology
MH  - Humans
MH  - Huntington Disease/diagnosis/genetics/pathology
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Mice
MH  - Molecular Imaging/*methods
MH  - Myotonic Dystrophy/diagnosis/genetics/pathology
MH  - Neurons/metabolism/pathology
MH  - Peptides/analysis/genetics/metabolism
MH  - RNA/*chemistry/genetics/metabolism
MH  - Spinocerebellar Ataxias/diagnosis/genetics/pathology
MH  - Tremor/diagnosis/genetics/pathology
MH  - *Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CAG foci
OT  - Fluorescence in situ hybridization
OT  - MBNL1 sequestration
OT  - Polyglutamine disorders
OT  - RNA toxicity
OT  - Trinucleotide repeat expansion diseases
EDAT- 2015/12/01 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/12/01 06:00
PHST- 2015/09/04 00:00 [received]
PHST- 2015/11/18 00:00 [revised]
PHST- 2015/11/21 00:00 [accepted]
PHST- 2015/12/01 06:00 [entrez]
PHST- 2015/12/01 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S1046-2023(15)30156-0 [pii]
AID - 10.1016/j.ymeth.2015.11.017 [doi]
PST - ppublish
SO  - Methods. 2016 Apr 1;98:115-123. doi: 10.1016/j.ymeth.2015.11.017. Epub 2015 Nov 
      23.

PMID- 26586700
OWN - NLM
STAT- MEDLINE
DCOM- 20161005
LR  - 20161230
IS  - 1550-8080 (Electronic)
IS  - 0091-7370 (Linking)
VI  - 45
IP  - 5
DP  - 2015 Fall
TI  - Optimization PCR for Detection CTG/CCTG-Repeat Expansions in the Diagnosis of 
      Myotonic Dystrophies.
PG  - 502-7
AB  - CONTEXT: Myotonic dystrophies (DMs) are a group of autosomal dominant 
      neuromuscular disorders which are caused by large CTG/CCTG-repeat expansions in 
      untranslated regions of DMPK/ZNF9 gene. The "phenotypic overlap" in DMs creates 
      complication in distinguishing patients with DM1 from patients with DM2 and 
      underscores the need for these patients to undergo genetic test; therefore, 
      detection and accurate sizing of the CTG/CCTG-repeat expansions are necessary. 
      Templates with long CTG/CCTG tandem repeats are difficult to amplify by 
      convention PCR. AIMS: The aim of our study was to develop an efficient, economic 
      amplification method which based on combination of primer design, modified 
      annealing, and extension conditions in PCR amplification. SETTINGS AND DESIGN: We 
      detected and analyzed the CTG-repeat expansions in patients having clinical, 
      electrophysiological, and muscle pathology features indicative of DMs by 
      optimization PCR. If no CTG-repeat expansions were detected, we subsequently 
      analyzed the CCTG-repeat expansions in the remaining patients. RESULTS: 42 
      participants included 25 DMs patients and 17 family members. 22 patients showed 
      CTG-repeat expansions, the CTG-repeat ranged from 53 to 683 and the average was 
      535; 3 patients showed CCTG-repeat expansions, the CCTG-repeat ranged from 400 to 
      450 and the average was 416. CONCLUSIONS: Molecular genetic tests are essential 
      for DMs diagnosis; Optimization PCR under the optimal conditions of primer 
      design, modified annealing, and extension conditions can be used for efficient 
      PCR in DMs diagnosis; Optimization PCR can greatly improve the positive detection 
      of DMs, provide an economic, accurate, and rapid method for routine diagnostic 
      use.
CI  - (c) 2015 by the Association of Clinical Scientists, Inc.
FAU - Meng, Yan-Xin
AU  - Meng YX
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Shen, Hong-Rui
AU  - Shen HR
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Zhao, Zhe
AU  - Zhao Z
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Bing, Qi
AU  - Bing Q
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Li, Nan
AU  - Li N
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Hu, Jing
AU  - Hu J
AD  - Department of Neuromuscular Disorders, The Third Hospital of Hebei Medical 
      University, Shijiazhuang, China Jinghu5510@163.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (CNBP protein, human)
RN  - 0 (DNA Primers)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Case-Control Studies
MH  - DNA Primers
MH  - DNA Repeat Expansion/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction/*methods
MH  - RNA-Binding Proteins/genetics
MH  - Trinucleotide Repeat Expansion/*genetics
OTO - NOTNLM
OT  - CTG/CCTG
OT  - GC-rich
OT  - Myotonia dystrophies
OT  - PCR analysis
EDAT- 2015/11/21 06:00
MHDA- 2016/10/07 06:00
CRDT- 2015/11/21 06:00
PHST- 2015/11/21 06:00 [entrez]
PHST- 2015/11/21 06:00 [pubmed]
PHST- 2016/10/07 06:00 [medline]
AID - 45/5/502 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2015 Fall;45(5):502-7.

PMID- 26502861
OWN - NLM
STAT- MEDLINE
DCOM- 20160711
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 19
DP  - 2015 Oct
TI  - A novel association between IL1-Ra (receptor antagonist) gene polymorphism and 
      T1DM in Al-Madina Al-Mounawra.
PG  - 3701-8
LID - 9606 [pii]
AB  - OBJECTIVE: The Interleukin-1 receptor antagonist (IL1-Ra) is initiated to 
      terminate the acute pro-inflammatory event and prevent chronic inflammation from 
      damaging healthy cells. We aim to draw the attention of IL1-Ra (VNTR) gene 
      polymorphism and determine whether IL1-Ra confer susceptibility to type 1 
      diabetes mellitus (T1DM) and evaluate the genotype and allele distribution of 
      IL1-Ra gene in a Saudi population. PATIENTS AND METHODS: Case control study 
      included (100) T1DM Saudi children, plus 102 healthy unrelated individuals as 
      control group. They were evaluated for variable number of tandem repeat (VNTR) of 
      IL1-Ra gene polymorphism. Polymerase chain reaction amplification of VNTR of 86bp 
      in intron 2 of IL1-Ra was performed. RESULTS: A1A1 and A1A2 genotypes with 
      alleles A1 and A2 frequency were the most common both in cases and controls 
      (healthy population); prevalence (28%, 56% & 57.8%, 39.2% respectively) and (58%, 
      38% and 77.5%, 22.5% respectively). In addition IL1-Ra gene polymorphism had 
      higher risk significantly different between diabetic children and controls. 
      (A1/A2) genotype had higher frequency statistically significant in DM patients 
      than controls [56% vs. 39.2%, p < 0.02] and had twice time risk [OR = 1.97, 95% 
      CI = 1.1-3.4, p < 0.02]. With further stratification, there was strong 
      association between diabetic patients carriage IL1-Ra (A2) allele and controls 
      [38% vs. 22.5%, p = 0.001] which had higher risk [OR = 2.11, 95% CI = 1.4-3.2, p 
      = 0.001] for susceptibility of diabetes. CONCLUSIONS: This study emphasizes a 
      positive association between IL1-Ra (VNTR) polymorphism and DM among Saudi 
      children. This may suggest that (A2) allele may play important role in disease 
      susceptibility.
FAU - Ali, R A
AU  - Ali RA
AD  - Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, 
      Taibah University, Al-Madina Al Mounwara, Kingdom Saudi Arabia. dr_raa@yahoo.com.
FAU - Saber, L M
AU  - Saber LM
FAU - Al-Harbi, A M
AU  - Al-Harbi AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
SB  - IM
MH  - Adolescent
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Interleukin 1 Receptor Antagonist Protein/*genetics
MH  - Male
MH  - Polymorphism, Genetic/*genetics
MH  - Saudi Arabia
EDAT- 2015/10/28 06:00
MHDA- 2016/07/12 06:00
CRDT- 2015/10/28 06:00
PHST- 2015/10/28 06:00 [entrez]
PHST- 2015/10/28 06:00 [pubmed]
PHST- 2016/07/12 06:00 [medline]
AID - 9606 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3701-8.

PMID- 26498872
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20151222
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 203
DP  - 2016 Jan 15
TI  - CTG-repeat expansions in the DMPK gene do not cause takotsubo syndrome.
PG  - 107-8
LID - S0167-5273(15)30674-4 [pii]
LID - 10.1016/j.ijcard.2015.10.112 [doi]
FAU - Bridgman, P G
AU  - Bridgman PG
AD  - Department of Cardiology, Christchurch Hospital, Christchurch, New Zealand. 
      Electronic address: paul.bridgman@cdhb.health.nz.
FAU - Finsterer, J
AU  - Finsterer J
AD  - Department of Neurology, Krankenanstalt Rudolfstiftung, Vienna, Austria.
FAU - Lacey, C
AU  - Lacey C
AD  - Department of Psychological Medicine, University of Otago, Christchurch, New 
      Zealand.
FAU - Kimber, B
AU  - Kimber B
AD  - Department of Psychological Medicine, University of Otago, Christchurch, New 
      Zealand.
FAU - Parkin, P J
AU  - Parkin PJ
AD  - Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
FAU - Miller, A L
AU  - Miller AL
AD  - Department of Pathology, University of Otago, Christchurch, New Zealand.
FAU - Kennedy, M A
AU  - Kennedy MA
AD  - Department of Pathology, University of Otago, Christchurch, New Zealand.
LA  - eng
PT  - Case Reports
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20151022
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Coronary Angiography
MH  - DNA/*genetics
MH  - DNA Repeat Expansion
MH  - Diagnosis, Differential
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Takotsubo Cardiomyopathy/diagnosis/*etiology/genetics
OTO - NOTNLM
OT  - Cardiac involvement
OT  - Genetics
OT  - Myotonic dystrophy type one
OT  - Takotsubo cardiomyopathy
OT  - Torsades de pointes
EDAT- 2015/10/27 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/10/27 06:00
PHST- 2015/10/05 00:00 [received]
PHST- 2015/10/13 00:00 [accepted]
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - S0167-5273(15)30674-4 [pii]
AID - 10.1016/j.ijcard.2015.10.112 [doi]
PST - ppublish
SO  - Int J Cardiol. 2016 Jan 15;203:107-8. doi: 10.1016/j.ijcard.2015.10.112. Epub 
      2015 Oct 22.

PMID- 26257173
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20220330
IS  - 2211-1247 (Electronic)
VI  - 12
IP  - 7
DP  - 2015 Aug 18
TI  - MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy 
      Brain.
PG  - 1159-68
LID - S2211-1247(15)00789-5 [pii]
LID - 10.1016/j.celrep.2015.07.029 [doi]
AB  - For some neurological disorders, disease is primarily RNA mediated due to 
      expression of non-coding microsatellite expansion RNAs (RNA(exp)). Toxicity is 
      thought to result from enhanced binding of proteins to these expansions and 
      depletion from their normal cellular targets. However, experimental evidence for 
      this sequestration model is lacking. Here, we use HITS-CLIP and pre-mRNA 
      processing analysis of human control versus myotonic dystrophy (DM) brains to 
      provide compelling evidence for this RNA toxicity model. MBNL2 binds directly to 
      DM repeat expansions in the brain, resulting in depletion from its normal RNA 
      targets with downstream effects on alternative splicing and polyadenylation. 
      Similar RNA processing defects were detected in Mbnl compound-knockout mice, 
      highlighted by dysregulation of Mapt splicing and fetal tau isoform expression in 
      adults. These results demonstrate that MBNL proteins are directly sequestered by 
      RNA(exp) in the DM brain and introduce a powerful experimental tool to evaluate 
      RNA-mediated toxicity in other expansion diseases.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Goodwin, Marianne
AU  - Goodwin M
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Mohan, Apoorva
AU  - Mohan A
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Batra, Ranjan
AU  - Batra R
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Lee, Kuang-Yung
AU  - Lee KY
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA; Department of Neurology, Chang Gung Memorial Hospital, Keelung 
      20401, Taiwan.
FAU - Charizanis, Konstantinos
AU  - Charizanis K
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA; InSiliGen LLC, Gainesville, FL 32606, USA.
FAU - Fernandez Gomez, Francisco Jose
AU  - Fernandez Gomez FJ
AD  - Inserm UMR S1172, Alzheimer and Tauopathies, Universite Lille Nord de France, 
      Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France.
FAU - Eddarkaoui, Sabiha
AU  - Eddarkaoui S
AD  - Inserm UMR S1172, Alzheimer and Tauopathies, Universite Lille Nord de France, 
      Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France.
FAU - Sergeant, Nicolas
AU  - Sergeant N
AD  - Inserm UMR S1172, Alzheimer and Tauopathies, Universite Lille Nord de France, 
      Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France.
FAU - Buee, Luc
AU  - Buee L
AD  - Inserm UMR S1172, Alzheimer and Tauopathies, Universite Lille Nord de France, 
      Centre Jean-Pierre Aubert, 1 Place Verdun, 59045 Lille, France.
FAU - Kimura, Takashi
AU  - Kimura T
AD  - Division of Neurology, Department of Internal Medicine, Hyogo College of 
      Medicine, Hyogo 663-8501, Japan.
FAU - Clark, H Brent
AU  - Clark HB
AD  - Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and 
      Genetics, Cell Biology, and Development, University of Minnesota Medical School, 
      Minneapolis, MN 55455, USA.
FAU - Dalton, Joline
AU  - Dalton J
AD  - Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and 
      Genetics, Cell Biology, and Development, University of Minnesota Medical School, 
      Minneapolis, MN 55455, USA.
FAU - Takamura, Kenji
AU  - Takamura K
AD  - Departments of Laboratory Medicine and Pathology, Neurology, Neurosurgery, and 
      Genetics, Cell Biology, and Development, University of Minnesota Medical School, 
      Minneapolis, MN 55455, USA.
FAU - Weyn-Vanhentenryck, Sebastien M
AU  - Weyn-Vanhentenryck SM
AD  - Department of Systems Biology, Department of Biochemistry and Molecular 
      Biophysics, Center for Motor Neuron Biology and Disease, Columbia University, New 
      York, NY 10032, USA.
FAU - Zhang, Chaolin
AU  - Zhang C
AD  - Department of Systems Biology, Department of Biochemistry and Molecular 
      Biophysics, Center for Motor Neuron Biology and Disease, Columbia University, New 
      York, NY 10032, USA.
FAU - Reid, Tammy
AU  - Reid T
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Ranum, Laura P W
AU  - Ranum LP
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA.
FAU - Day, John W
AU  - Day JW
AD  - Department of Neurology and Neurological Sciences, School of Medicine, Stanford 
      University, Palo Alto, CA 94305, USA.
FAU - Swanson, Maurice S
AU  - Swanson MS
AD  - Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and 
      the Genetics Institute, University of Florida, College of Medicine, Gainesville, 
      FL 32610, USA. Electronic address: mswanson@ufl.edu.
LA  - eng
SI  - GEO/GSE68890
GR  - R01 NS089676/NS/NINDS NIH HHS/United States
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - R00 GM095713/GM/NIGMS NIH HHS/United States
GR  - P01 NS058901/NS/NINDS NIH HHS/United States
GR  - GSE68890/PHS HHS/United States
GR  - NS058901/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150806
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MBNL2 protein, human)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA, Untranslated)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Animals
MH  - Brain/*metabolism
MH  - DNA Repeat Expansion
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Humans
MH  - Mice
MH  - Microsatellite Repeats
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - *RNA Splicing
MH  - RNA, Untranslated/*genetics
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - tau Proteins/genetics/metabolism
PMC - PMC4545389
MID - NIHMS709399
EDAT- 2015/08/11 06:00
MHDA- 2016/06/21 06:00
PMCR- 2016/08/18
CRDT- 2015/08/11 06:00
PHST- 2015/03/24 00:00 [received]
PHST- 2015/06/24 00:00 [revised]
PHST- 2015/07/14 00:00 [accepted]
PHST- 2015/08/11 06:00 [entrez]
PHST- 2015/08/11 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
PHST- 2016/08/18 00:00 [pmc-release]
AID - S2211-1247(15)00789-5 [pii]
AID - 10.1016/j.celrep.2015.07.029 [doi]
PST - ppublish
SO  - Cell Rep. 2015 Aug 18;12(7):1159-68. doi: 10.1016/j.celrep.2015.07.029. Epub 2015 
      Aug 6.

PMID- 26190529
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20220409
IS  - 2213-6711 (Electronic)
IS  - 2213-6711 (Linking)
VI  - 5
IP  - 2
DP  - 2015 Aug 11
TI  - Uncovering the Role of Hypermethylation by CTG Expansion in Myotonic Dystrophy 
      Type 1 Using Mutant Human Embryonic Stem Cells.
PG  - 221-31
LID - S2213-6711(15)00184-8 [pii]
LID - 10.1016/j.stemcr.2015.06.003 [doi]
AB  - CTG repeat expansion in DMPK, the cause of myotonic dystrophy type 1 (DM1), 
      frequently results in hypermethylation and reduced SIX5 expression. The 
      contribution of hypermethylation to disease pathogenesis and the precise 
      mechanism by which SIX5 expression is reduced are unknown. Using 14 different 
      DM1-affected human embryonic stem cell (hESC) lines, we characterized a 
      differentially methylated region (DMR) near the CTGs. This DMR undergoes 
      hypermethylation as a function of expansion size in a way that is specific to 
      undifferentiated cells and is associated with reduced SIX5 expression. Using 
      functional assays, we provide evidence for regulatory activity of the DMR, which 
      is lost by hypermethylation and may contribute to DM1 pathogenesis by causing 
      SIX5 haplo-insufficiency. This study highlights the power of hESCs in disease 
      modeling and describes a DMR that functions both as an exon coding sequence and 
      as a regulatory element whose activity is epigenetically hampered by a heritable 
      mutation.
CI  - Copyright (c) 2015 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Yanovsky-Dagan, Shira
AU  - Yanovsky-Dagan S
AD  - Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical 
      Center affiliated with the Hebrew University School of Medicine, Jerusalem 91031, 
      Israel.
FAU - Avitzour, Michal
AU  - Avitzour M
AD  - Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical 
      Center affiliated with the Hebrew University School of Medicine, Jerusalem 91031, 
      Israel.
FAU - Altarescu, Gheona
AU  - Altarescu G
AD  - Zohar PGD Lab, Medical Genetics Institute, Shaare Zedek Medical Center affiliated 
      with the Hebrew University School of Medicine, Jerusalem 91031, Israel.
FAU - Renbaum, Paul
AU  - Renbaum P
AD  - Zohar PGD Lab, Medical Genetics Institute, Shaare Zedek Medical Center affiliated 
      with the Hebrew University School of Medicine, Jerusalem 91031, Israel.
FAU - Eldar-Geva, Talia
AU  - Eldar-Geva T
AD  - IVF Unit, Shaare Zedek Medical Center affiliated with the Hebrew University 
      School of Medicine, Jerusalem 91031, Israel.
FAU - Schonberger, Oshrat
AU  - Schonberger O
AD  - IVF Unit, Shaare Zedek Medical Center affiliated with the Hebrew University 
      School of Medicine, Jerusalem 91031, Israel.
FAU - Mitrani-Rosenbaum, Stella
AU  - Mitrani-Rosenbaum S
AD  - Goldyne Savad Institute for Gene Therapy, Hadassah Hebrew University Medical 
      Center, Jerusalem 91240, Israel.
FAU - Levy-Lahad, Ephrat
AU  - Levy-Lahad E
AD  - Zohar PGD Lab, Medical Genetics Institute, Shaare Zedek Medical Center affiliated 
      with the Hebrew University School of Medicine, Jerusalem 91031, Israel.
FAU - Birnbaum, Ramon Y
AU  - Birnbaum RY
AD  - Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 
      84105, Israel.
FAU - Gepstein, Lior
AU  - Gepstein L
AD  - Sohnis Family Research Laboratory for Cardiac Electrophysiology and Regenerative 
      Medicine, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of 
      Technology, Haifa 31096, Israel.
FAU - Epsztejn-Litman, Silvina
AU  - Epsztejn-Litman S
AD  - Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical 
      Center affiliated with the Hebrew University School of Medicine, Jerusalem 91031, 
      Israel.
FAU - Eiges, Rachel
AU  - Eiges R
AD  - Stem Cell Research Laboratory, Medical Genetics Institute, Shaare Zedek Medical 
      Center affiliated with the Hebrew University School of Medicine, Jerusalem 91031, 
      Israel. Electronic address: rachela@szmc.org.il.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150716
PL  - United States
TA  - Stem Cell Reports
JT  - Stem cell reports
JID - 101611300
RN  - 0 (DMPK protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (SIX5 protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - CpG Islands
MH  - *DNA Methylation
MH  - *DNA Repeat Expansion
MH  - Embryonic Stem Cells/cytology/*metabolism
MH  - Epigenesis, Genetic
MH  - HEK293 Cells
MH  - Homeodomain Proteins/genetics/metabolism
MH  - Humans
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase/*genetics
PMC - PMC4618658
EDAT- 2015/07/21 06:00
MHDA- 2016/05/06 06:00
PMCR- 2015/07/16
CRDT- 2015/07/21 06:00
PHST- 2015/05/31 00:00 [received]
PHST- 2015/06/15 00:00 [revised]
PHST- 2015/06/15 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
PHST- 2015/07/16 00:00 [pmc-release]
AID - S2213-6711(15)00184-8 [pii]
AID - 10.1016/j.stemcr.2015.06.003 [doi]
PST - ppublish
SO  - Stem Cell Reports. 2015 Aug 11;5(2):221-31. doi: 10.1016/j.stemcr.2015.06.003. 
      Epub 2015 Jul 16.

PMID- 26103061
OWN - NLM
STAT- MEDLINE
DCOM- 20151208
LR  - 20231111
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Print)
IS  - 0022-2623 (Linking)
VI  - 58
IP  - 15
DP  - 2015 Aug 13
TI  - Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 
      Models.
PG  - 5770-80
LID - 10.1021/acs.jmedchem.5b00356 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a disease characterized by errors in 
      alternative splicing, or "mis-splicing". The causative agent of mis-splicing in 
      DM1 is an inherited CTG repeat expansion located in the 3' untranslated region of 
      the DM protein kinase gene. When transcribed, CUG repeat expansion RNA sequesters 
      muscleblind-like (MBNL) proteins, which constitute an important family of 
      alternative splicing regulators. Sequestration of MBNL proteins results in the 
      mis-splicing of its regulated transcripts. Previous work has demonstrated that 
      pentamidine, a diamidine which is currently FDA-approved as an antiparasitic 
      agent, was able to partially reverse mis-splicing in multiple DM1 models, albeit 
      at toxic concentrations. In this study, we characterized a series of pentamidine 
      analogues to determine their ability to reverse mis-splicing and their toxicity 
      in vivo. Experiments in cell and mouse models demonstrated that compound 13, also 
      known as furamidine, effectively reversed mis-splicing with equal efficacy and 
      reduced toxicity compared to pentamidine.
FAU - Siboni, Ruth B
AU  - Siboni RB
FAU - Bodner, Micah J
AU  - Bodner MJ
FAU - Khalifa, Muhammad M
AU  - Khalifa MM
FAU - Docter, Aaron G
AU  - Docter AG
FAU - Choi, Jessica Y
AU  - Choi JY
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  -  section signDepartment of Neurology, University of Osaka Graduate School of Medicine, Osaka 
      565-0871, Japan.
FAU - Haley, Michael M
AU  - Haley MM
FAU - Berglund, J Andrew
AU  - Berglund JA
LA  - eng
GR  - P30 ES000210/ES/NIEHS NIH HHS/United States
GR  - R01 AR059833/AR/NIAMS NIH HHS/United States
GR  - AR0599833/AR/NIAMS NIH HHS/United States
GR  - P30-ES00210/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150721
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
RN  - 0 (Amidines)
SB  - IM
MH  - Amidines/chemistry/pharmacology/*therapeutic use
MH  - Animals
MH  - Cells, Cultured
MH  - Disease Models, Animal
MH  - Male
MH  - Myotonic Dystrophy/*drug therapy
MH  - Structure-Activity Relationship
PMC - PMC4972181
MID - NIHMS804747
COIS- Conflicts of Interest: The authors declare the following competing financial 
      interest(s): The University of Oregon and J. Andrew Berglund have patented 
      pentamidine and analogues (US 8,436,049 B2) as possible compounds for therapeutic 
      use in Myotonic Dystrophy.
EDAT- 2015/06/24 06:00
MHDA- 2015/12/15 06:00
PMCR- 2016/08/03
CRDT- 2015/06/24 06:00
PHST- 2015/06/24 06:00 [entrez]
PHST- 2015/06/24 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2016/08/03 00:00 [pmc-release]
AID - 10.1021/acs.jmedchem.5b00356 [doi]
PST - ppublish
SO  - J Med Chem. 2015 Aug 13;58(15):5770-80. doi: 10.1021/acs.jmedchem.5b00356. Epub 
      2015 Jul 21.

PMID- 26092529
OWN - NLM
STAT- MEDLINE
DCOM- 20160422
LR  - 20220331
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Print)
IS  - 1754-8403 (Linking)
VI  - 8
IP  - 7
DP  - 2015 Jul 1
TI  - Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic 
      dystrophy type 1 Drosophila model.
PG  - 679-90
LID - 10.1242/dmm.018127 [doi]
AB  - Muscle mass wasting is one of the most debilitating symptoms of myotonic 
      dystrophy type 1 (DM1) disease, ultimately leading to immobility, respiratory 
      defects, dysarthria, dysphagia and death in advanced stages of the disease. In 
      order to study the molecular mechanisms leading to the degenerative loss of adult 
      muscle tissue in DM1, we generated an inducible Drosophila model of expanded CTG 
      trinucleotide repeat toxicity that resembles an adult-onset form of the disease. 
      Heat-shock induced expression of 480 CUG repeats in adult flies resulted in a 
      reduction in the area of the indirect flight muscles. In these model flies, 
      reduction of muscle area was concomitant with increased apoptosis and autophagy. 
      Inhibition of apoptosis or autophagy mediated by the overexpression of DIAP1, 
      mTOR (also known as Tor) or muscleblind, or by RNA interference (RNAi)-mediated 
      silencing of autophagy regulatory genes, achieved a rescue of the muscle-loss 
      phenotype. In fact, mTOR overexpression rescued muscle size to a size comparable 
      to that in control flies. These results were validated in skeletal muscle 
      biopsies from DM1 patients in which we found downregulated autophagy and 
      apoptosis repressor genes, and also in DM1 myoblasts where we found increased 
      autophagy. These findings provide new insights into the signaling pathways 
      involved in DM1 disease pathogenesis.
CI  - (c) 2015. Published by The Company of Biologists Ltd.
FAU - Bargiela, Ariadna
AU  - Bargiela A
AD  - Translational Genomics Group, Department of Genetics, University of Valencia, 
      Burjassot 46100, Spain INCLIVA Health Research Institute, Valencia 46010, Spain.
FAU - Cerro-Herreros, Estefania
AU  - Cerro-Herreros E
AD  - Translational Genomics Group, Department of Genetics, University of Valencia, 
      Burjassot 46100, Spain INCLIVA Health Research Institute, Valencia 46010, Spain.
FAU - Fernandez-Costa, Juan M
AU  - Fernandez-Costa JM
AD  - Translational Genomics Group, Department of Genetics, University of Valencia, 
      Burjassot 46100, Spain.
FAU - Vilchez, Juan J
AU  - Vilchez JJ
AD  - Neurology Section, Hospital Universitari La Fe, Valencia 46026, Spain Department 
      of Internal Medicine, University of Valencia, Valencia 46010, Spain Centro de 
      Investigaciones Biomedicas en Red sobre Enfermedades Neurodegenerativas 
      (CIBERNED), Institute Carlos III, Ministry of Economy and Competitiveness, Madrid 
      28049, Spain.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - INCLIVA Health Research Institute, Valencia 46010, Spain.
FAU - Artero, Ruben
AU  - Artero R
AD  - Translational Genomics Group, Department of Genetics, University of Valencia, 
      Burjassot 46100, Spain INCLIVA Health Research Institute, Valencia 46010, Spain 
      ruben.artero@uv.es.
LA  - eng
GR  - P40 OD018537/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
RN  - 0 (DIAP1 protein, Drosophila)
RN  - 0 (Drosophila Proteins)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (mbl protein, Drosophila)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Apoptosis/genetics
MH  - Autophagy/genetics
MH  - Disease Models, Animal
MH  - Drosophila Proteins/genetics
MH  - Drosophila melanogaster/genetics
MH  - Female
MH  - Genes, Insect
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/genetics
MH  - Muscular Atrophy/etiology/genetics/pathology
MH  - Myotonic Dystrophy/*etiology/genetics/pathology
MH  - Myotonin-Protein Kinase/genetics
MH  - Nuclear Proteins/genetics
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/genetics
MH  - Trinucleotide Repeat Expansion
MH  - Up-Regulation
PMC - PMC4486854
OTO - NOTNLM
OT  - Apoptosis
OT  - Autophagy
OT  - CTG repeat expansion
OT  - Dystrophy
OT  - Muscle atrophy
OT  - Muscleblind
COIS- Competing interests The authors declare no competing or financial interests.
EDAT- 2015/06/21 06:00
MHDA- 2016/04/23 06:00
PMCR- 2015/07/01
CRDT- 2015/06/21 06:00
PHST- 2015/06/21 06:00 [entrez]
PHST- 2015/06/21 06:00 [pubmed]
PHST- 2016/04/23 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - 8/7/679 [pii]
AID - DMM018127 [pii]
AID - 10.1242/dmm.018127 [doi]
PST - ppublish
SO  - Dis Model Mech. 2015 Jul 1;8(7):679-90. doi: 10.1242/dmm.018127.

PMID- 25958258
OWN - NLM
STAT- MEDLINE
DCOM- 20170419
LR  - 20170419
IS  - 2174-2030 (Electronic)
IS  - 0870-2551 (Linking)
VI  - 34
IP  - 5
DP  - 2015 May
TI  - Syncope and hyperCKemia as minimal manifestations of short CTG repeat expansions 
      in myotonic dystrophy type 1.
PG  - 361.e1-4
LID - S0870-2551(15)00107-9 [pii]
LID - 10.1016/j.repc.2014.11.018 [doi]
AB  - INTRODUCTION: Syncope and palpitations as the only initial manifestations of 
      myotonic dystrophy type 1 (MD1) due to a CTG expansion of 50-100 repeats have not 
      been reported. CASE REPORT: In a 55-year-old female with a family history of MD1 
      and a personal history of a single syncope, palpitations, and hyperCKemia, 70 CTG 
      repeats were detected in the DMPK gene. Her brother had presented atypical 
      clinical, electromyographic, and muscle biopsy features since the age of 35 but 
      had been diagnosed with MD1 after he later developed typical distal myotonia. He 
      died suddenly during an episode of syncope at the age of 53. A sister with 
      clinical myotonia died suddenly during sleep at the age of 45 and a second sister 
      with quadriparesis died from complications of intestinal rupture at age 52. A 
      third sister committed suicide at age 40 after developing recurrent syncopes, 
      while a fourth sister had hyperCKemia and foot-extensor weakness. The mother of 
      these five affected children died suddenly from myocardial rupture. CONCLUSIONS: 
      MD1 with <100 CTG repeats may exclusively manifest cardiologically. Family 
      screening for MD1 is important even in asymptomatic patients. MD1 may initially 
      manifest without typical features, while muscle biopsy may be misleading and 
      indicate glycogenosis. Close cardiac follow-up is important if MD1 manifests 
      cardiologically to prevent syncope or sudden cardiac death.
CI  - Copyright (c) 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier 
      Espana. All rights reserved.
FAU - Finsterer, Josef
AU  - Finsterer J
AD  - Kar Vienna, Vienna, Austria. Electronic address: fifigs1@yahoo.de.
FAU - Stollberger, Claudia
AU  - Stollberger C
AD  - Kar Vienna, Vienna, Austria.
FAU - Gencik, Martin
AU  - Gencik M
AD  - Kar Vienna, Vienna, Austria.
FAU - Hoftberger, Romana
AU  - Hoftberger R
AD  - Kar Vienna, Vienna, Austria.
FAU - Rahimi, Jasmin
AU  - Rahimi J
AD  - Kar Vienna, Vienna, Austria.
FAU - Mokocki, Johannes
AU  - Mokocki J
AD  - Kar Vienna, Vienna, Austria.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150507
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de 
      Cardiologia = Portuguese journal of cardiology : an official journal of the 
      Portuguese Society of Cardiology
JID - 8710716
RN  - EC 2.7.3.2 (Creatine Kinase)
SB  - IM
MH  - Creatine Kinase/*blood
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Myotonic Dystrophy/blood/*complications/*genetics
MH  - Pedigree
MH  - Syncope/blood/*etiology
OTO - NOTNLM
OT  - Arritmias ventriculares
OT  - Cardiac involvement
OT  - Curschman-Steinert disease
OT  - Distrofia miotonica
OT  - Doenca de Curshman-Steinert
OT  - Envolvimento cardiaco
OT  - Myotonic dystrophy
OT  - Perturbacao trinucleotide
OT  - Trinucleotide disorder
OT  - Ventricular arrhythmias
EDAT- 2015/05/11 06:00
MHDA- 2017/04/20 06:00
CRDT- 2015/05/11 06:00
PHST- 2014/09/01 00:00 [received]
PHST- 2014/11/15 00:00 [accepted]
PHST- 2015/05/11 06:00 [entrez]
PHST- 2015/05/11 06:00 [pubmed]
PHST- 2017/04/20 06:00 [medline]
AID - S0870-2551(15)00107-9 [pii]
AID - 10.1016/j.repc.2014.11.018 [doi]
PST - ppublish
SO  - Rev Port Cardiol. 2015 May;34(5):361.e1-4. doi: 10.1016/j.repc.2014.11.018. Epub 
      2015 May 7.

PMID- 25918532
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150428
LR  - 20201001
IS  - 1687-9627 (Print)
IS  - 1687-9635 (Electronic)
VI  - 2015
DP  - 2015
TI  - Myotonic dystrophy-1 complicated by factor-v (leiden) mutation.
PG  - 271639
LID - 10.1155/2015/271639 [doi]
LID - 271639
AB  - Objectives. Presence of a factor-V Leiden mutation in a patient with myotonic 
      dystrophy type 1 (DM1) has been reported only once. Here we report the second DM1 
      patient carrying a factor-V mutation who died from long-term complications of 
      this mutation. Case Report. A 66-year-old DM1 patient with multi-organ-disorder 
      syndrome developed a first deep venous thrombosis (DVT) and consecutive pulmonary 
      embolism (PE) at age 50 y. Acetyl-salicylic acid was given. One year later he 
      experienced a second DVT; that is why phenprocoumon was started. Despite 
      anticoagulation, he experienced a third DVT bilaterally and a second PE 
      bilaterally at 61 y; that is why a vena cava filter was additionally deployed. 
      Despite therapeutic anticoagulation, he experienced a vena cava filter thrombosis 
      at age 62 y. Genetic workup revealed a heterozygous factor-V mutation in addition 
      to a CTG-repeat expansion of 500. As a consequence of PE he developed chronic 
      obstructive pulmonary disease and experienced recurrent pulmonary infections, 
      which were lastly responsible for decease at age 66 y despite intensive care 
      measures. Conclusion. The heterozygous Leiden mutation may severely affect DM1 
      patients to such a degree that they die from its complications. If DM1 patients 
      present with unusual manifestations, search for causes other than a CTG-repeat 
      expansion is indicated.
FAU - Finsterer, Josef
AU  - Finsterer J
AD  - Krankenanstalt Rudolfstiftung, 1030 Vienna, Austria.
FAU - Stollberger, Claudia
AU  - Stollberger C
AD  - 2nd Medical Department with Cardiology and Intensive Care Medicine, 
      Krankenanstalt Rudolfstiftung, 1030 Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20150330
PL  - United States
TA  - Case Rep Med
JT  - Case reports in medicine
JID - 101512910
PMC - PMC4397038
EDAT- 2015/04/29 06:00
MHDA- 2015/04/29 06:01
PMCR- 2015/03/30
CRDT- 2015/04/29 06:00
PHST- 2015/01/18 00:00 [received]
PHST- 2015/03/10 00:00 [revised]
PHST- 2015/03/12 00:00 [accepted]
PHST- 2015/04/29 06:00 [entrez]
PHST- 2015/04/29 06:00 [pubmed]
PHST- 2015/04/29 06:01 [medline]
PHST- 2015/03/30 00:00 [pmc-release]
AID - 10.1155/2015/271639 [doi]
PST - ppublish
SO  - Case Rep Med. 2015;2015:271639. doi: 10.1155/2015/271639. Epub 2015 Mar 30.

PMID- 25785276
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2015
DP  - 2015
TI  - Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients 
      with poorly controlled type 2 diabetes.
PG  - 176949
LID - 10.1155/2015/176949 [doi]
LID - 176949
AB  - AIM: The relationship between genetic polymorphisms of the glucagon-like 
      peptide-1 (GLP-1) receptor (GLP1R) gene and unresponsiveness to GLP-1 analogue 
      treatment in patients with poorly controlled type 2 diabetes mellitus (DM) is 
      unclear. METHODS: Thirty-six patients with poorly controlled type 2 DM were 
      enrolled and they received six days of continuous subcutaneous insulin infusion 
      for this study. After the normalization of blood glucose in the first 3 days, the 
      patients then received a combination therapy with injections of the GLP-1 
      analogue, exenatide, for another 3 days. All 13 exons and intron-exon boundaries 
      of the GLP1R gene were amplified to investigate the association. RESULTS: The 
      short tandem repeat at 8GA/7GA (rs5875654) had complete linkage disequilibrium 
      (LD, with r2 = 1) with single nucleotide polymorphism (SNP) rs761386. 
      Quantitative trait loci analysis of GLP1R gene variation with clinical response 
      of GLP1 analogue showed the missense rs3765467 and rs761386 significantly 
      associated with changes in the standard deviation of plasma glucose 
      (SDPG(baseline) - SDPG(treatment with GLP-1 analogue)) (P = 0.041 and 0.019, 
      resp.). The reported P values became insignificant after multiple testing 
      adjustments. CONCLUSION: The variable response to the GLP-1 analogue was not 
      statistically correlated with polymorphisms of the GLP1R gene in patients with 
      poorly controlled type 2 DM.
FAU - Lin, Chia-Hung
AU  - Lin CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Taoyuan 333, Taiwan ; Graduate Institute of Clinical 
      Medical Sciences, Chang Gung University, Taoyuan 333, Taiwan.
FAU - Lee, Yun-Shien
AU  - Lee YS
AD  - Department of Biotechnology, Ming Chuan University, Taoyuan 333, Taiwan ; Genomic 
      Medicine Research Core Laboratory, Chang Gung Memorial Hospital, Taoyuan 333, 
      Taiwan.
FAU - Huang, Yu-Yao
AU  - Huang YY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Taoyuan 333, Taiwan.
FAU - Hsieh, Sheng-Hwu
AU  - Hsieh SH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Taoyuan 333, Taiwan.
FAU - Chen, Zih-Syuan
AU  - Chen ZS
AD  - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 
      333, Taiwan.
FAU - Tsai, Chi-Neu
AU  - Tsai CN
AD  - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 
      333, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150215
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Insulin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/*genetics/*metabolism
MH  - Female
MH  - Genotype
MH  - Glucagon-Like Peptide 1/*genetics/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/genetics
MH  - Glucose Tolerance Test
MH  - Hospitalization
MH  - Humans
MH  - Hypoglycemia/genetics
MH  - Infusions, Subcutaneous
MH  - Insulin/administration & dosage/therapeutic use
MH  - Linkage Disequilibrium
MH  - Male
MH  - Microsatellite Repeats
MH  - Middle Aged
MH  - Mutation, Missense
MH  - Polymorphism, Genetic
MH  - Polymorphism, Single Nucleotide
MH  - Quantitative Trait Loci
MH  - Sequence Analysis, DNA
PMC - PMC4345081
EDAT- 2015/03/19 06:00
MHDA- 2015/12/19 06:00
PMCR- 2015/02/15
CRDT- 2015/03/19 06:00
PHST- 2014/09/26 00:00 [received]
PHST- 2014/12/22 00:00 [revised]
PHST- 2015/01/05 00:00 [accepted]
PHST- 2015/03/19 06:00 [entrez]
PHST- 2015/03/19 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
PHST- 2015/02/15 00:00 [pmc-release]
AID - 10.1155/2015/176949 [doi]
PST - ppublish
SO  - J Diabetes Res. 2015;2015:176949. doi: 10.1155/2015/176949. Epub 2015 Feb 15.

PMID- 25712547
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20240104
IS  - 1552-4833 (Electronic)
IS  - 1552-4825 (Linking)
VI  - 167A
IP  - 4
DP  - 2015 Apr
TI  - Anticipation in myotonic dystrophy type 1 parents with small CTG expansions.
PG  - 708-14
LID - 10.1002/ajmg.a.36950 [doi]
AB  - Myotonic dystrophy type 1 is the most common form of adult muscular dystrophy and 
      has the world's highest prevalence in the Saguenay-Lac-St-Jean region, due to a 
      founder effect. This autosomal dominant disorder results from an unstable CTG 
      repeat expansion in DMPK. This region of Canada has had a family screening and 
      predictive testing program for this disorder since 1988. Heterozygotes for small 
      expansions (50-100 CTG repeats) can be asymptomatic or minimally affected. The 
      aim of this study was to assess anticipation for these individuals. At the time 
      of this study, the molecular data of 40 individuals and their 76 affected 
      children were available. We compared 76 parent-child pairs. Most offspring 
      (92.1%) had a larger number of repeats than their parent and the median number of 
      repeats in the offspring was 325 (range, 57-2000). The number of CTG repeats was 
      significantly greater when the mutation was transmitted by a father (median, 425 
      repeats; range, 70-2000), than when it was transmitted by a mother (median, 200 
      repeats; range, 57-1400). The majority (65.8%) of children also had a more severe 
      phenotype than their parent but the sex of the parent had no significant 
      influence on the severity of the child's phenotype. No congenital phenotype was 
      observed. These results confirm that anticipation is present even when the parent 
      is heterozygous for a small CTG expansion. The parental sex has an impact on the 
      size of the repeat in the next generation, larger increases being transmitted by 
      males with a small expansion.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Pratte, Annabelle
AU  - Pratte A
AD  - Division of Genetic Counseling, CSSS Chicoutimi, Chicoutimi, Quebec, Canada.
FAU - Prevost, Claude
AU  - Prevost C
FAU - Puymirat, Jack
AU  - Puymirat J
FAU - Mathieu, Jean
AU  - Mathieu J
LA  - eng
GR  - CAR43283/Canadian Institutes of Health Research/Canada
GR  - MOP49556/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150225
PL  - United States
TA  - Am J Med Genet A
JT  - American journal of medical genetics. Part A
JID - 101235741
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Anticipation, Genetic
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Parents
MH  - Pedigree
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CTG repeat
OT  - DMPK gene
OT  - anticipation
OT  - genetic counseling
OT  - myotonic dystrophy
EDAT- 2015/02/26 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/02/26 06:00
PHST- 2014/03/21 00:00 [received]
PHST- 2014/12/21 00:00 [accepted]
PHST- 2015/02/26 06:00 [entrez]
PHST- 2015/02/26 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 10.1002/ajmg.a.36950 [doi]
PST - ppublish
SO  - Am J Med Genet A. 2015 Apr;167A(4):708-14. doi: 10.1002/ajmg.a.36950. Epub 2015 
      Feb 25.

PMID- 25655594
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20181202
IS  - 1724-6016 (Electronic)
IS  - 1120-6721 (Linking)
VI  - 25
IP  - 4
DP  - 2015 May 25
TI  - Primary cataract as a key to recognition of myotonic dystrophy type 1.
PG  - e46-9
LID - 0F6EFEEC-778C-4532-BE8F-7414FC937390 [pii]
LID - 10.5301/ejo.5000565 [doi]
AB  - PURPOSE: Primary cataract is often the initial manifestation of the adult-onset 
      type of myotonic dystrophy type 1 (DM1), the most common muscular dystrophy in 
      adults. It is caused by a CTG repeat expansion within the DMPK gene, and 
      anticipation may cause earlier onset and more severe symptoms in subsequent 
      generations. METHODS: We report a family with hereditary cataract, which was 
      initially classified as primary hereditary cataract. After presentation of 2 
      children with motor development delay and behavioral changes, DM1 was diagnosed. 
      Subsequently, various DM1 features were recognized in older family members. 
      CONCLUSIONS: This report aims to increase awareness among ophthalmologists of the 
      high prevalence of DM1 among young primary cataract patients. Ophthalmologists 
      can play a significant role in early diagnosis, since cataract frequently is the 
      first occasion that patients seek medical attention. Early recognition is crucial 
      since it enables adequate cardiac follow-up and allows counseling of couples of 
      childbearing age.
FAU - Voermans, Nicol C
AU  - Voermans NC
AD  - 1 Department of Neurology, Radboud University Medical Centre, Nijmegen - The 
      Netherlands.
FAU - Erasmus, Corrie E
AU  - Erasmus CE
FAU - Ockeloen, Charlotte W
AU  - Ockeloen CW
FAU - Van Engelen, Baziel G
AU  - Van Engelen BG
FAU - Eggink, Catharina A
AU  - Eggink CA
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150525
PL  - United States
TA  - Eur J Ophthalmol
JT  - European journal of ophthalmology
JID - 9110772
SB  - IM
MH  - Adult
MH  - Cataract/*diagnosis
MH  - Cataract Extraction
MH  - Child
MH  - Female
MH  - Humans
MH  - Lens Implantation, Intraocular
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis
MH  - Pedigree
MH  - Young Adult
EDAT- 2015/02/07 06:00
MHDA- 2015/09/22 06:00
CRDT- 2015/02/07 06:00
PHST- 2015/01/01 00:00 [accepted]
PHST- 2015/02/07 06:00 [entrez]
PHST- 2015/02/07 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - 0F6EFEEC-778C-4532-BE8F-7414FC937390 [pii]
AID - 10.5301/ejo.5000565 [doi]
PST - epublish
SO  - Eur J Ophthalmol. 2015 May 25;25(4):e46-9. doi: 10.5301/ejo.5000565.

PMID- 25606394
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150121
LR  - 20201001
IS  - 2214-5400 (Print)
IS  - 2214-5400 (Electronic)
IS  - 2214-5400 (Linking)
VI  - 2
DP  - 2014 Dec
TI  - Application of a reliable and rapid polymerase chain reaction based method in the 
      diagnosis of myotonic dystrophy type 1 (DM1) in India.
PG  - 106-13
LID - 10.1016/j.mgene.2013.12.001 [doi]
AB  - DM1 is caused by CTG repeat expansion in the 3'-UTR of the DMPK gene. DM1 
      patients have expansions of greater than 50 repeats and up to many thousands. The 
      intention of the present study is the establishment of reliable and rapid 
      polymerase chain reaction methodology in early screening of DM1 patients and 
      their family members. PCR followed by TP-PCR was assessed for screening of 27 
      cases (from 26 families) and 75 family members and 300 control samples. All 
      patients had CTG repeat expansion while forty seven (63%) and twenty eight (37%), 
      out of seventy five family members were heterozygous and homozygous respectively. 
      Similarly, two hundred thirty (76.77%) and seventy (23.33%), out of three hundred 
      control subjects were heterozygous and homozygous respectively and the number of 
      repeats varied from 5 to 35. Thirteen complete family screenings were done. Thus, 
      TP-PCR is a reliable and rapid molecular technique for the detection of CTG 
      repeat expansion in DM1.
FAU - Kumar, Ashok
AU  - Kumar A
AD  - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
FAU - Agarwal, Sarita
AU  - Agarwal S
AD  - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
FAU - Phadke, Shubha R
AU  - Phadke SR
AD  - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
FAU - Pradhan, Sunil
AU  - Pradhan S
AD  - Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
LA  - eng
PT  - Journal Article
DEP - 20140115
PL  - Netherlands
TA  - Meta Gene
JT  - Meta gene
JID - 101627670
PMC - PMC4287798
OTO - NOTNLM
OT  - CTG repeat
OT  - Myotonic dystrophy type 1 (DM1)
OT  - TPPCR
OT  - Triplet repeat disorder
EDAT- 2015/01/22 06:00
MHDA- 2015/01/22 06:01
PMCR- 2014/01/15
CRDT- 2015/01/22 06:00
PHST- 2013/09/26 00:00 [received]
PHST- 2013/11/26 00:00 [revised]
PHST- 2013/12/02 00:00 [accepted]
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/01/22 06:01 [medline]
PHST- 2014/01/15 00:00 [pmc-release]
AID - S2214-5400(13)00032-7 [pii]
AID - 10.1016/j.mgene.2013.12.001 [doi]
PST - epublish
SO  - Meta Gene. 2014 Jan 15;2:106-13. doi: 10.1016/j.mgene.2013.12.001. eCollection 
      2014 Dec.

PMID- 28198705
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2214-3599 (Print)
VI  - 2
IP  - 1
DP  - 2015
TI  - DM1 Patients with Small CTG Expansions are also at Risk of Severe Conduction 
      Abnormalities.
PG  - 99-105
AB  - BACKGROUND AND OBJECTIVES: A high risk of cardiac arrhythmias was reported in 
      myotonic dystrophy type 1 (DM1). The purpose of the study was to evaluate the 
      risk of severe electrocardiographic abnormalities in DM1 patients with small CTG 
      expansions. METHODS: We assessed the ECG done at DM1 diagnosis for 127 patients 
      with </=200 CTG repeats and for 82 of them who had >/=1 ECG over a period of 
      follow-up of 11.7 +/- 7.6 years (mean +/- SD). Criteria of severe ECG abnormality are 
      at least one of the following features: PR interval >/=240 msec, QRS duration >/=120 
      msec, second-degree or third-degree atrioventricular block, atrial fibrillation 
      or flutter, insertion of a pacemaker or cardioverter-defibrillator. RESULTS: At 
      baseline, ECG was normal for 109 patients out of 127 (85.8%) and only 4 patients 
      (3.1%) presented severe ECG abnormalities. At follow-up, 46 patients out of 82 
      (56.1%) had a normal ECG and 25 (30.5%) developed severe ECG abnormalities (p 
      &lt; 0.0001) including 6 of them who needed permanent pacemaker insertion. There 
      were also 3 sudden deaths during the follow-up period. Using multivariate Cox 
      regression analysis, age at entry (relative risk RR, 1.05; (95% CI 1.01-1.08; p = 
      0.012) and muscular weakness (MIRS) at the entry (RR, 2.03; 95% CI 1.28-3.22; p = 
      0.003) were significant risk factors for the development of severe ECG 
      abnormality. CONCLUSIONS: An increased risk of severe ECG abnormalitiesy and 
      cardiac events is observed even in DM1 patients with small CTG expansions and 
      warrants close cardiac follow-up similar to DM1 patients with larger CTG 
      expansions.
FAU - Denicourt, Maxime
AU  - Denicourt M
AD  - Neuromuscular Clinic, Jonquiere Hospital, Quebec, Canada.
FAU - Pham, Minh Trang
AU  - Pham MT
AD  - Neuromuscular Clinic, Jonquiere Hospital, Quebec, Canada.
FAU - Mathieu, Jean
AU  - Mathieu J
AD  - Neuromuscular Clinic, Jonquiere Hospital, Quebec, Canada.
FAU - Breton, Robert
AU  - Breton R
AD  - Neuromuscular Clinic, Jonquiere Hospital, Quebec, Canada.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Neuromuscul Dis
JT  - Journal of neuromuscular diseases
JID - 101649948
OTO - NOTNLM
OT  - Myotonic dystrophy
OT  - cardiac arrhythmias
OT  - electrocardiogram
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
CRDT- 2017/02/16 06:00
PHST- 2017/02/16 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PST - ppublish
SO  - J Neuromuscul Dis. 2015;2(1):99-105.

PMID- 25495904
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20181113
IS  - 1471-2350 (Electronic)
IS  - 1471-2350 (Linking)
VI  - 15
DP  - 2014 Dec 12
TI  - PCR amplification of a triple-repeat genetic target directly from whole blood in 
      15 minutes as a proof-of-principle PCR study for direct sample analysis for a 
      clinically relevant target.
PG  - 130
LID - 10.1186/s12881-014-0130-5 [doi]
LID - 130
AB  - BACKGROUND: Most PCR-based diagnostics are still considered time- and 
      labor-intensive due to disparate purification, amplification, and detection 
      steps. Advancements in PCR enzymes and buffer chemistry have increased inhibitor 
      tolerance, facilitating PCR directly from crude samples. Obviating the need for 
      DNA purification, while lacking a concentration step, these direct sample methods 
      are particularly apt for human genetic testing. However, direct PCR protocols 
      have traditionally employed thermal cyclers with slow ramp rates and conservative 
      hold times that significantly increase an assay's time-to-result. For this 
      proof-of-principle study, our objective was to significantly reduce sample 
      preparation and assay time for a PCR-based genetic test, for myotonic dystrophy 
      type 1 (DM1), by pairing an inhibitor-resistant enzyme mix with a rapid thermal 
      cycler to analyze samples directly in whole blood. METHODS: DM1 genetic screening 
      was done with an adapted conventional PCR approach that employed the Streck 
      Philisa(R) Thermal Cycler, the inhibitor-resistant NEBNext(R) High-Fidelity 2X PCR 
      Master Mix, and agarose gel electrophoresis or an Agilent 2100 Bioanalyzer for 
      detection. The Gene Link Myotonic Dystrophy Genemer Kit was used as a reference 
      assay kit to evaluate the rapid assay. RESULTS: In this work, a rapid and direct 
      PCR assay testing 10% whole blood as template has been developed as an 
      exclusionary screening assay for DM1, a triple-repeat genetic disorder. PCR 
      amplification was completed in 15 minutes using 30 cycles, including in situ 
      hot-start/cell lysis. Out of the 40 donors screened, this assay identified 23 
      (57.5%) as DM1 negative suggesting no need for further testing. These data are 
      100% concordant with data collected using the commercially available Gene Link 
      Genemer Kit per the kit-specific PCR protocol. CONCLUSIONS: The PCR assay 
      described in this study amplified DM1 short tandem repeats in 15 minutes. By 
      eliminating sample purification and slower conventional PCR protocols, we 
      demonstrated how adaptation of current PCR technology and chemistries can produce 
      a simple-to-use exclusionary screening assay that is independent of up-front 
      sample prep, improving a clinical lab technician's time-to-result. We envision 
      this direct and rapid methodology could be applied to other conventional 
      PCR-based genetic tests and sample matrices where genomic DNA is targeted for 
      analysis within a given molecular diagnostic platform.
FAU - Connelly, Christopher M
AU  - Connelly CM
AD  - Streck, Inc., 7002 S. 109th Street, LaVista, Omaha, NE, 68128, USA. 
      cconnelly@Streck.com.
FAU - Porter, Laura R
AU  - Porter LR
AD  - Streck, Inc., 7002 S. 109th Street, LaVista, Omaha, NE, 68128, USA. 
      lporter@Streck.com.
FAU - TerMaat, Joel R
AU  - TerMaat JR
AD  - Streck, Inc., 7002 S. 109th Street, LaVista, Omaha, NE, 68128, USA. 
      jtermaat@huskers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141212
PL  - England
TA  - BMC Med Genet
JT  - BMC medical genetics
JID - 100968552
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Female
MH  - Genetic Testing/methods
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*blood/genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Polymerase Chain Reaction/*methods
MH  - Time Factors
MH  - *Trinucleotide Repeat Expansion
PMC - PMC4411754
EDAT- 2014/12/17 06:00
MHDA- 2015/07/03 06:00
PMCR- 2014/12/12
CRDT- 2014/12/16 06:00
PHST- 2013/10/17 00:00 [received]
PHST- 2014/11/24 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
PHST- 2014/12/12 00:00 [pmc-release]
AID - s12881-014-0130-5 [pii]
AID - 130 [pii]
AID - 10.1186/s12881-014-0130-5 [doi]
PST - epublish
SO  - BMC Med Genet. 2014 Dec 12;15:130. doi: 10.1186/s12881-014-0130-5.

PMID- 25487787
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20220408
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 52
IP  - 2
DP  - 2015 Aug
TI  - Metabolic syndrome in patients with myotonic dystrophy type 1.
PG  - 273-7
LID - 10.1002/mus.24540 [doi]
AB  - INTRODUCTION: The aim of this study was to assess the frequency and features of 
      metabolic syndrome (MetS) in myotonic dystrophy type 1 (DM1). METHODS: We studied 
      66 DM1 patients (50% men, aged 41.9 +/- 10.5 years, disease duration of 19.3 +/- 8.6 
      years). New worldwide consensus criteria for MetS from 2009 were used. RESULTS: 
      Components of MetS were present at the following frequencies: 
      hypertriglyceridemia 67%; low HDL cholesterol 35%; hypertension 18%; central 
      obesity 14%; and hyperglycemia 9%. MetS was present in 11 (17%) patients. The 
      presence of MetS was not associated with patients' gender, age, disease severity, 
      disease duration, or CTG repeat length (P > 0.05). Patients with MetS had 
      significantly lower total SF-36 scores as a measure of quality of life in 
      comparison to patients without MetS (P < 0.05). CONCLUSION: Although certain 
      components of MetS were very frequent in patients with DM1, only 17% met the 
      criteria for MetS.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Vujnic, Milorad
AU  - Vujnic M
AD  - Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, 
      Bosnia and Herzegovina.
FAU - Peric, Stojan
AU  - Peric S
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia.
FAU - Popovic, Srdjan
AU  - Popovic S
AD  - Endocrinology Clinic, Clinical Center of Serbia, School of Medicine, University 
      of Belgrade, Belgrade, Serbia.
FAU - Raseta, Nela
AU  - Raseta N
AD  - Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, 
      Bosnia and Herzegovina.
FAU - Ralic, Vesna
AU  - Ralic V
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia.
FAU - Dobricic, Valerija
AU  - Dobricic V
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia.
FAU - Novakovic, Ivana
AU  - Novakovic I
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia.
FAU - Rakocevic-Stojanovic, Vidosava
AU  - Rakocevic-Stojanovic V
AD  - Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of 
      Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150619
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Syndrome/*diagnosis/*epidemiology/physiopathology
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/*epidemiology/physiopathology
OTO - NOTNLM
OT  - dyslipidemia
OT  - hypertension
OT  - metabolic syndrome
OT  - myotonic dystrophy type 1
OT  - obesity
EDAT- 2014/12/10 06:00
MHDA- 2015/10/17 06:00
CRDT- 2014/12/10 06:00
PHST- 2014/12/04 00:00 [accepted]
PHST- 2014/12/10 06:00 [entrez]
PHST- 2014/12/10 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
AID - 10.1002/mus.24540 [doi]
PST - ppublish
SO  - Muscle Nerve. 2015 Aug;52(2):273-7. doi: 10.1002/mus.24540. Epub 2015 Jun 19.

PMID- 25424323
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20181113
IS  - 1750-1172 (Electronic)
IS  - 1750-1172 (Linking)
VI  - 9
DP  - 2014 Nov 26
TI  - Comparisons of intellectual capacities between mild and classic adult-onset 
      phenotypes of myotonic dystrophy type 1 (DM1).
PG  - 186
LID - 10.1186/s13023-014-0186-5 [doi]
LID - 186
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is an autosomal dominant genetic 
      multisystem disorder and the commonest adult-onset form of muscular dystrophy. 
      DM1 results from the expansion of an unstable trinucleotide 
      cytosine-thymine-guanine (CTG) repeat mutation. CTG repeats in DM1 patients can 
      range from 50 to several thousands, with a tendency toward increased repeats with 
      successive generations (anticipation). Associated findings can include 
      involvements in almost every systems, including the brain, and cognitive 
      abnormalities occur in the large majority of patients. The objectives are to 
      describe and compare the intellectual abilities of a large sample of DM1 patients 
      with mild and classic adult-onset phenotypes, to estimate the validity of the 
      Wechsler Adult Intelligence Scale-Revised (WAIS-R) in DM1 patients with muscular 
      weakness, and to appraise the relationship of intelligence quotient (IQ) to CTG 
      repeat length, age at onset of symptoms, and disease duration. METHODS: A 
      seven-subtest WAIS-R was administered to 37 mild and 151 classic adult-onset DM1 
      patients to measure their Full-Scale (FSIQ), Verbal (VIQ) and Performance IQ 
      (PIQ). To control for potential bias due to muscular weakness, Standard 
      Progressive Matrices (SPM), a motor-independent test of intelligence, were also 
      completed. RESULTS: Total mean FSIQ was 82.6 corresponding to low average IQ, and 
      82% were below an average intelligence. Mild DM1 patients had a higher mean FSIQ 
      (U=88.7 vs 81.1, p<0.001), VIQ (U=87.8 vs 82.3, p=0.001), and PIQ (U=94.8 vs 
      83.6, p<0.001) than classic adult-onset DM1 patients. In both mild and classic 
      adult-onset patients, all subtests mean scaled scores were below the normative 
      sample mean. FSIQ also strongly correlate with SPM (r s =0.67, p<0.001), 
      indicating that low intelligence scores are not a consequence of motor 
      impairment. FSIQ scores decreased with both the increase of (CTG)n (r s =-0.41, 
      p<0.001) and disease duration (r s =-0.26, p=0.003). CONCLUSIONS: Results show 
      that intellectual impairment is an extremely common and important feature in DM1, 
      not only among the classic adult-onset patients but also among the least severe 
      forms of DM1, with low IQ scores compared to general reference population. Health 
      care providers involved in the follow-up of these patients should be aware of 
      their intellectual capacities and should adapt their interventions accordingly.
FAU - Jean, Stephane
AU  - Jean S
AD  - Clinique des maladies neuromusculaires, Centre de readaptation en deficience 
      physique Le Parcours, Centre de sante et de services sociaux de Jonquiere, 2230, 
      rue de l'Hopital, C.P. 1200, Jonquiere, Quebec, G7X 7X2, Canada. 
      stephane.jean.csssc@ssss.gouv.qc.ca.
FAU - Richer, Louis
AU  - Richer L
AD  - Departement des sciences de la sante, Universite du Quebec a Chicoutimi, 555, 
      boul. de l'Universite, Chicoutimi, Quebec, G7H 2B1, Canada. louis_richer@uqac.ca.
FAU - Laberge, Luc
AU  - Laberge L
AD  - Departement des sciences de la sante, Universite du Quebec a Chicoutimi, 555, 
      boul. de l'Universite, Chicoutimi, Quebec, G7H 2B1, Canada. luc_laberge@uqac.ca.
AD  - ECOBES - Recherche et transfert, Cegep de Jonquiere, Quebec, Canada. 
      luc_laberge@uqac.ca.
AD  - Faculte de medecine et des sciences de la sante, Universite de Sherbrooke, 
      Quebec, Canada. luc_laberge@uqac.ca.
FAU - Mathieu, Jean
AU  - Mathieu J
AD  - Clinique des maladies neuromusculaires, Centre de readaptation en deficience 
      physique Le Parcours, Centre de sante et de services sociaux de Jonquiere, 2230, 
      rue de l'Hopital, C.P. 1200, Jonquiere, Quebec, G7X 7X2, Canada. 
      j.mathieu@usherbrooke.ca.
AD  - Faculte de medecine et des sciences de la sante, Universite de Sherbrooke, 
      Quebec, Canada. j.mathieu@usherbrooke.ca.
LA  - eng
GR  - CAR43283/Canadian Institutes of Health Research/Canada
GR  - MOP49556/Canadian Institutes of Health Research/Canada
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141126
PL  - England
TA  - Orphanet J Rare Dis
JT  - Orphanet journal of rare diseases
JID - 101266602
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Intellectual Disability/*diagnosis/epidemiology/*psychology
MH  - *Intelligence
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/epidemiology/*psychology
MH  - *Phenotype
MH  - Wechsler Scales/standards
MH  - Young Adult
PMC - PMC4247010
EDAT- 2014/11/27 06:00
MHDA- 2015/10/31 06:00
PMCR- 2014/11/26
CRDT- 2014/11/27 06:00
PHST- 2014/10/06 00:00 [received]
PHST- 2014/11/07 00:00 [accepted]
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
PHST- 2014/11/26 00:00 [pmc-release]
AID - s13023-014-0186-5 [pii]
AID - 186 [pii]
AID - 10.1186/s13023-014-0186-5 [doi]
PST - epublish
SO  - Orphanet J Rare Dis. 2014 Nov 26;9:186. doi: 10.1186/s13023-014-0186-5.

PMID- 25385052
OWN - NLM
STAT- MEDLINE
DCOM- 20151202
LR  - 20181113
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 262
IP  - 2
DP  - 2015 Feb
TI  - Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by 
      transcranial sonography.
PG  - 365-74
LID - 10.1007/s00415-014-7566-6 [doi]
AB  - Myotonic dystrophies (DMs) are clinically similar but distinct multisystemic 
      diseases related to different repeat expansion mutations. CNS involvement is one 
      important aspect of both, myotonic dystrophy type 1 and type 2 (DM1, DM2). 
      Transcran ial sonography (TCS) has become a reliable diagnostic tool in the 
      evaluation of several CNS disorders. The aim of this study was to evaluate 
      TCS-findings in DM-patients in correlation with their clinical status. Thirty-one 
      DM-patients (DM1 = 17; DM2 = 14) were examined clinically and sonographically by 
      independent physicians. Echogenicities of basal ganglia and mesencephalic regions 
      were assessed according to the examination protocol for extrapyramidal disorders 
      using a Toshiba Aplio((R)) XG ultrasound system. TCS abnormalities were correlated 
      to clinical findings and secondly compared to 31 controls. Ventricle diameters 
      were additionally compared to 3T-MRI volumetry. Nine patients (29 %) showed 
      hyperechogenicity of substantia nigra. Mesencephalic raphe was hypoechogenic in 
      nine (29 %) DM-patients and was more frequently in DM1 patients (p = 0.021). 
      Width of third ventricle was significantly larger in the patient group (p = 
      0.021) and correlated with MRI-based volumetry (R (2) = 0.756). Pathological 
      raphe signal was observed mainly in patients suffering from daytime sleepiness 
      (sensitivity = 42.1 %, specificity = 88.9 %, p = 0,044), while alterations did 
      not correlate with symptoms of depression. As a novel finding, a relation between 
      mesencephalic raphe echogenicity and excessive daytime sleepiness could be 
      identified in our DM-patients. An alteration of serotonergic raphe structures 
      might be involved in the pathogenesis of hypersomnia in DM. TCS allows for 
      measurement of third ventricle enlargement as a feasible bedside test.
FAU - Krogias, Christos
AU  - Krogias C
AD  - Department of Neurology, Ruhr University Bochum St. Josef-Hospital, Gudrunstr. 
      56, 44791, Bochum, Germany, christos.krogias@rub.de.
FAU - Bellenberg, Barbara
AU  - Bellenberg B
FAU - Prehn, Christian
AU  - Prehn C
FAU - Schneider, Ruth
AU  - Schneider R
FAU - Meves, Saskia H
AU  - Meves SH
FAU - Gold, Ralf
AU  - Gold R
FAU - Lukas, Carsten
AU  - Lukas C
FAU - Schneider-Gold, Christiane
AU  - Schneider-Gold C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141111
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - Adult
MH  - Brain/*pathology
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnostic imaging/*pathology
MH  - Neuropsychological Tests
MH  - Ultrasonography, Doppler, Transcranial/*methods
MH  - Young Adult
EDAT- 2014/11/12 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/11/12 06:00
PHST- 2014/07/30 00:00 [received]
PHST- 2014/10/28 00:00 [accepted]
PHST- 2014/10/16 00:00 [revised]
PHST- 2014/11/12 06:00 [entrez]
PHST- 2014/11/12 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1007/s00415-014-7566-6 [doi]
PST - ppublish
SO  - J Neurol. 2015 Feb;262(2):365-74. doi: 10.1007/s00415-014-7566-6. Epub 2014 Nov 
      11.

PMID- 25328514
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141020
LR  - 20231110
IS  - 1687-6105 (Print)
IS  - 1687-6113 (Electronic)
IS  - 1687-6113 (Linking)
VI  - 2014
DP  - 2014
TI  - IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus 
      Erythematosus.
PG  - 953597
LID - 10.1155/2014/953597 [doi]
LID - 953597
AB  - Polymorphisms in the cytokine genes and their natural antagonists are thought to 
      influence the predisposition to dermatomyositis (DM) and systemic lupus 
      erythematosus (SLE). A variable number tandem repeat (VNTR) polymorphism of 86 bp 
      in intron 2 of the interleukin-1 receptor antagonist (IL-1RN) gene leads to the 
      existence of five different alleles which cause differences in the production of 
      both IL-1RA (interleukin-1 receptor antagonist) and IL-1beta. The aim of this 
      case-control study was to investigate the association between the IL-1RN VNTR 
      polymorphism and the susceptibility to DM and SLE in Bulgarian patients. 
      Altogether 91 patients, 55 with SLE and 36 with DM, as well as 112 unrelated 
      healthy controls, were included in this study. Only three alleles were identified 
      in both patients and controls ((1) four repeats, (2) two repeats, and (3) five 
      repeats). The IL-1RN*2 allele (P = 0.02, OR 2.5, and 95% CI 1.2-5.4) and the 
      1/2+2/2 genotypes were found prevalent among the SLE patients (P = 0.05, OR 2.6, 
      and 95% CI 1-6.3). No association was found between this polymorphism and the ACR 
      criteria for SLE as well as with the susceptibility to DM. Our results indicate 
      that the IL-1RN VNTR polymorphism might play a role in the susceptibility of SLE 
      but not DM.
FAU - Kamenarska, Zornitsa
AU  - Kamenarska Z
AUID- ORCID: 0000-0003-0401-4189
AD  - Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, 
      Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria.
FAU - Dzhebir, Gyulnas
AU  - Dzhebir G
AUID- ORCID: 0000-0002-3209-4545
AD  - Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, 
      Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria.
FAU - Hristova, Maria
AU  - Hristova M
AUID- ORCID: 0000-0002-4526-147X
AD  - Department of Clinical Laboratory and Clinical Immunology and Department of 
      Nephrology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, 
      Bulgaria.
FAU - Savov, Alexey
AU  - Savov A
AD  - National Genetic Laboratory, Maichin Dom Hospital, 2 Zdrave Street, 1431 Sofia, 
      Bulgaria.
FAU - Vinkov, Anton
AU  - Vinkov A
AUID- ORCID: 0000-0002-8923-3892
AD  - 28 Diagnostic and Consultative Center-Sofia, 1 Iliya Beshkov Street, 1592 Sofia, 
      Bulgaria.
FAU - Kaneva, Radka
AU  - Kaneva R
AD  - Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, 
      Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria.
FAU - Mitev, Vanio
AU  - Mitev V
AD  - Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, 
      Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria.
FAU - Dourmishev, Lyubomir
AU  - Dourmishev L
AUID- ORCID: 0000-0001-8458-1241
AD  - Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi 
      Sofijski Street, 1431 Sofia, Bulgaria.
LA  - eng
PT  - Journal Article
DEP - 20140819
PL  - Egypt
TA  - Dermatol Res Pract
JT  - Dermatology research and practice
JID - 101312803
PMC - PMC4156996
EDAT- 2014/10/21 06:00
MHDA- 2014/10/21 06:01
PMCR- 2014/08/19
CRDT- 2014/10/21 06:00
PHST- 2014/06/14 00:00 [received]
PHST- 2014/08/07 00:00 [accepted]
PHST- 2014/10/21 06:00 [entrez]
PHST- 2014/10/21 06:00 [pubmed]
PHST- 2014/10/21 06:01 [medline]
PHST- 2014/08/19 00:00 [pmc-release]
AID - 10.1155/2014/953597 [doi]
PST - ppublish
SO  - Dermatol Res Pract. 2014;2014:953597. doi: 10.1155/2014/953597. Epub 2014 Aug 19.

PMID- 25307018
OWN - NLM
STAT- MEDLINE
DCOM- 20160225
LR  - 20211021
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 42
IP  - 2
DP  - 2015 Feb
TI  - Altered nuclear structure in myotonic dystrophy type 1-derived fibroblasts.
PG  - 479-88
LID - 10.1007/s11033-014-3791-4 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystem genetic disorder caused by a 
      triplet nucleotide repeat expansion in the 3' untranslated region of the 
      Dystrophia Myotonica-Protein Kinase (DMPK) gene. DMPK gene transcripts containing 
      CUG expanded repeats accumulate in nuclear foci and ultimately cause altered 
      splicing/gene expression of numerous secondary genes. The study of primary cell 
      cultures derived from patients with DM1 has allowed the identification and 
      further characterization of molecular mechanisms underlying the pathology in the 
      natural context of the disease. In this study we show for the first time impaired 
      nuclear structure in fibroblasts of DM1 patients. DM1-derived fibroblasts 
      exhibited altered localization of the nuclear envelope (NE) proteins emerin and 
      lamins A/C and B1 with concomitant increased size and altered shape of nuclei. 
      Abnormal NE organization is more common in DM1 fibroblasts containing abundant 
      nuclear foci, implying expression of the expanded RNA as determinant of nuclear 
      defects. That transient expression of the DMPK 3' UTR containing 960 CTG but not 
      with the 3' UTR lacking CTG repeats is sufficient to generate NE disruption in 
      normal fibroblasts confirms the direct impact of mutant RNA on NE architecture. 
      We also evidence nucleoli distortion in DM1 fibroblasts by immunostaining of the 
      nucleolar protein fibrillarin, implying a broader effect of the mutant RNA on 
      nuclear structure. In summary, these findings reveal that NE disruption, a 
      hallmark of laminopathy disorders, is a novel characteristic of DM1.
FAU - Rodriguez, R
AU  - Rodriguez R
AD  - Departamento de Genetica y Biologia Molecular, Centro de Investigacion y de 
      Estudios Avanzados del IPN (CINVESTAV-IPN), Av. IPN 2508 Col Zacatenco, 07360, 
      Mexico, D.F, Mexico.
FAU - Hernandez-Hernandez, O
AU  - Hernandez-Hernandez O
FAU - Magana, J J
AU  - Magana JJ
FAU - Gonzalez-Ramirez, R
AU  - Gonzalez-Ramirez R
FAU - Garcia-Lopez, E S
AU  - Garcia-Lopez ES
FAU - Cisneros, B
AU  - Cisneros B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141012
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
SB  - IM
MH  - Cell Nucleolus/pathology
MH  - Cell Nucleus/*pathology
MH  - Cells, Cultured
MH  - Fibroblasts/*metabolism/*pathology
MH  - Humans
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Trinucleotide Repeat Expansion
EDAT- 2014/10/14 06:00
MHDA- 2016/02/26 06:00
CRDT- 2014/10/14 06:00
PHST- 2014/04/09 00:00 [received]
PHST- 2014/10/03 00:00 [accepted]
PHST- 2014/10/14 06:00 [entrez]
PHST- 2014/10/14 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - 10.1007/s11033-014-3791-4 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2015 Feb;42(2):479-88. doi: 10.1007/s11033-014-3791-4. Epub 2014 
      Oct 12.

PMID- 25303993
OWN - NLM
STAT- MEDLINE
DCOM- 20150331
LR  - 20211021
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 42
IP  - 20
DP  - 2014 Nov 10
TI  - Modifications to toxic CUG RNAs induce structural stability, rescue mis-splicing 
      in a myotonic dystrophy cell model and reduce toxicity in a myotonic dystrophy 
      zebrafish model.
PG  - 12768-78
LID - 10.1093/nar/gku941 [doi]
AB  - CUG repeat expansions in the 3' UTR of dystrophia myotonica protein kinase (DMPK) 
      cause myotonic dystrophy type 1 (DM1). As RNA, these repeats elicit toxicity by 
      sequestering splicing proteins, such as MBNL1, into protein-RNA aggregates. 
      Structural studies demonstrate that CUG repeats can form A-form helices, 
      suggesting that repeat secondary structure could be important in pathogenicity. 
      To evaluate this hypothesis, we utilized structure-stabilizing RNA modifications 
      pseudouridine (Psi) and 2'-O-methylation to determine if stabilization of CUG 
      helical conformations affected toxicity. CUG repeats modified with Psi or 
      2'-O-methyl groups exhibited enhanced structural stability and reduced affinity 
      for MBNL1. Molecular dynamics and X-ray crystallography suggest a potential 
      water-bridging mechanism for Psi-mediated CUG repeat stabilization. Psi modification 
      of CUG repeats rescued mis-splicing in a DM1 cell model and prevented CUG repeat 
      toxicity in zebrafish embryos. This study indicates that the structure of toxic 
      RNAs has a significant role in controlling the onset of neuromuscular diseases.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic 
      Acids Research.
FAU - deLorimier, Elaine
AU  - deLorimier E
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Coonrod, Leslie A
AU  - Coonrod LA
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Copperman, Jeremy
AU  - Copperman J
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Taber, Alex
AU  - Taber A
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Reister, Emily E
AU  - Reister EE
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Sharma, Kush
AU  - Sharma K
AD  - Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Todd, Peter K
AU  - Todd PK
AD  - Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Guenza, Marina G
AU  - Guenza MG
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA.
FAU - Berglund, J Andrew
AU  - Berglund JA
AD  - Department of Chemistry and Biochemistry, Institute of Molecular Biology, 
      University of Oregon, Eugene, Oregon, USA aberglund@molbio.uoregon.edu.
LA  - eng
GR  - R01 NS086810/NS/NINDS NIH HHS/United States
GR  - R01 AR059833/AR/NIAMS NIH HHS/United States
GR  - AR059833/AR/NIAMS NIH HHS/United States
GR  - 1K08NS069809/NS/NINDS NIH HHS/United States
GR  - I21 BX001841/BX/BLRD VA/United States
GR  - K08 NS069809/NS/NINDS NIH HHS/United States
GR  - T32 GM007759/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20141010
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (RNA-Binding Proteins)
RN  - 059QF0KO0R (Water)
RN  - 1445-07-4 (Pseudouridine)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - *Alternative Splicing
MH  - Animals
MH  - Base Pair Mismatch
MH  - Disease Models, Animal
MH  - HeLa Cells
MH  - Humans
MH  - Methylation
MH  - Myotonic Dystrophy/*genetics
MH  - Nucleic Acid Conformation
MH  - Pseudouridine/chemistry
MH  - RNA/*chemistry
MH  - RNA-Binding Proteins/metabolism
MH  - Repetitive Sequences, Nucleic Acid
MH  - Water/chemistry
MH  - Zebrafish/genetics
PMC - PMC4227782
EDAT- 2014/10/12 06:00
MHDA- 2015/04/01 06:00
PMCR- 2014/10/10
CRDT- 2014/10/12 06:00
PHST- 2014/10/12 06:00 [entrez]
PHST- 2014/10/12 06:00 [pubmed]
PHST- 2015/04/01 06:00 [medline]
PHST- 2014/10/10 00:00 [pmc-release]
AID - gku941 [pii]
AID - 10.1093/nar/gku941 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2014 Nov 10;42(20):12768-78. doi: 10.1093/nar/gku941. Epub 
      2014 Oct 10.

PMID- 25168381
OWN - NLM
STAT- MEDLINE
DCOM- 20150824
LR  - 20211021
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 24
IP  - 1
DP  - 2015 Jan 1
TI  - NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity.
PG  - 251-64
LID - 10.1093/hmg/ddu443 [doi]
AB  - RNA toxicity is implicated in a number of disorders; especially those associated 
      with expanded repeat sequences, such as myotonic dystrophy (DM1). Previously, we 
      have shown increased NKX2-5 expression in RNA toxicity associated with DM1. Here, 
      we investigate the relationship between NKX2-5 expression and muscle pathology 
      due to RNA toxicity. In skeletal muscle from mice with RNA toxicity and 
      individuals with DM1, expression of Nkx2-5 or NKX2-5 and its downstream targets 
      are significantly correlated with severity of histopathology. Using C2C12 
      myoblasts, we show that over-expression of NKX2-5 or mutant DMPK 3'UTR results in 
      myogenic differentiation defects, which can be rescued by knockdown of Nkx2-5, 
      despite continued toxic RNA expression. Furthermore, in a mouse model of NKX2-5 
      over-expression, we find defects in muscle regeneration after induced damage, 
      similar to those seen in mice with RNA toxicity. Using mouse models of Nkx2-5 
      over-expression and depletion, we find that NKX2-5 levels modify disease 
      phenotypes in mice with RNA toxicity.
CI  - (c) The Author 2014. Published by Oxford University Press. All rights reserved. For 
      Permissions, please email: journals.permissions@oup.com.
FAU - Gladman, Jordan T
AU  - Gladman JT
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Yadava, Ramesh S
AU  - Yadava RS
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Mandal, Mahua
AU  - Mandal M
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Yu, Qing
AU  - Yu Q
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Kim, Yun K
AU  - Kim YK
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Mahadevan, Mani S
AU  - Mahadevan MS
AD  - Department of Pathology, University of Virginia, Charlottesville, VA 22908, USA 
      mahadevan@virginia.edu.
LA  - eng
GR  - R01 AR045992/AR/NIAMS NIH HHS/United States
GR  - R01 AR052771/AR/NIAMS NIH HHS/United States
GR  - 5R01AR045992/AR/NIAMS NIH HHS/United States
GR  - 1R01AR062189/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140828
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Homeobox Protein Nkx-2.5)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (NKX2-5 protein, human)
RN  - 0 (Nkx2-5 protein, mouse)
RN  - 0 (Transcription Factors)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - Cell Line
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Gene Knockout Techniques
MH  - Genes, Modifier
MH  - Homeobox Protein Nkx-2.5
MH  - Homeodomain Proteins/*genetics/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/*pathology
MH  - Muscular Dystrophies/*genetics/metabolism/pathology
MH  - Myotonin-Protein Kinase/genetics
MH  - RNA/*toxicity
MH  - Transcription Factors/*genetics/metabolism
PMC - PMC4262498
EDAT- 2014/08/30 06:00
MHDA- 2015/08/25 06:00
PMCR- 2016/01/01
CRDT- 2014/08/30 06:00
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/08/25 06:00 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - ddu443 [pii]
AID - 10.1093/hmg/ddu443 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2015 Jan 1;24(1):251-64. doi: 10.1093/hmg/ddu443. Epub 2014 Aug 
      28.

PMID- 25157497
OWN - NLM
STAT- MEDLINE
DCOM- 20150513
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 8
DP  - 2014
TI  - Oral administration of recombinant Lactococcus lactis expressing HSP65 and 
      tandemly repeated P277 reduces the incidence of type I diabetes in non-obese 
      diabetic mice.
PG  - e105701
LID - 10.1371/journal.pone.0105701 [doi]
LID - e105701
AB  - Diabetes mellitus type 1 (DM1) is an autoimmune disease that gradually destroys 
      insulin-producing beta-cells. We have previously reported that mucosal 
      administration of fusion protein of HSP65 with tandem repeats of P277 
      (HSP65-6P277) can reduce the onset of DM1 in non-obese diabetic (NOD) mice. To 
      deliver large amounts of the fusion protein and to enhance long-term immune 
      tolerance effects, in the present study, we investigated the efficacy of using 
      orally administrated L. lactis expressing HSP65-6P277 to reduce the incidence of 
      DM1 in NOD mice. L. lactis strain NZ9000 was engineered to express HSP65-6P277 
      either constitutively or by nisin induction. After immunization via gavage with 
      the recombinant L. lactis strains to groups of 4-week old female NOD mice for 36 
      weeks, we observed that oral administration of recombinant L. Lactis resulted in 
      the prevention of hyperglycemia, improved glucose tolerance and reduced 
      insulitis. Immunologic analysis showed that treatment with recombinant L. lactis 
      induced HSP65- and P277- specific T cell immuno-tolerance, as well as 
      antigen-specific proliferation of splenocytes. The results revealed that the 
      DM1-preventing function was in part caused by a reduction in the pro-inflammatory 
      cytokine IFN-gamma and an increase in the anti-inflammatory cytokine IL-10. Orally 
      administered recombinant L. lactis delivering HSP65-6P277 may be an effective 
      therapeutic approach in preventing DM1.
FAU - Ma, Yanjun
AU  - Ma Y
AD  - Forensic Center, Nanjing Forest Police College, Nanjing, People's Republic of 
      China; Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Liu, Jingjing
AU  - Liu J
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Hou, Jing
AU  - Hou J
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Dong, Yuankai
AU  - Dong Y
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Lu, Yong
AU  - Lu Y
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Jin, Liang
AU  - Jin L
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Cao, Rongyue
AU  - Cao R
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Li, Taiming
AU  - Li T
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
FAU - Wu, Jie
AU  - Wu J
AD  - Minigene Pharmacy Laboratory, School of life Science and Technology, China 
      Pharmaceutical University, Nanjing, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140826
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Chaperonin 60)
RN  - 0 (Cytokines)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (peptide 277, heat shock protein 60)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Chaperonin 60/genetics/*therapeutic use
MH  - Cytokines/immunology
MH  - Diabetes Mellitus, Type 1/epidemiology/immunology/*prevention & control
MH  - Female
MH  - Heat-Shock Proteins/genetics/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Lactococcus lactis/*genetics
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Peptide Fragments/genetics/*therapeutic use
MH  - Recombinant Fusion Proteins/genetics/*therapeutic use
MH  - T-Lymphocytes/cytology/immunology
PMC - PMC4144892
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/08/27 06:00
MHDA- 2015/05/15 06:00
PMCR- 2014/08/26
CRDT- 2014/08/27 06:00
PHST- 2014/04/25 00:00 [received]
PHST- 2014/07/22 00:00 [accepted]
PHST- 2014/08/27 06:00 [entrez]
PHST- 2014/08/27 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
PHST- 2014/08/26 00:00 [pmc-release]
AID - PONE-D-14-18033 [pii]
AID - 10.1371/journal.pone.0105701 [doi]
PST - epublish
SO  - PLoS One. 2014 Aug 26;9(8):e105701. doi: 10.1371/journal.pone.0105701. 
      eCollection 2014.

PMID- 24878509
OWN - NLM
STAT- MEDLINE
DCOM- 20150312
LR  - 20140714
IS  - 1095-953X (Electronic)
IS  - 0969-9961 (Linking)
VI  - 69
DP  - 2014 Sep
TI  - LDB3 splicing abnormalities are specific to skeletal muscles of patients with 
      myotonic dystrophy type 1 and alter its PKC binding affinity.
PG  - 200-5
LID - S0969-9961(14)00144-2 [pii]
LID - 10.1016/j.nbd.2014.05.026 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by transcription of CUG repeat RNA, 
      which causes sequestration of muscleblind-like 1 (MBNL1) and upregulation of CUG 
      triplet repeat RNA-binding protein (CUG-BP1). In DM1, dysregulation of these 
      proteins contributes to many aberrant splicing events, causing various symptoms 
      of the disorder. Here, we demonstrate the occurrence of aberrant splicing of LIM 
      domain binding 3 (LDB3) exon 11 in DM1 skeletal muscle. Exon array surveys, 
      RT-PCR, and western blotting studies demonstrated that exon 11 inclusion was DM1 
      specific and could be reproduced by transfection of a minigene containing the CTG 
      repeat expansion. Moreover, we found that the LDB3 exon 11-positive isoform had 
      reduced affinity for PKC compared to the exon 11-negative isoform. Since PKC 
      exhibits hyperactivation in DM1 and stabilizes CUG-BP1 by phosphorylation, 
      aberrant splicing of LDB3 may contribute to CUG-BP1 upregulation through changes 
      in its affinity for PKC.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Yamashita, Yoshihiro
AU  - Yamashita Y
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan.
FAU - Matsuura, Tohru
AU  - Matsuura T
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan; Division of Neurology, 
      Department of Medicine, Jichi Medical University, Shomotsuke, Japan. Electronic 
      address: tohrum@jichi.ac.jp.
FAU - Kurosaki, Tatsuaki
AU  - Kurosaki T
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan.
FAU - Amakusa, Yoshinobu
AU  - Amakusa Y
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan.
FAU - Kinoshita, Masanobu
AU  - Kinoshita M
AD  - Department of Frontier Health Sciences, Graduate School of Human Health Sciences, 
      Tokyo Metropolitan University, Tokyo, Japan.
FAU - Ibi, Tohru
AU  - Ibi T
AD  - Department of Neurology, Aichi Medical University School of Medicine, Aichi, 
      Japan.
FAU - Sahashi, Ko
AU  - Sahashi K
AD  - Department of Neurology, Aichi Medical University School of Medicine, Aichi, 
      Japan.
FAU - Ohno, Kinji
AU  - Ohno K
AD  - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya 
      University Graduate School of Medicine, Nagoya, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140527
PL  - United States
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Isoenzymes)
RN  - 0 (LDB3 protein, human)
RN  - 0 (LIM Domain Proteins)
RN  - 0 (Protein Isoforms)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*genetics/*metabolism
MH  - Adult
MH  - Aged
MH  - Child
MH  - Cohort Studies
MH  - Exons
MH  - Female
MH  - Humans
MH  - Infant
MH  - Isoenzymes
MH  - LIM Domain Proteins/*genetics/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*metabolism
MH  - Muscular Diseases/genetics/metabolism
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - Protein Isoforms
MH  - Protein Kinase C/*metabolism
MH  - RNA Splicing
MH  - Transfection
MH  - Trinucleotide Repeat Expansion
MH  - Young Adult
OTO - NOTNLM
OT  - CUG triplet repeat RNA-binding protein
OT  - LIM domain binding 3
OT  - Muscleblind-like 1
OT  - Myotonic dystrophy type 1
OT  - Protein kinase C
EDAT- 2014/06/01 06:00
MHDA- 2015/03/13 06:00
CRDT- 2014/06/01 06:00
PHST- 2014/01/24 00:00 [received]
PHST- 2014/05/06 00:00 [revised]
PHST- 2014/05/19 00:00 [accepted]
PHST- 2014/06/01 06:00 [entrez]
PHST- 2014/06/01 06:00 [pubmed]
PHST- 2015/03/13 06:00 [medline]
AID - S0969-9961(14)00144-2 [pii]
AID - 10.1016/j.nbd.2014.05.026 [doi]
PST - ppublish
SO  - Neurobiol Dis. 2014 Sep;69:200-5. doi: 10.1016/j.nbd.2014.05.026. Epub 2014 May 
      27.

PMID- 24838088
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20151113
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 21
IP  - 9
DP  - 2014 Sep
TI  - Risk of cancer in relatives of patients with myotonic dystrophy: a 
      population-based cohort study.
PG  - 1192-7
LID - 10.1111/ene.12466 [doi]
AB  - BACKGROUND AND PURPOSE: Myotonic dystrophies (DM) are autosomal dominantly 
      inherited neuromuscular disorders caused by unstable nucleotide repeat 
      expansions. DM and cancer have been associated, but the pathogenesis behind the 
      association remains unclear. It could relate to derived effects of the DM 
      genotype in which case non-DM relatives of DM patients would not be expected to 
      be at increased risk of cancer. To elucidate this, a population-based cohort 
      study investigating risk of cancer in relatives of DM patients was conducted. 
      METHODS: DM was identified using the National Danish Patient Registry and results 
      of genetic testing. Information on cancer was obtained from the Danish Cancer 
      Registry. A population-based cohort of 5 757 565 individuals with at least one 
      relative was established using the Danish Family Relations Database based on 
      kinship links in the Danish Civil Registration System. Familial aggregation of 
      cancer was evaluated by (incidence) rate ratios (RRs) comparing the rate of 
      cancer amongst relatives of patients with DM from 1977 to 2010 (exposed) with the 
      rate of cancer amongst persons with a relative of the same type but without DM 
      (non-exposed). RESULTS: In first-degree relatives of individuals with DM the 
      adjusted RR of cancer was 0.89 (95% confidence interval 0.71-1.12) overall, and 
      in stratified analyses 0.68 (0.37-1.12) before age 50 and 0.96 (0.74-1.23) at age 
      50 or older. CONCLUSIONS: The present study does not support an increased risk of 
      cancer in non-DM relatives of DM patients suggesting that cancer and DM are 
      associated through derived effects of the DM genotype.
CI  - (c) 2014 The Author(s) European Journal of Neurology (c) 2014 EAN.
FAU - Lund, M
AU  - Lund M
AD  - Department of Epidemiology Research, National Health Surveillance and Research, 
      Statens Serum Institut, Copenhagen, Denmark.
FAU - Diaz, L J
AU  - Diaz LJ
FAU - Gortz, S
AU  - Gortz S
FAU - Feenstra, B
AU  - Feenstra B
FAU - Duno, M
AU  - Duno M
FAU - Juncker, I
AU  - Juncker I
FAU - Eiberg, H
AU  - Eiberg H
FAU - Vissing, J
AU  - Vissing J
FAU - Wohlfahrt, J
AU  - Wohlfahrt J
FAU - Melbye, M
AU  - Melbye M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140517
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Cohort Studies
MH  - Community Health Planning
MH  - Databases, Factual
MH  - Denmark/epidemiology
MH  - *Family
MH  - Family Health
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology
MH  - Neoplasms/*epidemiology
MH  - Risk Factors
OTO - NOTNLM
OT  - cancer
OT  - epidemiology
OT  - family cancer risk
OT  - myotonic dystrophy
EDAT- 2014/05/20 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/05/20 06:00
PHST- 2013/12/11 00:00 [received]
PHST- 2014/04/07 00:00 [accepted]
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - 10.1111/ene.12466 [doi]
PST - ppublish
SO  - Eur J Neurol. 2014 Sep;21(9):1192-7. doi: 10.1111/ene.12466. Epub 2014 May 17.

PMID- 24824895
OWN - NLM
STAT- MEDLINE
DCOM- 20150723
LR  - 20220309
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Print)
IS  - 1547-6286 (Linking)
VI  - 11
IP  - 6
DP  - 2014
TI  - Small molecule kinase inhibitors alleviate different molecular features of 
      myotonic dystrophy type 1.
PG  - 742-54
LID - 28799 [pii]
AB  - Expandable (CTG)n repeats in the 3' UTR of the DMPK gene are a cause of myotonic 
      dystrophy type 1 (DM1), which leads to a toxic RNA gain-of-function disease. 
      Mutant RNAs with expanded CUG repeats are retained in the nucleus and aggregate 
      in discrete inclusions. These foci sequester splicing factors of the MBNL family 
      and trigger upregulation of the CUGBP family of proteins resulting in the 
      mis-splicing of their target transcripts. To date, many efforts to develop novel 
      therapeutic strategies have been focused on disrupting the toxic nuclear foci and 
      correcting aberrant alternative splicing via targeting mutant CUG repeats RNA; 
      however, no effective treatment for DM1 is currently available. Herein, we 
      present results of culturing of human DM1 myoblasts and fibroblasts with two 
      small-molecule ATP-binding site-specific kinase inhibitors, C16 and C51, which 
      resulted in the alleviation of the dominant-negative effects of CUG repeat 
      expansion. Reversal of the DM1 molecular phenotype includes a reduction of the 
      size and number of foci containing expanded CUG repeat transcripts, decreased 
      steady-state levels of CUGBP1 protein, and consequent improvement of the aberrant 
      alternative splicing of several pre-mRNAs misregulated in DM1.
FAU - Wojciechowska, Marzena
AU  - Wojciechowska M
AD  - Department of Molecular Biomedicine; Institute of Bioorganic Chemistry; Polish 
      Academy of Sciences; Noskowskiego; Poznan, Poland.
FAU - Taylor, Katarzyna
AU  - Taylor K
AD  - Department of Gene Expression; Institute of Molecular Biology and Biotechnology; 
      Adam Mickiewicz University; Umultowska 89; Poznan, Poland.
FAU - Sobczak, Krzysztof
AU  - Sobczak K
AD  - Department of Gene Expression; Institute of Molecular Biology and Biotechnology; 
      Adam Mickiewicz University; Umultowska 89; Poznan, Poland.
FAU - Napierala, Marek
AU  - Napierala M
AD  - Department of Biochemistry and Molecular Genetics and UAB Stem Cell Institute; 
      University of Alabama at Birmingham; Birmingham, AL USA.
FAU - Krzyzosiak, Wlodzimierz J
AU  - Krzyzosiak WJ
AD  - Department of Molecular Biomedicine; Institute of Bioorganic Chemistry; Polish 
      Academy of Sciences; Noskowskiego; Poznan, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140424
PL  - United States
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.- (Phosphotransferases)
SB  - IM
MH  - Alternative Splicing
MH  - CELF1 Protein
MH  - Cells, Cultured
MH  - Enzyme Inhibitors/chemistry/*pharmacology
MH  - Fibroblasts/drug effects/metabolism
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Myoblasts/drug effects/metabolism
MH  - Myotonic Dystrophy/drug therapy/enzymology/*genetics
MH  - Phosphotransferases/*antagonists & inhibitors
MH  - Protein Binding/drug effects
MH  - Protein Transport/drug effects
MH  - RNA Precursors
MH  - RNA Splicing
MH  - RNA, Messenger
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Transcription, Genetic
PMC - PMC4156505
OTO - NOTNLM
OT  - CUG Foci
OT  - CUGBP1 protein
OT  - MBNL1 protein
OT  - RNA splicing
OT  - RNA-binding proteins
OT  - myotonic dystrophy
OT  - protein kinases
OT  - protein phosphorylation
EDAT- 2014/05/16 06:00
MHDA- 2015/07/24 06:00
PMCR- 2015/06/01
CRDT- 2014/05/15 06:00
PHST- 2014/05/15 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2015/07/24 06:00 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - 28799 [pii]
AID - 2013RNABIOL0298R1 [pii]
AID - 10.4161/rna.28799 [doi]
PST - ppublish
SO  - RNA Biol. 2014;11(6):742-54. doi: 10.4161/rna.28799. Epub 2014 Apr 24.

PMID- 24795756
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140505
LR  - 20211021
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 5
DP  - 2014
TI  - Detection of large expansions in myotonic dystrophy type 1 using triplet primed 
      PCR.
PG  - 94
LID - 10.3389/fgene.2014.00094 [doi]
LID - 94
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disease 
      caused by expansion of a CTG trinucleotide repeat in the DMPK gene. Methodology 
      for genetic testing of DM1 is currently not optimal, in particular for the 
      early-onset patients in pediatric populations where large expanded (CTG)n alleles 
      are usually common. Individuals who are homozygous for a normal allele and 
      individuals who are heterozygous for one normal and one large expanded allele are 
      indistinguishable by conventional PCR, as both generate a single product of the 
      normal allele. Thus, reflex Southern blot has often been needed to distinguish 
      these cases. With the aim to decrease the need for reflex Southern blot tests, a 
      novel, single-tube CTG repeat primed PCR technology was designed to distinguish 
      the true homozygous patients from the individuals whose large alleles are missed 
      by conventional PCR. The method utilizes two gene-specific primers that flank the 
      triplet repeat region and a third primer set complementary to the repeated region 
      to detect the large alleles. Compared to traditional PCR, this novel 
      Triplet-repeat Primed PCR can detect the presence of large expanded alleles with 
      demonstrating a ladder pattern. Using this single-step protocol, 45 specimens 
      were tested. The alleles with sizes~i~85 repeats were determined by the gene 
      specific primers. 13 abnormal alleles, which were missed by conventional PCR, 
      were successfully detected by the Triplet-repeat Primed PCR. All the abnormal 
      alleles were confirmed and measured by Southern Blot analysis. In summary, 
      optimized Triplet-Primed PCR (TP-PCR) can accurately detect the presence of the 
      large expanded alleles. With the ability to distinguish the true homozygous 
      patients from the false negative homozygous individuals, the application of the 
      optimized TP-PCR can significantly reduce the need of Southern Blot tests.
FAU - Singh, Susmita
AU  - Singh S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine Indianapolis, IN, USA.
FAU - Zhang, Amy
AU  - Zhang A
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine Indianapolis, IN, USA.
FAU - Dlouhy, Stephen
AU  - Dlouhy S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine Indianapolis, IN, USA.
FAU - Bai, Shaochun
AU  - Bai S
AD  - Department of Medical and Molecular Genetics, Indiana University School of 
      Medicine Indianapolis, IN, USA.
LA  - eng
PT  - Journal Article
DEP - 20140424
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC4006065
OTO - NOTNLM
OT  - CTG
OT  - allelic expansion
OT  - myotonic dystrophy type 1 (DM1)
OT  - trinucleotide repeat
OT  - triplet-repeat primed PCR
EDAT- 2014/05/06 06:00
MHDA- 2014/05/06 06:01
PMCR- 2014/04/24
CRDT- 2014/05/06 06:00
PHST- 2014/03/04 00:00 [received]
PHST- 2014/04/03 00:00 [accepted]
PHST- 2014/05/06 06:00 [entrez]
PHST- 2014/05/06 06:00 [pubmed]
PHST- 2014/05/06 06:01 [medline]
PHST- 2014/04/24 00:00 [pmc-release]
AID - 10.3389/fgene.2014.00094 [doi]
PST - epublish
SO  - Front Genet. 2014 Apr 24;5:94. doi: 10.3389/fgene.2014.00094. eCollection 2014.

PMID- 24781112
OWN - NLM
STAT- MEDLINE
DCOM- 20150122
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 4
DP  - 2014
TI  - Development of an AP-FRET based analysis for characterizing RNA-protein 
      interactions in myotonic dystrophy (DM1).
PG  - e95957
LID - 10.1371/journal.pone.0095957 [doi]
LID - e95957
AB  - Forster Resonance Energy Transfer (FRET) microscopy is a powerful tool used to 
      identify molecular interactions in live or fixed cells using a non-radiative 
      transfer of energy from a donor fluorophore in the excited state to an acceptor 
      fluorophore in close proximity. FRET can be a very sensitive tool to study 
      protein-protein and/or protein-nucleic acids interactions. RNA toxicity is 
      implicated in a number of disorders; especially those associated with expanded 
      repeat sequences, such as myotonic dystrophy. Myotonic dystrophy (DM1) is caused 
      by a (CTG)n repeat expansion in the 3' UTR of the DMPK gene which results in 
      nuclear retention of mutant DMPK transcripts in RNA foci. This results in toxic 
      gain-of-function effects mediated through altered functions of RNA-binding 
      proteins (e.g. MBNL1, hnRNPH, CUGBP1). In this study we demonstrate the potential 
      of a new acceptor photobleaching assay to measure FRET (AP-FRET) between RNA and 
      protein. We chose to focus on the interaction between MBNL1 and mutant DMPK mRNA 
      in cells from DM1 patients due to the strong microscopic evidence of their 
      co-localization. Using this technique we have direct evidence of intracellular 
      interaction between MBNL1 and the DMPK RNA. Furthermore using the AP-FRET assay 
      and MBNL1 mutants, we show that all four zinc-finger motifs in MBNL1 are crucial 
      for MBNL1-RNA foci interactions. The data derived using this new assay provides 
      compelling evidence for the interaction between RNA binding proteins and RNA 
      foci, and mechanistic insights into MBNL1-RNA foci interaction demonstrating the 
      power of AP-FRET in examining RNA-Protein interactions in DM1.
FAU - Rehman, Shagufta
AU  - Rehman S
AD  - Department of Pathology, University of Virginia, Charlottesville, Virginia, 
      United States of America.
FAU - Gladman, Jordan T
AU  - Gladman JT
AD  - Department of Pathology, University of Virginia, Charlottesville, Virginia, 
      United States of America.
FAU - Periasamy, Ammasi
AU  - Periasamy A
AD  - Department of Biology, University of Virginia, Charlottesville, Virginia, United 
      States of America.
FAU - Sun, Yuansheng
AU  - Sun Y
AD  - Department of Biology, University of Virginia, Charlottesville, Virginia, United 
      States of America.
FAU - Mahadevan, Mani S
AU  - Mahadevan MS
AD  - Department of Pathology, University of Virginia, Charlottesville, Virginia, 
      United States of America.
LA  - eng
GR  - R01 AR052771/AR/NIAMS NIH HHS/United States
GR  - S10 RR025616/RR/NCRR NIH HHS/United States
GR  - R01-AR052771/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140429
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Fluorescence Resonance Energy Transfer
MH  - Humans
MH  - Myotonic Dystrophy/*metabolism
MH  - Myotonin-Protein Kinase/genetics
MH  - Polymerase Chain Reaction
MH  - RNA, Messenger/*metabolism
MH  - RNA-Binding Proteins/*metabolism
PMC - PMC4004549
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/05/02 06:00
MHDA- 2015/01/23 06:00
PMCR- 2014/04/29
CRDT- 2014/05/01 06:00
PHST- 2014/01/09 00:00 [received]
PHST- 2014/03/31 00:00 [accepted]
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2015/01/23 06:00 [medline]
PHST- 2014/04/29 00:00 [pmc-release]
AID - PONE-D-14-01019 [pii]
AID - 10.1371/journal.pone.0095957 [doi]
PST - epublish
SO  - PLoS One. 2014 Apr 29;9(4):e95957. doi: 10.1371/journal.pone.0095957. eCollection 
      2014.

PMID- 24715907
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140409
LR  - 20211021
IS  - 1687-9627 (Print)
IS  - 1687-9635 (Electronic)
VI  - 2014
DP  - 2014
TI  - Assessment of Premutation in Myotonic Dystrophy Type 1 Affected Family Members by 
      TP-PCR and Genetic Counseling.
PG  - 289643
LID - 10.1155/2014/289643 [doi]
LID - 289643
AB  - Myotonic dystrophy type 1 (DM1) is caused by the expansion of an unstable CTG 
      repeat located in the 3'-UTR of (DMPK) the DM protein kinase gene. Patients with 
      DM1 have expansions of greater than 50 repeats and up to many thousands. In the 
      present study we aimed to evaluate the utility of TP-PCR in diagnostics as well 
      as the assessment of premutation carriers in proband families. Twenty-seven DM1 
      cases were enrolled (from twenty-six families) and the 13 families of these cases 
      came forward for family screening. The patient group constitute 22 males and 5 
      females and the average age of onset was 32.8 years (range 17 to 52). All 
      clinically diagnosed DM1 cases and their family members DNA samples were analyzed 
      by TP-PCR. All the cases were found to be positive for the CTG repeat expansion. 
      Among those five families, four had at least an asymptomatic carrier. In the 
      remaining one family other than the proband none was found to be neither affected 
      nor asymptomatic. We reconfirmed the utility of PCR based screening for DM1 as 
      being reliable and rapid molecular test and it should be used as an initial 
      screening test for all patients with DM and their family members for initial 
      screening purpose.
FAU - Kumar, Ashok
AU  - Kumar A
AD  - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
FAU - Agarwal, Sarita
AU  - Agarwal S
AD  - Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
FAU - Pradhan, Sunil
AU  - Pradhan S
AD  - Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical 
      Sciences, Lucknow 226014, India.
LA  - eng
PT  - Journal Article
DEP - 20140223
PL  - United States
TA  - Case Rep Med
JT  - Case reports in medicine
JID - 101512910
PMC - PMC3970441
EDAT- 2014/04/10 06:00
MHDA- 2014/04/10 06:01
PMCR- 2014/02/23
CRDT- 2014/04/10 06:00
PHST- 2013/10/19 00:00 [received]
PHST- 2013/12/25 00:00 [revised]
PHST- 2013/12/27 00:00 [accepted]
PHST- 2014/04/10 06:00 [entrez]
PHST- 2014/04/10 06:00 [pubmed]
PHST- 2014/04/10 06:01 [medline]
PHST- 2014/02/23 00:00 [pmc-release]
AID - 10.1155/2014/289643 [doi]
PST - ppublish
SO  - Case Rep Med. 2014;2014:289643. doi: 10.1155/2014/289643. Epub 2014 Feb 23.

PMID- 24705798
OWN - NLM
STAT- MEDLINE
DCOM- 20150226
LR  - 20211021
IS  - 1364-6753 (Electronic)
IS  - 1364-6745 (Linking)
VI  - 15
IP  - 3
DP  - 2014 Aug
TI  - Coexistence of DMPK gene expansion and CLCN1 missense mutation in the same 
      patient.
PG  - 213-4
LID - 10.1007/s10048-014-0402-4 [doi]
FAU - Kassardjian, Charles D
AU  - Kassardjian CD
AD  - Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, 
      USA.
FAU - Milone, Margherita
AU  - Milone M
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20140405
PL  - United States
TA  - Neurogenetics
JT  - Neurogenetics
JID - 9709714
RN  - 0 (CLC-1 channel)
RN  - 0 (Chloride Channels)
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
SB  - IM
MH  - Adult
MH  - Chloride Channels/*genetics
MH  - DNA Repeat Expansion
MH  - Female
MH  - Humans
MH  - Mutation, Missense
MH  - Myotonia Congenita/complications/diagnosis/*genetics
MH  - Myotonic Dystrophy/complications/diagnosis/*genetics
MH  - Myotonin-Protein Kinase/*genetics
MH  - Young Adult
EDAT- 2014/04/08 06:00
MHDA- 2015/02/27 06:00
CRDT- 2014/04/08 06:00
PHST- 2014/03/19 00:00 [received]
PHST- 2014/03/26 00:00 [accepted]
PHST- 2014/04/08 06:00 [entrez]
PHST- 2014/04/08 06:00 [pubmed]
PHST- 2015/02/27 06:00 [medline]
AID - 10.1007/s10048-014-0402-4 [doi]
PST - ppublish
SO  - Neurogenetics. 2014 Aug;15(3):213-4. doi: 10.1007/s10048-014-0402-4. Epub 2014 
      Apr 5.

PMID- 24673412
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20140916
IS  - 1460-2202 (Electronic)
IS  - 0271-3683 (Linking)
VI  - 39
IP  - 10
DP  - 2014 Oct
TI  - Association between a 27-bp variable number of tandem repeat polymorphism in 
      intron 4 of the eNOS gene and risk for diabetic retinopathy Type 2 diabetes 
      mellitus: a meta-analysis.
PG  - 1052-8
LID - 10.3109/02713683.2014.894078 [doi]
AB  - PURPOSE: Imbalance in the production of endothelial nitric oxide synthase (eNOS), 
      which plays an essential role in retinal vascular function, can lead to the 
      development of diabetic retinopathy (DR). To thoroughly address this issue, we 
      performed an updated meta-analysis to evaluate the association between the eNOS 
      27VNTR (4b/4a) polymorphism and DR in type 2 diabetes mellitus (T2DM). METHODS: A 
      search was conducted of PubMed and Chinese language (WanFang) databases through 3 
      March 2013. Data were retrieved in a systematic manner and analyzed using Stata 
      Statistical Software. Crude odds ratios (ORs) with 95% confidence intervals (CIs) 
      were used to assess the strength of associations. RESULTS: Based on the search 
      criteria for DR susceptibility related to the 27VNTR (4b/4a) polymorphism of the 
      eNOS gene, 16 case-control studies (15 articles), comprising 3227 T2DM patients 
      with DR and 3437 T2DM patients without DR, were retrieved. Although no 
      significant associations were uncovered in either the overall analysis or DR 
      subtype groups, a decreased association was detected between the African- 
      (allelic contrast: OR = 0.75, 95% CI = 0.65-0.88) or population-based (PB) 
      studies (dominant genetic model: OR = 0.91, 95% CI = 0.83-0.98) and the eNOS 
      27VNTR (4b/4a) polymorphism. Stratification according to average duration of DM 
      revealed that T2DM patients with histories of >10 years had an elevated 
      susceptibility to DR compared with those with histories of shorter durations 
      (homozygote comparison: OR = 1.67, 95% CI = 1.09-2.58). CONCLUSIONS: The present 
      meta-analysis suggests that the eNOS 27VNTR (4b/4a) polymorphism potentially 
      decreases the risk of developing DR in T2DM African individuals. The higher 
      degree of susceptibility in patients with longer (>10 years) durations of DM is 
      indicative of the involvement of a gene-environment interaction in determining 
      the risk for DR. Further studies, based on larger sample sizes and additional 
      gene-environment interactions, should be conducted to elucidate the role of eNOS 
      gene polymorphisms, especially 27VNTR (4b/4a), in the risk for DR.
FAU - Qian-Qian, Yu
AU  - Qian-Qian Y
AD  - Department of Ophthalmology, Affiliated Wuxi People's Hospital of Nanjing Medical 
      University , Wuxi, Jiangsu , China.
FAU - Yong, Yao
AU  - Yong Y
FAU - Jing, Zhu
AU  - Jing Z
FAU - Dong-Hong, Fu
AU  - Dong-Hong F
FAU - Tian-Hua, Xie
AU  - Tian-Hua X
FAU - Li, Yin
AU  - Li Y
FAU - Lan, Luan
AU  - Lan L
FAU - Jia, Cao
AU  - Jia C
FAU - Zhe-Yao, Gu
AU  - Zhe-Yao G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20140327
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Diabetic Retinopathy/*genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Introns/*genetics
MH  - Minisatellite Repeats/*genetics
MH  - Nitric Oxide Synthase Type III/*genetics
MH  - Odds Ratio
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic/*genetics
MH  - Polymorphism, Restriction Fragment Length
MH  - Risk Factors
OTO - NOTNLM
OT  - 27VNTR (4b/4a)
OT  - decreased risk
OT  - diabetic retinopathy
OT  - enos
OT  - meta-analysis type 2 diabetes mellitus
OT  - polymorphism
EDAT- 2014/03/29 06:00
MHDA- 2015/05/13 06:00
CRDT- 2014/03/29 06:00
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.3109/02713683.2014.894078 [doi]
PST - ppublish
SO  - Curr Eye Res. 2014 Oct;39(10):1052-8. doi: 10.3109/02713683.2014.894078. Epub 
      2014 Mar 27.

PMID- 24527956
OWN - NLM
STAT- MEDLINE
DCOM- 20150709
LR  - 20181202
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 130
IP  - 5
DP  - 2014 Nov
TI  - Facial memory deficits in myotonic dystrophy type 1.
PG  - 312-8
LID - 10.1111/ane.12228 [doi]
AB  - OBJECTIVES: To evaluate facial memory ability (FMA) in patients with myotonic 
      dystrophy type 1 (DM1). We also explored the relationship between FMA and 
      neuropsychological data, disease-related factors, and CTG repeat expansion size. 
      MATERIALS AND METHODS: Patients with DM1 (n = 33) and healthy subjects (n = 30) 
      were tested with the faces task of the Rivermead Behavioural Memory Test - 
      Extended version (RBMT-E) and an additional set of neuropsychological tests. 
      Clinical data were collected, and CTG repeat size was quantified in blood 
      lymphocytes. RESULTS: Low results on the faces task were more common in patients 
      with DM1 compared with healthy subjects (P < 0.05), with 36% of the patients 
      showing a poor/impaired performance. DM1 patients with deficits in FMA performed 
      significantly worse on tests measuring visual-construction ability and memory. 
      Furthermore, these patients more often falsely recognised unknown faces as known. 
      Deficits in FMA were not associated with any disease-related factor, including 
      CTG repeat expansion size. CONCLUSIONS: These findings revealed deficits in FMA 
      in the DM1 group, which was associated with reduced construction- and visual 
      memory ability.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kleberg, J L
AU  - Kleberg JL
AD  - Department of Psychology, University of Gothenburg, Gothenburg, Sweden; 
      Department of Psychology, Uppsala University, Uppsala, Sweden.
FAU - Lindberg, C
AU  - Lindberg C
FAU - Winblad, S
AU  - Winblad S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140215
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Memory Disorders/*etiology
MH  - Middle Aged
MH  - Myotonic Dystrophy/genetics/*psychology
MH  - Neuropsychological Tests
MH  - Trinucleotide Repeat Expansion
OTO - NOTNLM
OT  - CTG repeats
OT  - cognition
OT  - facial memory
OT  - myotonic dystrophy type 1
EDAT- 2014/02/18 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/02/18 06:00
PHST- 2014/01/14 00:00 [accepted]
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1111/ane.12228 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2014 Nov;130(5):312-8. doi: 10.1111/ane.12228. Epub 2014 Feb 
      15.

PMID- 24455203
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140123
LR  - 20211021
IS  - 2090-0201 (Print)
IS  - 2090-021X (Electronic)
IS  - 2090-0201 (Linking)
VI  - 2013
DP  - 2013
TI  - Comparative (computational) analysis of the DNA methylation status of 
      trinucleotide repeat expansion diseases.
PG  - 689798
LID - 10.1155/2013/689798 [doi]
LID - 689798
AB  - Previous studies have examined DNA methylation in different trinucleotide repeat 
      diseases. We have combined this data and used a pattern searching algorithm to 
      identify motifs in the DNA surrounding aberrantly methylated CpGs found in the 
      DNA of patients with one of the three trinucleotide repeat (TNR) expansion 
      diseases: fragile X syndrome (FRAXA), myotonic dystrophy type I (DM1), or 
      Friedreich's ataxia (FRDA). We examined sequences surrounding both the variably 
      methylated (VM) CpGs, which are hypermethylated in patients compared with 
      unaffected controls, and the nonvariably methylated CpGs which remain either 
      always methylated (AM) or never methylated (NM) in both patients and controls. 
      Using the J48 algorithm of WEKA analysis, we identified that two patterns are all 
      that is necessary to classify our three regions CCGG * which is found in VM and 
      not in AM regions and AATT * which distinguished between NM and VM + AM using 
      proportional frequency. Furthermore, comparing our software with MEME software, 
      we have demonstrated that our software identifies more patterns than MEME in 
      these short DNA sequences. Thus, we present evidence that the DNA sequence 
      surrounding CpG can influence its susceptibility to be de novo methylated in a 
      disease state associated with a trinucleotide repeat.
FAU - Ghorbani, Mohammadmersad
AU  - Ghorbani M
AD  - Department of Information Systems and Computing, Brunel University, Uxbridge 
      Middlesex UB8 3PH, UK.
FAU - Taylor, Simon J E
AU  - Taylor SJ
AD  - Department of Information Systems and Computing, Brunel University, Uxbridge 
      Middlesex UB8 3PH, UK.
FAU - Pook, Mark A
AU  - Pook MA
AD  - Division of Biosciences, School of Health Sciences & Social Care, Brunel 
      University, Uxbridge Middlesex UB8 3PH, UK.
FAU - Payne, Annette
AU  - Payne A
AD  - Department of Information Systems and Computing, Brunel University, Uxbridge 
      Middlesex UB8 3PH, UK.
LA  - eng
PT  - Journal Article
DEP - 20131223
PL  - United States
TA  - J Nucleic Acids
JT  - Journal of nucleic acids
JID - 101533042
PMC - PMC3884633
EDAT- 2014/01/24 06:00
MHDA- 2014/01/24 06:01
PMCR- 2013/12/23
CRDT- 2014/01/24 06:00
PHST- 2013/07/03 00:00 [received]
PHST- 2013/10/11 00:00 [revised]
PHST- 2013/10/15 00:00 [accepted]
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/01/24 06:01 [medline]
PHST- 2013/12/23 00:00 [pmc-release]
AID - 10.1155/2013/689798 [doi]
PST - ppublish
SO  - J Nucleic Acids. 2013;2013:689798. doi: 10.1155/2013/689798. Epub 2013 Dec 23.

PMID- 24455202
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140123
LR  - 20240104
IS  - 2090-0201 (Print)
IS  - 2090-021X (Electronic)
IS  - 2090-0201 (Linking)
VI  - 2013
DP  - 2013
TI  - Transcriptionally Repressive Chromatin Remodelling and CpG Methylation in the 
      Presence of Expanded CTG-Repeats at the DM1 Locus.
PG  - 567435
LID - 10.1155/2013/567435 [doi]
LID - 567435
AB  - An expanded CTG-repeat in the 3' UTR of the DMPK gene is responsible for myotonic 
      dystrophy type I (DM1). Somatic and intergenerational instability cause the 
      disease to become more severe during life and in subsequent generations. Evidence 
      is accumulating that trinucleotide repeat instability and disease progression 
      involve aberrant chromatin dynamics. We explored the chromatin environment in 
      relation to expanded CTG-repeat tracts in hearts from transgenic mice carrying 
      the DM1 locus with different repeat lengths. Using bisulfite sequencing we 
      detected abundant CpG methylation in the regions flanking the expanded 
      CTG-repeat. CpG methylation was postulated to affect CTCF binding but we found 
      that CTCF binding is not affected by CTG-repeat length in our transgenic mice. We 
      detected significantly decreased DMPK sense and SIX5 transcript expression levels 
      in mice with expanded CTG-repeats. Expression of the DM1 antisense transcript was 
      barely affected by CTG-repeat expansion. In line with altered gene expression, 
      ChIP studies revealed a locally less active chromatin conformation around the 
      expanded CTG-repeat, namely, decreased enrichment of active histone mark 
      H3K9/14Ac and increased H3K9Me3 enrichment (repressive chromatin mark). We also 
      observed binding of PCNA around the repeats, a candidate that could launch 
      chromatin remodelling cascades at expanded repeats, ultimately affecting gene 
      transcription and repeat instability.
FAU - Brouwer, Judith Rixt
AU  - Brouwer JR
AD  - Inserm U781, Hopital Broussais, Batiment Leriche, porte 9, 96 rue Didot, 75014 
      Paris, France ; Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      156 rue de Vaugirard, 75015 Paris, France.
FAU - Huguet, Aline
AU  - Huguet A
AD  - Inserm U781, Hopital Broussais, Batiment Leriche, porte 9, 96 rue Didot, 75014 
      Paris, France ; Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      156 rue de Vaugirard, 75015 Paris, France.
FAU - Nicole, Annie
AU  - Nicole A
AD  - Inserm U781, Hopital Broussais, Batiment Leriche, porte 9, 96 rue Didot, 75014 
      Paris, France ; Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      156 rue de Vaugirard, 75015 Paris, France.
FAU - Munnich, Arnold
AU  - Munnich A
AD  - Inserm U781, Hopital Broussais, Batiment Leriche, porte 9, 96 rue Didot, 75014 
      Paris, France ; Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      156 rue de Vaugirard, 75015 Paris, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Inserm U781, Hopital Broussais, Batiment Leriche, porte 9, 96 rue Didot, 75014 
      Paris, France ; Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      156 rue de Vaugirard, 75015 Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20131223
PL  - United States
TA  - J Nucleic Acids
JT  - Journal of nucleic acids
JID - 101533042
PMC - PMC3884603
EDAT- 2014/01/24 06:00
MHDA- 2014/01/24 06:01
PMCR- 2013/12/23
CRDT- 2014/01/24 06:00
PHST- 2013/08/28 00:00 [received]
PHST- 2013/10/22 00:00 [accepted]
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/01/24 06:01 [medline]
PHST- 2013/12/23 00:00 [pmc-release]
AID - 10.1155/2013/567435 [doi]
PST - ppublish
SO  - J Nucleic Acids. 2013;2013:567435. doi: 10.1155/2013/567435. Epub 2013 Dec 23.

PMID- 24417793
OWN - NLM
STAT- MEDLINE
DCOM- 20150105
LR  - 20211203
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 21
IP  - 7
DP  - 2014 Jul
TI  - Correlation between distribution of muscle weakness, electrophysiological 
      findings and CTG expansion in myotonic dystrophy.
PG  - 1123-6
LID - S0967-5868(13)00611-5 [pii]
LID - 10.1016/j.jocn.2013.09.016 [doi]
AB  - Myotonic dystrophy type 1 (DM-1) is a multi-system disorder affecting the 
      muscles, brain, cardiovascular system, endocrine system, eyes and skin. Diagnosis 
      is made by clinical, electrodiagnostic and genetic studies. This study aimed to 
      determine the correlation between CTG expansion and distribution of muscle 
      weakness and clinical and electrophysiological findings. Genetically confirmed 
      DM-1 patients presenting to Shariati Hospital between 2005 and 2011 were included 
      in this study. Clinical, electrodiagnostic and genetic testing was performed and 
      the correlation between CTG expansion and distribution of muscle weakness and 
      clinical and electromyographic findings was studied. Thirty-three genetically 
      confirmed DM-1 patients were enrolled. Myotonia, bifacial weakness and distal 
      upper limb weakness were seen in all patients. Diabetes mellitus was found in one 
      patient (3%), cardiac disturbance in eight (24.2%), cataracts in eight (24.2%), 
      hypogonadism in five (15.2%), frontal baldness in 13 (39.4%), temporalis wasting 
      in 14 (42.4%), temporomandibular joint disorder in seven (21.2%) and mental 
      retardation in eight (24.2%). The mean number of CTG repeats, measured by 
      Southern blot, was 8780 (range 500-15,833). A negative correlation was found 
      between CTG expansion and age of onset. Temporalis wasting and mental retardation 
      were positively correlated with CTG expansion. No relationship was found between 
      weakness distribution, electromyographic findings, other systemic features and 
      CTG expansion. In this study of DM-1 in Iran, we found a correlation between CTG 
      expansion and age of onset, temporalis wasting and mental disability. No 
      correlation between CTG expansion and electrodiagnostic and other clinical 
      findings were detected.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Khoshbakht, Roya
AU  - Khoshbakht R
AD  - Department of Neurology, Tehran University of Medical Sciences, Shariati 
      Hospital, North Karegar Street, Tehran 14114, Iran.
FAU - Soltanzadeh, Akbar
AU  - Soltanzadeh A
AD  - Department of Neurology, Tehran University of Medical Sciences, Shariati 
      Hospital, North Karegar Street, Tehran 14114, Iran.
FAU - Zamani, Babak
AU  - Zamani B
AD  - Department of Neurology, Tehran University of Medical Sciences, Shariati 
      Hospital, North Karegar Street, Tehran 14114, Iran.
FAU - Abdi, Siyamak
AU  - Abdi S
AD  - Department of Neurology, Tehran University of Medical Sciences, Shariati 
      Hospital, North Karegar Street, Tehran 14114, Iran.
FAU - Gharagozli, Kourosh
AU  - Gharagozli K
AD  - Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Kahrizi, Kimia
AU  - Kahrizi K
AD  - Genetics Research Center, University of Social Welfare and Rehabilitation 
      Sciences, Tehran, Iran.
FAU - Khoshbakht, Rahem
AU  - Khoshbakht R
AD  - Department of Pathobiology, School of Veterinary Medicine, University of Shiraz, 
      Iran.
FAU - Nafissi, Shahriar
AU  - Nafissi S
AD  - Department of Neurology, Tehran University of Medical Sciences, Shariati 
      Hospital, North Karegar Street, Tehran 14114, Iran. Electronic address: 
      nafisi@sina.tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20131118
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Electromyography
MH  - Evoked Potentials, Motor/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness/*etiology
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - Neural Conduction/genetics
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Statistics as Topic
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - CTG expansion
OT  - Clinical manifestation
OT  - Exercise
OT  - Myotonic dystrophy
EDAT- 2014/01/15 06:00
MHDA- 2015/01/06 06:00
CRDT- 2014/01/15 06:00
PHST- 2012/06/16 00:00 [received]
PHST- 2013/09/09 00:00 [revised]
PHST- 2013/09/24 00:00 [accepted]
PHST- 2014/01/15 06:00 [entrez]
PHST- 2014/01/15 06:00 [pubmed]
PHST- 2015/01/06 06:00 [medline]
AID - S0967-5868(13)00611-5 [pii]
AID - 10.1016/j.jocn.2013.09.016 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2014 Jul;21(7):1123-6. doi: 10.1016/j.jocn.2013.09.016. Epub 
      2013 Nov 18.

PMID- 24367268
OWN - NLM
STAT- MEDLINE
DCOM- 20140820
LR  - 20240104
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Print)
IS  - 1553-7390 (Linking)
VI  - 9
IP  - 12
DP  - 2013
TI  - Detection of slipped-DNAs at the trinucleotide repeats of the myotonic dystrophy 
      type I disease locus in patient tissues.
PG  - e1003866
LID - 10.1371/journal.pgen.1003866 [doi]
LID - e1003866
AB  - Slipped-strand DNAs, formed by out-of-register mispairing of repeat units on 
      complementary strands, were proposed over 55 years ago as transient intermediates 
      in repeat length mutations, hypothesized to cause at least 40 neurodegenerative 
      diseases. While slipped-DNAs have been characterized in vitro, evidence of 
      slipped-DNAs at an endogenous locus in biologically relevant tissues, where 
      instability varies widely, is lacking. Here, using an anti-DNA junction antibody 
      and immunoprecipitation, we identify slipped-DNAs at the unstable trinucleotide 
      repeats (CTG)n*(CAG)n of the myotonic dystrophy disease locus in patient brain, 
      heart, muscle and other tissues, where the largest expansions arise in 
      non-mitotic tissues such as cortex and heart, and are smallest in the cerebellum. 
      Slipped-DNAs are shown to be present on the expanded allele and in chromatinized 
      DNA. Slipped-DNAs are present as clusters of slip-outs along a DNA, with each 
      slip-out having 1-100 extrahelical repeats. The allelic levels of slipped-DNA 
      containing molecules were significantly greater in the heart over the cerebellum 
      (relative to genomic equivalents of pre-IP input DNA) of a DM1 individual; an 
      enrichment consistent with increased allelic levels of slipped-DNA structures in 
      tissues having greater levels of CTG instability. Surprisingly, this supports the 
      formation of slipped-DNAs as persistent mutation products of repeat instability, 
      and not merely as transient mutagenic intermediates. These findings further our 
      understanding of the processes of mutation and genetic variation.
FAU - Axford, Michelle M
AU  - Axford MM
AD  - Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada ; Department of Molecular Genetics, University of Toronto, Toronto, 
      Ontario, Canada.
FAU - Wang, Yuh-Hwa
AU  - Wang YH
AD  - Department of Biochemistry, Wake Forest University School of Medicine, 
      Winston-Salem, North Carolina, United States of America.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, University of Rochester School of Medicine and 
      Dentistry, Rochester, New York, United States of America.
FAU - Zannis-Hadjopoulos, Maria
AU  - Zannis-Hadjopoulos M
AD  - Goodman Cancer Research Centre and Department of Biochemistry, McGill University, 
      Montreal, Quebec, Canada.
FAU - Thornton, Charles A
AU  - Thornton CA
AD  - Department of Neurology, University of Rochester School of Medicine and 
      Dentistry, Rochester, New York, United States of America.
FAU - Pearson, Christopher E
AU  - Pearson CE
AD  - Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Ontario, 
      Canada ; Department of Molecular Genetics, University of Toronto, Toronto, 
      Ontario, Canada.
LA  - eng
GR  - FRN94966/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131219
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Chromatin)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Antibodies, Antinuclear/*genetics
MH  - Chromatin/genetics
MH  - DNA/chemistry/*genetics
MH  - Humans
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Nucleic Acid Conformation
MH  - Tissue Distribution
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3868534
COIS- The authors have declared that no competing interests exist.
EDAT- 2013/12/25 06:00
MHDA- 2014/08/21 06:00
PMCR- 2013/12/01
CRDT- 2013/12/25 06:00
PHST- 2012/10/31 00:00 [received]
PHST- 2013/08/25 00:00 [accepted]
PHST- 2013/12/25 06:00 [entrez]
PHST- 2013/12/25 06:00 [pubmed]
PHST- 2014/08/21 06:00 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - PGENETICS-D-12-02717 [pii]
AID - 10.1371/journal.pgen.1003866 [doi]
PST - ppublish
SO  - PLoS Genet. 2013;9(12):e1003866. doi: 10.1371/journal.pgen.1003866. Epub 2013 Dec 
      19.

PMID- 24270677
OWN - NLM
STAT- MEDLINE
DCOM- 20140528
LR  - 20211021
IS  - 1536-4798 (Electronic)
IS  - 0277-3740 (Print)
IS  - 0277-3740 (Linking)
VI  - 33
IP  - 1
DP  - 2014 Jan
TI  - Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case 
      series.
PG  - 96-8
LID - 10.1097/ICO.0000000000000018 [doi]
AB  - PURPOSE: The aim was to report 4 cases of Fuchs endothelial corneal dystrophy 
      (FECD) in patients with an established diagnosis of myotonic dystrophy (DM) and 
      suggest a mechanism for their association based on the known molecular genetics 
      and potential pathophysiological parallels of DM and FECD. METHODS: We reviewed 
      all available medical records and pathology slides for the 4 reported cases from 
      the Department of Ophthalmology at Oregon Health and Science University's Casey 
      Eye Institute and Devers Eye Institute at the Legacy Good Samaritan Medical 
      Center in Portland, OR. RESULTS: Four patients were found to have DM and 
      bilateral corneal guttae, consistent with the diagnosis of FECD. All the 
      identified patients were female and were aged between 34 and 63, and 2 patients 
      were related (mother and daughter). The corneal specimens from 2 of the 4 
      patients who had undergone a corneal transplant were pathologically confirmed to 
      be consistent with the diagnosis of FECD. CONCLUSIONS: To our knowledge, FECD has 
      not been previously reported in association with DM. Because both diseases are 
      somewhat prevalent in the United States, it is possible that their coexistence is 
      merely a coincidence in these patients. However, recent studies into the 
      pathogenesis of each disease have shown more parallels between FECD and DM, 
      suggesting the possibility of a noncoincidental association. Potential mutual 
      pathogenic mechanisms may involve altered protein expression causing the 
      deregulation of ion homeostasis, an unstable intronic trinucleotide repeat 
      expansion, or activation of the unfolded protein response and oxidative stress 
      pathways.
FAU - Gattey, Devin
AU  - Gattey D
AD  - *Casey Eye Institute, Oregon Health and Science University, Portland, OR; daggerCase 
      Western Reserve University School of Medicine, Cleveland, OH; double daggerDepartment of 
      Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, 
      NE;  section signDevers Eye Institute, Portland, OR; and  paragraph signWilmer Eye Institute, Johns Hopkins 
      Medical Institutions, Baltimore, MD.
FAU - Zhu, Angela Y
AU  - Zhu AY
FAU - Stagner, Anna
AU  - Stagner A
FAU - Terry, Mark A
AU  - Terry MA
FAU - Jun, Albert S
AU  - Jun AS
LA  - eng
GR  - R01 EY019874/EY/NEI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cornea
JT  - Cornea
JID - 8216186
SB  - IM
CIN - Cornea. 2017 Oct;36(10 ):e25-e27. PMID: 28691947
CIN - Cornea. 2017 Oct;36(10 ):e24-e25. PMID: 28820792
MH  - Adult
MH  - Female
MH  - Fuchs' Endothelial Dystrophy/*etiology
MH  - Humans
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications
PMC - PMC3898337
MID - NIHMS541736
COIS- Conflict of Interest Disclosures: None
EDAT- 2013/11/26 06:00
MHDA- 2014/05/29 06:00
PMCR- 2015/01/01
CRDT- 2013/11/26 06:00
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2014/05/29 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.1097/ICO.0000000000000018 [doi]
PST - ppublish
SO  - Cornea. 2014 Jan;33(1):96-8. doi: 10.1097/ICO.0000000000000018.

PMID- 24269018
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20220318
IS  - 1558-1497 (Electronic)
IS  - 0197-4580 (Print)
IS  - 0197-4580 (Linking)
VI  - 35
IP  - 4
DP  - 2014 Apr
TI  - Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral 
      sclerosis.
PG  - 936.e1-4
LID - S0197-4580(13)00426-0 [pii]
LID - 10.1016/j.neurobiolaging.2013.09.024 [doi]
AB  - Intermediate-length polyglutamine expansions in ataxin 2 are a risk factor for 
      amyotrophic lateral sclerosis (ALS). The polyglutamine tract is encoded by a 
      trinucleotide repeat in a coding region of the ataxin 2 gene (ATXN2). Noncoding 
      nucleotide repeat expansions in several genes are also associated with 
      neurodegenerative and neuromuscular diseases. For example, hexanucleotide repeat 
      expansions located in a noncoding region of C9ORF72 are the most common cause of 
      ALS. We sought to assess a potential larger role of noncoding nucleotide repeat 
      expansions in ALS. We analyzed the nucleotide repeat lengths of 6 genes (ATXN8, 
      ATXN10, PPP2R2B, NOP56, DMPK, and JPH3) that have previously been associated with 
      neurologic or neuromuscular disorders, in several hundred sporadic patients with 
      ALS and healthy control subjects. We report no association between ALS and repeat 
      length in any of these genes, suggesting that variation in the noncoding 
      repetitive regions in these genes does not contribute to ALS.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Figley, Matthew D
AU  - Figley MD
AD  - Department of Genetics, Stanford University School of Medicine, Standford, CA, 
      USA; Stanford Neuroscience Graduate Program, Stanford University School of 
      Medicine, Stanford, CA, USA.
FAU - Thomas, Anna
AU  - Thomas A
AD  - Department of Genetics, Stanford University School of Medicine, Standford, CA, 
      USA; Presentation High School, San Jose, CA, USA.
FAU - Gitler, Aaron D
AU  - Gitler AD
AD  - Department of Genetics, Stanford University School of Medicine, Standford, CA, 
      USA. Electronic address: agitler@stanford.edu.
LA  - eng
GR  - R01NS073660/NS/NINDS NIH HHS/United States
GR  - DP2 OD004417/OD/NIH HHS/United States
GR  - T32 MH020016/MH/NIMH NIH HHS/United States
GR  - DP2OD004417/OD/NIH HHS/United States
GR  - T32 HG000044/HG/NHGRI NIH HHS/United States
GR  - R01 NS073660/NS/NINDS NIH HHS/United States
GR  - R01NS065317/NS/NINDS NIH HHS/United States
GR  - R01 NS065317/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20131023
PL  - United States
TA  - Neurobiol Aging
JT  - Neurobiology of aging
JID - 8100437
RN  - 0 (ATXN10 protein, human)
RN  - 0 (ATXN8 protein, human)
RN  - 0 (Ataxin-10)
RN  - 0 (Ataxins)
RN  - 0 (DMPK protein, human)
RN  - 0 (NOP56 protein, human)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Peptides)
RN  - 0 (RNA, Untranslated)
RN  - 26700-71-0 (polyglutamine)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.1.3.16 (PPP2R2B protein, human)
RN  - EC 3.1.3.16 (Protein Phosphatase 2)
SB  - IM
MH  - Adult
MH  - Amyotrophic Lateral Sclerosis/*genetics
MH  - Ataxin-10
MH  - Ataxins
MH  - Genetic Predisposition to Disease/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonin-Protein Kinase
MH  - Nerve Tissue Proteins/*genetics
MH  - Nuclear Proteins/genetics
MH  - Open Reading Frames/*genetics
MH  - Peptides/*genetics
MH  - Protein Phosphatase 2/genetics
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA, Untranslated/genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Risk Factors
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3880650
MID - NIHMS534610
OTO - NOTNLM
OT  - ALS
OT  - Ataxin
OT  - Noncoding
OT  - Nucleotide repeat expansion
OT  - polyQ
COIS- Disclosure Statement: The authors state no actual or potential conflicts of 
      interest exist
EDAT- 2013/11/26 06:00
MHDA- 2014/09/30 06:00
PMCR- 2015/04/01
CRDT- 2013/11/26 06:00
PHST- 2013/08/27 00:00 [received]
PHST- 2013/09/16 00:00 [revised]
PHST- 2013/09/19 00:00 [accepted]
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - S0197-4580(13)00426-0 [pii]
AID - 10.1016/j.neurobiolaging.2013.09.024 [doi]
PST - ppublish
SO  - Neurobiol Aging. 2014 Apr;35(4):936.e1-4. doi: 
      10.1016/j.neurobiolaging.2013.09.024. Epub 2013 Oct 23.

PMID- 24196578
OWN - NLM
STAT- MEDLINE
DCOM- 20141126
LR  - 20211021
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 22
IP  - 2
DP  - 2014 Feb
TI  - Treatment of type 1 myotonic dystrophy by engineering site-specific RNA 
      endonucleases that target (CUG)(n) repeats.
PG  - 312-320
LID - S1525-0016(16)31152-2 [pii]
LID - 10.1038/mt.2013.251 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by the expansion of (CTG)n in the 3' 
      untranslated region of the dystrophia myotonica-protein kinase (DMPK) gene, which 
      is transcribed as (CUG)n repeats that accumulate in the nucleus. The RNA repeats 
      specifically sequester or change the expression levels of several RNA-binding 
      proteins, leading to aberrant splicing of many target genes. In this study, we 
      developed artificial site-specific RNA endonucleases (ASREs) that specifically 
      bind and cleave (CUG)n repeats RNA. We have generated one ASRE that can target 
      the expanded RNA repeats in DM1 patient cells and specifically degrade the 
      pathogenic DMPK messenger RNAs with minimal effect on wild-type alleles. Such 
      ASRE treatment significantly decreased the number of nuclear foci in DM1 patient 
      cells and can reverse the missplicing of many genes affected in DM1 patients. 
      Taken together, the application of ASRE provides a new route of gene therapy for 
      DM1 treatment.
FAU - Zhang, Wenjing
AU  - Zhang W
AD  - Institute of Biochemistry, College of Life Sciences, Zhejiang University, 
      Hangzhou, China; Department of Pharmacology and Lineberger Comprehensive Cancer 
      Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 
      USA.
FAU - Wang, Yang
AU  - Wang Y
AD  - Department of Pharmacology and Lineberger Comprehensive Cancer Center, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
FAU - Dong, Shuyun
AU  - Dong S
AD  - Department of Pharmacology and Lineberger Comprehensive Cancer Center, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of 
      Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, 
      Utah, USA.
FAU - Choudhury, Rajarshi
AU  - Choudhury R
AD  - Department of Pharmacology and Lineberger Comprehensive Cancer Center, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
FAU - Jin, Yongfeng
AU  - Jin Y
AD  - Institute of Biochemistry, College of Life Sciences, Zhejiang University, 
      Hangzhou, China.
FAU - Wang, Zefeng
AU  - Wang Z
AD  - Department of Pharmacology and Lineberger Comprehensive Cancer Center, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Macro Science 
      Solutions LLP, Chapel Hill, North Carolina, USA. Electronic address: 
      zefeng@med.unc.edu.
LA  - eng
GR  - R21 AR061640/AR/NIAMS NIH HHS/United States
GR  - R21AR061640/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20131023
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - EC 3.1.- (Endoribonucleases)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Catalytic Domain
MH  - Cell Line
MH  - Endoribonucleases/chemistry/genetics/*metabolism
MH  - Gene Expression
MH  - Humans
MH  - Hydrolysis
MH  - Myotonic Dystrophy/enzymology/*genetics/therapy
MH  - Protein Binding
MH  - *Trinucleotide Repeats/genetics
PMC - PMC3916045
EDAT- 2013/11/08 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/02/01
CRDT- 2013/11/08 06:00
PHST- 2013/06/07 00:00 [received]
PHST- 2013/10/17 00:00 [accepted]
PHST- 2013/11/08 06:00 [entrez]
PHST- 2013/11/08 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/02/01 00:00 [pmc-release]
AID - S1525-0016(16)31152-2 [pii]
AID - 10.1038/mt.2013.251 [doi]
PST - ppublish
SO  - Mol Ther. 2014 Feb;22(2):312-320. doi: 10.1038/mt.2013.251. Epub 2013 Oct 23.

PMID- 24092878
OWN - NLM
STAT- MEDLINE
DCOM- 20140908
LR  - 20211203
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Print)
IS  - 1754-8403 (Linking)
VI  - 7
IP  - 1
DP  - 2014 Jan
TI  - Transcriptional changes and developmental abnormalities in a zebrafish model of 
      myotonic dystrophy type 1.
PG  - 143-55
LID - 10.1242/dmm.012427 [doi]
AB  - Myotonic dystrophy type I (DM1) is a multi-system, autosomal dominant disorder 
      caused by expansion of a CTG repeat sequence in the 3'UTR of the DMPK gene. The 
      size of the repeat sequence correlates with age at onset and disease severity, 
      with large repeats leading to congenital forms of DM1 associated with hypotonia 
      and intellectual disability. In models of adult DM1, expanded CUG repeats lead to 
      an RNA toxic gain of function, mediated at least in part by sequestering specific 
      RNA splicing proteins, most notably muscleblind-related (MBNL) proteins. However, 
      the impact of CUG RNA repeat expression on early developmental processes is not 
      well understood. To better understand early developmental processes in DM1, we 
      utilized the zebrafish, Danio rerio, as a model system. Direct injection of 
      (CUG)91 repeat-containing mRNA into single-cell embryos induces toxicity in the 
      nervous system and muscle during early development. These effects manifest as 
      abnormal morphology, behavioral abnormalities and broad transcriptional changes, 
      as shown by cDNA microarray analysis. Co-injection of zebrafish mbnl2 RNA 
      suppresses (CUG)91 RNA toxicity and reverses the associated behavioral and 
      transcriptional abnormalities. Taken together, these findings suggest that early 
      expression of exogenously transcribed CUG repeat RNA can disrupt normal muscle 
      and nervous system development and provides a new model for DM1 research that is 
      amenable to small-molecule therapeutic development.
FAU - Todd, Peter K
AU  - Todd PK
AD  - Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
FAU - Ackall, Feras Y
AU  - Ackall FY
FAU - Hur, Junguk
AU  - Hur J
FAU - Sharma, Kush
AU  - Sharma K
FAU - Paulson, Henry L
AU  - Paulson HL
FAU - Dowling, James J
AU  - Dowling JJ
LA  - eng
GR  - R01 NS086810/NS/NINDS NIH HHS/United States
GR  - R01NS038712]/NS/NINDS NIH HHS/United States
GR  - 1K08AR054835/AR/NIAMS NIH HHS/United States
GR  - K08 AR054835/AR/NIAMS NIH HHS/United States
GR  - K08NS69809/NS/NINDS NIH HHS/United States
GR  - R01 NS038712/NS/NINDS NIH HHS/United States
GR  - K08 NS069809/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20131002
PL  - England
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DNA, Complementary)
RN  - 0 (Nucleotides)
RN  - 0 (RNA, Messenger)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Animals
MH  - DNA, Complementary/metabolism
MH  - Disease Models, Animal
MH  - *Gene Expression Regulation
MH  - Green Fluorescent Proteins/metabolism
MH  - Muscle Hypotonia/genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Nucleotides/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Phenotype
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA Splicing
MH  - RNA, Messenger/metabolism
MH  - Transcription, Genetic
MH  - Zebrafish
PMC - PMC3882056
OTO - NOTNLM
OT  - CUG repeat
OT  - Muscleblind
OT  - Neurodegeneration
OT  - Nucleotide repeat
EDAT- 2013/10/05 06:00
MHDA- 2014/09/10 06:00
PMCR- 2014/01/01
CRDT- 2013/10/05 06:00
PHST- 2013/10/05 06:00 [entrez]
PHST- 2013/10/05 06:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - dmm.012427 [pii]
AID - 0070143 [pii]
AID - 10.1242/dmm.012427 [doi]
PST - ppublish
SO  - Dis Model Mech. 2014 Jan;7(1):143-55. doi: 10.1242/dmm.012427. Epub 2013 Oct 2.

PMID- 24047873
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20211021
IS  - 1742-5662 (Electronic)
IS  - 1742-5689 (Print)
IS  - 1742-5662 (Linking)
VI  - 10
IP  - 88
DP  - 2013 Nov 6
TI  - Modelling and inference reveal nonlinear length-dependent suppression of somatic 
      instability for small disease associated alleles in myotonic dystrophy type 1 and 
      Huntington disease.
PG  - 20130605
LID - 10.1098/rsif.2013.0605 [doi]
LID - 20130605
AB  - More than 20 human genetic diseases are associated with inheriting an unstable 
      expanded DNA simple sequence tandem repeat, for example, CTG 
      (cytosine-thymine-guanine) repeats in myotonic dystrophy type 1 (DM1) and CAG 
      (cytosine-adenine-guanine) repeats in Huntington disease (HD). These sequences 
      mutate by changing the number of repeats not just between generations, but also 
      during the lifetime of affected individuals. Levels of somatic instability 
      contribute to disease onset and progression but as changes are tissue-specific, 
      age- and repeat length-dependent, interpretation of the level of somatic 
      instability in an individual is confounded by these considerations. Mathematical 
      models, fitted to CTG repeat length distributions derived from blood DNA, from a 
      large cohort of DM1-affected or at risk individuals, have recently been used to 
      quantify inherited repeat lengths and mutation rates. Taking into account age, 
      the estimated mutation rates are lower than predicted among individuals with 
      small alleles (inherited repeat lengths less than 100 CTGs), suggesting that 
      these rates may be suppressed at the lower end of the disease-causing range. In 
      this study, we propose that a length-specific effect operates within this range 
      and tested this hypothesis using a model comparison approach. To calibrate the 
      extended model, we used data derived from blood DNA from DM1 individuals and, for 
      the first time, buccal DNA from HD individuals. In a novel application of this 
      extended model, we identified individuals whose effective repeat length, with 
      regards to somatic instability, is less than their actual repeat length. A 
      plausible explanation for this distinction is that the expanded repeat tract is 
      compromised by interruptions or other unusual features. We quantified effective 
      length for a large cohort of DM1 individuals and showed that effective length 
      better predicts age of onset than inherited repeat length, thus improving the 
      genotype-phenotype correlation. Under the extended model, we removed some of the 
      bias in mutation rates making them less length-dependent. Consequently, rates 
      adjusted in this way will be better suited as quantitative traits to investigate 
      cis- or trans-acting modifiers of somatic mosaicism, disease onset and 
      progression.
FAU - Higham, Catherine F
AU  - Higham CF
AD  - School of Mathematics and Statistics, College of Science and Engineering, 
      University of Glasgow, Glasgow G12 8QQ, UK. catherine.higham@glasgow.ac.uk
FAU - Monckton, Darren G
AU  - Monckton DG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130918
PL  - England
TA  - J R Soc Interface
JT  - Journal of the Royal Society, Interface
JID - 101217269
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - *Alleles
MH  - Cohort Studies
MH  - Female
MH  - *Genetic Association Studies
MH  - *Genomic Instability
MH  - Humans
MH  - Huntington Disease/*genetics
MH  - Male
MH  - Middle Aged
MH  - *Models, Genetic
MH  - Myotonic Dystrophy/*genetics
MH  - Quantitative Trait, Heritable
MH  - Trinucleotide Repeats
PMC - PMC3785826
OTO - NOTNLM
OT  - Huntington disease
OT  - mathematical modelling
OT  - mutation rates
OT  - myotonic dystrophy type 1
OT  - somatic instability
OT  - statistical inference
EDAT- 2013/09/21 06:00
MHDA- 2014/03/26 06:00
PMCR- 2014/11/06
CRDT- 2013/09/20 06:00
PHST- 2013/09/20 06:00 [entrez]
PHST- 2013/09/21 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
PHST- 2014/11/06 00:00 [pmc-release]
AID - rsif.2013.0605 [pii]
AID - rsif20130605 [pii]
AID - 10.1098/rsif.2013.0605 [doi]
PST - epublish
SO  - J R Soc Interface. 2013 Sep 18;10(88):20130605. doi: 10.1098/rsif.2013.0605. 
      Print 2013 Nov 6.

PMID- 23933738
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20211203
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 22
IP  - 25
DP  - 2013 Dec 20
TI  - Length-dependent CTG.CAG triplet-repeat expansion in myotonic dystrophy 
      patient-derived induced pluripotent stem cells.
PG  - 5276-87
LID - 10.1093/hmg/ddt386 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an inherited dominant muscular dystrophy 
      caused by expanded CTG.CAG triplet repeats in the 3' untranslated region of the 
      DMPK1 gene, which produces a toxic gain-of-function CUG RNA. It has been shown 
      that the severity of disease symptoms, age of onset and progression are related 
      to the length of the triplet repeats. However, the mechanism(s) of CTG.CAG 
      triplet-repeat instability is not fully understood. Herein, induced pluripotent 
      stem cells (iPSCs) were generated from DM1 and Huntington's disease patient 
      fibroblasts. We isolated 41 iPSC clones from DM1 fibroblasts, all showing 
      different CTG.CAG repeat lengths, thus demonstrating somatic instability within 
      the initial fibroblast population. During propagation of the iPSCs, the repeats 
      expanded in a manner analogous to the expansion seen in somatic cells from DM1 
      patients. The correlation between repeat length and expansion rate identified the 
      interval between 57 and 126 repeats as being an important length threshold where 
      expansion rates dramatically increased. Moreover, longer repeats showed faster 
      triplet-repeat expansion. However, the overall tendency of triplet repeats to 
      expand ceased on differentiation into differentiated embryoid body or 
      neurospheres. The mismatch repair components MSH2, MSH3 and MSH6 were highly 
      expressed in iPSCs compared with fibroblasts, and only occupied the DMPK1 gene 
      harboring longer CTG.CAG triplet repeats. In addition, shRNA silencing of MSH2 
      impeded CTG.CAG triplet-repeat expansion. The information gained from these 
      studies provides new insight into a general mechanism of triplet-repeat expansion 
      in iPSCs.
FAU - Du, Jintang
AU  - Du J
AD  - Department of Cell and Molecular Biology, The Scripps Research Institute, 10550 
      N. Torrey Pines Road, La Jolla, CA 92037, USA.
FAU - Campau, Erica
AU  - Campau E
FAU - Soragni, Elisabetta
AU  - Soragni E
FAU - Jespersen, Christine
AU  - Jespersen C
FAU - Gottesfeld, Joel M
AU  - Gottesfeld JM
LA  - eng
PT  - Journal Article
DEP - 20130809
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (G-T mismatch-binding protein)
RN  - 0 (MSH3 protein, human)
RN  - 0 (MutS Homolog 3 Protein)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.6.1.3 (MSH2 protein, human)
RN  - EC 3.6.1.3 (MutS Homolog 2 Protein)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Cell Culture Techniques
MH  - DNA-Binding Proteins/biosynthesis/genetics
MH  - Fibroblasts/metabolism/pathology
MH  - Gene Expression Regulation
MH  - Humans
MH  - Huntington Disease/genetics/pathology
MH  - MutS Homolog 2 Protein/biosynthesis/genetics
MH  - MutS Homolog 3 Protein
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Pluripotent Stem Cells/*metabolism/pathology
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3842182
EDAT- 2013/08/13 06:00
MHDA- 2014/07/09 06:00
PMCR- 2014/12/20
CRDT- 2013/08/13 06:00
PHST- 2013/08/13 06:00 [entrez]
PHST- 2013/08/13 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
PHST- 2014/12/20 00:00 [pmc-release]
AID - ddt386 [pii]
AID - 10.1093/hmg/ddt386 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2013 Dec 20;22(25):5276-87. doi: 10.1093/hmg/ddt386. Epub 2013 Aug 
      9.

PMID- 23922231
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20141120
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 22
IP  - 25
DP  - 2013 Dec 20
TI  - A defective Krab-domain zinc-finger transcription factor contributes to altered 
      myogenesis in myotonic dystrophy type 1.
PG  - 5188-98
LID - 10.1093/hmg/ddt373 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a 
      non-coding CTG repeat expansion that, in particular, provokes functional 
      alteration of CUG-binding proteins. As a consequence, several genes with 
      misregulated alternative splicing have been linked to clinical symptoms. In our 
      search for additional molecular mechanisms that would trigger functional defects 
      in DM1, we took advantage of mutant gene-carrying human embryonic stem cell lines 
      to identify differentially expressed genes. Among the different genes found to be 
      misregulated by DM1 mutation, one strongly downregulated gene encodes a 
      transcription factor, ZNF37A. In this paper, we show that this defect in 
      expression, which derives from a loss of RNA stability, is controlled by the 
      RNA-binding protein, CUGBP1, and is associated with impaired myogenesis-a 
      functional defect reminiscent of that observed in DM1. Loss of the ZNF37A protein 
      results in changes in the expression of the subunit alpha1 of the receptor for the 
      interleukin 13. This suggests that the pathological molecular mechanisms linking 
      ZNF37A and myogenesis may involve the signaling pathway that is known to promote 
      myoblast recruitment during development and regeneration.
FAU - Gauthier, Morgane
AU  - Gauthier M
AD  - INSERM UMR 861, I-Stem AFM, Evry Cedex 91030, France.
FAU - Marteyn, Antoine
AU  - Marteyn A
FAU - Denis, Jerome Alexandre
AU  - Denis JA
FAU - Cailleret, Michel
AU  - Cailleret M
FAU - Giraud-Triboult, Karine
AU  - Giraud-Triboult K
FAU - Aubert, Sophie
AU  - Aubert S
FAU - Lecuyer, Camille
AU  - Lecuyer C
FAU - Marie, Joelle
AU  - Marie J
FAU - Furling, Denis
AU  - Furling D
FAU - Vernet, Remi
AU  - Vernet R
FAU - Yanguas, Clara
AU  - Yanguas C
FAU - Baldeschi, Christine
AU  - Baldeschi C
FAU - Pietu, Genevieve
AU  - Pietu G
FAU - Peschanski, Marc
AU  - Peschanski M
FAU - Martinat, Cecile
AU  - Martinat C
LA  - eng
PT  - Journal Article
DEP - 20130806
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (IL13RA1 protein, human)
RN  - 0 (Interleukin-13 Receptor alpha1 Subunit)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (zinc finger protein 37A, human)
SB  - IM
MH  - Alternative Splicing/*genetics
MH  - Cell Line
MH  - Cell Nucleus/genetics/metabolism
MH  - Embryonic Stem Cells
MH  - Humans
MH  - Interleukin-13 Receptor alpha1 Subunit/genetics/metabolism
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - Muscle Development/*genetics
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Signal Transduction/genetics
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2013/08/08 06:00
MHDA- 2014/07/09 06:00
CRDT- 2013/08/08 06:00
PHST- 2013/08/08 06:00 [entrez]
PHST- 2013/08/08 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
AID - ddt373 [pii]
AID - 10.1093/hmg/ddt373 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2013 Dec 20;22(25):5188-98. doi: 10.1093/hmg/ddt373. Epub 2013 Aug 
      6.

PMID- 23845777
OWN - NLM
STAT- MEDLINE
DCOM- 20131105
LR  - 20130830
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 528
IP  - 2
DP  - 2013 Oct 10
TI  - Molecular characterization of WFS1 in an Iranian family with Wolfram syndrome 
      reveals a novel frameshift mutation associated with early symptoms.
PG  - 309-13
LID - S0378-1119(13)00797-X [pii]
LID - 10.1016/j.gene.2013.06.040 [doi]
AB  - Wolfram syndrome (WS) is a rare autosomal recessive neurodegenerative disorder 
      that represents a likely source of childhood diabetes especially among countries 
      in the consanguinity belt. The main responsible gene is WFS1 for which over one 
      hundred mutations have been reported from different ethnic groups. The aim of 
      this study was to identify the molecular etiology of WS and to perform a possible 
      genotype-phenotype correlation in Iranian kindred. An Iranian family with two 
      patients was clinically studied and WS was suspected. Genetic linkage analysis 
      via 5 STR markers was carried out. For identification of mutations, DNA 
      sequencing of WFS1 including all the exons, exon-intron boundaries and the 
      promoter was performed. Linkage analysis indicated linkage to the WFS1 region. 
      After DNA sequencing of WFS1, one novel pathogenic mutation, which causes 
      frameshift alteration c.2177_2178insTCTTC (or c.2173_2177dupTCTTC) in exon eight, 
      was found. The genotype-phenotype correlation analysis suggests that the presence 
      of the homozygous mutation may be associated with early onset of disease 
      symptoms. This study stresses the necessity of considering the molecular analysis 
      of WFS1 in childhood diabetes with some symptoms of WS.
CI  - (c) 2013 Elsevier B.V. All rights reserved.
FAU - Sobhani, Maryam
AU  - Sobhani M
AD  - Department of Medical Genetics, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Tabatabaiefar, Mohammad Amin
AU  - Tabatabaiefar MA
FAU - Rajab, Asadollah
AU  - Rajab A
FAU - Kajbafzadeh, Abdol-Mohammad
AU  - Kajbafzadeh AM
FAU - Noori-Daloii, Mohammad Reza
AU  - Noori-Daloii MR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130708
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Membrane Proteins)
RN  - 0 (wolframin protein)
SB  - IM
MH  - Amino Acid Sequence
MH  - Base Sequence
MH  - Child, Preschool
MH  - Consanguinity
MH  - DNA Mutational Analysis
MH  - Female
MH  - *Frameshift Mutation
MH  - Genetic Association Studies
MH  - Genetic Linkage
MH  - Humans
MH  - Iran
MH  - Membrane Proteins/chemistry/*genetics
MH  - Microsatellite Repeats
MH  - Molecular Sequence Data
MH  - *Mutagenesis, Insertional
MH  - Pedigree
MH  - Wolfram Syndrome/*genetics
MH  - Young Adult
OTO - NOTNLM
OT  - BLAST
OT  - Basic Local Alignment Search Tool
OT  - DI
OT  - DI-DM-OA-D
OT  - DM
OT  - DNA
OT  - Dup
OT  - EDTA
OT  - FVC
OT  - Genetic linkage analysis
OT  - Iran
OT  - LOD
OT  - NCBI
OT  - National Center for Biotechnology Information
OT  - Novel mutation
OT  - OA
OT  - PAGE
OT  - PCR
OT  - SLINK
OT  - STR
OT  - VCUG
OT  - WFS1
OT  - WS
OT  - Wolfram syndrome
OT  - Wolfram syndrome 1 gene
OT  - aa
OT  - amino acid
OT  - dNTP
OT  - ddH2O
OT  - deoxyribonucleic acid
OT  - deoxyribonucleotide triphosphate
OT  - diabetes insipidus
OT  - diabetes insipidus, diabetes mellitus, optic atrophy and deafness
OT  - diabetes mellitus
OT  - double-distilled dihydrogen monoxide/water
OT  - duplication
OT  - ethylenediaminetetraacetic acid
OT  - frequency volume chart
OT  - logarithm of odds
OT  - optic atrophy
OT  - polyacrylamide gel electrophoresis
OT  - polymerase chain reaction
OT  - short tandem repeats
OT  - simulation of linkage
OT  - voiding cystourethrogram
EDAT- 2013/07/13 06:00
MHDA- 2013/11/06 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/01/15 00:00 [received]
PHST- 2013/06/10 00:00 [revised]
PHST- 2013/06/11 00:00 [accepted]
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2013/11/06 06:00 [medline]
AID - S0378-1119(13)00797-X [pii]
AID - 10.1016/j.gene.2013.06.040 [doi]
PST - ppublish
SO  - Gene. 2013 Oct 10;528(2):309-13. doi: 10.1016/j.gene.2013.06.040. Epub 2013 Jul 
      8.

PMID- 23811192
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20130930
IS  - 1878-1519 (Electronic)
IS  - 1569-9048 (Linking)
VI  - 189
IP  - 1
DP  - 2013 Oct 1
TI  - Respiratory failure in a mouse model of myotonic dystrophy does not correlate 
      with the CTG repeat length.
PG  - 22-6
LID - S1569-9048(13)00220-6 [pii]
LID - 10.1016/j.resp.2013.06.014 [doi]
AB  - Myotonic dystrophy (DM1) is a multisystemic disease caused by an expansion of CTG 
      repeats in the region of DMPK, the gene encoding DM protein kinase. The severity 
      of muscle disability in DM1 correlates with the size of CTG expansion. As 
      respiratory failure is one of the main causes of death in DM1, we investigated 
      the correlation between respiratory impairment and size of the (CTG)n repeat in 
      DM1 animal models. Using pressure plethysmography the respiratory function was 
      assessed in control and transgenic mice carrying either 600 (DM600) or >1300 CTG 
      repeats (DMSXL). The statistical analysis of respiratory parameters revealed that 
      both DM1 transgenic mice sub-lines show respiratory impairment compared to 
      control mice. In addition, there is no significant difference in breathing 
      functions between the DM600 and DMSXL mice. In conclusion, these results indicate 
      that respiratory impairment is present in both transgenic mice sub-lines, but the 
      severity of respiratory failure is not related to the size of the (CTG)n 
      expansion.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Panaite, Petrica-Adrian
AU  - Panaite PA
AD  - Department of Clinical Neurosciences, University Hospital, Lausanne, Switzerland.
FAU - Kuntzer, Thierry
AU  - Kuntzer T
FAU - Gourdon, Genevieve
AU  - Gourdon G
FAU - Barakat-Walter, Ibtissam
AU  - Barakat-Walter I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130627
PL  - Netherlands
TA  - Respir Physiol Neurobiol
JT  - Respiratory physiology & neurobiology
JID - 101140022
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/complications/*genetics/physiopathology
MH  - Plethysmography
MH  - Respiratory Insufficiency/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats/genetics
OTO - NOTNLM
OT  - CTG trinucleotide
OT  - DM1 transgenic mice
OT  - Myotonic dystrophy type 1
OT  - Pressure plethysmography
OT  - Respiratory failure
EDAT- 2013/07/03 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/07/02 06:00
PHST- 2013/05/15 00:00 [received]
PHST- 2013/06/20 00:00 [revised]
PHST- 2013/06/20 00:00 [accepted]
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - S1569-9048(13)00220-6 [pii]
AID - 10.1016/j.resp.2013.06.014 [doi]
PST - ppublish
SO  - Respir Physiol Neurobiol. 2013 Oct 1;189(1):22-6. doi: 
      10.1016/j.resp.2013.06.014. Epub 2013 Jun 27.

PMID- 23570879
OWN - NLM
STAT- MEDLINE
DCOM- 20130715
LR  - 20211203
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 522
IP  - 2
DP  - 2013 Jun 15
TI  - Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder.
PG  - 226-30
LID - S0378-1119(13)00328-4 [pii]
LID - 10.1016/j.gene.2013.03.059 [doi]
AB  - Myotonic dystrophy is a progressive multisystem genetic disorder affecting about 
      1 in 8000 people worldwide. The unstable repeat expansions of (CTG)n or (CCTG)n 
      in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy: 
      (i) myotonic dystrophy type 1 (DM1) and (ii) myotonic dystrophy type 2 (DM2) 
      respectively. There is currently no cure but supportive management helps equally 
      to reduce the morbidity and mortality and patients need close follow up to pay 
      attention to their clinical problems. This review will focus on the clinical 
      features, molecular view and genetics, diagnosis and management of DM1.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Kumar, Ashok
AU  - Kumar A
FAU - Agarwal, Sarita
AU  - Agarwal S
FAU - Agarwal, Divya
AU  - Agarwal D
FAU - Phadke, Shubha R
AU  - Phadke SR
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
DEP - 20130406
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (CNBP protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - Molecular Diagnostic Techniques
MH  - Muscle Relaxation/physiology
MH  - Muscle Weakness/genetics/therapy
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA/metabolism
MH  - RNA-Binding Proteins/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2013/04/11 06:00
MHDA- 2013/07/17 06:00
CRDT- 2013/04/11 06:00
PHST- 2012/01/31 00:00 [received]
PHST- 2012/12/28 00:00 [revised]
PHST- 2013/03/16 00:00 [accepted]
PHST- 2013/04/11 06:00 [entrez]
PHST- 2013/04/11 06:00 [pubmed]
PHST- 2013/07/17 06:00 [medline]
AID - S0378-1119(13)00328-4 [pii]
AID - 10.1016/j.gene.2013.03.059 [doi]
PST - ppublish
SO  - Gene. 2013 Jun 15;522(2):226-30. doi: 10.1016/j.gene.2013.03.059. Epub 2013 Apr 
      6.

PMID- 23319325
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20211203
IS  - 1522-1709 (Electronic)
IS  - 1520-9512 (Linking)
VI  - 17
IP  - 3
DP  - 2013 Sep
TI  - Genetics correlates with lung function and nocturnal ventilation in myotonic 
      dystrophy.
PG  - 1087-92
LID - 10.1007/s11325-013-0807-6 [doi]
AB  - BACKGROUND: Dystrophia myotonica (DM) is the most frequent adult-onset muscular 
      dystrophy. Type 1 is caused by the cytosine-thymine-guanine (CTG) repeat 
      expansion in the DM protein kinase gene. Respiratory muscle weakness and altered 
      central ventilatory control lead to hypercapnia and lung volume restriction. 
      PURPOSE: This study aims to review the respiratory involvement in DM patients and 
      study its relation with genetics. METHODS: Retrospective study of patients with 
      DM referred for respiratory assessment was made. Noninvasive ventilation (NIV) 
      was considered to daytime hypercapnia or symptoms of nocturnal hypoventilation. 
      RESULTS: Forty-two consecutive patients (37.9 +/- 13.6 years) were evaluated. Mean 
      CTG length was 642.8 +/- 439.2 repeats. In the first evaluation, mean forced vital 
      capacity (FVC) was 74.4 +/- 20.2 %, maximal expiratory pressure (MEP) 35 +/- 16 %, 
      maximal inspiratory pressure 52 +/- 23 %, peak cough flow (PCF) 327.3 +/- 97.7 L/min, 
      arterial pressure of oxygen 79.7 +/- 11.3 mmHg, arterial pressure of carbon dioxide 
      45.5 +/- 6.2 mmHg, overnight minimal peripheral oxygen saturation (SpO2) 79.6 +/- 
      11.6 %, and apnea-hypopnea index 13.9 +/- 9.9. CTG length was found to be related 
      with MEP (r = -0.67; p = 0.001) and SpO2 (r = -0.37; p = 0.039). NIV was started 
      in 25 patients. Ventilated patients had lower FVC (2.19 to 3.21 L; p < 0.001) and 
      PCF (285.3 to 388.5 L/min; p = 0.003) and more CTG repeats (826.6 to 388.5 
      repeats; p = 0.02). NIV compliance was poor in seven patients (28 %) and related 
      with hypercapnia (r = 0.87; p = 0.002) and inspiratory positive airway pressure 
      setting (r = 0.65; p = 0.009). Ventilation improved symptoms and nocturnal 
      hypoventilation. Comparing the first and last evaluations, only PCF was 
      significantly lower (275.0 to 310.8 L/min; p = 0.019). CONCLUSIONS: Ventilatory 
      insufficiency is very common in patients with DM and CTG length may be useful to 
      predict it. Prolonged NIV improves symptoms, nocturnal hypoventilation and 
      maintains daily blood gases. Routine evaluation of PCF should not be forgotten 
      and assisted coughing training provided.
FAU - Monteiro, Regina
AU  - Monteiro R
AD  - Pulmonology Department, Hospital Center of Vila Nova de Gaia/Espinho, Unidade 1, 
      4434-502 Vila Nova de Gaia, Portugal.
FAU - Bento, Joao
AU  - Bento J
FAU - Goncalves, Miguel R
AU  - Goncalves MR
FAU - Pinto, Tiago
AU  - Pinto T
FAU - Winck, Joao Carlos
AU  - Winck JC
LA  - eng
PT  - Journal Article
DEP - 20130115
PL  - Germany
TA  - Sleep Breath
JT  - Sleep & breathing = Schlaf & Atmung
JID - 9804161
RN  - 0 (DMPK protein, human)
RN  - 142M471B3J (Carbon Dioxide)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Carbon Dioxide/*blood
MH  - Female
MH  - Humans
MH  - *Lung Volume Measurements
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/*genetics/therapy
MH  - Myotonin-Protein Kinase
MH  - Oxygen/*blood
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Respiratory Insufficiency/diagnosis/genetics/therapy
MH  - Retrospective Studies
MH  - Sleep Apnea, Obstructive/*diagnosis/*genetics/therapy
MH  - Trinucleotide Repeat Expansion
MH  - Young Adult
EDAT- 2013/01/16 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/01/16 06:00
PHST- 2012/11/02 00:00 [received]
PHST- 2013/01/07 00:00 [accepted]
PHST- 2012/12/28 00:00 [revised]
PHST- 2013/01/16 06:00 [entrez]
PHST- 2013/01/16 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - 10.1007/s11325-013-0807-6 [doi]
PST - ppublish
SO  - Sleep Breath. 2013 Sep;17(3):1087-92. doi: 10.1007/s11325-013-0807-6. Epub 2013 
      Jan 15.

PMID- 23308382
OWN - NLM
STAT- MEDLINE
DCOM- 20130923
LR  - 20211203
IS  - 2159-3345 (Electronic)
IS  - 2159-3337 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Apr
TI  - Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes 
      mutant RNA toxicity in a mouse model of myotonic dystrophy.
PG  - 109-17
LID - 10.1089/nat.2012.0404 [doi]
AB  - Expansions of CUG trinucleotide sequences in RNA transcripts provide the basis 
      for toxic RNA gain-of-function that leads to detrimental changes in RNA 
      metabolism. A CTG repeat element normally resides in the 3' untranslated region 
      of the dystrophia myotonica-protein kinase (DMPK) gene, but when expanded it is 
      the genetic lesion of myotonic dystrophy type 1 (DM1), a hereditary neuromuscular 
      disease. The pathogenic DMPK transcript containing the CUG expansion is retained 
      in ribonuclear foci as part of a complex with RNA-binding proteins such as 
      muscleblind-like 1 (MBNL1), resulting in aberrant splicing of numerous RNA 
      transcripts and consequent physiological abnormalities including myotonia. 
      Herein, we demonstrate molecular and physiological amelioration of the toxic 
      effects of mutant RNA in the HSA(LR) mouse model of DM1 by systemic 
      administration of peptide-linked morpholino (PPMO) antisense oligonucleotides 
      bearing a CAG repeat sequence. Intravenous administration of PPMO conjugates to 
      HSA(LR) mice led to redistribution of Mbnl1 protein in myonuclei and corrections 
      in abnormal RNA splicing. Additionally, myotonia was completely eliminated in 
      PPMO-treated HSA(LR) mice. These studies provide proof of concept that 
      neutralization of RNA toxicity by systemic delivery of antisense oligonucleotides 
      that target the CUG repeat is an effective therapeutic approach for treating the 
      skeletal muscle aspects of DM1 pathology.
FAU - Leger, Andrew J
AU  - Leger AJ
AD  - Genzyme, a Sanofi Company , Framingham, MA 01701, USA. andrew.leger@genzyme.com
FAU - Mosquea, Leocadia M
AU  - Mosquea LM
FAU - Clayton, Nicholas P
AU  - Clayton NP
FAU - Wu, I-Huan
AU  - Wu IH
FAU - Weeden, Timothy
AU  - Weeden T
FAU - Nelson, Carol A
AU  - Nelson CA
FAU - Phillips, Lucy
AU  - Phillips L
FAU - Roberts, Errin
AU  - Roberts E
FAU - Piepenhagen, Peter A
AU  - Piepenhagen PA
FAU - Cheng, Seng H
AU  - Cheng SH
FAU - Wentworth, Bruce M
AU  - Wentworth BM
LA  - eng
PT  - Journal Article
DEP - 20130111
PL  - United States
TA  - Nucleic Acid Ther
JT  - Nucleic acid therapeutics
JID - 101562758
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (Morpholinos)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Peptides)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Morpholinos/*administration & dosage/chemistry
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - Myotonin-Protein Kinase
MH  - Oligonucleotides, Antisense/administration & dosage
MH  - Peptides/*administration & dosage/chemistry
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA/genetics/toxicity
MH  - RNA Splicing/genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Trinucleotide Repeats/genetics
EDAT- 2013/01/12 06:00
MHDA- 2013/09/24 06:00
CRDT- 2013/01/12 06:00
PHST- 2013/01/12 06:00 [entrez]
PHST- 2013/01/12 06:00 [pubmed]
PHST- 2013/09/24 06:00 [medline]
AID - 10.1089/nat.2012.0404 [doi]
PST - ppublish
SO  - Nucleic Acid Ther. 2013 Apr;23(2):109-17. doi: 10.1089/nat.2012.0404. Epub 2013 
      Jan 11.

PMID- 26317000
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150828
LR  - 20201001
IS  - 2090-858X (Print)
IS  - 2090-8601 (Electronic)
IS  - 2090-8601 (Linking)
VI  - 2013
DP  - 2013
TI  - Simple Repeat-Primed PCR Analysis of the Myotonic Dystrophy Type 1 Gene in a 
      Clinical Diagnostics Environment.
PG  - 857564
LID - 10.1155/2013/857564 [doi]
LID - 857564
AB  - Myotonic dystrophy type 1 is an autosomal dominant neuromuscular disorder that is 
      caused by the expansion of a CTG trinucleotide repeat in the DMPK gene. The 
      confirmation of a clinical diagnosis of DM-1 usually involves PCR amplification 
      of the CTG repeat-containing region and subsequent sizing of the amplification 
      products in order to deduce the number of CTG repeats. In the case of repeat 
      hyperexpansions, Southern blotting is also used; however, the latter has largely 
      been superseded by triplet repeat-primed PCR (TP-PCR), which does not yield a CTG 
      repeat number but nevertheless provides a means of stratifying patients regarding 
      their disease severity. We report here a combination of forward and reverse 
      TP-PCR primers that allows for the simple and effective scoring of both the size 
      of smaller alleles and the presence or absence of expanded repeat sequences. In 
      addition, the CTG repeat-containing TP-PCR forward primer can target both the 
      DM-1 and Huntington disease genes, thereby streamlining the work flow for 
      confirmation of clinical diagnoses in a diagnostic laboratory.
FAU - Dryland, Philippa A
AU  - Dryland PA
AD  - Diagnostic Genetics, LabPlus, Auckland City Hospital, P.O. Box 110031, Auckland 
      1148, New Zealand.
FAU - Doherty, Elaine
AU  - Doherty E
AD  - Diagnostic Genetics, LabPlus, Auckland City Hospital, P.O. Box 110031, Auckland 
      1148, New Zealand.
FAU - Love, Jennifer M
AU  - Love JM
AD  - Diagnostic Genetics, LabPlus, Auckland City Hospital, P.O. Box 110031, Auckland 
      1148, New Zealand.
FAU - Love, Donald R
AU  - Love DR
AD  - Diagnostic Genetics, LabPlus, Auckland City Hospital, P.O. Box 110031, Auckland 
      1148, New Zealand ; School of Biological Sciences, University of Auckland, 
      Private Bag 92019, Auckland 1142, New Zealand.
LA  - eng
PT  - Journal Article
DEP - 20131111
PL  - United States
TA  - J Neurodegener Dis
JT  - Journal of neurodegenerative diseases
JID - 101622104
PMC - PMC4437349
EDAT- 2013/01/01 00:00
MHDA- 2013/01/01 00:01
PMCR- 2013/11/11
CRDT- 2015/08/29 06:00
PHST- 2013/03/31 00:00 [received]
PHST- 2013/09/18 00:00 [revised]
PHST- 2013/09/19 00:00 [accepted]
PHST- 2015/08/29 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2013/01/01 00:01 [medline]
PHST- 2013/11/11 00:00 [pmc-release]
AID - 10.1155/2013/857564 [doi]
PST - ppublish
SO  - J Neurodegener Dis. 2013;2013:857564. doi: 10.1155/2013/857564. Epub 2013 Nov 11.

PMID- 25003003
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140708
LR  - 20211021
IS  - 2167-5511 (Print)
IS  - 2167-5511 (Electronic)
IS  - 2167-5511 (Linking)
VI  - 1
DP  - 2013
TI  - Synaptic protein dysregulation in myotonic dystrophy type 1: Disease 
      neuropathogenesis beyond missplicing.
PG  - e25553
LID - 10.4161/rdis.25553 [doi]
LID - e25553
AB  - The toxicity of expanded transcripts in myotonic dystrophy type 1 (DM1) is mainly 
      mediated by the disruption of alternative splicing. However, the detailed disease 
      mechanisms in the central nervous system (CNS) have not been fully elucidated. In 
      our recent study, we demonstrated that the accumulation of mutant transcripts in 
      the CNS of a mouse model of DM1 disturbs splicing in a region-specific manner. We 
      now discuss that the spatial- and temporal-regulated expression of splicing 
      factors may contribute to the region-specific spliceopathy in DM1 brains. In the 
      search for disease mechanisms operating in the CNS, we found that the expression 
      of expanded CUG-containing RNA affects the expression and phosphorylation of 
      synaptic vesicle proteins, possibly contributing to DM1 neurological phenotypes. 
      Although mediated by splicing regulators with a described role in DM1, the 
      misregulation of synaptic proteins was not associated with missplicing of their 
      coding transcripts, supporting the view that DM1 mechanisms in the CNS have also 
      far-reaching implications beyond the disruption of a splicing program.
FAU - Hernandez-Hernandez, Oscar
AU  - Hernandez-Hernandez O
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Laboratorio de 
      Medicina Genomica; Departamento de Genetica; Instituto Nacional de 
      Rehabilitacion; Calzada Mexico Xochimilco, Mexico.
FAU - Sicot, Geraldine
AU  - Sicot G
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Dinca, Diana M
AU  - Dinca DM
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Huguet, Aline
AU  - Huguet A
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Nicole, Annie
AU  - Nicole A
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Buee, Luc
AU  - Buee L
AD  - Inserm U837-1; Alzheimer and Tauopathies; Universite Lille Nord de France; Centre 
      Jean Pierre Aubert; Lille, France.
FAU - Munnich, Arnold
AU  - Munnich A
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Sergeant, Nicolas
AU  - Sergeant N
AD  - Inserm U837-1; Alzheimer and Tauopathies; Universite Lille Nord de France; Centre 
      Jean Pierre Aubert; Lille, France.
FAU - Gourdon, Genevieve
AU  - Gourdon G
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
FAU - Gomes-Pereira, Mario
AU  - Gomes-Pereira M
AD  - Inserm U781; Hopital Necker Enfants Malades; Paris, France ; Universite Paris 
      Descartes-Sorbonne Paris Cite; Institut Imagine; Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20130626
PL  - United States
TA  - Rare Dis
JT  - Rare diseases (Austin, Tex.)
JID - 101603407
PMC - PMC3927487
OTO - NOTNLM
OT  - RAB3A
OT  - RNA splicing
OT  - RNA toxicity
OT  - central nervous system
OT  - myotonic dystrophy type 1
OT  - synapsin I
OT  - synaptic function
OT  - synaptic protein
OT  - transgenic mice
OT  - trinucleotide repeat expansion
EDAT- 2013/01/01 00:00
MHDA- 2013/01/01 00:01
PMCR- 2013/06/26
CRDT- 2014/07/09 06:00
PHST- 2013/05/17 00:00 [received]
PHST- 2013/06/24 00:00 [revised]
PHST- 2013/06/25 00:00 [accepted]
PHST- 2014/07/09 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2013/01/01 00:01 [medline]
PHST- 2013/06/26 00:00 [pmc-release]
AID - 2013RAREDIS034R [pii]
AID - 10.4161/rdis.25553 [doi]
PST - epublish
SO  - Rare Dis. 2013 Jun 26;1:e25553. doi: 10.4161/rdis.25553. eCollection 2013.

PMID- 23263591
OWN - NLM
STAT- MEDLINE
DCOM- 20131205
LR  - 20211203
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 260
IP  - 5
DP  - 2013 May
TI  - Molecular, clinical, and muscle studies in myotonic dystrophy type 1 (DM1) 
      associated with novel variant CCG expansions.
PG  - 1245-57
LID - 10.1007/s00415-012-6779-9 [doi]
AB  - We assessed clinical, molecular and muscle histopathological features in five 
      unrelated Italian DM1 patients carrying novel variant pathological expansions 
      containing CCG interruptions within the 3'-end of the CTG array at the DMPK 
      locus, detected by bidirectional triplet primed PCR (TP-PCR) and sequencing. 
      Three patients had a negative DM1 testing by routine long-range PCR; the other 
      two patients were identified among 100 unrelated DM1 cases and re-evaluated to 
      estimate the prevalence of variant expansions. The overall prevalence was 4.8 % 
      in our study cohort. There were no major clinical differences between variant and 
      non-variant DM1 patients, except for cognitive involvement. Muscle RNA-FISH, 
      immunofluorescence for MBNL1 and RT-PCR analysis documented the presence of 
      ribonuclear inclusions, their co-localization with MBNL1, and an aberrant 
      splicing pattern involved in DM1 pathogenesis, without any obvious differences 
      between variant and non-variant DM1 patients. Therefore, this study shows that 
      the CCG interruptions at the 3'-end of expanded DMPK alleles do not produce 
      qualitative effects on the RNA-mediated toxic gain-of-function in DM1 muscle 
      tissues. Finally, our results support the conclusion that different patterns of 
      CCG interruptions within the CTG array could modulate the DM1 clinical phenotype, 
      variably affecting the mutational dynamics of the variant repeat.
FAU - Santoro, Massimo
AU  - Santoro M
AD  - Fondazione Don Carlo Gnocchi, ONLUS, Milan, Italy.
FAU - Masciullo, Marcella
AU  - Masciullo M
FAU - Pietrobono, Roberta
AU  - Pietrobono R
FAU - Conte, Giulia
AU  - Conte G
FAU - Modoni, Anna
AU  - Modoni A
FAU - Bianchi, Maria Laura E
AU  - Bianchi ML
FAU - Rizzo, Valentina
AU  - Rizzo V
FAU - Pomponi, Maria Grazia
AU  - Pomponi MG
FAU - Tasca, Giorgio
AU  - Tasca G
FAU - Neri, Giovanni
AU  - Neri G
FAU - Silvestri, Gabriella
AU  - Silvestri G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121223
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (DMPK protein, human)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA Mutational Analysis
MH  - Electromyography
MH  - Exons/genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism/*pathology/physiopathology
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Myotonin-Protein Kinase
MH  - Neurologic Examination
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA-Binding Proteins/metabolism
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2012/12/25 06:00
MHDA- 2013/12/16 06:00
CRDT- 2012/12/25 06:00
PHST- 2012/09/24 00:00 [received]
PHST- 2012/11/28 00:00 [accepted]
PHST- 2012/11/22 00:00 [revised]
PHST- 2012/12/25 06:00 [entrez]
PHST- 2012/12/25 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1007/s00415-012-6779-9 [doi]
PST - ppublish
SO  - J Neurol. 2013 May;260(5):1245-57. doi: 10.1007/s00415-012-6779-9. Epub 2012 Dec 
      23.

PMID- 23209425
OWN - NLM
STAT- MEDLINE
DCOM- 20130513
LR  - 20240104
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Print)
IS  - 1553-7390 (Linking)
VI  - 8
IP  - 11
DP  - 2012
TI  - Molecular, physiological, and motor performance defects in DMSXL mice carrying 
      >1,000 CTG repeats from the human DM1 locus.
PG  - e1003043
LID - 10.1371/journal.pgen.1003043 [doi]
LID - e1003043
AB  - Myotonic dystrophy type 1 (DM1) is caused by an unstable CTG repeat expansion in 
      the 3'UTR of the DM protein kinase (DMPK) gene. DMPK transcripts carrying CUG 
      expansions form nuclear foci and affect splicing regulation of various RNA 
      transcripts. Furthermore, bidirectional transcription over the DMPK gene and 
      non-conventional RNA translation of repeated transcripts have been described in 
      DM1. It is clear now that this disease may involve multiple pathogenic pathways 
      including changes in gene expression, RNA stability and splicing regulation, 
      protein translation, and micro-RNA metabolism. We previously generated transgenic 
      mice with 45-kb of the DM1 locus and >300 CTG repeats (DM300 mice). After 
      successive breeding and a high level of CTG repeat instability, we obtained 
      transgenic mice carrying >1,000 CTG (DMSXL mice). Here we described for the first 
      time the expression pattern of the DMPK sense transcripts in DMSXL and human 
      tissues. Interestingly, we also demonstrate that DMPK antisense transcripts are 
      expressed in various DMSXL and human tissues, and that both sense and antisense 
      transcripts accumulate in independent nuclear foci that do not co-localize 
      together. Molecular features of DM1-associated RNA toxicity in DMSXL mice (such 
      as foci accumulation and mild missplicing), were associated with high mortality, 
      growth retardation, and muscle defects (abnormal histopathology, reduced muscle 
      strength, and lower motor performances). We have found that lower levels of 
      IGFBP-3 may contribute to DMSXL growth retardation, while increased proteasome 
      activity may affect muscle function. These data demonstrate that the human DM1 
      locus carrying very large expansions induced a variety of molecular and 
      physiological defects in transgenic mice, reflecting DM1 to a certain extent. As 
      a result, DMSXL mice provide an animal tool to decipher various aspects of the 
      disease mechanisms. In addition, these mice can be used to test the preclinical 
      impact of systemic therapeutic strategies on molecular and physiological 
      phenotypes.
FAU - Huguet, Aline
AU  - Huguet A
AD  - Inserm U781, Universite Paris Descartes-Sorbonne Paris Cite, Institut Imagine, 
      Hopital Necker-Enfants Malades, Paris, France.
FAU - Medja, Fadia
AU  - Medja F
FAU - Nicole, Annie
AU  - Nicole A
FAU - Vignaud, Alban
AU  - Vignaud A
FAU - Guiraud-Dogan, Celine
AU  - Guiraud-Dogan C
FAU - Ferry, Arnaud
AU  - Ferry A
FAU - Decostre, Valerie
AU  - Decostre V
FAU - Hogrel, Jean-Yves
AU  - Hogrel JY
FAU - Metzger, Friedrich
AU  - Metzger F
FAU - Hoeflich, Andreas
AU  - Hoeflich A
FAU - Baraibar, Martin
AU  - Baraibar M
FAU - Gomes-Pereira, Mario
AU  - Gomes-Pereira M
FAU - Puymirat, Jack
AU  - Puymirat J
FAU - Bassez, Guillaume
AU  - Bassez G
FAU - Furling, Denis
AU  - Furling D
FAU - Munnich, Arnold
AU  - Munnich A
FAU - Gourdon, Genevieve
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121129
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.4.- (Endopeptidases)
RN  - EC 3.4.99.- (insulin-like growth factor binding protein-3 protease)
SB  - IM
MH  - Animals
MH  - Cell Nucleus/metabolism
MH  - Endopeptidases/metabolism
MH  - Gene Expression Regulation
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - *Muscle, Skeletal/growth & development/physiopathology
MH  - *Myotonic Dystrophy/genetics/physiopathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - RNA Splicing
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC3510028
COIS- The authors have declared that no competing interests exist.
EDAT- 2012/12/05 06:00
MHDA- 2013/05/15 06:00
PMCR- 2012/11/01
CRDT- 2012/12/05 06:00
PHST- 2012/03/02 00:00 [received]
PHST- 2012/09/05 00:00 [accepted]
PHST- 2012/12/05 06:00 [entrez]
PHST- 2012/12/05 06:00 [pubmed]
PHST- 2013/05/15 06:00 [medline]
PHST- 2012/11/01 00:00 [pmc-release]
AID - PGENETICS-D-12-00540 [pii]
AID - 10.1371/journal.pgen.1003043 [doi]
PST - ppublish
SO  - PLoS Genet. 2012;8(11):e1003043. doi: 10.1371/journal.pgen.1003043. Epub 2012 Nov 
      29.

PMID- 23183533
OWN - NLM
STAT- MEDLINE
DCOM- 20130807
LR  - 20211203
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 21
IP  - 2
DP  - 2013 Feb
TI  - RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
PG  - 380-7
LID - 10.1038/mt.2012.222 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an RNA dominant disease caused by expression 
      of DM protein kinase (DMPK) transcripts that contain an expanded CUG repeat 
      (CUG(exp)). The toxic mRNA localizes to nuclear foci and sequesters proteins 
      involved in the regulation of alternative splicing, such as, muscleblind-like 1 
      (MBNL1). Here, we used synthetic short interfering RNAs (siRNAs) to target CUG 
      repeats and test the concept that inhibiting the expression of CUG(exp) RNA can 
      mitigate features of DM1 in transgenic mice. Intramuscular injection and 
      electroporation of siRNA resulted in ~70-80% downregulation of CUG(exp) 
      transcripts. A limited survey of endogenous mouse transcripts that contain 
      nonexpanded CUG or CAG repeats showed that most were not affected, though Txlnb 
      containing (CUG)(9) was significantly reduced. By this strategy, the number and 
      intensity of CUG(exp) nuclear foci were reduced and splicing of MBNL1-dependent 
      exons was improved. These data suggest that the expanded CUG repeats are a 
      potential target for allele-selective RNA interference.
FAU - Sobczak, Krzysztof
AU  - Sobczak K
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, New 
      York 14642, USA. ksobczak@amu.edu.pl
FAU - Wheeler, Thurman M
AU  - Wheeler TM
FAU - Wang, Wenli
AU  - Wang W
FAU - Thornton, Charles A
AU  - Thornton CA
LA  - eng
GR  - AR049077/AR/NIAMS NIH HHS/United States
GR  - U54NS48843/NS/NINDS NIH HHS/United States
GR  - R01 AR049077/AR/NIAMS NIH HHS/United States
GR  - K08 NS064293/NS/NINDS NIH HHS/United States
GR  - K08NS064293/NS/NINDS NIH HHS/United States
GR  - K24AR/NS48143/AR/NIAMS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121127
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alternative Splicing/genetics
MH  - Amino Acid Sequence
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Nucleus/chemistry/genetics
MH  - DNA-Binding Proteins/genetics/metabolism
MH  - Disease Models, Animal
MH  - Electromyography
MH  - Exons
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Mice
MH  - Mice, Transgenic
MH  - Microscopy, Fluorescence
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics/pathology/*therapy
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics/metabolism
MH  - *RNA Interference
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Small Interfering/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - *Trinucleotide Repeat Expansion
PMC - PMC3594017
EDAT- 2012/11/28 06:00
MHDA- 2013/08/08 06:00
PMCR- 2014/02/01
CRDT- 2012/11/28 06:00
PHST- 2012/11/28 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2013/08/08 06:00 [medline]
PHST- 2014/02/01 00:00 [pmc-release]
AID - S1525-0016(16)30598-6 [pii]
AID - 10.1038/mt.2012.222 [doi]
PST - ppublish
SO  - Mol Ther. 2013 Feb;21(2):380-7. doi: 10.1038/mt.2012.222. Epub 2012 Nov 27.

PMID- 23161457
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20211203
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 260
IP  - 4
DP  - 2013 Apr
TI  - MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 
      1.
PG  - 998-1003
LID - 10.1007/s00415-012-6740-y [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic autosomal dominant disorder 
      characterized by a highly variable phenotype and caused by an unstable CTG repeat 
      expansion in the 3' untranslated region of the dystrophia myotonica protein 
      kinase (DMPK) gene. Longer CTG repeat expansions often correlate with an 
      anticipated age at onset and CTG repeat number may account for 45-60 % of the 
      variance in disease severity. In order to search for candidate genes that could 
      act as modifiers of disease severity, we studied the association between 
      Muscleblind-like protein-1 (MBNL1) gene polymorphisms and the DM1 phenotype. In a 
      group of 301 patients diagnosed with DM1 based on clinical symptoms, diagnosis 
      was confirmed by molecular analysis of the DMPK gene. Patients were divided into 
      four subtypes. The first subtype corresponded to asymptomatic patients or those 
      with a mild phenotype, the second included those with a classic phenotype, the 
      third concerned childhood onset, and the fourth corresponded to the congenital 
      form of DM1. Three SNPs located in the MBNL1 gene promoter, rs323622, rs17283597, 
      and rs17433672, were studied. Case-control analysis revealed that allele 
      frequencies for the latter two were significantly associated with DM1 (p = 0.037 
      and p = 0.020). Multivariate linear regression analysis using phenotype as the 
      dependent variable demonstrated that the TT genotype of the third SNP, rs323622, 
      was associated with a more severe phenotype (p = 0.0034) and accounted for 1.88 % 
      of the variance in disease severity. We report the association of several genetic 
      variants of the MBNL1 gene with DM1 or with the severity of the disease.
FAU - Huin, Vincent
AU  - Huin V
AD  - INSERM UMR837, Alzheimer and Tauopathies, University Lille-Nord de France, USDL, 
      IMPRT, Jean-Pierre Aubert Research Center, Batiment Biserte, 1, Place de Verdun, 
      59045 Lille, France.
FAU - Vasseur, Francis
AU  - Vasseur F
FAU - Schraen-Maschke, Susanna
AU  - Schraen-Maschke S
FAU - Dhaenens, Claire-Marie
AU  - Dhaenens CM
FAU - Devos, Patrick
AU  - Devos P
FAU - Dupont, Kathy
AU  - Dupont K
FAU - Sergeant, Nicolas
AU  - Sergeant N
FAU - Buee, Luc
AU  - Buee L
FAU - Lacour, Arnaud
AU  - Lacour A
FAU - Hofmann-Radvanyi, Helene
AU  - Hofmann-Radvanyi H
FAU - Sablonniere, Bernard
AU  - Sablonniere B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121116
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Regression Analysis
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Young Adult
EDAT- 2012/11/20 06:00
MHDA- 2013/09/27 06:00
CRDT- 2012/11/20 06:00
PHST- 2012/08/21 00:00 [received]
PHST- 2012/10/29 00:00 [accepted]
PHST- 2012/10/16 00:00 [revised]
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - 10.1007/s00415-012-6740-y [doi]
PST - ppublish
SO  - J Neurol. 2013 Apr;260(4):998-1003. doi: 10.1007/s00415-012-6740-y. Epub 2012 Nov 
      16.

PMID- 23159592
OWN - NLM
STAT- MEDLINE
DCOM- 20130617
LR  - 20211203
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Linking)
VI  - 15
IP  - 1
DP  - 2013 Jan
TI  - Novel heat pulse extension-PCR-based method for detection of large CTG-repeat 
      expansions in myotonic dystrophy type 1.
PG  - 110-5
LID - S1525-1578(12)00265-6 [pii]
LID - 10.1016/j.jmoldx.2012.07.004 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal-dominant disease caused by an 
      expansion of CTG repeats in the 3' untranslated region of the Dystrophia 
      Myotonica Protein Kinase (DMPK) gene. Detection and accurate sizing of the 
      CTG-repeat expansions is clinically important, because the number of CTG repeats 
      correlates with the disease severity. Because difficulties in PCR amplification 
      over large expansions, molecular diagnosis of DM1 is still primarily based on 
      Southern blotting, which is technically demanding and time consuming and requires 
      large amounts of genomic DNA samples. We have recently discovered that the use of 
      multiple heat pulses during Heat Pulse Extension PCR (HPE-PCR) enables efficient 
      amplification over repetitive and GC-rich sequences. Based on this principle, we 
      have developed an assay for efficient amplification of large CTG-repeat 
      expansions seen in DM1 patients. The HPE-PCR method was able to amplify different 
      DMPK1 repeat expansions of up to 1750 CTG repeats in 78 clinical samples with a 
      varying degree of tissue heterogeneity, even in the presence of the short 
      wild-type allele. The CTG-repeat lengths and fragmentation patterns obtained with 
      HPE-PCR were fully concordant with the original diagnostic Southern blotting 
      results. This novel technique provides a PCR-based platform for molecular 
      diagnosis of DM1, and it has been adopted for routine diagnostic use.
CI  - Copyright (c) 2013 American Society for Investigative Pathology and the Association 
      for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
FAU - Orpana, Arto K
AU  - Orpana AK
AD  - HUSLAB, Laboratory of Genetics, Helsinki, Finland.
FAU - Ho, Tho H
AU  - Ho TH
FAU - Alagrund, Katariina
AU  - Alagrund K
FAU - Ridanpaa, Maaret
AU  - Ridanpaa M
FAU - Aittomaki, Kristiina
AU  - Aittomaki K
FAU - Stenman, Jakob
AU  - Stenman J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121114
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - DNA/genetics
MH  - DNA Fragmentation
MH  - DNA Mutational Analysis/methods
MH  - Genomics/methods
MH  - Humans
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction/*methods
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Reproducibility of Results
MH  - *Trinucleotide Repeat Expansion
EDAT- 2012/11/20 06:00
MHDA- 2013/06/19 06:00
CRDT- 2012/11/20 06:00
PHST- 2012/04/25 00:00 [received]
PHST- 2012/06/13 00:00 [revised]
PHST- 2012/07/13 00:00 [accepted]
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
AID - S1525-1578(12)00265-6 [pii]
AID - 10.1016/j.jmoldx.2012.07.004 [doi]
PST - ppublish
SO  - J Mol Diagn. 2013 Jan;15(1):110-5. doi: 10.1016/j.jmoldx.2012.07.004. Epub 2012 
      Nov 14.

PMID- 23139243
OWN - NLM
STAT- MEDLINE
DCOM- 20130705
LR  - 20220224
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 22
IP  - 4
DP  - 2013 Feb 15
TI  - Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved 
      in myotonic dystrophy type 1 patients.
PG  - 704-16
LID - 10.1093/hmg/dds478 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by the expansion of CTG repeats in the 
      3' untranslated region of the DMPK gene. Several missplicing events and 
      transcriptional alterations have been described in DM1 patients. A large number 
      of these defects have been reproduced in animal models expressing CTG repeats 
      alone. Recent studies have also reported miRNA dysregulation in DM1 patients. In 
      this work, a Drosophila model was used to investigate miRNA transcriptome 
      alterations in the muscle, specifically triggered by CTG expansions. Twenty 
      miRNAs were differentially expressed in CTG-expressing flies. Of these, 19 were 
      down-regulated, whereas 1 was up-regulated. This trend was confirmed for those 
      miRNAs conserved between Drosophila and humans (miR-1, miR-7 and miR-10) in 
      muscle biopsies from DM1 patients. Consistently, at least seven target 
      transcripts of these miRNAs were up-regulated in DM1 skeletal muscles. The 
      mechanisms involved in dysregulation of miR-7 included a reduction of its primary 
      precursor both in CTG-expressing flies and in DM1 patients. Additionally, a 
      regulatory role for Muscleblind (Mbl) was also suggested for miR-1 and miR-7, as 
      these miRNAs were down-regulated in flies where Mbl had been silenced. Finally, 
      the physiological relevance of miRNA dysregulation was demonstrated for miR-10, 
      since over-expression of this miRNA in Drosophila extended the lifespan of 
      CTG-expressing flies. Taken together, our results contribute to our understanding 
      of the origin and the role of miRNA alterations in DM1.
FAU - Fernandez-Costa, Juan M
AU  - Fernandez-Costa JM
AD  - Department of Genetics, University of Valencia, Burjasot 46100, Spain.
FAU - Garcia-Lopez, Amparo
AU  - Garcia-Lopez A
FAU - Zuniga, Sheila
AU  - Zuniga S
FAU - Fernandez-Pedrosa, Victoria
AU  - Fernandez-Pedrosa V
FAU - Felipo-Benavent, Amelia
AU  - Felipo-Benavent A
FAU - Mata, Manuel
AU  - Mata M
FAU - Jaka, Oihane
AU  - Jaka O
FAU - Aiastui, Ana
AU  - Aiastui A
FAU - Hernandez-Torres, Francisco
AU  - Hernandez-Torres F
FAU - Aguado, Begona
AU  - Aguado B
FAU - Perez-Alonso, Manuel
AU  - Perez-Alonso M
FAU - Vilchez, Jesus J
AU  - Vilchez JJ
FAU - Lopez de Munain, Adolfo
AU  - Lopez de Munain A
FAU - Artero, Ruben D
AU  - Artero RD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121108
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Drosophila Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (Nuclear Proteins)
RN  - 0 (mbl protein, Drosophila)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Cells, Cultured
MH  - Down-Regulation
MH  - Drosophila Proteins/metabolism
MH  - Drosophila melanogaster
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Regulation
MH  - Humans
MH  - Life Expectancy
MH  - Male
MH  - MicroRNAs/*genetics/metabolism
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Nuclear Proteins/metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Transcriptome
MH  - *Trinucleotide Repeat Expansion
EDAT- 2012/11/10 06:00
MHDA- 2013/07/06 06:00
CRDT- 2012/11/10 06:00
PHST- 2012/11/10 06:00 [entrez]
PHST- 2012/11/10 06:00 [pubmed]
PHST- 2013/07/06 06:00 [medline]
AID - dds478 [pii]
AID - 10.1093/hmg/dds478 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2013 Feb 15;22(4):704-16. doi: 10.1093/hmg/dds478. Epub 2012 Nov 
      8.

PMID- 22786587
OWN - NLM
STAT- MEDLINE
DCOM- 20121024
LR  - 20220331
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 79
IP  - 4
DP  - 2012 Jul 24
TI  - Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).
PG  - 348-57
LID - 10.1212/WNL.0b013e318260cbe6 [doi]
AB  - OBJECTIVE: To determine the most critical symptoms in a national myotonic 
      dystrophy type 1 (DM1) population and to identify the modifying factors that have 
      the greatest effect on the severity of these symptoms. METHODS: We performed a 
      cross-sectional study of 278 adult patients with DM1 from the national registry 
      of patients with DM1 between April and August 2010. We assessed the prevalence 
      and relative significance of 221 critical DM1 symptoms and 14 disease themes. 
      These symptoms and themes were chosen for evaluation based on prior interviews 
      with patients with DM1. Responses were categorized by age, CTG repeat length, 
      gender, and duration of symptoms. RESULTS: Participants with DM1 provided symptom 
      rating survey responses to address the relative frequency and importance of each 
      DM1 symptom. The symptomatic themes with the highest prevalence in DM1 were 
      problems with hands or arms (93.5%), fatigue (90.8%), myotonia (90.3%), and 
      impaired sleep or daytime sleepiness (87.9%). Participants identified fatigue and 
      limitations in mobility as the symptomatic themes that have the greatest effect 
      on their lives. We found an association between age and the average prevalence of 
      all themes (p < 0.01) and between CTG repeat length and the average effect of all 
      symptomatic themes on participant lives (p < 0.01). CONCLUSIONS: There are a wide 
      range of symptoms that significantly affect the lives of patients with DM1. These 
      symptoms, some previously underrecognized, have varying levels of importance in 
      the DM1 population and are nonlinearly dependent on patient age and CTG repeat 
      length.
FAU - Heatwole, Chad
AU  - Heatwole C
AD  - University of Rochester, Rochester, NY, USA. chad_heatwole@urmc.rochester.edu
FAU - Bode, Rita
AU  - Bode R
FAU - Johnson, Nicholas
AU  - Johnson N
FAU - Quinn, Christine
AU  - Quinn C
FAU - Martens, William
AU  - Martens W
FAU - McDermott, Michael P
AU  - McDermott MP
FAU - Rothrock, Nan
AU  - Rothrock N
FAU - Thornton, Charles
AU  - Thornton C
FAU - Vickrey, Barbara
AU  - Vickrey B
FAU - Victorson, David
AU  - Victorson D
FAU - Moxley, Richard 3rd
AU  - Moxley R 3rd
LA  - eng
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
GR  - 1K23-AR055947/AR/NIAMS NIH HHS/United States
GR  - U54NS48843-01/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120711
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
EIN - Neurology. 2012 Sep 25;79(13):1411
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Fatigue/*complications/physiopathology/psychology
MH  - Female
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/physiopathology/psychology
MH  - Qualitative Research
MH  - Quality of Life/*psychology
MH  - Severity of Illness Index
MH  - Sleep Wake Disorders/*complications/physiopathology/psychology
PMC - PMC3400095
EDAT- 2012/07/13 06:00
MHDA- 2012/10/25 06:00
PMCR- 2013/07/24
CRDT- 2012/07/13 06:00
PHST- 2012/07/13 06:00 [entrez]
PHST- 2012/07/13 06:00 [pubmed]
PHST- 2012/10/25 06:00 [medline]
PHST- 2013/07/24 00:00 [pmc-release]
AID - WNL.0b013e318260cbe6 [pii]
AID - WNL203935 [pii]
AID - 10.1212/WNL.0b013e318260cbe6 [doi]
PST - ppublish
SO  - Neurology. 2012 Jul 24;79(4):348-57. doi: 10.1212/WNL.0b013e318260cbe6. Epub 2012 
      Jul 11.

PMID- 22758909
OWN - NLM
STAT- MEDLINE
DCOM- 20131031
LR  - 20211021
IS  - 1365-2990 (Electronic)
IS  - 0305-1846 (Print)
IS  - 0305-1846 (Linking)
VI  - 39
IP  - 4
DP  - 2013 Jun
TI  - Altered expression and splicing of Ca(2+) metabolism genes in myotonic 
      dystrophies DM1 and DM2.
PG  - 390-405
LID - 10.1111/j.1365-2990.2012.01289.x [doi]
AB  - AIMS: Myotonic dystrophy types 1 and 2 (DM1 and DM2) are multisystem disorders 
      caused by similar repeat expansion mutations, with similar yet distinct clinical 
      features. Aberrant splicing of multiple effector genes, as well as dysregulation 
      of transcription and translation, has been suggested to underlie different 
      aspects of the complex phenotypes in DM1 and DM2. Ca(2+) plays a central role in 
      both muscle contraction and control of gene expression, and recent expression 
      profiling studies have indicated major perturbations of the Ca(2+) signalling 
      pathways in DM. Here we have further investigated the expression of genes and 
      proteins involved in Ca(2+) metabolism in DM patients, including Ca(2+) channels 
      and Ca(2+) binding proteins. METHODS: We used patient muscle biopsies to analyse 
      mRNA expression and splicing of genes by microarray expression profiling and 
      RT-PCR. We studied protein expression by immunohistochemistry and immunoblotting. 
      RESULTS: Most of the genes studied showed mRNA up-regulation in expression 
      profiling. When analysed by immunohistochemistry the Ca(2+) release channel 
      ryanodine receptor was reduced in DM1 and DM2, as was calsequestrin 2, a 
      sarcoplasmic reticulum lumen Ca(2+) storage protein. Abnormal splicing of ATP2A1 
      was more pronounced in DM2 than DM1. CONCLUSIONS: We observed abnormal mRNA and 
      protein expression in DM affecting several proteins involved in Ca(2+) 
      metabolism, with some differences between DM1 and DM2. Our protein expression 
      studies are suggestive of a post-transcriptional defect(s) in the myotonic 
      dystrophies.
CI  - (c) 2012 The Authors. Neuropathology and Applied Neurobiology (c) 2012 British 
      Neuropathological Society.
FAU - Vihola, A
AU  - Vihola A
AD  - Folkhalsan Institute of Genetics and Department of Medical Genetics, Haartman 
      Institute, University of Helsinki, Helsinki, Finland. anna.vihola@helsinki.fi
FAU - Sirito, M
AU  - Sirito M
FAU - Bachinski, L L
AU  - Bachinski LL
FAU - Raheem, O
AU  - Raheem O
FAU - Screen, M
AU  - Screen M
FAU - Suominen, T
AU  - Suominen T
FAU - Krahe, R
AU  - Krahe R
FAU - Udd, B
AU  - Udd B
LA  - eng
GR  - R01 AR048171/AR/NIAMS NIH HHS/United States
GR  - AR48171/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuropathol Appl Neurobiol
JT  - Neuropathology and applied neurobiology
JID - 7609829
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (DNA, Complementary)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ryanodine Receptor Calcium Release Channel)
RN  - 63231-63-0 (RNA)
RN  - EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases)
RN  - EC 7.2.2.10 (ATP2A1 protein, human)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Alternative Splicing
MH  - Blotting, Western
MH  - Calcium/*metabolism
MH  - Calcium-Binding Proteins/genetics/metabolism
MH  - DNA, Complementary/biosynthesis/genetics
MH  - Data Interpretation, Statistical
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Immunohistochemistry
MH  - Microarray Analysis
MH  - Microscopy, Confocal
MH  - Muscle, Skeletal/pathology
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - RNA/biosynthesis/genetics
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Ryanodine Receptor Calcium Release Channel/genetics/metabolism
MH  - Sarcoplasmic Reticulum Calcium-Transporting ATPases/genetics
PMC - PMC3882430
MID - NIHMS521593
COIS- Conflict of Interest The authors declare that they have no conflict of interest.
EDAT- 2012/07/05 06:00
MHDA- 2013/11/01 06:00
PMCR- 2014/06/01
CRDT- 2012/07/05 06:00
PHST- 2012/07/05 06:00 [entrez]
PHST- 2012/07/05 06:00 [pubmed]
PHST- 2013/11/01 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2990.2012.01289.x [doi]
PST - ppublish
SO  - Neuropathol Appl Neurobiol. 2013 Jun;39(4):390-405. doi: 
      10.1111/j.1365-2990.2012.01289.x.

PMID- 22643181
OWN - NLM
STAT- MEDLINE
DCOM- 20130429
LR  - 20211203
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 20
IP  - 12
DP  - 2012 Dec
TI  - Best practice guidelines and recommendations on the molecular diagnosis of 
      myotonic dystrophy types 1 and 2.
PG  - 1203-8
LID - 10.1038/ejhg.2012.108 [doi]
AB  - Myotonic dystrophy is an autosomal dominant, multisystem disorder that is 
      characterized by myotonic myopathy. The symptoms and severity of myotonic 
      dystrophy type l (DM1) ranges from severe and congenital forms, which frequently 
      result in death because of respiratory deficiency, through to late-onset baldness 
      and cataract. In adult patients, cardiac conduction abnormalities may occur and 
      cause a shorter life span. In subsequent generations, the symptoms in DM1 may 
      present at an earlier age and have a more severe course (anticipation). In 
      myotonic dystrophy type 2 (DM2), no anticipation is described, but cardiac 
      conduction abnormalities as in DM1 are observed and patients with DM2 
      additionally have muscle pain and stiffness. Both DM1 and DM2 are caused by 
      unstable DNA repeats in untranslated regions of different genes: A (CTG)n repeat 
      in the 3'-UTR of the DMPK gene and a (CCTG)n repeat in intron 1 of the CNBP 
      (formerly ZNF9) gene, respectively. The length of the (CTG)n repeat expansion in 
      DM1 correlates with disease severity and age of onset. Nevertheless, these repeat 
      sizes have limited predictive values on individual bases. Because of the disease 
      characteristics in DM1 and DM2, appropriate molecular testing and reporting is 
      very important for the optimal counseling in myotonic dystrophy. Here, we 
      describe best practice guidelines for clinical molecular genetic analysis and 
      reporting in DM1 and DM2, including presymptomatic and prenatal testing.
FAU - Kamsteeg, Erik-Jan
AU  - Kamsteeg EJ
AD  - Department of Human Genetics, Radboud University Nijmegen Medical Centre, 
      Nijmegen, The Netherlands.
FAU - Kress, Wolfram
AU  - Kress W
FAU - Catalli, Claudio
AU  - Catalli C
FAU - Hertz, Jens M
AU  - Hertz JM
FAU - Witsch-Baumgartner, Martina
AU  - Witsch-Baumgartner M
FAU - Buckley, Michael F
AU  - Buckley MF
FAU - van Engelen, Baziel G M
AU  - van Engelen BG
FAU - Schwartz, Marianne
AU  - Schwartz M
FAU - Scheffer, Hans
AU  - Scheffer H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120530
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (3' Untranslated Regions)
RN  - 0 (CNBP protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Female
MH  - Genetic Testing/*methods/standards
MH  - Humans
MH  - Introns
MH  - Molecular Diagnostic Techniques/*methods/standards
MH  - Myotonic Disorders/*diagnosis/genetics
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - Myotonin-Protein Kinase
MH  - Practice Guidelines as Topic
MH  - Pregnancy
MH  - Prenatal Diagnosis/methods/standards
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA-Binding Proteins/genetics
MH  - Repetitive Sequences, Nucleic Acid/genetics
MH  - Sequence Analysis, DNA/methods/standards
PMC - PMC3499739
EDAT- 2012/05/31 06:00
MHDA- 2013/04/30 06:00
PMCR- 2012/12/01
CRDT- 2012/05/31 06:00
PHST- 2012/05/31 06:00 [entrez]
PHST- 2012/05/31 06:00 [pubmed]
PHST- 2013/04/30 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - ejhg2012108 [pii]
AID - 10.1038/ejhg.2012.108 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2012 Dec;20(12):1203-8. doi: 10.1038/ejhg.2012.108. Epub 2012 
      May 30.

PMID- 22619053
OWN - NLM
STAT- MEDLINE
DCOM- 20130620
LR  - 20220330
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 259
IP  - 10
DP  - 2012 Oct
TI  - Correlates of tumor development in patients with myotonic dystrophy.
PG  - 2161-6
LID - 10.1007/s00415-012-6476-8 [doi]
AB  - Patients with myotonic dystrophy (DM) have recently been reported to be at 
      increased risk of tumor development, but clinical associations related to this 
      observation are unknown. We calculated the odds ratios (ORs) and 95 % confidence 
      intervals (CI) of self-reported tumor development by patients' demographic and 
      clinical characteristics to evaluate factors associated with tumor development in 
      DM patients, using data from the National Registry of Myotonic Dystrophy and 
      Facioscapulohumeral Dystrophy Patients and Family Members. Of the 911 
      participants, 47.5 % were male and 85.7 % had DM type 1 (DM1). Compared to DM1, 
      patients with DM type 2 (DM2) were older at registry enrollment (median age 55 
      vs. 44 years, p < 0.0001) and at DM diagnosis (median age 48 vs. 30 years, p < 
      0.0001); and more likely to be females (p = 0.001). At enrollment, 95 (10.4 %) DM 
      patients reported a history of benign or malignant tumor. Tumors were associated 
      with female gender (OR 1.9, 95 % CI 1.2-3.1, p = 0.007) and DM1 (OR 2.1, 95 % CI 
      1.1-4.1, p = 0.03). In a subgroup analysis of patients with blood-based DNA 
      testing results (397 DM1, 54 DM2), repeat expansion size was not associated with 
      tumor risk in DM1 (p = 0.26) or DM2 (p = 0.34). In conclusion, female gender and 
      DM1 subtype, but not DNA repeat expansion size, were associated with increased 
      risk of tumors in DM. Follow-up studies are warranted to determine if oncogenes 
      associated with dystrophia myotonica-protein kinase are altered in DM, and to 
      determine if repeat expansion size, as in our study, is not associated with tumor 
      development.
FAU - Das, Maya
AU  - Das M
AD  - Department of Epidemiology and Public Health, University of Maryland, Baltimore, 
      USA.
FAU - Moxley, Richard T 3rd
AU  - Moxley RT 3rd
FAU - Hilbert, James E
AU  - Hilbert JE
FAU - Martens, William B
AU  - Martens WB
FAU - Letren, Lisa
AU  - Letren L
FAU - Greene, Mark H
AU  - Greene MH
FAU - Gadalla, Shahinaz M
AU  - Gadalla SM
LA  - eng
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
GR  - Z01 CP010144-09/ImNIH/Intramural NIH HHS/United States
GR  - Z01 CP010144-10/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120523
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/genetics
MH  - Neoplasms/*epidemiology/*etiology
MH  - Risk Factors
MH  - Sex Factors
MH  - Young Adult
PMC - PMC3469723
MID - NIHMS387054
COIS- Conflict of interest: None
EDAT- 2012/05/24 06:00
MHDA- 2013/06/21 06:00
PMCR- 2013/10/01
CRDT- 2012/05/24 06:00
PHST- 2012/02/13 00:00 [received]
PHST- 2012/03/05 00:00 [accepted]
PHST- 2012/03/02 00:00 [revised]
PHST- 2012/05/24 06:00 [entrez]
PHST- 2012/05/24 06:00 [pubmed]
PHST- 2013/06/21 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - 10.1007/s00415-012-6476-8 [doi]
PST - ppublish
SO  - J Neurol. 2012 Oct;259(10):2161-6. doi: 10.1007/s00415-012-6476-8. Epub 2012 May 
      23.

PMID- 22595968
OWN - NLM
STAT- MEDLINE
DCOM- 20130206
LR  - 20240104
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 21
IP  - 16
DP  - 2012 Aug 15
TI  - Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 
      1 is a heritable quantitative trait and modifier of disease severity.
PG  - 3558-67
LID - 10.1093/hmg/dds185 [doi]
AB  - Deciphering the contribution of genetic instability in somatic cells is critical 
      to our understanding of many human disorders. Myotonic dystrophy type 1 (DM1) is 
      one such disorder that is caused by the expansion of a CTG repeat that shows 
      extremely high levels of somatic instability. This somatic instability has 
      compromised attempts to measure intergenerational repeat dynamics and infer 
      genotype-phenotype relationships. Using single-molecule PCR, we have 
      characterized more than 17 000 de novo somatic mutations from a large cohort of 
      DM1 patients. These data reveal that the estimated progenitor allele length is 
      the major modifier of age of onset. We find no evidence for a threshold above 
      which repeat length does not contribute toward age at onset, suggesting 
      pathogenesis is not constrained to a simple molecular switch such as nuclear 
      retention of the DMPK transcript or haploinsufficiency for DMPK and/or SIX5. 
      Importantly, we also show that age at onset is further modified by the level of 
      somatic instability; patients in whom the repeat expands more rapidly, develop 
      the symptoms earlier. These data establish a primary role for somatic instability 
      in DM1 severity, further highlighting it as a therapeutic target. In addition, we 
      show that the level of instability is highly heritable, implying a role for 
      individual-specific trans-acting genetic modifiers. Identifying these 
      trans-acting genetic modifiers will facilitate the formulation of novel therapies 
      that curtail the accumulation of somatic expansions and may provide clues to the 
      role these factors play in the development of cancer, aging and inherited disease 
      in the general population.
FAU - Morales, Fernando
AU  - Morales F
AD  - Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary 
      and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.
FAU - Couto, Jillian M
AU  - Couto JM
FAU - Higham, Catherine F
AU  - Higham CF
FAU - Hogg, Grant
AU  - Hogg G
FAU - Cuenca, Patricia
AU  - Cuenca P
FAU - Braida, Claudia
AU  - Braida C
FAU - Wilson, Richard H
AU  - Wilson RH
FAU - Adam, Berit
AU  - Adam B
FAU - del Valle, Gerardo
AU  - del Valle G
FAU - Brian, Roberto
AU  - Brian R
FAU - Sittenfeld, Mauricio
AU  - Sittenfeld M
FAU - Ashizawa, Tetsuo
AU  - Ashizawa T
FAU - Wilcox, Alison
AU  - Wilcox A
FAU - Wilcox, Douglas E
AU  - Wilcox DE
FAU - Monckton, Darren G
AU  - Monckton DG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120516
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (SIX5 protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Age of Onset
MH  - Aged
MH  - Alleles
MH  - Genetic Association Studies
MH  - Genomic Instability
MH  - Haploinsufficiency/genetics
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Middle Aged
MH  - Myotonic Dystrophy/epidemiology/*etiology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - *Quantitative Trait, Heritable
MH  - *Trinucleotide Repeat Expansion
EDAT- 2012/05/19 06:00
MHDA- 2013/02/07 06:00
CRDT- 2012/05/19 06:00
PHST- 2012/05/19 06:00 [entrez]
PHST- 2012/05/19 06:00 [pubmed]
PHST- 2013/02/07 06:00 [medline]
AID - dds185 [pii]
AID - 10.1093/hmg/dds185 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2012 Aug 15;21(16):3558-67. doi: 10.1093/hmg/dds185. Epub 2012 May 
      16.

PMID- 22459146
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20220310
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
VI  - 26
IP  - 7
DP  - 2012 Jul
TI  - A role for PLCbeta1 in myotonic dystrophies type 1 and 2.
PG  - 3042-8
LID - 10.1096/fj.11-200337 [doi]
AB  - Phosphoinositide-phospholipase C beta1 (PLCbeta1) plays a crucial role in the 
      initiation of the genetic program responsible for muscle differentiation. We 
      previously demonstrated that nuclear PLCbeta1 activates the cyclin D3 promoter 
      during the differentiation of myoblasts to myotubes, indicating that PLCbeta1 is 
      essential for cyclin D3 promoter activation and gene transcription, through 
      c-jun/AP1. Myotonic dystrophy (DM) is the most prevalent form of muscular 
      dystrophy in adults. DM type 1 (DM1) and type 2 (DM2) are dominantly inherited 
      multisystem disorders. DM1 is triggered by the pathological expansion of a 
      (CTG)(n) triplet repeat in the gene coding for DMPK, the dystrophia 
      myotonica-protein kinase, whereas a (CCTG)(n) tetranucleotide repeat expansion in 
      the ZNF9 gene, encoding a CCHC-type zinc finger protein, causes DM2. We found 
      that, unlike in normal myotubes, the level of expression of PLCbeta1 in DM1 and DM2 
      cells was already elevated in proliferating cells. Treatment with insulin induced 
      a dramatic decrease in the amount of PLCbeta1. During differentiation, cyclin D3 and 
      myogenin were elevated in normal myotubes, whereas differentiating DM1 and DM2 
      cells did not increase these proteins. Forced expression of PLCbeta1 in DM1 and DM2 
      cells increased the expression of differentiation markers, myogenin and cyclin 
      D3, and enhanced fusion of DM myoblasts. These results highlight again that PLCbeta1 
      expression is a key player in myoblast differentiation, functioning as a positive 
      regulator in the correction of delayed differentiation of skeletal muscle in DM 
      human myoblasts.
FAU - Faenza, Irene
AU  - Faenza I
AD  - Cellular Signaling Laboratory, Department of Human Anatomy, University of 
      Bologna, Bologna, Italy.
FAU - Blalock, William
AU  - Blalock W
FAU - Bavelloni, Alberto
AU  - Bavelloni A
FAU - Schoser, Benedikt
AU  - Schoser B
FAU - Fiume, Roberta
AU  - Fiume R
FAU - Pacella, Stephanie
AU  - Pacella S
FAU - Piazzi, Manuela
AU  - Piazzi M
FAU - D'Angelo, Antonietta
AU  - D'Angelo A
FAU - Cocco, Lucio
AU  - Cocco L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120329
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (CCND3 protein, human)
RN  - 0 (Cyclin D3)
RN  - 0 (Insulin)
RN  - 0 (MYOG protein, human)
RN  - 0 (Myogenin)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.1.4.11 (PLCB1 protein, human)
RN  - EC 3.1.4.11 (Phospholipase C beta)
SB  - IM
MH  - Cell Differentiation/genetics/physiology
MH  - Cells, Cultured
MH  - Cyclin D3/genetics/metabolism
MH  - Gene Expression Profiling
MH  - Humans
MH  - Insulin/pharmacology
MH  - Muscle Fibers, Skeletal/enzymology/pathology
MH  - Muscle, Skeletal/enzymology/pathology
MH  - Myoblasts, Skeletal/drug effects/enzymology/pathology
MH  - Myogenin/genetics/metabolism
MH  - Myotonic Disorders/*enzymology/*genetics
MH  - Myotonic Dystrophy/*enzymology/*genetics
MH  - Phospholipase C beta/*genetics/*metabolism
MH  - Recombinant Proteins/genetics/metabolism
MH  - Transfection
MH  - Up-Regulation
EDAT- 2012/03/31 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/03/31 06:00
PHST- 2012/03/31 06:00 [entrez]
PHST- 2012/03/31 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
AID - fj.11-200337 [pii]
AID - 10.1096/fj.11-200337 [doi]
PST - ppublish
SO  - FASEB J. 2012 Jul;26(7):3042-8. doi: 10.1096/fj.11-200337. Epub 2012 Mar 29.

PMID- 22427994
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20220316
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 7
IP  - 3
DP  - 2012
TI  - Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic 
      dystrophy brain.
PG  - e33218
LID - 10.1371/journal.pone.0033218 [doi]
LID - e33218
AB  - Myotonic dystrophy type 1 (DM1) is a multi-systemic disorder caused by a CTG 
      trinucleotide repeat expansion (CTG(exp)) in the DMPK gene. In skeletal muscle, 
      nuclear sequestration of the alternative splicing factor muscleblind-like 1 
      (MBNL1) explains the majority of the alternative splicing defects observed in the 
      HSA(LR) transgenic mouse model which expresses a pathogenic range CTG(exp). In 
      the present study, we addressed the possibility that MBNL1 sequestration by 
      CUG(exp) RNA also contributes to splicing defects in the mammalian brain. We 
      examined RNA from the brains of homozygous Mbnl1(DeltaE3/DeltaE3) knockout mice using 
      splicing-sensitive microarrays. We used RT-PCR to validate a subset of 
      alternative cassette exons identified by microarray analysis with brain tissues 
      from Mbnl1(DeltaE3/DeltaE3) knockout mice and post-mortem DM1 patients. Surprisingly, 
      splicing-sensitive microarray analysis of Mbnl1(DeltaE3/DeltaE3) brains yielded only 14 
      candidates for mis-spliced exons. While we confirmed that several of these 
      splicing events are perturbed in both Mbnl1 knockout and DM1 brains, the extent 
      of splicing mis-regulation in the mouse model was significantly less than 
      observed in DM1. Additionally, several alternative exons, including Grin1 exon 4, 
      App exon 7 and Mapt exons 3 and 9, which have previously been reported to be 
      aberrantly spliced in human DM1 brain, were spliced normally in the Mbnl1 
      knockout brain. The sequestration of MBNL1 by CUG(exp) RNA results in some of the 
      aberrant splicing events in the DM1 brain. However, we conclude that other 
      factors, possibly other MBNL proteins, likely contribute to splicing 
      mis-regulation in the DM1 brain.
FAU - Suenaga, Koichi
AU  - Suenaga K
AD  - Division of Neurology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya, Hyogo, Japan.
FAU - Lee, Kuang-Yung
AU  - Lee KY
FAU - Nakamori, Masayuki
AU  - Nakamori M
FAU - Tatsumi, Yoshiki
AU  - Tatsumi Y
FAU - Takahashi, Masanori P
AU  - Takahashi MP
FAU - Fujimura, Harutoshi
AU  - Fujimura H
FAU - Jinnai, Kenji
AU  - Jinnai K
FAU - Yoshikawa, Hiroo
AU  - Yoshikawa H
FAU - Du, Hongqing
AU  - Du H
FAU - Ares, Manuel Jr
AU  - Ares M Jr
FAU - Swanson, Maurice S
AU  - Swanson MS
FAU - Kimura, Takashi
AU  - Kimura T
LA  - eng
GR  - R01 GM084317/GM/NIGMS NIH HHS/United States
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - GM084317/GM/NIGMS NIH HHS/United States
GR  - P01 NS058901/NS/NINDS NIH HHS/United States
GR  - NS058901/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120313
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alternative Splicing/*genetics
MH  - Animals
MH  - Blotting, Southern
MH  - Brain/metabolism/*pathology
MH  - DNA-Binding Proteins/*genetics
MH  - Exons/genetics
MH  - Humans
MH  - Mice
MH  - Mice, Knockout
MH  - Microarray Analysis
MH  - Myotonic Dystrophy/*pathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA-Binding Proteins/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Statistics, Nonparametric
MH  - Trinucleotide Repeat Expansion/genetics
PMC - PMC3302840
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2012/03/20 06:00
MHDA- 2012/08/21 06:00
PMCR- 2012/03/13
CRDT- 2012/03/20 06:00
PHST- 2011/09/20 00:00 [received]
PHST- 2012/02/09 00:00 [accepted]
PHST- 2012/03/20 06:00 [entrez]
PHST- 2012/03/20 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
PHST- 2012/03/13 00:00 [pmc-release]
AID - PONE-D-11-18392 [pii]
AID - 10.1371/journal.pone.0033218 [doi]
PST - ppublish
SO  - PLoS One. 2012;7(3):e33218. doi: 10.1371/journal.pone.0033218. Epub 2012 Mar 13.

PMID- 22385162
OWN - NLM
STAT- MEDLINE
DCOM- 20130401
LR  - 20141120
IS  - 1540-8159 (Electronic)
IS  - 0147-8389 (Linking)
VI  - 35
IP  - 10
DP  - 2012 Oct
TI  - Predictors of atrio-ventricular conduction disease, long-term outcomes in 
      patients with myotonic dystrophy types I and II.
PG  - 1262-9
LID - 10.1111/j.1540-8159.2012.03351.x [doi]
AB  - BACKGROUND: Patients with myotonic dystrophy (DM) have an annual mortality of 
      approximately 3.5%, one-third of which is sudden cardiac death. The predictors of 
      cardiac conduction disease in these patients are incompletely defined. METHODS: A 
      single-center cohort study included 211 patients with DM type 1 (DM1) and 25 DM 
      type 2 (DM2). A severe electrocardiogram (ECG) abnormality was defined as a PR 
      interval of >/=240 ms or QRS duration of >/=120 ms. RESULTS: A severe ECG abnormality 
      was found in 24% of DM1 patients and 17% of DM2 patients. Among DM1 patients, 
      those with a severe ECG abnormality were older (41.6 +/- 14.6 vs 35.4 +/- 12.6 years) 
      and more likely to have hypertension (13.2% vs 4.2%, P = 0.038), heart failure 
      (4.4% vs 0%, P = 0.056), atrial arrhythmias (6.6% vs 0.7%, P < 0.001), a higher 
      number of trinucleotide repeats (689 +/- 451 vs 474 +/- 322, P = 0.01), and a family 
      history of sudden cardiac death (26.7% vs 5.6%, P < 0.001) or pacemaker 
      implantation (20% vs 0.7%, P < 0.001). Pacemakers or defibrillators were 
      implanted in 14% of all patients, including 65% of patients with severe ECG 
      abnormalities. During 57 +/- 46 months, 13 patients died (1.16% per year), 
      including three patients who died suddenly, two of whom had normally functioning 
      pacemakers. CONCLUSION: In DM1, atrio-ventricular conduction disease is 
      associated with increasing age, concomitant cardiovascular disease, nucleotide 
      repeat length, and family history. The systematic identification of conduction 
      disease and aggressive use of prophylactic pacemakers is associated with low rate 
      of sudden cardiac death.
CI  - (c)2012, The Authors. Journal compilation (c)2012 Wiley Periodicals, Inc.
FAU - Ha, Andrew H
AU  - Ha AH
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Tarnopolsky, Mark A
AU  - Tarnopolsky MA
FAU - Bergstra, T Graham
AU  - Bergstra TG
FAU - Nair, Girish M
AU  - Nair GM
FAU - Al-Qubbany, Atif
AU  - Al-Qubbany A
FAU - Healey, Jeff S
AU  - Healey JS
LA  - eng
PT  - Journal Article
DEP - 20120304
PL  - United States
TA  - Pacing Clin Electrophysiol
JT  - Pacing and clinical electrophysiology : PACE
JID - 7803944
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Arrhythmias, Cardiac/epidemiology
MH  - Atrioventricular Block/*epidemiology/therapy
MH  - Cohort Studies
MH  - Comorbidity
MH  - Death, Sudden, Cardiac/epidemiology/prevention & control
MH  - Defibrillators, Implantable
MH  - Electrocardiography
MH  - Female
MH  - Heart Failure/epidemiology
MH  - Humans
MH  - Hypertension/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Disorders/*epidemiology/therapy
MH  - Myotonic Dystrophy/*epidemiology/therapy
MH  - Pacemaker, Artificial
MH  - Prevalence
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Trinucleotide Repeat Expansion/physiology
EDAT- 2012/03/06 06:00
MHDA- 2013/04/02 06:00
CRDT- 2012/03/06 06:00
PHST- 2012/03/06 06:00 [entrez]
PHST- 2012/03/06 06:00 [pubmed]
PHST- 2013/04/02 06:00 [medline]
AID - 10.1111/j.1540-8159.2012.03351.x [doi]
PST - ppublish
SO  - Pacing Clin Electrophysiol. 2012 Oct;35(10):1262-9. doi: 
      10.1111/j.1540-8159.2012.03351.x. Epub 2012 Mar 4.

PMID- 22078098
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 4
DP  - 2011 Nov 11
TI  - Myoblasts generated by lentiviral mediated MyoD transduction of myotonic 
      dystrophy type 1 (DM1) fibroblasts can be used for assays of therapeutic 
      molecules.
PG  - 490
LID - 10.1186/1756-0500-4-490 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most common muscle dystrophy 
      in adults. The disease is caused by a triplet expansion in the 3'end of the 
      myotonic dystrophy protein kinase (DMPK) gene. In order to develop a human cell 
      model for investigation of possible effects of antisense and RNAi effector 
      molecules we have used lentiviral mediated myoD-forced myogenesis of DM1 patient 
      fibroblasts. FINDINGS: Transduced fibroblasts show a multinuclear phenotype and 
      express the differentiation marker myogenin. Furthermore, fluorescence in situ 
      hybridization (FISH) analysis revealed a statistical significant increase in the 
      amount of nuclear foci in DM1 patient fibroblasts after myogenesis. Finally, no 
      nuclear foci were found after treatment with oligonucleotides targeting the 
      repeat expansions. CONCLUSIONS: The abundance of nuclear foci in DM1 patient 
      fibroblasts increase following myogenesis, as visualized by FISH analysis. Foci 
      were eradicated after treatment with antisense oligonucleotides. Thus, we propose 
      that the current cell model is suitable for testing of novel treatment 
      modalities.
FAU - Larsen, Jan
AU  - Larsen J
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark. 
      thomas@humgen.au.dk.
FAU - Pettersson, Olof J
AU  - Pettersson OJ
FAU - Jakobsen, Maria
AU  - Jakobsen M
FAU - Thomsen, Rune
AU  - Thomsen R
FAU - Pedersen, Christina B
AU  - Pedersen CB
FAU - Hertz, Jens M
AU  - Hertz JM
FAU - Gregersen, Niels
AU  - Gregersen N
FAU - Corydon, Thomas J
AU  - Corydon TJ
FAU - Jensen, Thomas G
AU  - Jensen TG
LA  - eng
PT  - Journal Article
DEP - 20111111
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
PMC - PMC3226528
EDAT- 2011/11/15 06:00
MHDA- 2011/11/15 06:01
PMCR- 2011/11/11
CRDT- 2011/11/15 06:00
PHST- 2011/07/15 00:00 [received]
PHST- 2011/11/11 00:00 [accepted]
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2011/11/15 06:01 [medline]
PHST- 2011/11/11 00:00 [pmc-release]
AID - 1756-0500-4-490 [pii]
AID - 10.1186/1756-0500-4-490 [doi]
PST - epublish
SO  - BMC Res Notes. 2011 Nov 11;4:490. doi: 10.1186/1756-0500-4-490.

PMID- 22062891
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20211203
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 21
IP  - 4
DP  - 2012 Feb 15
TI  - Activation of the innate immune response and interferon signalling in myotonic 
      dystrophy type 1 and type 2 cataracts.
PG  - 852-62
LID - 10.1093/hmg/ddr515 [doi]
AB  - Myotonic dystrophy (DM) is caused by a triplet repeat expansion in the non-coding 
      region of either the DMPK (DM1) or CNBP (DM2) gene. Transcription of the expanded 
      region causes accumulation of double-stranded RNA (dsRNA) in DM cells. We sought 
      to determine how expression of triplet repeat RNA causes the varied phenotype 
      typical of DM. Global transcription was measured in DM and non-DM cataract 
      samples using Illumina Bead Arrays. DM samples were compared with non-DM samples 
      and lists of differentially expressed genes (P</= 0.05) were prepared. Gene set 
      enrichment analysis and the Interferome database were used to search for 
      significant patterns of gene expression in DM cells. Expression of individual 
      genes was measured using quantitative real-time polymerase chain reaction. DMPK 
      and CNBP expression was confirmed in native lens cells showing that a toxic RNA 
      gain of function mechanism could exist in lens. A high proportion, 83% in DM1 and 
      75% in DM2, of the significantly disregulated genes were shared by both forms of 
      the disease, suggesting a common mechanism. The upregulated genes in DM1 and DM2 
      were highly enriched in both interferon-regulated genes (IRGs) and genes 
      associated with the response to dsRNA and the innate immune response. The 
      characteristic fingerprint of IRGs and the signalling pathways identified in lens 
      cells support a role for dsRNA activation of the innate immune response in the 
      pathology of DM. This new evidence forms the basis for a novel hypothesis to 
      explain the complex mechanism of DM.
FAU - Rhodes, Jeremy D
AU  - Rhodes JD
AD  - School of Biological Sciences, University of East Anglia, Norwich, UK. 
      j.rhodes@uea.ac.uk
FAU - Lott, Martin C
AU  - Lott MC
FAU - Russell, Sarah L
AU  - Russell SL
FAU - Moulton, Vincent
AU  - Moulton V
FAU - Sanderson, Julie
AU  - Sanderson J
FAU - Wormstone, I Michael
AU  - Wormstone IM
FAU - Broadway, David C
AU  - Broadway DC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111106
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CNBP protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SIX5 protein, human)
RN  - 9008-11-1 (Interferons)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cataract/etiology/*genetics/immunology/pathology
MH  - Epithelial Cells/metabolism
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation
MH  - Homeodomain Proteins/metabolism
MH  - Humans
MH  - Immunity, Innate/*immunology
MH  - Interferons/immunology/*metabolism
MH  - Lens, Crystalline/pathology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Disorders/*complications/genetics
MH  - Myotonic Dystrophy/*complications/genetics
MH  - Myotonin-Protein Kinase
MH  - Oligonucleotide Array Sequence Analysis
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - RNA-Binding Proteins/metabolism
MH  - Signal Transduction
MH  - Transcriptome/genetics
EDAT- 2011/11/09 06:00
MHDA- 2012/07/10 06:00
CRDT- 2011/11/09 06:00
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
AID - ddr515 [pii]
AID - 10.1093/hmg/ddr515 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2012 Feb 15;21(4):852-62. doi: 10.1093/hmg/ddr515. Epub 2011 Nov 
      6.

PMID- 21971425
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20211203
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 19
IP  - 12
DP  - 2011 Dec
TI  - Stabilization of expanded (CTG)*(CAG) repeats by antisense oligonucleotides.
PG  - 2222-7
LID - 10.1038/mt.2011.191 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is caused by expansion of a CTG repeat in the 
      gene DMPK. The expansion is highly unstable in somatic cells, a feature that may 
      contribute to disease progression. The RNA expressed from the mutant allele 
      exerts a toxic gain of function, due to the presence of an expanded CUG repeat 
      (CUG(exp)). This RNA dominant mechanism is amenable to therapeutic intervention 
      with antisense oligonucleotides (ASOs). For example, CAG-repeat ASOs that bind 
      CUG(exp) RNA are beneficial in DM1 models by altering the protein interactions or 
      metabolism of the toxic RNA. Because CUG(exp) RNA has been shown to aggravate 
      instability of expanded CTG repeats, we studied whether CAG-repeat ASOs may also 
      affect this aspect of DM1. In human cells the instability of (CTG)(800) was 
      suppressed by addition of CAG-repeat ASOs to the culture media. In mice that 
      carry a DMPK transgene the somatic instability of (CTG)(800) was suppressed by 
      direct injection of CAG-repeat ASOs into muscle tissue. These results raise the 
      possibility that early intervention with ASOs to reduce RNA or protein toxicity 
      may have the additional benefit of stabilizing CTG:CAG repeats at subpathogenic 
      lengths.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, University of Rochester Medical Center, Rochester, New 
      York, USA.
FAU - Gourdon, Genevieve
AU  - Gourdon G
FAU - Thornton, Charles A
AU  - Thornton CA
LA  - eng
GR  - NIH/NS048843/NS/NINDS NIH HHS/United States
GR  - AR049077/AR/NIAMS NIH HHS/United States
GR  - R01 AR049077/AR/NIAMS NIH HHS/United States
GR  - AR48143/AR/NIAMS NIH HHS/United States
GR  - U54 NS048843-09/NS/NINDS NIH HHS/United States
GR  - K24 AR048143/AR/NIAMS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111004
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Oligonucleotides)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (RNA, Messenger)
RN  - 0 (locked nucleic acid)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Colonic Neoplasms/*genetics/therapy
MH  - Fibrosarcoma/*genetics/therapy
MH  - Humans
MH  - Injections, Intramuscular
MH  - Mice
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/*genetics/therapy
MH  - Myotonin-Protein Kinase
MH  - Oligonucleotides/chemistry/genetics
MH  - Oligonucleotides, Antisense/*pharmacology
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/genetics
MH  - Transgenes/genetics
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3242663
EDAT- 2011/10/06 06:00
MHDA- 2012/03/23 06:00
PMCR- 2012/12/01
CRDT- 2011/10/06 06:00
PHST- 2011/10/06 06:00 [entrez]
PHST- 2011/10/06 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - S1525-0016(16)32707-1 [pii]
AID - 10.1038/mt.2011.191 [doi]
PST - ppublish
SO  - Mol Ther. 2011 Dec;19(12):2222-7. doi: 10.1038/mt.2011.191. Epub 2011 Oct 4.

PMID- 21949239
OWN - NLM
STAT- MEDLINE
DCOM- 20120105
LR  - 20211203
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 286
IP  - 46
DP  - 2011 Nov 18
TI  - Myotonic dystrophy protein kinase is critical for nuclear envelope integrity.
PG  - 40296-306
LID - 10.1074/jbc.M111.241455 [doi]
AB  - Myotonic dystrophy 1 (DM1) is a multisystemic disease caused by a triplet 
      nucleotide repeat expansion in the 3' untranslated region of the gene coding for 
      myotonic dystrophy protein kinase (DMPK). DMPK is a nuclear envelope (NE) protein 
      that promotes myogenic gene expression in skeletal myoblasts. Muscular dystrophy 
      research has revealed the NE to be a key determinant of nuclear structure, gene 
      regulation, and muscle function. To investigate the role of DMPK in NE stability, 
      we analyzed DMPK expression in epithelial and myoblast cells. We found that DMPK 
      localizes to the NE and coimmunoprecipitates with Lamin-A/C. Overexpression of 
      DMPK in HeLa cells or C2C12 myoblasts disrupts Lamin-A/C and Lamin-B1 
      localization and causes nuclear fragmentation. Depletion of DMPK also disrupts NE 
      lamina, showing that DMPK is required for NE stability. Our data demonstrate for 
      the first time that DMPK is a critical component of the NE. These novel findings 
      suggest that reduced DMPK may contribute to NE instability, a common mechanism of 
      skeletal muscle wasting in muscular dystrophies.
FAU - Harmon, Erin B
AU  - Harmon EB
AD  - Cardiovascular Health Research Center, Sanford Research/USD, Sioux Falls, South 
      Dakota 57104, USA. erin.harmon@sanfordhealth.org
FAU - Harmon, Michelle L
AU  - Harmon ML
FAU - Larsen, Tricia D
AU  - Larsen TD
FAU - Yang, Jie
AU  - Yang J
FAU - Glasford, Joseph W
AU  - Glasford JW
FAU - Perryman, M Benjamin
AU  - Perryman MB
LA  - eng
GR  - P20 RR017662/RR/NCRR NIH HHS/United States
GR  - R01 HL064136/HL/NHLBI NIH HHS/United States
GR  - P20-RR-017662/RR/NCRR NIH HHS/United States
GR  - HL064136/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110926
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (DMPK protein, human)
RN  - 0 (Lamins)
RN  - 0 (Muscle Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Epithelial Cells/*enzymology/pathology
MH  - Gene Expression Regulation/genetics
MH  - HeLa Cells
MH  - Humans
MH  - Lamins/genetics/metabolism
MH  - Muscle Proteins/genetics/*metabolism
MH  - Myoblasts, Skeletal/*enzymology/pathology
MH  - Myotonic Dystrophy/*enzymology/genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Nuclear Envelope/*enzymology/genetics/pathology
MH  - Protein Serine-Threonine Kinases/genetics/*metabolism
PMC - PMC3220565
EDAT- 2011/09/29 06:00
MHDA- 2012/01/06 06:00
PMCR- 2012/11/18
CRDT- 2011/09/29 06:00
PHST- 2011/09/29 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/01/06 06:00 [medline]
PHST- 2012/11/18 00:00 [pmc-release]
AID - S0021-9258(20)50526-7 [pii]
AID - M111.241455 [pii]
AID - 10.1074/jbc.M111.241455 [doi]
PST - ppublish
SO  - J Biol Chem. 2011 Nov 18;286(46):40296-306. doi: 10.1074/jbc.M111.241455. Epub 
      2011 Sep 26.

PMID- 21795378
OWN - NLM
STAT- MEDLINE
DCOM- 20120116
LR  - 20211020
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 39
IP  - 20
DP  - 2011 Nov 1
TI  - CAG repeats mimic CUG repeats in the misregulation of alternative splicing.
PG  - 8938-51
LID - 10.1093/nar/gkr608 [doi]
AB  - Mutant transcripts containing expanded CUG repeats in the untranslated region are 
      a pathogenic factor in myotonic dystrophy type 1 (DM1). The mutant RNA sequesters 
      the muscleblind-like 1 (MBNL1) splicing factor and causes misregulation of the 
      alternative splicing of multiple genes that are linked to clinical symptoms of 
      the disease. In this study, we show that either long untranslated CAG repeat RNA 
      or short synthetic CAG repeats induce splicing aberrations typical of DM1. 
      Alternative splicing defects are also caused by translated CAG repeats in normal 
      cells transfected with a mutant ATXN3 gene construct and in cells derived from 
      spinocerebellar ataxia type 3 and Huntington's disease patients. Splicing 
      misregulation is unlikely to be caused by traces of antisense transcripts with 
      CUG repeats, and the possible trigger of this misregulation may be sequestration 
      of the MBNL1 protein with nuclear RNA inclusions containing expanded CAG repeat 
      transcripts. We propose that alternative splicing misregulation by mutant CAG 
      repeats may contribute to the pathological features of polyglutamine disorders.
FAU - Mykowska, Agnieszka
AU  - Mykowska A
AD  - Laboratory of Cancer Genetics, Institute of Bioorganic Chemistry, Polish Academy 
      of Sciences, Z. Noskowskiego 12/14, 61-704 Poznan, Poland.
FAU - Sobczak, Krzysztof
AU  - Sobczak K
FAU - Wojciechowska, Marzena
AU  - Wojciechowska M
FAU - Kozlowski, Piotr
AU  - Kozlowski P
FAU - Krzyzosiak, Wlodzimierz J
AU  - Krzyzosiak WJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110727
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Untranslated Regions)
SB  - IM
MH  - *Alternative Splicing
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - HeLa Cells
MH  - Humans
MH  - Huntington Disease/genetics
MH  - Machado-Joseph Disease/genetics
MH  - Myotonic Dystrophy/genetics
MH  - RNA-Binding Proteins/analysis
MH  - *Trinucleotide Repeat Expansion
MH  - Trinucleotide Repeats
MH  - *Untranslated Regions
PMC - PMC3203611
EDAT- 2011/07/29 06:00
MHDA- 2012/01/17 06:00
PMCR- 2011/07/27
CRDT- 2011/07/29 06:00
PHST- 2011/07/29 06:00 [entrez]
PHST- 2011/07/29 06:00 [pubmed]
PHST- 2012/01/17 06:00 [medline]
PHST- 2011/07/27 00:00 [pmc-release]
AID - gkr608 [pii]
AID - 10.1093/nar/gkr608 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2011 Nov 1;39(20):8938-51. doi: 10.1093/nar/gkr608. Epub 2011 
      Jul 27.

PMID- 21794030
OWN - NLM
STAT- MEDLINE
DCOM- 20120103
LR  - 20151119
IS  - 1365-2443 (Electronic)
IS  - 1356-9597 (Linking)
VI  - 16
IP  - 9
DP  - 2011 Sep
TI  - Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic 
      dystrophy type 1.
PG  - 961-72
LID - 10.1111/j.1365-2443.2011.01542.x [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic disease caused by a CTG repeat 
      expansion in the 3'-UTR of dystrophia myotonica-protein kinase. Aberrant 
      regulation of alternative splicing is a characteristic feature of DM. Dozens of 
      genes have been found to be abnormally spliced; however, few reported splicing 
      abnormalities explain the phenotypes of DM1 patients. Thus, we hypothesized that 
      other, unknown abnormal splicing events exist. Here, by using exon array, we 
      identified aberrant inclusion of myomesin 1 (MYOM1) exon 17a as a novel splicing 
      abnormality in DM1 muscle. A cellular splicing assay with a MYOM1 minigene 
      revealed that not only MBNL1-3 but also CELF1 and 2 decreased the inclusion of 
      MYOM1 exon 17a in HEK293T cells. Expression of expanded CUG repeat impeded MBNL1 
      activity but did not affect CELF1 activity on the splicing of MYOM1 minigene. Our 
      results suggest that the downregulation of MBNL proteins should lead to the 
      abnormal splicing of MYOM1 exon 17a in DM1 muscle.
CI  - (c) 2011 The Authors. Journal compilation (c) 2011 by the Molecular Biology Society 
      of Japan/Blackwell Publishing Ltd.
FAU - Koebis, Michinori
AU  - Koebis M
AD  - Department of Life Sciences, Graduate School of Arts and Sciences, The University 
      of Tokyo, Meguro-ku, Japan.
FAU - Ohsawa, Natsumi
AU  - Ohsawa N
FAU - Kino, Yoshihiro
AU  - Kino Y
FAU - Sasagawa, Noboru
AU  - Sasagawa N
FAU - Nishino, Ichizo
AU  - Nishino I
FAU - Ishiura, Shoichi
AU  - Ishiura S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110728
PL  - England
TA  - Genes Cells
JT  - Genes to cells : devoted to molecular & cellular mechanisms
JID - 9607379
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (Connectin)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (MYOM1 protein, human)
RN  - 0 (Muscle Proteins)
RN  - 0 (RNA Splice Sites)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alternative Splicing/*genetics
MH  - Base Sequence
MH  - CELF1 Protein
MH  - Connectin
MH  - Consensus Sequence
MH  - Exons
MH  - *Gene Expression Regulation
MH  - HEK293 Cells
MH  - Humans
MH  - Molecular Sequence Data
MH  - Muscle Proteins/*genetics
MH  - Muscle, Skeletal/metabolism
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - RNA Splice Sites
MH  - RNA-Binding Proteins/metabolism
EDAT- 2011/07/29 06:00
MHDA- 2012/01/04 06:00
CRDT- 2011/07/29 06:00
PHST- 2011/07/29 06:00 [entrez]
PHST- 2011/07/29 06:00 [pubmed]
PHST- 2012/01/04 06:00 [medline]
AID - 10.1111/j.1365-2443.2011.01542.x [doi]
PST - ppublish
SO  - Genes Cells. 2011 Sep;16(9):961-72. doi: 10.1111/j.1365-2443.2011.01542.x. Epub 
      2011 Jul 28.

PMID- 21694643
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20210108
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 90
IP  - 4
DP  - 2011 Jul
TI  - Organ dysfunction and muscular disability in myotonic dystrophy type 1.
PG  - 262-268
LID - 10.1097/MD.0b013e318226046b [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a multisystemic disorder characterized by 
      muscle weakness and multiple organ impairment, especially the eyes, lung, and 
      heart. We conducted the current study to analyze the prevalence and 
      intercorrelation among these disorders and their respective relationships with 
      muscular disability. We assessed medical history, anthropometric data, lung 
      volumes, arterial and venous blood samples, surface 12-lead electrocardiogram, 
      echocardiography, ophthalmologic examination, and muscular impairment rating 
      scale (MIRS) in 106 patients (48 male and 58 female) with DM1, aged 43.7 +/- 12.8 
      years. Obesity, hypertriglyceridemia, and diabetes were found in respectively 
      25.6%, 47.6%, and 17.1% of patients. Disabling cataract was found in 43.4%, and 
      was independently predicted by age and MIRS. Restrictive lung disease was noted 
      in 34%, and was predicted by MIRS, CTG repeat expansion, and body mass index. 
      Conduction disorders were found in 30.2% of patients and were predicted by left 
      ventricular ejection fraction, MIRS, and CTG repeat expansion.We found 
      significant relationships between cataract, restrictive lung disease, and 
      conduction disorders: patients with cataract and those with conduction disorders 
      exhibited more severe restrictive lung disease than the other patients. 
      Conversely, the relative risk of restrictive lung disease was 2.42 (1% confidence 
      interval [CI], 1.06-5.51) in patients with cataract and 2.54 (1% CI, 1.26-5.07) 
      in patients with conduction disorders. Multivariate analysis revealed that MIRS 
      was the only independent predictor for conduction disorders and restrictive lung 
      disease. MIRS >/=3 and MIRS >/=4 were the best simple cutoff values to predict, 
      respectively, lung and cardiac involvements.To conclude, muscular disability, 
      ophthalmologic, and cardiac and pulmonary involvement are strongly correlated. 
      Particular attention should be given to these entities in patients with distal or 
      proximal muscular weakness.
FAU - Kaminsky, Pierre
AU  - Kaminsky P
AD  - From Medecine Interne (PK, LP, JD), Laboratoire d'Explorations Fonctionnelles 
      Respiratoires (MP, BC), Cardiologie (BBP), Centre de Reference des Maladies 
      Neuromusculaires (PK), and EA3450-Nancy-Universite (MP, BC); Faculte de Medecine, 
      and Centre Hospitalier Universitaire de Nancy, Hopitaux de Brabois, Vandoeuvre, 
      France.
FAU - Poussel, Mathias
AU  - Poussel M
FAU - Pruna, Lelia
AU  - Pruna L
FAU - Deibener, Joelle
AU  - Deibener J
FAU - Chenuel, Bruno
AU  - Chenuel B
FAU - Brembilla-Perrot, Beatrice
AU  - Brembilla-Perrot B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cardiovascular Diseases/diagnosis/*epidemiology
MH  - Chi-Square Distribution
MH  - Cohort Studies
MH  - Comorbidity
MH  - Disease Progression
MH  - Eye Diseases/diagnosis/*epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Metabolic Diseases/diagnosis/*epidemiology
MH  - Middle Aged
MH  - Multiple Organ Failure/*diagnosis/mortality
MH  - Multivariate Analysis
MH  - Muscle Weakness/physiopathology
MH  - Myotonic Dystrophy/diagnosis/epidemiology
MH  - Prevalence
MH  - Respiratory Insufficiency/diagnosis/epidemiology
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2011/06/23 06:00
MHDA- 2011/08/31 06:00
CRDT- 2011/06/23 06:00
PHST- 2011/06/23 06:00 [entrez]
PHST- 2011/06/23 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
AID - 00005792-201107000-00006 [pii]
AID - 10.1097/MD.0b013e318226046b [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2011 Jul;90(4):262-268. doi: 10.1097/MD.0b013e318226046b.

PMID- 21622935
OWN - NLM
STAT- MEDLINE
DCOM- 20111025
LR  - 20211020
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Print)
IS  - 0022-2593 (Linking)
VI  - 48
IP  - 7
DP  - 2011 Jul
TI  - Replacement of the myotonic dystrophy type 1 CTG repeat with 'non-CTG repeat' 
      insertions in specific tissues.
PG  - 438-43
LID - 10.1136/jmg.2010.085944 [doi]
AB  - BACKGROUND: Recently, curious mutations have been reported to occur within the 
      (CTG)n repeat tract of the myotonic dystrophy type 1 (DM1) locus. For example, 
      the repeat, long presumed to be a pure repeat sequence, has now been revealed to 
      often contain interruption motifs in a proportion of cases with expansions. 
      Similarly, a few de novo somatic CTG expansions have been reported to arise from 
      non-expanded DM1 alleles with 5-37 units, thought to be genetically stable. AIMS 
      AND METHODS: This study has characterised a novel mutation configuration at the 
      DM1 CTG repeat that arose as somatic mosaicism in a juvenile onset DM1 patient 
      with a non-expanded allele of (CTG)12 and tissue specific expansions ranging from 
      (CTG)1100 to 6000. RESULTS: The mutation configuration replaced the CTG tract 
      with a non-CTG repeat insertion of 43 or 60 nucleotides, precisely placed in the 
      position of the CTG tract with proper flanking sequences. The inserts appeared to 
      arise from a longer human sequence on chromosome 4q12, and may have arisen 
      through DNA structure mediated somatic inter-gene recombination or 
      replication/repair template switching errors. De novo insertions were detected in 
      cerebral cortex and skeletal muscle, but not in heart or liver. Repeat tracts 
      with -1 or -2 CTG units were also detected in cerebellum, which may have arisen 
      by contractions of the short (CTG)12 allele. CONCLUSION: This non-CTG 
      configuration expands current understanding of the sequence variations that can 
      arise at this hypermutable site.
FAU - Axford, Michelle M
AU  - Axford MM
AD  - Genetics and Genome Biology, The Hospital for Sick Children, TMDT Building 101 
      College Street, 15th Floor, Rm 15-312 East Tower, Toronto, ON M5G 1L7, Canada.
FAU - Lopez-Castel, Arturo
AU  - Lopez-Castel A
FAU - Nakamori, Masayuki
AU  - Nakamori M
FAU - Thornton, Charles A
AU  - Thornton CA
FAU - Pearson, Christopher E
AU  - Pearson CE
LA  - eng
SI  - GENBANK/JF697199
SI  - GENBANK/JF697200
SI  - GENBANK/JF697201
GR  - K24 AR048143/AR/NIAMS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
GR  - CAPMC/CIHR/Canada
GR  - U54NS48843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20110527
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
SB  - IM
MH  - Alleles
MH  - Base Sequence
MH  - Cerebellum/metabolism
MH  - Cerebral Cortex/metabolism
MH  - Chromosomes, Human, Pair 4/genetics
MH  - Humans
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/metabolism
MH  - Mutagenesis, Insertional/*genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Organ Specificity/genetics
MH  - Sequence Alignment
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3379714
MID - NIHMS373246
COIS- Copyright license statement The authors declare no conflict of interest
EDAT- 2011/05/31 06:00
MHDA- 2011/10/26 06:00
PMCR- 2012/06/20
CRDT- 2011/05/31 06:00
PHST- 2011/05/31 06:00 [entrez]
PHST- 2011/05/31 06:00 [pubmed]
PHST- 2011/10/26 06:00 [medline]
PHST- 2012/06/20 00:00 [pmc-release]
AID - jmg.2010.085944 [pii]
AID - 10.1136/jmg.2010.085944 [doi]
PST - ppublish
SO  - J Med Genet. 2011 Jul;48(7):438-43. doi: 10.1136/jmg.2010.085944. Epub 2011 May 
      27.

PMID- 21511730
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20211020
IS  - 1477-9137 (Electronic)
IS  - 0021-9533 (Linking)
VI  - 124
IP  - Pt 10
DP  - 2011 May 15
TI  - Stochastic and reversible aggregation of mRNA with expanded CUG-triplet repeats.
PG  - 1703-14
LID - 10.1242/jcs.073270 [doi]
AB  - Transcripts containing expanded CNG repeats, which are found in several 
      neuromuscular diseases, are not exported from the nucleus and aggregate as 
      ribonuclear inclusions by an unknown mechanism. Using the MS2-GFP system, which 
      tethers fluorescent proteins to a specific mRNA, we followed the dynamics of 
      single CUG-repeat transcripts and RNA aggregation in living cells. Single 
      transcripts with 145 CUG repeats from the dystrophia myotonica-protein kinase 
      (DMPK) gene had reduced diffusion kinetics compared with transcripts containing 
      only five CUG repeats. Fluorescence recovery after photobleaching (FRAP) 
      experiments showed that CUG-repeat RNAs display a stochastic aggregation 
      behaviour, because individual RNA foci formed at different rates and displayed 
      different recoveries. Spontaneous clustering of CUG-repeat RNAs was also 
      observed, confirming the stochastic aggregation revealed by FRAP. The splicing 
      factor Mbnl1 colocalized with individual CUG-repeat transcripts and its 
      aggregation with RNA foci displayed the same stochastic behaviour as CUG-repeat 
      mRNAs. Moreover, depletion of Mbnl1 by RNAi resulted in decreased aggregation of 
      CUG-repeat transcripts after FRAP, supporting a direct role for Mbnl1 in CUG-rich 
      RNA foci formation. Our data reveal that nuclear CUG-repeat RNA aggregates are 
      labile, constantly forming and disaggregating structures, and that the Mbnl1 
      splicing factor is directly involved in the aggregation process.
FAU - Querido, Emmanuelle
AU  - Querido E
AD  - Department of Biochemistry, Universite de Montreal, 2900 Edouard-Montpetit, 
      Montreal, QC H3C 3J7, Canada.
FAU - Gallardo, Franck
AU  - Gallardo F
FAU - Beaudoin, Melissa
AU  - Beaudoin M
FAU - Menard, Catherine
AU  - Menard C
FAU - Chartrand, Pascal
AU  - Chartrand P
LA  - eng
GR  - 62501-1/Canadian Institutes of Health Research/Canada
GR  - NDS62501/CAPMC/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110421
PL  - England
TA  - J Cell Sci
JT  - Journal of cell science
JID - 0052457
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Fluorescence Recovery After Photobleaching/methods
MH  - Gene Expression Profiling
MH  - Mice
MH  - Myotonic Dystrophy/genetics/metabolism
MH  - RNA, Messenger/*genetics/*metabolism
MH  - Stochastic Processes
MH  - Transcription, Genetic
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
EDAT- 2011/04/23 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/04/23 06:00
PHST- 2011/04/23 06:00 [entrez]
PHST- 2011/04/23 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - jcs.073270 [pii]
AID - 10.1242/jcs.073270 [doi]
PST - ppublish
SO  - J Cell Sci. 2011 May 15;124(Pt 10):1703-14. doi: 10.1242/jcs.073270. Epub 2011 
      Apr 21.

PMID- 21484823
OWN - NLM
STAT- MEDLINE
DCOM- 20110607
LR  - 20141120
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 43
IP  - 5
DP  - 2011 May
TI  - Survival and CTG repeat expansion in adults with myotonic dystrophy type 1.
PG  - 648-51
LID - 10.1002/mus.21934 [doi]
AB  - INTRODUCTION: An association is observed between the severity of myotonic 
      dystrophy type 1 (DM1) and the genetic abnormality of cytosine-thymine-guanine 
      (CTG) repeat expansion. It is unknown whether an association exists between 
      survival and CTG repeat expansion. METHODS: In an adult 406-patient DM1 cohort, 
      the phenotype, including survival age, was evaluated in relation to CTG repeat 
      expansion. RESULTS: At study entry, age was 42 +/- 12 (range 18-78) years, with a 
      CTG repeat length of 629 +/- 386 (range 54-1965). An inverse correlation was 
      observed between CTG repeat length and the age at onset and younger DM1 
      phenotype. Over a follow-up of 9.2 +/- 3.1 years, 118 (29.1%) patients died, 
      including 60 of neuromuscular respiratory failure, 41 of cardiac causes, and 17 
      of non-neuromuscular, non-cardiac causes. There was an inverse relationship 
      between all-cause survival and CTG length (relative risk 5.4 per log repeat, 95% 
      confidence interval 2.9-10.2, P < 0.001). CONCLUSION: The data demonstrate a 
      genotype-mortality association in DM1.
CI  - Copyright (c) 2010 Wiley Periodicals, Inc.
FAU - Groh, William J
AU  - Groh WJ
AD  - Department of Medicine, Division Cardiology, Krannert Institute of Cardiology, 
      Indiana University, 1800 North Capitol, Room E300C, Indianapolis, Indiana 46202, 
      USA. wgroh@iupui.edu
FAU - Groh, Miriam R
AU  - Groh MR
FAU - Shen, Changyu
AU  - Shen C
FAU - Monckton, Darren G
AU  - Monckton DG
FAU - Bodkin, Cynthia L
AU  - Bodkin CL
FAU - Pascuzzi, Robert M
AU  - Pascuzzi RM
LA  - eng
GR  - MO1 RR00750-27S1/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 5Z93L87A1R (Guanine)
RN  - 8J337D1HZY (Cytosine)
RN  - QR26YLT7LT (Thymine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - *Cytosine/chemistry
MH  - Female
MH  - Follow-Up Studies
MH  - *Guanine/chemistry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/genetics/metabolism/mortality
MH  - Survival Rate/trends
MH  - *Thymine/chemistry
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Young Adult
EDAT- 2011/04/13 06:00
MHDA- 2011/06/08 06:00
CRDT- 2011/04/13 06:00
PHST- 2011/04/13 06:00 [entrez]
PHST- 2011/04/13 06:00 [pubmed]
PHST- 2011/06/08 06:00 [medline]
AID - 10.1002/mus.21934 [doi]
PST - ppublish
SO  - Muscle Nerve. 2011 May;43(5):648-51. doi: 10.1002/mus.21934.

PMID- 21437269
OWN - NLM
STAT- MEDLINE
DCOM- 20110721
LR  - 20211020
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Print)
IS  - 1553-7390 (Linking)
VI  - 7
IP  - 3
DP  - 2011 Mar
TI  - Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model 
      for myotonic dystrophy.
PG  - e1001340
LID - 10.1371/journal.pgen.1001340 [doi]
LID - e1001340
AB  - More than 20 human neurological and neurodegenerative diseases are caused by 
      simple DNA repeat expansions; among these, non-coding CTG repeat expansions are 
      the basis of myotonic dystrophy (DM1). Recent work, however, has also revealed 
      that many human genes have anti-sense transcripts, raising the possibility that 
      human trinucleotide expansion diseases may be comprised of pathogenic activities 
      due both to a sense expanded-repeat transcript and to an anti-sense 
      expanded-repeat transcript. We established a Drosophila model for DM1 and tested 
      the role of interactions between expanded CTG transcripts and expanded CAG repeat 
      transcripts. These studies revealed dramatically enhanced toxicity in flies 
      co-expressing CTG with CAG expanded repeats. Expression of the two transcripts 
      led to novel pathogenesis with the generation of dcr-2 and ago2-dependent 21-nt 
      triplet repeat-derived siRNAs. These small RNAs targeted the expression of 
      CAG-containing genes, such as Ataxin-2 and TATA binding protein (TBP), which bear 
      long CAG repeats in both fly and man. These findings indicate that the generation 
      of triplet repeat-derived siRNAs may dramatically enhance toxicity in human 
      repeat expansion diseases in which anti-sense transcription occurs.
FAU - Yu, Zhenming
AU  - Yu Z
AD  - Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Teng, Xiuyin
AU  - Teng X
FAU - Bonini, Nancy M
AU  - Bonini NM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110317
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
RN  - 0 (Drosophila Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Disease Models, Animal
MH  - Drosophila/*genetics/metabolism
MH  - Drosophila Proteins/genetics/metabolism/toxicity
MH  - Female
MH  - Gene Expression Regulation/physiology
MH  - Male
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - RNA, Small Interfering/genetics/*metabolism
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics/metabolism
MH  - Transcription, Genetic/genetics
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Trinucleotide Repeats/*genetics
PMC - PMC3060073
COIS- The authors have declared that no competing interests exist.
EDAT- 2011/03/26 06:00
MHDA- 2011/07/22 06:00
PMCR- 2011/03/01
CRDT- 2011/03/26 06:00
PHST- 2010/08/12 00:00 [received]
PHST- 2011/02/15 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/07/22 06:00 [medline]
PHST- 2011/03/01 00:00 [pmc-release]
AID - 10-PLGE-RA-3901R3 [pii]
AID - 10.1371/journal.pgen.1001340 [doi]
PST - ppublish
SO  - PLoS Genet. 2011 Mar;7(3):e1001340. doi: 10.1371/journal.pgen.1001340. Epub 2011 
      Mar 17.

PMID- 21371814
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20171116
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
VI  - 113
IP  - 6
DP  - 2011 Jul
TI  - IgG deficiency and expansion of CTG repeats in myotonic dystrophy.
PG  - 464-8
LID - 10.1016/j.clineuro.2011.02.003 [doi]
AB  - OBJECTIVES: Expansion of CTG repeats in myotonic dystrophy (DM1) alters the 
      regulated expression of numerous genes. It is considered to explain the major 
      clinical features of DM1. IgG deficiency is common in DM1 and is due to altered 
      FcRn-related hypercatabolism. We hypothesized that the IgG catabolic rate is 
      correlated with CTG repeat expansion. METHODS: Correlations between serum 
      immunoglobulin levels, peripheral lymphocyte subset counts and CTG repeat numbers 
      were performed in 52 DM1 patients. RESULTS: Serum IgG and IgG1 levels were below 
      the normal limit respectively in 54% and 72% of patients. Increasing CTG repeat 
      numbers were significantly correlated with decreasing serum IgG and IgG1 levels, 
      and with decreasing CD3(+) T-cell and CD3(+)-CD8(+) cell counts. An abnormal 
      immunoglobulin profile at protein electrophoresis was found in 4 patients. 
      CONCLUSION: We conclude that the catabolic rate of IgG is linked to expanded CTG 
      repeats, possibly involving an altered immune response.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Kaminsky, Pierre
AU  - Kaminsky P
AD  - Centre Hospitalier Universitaire de Nancy, Hopitaux de Brabois, Vandoeuvre Cedex, 
      France. p.kaminsky@chu-nancy.fr
FAU - Lesesve, Jean Francois
AU  - Lesesve JF
FAU - Jonveaux, Philippe
AU  - Jonveaux P
FAU - Pruna, Lelia
AU  - Pruna L
LA  - eng
PT  - Journal Article
DEP - 20110303
PL  - Netherlands
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
RN  - 0 (CD3 Complex)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - CD3 Complex/analysis
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - Humans
MH  - IgG Deficiency/*etiology/*genetics
MH  - Immunoglobulin A/analysis
MH  - Immunoglobulin G/analysis
MH  - Immunoglobulin M/analysis
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - T-Lymphocytes/immunology
MH  - Trinucleotide Repeats/*genetics
MH  - Young Adult
EDAT- 2011/03/05 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/03/05 06:00
PHST- 2009/10/27 00:00 [received]
PHST- 2011/02/03 00:00 [revised]
PHST- 2011/02/05 00:00 [accepted]
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - S0303-8467(11)00039-4 [pii]
AID - 10.1016/j.clineuro.2011.02.003 [doi]
PST - ppublish
SO  - Clin Neurol Neurosurg. 2011 Jul;113(6):464-8. doi: 
      10.1016/j.clineuro.2011.02.003. Epub 2011 Mar 3.

PMID- 21303839
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20230530
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Print)
IS  - 1754-8403 (Linking)
VI  - 4
IP  - 3
DP  - 2011 May
TI  - Zebrafish deficient for Muscleblind-like 2 exhibit features of myotonic 
      dystrophy.
PG  - 381-92
LID - 10.1242/dmm.004150 [doi]
AB  - Myotonic dystrophy (DM; also known as dystrophia myotonica) is an autosomal 
      dominant disorder that affects the heart, eyes, brain and endocrine system, but 
      the predominant symptoms are neuromuscular, with progressive muscle weakness and 
      wasting. DM presents in two forms, DM1 and DM2, both of which are caused by 
      nucleotide repeat expansions: CTG in the DMPK gene for DM1 and CCTG in ZNF9 
      (CNBP) for DM2. Previous studies have shown that the mutant mRNAs containing the 
      transcribed CUG or CCUG repeats are retained within the nuclei of cells from 
      individuals with DM, where they bind and sequester the muscleblind-like proteins 
      MBNL1, MBNL2 and MBNL3. It has been proposed that the sequestration of these 
      proteins plays a key role in determining the classic features of DM. However, the 
      functions of each of the three MBNL genes are not completely understood. We have 
      generated a zebrafish knockdown model in which we demonstrate that a lack of 
      mbnl2 function causes morphological abnormalities at the eye, heart, brain and 
      muscle levels, supporting an essential role for mbnl2 during embryonic 
      development. Major features of DM are replicated in our model, including muscle 
      defects and splicing abnormalities. We found that the absence of mbnl2 causes 
      disruption to the organization of myofibrils in skeletal and heart muscle of 
      zebrafish embryos, and a reduction in the amount of both slow and fast muscle 
      fibres. Notably, our findings included altered splicing patterns of two 
      transcripts whose expression is also altered in DM patients: clcn1 and tnnt2. The 
      studies described herein provide broader insight into the functions of MBNL2. 
      They also lend support to the hypothesis that the sequestration of this protein 
      is an important determinant in DM pathophysiology, and imply a direct role of 
      MBNL2 in splicing regulation of specific transcripts, which, when altered, 
      contributes to the DM phenotype.
FAU - Machuca-Tzili, Laura E
AU  - Machuca-Tzili LE
AD  - Institute of Genetics, University of Nottingham, Queen's Medical Centre, 
      Nottingham, NG7 2UH, UK.
FAU - Buxton, Sarah
AU  - Buxton S
FAU - Thorpe, Aaran
AU  - Thorpe A
FAU - Timson, Cathy M
AU  - Timson CM
FAU - Wigmore, Peter
AU  - Wigmore P
FAU - Luther, Pradeep K
AU  - Luther PK
FAU - Brook, J David
AU  - Brook JD
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - G0802629/MRC_/Medical Research Council/United Kingdom
GR  - BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110208
PL  - England
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
RN  - 0 (Mbnl2 protein, zebrafish)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Zebrafish Proteins)
SB  - IM
MH  - Alternative Splicing/drug effects/genetics
MH  - Animals
MH  - Base Sequence
MH  - Bone and Bones/abnormalities/drug effects/metabolism/pathology
MH  - Embryo, Nonmammalian/abnormalities/metabolism/pathology/ultrastructure
MH  - Gene Expression Regulation, Developmental/drug effects
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/drug effects/metabolism/pathology/ultrastructure
MH  - Myocardium/metabolism/pathology
MH  - Myotonic Dystrophy/metabolism/*pathology
MH  - Oligonucleotides, Antisense/pharmacology
MH  - Phenotype
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Zebrafish/embryology/genetics/*metabolism
MH  - Zebrafish Proteins/*deficiency/genetics/metabolism
PMC - PMC3097459
EDAT- 2011/02/10 06:00
MHDA- 2011/08/31 06:00
PMCR- 2011/05/01
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
PHST- 2011/05/01 00:00 [pmc-release]
AID - dmm.004150 [pii]
AID - 0040381 [pii]
AID - 10.1242/dmm.004150 [doi]
PST - ppublish
SO  - Dis Model Mech. 2011 May;4(3):381-92. doi: 10.1242/dmm.004150. Epub 2011 Feb 8.

PMID- 21245981
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20231212
IS  - 1347-5800 (Electronic)
IS  - 0044-5991 (Print)
IS  - 0044-5991 (Linking)
VI  - 43
IP  - 6
DP  - 2010 Dec 29
TI  - Neuropathology does not Correlate with Regional Differences in the Extent of 
      Expansion of CTG Repeats in the Brain with Myotonic Dystrophy Type 1.
PG  - 149-56
LID - 10.1267/ahc.10019 [doi]
AB  - Myotonic dystrophy (DM1) is known to be an adult-onset muscular dystrophy caused 
      by the expansion of CTG repeats within the 3' untranslated region of the 
      dystrophin myotonin protein kinase (DMPK) gene. The clinical features of DM1 
      include CNS symptoms, such as cognitive impairment and personality changes, the 
      pathogenesis of which remains to be elucidated. We hypothesized that the 
      distribution of neuropathological changes might be correlated with the extent of 
      the length of the CTG repeats in the DMPK genes in DM1 patients. We studied the 
      neuropathological changes in the brains of subjects with DM1 and investigated the 
      extent of somatic instability in terms of CTG repeat expansion in the different 
      brain regions of the same individuals by Southern blot analysis. The 
      neuropathological changes included etat crible in the cerebral deep white matter 
      and neurofibrillary tangles immunoreactive for phosphorylated tau in the 
      hippocampus and entorhinal cortex, both of which were compatible with the 
      subcortical dementia in DM1 patients. However, the length of the CTG repeats did 
      not correlate with the regional differences in the extent of neuropathological 
      changes. Our data suggested that pathomechanisms of dementia in DM1 might be more 
      multifactorial rather than a toxic gain-of-function due to mutant RNA.
FAU - Itoh, Kyoko
AU  - Itoh K
AD  - Department of Pathology and Applied Neurobiology, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi 
      Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Mitani, Maki
AU  - Mitani M
FAU - Kawamoto, Kunihiko
AU  - Kawamoto K
FAU - Futamura, Naonobu
AU  - Futamura N
FAU - Funakawa, Itaru
AU  - Funakawa I
FAU - Jinnai, Kenji
AU  - Jinnai K
FAU - Fushiki, Shinji
AU  - Fushiki S
LA  - eng
PT  - Journal Article
DEP - 20101218
PL  - Japan
TA  - Acta Histochem Cytochem
JT  - Acta histochemica et cytochemica
JID - 0147110
PMC - PMC3015052
OTO - NOTNLM
OT  - CTG repeats
OT  - dementia
OT  - dystrophin myotonin protein kinase
OT  - myotonic dystrophy (DM1)
OT  - neuropathology
EDAT- 2011/01/20 06:00
MHDA- 2011/01/20 06:01
PMCR- 2010/12/29
CRDT- 2011/01/20 06:00
PHST- 2010/07/08 00:00 [received]
PHST- 2010/11/01 00:00 [accepted]
PHST- 2011/01/20 06:00 [entrez]
PHST- 2011/01/20 06:00 [pubmed]
PHST- 2011/01/20 06:01 [medline]
PHST- 2010/12/29 00:00 [pmc-release]
AID - AHC10019 [pii]
AID - 10.1267/ahc.10019 [doi]
PST - ppublish
SO  - Acta Histochem Cytochem. 2010 Dec 29;43(6):149-56. doi: 10.1267/ahc.10019. Epub 
      2010 Dec 18.

PMID- 21217142
OWN - NLM
STAT- MEDLINE
DCOM- 20120106
LR  - 20171116
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 32
IP  - 10
DP  - 2011 May
TI  - Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new 
      pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus.
PG  - 1214-26
LID - 10.1093/eurheartj/ehq499 [doi]
AB  - AIMS: Diabetes mellitus (DM) is associated with high incidence of first and 
      recurrent cardiovascular events, especially acute coronary syndromes (ACSs); 
      however, the mechanisms involved are still unknown. We sought to investigate the 
      role of CD4(+)CD28(null)T-lymphocytes, a rare long-lived subset of T-lymphocytes 
      with proatherogenic and plaque-destabilizing properties, in the increased 
      cardiovascular risk associated with DM. METHODS AND RESULTS: 
      CD4(+)CD28(null)T-cell frequency was analysed by flow-cytometry in 60 DM patients 
      without overt cardiovascular disease (cDM), in 166 ACS patients with or without 
      DM (ACS/DM+, n= 51 and ACS/DM-, n= 115), and in 60 healthy individuals. The 
      incidence of cardiovascular events (death, myocardial infarction, unstable 
      angina) was assessed at 36 months follow-up. CD4+CD28(null)T-cell frequency 
      (median, range) was higher in ACS/DM+ (12.7%, 0.1-48) vs. ACS/DM- (3.9%, 0.2-35), 
      cDM (3.1%, 0.3-22.4), and controls (1.5%, 0.1-9.1) (P< 0.001 for all 
      comparisons). Notably, cDM patients had significantly higher CD4+CD28(null)T-cell 
      frequency than controls (P= 0.001). Glycosylated haemoglobin A(1c) was the only 
      parameter independently associated with CD4+CD28(null)T-cells in cDM. The 
      36-month event-free survival was significantly lower in cDM patients with 
      CD4+CD28(null)T-cells >/=4% (90th percentile of normal distribution) than in those 
      with CD4+CD28(null)T-cells <4% (P= 0.039). Among ACS patients, the 36-month 
      event-free survival was the lowest in those with DM and CD4+CD28(null)T-cells >/=4% 
      and highest in those without DM and CD4+CD28(null)T-cells <4% (P< 0.001), being 
      intermediate in those with only one of these features. CONCLUSIONS: In DM 
      patients, CD4+CD28(null)T-cells are expanded and are associated with poor 
      glycaemic control; they also correlate with the occurrence of a first 
      cardiovascular event and with a worse outcome after an ACS.
FAU - Giubilato, Simona
AU  - Giubilato S
AD  - Institute of Cardiology, Catholic University, Largo A. Gemelli, Rome, Italy.
FAU - Liuzzo, Giovanna
AU  - Liuzzo G
FAU - Brugaletta, Salvatore
AU  - Brugaletta S
FAU - Pitocco, Dario
AU  - Pitocco D
FAU - Graziani, Francesca
AU  - Graziani F
FAU - Smaldone, Costantino
AU  - Smaldone C
FAU - Montone, Rocco Antonio
AU  - Montone RA
FAU - Pazzano, Vincenzo
AU  - Pazzano V
FAU - Pedicino, Daniela
AU  - Pedicino D
FAU - Biasucci, Luigi Marzio
AU  - Biasucci LM
FAU - Ghirlanda, Giovanni
AU  - Ghirlanda G
FAU - Crea, Filippo
AU  - Crea F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110108
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (CD28 Antigens)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Acute Coronary Syndrome/drug therapy/*immunology
MH  - Age Factors
MH  - Aged
MH  - Analysis of Variance
MH  - CD28 Antigens/immunology
MH  - CD4-Positive T-Lymphocytes/physiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/drug therapy/*immunology
MH  - Diabetic Angiopathies/drug therapy/*immunology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Null/physiology
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - T-Lymphocyte Subsets/physiology
MH  - T-Lymphocytes/*physiology
EDAT- 2011/01/11 06:00
MHDA- 2012/01/10 06:00
CRDT- 2011/01/11 06:00
PHST- 2011/01/11 06:00 [entrez]
PHST- 2011/01/11 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
AID - ehq499 [pii]
AID - 10.1093/eurheartj/ehq499 [doi]
PST - ppublish
SO  - Eur Heart J. 2011 May;32(10):1214-26. doi: 10.1093/eurheartj/ehq499. Epub 2011 
      Jan 8.

PMID- 21204798
OWN - NLM
STAT- MEDLINE
DCOM- 20120216
LR  - 20141120
IS  - 1399-0004 (Electronic)
IS  - 0009-9163 (Linking)
VI  - 80
IP  - 6
DP  - 2011 Dec
TI  - Myotonia congenita and myotonic dystrophy in the same family: coexistence of a 
      CLCN1 mutation and expansion in the CNBP (ZNF9) gene.
PG  - 574-80
LID - 10.1111/j.1399-0004.2010.01616.x [doi]
AB  - Myotonia is characterized by hyperexcitability of the muscle cell membrane. 
      Myotonic disorders are divided into two main categories: non-dystrophic and 
      dystrophic myotonias. The non-dystrophic myotonias involve solely the muscle 
      system, whereas the dystrophic myotonias are characterized by multisystem 
      involvement and additional muscle weakness. Each category is further subdivided 
      into different groups according to additional clinical features or/and underlying 
      genetic defects. However, the phenotypes and the pathological mechanisms of these 
      myotonic disorders are still not entirely understood. Currently, four genes are 
      identified to be involved in myotonia: the muscle voltage-gated sodium and 
      chloride channel genes SCN4A and CLCN1, the myotonic dystrophy protein kinase 
      (DMPK) gene, and the CCHC-type zinc finger, nucleic acid binding protein gene 
      CNBP. Additional gene(s) and/or modifying factor(s) remain to be identified. In 
      this study, we investigated a large Norwegian family with clinically different 
      presentations of myotonic disorders. Molecular analysis revealed CCTG repeat 
      expansions in the CNBP gene in all affected members, confirming that they have 
      myotonic dystrophy type 2. However, a CLCN1 mutation c.1238C>G, causing 
      p.Phe413Cys, was also identified in several affected family members. 
      Heterozygosity for p.Phe413Cys seems to exaggerate the severity of myotonia and 
      thereby, to some degree, contributing to the pronounced variability in the 
      myotonic phenotype in this family.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Sun, C
AU  - Sun C
AD  - Department of Clinical Medicine - Medical Genetics, Faculty of Health Sciences, 
      University of Tromso, Tromso, Norway. chen.sun@helse-bergen.no
FAU - Van Ghelue, M
AU  - Van Ghelue M
FAU - Tranebjaerg, L
AU  - Tranebjaerg L
FAU - Thyssen, F
AU  - Thyssen F
FAU - Nilssen, O
AU  - Nilssen O
FAU - Torbergsen, T
AU  - Torbergsen T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110119
PL  - Denmark
TA  - Clin Genet
JT  - Clinical genetics
JID - 0253664
RN  - 0 (CLC-1 channel)
RN  - 0 (CNBP protein, human)
RN  - 0 (Chloride Channels)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Alleles
MH  - Child
MH  - Chloride Channels/*genetics
MH  - Female
MH  - Genetic Testing
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Muscle Weakness/genetics/pathology
MH  - Mutation
MH  - Myotonia Congenita/diagnosis/*genetics/pathology
MH  - Myotonic Disorders/diagnosis/genetics/pathology
MH  - Myotonic Dystrophy/diagnosis/*genetics/pathology
MH  - Norway
MH  - Pedigree
MH  - Phenotype
MH  - Pregnancy
MH  - RNA-Binding Proteins/*genetics
MH  - Young Adult
EDAT- 2011/01/06 06:00
MHDA- 2012/02/18 06:00
CRDT- 2011/01/06 06:00
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2012/02/18 06:00 [medline]
AID - 10.1111/j.1399-0004.2010.01616.x [doi]
PST - ppublish
SO  - Clin Genet. 2011 Dec;80(6):574-80. doi: 10.1111/j.1399-0004.2010.01616.x. Epub 
      2011 Jan 19.

PMID- 21173221
OWN - NLM
STAT- MEDLINE
DCOM- 20110210
LR  - 20240104
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 108
IP  - 1
DP  - 2011 Jan 4
TI  - Non-ATG-initiated translation directed by microsatellite expansions.
PG  - 260-5
LID - 10.1073/pnas.1013343108 [doi]
AB  - Trinucleotide expansions cause disease by both protein- and RNA-mediated 
      mechanisms. Unexpectedly, we discovered that CAG expansion constructs express 
      homopolymeric polyglutamine, polyalanine, and polyserine proteins in the absence 
      of an ATG start codon. This repeat-associated non-ATG translation (RAN 
      translation) occurs across long, hairpin-forming repeats in transfected cells or 
      when expansion constructs are integrated into the genome in lentiviral-transduced 
      cells and brains. Additionally, we show that RAN translation across human 
      spinocerebellar ataxia type 8 (SCA8) and myotonic dystrophy type 1 (DM1) CAG 
      expansion transcripts results in the accumulation of SCA8 polyalanine and DM1 
      polyglutamine expansion proteins in previously established SCA8 and DM1 mouse 
      models and human tissue. These results have implications for understanding 
      fundamental mechanisms of gene expression. Moreover, these toxic, unexpected, 
      homopolymeric proteins now should be considered in pathogenic models of 
      microsatellite disorders.
FAU - Zu, Tao
AU  - Zu T
AD  - Department of Genetics Cell Biology and Development, University of Minnesota 
      Medical School, Minneapolis, MN 55455, USA.
FAU - Gibbens, Brian
AU  - Gibbens B
FAU - Doty, Noelle S
AU  - Doty NS
FAU - Gomes-Pereira, Mario
AU  - Gomes-Pereira M
FAU - Huguet, Aline
AU  - Huguet A
FAU - Stone, Matthew D
AU  - Stone MD
FAU - Margolis, Jamie
AU  - Margolis J
FAU - Peterson, Mark
AU  - Peterson M
FAU - Markowski, Todd W
AU  - Markowski TW
FAU - Ingram, Melissa A C
AU  - Ingram MA
FAU - Nan, Zhenhong
AU  - Nan Z
FAU - Forster, Colleen
AU  - Forster C
FAU - Low, Walter C
AU  - Low WC
FAU - Schoser, Benedikt
AU  - Schoser B
FAU - Somia, Nikunj V
AU  - Somia NV
FAU - Clark, H Brent
AU  - Clark HB
FAU - Schmechel, Stephen
AU  - Schmechel S
FAU - Bitterman, Peter B
AU  - Bitterman PB
FAU - Gourdon, Genevieve
AU  - Gourdon G
FAU - Swanson, Maurice S
AU  - Swanson MS
FAU - Moseley, Melinda
AU  - Moseley M
FAU - Ranum, Laura P W
AU  - Ranum LP
LA  - eng
GR  - P30 CA77598/CA/NCI NIH HHS/United States
GR  - P30 CA077598/CA/NCI NIH HHS/United States
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - P50 CA101955/CA/NCI NIH HHS/United States
GR  - R01 NS040389/NS/NINDS NIH HHS/United States
GR  - R01NS040389/NS/NINDS NIH HHS/United States
GR  - P01 NS058901/NS/NINDS NIH HHS/United States
GR  - AR057220/AR/NIAMS NIH HHS/United States
GR  - P01NS058901/NS/NINDS NIH HHS/United States
GR  - R01 HL089249/HL/NHLBI NIH HHS/United States
GR  - P30 AR057220/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101220
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Codon, Initiator)
RN  - 0 (DNA Primers)
RN  - 0 (Peptides)
RN  - 25191-17-7 (polyalanine)
RN  - 25821-52-7 (polyserine)
RN  - 26700-71-0 (polyglutamine)
SB  - IM
MH  - Amino Acid Sequence
MH  - Blotting, Northern
MH  - Cell Line
MH  - Cloning, Molecular
MH  - Codon, Initiator/genetics
MH  - DNA Primers/genetics
MH  - Fluorescent Antibody Technique
MH  - Genetic Vectors
MH  - Humans
MH  - Immunoblotting
MH  - Immunohistochemistry
MH  - Immunoprecipitation
MH  - Lentivirus
MH  - Mass Spectrometry
MH  - Molecular Sequence Data
MH  - Mutagenesis
MH  - Myotonic Dystrophy/genetics
MH  - Peptides/genetics/metabolism
MH  - Protein Biosynthesis/*genetics/physiology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Spinocerebellar Ataxias/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC3017129
COIS- The authors declare no conflict of interest.
EDAT- 2010/12/22 06:00
MHDA- 2011/02/11 06:00
PMCR- 2010/12/20
CRDT- 2010/12/22 06:00
PHST- 2010/12/22 06:00 [entrez]
PHST- 2010/12/22 06:00 [pubmed]
PHST- 2011/02/11 06:00 [medline]
PHST- 2010/12/20 00:00 [pmc-release]
AID - 1013343108 [pii]
AID - 201013343 [pii]
AID - 10.1073/pnas.1013343108 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):260-5. doi: 10.1073/pnas.1013343108. 
      Epub 2010 Dec 20.

PMID- 21146669
OWN - NLM
STAT- MEDLINE
DCOM- 20110208
LR  - 20101214
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 160
IP  - 6
DP  - 2010 Dec
TI  - Increased mortality with left ventricular systolic dysfunction and heart failure 
      in adults with myotonic dystrophy type 1.
PG  - 1137-41, 1141.e1
LID - 10.1016/j.ahj.2010.07.032 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a neurologic disorder with known 
      cardiac involvement, including left ventricular systolic dysfunction (LVSD), 
      heart failure (HF), atrioventricular and intraventricular conduction system 
      disease, and sudden death. We studied the prevalence of these conditions and 
      associated findings in a large population with DM1. METHODS: History, physical 
      examination, genetic testing, and electrocardiography were performed on 406 
      patients with DM1, and cardiac imaging was performed on 180 (44.3%) of these 
      patients. RESULTS: Left ventricular systolic dysfunction and clinical HF were 
      found in 34 (18.9%) of 180 and in 23 (5.7%) of 406 of enrolled subjects, 
      respectively, yielding an overall prevalence of LVSD/HF in 41 (10.1%) of 406. 
      Increasing age, male sex, electrocardiographic conduction abnormalities, presence 
      of atrial and ventricular arrhythmias, and implanted devices were all 
      significantly associated with LVSD/HF, whereas cytosine-thiamine-guanine repeat 
      length and neuromuscular severity score were not. The interval>/=240 milliseconds 
      (relative risk 4.1, 95% CI 1.7-9.6, P=.001) and QRS duration>/=120 milliseconds 
      (relative risk 4.2, 95% CI 2.0-8.5, P<.001) were significant predictors of 
      LVSD/HF. The presence of LVSD/HF was also significantly associated with all-cause 
      death (relative risk 3.9, 95% CI 2.3-6.4, P<.001) and cardiac death (relative 
      risk 5.7, 95% CI 2.6-12.4, P<.001). CONCLUSIONS: A significant prevalence of 
      LVSD/HF exists in patients with DM1. The presence of LVSD/HF in DM1 is 
      significantly associated with all-cause and cardiac death.
CI  - Copyright (c) 2010 Mosby, Inc. All rights reserved.
FAU - Bhakta, Deepak
AU  - Bhakta D
AD  - Department of Medicine, Division (Krannert Institute) of Cardiology, Indiana 
      University, Indianapolis, IN 46202, USA. dbhakta@iupui.edu
FAU - Groh, Miriam R
AU  - Groh MR
FAU - Shen, Changyu
AU  - Shen C
FAU - Pascuzzi, Robert M
AU  - Pascuzzi RM
FAU - Groh, William J
AU  - Groh WJ
LA  - eng
SI  - ClinicalTrials.gov/NCT00622453
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - IM
MH  - Adult
MH  - Disease Progression
MH  - Electrocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure, Systolic/diagnosis/etiology/*mortality
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*complications/mortality
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Survival Rate/trends
MH  - United States/epidemiology
MH  - Ventricular Dysfunction, Left/diagnosis/etiology/*mortality
EDAT- 2010/12/15 06:00
MHDA- 2011/02/09 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/03/29 00:00 [received]
PHST- 2010/07/28 00:00 [accepted]
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/02/09 06:00 [medline]
AID - S0002-8703(10)00679-4 [pii]
AID - 10.1016/j.ahj.2010.07.032 [doi]
PST - ppublish
SO  - Am Heart J. 2010 Dec;160(6):1137-41, 1141.e1. doi: 10.1016/j.ahj.2010.07.032.

PMID- 21112106
OWN - NLM
STAT- MEDLINE
DCOM- 20130128
LR  - 20240312
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 156
IP  - 3
DP  - 2012 May 3
TI  - Increased temporal dispersion of myocardial repolarization in myotonic dystrophy 
      type 1: beyond the cardiac conduction system.
PG  - 259-64
LID - 10.1016/j.ijcard.2010.10.132 [doi]
AB  - BACKGROUND AND OBJECTIVES: The most frequently mechanism underlying sudden 
      cardiac death in myotonic dystrophy type 1 (DM1) is bradyarrhythmias due to 
      cardiac conduction abnormalities. However the risk of ventricular 
      tachyarrhythmias remains a concern in clinical management as well as in its 
      determinant. We therefore assessed autonomic nervous system activity aiming to 
      disclose differences in the QT variability index (QTVI)-a marker of temporal 
      myocardial repolarization lability-between DM1 patients and healthy controls. We 
      also investigated the possible differences within DM1 patients by subdividing 
      them according either to the presence of first degree atrioventricular block (1st 
      AVB) or to the cytosine-thymine-guanine (CTG) repeat expansion size. METHODS: 
      Sixty-two DM1 patients and 20 healthy subjects underwent neurological and 
      cardiological examinations, the latter including ECG, echocardiography and 
      24-hour Holter monitoring. All underwent a 5-minute ECG recording to assess heart 
      rate variability power spectral components, and the QTVI values. RESULTS: Power 
      spectral data, namely total power, low frequency power and high frequency power, 
      were lower, whereas QTVI values were higher in DM1 patients than in controls 
      (p<.0001). Higher QTVI values were found in DM1 subgroups with 1st AVB (p=.009) 
      and more than 500 CTG repeat (p=.014) with respect to DM1 patients without 1st 
      AVB and CTG<500. Spectral data did not significantly differ. At multivariable 
      analysis, QTVI and age were independently associated with PR interval and CTG 
      repeat. CONCLUSIONS: The increased values of QTVI argue in favour of an important 
      heart involvement extending beyond the conduction system. Whether QTVI could be 
      useful in predicting clinical course of DM1 clearly requires larger prospective 
      studies.
CI  - Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Magri, Damiano
AU  - Magri D
AD  - Cardiology Department, S. Andrea Hospital, "Sapienza" University of Rome, Rome, 
      Italy. damiano.magri@libero.it
FAU - Piccirillo, Gianfranco
AU  - Piccirillo G
FAU - Bucci, Elisabetta
AU  - Bucci E
FAU - Pignatelli, Giulia
AU  - Pignatelli G
FAU - Cauti, Filippo Maria
AU  - Cauti FM
FAU - Morino, Stefania
AU  - Morino S
FAU - Latino, Pamela
AU  - Latino P
FAU - Santini, Daria
AU  - Santini D
FAU - Marrara, Federica
AU  - Marrara F
FAU - Volpe, Massimo
AU  - Volpe M
FAU - Antonini, Giovanni
AU  - Antonini G
FAU - Testa, Marco
AU  - Testa M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101126
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
SB  - IM
MH  - Adult
MH  - Electrocardiography/methods
MH  - Female
MH  - Heart Conduction System/*physiology
MH  - Heart Rate/*physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*diagnosis/epidemiology/*physiopathology
MH  - Time Factors
EDAT- 2010/11/30 06:00
MHDA- 2013/01/29 06:00
CRDT- 2010/11/30 06:00
PHST- 2010/07/19 00:00 [received]
PHST- 2010/10/04 00:00 [revised]
PHST- 2010/10/31 00:00 [accepted]
PHST- 2010/11/30 06:00 [entrez]
PHST- 2010/11/30 06:00 [pubmed]
PHST- 2013/01/29 06:00 [medline]
AID - S0167-5273(10)00995-2 [pii]
AID - 10.1016/j.ijcard.2010.10.132 [doi]
PST - ppublish
SO  - Int J Cardiol. 2012 May 3;156(3):259-64. doi: 10.1016/j.ijcard.2010.10.132. Epub 
      2010 Nov 26.

PMID- 21103235
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211020
IS  - 1662-0631 (Print)
IS  - 1662-0631 (Electronic)
IS  - 1662-0631 (Linking)
VI  - 4
IP  - 1
DP  - 2010 Mar 17
TI  - Non-Alcoholic Steatohepatitis in Myotonic Dystrophy: DMPK Gene Mutation, Insulin 
      Resistance and Development of Steatohepatitis.
PG  - 100-103
AB  - Myotonic dystrophy is a multisystemic disorder characterized by repeat expansion 
      mutations of the dystrophia myotonica protein kinase (DMPK) gene resulting in a 
      defective muscular insulin receptor and insulin resistance. We describe a patient 
      with myotonic dystrophy who developed biopsy-proven non-alcoholic 
      steatohepatitis. We suggest that patients with myotonic dystrophy are at risk of 
      developing steatohepatitis. The relationship between defective insulin receptor 
      and development of steatohepatitis should be further investigated.
FAU - Bhardwaj, Rishi R
AU  - Bhardwaj RR
AD  - Department of Medicine, Weill-Cornell Medical College, The Methodist Hospital, 
      Houston, Tex., USA.
FAU - Duchini, Andrea
AU  - Duchini A
LA  - eng
PT  - Case Reports
DEP - 20100317
PL  - Switzerland
TA  - Case Rep Gastroenterol
JT  - Case reports in gastroenterology
JID - 101474819
PMC - PMC2988905
EDAT- 2010/11/26 06:00
MHDA- 2010/11/26 06:01
PMCR- 2010/03/17
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2010/11/26 06:01 [medline]
PHST- 2010/03/17 00:00 [pmc-release]
AID - 292093 [pii]
AID - crg0004-0100 [pii]
AID - 10.1159/000292093 [doi]
PST - epublish
SO  - Case Rep Gastroenterol. 2010 Mar 17;4(1):100-103. doi: 10.1159/000292093.

PMID- 21059769
OWN - NLM
STAT- MEDLINE
DCOM- 20110615
LR  - 20211020
IS  - 1460-2377 (Electronic)
IS  - 0953-8178 (Print)
IS  - 0953-8178 (Linking)
VI  - 22
IP  - 11
DP  - 2010 Nov
TI  - A panel of human cell-based artificial APC enables the expansion of long-lived 
      antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.
PG  - 863-73
LID - 10.1093/intimm/dxq440 [doi]
AB  - Many preclinical experiments have attested to the critical role of CD4(+) T cell 
      help in CD8(+) cytotoxic T lymphocyte (CTL)-mediated immunity. Recent clinical 
      trials have demonstrated that reinfusion of CD4(+) T cells can induce responses 
      in infectious diseases and cancer. However, few standardized and versatile 
      systems exist to expand antigen-specific CD4(+) T(h) for clinical use. K562 is a 
      human erythroleukemic cell line, which lacks expression of HLA class I and class 
      II, invariant chain and HLA-DM but expresses adhesion molecules such as 
      intercellular adhesion molecule-1 and leukocyte function-associated antigen-3. 
      With this unique immunologic phenotype, K562 has been tested in clinical trials 
      of cancer immunotherapy. Previously, we created a K562-based artificial 
      antigen-presenting cell (aAPC) that generates ex vivo long-lived 
      HLA-A2-restricted CD8(+) CTL with a central/effector memory phenotype armed with 
      potent effector function. We successfully generated a clinical version of this 
      aAPC and conducted a clinical trial where large numbers of anti-tumor CTL are 
      reinfused to cancer patients. In this article, we shifted focus to CD4(+) T cells 
      and developed a panel of novel K562-derived aAPC, where each expresses a 
      different single HLA-DR allele, invariant chain, HLA-DM, CD80, CD83 and CD64; 
      takes up soluble protein by endocytosis and processes and presents CD4(+) T-cell 
      peptides. Using this aAPC, we were able to determine novel DR-restricted CD4(+) 
      T-cell epitopes and expand long-lived CD4(+) T-cells specific for multiple 
      antigens without growing bystander Foxp3(+) regulatory T cells. Our results 
      suggest that K562-based aAPC may serve as a translatable platform to generate 
      both antigen-specific CD8(+) CTL and CD4(+) T(h).
FAU - Butler, Marcus O
AU  - Butler MO
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, 
      Boston, MA 02115, USA.
FAU - Ansen, Sascha
AU  - Ansen S
FAU - Tanaka, Makito
AU  - Tanaka M
FAU - Imataki, Osamu
AU  - Imataki O
FAU - Berezovskaya, Alla
AU  - Berezovskaya A
FAU - Mooney, Mary M
AU  - Mooney MM
FAU - Metzler, Genita
AU  - Metzler G
FAU - Milstein, Matthew I
AU  - Milstein MI
FAU - Nadler, Lee M
AU  - Nadler LM
FAU - Hirano, Naoto
AU  - Hirano N
LA  - eng
GR  - R01 CA148673-01/CA/NCI NIH HHS/United States
GR  - K22 CA129240-03/CA/NCI NIH HHS/United States
GR  - R01 CA148673/CA/NCI NIH HHS/United States
GR  - R01CA148673/CA/NCI NIH HHS/United States
GR  - CA87720/CA/NCI NIH HHS/United States
GR  - K22 CA129240/CA/NCI NIH HHS/United States
GR  - K22CA129240/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101108
PL  - England
TA  - Int Immunol
JT  - International immunology
JID - 8916182
RN  - 0 (HLA-DR Antigens)
SB  - IM
MH  - *Alleles
MH  - Antigen-Presenting Cells/*immunology
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Line
MH  - HLA-DR Antigens/*immunology
MH  - Humans
PMC - PMC2994545
EDAT- 2010/11/10 06:00
MHDA- 2011/06/16 06:00
PMCR- 2011/11/01
CRDT- 2010/11/10 06:00
PHST- 2010/11/10 06:00 [entrez]
PHST- 2010/11/10 06:00 [pubmed]
PHST- 2011/06/16 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - dxq440 [pii]
AID - 10.1093/intimm/dxq440 [doi]
PST - ppublish
SO  - Int Immunol. 2010 Nov;22(11):863-73. doi: 10.1093/intimm/dxq440. Epub 2010 Nov 8.

PMID- 21051337
OWN - NLM
STAT- MEDLINE
DCOM- 20110531
LR  - 20211020
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 39
IP  - 5
DP  - 2011 Mar
TI  - Determinants of R-loop formation at convergent bidirectionally transcribed 
      trinucleotide repeats.
PG  - 1749-62
LID - 10.1093/nar/gkq935 [doi]
AB  - R-loops have been described at immunoglobulin class switch sequences, prokaryotic 
      and mitochondrial replication origins, and disease-associated (CAG)n and (GAA)n 
      trinucleotide repeats. The determinants of trinucleotide R-loop formation are 
      unclear. Trinucleotide repeat expansions cause diseases including DM1 (CTG)n, 
      SCA1 (CAG)n, FRAXA (CGG)n, FRAXE (CCG)n and FRDA (GAA)n. Bidirectional convergent 
      transcription across these disease repeats can occur. We find R-loops formed when 
      CTG or CGG and their complementary strands CAG or CCG were transcribed; GAA 
      transcription, but not TTC, yielded R-loops. R-loop formation was sensitive to 
      DNA supercoiling, repeat length, insensitive to repeat interruptions, and formed 
      by extension of RNA:DNA hybrids in the RNA polymerase. R-loops arose by 
      transcription in one direction followed by transcription in the opposite 
      direction, and during simultaneous convergent bidirectional transcription of the 
      same repeat forming double R-loop structures. Since each transcribed disease 
      repeat formed R-loops suggests they may have biological functions.
FAU - Reddy, Kaalak
AU  - Reddy K
AD  - Program of Genetics & Genome Biology, The Hospital for Sick Children, 101 College 
      Street, East Tower, 15-312 TMDT, Toronto, Ontario M5G 1L7, Canada.
FAU - Tam, Mandy
AU  - Tam M
FAU - Bowater, Richard P
AU  - Bowater RP
FAU - Barber, Miriam
AU  - Barber M
FAU - Tomlinson, Matthew
AU  - Tomlinson M
FAU - Nichol Edamura, Kerrie
AU  - Nichol Edamura K
FAU - Wang, Yuh-Hwa
AU  - Wang YH
FAU - Pearson, Christopher E
AU  - Pearson CE
LA  - eng
GR  - MOP-94966/Canadian Institutes of Health Research/Canada
GR  - R01 CA085826/CA/NCI NIH HHS/United States
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101104
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (DNA, Superhelical)
RN  - 63231-63-0 (RNA)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - DNA/*chemistry/ultrastructure
MH  - DNA, Superhelical/chemistry
MH  - RNA/*chemistry/ultrastructure
MH  - *Transcription, Genetic
MH  - *Trinucleotide Repeats
PMC - PMC3061079
EDAT- 2010/11/06 06:00
MHDA- 2011/06/01 06:00
PMCR- 2010/11/04
CRDT- 2010/11/06 06:00
PHST- 2010/11/06 06:00 [entrez]
PHST- 2010/11/06 06:00 [pubmed]
PHST- 2011/06/01 06:00 [medline]
PHST- 2010/11/04 00:00 [pmc-release]
AID - gkq935 [pii]
AID - 10.1093/nar/gkq935 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2011 Mar;39(5):1749-62. doi: 10.1093/nar/gkq935. Epub 2010 Nov 
      4.

PMID- 20971734
OWN - NLM
STAT- MEDLINE
DCOM- 20110315
LR  - 20211020
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Print)
IS  - 0002-9440 (Linking)
VI  - 177
IP  - 6
DP  - 2010 Dec
TI  - Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 
      (ZNF9) in myotonic dystrophy type 2.
PG  - 3025-36
LID - 10.2353/ajpath.2010.100179 [doi]
AB  - The mutation that underlies myotonic dystrophy type 2 (DM2) is a (CCTG)n 
      expansion in intron 1 of zinc finger protein 9 (ZNF9). It has been suggested that 
      ZNF9 is of no consequence for disease pathogenesis. We determined the expression 
      levels of ZNF9 during muscle cell differentiation and in DM2 muscle by microarray 
      profiling, real-time RT-PCR, splice variant analysis, immunofluorescence, and 
      Western blotting. Our results show that in differentiating myoblasts, ZNF9 
      protein was localized primarily to the nucleus, whereas in mature muscle fibers, 
      it was cytoplasmic and organized in sarcomeric striations at the Z-disk. In 
      patients with DM2, ZNF9 was abnormally expressed. First, there was an overall 
      reduction in both the mRNA and protein levels. Second, the subcellular 
      localization of the ZNF9 protein was somewhat less cytoplasmic and more 
      membrane-bound. Third, our splice variant analysis revealed retention of intron 3 
      in an aberrant isoform, and fourth quantitative allele-specific expression 
      analysis showed the persistence of intron 1 sequences from the abnormal allele, 
      further suggesting that the mutant allele is incompletely spliced. Thus, the 
      decrease in total expression appears to be due to impaired splicing of the mutant 
      transcript. Our data indicate that ZNF9 expression in DM2 patients is altered at 
      multiple levels. Although toxic RNA effects likely explain overlapping phenotypic 
      manifestations between DM1 and DM2, abnormal ZNF9 levels in DM2 may account for 
      the differences in DM1.
FAU - Raheem, Olayinka
AU  - Raheem O
AD  - Neuromuscular Research Unit, University of Tampere and Tampere University 
      Hospital, Tampere, Finland. olayinka.raheem@uta.fi
FAU - Olufemi, Shodimu-Emmanuel
AU  - Olufemi SE
FAU - Bachinski, Linda L
AU  - Bachinski LL
FAU - Vihola, Anna
AU  - Vihola A
FAU - Sirito, Mario
AU  - Sirito M
FAU - Holmlund-Hampf, Jeanette
AU  - Holmlund-Hampf J
FAU - Haapasalo, Hannu
AU  - Haapasalo H
FAU - Li, Yi-Ping
AU  - Li YP
FAU - Udd, Bjarne
AU  - Udd B
FAU - Krahe, Ralf
AU  - Krahe R
LA  - eng
GR  - R01 AR048171/AR/NIAMS NIH HHS/United States
GR  - R01 AR48171/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20101022
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA Repeat Expansion/*physiology
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation/genetics
MH  - Humans
MH  - Male
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism/pathology
MH  - Mutation/physiology
MH  - Myotonic Disorders/genetics/metabolism/pathology
MH  - Myotonic Dystrophy
MH  - RNA-Binding Proteins/*genetics/metabolism
MH  - Tissue Distribution/genetics
MH  - Young Adult
PMC - PMC2993290
EDAT- 2010/10/26 06:00
MHDA- 2011/03/16 06:00
PMCR- 2011/12/01
CRDT- 2010/10/26 06:00
PHST- 2010/10/26 06:00 [entrez]
PHST- 2010/10/26 06:00 [pubmed]
PHST- 2011/03/16 06:00 [medline]
PHST- 2011/12/01 00:00 [pmc-release]
AID - S0002-9440(10)62927-6 [pii]
AID - 10.2353/ajpath.2010.100179 [doi]
PST - ppublish
SO  - Am J Pathol. 2010 Dec;177(6):3025-36. doi: 10.2353/ajpath.2010.100179. Epub 2010 
      Oct 22.

PMID- 20935170
OWN - NLM
STAT- MEDLINE
DCOM- 20110524
LR  - 20171116
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 20
IP  - 1
DP  - 2011 Jan 1
TI  - Huntington's and myotonic dystrophy hESCs: down-regulated trinucleotide repeat 
      instability and mismatch repair machinery expression upon differentiation.
PG  - 176-85
LID - 10.1093/hmg/ddq456 [doi]
AB  - Huntington's disease (HD) and myotonic dystrophy (DM1) are caused by 
      trinucleotide repeat expansions. The repeats show different instability patterns 
      according to the disorder, cell type and developmental stage. Here we studied the 
      behavior of these repeats in DM1- and HD-derived human embryonic stem cells 
      (hESCs) before and after differentiation, and its relationship to the DNA 
      mismatch repair (MMR). The relatively small (CAG)44 HD expansion was stable in 
      undifferentiated and differentiated HD hESCs. In contrast, the DM1 repeat showed 
      instability from the earliest passages onwards in DM1 hESCs with (CTG)250 or 
      (CTG)1800. Upon differentiation the DM1 repeat was stabilized. MMR genes, 
      including hMSH2, hMSH3 and hMSH6 were assessed at the transcript and protein 
      levels in differentiated cells. The coincidence of differentiation-induced 
      down-regulated MMR expression with reduced instability of the long expanded 
      repeats in hESCs is consistent with a known requirement of MMR proteins for 
      repeat instability in transgenic mice. This is the first demonstration of a 
      correlation between altered repeat instability of an endogenous DM1 locus and 
      natural MMR down-regulation, in contrast to the commonly used murine knock-down 
      systems.
FAU - Seriola, Anna
AU  - Seriola A
AD  - REGE, VUB, Brussels, Belgium.
FAU - Spits, Claudia
AU  - Spits C
FAU - Simard, Jodie P
AU  - Simard JP
FAU - Hilven, Pierre
AU  - Hilven P
FAU - Haentjens, Patrick
AU  - Haentjens P
FAU - Pearson, Christopher E
AU  - Pearson CE
FAU - Sermon, Karen
AU  - Sermon K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101008
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MSH3 protein, human)
RN  - 0 (MutS Homolog 3 Protein)
RN  - EC 3.6.1.3 (MSH2 protein, human)
RN  - EC 3.6.1.3 (MutS Homolog 2 Protein)
SB  - IM
MH  - Animals
MH  - Cell Differentiation
MH  - DNA Mismatch Repair/genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Down-Regulation
MH  - Embryonic Stem Cells/*pathology
MH  - Genomic Instability
MH  - Humans
MH  - Huntington Disease/genetics/*pathology
MH  - Mice
MH  - Mice, Transgenic
MH  - MutS Homolog 2 Protein/genetics
MH  - MutS Homolog 3 Protein
MH  - Myotonic Dystrophy/genetics/*pathology
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2010/10/12 06:00
MHDA- 2011/05/25 06:00
CRDT- 2010/10/12 06:00
PHST- 2010/10/12 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2011/05/25 06:00 [medline]
AID - ddq456 [pii]
AID - 10.1093/hmg/ddq456 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2011 Jan 1;20(1):176-85. doi: 10.1093/hmg/ddq456. Epub 2010 Oct 8.

PMID- 20801043
OWN - NLM
STAT- MEDLINE
DCOM- 20110310
LR  - 20211203
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 17
IP  - 12
DP  - 2010 Dec
TI  - CTG repeat lengths of the DMPK gene in myotonic dystrophy patients compared to 
      healthy controls in Thailand.
PG  - 1520-2
LID - 10.1016/j.jocn.2010.03.047 [doi]
AB  - Myotonic dystrophy (DM) is frequently associated with large expansions of the 
      cytosine-thymine-guanine (CTG) repeat in the myotonic dystrophy protein kinase 
      gene (DMPK). The frequency of distribution of the CTG repeat length in normal 
      alleles of several populations is well correlated with the prevalence of DM. 
      Therefore, we studied the CTG repeat length of the DMPK gene in DM patients and 
      controls in Thailand. Only seven typical patients with DM from six unrelated 
      families were identified, all with large pathological CTG repeat expansions (> 
      400 repeats) in the DMPK gene. Only 2.75% of controls had normal CTG repeat 
      alleles > 18 repeats. The frequency distribution of the CTG-repeat alleles in the 
      normal Thai population is similar to that of the Taiwanese population (chi(2) with 
      Yates correction = 1.393; p = 0.2379). These data suggest that the incidence of 
      DM might be rare in Thailand, where the risk of developing DM is possibly similar 
      to that in Taiwan.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Theerasasawat, S
AU  - Theerasasawat S
AD  - Division of Neurology, Department of Medicine, Faculty of Medicine, Ramathibodi 
      Hospital, Mahidol University, Bangkok 10400, Thailand.
FAU - Papsing, C
AU  - Papsing C
FAU - Pulkes, T
AU  - Pulkes T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100830
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - Myotonic Dystrophy/*epidemiology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction
MH  - Prevalence
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Thailand/epidemiology
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats
EDAT- 2010/08/31 06:00
MHDA- 2011/03/11 06:00
CRDT- 2010/08/31 06:00
PHST- 2009/10/27 00:00 [received]
PHST- 2010/02/15 00:00 [revised]
PHST- 2010/03/08 00:00 [accepted]
PHST- 2010/08/31 06:00 [entrez]
PHST- 2010/08/31 06:00 [pubmed]
PHST- 2011/03/11 06:00 [medline]
AID - S0967-5868(10)00354-1 [pii]
AID - 10.1016/j.jocn.2010.03.047 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2010 Dec;17(12):1520-2. doi: 10.1016/j.jocn.2010.03.047. Epub 
      2010 Aug 30.

PMID- 20736973
OWN - NLM
STAT- MEDLINE
DCOM- 20110328
LR  - 20221207
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 19
IP  - 1
DP  - 2011 Jan
TI  - Distinguishing the 4qA and 4qB variants is essential for the diagnosis of 
      facioscapulohumeral muscular dystrophy in the Chinese population.
PG  - 64-9
LID - 10.1038/ejhg.2010.143 [doi]
AB  - Facioscapulohumeral muscular dystrophy (FSHD) is the third most common inherited 
      muscular dystrophy with markedly clinical variability and complex genetic cause. 
      Several reports pertaining to the Caucasian population have confirmed that there 
      are 4qA and 4qB variants of the 4qter subtelomere, and FSHD is uniquely 
      associated with the 4qA variant. However, few data relevant to the Chinese 
      population have been published. In present paper, detailed clinical and genetic 
      re-evaluations were performed in members of four special families who had been 
      initially diagnosed as atypical or asymptomatic FSHD based only on the D4Z4 
      repeat length analysis. The FSHD-sized D4Z4 repeats in the probands from families 
      1, 2 and 3 were identified as 4qB variants. These patients were further confirmed 
      as limb-girdle muscular dystrophy (LGMD2) or myotonic dystrophy (DM1) by 
      molecular analyses. Specifically, we identified a 4qB variant on chromosome 10 in 
      the healthy members of the fourth FSHD family with complex D4Z4 rearrangements of 
      two exchanged repeat arrays. For the first time, we demonstrated in the Chinese 
      population that D4Z4 contractions on the 4qB variant do not cause FSHD and 4qB 
      variant on chromosome 10 might also represent intermediate structures in the 
      transition from 4q to 10q. Furthermore, our results emphasize that D4Z4 repeat 
      length analysis alone is not sufficient for the diagnosis of FSHD, especially 
      when used as an exclusion criterion. This analysis should be accompanied by 
      4qA/4qB variant determination and integrated chromosome assignments, especially 
      in patients with obscure and unclassified myopathies similar to atypical forms of 
      FSHD.
FAU - Wang, Zhi-Qiang
AU  - Wang ZQ
AD  - Department of Neurology and Institute of Neurology, First Affiliated Hospital, 
      Center of Neuroscience, Fujian Medical University, Fuzhou, China.
FAU - Wang, Ning
AU  - Wang N
FAU - van der Maarel, Silvere
AU  - van der Maarel S
FAU - Murong, Shen-Xing
AU  - Murong SX
FAU - Wu, Zhi-Ying
AU  - Wu ZY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100825
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Asian People/*genetics
MH  - Chromosomes, Human, Pair 10/*genetics
MH  - Chromosomes, Human, Pair 4/*genetics
MH  - Female
MH  - *Genetic Variation
MH  - Humans
MH  - Muscular Dystrophies, Limb-Girdle/diagnosis/genetics/physiopathology
MH  - Muscular Dystrophy, Facioscapulohumeral/*diagnosis/genetics/physiopathology
MH  - Pedigree
MH  - Repetitive Sequences, Nucleic Acid/*genetics
MH  - Telomere
PMC - PMC3039510
EDAT- 2010/08/26 06:00
MHDA- 2011/03/29 06:00
PMCR- 2012/01/01
CRDT- 2010/08/26 06:00
PHST- 2010/08/26 06:00 [entrez]
PHST- 2010/08/26 06:00 [pubmed]
PHST- 2011/03/29 06:00 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - ejhg2010143 [pii]
AID - 10.1038/ejhg.2010.143 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2011 Jan;19(1):64-9. doi: 10.1038/ejhg.2010.143. Epub 2010 Aug 
      25.

PMID- 20711191
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20211020
IS  - 1545-9985 (Electronic)
IS  - 1545-9985 (Linking)
VI  - 17
IP  - 9
DP  - 2010 Sep
TI  - Tissue- and age-specific DNA replication patterns at the CTG/CAG-expanded human 
      myotonic dystrophy type 1 locus.
PG  - 1079-87
LID - 10.1038/nsmb.1876 [doi]
AB  - Myotonic dystrophy, caused by DM1 CTG/CAG repeat expansions, shows varying 
      instability levels between tissues and across ages within patients. We determined 
      DNA replication profiles at the DM1 locus in patient fibroblasts and tissues from 
      DM1 transgenic mice of various ages showing different instability. In patient 
      cells, the repeat is flanked by two replication origins demarcated by CTCF sites, 
      with replication diminished at the expansion. In mice, the expansion replicated 
      from only the downstream origin (CAG as lagging template). In testes from mice of 
      three different ages, replication toward the repeat paused at the earliest age 
      and was relieved at later ages-coinciding with increased instability. Brain, 
      pancreas and thymus replication varied with CpG methylation at DM1 CTCF sites. 
      CTCF sites between progressing forks and repeats reduced replication depending on 
      chromatin. Thus, varying replication progression may affect tissue- and 
      age-specific repeat instability.
FAU - Cleary, John D
AU  - Cleary JD
AD  - Program of Genetics & Genome Biology, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Tome, Stephanie
AU  - Tome S
FAU - Lopez Castel, Arturo
AU  - Lopez Castel A
FAU - Panigrahi, Gagan B
AU  - Panigrahi GB
FAU - Foiry, Laurent
AU  - Foiry L
FAU - Hagerman, Katharine A
AU  - Hagerman KA
FAU - Sroka, Hana
AU  - Sroka H
FAU - Chitayat, David
AU  - Chitayat D
FAU - Gourdon, Genevieve
AU  - Gourdon G
FAU - Pearson, Christopher E
AU  - Pearson CE
LA  - eng
GR  - U54NS48843/NS/NINDS NIH HHS/United States
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100815
PL  - United States
TA  - Nat Struct Mol Biol
JT  - Nature structural & molecular biology
JID - 101186374
RN  - 0 (CCCTC-Binding Factor)
RN  - 0 (CTCF protein, human)
RN  - 0 (Ctcf protein, mouse)
RN  - 0 (Repressor Proteins)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - *Aging
MH  - Animals
MH  - Binding Sites
MH  - CCCTC-Binding Factor
MH  - Chromosomes, Human, Pair 19
MH  - CpG Islands
MH  - DNA/*metabolism
MH  - DNA Methylation
MH  - *DNA Replication
MH  - Genetic Loci
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - Organ Specificity
MH  - Repressor Proteins/metabolism
EDAT- 2010/08/17 06:00
MHDA- 2010/09/29 06:00
CRDT- 2010/08/17 06:00
PHST- 2010/02/05 00:00 [received]
PHST- 2010/06/24 00:00 [accepted]
PHST- 2010/08/17 06:00 [entrez]
PHST- 2010/08/17 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - nsmb.1876 [pii]
AID - 10.1038/nsmb.1876 [doi]
PST - ppublish
SO  - Nat Struct Mol Biol. 2010 Sep;17(9):1079-87. doi: 10.1038/nsmb.1876. Epub 2010 
      Aug 15.

PMID- 20685272
OWN - NLM
STAT- MEDLINE
DCOM- 20101103
LR  - 20151119
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 89
IP  - 2
DP  - 2010 Oct
TI  - Analysis of MTMR1 expression and correlation with muscle pathological features in 
      juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy 
      type 2 (DM2).
PG  - 158-68
LID - 10.1016/j.yexmp.2010.05.007 [doi]
AB  - Among genes abnormally expressed in myotonic dystrophy type1 (DM1), the 
      myotubularin-related 1 gene (MTMR1) was related to impaired muscle 
      differentiation. Therefore, we analyzed MTMR1 expression in correlation with 
      CUG-binding protein1 (CUG-BP1) and muscleblind-like1 protein (MBNL1) steady-state 
      levels and with morphological features in muscle tissues from DM1 and myotonic 
      dystrophy type 2 (DM2) patients. Semi-quantitative RT-PCR for MTMR1 was done on 
      muscle biopsies and primary muscle cultures. The presence of impaired muscle 
      fiber maturation was evaluated using immunochemistry for neural cell adhesion 
      molecule (NCAM), Vimentin and neonatal myosin heavy chain. CUG-BP1 and MBNL1 
      steady-state levels were estimated by Western blot. RNA-fluorescence in situ 
      hybridization combined with immunochemistry for CUG-BP1, MBNL1 and NCAM were 
      performed on serial muscle sections. An aberrant splicing of MTMR1 and a 
      significant amount of NCAM-positive myofibers were detected in DM1 and DM2 muscle 
      biopsies; these alterations correlated with DNA repeat expansion size only in 
      DM1. CUG-BP1 levels were increased only in DM1 muscles, while MBNL1 levels were 
      similar among DM1, DM2 and controls. Normal and NCAM-positive myofibers displayed 
      no differences either in the amount of ribonuclear foci and the intracellular 
      distribution of MBNL1 and CUG-BP1. In conclusion, an aberrant MTMR1 expression 
      and signs of altered myofiber maturation were documented in both DM1 and in DM2 
      muscle tissues. The more severe dysregulation of MTMR1 expression in DM1 versus 
      DM2, along with increased CUG-BP1 levels only in DM1 tissues, suggests that the 
      mutual antagonism between MBNL1 and CUG-BP1 on alternative splicing is more 
      unbalanced in DM1.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Santoro, Massimo
AU  - Santoro M
AD  - Department of Neuroscience, Center for Neuromuscular Disorders, Catholic 
      University of Sacred Heart, Rome, Italy.
FAU - Modoni, Anna
AU  - Modoni A
FAU - Masciullo, Marcella
AU  - Masciullo M
FAU - Gidaro, Teresa
AU  - Gidaro T
FAU - Broccolini, Aldobrando
AU  - Broccolini A
FAU - Ricci, Enzo
AU  - Ricci E
FAU - Tonali, Pietro Attilio
AU  - Tonali PA
FAU - Silvestri, Gabriella
AU  - Silvestri G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100601
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 3.1.3.48 (MTMR1 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatases, Non-Receptor)
SB  - IM
MH  - Adult
MH  - Alternative Splicing
MH  - CELF1 Protein
MH  - Case-Control Studies
MH  - Cells, Cultured
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscles/*metabolism/pathology
MH  - Myotonic Dystrophy/*genetics/*metabolism/pathology
MH  - Protein Tyrosine Phosphatases, Non-Receptor/genetics
MH  - RNA-Binding Proteins/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2010/08/06 06:00
MHDA- 2010/11/04 06:00
CRDT- 2010/08/06 06:00
PHST- 2010/01/13 00:00 [received]
PHST- 2010/04/28 00:00 [revised]
PHST- 2010/05/17 00:00 [accepted]
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2010/11/04 06:00 [medline]
AID - S0014-4800(10)00072-9 [pii]
AID - 10.1016/j.yexmp.2010.05.007 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2010 Oct;89(2):158-68. doi: 10.1016/j.yexmp.2010.05.007. Epub 
      2010 Jun 1.

PMID- 20644219
OWN - NLM
STAT- MEDLINE
DCOM- 20110128
LR  - 20220409
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 47
IP  - 10
DP  - 2010 Oct
TI  - Methylation of the CpG sites in the myotonic dystrophy locus does not correlate 
      with CTG expansion size or with the congenital form of the disease.
PG  - 700-3
LID - 10.1136/jmg.2009.074211 [doi]
AB  - We have studied the methylation status of the sequence 152 nucleotides upstream 
      of the CTG repeat of the DM1 locus in patients' peripheral blood. We used the 
      methylation-sensitive endonucleases SacII, HpaII and HhaI, followed by PCR. This 
      allowed to correlate the methylation status of each CTG allele with its size. 
      Contrary to previous findings, only the SacII site is often but not always 
      differentially methylated among expanded CTG alleles. Importantly, this 
      methylation was not restricted to congenital DM1, nor to large expansions, as it 
      was also present in DM1 patients with a classical phenotype and various expansion 
      sizes. On the other hand, we did not find any methylated alleles on the HhaI and 
      HpaII sites, as was reported by Steinbach et al, which is in line with the 
      results of Shaw and collaborators. The size range of the repeat expansions with 
      methylation was from as small as 300 to as large as 2800 repeats.
FAU - Spits, C
AU  - Spits C
AD  - Department of Embryology and Genetics, Vrije Universiteit Brussel, Laarbeeklaan 
      101, Brussels 1090, Belgium. claudia.spits@uzbrussel.be
FAU - Seneca, S
AU  - Seneca S
FAU - Hilven, P
AU  - Hilven P
FAU - Liebaers, I
AU  - Liebaers I
FAU - Sermon, K
AU  - Sermon K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100719
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 0 (DMPK protein, human)
RN  - 0 (Dinucleoside Phosphates)
RN  - 2382-65-2 (cytidylyl-3'-5'-guanosine)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.1.- (Endonucleases)
SB  - IM
MH  - Base Sequence
MH  - Dinucleoside Phosphates/genetics/*metabolism
MH  - Endonucleases/metabolism
MH  - Humans
MH  - Methylation
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Protein Serine-Threonine Kinases/chemistry/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats
EDAT- 2010/07/21 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/07/21 06:00
PHST- 2010/07/21 06:00 [entrez]
PHST- 2010/07/21 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - jmg.2009.074211 [pii]
AID - 10.1136/jmg.2009.074211 [doi]
PST - ppublish
SO  - J Med Genet. 2010 Oct;47(10):700-3. doi: 10.1136/jmg.2009.074211. Epub 2010 Jul 
      19.

PMID- 20635151
OWN - NLM
STAT- MEDLINE
DCOM- 20110526
LR  - 20211203
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 38
IP  - 2
DP  - 2011 Feb
TI  - Distribution of CTG repeats at the DMPK gene in myotonic dystrophy patients and 
      healthy individuals from the Mexican population.
PG  - 1341-6
LID - 10.1007/s11033-010-0235-7 [doi]
AB  - Myotonic dystrophy type 1 (DM1), the most common form of adult muscular 
      dystrophy, is caused by anormal expansion of CTG trinucleotide repeats located in 
      the 3'-untranslated region of the DMPK gene. The clinical features of DM1 are 
      multisystemic and highly variable, and the unstable nature of CTG expansion 
      causes wide genotypic and phenotypic presentations. In this study, we described 
      to our knowledge for the first time the molecular diagnosis of myotonic dystrophy 
      type 1 patients in the Mexican population, applying a fluorescent PCR method in 
      combination with capillary electrophoresis analysis of the amplified products. We 
      identified expanded alleles in 45 out of 50 patients (90%) with clinical features 
      of myotonic disease. Furthermore, genotyping of 400 healthy subjects revealed the 
      presence of 25 different alleles, ranging in size from 5 to 34 repeats. The most 
      frequent allele was 13 CTG repeats (38.87%) and the frequency for alleles over 18 
      CTG repeats was 6.7%. Molecular test is essential for DM1 diagnosis and 
      distribution of the CTG repeat alleles present in the Mexican population are 
      significantly different from those of other populations.
FAU - Magana, J J
AU  - Magana JJ
AD  - Department of Genetics, National Rehabilitation Institute, Calzada Mexico 
      Xochimilco. No. 289, Colonia Arenal Guadalupe, C.P. 14389, Mexico, DF, Mexico. 
      maganasm@hotmail.com
FAU - Cortes-Reynosa, P
AU  - Cortes-Reynosa P
FAU - Escobar-Cedillo, R
AU  - Escobar-Cedillo R
FAU - Gomez, R
AU  - Gomez R
FAU - Leyva-Garcia, N
AU  - Leyva-Garcia N
FAU - Cisneros, B
AU  - Cisneros B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100716
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Alleles
MH  - Case-Control Studies
MH  - Electrophoresis, Capillary
MH  - Genotype
MH  - Humans
MH  - Mexico
MH  - Myotonic Dystrophy/*ethnology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Phenotype
MH  - Polymerase Chain Reaction/methods
MH  - Prevalence
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
EDAT- 2010/07/17 06:00
MHDA- 2011/05/27 06:00
CRDT- 2010/07/17 06:00
PHST- 2010/05/11 00:00 [received]
PHST- 2010/06/11 00:00 [accepted]
PHST- 2010/07/17 06:00 [entrez]
PHST- 2010/07/17 06:00 [pubmed]
PHST- 2011/05/27 06:00 [medline]
AID - 10.1007/s11033-010-0235-7 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2011 Feb;38(2):1341-6. doi: 10.1007/s11033-010-0235-7. Epub 2010 
      Jul 16.

PMID- 20603324
OWN - NLM
STAT- MEDLINE
DCOM- 20101223
LR  - 20211020
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 19
IP  - 18
DP  - 2010 Sep 15
TI  - CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic 
      dystrophy type 1.
PG  - 3614-22
LID - 10.1093/hmg/ddq277 [doi]
AB  - The neuromuscular disease myotonic dystrophy type I (DM1) affects multiple organ 
      systems with the major symptoms being severe muscle weakness, progressive muscle 
      wasting and myotonia. The causative mutation in DM1 is a CTG repeat expansion in 
      the 3'-untranslated region of the DM protein kinase (DMPK) gene. RNA transcribed 
      from the expanded allele contains the expanded CUG repeats and leads to the 
      nuclear depletion of Muscleblind-like 1 (MBNL1) and to the increased steady-state 
      levels of CUG-binding protein 1 (CUGBP1). The pathogenic effects of MBNL1 
      depletion have previously been tested by the generation of MBNL1 knockout mice, 
      but the consequence of CUGBP1 overexpression in adult muscle is not known. In a 
      DM1 mouse model expressing RNA containing 960 CUG repeats in skeletal muscle, 
      CUGBP1 up-regulation is temporally correlated with severe muscle wasting. In this 
      study, we generated transgenic mice with doxycycline-inducible and skeletal 
      muscle-specific expression of CUGBP1. Adult mouse skeletal muscle overexpressing 
      CUGBP1 reproduces molecular and physiological defects of DM1 tissue. The results 
      from this study strongly suggest that CUGBP1 has a major role in DM1 skeletal 
      muscle pathogenesis.
FAU - Ward, Amanda J
AU  - Ward AJ
AD  - Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 
      77030, USA.
FAU - Rimer, Mendell
AU  - Rimer M
FAU - Killian, James M
AU  - Killian JM
FAU - Dowling, James J
AU  - Dowling JJ
FAU - Cooper, Thomas A
AU  - Cooper TA
LA  - eng
GR  - R01 HL045565/HL/NHLBI NIH HHS/United States
GR  - F31NS067740/NS/NINDS NIH HHS/United States
GR  - R01AR45653/AR/NIAMS NIH HHS/United States
GR  - R01GM076493/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100705
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - CELF1 Protein
MH  - *Disease Models, Animal
MH  - Female
MH  - *Gene Expression
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/*metabolism/pathology
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - RNA-Binding Proteins/*genetics/metabolism
MH  - Up-Regulation
PMC - PMC2928132
EDAT- 2010/07/07 06:00
MHDA- 2010/12/25 06:00
PMCR- 2011/09/15
CRDT- 2010/07/07 06:00
PHST- 2010/07/07 06:00 [entrez]
PHST- 2010/07/07 06:00 [pubmed]
PHST- 2010/12/25 06:00 [medline]
PHST- 2011/09/15 00:00 [pmc-release]
AID - ddq277 [pii]
AID - 10.1093/hmg/ddq277 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2010 Sep 15;19(18):3614-22. doi: 10.1093/hmg/ddq277. Epub 2010 Jul 
      5.

PMID- 20491895
OWN - NLM
STAT- MEDLINE
DCOM- 20151103
LR  - 20181202
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 18
IP  - 1
DP  - 2011 Jan
TI  - Brugada-like cardiac disease in myotonic dystrophy type 2: report of two 
      unrelated patients.
PG  - 191-4
LID - 10.1111/j.1468-1331.2010.03077.x [doi]
AB  - BACKGROUND: Myotonic dystrophy type 2 (DM2) is an autosomal dominant multisystem 
      disorder caused by CCTG repeat expansions within intron 1 of the ZNF9 gene on 
      chromosome 3q. Cardiac conduction disturbances, supraventricular arrhythmias, and 
      cardiomyopathy are described in DM2 but Brugada-like features have not yet been 
      reported. Brugada syndrome (BS) is a genetically heterogeneous cardiac conduction 
      disorder which is characterized by a significant ST-segment elevation upon ECG 
      evaluations and bears an increased risk for sudden cardiac death. CASE REPORTS: 
      We report two unrelated patients with genetically confirmed DM2 who developed 
      clinical relevant cardiac arrhythmias with syncopal events from 35 (patient 1) 
      and 47 years (patient 2). Brugada-like ECG findings were present in both 
      patients. Family history was negative for BS, but the mothers of both index 
      patients were also affected by DM2 and had different ventricular rhythm 
      disturbances. SCN5A gene sequencing revealed an unknown genetic variant c.4140 C 
      > A, p.N1380K, in patient 1, while no mutation was detected in patient 2. 
      DISCUSSION: Our observations may suggest that Brugada-like cardiac arrhythmias 
      can occur in DM2, as this seems also to be the case in DM1. The chance 
      association of two independent inherited disorders has to be considered and 
      cannot be excluded in one of our patients. However, on statistical grounds, this 
      possibility cannot explain all observed cases of DM with Brugada-like cardiac 
      disease.
FAU - Rudnik-Schoneborn, S
AU  - Rudnik-Schoneborn S
AD  - Institute of Human Genetics, RWTH Aachen University, Medical Faculty, Aachen, 
      Germany.
FAU - Schaupp, M
AU  - Schaupp M
FAU - Lindner, A
AU  - Lindner A
FAU - Kress, W
AU  - Kress W
FAU - Schulze-Bahr, E
AU  - Schulze-Bahr E
FAU - Zumhagen, S
AU  - Zumhagen S
FAU - Elbracht, M
AU  - Elbracht M
FAU - Zerres, K
AU  - Zerres K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adult
MH  - Brugada Syndrome/*etiology/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/genetics
EDAT- 2010/05/25 06:00
MHDA- 2015/11/04 06:00
CRDT- 2010/05/25 06:00
PHST- 2010/05/25 06:00 [entrez]
PHST- 2010/05/25 06:00 [pubmed]
PHST- 2015/11/04 06:00 [medline]
AID - ENE3077 [pii]
AID - 10.1111/j.1468-1331.2010.03077.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2011 Jan;18(1):191-4. doi: 10.1111/j.1468-1331.2010.03077.x.

PMID- 20479119
OWN - NLM
STAT- MEDLINE
DCOM- 20101101
LR  - 20211020
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 24
IP  - 10
DP  - 2010 Oct
TI  - Expansion of CUG RNA repeats causes stress and inhibition of translation in 
      myotonic dystrophy 1 (DM1) cells.
PG  - 3706-19
LID - 10.1096/fj.09-151159 [doi]
AB  - The purpose of this study was to investigate the role of the mutant CUGn RNA in 
      the induction of stress in type 1 myotonic dystrophy (DM1) cells and in the 
      stress-mediated inhibition of protein translation in DM1. To achieve our goals, 
      we performed HPLC-based purification of stress granules (SGs), immunoanalysis of 
      SGs with stress markers TIA-1, CUGBP1, and ph-eIF2, site-specific mutagenesis, 
      and examinations of RNA-protein and protein-protein interactions in myoblasts 
      from control and DM1 patients. The cause-and-effect relationships were addressed 
      in stable cells expressing mutant CUG repeats. We found that the mutant CUGn RNA 
      induces formation of SGs through the increase of the double-stranded 
      RNA-dependent protein kinase (PKR) and following inactivation of eIF2alpha, one of 
      the substrates of PKR. We show that SGs trap mRNA coding for the DNA repair and 
      remodeling factor MRG15 (MORF4L1), translation of which is regulated by CUGBP1. 
      As the result of the trapping, the levels of MRG15 are reduced in DM1 cells and 
      in CUG-expressing cells. These data show that CUG repeats cause stress in DM1 
      through the PKR-ph-eIF2alpha pathway inhibiting translation of certain mRNAs, such as 
      MRG15 mRNA. The repression of protein translation by stress might contribute to 
      the progressive muscle loss in DM1.
FAU - Huichalaf, Claudia
AU  - Huichalaf C
AD  - Department of Molecular Physiology and Biophysics, Baylor College of Medicine, 1 
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Sakai, Keiko
AU  - Sakai K
FAU - Jin, Bingwen
AU  - Jin B
FAU - Jones, Karlie
AU  - Jones K
FAU - Wang, Guo-Li
AU  - Wang GL
FAU - Schoser, Benedikt
AU  - Schoser B
FAU - Schneider-Gold, Christiane
AU  - Schneider-Gold C
FAU - Sarkar, Partha
AU  - Sarkar P
FAU - Pereira-Smith, Olivia M
AU  - Pereira-Smith OM
FAU - Timchenko, Nikolai
AU  - Timchenko N
FAU - Timchenko, Lubov
AU  - Timchenko L
LA  - eng
GR  - CA100070/CA/NCI NIH HHS/United States
GR  - AR044387/AR/NIAMS NIH HHS/United States
GR  - R01 AG025477/AG/NIA NIH HHS/United States
GR  - AG032134/AG/NIA NIH HHS/United States
GR  - AR044387-ARRA/AR/NIAMS NIH HHS/United States
GR  - R01 CA100070/CA/NCI NIH HHS/United States
GR  - AR052791/AR/NIAMS NIH HHS/United States
GR  - R01 AR052791/AR/NIAMS NIH HHS/United States
GR  - NS063298/NS/NINDS NIH HHS/United States
GR  - R01 AG032134/AG/NIA NIH HHS/United States
GR  - GM55188/GM/NIGMS NIH HHS/United States
GR  - R01 GM055188/GM/NIGMS NIH HHS/United States
GR  - AG025477/AG/NIA NIH HHS/United States
GR  - R03 NS063298/NS/NINDS NIH HHS/United States
GR  - R01 AR044387/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100517
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Blotting, Northern
MH  - Blotting, Western
MH  - CELF1 Protein
MH  - Cell Line
MH  - Chromatography, Gel
MH  - DNA Repair
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Phosphorylation
MH  - Protein Binding
MH  - Protein Biosynthesis/*genetics
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *Trinucleotide Repeats
PMC - PMC2996918
EDAT- 2010/05/19 06:00
MHDA- 2010/11/03 06:00
PMCR- 2011/10/01
CRDT- 2010/05/19 06:00
PHST- 2010/05/19 06:00 [entrez]
PHST- 2010/05/19 06:00 [pubmed]
PHST- 2010/11/03 06:00 [medline]
PHST- 2011/10/01 00:00 [pmc-release]
AID - fj.09-151159 [pii]
AID - 09-151159 [pii]
AID - 10.1096/fj.09-151159 [doi]
PST - ppublish
SO  - FASEB J. 2010 Oct;24(10):3706-19. doi: 10.1096/fj.09-151159. Epub 2010 May 17.

PMID- 20389286
OWN - NLM
STAT- MEDLINE
DCOM- 20100930
LR  - 20211020
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 18
IP  - 7
DP  - 2010 Jul
TI  - Regulated expansion of human pancreatic beta-cells.
PG  - 1389-96
LID - 10.1038/mt.2010.63 [doi]
AB  - Although pancreatic beta-cell transplantation may serve as a potential cure for 
      diabetes mellitus (DM), limited donor tissue availability poses a major 
      challenge. Thus, there is a great demand to find new sources for pancreatic 
      beta-cells. Here, we present a lentiviral vector-based approach to achieve 
      beta-cell proliferation through the beta-cell-specific activation of the 
      hepatocyte growth factor (HGF)/cmet signaling pathway. The methodology is based 
      on the beta-cell-specific expression of a ligand-inducible, chimeric receptor 
      (F36Vcmet), under transcriptional control of the promoter from the human insulin 
      gene, and its ability to induce HGF/cmet signaling in the presence of a synthetic 
      ligand (AP20187). High transduction efficiency of human pancreatic islets was 
      achieved utilizing this approach with chimeric receptor expression confined to 
      the beta-cell population. In addition, specific proliferation of human pancreatic 
      beta-cells was induced utilizing this approach. Selective, regulated beta-cell 
      expansion may help to provide greater availability of cells for transplantation 
      in patients with DM.
FAU - Pais, Eszter
AU  - Pais E
AD  - Division of Research Immunology/Bone Marrow Transplantation, Department of 
      Pediatrics, Childrens Hospital Los Angeles, Los Angeles, California, USA.
FAU - Park, Jean
AU  - Park J
FAU - Alexy, Tamas
AU  - Alexy T
FAU - Nikolian, Vahagn
AU  - Nikolian V
FAU - Ge, Shundi
AU  - Ge S
FAU - Shaw, Kit
AU  - Shaw K
FAU - Senadheera, Shantha
AU  - Senadheera S
FAU - Hardee, Cinnamon L
AU  - Hardee CL
FAU - Skelton, Dianne
AU  - Skelton D
FAU - Hollis, Roger
AU  - Hollis R
FAU - Crooks, Gay M
AU  - Crooks GM
FAU - Kohn, Donald B
AU  - Kohn DB
LA  - eng
PT  - Journal Article
DEP - 20100413
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Genetic Vectors/genetics
MH  - HT29 Cells
MH  - Hepatocyte Growth Factor/genetics/metabolism
MH  - Humans
MH  - Insulin-Secreting Cells/*cytology/metabolism
MH  - Lentivirus/genetics
MH  - Mice
MH  - Promoter Regions, Genetic/genetics
MH  - Tissue Culture Techniques
PMC - PMC2911252
EDAT- 2010/04/15 06:00
MHDA- 2010/10/01 06:00
PMCR- 2011/07/01
CRDT- 2010/04/15 06:00
PHST- 2010/04/15 06:00 [entrez]
PHST- 2010/04/15 06:00 [pubmed]
PHST- 2010/10/01 06:00 [medline]
PHST- 2011/07/01 00:00 [pmc-release]
AID - S1525-0016(16)31085-1 [pii]
AID - 10.1038/mt.2010.63 [doi]
PST - ppublish
SO  - Mol Ther. 2010 Jul;18(7):1389-96. doi: 10.1038/mt.2010.63. Epub 2010 Apr 13.

PMID- 20346670
OWN - NLM
STAT- MEDLINE
DCOM- 20100712
LR  - 20211203
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
VI  - 20
IP  - 5
DP  - 2010 May
TI  - Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions 
      is associated with the activation of the ubiquitin-proteasome pathway.
PG  - 319-25
LID - 10.1016/j.nmd.2010.03.006 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a neuromuscular disease caused by the 
      expansion of a CTG repeat in the DMPK gene and characterised by progressive 
      skeletal muscle weakness and wasting. To investigate the effects of the CTG 
      expansion on the physiological function of the skeletal muscles, we have used a 
      transgenic mouse model carrying the human DM1 region with 550 expanded CTG 
      repeats. Maximal force is reduced in the skeletal muscles of 10-month-old but not 
      in 3-month-old DM1 mice when compared to age-matched non-transgenic littermates. 
      The progressive weakness observed in the DM1 mice is directly related to the 
      reduced muscle mass and muscle fibre size. A significant increase in trypsin-like 
      proteasome activity and Fbxo32 expression is also measured in the DM1 muscles 
      indicating that an atrophic process mediated by the ubiquitin-proteasome pathway 
      may contribute to the progressive muscle wasting and weakness in the DM1 mice.
CI  - 2010 Elsevier B.V. All rights reserved.
FAU - Vignaud, Alban
AU  - Vignaud A
AD  - Universite Pierre et Marie Curie-Paris6, UMRS974, F-75013 Paris, France.
FAU - Ferry, Arnaud
AU  - Ferry A
FAU - Huguet, Aline
AU  - Huguet A
FAU - Baraibar, Martin
AU  - Baraibar M
FAU - Trollet, Capucine
AU  - Trollet C
FAU - Hyzewicz, Janek
AU  - Hyzewicz J
FAU - Butler-Browne, Gillian
AU  - Butler-Browne G
FAU - Puymirat, Jack
AU  - Puymirat J
FAU - Gourdon, Genevieve
AU  - Gourdon G
FAU - Furling, Denis
AU  - Furling D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100325
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Laminin)
RN  - 0 (Muscle Proteins)
RN  - 0 (Ubiquitin)
RN  - EC 2.3.2.27 (Fbxo32 protein, mouse)
RN  - EC 2.3.2.27 (SKP Cullin F-Box Protein Ligases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - EC 3.6.4.1 (Myosin Heavy Chains)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Hand Strength/physiology
MH  - Humans
MH  - Laminin/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle Proteins/metabolism
MH  - Muscle Strength/genetics
MH  - Muscle Weakness/genetics/*physiopathology
MH  - Muscle, Skeletal/*physiopathology
MH  - Myosin Heavy Chains/genetics/metabolism
MH  - Myotonic Dystrophy/genetics/*pathology
MH  - Myotonin-Protein Kinase
MH  - Proteasome Endopeptidase Complex/*metabolism
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - SKP Cullin F-Box Protein Ligases/metabolism
MH  - Signal Transduction/genetics
MH  - Statistics, Nonparametric
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Ubiquitin/*metabolism
EDAT- 2010/03/30 06:00
MHDA- 2010/07/14 06:00
CRDT- 2010/03/30 06:00
PHST- 2009/12/21 00:00 [received]
PHST- 2010/02/15 00:00 [revised]
PHST- 2010/03/03 00:00 [accepted]
PHST- 2010/03/30 06:00 [entrez]
PHST- 2010/03/30 06:00 [pubmed]
PHST- 2010/07/14 06:00 [medline]
AID - S0960-8966(10)00111-2 [pii]
AID - 10.1016/j.nmd.2010.03.006 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2010 May;20(5):319-25. doi: 10.1016/j.nmd.2010.03.006. Epub 
      2010 Mar 25.

PMID- 20228473
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20211203
IS  - 0028-3886 (Print)
IS  - 0028-3886 (Linking)
VI  - 58
IP  - 1
DP  - 2010 Jan-Feb
TI  - A rapid polymerase chain reaction-based test for screening Steinert's disease 
      (DM1).
PG  - 99-102
LID - 10.4103/0028-3886.60411 [doi]
AB  - Myotonic dystrophy (DM) is a multisystemic neuromuscular disorder caused by a 
      dynamic mutation of (CTG) trinucleotide repeats in the 3' untranslated region of 
      the myotonic dystrophy protein kinase gene (DMPK). The aim of the present study 
      was to establish the use of polymerase chain reaction (PCR)-based simple and 
      rapid method for initial sample screening. Only a minority of samples were tested 
      positive with the above method and need to be detected by tri primer (TP)-PCR and 
      Southern blotting which is more time consuming and involves use of radioactive 
      material. This study concerned 24 patients from nine families with a clinical 
      diagnosis of the DM1. DNA extracted from the blood was used for amplification of 
      the triplet repeat sequences at the DMPK loci. We obtained two bands for the 
      normal subjects and one band for patients corresponding to normal DMPK allele, 
      confirmed by the TP-PCR and the Southern blot. This rapid test for initial 
      screening of samples for the presence of DMPK mutations is economical and 
      reliable method. This method reduces the number of samples needing TP-PCR and 
      Southern blotting.
FAU - Hamzi, Khalil
AU  - Hamzi K
AD  - Medical Genetic Laboratory and Molecular Pathology, Medical School/Casablanca, 
      Morocco.
FAU - Bellayou, Hanane
AU  - Bellayou H
FAU - Slassi, Ilham
AU  - Slassi I
FAU - Nadifi, Sellama
AU  - Nadifi S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neurol India
JT  - Neurology India
JID - 0042005
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Family Health
MH  - Female
MH  - Genetic Testing/*methods
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Morocco
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction/*methods
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeats/genetics
MH  - Young Adult
EDAT- 2010/03/17 06:00
MHDA- 2010/06/11 06:00
CRDT- 2010/03/16 06:00
PHST- 2010/03/16 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
AID - ni_2010_58_1_99_60411 [pii]
AID - 10.4103/0028-3886.60411 [doi]
PST - ppublish
SO  - Neurol India. 2010 Jan-Feb;58(1):99-102. doi: 10.4103/0028-3886.60411.

PMID- 20221684
OWN - NLM
STAT- MEDLINE
DCOM- 20101104
LR  - 20181113
IS  - 1573-7330 (Electronic)
IS  - 1058-0468 (Print)
IS  - 1058-0468 (Linking)
VI  - 27
IP  - 6
DP  - 2010 Jun
TI  - The reproductive outcome of female patients with myotonic dystrophy type 1 (DM1) 
      undergoing PGD is not affected by the size of the expanded CTG repeat tract.
PG  - 327-33
LID - 10.1007/s10815-010-9392-9 [doi]
AB  - PURPOSE: This study aims to analyze the relationship between trinucleotide repeat 
      length and reproductive outcome in a large cohort of DM1 patients undergoing ICSI 
      and PGD. METHODS: Prospective cohort study. The effect of trinucleotide repeat 
      length on reproductive outcome per patient was analyzed using bivariate analysis 
      (T-test) and multivariate analysis using Kaplan-Meier and Cox regression 
      analysis. RESULTS: Between 1995 and 2005, 205 cycles of ICSI and PGD were carried 
      out for DM1 in 78 couples. The number of trinucleotide repeats does not have an 
      influence on reproductive outcome when adjusted for age, BMI, basal FSH values, 
      parity, infertility status and male or female affected. Cox regression analysis 
      indicates that cumulative live birth rate is not influenced by the number of 
      trinucleotide repeats. The only factor with a significant effect is age (p < 
      0.05). CONCLUSION: There is no evidence of an effect of trinucleotide repeat 
      length on reproductive outcome in patients undergoing ICSI and PGD.
FAU - Verpoest, Willem
AU  - Verpoest W
AD  - Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije 
      Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium. 
      willem.verpoest@uzbrussel.be
FAU - Seneca, Sara
AU  - Seneca S
FAU - De Rademaeker, Marjan
AU  - De Rademaeker M
FAU - Sermon, Karen
AU  - Sermon K
FAU - De Rycke, Martine
AU  - De Rycke M
FAU - De Vos, Michel
AU  - De Vos M
FAU - Haentjens, Patrick
AU  - Haentjens P
FAU - Devroey, Paul
AU  - Devroey P
FAU - Liebaers, Ingeborg
AU  - Liebaers I
LA  - eng
PT  - Journal Article
DEP - 20100311
PL  - Netherlands
TA  - J Assist Reprod Genet
JT  - Journal of assisted reproduction and genetics
JID - 9206495
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics
MH  - Pregnancy
MH  - Pregnancy Outcome/*genetics
MH  - *Preimplantation Diagnosis
MH  - Prospective Studies
MH  - *Sperm Injections, Intracytoplasmic
MH  - *Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
PMC - PMC2914592
EDAT- 2010/03/12 06:00
MHDA- 2010/11/05 06:00
PMCR- 2011/06/01
CRDT- 2010/03/12 06:00
PHST- 2009/11/12 00:00 [received]
PHST- 2010/01/14 00:00 [accepted]
PHST- 2010/03/12 06:00 [entrez]
PHST- 2010/03/12 06:00 [pubmed]
PHST- 2010/11/05 06:00 [medline]
PHST- 2011/06/01 00:00 [pmc-release]
AID - 9392 [pii]
AID - 10.1007/s10815-010-9392-9 [doi]
PST - ppublish
SO  - J Assist Reprod Genet. 2010 Jun;27(6):327-33. doi: 10.1007/s10815-010-9392-9. 
      Epub 2010 Mar 11.

PMID- 20179953
OWN - NLM
STAT- MEDLINE
DCOM- 20100813
LR  - 20211203
IS  - 1432-0533 (Electronic)
IS  - 0001-6322 (Linking)
VI  - 119
IP  - 4
DP  - 2010 Apr
TI  - Congenital myotonic dystrophy can show congenital fiber type disproportion 
      pathology.
PG  - 481-6
LID - 10.1007/s00401-010-0660-7 [doi]
AB  - Congenital myotonic dystrophy (CDM) is associated with markedly expanded CTG 
      repeats in DMPK. The presence of numerous immature fibers with peripheral halo is 
      a characteristic feature of CDM muscles together with hypotrophy of type 1 
      fibers. Smaller type 1 fibers with no structural abnormality are a definitive 
      criterion of congenital fiber type disproportion (CFTD). Nonetheless, we recently 
      came across a patient who was genetically confirmed as CDM, but had been earlier 
      diagnosed as CFTD when he was an infant. In this study, we performed clinical, 
      pathological, and genetic analyses in infantile patients pathologically diagnosed 
      as CFTD to evaluate CDM patients indistinguishable from CFTD. We examined CTG 
      repeat expansion in DMPK in 28 infantile patients pathologically diagnosed as 
      CFTD. Mutation screening of ACTA1 and TPM3 was performed, and we compared 
      clinical and pathological findings of 20 CDM patients with those of the other 
      cohorts. We identified four (14%) patients with CTG expansion in DMPK. ACTA1 
      mutation was identified in four (14%), and TPM3 mutation was found in two (7%) 
      patients. Fiber size disproportion was more prominent in patients with ACTA1 or 
      TPM3 mutations as compared to CFTD patients with CTG expansion. A further three 
      patients among 20 CDM patients showed pathological findings similar to CFTD. From 
      our results, CDM should be excluded in CFTD patients.
FAU - Tominaga, Kayo
AU  - Tominaga K
AD  - Department of Neuromuscular Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 
      187-8502, Japan.
FAU - Hayashi, Yukiko K
AU  - Hayashi YK
FAU - Goto, Kanako
AU  - Goto K
FAU - Minami, Narihiro
AU  - Minami N
FAU - Noguchi, Satoru
AU  - Noguchi S
FAU - Nonaka, Ikuya
AU  - Nonaka I
FAU - Miki, Tetsuro
AU  - Miki T
FAU - Nishino, Ichizo
AU  - Nishino I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100224
PL  - Germany
TA  - Acta Neuropathol
JT  - Acta neuropathologica
JID - 0412041
RN  - 0 (Actins)
RN  - 0 (DMPK protein, human)
RN  - 0 (TPM3 protein, human)
RN  - 0 (Tropomyosin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Actins/*genetics/metabolism
MH  - Diagnosis, Differential
MH  - Humans
MH  - Infant
MH  - *Muscle Fibers, Skeletal/metabolism/pathology
MH  - *Myopathies, Structural, Congenital/genetics/pathology
MH  - Myotonic Dystrophy/diagnosis/*genetics/*pathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - Trinucleotide Repeat Expansion
MH  - Tropomyosin/*genetics/metabolism
EDAT- 2010/02/25 06:00
MHDA- 2010/08/14 06:00
CRDT- 2010/02/25 06:00
PHST- 2009/11/19 00:00 [received]
PHST- 2010/02/15 00:00 [accepted]
PHST- 2010/02/15 00:00 [revised]
PHST- 2010/02/25 06:00 [entrez]
PHST- 2010/02/25 06:00 [pubmed]
PHST- 2010/08/14 06:00 [medline]
AID - 10.1007/s00401-010-0660-7 [doi]
PST - ppublish
SO  - Acta Neuropathol. 2010 Apr;119(4):481-6. doi: 10.1007/s00401-010-0660-7. Epub 
      2010 Feb 24.

PMID- 20174632
OWN - NLM
STAT- MEDLINE
DCOM- 20100930
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 5
IP  - 2
DP  - 2010 Feb 18
TI  - ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased 
      in myotonic dystrophy type 2.
PG  - e9301
LID - 10.1371/journal.pone.0009301 [doi]
LID - e9301
AB  - Myotonic dystrophy types 1 and 2 (DM1 and DM2) are forms of muscular dystrophy 
      that share similar clinical and molecular manifestations, such as myotonia, 
      muscle weakness, cardiac anomalies, cataracts, and the presence of defined 
      RNA-containing foci in muscle nuclei. DM2 is caused by an expansion of the 
      tetranucleotide CCTG repeat within the first intron of ZNF9, although the 
      mechanism by which the expanded nucleotide repeat causes the debilitating 
      symptoms of DM2 is unclear. Conflicting studies have led to two models for the 
      mechanisms leading to the problems associated with DM2. First, a gain-of-function 
      disease model hypothesizes that the repeat expansions in the transcribed RNA do 
      not directly affect ZNF9 function. Instead repeat-containing RNAs are thought to 
      sequester proteins in the nucleus, causing misregulation of normal cellular 
      processes. In the alternative model, the repeat expansions impair ZNF9 function 
      and lead to a decrease in the level of translation. Here we examine the normal in 
      vivo function of ZNF9. We report that ZNF9 associates with actively translating 
      ribosomes and functions as an activator of cap-independent translation of the 
      human ODC mRNA. This activity is mediated by direct binding of ZNF9 to the 
      internal ribosome entry site sequence (IRES) within the 5'UTR of ODC mRNA. ZNF9 
      can activate IRES-mediated translation of ODC within primary human myoblasts, and 
      this activity is reduced in myoblasts derived from a DM2 patient. These data 
      identify ZNF9 as a regulator of cap-independent translation and indicate that 
      ZNF9 activity may contribute mechanistically to the myotonic dystrophy type 2 
      phenotype.
FAU - Sammons, Morgan A
AU  - Sammons MA
AD  - Department of Biological Sciences, Vanderbilt University, Nashville, Tennessee, 
      United States of America.
FAU - Antons, Amanda K
AU  - Antons AK
FAU - Bendjennat, Mourad
AU  - Bendjennat M
FAU - Udd, Bjarne
AU  - Udd B
FAU - Krahe, Ralf
AU  - Krahe R
FAU - Link, Andrew J
AU  - Link AJ
LA  - eng
GR  - R01 GM064779/GM/NIGMS NIH HHS/United States
GR  - R21 AR055231/AR/NIAMS NIH HHS/United States
GR  - AR055231/AR/NIAMS NIH HHS/United States
GR  - GM064779/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20100218
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (5' Untranslated Regions)
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA Caps)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 4.1.1.17 (Ornithine Decarboxylase)
SB  - IM
MH  - 5' Untranslated Regions/genetics
MH  - Binding Sites
MH  - Blotting, Western
MH  - Cell Line
MH  - Cells, Cultured
MH  - HeLa Cells
MH  - Humans
MH  - Myoblasts/metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - Ornithine Decarboxylase/genetics
MH  - Protein Binding
MH  - *Protein Biosynthesis
MH  - RNA Caps/genetics
MH  - RNA Interference
MH  - RNA, Messenger/*genetics
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Ribosomes/metabolism
PMC - PMC2823779
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2010/02/23 06:00
MHDA- 2010/10/01 06:00
PMCR- 2010/02/18
CRDT- 2010/02/23 06:00
PHST- 2009/12/18 00:00 [received]
PHST- 2010/01/28 00:00 [accepted]
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/10/01 06:00 [medline]
PHST- 2010/02/18 00:00 [pmc-release]
AID - 09-PONE-RA-15025R1 [pii]
AID - 10.1371/journal.pone.0009301 [doi]
PST - epublish
SO  - PLoS One. 2010 Feb 18;5(2):e9301. doi: 10.1371/journal.pone.0009301.

PMID- 20171614
OWN - NLM
STAT- MEDLINE
DCOM- 20101103
LR  - 20211203
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 94
IP  - 5
DP  - 2010 Oct
TI  - Modification of the triplet repeat primed polymerase chain reaction method for 
      detection of the CTG repeat expansion in myotonic dystrophy type 1: application 
      in preimplantation genetic diagnosis.
PG  - 1674-9
LID - 10.1016/j.fertnstert.2009.10.050 [doi]
AB  - OBJECTIVE: To overcome problems associated with the use of triplet repeat primed 
      polymerase chain reaction (TP-PCR) in preimplantation genetic diagnosis (PGD) of 
      myotonic dystrophy type 1 (DM1). DESIGN: Clinical research study. SETTING: UCL 
      Centre for PGD and Centre for Reproductive and Genetic Health. PATIENT(S): Seven 
      couples undergoing PGD for DM1. INTERVENTION(S): A modified TP-PCR protocol 
      (mTP-PCR) for the reliable detection of both expanded and nonexpanded alleles in 
      DMPK was optimized using single lymphocytes. Four cycles of PGD were performed 
      with TP-PCR for diagnosis and a further 10 cycles with mTP-PCR. MAIN OUTCOME 
      MEASURE(S): Amplification efficiency, allele dropout, diagnosis rate, and 
      delivery rate. RESULT(S): Preliminary testing showed that the TP-PCR 
      amplification efficiency was higher using lymphocytes versus buccal cells. Single 
      lymphocytes gave very high amplification efficiencies for both protocols (99% to 
      100%). There were no false-positive or false-negative results for 148 single 
      lymphocytes tested with mTP-PCR compared with 9% (5 out of 54) false-positive 
      results with TP-PCR, indicating the improved accuracy of the modified protocol. 
      In embryos, the diagnosis rate was 95.6% with mTP-PCR and 75% with TP-PCR. 
      CONCLUSION(S): For PGD of DM1, mTP-PCR is recommended. It may also be applied as 
      a rapid screen for DMPK expansions in individuals with symptoms of DM1, relatives 
      of known mutation carriers, or in prenatal diagnosis.
CI  - Copyright (c) 2010 American Society for Reproductive Medicine. Published by 
      Elsevier Inc. All rights reserved.
FAU - Kakourou, Georgia
AU  - Kakourou G
AD  - UCL Centre for PGD, Institute for Women's Health, University College London, 
      London, United Kingdom.
FAU - Dhanjal, Seema
AU  - Dhanjal S
FAU - Mamas, Thalia
AU  - Mamas T
FAU - Serhal, Paul
AU  - Serhal P
FAU - Delhanty, Joy D
AU  - Delhanty JD
FAU - SenGupta, Sioban B
AU  - SenGupta SB
LA  - eng
PT  - Journal Article
DEP - 20100219
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Base Sequence
MH  - False Negative Reactions
MH  - False Positive Reactions
MH  - Female
MH  - Genetic Testing
MH  - Humans
MH  - Lymphocytes
MH  - Male
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/classification/*diagnosis/*genetics
MH  - Myotonin-Protein Kinase
MH  - Nucleic Acid Amplification Techniques
MH  - Polymerase Chain Reaction/*methods
MH  - Preimplantation Diagnosis/*methods
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 2010/02/23 06:00
MHDA- 2010/11/04 06:00
CRDT- 2010/02/23 06:00
PHST- 2009/08/07 00:00 [received]
PHST- 2009/09/22 00:00 [revised]
PHST- 2009/10/27 00:00 [accepted]
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/11/04 06:00 [medline]
AID - S0015-0282(09)03970-3 [pii]
AID - 10.1016/j.fertnstert.2009.10.050 [doi]
PST - ppublish
SO  - Fertil Steril. 2010 Oct;94(5):1674-9. doi: 10.1016/j.fertnstert.2009.10.050. Epub 
      2010 Feb 19.

PMID- 20080938
OWN - NLM
STAT- MEDLINE
DCOM- 20100917
LR  - 20220409
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
VI  - 19
IP  - 8
DP  - 2010 Apr 15
TI  - Variant CCG and GGC repeats within the CTG expansion dramatically modify 
      mutational dynamics and likely contribute toward unusual symptoms in some 
      myotonic dystrophy type 1 patients.
PG  - 1399-412
LID - 10.1093/hmg/ddq015 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is one of the most variable inherited human 
      disorders. It is characterized by the involvement of multiple tissues and is 
      caused by the expansion of a highly unstable CTG repeat. Variation in disease 
      severity is partially accounted for by the number of CTG repeats inherited. 
      However, the basis of the variable tissue-specific symptoms is unknown. We have 
      determined that an unusual Dutch family co-segregating DM1, Charcot-Marie-Tooth 
      neuropathy, encephalopathic attacks and early hearing loss, carries a complex 
      variant repeat at the DM1 locus. The mutation comprises an expanded CTG tract at 
      the 5'-end and a complex array of CTG repeats interspersed with multiple GGC and 
      CCG repeats at the 3'-end. The complex variant repeat tract at the 3'-end of the 
      array is relatively stable in both blood DNA and the maternal germ line, although 
      the 5'-CTG tract remains genetically unstable and prone to expansion. 
      Surprisingly though, even the pure 5'-CTG tract is more stable in blood DNA and 
      the maternal germ line than archetypal DM1 alleles of a similar size. Complex 
      variant repeats were also identified at the 3'-end of the CTG array of 
      approximately 3-4% of unrelated DM1 patients. The observed polarity and the 
      stabilizing effect of the variant repeats implicate a cis-acting modifier of 
      mutational dynamics in the 3'-flanking DNA. The presence of such variant repeats 
      very likely contributes toward the unusual symptoms in the Dutch family and 
      additional symptomatic variation in DM1 via affects on both RNA toxicity and 
      somatic instability.
FAU - Braida, Claudia
AU  - Braida C
AD  - Molecular Genetics, Faculty of Biomedical and Life Sciences, University of 
      Glasgow, University Avenue, Glasgow G12 8QQ, UK.
FAU - Stefanatos, Rhoda K A
AU  - Stefanatos RK
FAU - Adam, Berit
AU  - Adam B
FAU - Mahajan, Navdeep
AU  - Mahajan N
FAU - Smeets, Hubert J M
AU  - Smeets HJ
FAU - Niel, Florence
AU  - Niel F
FAU - Goizet, Cyril
AU  - Goizet C
FAU - Arveiler, Benoit
AU  - Arveiler B
FAU - Koenig, Michel
AU  - Koenig M
FAU - Lagier-Tourenne, Clotilde
AU  - Lagier-Tourenne C
FAU - Mandel, Jean-Louis
AU  - Mandel JL
FAU - Faber, Catharina G
AU  - Faber CG
FAU - de Die-Smulders, Christine E M
AU  - de Die-Smulders CE
FAU - Spaans, Frank
AU  - Spaans F
FAU - Monckton, Darren G
AU  - Monckton DG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100115
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Alleles
MH  - Female
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Pedigree
MH  - *Trinucleotide Repeat Expansion
MH  - *Trinucleotide Repeats
EDAT- 2010/01/19 06:00
MHDA- 2010/09/21 06:00
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
AID - ddq015 [pii]
AID - 10.1093/hmg/ddq015 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2010 Apr 15;19(8):1399-412. doi: 10.1093/hmg/ddq015. Epub 2010 Jan 
      15.

PMID- 20074967
OWN - NLM
STAT- MEDLINE
DCOM- 20100430
LR  - 20211203
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 17
IP  - 3
DP  - 2010 Mar
TI  - Possible de novo CTG repeat expansion in the DMPK gene of a patient with 
      cardiomyopathy.
PG  - 408-9
LID - 10.1016/j.jocn.2009.06.010 [doi]
AB  - CTG triplet repeats of "normal" length in the myotonic dystrophy protein kinase 
      (DMPK) gene have been previously believed to be stable and new pathological 
      expansion was not believed to occur. Here we report possible de novo CTG repeat 
      expansion in the DMPK gene in a patient with cardiomyopathy, who was not 
      diagnosed as having myotonic dystrophy type 1 (DM1) by conventional genetic 
      tests.
CI  - Copyright 2009 Elsevier Ltd. All rights reserved.
FAU - Furutama, Daisuke
AU  - Furutama D
AD  - First Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-cho, 
      Takatsuki 569-8686, Japan. in1003@poh.osaka-med.ac.jp
FAU - Negoro, Nobuyuki
AU  - Negoro N
FAU - Terasaki, Fumio
AU  - Terasaki F
FAU - Tsuji-Matsuyama, Kuniko
AU  - Tsuji-Matsuyama K
FAU - Sakai, Reiko
AU  - Sakai R
FAU - Maeda, Tamaki
AU  - Maeda T
FAU - Tanaka, Toshifumi
AU  - Tanaka T
FAU - Hoshiga, Masaaki
AU  - Hoshiga M
FAU - Ishihara, Tadashi
AU  - Ishihara T
FAU - Ohsawa, Nakaaki
AU  - Ohsawa N
FAU - Hanafusa, Toshiaki
AU  - Hanafusa T
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100113
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Aged
MH  - Cardiomyopathies/*genetics
MH  - Echocardiography/methods
MH  - Female
MH  - Humans
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2010/01/16 06:00
MHDA- 2010/05/01 06:00
CRDT- 2010/01/16 06:00
PHST- 2008/08/04 00:00 [received]
PHST- 2009/06/01 00:00 [revised]
PHST- 2009/06/08 00:00 [accepted]
PHST- 2010/01/16 06:00 [entrez]
PHST- 2010/01/16 06:00 [pubmed]
PHST- 2010/05/01 06:00 [medline]
AID - S0967-5868(09)00412-3 [pii]
AID - 10.1016/j.jocn.2009.06.010 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2010 Mar;17(3):408-9. doi: 10.1016/j.jocn.2009.06.010. Epub 2010 
      Jan 13.

PMID- 19946639
OWN - NLM
STAT- MEDLINE
DCOM- 20100426
LR  - 20211203
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 4
IP  - 11
DP  - 2009 Nov 25
TI  - A tail-anchored myotonic dystrophy protein kinase isoform induces perinuclear 
      clustering of mitochondria, autophagy, and apoptosis.
PG  - e8024
LID - 10.1371/journal.pone.0008024 [doi]
LID - e8024
AB  - BACKGROUND: Studies on the myotonic dystrophy protein kinase (DMPK) gene and gene 
      products have thus far mainly concentrated on the fate of length mutation in the 
      (CTG)n repeat at the DNA level and consequences of repeat expansion at the RNA 
      level in DM1 patients and disease models. Surprisingly little is known about the 
      function of DMPK protein products. METHODOLOGY/PRINCIPAL FINDINGS: We demonstrate 
      here that transient expression of one major protein product of the human gene, 
      the hDMPK A isoform with a long tail anchor, results in mitochondrial 
      fragmentation and clustering in the perinuclear region. Clustering occurred in a 
      variety of cell types and was enhanced by an intact tubulin cytoskeleton. In 
      addition to morphomechanical changes, hDMPK A expression induces physiological 
      changes like loss of mitochondrial membrane potential, increased autophagy 
      activity, and leakage of cytochrome c from the mitochondrial intermembrane space 
      accompanied by apoptosis. Truncation analysis using YFP-hDMPK A fusion constructs 
      revealed that the protein's tail domain was necessary and sufficient to evoke 
      mitochondrial clustering behavior. CONCLUSION/SIGNIFICANCE: Our data suggest that 
      the expression level of the DMPK A isoform needs to be tightly controlled in 
      cells where the hDMPK gene is expressed. We speculate that aberrant splice 
      isoform expression might be a codetermining factor in manifestation of specific 
      DM1 features in patients.
FAU - Oude Ophuis, Ralph J A
AU  - Oude Ophuis RJ
AD  - Department of Cell Biology, Nijmegen Centre for Molecular Life Sciences, Radboud 
      University Nijmegen Medical Centre, Nijmegen, The Netherlands.
FAU - Wijers, Mietske
AU  - Wijers M
FAU - Bennink, Miranda B
AU  - Bennink MB
FAU - van de Loo, Fons A J
AU  - van de Loo FA
FAU - Fransen, Jack A M
AU  - Fransen JA
FAU - Wieringa, Be
AU  - Wieringa B
FAU - Wansink, Derick G
AU  - Wansink DG
LA  - eng
PT  - Journal Article
DEP - 20091125
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Bacterial Proteins)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Luminescent Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (yellow fluorescent protein, Bacteria)
RN  - 9007-43-6 (Cytochromes c)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - *Apoptosis
MH  - *Autophagy
MH  - Bacterial Proteins/chemistry
MH  - Cytochromes c/metabolism
MH  - DNA/genetics
MH  - HeLa Cells
MH  - Humans
MH  - Luminescent Proteins/chemistry
MH  - Membrane Potentials
MH  - Mice
MH  - Microtubules/metabolism
MH  - Mitochondria/*metabolism
MH  - Mitochondrial Membranes/metabolism
MH  - *Mutation
MH  - Myotonin-Protein Kinase
MH  - Protein Isoforms
MH  - Protein Serine-Threonine Kinases/*chemistry
MH  - Protein Structure, Tertiary
PMC - PMC2778554
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2009/12/01 06:00
MHDA- 2010/04/27 06:00
PMCR- 2009/11/25
CRDT- 2009/12/01 06:00
PHST- 2009/06/10 00:00 [received]
PHST- 2009/11/04 00:00 [accepted]
PHST- 2009/12/01 06:00 [entrez]
PHST- 2009/12/01 06:00 [pubmed]
PHST- 2010/04/27 06:00 [medline]
PHST- 2009/11/25 00:00 [pmc-release]
AID - 09-PONE-RA-10933R1 [pii]
AID - 10.1371/journal.pone.0008024 [doi]
PST - epublish
SO  - PLoS One. 2009 Nov 25;4(11):e8024. doi: 10.1371/journal.pone.0008024.

PMID- 19839828
OWN - NLM
STAT- MEDLINE
DCOM- 20100106
LR  - 20211020
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Print)
IS  - 0886-022X (Linking)
VI  - 31
IP  - 6
DP  - 2009
TI  - Simvastatin reverses podocyte injury but not mesangial expansion in early stage 
      type 2 diabetes mellitus.
PG  - 503-13
AB  - Statins may confer renal protection in a variety of glomerular diseases, 
      including diabetic nephropathy (DN). However, various glomerular lesions have 
      different etiologies and may have different responses to statins. This study was 
      performed to determine the differential effects of simvastatin (SMV) on 
      glomerular pathology including mesangial expansion and podocyte injury in a mouse 
      model of early stage type 2 diabetes mellitus (DM). Type 2 DM was induced in male 
      C57BL/6 mice by feeding a high fat diet (HF; 45 kcal% fat). After 22 weeks, one 
      group of HF mice was treated with SMV (HF-SMV; 7 mug/day/g BW) and another group 
      was treated with vehicle (HF-vehicle) for 4 weeks via osmotic mini-pump. A third 
      group served as age-matched normal diet vehicle controls (ND-vehicle; 10 kcal% 
      fat). At the end of treatment, glomerular morphology was evaluated in a blind 
      manner to determine the progression of DN. Body weight, blood glucose, insulin, 
      HDL-cholesterol and triglycerides, but not LDL-cholesterol, were increased in HF 
      mice. Over the course of treatment, the 24-hour urinary albumin excretion (UAE) 
      was unchanged in ND-vehicle. HF mice exhibited elevated UAE, which decreased with 
      SMV, but was unchanged with vehicle. The absolute mesangial volume and the 
      relative mesangial volume per glomerular volume increased in HF-vehicle and 
      remained elevated with SMV treatment. The immuno-staining of nephrin, a protein 
      marker of the integrity of podocyte slit diaphragms, was decreased in HF-vehicle; 
      however, the nephrin quantity of the HF-SMV group was not different from 
      ND-vehicle. It is concluded that SMV reverses podocyte damage, but does not 
      affect mesangial expansion in the kidneys of early stage proteinuria of type 2 
      DM.
FAU - Wei, P
AU  - Wei P
AD  - Department of Cellular and Integrative Physiology, University of Nebraska Medical 
      Center, 985850 Nebraska Medical Center, Omaha, Nebraska 68198-5850, USA.
FAU - Grimm, P R
AU  - Grimm PR
FAU - Settles, D C
AU  - Settles DC
FAU - Balwanz, C R
AU  - Balwanz CR
FAU - Padanilam, B J
AU  - Padanilam BJ
FAU - Sansom, S C
AU  - Sansom SC
LA  - eng
GR  - R01 DK073070/DK/NIDDK NIH HHS/United States
GR  - R01 DK073070-01A1/DK/NIDDK NIH HHS/United States
GR  - 5R01 DK073070/DK/NIDDK NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Blood Glucose)
RN  - AGG2FN16EV (Simvastatin)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Experimental/*drug therapy/pathology
MH  - Diabetes Mellitus, Type 2/*drug therapy/pathology
MH  - Disease Models, Animal
MH  - Glomerular Mesangium/*drug effects/pathology
MH  - Immunohistochemistry
MH  - Kidney Function Tests
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microscopy, Electron
MH  - Organ Size
MH  - Podocytes/*drug effects/pathology
MH  - Probability
MH  - Random Allocation
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Simvastatin/*pharmacology
PMC - PMC3133959
MID - NIHMS304908
EDAT- 2009/10/21 06:00
MHDA- 2010/01/07 06:00
PMCR- 2011/07/12
CRDT- 2009/10/21 06:00
PHST- 2009/10/21 06:00 [entrez]
PHST- 2009/10/21 06:00 [pubmed]
PHST- 2010/01/07 06:00 [medline]
PHST- 2011/07/12 00:00 [pmc-release]
AID - 10.1080/08860220902963848 [pii]
AID - 10.1080/08860220902963848 [doi]
PST - ppublish
SO  - Ren Fail. 2009;31(6):503-13. doi: 10.1080/08860220902963848.

PMID- 19715468
OWN - NLM
STAT- MEDLINE
DCOM- 20100111
LR  - 20160511
IS  - 1945-0257 (Electronic)
IS  - 1945-0257 (Linking)
VI  - 13
IP  - 5
DP  - 2009 Oct
TI  - New analysis method of myotonic dystrophy 1 based on quantitative fluorescent 
      polymerase chain reaction.
PG  - 651-5
LID - 10.1089/gtmb.2009.0050 [doi]
AB  - Molecular genetic testing of myotonic dystrophy type 1 (DM1) is based on the 
      identification and determination of a cytosine-thymine-guanine (CTG) repeat 
      expansion in the DMPK gene. This is usually done by Southern blot analysis-a 
      time-consuming and very laborious technique requiring high molecular weight DNA. 
      The aim of our study was to develop a highly sensitive, rapid, and cost-effective 
      molecular analysis characterizing the CTG repeat region of the DMPK gene based on 
      a two-step polymerase chain reaction (PCR) protocol. (1) For the detection of 
      alleles of up to 100 repeats, a quantitative fluorescent (QF) amplification with 
      primers flanking the repeat region of the DM1 locus and two reference genes (PAX2 
      and DHCR7) for standardization was used. By this method it was possible to 
      identify both homozygous and heterozygous DM1 alleles. (2) Long PCR was only 
      performed if a single wild-type allele was detected that gave a QF-PCR signal of 
      only half intensity compared to a homozygous sample. The results obtained using 
      combined QF and Long PCR are highly accurate compared with Southern blot 
      analysis. We conclude that our new rapid analysis is reliable for genetic testing 
      of DM1 patients.
FAU - Skrzypczak-Zielinska, Marzena
AU  - Skrzypczak-Zielinska M
AD  - Institute of Human Genetics, University of Leipzig, Leipzig, Germany.
FAU - Sulek-Piatkowska, Anna
AU  - Sulek-Piatkowska A
FAU - Mierzejewski, Marek
AU  - Mierzejewski M
FAU - Froster, Ursula G
AU  - Froster UG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
RN  - 0 (DNA Primers)
SB  - IM
MH  - Base Sequence
MH  - Blotting, Southern
MH  - DNA Primers
MH  - Fluorescence
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Polymerase Chain Reaction/*methods
EDAT- 2009/09/01 06:00
MHDA- 2010/01/12 06:00
CRDT- 2009/09/01 09:00
PHST- 2009/09/01 09:00 [entrez]
PHST- 2009/09/01 06:00 [pubmed]
PHST- 2010/01/12 06:00 [medline]
AID - 10.1089/gtmb.2009.0050 [doi]
PST - ppublish
SO  - Genet Test Mol Biomarkers. 2009 Oct;13(5):651-5. doi: 10.1089/gtmb.2009.0050.

PMID- 19632331
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20211203
IS  - 1095-953X (Electronic)
IS  - 0969-9961 (Linking)
VI  - 36
IP  - 1
DP  - 2009 Oct
TI  - Absence of a differentiation defect in muscle satellite cells from DM2 patients.
PG  - 181-90
LID - 10.1016/j.nbd.2009.07.009 [doi]
AB  - Myotonic dystrophy type 1 (DM1) and type II (DM2) are dominantly inherited 
      multisystemic disorders. DM1 is triggered by the pathological expansion of a 
      (CTG)(n) triplet repeat in the DMPK gene, whereas a (CCTG)(n) tetranucleotide 
      repeat expansion in the ZNF9 gene causes DM2. Both forms of the disease share 
      several features, even though the causative mutations and the loci involved 
      differ. Important distinctions exist, such as the lack of a congenital form of 
      DM2. The reason for these disparities is unknown. In this study, we characterized 
      skeletal muscle satellite cells from adult DM2 patients to provide an in vitro 
      model for the disease. We used muscle cells from DM1 biopsies as a comparison 
      tool. Our main finding is that DM2 satellite cells differentiate normally in 
      vitro. Myotube formation was similar to unaffected controls. In contrast, fetal 
      DM1 cells were deficient in that ability. Consistent with this observation, the 
      myogenic program in DM2 was intact but is compromised in fetal DM1 cells. 
      Although expression of the ZNF9 gene was enhanced in DM2 during differentiation, 
      the levels of the ZNF9 protein were substantially reduced. This suggests that the 
      presence of a large CCTG tract impairs the translation of the ZNF9 mRNA. 
      Additionally, DM2 muscle biopsies displayed the altered splicing of the insulin 
      receptor mRNA, correlating with insulin resistance in the patients. Finally, 
      CUGBP1 steady-state protein levels were unchanged in DM2 cultured muscle cells 
      and in DM2 muscle biopsies relative to controls, whereas they are increased in 
      DM1 muscle cells. Our findings suggest that the myogenic program throughout 
      muscle development and tissue regeneration is intact in DM2.
FAU - Pelletier, Richard
AU  - Pelletier R
AD  - Human Genetics Research Unit, Laval University, CHUQ, Pavillon CHUL, Ste-Foy, 
      Quebec, Canada, G1V 4G2. richard.pelletier@crchul.ulaval.ca
FAU - Hamel, Frederic
AU  - Hamel F
FAU - Beaulieu, Daniel
AU  - Beaulieu D
FAU - Patry, Lysanne
AU  - Patry L
FAU - Haineault, Caroline
AU  - Haineault C
FAU - Tarnopolsky, Mark
AU  - Tarnopolsky M
FAU - Schoser, Benedikt
AU  - Schoser B
FAU - Puymirat, Jack
AU  - Puymirat J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090724
PL  - United States
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (CNBP protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Alternative Splicing/genetics
MH  - Analysis of Variance
MH  - CELF1 Protein
MH  - Cell Differentiation/*genetics
MH  - Cells, Cultured
MH  - Female
MH  - Fetus
MH  - Gene Expression Regulation/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*pathology
MH  - Myotonic Disorders/*classification/*pathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Receptor, Insulin/genetics/metabolism
MH  - Satellite Cells, Skeletal Muscle/*physiology
MH  - Trinucleotide Repeat Expansion
EDAT- 2009/07/28 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/07/28 09:00
PHST- 2009/03/20 00:00 [received]
PHST- 2009/07/07 00:00 [revised]
PHST- 2009/07/16 00:00 [accepted]
PHST- 2009/07/28 09:00 [entrez]
PHST- 2009/07/28 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - S0969-9961(09)00180-6 [pii]
AID - 10.1016/j.nbd.2009.07.009 [doi]
PST - ppublish
SO  - Neurobiol Dis. 2009 Oct;36(1):181-90. doi: 10.1016/j.nbd.2009.07.009. Epub 2009 
      Jul 24.

PMID- 19627641
OWN - NLM
STAT- MEDLINE
DCOM- 20100625
LR  - 20220330
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Linking)
VI  - 40
IP  - 3
DP  - 2010 Mar
TI  - Cognitive/personality pattern and triplet expansion size in adult myotonic 
      dystrophy type 1 (DM1): CTG repeats, cognition and personality in DM1.
PG  - 487-95
LID - 10.1017/S0033291709990602 [doi]
AB  - BACKGROUND: Although central nervous system (CNS) involvement in adult myotonic 
      dystrophy type 1 (DM1) was described long ago, the large number of variables 
      affecting the cognitive and personality profile have made it difficult to 
      determine the effect of DM1 on the brain. The aim of this study was to define the 
      cognitive and personality patterns in adult DM1 patients, and to analyse the 
      relationship between these clinical patterns and their association with the 
      underlying molecular defect. METHOD: We examined 121 adult DM1 patients with 
      confirmed molecular CTG repeat expansion and 54 control subjects using 
      comprehensive neuropsychological tests and personality assessments with the 
      Millon Clinical Multiaxial Inventory (MCMI)-II. We used a multiple linear 
      regression model to assess the effect of each variable on cognition and 
      personality adjusted to the remainders. RESULTS: Patients performed significantly 
      worse than controls in tests measuring executive function (principally cognitive 
      inflexibility) and visuoconstructive ability. In the personality profile, some 
      paranoid and aggressive traits were predominant. Furthermore, there was a 
      significant negative correlation between the CTG expansion size and many of the 
      neuropsychological and personality measures. The molecular defect also correlated 
      with patients' daytime somnolence. CONCLUSIONS: Besides muscular symptomatology, 
      there is significant CTG-dependent involvement of the CNS in adult DM1 patients. 
      Our data indicate that the cognitive impairment predominantly affects the 
      fronto-parietal lobe.
FAU - Sistiaga, A
AU  - Sistiaga A
AD  - Experimental Unit, Hospital Donostia, San Sebastian, Spain. 
      andone.sistiagaberrondo@osakidetza.net
FAU - Urreta, I
AU  - Urreta I
FAU - Jodar, M
AU  - Jodar M
FAU - Cobo, A M
AU  - Cobo AM
FAU - Emparanza, J
AU  - Emparanza J
FAU - Otaegui, D
AU  - Otaegui D
FAU - Poza, J J
AU  - Poza JJ
FAU - Merino, J J
AU  - Merino JJ
FAU - Imaz, H
AU  - Imaz H
FAU - Marti-Masso, J F
AU  - Marti-Masso JF
FAU - Lopez de Munain, A
AU  - Lopez de Munain A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090723
PL  - England
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Blotting, Southern/methods
MH  - Cognition Disorders/diagnosis/*epidemiology/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology/genetics/*psychology
MH  - Myotonin-Protein Kinase
MH  - Neuropsychological Tests/statistics & numerical data
MH  - *Personality
MH  - Personality Inventory/statistics & numerical data
MH  - Polymerase Chain Reaction/methods
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Psychiatric Status Rating Scales/statistics & numerical data
MH  - Repetitive Sequences, Nucleic Acid
MH  - Spain/epidemiology
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Young Adult
EDAT- 2009/07/25 09:00
MHDA- 2010/06/26 06:00
CRDT- 2009/07/25 09:00
PHST- 2009/07/25 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2010/06/26 06:00 [medline]
AID - S0033291709990602 [pii]
AID - 10.1017/S0033291709990602 [doi]
PST - ppublish
SO  - Psychol Med. 2010 Mar;40(3):487-95. doi: 10.1017/S0033291709990602. Epub 2009 Jul 
      23.

PMID- 19516957
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1389-2029 (Print)
IS  - 1875-5488 (Electronic)
IS  - 1389-2029 (Linking)
VI  - 9
IP  - 8
DP  - 2008 Dec
TI  - Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein 
      Kinase Gene.
PG  - 509-16
LID - 10.2174/138920208786847944 [doi]
AB  - Myotonic Dystrophy type 1 (DM1) is a multi-system disorder characterized by 
      muscle wasting, myotonia, cardiac conduction defects, cataracts, and 
      neuropsychological dysfunction. DM1 is caused by expansion of a CTG repeat in the 
      3 untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) 
      gene. A body of work demonstrates that DMPK mRNAs containing abnormally expanded 
      CUG repeats are toxic to several cell types. A core mechanism underlying symptoms 
      of DM1 is that mutant DMPK RNA interferes with the developmentally regulated 
      alternative splicing of defined pre-mRNAs. Expanded CUG repeats fold into ds(CUG) 
      hairpins that sequester nuclear proteins including human Muscleblind-like (MBNL) 
      and hnRNP H alternative splicing factors. DM1 cells activate CELF family member 
      CUG-BP1 protein through hyperphosphorylation and stabilization in the cell 
      nucleus. CUG-BP1 and MBNL1 proteins act antagonistically in exon selection in 
      several pre-mRNA transcripts, thus MBNL1 sequestration and increase in nuclear 
      activity of CUG-BP1 both act synergistically to missplice defined transcripts. 
      Mutant DMPK-mediated effect on subcellular localization, and defective 
      phosphorylation of cytoplasmic CUG-BP1, have additionally been linked to 
      defective translation of p21 and MEF2A in DM1, possibly explaining delayed 
      differentiation of DM1 muscle cells. Mutant DMPK transcripts bind and sequester 
      transcription factors such as Specificity protein 1 leading to reduced 
      transcription of selected genes. Recently, transcripts containing long hairpin 
      structures of CUG repeats have been shown to be a Dicer ribonuclease target and 
      Dicer-induced downregulation of the mutant DMPK transcripts triggers silencing 
      effects on RNAs containing long complementary repeats. In summary, mutant DMPK 
      transcripts alter gene transcription, alternative splicing, and translation of 
      specific gene transcripts, and have the ability to trigger gene-specific 
      silencing effects in DM1 cells. Therapies aimed at reversing these gene 
      expression alterations should prove effective ways to treat DM1.
FAU - Llamusi, Beatriz
AU  - Llamusi B
AD  - Department of Genetics, University of Valencia, Doctor Moliner, 50, E46100 
      Burjasot, Valencia, Spain.
FAU - Artero, Ruben
AU  - Artero R
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Genomics
JT  - Current genomics
JID - 100960527
PMC - PMC2694559
EDAT- 2009/06/12 09:00
MHDA- 2009/06/12 09:01
PMCR- 2009/06/01
CRDT- 2009/06/12 09:00
PHST- 2008/04/07 00:00 [received]
PHST- 2008/06/18 00:00 [revised]
PHST- 2008/06/24 00:00 [accepted]
PHST- 2009/06/12 09:00 [entrez]
PHST- 2009/06/12 09:00 [pubmed]
PHST- 2009/06/12 09:01 [medline]
PHST- 2009/06/01 00:00 [pmc-release]
AID - CG-9-509 [pii]
AID - 10.2174/138920208786847944 [doi]
PST - ppublish
SO  - Curr Genomics. 2008 Dec;9(8):509-16. doi: 10.2174/138920208786847944.

PMID- 19472917
OWN - NLM
STAT- MEDLINE
DCOM- 20090624
LR  - 20211020
IS  - 1128-2460 (Print)
IS  - 1128-2460 (Linking)
VI  - 27
IP  - 3
DP  - 2008 Dec
TI  - Analysis of Single Nucleotide Polymorphisms (SNPs) of the small-conductance 
      calcium activated potassium channel (SK3) gene as genetic modifier of the cardiac 
      phenotype in myotonic dystrophy type 1 patients.
PG  - 82-9
AB  - Myotonic dystrophy type 1 (DM1) is the most frequently inherited neuromuscular 
      disease in adults. It is a multisystemic disorder with major cardiac involvement 
      most commonly represented by first-degree atrioventricular heart block (AVB), 
      followed by different degrees of bundle-branch and intraventricular blocks In 
      search for candidate genes, modifiers of the AVB phenotype in DM1, the expression 
      of the small-conductance calcium activated potassium channel (SK3) gene was 
      analysed in muscle biopsies from DM1 patients. The association between SK3 
      polymorphisms and the AVB phenotype was then studied analyzing 40 DM1 patients 
      with AVB and 40 age-matched DM1 affected individuals with no ECG abnormalities. 
      [CTG]n repeat length and cardiac clinical picture were also assessed for 
      correlation. QRT-PCR experiments showed an over-expression of the SK3 transcript 
      in DM1 muscle biopsies compared to healthy controls. However, no statistical 
      association between the AVB phenotype and either the [CTG]n expansion length or 
      the presence of specific SNPs in the SK3 gene were detected. These findings 
      suggest that modifier genes, other than SK3, should be identified in order to 
      explain the cardiac phenotypic variability among DM1 patients.
FAU - Rinaldi, F
AU  - Rinaldi F
AD  - Department of Biopathology, University of Rome Tor Vergata, Rome, Italy.
FAU - Botta, A
AU  - Botta A
FAU - Vallo, L
AU  - Vallo L
FAU - Contino, G
AU  - Contino G
FAU - Morgante, A
AU  - Morgante A
FAU - Iraci, R
AU  - Iraci R
FAU - Catalli, C
AU  - Catalli C
FAU - Silvestri, G
AU  - Silvestri G
FAU - Ventriglia, V M
AU  - Ventriglia VM
FAU - Politano, L
AU  - Politano L
FAU - Novelli, G
AU  - Novelli G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Acta Myol
JT  - Acta myologica : myopathies and cardiomyopathies : official journal of the 
      Mediterranean Society of Myology
JID - 9811169
RN  - 0 (KCNN3 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Small-Conductance Calcium-Activated Potassium Channels)
SB  - IM
MH  - Adult
MH  - Atrioventricular Block/epidemiology/*genetics
MH  - Biopsy
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Female
MH  - Gene Frequency/genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - *Phenotype
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - RNA, Messenger/metabolism
MH  - Risk Factors
MH  - Small-Conductance Calcium-Activated Potassium Channels/*genetics/metabolism
PMC - PMC2858941
EDAT- 2009/05/29 09:00
MHDA- 2009/06/25 09:00
PMCR- 2008/12/01
CRDT- 2009/05/29 09:00
PHST- 2009/05/29 09:00 [entrez]
PHST- 2009/05/29 09:00 [pubmed]
PHST- 2009/06/25 09:00 [medline]
PHST- 2008/12/01 00:00 [pmc-release]
PST - ppublish
SO  - Acta Myol. 2008 Dec;27(3):82-9.

PMID- 19470458
OWN - NLM
STAT- MEDLINE
DCOM- 20090706
LR  - 20211020
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Print)
IS  - 0027-8424 (Linking)
VI  - 106
IP  - 23
DP  - 2009 Jun 9
TI  - The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate 
      splicing.
PG  - 9203-8
LID - 10.1073/pnas.0900342106 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is a genetic disorder linked to a (CTG)(n) repeat 
      expansion in the 3' untranslated region of the DMPK gene. Upon transcription in 
      the nucleus, the CUG repeats form a stable RNA stem-loop that sequesters the 
      RNA-binding protein MBNL1 from its normal function in the cell. MBNL1 regulates 
      the alternative splicing of many pre-mRNAs, and upon MBNL1's sequestration, the 
      alternative splicing of many genes is mis-regulated, leading to disease symptoms. 
      MBNL1 is known to bind directly to at least 3 of the pre-mRNAs that it regulates, 
      but how MBNL1 binding mechanistically regulates alternative splicing is unclear. 
      Here, we demonstrate that MBNL1 controls the splicing of exon 5 in the cardiac 
      troponin T (cTNT) pre-mRNA by competing directly with the essential splicing 
      factor U2AF65 for binding at the 3' end of intron 4. When U2AF65 is prevented 
      from binding to the pre-mRNA, the U2 snRNP can no longer be recruited and the 
      following exon is skipped. Furthermore, MBNL1 and U2AF65 appear to compete by 
      binding to mutually exclusive RNA structures. When bound by splicing factors, the 
      3' end of intron 4 can form either a stem-loop or a single-stranded structure. 
      MBNL1 binds a portion of the intron as a stem-loop, whereas U2AF65 binds the same 
      region in a single-strand structure. Mutations that strengthen the stem-loop 
      decrease U2AF65 binding affinity and also repress exon 5 inclusion, independently 
      of MBNL1. Thus, U2AF65 binding can be blocked either by MBNL1 binding or by the 
      stabilization of RNA secondary structure.
FAU - Warf, M Bryan
AU  - Warf MB
AD  - Institute of Molecular Biology and Department of Chemistry, University of Oregon, 
      Eugene, OR 97403, USA.
FAU - Diegel, Julien V
AU  - Diegel JV
FAU - von Hippel, Peter H
AU  - von Hippel PH
FAU - Berglund, J Andrew
AU  - Berglund JA
LA  - eng
GR  - R01 GM015792/GM/NIGMS NIH HHS/United States
GR  - R01 AR053903/AR/NIAMS NIH HHS/United States
GR  - GM-15792/GM/NIGMS NIH HHS/United States
GR  - AR053903/AR/NIAMS NIH HHS/United States
GR  - T32 GM007759/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090526
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (MBNL1 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (Splicing Factor U2AF)
RN  - 0 (Troponin T)
RN  - 0 (U2AF2 protein, human)
SB  - IM
MH  - Base Sequence
MH  - Humans
MH  - Introns
MH  - Molecular Sequence Data
MH  - Nuclear Proteins/*metabolism
MH  - Nucleic Acid Conformation
MH  - *RNA Splicing
MH  - RNA-Binding Proteins/*metabolism
MH  - Ribonucleoproteins/*metabolism
MH  - Splicing Factor U2AF
MH  - Troponin T/genetics
PMC - PMC2695092
COIS- The authors declare no conflict of interest.
EDAT- 2009/05/28 09:00
MHDA- 2009/07/07 09:00
PMCR- 2009/12/09
CRDT- 2009/05/28 09:00
PHST- 2009/05/28 09:00 [entrez]
PHST- 2009/05/28 09:00 [pubmed]
PHST- 2009/07/07 09:00 [medline]
PHST- 2009/12/09 00:00 [pmc-release]
AID - 0900342106 [pii]
AID - 8138 [pii]
AID - 10.1073/pnas.0900342106 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9203-8. doi: 
      10.1073/pnas.0900342106. Epub 2009 May 26.

PMID- 19246640
OWN - NLM
STAT- MEDLINE
DCOM- 20090428
LR  - 20220309
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Print)
IS  - 0002-9440 (Linking)
VI  - 174
IP  - 4
DP  - 2009 Apr
TI  - Large CTG repeats trigger p16-dependent premature senescence in myotonic 
      dystrophy type 1 muscle precursor cells.
PG  - 1435-42
LID - 10.2353/ajpath.2009.080560 [doi]
AB  - A CTG repeat amplification is responsible for the dominantly inherited 
      neuromuscular disorder, myotonic dystrophy type 1 (DM1), which is characterized 
      by progressive muscle wasting and weakness. The expanded (CTG)n tract not only 
      alters the myogenic differentiation of the DM1 muscle precursor cells but also 
      reduces their proliferative capacity. In this report, we show that these muscle 
      precursor cells containing large CTG expansion sequences have not exhausted their 
      proliferative capacity, but have entered into premature senescence. We 
      demonstrate that an abnormal accumulation of p16 is responsible for this defect 
      because the abolition of p16 activity overcomes early growth arrest and restores 
      an extended proliferative capacity. Our results suggest that the accelerated 
      telomere shortening measured in DM1 cells does not contribute to the aberrant 
      induction of p16. We propose that a cellular stress related to the amplified CTG 
      repeat promotes premature senescence mediated by a p16-dependent pathway in DM1 
      muscle precursor cells. This mechanism is responsible for the reduced 
      proliferative capacity of the DM1 muscle precursor cells and could participate in 
      both the impaired regeneration and atrophy observed in the DM1 muscles containing 
      large CTG expansions.
FAU - Bigot, Anne
AU  - Bigot A
AD  - Universite Pierre et Marie Curie Paris 6, UMR 787, Paris, France.
FAU - Klein, Arnaud F
AU  - Klein AF
FAU - Gasnier, Erwan
AU  - Gasnier E
FAU - Jacquemin, Virginie
AU  - Jacquemin V
FAU - Ravassard, Philippe
AU  - Ravassard P
FAU - Butler-Browne, Gillian
AU  - Butler-Browne G
FAU - Mouly, Vincent
AU  - Mouly V
FAU - Furling, Denis
AU  - Furling D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090226
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
SB  - IM
MH  - Blotting, Western
MH  - Cell Proliferation
MH  - Cellular Senescence/*genetics
MH  - *Cyclin-Dependent Kinase Inhibitor p16
MH  - Fetus
MH  - Humans
MH  - Immunohistochemistry
MH  - Myoblasts/*pathology
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Satellite Cells, Skeletal Muscle/*pathology
MH  - Telomere/metabolism
MH  - Trinucleotide Repeats/*genetics
PMC - PMC2671374
EDAT- 2009/02/28 09:00
MHDA- 2009/04/29 09:00
PMCR- 2009/10/01
CRDT- 2009/02/28 09:00
PHST- 2009/02/28 09:00 [entrez]
PHST- 2009/02/28 09:00 [pubmed]
PHST- 2009/04/29 09:00 [medline]
PHST- 2009/10/01 00:00 [pmc-release]
AID - S0002-9440(10)61000-0 [pii]
AID - 10.2353/ajpath.2009.080560 [doi]
PST - ppublish
SO  - Am J Pathol. 2009 Apr;174(4):1435-42. doi: 10.2353/ajpath.2009.080560. Epub 2009 
      Feb 26.

PMID- 19152242
OWN - NLM
STAT- MEDLINE
DCOM- 20090609
LR  - 20191111
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 56
IP  - 1
DP  - 2009
TI  - Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a 
      pilot study.
PG  - 26-32
AB  - Pancreatic cancer (PC) is one of the most frequent gastrointestinal malignancies 
      with extremely poor prognosis. In spite of a relative low incidence of PC, in 
      comparison with other cancers, PC is the fourth leading cause of cancer death in 
      USA in both sexes. The available data clearly suggest that diabetes mellitus (DM) 
      can be both a long-standing cause of PC and an early manifestation of the 
      disease. Besides of DM, insulin resistance and high insulin levels are linked as 
      well with increased cancer risk, including PC. The variable number of tandem 
      repeats (VNTR) locus upstream of the insulin gene (INS) regulates insulin 
      expression and has been associated with susceptibility to many diseases including 
      DM. It is known that there is nearly complete linkage disequilibrium of the 
      insulin variable tandem of repeats (INS-VNTR) alleles I/III with neighboring -23 
      HphI A/T single nucleotide polymorphism (SNP) in Caucasians. Therefore, we have 
      studied the association between SNP of -23HphI in promoter of INS with PC, DM 
      Type 2 (2TDM) and healthy controls. In this study we investigated 153 subjects 
      (86 M/67 F); 51 patients with newly-diagnosed PC (31 M/20 F), 45 patients with 
      2TDM (29 M/16 F) and 57 healthy control subjects (26 M/31 F). The polymorphism of 
      -23HphI (A/T) in the promoter of INS was determined by the combination of 
      polymerase chain reaction (PCR) with the restriction fragment length polymorphism 
      (RFLP) methods. The results obtained by the PCR-RFLP analyses of SNP -23HphI were 
      confirmed by a direct studied locus sequencing of the genomic DNA. The frequency 
      of abnormal glucose metabolism (both DM and impaired fasting glucose) was 88 % 
      (45/51) in PC group. The AA genotype in SNP -23HphI was more prevalent (67 % vs. 
      47 %; P<0.05) among PC patients compared to controls. Additionally, statistically 
      significant differences were found in frequencies (%) of genotypes AA/AT/TT in 
      groups with PC (67/27/6), 2TDM (53/40/7) compared to healthy controls (37/46/17) 
      (P<0.05). Moreover, a statistically significant effect of -23HphI A/T 
      polymorphism on tumor staging was found (P< 0.05). Polymorphism of -23HphI (A/T) 
      in the promoter of INS may play a role in the pathogenesis of PC and could 
      contribute to tumor staging. Key words: pancreatic cancer; insulin gene 
      regulation; polymorphism of -23HphI; diabetes mellitus; disorders of 
      glucoregulation.
FAU - Krechler, T
AU  - Krechler T
AD  - 4th Department of Medicine, 1st Faculty of Medicine, Charles University and 
      General Teaching Hospital, Prague, Czech Republic. krechler@vfn.cz
FAU - Jachymova, M
AU  - Jachymova M
FAU - Pavlikova, M
AU  - Pavlikova M
FAU - Vecka, M
AU  - Vecka M
FAU - Zeman, M
AU  - Zeman M
FAU - Krska, Z
AU  - Krska Z
FAU - Svestka, T
AU  - Svestka T
FAU - Zak, A
AU  - Zak A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
RN  - 0 (Insulin)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/complications/genetics
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Insulin/*genetics
MH  - Male
MH  - Middle Aged
MH  - Minisatellite Repeats/genetics
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/complications/*genetics/*pathology
MH  - Pilot Projects
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Restriction Fragment Length
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Promoter Regions, Genetic/*genetics
EDAT- 2009/01/20 09:00
MHDA- 2009/06/10 09:00
CRDT- 2009/01/20 09:00
PHST- 2009/01/20 09:00 [entrez]
PHST- 2009/01/20 09:00 [pubmed]
PHST- 2009/06/10 09:00 [medline]
AID - 10.4149/neo_2009_01_26 [doi]
PST - ppublish
SO  - Neoplasma. 2009;56(1):26-32. doi: 10.4149/neo_2009_01_26.

PMID- 18798829
OWN - NLM
STAT- MEDLINE
DCOM- 20090626
LR  - 20221207
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 119
IP  - 5
DP  - 2009 May
TI  - CTG repeats at the myotonic protein kinase gene in a healthy Chilean population 
      sample.
PG  - 321-4
LID - 10.1111/j.1600-0404.2008.01096.x [doi]
AB  - OBJECTIVES: To study the variability at the myotonic dystrophy protein kinase 
      (DMPK) gene in a Chilean sample of healthy people. DM1 is an autosomal dominant 
      disorder caused by an expansion of a (CTG) repeat at the 3'-UTR of the gene DMPK. 
      Healthy individuals have alleles under 35 repeats and diseased individuals have 
      over 50. METHODS: Genotyping the number of (CTG) repeats at this gene in a sample 
      of healthy Chilean people. RESULTS: Allele frequencies were significantly 
      different from those of other populations. The most frequent allele was with five 
      repeats. The frequency of larger alleles (>18 CTG repeats) was 11%, close to the 
      European frequency (12%) and higher than the Japanese (8%) and Aboriginal 
      Pehuenche samples (8%). CONCLUSIONS: Allelic frequencies in the Chilean sample 
      studied were intermediate between those of the two ancestral populations 
      (European and Pehuenche).
FAU - Amenabar, F
AU  - Amenabar F
AD  - Programa de Genetica Humana, ICBM, Facultad de Medicina, Universidad de Chile.
FAU - Jorquera, H
AU  - Jorquera H
FAU - Acuna, M
AU  - Acuna M
FAU - Cifuentes, L
AU  - Cifuentes L
LA  - eng
PT  - Journal Article
DEP - 20080916
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (DMPK protein, human)
RN  - 0 (Genetic Markers)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Asian People/genetics
MH  - Chile/epidemiology/ethnology
MH  - Chromosome Disorders/epidemiology/ethnology/genetics
MH  - DNA Mutational Analysis
MH  - Ethnicity/genetics
MH  - Gene Frequency/genetics
MH  - Genes, Dominant/genetics
MH  - Genetic Markers/genetics
MH  - Genetic Predisposition to Disease/*genetics
MH  - Genetic Testing
MH  - Genotype
MH  - Heterozygote
MH  - Humans
MH  - Muscle, Skeletal/enzymology/physiopathology
MH  - Mutation/*genetics
MH  - Myotonic Dystrophy/epidemiology/ethnology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Reference Values
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - White People/genetics
EDAT- 2008/09/19 09:00
MHDA- 2009/06/27 09:00
CRDT- 2008/09/19 09:00
PHST- 2008/09/19 09:00 [pubmed]
PHST- 2009/06/27 09:00 [medline]
PHST- 2008/09/19 09:00 [entrez]
AID - ANE1096 [pii]
AID - 10.1111/j.1600-0404.2008.01096.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2009 May;119(5):321-4. doi: 10.1111/j.1600-0404.2008.01096.x. 
      Epub 2008 Sep 16.

PMID- 18729234
OWN - NLM
STAT- MEDLINE
DCOM- 20090116
LR  - 20211203
IS  - 1058-8388 (Print)
IS  - 1058-8388 (Linking)
VI  - 237
IP  - 9
DP  - 2008 Sep
TI  - Myotonic dystrophy protein kinase is expressed in embryonic myocytes and is 
      required for myotube formation.
PG  - 2353-66
LID - 10.1002/dvdy.21653 [doi]
AB  - Myotonic dystrophy (DM1) is a multi-systemic disease caused by a triplet 
      nucleotide repeat expansion in the 3' untranslated region of the gene coding for 
      myotonic dystrophy protein kinase (DMPK). The primary pathophysiology of DM1 is 
      thought to result from RNA transport and processing defects. The function of DMPK 
      in development or any potential role in DM1 remains unknown. Here we report a 
      novel role for DMPK in myogenesis. We have discovered a specific expression 
      pattern of DMPK in mouse and chick embryonic development. DMPK is expressed in 
      postmitotic cardiac and skeletal myocytes and developmental signaling centers. 
      During cardiac myocyte maturation, DMPK migrates from perinuclear to cellular 
      membrane localization. Manipulating DMPK levels in cultured cardiac and skeletal 
      myocytes has revealed a key role for DMPK in myocyte differentiation. 
      Overexpression of DMPK induces cell rounding and apoptosis in myocytes. In 
      addition, DMPK is necessary for myogenin expression in differentiating C2C12 
      myoblasts.
FAU - Harmon, Erin B
AU  - Harmon EB
AD  - Cardiovascular Research Center, Sanford Research/USD, Sioux Falls, South Dakota, 
      USA.
FAU - Harmon, Michelle L
AU  - Harmon ML
FAU - Larsen, Tricia D
AU  - Larsen TD
FAU - Paulson, Alicia F
AU  - Paulson AF
FAU - Perryman, M Benjamin
AU  - Perryman MB
LA  - eng
GR  - P20 RR017662/RR/NCRR NIH HHS/United States
GR  - 5R01HL064136/HL/NHLBI NIH HHS/United States
GR  - 5P20RR017662/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Dev Dyn
JT  - Developmental dynamics : an official publication of the American Association of 
      Anatomists
JID - 9201927
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/physiology
MH  - Blotting, Western
MH  - Cell Differentiation/physiology
MH  - Cell Line
MH  - Cells, Cultured
MH  - Chick Embryo
MH  - Chickens
MH  - Green Fluorescent Proteins/genetics/metabolism
MH  - Immunohistochemistry
MH  - Mice
MH  - Microscopy, Confocal
MH  - Muscle Cells/cytology/*metabolism
MH  - Muscle Fibers, Skeletal/cytology/*metabolism
MH  - Myocytes, Cardiac/cytology/*metabolism
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - Recombinant Fusion Proteins/genetics/metabolism
MH  - Transfection
EDAT- 2008/08/30 09:00
MHDA- 2009/01/17 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2009/01/17 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
AID - 10.1002/dvdy.21653 [doi]
PST - ppublish
SO  - Dev Dyn. 2008 Sep;237(9):2353-66. doi: 10.1002/dvdy.21653.

PMID- 18637827
OWN - NLM
STAT- MEDLINE
DCOM- 20081222
LR  - 20151119
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 15
IP  - 9
DP  - 2008 Sep
TI  - Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic 
      dystrophy type 1.
PG  - 947-52
LID - 10.1111/j.1468-1331.2008.02217.x [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is associated with brain morphology 
      changes including neurofibrillary degeneration. METHODS: We have examined 
      cerebrospinal fluid (CSF) markers indicative of neuronal degeneration and 
      amyloidogenesis; total tau (T-tau), phosphorylated tau (P-tau) and beta amyloid 
      1-42 (Abeta42), in 32 patients with DM1. RESULTS AND CONCLUSIONS: Associations 
      between CSF markers and CTG repeat expansion size, brain MRI findings, and 
      neuropsychological test results were analysed. As compared with matched controls 
      Abeta42 was significantly decreased (P = 0.001), whilst levels of T-tau were 
      increased (P < 0.001). No difference was found between measures considering P-tau 
      levels. At present the clinical implications of these findings is unclear, 
      because of an overlap between CSF values of DM1 patients and healthy controls, 
      but also regarding modest associations between CSF markers and other measures. 
      However notably, the Tau pathology, as seen in DM1, differs from Alzheimers 
      disease, considering the lack of increased levels of P-tau.
FAU - Winblad, S
AU  - Winblad S
AD  - Neuromuscular Centre, Department of Neurology, Sahlgrenska University Hospital, 
      Goteborg, Sweden.
FAU - Mansson, J E
AU  - Mansson JE
FAU - Blennow, K
AU  - Blennow K
FAU - Jensen, C
AU  - Jensen C
FAU - Samuelsson, L
AU  - Samuelsson L
FAU - Lindberg, C
AU  - Lindberg C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080714
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
RN  - 0 (MAPT protein, human)
RN  - 0 (Peptide Fragments)
RN  - 0 (amyloid beta-protein (1-42))
RN  - 0 (tau Proteins)
SB  - IM
MH  - Adult
MH  - Amyloid beta-Peptides/*cerebrospinal fluid
MH  - Biomarkers/cerebrospinal fluid
MH  - Brain/pathology
MH  - Cerebral Ventricles/pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*cerebrospinal fluid/pathology
MH  - Neuropsychological Tests
MH  - Peptide Fragments/*cerebrospinal fluid
MH  - Phosphorylation
MH  - Protein Processing, Post-Translational
MH  - tau Proteins/*cerebrospinal fluid/chemistry
EDAT- 2008/07/22 09:00
MHDA- 2008/12/23 09:00
CRDT- 2008/07/22 09:00
PHST- 2008/07/22 09:00 [pubmed]
PHST- 2008/12/23 09:00 [medline]
PHST- 2008/07/22 09:00 [entrez]
AID - ENE2217 [pii]
AID - 10.1111/j.1468-1331.2008.02217.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2008 Sep;15(9):947-52. doi: 10.1111/j.1468-1331.2008.02217.x. Epub 
      2008 Jul 14.

PMID- 18611984
OWN - NLM
STAT- MEDLINE
DCOM- 20081210
LR  - 20211203
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 45
IP  - 10
DP  - 2008 Oct
TI  - The CTG repeat expansion size correlates with the splicing defects observed in 
      muscles from myotonic dystrophy type 1 patients.
PG  - 639-46
LID - 10.1136/jmg.2008.058909 [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 is caused by an unstable (CTG)n repetition 
      located in the 3'UTR of the DM protein kinase gene (DMPK). Untranslated expanded 
      DMPK transcripts are retained in ribonuclear foci which sequester CUG-binding 
      proteins essential for the maturation of pre-mRNAs. AIM: To investigate the 
      effects of CTG expansion length on three molecular parameters associated with the 
      DM1 muscle pathology: (1) the expression level of the DMPK gene; (2) the degree 
      of splicing misregulation; and (3) the number of ribonuclear foci. METHODS: 
      Splicing analysis of the IR, MBNL1, c-TNT and CLCN1 genes, RNA-FISH experiments 
      and determination of the DMPK expression on muscle samples from DM1 patients with 
      an expansion below 500 repetitions (n = 6), DM1 patients carrying a mutation 
      above 1000 CTGs (n = 6), and from controls (n = 6). RESULTS: The level of 
      aberrant splicing of the IR, MBNL1, c-TNT and CLCN1 genes is different between 
      the two groups of DM1 muscle samples and correlates with the CTG repeat length. 
      RNA-FISH analysis revealed that the number of ribonuclear foci in DM1 muscle 
      sections increases in patients with a higher (CTG)n number. No relationships were 
      found between the expression level of the DMPK gene transcript and average 
      expansion sizes. CONCLUSION: The CTG repeat length plays a key role in the extent 
      of splicing misregulation and foci formation, thus providing a useful link 
      between the genotype and the molecular cellular phenotype in DM1.
FAU - Botta, A
AU  - Botta A
AD  - Tor Vergata University of Rome, Department of Biopathology, Via Montpellier, 1, 
      00133 Rome, Italy. abottait@yahoo.it
FAU - Rinaldi, F
AU  - Rinaldi F
FAU - Catalli, C
AU  - Catalli C
FAU - Vergani, L
AU  - Vergani L
FAU - Bonifazi, E
AU  - Bonifazi E
FAU - Romeo, V
AU  - Romeo V
FAU - Loro, E
AU  - Loro E
FAU - Viola, A
AU  - Viola A
FAU - Angelini, C
AU  - Angelini C
FAU - Novelli, G
AU  - Novelli G
LA  - eng
GR  - GGP07250/TI_/Telethon/Italy
GR  - GTB07001/TI_/Telethon/Italy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080708
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 0 (DMPK protein, human)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Exons
MH  - Gene Expression
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Muscle, Skeletal/*metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - RNA/metabolism
MH  - *RNA Splicing
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *Trinucleotide Repeat Expansion
EDAT- 2008/07/10 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/07/10 09:00
PHST- 2008/07/10 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/07/10 09:00 [entrez]
AID - jmg.2008.058909 [pii]
AID - 10.1136/jmg.2008.058909 [doi]
PST - ppublish
SO  - J Med Genet. 2008 Oct;45(10):639-46. doi: 10.1136/jmg.2008.058909. Epub 2008 Jul 
      8.

PMID- 18563724
OWN - NLM
STAT- MEDLINE
DCOM- 20080902
LR  - 20211203
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 38
IP  - 1
DP  - 2008 Jul
TI  - Myotonic dystrophy type 1 coexisting with myasthenia gravis and thymoma.
PG  - 916-20
LID - 10.1002/mus.21046 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal-dominant multisystemic disorder 
      that may rarely be associated with benign and malignant neoplasms. Cases of both 
      thymoma and myasthenia gravis in association with DM1 are extremely rare. A 
      literature review revealed only three prior reports. We present a 51-year-old man 
      with a family history of DM1 and fluctuating diplopia and ptosis, who was found 
      to have acetylcholine receptor-binding antibodies, thymoma, and a clinical 
      presentation compatible with ocular myasthenia gravis as well as positive genetic 
      testing for DM1. Needle electromyographic (EMG) study demonstrated diffuse runs 
      of myotonic discharges in multiple muscles, consistent with the diagnosis of DM1. 
      Single-fiber EMG showed both increased jitter and blocking. Due to somatic 
      instability, which has been shown previously in DM1, the myotonin protein kinase 
      (DMPK) gene appears to act as a tumor suppressor. Therefore, abnormal CTG repeat 
      expansions in the gene could lead to the development of thymoma and myasthenia 
      gravis.
CI  - (c) 2008 Wiley Periodicals, Inc.
FAU - Feyma, Timothy
AU  - Feyma T
AD  - Department of Neurology, University of Washington Medical Center, 1959 NE Pacific 
      Street, Seattle, WA 98195, USA.
FAU - Carter, Gregory T
AU  - Carter GT
FAU - Weiss, Michael D
AU  - Weiss MD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (DMPK protein, human)
RN  - 0 (Receptors, Cholinergic)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Action Potentials/physiology
MH  - DNA Repeat Expansion/genetics
MH  - Diplopia/pathology/physiopathology
MH  - Electromyography
MH  - Electrophysiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Motor Neurons/pathology/physiology
MH  - Muscle Fibers, Skeletal/pathology/physiology
MH  - Myasthenia Gravis/*complications/*pathology
MH  - Myotonic Dystrophy/*complications/genetics/*pathology
MH  - Myotonin-Protein Kinase
MH  - Oculomotor Muscles/pathology/physiopathology
MH  - Protein Serine-Threonine Kinases/genetics/metabolism
MH  - Receptors, Cholinergic/biosynthesis/genetics
MH  - Thymoma/*complications/*pathology
MH  - Thymus Neoplasms/*complications/*pathology
EDAT- 2008/06/20 09:00
MHDA- 2008/09/03 09:00
CRDT- 2008/06/20 09:00
PHST- 2008/06/20 09:00 [pubmed]
PHST- 2008/09/03 09:00 [medline]
PHST- 2008/06/20 09:00 [entrez]
AID - 10.1002/mus.21046 [doi]
PST - ppublish
SO  - Muscle Nerve. 2008 Jul;38(1):916-20. doi: 10.1002/mus.21046.

PMID- 18561181
OWN - NLM
STAT- MEDLINE
DCOM- 20080829
LR  - 20090112
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 51
IP  - 4
DP  - 2008 Oct
TI  - Differences in CTG triplet repeat expansion in leukemic cells and normal 
      lymphocytes from a 14-year-old female with congenital myotonic dystrophy.
PG  - 563-5
LID - 10.1002/pbc.21654 [doi]
AB  - We describe a rare case of acute lymphoblastic leukemia in a 14-year-old female 
      with congenital myotonic dystrophy manifested as mental retardation, extensive 
      contractures of multiple joints of the lower extremities, and severe scoliosis. 
      Because of the potential toxicity of chemotherapy and the patient's poor 
      performance status, a modified chemotherapy regimen was administered. Analysis of 
      the greatly expanded number of CTG repeats at the 3' untranslated region of DMPK 
      gene showed that the number of repeats was 233 greater in leukemic cells than in 
      normal lymphocytes; this elongation may have occurred during the cellular 
      proliferation of leukemic clones.
CI  - (c) 2008 Wiley-Liss, Inc.
FAU - Akiyama, Masaharu
AU  - Akiyama M
AD  - Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan. 
      makiyama@jikei.ac.jp
FAU - Yuza, Yuki
AU  - Yuza Y
FAU - Yokokawa, Yuichi
AU  - Yokokawa Y
FAU - Yokoi, Kentaro
AU  - Yokoi K
FAU - Ariga, Masamichi
AU  - Ariga M
FAU - Eto, Yoshikatsu
AU  - Eto Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
SB  - IM
MH  - Adolescent
MH  - Female
MH  - Humans
MH  - Lymphocytes/*metabolism
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications/*genetics
MH  - *Trinucleotide Repeats
EDAT- 2008/06/19 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/06/19 09:00
PHST- 2008/06/19 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/06/19 09:00 [entrez]
AID - 10.1002/pbc.21654 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2008 Oct;51(4):563-5. doi: 10.1002/pbc.21654.

PMID- 18559347
OWN - NLM
STAT- MEDLINE
DCOM- 20081003
LR  - 20211020
IS  - 0021-9258 (Print)
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 283
IP  - 33
DP  - 2008 Aug 15
TI  - The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA 
      in muscle cells: implications for myotonic dystrophy.
PG  - 22457-63
LID - 10.1074/jbc.M802803200 [doi]
AB  - Type I myotonic dystrophy (DM1) is caused by a triplet repeat expansion in the 
      3'-untranslated region (UTR) of the dystrophia myotonia protein kinase (DMPK) 
      gene. Pathogenesis is closely linked with production of a toxic RNA from the 
      mutant allele, which interferes with function of several RNA-binding proteins, 
      including CUGBP1. Here we show that expression of a mutant DMPK 3'-UTR containing 
      960 CUG repeats is sufficient to increase expression and stability of an mRNA 
      encoding the potent proinflammatory cytokine, tumor necrosis factor (TNF). CUGBP1 
      specifically recognizes sequences within the TNF 3'-UTR that are dissimilar from 
      its canonical UG-rich binding site. Depletion of CUGBP1 from mouse myoblasts 
      results in increased abundance of TNF mRNA through stabilization of the 
      transcript. Moreover, activation of the protein kinase C pathway by treatment 
      with phorbol ester, which has been shown previously to result in CUGBP1 
      phosphorylation, also causes TNF mRNA stabilization. Our results suggest that the 
      elevated serum TNF seen in DM1 patients may be derived from muscle where it is 
      induced by expression of toxic DMPK RNA. Importantly, overexpression of this 
      potent cytokine could contribute to the muscle wasting and insulin resistance 
      that are characteristic of this debilitating disease.
FAU - Zhang, Libin
AU  - Zhang L
AD  - Department of Microbiology, Immunology, and Pathology, Colorado State University, 
      Fort Collins, Colorado 80523, USA.
FAU - Lee, Jerome E
AU  - Lee JE
FAU - Wilusz, Jeffrey
AU  - Wilusz J
FAU - Wilusz, Carol J
AU  - Wilusz CJ
LA  - eng
GR  - GM 072481/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080616
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, mouse)
RN  - 0 (DNA Primers)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.13 (Protein Kinase C)
SB  - IM
MH  - Animals
MH  - CELF1 Protein
MH  - Cells, Cultured
MH  - DNA Primers
MH  - Gene Expression Regulation
MH  - Homeostasis
MH  - Humans
MH  - Mice
MH  - Myoblasts/physiology
MH  - Myotonic Dystrophy/*genetics
MH  - Phosphorylation
MH  - Plasmids
MH  - Protein Kinase C/metabolism
MH  - RNA/genetics
MH  - RNA, Messenger/*genetics
MH  - RNA, Small Interfering/genetics
MH  - RNA-Binding Proteins/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transfection
MH  - Tumor Necrosis Factor-alpha/*genetics
PMC - PMC2504872
EDAT- 2008/06/19 09:00
MHDA- 2008/10/04 09:00
PMCR- 2009/08/15
CRDT- 2008/06/19 09:00
PHST- 2008/06/19 09:00 [pubmed]
PHST- 2008/10/04 09:00 [medline]
PHST- 2008/06/19 09:00 [entrez]
PHST- 2009/08/15 00:00 [pmc-release]
AID - S0021-9258(20)74777-0 [pii]
AID - 22457 [pii]
AID - 10.1074/jbc.M802803200 [doi]
PST - ppublish
SO  - J Biol Chem. 2008 Aug 15;283(33):22457-63. doi: 10.1074/jbc.M802803200. Epub 2008 
      Jun 16.

PMID- 18421899
OWN - NLM
STAT- MEDLINE
DCOM- 20080529
LR  - 20211020
IS  - 1128-2460 (Print)
IS  - 1128-2460 (Linking)
VI  - 26
IP  - 2
DP  - 2007 Oct
TI  - Cardiac autonomic nervous system in patients with myotonic dystrophy type 1.
PG  - 112-4
AB  - The purpose of the present study was to evaluate cardiac autonomic nervous system 
      (ANS) in patients with myotonic dystrophy type 1 (DM1). The function of ANS was 
      studied in 20 patients with DM1 and 15 healthy controls. All subjects were 
      investigated by a battery of six cardiovascular autonomic tests and power 
      spectral analysis of heart rate variability (HRV). Only one patient had normal 
      autonomic function. Two (10%) patients had mild, 10 (50%) moderate and 7 (35%) 
      severe autonomic dysfunction. Thirteen (65%) patients had vagal and 4 (20%) 
      sympathetic hyperactivity. Seven (35%) patients had vagal and 15 (75%) 
      sympathetic dysfunction. Eighteen (90%) patients had orthostatic hypotension. The 
      24-hour time domain parameters of SDNN (SD of the NN interval) and total power 
      were significantly lower in DM1 patients than in healthy controls (p < 0.05). 
      However, other parameters of HRV, such as SDANN (SD of the mean NN, 5-minute 
      interval), low frequency (LF), high frequency (HF) power and the LF/HF ratio were 
      somewhat lower in patients with DM1 than in controls, but this was not 
      statistically significant. There was no significant relationship between 
      autonomic dysfunction and the severity of the disease or CTG repeat length. There 
      was also no correlation between HRV and age. Our findings suggest that 
      sympathetic dysfunction and vagal predominance may both occur in patients with 
      DM1.
FAU - Rakocevic-Stojanovic, V
AU  - Rakocevic-Stojanovic V
AD  - Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia. 
      vidosava_r@yahoo.co.uk
FAU - Milovanovic, B
AU  - Milovanovic B
FAU - Ivic, N
AU  - Ivic N
FAU - Ille, T
AU  - Ille T
FAU - Marjanovic, I
AU  - Marjanovic I
FAU - Stevic, Z
AU  - Stevic Z
FAU - Pavlovic, S
AU  - Pavlovic S
FAU - Lavrnic, D
AU  - Lavrnic D
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Acta Myol
JT  - Acta myologica : myopathies and cardiomyopathies : official journal of the 
      Mediterranean Society of Myology
JID - 9811169
SB  - IM
MH  - Adult
MH  - Autonomic Nervous System/*physiopathology
MH  - Autonomic Nervous System Diseases/*diagnosis/physiopathology
MH  - Case-Control Studies
MH  - Female
MH  - Heart/*innervation
MH  - *Heart Rate
MH  - Humans
MH  - Hypotension, Orthostatic/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*physiopathology
MH  - Sympathetic Nervous System/physiopathology
MH  - Vagus Nerve/physiopathology
PMC - PMC2949576
EDAT- 2008/04/22 09:00
MHDA- 2008/05/30 09:00
PMCR- 2007/10/01
CRDT- 2008/04/22 09:00
PHST- 2008/04/22 09:00 [pubmed]
PHST- 2008/05/30 09:00 [medline]
PHST- 2008/04/22 09:00 [entrez]
PHST- 2007/10/01 00:00 [pmc-release]
PST - ppublish
SO  - Acta Myol. 2007 Oct;26(2):112-4.

PMID- 18418692
OWN - NLM
STAT- MEDLINE
DCOM- 20090515
LR  - 20211020
IS  - 1473-4230 (Electronic)
IS  - 1473-4222 (Linking)
VI  - 7
IP  - 2
DP  - 2008
TI  - Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes.
PG  - 150-8
LID - 10.1007/s12311-008-0010-7 [doi]
AB  - Spinocerebellar ataxia type 8 (SCA8) is a dominantly inherited, slowly 
      progressive neurodegenerative disorder caused by a CTG.CAG repeat expansion 
      located on chromosome 13q21. The expansion mutation was isolated directly from 
      the DNA of a single patient using RAPID cloning and subsequently shown to 
      co-segregate with disease in additional ataxia families including a 
      seven-generation kindred (the MN-A family). The size-dependent penetrance of the 
      repeat found in the large MN-A kindred makes it appear as though some parts of 
      the family have a dominant disorder while other parts of this same family have 
      recessive or sporadic forms of ataxia. While the linkage and size-dependent 
      penetrance of the SCA8 CTG.CAG expansion in the MN-A family argue that the SCA8 
      expansion causes ataxia, the reduced penetrance in other SCA8 families and the 
      discovery of expansions in the general population have led to a controversy 
      surrounding whether or not the SCA8 expansion is pathogenic. A recently reported 
      mouse model in which SCA8 BAC-expansion but not BAC-control lines develop a 
      progressive neurological phenotype now demonstrates the pathogenicity of the 
      (CTG.CAG)(n) expansion. These mice show a loss of cerebellar GABAergic inhibition 
      and, similar to human patients, have 1C2-positive intranuclear inclusions in 
      Purkinje cells and other neurons. Additional studies demonstrate that the SCA8 
      expansion is expressed in both directions (CUG and CAG) and that a novel gene 
      expressed in the CAG direction encodes a pure polyglutamine expansion protein 
      (ataxin 8, ATXN8). Moreover, the expression of non-coding (CUG)(n) expansion 
      transcripts (ataxin 8 opposite strand, ATXN8OS) and the discovery of intranuclear 
      polyglutamine inclusions suggest SCA8 pathogenesis may involve toxic 
      gain-of-function mechanisms at both the protein and RNA levels. Our data, 
      combined with the recently reported antisense transcripts spanning the DM1 repeat 
      expansion in the CAG direction and the growing number of reports of antisense 
      transcripts expressed throughout the mammalian genome, raises the possibility 
      that bidirectional expression across pathogenic microsatellite expansions may 
      occur in other expansion disorders, and that potential pathogenic effects of 
      mutations expressed from both strands should be considered.
FAU - Ikeda, Yoshio
AU  - Ikeda Y
AD  - Department of Genetics, Cell Biology, and Development, University of Minnesota, 
      Minneapolis, MN 55455, USA.
FAU - Daughters, Randy S
AU  - Daughters RS
FAU - Ranum, Laura P W
AU  - Ranum LP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cerebellum
JT  - Cerebellum (London, England)
JID - 101089443
RN  - 0 (ATXN8 protein, human)
RN  - 0 (ATXN8OS gene product, human)
RN  - 0 (DNA, Complementary)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Peptides)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (RNA, Untranslated)
RN  - 26700-71-0 (polyglutamine)
SB  - IM
MH  - Animals
MH  - Brain/pathology
MH  - Chromosome Mapping
MH  - DNA, Complementary/genetics
MH  - Genes, Dominant
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Mice
MH  - *Mutation
MH  - Nerve Tissue Proteins/*genetics
MH  - Neurons/physiology
MH  - Peptides/*genetics
MH  - RNA, Long Noncoding
MH  - RNA, Untranslated
MH  - Reference Values
MH  - Spinocerebellar Ataxias/*genetics/pathology
MH  - Transcription, Genetic
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2008/04/18 09:00
MHDA- 2009/05/16 09:00
CRDT- 2008/04/18 09:00
PHST- 2008/04/18 09:00 [pubmed]
PHST- 2009/05/16 09:00 [medline]
PHST- 2008/04/18 09:00 [entrez]
AID - 10.1007/s12311-008-0010-7 [doi]
PST - ppublish
SO  - Cerebellum. 2008;7(2):150-8. doi: 10.1007/s12311-008-0010-7.

PMID- 18337099
OWN - NLM
STAT- MEDLINE
DCOM- 20080813
LR  - 20080428
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 18
IP  - 4
DP  - 2008 Apr
TI  - Familial aggregation of white matter lesions in myotonic dystrophy type 1.
PG  - 299-305
LID - 10.1016/j.nmd.2008.01.008 [doi]
AB  - This study aimed to determine whether white matter lesions, previously described 
      as a frequent feature in myotonic dystrophy type 1 (DM1), aggregate within DM1 
      families or are sporadic findings, and to explore the relationship between these 
      lesions and clinical or genetic features. Brain MRI of 60 DM1 patients belonging 
      to 22 families were evaluated and white matter lesions were rated according to a 
      semiquantitative method. Presence and extent of lobar, temporal or 
      periventricular lesions showed a significant association with the family history 
      of lesions and the disease duration, and no association with the CTG repeat size. 
      Furthermore, parent-offspring and sibling pairs showed a significant positive 
      concordance for lesion severity. White matter lesions demonstrate familial 
      aggregation in DM1 and no relationship with CTG repeat length. These findings 
      suggest that other genetic causes and/or unknown environmental factors influence 
      the occurrence and severity of lesions in patients carrying the DM1 genetic 
      defect.
FAU - Di Costanzo, Alfonso
AU  - Di Costanzo A
AD  - Department of Health Sciences, University of Molise, Via Giovanni Paolo II, 86100 
      Campobasso, Italy. alfonso.dicostanzo@unimol.it
FAU - Santoro, Lucio
AU  - Santoro L
FAU - de Cristofaro, Mario
AU  - de Cristofaro M
FAU - Manganelli, Fiore
AU  - Manganelli F
FAU - Di Salle, Francesco
AU  - Di Salle F
FAU - Tedeschi, Gioacchino
AU  - Tedeschi G
LA  - eng
PT  - Journal Article
DEP - 20080311
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - *Family Health
MH  - Female
MH  - Humans
MH  - Imaging, Three-Dimensional/methods
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/genetics/*pathology
MH  - Nerve Tissue/*pathology
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 2008/03/14 09:00
MHDA- 2008/08/14 09:00
CRDT- 2008/03/14 09:00
PHST- 2007/10/28 00:00 [received]
PHST- 2008/01/12 00:00 [revised]
PHST- 2008/01/30 00:00 [accepted]
PHST- 2008/03/14 09:00 [pubmed]
PHST- 2008/08/14 09:00 [medline]
PHST- 2008/03/14 09:00 [entrez]
AID - S0960-8966(08)00026-6 [pii]
AID - 10.1016/j.nmd.2008.01.008 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2008 Apr;18(4):299-305. doi: 10.1016/j.nmd.2008.01.008. Epub 
      2008 Mar 11.

PMID- 18299519
OWN - NLM
STAT- MEDLINE
DCOM- 20080307
LR  - 20080226
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 70
IP  - 9
DP  - 2008 Feb 26
TI  - Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic 
      dystrophy type 1.
PG  - 677-85
LID - 10.1212/01.wnl.0000302174.08951.cf [doi]
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by 
      a CTG repeat expansion in the DMPK gene. Aberrant messenger RNA (mRNA) splicing 
      of several genes has been reported to explain some of the symptoms in DM1, but 
      the cause of muscle wasting is still unknown. By contrast, many forms of muscular 
      dystrophy are caused by abnormalities of the dystrophin-glycoprotein complex 
      (DGC). alpha-Dystrobrevin is a key component of the DGC in striated muscle and 
      plays important roles in maturation and signal transduction by interacting with 
      alpha-syntrophin. The goal of this study was to investigate alternative splicing 
      of alpha-dystrobrevin in DM1 and examine alpha-syntrophin binding of different 
      alpha-dystrobrevin splice isoforms. METHODS: Splicing patterns of 
      alpha-dystrobrevin in DM1 muscle were studied by reverse-transcriptase PCR. 
      Expression of the variant splice isoform was examined by immunoblotting and 
      immunohistochemistry. Alternatively spliced isoforms were expressed in cultured 
      cells to investigate interaction with alpha-syntrophin. alpha-Syntrophin 
      expression was examined by immunoblotting. RESULTS: alpha-Dystrobrevin mRNA 
      including exons 11A and 12 was increased in both skeletal and cardiac muscle of 
      DM1 patients. The aberrantly spliced alpha-dystrobrevin isoform was localized to 
      the sarcolemma, and showed increased binding with alpha-syntrophin. Furthermore, 
      levels of alpha-syntrophin associated with the DGC were increased in DM1 muscle. 
      CONCLUSION: Alternative splicing of alpha-dystrobrevin is dysregulated in 
      myotonic dystrophy type 1 (DM1) muscle, resulting in changes in alpha-syntrophin 
      binding. These results raise the possibility that effects on alpha-dystrobrevin 
      splicing may influence signaling in DM1 muscle cells.
FAU - Nakamori, M
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, Osaka, 
      Japan.
FAU - Kimura, T
AU  - Kimura T
FAU - Kubota, T
AU  - Kubota T
FAU - Matsumura, T
AU  - Matsumura T
FAU - Sumi, H
AU  - Sumi H
FAU - Fujimura, H
AU  - Fujimura H
FAU - Takahashi, M P
AU  - Takahashi MP
FAU - Sakoda, S
AU  - Sakoda S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Dystrophin-Associated Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (dystrobrevin)
RN  - 0 (syntrophin alpha1)
SB  - IM
MH  - Age Factors
MH  - Alternative Splicing/*genetics
MH  - Animals
MH  - Calcium-Binding Proteins/genetics
MH  - Cell Line
MH  - Dystrophin-Associated Proteins/*genetics
MH  - Exons/genetics
MH  - Membrane Proteins/genetics
MH  - Mice
MH  - Mice, Transgenic
MH  - Motor Neuron Disease/genetics/pathology
MH  - Muscle Proteins/genetics
MH  - Muscle, Skeletal/pathology
MH  - Muscular Dystrophies, Limb-Girdle/genetics/pathology
MH  - Myocardium/pathology
MH  - Myotonic Dystrophy/diagnosis/*genetics/pathology
MH  - Polymyositis/genetics/pathology
MH  - RNA Splicing/*genetics
MH  - Reference Values
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sarcolemma/pathology
MH  - Species Specificity
MH  - Transcription, Genetic/genetics
MH  - Transfection
MH  - Trinucleotide Repeats
EDAT- 2008/02/27 09:00
MHDA- 2008/03/08 09:00
CRDT- 2008/02/27 09:00
PHST- 2008/02/27 09:00 [pubmed]
PHST- 2008/03/08 09:00 [medline]
PHST- 2008/02/27 09:00 [entrez]
AID - 70/9/677 [pii]
AID - 10.1212/01.wnl.0000302174.08951.cf [doi]
PST - ppublish
SO  - Neurology. 2008 Feb 26;70(9):677-85. doi: 10.1212/01.wnl.0000302174.08951.cf.

PMID- 18279373
OWN - NLM
STAT- MEDLINE
DCOM- 20080624
LR  - 20111117
IS  - 1744-313X (Electronic)
IS  - 1744-3121 (Linking)
VI  - 35
IP  - 2
DP  - 2008 Apr
TI  - HLA DRB1, DQB1 and insulin promoter VNTR polymorphisms: interactions and the 
      association with adult-onset diabetes mellitus in Czech patients.
PG  - 133-40
LID - 10.1111/j.1744-313X.2008.00749.x [doi]
AB  - Both the human leucocyte antigen (HLA) DRB1 and the HLA DQB1 gene loci play a 
      role in the development and progression of autoimmune diabetes mellitus (T1DM). 
      Similarly, the insulin promoter variable number tandem repeats (INS-VNTR) 
      polymorphism is also involved in the pathogenesis of diabetes mellitus (DM). We 
      studied the association between each of these polymorphisms and DM diagnosed in 
      patients older than age 35 years. Furthermore, we analysed possible interactions 
      between HLA DRB1/DQB1 and INS-VNTR polymorphisms. Based on C-peptide and GADA 
      levels we were able to distinguish three types of diabetes: T1DM, latent 
      autoimmune diabetes in adults (LADA) and T2DM. INS-VNTR was genotyped indirectly 
      by typing INS-23HphI A/T polymorphism. The genotype and allele frequencies of 
      INS-23HphI did not differ between each of the diabetic groups and group of 
      healthy subjects. We did, however, observe an association between the INS-23HphI 
      alleles, genotypes and C-peptide secretion in all diabetic patients: A allele 
      frequency was 86.2% in the C-peptide-negative group vs. 65.4% in the 
      C-peptide-positive group (P(corr.) < 0.005); AA genotype was found to be 72.4% in 
      the C-peptide-negative group vs. 42.6% in the C-peptide-positive groups (P(corr.) 
      < 0.01). The HLA genotyping revealed a significantly higher frequency of HLA 
      DRB1*03 allele in both T1DM and LADA groups when compared to healthy subjects: 
      T1DM (25.7%) vs. control group (10.15%), odds ratio (OR) = 3.06, P < 0.05; LADA 
      (27.6%) vs. control (10.15%), OR = 3.37, P < 0.01. The simultaneous presence of 
      both HLA DRB1*04 and INS-23HphI AA genotype was detected in 37.5% of the T1DM 
      group compared to only 9.2% of the healthy individuals group (OR = 5.9, P(corr.) 
      < 0.007). We summarize that in the Central Bohemian population of the Czech 
      Republic, the INS-23HphI A allele appears to be associated with a decrease in 
      pancreatic beta cell secretory activity. HLA genotyping points to at least a 
      partial difference in mechanism, which leads to T1DM and LADA development as well 
      as a more diverse genetic predisposition in juvenile- and adult-onset diabetes. 
      The simultaneous effect of HLA and INS-VNTR alleles/genotypes predispose 
      individuals to an increased risk of diabetes development.
FAU - Cejkova, P
AU  - Cejkova P
AD  - Department of Cell and Molecular Biology, Third Faculty of Medicine, Charles 
      University, Prague, Czech Republic. Pavlina.Cejkova@lf3.cuni.cz
FAU - Novota, P
AU  - Novota P
FAU - Cerna, M
AU  - Cerna M
FAU - Kolostova, K
AU  - Kolostova K
FAU - Novakova, D
AU  - Novakova D
FAU - Kucera, P
AU  - Kucera P
FAU - Novak, J
AU  - Novak J
FAU - Andel, M
AU  - Andel M
FAU - Weber, P
AU  - Weber P
FAU - Zdarsky, E
AU  - Zdarsky E
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20080211
PL  - England
TA  - Int J Immunogenet
JT  - International journal of immunogenetics
JID - 101232337
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Alleles
MH  - Czech Republic
MH  - Diabetes Mellitus, Type 1/*genetics/immunology
MH  - Female
MH  - Gene Frequency/genetics/immunology
MH  - Genetic Predisposition to Disease
MH  - HLA-DQ Antigens/*genetics/immunology
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/*genetics/immunology
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Insulin/*genetics/immunology
MH  - Male
MH  - Middle Aged
MH  - Minisatellite Repeats/*genetics/immunology
MH  - *Polymorphism, Genetic
MH  - Promoter Regions, Genetic/*genetics/immunology
MH  - Risk Factors
EDAT- 2008/02/19 09:00
MHDA- 2008/06/25 09:00
CRDT- 2008/02/19 09:00
PHST- 2008/02/19 09:00 [pubmed]
PHST- 2008/06/25 09:00 [medline]
PHST- 2008/02/19 09:00 [entrez]
AID - EJI749 [pii]
AID - 10.1111/j.1744-313X.2008.00749.x [doi]
PST - ppublish
SO  - Int J Immunogenet. 2008 Apr;35(2):133-40. doi: 10.1111/j.1744-313X.2008.00749.x. 
      Epub 2008 Feb 11.

PMID- 18228241
OWN - NLM
STAT- MEDLINE
DCOM- 20081204
LR  - 20220330
IS  - 1552-485X (Electronic)
IS  - 1552-4841 (Linking)
VI  - 147B
IP  - 6
DP  - 2008 Sep 5
TI  - Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 
      individuals with congenital and childhood forms.
PG  - 918-26
LID - 10.1002/ajmg.b.30698 [doi]
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an 
      expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study 
      were to classify a cohort of children with DM1, to describe their 
      neuropsychiatric problems and cognitive level, to estimate the size of the CTG 
      expansion, and to correlate the molecular findings with the neuropsychiatric 
      problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 
      (CTG repeats > 40) were included in the study. The following instruments were 
      used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental 
      Development Scales, and the Wechsler Scales. Based on age at onset and presenting 
      symptoms, the children were divided into four DM1 groups; severe congenital (n = 
      19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). 
      Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder 
      was the most common diagnosis present in 35% of the subjects. Eighty-six percent 
      of the individuals with DM1 had mental retardation (MR), most of them moderate or 
      severe MR. ASD was significantly correlated with the DM1 form; the more severe 
      the form of DM1, the higher the frequency of ASD. The frequency of ASD increased 
      with increasing CTG repeat expansions. ASD and/or other neuropsychiatric 
      disorders such as attention deficit hyperactivity disorder, and Tourette's 
      disorder were found in 54% of the total DM1 group. In conclusion, awareness of 
      ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate 
      the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in 
      DM1.
CI  - 2008 Wiley-Liss, Inc.
FAU - Ekstrom, Anne-Berit
AU  - Ekstrom AB
AD  - Department of Pediatrics, Northern Alvsborg County Hospital, Trollhattan, Sweden. 
      anne-berit.ekstrom@vgregion.se
FAU - Hakenas-Plate, Louise
AU  - Hakenas-Plate L
FAU - Samuelsson, Lena
AU  - Samuelsson L
FAU - Tulinius, Mar
AU  - Tulinius M
FAU - Wentz, Elisabet
AU  - Wentz E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the 
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Algorithms
MH  - Autistic Disorder/classification/diagnosis/epidemiology/*genetics
MH  - Child
MH  - Child, Preschool
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Inheritance Patterns
MH  - Intelligence/genetics/physiology
MH  - Male
MH  - Mental Disorders/epidemiology/genetics/physiopathology
MH  - Mental Processes/physiology
MH  - Myotonic Disorders/congenital/diagnosis/epidemiology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion/physiology
EDAT- 2008/01/30 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/01/30 09:00
PHST- 2008/01/30 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/01/30 09:00 [entrez]
AID - 10.1002/ajmg.b.30698 [doi]
PST - ppublish
SO  - Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):918-26. doi: 
      10.1002/ajmg.b.30698.

PMID- 18213375
OWN - NLM
STAT- MEDLINE
DCOM- 20080808
LR  - 20211020
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 3
IP  - 1
DP  - 2008 Jan 23
TI  - Repeat length and RNA expression level are not primary determinants in CUG 
      expansion toxicity in Drosophila models.
PG  - e1466
LID - 10.1371/journal.pone.0001466 [doi]
LID - e1466
AB  - Evidence for an RNA gain-of-function toxicity has now been provided for an 
      increasing number of human pathologies. Myotonic dystrophies (DM) belong to a 
      class of RNA-dominant diseases that result from RNA repeat expansion toxicity. 
      Specifically, DM of type 1 (DM1), is caused by an expansion of CUG repeats in the 
      3'UTR of the DMPK protein kinase mRNA, while DM of type 2 (DM2) is linked to an 
      expansion of CCUG repeats in an intron of the ZNF9 transcript (ZNF9 encodes a 
      zinc finger protein). In both pathologies the mutant RNA forms nuclear foci. The 
      mechanisms that underlie the RNA pathogenicity seem to be rather complex and not 
      yet completely understood. Here, we describe Drosophila models that might help 
      unravelling the molecular mechanisms of DM1-associated CUG expansion toxicity. We 
      generated transgenic flies that express inducible repeats of different type (CUG 
      or CAG) and length (16, 240, 480 repeats) and then analyzed transgene 
      localization, RNA expression and toxicity as assessed by induced lethality and 
      eye neurodegeneration. The only line that expressed a toxic RNA has a (CTG)(240) 
      insertion. Moreover our analysis shows that its level of expression cannot 
      account for its toxicity. In this line, (CTG)(240.4), the expansion inserted in 
      the first intron of CG9650, a zinc finger protein encoding gene. Interestingly, 
      CG9650 and (CUG)(240.4) expansion RNAs were found in the same nuclear foci. In 
      conclusion, we suggest that the insertion context is the primary determinant for 
      expansion toxicity in Drosophila models. This finding should contribute to the 
      still open debate on the role of the expansions per se in Drosophila and in human 
      pathogenesis of RNA-dominant diseases.
FAU - Le Mee, Gwenn
AU  - Le Mee G
AD  - Institut de Genetique Humaine, Unite Propre de Recherche 1142, Centre National de 
      la Recherche Scientifique, Montpellier, France.
FAU - Ezzeddine, Nader
AU  - Ezzeddine N
FAU - Capri, Michele
AU  - Capri M
FAU - Ait-Ahmed, Ounissa
AU  - Ait-Ahmed O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080123
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Cloning, Molecular
MH  - Drosophila
MH  - In Situ Hybridization, Fluorescence
MH  - *Models, Biological
MH  - RNA/*genetics
MH  - *Trinucleotide Repeats
PMC - PMC2186381
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2008/01/24 09:00
MHDA- 2008/08/09 09:00
PMCR- 2008/01/23
CRDT- 2008/01/24 09:00
PHST- 2007/10/23 00:00 [received]
PHST- 2007/12/19 00:00 [accepted]
PHST- 2008/01/24 09:00 [pubmed]
PHST- 2008/08/09 09:00 [medline]
PHST- 2008/01/24 09:00 [entrez]
PHST- 2008/01/23 00:00 [pmc-release]
AID - 07-PONE-RA-02567R1 [pii]
AID - 10.1371/journal.pone.0001466 [doi]
PST - epublish
SO  - PLoS One. 2008 Jan 23;3(1):e1466. doi: 10.1371/journal.pone.0001466.

PMID- 18184345
OWN - NLM
STAT- MEDLINE
DCOM- 20080303
LR  - 20211203
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 117
IP  - 2
DP  - 2008 Feb
TI  - Correlation among subcortical white matter lesions, intelligence and CTG repeat 
      expansion in classic myotonic dystrophy type 1.
PG  - 101-7
LID - 10.1111/j.1600-0404.2007.00911.x [doi]
AB  - OBJECTIVES: To analyze the correlation among intelligence, brain magnetic 
      resonance images (MRI) and genotype in classic myotonic dystrophy type 1 (DM1) 
      patients. MATERIALS AND METHODS: Seventeen patients with classic DM1 were 
      administered intelligence and neuropsychological tests and brain MRI focusing on 
      a semi-quantitative rating scale of subcortical white matter lesions (WMLs). 
      Statistical analysis was measured to evaluate the correlation among clinical 
      manifestations, intelligence, brain MRI abnormalities, and CTG repeat expansion. 
      RESULTS: There were statistically significant correlations between intelligence 
      test and insular WMLs for all DM1 patients and between intelligence quotient and 
      temporal WMLs for those patients with less than 400 of the CTG repeat size. We 
      also documented that temporal WMLs were related to the disease course, and 
      frontal WMLs were correlated with aging in all DM1 patients. However, a poor 
      correlation was found among CTG repeat size and clinical pictures, 
      neuropsychological impairments, and brain MRI abnormalities in all DM1 patients. 
      CONCLUSION: These results suggest that subcortical WMLs are correlated with focal 
      dementia in classic DM1 patients. Temporal and insular WMLs may be responsible 
      for the global intellectual dysfunction of adult DM1 patients.
FAU - Kuo, H-C
AU  - Kuo HC
AD  - Department of Neurology, Chang Gung Memorial Hospital and College of Medicine, 
      Chang Gung University, Taipei, Taiwan.
FAU - Hsieh, Y-C
AU  - Hsieh YC
FAU - Wang, H-M
AU  - Wang HM
FAU - Chuang, W-L
AU  - Chuang WL
FAU - Huang, C-C
AU  - Huang CC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brain/*pathology
MH  - Female
MH  - Humans
MH  - Intelligence/*physiology
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Middle Aged
MH  - *Myotonic Dystrophy/genetics/pathology/physiopathology
MH  - Myotonin-Protein Kinase
MH  - Neuroglia/*pathology
MH  - Neuropsychological Tests/statistics & numerical data
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Statistics, Nonparametric
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2008/01/11 09:00
MHDA- 2008/03/04 09:00
CRDT- 2008/01/11 09:00
PHST- 2008/01/11 09:00 [pubmed]
PHST- 2008/03/04 09:00 [medline]
PHST- 2008/01/11 09:00 [entrez]
AID - ANE911 [pii]
AID - 10.1111/j.1600-0404.2007.00911.x [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2008 Feb;117(2):101-7. doi: 10.1111/j.1600-0404.2007.00911.x.

PMID- 18177861
OWN - NLM
STAT- MEDLINE
DCOM- 20080620
LR  - 20220330
IS  - 0014-4886 (Print)
IS  - 0014-4886 (Linking)
VI  - 210
IP  - 2
DP  - 2008 Apr
TI  - Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 
      brain: two individual consequences of CUG trinucleotide repeats.
PG  - 467-78
LID - 10.1016/j.expneurol.2007.11.020 [doi]
AB  - Neurofibrillary degeneration is often observed in the brain of patients with type 
      1 myotonic dystrophy (DM1). It consists principally of the aggregation of Tau 
      isoforms that lack exon 2/3 encoded sequences, and is the consequence of the 
      modified splicing of Tau pre-mRNA. In experimental models of DM1, the splicing of 
      several transcripts is modified due to the loss of Muscleblind-like 1 (MBNL1) 
      function. In the present study, we demonstrate that the MBNL1 protein is also 
      present in the human brain, and consists of several isoforms, as shown by RT-PCR 
      and sequencing. In comparison with controls, we show that the adult DM1 brain 
      exhibits modifications in the splicing of MBNL1, with the preferential expression 
      of long MBNL1 isoforms--a splicing pattern similar to that seen in the fetal 
      human brain. In cultured HeLa cells, the presence of long CUG repeats, such as 
      those found in the DM1 mutation, leads to similar changes in the splicing pattern 
      of MBNL1, and the localization of MBNL1 in nuclear RNA foci. Long CUG repeats 
      also reproduce the repression of Tau exon 2/3 inclusion, as in the human disease, 
      suggesting that their effect on MBNL1 expression may lead to changes in Tau 
      splicing. However, while an overall reduction in the expression of MBNL1 mimics 
      the effect of the DM1 mutation, none of the MBNL1 isoforms tested so far 
      modulates the endogenous splicing of Tau. The modified splicing of Tau thus 
      results from a possibly CUG-mediated loss of function of MBNL1, but not from 
      changes in the MBNL1 expression pattern.
FAU - Dhaenens, C M
AU  - Dhaenens CM
AD  - Inserm, U837, place de Verdun, 59045 Lille, France.
FAU - Schraen-Maschke, S
AU  - Schraen-Maschke S
FAU - Tran, H
AU  - Tran H
FAU - Vingtdeux, V
AU  - Vingtdeux V
FAU - Ghanem, D
AU  - Ghanem D
FAU - Leroy, O
AU  - Leroy O
FAU - Delplanque, J
AU  - Delplanque J
FAU - Vanbrussel, E
AU  - Vanbrussel E
FAU - Delacourte, A
AU  - Delacourte A
FAU - Vermersch, P
AU  - Vermersch P
FAU - Maurage, C A
AU  - Maurage CA
FAU - Gruffat, H
AU  - Gruffat H
FAU - Sergeant, A
AU  - Sergeant A
FAU - Mahadevan, M S
AU  - Mahadevan MS
FAU - Ishiura, S
AU  - Ishiura S
FAU - Buee, L
AU  - Buee L
FAU - Cooper, T A
AU  - Cooper TA
FAU - Caillet-Boudin, M L
AU  - Caillet-Boudin ML
FAU - Charlet-Berguerand, N
AU  - Charlet-Berguerand N
FAU - Sablonniere, B
AU  - Sablonniere B
FAU - Sergeant, N
AU  - Sergeant N
LA  - eng
GR  - R01 HL045565/HL/NHLBI NIH HHS/United States
GR  - AR 45653/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20071204
PL  - United States
TA  - Exp Neurol
JT  - Experimental neurology
JID - 0370712
RN  - 0 (MBNL1 protein, human)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (tau Proteins)
RN  - 147336-22-9 (Green Fluorescent Proteins)
SB  - IM
MH  - Adult
MH  - *Alternative Splicing
MH  - Animals
MH  - Brain/*metabolism
MH  - COS Cells
MH  - Chlorocebus aethiops
MH  - Cloning, Molecular/methods
MH  - Fetus
MH  - Gene Expression Regulation
MH  - Green Fluorescent Proteins/genetics/metabolism
MH  - HeLa Cells
MH  - Humans
MH  - Middle Aged
MH  - *Myotonic Dystrophy/genetics/metabolism/pathology
MH  - Protein Isoforms/genetics/metabolism
MH  - RNA-Binding Proteins/*metabolism
MH  - Transfection/methods
MH  - *Trinucleotide Repeats
MH  - tau Proteins/*metabolism
EDAT- 2008/01/08 09:00
MHDA- 2008/06/21 09:00
CRDT- 2008/01/08 09:00
PHST- 2007/08/06 00:00 [received]
PHST- 2007/11/15 00:00 [revised]
PHST- 2007/11/16 00:00 [accepted]
PHST- 2008/01/08 09:00 [pubmed]
PHST- 2008/06/21 09:00 [medline]
PHST- 2008/01/08 09:00 [entrez]
AID - S0014-4886(07)00436-0 [pii]
AID - 10.1016/j.expneurol.2007.11.020 [doi]
PST - ppublish
SO  - Exp Neurol. 2008 Apr;210(2):467-78. doi: 10.1016/j.expneurol.2007.11.020. Epub 
      2007 Dec 4.

PMID- 17987120
OWN - NLM
STAT- MEDLINE
DCOM- 20080821
LR  - 20211203
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 2
IP  - 11
DP  - 2007 Nov 7
TI  - Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and 
      muscle insulin action.
PG  - e1134
LID - e1134
AB  - Myotonic dystrophy 1 (DM1) is caused by a CTG expansion in the 3'-unstranslated 
      region of the DMPK gene, which encodes a serine/threonine protein kinase. One of 
      the common clinical features of DM1 patients is insulin resistance, which has 
      been associated with a pathogenic effect of the repeat expansions. Here we show 
      that DMPK itself is a positive modulator of insulin action. DMPK-deficient 
      (dmpk-/-) mice exhibit impaired insulin signaling in muscle tissues but not in 
      adipocytes and liver, tissues in which DMPK is not expressed. Dmpk-/- mice 
      display metabolic derangements such as abnormal glucose tolerance, reduced 
      glucose uptake and impaired insulin-dependent GLUT4 trafficking in muscle. Using 
      DMPK mutants, we show that DMPK is required for a correct intracellular 
      trafficking of insulin and IGF-1 receptors, providing a mechanism to explain the 
      molecular and metabolic phenotype of dmpk-/- mice. Taken together, these findings 
      indicate that reduced DMPK expression may directly influence the onset of 
      insulin-resistance in DM1 patients and point to dmpk as a new candidate gene for 
      susceptibility to type 2-diabetes.
FAU - Llagostera, Esther
AU  - Llagostera E
AD  - Departament de Bioquimica i Biologia Molecular, Facultat de Biologia, Universitat 
      de Barcelona, Barcelona, Spain.
FAU - Catalucci, Daniele
AU  - Catalucci D
FAU - Marti, Luc
AU  - Marti L
FAU - Liesa, Marc
AU  - Liesa M
FAU - Camps, Marta
AU  - Camps M
FAU - Ciaraldi, Theodore P
AU  - Ciaraldi TP
FAU - Kondo, Richard
AU  - Kondo R
FAU - Reddy, Sita
AU  - Reddy S
FAU - Dillmann, Wolfgang H
AU  - Dillmann WH
FAU - Palacin, Manuel
AU  - Palacin M
FAU - Zorzano, Antonio
AU  - Zorzano A
FAU - Ruiz-Lozano, Pilar
AU  - Ruiz-Lozano P
FAU - Gomis, Ramon
AU  - Gomis R
FAU - Kaliman, Perla
AU  - Kaliman P
LA  - eng
GR  - R01 HL065484/HL/NHLBI NIH HHS/United States
GR  - R56 HL065484/HL/NHLBI NIH HHS/United States
GR  - HL065484/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20071107
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Insulin)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Glucose/*metabolism
MH  - *Homeostasis
MH  - Insulin/*physiology
MH  - Mice
MH  - Muscle, Skeletal/*metabolism
MH  - Myocardium/*metabolism
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - Receptor, Insulin/metabolism
PMC - PMC2043489
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2007/11/08 09:00
MHDA- 2008/08/22 09:00
PMCR- 2007/11/07
CRDT- 2007/11/08 09:00
PHST- 2007/08/09 00:00 [received]
PHST- 2007/10/14 00:00 [accepted]
PHST- 2007/11/08 09:00 [pubmed]
PHST- 2008/08/22 09:00 [medline]
PHST- 2007/11/08 09:00 [entrez]
PHST- 2007/11/07 00:00 [pmc-release]
AID - 07-PONE-RA-01964 [pii]
AID - 10.1371/journal.pone.0001134 [doi]
PST - epublish
SO  - PLoS One. 2007 Nov 7;2(11):e1134. doi: 10.1371/journal.pone.0001134.

PMID- 17950578
OWN - NLM
STAT- MEDLINE
DCOM- 20080214
LR  - 20211203
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1772
IP  - 11-12
DP  - 2007 Dec
TI  - DM1 CTG expansions affect insulin receptor isoforms expression in various tissues 
      of transgenic mice.
PG  - 1183-91
AB  - Myotonic dystrophy (DM1) is a dominant autosomal multisystemic disorder caused by 
      the expansion of an unstable CTG trinucleotide repeat in the 3' untranslated 
      region of the DMPK gene. Nuclear accumulation of the enlarged CUG-containing DMPK 
      transcripts has a deleterious effect on the regulation of alternative splicing of 
      some RNAs and has a central role in causing the symptoms of DM1. In particular, 
      Insulin Receptor (IR) mRNA splicing defects have been observed in the muscle of 
      DM1 patients. In this study, we have investigated IR splicing in 
      insulin-responsive tissues (i.e. skeletal muscles, adipose tissue, liver) and 
      pancreas and we have studied glucose metabolism in mice carrying the human 
      genomic DM1 region with expanded (>350 CTG) or normal (20 CTG) repeats and in 
      wild-type mice. Mice carrying DM1 expansions displayed a tissue- and 
      age-dependent abnormal regulation of IR mRNA splicing in all the tissues that we 
      investigated. Furthermore, these mice showed a basal hyperglycemia and glucose 
      intolerance which disappeared with age. Our findings show that deregulation of IR 
      splicing due to the DM1 mutation can occur in different mouse tissues, suggesting 
      that CTG repeat expansions might also result in IR misplicing not only in muscles 
      but also in other tissues in DM1 patients.
FAU - Guiraud-Dogan, Celine
AU  - Guiraud-Dogan C
AD  - INSERM, U781, Hopital Necker-Enfants Malades, Universite Rene Descartes Paris V, 
      149 rue de Sevres, 75743 Paris cedex 15, France.
FAU - Huguet, Aline
AU  - Huguet A
FAU - Gomes-Pereira, Mario
AU  - Gomes-Pereira M
FAU - Brisson, Edith
AU  - Brisson E
FAU - Bassez, Guillaume
AU  - Bassez G
FAU - Junien, Claudine
AU  - Junien C
FAU - Gourdon, Genevieve
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070915
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Insulin)
RN  - 0 (Mutant Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aging
MH  - Alternative Splicing/genetics
MH  - Animals
MH  - Gene Expression Profiling
MH  - Glucose/metabolism
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hypothalamus/metabolism
MH  - Insulin/metabolism
MH  - Insulin Secretion
MH  - Mice
MH  - Mice, Transgenic
MH  - Mutant Proteins/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Organ Specificity
MH  - Pancreas/enzymology/pathology
MH  - Protein Isoforms/genetics
MH  - Protein Serine-Threonine Kinases/metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptor, Insulin/*genetics/metabolism
MH  - Transgenes
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2007/10/24 09:00
MHDA- 2008/02/15 09:00
CRDT- 2007/10/24 09:00
PHST- 2007/05/07 00:00 [received]
PHST- 2007/08/28 00:00 [revised]
PHST- 2007/08/28 00:00 [accepted]
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2008/02/15 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
AID - S0925-4439(07)00185-8 [pii]
AID - 10.1016/j.bbadis.2007.08.004 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2007 Dec;1772(11-12):1183-91. doi: 
      10.1016/j.bbadis.2007.08.004. Epub 2007 Sep 15.

PMID- 17942744
OWN - NLM
STAT- MEDLINE
DCOM- 20080118
LR  - 20211020
IS  - 1469-9001 (Electronic)
IS  - 1355-8382 (Print)
IS  - 1355-8382 (Linking)
VI  - 13
IP  - 12
DP  - 2007 Dec
TI  - MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and 
      its pre-mRNA substrate cardiac troponin T.
PG  - 2238-51
AB  - Myotonic dystrophy (DM) is a genetic disorder with multisystemic symptoms that is 
      caused by expression (as RNA) of expanded repeats of CTG or CCTG in the genome. 
      It is hypothesized that the RNA splicing factor muscleblind-like (MBNL) is 
      sequestered to the expanded CUG or CCUG RNAs. Mislocalization of MBNL results in 
      missplicing of a subset of pre-mRNAs that are linked to the symptoms found in DM 
      patients. We demonstrate that MBNL can bind short structured CUG and CCUG repeats 
      with high affinity and specificity. Only 6 base pairs are necessary for MBNL 
      binding: two pyrimidine mismatches and four guanosine-cytosine base pairs in a 
      stem. MBNL also has a preference for pyrimidine mismatches, but many other 
      mismatches are tolerated with decreased affinity. We also demonstrate that MBNL 
      binds the helical region of a stem-loop in the endogenous pre-mRNA target, the 
      cardiac troponin T (cTNT) pre-mRNA. The stem-loop contains two mismatches and 
      resembles both CUG and CCUG repeats. In vivo splicing results indicate that 
      MBNL-regulated splicing is dependent upon the formation of stem-loops recognized 
      by MBNL. These results suggest that MBNL may bind all of its RNA substrates, both 
      normal and pathogenic, as structured stem-loops containing pyrimidine mismatches.
FAU - Warf, M Bryan
AU  - Warf MB
AD  - Department of Chemistry, University of Oregon, Eugene, Oregon 97403, USA.
FAU - Berglund, J Andrew
AU  - Berglund JA
LA  - eng
GR  - GM-07759/GM/NIGMS NIH HHS/United States
GR  - R01 GM015792/GM/NIGMS NIH HHS/United States
GR  - R01 AR053903/AR/NIAMS NIH HHS/United States
GR  - GM-15792/GM/NIGMS NIH HHS/United States
GR  - AR053903/AR/NIAMS NIH HHS/United States
GR  - T32 GM007759/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20071017
PL  - United States
TA  - RNA
JT  - RNA (New York, N.Y.)
JID - 9509184
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Troponin T)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Base Pair Mismatch
MH  - Base Pairing
MH  - Base Sequence
MH  - Genetic Code
MH  - Humans
MH  - Introns
MH  - Kinetics
MH  - Molecular Sequence Data
MH  - Myocardium/*metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - RNA/*chemistry/genetics/*metabolism
MH  - RNA Precursors/*genetics
MH  - RNA, Messenger/*genetics
MH  - RNA-Binding Proteins/*metabolism
MH  - *Trinucleotide Repeat Expansion
MH  - Troponin T/*genetics/*metabolism
PMC - PMC2080590
EDAT- 2007/10/19 09:00
MHDA- 2008/01/19 09:00
PMCR- 2008/06/01
CRDT- 2007/10/19 09:00
PHST- 2007/10/19 09:00 [pubmed]
PHST- 2008/01/19 09:00 [medline]
PHST- 2007/10/19 09:00 [entrez]
PHST- 2008/06/01 00:00 [pmc-release]
AID - rna.610607 [pii]
AID - RA [pii]
AID - 10.1261/rna.610607 [doi]
PST - ppublish
SO  - RNA. 2007 Dec;13(12):2238-51. doi: 10.1261/rna.610607. Epub 2007 Oct 17.

PMID- 17877752
OWN - NLM
STAT- MEDLINE
DCOM- 20080104
LR  - 20221207
IS  - 0009-9163 (Print)
IS  - 0009-9163 (Linking)
VI  - 72
IP  - 5
DP  - 2007 Nov
TI  - DMPK-associated myotonic dystrophy and CTG repeats in Alabama African Americans.
PG  - 448-53
AB  - Myotonic dystrophy type 1 (DM1) is a result of a CTG expansion in the 
      3'-untranslated region of the DMPK gene. DM1 is rare among African blacks who 
      have fewer large CTG repeats in the normal range than other racial/ethnic groups. 
      Neither the prevalence of DM1 nor the relationship of CTG expansion to clinical 
      status in African Americans (AAs) is well documented. We describe two AA brothers 
      with DM1, each of whom had CTG repeats of 5/639; their father was reported to 
      have DM1 and had CTG repeats of 5/60. Other family members had CTG repeats of 
      5-14. An unrelated AA patient from a second kinship also had DM1; an analysis 
      revealed CTG repeats of 27/191. In 161 Alabama AA control subjects, we observed 
      18 CTG alleles from 5 to 28 repeats; the most common allele had five CTG repeats. 
      The frequency of CTG repeats >or=15 were greater (p < 0.0003) in Pygmy, Amhara 
      Ethiopian, Ashkenazi Jewish, North African Jewish, Israeli Muslim Arab, European 
      white, and Japanese populations than in the Alabama AA population. These data 
      suggest that the risk for DM1 in AAs is intermediate between that of African 
      blacks and whites of European descent.
FAU - Acton, R T
AU  - Acton RT
AD  - Department of Microbiology, University of Alabama, Birmingham, AL 35294-0005, 
      USA. acton@uab.edu
FAU - Rivers, C A
AU  - Rivers CA
FAU - Watson, B
AU  - Watson B
FAU - Oh, S J
AU  - Oh SJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070917
PL  - Denmark
TA  - Clin Genet
JT  - Clinical genetics
JID - 0253664
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Black or African American/*genetics
MH  - Alabama
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Trinucleotide Repeats
EDAT- 2007/09/20 09:00
MHDA- 2008/01/05 09:00
CRDT- 2007/09/20 09:00
PHST- 2007/09/20 09:00 [pubmed]
PHST- 2008/01/05 09:00 [medline]
PHST- 2007/09/20 09:00 [entrez]
AID - CGE883 [pii]
AID - 10.1111/j.1399-0004.2007.00883.x [doi]
PST - ppublish
SO  - Clin Genet. 2007 Nov;72(5):448-53. doi: 10.1111/j.1399-0004.2007.00883.x. Epub 
      2007 Sep 17.

PMID- 17728322
OWN - NLM
STAT- MEDLINE
DCOM- 20080122
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 16
IP  - 23
DP  - 2007 Dec 1
TI  - Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic 
      dystrophy type 1.
PG  - 2834-43
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder 
      associated with an expansion of CTG trinucleotide repeats in the 3'-untranslated 
      region of the myotonic dystrophy protein kinase (DMPK) gene. The RNA 
      gain-of-function hypothesis proposes that mutant DMPK mRNA alters the function 
      and localization of alternative splicing regulators, which are critical for 
      normal RNA processing. Previously, we found alternative splicing variants of 
      sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase 1 (SERCA1), which excluded exon 
      22, in skeletal muscle of DM1 patients. In the present study, we analyzed the 
      molecular mechanisms responsible for the splicing dysregulation of SERCA1. Five 
      'YGCU(U/G)Y' motifs that could potentially serve as Muscleblind-like 1, 
      (MBNL1)-binding motifs, are included downstream from the SERCA1 exon 22. Exon 
      trapping experiments showed that MBNL1 acts on the 'YGCU(U/G)Y' motif, and 
      positively regulates exon 22 splicing. Of the five MBNL1 motifs in intron 22, the 
      second and third sites were important for regulation of exon 22 splicing, but the 
      other three binding sites were not required. Overexpression of the CUG repeat 
      expansion of DMPK mRNA resulted in exclusion of exon 22 of SERCA1. These results 
      suggest that sequestration of MBNL1 into the CUG repeat expansion of DMPK mRNA 
      could cause the exclusion of SERCA1 exon 22, and the expression of this aberrant 
      splicing form of SERCA1 could affect the regulation of Ca(2+) concentration of 
      sarcoplasmic reticulum in DM patients.
FAU - Hino, Shin-Ichiro
AU  - Hino S
AD  - Department of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, 
      Japan.
FAU - Kondo, Shinichi
AU  - Kondo S
FAU - Sekiya, Hiroshi
AU  - Sekiya H
FAU - Saito, Atsushi
AU  - Saito A
FAU - Kanemoto, Soshi
AU  - Kanemoto S
FAU - Murakami, Tomohiko
AU  - Murakami T
FAU - Chihara, Kazuyasu
AU  - Chihara K
FAU - Aoki, Yuri
AU  - Aoki Y
FAU - Nakamori, Masayuki
AU  - Nakamori M
FAU - Takahashi, Masanori P
AU  - Takahashi MP
FAU - Imaizumi, Kazunori
AU  - Imaizumi K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070829
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases)
RN  - EC 7.2.2.10 (ATP2A1 protein, human)
SB  - IM
MH  - 3' Untranslated Regions
MH  - *Alternative Splicing
MH  - Animals
MH  - Base Sequence
MH  - Binding Sites/genetics
MH  - Cell Line
MH  - DNA/genetics
MH  - Exons
MH  - Humans
MH  - Introns
MH  - Mice
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/classification/*enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Sarcoplasmic Reticulum Calcium-Transporting ATPases/*genetics
MH  - Transfection
MH  - Trinucleotide Repeat Expansion
EDAT- 2007/08/31 09:00
MHDA- 2008/01/23 09:00
CRDT- 2007/08/31 09:00
PHST- 2007/08/31 09:00 [pubmed]
PHST- 2008/01/23 09:00 [medline]
PHST- 2007/08/31 09:00 [entrez]
AID - ddm239 [pii]
AID - 10.1093/hmg/ddm239 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2007 Dec 1;16(23):2834-43. doi: 10.1093/hmg/ddm239. Epub 2007 Aug 
      29.

PMID- 17645799
OWN - NLM
STAT- MEDLINE
DCOM- 20071025
LR  - 20211203
IS  - 1471-2199 (Electronic)
IS  - 1471-2199 (Linking)
VI  - 8
DP  - 2007 Jul 23
TI  - Somatic CTG*CAG repeat instability in a mouse model for myotonic dystrophy type 1 
      is associated with changes in cell nuclearity and DNA ploidy.
PG  - 61
AB  - BACKGROUND: Trinucleotide instability is a hallmark of degenerative neurological 
      diseases like Huntington's disease, some forms of spinocerebellar ataxia and 
      myotonic dystrophy type 1 (DM1). To investigate the effect of cell type and cell 
      state on the behavior of the DM1 CTG*CAG repeat, we studied a knock-in mouse 
      model for DM1 at different time points during ageing and followed how repeat fate 
      in cells from liver and pancreas is associated with polyploidization and changes 
      in nuclearity after the onset of terminal differentiation. RESULTS: After 
      separation of liver hepatocytes and pancreatic acinar cells in pools with 2n, 4n 
      or 8n DNA, we analyzed CTG*CAG repeat length variation by resolving PCR products 
      on an automated PAGE system. We observed that somatic CTG*CAG repeat expansion in 
      our DM1 mouse model occurred almost uniquely in the fraction of cells with high 
      cell nuclearity and DNA ploidy and aggravated with aging. CONCLUSION: Our 
      findings suggest that post-replicative and terminal-differentiation events, 
      coupled to changes in cellular DNA content, form a preconditional state that 
      influences the control of DNA repair or recombination events involved in 
      trinucleotide expansion in liver hepatocytes and pancreatic acinar cells.
FAU - van den Broek, Walther J A A
AU  - van den Broek WJ
AD  - Department of Cell Biology, Nijmegen Centre for Molecular Life Sciences, Radboud 
      University Nijmegen Medical Centre, The Netherlands. w.vandenbroek@ncmls.ru.nl 
      <w.vandenbroek@ncmls.ru.nl>
FAU - Wansink, Derick G
AU  - Wansink DG
FAU - Wieringa, Be
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070723
PL  - England
TA  - BMC Mol Biol
JT  - BMC molecular biology
JID - 100966983
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Aging/physiology
MH  - Animals
MH  - Base Sequence
MH  - Cell Differentiation/genetics
MH  - Cell Nucleus/genetics/metabolism
MH  - Cells, Cultured
MH  - Flow Cytometry
MH  - Genomic Instability/*genetics
MH  - Hepatocytes/cytology/metabolism
MH  - Humans
MH  - Liver/cytology/metabolism
MH  - Mice
MH  - Mice, Transgenic
MH  - Myocardium/cytology/metabolism
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Pancreas/cytology/metabolism
MH  - *Ploidies
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC1940261
EDAT- 2007/07/25 09:00
MHDA- 2007/10/27 09:00
PMCR- 2007/07/23
CRDT- 2007/07/25 09:00
PHST- 2006/10/12 00:00 [received]
PHST- 2007/07/23 00:00 [accepted]
PHST- 2007/07/25 09:00 [pubmed]
PHST- 2007/10/27 09:00 [medline]
PHST- 2007/07/25 09:00 [entrez]
PHST- 2007/07/23 00:00 [pmc-release]
AID - 1471-2199-8-61 [pii]
AID - 10.1186/1471-2199-8-61 [doi]
PST - epublish
SO  - BMC Mol Biol. 2007 Jul 23;8:61. doi: 10.1186/1471-2199-8-61.

PMID- 17587223
OWN - NLM
STAT- MEDLINE
DCOM- 20071004
LR  - 20220408
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 36
IP  - 3
DP  - 2007 Sep
TI  - Computerized hand grip myometry reliably measures myotonia and muscle strength in 
      myotonic dystrophy (DM1).
PG  - 320-8
AB  - The aim of this study was to develop a reliable, sensitive, quantitative measure 
      of grip myotonia and strength and to determine whether CTG repeat length is 
      correlated with grip myotonia and with muscle strength in myotonic dystrophy type 
      1 (DM1). Three maximum voluntary isometric contractions (MVICs) of the finger 
      flexors (i.e., handgrip) were recorded on 2 successive days using a computerized 
      handgrip myometer in 29 genetically confirmed DM1 patients and 17 normals. An 
      automated computer program calculated MVIC peak force (PF) and relaxation times 
      (RTs) along the declining (relaxation) phase of the force recordings at 90%, 75%, 
      50%, 10%, and 5% of PF. Patients also underwent quantitative strength testing 
      (QST) manual muscle testing (MMT). The patients had longer grip RTs and lower PFs 
      than normals. RT (90% to 5%) was above the normal mean +2.5 SD in 25 (86%) 
      patients. In DM1, prolongation of RT was mainly in the terminal (50% to 5%), 
      rather than the initial (90% to 50%) phase of relaxation. PFs and RTs for each 
      patient were reproducible on consecutive days. RTs were positively correlated 
      with leukocyte CTG repeat length, whereas measures of muscle strength, such as 
      PF, QST, and MMT, were negatively correlated with repeat length. We conclude that 
      computerized handgrip myometry provides a sensitive, reliable measure of myotonia 
      and strength in DM1 and offers a method to assess natural history and response to 
      treatment.
FAU - Moxley, Richard T 3rd
AU  - Moxley RT 3rd
AD  - Department of Neurology, University of Rochester Medical Center, Box 673, 601 
      Elmwood Avenue, Rochester, New York 14642, USA. 
      RichardT_Moxley@urmc.rochester.edu
FAU - Logigian, Eric L
AU  - Logigian EL
FAU - Martens, William B
AU  - Martens WB
FAU - Annis, Chris L
AU  - Annis CL
FAU - Pandya, Shree
AU  - Pandya S
FAU - Moxley, Richard T 4th
AU  - Moxley RT 4th
FAU - Barbieri, Cheryl A
AU  - Barbieri CA
FAU - Dilek, Nuran
AU  - Dilek N
FAU - Wiegner, Allen W
AU  - Wiegner AW
FAU - Thornton, Charles A
AU  - Thornton CA
LA  - eng
GR  - 5 M01 RR00044/RR/NCRR NIH HHS/United States
GR  - FD-R-001662/FD/FDA HHS/United States
GR  - R01 AR44069A/AR/NIAMS NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Computers
MH  - Female
MH  - *Hand Strength
MH  - Humans
MH  - Isometric Contraction/genetics
MH  - Male
MH  - Middle Aged
MH  - Muscle Relaxation/genetics
MH  - Muscle Strength/genetics/*physiology
MH  - Muscle, Skeletal/*physiopathology
MH  - Myotonia/*diagnosis/genetics
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - *Software
MH  - Trinucleotide Repeats/genetics
EDAT- 2007/06/26 09:00
MHDA- 2007/10/05 09:00
CRDT- 2007/06/26 09:00
PHST- 2007/06/26 09:00 [pubmed]
PHST- 2007/10/05 09:00 [medline]
PHST- 2007/06/26 09:00 [entrez]
AID - 10.1002/mus.20822 [doi]
PST - ppublish
SO  - Muscle Nerve. 2007 Sep;36(3):320-8. doi: 10.1002/mus.20822.

PMID- 17487865
OWN - NLM
STAT- MEDLINE
DCOM- 20070907
LR  - 20070730
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 36
IP  - 2
DP  - 2007 Aug
TI  - Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy.
PG  - 251-7
AB  - Myotonic dystrophy type1 (DM1) is a multisystemic disorder caused by a CTG repeat 
      expansion in the DMPK gene. Aberrant mRNA splicing of several genes has been 
      reported to contribute to some of the symptoms, including myotonia and insulin 
      resistance, but the cause of muscle wasting is unknown. Dystrophin is a 
      cytoskeletal protein that is required for structural stability and signaling at 
      the sarcolemma and has several spliced isoforms. We investigated the alternative 
      splicing of dystrophin in skeletal and cardiac muscle of DM1 patients by using 
      reverse transcriptase-polymerase chain reaction and found that dystrophin 
      isoforms lacking exon 71 or 78, which is suggested to encode an important region 
      for protein binding and hydrophobicity, were significantly increased. We suggest 
      that the aberrantly spliced dystrophin is responsible for the muscle wasting in 
      DM1.
FAU - Nakamori, Masayuki
AU  - Nakamori M
AD  - Department of Neurology, Osaka University Graduate School of Medicine, D-4, 2-2 
      Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Kimura, Takashi
AU  - Kimura T
FAU - Fujimura, Harutoshi
AU  - Fujimura H
FAU - Takahashi, Masanori P
AU  - Takahashi MP
FAU - Sakoda, Saburo
AU  - Sakoda S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Dystrophin)
SB  - IM
MH  - Adult
MH  - Alternative Splicing/*genetics
MH  - Dystrophin/*genetics
MH  - Exons/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/*genetics/pathology
EDAT- 2007/05/10 09:00
MHDA- 2007/09/08 09:00
CRDT- 2007/05/10 09:00
PHST- 2007/05/10 09:00 [pubmed]
PHST- 2007/09/08 09:00 [medline]
PHST- 2007/05/10 09:00 [entrez]
AID - 10.1002/mus.20809 [doi]
PST - ppublish
SO  - Muscle Nerve. 2007 Aug;36(2):251-7. doi: 10.1002/mus.20809.

PMID- 17383831
OWN - NLM
STAT- MEDLINE
DCOM- 20070613
LR  - 20240312
IS  - 0378-1119 (Print)
IS  - 0378-1119 (Linking)
VI  - 393
IP  - 1-2
DP  - 2007 May 15
TI  - Haploinsufficiency of yeast FEN1 causes instability of expanded CAG/CTG tracts in 
      a length-dependent manner.
PG  - 110-5
AB  - Trinucleotide repeat diseases, such as Huntington's disease, are caused by the 
      expansion of trinucleotide repeats above a threshold of about 35 repeats. Once 
      expanded, the repeats are unstable and tend to expand further both in somatic 
      cells and during transmission, resulting in a more severe disease phenotype. Flap 
      endonuclease 1 (Fen1), has an endonuclease activity specific for 5' flap 
      structures and is involved in Okazaki fragment processing and base excision 
      repair. Fen1 also plays an important role in preventing instability of CAG/CTG 
      trinucleotide repeat sequences, as the expansion frequency of CAG/CTG repeats is 
      increased in FEN1 mutants in vitro and in yeast cells defective for the yeast 
      homolog, RAD27. Here we have tested whether one copy of yeast FEN1 is enough to 
      maintain CAG/CTG tract stability in diploid yeast cells. We found that CAG/CTG 
      repeats are stable in RAD27 +/- cells if the tract is 70 repeats long and exhibit 
      a slightly increased expansion frequency if the tract is 85 or 130 repeats long. 
      However for CAG-155 tracts, the repeat expansion frequency in RAD27 +/- cells is 
      significantly higher than in RAD27 +/+ cells. This data indicates that cells 
      containing longer CAG/CTG repeats need more Fen1 protein to maintain tract 
      stability and that maintenance of long CAG/CTG repeats is particularly sensitive 
      to Fen1 levels. Our results may explain the relatively small effects seen in the 
      Huntington's disease (HD) FEN1 +/- heterozygous mice and myotonic dystrophy type 
      1 (DM1) FEN1 +/- heterozygous mice, and suggest that inefficient flap processing 
      by Fen1 could play a role in the continued expansions seen in humans with 
      trinucleotide repeat expansion diseases.
FAU - Yang, Jiahui
AU  - Yang J
AD  - Department of Biology, Tufts University, Medford, MA 02155, USA.
FAU - Freudenreich, Catherine H
AU  - Freudenreich CH
LA  - eng
GR  - R01 GM063066/GM/NIGMS NIH HHS/United States
GR  - GM63066/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070212
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Saccharomyces cerevisiae Proteins)
RN  - EC 3.1.- (Flap Endonucleases)
RN  - EC 3.1.11.5 (RAD27 protein, S cerevisiae)
SB  - IM
MH  - Base Sequence
MH  - Flap Endonucleases/*genetics
MH  - Genome, Fungal/*genetics
MH  - *Genomic Instability
MH  - *Haploidy
MH  - Heterozygote
MH  - Saccharomyces cerevisiae/cytology/*enzymology/*genetics
MH  - Saccharomyces cerevisiae Proteins/genetics
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Up-Regulation/genetics
PMC - PMC1904339
MID - NIHMS22405
EDAT- 2007/03/27 09:00
MHDA- 2007/06/15 09:00
PMCR- 2007/06/29
CRDT- 2007/03/27 09:00
PHST- 2006/08/17 00:00 [received]
PHST- 2007/01/23 00:00 [revised]
PHST- 2007/01/24 00:00 [accepted]
PHST- 2007/03/27 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/03/27 09:00 [entrez]
PHST- 2007/06/29 00:00 [pmc-release]
AID - S0378-1119(07)00072-8 [pii]
AID - 10.1016/j.gene.2007.01.025 [doi]
PST - ppublish
SO  - Gene. 2007 May 15;393(1-2):110-5. doi: 10.1016/j.gene.2007.01.025. Epub 2007 Feb 
      12.

PMID- 17318633
OWN - NLM
STAT- MEDLINE
DCOM- 20071121
LR  - 20070713
IS  - 0001-6322 (Print)
IS  - 0001-6322 (Linking)
VI  - 114
IP  - 2
DP  - 2007 Aug
TI  - The expansion of 300 CTG repeats in myotonic dystrophy transgenic mice does not 
      induce sensory or motor neuropathy.
PG  - 175-85
AB  - Although many studies have been carried out to verify the involvement of the 
      peripheral nervous system (PNS) in dystrophia myotonica (DM1) patients, the 
      results remain controversial. The generation of DM1 transgenic mice displaying 
      the human DM1 phenotype provides a useful tool to investigate the type and 
      incidence of structural abnormalities in the PNS. In the present study, the 
      morphological and morphometric analysis of semi-thin sections of sciatic and 
      sural nerves, lumbar dorsal root ganglia (DRG) and lumbar spinal cords revealed 
      that in DM1 transgenic mice carrying 300 CTG repeats, there is no change in the 
      number and diameter of myelinated axons compared to wild type. Only a 
      non-significant reduction in the percentage of thin myelinated axons was detected 
      in electron micrographs of ultra-thin sciatic nerve sections. Analysis of the 
      number of neurons did not reveal a loss in number of either sensory neurons in 
      the lumbar DRG or motor neurons in the lumbar spinal cord in these DM1 mice. 
      Furthermore, in hind limb muscle sections, stained with a neurofilament antibody 
      and alpha-bungarotoxin, the intramuscular axon arborization appeared normal in 
      DM1 mice and undistinguishable from that in wild-type mice. Moreover, in DM1 
      mice, there was no irregularity in the structure or an increase in the endplate 
      area. Also statistical analysis did not show an increase in endplate density or 
      in the concentration of acetylcholine receptors. Altogether, these results 
      suggest that 300 CTG repeats are not sufficient to induce axonopathy, 
      demyelination or neuronopathies in this transgenic mouse model.
FAU - Gantelet, E
AU  - Gantelet E
AD  - Laboratory of Neurology Research, Lausanne University Hospital (CHUV), rue du 
      Bugnon 46, 1011, Lausanne, Switzerland.
FAU - Kraftsik, R
AU  - Kraftsik R
FAU - Delaloye, S
AU  - Delaloye S
FAU - Gourdon, G
AU  - Gourdon G
FAU - Kuntzer, T
AU  - Kuntzer T
FAU - Barakat-Walter, I
AU  - Barakat-Walter I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070222
PL  - Germany
TA  - Acta Neuropathol
JT  - Acta neuropathologica
JID - 0412041
SB  - IM
MH  - Animals
MH  - Axons/ultrastructure
MH  - Demyelinating Diseases
MH  - Ganglia, Spinal/ultrastructure
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Microscopy, Electron, Transmission
MH  - Motor Neurons/ultrastructure
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Neuromuscular Junction/ultrastructure
MH  - Neurons, Afferent/ultrastructure
MH  - Peripheral Nervous System Diseases/*genetics/*pathology
MH  - Sciatic Nerve/ultrastructure
MH  - Spinal Cord/ultrastructure
MH  - Sural Nerve/ultrastructure
MH  - *Trinucleotide Repeat Expansion
EDAT- 2007/02/24 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/02/24 09:00
PHST- 2006/12/22 00:00 [received]
PHST- 2007/01/30 00:00 [accepted]
PHST- 2007/01/30 00:00 [revised]
PHST- 2007/02/24 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/02/24 09:00 [entrez]
AID - 10.1007/s00401-007-0205-x [doi]
PST - ppublish
SO  - Acta Neuropathol. 2007 Aug;114(2):175-85. doi: 10.1007/s00401-007-0205-x. Epub 
      2007 Feb 22.

PMID- 17209971
OWN - NLM
STAT- MEDLINE
DCOM- 20070215
LR  - 20190816
IS  - 0012-1622 (Print)
IS  - 0012-1622 (Linking)
VI  - 49
IP  - 1
DP  - 2007 Jan
TI  - Orofacial dysfunction in children and adolescents with myotonic dystrophy.
PG  - 18-22
AB  - Myotonic dystrophy (DM) is a neuromuscular disorder caused by an expansion of a 
      CTG repeat sequence on chromosome 19q13. The aim of the present study was to 
      describe the characteristics and prevalence of oral motor dysfunction in a cohort 
      of children and adolescents with DM and to correlate different aspects of oral 
      motor function with the type of DM and sex. Fifty-six individuals with DM (30 
      males, 26 females; median age 13y 2mo; range 2y 6mo-21y 5mo) were compared with 
      healthy controls. They were divided into four subgroups: severe congenital DM 
      (n=18); mild congenital DM (n=18); childhood DM (n=18); and classical DM (n=2). A 
      speech-language pathologist assessed different variables of oral motor function, 
      intelligibility, and lip force. The families used a questionnaire to report on 
      eating difficulties and drooling. All individuals with DM had impaired facial 
      expression. Intelligibility was moderately or severely reduced in 30 patients 
      (60%), excluding six patients without speech. Most had a moderate or severe 
      impairment of lip motility (76.0%), tongue motility (52.2%), and lip force 
      (69.2%), causing deviant production of bilabial and dental consonants. The 
      families reported problems with eating (51.9%) and drooling (37.0%). Oral motor 
      dysfunction was most prominent in congenital DM, and males were more affected 
      than females.
FAU - Sjogreen, Lotta
AU  - Sjogreen L
AD  - Mun-H-Center Orofacial Resource Centre for Rare Disorders and Department of 
      Speech Pathology, Institute of Neuroscience and Physiology, Sahlgrenska Academy 
      at Goteborg, Goteborg, Sweden. lotta.sjogreen@vgregion.se
FAU - Engvall, Monica
AU  - Engvall M
FAU - Ekstrom, Anne-Berit
AU  - Ekstrom AB
FAU - Lohmander, Anette
AU  - Lohmander A
FAU - Kiliaridis, Stavros
AU  - Kiliaridis S
FAU - Tulinius, Mar
AU  - Tulinius M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Dev Med Child Neurol
JT  - Developmental medicine and child neurology
JID - 0006761
SB  - IM
MH  - Adolescent
MH  - Articulation Disorders/diagnosis/epidemiology/physiopathology
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Dyskinesia, Drug-Induced/diagnosis/*epidemiology/*physiopathology
MH  - Female
MH  - Humans
MH  - Lip/physiopathology
MH  - Male
MH  - Myotonic Dystrophy/*epidemiology/genetics
MH  - Observer Variation
MH  - Parents
MH  - Phonetics
MH  - Prevalence
MH  - Severity of Illness Index
MH  - Sex Distribution
EDAT- 2007/01/11 09:00
MHDA- 2007/02/16 09:00
CRDT- 2007/01/11 09:00
PHST- 2007/01/11 09:00 [pubmed]
PHST- 2007/02/16 09:00 [medline]
PHST- 2007/01/11 09:00 [entrez]
AID - DMCN0060a [pii]
AID - 10.1017/s0012162207000060.x [doi]
PST - ppublish
SO  - Dev Med Child Neurol. 2007 Jan;49(1):18-22. doi: 10.1017/s0012162207000060.x.

PMID- 17205963
OWN - NLM
STAT- MEDLINE
DCOM- 20070724
LR  - 20221207
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 22
IP  - 4
DP  - 2007 Apr
TI  - A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic 
      end-stage renal disease in European Americans.
PG  - 1131-5
AB  - BACKGROUND: Four linkage analyses have identified a region on chromosome 18q22-23 
      that appears to harbour a diabetic nephropathy (DN) susceptibility locus. A 
      trinucleotide repeat sequence in exon 2 of the carnosinase gene (CNDP1) residing 
      on 18q22.3 was subsequently associated with DN in European Caucasians and Arabs. 
      METHODS: We evaluated the role of the CNDP1 5 leucine/5 leucine (5-5) 
      polymorphism (CNDP1 Mannheim) in diabetic end-stage renal disease (ESRD) 
      susceptibility in 858 European Americans: 294 with type 2 DN-associated ESRD 
      (DN-ESRD), 258 with diabetes mellitus (DM) lacking nephropathy and 306 healthy 
      controls. RESULTS: Subjects with DM lacking nephropathy were significantly more 
      likely to be homozygous for the 5-leucine repeat CNDP1 genotype (5-5), compared 
      with those with DN-ESRD (P=0.02). Healthy controls were also more likely to be 
      homozygous for the 5-5 genotype, compared with those with DN-ESRD (P=0.008). No 
      significant difference in 5-5 genotype frequency was observed between healthy 
      controls and DM cases without nephropathy (P=0.74). CONCLUSION: European 
      Americans homozygous for the 5-5 leucine repeat polymorphism in the CNDP1 gene 
      are at significantly reduced risk for developing diabetic ESRD. This replicates 
      the CNDP1 gene association with DN that was initially detected in European 
      Caucasians and in Arabs, and further demonstrates that the CNDP1 gene and 
      carnosine pathway appear to play a role in susceptibility to DN.
FAU - Freedman, Barry I
AU  - Freedman BI
AD  - Department of Internal Medicine, Center for Human Genomics, Wake Forest 
      University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 
      27157-1053, USA. bfreedma@wfubmc.edu
FAU - Hicks, Pamela J
AU  - Hicks PJ
FAU - Sale, Michele M
AU  - Sale MM
FAU - Pierson, Eric D
AU  - Pierson ED
FAU - Langefeld, Carl D
AU  - Langefeld CD
FAU - Rich, Stephen S
AU  - Rich SS
FAU - Xu, Jianzhao
AU  - Xu J
FAU - McDonough, Caitrin
AU  - McDonough C
FAU - Janssen, Bart
AU  - Janssen B
FAU - Yard, Benito A
AU  - Yard BA
FAU - van der Woude, Fokko J
AU  - van der Woude FJ
FAU - Bowden, Donald W
AU  - Bowden DW
LA  - eng
GR  - M01 RR07122/RR/NCRR NIH HHS/United States
GR  - R01 DK066358/DK/NIDDK NIH HHS/United States
GR  - R01 DK070942/DK/NIDDK NIH HHS/United States
GR  - R01 DK53591/DK/NIDDK NIH HHS/United States
GR  - R01 HL67348/HL/NHLBI NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070105
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 8HO6PVN24W (Carnosine)
RN  - EC 3.4.13.- (Dipeptidases)
RN  - EC 3.4.13.18 (aminoacyl-histidine dipeptidase)
RN  - GMW67QNF9C (Leucine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Carnosine/physiology
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/ethnology/genetics
MH  - Diabetic Nephropathies/*ethnology/*genetics
MH  - Dipeptidases/*genetics
MH  - Europe/ethnology
MH  - Female
MH  - Genetic Linkage
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Kidney Failure, Chronic/*ethnology/*genetics
MH  - Leucine/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Risk Factors
MH  - Trinucleotide Repeats/*genetics
MH  - United States/epidemiology
MH  - White People/ethnology/genetics
EDAT- 2007/01/09 09:00
MHDA- 2007/07/25 09:00
CRDT- 2007/01/09 09:00
PHST- 2007/01/09 09:00 [pubmed]
PHST- 2007/07/25 09:00 [medline]
PHST- 2007/01/09 09:00 [entrez]
AID - gfl717 [pii]
AID - 10.1093/ndt/gfl717 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2007 Apr;22(4):1131-5. doi: 10.1093/ndt/gfl717. Epub 
      2007 Jan 5.

PMID- 17204048
OWN - NLM
STAT- MEDLINE
DCOM- 20070309
LR  - 20211203
IS  - 0009-9163 (Print)
IS  - 0009-9163 (Linking)
VI  - 71
IP  - 1
DP  - 2007 Jan
TI  - The correlation of CTG repeat length with material and social deprivation in 
      myotonic dystrophy.
PG  - 59-66
AB  - Socioeconomic deprivation has long been recognized as a prominent feature of 
      myotonic dystrophy type 1 (DM1), but studies performed before the discovery of 
      the mutation causing DM1 may have suffered an ascertainment bias towards the more 
      severe forms of the disease. We have sought to clarify the relationship between 
      CTG repeats, muscular impairment, and socioeconomic characteristics of 200 
      patients with DM1. Patients with DM1 reported lower educational attainment, lower 
      employment rate, lower family income, and higher reliance on social assistance 
      than the reference population. Logistic regression showed, on one hand, that CTG 
      repeats and marital status were significant predictors of social assistance 
      recipiency and, on the other hand, that CTG repeats and gender were significant 
      predictors of low social support from family, after adjustment for age, gender, 
      degree of muscular impairment, CTG repeats, educational level, and marital 
      status. For example, each additional 100 CTG repeats was found to increase the 
      odds of relying on social assistance by about 35% and having low social support 
      by about 22%. The chances of experiencing socioeconomic deprivation are loaded 
      heavily against patients with DM1. The relationship between increased CTG repeat 
      length and higher risk of material and social deprivation must be acknowledged in 
      the clinical management of DM1.
FAU - Laberge, L
AU  - Laberge L
AD  - Groupe ECOBES, Cegep de Jonquiere, Universite du Quebec, a Chicoutimi, Quebec, 
      Canada.
FAU - Veillette, S
AU  - Veillette S
FAU - Mathieu, J
AU  - Mathieu J
FAU - Auclair, J
AU  - Auclair J
FAU - Perron, M
AU  - Perron M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Clin Genet
JT  - Clinical genetics
JID - 0253664
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Quebec
MH  - Sex Factors
MH  - Socioeconomic Factors
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2007/01/06 09:00
MHDA- 2007/03/10 09:00
CRDT- 2007/01/06 09:00
PHST- 2007/01/06 09:00 [pubmed]
PHST- 2007/03/10 09:00 [medline]
PHST- 2007/01/06 09:00 [entrez]
AID - CGE732 [pii]
AID - 10.1111/j.1399-0004.2007.00732.x [doi]
PST - ppublish
SO  - Clin Genet. 2007 Jan;71(1):59-66. doi: 10.1111/j.1399-0004.2007.00732.x.

PMID- 17158949
OWN - NLM
STAT- MEDLINE
DCOM- 20070222
LR  - 20220309
IS  - 0022-1295 (Print)
IS  - 1540-7748 (Electronic)
IS  - 0022-1295 (Linking)
VI  - 129
IP  - 1
DP  - 2007 Jan
TI  - Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy.
PG  - 79-94
AB  - Muscle degeneration and myotonia are clinical hallmarks of myotonic dystrophy 
      type 1 (DM1), a multisystemic disorder caused by a CTG repeat expansion in the 3' 
      untranslated region of the myotonic dystrophy protein kinase (DMPK) gene. 
      Transgenic mice engineered to express mRNA with expanded (CUG)(250) repeats 
      (HSA(LR) mice) exhibit prominent myotonia and altered splicing of muscle chloride 
      channel gene (Clcn1) transcripts. We used whole-cell patch clamp recordings and 
      nonstationary noise analysis to compare and biophysically characterize the 
      magnitude, kinetics, voltage dependence, and single channel properties of the 
      skeletal muscle chloride channel (ClC-1) in individual flexor digitorum brevis 
      (FDB) muscle fibers isolated from 1-3-wk-old wild-type and HSA(LR) mice. The 
      results indicate that peak ClC-1 current density at -140 mV is reduced >70% 
      (-48.5 +/- 3.6 and -14.0 +/- 1.6 pA/pF, respectively) and the kinetics of channel 
      deactivation increased in FDB fibers obtained from 18-20- d-old HSA(LR) mice. 
      Nonstationary noise analysis revealed that the reduction in ClC-1 current density 
      in HSA(LR) FDB fibers results from a large reduction in ClC-1 channel density 
      (170 +/- 21 and 58 +/- 11 channels/pF in control and HSA(LR) fibers, 
      respectively) and a modest decrease in maximal channel open probability(0.91 +/- 
      0.01 and 0.75 +/- 0.03, respectively). Qualitatively similar results were 
      observed for ClC-1 channel activity in knockout mice for muscleblind-like 1 
      (Mbnl1(DeltaE3/DeltaE3)), a second murine model of DM1 that exhibits prominent 
      myotonia and altered Clcn1 splicing (Kanadia et al., 2003). These results support 
      a molecular mechanism for myotonia in DM1 in which a reduction in both the number 
      of functional sarcolemmal ClC-1 and maximal channel open probability, as well as 
      an acceleration in the kinetics of channel deactivation, results from CUG 
      repeat-containing mRNA molecules sequestering Mbnl1 proteins required for proper 
      CLCN1 pre-mRNA splicing and chloride channel function.
FAU - Lueck, John D
AU  - Lueck JD
AD  - Department of Physiology and Pharmacology, University of Rochester, Rochester, NY 
      14642, USA.
FAU - Mankodi, Ami
AU  - Mankodi A
FAU - Swanson, Maurice S
AU  - Swanson MS
FAU - Thornton, Charles A
AU  - Thornton CA
FAU - Dirksen, Robert T
AU  - Dirksen RT
LA  - eng
GR  - R29 AR044657/AR/NIAMS NIH HHS/United States
GR  - R01 AR046806/AR/NIAMS NIH HHS/United States
GR  - R01 AR044657-12/AR/NIAMS NIH HHS/United States
GR  - T32DE07202/DE/NIDCR NIH HHS/United States
GR  - AR46806/AR/NIAMS NIH HHS/United States
GR  - T32 DE007202/DE/NIDCR NIH HHS/United States
GR  - AR44657/AR/NIAMS NIH HHS/United States
GR  - R01 AR044657/AR/NIAMS NIH HHS/United States
GR  - AR050762/AR/NIAMS NIH HHS/United States
GR  - K24 AR048143/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20061211
PL  - United States
TA  - J Gen Physiol
JT  - The Journal of general physiology
JID - 2985110R
RN  - 0 (CLC-1 channel)
RN  - 0 (Chloride Channels)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Chloride Channels/*genetics/*physiology
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle Fibers, Skeletal/cytology/metabolism/physiology
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Patch-Clamp Techniques
MH  - RNA Splicing
MH  - RNA, Messenger/genetics/metabolism
PMC - PMC2151606
EDAT- 2006/12/13 09:00
MHDA- 2007/02/23 09:00
PMCR- 2007/07/01
CRDT- 2006/12/13 09:00
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/02/23 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
PHST- 2007/07/01 00:00 [pmc-release]
AID - jgp.200609635 [pii]
AID - 200609635 [pii]
AID - 10.1085/jgp.200609635 [doi]
PST - ppublish
SO  - J Gen Physiol. 2007 Jan;129(1):79-94. doi: 10.1085/jgp.200609635. Epub 2006 Dec 
      11.

PMID- 17150182
OWN - NLM
STAT- MEDLINE
DCOM- 20070212
LR  - 20061215
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 352
IP  - 3
DP  - 2007 Jan 19
TI  - Length-dependent toxicity of untranslated CUG repeats on Caenorhabditis elegans.
PG  - 774-9
AB  - Expansion of CTG repeat within the 3'-untranslated region of the DMPK gene causes 
      the most common neuromuscular disorder, myotonic dystrophy type 1 (DM1), through 
      a RNA trans-dominant mechanism. Here, we explore Caenorhabditis elegans as a 
      model system to investigate the repeat size-dependent toxic effect by expression 
      of green fluorescent protein (GFP) transcripts with various lengths of 
      untranslatable CUG repeats (CUG5, CUG30, CUG83, CUG125, and CUG213) in body wall 
      muscles. CUG213 animals died during embryogenesis or showed retarded growth at 
      larval stages due to defective muscle development. CUG125 animals, although can 
      produce offspring, exhibited uncoordinated muscle function, deviated 
      electropharyngeogram, and an age-dependent abnormality in muscle structure. Most 
      CUG83 animals had normal muscle structure and function as those expressing 30 and 
      shorter repeats. Our results demonstrate for the first time that the in vivo 
      toxicity of CUG repeats is repeat length- and growth-regulated and suggest that 
      expanded CUG repeats are sufficient to cause congenital-like phenotypes in living 
      organisms.
FAU - Chen, Kuan-Yu
AU  - Chen KY
AD  - Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, ROC.
FAU - Pan, Huichin
AU  - Pan H
FAU - Lin, Min-Jon
AU  - Lin MJ
FAU - Li, Yet-Young
AU  - Li YY
FAU - Wang, Li-Chun
AU  - Wang LC
FAU - Wu, Yi-Chun
AU  - Wu YC
FAU - Hsiao, Kuang-Ming
AU  - Hsiao KM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061127
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Untranslated Regions)
SB  - IM
MH  - Animals
MH  - Animals, Genetically Modified
MH  - Caenorhabditis elegans/*genetics
MH  - Muscle, Skeletal/*pathology/*physiopathology
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Repetitive Sequences, Nucleic Acid/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Untranslated Regions/*genetics
EDAT- 2006/12/08 09:00
MHDA- 2007/02/13 09:00
CRDT- 2006/12/08 09:00
PHST- 2006/11/09 00:00 [received]
PHST- 2006/11/17 00:00 [accepted]
PHST- 2006/12/08 09:00 [pubmed]
PHST- 2007/02/13 09:00 [medline]
PHST- 2006/12/08 09:00 [entrez]
AID - S0006-291X(06)02575-7 [pii]
AID - 10.1016/j.bbrc.2006.11.102 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2007 Jan 19;352(3):774-9. doi: 
      10.1016/j.bbrc.2006.11.102. Epub 2006 Nov 27.

PMID- 17145685
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20211203
IS  - 0020-7454 (Print)
IS  - 0020-7454 (Linking)
VI  - 116
IP  - 12
DP  - 2006 Dec
TI  - Clinical case report atypical myopathy in a young girl with 91 CTG repeats in DM1 
      locus and a positive DM1 family history.
PG  - 1509-18
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant inheritable disease 
      associated with an expansion of CTG repeats in the 3' UTR of the DMPK gene. The 
      subject is an 11-year-old girl with atypical myopathy. Because the proband's 
      family has a positive DM1 history, a molecular-genetic analysis for DM1 was 
      performed. This study showed that proband had a small DMPK expansion (91 CTG 
      repeats) although the observed myopathy would not normally be associated with 
      DM1. These results show how the phenotypic manifestation of DM1 can have unusual 
      symptoms with a completely unexpected relationship to genotype.
FAU - Savic, Dusanka
AU  - Savic D
AD  - Faculty of Biology, University of Belgrade, Belgrade, Serbia and Montenegro.
FAU - Keckarevic, Dusan
AU  - Keckarevic D
FAU - Brankovic-Sreckovic, Vesna
AU  - Brankovic-Sreckovic V
FAU - Apostolski, Slobodan
AU  - Apostolski S
FAU - Todorovic, Slobodanka
AU  - Todorovic S
FAU - Romac, Stanka
AU  - Romac S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - DNA Mutational Analysis
MH  - Family Health
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Phenotype
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2006/12/06 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/12/06 09:00
PHST- 2006/12/06 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/12/06 09:00 [entrez]
AID - XMNVK2P482087586 [pii]
AID - 10.1080/00207450600553182 [doi]
PST - ppublish
SO  - Int J Neurosci. 2006 Dec;116(12):1509-18. doi: 10.1080/00207450600553182.

PMID- 17114933
OWN - NLM
STAT- MEDLINE
DCOM- 20090715
LR  - 20190516
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Linking)
VI  - 2
IP  - 4
DP  - 2005 Oct-Dec
TI  - Polymorphic CUG repeats in human mRNAs and their effects on gene expression.
PG  - 149-56
AB  - Expanded CUG repeats in the 3'-untranslated region (UTR) of the gene encoding 
      myotonic dystrophy protein kinase (DMPK) cause myotonic dystrophy type 1 disease 
      (DM1). The presence of such repeats has been found to impede gene expression at 
      several levels in model systems. We took a bioinformatic approach to survey all 
      human mRNA sequences for polymorphic CUG repeats. Our survey revealed that CUG 
      repeats occur widely in various regions of mRNAs, with higher frequency in 
      protein coding regions than 5'-UTRs or 3'-UTRs. About 30 genes were found to 
      contain CUG repeats that are polymorphic in the number of repeats, suggesting the 
      potential to expand or shrink. However, long polymorphic repeats were restricted 
      to the 3'-UTR of the DMPK gene and the coding region of the ribosomal protein L14 
      gene. Using cell-free translation systems, we showed that extended CUG repeats 
      can inhibit protein synthesis in vitro in the rabbit reticulocyte lysate, but not 
      in wheat germ extracts, consistent with our previous finding of an interaction of 
      CUG repeats with the protein kinase PKR. In transfected cells, CUG repeats can 
      inhibit gene expression both in cis and in trans. However, observations with 
      PKR-minus cells indicate that these effects are not primarily attributable to the 
      interaction of extended CUG repeats with PKR. Northwestern blotting detected the 
      presence in human cells of more CUG-binding proteins than are currently known.
FAU - Tian, Bin
AU  - Tian B
AD  - Department of Biochemistry and Molecular Biology, New Jersey Medical School, 
      University of Medicine and Dentistry of New Jersey, Newark, New Jersey 
      07101-1709, USA. btian@umdnj.edu <btian@umdnj.edu>
FAU - Mukhopadhyay, Rupa
AU  - Mukhopadhyay R
FAU - Mathews, Michael B
AU  - Mathews MB
LA  - eng
GR  - R01 AI34552/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20051227
PL  - United States
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Gene Expression Regulation/*physiology
MH  - Humans
MH  - Mice
MH  - Mice, Knockout
MH  - Polymorphism, Genetic/*genetics/physiology
MH  - RNA, Messenger/*genetics/physiology
MH  - Rabbits
MH  - Trinucleotide Repeats/*genetics/physiology
MH  - Triticum
EDAT- 2006/11/23 09:00
MHDA- 2009/07/16 09:00
CRDT- 2006/11/23 09:00
PHST- 2006/11/23 09:00 [pubmed]
PHST- 2009/07/16 09:00 [medline]
PHST- 2006/11/23 09:00 [entrez]
AID - 2446 [pii]
AID - 10.4161/rna.2.4.2446 [doi]
PST - ppublish
SO  - RNA Biol. 2005 Oct-Dec;2(4):149-56. doi: 10.4161/rna.2.4.2446. Epub 2005 Dec 27.

PMID- 16978612
OWN - NLM
STAT- MEDLINE
DCOM- 20061109
LR  - 20061115
IS  - 0014-5793 (Print)
IS  - 0014-5793 (Linking)
VI  - 580
IP  - 22
DP  - 2006 Oct 2
TI  - Fen1 does not control somatic hypermutability of the (CTG)(n)*(CAG)(n) repeat in 
      a knock-in mouse model for DM1.
PG  - 5208-14
AB  - The mechanism of trinucleotide repeat expansion, an important cause of 
      neuromuscular and neurodegenerative diseases, is poorly understood. We report 
      here on the study of the role of flap endonuclease 1 (Fen1), a structure-specific 
      nuclease with both 5' flap endonuclease and 5'-3' exonuclease activity, in the 
      somatic hypermutability of the (CTG)(n)*(CAG)(n) repeat of the DMPK gene in a 
      mouse model for myotonic dystrophy type 1 (DM1). By intercrossing mice with Fen1 
      deficiency with transgenics with a DM1 (CTG)(n)*(CAG)(n) repeat (where 104n110), 
      we demonstrate that Fen1 is not essential for faithful maintenance of this repeat 
      in early embryonic cleavage divisions until the blastocyst stage. Additionally, 
      we found that the frequency of somatic DM1 (CTG)(n)*(CAG)(n) repeat instability 
      was essentially unaltered in mice with Fen1 haploinsufficiency up to 1.5 years of 
      age. Based on these findings, we propose that Fen1, despite its role in DNA 
      repair and replication, is not primarily involved in maintaining stability at the 
      DM1 locus.
FAU - van den Broek, Walther J A A
AU  - van den Broek WJ
AD  - Department of Cell Biology, Radboud University Nijmegen Medical Centre, Nijmegen 
      Centre for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The 
      Netherlands.
FAU - Nelen, Marcel R
AU  - Nelen MR
FAU - van der Heijden, Godfried W
AU  - van der Heijden GW
FAU - Wansink, Derick G
AU  - Wansink DG
FAU - Wieringa, Be
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060905
PL  - England
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
RN  - EC 3.1.- (Flap Endonucleases)
SB  - IM
MH  - Aging/genetics/metabolism
MH  - Animals
MH  - Blastocyst/enzymology
MH  - DNA Repair/*genetics
MH  - DNA Replication/*genetics
MH  - Disease Models, Animal
MH  - Flap Endonucleases/*genetics/metabolism
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Quantitative Trait Loci/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2006/09/19 09:00
MHDA- 2006/11/11 09:00
CRDT- 2006/09/19 09:00
PHST- 2006/06/12 00:00 [received]
PHST- 2006/08/15 00:00 [revised]
PHST- 2006/08/20 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2006/11/11 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S0014-5793(06)01034-9 [pii]
AID - 10.1016/j.febslet.2006.08.059 [doi]
PST - ppublish
SO  - FEBS Lett. 2006 Oct 2;580(22):5208-14. doi: 10.1016/j.febslet.2006.08.059. Epub 
      2006 Sep 5.

PMID- 16927100
OWN - NLM
STAT- MEDLINE
DCOM- 20070430
LR  - 20220716
IS  - 0340-6717 (Print)
IS  - 0340-6717 (Linking)
VI  - 120
IP  - 4
DP  - 2006 Nov
TI  - Flies deficient in Muscleblind protein model features of myotonic dystrophy with 
      altered splice forms of Z-band associated transcripts.
PG  - 487-99
AB  - Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disorder 
      characterised by muscle weakness and wasting. There are two forms of DM; both of 
      which are caused by the expansion of repeated DNA sequences. DM1 is associated 
      with a CTG repeat located in the 3' untranslated region of a gene, DMPK and DM2 
      with a tetranucleotide repeat expansion, CCTG, located in the first intron of a 
      different gene, ZNF9. Recent data suggest a dominant RNA gain-of-function 
      mechanism underlying DM, as transcripts containing either CUG or CCUG repeat 
      expansions accumulate as foci in the nuclei of DM1 and DM2 cells respectively, 
      where they exert a toxic effect, sequestering specific RNA binding proteins such 
      as Muscleblind, which leads to splicing defects and the disruption of normal 
      cellular functions. Z-band disruption is a well-known histological feature of DM1 
      muscle, which has also been reported in Muscleblind deficient flies. In order to 
      determine whether there is a common molecular basis for this abnormality we have 
      examined the alternative splicing pattern of transcripts that encode proteins 
      associated with the Z-band in both organisms. Our results demonstrate that the 
      missplicing of ZASP/LDB3 leads to the expression of an isoform in DM1 patient 
      muscle, which is not present in normal controls, nor in other myopathies. 
      Furthermore the Drosophila homologue, CG30084, is also misspliced, in Muscleblind 
      deficient flies. Another Z-band transcript, alpha actinin, is misspliced in mbl 
      mutant flies, but not in DM1 patient samples. These results point to similarities 
      but subtle differences in the molecular breakdown of Z-band structures in flies 
      and DM patients and emphasise the relevance of Muscleblind proteins in DM 
      pathophysiology.
FAU - Machuca-Tzili, Laura
AU  - Machuca-Tzili L
AD  - Institute of Genetics, University of Nottingham, Queen's Medical Centre, 
      Nottingham, UK.
FAU - Thorpe, Helena
AU  - Thorpe H
FAU - Robinson, Thelma E
AU  - Robinson TE
FAU - Sewry, Caroline
AU  - Sewry C
FAU - Brook, J David
AU  - Brook JD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060823
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Drosophila Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (mbl protein, Drosophila)
RN  - 11003-00-2 (Actinin)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Actinin/genetics
MH  - Adaptor Proteins, Signal Transducing/genetics
MH  - Adult
MH  - *Alternative Splicing
MH  - Amino Acid Sequence
MH  - Animals
MH  - Disease Models, Animal
MH  - Drosophila Proteins/deficiency/*genetics
MH  - Drosophila melanogaster/embryology/*genetics/metabolism
MH  - Gene Expression Regulation, Developmental
MH  - Humans
MH  - Molecular Sequence Data
MH  - Muscle Proteins/*genetics
MH  - Muscle, Skeletal/embryology/metabolism/pathology
MH  - Mutation
MH  - Myotonic Dystrophy/embryology/*genetics/pathology
MH  - Nuclear Proteins/deficiency/*genetics
MH  - Protein Isoforms/genetics
MH  - RNA/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sequence Homology, Amino Acid
MH  - Sequence Homology, Nucleic Acid
MH  - Transcription, Genetic
EDAT- 2006/08/24 09:00
MHDA- 2007/05/01 09:00
CRDT- 2006/08/24 09:00
PHST- 2006/03/24 00:00 [received]
PHST- 2006/07/03 00:00 [accepted]
PHST- 2006/08/24 09:00 [pubmed]
PHST- 2007/05/01 09:00 [medline]
PHST- 2006/08/24 09:00 [entrez]
AID - 10.1007/s00439-006-0228-8 [doi]
PST - ppublish
SO  - Hum Genet. 2006 Nov;120(4):487-99. doi: 10.1007/s00439-006-0228-8. Epub 2006 Aug 
      23.

PMID- 16920640
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20080815
IS  - 1121-760X (Print)
IS  - 1121-760X (Linking)
VI  - 50
IP  - 3
DP  - 2006 Jul-Sep
TI  - Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker 
      of DM1 and DM2.
PG  - 177-82
AB  - Myotonic dystrophies (DM) are repeat expansion diseases in which expanded CTG 
      (DM1) and CCTG (DM2) repeats cause the disease. Mutant transcripts containing 
      CUG/CCUG repeats are retained in muscle nuclei producing ribonuclear inclusions, 
      which can bind specific RNA-binding proteins, leading to a reduction in their 
      activity. The sequestration of muscleblind-like proteins (MBNLs), a family of 
      alternative splicing factors, appears to be involved in splicing defects 
      characteristic of DM pathologies. To determine whether MBNL1 nuclear 
      sequestration is a feature of DM pathologies, we have examined the in vivo 
      distribution of MBNL1 in muscle sections from genetically confirmed DM1 (n=7) and 
      DM2 (n=9) patients, patients with other myotonic disorders (n=11) and from 
      patients with disorders caused by repeat expansions, but not DM1/DM2 (n=3). The 
      results of our immunofluorescence study indicate that, among patients examined, 
      MBNL1 nuclear sequestration in protein foci is a molecular pathology marker of 
      DM1 and DM2 patients where ribonuclear inclusions of transcripts with expanded 
      CUG/CCUG repeats are also present. These findings indicate that MBNLs might be 
      important targets for therapeutic interventions to correct some of the specific 
      features of DM pathology.
FAU - Cardani, R
AU  - Cardani R
AD  - Department of Molecular Biology and Biotechnologies, University of Milan, Italy.
FAU - Mancinelli, E
AU  - Mancinelli E
FAU - Rotondo, G
AU  - Rotondo G
FAU - Sansone, V
AU  - Sansone V
FAU - Meola, G
AU  - Meola G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur J Histochem
JT  - European journal of histochemistry : EJH
JID - 9207930
RN  - 0 (Genetic Markers)
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Cell Nucleus
MH  - DNA Repeat Expansion
MH  - *Genetic Markers
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Muscle, Skeletal/cytology/metabolism/pathology
MH  - Myotonic Dystrophy/classification/*genetics/*metabolism/pathology
MH  - RNA-Binding Proteins/genetics/*metabolism
EDAT- 2006/08/22 09:00
MHDA- 2007/03/16 09:00
CRDT- 2006/08/22 09:00
PHST- 2006/08/22 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2006/08/22 09:00 [entrez]
PST - ppublish
SO  - Eur J Histochem. 2006 Jul-Sep;50(3):177-82.

PMID- 16864772
OWN - NLM
STAT- MEDLINE
DCOM- 20061025
LR  - 20240324
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 103
IP  - 31
DP  - 2006 Aug 1
TI  - Reversal of RNA missplicing and myotonia after muscleblind overexpression in a 
      mouse poly(CUG) model for myotonic dystrophy.
PG  - 11748-53
AB  - RNA-mediated pathogenesis is a recently developed disease model that proposes 
      that certain types of mutant genes produce toxic transcripts that inhibit the 
      activities of specific proteins. This pathogenesis model was proposed first for 
      the neuromuscular disease myotonic dystrophy (DM), which is associated with the 
      expansion of structurally related (CTG)(n) and (CCTG)(n) microsatellites in two 
      unrelated genes. At the RNA level, these expansions form stable hairpins that 
      alter the pre-mRNA splicing activities of two antagonistic factor families, the 
      MBNL and CELF proteins. It is unclear which altered activity is primarily 
      responsible for disease pathogenesis and whether other factors and biochemical 
      pathways are involved. Here, we show that overexpression of Mbnl1 in vivo 
      mediated by transduction of skeletal muscle with a recombinant adeno-associated 
      viral vector rescues disease-associated muscle hyperexcitability, or myotonia, in 
      the HSA(LR) poly(CUG) mouse model for DM. Myotonia reversal occurs concurrently 
      with restoration of the normal adult-splicing patterns of four pre-mRNAs that are 
      misspliced during postnatal development in DM muscle. Our results support the 
      hypothesis that the loss of MBNL1 activity is a primary pathogenic event in the 
      development of RNA missplicing and myotonia in DM and provide a rationale for 
      therapeutic strategies designed either to overexpress MBNL1 or inhibit MBNL1 
      interactions with CUG and CCUG repeat expansions.
FAU - Kanadia, Rahul N
AU  - Kanadia RN
AD  - Department of Molecular Genetics and Microbiology, University of Florida College 
      of Medicine, Gainesville, FL 32610, USA.
FAU - Shin, Jihae
AU  - Shin J
FAU - Yuan, Yuan
AU  - Yuan Y
FAU - Beattie, Stuart G
AU  - Beattie SG
FAU - Wheeler, Thurman M
AU  - Wheeler TM
FAU - Thornton, Charles A
AU  - Thornton CA
FAU - Swanson, Maurice S
AU  - Swanson MS
LA  - eng
GR  - NS48843/NS/NINDS NIH HHS/United States
GR  - L30 AR053072/AR/NIAMS NIH HHS/United States
GR  - AR46799/AR/NIAMS NIH HHS/United States
GR  - P50 NS048843/NS/NINDS NIH HHS/United States
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - K24 AR048143/AR/NIAMS NIH HHS/United States
GR  - U54 NS048843/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20060724
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Cell Line
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Disease Models, Animal
MH  - Electromyography
MH  - Exons
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/cytology/physiology/physiopathology
MH  - *Myotonia/genetics/therapy
MH  - *Myotonic Dystrophy/genetics/therapy
MH  - Protein Isoforms/genetics/metabolism
MH  - RNA Precursors/metabolism
MH  - *RNA Splicing
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - *Trinucleotide Repeat Expansion
PMC - PMC1544241
COIS- Conflict of interest statement: M.S.S. is associated with a gene therapy company 
      that has optioned a license for AAV-mediated correction of myotonic dystrophy.
EDAT- 2006/07/26 09:00
MHDA- 2006/10/26 09:00
PMCR- 2007/02/01
CRDT- 2006/07/26 09:00
PHST- 2006/07/26 09:00 [pubmed]
PHST- 2006/10/26 09:00 [medline]
PHST- 2006/07/26 09:00 [entrez]
PHST- 2007/02/01 00:00 [pmc-release]
AID - 0604970103 [pii]
AID - 2984 [pii]
AID - 10.1073/pnas.0604970103 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11748-53. doi: 
      10.1073/pnas.0604970103. Epub 2006 Jul 24.

PMID- 16753177
OWN - NLM
STAT- MEDLINE
DCOM- 20060814
LR  - 20211203
IS  - 0022-2836 (Print)
IS  - 0022-2836 (Linking)
VI  - 360
IP  - 1
DP  - 2006 Jun 30
TI  - DM2 CCTG*CAGG repeats are crossover hotspots that are more prone to expansions 
      than the DM1 CTG*CAG repeats in Escherichia coli.
PG  - 21-36
AB  - Myotonic dystrophy type 2 (DM2) is caused by the extreme expansion of the 
      repeating tetranucleotide CCTG*CAGG sequence from <30 repeats in normal 
      individuals to approximately 11,000 for the full mutation in certain patients. 
      This repeat is in intron 1 of the zinc finger protein 9 gene on chromosome 3q21. 
      Since prior work demonstrated that CTG*CAG and GAA*TTC triplet repeats 
      (responsible for DM1 and Friedreich's ataxia, respectively) can expand by genetic 
      recombination, we investigated the capacity of the DM2 tetranucleotide repeats to 
      also expand during this process. Both gene conversion and unequal crossing over 
      are attractive mechanisms to effect these very large expansions. (CCTG*CAGG)n 
      (where n=30, 75, 114 or 160) repeats showed high recombination crossover 
      frequencies (up to 27-fold higher than the non-repeating control) in an 
      intramolecular plasmid system in Escherichia coli. Furthermore, a distinct 
      orientation effect was observed where orientation II (CAGG on the leading strand 
      template) was more prone to recombine. Expansions of up to double the length of 
      the tetranucleotide repeats were found. Also, the repeating tetranucleotide 
      sequence was more prone to expansions (to give lengths longer than a single 
      repeating tract) than deletions as observed for the CTG*CAG and GAA*TTC repeats. 
      We determined that the DM2 tetranucleotide repeats showed a lower thermodynamic 
      stability when compared to the DM1 trinucleotide repeats, which could make them 
      better targets for DNA repair events, thus explaining their expansion-prone 
      behavior. Genetic studies in SOS-repair mutants revealed high frequencies of 
      recombination crossovers although the SOS-response itself was not induced. Thus, 
      the genetic instabilities of the CCTG*CAGG repeats may be mediated by a 
      recombination-repair mechanism that is influenced by DNA structure.
FAU - Dere, Ruhee
AU  - Dere R
AD  - Institute of Biosciences and Technology, Center for Genome Research, Texas A&M 
      University System Health Science Center, Texas Medical Center, 2121 W. Holcombe 
      Blvd., Houston, TX 77030-3303, USA.
FAU - Wells, Robert D
AU  - Wells RD
LA  - eng
GR  - ES11347/ES/NIEHS NIH HHS/United States
GR  - NS37554/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20060519
PL  - Netherlands
TA  - J Mol Biol
JT  - Journal of molecular biology
JID - 2985088R
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Chromosome Mapping
MH  - Chromosomes, Human, Pair 3
MH  - DNA Repair
MH  - Escherichia coli/*genetics/metabolism
MH  - Humans
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Plasmids/metabolism
MH  - Protein Serine-Threonine Kinases/chemistry/*genetics
MH  - Recombination, Genetic
MH  - Species Specificity
MH  - Thermodynamics
MH  - Zinc Fingers
EDAT- 2006/06/07 09:00
MHDA- 2006/08/15 09:00
CRDT- 2006/06/07 09:00
PHST- 2006/02/10 00:00 [received]
PHST- 2006/04/27 00:00 [revised]
PHST- 2006/05/04 00:00 [accepted]
PHST- 2006/06/07 09:00 [pubmed]
PHST- 2006/08/15 09:00 [medline]
PHST- 2006/06/07 09:00 [entrez]
AID - S0022-2836(06)00578-X [pii]
AID - 10.1016/j.jmb.2006.05.012 [doi]
PST - ppublish
SO  - J Mol Biol. 2006 Jun 30;360(1):21-36. doi: 10.1016/j.jmb.2006.05.012. Epub 2006 
      May 19.

PMID- 16716318
OWN - NLM
STAT- MEDLINE
DCOM- 20060801
LR  - 20211203
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
VI  - 86
IP  - 1
DP  - 2006 Jul
TI  - Instability in the transmission of the myotonic dystrophy CTG repeat in human 
      oocytes and preimplantation embryos.
PG  - 98-105
AB  - OBJECTIVE: To elucidate the timing and variability of CTG repeat expansion within 
      the human dystrophia myotonica protein kinase (DMPK) gene in early development. 
      DESIGN: Triplet-primed polymerase chain reaction was used to amplify the expanded 
      CTG repeat in oocytes and embryos obtained from myotonic dystrophy 1 (DM1) 
      patients, and a heminested polymerase chain reaction approach was used to amplify 
      the normal CTG repeats in supernumerary IVF embryos. SETTING: University hospital 
      laboratory. PATIENT(S): Two DM1-affected females undergoing preimplantation 
      genetic diagnosis who carried different CTG repeats. Also, 61 IVF patients who 
      carried a (CTG)(5-18) and (CTG)(19-37) normal DMPK repeat. INTERVENTION(S): None. 
      MAIN OUTCOME MEASURE(S): The degree of expansion of the repeat in the oocytes and 
      embryos compared with the DM1-affected maternal repeat and the size of the 
      (CTG)(19-37) repeat compared with the parental size in IVF embryos. RESULT(S): 
      The degree of repeat expansion was greater than the DM1 maternal lymphocyte for 
      two of four oocytes, including a germinal vesicle-stage oocyte and 17 of 20 
      three-cell to blastocyst stage embryos. A change in the (CTG)(19-37) repeat was 
      seen in 7 (7%) of 95 paternal transmissions but in no maternal transmissions. 
      CONCLUSION(S): Because the repeat was already expanded in the immature oocyte, 
      the initial expansion most likely occurs during oogenesis. A variable degree of 
      DMPK(CTG)(n) expansion in the embryo is seen from different mothers. In addition, 
      instability in paternal transmission of normal-range (CTG)(19-37) repeats occurs 
      at the level of the embryo.
FAU - Dean, Nicola L
AU  - Dean NL
AD  - Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, 
      Canada.
FAU - Tan, Seang Lin
AU  - Tan SL
FAU - Ao, Asangla
AU  - Ao A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060523
PL  - United States
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Blastocyst/*physiology
MH  - Cells, Cultured
MH  - Chromosome Mapping
MH  - DNA Mutational Analysis
MH  - Female
MH  - Genetic Predisposition to Disease/genetics
MH  - Genetic Variation/genetics
MH  - Genomic Instability/genetics
MH  - Humans
MH  - Muscular Dystrophies/*congenital/*genetics
MH  - Myotonin-Protein Kinase
MH  - Oocytes/*physiology
MH  - Pregnancy
MH  - Prenatal Diagnosis
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2006/05/24 09:00
MHDA- 2006/08/02 09:00
CRDT- 2006/05/24 09:00
PHST- 2005/08/31 00:00 [received]
PHST- 2005/12/05 00:00 [revised]
PHST- 2005/12/05 00:00 [accepted]
PHST- 2006/05/24 09:00 [pubmed]
PHST- 2006/08/02 09:00 [medline]
PHST- 2006/05/24 09:00 [entrez]
AID - S0015-0282(06)00541-3 [pii]
AID - 10.1016/j.fertnstert.2005.12.025 [doi]
PST - ppublish
SO  - Fertil Steril. 2006 Jul;86(1):98-105. doi: 10.1016/j.fertnstert.2005.12.025. Epub 
      2006 May 23.

PMID- 16696870
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20060706
LR  - 20211020
IS  - 1744-9081 (Electronic)
IS  - 1744-9081 (Linking)
VI  - 2
DP  - 2006 May 15
TI  - Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy 
      type 1 (DM1).
PG  - 16
AB  - BACKGROUND: This study was designed to investigate cognitive abilities and their 
      correlations with CTG repeat expansion size in classical Myotonic dystrophy type 
      1 (DM1), given that earlier studies have indicated cognitive deficits, possibly 
      correlating with blood CTG repeats expansion size. METHODS: A measurement of CTG 
      repeat expansion in lymphocytes and an extensive neuropsychological examination 
      was made in 47 patients (25 women and 22 men). Individual results in the 
      examination were compared with normative data. RESULTS: A substantial proportion 
      of patients with DM1 (> 40%) scored worse in comparison to normative collectives 
      on tests measuring executive, arithmetic, attention, speed and visuospatial 
      abilities. We found significant correlations between longer CTG repeat expansion 
      size and lower results on most tests associated with these abilities. 
      Furthermore, the association between executive (frontal) deficits and DM1 were 
      strengthened when considering both test results and correlations with CTG repeat 
      expansion size in lymphocytes. CONCLUSION: This study showed deficits in several 
      cognitive abilities when patients with DM1 are compared to normative collectives. 
      Some of the neuropsychological tests associated with these abilities are 
      correlated to CTG repeat expansion size in blood. These data highlight the 
      importance of considering cognitive deficits when seeing patients with classical 
      DM1 in clinical practice, but also the utility of using blood CTG repeat 
      expansion size as a broad predictor of finding cognitive deficit in DM1.
FAU - Winblad, Stefan
AU  - Winblad S
AD  - Department of Psychology, Goteborg University, Goteborg, Sweden. 
      stefan.winblad@vgregion.se
FAU - Lindberg, Christopher
AU  - Lindberg C
FAU - Hansen, Stefan
AU  - Hansen S
LA  - eng
PT  - Journal Article
DEP - 20060515
PL  - England
TA  - Behav Brain Funct
JT  - Behavioral and brain functions : BBF
JID - 101245751
PMC - PMC1475858
EDAT- 2006/05/16 09:00
MHDA- 2006/05/16 09:01
PMCR- 2006/05/15
CRDT- 2006/05/16 09:00
PHST- 2006/04/27 00:00 [received]
PHST- 2006/05/15 00:00 [accepted]
PHST- 2006/05/16 09:00 [pubmed]
PHST- 2006/05/16 09:01 [medline]
PHST- 2006/05/16 09:00 [entrez]
PHST- 2006/05/15 00:00 [pmc-release]
AID - 1744-9081-2-16 [pii]
AID - 10.1186/1744-9081-2-16 [doi]
PST - epublish
SO  - Behav Brain Funct. 2006 May 15;2:16. doi: 10.1186/1744-9081-2-16.

PMID- 16624843
OWN - NLM
STAT- MEDLINE
DCOM- 20060921
LR  - 20080513
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 15
IP  - 11
DP  - 2006 Jun 1
TI  - DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence 
      or effects on ZNF9 mRNA processing or protein expression.
PG  - 1808-15
AB  - Myotonic dystrophy type 2 (DM2) is caused by a CCTG expansion mutation in intron 
      1 of the zinc finger protein 9 (ZNF9) gene. The mean expansion size in patients 
      is larger than for DM1 or any previously reported disorder (mean=5000 CCTGs; 
      range=75-11 000), and similar to DM1, repeats containing ribonuclear inclusions 
      accumulate in affected DM2 tissue. Although an RNA gain-of-function mechanism 
      involving DM1 CUG or DM2 CCUG expansion transcripts is now well established, 
      still debated are the potential role that flanking sequences within the DMPK 
      3'-UTR may have on disease pathogenesis and whether or not decreased expression 
      of DMPK, ZNF9 or neighboring genes at these loci contribute to disease. To 
      address these questions in DM2, we have examined the nucleic acid content of the 
      ribonuclear inclusions and the effects of these large expansions on ZNF9 
      expression. Using cell lines either haploid or homozygous for the expansion, as 
      well as skeletal muscle biopsy tissue, we demonstrate that pre-mRNAs containing 
      large CCUG expansions are normally spliced and exported from the nucleus, that 
      the expansions do not decrease ZNF9 expression at the mRNA or protein level, and 
      that the ribonuclear inclusions are enriched for the CCUG expansion, but not 
      intronic flanking sequences. These data suggest that the downstream molecular 
      effects of the DM2 mutation are triggered by the accumulation of CCUG repeat 
      tract alone.
FAU - Margolis, Jamie M
AU  - Margolis JM
AD  - Department of Genetics, Cell Biology and Development, University of Minnesota, 
      420 Delaware Street SE, Minneapolis, MN 55455, USA.
FAU - Schoser, Benedikt G
AU  - Schoser BG
FAU - Moseley, Melinda L
AU  - Moseley ML
FAU - Day, John W
AU  - Day JW
FAU - Ranum, Laura P W
AU  - Ranum LP
LA  - eng
GR  - NS 035870/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20060419
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Alternative Splicing
MH  - Biopsy
MH  - Cell Line
MH  - Cytoplasm/metabolism
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Introns
MH  - Muscle, Skeletal/*metabolism
MH  - Mutation
MH  - Protein Transport
MH  - RNA/metabolism
MH  - RNA-Binding Proteins/genetics/*physiology
EDAT- 2006/04/21 09:00
MHDA- 2006/09/22 09:00
CRDT- 2006/04/21 09:00
PHST- 2006/04/21 09:00 [pubmed]
PHST- 2006/09/22 09:00 [medline]
PHST- 2006/04/21 09:00 [entrez]
AID - ddl103 [pii]
AID - 10.1093/hmg/ddl103 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2006 Jun 1;15(11):1808-15. doi: 10.1093/hmg/ddl103. Epub 2006 Apr 
      19.

PMID- 16462497
OWN - NLM
STAT- MEDLINE
DCOM- 20060224
LR  - 20131121
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
VI  - 29
IP  - 1
DP  - 2006 Feb
TI  - Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
PG  - 14-20
AB  - OBJECTIVES: The number of CAG repeats on the androgen receptor (AR) gene is 
      inversely proportional to transcriptional activity. The purpose of this study was 
      to determine if short-term androgen deprivation therapy (RT + HT) can improve 
      outcome in patients with tumors with short CAG repeats (<19). MATERIALS AND 
      METHODS: Prostate cancer patients were randomized to receive either radiotherapy 
      (RT) alone or (RT + HT) in the RTOG 86-10 study. CAG repeats were measured in 94 
      tumor specimens (21%; test cohort) of the 456 (parent cohort) analyzable cases. 
      AR flow cytometry measurements were done on 13 patients. The effect on local 
      failure (LF), distant metastases (DM), prostate cancer survival (PSS), and 
      overall survival (OS) was studied. RESULTS: Pretreatment characteristics and 
      assigned treatment arm were not significantly different between the parent and 
      test groups except for a significantly higher risk of death (P = 0.049) in the 
      test group. The median CAG repeat was 19. There were no significant differences 
      in stage, or Gleason score between high (19 or greater) and low CAG (<19) 
      patients within each treatment group. Number of CAG repeats alone did not 
      significantly influence LF, DM, PSS, and OS. However, when the CAG repeat outcome 
      was studied in conjunction with androgen deprivation therapy, patients with CAG 
      <19 who received H + RT had improved local control as compared with patients who 
      received RT alone (P = 0.026, 5-year rates 4.6% versus 36.4%) and improved local 
      control over patients with CAG > or =19 that received H + RT (P = 0.028). 
      CONCLUSIONS: Patients with short CAG repeats show a local control benefit with 
      short-term androgen deprivation therapy, but no improvement in survival.
FAU - Abdel-Wahab, May
AU  - Abdel-Wahab M
AD  - Department of Radiation Oncology, University of Miami School of Medicine, Miami, 
      FL 33136, USA. mwahab@med.miami.edu
FAU - Berkey, Brian A
AU  - Berkey BA
FAU - Krishan, Awtar
AU  - Krishan A
FAU - O'Brien, Tom
AU  - O'Brien T
FAU - Hammond, Elizabeth
AU  - Hammond E
FAU - Roach, Mack 3rd
AU  - Roach M 3rd
FAU - Lawton, Colleen
AU  - Lawton C
FAU - Pilepich, Milijenko
AU  - Pilepich M
FAU - Markoe, Arnold
AU  - Markoe A
FAU - Pollack, Alan
AU  - Pollack A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Androgen Antagonists)
RN  - 0 (Receptors, Androgen)
RN  - 0F65R8P09N (Goserelin)
SB  - IM
MH  - Androgen Antagonists/therapeutic use
MH  - Combined Modality Therapy
MH  - Flow Cytometry
MH  - Goserelin/therapeutic use
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Prostatic Neoplasms/drug therapy/*genetics/*radiotherapy
MH  - Receptors, Androgen/*genetics
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - *Trinucleotide Repeats
EDAT- 2006/02/08 09:00
MHDA- 2006/02/25 09:00
CRDT- 2006/02/08 09:00
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/02/25 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
AID - 00000421-200602000-00005 [pii]
AID - 10.1097/01.coc.0000195085.34162.88 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2006 Feb;29(1):14-20. doi: 10.1097/01.coc.0000195085.34162.88.

PMID- 16455793
OWN - NLM
STAT- MEDLINE
DCOM- 20060417
LR  - 20061115
IS  - 1460-2156 (Electronic)
IS  - 0006-8950 (Linking)
VI  - 129
IP  - Pt 4
DP  - 2006 Apr
TI  - Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis.
PG  - 986-95
AB  - Inclusion body myositis (IBM) is the most frequent inflammatory myopathy over the 
      age of fifty. Pathological findings suggest that two processes may contribute to 
      IBM pathogenesis: a primary degenerative process affecting muscle fibre and/or an 
      autoimmune process mediated by major histocompatibility complex (MHC) 
      class-I-restricted cytotoxic CD8+ T cells. Previous studies have demonstrated 
      that muscle-infiltrating CD8+ T cells in IBM display restricted expression of 
      T-cell receptor (TCR)-BV families or evidenced oligoclonal T-cell expansions. 
      This study was performed to investigate whether blood T cells similarly exhibit 
      clonal expansions due to the recirculation of muscle-infiltrating T cells in the 
      periphery. For this, we studied the T-cell repertoire of 17 IBM patients by 
      complementarity-determining-region (CDR) 3 length distribution (immunoscope) 
      analysis of TCR-B transcripts. Mean age was 68 years (range 53-88) and mean 
      duration of the disease was 6.5 years (2-20). Oligoclonal T-cell expansions were 
      observed in the blood of IBM patients. The quantitative average perturbation D 
      index was significantly increased in IBM patients [D = 13.7% +/- 1.2%, mean +/- 
      standard error of measurement (SEM)] as compared with 17 age-matched controls 
      suffering from connective tissue diseases not associated with T-cell repertoire 
      perturbation, that is, dermatomyositis (DM) and systemic sclerosis (9.3 +/- 0.6%, 
      P < 0.005). Nevertheless, there was no correlation between the level of blood 
      perturbation and muscle inflammation. Sorting experiments showed that these 
      perturbations were due to oligoclonal expansions of CD8+ T cells. In the three 
      IBM patients analysed, we could relate the blood expansions to T-cell clones also 
      found in muscle. The clonally expanded blood T cells dramatically responded to 
      interleukin-2 (IL-2) in vitro, suggesting that they had been primed in vivo, 
      presumably in response to yet unknown muscle auto-antigens. Together, our results 
      indicate that clonally expanded muscle-infiltrating CD8+ T cells re-circulate in 
      the blood and support the concept of a CD8+ T-cell-mediated autoimmune component 
      in IBM, similarly to what is observed in polymyositis (PM).
FAU - Dimitri, Dalia
AU  - Dimitri D
AD  - Service de medecine interne 1, Hopital Pitie-Salpetriere, Paris, France.
FAU - Benveniste, Olivier
AU  - Benveniste O
FAU - Dubourg, Odile
AU  - Dubourg O
FAU - Maisonobe, Thierry
AU  - Maisonobe T
FAU - Eymard, Bruno
AU  - Eymard B
FAU - Amoura, Zahir
AU  - Amoura Z
FAU - Jean, Laetitia
AU  - Jean L
FAU - Tiev, Kiet
AU  - Tiev K
FAU - Piette, Jean-Charles
AU  - Piette JC
FAU - Klatzmann, David
AU  - Klatzmann D
FAU - Herson, Serge
AU  - Herson S
FAU - Boyer, Olivier
AU  - Boyer O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060202
PL  - England
TA  - Brain
JT  - Brain : a journal of neurology
JID - 0372537
RN  - 0 (Complementarity Determining Regions)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Autoimmune Diseases/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Movement/immunology
MH  - Cells, Cultured
MH  - Complementarity Determining Regions/analysis
MH  - Female
MH  - Humans
MH  - Interleukin-2/immunology
MH  - Lymphocyte Activation/immunology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*immunology
MH  - Myositis, Inclusion Body/*immunology/pathology
MH  - Severity of Illness Index
MH  - T-Lymphocyte Subsets/immunology
EDAT- 2006/02/04 09:00
MHDA- 2006/04/18 09:00
CRDT- 2006/02/04 09:00
PHST- 2006/02/04 09:00 [pubmed]
PHST- 2006/04/18 09:00 [medline]
PHST- 2006/02/04 09:00 [entrez]
AID - awl020 [pii]
AID - 10.1093/brain/awl020 [doi]
PST - ppublish
SO  - Brain. 2006 Apr;129(Pt 4):986-95. doi: 10.1093/brain/awl020. Epub 2006 Feb 2.

PMID- 16427644
OWN - NLM
STAT- MEDLINE
DCOM- 20070109
LR  - 20061002
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 189
IP  - 1
DP  - 2006 Nov
TI  - Endothelial nitric oxide synthase haplotypes affect the susceptibility to 
      hypertension in patients with type 2 diabetes mellitus.
PG  - 241-6
AB  - Type 2 diabetes mellitus (T2DM) and hypertension (HT) commonly coexist. While 
      endothelial nitric oxide synthase (eNOS) haplotypes have been associated with HT, 
      it is unknown whether eNOS genotypes/haplotypes are associated with altered 
      susceptibility to HT in patients with T2DM. We studied the distribution of three 
      eNOS genetic polymorphisms: a single nucleotide polymorphism in the promoter 
      region (T(-786)C), in exon 7 (Glu298Asp), and a variable number of tandem repeats 
      in intron 4(b/a). Genotypes were determined for 102 healthy controls, 119 
      patients with HT, 66 patients with T2DM, and 113 patients with T2DM+HT. In 
      addition, we also compared the distribution of eNOS haplotypes in the four groups 
      of subjects. No differences were found in genotype and allele distribution among 
      the four groups. Conversely, the haplotypes "C Glu b" and "C Asp b" were, 
      respectively, more and less common in healthy controls than in HT or in T2DM+HT 
      groups (24% versus 6% and 5%, respectively; both P<0.00625; and 8% versus 18% and 
      18%, respectively; both P<0.00625). Moreover, DM patients presented an overall 
      distribution of eNOS haplotypes that was not different from healthy controls 
      (P>0.05). Additionally, the haplotypes "C Glu b" and "C Asp b" were, 
      respectively, more and less common in T2DM group than in T2DM+HT group (19% 
      versus 5%; and 7% versus 18%, respectively; both P<0.00625). Our findings suggest 
      a protective effect for eNOS haplotype "C Glu b" against the development of 
      hypertension, and that haplotype "C Asp b" increases the susceptibility to 
      hypertension in patients without or with T2DM.
FAU - Sandrim, Valeria C
AU  - Sandrim VC
AD  - Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of 
      Sao Paulo, Av. Bandeirantes, 3900, 14049-900 Ribeirao Preto, SP, Brazil.
FAU - de Syllos, Roger W C
AU  - de Syllos RW
FAU - Lisboa, Hugo R K
AU  - Lisboa HR
FAU - Tres, Glaucia S
AU  - Tres GS
FAU - Tanus-Santos, Jose E
AU  - Tanus-Santos JE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060120
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 9007-49-2 (DNA)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Alleles
MH  - DNA/*genetics
MH  - Diabetes Mellitus, Type 2/*complications/enzymology
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Haplotypes
MH  - Humans
MH  - Hypertension/complications/enzymology/*genetics
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide Synthase Type III/blood/*genetics
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Prognosis
MH  - Risk Factors
EDAT- 2006/01/24 09:00
MHDA- 2007/01/11 09:00
CRDT- 2006/01/24 09:00
PHST- 2005/10/24 00:00 [received]
PHST- 2005/12/01 00:00 [revised]
PHST- 2005/12/14 00:00 [accepted]
PHST- 2006/01/24 09:00 [pubmed]
PHST- 2007/01/11 09:00 [medline]
PHST- 2006/01/24 09:00 [entrez]
AID - S0021-9150(05)00833-6 [pii]
AID - 10.1016/j.atherosclerosis.2005.12.011 [doi]
PST - ppublish
SO  - Atherosclerosis. 2006 Nov;189(1):241-6. doi: 
      10.1016/j.atherosclerosis.2005.12.011. Epub 2006 Jan 20.

PMID- 16421126
OWN - NLM
STAT- MEDLINE
DCOM- 20060313
LR  - 20211203
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 77
IP  - 2
DP  - 2006 Feb
TI  - Facial emotion recognition in myotonic dystrophy type 1 correlates with CTG 
      repeat expansion.
PG  - 219-23
AB  - OBJECTIVE: To investigate the ability of patients with myotonic dystrophy type 1 
      to recognise basic facial emotions. We also explored the relationship between 
      facial emotion recognition, neuropsychological data, personality, and CTG repeat 
      expansion data in the DM-1 group. METHODS: In total, 50 patients with DM-1 (28 
      women and 22 men) participated, with 41 healthy controls. Recognition of facial 
      emotional expressions was assessed using photographs of basic emotions. A set of 
      tests measured cognition and personality dimensions, and CTG repeat size was 
      quantified in blood lymphocytes. RESULTS: Patients with DM-1 showed impaired 
      recognition of facial emotions compared with controls. A significant negative 
      correlation was found between total score of emotion recognition in a forced 
      choice task and CTG repeat size. Furthermore, specific cognitive functions 
      (vocabulary, visuospatial construction ability, and speed) and personality 
      dimensions (reward dependence and cooperativeness) correlated with scores on the 
      forced choice emotion recognition task. CONCLUSION: These findings revealed a CTG 
      repeat dependent facial emotion recognition deficit in the DM-1 group, which was 
      associated with specific neuropsychological functions. Furthermore, a correlation 
      was found between facial emotional recognition ability and personality dimensions 
      associated with sociability. This adds a new clinically relevant dimension in the 
      cognitive deficits associated with DM-1.
FAU - Winblad, S
AU  - Winblad S
AD  - Department of Psychology, Goteborg University, Sweden. stefan.winblad@vgregion.se
FAU - Hellstrom, P
AU  - Hellstrom P
FAU - Lindberg, C
AU  - Lindberg C
FAU - Hansen, S
AU  - Hansen S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Cognition Disorders/genetics/psychology
MH  - Discrimination Learning/*physiology
MH  - Emotions/*physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/psychology
MH  - Myotonin-Protein Kinase
MH  - Neuropsychological Tests/statistics & numerical data
MH  - *Nonverbal Communication
MH  - Personality Inventory/statistics & numerical data
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Psychometrics/statistics & numerical data
MH  - Reference Values
MH  - Statistics as Topic
MH  - *Trinucleotide Repeats
PMC - PMC2077576
COIS- Competing interests: none
EDAT- 2006/01/20 09:00
MHDA- 2006/03/15 09:00
PMCR- 2009/02/01
CRDT- 2006/01/20 09:00
PHST- 2006/01/20 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2006/01/20 09:00 [entrez]
PHST- 2009/02/01 00:00 [pmc-release]
AID - 77/2/219 [pii]
AID - jn70763 [pii]
AID - 10.1136/jnnp.2005.070763 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):219-23. doi: 
      10.1136/jnnp.2005.070763.

PMID- 16401743
OWN - NLM
STAT- MEDLINE
DCOM- 20060302
LR  - 20171116
IS  - 0003-9942 (Print)
IS  - 0003-9942 (Linking)
VI  - 63
IP  - 1
DP  - 2006 Jan
TI  - Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene 
      and another gene produce novel phenotypes.
PG  - 112-7
AB  - BACKGROUND: Mutations in the peripheral myelin protein 22 (PMP-22) gene are the 
      most common cause of Charcot-Marie-Tooth neuropathy and may rarely occur in 
      combination with other neurogenetic diseases. OBJECTIVE: To characterize 3 
      families having a mutation in PMP-22 in addition to another neurogenetic disease 
      mutation. DESIGN: Clinical, electrophysiologic, and genetic evaluations were made 
      of 3 families with more than 1 genetic neuromuscular disease. SETTING AND 
      PATIENTS: Family members were evaluated in neurogenetic and muscular dystrophy 
      clinics in a university medical center setting. RESULTS: Three unusual families 
      were found: (1) 2 young brothers each having a PMP-22 duplication and a missense 
      mutation in the GJB1 (Connexin-32) gene; (2) a 32-year-old woman having a PMP-22 
      duplication and a 1000-fold CTG repeat expansion in the DMPK gene (DM1 myotonic 
      dystrophy); and (3) a 39-year-old man with a PMP-22 deletion and a missense 
      mutation in the ABCD1 gene (adrenomyeloneuropathy). The mutations were 
      "additive," causing a more severe phenotype than expected with each individual 
      disease and coinciding with the important impact of each gene on peripheral nerve 
      function. CONCLUSIONS: Individuals having 2 separate mutations in neuromuscular 
      disease-related genes may develop unusually severe phenotypes. Neurologists 
      should be alert to this possibility.
FAU - Hodapp, Julie A
AU  - Hodapp JA
AD  - Department of Rehabilitation Medicine, School of Medicine, University of 
      Washington, Seattle, USA.
FAU - Carter, Gregory T
AU  - Carter GT
FAU - Lipe, Hillary P
AU  - Lipe HP
FAU - Michelson, Sara J
AU  - Michelson SJ
FAU - Kraft, George H
AU  - Kraft GH
FAU - Bird, Thomas D
AU  - Bird TD
LA  - eng
GR  - U54-AR5074101/AR/NIAMS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Neurol
JT  - Archives of neurology
JID - 0372436
RN  - 0 (Myelin Proteins)
RN  - 0 (PMP22 protein, human)
SB  - IM
EIN - Arch Neurol. 2006 Apr;63(4):501
MH  - Adult
MH  - Child
MH  - DNA Mutational Analysis/methods
MH  - Electromyography/methods
MH  - *Family Health
MH  - Female
MH  - Genetic Carrier Screening
MH  - Heredodegenerative Disorders, Nervous System/*genetics/physiopathology
MH  - Humans
MH  - Male
MH  - Muscular Diseases/genetics/physiopathology
MH  - Mutation/*genetics
MH  - Myelin Proteins/*genetics
MH  - Neural Conduction/physiology
MH  - *Phenotype
EDAT- 2006/01/13 09:00
MHDA- 2006/03/03 09:00
CRDT- 2006/01/13 09:00
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2006/03/03 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - 63/1/112 [pii]
AID - 10.1001/archneur.63.1.112 [doi]
PST - ppublish
SO  - Arch Neurol. 2006 Jan;63(1):112-7. doi: 10.1001/archneur.63.1.112.

PMID- 16376058
OWN - NLM
STAT- MEDLINE
DCOM- 20060410
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1762
IP  - 3
DP  - 2006 Mar
TI  - Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy 
      type II (DM2).
PG  - 329-34
AB  - Myotonic dystrophy is caused by two different mutations: a (CTG)n expansion in 3' 
      UTR region of the DMPK gene (DM1) and a (CCTG)n expansion in intron 1 of the ZNF9 
      gene (DM2). The most accredited mechanism for DM pathogenesis is an RNA 
      gain-of-function. Other findings suggest a contributory role of 
      DMPK-insufficiency in DM1. To address the issue of ZNF9 role in DM2, we have 
      analyzed the effects of (CCTG)n expansion on ZNF9 expression in lymphoblastoid 
      cell lines (n=4) from DM2 patients. We did not observe any significant alteration 
      in ZNF9 mRNA and protein levels, as shown by QRT-PCR and Western blot analyses. 
      Additional RT-PCR experiments demonstrated that ZNF9 pre-mRNA splicing pattern, 
      which includes two isoforms, is unmodified in DM2 cells. Our results indicate 
      that the (CCTG)n expansion in the ZNF9 intron does not appear to have a direct 
      consequence on the expression of the gene itself.
FAU - Botta, Annalisa
AU  - Botta A
AD  - Department of Biopathology, Tor Vergata University, Rome, Italy.
FAU - Caldarola, Sara
AU  - Caldarola S
FAU - Vallo, Laura
AU  - Vallo L
FAU - Bonifazi, Emanuela
AU  - Bonifazi E
FAU - Fruci, Doriana
AU  - Fruci D
FAU - Gullotta, Francesca
AU  - Gullotta F
FAU - Massa, Roberto
AU  - Massa R
FAU - Novelli, Giuseppe
AU  - Novelli G
FAU - Loreni, Fabrizio
AU  - Loreni F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051206
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (CNBP protein, human)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - *Base Sequence
MH  - Cells, Cultured
MH  - *DNA Repeat Expansion
MH  - *Gene Expression Regulation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Introns
MH  - Lymphocytes/cytology/physiology
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - Phenotype
MH  - Protein Isoforms/genetics/metabolism
MH  - RNA Precursors/metabolism
MH  - RNA Splicing
MH  - *RNA-Binding Proteins/genetics/metabolism
MH  - Recombinant Fusion Proteins/genetics/metabolism
MH  - Zinc Fingers
EDAT- 2005/12/27 09:00
MHDA- 2006/04/11 09:00
CRDT- 2005/12/27 09:00
PHST- 2005/06/28 00:00 [received]
PHST- 2005/10/07 00:00 [revised]
PHST- 2005/11/08 00:00 [accepted]
PHST- 2005/12/27 09:00 [pubmed]
PHST- 2006/04/11 09:00 [medline]
PHST- 2005/12/27 09:00 [entrez]
AID - S0925-4439(05)00173-0 [pii]
AID - 10.1016/j.bbadis.2005.11.004 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2006 Mar;1762(3):329-34. doi: 10.1016/j.bbadis.2005.11.004. 
      Epub 2005 Dec 6.

PMID- 16193250
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20220129
IS  - 1590-1874 (Print)
IS  - 1590-1874 (Linking)
VI  - 26
IP  - 4
DP  - 2005 Oct
TI  - Decreased expression of DMPK: correlation with CTG repeat expansion and fibre 
      type composition in myotonic dystrophy type 1.
PG  - 235-42
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease caused by a 
      trinucleotide repeat-expansion, cytosine-thymine-guanine (CTG)n, in the 3' 
      untranslated region of a gene encoding the myotonic dystrophy protein kinase 
      (DMPK). To correlate CTG expansion and protein expression, we studied muscle 
      specimens from 16 adult DM1 patients using three anti-DMPK antibodies for 
      immunoblotting. We estimated the amount of the full-length DMPK (85 kDa) in 
      muscle biopsies from normal controls and from DM1 patients carrying different 
      (CTG)n expansions. We found that DMPK concentration was decreased to about 50% in 
      DM patients' muscles; the protein decrease did not seem correlated with the CTG 
      repeat length. However, the fibre type composition in skeletal muscle seemed 
      somehow to affect DMPK decrease, as the lowest level of the enzyme was found in 
      patients with the lowest content of type 1 fibre.
FAU - Salvatori, S
AU  - Salvatori S
AD  - Department of Biomedical Sciences, University of Padova, Viale G. Colombo 3, 
      Padova, Italy. sergio.salvatori@unipd.it
FAU - Fanin, M
AU  - Fanin M
FAU - Trevisan, C P
AU  - Trevisan CP
FAU - Furlan, S
AU  - Furlan S
FAU - Reddy, S
AU  - Reddy S
FAU - Nagy, J I
AU  - Nagy JI
FAU - Angelini, C
AU  - Angelini C
LA  - eng
GR  - GTF02009/TI_/Telethon/Italy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Neurol Sci
JT  - Neurological sciences : official journal of the Italian Neurological Society and 
      of the Italian Society of Clinical Neurophysiology
JID - 100959175
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Biopsy
MH  - *Gene Expression Regulation, Enzymologic
MH  - Humans
MH  - Immunohistochemistry
MH  - Middle Aged
MH  - Muscle, Skeletal/enzymology/pathology
MH  - Myotonic Dystrophy/classification/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - *Trinucleotide Repeat Expansion
EDAT- 2005/09/30 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/09/30 09:00
PHST- 2005/03/30 00:00 [received]
PHST- 2005/07/12 00:00 [accepted]
PHST- 2005/09/30 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/09/30 09:00 [entrez]
AID - 10.1007/s10072-005-0466-x [doi]
PST - ppublish
SO  - Neurol Sci. 2005 Oct;26(4):235-42. doi: 10.1007/s10072-005-0466-x.

PMID- 16027111
OWN - NLM
STAT- MEDLINE
DCOM- 20050727
LR  - 20211203
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 33
IP  - 12
DP  - 2005
TI  - HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a 
      distal branch point sequence.
PG  - 3866-74
AB  - Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder 
      associated with a (CUG)n expansion in the 3'-untranslated region of the DMPK (DM1 
      protein kinase) gene. Mutant DMPK mRNAs containing the trinucleotide expansion 
      are retained in the nucleus of DM1 cells and form discrete foci. The nuclear 
      sequestration of RNA binding proteins and associated factors binding to the CUG 
      expansions is believed to be responsible for several of the splicing defects 
      observed in DM1 patients and could ultimately be linked to DM1 muscular 
      pathogenesis. Several RNA binding proteins capable of co-localizing with the 
      nuclear-retained mutant DMPK mRNAs have already been identified but none can 
      account for the nuclear retention of the mutant transcripts. Here, we have 
      employed a modified UV crosslinking assay to isolate proteins bound to mutant 
      DMPK-derived RNA and have identified hnRNP H as an abundant candidate. The 
      specific binding of hnRNP H requires not only a CUG repeat expansion but also a 
      splicing branch point distal to the repeats. Suppression of hnRNP H expression by 
      RNAi rescued nuclear retention of RNA with CUG repeat expansions. The 
      identification of hnRNP H as a factor capable of binding and possibly modulating 
      nuclear retention of mutant DMPK mRNA may prove to be an important link in our 
      understanding of the molecular mechanisms that lead to DM1 pathogenesis.
FAU - Kim, Dong-Ho
AU  - Kim DH
AD  - Department of Molecular Biology, Beckman Research Institute of the City of Hope 
      Duarte, CA, USA.
FAU - Langlois, Marc-Andre
AU  - Langlois MA
FAU - Lee, Kwang-Back
AU  - Lee KB
FAU - Riggs, Arthur D
AU  - Riggs AD
FAU - Puymirat, Jack
AU  - Puymirat J
FAU - Rossi, John J
AU  - Rossi JJ
LA  - eng
GR  - AI29329/AI/NIAID NIH HHS/United States
GR  - R01 HL074704/HL/NHLBI NIH HHS/United States
GR  - R37 AI029329/AI/NIAID NIH HHS/United States
GR  - HL074704/HL/NHLBI NIH HHS/United States
GR  - R01 AI029329/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050715
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (Heterogeneous-Nuclear Ribonucleoprotein Group F-H)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/chemistry
MH  - Active Transport, Cell Nucleus
MH  - Cell Line
MH  - Cell Nucleus/*metabolism
MH  - *DNA Repeat Expansion
MH  - Dimerization
MH  - Heterogeneous-Nuclear Ribonucleoprotein Group F-H/antagonists & 
      inhibitors/genetics/*physiology
MH  - Humans
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/biosynthesis/*genetics
MH  - RNA Interference
MH  - RNA Splicing
MH  - RNA, Messenger/analysis/*chemistry/*metabolism
MH  - Repetitive Sequences, Nucleic Acid
PMC - PMC1176012
EDAT- 2005/07/20 09:00
MHDA- 2005/07/28 09:00
PMCR- 2005/07/15
CRDT- 2005/07/20 09:00
PHST- 2005/07/20 09:00 [pubmed]
PHST- 2005/07/28 09:00 [medline]
PHST- 2005/07/20 09:00 [entrez]
PHST- 2005/07/15 00:00 [pmc-release]
AID - 33/12/3866 [pii]
AID - 10.1093/nar/gki698 [doi]
PST - epublish
SO  - Nucleic Acids Res. 2005 Jul 15;33(12):3866-74. doi: 10.1093/nar/gki698. Print 
      2005.

PMID- 15991869
OWN - NLM
STAT- MEDLINE
DCOM- 20050802
LR  - 20190816
IS  - 0012-1622 (Print)
IS  - 0012-1622 (Linking)
VI  - 47
IP  - 7
DP  - 2005 Jul
TI  - Myotonic dystrophy: muscle involvement in relation to disease type and size of 
      expanded CTG-repeat sequence.
PG  - 478-85
AB  - This study aimed to: classify a cohort of children and adolescents with myotonic 
      dystrophy (dystrophia myotonica: DM) into congenital and childhood onset forms; 
      estimate CTG expansion size; and quantify muscle strength, contractures, and 
      motor function in children with DM and compare results with those of controls. 
      Participants were clinically examined, medical records were reviewed, and 
      isometric muscle strength, contractures, and motor function were measured. 
      Participants were: 42 children with DM (18 females, 24 males; mean age 8y 9mo [SD 
      4y 7mo], range 10mo to 17y) and 42 age- and sex-matched, healthy controls. 
      Children with DM were divided into three groups: severe congenital (n=13), mild 
      congenital (n=15), and childhood (n=14). Children with childhood DM were 
      significantly weaker than controls (wrist and ankle dorsiflexors [p=0.0044, 
      p=0.0044 respectively]; hip abductors and flexors [p=0.0464, p=0.0217]; and knee 
      flexors and extensors: [p=0.0382, p=0.0033]). Children with mild congenital DM 
      were significantly weaker than controls in all assessed muscle groups. 
      Contractures and skeletal deformities were more frequent at time of investigation 
      than at birth, suggesting that foot and spine deformities in particular increase 
      over time. Motor function score was significantly lower for children with DM than 
      for controls. Children with severe congenital DM had the lowest motor function, 
      with correlation between motor function and size of CTG repeat (p=-0.743). 
      Children found jumping, heel standing, and head lifting the most difficult items 
      to perform but few had difficulty walking, running, or stair climbing. DM in 
      children is a heterogeneous disorder with a wide spectrum of muscle involvement, 
      and owing to increased risk of contractures and skeletal deformities, regular 
      follow-ups are recommended.
FAU - Kroksmark, Anna-Karin
AU  - Kroksmark AK
AD  - Department of Paediatrics, The Queen Silvia Children's Hospital, Sahlgrenska 
      University Hospital, S-416 85 Goteborg, Sweden. anna-karin.kroksmark@vgregion.se
FAU - Ekstrom, Anne-Berit
AU  - Ekstrom AB
FAU - Bjorck, Eva
AU  - Bjorck E
FAU - Tulinius, Mar
AU  - Tulinius M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Dev Med Child Neurol
JT  - Developmental medicine and child neurology
JID - 0006761
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - DNA/isolation & purification
MH  - Female
MH  - Humans
MH  - Infant
MH  - Isometric Contraction/physiology
MH  - Male
MH  - Motor Activity/physiology
MH  - Muscle, Skeletal/*physiopathology
MH  - Myotonic Dystrophy/classification/*genetics/physiopathology
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Walking/physiology
EDAT- 2005/07/05 09:00
MHDA- 2005/08/03 09:00
CRDT- 2005/07/05 09:00
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2005/08/03 09:00 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - 10.1017/s0012162205000927 [doi]
PST - ppublish
SO  - Dev Med Child Neurol. 2005 Jul;47(7):478-85. doi: 10.1017/s0012162205000927.

PMID- 15972723
OWN - NLM
STAT- MEDLINE
DCOM- 20051201
LR  - 20191210
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 14
IP  - 15
DP  - 2005 Aug 1
TI  - Altered mRNA splicing of the skeletal muscle ryanodine receptor and 
      sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1.
PG  - 2189-200
AB  - Myotonic dystrophy type 1 (DM1) is a debilitating multisystemic disorder caused 
      by a CTG repeat expansion in the DMPK gene. Aberrant splicing of several genes 
      has been reported to contribute to some symptoms of DM1, but the cause of muscle 
      weakness in DM1 and elevated Ca2+ concentrations in cultured DM muscle cells is 
      unknown. Here, we investigated the alternative splicing of mRNAs of two major 
      proteins of the sarcoplasmic reticulum, the ryanodine receptor 1 (RyR1) and 
      sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) 1 or 2. The fetal 
      variants, ASI(-) of RyR1 which lacks residue 3481-3485, and SERCA1b which differs 
      at the C-terminal were significantly increased in skeletal muscles from DM1 
      patients and the transgenic mouse model of DM1 (HSA(LR)). In addition, a novel 
      variant of SERCA2 was significantly decreased in DM1 patients. The total amount 
      of mRNA for RyR1, SERCA1 and SERCA2 in DM1 and the expression levels of their 
      proteins in HSA(LR) mice were not significantly different. However, heterologous 
      expression of ASI(-) in cultured cells showed decreased affinity for 
      [3H]ryanodine but similar Ca2+ dependency, and decreased channel activity in 
      single-channel recording when compared with wild-type (WT) RyR1. In support of 
      this, RyR1-knockout myotubes expressing ASI(-) exhibited a decreased incidence of 
      Ca2+ oscillations during caffeine exposure compared with that observed for 
      myotubes expressing WT-RyR1. We suggest that aberrant splicing of RyR1 and SERCA1 
      mRNAs might contribute to impaired Ca2+ homeostasis in DM1 muscle.
FAU - Kimura, Takashi
AU  - Kimura T
AD  - Division of Molecular Bioscience, John Curtin School of Medical Research, 
      Australian National University, PO Box 334, Canberra ACT 2601, Australia.
FAU - Nakamori, Masayuki
AU  - Nakamori M
FAU - Lueck, John D
AU  - Lueck JD
FAU - Pouliquin, Pierre
AU  - Pouliquin P
FAU - Aoike, Futoshi
AU  - Aoike F
FAU - Fujimura, Harutoshi
AU  - Fujimura H
FAU - Dirksen, Robert T
AU  - Dirksen RT
FAU - Takahashi, Masanori P
AU  - Takahashi MP
FAU - Dulhunty, Angela F
AU  - Dulhunty AF
FAU - Sakoda, Saburo
AU  - Sakoda S
LA  - eng
GR  - AR050762/AR/NIAMS NIH HHS/United States
GR  - AR44657/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050622
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Atp2a1 protein, mouse)
RN  - 0 (Calcium Channels)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - 0 (Ryanodine Receptor Calcium Release Channel)
RN  - 15662-33-6 (Ryanodine)
RN  - 3G6A5W338E (Caffeine)
RN  - EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases)
RN  - EC 7.2.2.10 (ATP2A1 protein, human)
RN  - EC 7.2.2.10 (ATP2A2 protein, human)
RN  - EC 7.2.2.10 (Atp2a2 protein, mouse)
RN  - EC 7.2.2.10 (Calcium-Transporting ATPases)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - *Alternative Splicing
MH  - Animals
MH  - Caffeine/pharmacology
MH  - Calcium/analysis/metabolism
MH  - Calcium Channels/metabolism
MH  - Calcium-Transporting ATPases/*genetics/metabolism
MH  - Cells, Cultured
MH  - Genetic Variation
MH  - Humans
MH  - Mice
MH  - Muscle Fibers, Skeletal/metabolism
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - Protein Binding
MH  - Protein Isoforms/genetics/metabolism
MH  - RNA, Messenger/metabolism
MH  - Ryanodine/metabolism
MH  - Ryanodine Receptor Calcium Release Channel/*genetics/metabolism
MH  - Sarcoplasmic Reticulum/metabolism
MH  - Sarcoplasmic Reticulum Calcium-Transporting ATPases
MH  - Transfection
EDAT- 2005/06/24 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/24 09:00
PHST- 2005/06/24 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/24 09:00 [entrez]
AID - ddi223 [pii]
AID - 10.1093/hmg/ddi223 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2005 Aug 1;14(15):2189-200. doi: 10.1093/hmg/ddi223. Epub 2005 Jun 
      22.

PMID- 15961406
OWN - NLM
STAT- MEDLINE
DCOM- 20051128
LR  - 20240104
IS  - 0021-9533 (Print)
IS  - 0021-9533 (Linking)
VI  - 118
IP  - Pt 13
DP  - 2005 Jul 1
TI  - Colocalization of muscleblind with RNA foci is separable from mis-regulation of 
      alternative splicing in myotonic dystrophy.
PG  - 2923-33
AB  - Myotonic dystrophy type I (DM1), which is caused by a non-coding CTG-repeat 
      expansion in the dystrophia myotonica-protein kinase (DMPK) gene, is an 
      RNA-mediated disease. Expanded CUG repeats in transcripts of mutant DMPK form 
      nuclear foci that recruit muscleblind-like (MBNL) proteins, a family of 
      alternative splicing factors. Although transcripts of mutant DMPK and MBNL 
      proteins accumulate in nuclear RNA foci, it is not clear whether foci formation 
      is required for splicing mis-regulation. Here, we use a co-transfection strategy 
      to show that both CUG and CAG repeats form RNA foci that colocalize with green 
      fluorescent protein (GFP)-MBNL1 and endogenous MBNL1. However, only CUG repeats 
      alter splicing of the two tested pre-mRNAs, cardiac troponin T (cTNT) and insulin 
      receptor (IR). Using FRAP, we demonstrate that GFP-MBNL1 in CUG and CAG foci have 
      similar half-times of recovery and fractions of immobile molecules, suggesting 
      that GFP-MBNL1 is bound by both CUG and CAG repeats. We also find an immobile 
      fraction of GFP-MBNL1 in DM1 fibroblasts and a similar rapid exchange in 
      endogenous CUG RNA foci. Therefore, formation of RNA foci and disruption of 
      MBNL1-regulated splicing are separable events.
FAU - Ho, Thai H
AU  - Ho TH
AD  - Department of Molecular and Cellular Biology, Baylor College of Medicine, One 
      Baylor Plaza, Houston, TX 77030, USA.
FAU - Savkur, Rajesh S
AU  - Savkur RS
FAU - Poulos, Michael G
AU  - Poulos MG
FAU - Mancini, Michael A
AU  - Mancini MA
FAU - Swanson, Maurice S
AU  - Swanson MS
FAU - Cooper, Thomas A
AU  - Cooper TA
LA  - eng
GR  - AR46799/AR/NIAMS NIH HHS/United States
GR  - NS48843/NS/NINDS NIH HHS/United States
GR  - R01AR45653/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050616
PL  - England
TA  - J Cell Sci
JT  - Journal of cell science
JID - 0052457
RN  - 0 (MBNL1 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adult
MH  - *Alternative Splicing
MH  - Cell Line
MH  - Cell Nucleus/*genetics/metabolism
MH  - Exons
MH  - Fibroblasts/metabolism/ultrastructure
MH  - Gene Expression
MH  - Green Fluorescent Proteins/genetics/metabolism
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Myotonic Dystrophy/classification/*genetics/*metabolism
MH  - RNA/*genetics/metabolism
MH  - RNA-Binding Proteins/*genetics/metabolism
MH  - Time Factors
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 2005/06/18 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/18 09:00
PHST- 2005/06/18 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/18 09:00 [entrez]
AID - jcs.02404 [pii]
AID - 10.1242/jcs.02404 [doi]
PST - ppublish
SO  - J Cell Sci. 2005 Jul 1;118(Pt 13):2923-33. doi: 10.1242/jcs.02404. Epub 2005 Jun 
      16.

PMID- 15843400
OWN - NLM
STAT- MEDLINE
DCOM- 20051128
LR  - 20151119
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 14
IP  - 11
DP  - 2005 Jun 1
TI  - Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in 
      myotonic dystrophy.
PG  - 1539-47
AB  - Myotonic dystrophy type I (DM1) is an RNA-mediated disease caused by a non-coding 
      CTG repeat expansion. A key feature of the RNA-mediated pathogenesis model for DM 
      is the disrupted splicing of specific pre-mRNA targets. A link has been 
      established between splicing regulation by CUG-BP1, a member of the CELF family 
      of proteins, and DM1 pathogenesis. To determine whether increased CUG-BP1 
      function was sufficient to model DM, transgenic mice overexpressing CUG-BP1 
      (MCKCUG-BP1) in heart and skeletal muscle, two tissues affected in DM1, were 
      generated. Histological and electron microscopic analyses of skeletal muscle 
      reveal common pathological features with DM tissues: chains of central nuclei, 
      degenerating fibers and centralized NADH reactivity. MCKCUG-BP1 mice have 
      disrupted splicing of three CELF target pre-mRNAs, cardiac troponin T (Tnnt2), 
      myotubularin-related 1 gene (Mtmr1) and the muscle-specific chloride channel 
      (Clcn1), consistent with that observed in DM heart and skeletal muscle. The 
      results are consistent with a mechanism for DM pathogenesis in which expanded 
      repeats result in increased CUG-BP1 activity and/or other CELF family members and 
      have trans-dominant effects on specific pre-mRNA targets.
FAU - Ho, Thai H
AU  - Ho TH
AD  - Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, 
      TX 77030, USA.
FAU - Bundman, Donnie
AU  - Bundman D
FAU - Armstrong, Dawna L
AU  - Armstrong DL
FAU - Cooper, Thomas A
AU  - Cooper TA
LA  - eng
GR  - R01AR45653/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050420
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (DNA Primers)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - Base Sequence
MH  - CELF1 Protein
MH  - DNA Primers
MH  - Mice
MH  - Mice, Transgenic
MH  - Microscopy, Electron, Transmission
MH  - Muscle, Skeletal/metabolism/ultrastructure
MH  - Myocardium/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - *RNA Splicing
MH  - RNA-Binding Proteins/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2005/04/22 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/04/22 09:00
PHST- 2005/04/22 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/04/22 09:00 [entrez]
AID - ddi162 [pii]
AID - 10.1093/hmg/ddi162 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2005 Jun 1;14(11):1539-47. doi: 10.1093/hmg/ddi162. Epub 2005 Apr 
      20.

PMID- 15770673
OWN - NLM
STAT- MEDLINE
DCOM- 20050707
LR  - 20071114
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 31
IP  - 6
DP  - 2005 Jun
TI  - Familial clustering of muscular and cardiac involvement in myotonic dystrophy 
      type 1.
PG  - 719-24
AB  - Myotonic dystrophy type 1 (DM1) is associated with both skeletal and cardiac 
      muscle involvement. The aim of the present study was to determine whether 
      familial clustering is observed in the severity of muscle involvement in DM1. We 
      evaluated 51 sibling groups constituting 112 patients with genetically-verified 
      DM1. The siblings were similar to each other in age, cytosine-thymine-guanine 
      (CTG) repeat length, age at disease onset, muscular impairment rating score, and 
      electrocardiographic markers of cardiac conduction disease. After adjusting for 
      the similarities between siblings in age and CTG repeat length, the siblings 
      remained similar to each other in measures of both skeletal and cardiac muscle 
      involvement. These results suggest that factors other than CTG repeat length play 
      a role in the severity and progression of the degenerative skeletal and cardiac 
      muscle disease in DM1.
FAU - Groh, William J
AU  - Groh WJ
AD  - Department of Medicine, Krannert Institute of Cardiology, Indiana University, 
      1800 North Capitol, Room E406, Indianapolis, Indiana 46202, USA. wgroh@iupui.edu
FAU - Lowe, Miriam R
AU  - Lowe MR
FAU - Simmons, Zachary
AU  - Simmons Z
FAU - Bhakta, Deepak
AU  - Bhakta D
FAU - Pascuzzi, Robert M
AU  - Pascuzzi RM
LA  - eng
GR  - M01 RR00750-27S1/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Cardiomyopathies/epidemiology/genetics/*physiopathology
MH  - Cluster Analysis
MH  - Disease Progression
MH  - Female
MH  - Genetic Markers/genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - Heart/*physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology/*physiopathology
MH  - Myocardium/*pathology
MH  - Myotonic Dystrophy/epidemiology/genetics/*physiopathology
MH  - Registries/statistics & numerical data
MH  - Siblings
MH  - Trinucleotide Repeats/genetics
EDAT- 2005/03/17 09:00
MHDA- 2005/07/08 09:00
CRDT- 2005/03/17 09:00
PHST- 2005/03/17 09:00 [pubmed]
PHST- 2005/07/08 09:00 [medline]
PHST- 2005/03/17 09:00 [entrez]
AID - 10.1002/mus.20310 [doi]
PST - ppublish
SO  - Muscle Nerve. 2005 Jun;31(6):719-24. doi: 10.1002/mus.20310.

PMID- 15750273
OWN - NLM
STAT- MEDLINE
DCOM- 20050517
LR  - 20211203
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 44
IP  - 2
DP  - 2005 Feb
TI  - Re-entry circuit in ventricular tachycardia due to focal fatty-fibrosis in a 
      patient with myotonic dystrophy.
PG  - 129-35
AB  - A 69-year-old man with a recurrent ventricular tachycardia (VT) was admitted. The 
      patient was diagnosed as myotonic dystrophy type 1 (DM1) and DNA analysis 
      revealed 1,800 CTG-repeat expansion in the myotonic dystrophy protein kinase 
      (DMPK) gene. Ultrasonic cardiogram (UCG), left ventriculogram (LVG) and magnetic 
      resonance imaging (MRI) did not show any abnormal sign including fatty 
      infiltration. But, endomyocardial biopsy obtained from ventricular outflow tract 
      revealed severe fatty infiltration and interstitial fibrosis. Radiofrequency 
      catheter ablation at the biopsy site could eliminate VT, so it was strongly 
      suggested that the re-entry circuit was formed by focal fatty-fibrosis. Careful 
      observation should be continued for a long period.
FAU - Muraoka, Hideyuki
AU  - Muraoka H
AD  - First Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-machi, 
      Takatsuki 569-0801.
FAU - Negoro, Nobuyuki
AU  - Negoro N
FAU - Terasaki, Fumio
AU  - Terasaki F
FAU - Nakakoji, Takahiro
AU  - Nakakoji T
FAU - Kojima, Shigeyuki
AU  - Kojima S
FAU - Hoshiga, Masaaki
AU  - Hoshiga M
FAU - Sugino, Masakazu
AU  - Sugino M
FAU - Hosokawa, Takafumi
AU  - Hosokawa T
FAU - Ishihara, Tadashi
AU  - Ishihara T
FAU - Hanafusa, Toshiaki
AU  - Hanafusa T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adipose Tissue/*pathology
MH  - Aged
MH  - Biopsy
MH  - Cardiomyopathies/*complications/diagnosis
MH  - Catheter Ablation
MH  - DNA/analysis
MH  - Diagnosis, Differential
MH  - Electrocardiography
MH  - Fibrosis
MH  - Heart Rate/*physiology
MH  - Heart Ventricles/diagnostic imaging/pathology
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Myotonic Dystrophy/*complications/diagnosis/enzymology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Radionuclide Ventriculography
MH  - Tachycardia, Ventricular/*etiology/physiopathology/surgery
MH  - Ultrasonography
EDAT- 2005/03/08 09:00
MHDA- 2005/05/18 09:00
CRDT- 2005/03/08 09:00
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2005/05/18 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
AID - JST.JSTAGE/internalmedicine/44.129 [pii]
AID - 10.2169/internalmedicine.44.129 [doi]
PST - ppublish
SO  - Intern Med. 2005 Feb;44(2):129-35. doi: 10.2169/internalmedicine.44.129.

PMID- 15748612
OWN - NLM
STAT- MEDLINE
DCOM- 20050908
LR  - 20220331
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 354
IP  - 1-2
DP  - 2005 Apr
TI  - eNOS gene intron 4 a/b VNTR polymorphism is a risk factor for coronary artery 
      disease in Southern Turkey.
PG  - 153-8
AB  - BACKGROUND: Nitric oxide (NO) plays a major role in the regulation of vascular 
      tone Associations between NO genotypes, coronary artery disease (CAD) and other 
      risk factors have been described by many authors. The aim of this study was to 
      investigate the role of endothelial nitric oxide synthase (eNOS) gene intron 4 
      a/b variable number of tandem repeats (VNTR) polymorphism and other risk factors 
      in the development of CAD in subjects living in Southern Turkey. METHODS: 
      Two-hundred and sixty-six patients (154 males and 112 females, aged between 30 
      and 80 years, mean 52.4+/-10.3) whose coronary arteries were evaluated by means 
      of coronary angiography were enrolled in the study. Of the total, 133 had CAD 
      (Group I) and the remaining had normal coronary arteries (Group II). The eNOS 
      gene intron 4 a/b VNTR polymorphism was analyzed by polymerase chain reaction. 
      The plasma lipid levels and other risk factors were also determined in all 
      subjects. RESULTS: The a allele frequencies and genotypes carrying a allele were 
      significantly higher in Group I. Plasma lipids, except HDL-C, were also increased 
      in this group. We found that hypertension (HT), diabetes mellitus (DM), male 
      gender, age and smoking were the independent predictors of CAD. CONCLUSION: a 
      allele of eNOS intron 4 a/b VNTR polymorphism is not an independent predictor of 
      CAD. eNOS intron 4 a/b polymorphism (presence of a allele) is a risk factor in 
      addition to HT, DM, male gender, age and smoking for the development of CAD in 
      Southern Turkey.
FAU - Matyar, Selcuk
AU  - Matyar S
AD  - Cukurova University, School of Medicine, Department of Biochemistry, 01330, 
      Balcali, Adana, Turkey.
FAU - Attila, Gulen
AU  - Attila G
FAU - Acarturk, Esmeray
AU  - Acarturk E
FAU - Akpinar, Onur
AU  - Akpinar O
FAU - Inal, Tamer
AU  - Inal T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20050125
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Coronary Artery Disease/blood/epidemiology/*genetics
MH  - Female
MH  - *Genetic Variation
MH  - Humans
MH  - Introns
MH  - Male
MH  - Middle Aged
MH  - Minisatellite Repeats/*genetics
MH  - Nitric Oxide Synthase/blood/*genetics
MH  - Nitric Oxide Synthase Type III
MH  - Polymorphism, Genetic/*genetics
MH  - Risk Factors
MH  - Turkey/epidemiology
EDAT- 2005/03/08 09:00
MHDA- 2005/09/09 09:00
CRDT- 2005/03/08 09:00
PHST- 2004/11/12 00:00 [received]
PHST- 2004/11/22 00:00 [revised]
PHST- 2004/11/22 00:00 [accepted]
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2005/09/09 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
AID - S0009-8981(04)00563-7 [pii]
AID - 10.1016/j.cccn.2004.11.022 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2005 Apr;354(1-2):153-8. doi: 10.1016/j.cccn.2004.11.022. Epub 
      2005 Jan 25.

PMID- 15718211
OWN - NLM
STAT- MEDLINE
DCOM- 20050714
LR  - 20191109
IS  - 1121-760X (Print)
IS  - 1121-760X (Linking)
VI  - 48
IP  - 4
DP  - 2004 Oct-Dec
TI  - Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 
      (DM2) by FISH on muscle biopsy.
PG  - 437-42
AB  - Myotonic dystrophy type 2 (DM2) is a dominantly inherited disorder with 
      multisystemic clinical features, caused by a CCTG repeat expansion in intron 1 of 
      the zinc finger protein 9 (ZNF9) gene. The mutant transcripts are retained in the 
      nucleus forming multiple discrete foci also called ribonuclear inclusions. The 
      size and the somatic instability of DM2 expansion complicate the molecular 
      diagnosis of DM2. In our study fluorescence-labeled CAGG-repeat oligonucleotides 
      were hybridized to muscle biopsies to investigate if fluorescence in situ 
      hybridization (FISH), a relatively quick and simple procedure, could be used as a 
      method to diagnose DM2. When FISH was performed with (CAGG)5 probe, nuclear foci 
      of mutant RNA were present in all genetically confirmed DM2 patients (n=17) and 
      absent in all patients with myotonic dystrophy type 1 (DM1; n=5) or with other 
      muscular disease (n=17) used as controls. In contrast, foci were observed both in 
      DM1 and DM2 myonuclei when muscle tissue were hybridized with (CAG)6CA probe 
      indicating that this probe is not specific for DM2 identification. The consistent 
      detection of ribonuclear inclusions in DM2 muscles and their absence in DM1, in 
      agreement with the clinical diagnosis and with leukocyte (CCTG)n expansion, 
      suggests that fluorescence in situ hybridization using (CAGG)5 probes, may be a 
      specific method to distinguish between DM1 and DM2. Moreover, the procedure is 
      simple, and readily applicable in any pathology laboratory.
FAU - Cardani, R
AU  - Cardani R
AD  - Dipartimento di Fisiologia e Biochimica Generali, Universita di Milano, Italy.
FAU - Mancinelli, E
AU  - Mancinelli E
FAU - Sansone, V
AU  - Sansone V
FAU - Rotondo, G
AU  - Rotondo G
FAU - Meola, G
AU  - Meola G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur J Histochem
JT  - European journal of histochemistry : EJH
JID - 9207930
RN  - 0 (Molecular Probes)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Base Sequence
MH  - Biopsy
MH  - *DNA Repeat Expansion
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Molecular Probes
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/*pathology
MH  - Myotonic Dystrophy/*genetics/pathology
EDAT- 2005/02/19 09:00
MHDA- 2005/07/15 09:00
CRDT- 2005/02/19 09:00
PHST- 2005/02/19 09:00 [pubmed]
PHST- 2005/07/15 09:00 [medline]
PHST- 2005/02/19 09:00 [entrez]
AID - 10.4081/918 [doi]
PST - ppublish
SO  - Eur J Histochem. 2004 Oct-Dec;48(4):437-42. doi: 10.4081/918.

PMID- 15704146
OWN - NLM
STAT- MEDLINE
DCOM- 20050707
LR  - 20091119
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 31
IP  - 6
DP  - 2005 Jun
TI  - Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2.
PG  - 764-7
AB  - A 49-year-old man had an 8-year history of persistent, isolated elevation of 
      serum creatine kinase (hyper-CK-emia) without muscle symptoms, and no 
      electromyographic evidence of myotonia; his muscle biopsy showed features 
      reminiscent of myotonic dystrophy (DM), with morphometric findings consistent 
      with those described in DM type 2 (DM2). Genetic studies excluded mutations in 
      the DM type 1 (DM1) gene, but revealed a CCTG repeat expansion in the ZNF9 gene, 
      which is associated with DM2. Our data suggest that in asymptomatic patients with 
      persistent hyper-CK-emia, DM2 should be considered in the differential diagnosis.
FAU - Merlini, Luciano
AU  - Merlini L
AD  - Neuromuscular Unit, Istituti Ortopedici Rizzoli, Bologna, Italy.
FAU - Sabatelli, Patrizia
AU  - Sabatelli P
FAU - Columbaro, Marta
AU  - Columbaro M
FAU - Bonifazi, Emanuela
AU  - Bonifazi E
FAU - Pisani, Valerio
AU  - Pisani V
FAU - Massa, Roberto
AU  - Massa R
FAU - Novelli, Giuseppe
AU  - Novelli G
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 2.7.3.2 (Creatine Kinase)
SB  - IM
MH  - Biopsy
MH  - Creatine Kinase/*blood
MH  - DNA Mutational Analysis
MH  - Diagnosis, Differential
MH  - Genetic Testing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Fibers, Skeletal/*enzymology/pathology
MH  - Muscle, Skeletal/*enzymology/pathology/physiopathology
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*enzymology/*genetics/pathology
MH  - RNA-Binding Proteins/genetics
MH  - Trinucleotide Repeats/genetics
MH  - Up-Regulation/genetics
EDAT- 2005/02/11 09:00
MHDA- 2005/07/08 09:00
CRDT- 2005/02/11 09:00
PHST- 2005/02/11 09:00 [pubmed]
PHST- 2005/07/08 09:00 [medline]
PHST- 2005/02/11 09:00 [entrez]
AID - 10.1002/mus.20289 [doi]
PST - ppublish
SO  - Muscle Nerve. 2005 Jun;31(6):764-7. doi: 10.1002/mus.20289.

PMID- 15684391
OWN - NLM
STAT- MEDLINE
DCOM- 20050316
LR  - 20211203
IS  - 0270-7306 (Print)
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Linking)
VI  - 25
IP  - 4
DP  - 2005 Feb
TI  - Divergent mitochondrial and endoplasmic reticulum association of DMPK splice 
      isoforms depends on unique sequence arrangements in tail anchors.
PG  - 1402-14
AB  - Myotonic dystrophy protein kinase (DMPK) is a Ser/Thr-type protein kinase with 
      unknown function, originally identified as the product of the gene that is 
      mutated by triplet repeat expansion in patients with myotonic dystrophy type 1 
      (DM1). Alternative splicing of DMPK transcripts results in multiple protein 
      isoforms carrying distinct C termini. Here, we demonstrate by expressing 
      individual DMPKs in various cell types, including C(2)C(12) and DMPK(-/-) 
      myoblast cells, that unique sequence arrangements in these tails control the 
      specificity of anchoring into intracellular membranes. Mouse DMPK A and C were 
      found to associate specifically with either the endoplasmic reticulum (ER) or the 
      mitochondrial outer membrane, whereas the corresponding human DMPK A and C 
      proteins both localized to mitochondria. Expression of mouse and human DMPK A-but 
      not C-isoforms in mammalian cells caused clustering of ER or mitochondria. 
      Membrane association of DMPK isoforms was resistant to alkaline conditions, and 
      mutagenesis analysis showed that proper anchoring was differentially dependent on 
      basic residues flanking putative transmembrane domains, demonstrating that DMPK 
      tails form unique tail anchors. This work identifies DMPK as the first kinase in 
      the class of tail-anchored proteins, with a possible role in organelle 
      distribution and dynamics.
FAU - van Herpen, Rene E M A
AU  - van Herpen RE
AD  - Department of Cell Biology, NCMLS, Geert Grooteplein 28, P.O. Box 9101, 6500 HB 
      Nijmegen, The Netherlands.
FAU - Oude Ophuis, Ralph J A
AU  - Oude Ophuis RJ
FAU - Wijers, Mietske
AU  - Wijers M
FAU - Bennink, Miranda B
AU  - Bennink MB
FAU - van de Loo, Fons A J
AU  - van de Loo FA
FAU - Fransen, Jack
AU  - Fransen J
FAU - Wieringa, Be
AU  - Wieringa B
FAU - Wansink, Derick G
AU  - Wansink DG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Protein Isoforms)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alternative Splicing/*physiology
MH  - Amino Acid Sequence
MH  - Animals
MH  - COS Cells
MH  - Cells, Cultured
MH  - Chlorocebus aethiops
MH  - Endoplasmic Reticulum/*enzymology/ultrastructure
MH  - HeLa Cells
MH  - Humans
MH  - Intracellular Membranes/enzymology/ultrastructure
MH  - Mice
MH  - Microscopy, Immunoelectron
MH  - Mitochondria/*enzymology/ultrastructure
MH  - Molecular Sequence Data
MH  - Myoblasts/*enzymology/ultrastructure
MH  - Myotonic Dystrophy/metabolism
MH  - Myotonin-Protein Kinase
MH  - NIH 3T3 Cells
MH  - Protein Isoforms/metabolism
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Trinucleotide Repeat Expansion/physiology
PMC - PMC548020
EDAT- 2005/02/03 09:00
MHDA- 2005/03/17 09:00
PMCR- 2005/02/01
CRDT- 2005/02/03 09:00
PHST- 2005/02/03 09:00 [pubmed]
PHST- 2005/03/17 09:00 [medline]
PHST- 2005/02/03 09:00 [entrez]
PHST- 2005/02/01 00:00 [pmc-release]
AID - 25/4/1402 [pii]
AID - 1673-04 [pii]
AID - 10.1128/MCB.25.4.1402-1414.2005 [doi]
PST - ppublish
SO  - Mol Cell Biol. 2005 Feb;25(4):1402-14. doi: 10.1128/MCB.25.4.1402-1414.2005.

PMID- 15576360
OWN - NLM
STAT- MEDLINE
DCOM- 20041223
LR  - 20181113
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Print)
IS  - 0305-1048 (Linking)
VI  - 32
IP  - 21
DP  - 2004
TI  - Chemotherapeutic deletion of CTG repeats in lymphoblast cells from DM1 patients.
PG  - 6334-46
AB  - Myotonic dystrophy type 1 (DM1) is caused by the expansion of a (CTG).(CAG) 
      repeat in the DMPK gene on chromosome 19q13.3. At least 17 neurological diseases 
      have similar genetic mutations, the expansion of DNA repeats. In most of these 
      disorders, the disease severity is related to the length of the repeat expansion, 
      and in DM1 the expanded repeat undergoes further elongation in somatic and 
      germline tissues. At present, in this class of diseases, no therapeutic approach 
      exists to prevent or slow the repeat expansion and thereby reduce disease 
      severity or delay disease onset. We present initial results testing the 
      hypothesis that repeat deletion may be mediated by various chemotherapeutic 
      agents. Three lymphoblast cell lines derived from two DM1 patients treated with 
      either ethylmethanesulfonate (EMS), mitomycin C, mitoxantrone or doxorubicin, at 
      therapeutic concentrations, accumulated deletions following treatment. Treatment 
      with EMS frequently prevented the repeat expansion observed during growth in 
      culture. A significant reduction of CTG repeat length by 100-350 (CTG).(CAG) 
      repeats often occurred in the cell population following treatment with these 
      drugs. Potential mechanisms of drug-induced deletion are presented.
FAU - Hashem, Vera I
AU  - Hashem VI
AD  - Center for Genome Research, Institute of Biosciences and Technology, Texas A&M 
      University System Health Sciences Center, 2121 West Holcombe Boulevard, Houston, 
      TX 77030-3303, USA.
FAU - Pytlos, Malgorzata J
AU  - Pytlos MJ
FAU - Klysik, Elzbieta A
AU  - Klysik EA
FAU - Tsuji, Kuniko
AU  - Tsuji K
FAU - Khajavi, Mehrdad
AU  - Khajavi M
FAU - Ashizawa, Tetsuo
AU  - Ashizawa T
FAU - Sinden, Richard R
AU  - Sinden RR
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041201
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 50SG953SK6 (Mitomycin)
RN  - 80168379AG (Doxorubicin)
RN  - 9H154DI0UP (Ethyl Methanesulfonate)
RN  - BZ114NVM5P (Mitoxantrone)
SB  - IM
EIN - Nucleic Acids Res. 2004 Dec;32(22):6717. Khajav, Merhdad [corrected to Khajavi, 
      Mehrdad]
MH  - Alleles
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Cell Line
MH  - Doxorubicin/therapeutic use
MH  - Ethyl Methanesulfonate/therapeutic use
MH  - Humans
MH  - Lymphocytes/cytology/drug effects
MH  - Mitomycin/therapeutic use
MH  - Mitoxantrone/therapeutic use
MH  - Myotonic Dystrophy/*drug therapy/*genetics
MH  - Trinucleotide Repeat Expansion/*drug effects
PMC - PMC535684
EDAT- 2004/12/04 09:00
MHDA- 2004/12/24 09:00
PMCR- 2004/12/01
CRDT- 2004/12/04 09:00
PHST- 2004/12/04 09:00 [pubmed]
PHST- 2004/12/24 09:00 [medline]
PHST- 2004/12/04 09:00 [entrez]
PHST- 2004/12/01 00:00 [pmc-release]
AID - 32/21/6334 [pii]
AID - gkh976 [pii]
AID - 10.1093/nar/gkh976 [doi]
PST - epublish
SO  - Nucleic Acids Res. 2004 Dec 1;32(21):6334-46. doi: 10.1093/nar/gkh976. Print 
      2004.

PMID- 15489504
OWN - NLM
STAT- MEDLINE
DCOM- 20050225
LR  - 20211203
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 280
IP  - 2
DP  - 2005 Jan 14
TI  - The myotonic dystrophy type 1 triplet repeat sequence induces gross deletions and 
      inversions.
PG  - 941-52
AB  - The capacity of (CTG.CAG)n and (GAA.TTC)n repeat tracts in plasmids to induce 
      mutations in DNA flanking regions was evaluated in Escherichia coli. Long repeats 
      of these sequences are involved in the etiology of myotonic dystrophy type 1 and 
      Friedreich's ataxia, respectively. Long (CTG.CAG)n (where n = 98 and 175) caused 
      the deletion of most, or all, of the repeats and the flanking GFP gene. Deletions 
      of 0.6-1.8 kbp were found as well as inversions. Shorter repeat tracts (where n = 
      0 or 17) were essentially inert, as observed for the (GAA.TTC)176-containing 
      plasmid. The orientation of the triplet repeat sequence (TRS) relative to the 
      unidirectional origin of replication had a pronounced effect, signaling the 
      participation of replication and/or repair systems. Also, when the TRS was 
      transcribed, the level of deletions was greatly elevated. Under certain 
      conditions, 30-50% of the products contained gross deletions. DNA sequence 
      analyses of the breakpoint junctions in 47 deletions revealed the presence of 
      1-8-bp direct or inverted homologies in all cases. Also, the presence of non-B 
      folded conformations (i.e. slipped structures, cruciforms, or triplexes) at or 
      near the breakpoints was predicted in all cases. This genetic behavior, which was 
      previously unrecognized for a TRS, may provide the basis for a new type of 
      instability of the myotonic dystrophy protein kinase (DMPK) gene in patients with 
      a full mutation.
FAU - Wojciechowska, Marzena
AU  - Wojciechowska M
AD  - Center for Genome Research Institute of Biosciences and Technology, Texas A & M 
      University System Health Science Center, Texas Medical Center, Houston, Texas 
      77030, USA.
FAU - Bacolla, Albino
AU  - Bacolla A
FAU - Larson, Jacquelynn E
AU  - Larson JE
FAU - Wells, Robert D
AU  - Wells RD
LA  - eng
GR  - ES11347/ES/NIEHS NIH HHS/United States
GR  - NS37554/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20041015
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA, Bacterial)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Base Sequence
MH  - Chromosome Breakage/genetics
MH  - *Chromosome Deletion
MH  - Chromosome Inversion/*genetics
MH  - DNA, Bacterial/genetics
MH  - Escherichia coli/*genetics
MH  - Friedreich Ataxia/genetics
MH  - Genes, Reporter/genetics
MH  - Genotype
MH  - Green Fluorescent Proteins/genetics
MH  - Humans
MH  - Models, Genetic
MH  - Mutagenesis/genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Physical Chromosome Mapping
MH  - Plasmids/genetics
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Restriction Mapping
MH  - Sequence Deletion/*genetics
MH  - Transcription, Genetic/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 2004/10/19 09:00
MHDA- 2005/02/26 09:00
CRDT- 2004/10/19 09:00
PHST- 2004/10/19 09:00 [pubmed]
PHST- 2005/02/26 09:00 [medline]
PHST- 2004/10/19 09:00 [entrez]
AID - S0021-9258(20)76461-6 [pii]
AID - 10.1074/jbc.M410427200 [doi]
PST - ppublish
SO  - J Biol Chem. 2005 Jan 14;280(2):941-52. doi: 10.1074/jbc.M410427200. Epub 2004 
      Oct 15.

PMID- 15462191
OWN - NLM
STAT- MEDLINE
DCOM- 20041101
LR  - 20211203
IS  - 0019-5189 (Print)
IS  - 0019-5189 (Linking)
VI  - 42
IP  - 9
DP  - 2004 Sep
TI  - (CTG)n expansion at DMPK locus seen only in muscle tissue: a novel case.
PG  - 937-40
AB  - Triplet repeat expansion in 3 untranslated region of myotonic dystrophy protein 
      kinase (DMPK) gene has been implicated as causative in myotonic dystrophy (DM). 
      In cases of DM, high levels of somatic instability have been reported, in which 
      inter-tissue repeat length differences as large as 3000 repeats have been 
      observed. This study highlights the inter-tissue (CTG)n expansion variability at 
      the DMPK locus. Molecular analysis of DMPK gene, encompassing the triplet repeat 
      expansion, was carried out in 31 individuals (11 clinically identified DM 
      patients, 20 controls). All controls showed a 2.1kb band (upto 35 CTG repeats), 
      while four cases exhibited an expansion (>50 repeats). A novel observation was 
      made in one case, wherein the DNA from lymphocytes showed a normal 2.1kb band 
      while the muscle tissue DNA from the same patient was heterozygous for normal and 
      4.3 kb band (>700 repeats). Our results suggested that because inter-tissue 
      variability existed in the (CTG)n repeat number at DMPK locus, an attempt should 
      be made to evaluate affected tissue along with blood wherever possible prior to 
      making a final diagnosis. This is important not only for diagnosis and prenatal 
      analysis, but also while providing genetic counseling to families.
FAU - Hasan, Qurratulain
AU  - Hasan Q
AD  - Department of Genetics, Bhagwan Mahavir Medical Research Centre, Hyderabad 500 
      004, India. qhasan2000@yahoo.com
FAU - Mohan, Vasavi
AU  - Mohan V
FAU - Ahuja, Y R
AU  - Ahuja YR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Exp Biol
JT  - Indian journal of experimental biology
JID - 0233411
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/*genetics
MH  - Adult
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - DNA/genetics
MH  - Female
MH  - Humans
MH  - Infant
MH  - Lymphocytes/enzymology/pathology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/enzymology/*pathology
MH  - Myotonic Dystrophy/*diagnosis/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2004/10/07 09:00
MHDA- 2004/11/02 09:00
CRDT- 2004/10/07 09:00
PHST- 2004/10/07 09:00 [pubmed]
PHST- 2004/11/02 09:00 [medline]
PHST- 2004/10/07 09:00 [entrez]
PST - ppublish
SO  - Indian J Exp Biol. 2004 Sep;42(9):937-40.

PMID- 15459182
OWN - NLM
STAT- MEDLINE
DCOM- 20050321
LR  - 20220409
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 13
IP  - 23
DP  - 2004 Dec 1
TI  - Genome-wide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian 
      cells.
PG  - 2979-89
AB  - Many neurological diseases, including myotonic dystrophy, Huntington's disease 
      and several spinocerebellar ataxias, result from intergenerational increases in 
      the length of a CTG.CAG repeat tract. Although the basis for intergenerational 
      repeat expansion is unclear, repeat tracts are especially unstable during 
      germline development and production of gametes. Mammalian development is 
      characterized by waves of genome-wide demethylation and remethylation. To test 
      whether changes in methylation status might contribute to trinucleotide repeat 
      instability, we examined the effects of DNA methyltransferase inhibitors on 
      trinucleotide repeat stability in mammalian cells. Using a selectable genetic 
      system for detection of repeat contractions in CHO cells, we showed that the rate 
      of contractions increased >1000-fold upon treatment with the DNA 
      methyltransferase inhibitor 5-aza-deoxycytidine (5-aza-CdR). The link between DNA 
      demethylation and repeat instability was strengthened by similar results obtained 
      with hydralazine treatment, which inhibits expression of DNA methyltransferase. 
      In human cells from myotonic dystrophy patients, treatment with 5-aza-CdR 
      strongly destabilized repeat tracts in the DMPK gene, with a clear bias toward 
      expansion. The bias toward expansion events and changes in repeat length that 
      occur in jumps, rather than by accumulation of small changes, are reminiscent of 
      the intergenerational repeat instability observed in human patients. The dramatic 
      destabilizing effect of DNA methyltransferase inhibitors supports the hypothesis 
      that changes in methylation patterns during epigenetic reprogramming may trigger 
      the intergenerational repeat expansions that lead to disease.
FAU - Gorbunova, Vera
AU  - Gorbunova V
AD  - Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor 
      College of Medicine, Houston, TX 77030, USA.
FAU - Seluanov, Andrei
AU  - Seluanov A
FAU - Mittelman, David
AU  - Mittelman D
FAU - Wilson, John H
AU  - Wilson JH
LA  - eng
GR  - GM38219/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20040930
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 26NAK24LS8 (Hydralazine)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Animals
MH  - Azacitidine/*analogs & derivatives/pharmacology
MH  - CHO Cells
MH  - CpG Islands
MH  - Cricetinae
MH  - *DNA Methylation/drug effects
MH  - Decitabine
MH  - *Genome, Human
MH  - Humans
MH  - Hydralazine/pharmacology
EDAT- 2004/10/02 05:00
MHDA- 2005/03/22 09:00
CRDT- 2004/10/02 05:00
PHST- 2004/10/02 05:00 [pubmed]
PHST- 2005/03/22 09:00 [medline]
PHST- 2004/10/02 05:00 [entrez]
AID - ddh317 [pii]
AID - 10.1093/hmg/ddh317 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2004 Dec 1;13(23):2979-89. doi: 10.1093/hmg/ddh317. Epub 2004 Sep 
      30.

PMID- 15336691
OWN - NLM
STAT- MEDLINE
DCOM- 20041014
LR  - 20211203
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 14
IP  - 8-9
DP  - 2004 Sep
TI  - In situ hybridization analysis of Dmpk mRNA in adult mouse tissues.
PG  - 497-506
AB  - Myotonic dystrophy1 (DM1) is an autosomal dominant, multi-system disorder 
      resulting from a CTG repeat expansion located in the 3' untranslated region of 
      DMPK and immediately in the 5' of SIX5. Skeletal muscle, heart and smooth muscle 
      are prominently affected in DM1. Endocrine abnormalities, gonadal atrophy, brain, 
      skin, skeletal, immune and respiratory defects are also features of the disorder. 
      Both DMPK and SIX5 levels are decreased in DM1 patients. Importantly, expression 
      of mutant mRNAs encoding expanded CUG repeats has been shown to alter the 
      activity of CUG repeat binding proteins in DM1. Mouse models have demonstrated 
      that decreased levels of Dmpk, Six5 and the expression of expanded CUG repeats 
      independently contribute to the development of DM1 pathology. However, an 
      important gap in these studies is a lack of clear understanding of the expression 
      pattern of Dmpk. We demonstrate that Dmpk mRNA is expressed in a range of adult 
      mouse tissues that show pathology in DM1 including skeletal muscle, heart, smooth 
      muscle, bone, testis, pituitary, brain, eye, skin, thymus and lung. Thus DMPK 
      loss or CUG repeat expansion could contribute to DM1 pathology to these tissues. 
      Dmpk mRNA is not detected in the ovary, pancreas or kidney. Significantly, Dmpk 
      mRNA is expressed in the intestinal epithelium, cartilage and liver, which have 
      not been reported to show consistent abnormalities in Dmpk(-/-) mice or in 
      transgenic animals expressing CUG repeats. Taken together these data suggest that 
      Dmpk loss or CUG repeat expression per se may not be sufficient to initiate 
      pathology and are consistent with the hypothesis that coexpression of specific 
      CUG repeat binding proteins with the mutant Dmpk mRNA or deregulation of genes 
      such as Six5 that flank the CTG repeat tract may be necessary for DM1 to 
      manifest.
FAU - Sarkar, Partha S
AU  - Sarkar PS
AD  - Institute for Genetic Medicine, University of Southern California, Keck School of 
      Medicine, Los Angeles, CA 90033, USA.
FAU - Han, Jennifer
AU  - Han J
FAU - Reddy, Sita
AU  - Reddy S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (DMPK protein, mouse)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Blotting, Northern/methods
MH  - Bone and Bones/metabolism
MH  - Brain/metabolism
MH  - Cartilage/metabolism
MH  - Female
MH  - Gene Expression Regulation/*physiology
MH  - Heart
MH  - In Situ Hybridization/*methods
MH  - Intestinal Mucosa/metabolism
MH  - Liver/metabolism
MH  - Lung/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Muscles/metabolism
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Sex Factors
MH  - Skin/metabolism
MH  - Testis/metabolism
MH  - Thymus Gland/metabolism
EDAT- 2004/09/01 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/09/01 05:00
PHST- 2004/02/09 00:00 [received]
PHST- 2004/03/22 00:00 [revised]
PHST- 2004/03/24 00:00 [accepted]
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - S0960896604000999 [pii]
AID - 10.1016/j.nmd.2004.03.012 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2004 Sep;14(8-9):497-506. doi: 10.1016/j.nmd.2004.03.012.

PMID- 15322428
OWN - NLM
STAT- MEDLINE
DCOM- 20050201
LR  - 20080513
IS  - 1052-9551 (Print)
IS  - 1052-9551 (Linking)
VI  - 13
IP  - 3
DP  - 2004 Sep
TI  - A long PCR-based molecular protocol for detecting normal and expanded ZNF9 
      alleles in myotonic dystrophy type 2.
PG  - 164-6
AB  - Myotonic dystrophy type 2 (DM2) lacks the expansion on chromosome 19q13 present 
      in DM1 and is characterized by a mutation on 3q21. It has been shown that the DM2 
      mutation is a huge [CCTG]n repeat expansion in intron 1 of the zinc finger 
      protein 9 (ZNF9) gene. The longest normal allele observed has a approximately 30 
      CCTG repeat, whereas the range of expansion is extremely variable, starting from 
      75 up to 11,000 CCTGs. Direct analysis by Southern blot, after restriction enzyme 
      digestion of genomic DNA, was the first method chosen for studying the DM2 
      mutation. However, the expansion size and the elevated grade of somatic 
      instability have limited the sensitivity of the test to approximately 80% of 
      known carriers. We developed a long PCR-formatted protocol, which involves a 
      single genomic in vitro amplification, followed by agarose gel electrophoresis 
      and oligospecific hybridization. We were able to detect normal alleles and 
      expanded ZNF9 alleles, starting from low amounts of genomic DNA (>/= 1 ng) in 
      virtually all the DM2 patients analyzed, obtaining a molecular detection rate of 
      100%. This method is quick, sensitive, and reproducible, and it reduces the cost 
      of diagnostic laboratory processing for DM2 diagnosis.
FAU - Bonifazi, Emanuela
AU  - Bonifazi E
AD  - Department of Biopathology and Diagnosting Imaging, Tor Vergata University of 
      Rome, Rome, Italy.
FAU - Vallo, Laura
AU  - Vallo L
FAU - Giardina, Emiliano
AU  - Giardina E
FAU - Botta, Annalisa
AU  - Botta A
FAU - Novelli, Giuseppe
AU  - Novelli G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diagn Mol Pathol
JT  - Diagnostic molecular pathology : the American journal of surgical pathology, part 
      B
JID - 9204924
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Alleles
MH  - Blotting, Southern
MH  - Electrophoresis, Agar Gel
MH  - Humans
MH  - In Situ Hybridization
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Polymerase Chain Reaction/*methods
MH  - RNA-Binding Proteins/*analysis/*genetics
EDAT- 2004/08/24 05:00
MHDA- 2005/02/03 09:00
CRDT- 2004/08/24 05:00
PHST- 2004/08/24 05:00 [pubmed]
PHST- 2005/02/03 09:00 [medline]
PHST- 2004/08/24 05:00 [entrez]
AID - 00019606-200409000-00006 [pii]
PST - ppublish
SO  - Diagn Mol Pathol. 2004 Sep;13(3):164-6.

PMID- 15292165
OWN - NLM
STAT- MEDLINE
DCOM- 20041115
LR  - 20210209
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 279
IP  - 40
DP  - 2004 Oct 1
TI  - Hairpin structure-forming propensity of the (CCTG.CAGG) tetranucleotide repeats 
      contributes to the genetic instability associated with myotonic dystrophy type 2.
PG  - 41715-26
AB  - The genetic instabilities of (CCTG.CAGG)(n) tetranucleotide repeats were 
      investigated to evaluate the molecular mechanisms responsible for the massive 
      expansions found in myotonic dystrophy type 2 (DM2) patients. DM2 is caused by an 
      expansion of the repeat from the normal allele of 26 to as many as 11,000 
      repeats. Genetic expansions and deletions were monitored in an African green 
      monkey kidney cell culture system (COS-7 cells) as a function of the length (30, 
      114, or 200 repeats), orientation, or proximity of the repeat tracts to the 
      origin (SV40) of replication. As found for CTG.CAG repeats related to DM1, the 
      instabilities were greater for the longer tetranucleotide repeat tracts. Also, 
      the expansions and deletions predominated when cloned in orientation II (CAGG on 
      the leading strand template) rather than I and when cloned proximal rather than 
      distal to the replication origin. Biochemical studies on synthetic d(CAGG)(26) 
      and d(CCTG)(26) as models of unpaired regions of the replication fork revealed 
      that d(CAGG)(26) has a marked propensity to adopt a defined base paired hairpin 
      structure, whereas the complementary d(CCTG)(26) lacks this capacity. The effect 
      of orientation described above differs from all previous results with three 
      triplet repeat sequences (including CTG.CAG), which are also involved in the 
      etiologies of other hereditary neurological diseases. However, similar to the 
      triplet repeat sequences, the ability of one of the two strands to form a more 
      stable folded structure, in our case the CAGG strand, explains this unorthodox 
      "reversed" behavior.
FAU - Dere, Ruhee
AU  - Dere R
AD  - Institute of Biosciences and Technology, Center for Genome Research, Texas A and 
      M University System Health Science Center, Texas Medical Center, Houston, Texas 
      77030-3303, USA.
FAU - Napierala, Marek
AU  - Napierala M
FAU - Ranum, Laura P W
AU  - Ranum LP
FAU - Wells, Robert D
AU  - Wells RD
LA  - eng
GR  - ES11347/ES/NIEHS NIH HHS/United States
GR  - NS35870/NS/NINDS NIH HHS/United States
GR  - NS37554/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20040729
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (RNA-Binding Proteins)
SB  - IM
MH  - Animals
MH  - COS Cells
MH  - Chlorocebus aethiops
MH  - Cloning, Molecular
MH  - DNA Repeat Expansion
MH  - DNA Replication
MH  - *DNA Sequence, Unstable
MH  - *Microsatellite Repeats
MH  - Myotonic Dystrophy/etiology/*genetics
MH  - Nucleic Acid Conformation
MH  - RNA-Binding Proteins/genetics
MH  - Replication Origin
EDAT- 2004/08/05 05:00
MHDA- 2004/11/16 09:00
CRDT- 2004/08/05 05:00
PHST- 2004/08/05 05:00 [pubmed]
PHST- 2004/11/16 09:00 [medline]
PHST- 2004/08/05 05:00 [entrez]
AID - S0021-9258(20)72637-2 [pii]
AID - 10.1074/jbc.M406415200 [doi]
PST - ppublish
SO  - J Biol Chem. 2004 Oct 1;279(40):41715-26. doi: 10.1074/jbc.M406415200. Epub 2004 
      Jul 29.

PMID- 15286433
OWN - NLM
STAT- MEDLINE
DCOM- 20041216
LR  - 20220408
IS  - 0250-8095 (Print)
IS  - 0250-8095 (Linking)
VI  - 24
IP  - 4
DP  - 2004 Jul-Aug
TI  - Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes 
      are associated with kidney failure in Korean patients with type 2 diabetes 
      mellitus.
PG  - 410-4
AB  - BACKGROUND/AIM: Cytokines play an important role in the pathogenesis of kidney 
      diseases. The aim of the study was to investigate the impact of interleukin 
      (IL)-1 cluster genes on diabetic nephropathy in Korean patients with type 2 
      diabetes mellitus (DM). METHODS: We investigated -511 C/T polymorphism of IL-1 
      beta and tandem repeat polymorphism in intron 2 of IL-1 receptor antagonist in 
      type 2 DM patients with end-stage kidney failure as compared with patients 
      without nephropathy. RESULTS: The IL1B2 allele was found more frequently in 
      patients with kidney failure than in controls (57.4 vs. 46.1%, p < 0.05). An 
      excessive homozygous carriage of IL1B2 was found in patients with kidney failure 
      when compared with controls (30.5 vs. 18.3%, p < 0.05). The allelic frequency of 
      IL1RN*2 was also higher in cases than in controls without nephropathy (8.4 vs. 
      2.8 %, p < 0.05). The carriage rate of IL1RN*2 was significantly associated with 
      an increased risk of kidney failure (15.8 vs. 5.6%; OR 3.19, 95% CI 1.24-8.17). 
      The risk of kidney failure was highest in those carrying both IL1RN*2 and IL1B2 
      (OR 3.90, 95% CI 1.34-11.40). CONCLUSION: IL1B2 and IL1RN*2 genotypes of the IL-1 
      cluster genes are associated with diabetic nephropathy in Korean patients with 
      type 2 DM.
FAU - Lee, Sang Ho
AU  - Lee SH
AD  - Department of Nephrology, College of Medicine, Kyung-Hee University, Seoul 
      130-702, Korea.
FAU - Ihm, Chun-Gyoo
AU  - Ihm CG
FAU - Sohn, Seong Dong
AU  - Sohn SD
FAU - Lee, Tae Won
AU  - Lee TW
FAU - Kim, Myung Jae
AU  - Kim MJ
FAU - Koh, Gwanpyo
AU  - Koh G
FAU - Oh, Seung Joon
AU  - Oh SJ
FAU - Woo, Jeoung-Taek
AU  - Woo JT
FAU - Kim, Sung Woon
AU  - Kim SW
FAU - Kim, Jin Woo
AU  - Kim JW
FAU - Kim, Young Seol
AU  - Kim YS
FAU - Lee, Byung Cheol
AU  - Lee BC
FAU - Kim, Seong Do
AU  - Kim SD
FAU - Cho, Byoung Soo
AU  - Cho BS
FAU - Lee, Hee-Jae
AU  - Lee HJ
FAU - Chung, Joo-Ho
AU  - Chung JH
LA  - eng
PT  - Journal Article
DEP - 20040730
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (IL1RN protein, human)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - 0 (Interleukin-1)
RN  - 0 (Sialoglycoproteins)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/epidemiology/*genetics
MH  - Diabetic Nephropathies/epidemiology/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/epidemiology
MH  - Genotype
MH  - Humans
MH  - Interleukin 1 Receptor Antagonist Protein
MH  - Interleukin-1/*genetics
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Multigene Family
MH  - *Polymorphism, Genetic
MH  - Risk Factors
MH  - Sialoglycoproteins/*genetics
EDAT- 2004/08/03 05:00
MHDA- 2004/12/17 09:00
CRDT- 2004/08/03 05:00
PHST- 2004/03/18 00:00 [received]
PHST- 2004/06/17 00:00 [accepted]
PHST- 2004/08/03 05:00 [pubmed]
PHST- 2004/12/17 09:00 [medline]
PHST- 2004/08/03 05:00 [entrez]
AID - 80044 [pii]
AID - 10.1159/000080044 [doi]
PST - ppublish
SO  - Am J Nephrol. 2004 Jul-Aug;24(4):410-4. doi: 10.1159/000080044. Epub 2004 Jul 30.

PMID- 15284213
OWN - NLM
STAT- MEDLINE
DCOM- 20050309
LR  - 20061115
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 19
IP  - 9
DP  - 2004 Sep
TI  - CTG amplification in the DM1PK gene is not associated with idiopathic male 
      subfertility.
PG  - 2084-7
AB  - BACKGROUND: Polymorphism in the CTG triplet number in the myotonic dystrophy type 
      1 (DM1PK) gene has been proposed as being associated with idiopathic azoospermia. 
      The aim of this study was to investigate whether the CTG trinucleotide 
      amplification in the DM1PK gene is associated with male subfertility. METHODS: We 
      evaluated 107 subfertile patients, male partners of infertile couples, affected 
      by non-obstructive azoospermia (n = 38) and oligoasthenoteratozoospermia (OAT) (n 
      = 69), and 102 men with proven fertility. Main outcome measures were CTG repeat 
      size in the DM1PK gene, testicular volume, sperm concentration, rapid progressive 
      motility, normal morphology, serum FSH levels, testicular histology and Johnsen 
      score. RESULTS: In subfertile males, no minimal mutation or mutation carriers 
      were found. The difference in the number of CTG repeat lengths between the groups 
      was not statistically significant (P = 0.825). There was no correlation between 
      the number of CTG repeats and the clinical parameters of subfertile patients: 
      testicular volume, sperm concentration, rapid progressive motility, normal 
      morphology, FSH level, testicular histology and Johnsen score. CONCLUSIONS: The 
      number of CTG repeats in the normal or mutational range of DM1PK gene is 
      associated with neither idiopathic male subfertility nor with clinical 
      characteristics of male subfertility.
FAU - Kunej, Tanja
AU  - Kunej T
AD  - Division of Medical Genetics, Department of Obstetrics and Gynecology, University 
      Medical Centre, 1000 Ljubljana, Slovenia.
FAU - Teran, Natasa
AU  - Teran N
FAU - Zorn, Branko
AU  - Zorn B
FAU - Peterlin, Borut
AU  - Peterlin B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040729
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
SB  - IM
MH  - Adult
MH  - Alleles
MH  - *Gene Amplification
MH  - Heterozygote
MH  - Humans
MH  - Infertility, Male/*genetics/pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Oligospermia/genetics
MH  - *Trinucleotide Repeats
EDAT- 2004/07/31 05:00
MHDA- 2005/03/10 09:00
CRDT- 2004/07/31 05:00
PHST- 2004/07/31 05:00 [pubmed]
PHST- 2005/03/10 09:00 [medline]
PHST- 2004/07/31 05:00 [entrez]
AID - deh382 [pii]
AID - 10.1093/humrep/deh382 [doi]
PST - ppublish
SO  - Hum Reprod. 2004 Sep;19(9):2084-7. doi: 10.1093/humrep/deh382. Epub 2004 Jul 29.

PMID- 15215218
OWN - NLM
STAT- MEDLINE
DCOM- 20041015
LR  - 20131121
IS  - 1460-2156 (Electronic)
IS  - 0006-8950 (Linking)
VI  - 127
IP  - Pt 9
DP  - 2004 Sep
TI  - A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: 
      phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24.
PG  - 1979-92
AB  - The majority of proximal myotonic myopathy syndromes reported so far have been 
      related to the myotonic dystrophy (DM) type 2 (DM2) mutation, an expanded (CCTG)n 
      repeat in the ZNF9 gene. Here, we describe the phenotype and the histological 
      features in muscle and brain of the first large pedigree with a non-myotonic 
      dystrophy type 1 (DM1) non-DM2 multisystem myotonic disorder associated with 
      severe frontotemporal dementia. Thirty individuals from three generations 
      underwent detailed neurological, neuropsychological, electrophysiological, brain 
      imaging and molecular analyses. Ten of them had proximal muscle weakness at 
      onset, clinical/electrical myotonia and DM-type cataracts. The mean age at onset 
      was 46.7 +/- 12.6 years (range: 32-69). Dementia was observed later in the course 
      of the disease. On muscle biopsies, rare nuclear clumps, rimmed vacuoles and 
      small angulated type 1 and type 2 fibres were seen early in the disease. They 
      were replaced by fibrous adipose tissue at later stages. Immunohistochemical 
      analysis of myosin heavy chain isoforms showed no selective fibre type 
      atrophy-both type 1 and type 2 fibres being affected. Cortical atrophy without 
      white matter lesions was seen on brain MRI. A brain single photon emission 
      computed tomography (SPECT) study revealed marked frontotemporal hypoperfusion. 
      Post-mortem examination of the brains of two patients showing prominent 
      frontotemporal spongiosis, neuronal loss and rare neuronal and glial tau 
      inclusions suggested frontotemporal dementia. Western blot analyses of the tau 
      protein showed a triplet of isoforms (60, 64 and 69 kDa) in neocortical areas, 
      and a doublet (64 and 69 kDa) in subcortical areas that distinguish our myotonic 
      disorder from other's myotonic dystrophies. Molecular analyses failed to detect a 
      repeat expansion in the DMPK and ZNF9 genes excluding both DM1 and DM2, whereas a 
      genome-wide linkage analysis strongly suggested a linkage to chromosome 15q21-24. 
      This previously unreported multisystem myotonic disorder including findings 
      resembling DM1, DM2 and frontotemporal dementia provides further evidence of the 
      clinical and genetic heterogeneity of the myotonic dystrophies. We propose to 
      designate this disease myotonic dystrophy type 3, DM3.
FAU - Le Ber, Isabelle
AU  - Le Ber I
AD  - Departement de Neurologie, Centre Hospitalo-Universitaire Charles Nicolle, Rouen, 
      France.
FAU - Martinez, Maria
AU  - Martinez M
FAU - Campion, Dominique
AU  - Campion D
FAU - Laquerriere, Annie
AU  - Laquerriere A
FAU - Betard, Christine
AU  - Betard C
FAU - Bassez, Guillaume
AU  - Bassez G
FAU - Girard, Carol
AU  - Girard C
FAU - Saugier-Veber, Pascale
AU  - Saugier-Veber P
FAU - Raux, Gregory
AU  - Raux G
FAU - Sergeant, Nicolas
AU  - Sergeant N
FAU - Magnier, Patrick
AU  - Magnier P
FAU - Maisonobe, Thierry
AU  - Maisonobe T
FAU - Eymard, Bruno
AU  - Eymard B
FAU - Duyckaerts, Charles
AU  - Duyckaerts C
FAU - Delacourte, Andre
AU  - Delacourte A
FAU - Frebourg, Thierry
AU  - Frebourg T
FAU - Hannequin, Didier
AU  - Hannequin D
LA  - eng
PT  - Journal Article
DEP - 20040623
PL  - England
TA  - Brain
JT  - Brain : a journal of neurology
JID - 0372537
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (tau Proteins)
RN  - EC 3.6.4.1 (Myosin Heavy Chains)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Chromosome Mapping/methods
MH  - Chromosomes, Human, Pair 15/*genetics
MH  - Dementia/complications/*genetics/pathology
MH  - Female
MH  - Genetic Linkage/genetics
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness/etiology/genetics/pathology
MH  - Muscle, Skeletal/pathology
MH  - Myosin Heavy Chains/analysis
MH  - Myotonic Disorders/complications/*genetics/pathology
MH  - Pedigree
MH  - Phenotype
MH  - RNA-Binding Proteins/genetics
MH  - Sex Ratio
MH  - tau Proteins/analysis
EDAT- 2004/06/25 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/06/25 05:00
PHST- 2004/06/25 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/06/25 05:00 [entrez]
AID - awh216 [pii]
AID - 10.1093/brain/awh216 [doi]
PST - ppublish
SO  - Brain. 2004 Sep;127(Pt 9):1979-92. doi: 10.1093/brain/awh216. Epub 2004 Jun 23.

PMID- 15201457
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20061115
IS  - 1064-3745 (Print)
IS  - 1064-3745 (Linking)
VI  - 277
DP  - 2004
TI  - Analysis of CTG repeats using DM1 model mice.
PG  - 185-97
AB  - This chapter describes how transgenic mice can be made with human genomic DNA 
      fragments cloned from DM1 patients' DNA and how the CTG repeat instability is 
      assessed over generations and in different tissues. Construction of cosmid 
      libraries is fully reported from the extraction of high-molecular-weight DNA from 
      patients' lymphoid cell lines, to the screening and mapping of the positive 
      clones. After establishment of transgenic lines, we explained the methods used to 
      analyze (a) the CTG repeats that are inherited from the transgenic parents, with 
      regard to age, sex, and parental CTG repeat sizes, and (b) the CTG repeat-length 
      variations that can be observed in somatic tissues and in sperm.
FAU - Savouret, Cedric
AU  - Savouret C
AD  - INSERM UR383, Hospital Necker-Enfants Malades, Universite Rene Descartes Paris V, 
      France.
FAU - Junien, Claudine
AU  - Junien C
FAU - Gourdon, Genevieve
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (DNA Primers)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Cosmids
MH  - DNA Primers
MH  - Mice
MH  - Mice, Transgenic
MH  - *Models, Animal
MH  - *Trinucleotide Repeats
EDAT- 2004/06/18 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/06/18 05:00
PHST- 2004/06/18 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/06/18 05:00 [entrez]
AID - 1-59259-804-8:185 [pii]
AID - 10.1385/1-59259-804-8:185 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2004;277:185-97. doi: 10.1385/1-59259-804-8:185.

PMID- 15114529
OWN - NLM
STAT- MEDLINE
DCOM- 20040706
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 74
IP  - 6
DP  - 2004 Jun
TI  - Insulin receptor splicing alteration in myotonic dystrophy type 2.
PG  - 1309-13
AB  - Myotonic dystrophy (DM) is caused by either an untranslated CTG expansion in the 
      3' untranslated region of the DMPK gene on chromosome 19 (dystrophia myotonica 
      type 1 [DM1]), or an untranslated CCTG tetranucleotide repeat expansion in intron 
      1 of the ZNF9 gene on chromosome 3 (dystrophia myotonica type 2 [DM2]). 
      RNA-binding proteins adhere to transcripts of the repeat expansions that 
      accumulate in the nucleus, and a trans-dominant dysregulation of pre-mRNA 
      alternative splicing has been demonstrated for several genes. In muscle from 
      patients with DM1, altered insulin-receptor splicing to the nonmuscle isoform 
      corresponds to the insulin insensitivity and diabetes that are part of the DM 
      phenotype; because of insulin-receptor species differences, this effect is not 
      seen in mouse models of the disease. We now demonstrate that comparable splicing 
      abnormalities occur in DM2 muscle prior to the development of muscle 
      histopathology, thus demonstrating an early pathogenic effect of RNA expansions.
FAU - Savkur, R S
AU  - Savkur RS
AD  - Department of Pathology, Baylor University, Houston, TX, USA.
FAU - Philips, A V
AU  - Philips AV
FAU - Cooper, T A
AU  - Cooper TA
FAU - Dalton, J C
AU  - Dalton JC
FAU - Moseley, M L
AU  - Moseley ML
FAU - Ranum, L P W
AU  - Ranum LP
FAU - Day, J W
AU  - Day JW
LA  - eng
GR  - M01 RR000400/RR/NCRR NIH HHS/United States
GR  - R01 AR045653/AR/NIAMS NIH HHS/United States
GR  - R01 NS035870/NS/NINDS NIH HHS/United States
GR  - R01AR45653/AR/NIAMS NIH HHS/United States
GR  - M01RR00400/RR/NCRR NIH HHS/United States
GR  - R01NS35870/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20040426
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (RNA Probes)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alternative Splicing/*genetics
MH  - Case-Control Studies
MH  - Female
MH  - Glucose/metabolism
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Insulin Resistance/*genetics
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/diagnosis/*genetics/pathology
MH  - RNA Probes
MH  - RNA, Messenger/genetics/metabolism
MH  - Receptor, Insulin/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC1182097
EDAT- 2004/04/29 05:00
MHDA- 2004/07/09 05:00
PMCR- 2004/12/01
CRDT- 2004/04/29 05:00
PHST- 2004/01/30 00:00 [received]
PHST- 2004/04/02 00:00 [accepted]
PHST- 2004/04/29 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2004/04/29 05:00 [entrez]
PHST- 2004/12/01 00:00 [pmc-release]
AID - S0002-9297(07)62859-6 [pii]
AID - 41003 [pii]
AID - 10.1086/421528 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2004 Jun;74(6):1309-13. doi: 10.1086/421528. Epub 2004 Apr 26.

PMID- 15099703
OWN - NLM
STAT- MEDLINE
DCOM- 20040720
LR  - 20151119
IS  - 0168-0102 (Print)
IS  - 0168-0102 (Linking)
VI  - 49
IP  - 1
DP  - 2004 May
TI  - Altered expression of CUG binding protein 1 mRNA in myotonic dystrophy 1: 
      possible RNA-RNA interaction.
PG  - 47-54
AB  - The triplet repeats mutation, which causes myotonic dystrophy 1 (DM1), is thought 
      to have a dominant negative effect on RNA levels. In light of previous results 
      using differential display analysis, the present study focused on the expression 
      of CUG binding protein 1 (CUGBP1) mRNA. Northern blot analysis demonstrated that 
      the quantity of CUGBP1 mRNA in three DM1 patients was approximately 70% of that 
      observed in three normal controls (P < 0.05). In addition, a semi-quantitative 
      RT-PCR assay showed that the relative amount of CUGBP1 mRNA was reduced in muscle 
      biopsy samples from 10 DM1 patients compared to that from five normal individuals 
      (P < 0.01) and 10 myopathic disease controls (P < 0.01). The amount of CUGBP1 
      mRNA was negatively correlated with the size of the CTG expansion (r = -0.85, P < 
      0.05). In vitro RNA-RNA binding experiments demonstrated that the incubation of 
      expanded CUG repeats with CUGBP1 RNA generated a higher molecular weight band, 
      which was digested by RNase III. The CUGBP1 mRNA was found to contain several CAG 
      repeat sequences. These results suggest that the CUG expansion may bind to 
      complementary sequences within the CUGBP1 mRNA and that this molecular 
      interaction may affect CUGBP1 mRNA expression in DM1.
FAU - Watanabe, Tomoji
AU  - Watanabe T
AD  - Department of Neurology, Toranomon Hospital and Okinaka Memorial Institute for 
      Medical Research, 222 Toranomon, Minato-ku, Tokyo 105-0001, Japan. 
      watanabe-t@toranomon.gr.jp
FAU - Takagi, Akio
AU  - Takagi A
FAU - Sasagawa, Noboru
AU  - Sasagawa N
FAU - Ishiura, Shoichi
AU  - Ishiura S
FAU - Nakase, Hirofumi
AU  - Nakase H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Neurosci Res
JT  - Neuroscience research
JID - 8500749
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adult
MH  - Biopsy/methods
MH  - Blotting, Northern/methods
MH  - CELF1 Protein
MH  - Female
MH  - *Gene Expression Regulation
MH  - Humans
MH  - In Vitro Techniques
MH  - Male
MH  - Myotonic Dystrophy/genetics/*metabolism
MH  - Protein Binding/physiology
MH  - RNA/*metabolism
MH  - RNA, Messenger/metabolism
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Trinucleotide Repeat Expansion/physiology
EDAT- 2004/04/22 05:00
MHDA- 2004/07/21 05:00
CRDT- 2004/04/22 05:00
PHST- 2003/11/04 00:00 [received]
PHST- 2004/01/20 00:00 [accepted]
PHST- 2004/04/22 05:00 [pubmed]
PHST- 2004/07/21 05:00 [medline]
PHST- 2004/04/22 05:00 [entrez]
AID - S0168010204000239 [pii]
AID - 10.1016/j.neures.2004.01.008 [doi]
PST - ppublish
SO  - Neurosci Res. 2004 May;49(1):47-54. doi: 10.1016/j.neures.2004.01.008.

PMID- 15079005
OWN - NLM
STAT- MEDLINE
DCOM- 20040802
LR  - 20211203
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 62
IP  - 7
DP  - 2004 Apr 13
TI  - Leukocyte CTG repeat length correlates with severity of myotonia in myotonic 
      dystrophy type 1.
PG  - 1081-9
AB  - OBJECTIVE: To quantitate hand muscle myotonia and to assess the relationship 
      between CTG repeat length and myotonia in myotonic dystrophy type 1 (DM1). 
      METHODS: First dorsal interosseous twitch and tetanic contractions evoked by 
      single and 10-Hz ulnar nerve stimulation were recorded with a force transducer in 
      15 patients with genetically confirmed DM1 and 15 control subjects. An automated 
      computer program analyzed three single and three tetanic recordings per subject 
      on 2 successive days by placing cursors along the declining (relaxation) phase of 
      the force recordings at 90, 50, and 5% of peak force (PF) and calculating 
      relaxation times (RT) between these points. RESULTS: Tetanic and twitch RT was 
      longer and PF lower in patients than subjects. RT (90 to 5%) was above the normal 
      mean + 2.5 SD in 13 tetanic (87%) and 11 (73%) twitch patient recordings. In DM1, 
      prolongation of RT was due mainly to delay in the terminal (50 to 5%), rather 
      than the initial (90 to 50%) phase of relaxation, and was much greater in tetanic 
      than single-twitch recordings. Mean test-retest variability was 19% for tetanic 
      RT and 16% for tetanic PF. In DM1, both tetanic and twitch RT were positively 
      correlated with leukocyte CTG repeat length. CONCLUSIONS: In DM1, myotonia of 
      intrinsic hand muscles can be quantitated reliably by automated analysis of 
      tetanic and twitch RT, targeting, in particular, the terminal phase of muscle 
      relaxation after tetanic stimulation. Severity of hand muscle myotonia depends on 
      CTG repeat length consistent with a "triplet repeat dosage" effect on chloride 
      channel mRNA splicing and function.
FAU - Logigian, E L
AU  - Logigian EL
AD  - Department of Neurology, University of Rochester, NY, USA. 
      eric_logigian@urmc.rochester.edu
FAU - Moxley, R T 4th
AU  - Moxley RT 4th
FAU - Blood, C L
AU  - Blood CL
FAU - Barbieri, C A
AU  - Barbieri CA
FAU - Martens, W B
AU  - Martens WB
FAU - Wiegner, A W
AU  - Wiegner AW
FAU - Thornton, C A
AU  - Thornton CA
FAU - Moxley, R T 3rd
AU  - Moxley RT 3rd
LA  - eng
GR  - 5 M01 RR00044/RR/NCRR NIH HHS/United States
GR  - FD-R-001662/FD/FDA HHS/United States
GR  - R01 AR44069A/AR/NIAMS NIH HHS/United States
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Electric Stimulation
MH  - Electrodiagnosis/instrumentation/*methods
MH  - Feasibility Studies
MH  - Female
MH  - Hand/physiopathology
MH  - Humans
MH  - *Leukocytes/chemistry
MH  - Male
MH  - Middle Aged
MH  - Muscle Contraction/genetics
MH  - Muscle, Skeletal/physiopathology
MH  - Myotonic Dystrophy/*diagnosis/*genetics/physiopathology
MH  - Myotonin-Protein Kinase
MH  - Predictive Value of Tests
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Ulnar Nerve/physiopathology
EDAT- 2004/04/14 05:00
MHDA- 2004/08/03 05:00
CRDT- 2004/04/14 05:00
PHST- 2004/04/14 05:00 [pubmed]
PHST- 2004/08/03 05:00 [medline]
PHST- 2004/04/14 05:00 [entrez]
AID - 10.1212/01.wnl.0000118206.49652.a3 [doi]
PST - ppublish
SO  - Neurology. 2004 Apr 13;62(7):1081-9. doi: 10.1212/01.wnl.0000118206.49652.a3.

PMID- 15019706
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20071114
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 14
IP  - 4
DP  - 2004 Apr
TI  - New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in 
      myotonic dystrophy type 2 (DM2).
PG  - 274-83
AB  - Myotonic dystrophy types 1 and 2 are autosomal dominant, multisystemic disorders 
      with many similarities in their clinical manifestations. Myotonic dystrophy type 
      1 is caused by a (CTG)n expansion in the 3' untranslated region of the DMPK gene 
      in 19q13.3 and myotonic dystrophy type 2 by a (CCTG)n expansion in intron 1 of 
      ZNF9 in 3q21.3. However, the clinical diagnosis of myotonic dystrophy type 2 is 
      more complex than that of myotonic dystrophy type 1, and conventional molecular 
      genetic methods used for diagnosing myotonic dystrophy type 1 are insufficient 
      for myotonic dystrophy type 2. Herein we describe two in situ hybridization 
      protocols for the myotonic dystrophy type 2 mutation detection. Chromogenic in 
      situ hybridization was used to detect both the genomic expansion and the mutant 
      transcripts in muscle biopsy sections. Chromogenic in situ hybridization can be 
      used in routine myotonic dystrophy type 2 diagnostics. Fluorescence in situ 
      hybridization on extended DNA fibers was used to directly visualize the myotonic 
      dystrophy type 2 mutation and to estimate the repeat expansion sizes.
FAU - Sallinen, R
AU  - Sallinen R
AD  - Section of Cancer Genetics, Department of Molecular Genetics, University of Texas 
      M. D. Anderson Cancer Center, Houston, TX, USA.
FAU - Vihola, A
AU  - Vihola A
FAU - Bachinski, L L
AU  - Bachinski LL
FAU - Huoponen, K
AU  - Huoponen K
FAU - Haapasalo, H
AU  - Haapasalo H
FAU - Hackman, P
AU  - Hackman P
FAU - Zhang, S
AU  - Zhang S
FAU - Sirito, M
AU  - Sirito M
FAU - Kalimo, H
AU  - Kalimo H
FAU - Meola, G
AU  - Meola G
FAU - Horelli-Kuitunen, N
AU  - Horelli-Kuitunen N
FAU - Wessman, M
AU  - Wessman M
FAU - Krahe, R
AU  - Krahe R
FAU - Udd, B
AU  - Udd B
LA  - eng
GR  - R01 AR8171/AR/NIAMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (Indoles)
RN  - 0 (RNA, Messenger)
RN  - 47165-04-8 (DAPI)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Biopsy/methods
MH  - DNA Repeat Expansion/*genetics
MH  - Electrophoresis, Capillary/methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Indoles/metabolism
MH  - Linkage Disequilibrium
MH  - Male
MH  - Middle Aged
MH  - Molecular Diagnostic Techniques/*methods
MH  - Muscles/metabolism
MH  - *Mutation
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - RNA, Messenger/biosynthesis
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
EDAT- 2004/03/17 05:00
MHDA- 2004/05/11 05:00
CRDT- 2004/03/17 05:00
PHST- 2003/11/04 00:00 [received]
PHST- 2003/12/08 00:00 [revised]
PHST- 2004/01/08 00:00 [accepted]
PHST- 2004/03/17 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2004/03/17 05:00 [entrez]
AID - S0960896604000082 [pii]
AID - 10.1016/j.nmd.2004.01.002 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2004 Apr;14(4):274-83. doi: 10.1016/j.nmd.2004.01.002.

PMID- 14996041
OWN - NLM
STAT- MEDLINE
DCOM- 20040617
LR  - 20191108
IS  - 0962-1105 (Print)
IS  - 0962-1105 (Linking)
VI  - 13
IP  - 1
DP  - 2004 Mar
TI  - Sleep complaints in patients with myotonic dystrophy.
PG  - 95-100
AB  - The aim of this study was to document the clinical picture of excessive daytime 
      sleepiness (EDS) and of other sleep disturbances, and to study the relationship 
      of daytime sleepiness to anthropometric data, muscular impairment, and CTG 
      trinucleotide repeat expansion in myotonic dystrophy type 1 (DM1). A total of 157 
      DM1 patients were surveyed using a modified version of the Sleep Questionnaire 
      and Assessment of Wakefulness. Other measurements included muscular impairment 
      rating and the size of the trinucleotide repeat. Factor analysis and reliability 
      estimates were used to produce a daytime sleepiness scale with five items of the 
      questionnaire. Thirty-eight healthy family members were studied as control 
      subjects. It was found that EDS was present in 33.1% of DM1 patients. Severity of 
      daytime sleepiness correlated with the degree of muscular impairment but not with 
      age, gender, body mass index, age at onset of symptoms, duration of illness, and 
      CTG repeat. DM1 patients reported a longer sleep period, a less restorative 
      sleep, and more difficulty falling asleep, being alert in the morning and staying 
      awake after meals than controls, but a similar incidence of narcolepsy auxiliary 
      symptoms. Compared with DM1 patients without EDS, those with EDS reported greater 
      hypnagogic hallucinations, and greater pain associated with nocturnal awakenings 
      and in their legs upon morning awakenings. In sum, both DM1 patients with and 
      without EDS exhibit characteristics of sleep duration and sleepiness comparable 
      with those found in idiopathic hypersomnia. The severity of daytime sleepiness is 
      weakly related to the extent of muscular impairment but not to CTG repeat.
FAU - Laberge, Luc
AU  - Laberge L
AD  - Clinical Research Unit, Chicoutimi Hospital and Universite du Quebec a 
      Chicoutimi, Saguenay, Quebec, Canada. laberluc@saglac.qc.ca
FAU - Begin, Paul
AU  - Begin P
FAU - Montplaisir, Jacques
AU  - Montplaisir J
FAU - Mathieu, Jean
AU  - Mathieu J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Sleep Res
JT  - Journal of sleep research
JID - 9214441
SB  - IM
MH  - Adult
MH  - Anthropometry
MH  - Disorders of Excessive Somnolence/diagnosis/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscle, Skeletal/physiopathology
MH  - Myotonic Dystrophy/*epidemiology/physiopathology/*psychology
MH  - Prevalence
MH  - Restless Legs Syndrome/epidemiology
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
EDAT- 2004/03/05 05:00
MHDA- 2004/06/18 05:00
CRDT- 2004/03/05 05:00
PHST- 2004/03/05 05:00 [pubmed]
PHST- 2004/06/18 05:00 [medline]
PHST- 2004/03/05 05:00 [entrez]
AID - 385 [pii]
AID - 10.1111/j.1365-2869.2004.00385.x [doi]
PST - ppublish
SO  - J Sleep Res. 2004 Mar;13(1):95-100. doi: 10.1111/j.1365-2869.2004.00385.x.

PMID- 14760317
OWN - NLM
STAT- MEDLINE
DCOM- 20040326
LR  - 20071114
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 147
IP  - 2
DP  - 2004 Feb
TI  - Prevalence of structural cardiac abnormalities in patients with myotonic 
      dystrophy type I.
PG  - 224-7
AB  - BACKGROUND: Myotonic dystrophy type 1 (DM1) is a neurological disorder with known 
      cardiac involvement, including conduction disturbances, arrhythmias, and 
      ventricular dysfunction. We studied which clinical and electrocardiographic 
      features are associated with structural cardiac abnormalities. METHODS: History, 
      physical examination, electrocardiography, and genetic testing were performed on 
      382 patients with DM1, and cardiac imaging was performed on 100 of these 
      patients. RESULTS: Clinical congestive heart failure was found in 7 of the 382 
      patients (1.8%). Structural cardiac abnormalities determined with cardiac imaging 
      included left ventricular hypertrophy (19.8%), left ventricular dilatation 
      (18.6%), left ventricular systolic dysfunction (14.0%), mitral valve prolapse 
      (13.7%), regional wall motion abnormality (11.2%), and left atrial dilatation 
      (6.3%). Left ventricular systolic dysfunction was associated with increasing age 
      (relative risk [RR], 1.9 per decade; 95% CI, 1.1-3.2; P =.02), 
      cytosine-thymine-guanine (CTG) repeat length (RR, 2.8 per 500 repeats; 95% CI, 
      1.3-6.3; P =.01), P-R >200 ms (RR, 14.7; 95% CI, 3.0-73.1; P =.001), and QRS >120 
      ms (RR, 5.7; 95% CI, 1.5-21.8; P =.01). P-R >200 ms was predictive of regional 
      wall motion abnormalities. QRS >120 ms correlated with regional wall motion 
      abnormalities and left atrial dilatation. CONCLUSIONS: Several clinical and 
      electrocardiographic findings in patients with DM1 are significantly associated 
      with structural heart abnormalities. These results suggest an underlying genetic 
      and pathophysiologic correlate that may lead to cardiac disease in these 
      patients.
FAU - Bhakta, Deepak
AU  - Bhakta D
AD  - Department of Medicine, Krannert Institute of Cardiology, Indiana University, 
      Indianapolis, Ind 46202, USA. dbhakta@iupui.edu
FAU - Lowe, Miriam R
AU  - Lowe MR
FAU - Groh, William J
AU  - Groh WJ
LA  - eng
GR  - M01-RR00750-27S1/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - IM
CIN - Am Heart J. 2004 Dec;148(6):e33; author reply e34. PMID: 15632870
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Heart Diseases/*complications/epidemiology/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*complications/genetics
MH  - Prevalence
EDAT- 2004/02/05 05:00
MHDA- 2004/03/27 05:00
CRDT- 2004/02/05 05:00
PHST- 2004/02/05 05:00 [pubmed]
PHST- 2004/03/27 05:00 [medline]
PHST- 2004/02/05 05:00 [entrez]
AID - S0002870303006367 [pii]
AID - 10.1016/j.ahj.2003.08.008 [doi]
PST - ppublish
SO  - Am Heart J. 2004 Feb;147(2):224-7. doi: 10.1016/j.ahj.2003.08.008.

PMID- 14745066
OWN - NLM
STAT- MEDLINE
DCOM- 20050114
LR  - 20190514
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 62
IP  - 2
DP  - 2004 Jan 27
TI  - Germline mutational dynamics in myotonic dystrophy type 1 males: allele length 
      and age effects.
PG  - 269-74
AB  - BACKGROUND: The CTG repeat expansion causing myotonic dystrophy type 1 is 
      unstable in the germline, and frequent intergenerational length changes are 
      observed, giving rise to the unusual genetics of the disorder. The repeat is also 
      somatically unstable, and expanded alleles accumulate throughout life, thus 
      compromising simple measures of intergenerational stability. OBJECTIVE: To gain a 
      better understanding of the intergenerational dynamics of the DM1 repeat in the 
      male germline. METHODS: We used sensitive small pool PCR procedures to analyze 
      sperm and somatic DNA from 22 DM1 men of different ages, CTG repeat length, and 
      clinical form. RESULTS: High levels of repeat length variation heavily biased 
      toward further expansions were observed in the sperm of all DM1 men. Progenitor 
      allele length was revealed as a major modifier of interindividual variation, with 
      the largest length changes observed for premutation and protomutation alleles and 
      the highest frequency of contractions in full mutation alleles. However, despite 
      clear increases in the degree of somatic mosaicism, no differences were observed 
      in replicate sperm samples obtained from two men during a 4-year period. 
      CONCLUSIONS: Progenitor allele length is a major modifier of the mutational 
      dynamics of the DM1 repeat in the male germline, but surprisingly age is not. 
      Therefore, other as yet unidentified modifiers must be responsible for the 
      considerable residual interindividual variation that cannot be accounted for by 
      these factors.
FAU - Martorell, L
AU  - Martorell L
AD  - Servei de Genetica, Hospital de Sant Pau, Barcelona, Spain. 
      mmartorells@hsp.santpau.es
FAU - Gamez, J
AU  - Gamez J
FAU - Cayuela, M L
AU  - Cayuela ML
FAU - Gould, F K
AU  - Gould FK
FAU - McAbney, J P
AU  - McAbney JP
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - Monckton, D G
AU  - Monckton DG
FAU - Baiget, M
AU  - Baiget M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Alleles
MH  - Child
MH  - Child, Preschool
MH  - DNA/genetics
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Polymerase Chain Reaction
MH  - Spermatozoa/chemistry
MH  - Trinucleotide Repeats
EDAT- 2004/01/28 05:00
MHDA- 2005/01/15 09:00
CRDT- 2004/01/28 05:00
PHST- 2004/01/28 05:00 [pubmed]
PHST- 2005/01/15 09:00 [medline]
PHST- 2004/01/28 05:00 [entrez]
AID - 10.1212/wnl.62.2.269 [doi]
PST - ppublish
SO  - Neurology. 2004 Jan 27;62(2):269-74. doi: 10.1212/wnl.62.2.269.

PMID- 14734627
OWN - NLM
STAT- MEDLINE
DCOM- 20041028
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 13
IP  - 6
DP  - 2004 Mar 15
TI  - Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR.
PG  - 589-600
AB  - Myotonic dystrophy (DM1) is a multisystemic disorder caused by a CTG repeat 
      expansion within the 3'-UTR of the DMPK gene. DM1 is characterized by delayed 
      muscle development, muscle weakness and wasting, cardiac conduction 
      abnormalities, cognitive defects and cataracts. Recent studies have demonstrated 
      that the disease mechanism involves a dominant gain-of-function conferred upon 
      mutant transcripts by expanded repeats. However, further attempts to model 
      aspects of DM muscle pathology in cultured myoblasts suggest that 3'-UTR 
      sequences flanking the CTG repeat tract are also required for full expression of 
      the disease phenotype. Here, we report that overexpression of the DMPK 3'-UTR 
      including either wild-type (11) or expanded (91) CTG repeats results in aberrant 
      and delayed muscle development in fetal transgenic mice. In addition, transgenic 
      animals with both expanded and wild-type CTG repeats display muscle atrophy at 3 
      months of age. Primary myoblast cultures from both 11 and 91 repeat mice display 
      reduced fusion potential, but a greater reduction is observed in the 91 repeat 
      cultures. Taken together, these data indicate that overexpression of the DMPK 
      3'-UTR interferes with normal muscle development in mice and that this is 
      exacerbated by inclusion of a mutant repeat. This suggests that the delayed 
      muscle development in DM1 involves an interplay between the expanded CTG repeat 
      and adjacent 3'-UTR sequences.
FAU - Storbeck, Christopher J
AU  - Storbeck CJ
AD  - Solange-Gauthier-Karsh Molecular Genetics Laboartory, Children's Hospital of 
      Eastern Ontario Research Institute, Ottawa, Canada.
FAU - Drmanic, Suzana
AU  - Drmanic S
FAU - Daniel, Kate
AU  - Daniel K
FAU - Waring, James D
AU  - Waring JD
FAU - Jirik, Frank R
AU  - Jirik FR
FAU - Parry, David J
AU  - Parry DJ
FAU - Ahmed, Nazim
AU  - Ahmed N
FAU - Sabourin, Luc A
AU  - Sabourin LA
FAU - Ikeda, Joh-E
AU  - Ikeda JE
FAU - Korneluk, Robert G
AU  - Korneluk RG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20040120
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Luminescent Proteins)
RN  - 0 (MYOG protein, human)
RN  - 0 (Myog protein, mouse)
RN  - 0 (Myogenin)
RN  - 0 (RNA, Messenger)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Animals
MH  - Blotting, Northern
MH  - Blotting, Western
MH  - Disease Models, Animal
MH  - *Gene Expression Regulation
MH  - Green Fluorescent Proteins
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Luminescent Proteins
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle Development/*genetics
MH  - Myoblasts/physiology
MH  - Myogenin/genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transgenes/genetics
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 2004/01/22 05:00
MHDA- 2004/10/29 09:00
CRDT- 2004/01/22 05:00
PHST- 2004/01/22 05:00 [pubmed]
PHST- 2004/10/29 09:00 [medline]
PHST- 2004/01/22 05:00 [entrez]
AID - ddh064 [pii]
AID - 10.1093/hmg/ddh064 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2004 Mar 15;13(6):589-600. doi: 10.1093/hmg/ddh064. Epub 2004 Jan 
      20.

PMID- 14701736
OWN - NLM
STAT- MEDLINE
DCOM- 20040218
LR  - 20211203
IS  - 0270-7306 (Print)
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Linking)
VI  - 24
IP  - 2
DP  - 2004 Jan
TI  - MSH2-dependent germinal CTG repeat expansions are produced continuously in 
      spermatogonia from DM1 transgenic mice.
PG  - 629-37
AB  - Myotonic dystrophy type 1 is a neuromuscular affection associated with the 
      expansion of an unstable CTG repeat in the DM protein kinase gene. The disease is 
      characterized by somatic tissue-specific mosaicism and very high 
      intergenerational instability with a strong bias towards expansions. We used 
      transgenic mice carrying more than 300 unstable CTG repeats within their large 
      human genomic environment to investigate the dynamics of CTG repeat germinal 
      mosaicism in males. Germinal mosaicism towards expansions was already present in 
      spermatozoa at 7 weeks of age and continued to increase with age, suggesting that 
      expansions are continuously produced throughout life. To determine the precise 
      stage at which germinal expansions occur during spermatogenesis, we sorted and 
      collected the different germ cell types produced during spermatogenesis from 
      males of different ages and analyzed the CTG repeat mosaicism in each fraction. 
      Strong mosaicisms towards expansions were already observed in spermatogonia 
      before meiosis. In transgenic Msh2-deficient mice, germinal instability of the 
      CTG repeats (only contractions) also occurs premeiotically. No significant 
      difference in mosaicism was detected between spermatogonia and spermatozoa, 
      arguing against continued expansions during postmeiotic stages. This indicates 
      that germinal expansions are produced at the beginning of spermatogenesis, in 
      spermatogonia, by a meiosis-independent mechanism involving MSH2.
FAU - Savouret, Cedric
AU  - Savouret C
AD  - INSERM U383 Genetique, Chromosome et Cancer, Clinique M. Lamy 2eme etage, Hopital 
      Necker Enfants Malades, 149 rue de Sevres, 75015 Paris, France.
FAU - Garcia-Cordier, Corinne
AU  - Garcia-Cordier C
FAU - Megret, Jerome
AU  - Megret J
FAU - te Riele, Hein
AU  - te Riele H
FAU - Junien, Claudine
AU  - Junien C
FAU - Gourdon, Genevieve
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.6.1.3 (MSH2 protein, human)
RN  - EC 3.6.1.3 (Msh2 protein, mouse)
RN  - EC 3.6.1.3 (MutS Homolog 2 Protein)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - *DNA-Binding Proteins
MH  - Genomic Instability
MH  - Humans
MH  - Male
MH  - Meiosis/genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Mosaicism
MH  - MutS Homolog 2 Protein
MH  - Myotonic Dystrophy/genetics/metabolism
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Proto-Oncogene Proteins/deficiency/genetics/*metabolism
MH  - Spermatogenesis/genetics
MH  - Spermatogonia/*metabolism
MH  - *Trinucleotide Repeat Expansion
PMC - PMC343816
EDAT- 2004/01/01 05:00
MHDA- 2004/02/19 05:00
PMCR- 2004/01/01
CRDT- 2004/01/01 05:00
PHST- 2004/01/01 05:00 [pubmed]
PHST- 2004/02/19 05:00 [medline]
PHST- 2004/01/01 05:00 [entrez]
PHST- 2004/01/01 00:00 [pmc-release]
AID - 1331 [pii]
AID - 10.1128/MCB.24.2.629-637.2004 [doi]
PST - ppublish
SO  - Mol Cell Biol. 2004 Jan;24(2):629-37. doi: 10.1128/MCB.24.2.629-637.2004.

PMID- 14681885
OWN - NLM
STAT- MEDLINE
DCOM- 20040114
LR  - 20091119
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 54
IP  - 6
DP  - 2003 Dec
TI  - Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2.
PG  - 760-8
AB  - Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are caused by genomic expansions 
      of CTG or CCTG repeats. When transcribed, these mutations give rise to repeat 
      expansion RNAs that form nuclear inclusions and compromise the function of 
      myonuclei. Here, we have used in situ hybridization and immunofluorescence to 
      compare DM1 and DM2 and search for proteins that associate with the RNA nuclear 
      (ribonuclear) inclusions. Although muscle disease is generally more severe in 
      DM1, the ribonuclear inclusions were 8- to 13-fold more intense in DM2, implying 
      greater amounts of repeat expansion RNA. Expression of repeat expansion RNA in 
      myoblasts has been implicated in the pathogenesis of congenital DM1. However, we 
      found that repeat expansion RNA is also expressed in myoblasts in DM2, a disorder 
      that has not been associated with a congenital phenotype. Of 10 putative CUG 
      binding proteins tested for colocalization with mutant RNA, only proteins in the 
      muscleblind family were recruited into ribonuclear inclusions. Previous studies 
      have shown activation of the protein kinase, PKR, by expanded CUG repeats in 
      vitro. However, breeding experiments utilizing PKR knockout mice indicate that 
      this kinase is not required for disease pathogenesis in a transgenic mouse model 
      of DM1. We conclude that ribonuclear inclusions are a key feature of the muscle 
      pathology in DM and that sequestration of muscleblind proteins may have a direct 
      role in the disease process.
FAU - Mankodi, Ami
AU  - Mankodi A
AD  - Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
FAU - Teng-Umnuay, Patana
AU  - Teng-Umnuay P
FAU - Krym, Matt
AU  - Krym M
FAU - Henderson, Don
AU  - Henderson D
FAU - Swanson, Maurice
AU  - Swanson M
FAU - Thornton, Charles A
AU  - Thornton CA
LA  - eng
GR  - AR 46799/AR/NIAMS NIH HHS/United States
GR  - AR 46806/AR/NIAMS NIH HHS/United States
GR  - AR 48183/AR/NIAMS NIH HHS/United States
GR  - AR 49077/AR/NIAMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (eIF-2 Kinase)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Intranuclear Inclusion Bodies/enzymology/*genetics/*metabolism/*pathology
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/enzymology/*pathology
MH  - Mutation
MH  - Myotonic Dystrophy/enzymology/*genetics/pathology
MH  - RNA/*metabolism
MH  - eIF-2 Kinase/deficiency/genetics
EDAT- 2003/12/19 05:00
MHDA- 2004/01/15 05:00
CRDT- 2003/12/19 05:00
PHST- 2003/12/19 05:00 [pubmed]
PHST- 2004/01/15 05:00 [medline]
PHST- 2003/12/19 05:00 [entrez]
AID - 10.1002/ana.10763 [doi]
PST - ppublish
SO  - Ann Neurol. 2003 Dec;54(6):760-8. doi: 10.1002/ana.10763.

PMID- 14678805
OWN - NLM
STAT- MEDLINE
DCOM- 20040226
LR  - 20211203
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 13
IP  - 10
DP  - 2003 Dec
TI  - Relation of CTG expansion and clinical variables to electrocardiogram conduction 
      abnormalities and sudden death in patients with myotonic dystrophy.
PG  - 822-6
AB  - We prospectively followed 63 patients with myotonic dystrophy (DM) after 
      establishing diagnosis of DM for an average 8 years in an attempt to detect 
      conduction disturbances (by electrocardiography and/or Holter monitoring) and 
      sudden cardiac events (sudden death, cardiac syncope) and correlate them to 
      potential predicting factors (CTG repeat expansion in the myotonin protein kinase 
      gene and several clinical variables: clinical type and duration of DM, age and 
      sex). Twenty-six patients developed conduction disturbances, five patients died 
      suddenly, and two patients experienced cardiac syncope necessitating urgent 
      implantation of pacemaker. Analysis showed no significant correlation between 
      conduction disturbances and/or cardiac events and CTG expansion. Furthermore, no 
      correlation was found with type of DM, whereas conduction disturbances and sudden 
      cardiac events correlated with patients' age, duration of disease and male sex. 
      Results on our cohort of DM patients show that CTG expansion has no role in 
      predicting neither conduction abnormalities nor sudden death. It seems that risk 
      of sudden death increases with duration of disease and age, and that risk is 
      higher in male patients.
FAU - Sabovic, M
AU  - Sabovic M
AD  - Division of Medical Genetics, Department of Obstetrics and Gynecology, University 
      Medical Centre, Ljubljana, Slovenia. miso.sabovic@trnovo.kclj.si
FAU - Medica, I
AU  - Medica I
FAU - Logar, N
AU  - Logar N
FAU - Mandic, E
AU  - Mandic E
FAU - Zidar, J
AU  - Zidar J
FAU - Peterlin, B
AU  - Peterlin B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Age of Onset
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Death, Sudden, Cardiac/*etiology
MH  - Electrocardiography
MH  - Female
MH  - Genetic Predisposition to Disease/*genetics
MH  - Heart Block/*genetics/physiopathology
MH  - Heart Conduction System/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/enzymology/*genetics/*physiopathology
MH  - Myotonin-Protein Kinase
MH  - Prospective Studies
MH  - Protein Serine-Threonine Kinases/deficiency/genetics
MH  - Sex Factors
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2003/12/18 05:00
MHDA- 2004/02/27 05:00
CRDT- 2003/12/18 05:00
PHST- 2003/12/18 05:00 [pubmed]
PHST- 2004/02/27 05:00 [medline]
PHST- 2003/12/18 05:00 [entrez]
AID - S096089660300138X [pii]
AID - 10.1016/s0960-8966(03)00138-x [doi]
PST - ppublish
SO  - Neuromuscul Disord. 2003 Dec;13(10):822-6. doi: 10.1016/s0960-8966(03)00138-x.

PMID- 14671308
OWN - NLM
STAT- MEDLINE
DCOM- 20031229
LR  - 20240104
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Linking)
VI  - 302
IP  - 5652
DP  - 2003 Dec 12
TI  - A muscleblind knockout model for myotonic dystrophy.
PG  - 1978-80
AB  - The neuromuscular disease myotonic dystrophy (DM) is caused by microsatellite 
      repeat expansions at two different genomic loci. Mutant DM transcripts are 
      retained in the nucleus together with the muscleblind (Mbnl) proteins, and these 
      abnormal RNAs somehow interfere with pre-mRNA splicing regulation. Here, we show 
      that disruption of the mouse Mbnl1 gene leads to muscle, eye, and RNA splicing 
      abnormalities that are characteristic of DM disease. Our results support the 
      hypothesis that manifestations of DM can result from sequestration of specific 
      RNA binding proteins by a repetitive element expansion in a mutant RNA.
FAU - Kanadia, Rahul N
AU  - Kanadia RN
AD  - Department of Molecular Genetics and Microbiology, Powell Gene Therapy Center, 
      Gainesville, FL 32610, USA.
FAU - Johnstone, Karen A
AU  - Johnstone KA
FAU - Mankodi, Ami
AU  - Mankodi A
FAU - Lungu, Codrin
AU  - Lungu C
FAU - Thornton, Charles A
AU  - Thornton CA
FAU - Esson, Douglas
AU  - Esson D
FAU - Timmers, Adrian M
AU  - Timmers AM
FAU - Hauswirth, William W
AU  - Hauswirth WW
FAU - Swanson, Maurice S
AU  - Swanson MS
LA  - eng
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - AR46799/AR/NIAMS NIH HHS/United States
GR  - AR46806/AR/NIAMS NIH HHS/United States
GR  - AR48143/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (CLC-1 channel)
RN  - 0 (Chloride Channels)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Mbnl1 protein, mouse)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Troponin T)
SB  - IM
MH  - Alternative Splicing
MH  - Animals
MH  - CELF1 Protein
MH  - Cataract/etiology/pathology
MH  - Cell Nucleus/metabolism
MH  - Chloride Channels/genetics/metabolism
MH  - DNA-Binding Proteins
MH  - Disease Models, Animal
MH  - Electromyography
MH  - Exons
MH  - Gene Targeting
MH  - Introns
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Muscle Fibers, Skeletal/pathology
MH  - Muscle Relaxation
MH  - Muscle, Skeletal/pathology/physiopathology
MH  - Myocardium/metabolism
MH  - Myotonic Dystrophy/*genetics/pathology/*physiopathology
MH  - Protein Isoforms
MH  - RNA Splicing
MH  - RNA-Binding Proteins/*genetics/metabolism/*physiology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion
MH  - Troponin T/genetics/metabolism
EDAT- 2003/12/13 05:00
MHDA- 2003/12/31 05:00
CRDT- 2003/12/13 05:00
PHST- 2003/12/13 05:00 [pubmed]
PHST- 2003/12/31 05:00 [medline]
PHST- 2003/12/13 05:00 [entrez]
AID - 302/5652/1978 [pii]
AID - 10.1126/science.1088583 [doi]
PST - ppublish
SO  - Science. 2003 Dec 12;302(5652):1978-80. doi: 10.1126/science.1088583.

PMID- 14597103
OWN - NLM
STAT- MEDLINE
DCOM- 20040302
LR  - 20190827
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 144
IP  - 1-2
DP  - 2003 Nov
TI  - Lack of correlation between the reduction of serum immunoglobulin concentration 
      and the CTG repeat expansion in patients with type 1 dystrophia [correction of 
      Dystrofia] myotonica.
PG  - 100-4
AB  - The length of the CTG repeat in the 3' untranslated region of the DMPK gene is 
      considered to be associated with clinical severity in type 1 Dystrofia Myotonica 
      (DM1) and has also been suggested to correlate with the degree of deficiency of 
      IgG noted in these patients. Total serum level of IgG and IgG subclasses was 
      therefore measured in 61 Swedish patients with DM1, the largest number of 
      patients investigated to date in this respect. Almost half (44%) of the DM1 
      patients showed a serum concentration of IgG below the normal range. Deficiency 
      of IgG1, IgG2 or IgG3 was noted in 26%, 7% and 20% of the patients, respectively. 
      As transcription of genes 3' of the DMPK gene on chromosome 19 is reduced in DM1 
      patients, a decreased expression of the alpha chain of the receptor involved in 
      IgG catabolism, FcRn, may theoretically be responsible for the low serum IgG in 
      DM1 patients. No correlation was however found between the number of CTG repeats, 
      levels of FcRn transcripts in either muscle tissue or lymphocytes and serum IgG 
      levels.
FAU - Pan-Hammarstrom, Qiang
AU  - Pan-Hammarstrom Q
AD  - Division of Clinical Immunology, F79, Department of Laboratory Medicine, 
      Karolinska Institute at Huddinge University Hospital, SE-14186 Stockholm, Sweden.
FAU - Wen, Sicheng
AU  - Wen S
FAU - Ghanaat-Pour, Hamedeh
AU  - Ghanaat-Pour H
FAU - Solders, Goran
AU  - Solders G
FAU - Forsberg, Hakan
AU  - Forsberg H
FAU - Hammarstrom, Lennart
AU  - Hammarstrom L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Fc)
RN  - TW3XAW0RCY (Fc receptor, neonatal)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Down-Regulation/immunology
MH  - Female
MH  - Histocompatibility Antigens Class I
MH  - Humans
MH  - IgG Deficiency/genetics/*immunology
MH  - Immunoglobulin G/*blood/classification
MH  - Lymphocyte Subsets/metabolism
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism/pathology
MH  - Myotonic Dystrophy/classification/*genetics/*immunology
MH  - Receptors, Fc/biosynthesis/blood/genetics
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2003/11/05 05:00
MHDA- 2004/03/03 05:00
CRDT- 2003/11/05 05:00
PHST- 2003/11/05 05:00 [pubmed]
PHST- 2004/03/03 05:00 [medline]
PHST- 2003/11/05 05:00 [entrez]
AID - S0165572803002716 [pii]
AID - 10.1016/s0165-5728(03)00271-6 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2003 Nov;144(1-2):100-4. doi: 10.1016/s0165-5728(03)00271-6.

PMID- 14574643
OWN - NLM
STAT- MEDLINE
DCOM- 20040819
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 73
IP  - 5
DP  - 2003 Nov
TI  - Replication inhibitors modulate instability of an expanded trinucleotide repeat 
      at the myotonic dystrophy type 1 disease locus in human cells.
PG  - 1092-105
AB  - Gene-specific CTG/CAG repeat expansion is associated with at least 14 human 
      diseases, including myotonic dystrophy type 1 (DM1). Most of our understanding of 
      trinucleotide instability is from nonhuman models, which have presented mixed 
      results, supporting replication errors or processes independent of cell division 
      as causes. Nevertheless, the mechanism occurring at the disease loci in patient 
      cells is poorly understood. Using primary fibroblasts derived from a fetus with 
      DM1, we have shown that spontaneous expansion of the diseased (CTG)(216) allele 
      occurred in proliferating cells but not in quiescent cells. Expansions were 
      "synchronous," with mutation frequencies approaching 100%. Furthermore, cells 
      were treated with agents known to alter DNA synthesis but not to directly damage 
      DNA. Inhibiting replication initiation with mimosine had no effect upon 
      instability. Inhibiting both leading- and lagging-strand synthesis with 
      aphidicolin or blocking only lagging strand synthesis with emetine significantly 
      enhanced CTG expansions. It was striking that only the expanded DM1 allele was 
      altered, leaving the normal allele, (CTG)(12), and other repeat loci unaffected. 
      Standard and small-pool polymerase chain reaction revealed that inhibitors 
      enhanced the magnitude of short expansions in most cells threefold, whereas 
      11%-25% of cells experienced gains of 122-170 repeats, to sizes of 
      (CTG)(338)-(CTG)(386). Similar results were observed for an adult DM1 cell line. 
      Our results support a role for the perturbation of replication fork dynamics in 
      DM1 CTG expansions within patient fibroblasts. This is the first report that 
      repeat-length alterations specific to a disease allele can be modulated by 
      exogenously added compounds.
FAU - Yang, Zhi
AU  - Yang Z
AD  - Program of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, 
      Ontario, Canada.
FAU - Lau, Rachel
AU  - Lau R
FAU - Marcadier, Julien L
AU  - Marcadier JL
FAU - Chitayat, David
AU  - Chitayat D
FAU - Pearson, Christopher E
AU  - Pearson CE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20031021
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 38966-21-1 (Aphidicolin)
RN  - 500-44-7 (Mimosine)
RN  - X8D5EPO80M (Emetine)
SB  - IM
MH  - Aphidicolin/*pharmacology
MH  - Base Sequence
MH  - Cell Division/drug effects
MH  - Cell Line
MH  - Cells, Cultured
MH  - Clone Cells/cytology/drug effects
MH  - DNA Replication/*drug effects
MH  - Emetine/*pharmacology
MH  - Female
MH  - Fibroblasts/cytology
MH  - Genomic Instability/*drug effects
MH  - Humans
MH  - Mimosine/*pharmacology
MH  - Myotonic Dystrophy/*genetics
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion/*genetics
PMC - PMC1180489
EDAT- 2003/10/24 05:00
MHDA- 2004/08/20 05:00
PMCR- 2004/05/01
CRDT- 2003/10/24 05:00
PHST- 2003/06/09 00:00 [received]
PHST- 2003/08/26 00:00 [accepted]
PHST- 2003/10/24 05:00 [pubmed]
PHST- 2004/08/20 05:00 [medline]
PHST- 2003/10/24 05:00 [entrez]
PHST- 2004/05/01 00:00 [pmc-release]
AID - S0002-9297(07)61972-7 [pii]
AID - 40207 [pii]
AID - 10.1086/379523 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2003 Nov;73(5):1092-105. doi: 10.1086/379523. Epub 2003 Oct 21.

PMID- 14510658
OWN - NLM
STAT- MEDLINE
DCOM- 20040319
LR  - 20200319
IS  - 1082-720X (Print)
IS  - 1542-474X (Electronic)
IS  - 1082-720X (Linking)
VI  - 8
IP  - 3
DP  - 2003 Jul
TI  - Heart rate variability declines with increasing age and CTG repeat length in 
      patients with myotonic dystrophy type 1.
PG  - 227-32
AB  - BACKGROUND: Cardiac myopathy manifesting as arrhythmias is common in the 
      neurological disease, myotonic dystrophy type 1 (DM1). The purpose of the present 
      study was to evaluate heart rate variability (HRV) in patients with DM1. METHODS: 
      In a multicenter study, history, ECG, and genetic testing were performed in DM1 
      patients. RESULTS: In 289 patients in whom the diagnosis of DM1 was confirmed by 
      a prolonged cytosine-thymine-guanine (CTG) repeat length the most common 
      ambulatory ECG abnormality was frequent ventricular ectopy (16.3%). The 24-hour 
      time domain parameters of SDNN (SD of the NN interval) and SDANN (SD of the mean 
      NN, 5-minute interval) declined as age and CTG repeat length increased (SDNN: 
      -8.5 ms per decade, 95% confidence intervals [CI]-12.9, -4.2, -8.7 ms per 500 CTG 
      repeats, CI -15.7, -1.8, r=0.24, P<0.001; SDANN: -8.1 ms per decade, CI -12.4, 
      -3.8, -8.8 ms per 500 CTG repeats, CI -15.7, -1.9, r=0.23, P<0.001). Short-term 
      frequency domain parameters declined with age only (total power: -658 ms2 per 
      decade, CI: -984, -331, r=0.23, P<0.001; low frequency (LF) power -287 ms2 per 
      decade, CI: -397, -178, r=0.30, P<0.001; high frequency (HF) power: -267 ms2 per 
      decade, CI: -386, -144, r=0.25, P<0.001). The LF/HF ratio increased as the 
      patient aged (0.5 per decade, CI: 0.1, 0.9, r=0.13, P=0.03). CONCLUSIONS: In DM1 
      patients a decline in HRV is observed as the patient ages and CTG repeat length 
      increases.
FAU - Hardin, Bradley A
AU  - Hardin BA
AD  - Krannert Institute of Cardiology, Indiana University School of Medicine, 
      Indianapolis, Indiana 46202, USA.
FAU - Lowe, Miriam R
AU  - Lowe MR
FAU - Bhakta, Deepak
AU  - Bhakta D
FAU - Groh, William J
AU  - Groh WJ
LA  - eng
GR  - M01-RR00750-27S1/RR/NCRR NIH HHS/United States
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Noninvasive Electrocardiol
JT  - Annals of noninvasive electrocardiology : the official journal of the 
      International Society for Holter and Noninvasive Electrocardiology, Inc
JID - 9607443
RN  - 0 (Genetic Markers)
RN  - 0 (Pyrimidine Dimers)
RN  - 5Z93L87A1R (Guanine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Arrhythmias, Cardiac/epidemiology/genetics/physiopathology
MH  - Autonomic Nervous System/physiology
MH  - Electrocardiography, Ambulatory
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Markers/genetics
MH  - Genetic Predisposition to Disease/genetics
MH  - Guanine/*physiology
MH  - Heart Conduction System/pathology/physiopathology
MH  - Heart Rate/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myotonic Dystrophy/epidemiology/*genetics/physiopathology
MH  - Observer Variation
MH  - Pyrimidine Dimers/*genetics
MH  - Registries
MH  - Statistics as Topic
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Trinucleotide Repeats/*genetics
PMC - PMC6931928
EDAT- 2003/09/27 05:00
MHDA- 2004/03/20 05:00
PMCR- 2003/07/08
CRDT- 2003/09/27 05:00
PHST- 2003/09/27 05:00 [pubmed]
PHST- 2004/03/20 05:00 [medline]
PHST- 2003/09/27 05:00 [entrez]
PHST- 2003/07/08 00:00 [pmc-release]
AID - 08310 [pii]
AID - ANEC08310 [pii]
AID - 10.1046/j.1542-474x.2003.08310.x [doi]
PST - ppublish
SO  - Ann Noninvasive Electrocardiol. 2003 Jul;8(3):227-32. doi: 
      10.1046/j.1542-474x.2003.08310.x.

PMID- 14505273
OWN - NLM
STAT- MEDLINE
DCOM- 20031121
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 73
IP  - 4
DP  - 2003 Oct
TI  - Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation 
      of the repeat tract.
PG  - 849-62
AB  - Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, 
      can be caused by a mutation on either chromosome 19 (DM1) or 3 (DM2). In 2001, we 
      demonstrated that DM2 is caused by a CCTG expansion in intron 1 of the zinc 
      finger protein 9 (ZNF9) gene. To investigate the ancestral origins of the DM2 
      expansion, we compared haplotypes for 71 families with genetically confirmed DM2, 
      using 19 short tandem repeat markers that we developed that flank the repeat 
      tract. All of the families are white, with the majority of Northern 
      European/German descent and a single family from Afghanistan. Several conserved 
      haplotypes spanning >700 kb appear to converge into a single haplotype near the 
      repeat tract. The common interval that is shared by all families with DM2 
      immediately flanks the repeat, extending up to 216 kb telomeric and 119 kb 
      centromeric of the CCTG expansion. The DM2 repeat tract contains the complex 
      repeat motif (TG)(n)(TCTG)(n)(CCTG)(n). The CCTG portion of the repeat tract is 
      interrupted on normal alleles, but, as in other expansion disorders, these 
      interruptions are lost on affected alleles. We examined haplotypes of 228 control 
      chromosomes and identified a potential premutation allele with an uninterrupted 
      (CCTG)(20) on a haplotype that was identical to the most common affected 
      haplotype. Our data suggest that the predominant Northern European ancestry of 
      families with DM2 resulted from a common founder and that the loss of 
      interruptions within the CCTG portion of the repeat tract may predispose alleles 
      to further expansion. To gain insight into possible function of the repeat tract, 
      we looked for evolutionary conservation. The complex repeat motif and flanking 
      sequences within intron 1 are conserved among human, chimpanzee, gorilla, mouse, 
      and rat, suggesting a conserved biological function.
FAU - Liquori, Christina L
AU  - Liquori CL
AD  - Institute of Human Genetics, and Department of Genetics, Cell Biology, and 
      Development, University of Minnesota, Minneapolis, MN 55455, USA.
FAU - Ikeda, Yoshio
AU  - Ikeda Y
FAU - Weatherspoon, Marcy
AU  - Weatherspoon M
FAU - Ricker, Kenneth
AU  - Ricker K
FAU - Schoser, Benedikt G H
AU  - Schoser BG
FAU - Dalton, Joline C
AU  - Dalton JC
FAU - Day, John W
AU  - Day JW
FAU - Ranum, Laura P W
AU  - Ranum LP
LA  - eng
SI  - GENBANK/AF388525
GR  - R01 NS035870/NS/NINDS NIH HHS/United States
GR  - NS35870/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20030922
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (DNA Primers)
SB  - IM
MH  - Adult
MH  - Base Sequence
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 19
MH  - *Chromosomes, Human, Pair 3
MH  - Conserved Sequence
MH  - DNA Primers
MH  - Europe/epidemiology
MH  - *Evolution, Molecular
MH  - Family
MH  - *Founder Effect
MH  - Haplotypes
MH  - Humans
MH  - Introns
MH  - Microsatellite Repeats/genetics
MH  - Molecular Sequence Data
MH  - *Mutation
MH  - Myotonic Dystrophy/classification/*genetics
MH  - Polymorphism, Genetic
MH  - Recombination, Genetic
MH  - Reference Values
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Sarcoma Virus, Woolly Monkey
MH  - Trinucleotide Repeats/genetics
PMC - PMC1180607
EDAT- 2003/09/25 05:00
MHDA- 2003/12/03 05:00
PMCR- 2004/04/01
CRDT- 2003/09/25 05:00
PHST- 2003/05/29 00:00 [received]
PHST- 2003/07/18 00:00 [accepted]
PHST- 2003/09/25 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/09/25 05:00 [entrez]
PHST- 2004/04/01 00:00 [pmc-release]
AID - S0002-9297(07)63633-7 [pii]
AID - 40173 [pii]
AID - 10.1086/378720 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2003 Oct;73(4):849-62. doi: 10.1086/378720. Epub 2003 Sep 22.

PMID- 12970845
OWN - NLM
STAT- MEDLINE
DCOM- 20031121
LR  - 20210108
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 73
IP  - 4
DP  - 2003 Oct
TI  - Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in 
      patients with proximal myotonic myopathy/proximal myotonic dystrophy of different 
      European origins: a single shared haplotype indicates an ancestral founder 
      effect.
PG  - 835-48
AB  - Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is 
      a clinically and genetically heterogeneous neuromuscular disorder. DM is 
      characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, 
      and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in 
      the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly 
      of German descent and with clinically variable presentation that included 
      proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 
      mutation, showed linkage to the 3q21 region and were recently shown to segregate 
      a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 
      3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and 
      proximal myotonic dystrophy, from geographically distinct populations. All 
      patients have the DM2 (CCTG)(n) expansion. To study the evolution of this 
      mutation, we constructed a comprehensive physical map of the DM2 region around 
      ZNF9. High-resolution haplotype analysis of disease chromosomes with five 
      microsatellite and 22 single-nucleotide polymorphism markers around the DM2 
      mutation identified extensive linkage disequilibrium and a single shared 
      haplotype of at least 132 kb among patients from the different populations. With 
      the exception of the (CCTG)(n) expansion, the available markers indicate that the 
      DM2 haplotype is identical to the most common haplotype in normal individuals. 
      This situation is reminiscent of that seen in DM1. Taken together, these data 
      suggest a single founding mutation in DM2 patients of European origin. We 
      estimate the age of the founding haplotype and of the DM2 (CCTG) expansion 
      mutation to be approximately 200-540 generations.
FAU - Bachinski, Linda L
AU  - Bachinski LL
AD  - Section of Cancer Genetics, Department of Molecular Genetics, University of Texas 
      M. D. Anderson Cancer Center, Houston, TX 77030, USA.
FAU - Udd, Bjarne
AU  - Udd B
FAU - Meola, Giovanni
AU  - Meola G
FAU - Sansone, Valeria
AU  - Sansone V
FAU - Bassez, Guillaume
AU  - Bassez G
FAU - Eymard, Bruno
AU  - Eymard B
FAU - Thornton, Charles A
AU  - Thornton CA
FAU - Moxley, Richard T
AU  - Moxley RT
FAU - Harper, Peter S
AU  - Harper PS
FAU - Rogers, Mark T
AU  - Rogers MT
FAU - Jurkat-Rott, Karin
AU  - Jurkat-Rott K
FAU - Lehmann-Horn, Frank
AU  - Lehmann-Horn F
FAU - Wieser, Thomas
AU  - Wieser T
FAU - Gamez, Josep
AU  - Gamez J
FAU - Navarro, Carmen
AU  - Navarro C
FAU - Bottani, Armand
AU  - Bottani A
FAU - Kohler, Andre
AU  - Kohler A
FAU - Shriver, Mark D
AU  - Shriver MD
FAU - Sallinen, Riitta
AU  - Sallinen R
FAU - Wessman, Maija
AU  - Wessman M
FAU - Zhang, Shanxiang
AU  - Zhang S
FAU - Wright, Fred A
AU  - Wright FA
FAU - Krahe, Ralf
AU  - Krahe R
LA  - eng
SI  - GENBANK/AC022944
SI  - GENBANK/AC108673
SI  - GENBANK/AC112484
SI  - GENBANK/AC135587
SI  - RefSeq/NT_006025
GR  - P30 CA016058/CA/NCI NIH HHS/United States
GR  - R01 AR048171/AR/NIAMS NIH HHS/United States
GR  - P30 CA16058/CA/NCI NIH HHS/United States
GR  - R01 AR48171/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20030910
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
SB  - IM
MH  - Base Sequence
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 3
MH  - Europe/ethnology
MH  - Female
MH  - *Founder Effect
MH  - Haplotypes
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Microsatellite Repeats/*genetics
MH  - Models, Genetic
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/classification/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction/methods
MH  - *Polymorphism, Single Nucleotide
MH  - United States
PMC - PMC1180606
EDAT- 2003/09/13 05:00
MHDA- 2003/12/03 05:00
PMCR- 2004/04/01
CRDT- 2003/09/13 05:00
PHST- 2003/05/08 00:00 [received]
PHST- 2003/07/18 00:00 [accepted]
PHST- 2003/09/13 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/09/13 05:00 [entrez]
PHST- 2004/04/01 00:00 [pmc-release]
AID - S0002-9297(07)63632-5 [pii]
AID - 40095 [pii]
AID - 10.1086/378566 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2003 Oct;73(4):835-48. doi: 10.1086/378566. Epub 2003 Sep 10.

PMID- 12963369
OWN - NLM
STAT- MEDLINE
DCOM- 20031021
LR  - 20190710
IS  - 0022-2836 (Print)
IS  - 0022-2836 (Linking)
VI  - 332
IP  - 3
DP  - 2003 Sep 19
TI  - Slipped (CTG).(CAG) repeats of the myotonic dystrophy locus: surface probing with 
      anti-DNA antibodies.
PG  - 585-600
AB  - At least 15 human diseases have been associated with the length-dependent 
      expansion of gene-specific (CTG).(CAG) repeats, including myotonic dystrophy 
      (DM1) and spinocerebellar ataxia type 1 (SCA1). Repeat expansion is likely to 
      involve unusual DNA structures. We have structurally characterized such DNA, with 
      (CTG)(n).(CAG)(n) repeats of varying length (n=17-79), by high-resolution gel 
      electrophoresis, and have probed their surfaces with anti-DNA antibodies of known 
      specificities. We prepared homoduplex S-DNAs, which are (CTG)x.(CAG)y where x=y, 
      and heteroduplex SI-DNAs, which are hybrids where x>y or x<y. S-DNAs formed many 
      different species of slipped isomers, as indicated by its multiple 
      electrophoretic species. In contrast, SI-DNAs formed distinct structures, as 
      indicated by the limited electrophoretic species for all possible repeat length 
      pairings. Sister SI-DNAs with an excess of CAG repeats always migrated slower 
      than their sister SI-DNAs with an excess of CTG repeats. Strikingly, both the 
      propensity to form slipped structures and the pattern of S-DNAs, but not SI-DNAs, 
      varied for similar lengths of CTG/CAG repeats between the DM1 and SCA1 loci, 
      highlighting a role for flanking cis-elements in S-DNA but not SI-DNA formation. 
      Slipped structures bound structure and nucleotide-specific anti-DNA antibodies. 
      Binding of anti-B-DNA antibodies was reduced for both S-DNAs and SI-DNAs relative 
      to their linear forms. SI-DNAs bound anti-Z-DNA antibodies, while both S and 
      SI-DNAs bound anti-cruciform antibodies, revealing shared characteristics between 
      the corresponding DNA structures and slipped DNAs. Such features of the repeats 
      may be recognized by cellular proteins known to bind such structures.
FAU - Tam, Mandy
AU  - Tam M
AD  - Program of Genetics and Genomic Biology, The Hospital for Sick Children, Room 
      11-135, 555 University Avenue, Elm Wing, M5G 1X8, Toronto, Ont., Canada
FAU - Erin Montgomery, S
AU  - Erin Montgomery S
FAU - Kekis, Mariana
AU  - Kekis M
FAU - Stollar, B David
AU  - Stollar BD
FAU - Price, Gerald B
AU  - Price GB
FAU - Pearson, Christopher E
AU  - Pearson CE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Mol Biol
JT  - Journal of molecular biology
JID - 2985088R
RN  - 0 (ATXN1 protein, human)
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Ataxin-1)
RN  - 0 (Ataxins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Nucleic Acid Heteroduplexes)
RN  - 0 (Nucleosides)
RN  - 9007-49-2 (DNA)
RN  - I38ZP9992A (Magnesium)
SB  - IM
MH  - Antibodies, Antinuclear/*metabolism
MH  - Antibody Specificity
MH  - Ataxin-1
MH  - Ataxins
MH  - Base Pairing
MH  - DNA/chemistry/immunology/metabolism
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Humans
MH  - Magnesium/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Nerve Tissue Proteins/genetics
MH  - Nuclear Proteins/genetics
MH  - *Nucleic Acid Conformation
MH  - Nucleic Acid Heteroduplexes
MH  - Nucleosides/immunology
MH  - Surface Properties
MH  - Trinucleotide Repeats/*immunology
EDAT- 2003/09/10 05:00
MHDA- 2003/10/22 05:00
CRDT- 2003/09/10 05:00
PHST- 2003/09/10 05:00 [pubmed]
PHST- 2003/10/22 05:00 [medline]
PHST- 2003/09/10 05:00 [entrez]
AID - S0022283603008805 [pii]
AID - 10.1016/s0022-2836(03)00880-5 [doi]
PST - ppublish
SO  - J Mol Biol. 2003 Sep 19;332(3):585-600. doi: 10.1016/s0022-2836(03)00880-5.

PMID- 12902623
OWN - NLM
STAT- MEDLINE
DCOM- 20031212
LR  - 20171101
IS  - 0251-5350 (Print)
IS  - 0251-5350 (Linking)
VI  - 22
IP  - 5
DP  - 2003 Sep-Oct
TI  - Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan.
PG  - 283-9
AB  - To investigate the prevalence and genetic characteristics of myotonic dystrophy 
      type 1 (DM1) in Taiwan, DM-suspected patients and their families identified 
      during the period of 1990-2001 had their clinical records reevaluated and the CTG 
      repeat sizes at the DM1 locus examined. A total of 96 subjects belonging to 26 
      families were identified as DM1 patients, which gave a minimal disease prevalence 
      of 0.46/100,000 inhabitants. Clinical anticipation was frequently observed in 
      affected families, even in some parent-child pairs with transmission contraction 
      of the CTG repeat size. The inverse correlation between age at onset and CTG 
      repeat length was significant only in patients with small expansions. In 
      addition, a DM1 carrier with a childhood-onset son was found to have CTG length 
      heterogeneity in the range of 40-50, indicating that premutation alleles could be 
      unstable during gametogenesis as well as in somatic tissues. Our data 
      demonstrated that DM1 is a rare disease in Taiwan and showed that transmission 
      contraction of repeat size is more likely to occur in alleles with large repeats.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Hsiao, K M
AU  - Hsiao KM
AD  - Department of Life Sciences, Chung Shan Medical University, No. 110 Sec. 1 
      Chien-Kuo North Road, Taichung, Taiwan 402, ROC. kmh@csmu.edu.tw
FAU - Chen, S S
AU  - Chen SS
FAU - Li, S Y
AU  - Li SY
FAU - Chiang, S Y
AU  - Chiang SY
FAU - Lin, H M
AU  - Lin HM
FAU - Pan, H
AU  - Pan H
FAU - Huang, C C
AU  - Huang CC
FAU - Kuo, H C
AU  - Kuo HC
FAU - Jou, S B
AU  - Jou SB
FAU - Su, C C
AU  - Su CC
FAU - Ro, L S
AU  - Ro LS
FAU - Liu, C S
AU  - Liu CS
FAU - Lo, M C
AU  - Lo MC
FAU - Chen, C M
AU  - Chen CM
FAU - Lin, C C
AU  - Lin CC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Neuroepidemiology
JT  - Neuroepidemiology
JID - 8218700
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - DNA/blood/genetics
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*epidemiology/*genetics
MH  - Polymerase Chain Reaction
MH  - Taiwan/epidemiology
MH  - Trinucleotide Repeats/genetics
EDAT- 2003/08/07 05:00
MHDA- 2003/12/13 05:00
CRDT- 2003/08/07 05:00
PHST- 2003/08/07 05:00 [pubmed]
PHST- 2003/12/13 05:00 [medline]
PHST- 2003/08/07 05:00 [entrez]
AID - 71191 [pii]
AID - 10.1159/000071191 [doi]
PST - ppublish
SO  - Neuroepidemiology. 2003 Sep-Oct;22(5):283-9. doi: 10.1159/000071191.

PMID- 12727989
OWN - NLM
STAT- MEDLINE
DCOM- 20030528
LR  - 20220408
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 88
IP  - 5
DP  - 2003 May
TI  - Selective beta-cell loss and alpha-cell expansion in patients with type 2 
      diabetes mellitus in Korea.
PG  - 2300-8
AB  - In the presence of obesity, beta-cell mass needs to be increased to compensate 
      for the accompanying demands and maintain euglycemia. However, in Korea, the 
      majority of type 2 diabetic patients are nonobese. We determined the absolute 
      masses, relative volumes, and ratio of alpha- and beta-cell in the pancreas and 
      islets in normal and diabetic Korean subjects to correlate these findings with 
      the clinical characteristics. Whole pancreases procured from organ donors were 
      divided into 24 parts (control 1, n = 9). Tissue was also obtained by surgical 
      resection after 35 partial pancreatectomies: in 25 diabetic patients, 10 age- and 
      body mass index (BMI)-matched patients of benign or malignant pancreatic tumor 
      without diabetes mellitus (DM) (control 2). Morphometric quantifications were 
      performed. In control 1, the relative volume of beta-cells was 2.1 +/- 0.9%, and 
      the total beta-cell mass was 1.3 +/- 0.3 g. The relative volume of beta-cells was 
      found to be variable (control 1, 2.1 +/- 0.9%; control 2, 1.9 +/- 0.7%; DM, 1.4 
      +/- 1.0%; P < 0.05 DM vs. control 1 and 2) and showed good correlation with BMI 
      (control 1, r(2) = 0.64; DM, r(2) = 0.55; all subjects, r(2) = 0.38; P < 0.05). 
      Notably, in type 2 diabetic patients, the ratio of alpha-cell area to beta-cell 
      area in the islet was higher than in control 1 and 2 (0.81 +/- 0.4 vs. 0.29 +/- 
      0.2, 0.20 +/- 0.1, P < 0.05). Additionally, significant alpha-cell expansion and 
      a decreased beta-cell fraction were predominantly observed in larger islets 
      (islet area, >6415 micro m(2); P < 0.05) in control 1 and diabetic patients. The 
      relative volume of beta-cell was found to be correlated with BMI in diabetic 
      patients and normal organ donors. Moreover, decreased beta-cell but increased 
      alpha-cell proportion in the islets suggests for a selective beta-cell loss in 
      the pathogenesis of Korean type 2 diabetes.
FAU - Yoon, Kun Ho
AU  - Yoon KH
AD  - Department of Endocrinology and Metabolism, Immunology, and Cell Biology Core 
      Laboratory, Institutes of Medical Science, The Catholic University of Korea, 
      Seoul, Korea 137-701. yoonk@catholic.ac.kr
FAU - Ko, Seung Hyun
AU  - Ko SH
FAU - Cho, Jae Hyoung
AU  - Cho JH
FAU - Lee, Jung Min
AU  - Lee JM
FAU - Ahn, Yu Bae
AU  - Ahn YB
FAU - Song, Ki Ho
AU  - Song KH
FAU - Yoo, Soon Jib
AU  - Yoo SJ
FAU - Kang, Moo Il
AU  - Kang MI
FAU - Cha, Bong Yun
AU  - Cha BY
FAU - Lee, Kwang Woo
AU  - Lee KW
FAU - Son, Ho Young
AU  - Son HY
FAU - Kang, Sung Koo
AU  - Kang SK
FAU - Kim, Hee Seung
AU  - Kim HS
FAU - Lee, In Kyu
AU  - Lee IK
FAU - Bonner-Weir, Susan
AU  - Bonner-Weir S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Body Mass Index
MH  - Cell Size
MH  - Diabetes Mellitus, Type 2/*pathology
MH  - Female
MH  - Humans
MH  - Insulin/analysis
MH  - Islets of Langerhans/*pathology
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Pancreatectomy
MH  - Pancreatic Neoplasms/pathology
MH  - Tissue Donors
EDAT- 2003/05/03 05:00
MHDA- 2003/05/29 05:00
CRDT- 2003/05/03 05:00
PHST- 2003/05/03 05:00 [pubmed]
PHST- 2003/05/29 05:00 [medline]
PHST- 2003/05/03 05:00 [entrez]
AID - 10.1210/jc.2002-020735 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2003 May;88(5):2300-8. doi: 10.1210/jc.2002-020735.

PMID- 12630069
OWN - NLM
STAT- MEDLINE
DCOM- 20030507
LR  - 20211203
IS  - 1368-5538 (Print)
IS  - 1368-5538 (Linking)
VI  - 5
IP  - 4
DP  - 2002 Dec
TI  - The pleiotropic expression of the myotonic dystrophy protein kinase gene 
      illustrates the complex relationships between genetic, biological and clinical 
      covariates of male aging.
PG  - 223-32
AB  - Aging is a complex process modulated by multiple interactions between 
      environmental and genetic factors. Myotonic dystrophy (DM1) is an autosomal 
      dominant disorder caused by an unstable (CTG)n repeat expansion in the DM1 
      protein kinase (DMPK) gene. The affected male patients' life expectancy at birth 
      (53.2 years) is more than two decades below that observed in most occidental 
      populations. The DMPK gene expression is pleiotropic and includes the premature 
      expression of several age-related signs, symptoms and metabolic disturbances 
      including hormonal dysfunctions, progressive decrease in muscular mass, presenile 
      cataracts, alopecia, reduced alertness, insulin resistance, dyslipidemia, 
      erectile dysfunction and hypogonadism. The aim of this study was to analyze the 
      relationship between aging covariates and the severity of DM1 expression in 136 
      DM1 male subjects. DM1 clinical expression was assessed on a validated 
      neuromuscular disability rating scale and was correlated with plasma total 
      testosterone (rs = -0.31, p < 0.001), luteinizing hormone (LH) (rs = 0.52, p < 
      0.001) and follicle stimulating hormone (FSH) (rs = 0.54, p < 0.001) levels. 
      Following LH releasing hormone stimulation, FSH and LH concentrations increased 
      as a function of DM1 severity (p < 0.05). Muscular disability in DM1 was also 
      positively associated with fasting plasma insulin and triglyceride concentrations 
      (p < 0.05). The association of plasma apolipoprotein B and low-density 
      lipoprotein cholesterol levels with DM1 was not linear across their distribution 
      and tended to reflect cell membrane damage progression. These results suggest 
      that DM1, a simple Mendelian trait, can represent a valuable model to illustrate 
      the complex relationships between variables associated with male aging.
FAU - Brisson, D
AU  - Brisson D
AD  - Lipid Research Group and University of Montreal Community Genomic Medicine 
      Center, Chicoutimi Hospital, Quebec, Canada.
FAU - Houde, G
AU  - Houde G
FAU - St-Pierre, J
AU  - St-Pierre J
FAU - Vohl, M C
AU  - Vohl MC
FAU - Mathieu, J
AU  - Mathieu J
FAU - Gaudet, D
AU  - Gaudet D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aging Male
JT  - The aging male : the official journal of the International Society for the Study 
      of the Aging Male
JID - 9808210
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aging/*genetics/*physiology
MH  - Disability Evaluation
MH  - Gene Expression/*genetics/*physiology
MH  - Humans
MH  - Hypothalamo-Hypophyseal System/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Myotonin-Protein Kinase
MH  - Pituitary-Adrenal System/physiopathology
MH  - Protein Serine-Threonine Kinases/*genetics/*physiology
MH  - Severity of Illness Index
EDAT- 2003/03/13 04:00
MHDA- 2003/05/08 05:00
CRDT- 2003/03/13 04:00
PHST- 2003/03/13 04:00 [pubmed]
PHST- 2003/05/08 05:00 [medline]
PHST- 2003/03/13 04:00 [entrez]
PST - ppublish
SO  - Aging Male. 2002 Dec;5(4):223-32.

PMID- 12614928
OWN - NLM
STAT- MEDLINE
DCOM- 20030423
LR  - 20190724
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 207
IP  - 1-2
DP  - 2003 Mar 15
TI  - Middle latency auditory-evoked potentials in myotonic dystrophy: relation to the 
      size of the CTG trinucleotide repeat and intelligent quotient.
PG  - 31-6
AB  - OBJECTIVE: Major components of MLAEPs are thought to originate in the temporal 
      lobe. Absence of the Pb potential has been demonstrated in MLAEPs in Alzheimer's 
      disease and demented Parkinson's disease patients. To validate usefulness of 
      middle latency auditory-evoked potentials (MLAEPs) in evaluating the central 
      nervous system (CNS) involvement of myotonic dystrophy (MyD). METHODS: MLAEPs 
      were recorded in eight patients with MyD and nine normal control subjects. In the 
      patient group, the size of the CTG triplet repeat expansion within the dystrophia 
      myotonica protein kinase (DMPK) gene and the revised Wechsler Adult Intelligence 
      Scale (WAIS-R) were also assessed. RESULTS: The latency of the Nb potential 
      showed a significant correlation with the size of the CTG repeat expansion 
      (r=0.734, P=0.036). The Pb latency also tended to prolong according to CTG 
      amplification (r=0.644, P=0.087). The amplitudes of Na and Pa significantly 
      increased compared with those of normal control subjects (P=0.024 and 0.016, 
      respectively). However, they did not correlate with IQ or CTG amplification. 
      CONCLUSIONS: Abnormal MLAEPs may indicate CNS involvement in MyD. Although the 
      precise generating mechanisms of Nb are unclear, the correlation of Nb latency 
      with CTG amplification suggests that MLAEPs can reflect the extent of genetic 
      abnormality.
FAU - Arakawa, Kenji
AU  - Arakawa K
AD  - Department of Neurology, National Center of Neurology and Psychiatry, Tokyo, 
      Japan. arakawa@tikugo.hosp.go.jp
FAU - Tomi, Hideaki
AU  - Tomi H
FAU - Tobimatsu, Shozo
AU  - Tobimatsu S
FAU - Kira, Jun-ichi
AU  - Kira J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
SB  - IM
MH  - Adult
MH  - Aged
MH  - Evoked Potentials, Auditory/*genetics
MH  - Female
MH  - Humans
MH  - Intelligence/*genetics
MH  - Intelligence Tests/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*psychology
MH  - Reaction Time/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 2003/03/05 04:00
MHDA- 2003/04/24 05:00
CRDT- 2003/03/05 04:00
PHST- 2003/03/05 04:00 [pubmed]
PHST- 2003/04/24 05:00 [medline]
PHST- 2003/03/05 04:00 [entrez]
AID - S0022510X02003544 [pii]
AID - 10.1016/s0022-510x(02)00354-4 [doi]
PST - ppublish
SO  - J Neurol Sci. 2003 Mar 15;207(1-2):31-6. doi: 10.1016/s0022-510x(02)00354-4.

PMID- 12601109
OWN - NLM
STAT- MEDLINE
DCOM- 20040129
LR  - 20221207
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 60
IP  - 4
DP  - 2003 Feb 25
TI  - Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
PG  - 657-64
AB  - BACKGROUND: Myotonic dystrophy types 1 (DM1) and 2 (DM2/proximal myotonic 
      myopathy PROMM) are dominantly inherited disorders with unusual multisystemic 
      clinical features. The authors have characterized the clinical and molecular 
      features of DM2/PROMM, which is caused by a CCTG repeat expansion in intron 1 of 
      the zinc finger protein 9 (ZNF9) gene. METHODS: Three-hundred and seventy-nine 
      individuals from 133 DM2/PROMM families were evaluated genetically, and in 234 
      individuals clinical and molecular features were compared. RESULTS: Among 
      affected individuals 90% had electrical myotonia, 82% weakness, 61% cataracts, 
      23% diabetes, and 19% cardiac involvement. Because of the repeat tract's 
      unprecedented size (mean approximately 5,000 CCTGs) and somatic instability, 
      expansions were detectable by Southern analysis in only 80% of known carriers. 
      The authors developed a repeat assay that increased the molecular detection rate 
      to 99%. Only 30% of the positive samples had single sizeable expansions by 
      Southern analysis, and 70% showed multiple bands or smears. Among the 101 
      individuals with single expansions, repeat size did not correlate with age at 
      disease onset. Affected offspring had markedly shorter expansions than their 
      affected parents, with a mean size difference of -17 kb (-4,250 CCTGs). 
      CONCLUSIONS: DM2 is present in a large number of families of northern European 
      ancestry. Clinically, DM2 resembles adult-onset DM1, with myotonia, muscular 
      dystrophy, cataracts, diabetes, testicular failure, hypogammaglobulinemia, and 
      cardiac conduction defects. An important distinction is the lack of a congenital 
      form of DM2. The clinical and molecular parallels between DM1 and DM2 indicate 
      that the multisystemic features common to both diseases are caused by CUG or CCUG 
      expansions expressed at the RNA level.
FAU - Day, J W
AU  - Day JW
AD  - Institute of Human Genetics, Department of Neurology, University of Minnesota 
      School of Medicine, Minneapolis, MN 55455, USA. johnday@umn.edu
FAU - Ricker, K
AU  - Ricker K
FAU - Jacobsen, J F
AU  - Jacobsen JF
FAU - Rasmussen, L J
AU  - Rasmussen LJ
FAU - Dick, K A
AU  - Dick KA
FAU - Kress, W
AU  - Kress W
FAU - Schneider, C
AU  - Schneider C
FAU - Koch, M C
AU  - Koch MC
FAU - Beilman, G J
AU  - Beilman GJ
FAU - Harrison, A R
AU  - Harrison AR
FAU - Dalton, J C
AU  - Dalton JC
FAU - Ranum, L P W
AU  - Ranum LP
LA  - eng
GR  - M01-RR00400/RR/NCRR NIH HHS/United States
GR  - NS35870/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (CNBP protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Aged, 80 and over
MH  - Arrhythmias, Cardiac/diagnosis/epidemiology/genetics
MH  - Blotting, Southern
MH  - Cataract/diagnosis/epidemiology/genetics
MH  - Child
MH  - Comorbidity
MH  - DNA Repeat Expansion/genetics
MH  - Disease Progression
MH  - Female
MH  - Genes, Dominant
MH  - Genetic Testing/*methods
MH  - Germany/epidemiology/ethnology
MH  - Humans
MH  - Introns/genetics
MH  - Male
MH  - Middle Aged
MH  - Minnesota/epidemiology
MH  - Muscles/pathology
MH  - Myotonic Dystrophy/*diagnosis/epidemiology/*genetics
MH  - Pedigree
MH  - Poland/ethnology
MH  - Polymerase Chain Reaction
MH  - RNA/genetics
MH  - RNA-Binding Proteins/*genetics
MH  - White People/genetics
EDAT- 2003/02/26 04:00
MHDA- 2004/01/30 05:00
CRDT- 2003/02/26 04:00
PHST- 2003/02/26 04:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/02/26 04:00 [entrez]
AID - 10.1212/01.wnl.0000054481.84978.f9 [doi]
PST - ppublish
SO  - Neurology. 2003 Feb 25;60(4):657-64. doi: 10.1212/01.wnl.0000054481.84978.f9.

PMID- 12427866
OWN - NLM
STAT- MEDLINE
DCOM- 20021220
LR  - 20211203
IS  - 0021-9525 (Print)
IS  - 1540-8140 (Electronic)
IS  - 0021-9525 (Linking)
VI  - 159
IP  - 3
DP  - 2002 Nov 11
TI  - Mutant DMPK 3'-UTR transcripts disrupt C2C12 myogenic differentiation by 
      compromising MyoD.
PG  - 419-29
AB  - Myotonic dystrophy (DM) is caused by two similar noncoding repeat expansion 
      mutations (DM1 and DM2). It is thought that both mutations produce pathogenic RNA 
      molecules that accumulate in nuclear foci. The DM1 mutation is a CTG expansion in 
      the 3' untranslated region (3'-UTR) of dystrophia myotonica protein kinase 
      (DMPK). In a cell culture model, mutant transcripts containing a (CUG)200 DMPK 
      3'-UTR disrupt C2C12 myoblast differentiation; a phenotype similar to what is 
      observed in myoblast cultures derived from DM1 patient muscle. Here, we have used 
      our cell culture model to investigate how the mutant 3'-UTR RNA disrupts 
      differentiation. We show that MyoD protein levels are compromised in cells that 
      express mutant DMPK 3'-UTR transcripts. MyoD, a transcription factor required for 
      the differentiation of myoblasts during muscle regeneration, activates 
      differentiation-specific genes by binding E-boxes. MyoD levels are significantly 
      reduced in myoblasts expressing the mutant 3'-UTR RNA within the first 6 h under 
      differentiation conditions. This reduction correlates with blunted E-box-mediated 
      gene expression at time points that are critical for initiating differentiation. 
      Importantly, restoring MyoD levels rescues the differentiation defect. We 
      conclude that mutant DMPK 3'-UTR transcripts disrupt myoblast differentiation by 
      reducing MyoD levels below a threshold required to activate the differentiation 
      program.
FAU - Amack, Jeffrey D
AU  - Amack JD
AD  - Laboratory of Genetics, University of Wisconsin-Madison, Madison, WI 53706, USA.
FAU - Reagan, Shannon R
AU  - Reagan SR
FAU - Mahadevan, Mani S
AU  - Mahadevan MS
LA  - eng
GR  - R01 AR045992/AR/NIAMS NIH HHS/United States
GR  - R01 AR 45992-01/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20021111
PL  - United States
TA  - J Cell Biol
JT  - The Journal of cell biology
JID - 0375356
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MYF5 protein, human)
RN  - 0 (MYOG protein, human)
RN  - 0 (Muscle Proteins)
RN  - 0 (Myf5 protein, mouse)
RN  - 0 (MyoD Protein)
RN  - 0 (Myog protein, mouse)
RN  - 0 (Myogenic Regulatory Factor 5)
RN  - 0 (Myogenin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/*genetics
MH  - Animals
MH  - Cell Differentiation/*physiology
MH  - Cells, Cultured
MH  - *DNA-Binding Proteins
MH  - Gene Expression Regulation, Developmental
MH  - Genes, Reporter
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Mice
MH  - Models, Biological
MH  - Muscle Proteins/metabolism
MH  - Mutation
MH  - MyoD Protein/genetics/*metabolism
MH  - Myoblasts/cytology/*physiology
MH  - Myogenic Regulatory Factor 5
MH  - Myogenin/metabolism
MH  - Myotonic Dystrophy/genetics/*metabolism
MH  - Myotonin-Protein Kinase
MH  - Promoter Regions, Genetic
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - RNA/genetics/metabolism
MH  - Recombinant Fusion Proteins/genetics/metabolism
MH  - *Trans-Activators
MH  - Transcription Factors/metabolism
PMC - PMC2173077
EDAT- 2002/11/13 04:00
MHDA- 2002/12/21 04:00
PMCR- 2003/05/11
CRDT- 2002/11/13 04:00
PHST- 2002/11/13 04:00 [pubmed]
PHST- 2002/12/21 04:00 [medline]
PHST- 2002/11/13 04:00 [entrez]
PHST- 2003/05/11 00:00 [pmc-release]
AID - jcb.200206020 [pii]
AID - 200206020 [pii]
AID - 10.1083/jcb.200206020 [doi]
PST - ppublish
SO  - J Cell Biol. 2002 Nov 11;159(3):419-29. doi: 10.1083/jcb.200206020. Epub 2002 Nov 
      11.

PMID- 12150945
OWN - NLM
STAT- MEDLINE
DCOM- 20020829
LR  - 20211203
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 295
IP  - 2
DP  - 2002 Jul 12
TI  - Expanded CTG repeats inhibit neuronal differentiation of the PC12 cell line.
PG  - 289-94
AB  - Myotonic dystrophy (DM) is a dominant neuromuscular disorder caused by the 
      expansion of trinucleotide CTG repeats in the 3-untranslated region (3'-UTR) of 
      the MtPK gene. Although DM-associated mental retardation suggests that neuronal 
      functions are disturbed by the expansion mutation, the effect of this alteration 
      in neuronal cells has not been approached. In this study we established stable 
      transfectans of PC12 neuronal cell line expressing the reporter gene CAT alone 
      (empty-vector clone) or fused to the MtPK 3'-UTR with 5, 60, or 90 CTG repeats 
      (CTG5, CTG60, and CTG90 clones, respectively). CTG90 cells exhibited a 
      suppression of NGF-induced neuronal differentiation while empty-vector, CTG5 and 
      CTG60 clones differentiated normally. CTG90 cells displayed normal activation of 
      early differentiation markers, ERK1/2, but the up-regulation of the late marker 
      MAP2 was dramatically reduced. Our neuronal cell system provides the first 
      information of how the mutant MtPK 3'-UTR mRNA affects neuronal functions.
FAU - Quintero-Mora, Maria Leonor
AU  - Quintero-Mora ML
AD  - Departamento de Genetica y Biologia Molecular, Centro de Investigacion y Estudios 
      Avanzados del IPN, Avenida Instituto Politecnico Nacional 2508, Apartado Postal 
      14-740, C.P. 07000 Mexico D.F., Mexico.
FAU - Depardon, Francisco
AU  - Depardon F
FAU - JamesWaring
AU  - JamesWaring
FAU - Robert G Korneluk
AU  - Robert G Korneluk
FAU - Cisneros, Bulmaro
AU  - Cisneros B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (3' Untranslated Regions)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Animals
MH  - Cell Differentiation/*genetics
MH  - Clone Cells
MH  - Myotonic Dystrophy/genetics
MH  - Myotonin-Protein Kinase
MH  - Neurons/*cytology
MH  - PC12 Cells
MH  - Protein Kinases/genetics
MH  - *Protein Serine-Threonine Kinases
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - *Trinucleotide Repeats
EDAT- 2002/08/02 10:00
MHDA- 2002/08/30 10:01
CRDT- 2002/08/02 10:00
PHST- 2002/08/02 10:00 [pubmed]
PHST- 2002/08/30 10:01 [medline]
PHST- 2002/08/02 10:00 [entrez]
AID - S0006291X02006605 [pii]
AID - 10.1016/s0006-291x(02)00660-5 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2002 Jul 12;295(2):289-94. doi: 
      10.1016/s0006-291x(02)00660-5.

PMID- 12111301
OWN - NLM
STAT- MEDLINE
DCOM- 20020920
LR  - 20071115
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 249
IP  - 6
DP  - 2002 Jun
TI  - Cardiac involvement and CTG expansion in myotonic dystrophy.
PG  - 693-8
AB  - Although cardiac complications are well known in myotonic dystrophy (DM), 
      patients rarely manifest symptoms of cardiac disease, and if so they most often 
      show conduction abnormalities or arrhythmia. In this study, specific cardiac 
      findings were reviewed in 79 patients with DM. No correlation was found between 
      the cardiac assessments and the CTG expansion. Thus, for a single patient the 
      cardiac involvement in the disease can not be predicted from the findings of the 
      genetic investigation. On the other hand, a clear positive relationship of the PR 
      interval with the QRS duration was revealed, as well as a positive correlation 
      between the age of the DM patient and the QRS duration, which increases with 0,54 
      ms/year. Systolic dysfunction, evaluated by transthoracic echocardiography, seems 
      to be quite uncommon. In 32 % of the patients with a normal ECG, the 24 h Holter 
      monitoring showed arrhythmias and conduction abnormalities. Based on these 
      findings we recommend a follow up of DM patients not only based on the ECG, but 
      also through 24 h Holter monitoring.
FAU - Merlevede, Karen
AU  - Merlevede K
AD  - Department of Neurology, AZ KLINA, Augustijnslei 100, 2930 Brasschaat, Belgium. 
      Karen.Merlevede@klina.be
FAU - Vermander, Dimitri
AU  - Vermander D
FAU - Theys, Paul
AU  - Theys P
FAU - Legius, Eric
AU  - Legius E
FAU - Ector, Hugo
AU  - Ector H
FAU - Robberecht, Wim
AU  - Robberecht W
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arrhythmia, Sinus/genetics/physiopathology
MH  - Arrhythmias, Cardiac/*genetics/physiopathology
MH  - Atrial Fibrillation/genetics/physiopathology
MH  - Cardiac Complexes, Premature/genetics/physiopathology
MH  - Child
MH  - Child, Preschool
MH  - Echocardiography
MH  - Electrocardiography
MH  - Female
MH  - Heart Block/*genetics/physiopathology
MH  - Heart Conduction System/pathology/*physiopathology
MH  - Heart Ventricles/pathology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/pathology/physiopathology
MH  - Monitoring, Physiologic
MH  - Myotonic Dystrophy/*complications/*genetics/physiopathology
MH  - Sinoatrial Block/genetics/physiopathology
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2002/07/12 10:00
MHDA- 2002/09/21 10:01
CRDT- 2002/07/12 10:00
PHST- 2002/07/12 10:00 [pubmed]
PHST- 2002/09/21 10:01 [medline]
PHST- 2002/07/12 10:00 [entrez]
AID - 10.1007/s00415-002-0692-6 [doi]
PST - ppublish
SO  - J Neurol. 2002 Jun;249(6):693-8. doi: 10.1007/s00415-002-0692-6.

PMID- 12042281
OWN - NLM
STAT- MEDLINE
DCOM- 20030107
LR  - 20190513
IS  - 0268-1161 (Print)
IS  - 0268-1161 (Linking)
VI  - 17
IP  - 6
DP  - 2002 Jun
TI  - Increased (CTG/CAG)(n) lengths in myotonic dystrophy type 1 and Machado-Joseph 
      disease genes in idiopathic azoospermia patients.
PG  - 1578-83
AB  - BACKGROUND: An increase in CAG trinucleotide repeat length in the androgen 
      receptor (AR) gene has been linked to idiopathic azoospermia. METHODS: In order 
      to test whether other (CAG/CTG)(n) loci are also affected, the (CAG/CTG)(n) 
      frequency distribution at myotonic dystrophy type 1 (DM1), Machado-Joseph disease 
      (MJD), dentatorubral-pallidoluysian atrophy (DRPLA) and spinocerebellar ataxia 
      type 8 (SCA8) loci, in addition to the AR gene, was investigated in 48 
      azoospermia patients and 47 controls. RESULTS: The median CAG repeat length in 
      the AR gene was significantly longer in azoospermia patients than in controls (23 
      versus 21, P < 0.001). Significant differences were also noted in the upper tails 
      of trinucleotide repeat length distributions at both DM1 and MJD loci between the 
      two populations. At the DM1 locus, alleles of more than 18 repeats were observed 
      only in azoospermia patients, and not in controls (P = 0.014). At the MJD locus, 
      the frequency of normal alleles (ANs) with 29 or more CAG repeats was also much 
      higher in azoospermia patients (29.2 versus 7.4%; P = 0.0001). However, the 
      repeat length distribution at DRPLA and SCA8 loci did not differ in the two 
      groups. CONCLUSIONS: These data indicated that, at least in a subset of 
      azoospermia patients, there was an increase in the number of trinucleotide 
      repeats in some disease loci. Thus, it is noteworthy to evaluate whether 
      offspring of these azoospermia patients, if born by assisted reproductive 
      technologies, have an increased risk of trinucleotide repeat diseases.
FAU - Pan, Huichin
AU  - Pan H
AD  - Department of Life Sciences, Chung Shan Medical University, Taichung, Taiwan, 
      Republic of China.
FAU - Li, Yet-Young
AU  - Li YY
FAU - Li, Tung-Cheng
AU  - Li TC
FAU - Tsai, Wen-Tin
AU  - Tsai WT
FAU - Li, Shuan-Yow
AU  - Li SY
FAU - Hsiao, Kuang-Ming
AU  - Hsiao KM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Base Sequence
MH  - Case-Control Studies
MH  - DNA/genetics
MH  - Humans
MH  - Machado-Joseph Disease/complications/*genetics
MH  - Male
MH  - Myoclonic Epilepsies, Progressive/complications/genetics
MH  - Myotonic Dystrophy/classification/complications/*genetics
MH  - Oligospermia/etiology/*genetics
MH  - Risk Factors
MH  - Spinocerebellar Ataxias/classification/complications/genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2002/06/04 10:00
MHDA- 2003/01/08 04:00
CRDT- 2002/06/04 10:00
PHST- 2002/06/04 10:00 [pubmed]
PHST- 2003/01/08 04:00 [medline]
PHST- 2002/06/04 10:00 [entrez]
AID - 10.1093/humrep/17.6.1578 [doi]
PST - ppublish
SO  - Hum Reprod. 2002 Jun;17(6):1578-83. doi: 10.1093/humrep/17.6.1578.

PMID- 12035844
OWN - NLM
STAT- MEDLINE
DCOM- 20021108
LR  - 20131121
IS  - 0317-1671 (Print)
IS  - 0317-1671 (Linking)
VI  - 29
IP  - 2
DP  - 2002 May
TI  - A patient with proximal myotonic myopathy and parkinsonism.
PG  - 188-90
AB  - INTRODUCTION: There are two case reports of patients who had proximal myotonic 
      myopathy (PROMM)/myotonic dystrophy (DM) Type 1 and parkinsonism. The combination 
      of myotonic myopathy and parkinsonism is so rare that it may appear to be just a 
      coincidence. However, previous neuropathological examinations of patients who had 
      myotonic dystrophy showed that there were intracytoplasmic inclusion bodies in 
      the nigra and striatum, which raises the possibility that myotonic myopathy may 
      be associated with parkinsonism. In this report we describe a patient with PROMM 
      and a clinically definite parkinsonism to highlight this possibility. CASE 
      REPORT: A 65-year-old man developed proximal muscle weakness, myotonia and 
      atrophy around the age of 55 and was diagnosed as having PROMM at the age of 62. 
      Needle electromyography and muscle biopsy supported the diagnosis. A gene study 
      of the DM Type 1 showed a normal CTG repeat length. At age 63, he developed rest 
      tremor, bradykinesia, hypomimia, stooped posture, and gait disturbance. The 
      postural instability worsened rapidly. The tremor and rigidity were much worse in 
      his right side, where myotonia was more severe. Levodopa therapy was only 
      partially effective. CONCLUSION: This is a case report of a patient with PROMM 
      that shows an association with a rapidly progressive form of parkinsonism. We 
      suggest that this may be a novel form of a neurodegenerative disorder, which we 
      name 'Parkinsonism-Myotonic Myopathy-Complex'.
FAU - Chu, Kon
AU  - Chu K
AD  - Department of Neurology and Clinical Research Institute, Seoul National 
      University Hospital, Korea.
FAU - Cho, Jin-Whan
AU  - Cho JW
FAU - Song, Eun-Chol
AU  - Song EC
FAU - Jeon, Beom S
AU  - Jeon BS
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Can J Neurol Sci
JT  - The Canadian journal of neurological sciences. Le journal canadien des sciences 
      neurologiques
JID - 0415227
RN  - 0 (Antiparkinson Agents)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Antiparkinson Agents/therapeutic use
MH  - Brain/pathology
MH  - Humans
MH  - Levodopa/therapeutic use
MH  - Male
MH  - Muscles/physiopathology
MH  - Myotonic Disorders/*complications/pathology/*physiopathology
MH  - Parkinsonian Disorders/*complications/drug therapy/pathology/*physiopathology
EDAT- 2002/05/31 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/05/31 10:00
PHST- 2002/05/31 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/05/31 10:00 [entrez]
PST - ppublish
SO  - Can J Neurol Sci. 2002 May;29(2):188-90.

PMID- 12013582
OWN - NLM
STAT- MEDLINE
DCOM- 20020529
LR  - 20190901
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 248
IP  - 12
DP  - 2001 Dec
TI  - Stapedial reflex in myotonic dystrophy type 1 and CTG repeat expansion.
PG  - 1056-61
AB  - The severity of clinical symptoms of myotonic dystrophy type 1 (DM1) has been 
      shown to be closely related to the size of a CTG triplet repeat in the gene 
      encoding myotonin protein kinase. Neuro-otological examinations that include eye 
      movement and stapedial reflex (SR) tests can contribute to the quantitative 
      evaluation of muscular involvement in DM1. We previously found that saccadic eye 
      movement velocity in DM1 patients was significantly lower than that in control 
      subjects and that the saccadic velocity and size of the CTG triplet repeat in DM1 
      patients had a strong inverse correlation. We now report a case-control study 
      that compared the SR wave form (latency: L, contraction time: C50, and relaxation 
      time: D50) measured by the acoustic impedance method in 13 patients with DM1 and 
      in 14 control subjects matched for age and sex. The correlation between the SR 
      wave form and CTG repeat length in DM1 patients obtained by Southern blot 
      analysis with EcoRI was also examined. We found (1) no significant difference 
      between the pure tone audiometric threshold at 500 Hz in the DM1 patients and 
      that in the control subjects; (2) or between the SR thresholds in the patients 
      and controls (500 Hz stimuli); (3) C50 and D50 in DM1 patients to be 
      significantly prolonged, whereas L was not; (4) C50 and D50 in DM1 patients to be 
      significantly correlated with CTG repeat length, whereas L was not. Measurement 
      of SR by the acoustic impedance method is completely non-invasive, causes no 
      discomfort to the subject, and does not depend on the person's effort or 
      cooperation. Our findings show that SR measurement can be used for a quantitative 
      evaluation of muscle involvement in DM1. We believe that the prolongation of D50 
      in DM1 is caused by myotonia, which has to be confirmed by further clinical and 
      pathological studies.
FAU - Osanai, R
AU  - Osanai R
AD  - Department of Otolaryngology, Saitama Medical Centre, Saitama Medical School, 
      Kawagoe, Japan. oryuichi@saitama-med.ac.jp
FAU - Kinoshita, M
AU  - Kinoshita M
FAU - Hirose, K
AU  - Hirose K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA/analysis/genetics
MH  - Eye Movements/genetics/*physiology
MH  - Female
MH  - Hearing/genetics/*physiology
MH  - Hearing Tests
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Contraction/physiology
MH  - Muscle Relaxation/physiology
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Reflex/genetics/*physiology
MH  - Repetitive Sequences, Nucleic Acid/genetics
MH  - Tympanic Membrane/physiology
EDAT- 2002/05/16 10:00
MHDA- 2002/05/30 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/05/30 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - 10.1007/s004150170025 [doi]
PST - ppublish
SO  - J Neurol. 2001 Dec;248(12):1056-61. doi: 10.1007/s004150170025.

PMID- 11993794
OWN - NLM
STAT- MEDLINE
DCOM- 20021104
LR  - 20190605
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 41
IP  - 4
DP  - 2002 Apr
TI  - A patient with myotonic dystrophy type 1 (DM 1) accompanied by laryngeal and 
      renal cell carcinomas had a small CTG triplet repeat expansion but no somatic 
      instability in normal tissues.
PG  - 312-8
AB  - We examined (CTG)n lengths in various tissues from a 70-year-old man with 
      myotonic dystrophy type 1 (DM 1) who had a small 60-70 (CTG), expansion in his 
      leukocytes. He died of renal cell carcinoma 5 years after a total laryngectomy 
      for laryngeal carcinoma. Southern blot and polymerase chain reaction analyses 
      were done on tissues obtained at autopsy. In the various normal tissues, (CTG). 
      lengths were almost all the same size, whereas the renal cell carcinoma and 
      metastatic tissues had longer lengths. When compared with the lengths in 
      leukocytes about 5 years previously, (CTG)n lengths in the normal tissues were 
      the same size. These findings suggest that both somatic instability and 
      age-dependent (CTG). expansion in DM 1 patients with a small expansion may be 
      less dominant than in patients with large expansions.
FAU - Kinoshita, Masanobu
AU  - Kinoshita M
AD  - Fourth Department of Internal Medicine, Saitama Medical Center.
FAU - Osanai, Ryuichi
AU  - Osanai R
FAU - Kikkawa, Masaru
AU  - Kikkawa M
FAU - Adachi, Akiko
AU  - Adachi A
FAU - Ohtake, Toshiyuki
AU  - Ohtake T
FAU - Komori, Tetsuo
AU  - Komori T
FAU - Hashimoto, Kohzo
AU  - Hashimoto K
FAU - Itoyama, Shinnji
AU  - Itoyama S
FAU - Mitarai, Tetsuya
AU  - Mitarai T
FAU - Hirose, Kazuhiko
AU  - Hirose K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (DNA, Neoplasm)
SB  - IM
CIN - Intern Med. 2002 Apr;41(4):253. PMID: 11993783
MH  - Anticipation, Genetic
MH  - Autopsy
MH  - Blotting, Southern
MH  - Carcinoma, Renal Cell/complications/*genetics
MH  - Carcinoma, Squamous Cell/complications/*genetics
MH  - DNA, Neoplasm/analysis
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Laryngeal Neoplasms/complications/*genetics
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/complications/*genetics
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2002/05/08 10:00
MHDA- 2002/11/26 04:00
CRDT- 2002/05/08 10:00
PHST- 2002/05/08 10:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/05/08 10:00 [entrez]
AID - 10.2169/internalmedicine.41.312 [doi]
PST - ppublish
SO  - Intern Med. 2002 Apr;41(4):312-8. doi: 10.2169/internalmedicine.41.312.

PMID- 11978764
OWN - NLM
STAT- MEDLINE
DCOM- 20020923
LR  - 20190513
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 11
IP  - 9
DP  - 2002 May 1
TI  - Identification of transcriptional targets for Six5: implication for the 
      pathogenesis of myotonic dystrophy type 1.
PG  - 1045-58
AB  - Myotonic dystrophy 1 (DM1) is the most common inherited neuromuscular disease in 
      adults. The disorder, characterized by myotonia, muscle wasting and weakness, 
      cataract, insulin resistance, and mental impairment, is caused by the expansion 
      of an unstable CTG repeat located in the 3' untranslated region of DMPK. The 
      repeat expansion suppresses the expression of the homeobox gene SIX5. We describe 
      here an experimental system to identify downstream transcriptional targets of 
      mouse Six5 in order to elucidate the role of SIX5 in the pathogenesis of DM1 and 
      development. By overexpressing a constitutively active Six5 (VP16-Six5wt) using 
      adenovirus-mediated gene transfer in P19 cells and subsequent expression 
      profiling using cDNA arrays, 21 genes, whose expression level increased by the 
      treatment, were identified as potential target genes. Genes expressed in the 
      somites, skeletal muscles, brain and meninges comprised the majority, suggesting 
      the role of Six5 in the development and function of mesodermal tissues and brain. 
      We provide evidence that Igfbp5 encoding a component of IGF signaling is a direct 
      Six5-target. Moreover, the overall expression level of Igfbp5 was decreased in 
      Six5-deficient mouse fibroblasts, and the response of human IGFBP5 to 
      MyoD-induced muscle conversion was altered in cells of DM1 patients. Our results 
      not only identify Six5 as an activator that directs Igfbp5 expression but also 
      suggest that reduced SIX5 expression in DM1 might contribute to specific aspects 
      of the DM1 phenotype.
FAU - Sato, Shigeru
AU  - Sato S
AD  - Department of Biology, Jichi Medical School, Minamikawachi, Tochigi 329-0498, 
      Japan.
FAU - Nakamura, Miwa
AU  - Nakamura M
FAU - Cho, Diane H
AU  - Cho DH
FAU - Tapscott, Stephen J
AU  - Tapscott SJ
FAU - Ozaki, Hidenori
AU  - Ozaki H
FAU - Kawakami, Kiyoshi
AU  - Kawakami K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA Primers)
RN  - 0 (Herpes Simplex Virus Protein Vmw65)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 5)
RN  - 0 (SIX5 protein, human)
RN  - 0 (Six5 protein, mouse)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Base Sequence
MH  - Brain/metabolism
MH  - COS Cells/metabolism
MH  - DNA Primers/chemistry
MH  - Fibroblasts/metabolism
MH  - Gene Expression Profiling
MH  - Herpes Simplex Virus Protein Vmw65/metabolism
MH  - Homeodomain Proteins/*genetics/metabolism
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 5/genetics/metabolism
MH  - Insulin-Like Growth Factor II/metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/metabolism
MH  - Mutagenesis, Site-Directed
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Oligonucleotide Array Sequence Analysis
MH  - Polymerase Chain Reaction
MH  - Transfection
MH  - Tumor Cells, Cultured
EDAT- 2002/04/30 10:00
MHDA- 2002/09/24 06:00
CRDT- 2002/04/30 10:00
PHST- 2002/04/30 10:00 [pubmed]
PHST- 2002/09/24 06:00 [medline]
PHST- 2002/04/30 10:00 [entrez]
AID - 10.1093/hmg/11.9.1045 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2002 May 1;11(9):1045-58. doi: 10.1093/hmg/11.9.1045.

PMID- 11888847
OWN - NLM
STAT- MEDLINE
DCOM- 20020423
LR  - 20190906
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 146
IP  - 3
DP  - 2002 Mar
TI  - Abnormal release of incretins and cortisol after oral glucose in subjects with 
      insulin-resistant myotonic dystrophy.
PG  - 397-405
AB  - OBJECTIVE: Although the incretins, gastric inhibitory polypeptide (GIP) and 
      glucagon-like peptide-1 (GLP-1), as well as glucagon and cortisol, are known to 
      influence islet function, the role of these hormones in conditions of insulin 
      resistance and development of type 2 diabetes is unknown. An interesting model 
      for the study of hormonal perturbations accompanying marked insulin resistance 
      without concomitant diabetes is myotonic dystrophy (DM1). DESIGN: The work was 
      carried out in an out-patient setting. METHODS: An oral glucose tolerance test 
      was performed in 18 males with DM1 and 18 controls to examine the release of 
      incretins and counter-regulatory hormones. Genetic analyses were also performed 
      in patients. RESULTS: We found that the increment in GLP-1 after oral glucose was 
      significantly greater in patients, while there was no significant difference in 
      GIP or glucagon responses between patients and controls, although long CTG repeat 
      expansions were associated with a more pronounced GIP response. Interestingly, 
      the GLP-1 response to oral glucose correlated with the insulin response in 
      patients but not in controls whereas, in controls, the insulin response closely 
      correlated with the GIP response. Furthermore, cortisol and ACTH levels increased 
      paradoxically in patients after glucose; this was more pronounced in patients 
      with long CTG repeat expansions. CONCLUSIONS: This study showed that the GLP-1 
      and ACTH/cortisol responses to oral glucose are abnormal in insulin-resistant DM1 
      patients and that CTG triplet repeats are linked to GIP release. These 
      abnormalities may contribute both to the severe insulin resistance and 
      hyperinsulinemia in DM1 and to the preservation of adequate islet function, 
      enabling glucose tolerance to be normal in spite of this marked insulin 
      resistance in DM1.
FAU - Johansson, Asa
AU  - Johansson A
AD  - Department of Public Health and Clinical Medicine, Umea University Hospital, 
      Umea, Sweden.
FAU - Olsson, Tommy
AU  - Olsson T
FAU - Cederquist, Kristina
AU  - Cederquist K
FAU - Forsberg, Hakan
AU  - Forsberg H
FAU - Holst, Jens J
AU  - Holst JJ
FAU - Seckl, Jonathan R
AU  - Seckl JR
FAU - Ahren, Bo
AU  - Ahren B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Gastrointestinal Hormones)
RN  - 0 (Peptide Fragments)
RN  - 119637-73-9 (glucagon-like peptide 1 (7-36)amide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-49-2 (DNA)
RN  - 9007-92-5 (Glucagon)
RN  - IY9XDZ35W2 (Glucose)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Body Composition/physiology
MH  - DNA/analysis/genetics
MH  - Dose-Response Relationship, Drug
MH  - Gastrointestinal Hormones/*genetics/*metabolism
MH  - Glucagon
MH  - Glucagon-Like Peptide 1
MH  - Glucagon-Like Peptides
MH  - Glucose/*pharmacology
MH  - Humans
MH  - Hydrocortisone/*genetics/*metabolism
MH  - Insulin Resistance/*genetics/*physiology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - Peptide Fragments/*genetics/*metabolism
MH  - Regression Analysis
MH  - Repetitive Sequences, Nucleic Acid
EDAT- 2002/03/13 10:00
MHDA- 2002/04/24 10:01
CRDT- 2002/03/13 10:00
PHST- 2002/03/13 10:00 [pubmed]
PHST- 2002/04/24 10:01 [medline]
PHST- 2002/03/13 10:00 [entrez]
AID - 146397 [pii]
AID - 10.1530/eje.0.1460397 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2002 Mar;146(3):397-405. doi: 10.1530/eje.0.1460397.

PMID- 11809728
OWN - NLM
STAT- MEDLINE
DCOM- 20020507
LR  - 20210108
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 11
IP  - 2
DP  - 2002 Jan 15
TI  - Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in 
      mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins.
PG  - 191-8
AB  - The mechanism of expansion of the (CTG)n repeat in myotonic dystrophy (DM1) 
      patients and the cause of its pathobiological effects are still largely unknown. 
      Most likely, long repeats exert toxicity at the level of nuclear RNA transport or 
      splicing. Here, we analyse cis- and trans-acting parameters that determine repeat 
      behaviour in novel mouse models for DM1. Our mice carry 'humanized' myotonic 
      dystrophy protein kinase (Dmpk) allele(s) with either a (CTG)84 or a (CTG)11 
      repeat, inserted at the correct position into the endogenous DM locus. Unlike in 
      the human situation, the (CTG)84 repeat in the syntenic mouse environment was 
      relatively stable during intergenerational segregation. However, somatic tissues 
      showed substantial repeat expansions which were progressive upon aging and 
      prominent in kidney, and in stomach and small intestine, where it was cell-type 
      restricted. Other tissues examined showed only marginal size changes. The (CTG)11 
      allele was completely stable, as anticipated. Introducing the (CTG)84 allele into 
      an Msh3-deficient background completely blocked the somatic repeat instability. 
      In contrast, Msh6 deficiency resulted in a significant increase in the frequency 
      of somatic expansions. Competition of Msh3 and Msh6 for binding to Msh2 in 
      functional complexes with different DNA mismatch-recognition specificity may 
      explain why the somatic (CTG)n expansion rate is differentially affected by 
      ablation of Msh3 and Msh6.
FAU - van den Broek, Walther J A A
AU  - van den Broek WJ
AD  - Department of Cell Biology, UMC Nijmegen, Nijmegen Center for Molecular Life 
      Sciences, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
FAU - Nelen, Marcel R
AU  - Nelen MR
FAU - Wansink, Derick G
AU  - Wansink DG
FAU - Coerwinkel, Marga M
AU  - Coerwinkel MM
FAU - te Riele, Hein
AU  - te Riele H
FAU - Groenen, Patricia J T A
AU  - Groenen PJ
FAU - Wieringa, Be
AU  - Wieringa B
LA  - eng
SI  - GENBANK/L08835
SI  - GENBANK/Z38015
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (G-T mismatch-binding protein)
RN  - 0 (MSH3 protein, human)
RN  - 0 (Msh6 protein, mouse)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (MutS Homolog 3 Protein)
RN  - EC 6.5.1.- (DNA Ligases)
RN  - Y49M64GZ4Q (multidrug resistance-associated protein 1)
SB  - IM
MH  - Animals
MH  - Base Pair Mismatch
MH  - DNA Ligases/metabolism
MH  - *DNA Repair
MH  - DNA-Binding Proteins/genetics/*physiology
MH  - Female
MH  - *Gene Expression Regulation
MH  - Male
MH  - Mice
MH  - Molecular Sequence Data
MH  - *Multidrug Resistance-Associated Proteins
MH  - MutS Homolog 3 Protein
MH  - Myotonic Dystrophy/etiology/*genetics
MH  - Trinucleotide Repeat Expansion
MH  - Trinucleotide Repeats/*genetics
EDAT- 2002/01/26 10:00
MHDA- 2002/05/08 10:01
CRDT- 2002/01/26 10:00
PHST- 2002/01/26 10:00 [pubmed]
PHST- 2002/05/08 10:01 [medline]
PHST- 2002/01/26 10:00 [entrez]
AID - 10.1093/hmg/11.2.191 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2002 Jan 15;11(2):191-8. doi: 10.1093/hmg/11.2.191.

PMID- 11807410
OWN - NLM
STAT- MEDLINE
DCOM- 20020517
LR  - 20191105
IS  - 0955-8829 (Print)
IS  - 0955-8829 (Linking)
VI  - 11
IP  - 4
DP  - 2001 Dec
TI  - Is the 31 CAG repeat allele of the spinocerebellar ataxia 1 (SCA1) gene locus 
      non-specifically associated with trinucleotide expansion diseases?
PG  - 201-5
AB  - A number of human hereditary neuromuscular and neurodegenerative disorders are 
      caused by the expansion of trinucleotide repeats within certain genes. The 
      molecular mechanisms that underlie these expansions are not yet known. We have 
      analyzed six trinucleotide repeat-containing loci [spinocerebellar ataxias (SCA1, 
      SCA3, SCA8), dentatorubral-pallidoluysian atrophy (DRPLA), Huntington chorea (HD) 
      and fragile X syndrome (FRAXA)] in myotonic dystrophy type 1 (DM1) patients (n = 
      52). As controls, we analyzed two groups of subjects: healthy control subjects (n 
      =133), and a group of patients with non-triplet neuromuscular diseases (n = 68) 
      caused by point mutations, deletions or duplications (spinal muscular atrophy, 
      Charcot-Marie-Tooth disease, type 1A, hereditary neuropathy with liability to 
      pressure palsies, and Duchenne and Becker muscular dystrophy). Allele frequency 
      distributions for all tested loci were similar in these three groups with the 
      exception of the SCA1 locus. In DM1 patients, the SCA1 allele with 31 CAG repeats 
      account for 40.4% of all chromosomes tested, which is significantly higher than 
      in two other groups (11.3% in healthy controls and 6.6% in the group of 
      non-triplet diseased patients; P < 0.001, Fisher's exact test). This is 
      consistent with our previous findings in HD patients. The absence of this 
      association in non-triplet diseases as well as in healthy controls could indicate 
      a possible role of this SCA1 allele with 31 repeats in triplet diseases. Here we 
      discuss a possible role of the SCA1 region in pathological trinucleotide repeat 
      expansions.
FAU - Savic, D
AU  - Savic D
AD  - Faculty of Biology, University of Belgrade, Belgrade, Yugoslavia.
FAU - Topisirovic, I
AU  - Topisirovic I
FAU - Keckarevic, M
AU  - Keckarevic M
FAU - Keckarevic, D
AU  - Keckarevic D
FAU - Major, T
AU  - Major T
FAU - Culjkovic, B
AU  - Culjkovic B
FAU - Stojkovic, O
AU  - Stojkovic O
FAU - Rakocevic-Stojanovic, V
AU  - Rakocevic-Stojanovic V
FAU - Mladenovic, J
AU  - Mladenovic J
FAU - Todorovic, S
AU  - Todorovic S
FAU - Apostolski, S
AU  - Apostolski S
FAU - Romac, S
AU  - Romac S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Psychiatr Genet
JT  - Psychiatric genetics
JID - 9106748
RN  - 0 (ATXN1 protein, human)
RN  - 0 (Ataxin-1)
RN  - 0 (Ataxins)
RN  - 0 (DNA Primers)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Alleles
MH  - Ataxin-1
MH  - Ataxins
MH  - Base Sequence
MH  - DNA/blood/genetics
MH  - DNA Primers
MH  - Female
MH  - Gene Frequency
MH  - Humans
MH  - Male
MH  - Nerve Tissue Proteins/*genetics
MH  - Nuclear Proteins/*genetics
MH  - Reference Values
MH  - Spinocerebellar Ataxias/*genetics
MH  - *Trinucleotide Repeats
EDAT- 2002/01/25 10:00
MHDA- 2002/05/23 10:01
CRDT- 2002/01/25 10:00
PHST- 2002/01/25 10:00 [pubmed]
PHST- 2002/05/23 10:01 [medline]
PHST- 2002/01/25 10:00 [entrez]
AID - 10.1097/00041444-200112000-00004 [doi]
PST - ppublish
SO  - Psychiatr Genet. 2001 Dec;11(4):201-5. doi: 10.1097/00041444-200112000-00004.

PMID- 11793472
OWN - NLM
STAT- MEDLINE
DCOM- 20020305
LR  - 20211203
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Linking)
VI  - 19
IP  - 2
DP  - 2002 Feb
TI  - 250 CTG repeats in DMPK is a threshold for correlation of expansion size and age 
      at onset of juvenile-adult DM1.
PG  - 131-9
AB  - Myotonic dystrophy type 1 (DM1) is associated with an expansion of CTG repeats in 
      the 3'UTR of the DMPK gene. It is accepted, as in other trinucleotide diseases, 
      that the number of the repeats is correlated with age at onset and severity of 
      the disease. However, assessment of genotype-phenotype correlation in DM1 is 
      complicated with the expansion-biased somatic instability of mutant alleles over 
      time and difficulties in precise assessment of the number of repeats by standard 
      Southern blot hybridization. In order to clarify this issue we defined DM1 
      expansion size in lymphocytes by three parameters: size of progenitor, average, 
      and largest allele, using a more precise small-pool/long-range PCR technique. We 
      found a negative linear correlation of age at onset and average expansion size in 
      juvenile-adult DM1 patients (35 out of 46) whose progenitor allele is less than 
      245 repeats long. Our result favors the hypothesis of the existence of a 
      threshold in the progenitor allele size beyond which number of CTG repeats does 
      not influence age at onset. Potential clinical significance is that the average 
      allele size could be a useful indicator for the age at onset in juvenile-adult 
      DM1 patients with relatively short progenitor allele. To test whether somatic 
      instability of mutant alleles influences the progression of DM1, patients were 
      divided in three phenotypic classes according to the severity of neuromuscular 
      symptoms. We showed that the largest expansion in each DM1 phenotypic class 
      reflects somatic instability of mutant allele over time independently of 
      progenitor allele size and patient's age at sampling. The mean of the largest 
      expansion was significantly different between phenotypic classes, implying the 
      possible association between expansion-biased somatic instability of mutant 
      alleles over time and progression of neuromuscular symptoms.
CI  - Copyright 2002 Wiley-Liss, Inc.
FAU - Savic, Dusanka
AU  - Savic D
AD  - Faculty of Biology, University of Belgrade, Belgrade, Yugoslavia.
FAU - Rakocvic-Stojanovic, Vidosava
AU  - Rakocvic-Stojanovic V
FAU - Keckarevic, Dusan
AU  - Keckarevic D
FAU - Culjkovic, Biljana
AU  - Culjkovic B
FAU - Stojkovic, Oliver
AU  - Stojkovic O
FAU - Mladenovic, Jelena
AU  - Mladenovic J
FAU - Todorovic, Slobodanka
AU  - Todorovic S
FAU - Apostolski, Slobodan
AU  - Apostolski S
FAU - Romac, Stanka
AU  - Romac S
LA  - eng
SI  - GDB/119097
SI  - GDB/697132
SI  - GENBANK/L00727
SI  - GENBANK/L08835
SI  - GENBANK/X84813
SI  - OMIM/160900
SI  - OMIM/600963
SI  - OMIM/605377
PT  - Journal Article
PL  - United States
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Alleles
MH  - Analysis of Variance
MH  - Disease Progression
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Lymphocytes/metabolism
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Mutation/*genetics
MH  - Myotonic Dystrophy/epidemiology/*genetics/*physiopathology
MH  - Myotonin-Protein Kinase
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Time Factors
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 2002/01/17 10:00
MHDA- 2002/03/07 10:01
CRDT- 2002/01/17 10:00
PHST- 2002/01/17 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2002/01/17 10:00 [entrez]
AID - 10.1002/humu.10027 [pii]
AID - 10.1002/humu.10027 [doi]
PST - ppublish
SO  - Hum Mutat. 2002 Feb;19(2):131-9. doi: 10.1002/humu.10027.

PMID- 11726559
OWN - NLM
STAT- MEDLINE
DCOM- 20020131
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 23
DP  - 2001 Nov 1
TI  - Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats 
      display muscular and brain abnormalities.
PG  - 2717-26
AB  - The autosomal dominant mutation causing myotonic dystrophy (DM1) is a CTG repeat 
      expansion in the 3'-UTR of the DM protein kinase (DMPK) gene. This multisystemic 
      disorder includes myotonia, progressive weakness and wasting of skeletal muscle 
      and extramuscular symptoms such as cataracts, testicular atrophy, endocrine and 
      cognitive dysfunction. The mechanisms underlying its pathogenesis are complex. 
      Recent reports have revealed that DMPK gene haploinsufficiency may account for 
      cardiac conduction defects whereas cataracts may be due to haploinsufficiency of 
      the neighboring gene, the DM-associated homeobox protein (DMAHP or SIX5) gene. 
      Furthermore, mice expressing the CUG expansion in an unrelated mRNA develop 
      myotonia and myopathy, consistent with an RNA gain of function. We demonstrated 
      that transgenic mice carrying the CTG expansion in its human DM1 context (>45 kb) 
      and producing abnormal DMPK mRNA with at least 300 CUG repeats, displayed 
      clinical, histological, molecular and electrophysiological abnormalities in 
      skeletal muscle consistent with those observed in DM1 patients. Like DM1 
      patients, these transgenic mice show abnormal tau expression in the brain. These 
      results provide further evidence for the RNA trans-dominant effect of the CUG 
      expansion, not only in muscle, but also in brain.
FAU - Seznec, H
AU  - Seznec H
AD  - INSERM UR383, Hopital Necker-Enfants Malades, Universite Rene Descartes Paris V, 
      149-161 rue de Sevres, 75743 Paris Cedex 15, France.
FAU - Agbulut, O
AU  - Agbulut O
FAU - Sergeant, N
AU  - Sergeant N
FAU - Savouret, C
AU  - Savouret C
FAU - Ghestem, A
AU  - Ghestem A
FAU - Tabti, N
AU  - Tabti N
FAU - Willer, J C
AU  - Willer JC
FAU - Ourth, L
AU  - Ourth L
FAU - Duros, C
AU  - Duros C
FAU - Brisson, E
AU  - Brisson E
FAU - Fouquet, C
AU  - Fouquet C
FAU - Butler-Browne, G
AU  - Butler-Browne G
FAU - Delacourte, A
AU  - Delacourte A
FAU - Junien, C
AU  - Junien C
FAU - Gourdon, G
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (RNA, Messenger)
RN  - 0 (tau Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Brain/*abnormalities/metabolism
MH  - Cell Nucleus/metabolism
MH  - Cells, Cultured
MH  - Electromyography
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/*abnormalities/cytology
MH  - Myotonia/genetics/physiopathology
MH  - Myotonic Dystrophy/genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Phenotype
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Trinucleotide Repeats/genetics
MH  - tau Proteins/metabolism
EDAT- 2001/12/01 10:00
MHDA- 2002/02/01 10:01
CRDT- 2001/12/01 10:00
PHST- 2001/12/01 10:00 [pubmed]
PHST- 2002/02/01 10:01 [medline]
PHST- 2001/12/01 10:00 [entrez]
AID - 10.1093/hmg/10.23.2717 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Nov 1;10(23):2717-26. doi: 10.1093/hmg/10.23.2717.

PMID- 11719279
OWN - NLM
STAT- MEDLINE
DCOM- 20020207
LR  - 20190719
IS  - 0361-9230 (Print)
IS  - 0361-9230 (Linking)
VI  - 56
IP  - 3-4
DP  - 2001 Oct-Nov 1
TI  - Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic 
      dystrophy.
PG  - 405-10
AB  - Steinert's myotonic dystrophy (DM) is a genetic autosomal dominant disease and 
      the most frequent muscular dystrophy in adulthood. Although causative mutation is 
      recognized as a CTG trinucleotide expansion on 19q13.3, pathogenic mechanisms of 
      multisystem involvement of DM are still under debate. It has been suggested that 
      mitochondrial abnormalities can occur in this disease and deficiency of coenzyme 
      Q 10 (CoQ10) has been considered one possible cause for this. The aim of this 
      investigation was to evaluate, in 35 DM patients, CoQ10 blood levels and relate 
      them to the degree of CTG expansion as well as to the amount of lactate 
      production in exercising muscle as indicator of mitochondrial dysfunction. CoQ10 
      concentrations appeared significantly reduced with respect to normal controls: 
      0.85 +/- 0.25 vs. 1.58 +/- 0.28 microg/ml (p < 0.05). Mean values of blood 
      lactate were significantly higher in DM patients than controls (p < 0.05) both in 
      resting conditions (2.9 +/- 0.55 vs. 1.44 +/- 1.11 mmol/L) and at the exercise 
      peak (6.77 +/- 1.79 vs. 4.90 +/- 0.59 mmol/L), while exercise lactate threshold 
      was anticipated (30-50% vs. 60-70% of the predicted normal maximal power output, 
      p < 0.05). Statistical analysis showed that serum CoQ10 levels were significantly 
      (p < 0.05) inversely correlated with both CTG expansion degree and lactate values 
      at exercise lactate threshold level. Our data indicates the occurrence of reduced 
      CoQ10 levels in DM, possibly related to disease pathogenic mechanisms associated 
      with abnormal CTG trinucleotide amplification.
FAU - Siciliano, G
AU  - Siciliano G
AD  - Department of Neuroscience, Neurological Clinics, University of Pisa, Pisa, 
      Italy. g.sicilia@med.unipi.it
FAU - Mancuso, M
AU  - Mancuso M
FAU - Tedeschi, D
AU  - Tedeschi D
FAU - Manca, M L
AU  - Manca ML
FAU - Renna, M R
AU  - Renna MR
FAU - Lombardi, V
AU  - Lombardi V
FAU - Rocchi, A
AU  - Rocchi A
FAU - Martelli, F
AU  - Martelli F
FAU - Murri, L
AU  - Murri L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
RN  - 0 (Coenzymes)
RN  - 1339-63-5 (Ubiquinone)
RN  - 33X04XA5AT (Lactic Acid)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Adult
MH  - Child
MH  - Coenzymes
MH  - Female
MH  - Humans
MH  - Lactic Acid/*blood
MH  - Male
MH  - Middle Aged
MH  - Mitochondria/metabolism
MH  - Myotonic Dystrophy/*blood/*genetics
MH  - Phenotype
MH  - Physical Exertion
MH  - Predictive Value of Tests
MH  - *Trinucleotide Repeat Expansion
MH  - Ubiquinone/*analogs & derivatives/*blood/metabolism
EDAT- 2001/11/24 10:00
MHDA- 2002/02/08 10:01
CRDT- 2001/11/24 10:00
PHST- 2001/11/24 10:00 [pubmed]
PHST- 2002/02/08 10:01 [medline]
PHST- 2001/11/24 10:00 [entrez]
AID - S0361-9230(01)00653-0 [pii]
AID - 10.1016/s0361-9230(01)00653-0 [doi]
PST - ppublish
SO  - Brain Res Bull. 2001 Oct-Nov 1;56(3-4):405-10. doi: 
      10.1016/s0361-9230(01)00653-0.

PMID- 11686919
OWN - NLM
STAT- MEDLINE
DCOM- 20020222
LR  - 20211203
IS  - 0021-924X (Print)
IS  - 0021-924X (Linking)
VI  - 130
IP  - 5
DP  - 2001 Nov
TI  - Coexpression of the CUG-binding protein reduces DM protein kinase expression in 
      COS cells.
PG  - 581-7
AB  - Myotonic dystrophy (DM) is the most common form of adult onset muscular 
      dystrophy. Patients have a large CTG repeat expansion in the 3' untranslated 
      region of the DMPK gene, which encodes DM protein kinase. RNA trans-dominant 
      models, which hypothesize that the expanded CUG trinucleotide repeat on DMPK mRNA 
      sequesters a factor or disrupts the RNA metabolism of the DMPK mRNA itself and 
      other mRNAs in a trans dominant manner, have been proposed. A candidate for the 
      sequestered factor, termed CUG-binding protein (CUG-BP), exists in several 
      alternatively spliced isoforms. We found a human isoform with a twelve base 
      insertion (deduced amino acids Leu-Tyr-Leu-Gln) and an isoform with a three base 
      insertion (deduced amino acid Ala) insertion. In order to elucidate the effects 
      of CUG-BP on DMPK expression, we introduced CUG-BP and DMPK cDNA transiently into 
      COS-7 cells. Cotransfection of CUG-BP did not significantly affect the expression 
      of either wild type or mutant DMPK at the mRNA level. On the other hand, 
      cotransfection of CUG-BP significantly affected the expression of both the wild 
      type and mutant DMPKs at the protein level. This reduction was remarkable when 
      the mutant DMPK construct was used.
FAU - Takahashi, N
AU  - Takahashi N
AD  - Department of Life Sciences, Graduate School of Arts and Sciences, The University 
      of Tokyo, Komaba, Meguro-ku, Tokyo 153-8902, Japan.
FAU - Sasagawa, N
AU  - Sasagawa N
FAU - Usuki, F
AU  - Usuki F
FAU - Kino, Y
AU  - Kino Y
FAU - Kawahara, H
AU  - Kawahara H
FAU - Sorimachi, H
AU  - Sorimachi H
FAU - Maeda, T
AU  - Maeda T
FAU - Suzuki, K
AU  - Suzuki K
FAU - Ishiura, S
AU  - Ishiura S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Biochem
JT  - Journal of biochemistry
JID - 0376600
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - 24937-83-5 (Poly A)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - CELF1 Protein
MH  - COS Cells
MH  - Chlorocebus aethiops
MH  - Down-Regulation
MH  - *Gene Expression
MH  - Humans
MH  - Mice
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Myotonic Dystrophy/genetics
MH  - Myotonin-Protein Kinase
MH  - Poly A/genetics
MH  - Protein Biosynthesis
MH  - Protein Isoforms
MH  - Protein Serine-Threonine Kinases/*biosynthesis/genetics
MH  - RNA, Messenger/analysis/biosynthesis
MH  - RNA-Binding Proteins/*biosynthesis/genetics
MH  - Ribonucleoproteins/*biosynthesis/genetics
MH  - Tissue Distribution
MH  - Trinucleotide Repeats/genetics
EDAT- 2001/11/01 10:00
MHDA- 2002/02/23 10:01
CRDT- 2001/11/01 10:00
PHST- 2001/11/01 10:00 [pubmed]
PHST- 2002/02/23 10:01 [medline]
PHST- 2001/11/01 10:00 [entrez]
AID - 10.1093/oxfordjournals.jbchem.a003022 [doi]
PST - ppublish
SO  - J Biochem. 2001 Nov;130(5):581-7. doi: 10.1093/oxfordjournals.jbchem.a003022.

PMID- 11592825
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20211203
IS  - 1096-7192 (Print)
IS  - 1096-7192 (Linking)
VI  - 74
IP  - 1-2
DP  - 2001 Sep-Oct
TI  - Effect of triplet repeat expansion on chromatin structure and expression of DMPK 
      and neighboring genes, SIX5 and DMWD, in myotonic dystrophy.
PG  - 281-91
AB  - Myotonic dystrophy (DM), an autosomal dominant neuromuscular disease, is 
      associated with expansion of a polymorphic (CTG)n repeat in the 3'-untranslated 
      region of the DM protein kinase (DMPK) gene. The repeat expansion results in 
      decreased levels of DMPK mRNA and protein, but the mechanism for this decreased 
      expression is unknown. Loss of a nuclease-hypersensitive site in the region of 
      the repeat expansion has been observed in muscle and skin fibroblasts from DM 
      patients, indicating a change in local chromatin structure. This change in 
      chromatin structure has been proposed as a mechanism whereby the expression of 
      DMPK and neighboring genes, sine oculis homeobox (Drosophila) homolog 5 (SIX5) 
      and dystrophia myotonica-containing WD repeat motif (DMWD), might be affected. We 
      have developed a polymerase chain reaction (PCR)-based method to assay the 
      chromatin sensitivity of the region adjacent to the repeat expansion in somatic 
      cell hybrids carrying either normal or affected DMPK alleles and show that 
      hybrids carrying expanded alleles exhibit decreased sensitivity to PvuII 
      digestion in this region. Semiquantitative multiplex reverse transcriptase PCR 
      (RT/PCR) assays of gene expression from the chromosomes carrying the expanded 
      alleles showed marked reduction of DMPK mRNA, partial inhibition of SIX5 
      expression from a congenital DM chromosome, and no reduction of DMWD mRNA. Nested 
      RT/PCR analysis of DMPK mRNA from somatic cell hybrids carrying the repeat 
      expansions revealed that most of the DMPK transcripts expressed from the expanded 
      alleles lacked exons 13 and 14, whereas full-length transcripts were expressed 
      predominantly from the normal alleles. These results suggest that the CTG repeat 
      expansion leads to a decrease in DMPK mRNA levels by affecting splicing at the 3' 
      end of the DMPK pre-mRNA transcript.
CI  - Copyright 2001 Academic Press.
FAU - Frisch, R
AU  - Frisch R
AD  - Department of Medical Research, Nemours Children's Clinic, Wilmington, Delaware 
      19803, USA.
FAU - Singleton, K R
AU  - Singleton KR
FAU - Moses, P A
AU  - Moses PA
FAU - Gonzalez, I L
AU  - Gonzalez IL
FAU - Carango, P
AU  - Carango P
FAU - Marks, H G
AU  - Marks HG
FAU - Funanage, V L
AU  - Funanage VL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Genet Metab
JT  - Molecular genetics and metabolism
JID - 9805456
RN  - 0 (Chromatin)
RN  - 0 (DMPK protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (SIX5 protein, human)
RN  - 5Z93L87A1R (Guanine)
RN  - 8J337D1HZY (Cytosine)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - QR26YLT7LT (Thymine)
SB  - IM
MH  - Cells, Cultured
MH  - Chromatin/*genetics
MH  - Cytosine
MH  - Gene Expression Regulation, Enzymologic
MH  - Guanine
MH  - Homeodomain Proteins/biosynthesis/*genetics
MH  - Humans
MH  - Muscular Dystrophies/enzymology/*genetics/metabolism
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*enzymology/*genetics/metabolism
MH  - Myotonin-Protein Kinase
MH  - Nucleic Acid Conformation
MH  - Protein Serine-Threonine Kinases/biosynthesis/*genetics
MH  - RNA Splicing/genetics
MH  - RNA, Messenger/genetics
MH  - Thymine
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2001/10/11 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/11 10:00
PHST- 2001/10/11 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/11 10:00 [entrez]
AID - S1096-7192(01)93229-9 [pii]
AID - 10.1006/mgme.2001.3229 [doi]
PST - ppublish
SO  - Mol Genet Metab. 2001 Sep-Oct;74(1-2):281-91. doi: 10.1006/mgme.2001.3229.

PMID- 11590133
OWN - NLM
STAT- MEDLINE
DCOM- 20011220
LR  - 20190605
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 19
DP  - 2001 Sep 15
TI  - Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 
      1 and 2.
PG  - 2165-70
AB  - The phenotypes in myotonic dystrophy types 1 and 2 (DM1 and DM2) are similar, 
      suggesting a shared pathophysiologic mechanism. DM1 is caused by expansion of a 
      CTG repeat in the DMPK gene. Pathogenic effects of this mutation are likely to be 
      mediated, at least in part, by the expanded CUG repeat in mutant mRNA. The mutant 
      transcripts are retained in the nucleus in multiple discrete foci. We 
      investigated the possibility that DM2 is also caused by expansion of a CTG repeat 
      or related sequence. Analysis of DNA by repeat expansion detection methods, and 
      RNA by ribonuclease protection, did not show an expanded CTG or CUG repeat in 
      DM2. However, hybridization of muscle sections with fluorescence-labeled 
      CAG-repeat oligonucleotides showed nuclear foci in DM2 similar to those seen in 
      DM1. Nuclear foci were present in all patients with symptomatic DM1 (n = 9) or 
      DM2 (n = 9) but not in any disease controls or healthy subjects (n = 23). The 
      foci were not seen with CUG- or GUC-repeat probes. Foci in DM2 were distinguished 
      from DM1 by lower stability of the probe-target duplex, suggesting that a 
      sequence related to the DM1 CUG expansion accumulates in the DM2 nucleus. 
      Muscleblind proteins, which interact with expanded CUG repeats in vitro, 
      localized to the nuclear foci in both DM1 and DM2. These results support the idea 
      that nuclear accumulation of mutant RNA is pathogenic in DM1, suggest that a 
      similar disease process occurs in DM2, and point to a role for muscleblind in the 
      pathogenesis of both disorders.
FAU - Mankodi, A
AU  - Mankodi A
AD  - Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA.
FAU - Urbinati, C R
AU  - Urbinati CR
FAU - Yuan, Q P
AU  - Yuan QP
FAU - Moxley, R T
AU  - Moxley RT
FAU - Sansone, V
AU  - Sansone V
FAU - Krym, M
AU  - Krym M
FAU - Henderson, D
AU  - Henderson D
FAU - Schalling, M
AU  - Schalling M
FAU - Swanson, M S
AU  - Swanson MS
FAU - Thornton, C A
AU  - Thornton CA
LA  - eng
GR  - AR46799/AR/NIAMS NIH HHS/United States
GR  - AR46806/AR/NIAMS NIH HHS/United States
GR  - RR00044/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Drosophila Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (mbl protein, Drosophila)
RN  - 63231-63-0 (RNA)
RN  - EC 3.1.- (Ribonucleases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Cell Nucleus/metabolism
MH  - Drosophila
MH  - *Drosophila Proteins
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/metabolism
MH  - Myotonic Dystrophy/*genetics
MH  - Nuclear Proteins/*genetics/metabolism
MH  - RNA/*metabolism
MH  - Ribonucleases/metabolism
MH  - Trinucleotide Repeats/genetics
EDAT- 2001/10/09 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/09 10:00
PHST- 2001/10/09 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/09 10:00 [entrez]
AID - 10.1093/hmg/10.19.2165 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Sep 15;10(19):2165-70. doi: 10.1093/hmg/10.19.2165.

PMID- 11590131
OWN - NLM
STAT- MEDLINE
DCOM- 20011220
LR  - 20220330
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 19
DP  - 2001 Sep 15
TI  - Dysregulation of human brain microtubule-associated tau mRNA maturation in 
      myotonic dystrophy type 1.
PG  - 2143-55
AB  - Intraneuronal aggregates of hyperphosphorylated tau proteins, referred to as 
      pathological tau, are found in brain areas of demented patients affected by 
      numerous different neurodegenerative disorders. We previously described a 
      particular biochemical profile of pathological tau proteins in myotonic dystrophy 
      type 1 (DM1). This multisystemic disorder is characterized by an unstable CTG 
      repeat expansion in the 3'-untranslated region of the DM protein kinase gene. In 
      the human central nervous system, tau proteins consist of six isoforms that 
      differ by the presence or absence of the alternatively spliced exons 2, 3 and 10. 
      Here we show that the pattern of tau isoforms aggregated in DM1 brain lesions is 
      characteristic. It consists mainly of the aggregation of the shortest human tau 
      isoform. A disruption in normal tau isoform expression consisting of a reduced 
      expression of tau isoforms containing the exon 2 was observed at both the mRNA 
      and protein levels. Large expanded CTG repeats were detected and showed marked 
      somatic heterogeneity between DM1 cases and in cortical brains regions analysed. 
      Our data suggest a relationship between the CTG repeat expansion and the 
      alteration of tau expression showing that DM1 is a peculiar tauopathy.
FAU - Sergeant, N
AU  - Sergeant N
AD  - INSERM U422, Groupe VCDN, 1 place de Verdun, 59045 Lille Cedex, France.
FAU - Sablonniere, B
AU  - Sablonniere B
FAU - Schraen-Maschke, S
AU  - Schraen-Maschke S
FAU - Ghestem, A
AU  - Ghestem A
FAU - Maurage, C A
AU  - Maurage CA
FAU - Wattez, A
AU  - Wattez A
FAU - Vermersch, P
AU  - Vermersch P
FAU - Delacourte, A
AU  - Delacourte A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA Primers)
RN  - 0 (Isoenzymes)
RN  - 0 (RNA, Messenger)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Adult
MH  - Blotting, Western
MH  - Brain/*metabolism
MH  - DNA Primers/chemistry
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Exons
MH  - Humans
MH  - Isoenzymes/genetics/metabolism
MH  - Male
MH  - Microtubules/*metabolism
MH  - Middle Aged
MH  - Myotonic Dystrophy/*metabolism
MH  - Phosphorylation
MH  - RNA Splicing
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Trinucleotide Repeats/genetics
MH  - tau Proteins/*metabolism
EDAT- 2001/10/09 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/09 10:00
PHST- 2001/10/09 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/09 10:00 [entrez]
AID - 10.1093/hmg/10.19.2143 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Sep 15;10(19):2143-55. doi: 10.1093/hmg/10.19.2143.

PMID- 11555624
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 18
DP  - 2001 Sep 1
TI  - The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient 
      to disrupt C2C12 myoblast differentiation.
PG  - 1879-87
AB  - Myotonic dystrophy type 1 (DM1) is a dominant neuromuscular disorder caused by a 
      trinucleotide (CTG) repeat expansion. Mutant DMPK 3'-untranslated region (3'-UTR) 
      transcripts aggregate in nuclear foci and are thought to impose dominant-negative 
      effects by interacting with RNA binding proteins. We demonstrated previously that 
      the mutant 3'-UTR RNA disrupted C2C12 myoblast differentiation, and that the CUG 
      expansion was necessary for this effect. Several proteins are known to interact 
      with the CUG tract or the region 3' (distal) to it. Here, using a library of 
      transfected C2C12 clones, we show that although transcripts containing a CUG 
      expansion alone or a CUG expansion plus the distal region of the DMPK 3'-UTR 
      accumulate into RNA foci, neither of these RNAs affect C2C12 myogenesis. Thus, 
      RNA foci formation, and perturbation of any RNA binding factors involved in this 
      process, are not sufficient to block myoblast differentiation. Interestingly, we 
      found that transcripts containing expanded CUG tracts can form both nuclear and 
      cytoplasmic RNA foci, demonstrating that factors involved in foci formation are 
      present in the nucleus and cytoplasm. RNA analysis of myogenic markers revealed 
      that the mutant DMPK 3'-UTR mRNA does not affect myoblast determination factors 
      MyoD or Myf5, but significantly impedes upregulation of the differentiation 
      factors myogenin and p21. C2C12 provide a good model to study adult muscle 
      regeneration. Our observations in this system may be relevant to the lack of a 
      regenerative response to continued muscle wasting in DM, and point to defects in 
      early events in the myogenic response to muscle damage.
FAU - Amack, J D
AU  - Amack JD
AD  - Laboratory of Genetics, University of Wisconsin Medical School, 445 Henry Mall, 
      Room 5322, Madison, WI 53706, USA.
FAU - Mahadevan, M S
AU  - Mahadevan MS
LA  - eng
GR  - R01 AR045992/AR/NIAMS NIH HHS/United States
GR  - R01 AR45992-01/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Cyclins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Luminescent Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (MyoD Protein)
RN  - 0 (Myogenic Regulatory Factor 5)
RN  - 0 (Myogenin)
RN  - 0 (RNA, Messenger)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Trans-Activators)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Animals
MH  - Cell Differentiation/*genetics
MH  - Cell Line
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Cyclins/analysis
MH  - Cytoplasm/metabolism
MH  - *DNA-Binding Proteins
MH  - Gene Expression
MH  - Green Fluorescent Proteins
MH  - Immunohistochemistry
MH  - Luminescent Proteins/genetics/metabolism
MH  - Muscle Proteins/analysis
MH  - Muscle, Skeletal/chemistry/cytology/*metabolism
MH  - Mutation
MH  - MyoD Protein/analysis
MH  - Myogenic Regulatory Factor 5
MH  - Myogenin/analysis
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Recombinant Fusion Proteins/genetics/metabolism
MH  - Time Factors
MH  - *Trans-Activators
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2001/09/14 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/14 10:00
PHST- 2001/09/14 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/14 10:00 [entrez]
AID - 10.1093/hmg/10.18.1879 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Sep 1;10(18):1879-87. doi: 10.1093/hmg/10.18.1879.

PMID- 11526199
OWN - NLM
STAT- MEDLINE
DCOM- 20020111
LR  - 20211203
IS  - 1531-2267 (Electronic)
IS  - 1094-8341 (Linking)
VI  - 6
IP  - 3
DP  - 2001 Aug 28
TI  - Skeletal muscle Na currents in mice heterozygous for Six5 deficiency.
PG  - 153-8
AB  - Myotonic dystrophy results from a trinucleotide repeat expansion between the 
      myotonic dystrophy protein kinase gene (Dmpk), which encodes a serine-threonine 
      protein kinase, and the Six5 gene, which encodes a homeodomain protein. The 
      disease is characterized by late bursts of skeletal muscle Na channel openings, 
      and this is recapitulated in Dmpk -/- and Dmpk +/- murine skeletal muscle. To 
      test whether deficiency of the nearby Six5 gene also affected Na channel gating 
      in murine skeletal muscle, we measured Na currents from cell-attached patches in 
      Six5 +/- mice and age-matched wild-type and Dmpk +/- mice. Late bursts of Na 
      channel activity were defined as an opening probability >10% measured from 10 to 
      110 ms after depolarization. There was no significant difference in the 
      occurrence of late Na channel bursts in wild-type and Six5 +/- muscle, whereas in 
      Dmpk +/- muscle there was greater than fivefold increase in late bursts (P < 
      0.001). Compared with wild-type mice, Na current amplitude was unchanged in Six5 
      +/- muscle, whereas in Dmpk +/- muscle it was 36% reduced (P < 0.05). Thus, since 
      Six5 +/- mice do not exhibit the Na channel gating abnormality of Dmpk 
      deficiency, we conclude that Six5 deficiency does not contribute to the Na 
      channel gating abnormality seen in dystrophia myotonica patients.
FAU - Mistry, D J
AU  - Mistry DJ
AD  - Cardiovascular Division, Department of Internal Medicine, Cardiovascular Research 
      Center, University of Virginia Health System, Charlottesville, Virginia 22908, 
      USA.
FAU - Moorman, J R
AU  - Moorman JR
FAU - Reddy, S
AU  - Reddy S
FAU - Mounsey, J P
AU  - Mounsey JP
LA  - eng
PT  - Journal Article
DEP - 20010828
PL  - United States
TA  - Physiol Genomics
JT  - Physiological genomics
JID - 9815683
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Six5 protein, mouse)
RN  - 0 (Sodium Channels)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Genotype
MH  - Heterozygote
MH  - Homeodomain Proteins/genetics/*metabolism
MH  - Membrane Potentials/*physiology
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Mice, Knockout
MH  - Muscle, Skeletal/cytology/*physiology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/deficiency/genetics
MH  - Sodium Channels/*physiology
MH  - Time Factors
EDAT- 2001/08/30 10:00
MHDA- 2002/01/12 10:01
CRDT- 2001/08/30 10:00
PHST- 2001/08/30 10:00 [pubmed]
PHST- 2002/01/12 10:01 [medline]
PHST- 2001/08/30 10:00 [entrez]
AID - 6/3/153 [pii]
AID - 10.1152/physiolgenomics.2001.6.3.153 [doi]
PST - epublish
SO  - Physiol Genomics. 2001 Aug 28;6(3):153-8. doi: 
      10.1152/physiolgenomics.2001.6.3.153.

PMID- 11285251
OWN - NLM
STAT- MEDLINE
DCOM- 20010705
LR  - 20190513
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 10
IP  - 8
DP  - 2001 Apr 1
TI  - "Mitotic drive" of expanded CTG repeats in myotonic dystrophy type 1 (DM1).
PG  - 855-63
AB  - In myotonic dystrophy type 1 (DM1), an expanded CTG repeat shows repeat size 
      instability in somatic and germ line tissues with a strong bias toward further 
      expansion. To investigate the mechanism of this expansion bias, 29 DM1 and six 
      normal lymphoblastoid cell lines (LBCLs) were single-cell cloned from blood cells 
      of 18 DM1 patients and six normal subjects. In all 29 cell lines, the expanded 
      CTG repeat alleles gradually shifted toward further expansion by "step-wise" 
      mutations. Of these 29 cell lines, eight yielded a rapidly proliferating mutant 
      with a gain of large repeat size that became the major allele population, 
      eventually replacing the progenitor allele population. By mixing cell lines with 
      different repeat expansions, we found that cells with larger CTG repeat expansion 
      had a growth advantage over those with smaller expansions in culture. This growth 
      advantage was attributable to increased cell proliferation mediated by Erk1,2 
      activation, which is negatively regulated by p21(WAF1). This phenomenon, which we 
      designated "mitotic drive" , is a novel mechanism which can explain the expansion 
      bias of DM1 CTG repeat instability at the tissue level, on a basis independent of 
      the DNA-based expansion models. The lifespans of the DM1 LBCLs were significantly 
      shorter than normal cell lines. Thus, we propose a hypothesis that DM1 LBCLs 
      drive themselves to extinction through a process related to increased 
      proliferation.
FAU - Khajavi, M
AU  - Khajavi M
AD  - Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, 
      TX 77030, USA.
FAU - Tari, A M
AU  - Tari AM
FAU - Patel, N B
AU  - Patel NB
FAU - Tsuji, K
AU  - Tsuji K
FAU - Siwak, D R
AU  - Siwak DR
FAU - Meistrich, M L
AU  - Meistrich ML
FAU - Terry, N H
AU  - Terry NH
FAU - Ashizawa, T
AU  - Ashizawa T
LA  - eng
GR  - CA78973-02/CA/NCI NIH HHS/United States
GR  - P01 CA-06294/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Cyclins)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Cell Division
MH  - Cell Line
MH  - Cell Survival
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Cyclins/metabolism
MH  - Enzyme Activation
MH  - Humans
MH  - Mitogen-Activated Protein Kinase 1/metabolism
MH  - Mitogen-Activated Protein Kinase 3
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Mitosis/*physiology
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2001/04/04 10:00
MHDA- 2001/07/06 10:01
CRDT- 2001/04/04 10:00
PHST- 2001/04/04 10:00 [pubmed]
PHST- 2001/07/06 10:01 [medline]
PHST- 2001/04/04 10:00 [entrez]
AID - 10.1093/hmg/10.8.855 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2001 Apr 1;10(8):855-63. doi: 10.1093/hmg/10.8.855.

PMID- 11260612
OWN - NLM
STAT- MEDLINE
DCOM- 20010719
LR  - 20190906
IS  - 0197-3851 (Print)
IS  - 0197-3851 (Linking)
VI  - 21
IP  - 3
DP  - 2001 Mar
TI  - A successful strategy for preimplantation genetic diagnosis of myotonic dystrophy 
      using multiplex fluorescent PCR.
PG  - 223-32
AB  - The most common form of inherited muscular dystrophy in adults is myotonic 
      dystrophy (DM), an autosomal-dominant disease caused by the expansion of an 
      unstable CTG repeat sequence in the 3' untranslated region of the myotonin 
      protein kinase (DMPK) gene. Expanded (mutant) CTG repeat sequences are refractory 
      to conventional PCR, but alleles with a number of repeats within the normal range 
      can be readily amplified and detected. Preimplantation genetic diagnosis (PGD) of 
      DM has been successfully applied. However, a misdiagnosis using the reported 
      protocol was recently documented. Two new PGD protocols for DM have been 
      developed which utilise multiplex fluorescent PCR. Ideally a linked polymorphic 
      marker, APOC2, is amplified in addition to the normal DMPK alleles, thus 
      providing a back-up diagnostic result. However, the two couples reported in the 
      present study were not fully informative at the APOC2 locus and so an unlinked 
      short tandem repeat (STR) marker, D21S1414, was substituted. The highly 
      polymorphic nature of the D21S1414, DMPK and APOC2 loci means that a very simple 
      genetic fingerprint can be generated by analyses of these loci. This allows most 
      DNA contaminants to be detected. Contamination is a significant problem for PGD 
      and is the primary reason for the inclusion of D21S1414 and APOC2 in this 
      protocol. This paper reports the first clinical experience and pregnancies 
      following PGD for DM using a multiplex fluorescent PCR protocol.
CI  - Copyright 2001 John Wiley & Sons, Ltd.
FAU - Piyamongkol, W
AU  - Piyamongkol W
AD  - UCL Centre for Preimplantation Genetic Diagnosis and the Assisted Conception 
      Unit, Department of Obstetrics & Gynaecology, University College London, 86-96 
      Chenies Mews, London WC1E 6HX, UK.
FAU - Harper, J C
AU  - Harper JC
FAU - Sherlock, J K
AU  - Sherlock JK
FAU - Doshi, A
AU  - Doshi A
FAU - Serhal, P F
AU  - Serhal PF
FAU - Delhanty, J D
AU  - Delhanty JD
FAU - Wells, D
AU  - Wells D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Prenat Diagn
JT  - Prenatal diagnosis
JID - 8106540
SB  - IM
MH  - Adult
MH  - Female
MH  - Fluorescence
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis
MH  - *Polymerase Chain Reaction/methods
MH  - Predictive Value of Tests
MH  - Pregnancy
MH  - *Preimplantation Diagnosis/methods
EDAT- 2001/03/22 10:00
MHDA- 2001/07/20 10:01
CRDT- 2001/03/22 10:00
PHST- 2001/03/22 10:00 [pubmed]
PHST- 2001/07/20 10:01 [medline]
PHST- 2001/03/22 10:00 [entrez]
AID - 10.1002/1097-0223(200103)21:3<223::AID-PD52>3.0.CO;2-3 [pii]
AID - 10.1002/1097-0223(200103)21:3<223::aid-pd52>3.0.co;2-3 [doi]
PST - ppublish
SO  - Prenat Diagn. 2001 Mar;21(3):223-32. doi: 
      10.1002/1097-0223(200103)21:3<223::aid-pd52>3.0.co;2-3.

PMID- 11254171
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20150901
IS  - 0255-6596 (Print)
IS  - 0255-6596 (Linking)
VI  - 25
IP  - 1
DP  - 2001 Jan
TI  - Delineation of CTG repeats and clinical features in a Taiwanese myotonic 
      dystrophy family.
PG  - 40-4
AB  - Myotonic dystrophy (DM) is an inherited, autosomal dominant muscular disease 
      which is primarily caused by a CTG trinucleotide expansion mutation on chromosome 
      19q13.3. The size of this trinucleotide repeat is related both to the age of 
      onset and to the severity of the clinical manifestation. This disease is very 
      rare in Taiwan, and clinical and genetic study on DM has not yet been documented 
      in this area. Here, we present both clinical features and degrees of CTG 
      expansion for a Taiwanese DM family. All of the DM patients examined in this 
      family showed obvious clinical manifestations by age 30, which included facial 
      and limb muscle weakness with atrophy, myotonia, and ptosis. In addition, 
      individual DM members also exhibited variable phenotypes, which may reflect the 
      complexity of the pathogenic mechanism. Because the collection of blood specimens 
      was considered to be an invasive procedure, a genetic study on this DM family was 
      performed using buccal cells. Our results confirmed that four members showing 
      classic symptoms of DM had CTG repeat expansion in the DMI locus, and that one 
      member with ptosis and minor muscle weakness in the right foot was a normal 
      homozygote for CTG repeat. These data demonstrate that buccal cells can provide 
      clear and reliable results, and thus, are suitable for a family study of DM.
FAU - Jou, S B
AU  - Jou SB
AD  - Department of Neurology, China Medical College Hospital, Taichung, Taiwan, ROC.
FAU - Lin, H M
AU  - Lin HM
FAU - Pan, H
AU  - Pan H
FAU - Chiu, Y L
AU  - Chiu YL
FAU - Li, S Y
AU  - Li SY
FAU - Lee, C C
AU  - Lee CC
FAU - Hsiao, K M
AU  - Hsiao KM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China (Republic : 1949- )
TA  - Proc Natl Sci Counc Repub China B
JT  - Proceedings of the National Science Council, Republic of China. Part B, Life 
      sciences
JID - 8502426
SB  - IM
MH  - Alleles
MH  - Blotting, Southern
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Mouth Mucosa/ultrastructure
MH  - Myotonic Dystrophy/epidemiology/*genetics
MH  - Pedigree
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Taiwan/epidemiology
MH  - *Trinucleotide Repeat Expansion
EDAT- 2001/03/20 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/03/20 10:00
PHST- 2001/03/20 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/03/20 10:00 [entrez]
PST - ppublish
SO  - Proc Natl Sci Counc Repub China B. 2001 Jan;25(1):40-4.

PMID- 11124939
OWN - NLM
STAT- MEDLINE
DCOM- 20010621
LR  - 20210209
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 276
IP  - 11
DP  - 2001 Mar 16
TI  - RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.
PG  - 7820-6
AB  - An RNA CUG triplet repeat binding protein, CUGBP1, regulates splicing and 
      translation of various RNAs. Expansion of RNA CUG repeats in the 3'-untranslated 
      repeat of the mutant myotonin protein kinase (DMPK) mRNA in myotonic dystrophy 
      (DM) is associated with alterations in binding activity of CUGBP1. To investigate 
      whether CUGBP1 is directly affected by expansion of CUG repeats in DM tissues, we 
      examined the intracellular status of CUGBP1 in DM patients as well as in cultured 
      cells over expressing RNA CUG repeats. The analysis of RNA-protein complexes 
      showed that, in control tissues, the majority of CUGBP1 is free of RNA, whereas 
      in DM patients the majority of CUGBP1 is associated with RNA containing CUG 
      repeats. Similarly to DM patients, overexpression of RNA CUG repeats in cultured 
      cells results in the re-allocation of CUGBP1 from a free state to the RNA.protein 
      complexes containing CUG repeats. CUG repeat-dependent translocation of CUGBP1 
      into RNA-protein complexes is associated with increased levels of CUGBP1 protein 
      and its binding activity. Experiments with cyclohexamide-dependent block of 
      protein synthesis showed that the half-life of CUGBP1 is increased in cells 
      expressing CUG repeats. Alteration of CUGBP1 in DM is accompanied by alteration 
      in translation of a transcription factor CCAAT/enhancer-binding protein beta 
      (C/EBPbeta), which has been previously described to be a target of CUGBP1. 
      Analysis of C/EBPbeta isoforms in DM patients with altered levels of CUGBP1 
      showed that translation of a dominant negative isoform, LIP, is induced by 
      CUGBP1. Results of this paper demonstrate that the expansion of CUG repeats in DM 
      affects RNA-binding proteins and leads to alteration in RNA processing.
FAU - Timchenko, N A
AU  - Timchenko NA
AD  - Department of Pathology and Huffington Center on Aging, Baylor College of 
      Medicine, Houston, Texas 77030, USA.
FAU - Cai, Z J
AU  - Cai ZJ
FAU - Welm, A L
AU  - Welm AL
FAU - Reddy, S
AU  - Reddy S
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - Timchenko, L T
AU  - Timchenko LT
LA  - eng
GR  - AG00765-01/AG/NIA NIH HHS/United States
GR  - AG16392/AG/NIA NIH HHS/United States
GR  - AR10D443887/AR/NIAMS NIH HHS/United States
GR  - GM55188-01/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20001221
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (CCAAT-Enhancer-Binding Protein-beta)
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Animals
MH  - CCAAT-Enhancer-Binding Protein-beta/genetics
MH  - CELF1 Protein
MH  - COS Cells
MH  - Myotonic Dystrophy/genetics
MH  - RNA/*chemistry/metabolism
MH  - RNA, Messenger/metabolism
MH  - RNA-Binding Proteins/analysis/*metabolism
MH  - Ribonucleoproteins/analysis/*metabolism
MH  - *Trinucleotide Repeats
EDAT- 2000/12/23 00:00
MHDA- 2001/06/22 10:01
CRDT- 2000/12/23 00:00
PHST- 2000/12/23 00:00 [pubmed]
PHST- 2001/06/22 10:01 [medline]
PHST- 2000/12/23 00:00 [entrez]
AID - S0021-9258(19)32121-0 [pii]
AID - 10.1074/jbc.M005960200 [doi]
PST - ppublish
SO  - J Biol Chem. 2001 Mar 16;276(11):7820-6. doi: 10.1074/jbc.M005960200. Epub 2000 
      Dec 21.

PMID- 11098287
OWN - NLM
STAT- MEDLINE
DCOM- 20010531
LR  - 20101118
IS  - 0300-9009 (Print)
IS  - 0300-9009 (Linking)
VI  - 100
IP  - 3
DP  - 2000 Sep
TI  - The expanding clinical and genetic spectrum of the myotonic dystrophies.
PG  - 151-5
AB  - Core features of the dominantly inherited myotonic dystrophies are myotonia, 
      muscle weakness and cataract. Classic myotonic dystrophy (Steinert's disease) has 
      been defined as a genetic entity by the underlying CTG repeat expansion on 
      chromosome 19q13.3 (= DM1 locus). Later on, another disorder similar to but 
      different from myotonic dystrophy was described as proximal myotonic myopathy 
      (PROMM). The majority of PROMM families have been linked to a recently discovered 
      locus on chromosome 3q21 (= DM2 locus).--This article analyses the clinical 
      features of 70 patients from 14 German PROMM families linked to the 3q locus. In 
      contrast to Steinert's disease, these patients did not reveal mental deficiency; 
      no congenital type was found; weakness was mainly located in the proximal leg 
      muscles; clinical myotonia was very mild and sometimes absent; episodes of pain 
      occurred. In the majority of patients, the disorder seems to be more benign 
      compared to Steinert's disease. However, life threatening cardiac involvement is 
      possible; rarely, muscle weakness may progress until the patient is 
      bedridden.--Some families with a PROMM-like phenotype do not link to the locus on 
      3q. The group of the myotonic dystrophies will get new members in the future.
FAU - Ricker, K
AU  - Ricker K
AD  - Department of Neurology, University of Wurzburg, Germany. 
      Kenneth.Ricker@Z-online.de
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cataract/etiology/physiopathology
MH  - Female
MH  - Genetic Linkage/genetics
MH  - Germany/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle Weakness/etiology/*physiopathology
MH  - Myotonia/etiology/physiopathology
MH  - Myotonic Disorders/complications/genetics/*physiopathology
MH  - Myotonic Dystrophy/diagnosis/genetics/physiopathology
MH  - Pedigree
EDAT- 2000/12/01 11:00
MHDA- 2001/06/02 10:01
CRDT- 2000/12/01 11:00
PHST- 2000/12/01 11:00 [pubmed]
PHST- 2001/06/02 10:01 [medline]
PHST- 2000/12/01 11:00 [entrez]
PST - ppublish
SO  - Acta Neurol Belg. 2000 Sep;100(3):151-5.

PMID- 11078267
OWN - NLM
STAT- MEDLINE
DCOM- 20001201
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 85
IP  - 5
DP  - 2000 Mar 1
TI  - Comparison of coronary stent expansion by intravascular ultrasonic imaging in 
      younger versus older patients with diabetes mellitus.
PG  - 559-62
AB  - The poor long-term outcome in young diabetic patients receiving stents is not 
      well understood. The purpose of this study was to characterize the pastprocedural 
      results of stent placement in diabetic patients using intravascular ultrasound to 
      identify factors that might be associated with poor clinical outcome. The acute 
      dimensions from intravascular ultrasound studies after stent deployment at 5 
      sites were measured from 39 coronary segments from patients with diabetes 
      mellitus (DM) and 161 segments from nondiabetic patients (non-DM). Within these 2 
      groups, segments were subgrouped into young (y) and old (o) in reference to the 
      mean study age of 64 years, forming 4 groups: yDM (n = 20), y non-DM (n = 65), 
      oDM (n = 19), and o non-DM (n = 96). Results are reported as mean +/- 1 SD. 
      Diabetic patients had smaller mean lumen area within the treated segment than o 
      non-DM (8.37+/-2.59 vs. 9.11+/-3.35 mm2, p<0.01). These differences were more 
      pronounced at the distal reference vessel lumen of yDM than y non-DM (7.6+/-2.3 
      vs. 10.3+/-4.5 mm2, p<0.003), and were associated with greater percent plaque 
      area in the distal reference vessel (43.4+/-13% vs. 34.1+/-11.2%, p<0.003). In 
      young diabetic patients undergoing elective stent placement, underexpansion of 
      the stented segment is common, which may contribute to the relatively poor 
      long-term outcome in these patients. We suggest that when stenting is the 
      procedure of choice in this subgroup of high-risk patients, special attention 
      should be given to optimizing lumen dimensions.
FAU - Gilutz, H
AU  - Gilutz H
AD  - Division of Cardiovascular Medicine, Stanford University School of Medicine, 
      California, USA. gilutz@bgumail.bgu.ac.il
FAU - Russo, R J
AU  - Russo RJ
FAU - Tsameret, I
AU  - Tsameret I
FAU - Fitzgerald, P J
AU  - Fitzgerald PJ
FAU - Yock, P G
AU  - Yock PG
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Cohort Studies
MH  - Coronary Disease/*diagnostic imaging/therapy
MH  - Coronary Vessels/*diagnostic imaging
MH  - Diabetic Angiopathies/*diagnostic imaging/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Factors
MH  - *Stents
MH  - Treatment Outcome
MH  - *Ultrasonography, Interventional
EDAT- 2000/11/15 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/11/15 11:00
PHST- 2000/11/15 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/15 11:00 [entrez]
AID - S0002-9149(99)00811-5 [pii]
AID - 10.1016/s0002-9149(99)00811-5 [doi]
PST - ppublish
SO  - Am J Cardiol. 2000 Mar 1;85(5):559-62. doi: 10.1016/s0002-9149(99)00811-5.

PMID- 11027837
OWN - NLM
STAT- MEDLINE
DCOM- 20001130
LR  - 20191025
IS  - 0301-472X (Print)
IS  - 0301-472X (Linking)
VI  - 28
IP  - 10
DP  - 2000 Oct
TI  - Increased expansion and differentiation of cord blood products using a two-step 
      expansion culture.
PG  - 1181-6
AB  - OBJECTIVE: [corrected] The use of allogeneic cord blood (CB) products as a source 
      of cellular support for patients receiving high-dose chemotherapy has been 
      limited primarily to smaller children due to the low numbers of cells in a CB 
      unit. Ex vivo expansion of CB cells has been proposed as a method to increase the 
      number of cells available for transplantation. Following high-dose chemotherapy 
      administration, we transplanted adult patients with CB expanded in static culture 
      for 10 days, in DM containing stem cell factor (SCF), granulocyte 
      colony-stimulating factor (G-CSF), and megakaryocyte growth and development 
      factor (MGDF). Patients achieved neutrophil engraftment in a median of 26 days 
      (range 15 to 45). In an attempt to hasten the time to neutrophil engraftment, we 
      developed a two-step culture system that results in increased expansion of total 
      nucleated cells and further maturation of neutrophil precursors. MATERIALS AND 
      METHODS: CD34(+) cells isolated from CB products were cultured for 7 days at 37 
      degrees C in 100-mL Teflon culture bags containing 50 mL of DM containing SCF, 
      G-CSF, and MGDF (100 ng/mL). The cells were harvested from these bags after 7 
      days of incubation at 37 degrees C and transferred to 1-L Teflon bags containing 
      1 L of DM plus SCF, G-CSF, and MGDF. After a second culture period of 7 days, the 
      cells were harvested, washed, and assayed for mature (granulocyte-macrophage 
      colony-forming cells [GM-CFC]) and primitive progenitor cells (high proliferative 
      potential colony-forming cells [HPP-CFC]). RESULTS: The two-step cultures 
      resulted in a median total nucleated cell expansion of 438-fold (range 286 to 
      952, N = 11); the original one-step cultures resulted in a median expansion of 
      98-fold (range 59 to 350, N = 5). Equivalent expansion of committed progenitor 
      cells (GM-CFC) and primitive progenitor cells (HPP-CFC) was obtained. CD34(+) 
      cells were expanded a median of 29-fold in the two-step cultures (N = 11). The 
      two-step culture contained more mature neutrophil cells, by morphologic 
      examination, than the one-step cultures, similar to ex vivo expanded peripheral 
      blood progenitor cells (PBPC). CONCLUSION: The two-step ex vivo expansion 
      conditions described for CB resulted in increased numbers of total nucleated 
      cells, GM-CFC, HPP-CFC, and CD34(+) cells and morphologically resembled ex vivo 
      expanded PBPC, which have been shown to provide more rapid neutrophil engraftment 
      than unexpanded PBPC. We propose that the availability of increased numbers of 
      expanded CB cells may result in more rapid engraftment of neutrophils following 
      infusion to transplant recipients.
FAU - McNiece, I
AU  - McNiece I
AD  - Experimental Hematology Laboratory, BMT Program, University of Colorado Health 
      Sciences Center, Denver, CO 80262, USA. ian.mcniece@uchsc.edu
FAU - Kubegov, D
AU  - Kubegov D
FAU - Kerzic, P
AU  - Kerzic P
FAU - Shpall, E J
AU  - Shpall EJ
FAU - Gross, S
AU  - Gross S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
RN  - 0 (Antigens, CD34)
RN  - 0 (Culture Media)
RN  - 0 (Stem Cell Factor)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 9014-42-0 (Thrombopoietin)
SB  - IM
MH  - Antigens, CD34/analysis
MH  - Cell Culture Techniques/*methods
MH  - *Cell Differentiation
MH  - *Cell Division
MH  - Cell Separation
MH  - Culture Media
MH  - Fetal Blood/*cytology
MH  - Flow Cytometry
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - Granulocytes/cytology
MH  - Hematopoietic Stem Cells/cytology
MH  - Humans
MH  - Immunophenotyping
MH  - Macrophages/cytology
MH  - Neutrophils/cytology
MH  - Stem Cell Factor/pharmacology
MH  - Thrombopoietin/pharmacology
EDAT- 2000/10/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/12 11:00
PHST- 2000/10/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/12 11:00 [entrez]
AID - S0301-472X(00)00520-8 [pii]
AID - 10.1016/s0301-472x(00)00520-8 [doi]
PST - ppublish
SO  - Exp Hematol. 2000 Oct;28(10):1181-6. doi: 10.1016/s0301-472x(00)00520-8.

PMID- 11013451
OWN - NLM
STAT- MEDLINE
DCOM- 20001027
LR  - 20211203
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Linking)
VI  - 16
IP  - 4
DP  - 2000 Oct
TI  - Molecular anatomy of CTG expansion in myotonin protein kinase gene among myotonic 
      dystrophy patients from eastern India.
PG  - 372
AB  - We have studied the CTG repeat sizes in the DMPK gene and six biallelic markers 
      which are in complete linkage disequlibrium with Caucasian DM patients, to 
      identify any common founder haplotype in 30 clinically diagnosed unrelated DM 
      patients from eastern India. Our results revealed that in 27 patients (90%), CTG 
      expansion took place on a DraIII(-) - HhaI(-) - Alu(+) - HinfI(+) - Fnu4H I(-) - 
      TaqI(+) haplotype (haplotype I), similar to what have been published for 
      Caucasoid and other DM patients. However, in three patients (10%), the expansion 
      of CTG repeat was on DraIII(+) - HhaI(+) - Alu(+) - HinfI(-) - Fnu4H I(+) - 
      TaqI(-) background (haplotype II), indicating a new haplotype. The distribution 
      of haplotypes in 52 normal individuals of eastern India revealed that percentage 
      of haplotypes I and II were 23.1% and 7.7% respectively in normal chromosomes. 
      Haplotype II is absent among Caucasian DM patients as well as normal individuals 
      indicating that this particular haplotype may be characteristic of the Indian 
      population. Hum Mutat 16:372, 2000.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Basu, P
AU  - Basu P
AD  - Crystallography and Molecular Biology Division, Saha Institute of Nuclear 
      Physics, 1/AF, Bidhan Nagar, Calcutta-700 064.
FAU - Gangopadhaya, P K
AU  - Gangopadhaya PK
FAU - Mukherjee, S C
AU  - Mukherjee SC
FAU - Das, S K
AU  - Das SK
FAU - Sinha, K K
AU  - Sinha KK
FAU - Bhattacharyya, N P
AU  - Bhattacharyya NP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Female
MH  - Haplotypes/genetics
MH  - Humans
MH  - India/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*enzymology/epidemiology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - Trinucleotide Repeat Expansion/*genetics
EDAT- 2000/10/03 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/03 11:00
PHST- 2000/10/03 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/03 11:00 [entrez]
AID - 10.1002/1098-1004(200010)16:4<372::AID-HUMU13>3.0.CO;2-G [pii]
AID - 10.1002/1098-1004(200010)16:4<372::AID-HUMU13>3.0.CO;2-G [doi]
PST - ppublish
SO  - Hum Mutat. 2000 Oct;16(4):372. doi: 
      10.1002/1098-1004(200010)16:4<372::AID-HUMU13>3.0.CO;2-G.

PMID- 11001736
OWN - NLM
STAT- MEDLINE
DCOM- 20000921
LR  - 20211203
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 289
IP  - 5485
DP  - 2000 Sep 8
TI  - Deconstructing myotonic dystrophy.
PG  - 1701-2
AB  - Triplet repeat diseases are disorders in which there is expansion of a repeat 
      sequence of three nucleotides in the affected gene. Although the pathology 
      usually results from production of a defective protein, myotonic dystrophy (DM) 
      has proved to be a puzzle because the expanded repeats appear in a non-coding 
      region of the affected DMPK gene. In a Perspective, Tapscott explains how 
      findings from a new mouse model of DM (Mankodi et al.) could solve this paradox.
FAU - Tapscott, S J
AU  - Tapscott SJ
AD  - Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 
      98109, USA. stapscot@fhcrc.org
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (SIX5 protein, human)
RN  - 0 (Six5 protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
CON - Science. 2000 Sep 8;289(5485):1769-73. PMID: 10976074
MH  - 3' Untranslated Regions
MH  - Animals
MH  - Anticipation, Genetic
MH  - Cataract/etiology
MH  - Chromosomes, Human, Pair 19
MH  - Chromosomes, Human, Pair 3
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Heart Conduction System/physiopathology
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Mice
MH  - Mice, Knockout
MH  - Muscle, Skeletal/metabolism/pathology/physiopathology
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology/physiopathology
MH  - Myotonin-Protein Kinase
MH  - Phenotype
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - RNA Processing, Post-Transcriptional
MH  - RNA, Messenger/*genetics/metabolism
MH  - RNA-Binding Proteins/metabolism
MH  - *Trinucleotide Repeat Expansion
EDAT- 2000/09/23 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/09/23 11:00
PHST- 2000/09/23 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/09/23 11:00 [entrez]
AID - 10.1126/science.289.5485.1701 [doi]
PST - ppublish
SO  - Science. 2000 Sep 8;289(5485):1701-2. doi: 10.1126/science.289.5485.1701.

PMID- 10970838
OWN - NLM
STAT- MEDLINE
DCOM- 20001024
LR  - 20240104
IS  - 0261-4189 (Print)
IS  - 1460-2075 (Electronic)
IS  - 0261-4189 (Linking)
VI  - 19
IP  - 17
DP  - 2000 Sep 1
TI  - Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with 
      myotonic dystrophy.
PG  - 4439-48
AB  - Myotonic dystrophy (DM1) is an autosomal dominant neuromuscular disorder 
      associated with a (CTG)(n) expansion in the 3'-untranslated region of the DM1 
      protein kinase (DMPK) gene. To explain disease pathogenesis, the RNA dominance 
      model proposes that the DM1 mutation produces a gain-of-function at the RNA level 
      in which CUG repeats form RNA hairpins that sequester nuclear factors required 
      for proper muscle development and maintenance. Here, we identify the triplet 
      repeat expansion (EXP) RNA-binding proteins as candidate sequestered factors. As 
      predicted by the RNA dominance model, binding of the EXP proteins is specific for 
      dsCUG RNAs and proportional to the size of the triplet repeat expansion. 
      Remarkably, the EXP proteins are homologous to the Drosophila muscleblind 
      proteins required for terminal differentiation of muscle and photoreceptor cells. 
      EXP expression is also activated during mammalian myoblast differentiation, but 
      the EXP proteins accumulate in nuclear foci in DM1 cells. We propose that DM1 
      disease is caused by aberrant recruitment of the EXP proteins to the DMPK 
      transcript (CUG)(n) expansion.
FAU - Miller, J W
AU  - Miller JW
AD  - Department of Molecular Genetics and Microbiology, Centers for Gene Therapy and 
      Mammalian Genetics, University of Florida College of Medicine, Gainesville, FL 
      32610, USA.
FAU - Urbinati, C R
AU  - Urbinati CR
FAU - Teng-Umnuay, P
AU  - Teng-Umnuay P
FAU - Stenberg, M G
AU  - Stenberg MG
FAU - Byrne, B J
AU  - Byrne BJ
FAU - Thornton, C A
AU  - Thornton CA
FAU - Swanson, M S
AU  - Swanson MS
LA  - eng
GR  - R01 AR046799/AR/NIAMS NIH HHS/United States
GR  - AR46799/AR/NIAMS NIH HHS/United States
GR  - GM46272/GM/NIGMS NIH HHS/United States
GR  - T32AI07110-18/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - EMBO J
JT  - The EMBO journal
JID - 8208664
RN  - 0 (DNA Primers)
RN  - 0 (Drosophila Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (mbl protein, Drosophila)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Cell Nucleus/metabolism
MH  - DNA/metabolism
MH  - DNA Primers
MH  - Drosophila
MH  - *Drosophila Proteins
MH  - HeLa Cells
MH  - Humans
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Nuclear Proteins/*genetics/metabolism
MH  - RNA-Binding Proteins/genetics/metabolism
MH  - Sequence Homology, Amino Acid
MH  - *Trinucleotide Repeats
PMC - PMC302046
EDAT- 2000/09/06 11:00
MHDA- 2001/02/28 10:01
PMCR- 2001/09/01
CRDT- 2000/09/06 11:00
PHST- 2000/09/06 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/06 11:00 [entrez]
PHST- 2001/09/01 00:00 [pmc-release]
AID - cdd422 [pii]
AID - 10.1093/emboj/19.17.4439 [doi]
PST - ppublish
SO  - EMBO J. 2000 Sep 1;19(17):4439-48. doi: 10.1093/emboj/19.17.4439.

PMID- 10958655
OWN - NLM
STAT- MEDLINE
DCOM- 20001121
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 9
IP  - 14
DP  - 2000 Sep 1
TI  - Characterization of a monoclonal antibody panel shows that the myotonic dystrophy 
      protein kinase, DMPK, is expressed almost exclusively in muscle and heart.
PG  - 2167-73
AB  - Myotonic dystrophy (DM) is a multisystemic disorder caused by an inherited CTG 
      repeat expansion which affects three genes encoding the DM protein kinase (DMPK), 
      a homeobox protein Six5 and a protein containing WD repeats. Using a panel of 16 
      monoclonal antibodies against several different DMPK epitopes we detected DMPK, 
      as a single protein of approximately 80 kDa, only in skeletal muscle, cardiac 
      muscle and, to a lesser extent, smooth muscle. Many earlier reports of DMPK with 
      different sizes and tissue distributions appear to be due to antibody 
      cross-reactions with more abundant proteins. One such antibody, MANDM1, was used 
      to isolate two related protein kinases, MRCK alpha and beta, from a human brain 
      cDNA library and the shared epitope was located at the catalytic site of DMPK 
      using a phage-displayed random peptide library. The peptide library also 
      identified an epitope shared between DMPK and a 55 kDa muscle-specific protein. 
      The results suggest that effects of the repeat expansion on the DMPK gene may be 
      responsible for muscle and heart features of DM, whereas clinical changes in 
      other tissues may be due to effects on the other two genes.
FAU - Lam, L T
AU  - Lam LT
AD  - MRIC Biochemistry Group, PP18, North East Wales Institute, Mold Road, Wrexham 
      LL11 2AW, UK.
FAU - Pham, Y C
AU  - Pham YC
FAU - Nguyen, T M
AU  - Nguyen TM
FAU - Morris, G E
AU  - Morris GE
LA  - eng
SI  - GENBANK/AF250871
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA, Complementary)
RN  - 0 (Epitopes)
RN  - 0 (Peptide Library)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antibodies, Monoclonal/*chemistry
MH  - Base Sequence
MH  - Blotting, Western
MH  - Brain/metabolism
MH  - Catalytic Domain
MH  - DNA, Complementary/metabolism
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Epitopes
MH  - Gene Library
MH  - Humans
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/metabolism
MH  - Muscle, Smooth/metabolism
MH  - Muscles/*metabolism
MH  - Myocardium/*metabolism
MH  - Myotonic Dystrophy/genetics/metabolism
MH  - Myotonin-Protein Kinase
MH  - Peptide Library
MH  - Protein Serine-Threonine Kinases/*biosynthesis/chemistry/genetics
MH  - Protein Structure, Tertiary
MH  - Sequence Homology, Amino Acid
MH  - Tissue Distribution
MH  - Trinucleotide Repeat Expansion
EDAT- 2000/08/25 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/25 11:00
PHST- 2000/08/25 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/25 11:00 [entrez]
AID - 10.1093/hmg/9.14.2167 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2000 Sep 1;9(14):2167-73. doi: 10.1093/hmg/9.14.2167.

PMID- 10951446
OWN - NLM
STAT- MEDLINE
DCOM- 20000920
LR  - 20190915
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 23
IP  - 9
DP  - 2000 Sep
TI  - Reduced expression of DMAHP/SIX5 gene in myotonic dystrophy muscle.
PG  - 1421-6
AB  - In myotonic dystrophy (DM), the expansion of CTG triplet repeats in the 
      3'-untranslated region of DM-protein kinase (DMPK) is a causal gene mutation. 
      However, the pathogenic molecular mechanism of CTG repeat expansion for DM 
      phenotypic expression is unclear. To investigate this issue, we examined the 
      influence of CTG repeat expansion on the expression levels of DMPK gene and 
      3'-flanking DM locus-associated homeodomain protein (DMAHP)/SIX5 gene in the 
      muscles of DM patients. We isolated RNA from muscle tissues of six DM patients 
      and six controls, and performed a competitive reverse transcriptional polymerase 
      chain reaction (RT-PCR) assay. The total mRNA level of DMAHP/SIX5 was 
      significantly lower in DM than in controls, but the DMPK mRNA level was 
      unchanged. Our results suggest that CTG repeat expansion influences the 
      expression of genes other than DMPK to cause the DM phenotype.
CI  - Copyright 2000 John Wiley & Sons, Inc.
FAU - Inukai, A
AU  - Inukai A
AD  - Department of Neurology, Nagoya University School of Medicine, Japan.
FAU - Doyu, M
AU  - Doyu M
FAU - Kato, T
AU  - Kato T
FAU - Liang, Y
AU  - Liang Y
FAU - Kuru, S
AU  - Kuru S
FAU - Yamamoto, M
AU  - Yamamoto M
FAU - Kobayashi, Y
AU  - Kobayashi Y
FAU - Sobue, G
AU  - Sobue G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (SIX5 protein, human)
SB  - IM
MH  - Adult
MH  - Female
MH  - Homeodomain Proteins/genetics/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*metabolism
MH  - Myotonic Dystrophy/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
EDAT- 2000/08/22 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/08/22 11:00
PHST- 2000/08/22 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/08/22 11:00 [entrez]
AID - 10.1002/1097-4598(200009)23:9<1421::AID-MUS14>3.0.CO;2-Y [pii]
AID - 10.1002/1097-4598(200009)23:9<1421::aid-mus14>3.0.co;2-y [doi]
PST - ppublish
SO  - Muscle Nerve. 2000 Sep;23(9):1421-6. doi: 
      10.1002/1097-4598(200009)23:9<1421::aid-mus14>3.0.co;2-y.

PMID- 10932272
OWN - NLM
STAT- MEDLINE
DCOM- 20000821
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 55
IP  - 3
DP  - 2000 Aug 8
TI  - Proximal myotonic myopathy: evidence for anticipation in families with linkage to 
      chromosome 3q.
PG  - 383-8
AB  - OBJECTIVE: To investigate anticipation in proximal myotonic myopathy (PROMM). 
      BACKGROUND: PROMM is a recently described autosomal dominantly inherited disorder 
      similar to but distinct from myotonic dystrophy (DM). DM belongs to the group of 
      inherited disorders with anticipation caused by an unstable trinucleotide repeat 
      expansion. In PROMM, no mutation has been identified, although PROMM has recently 
      been mapped to a gene locus on chromosome 3q. METHODS: We investigated 10 German 
      families with the PROMM phenotype and linkage to chromosome 3q. We based our 
      analysis of anticipation on the age of disease onset. Anticipation was assumed if 
      the offspring had first symptoms earlier in life than his or her affected parent. 
      For statistical analysis Independence Estimating Equations (IEE) and a 
      Monte-Carlo bootstrap were used. RESULTS: In 27 affected living parent-offspring 
      pairs from these 10 families, the mean difference of disease onset was 18.8 years 
      with either statistical analysis (p < 10-14 and p < 10-15). The mean disease 
      onset interval in years was greater in father-offspring as compared to the 
      mother-offspring pairs (p < 0.05; IEE). CONCLUSION: Our findings suggest the 
      occurrence of anticipation in parent-offspring pairs from families with the PROMM 
      phenotype and linkage to chromosome 3q. The different disease onset intervals in 
      mother-offspring and father-offspring pairs could indicate a mild 
      parent-of-origin effect. These observations are compatible with the suggestion 
      that PROMM, like DM, may be a trinucleotide repeat associated disorder. In 
      contrast to DM, anticipation in PROMM is milder, a congenital form does not seem 
      to occur, and fertility does not appear to be affected.
FAU - Schneider, C
AU  - Schneider C
AD  - Department of Neurology, University of Wurzburg, Germany. 
      chris.schneider@mail.uni-wuerzburg.de
FAU - Ziegler, A
AU  - Ziegler A
FAU - Ricker, K
AU  - Ricker K
FAU - Grimm, T
AU  - Grimm T
FAU - Kress, W
AU  - Kress W
FAU - Reimers, C D
AU  - Reimers CD
FAU - Meinck, H
AU  - Meinck H
FAU - Reiners, K
AU  - Reiners K
FAU - Toyka, K V
AU  - Toyka KV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - *Chromosomes, Human, Pair 3
MH  - Family Health
MH  - Female
MH  - *Genetic Linkage
MH  - Genetic Testing
MH  - Germany/epidemiology
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Monte Carlo Method
MH  - Myotonic Disorders/diagnosis/epidemiology/*genetics
MH  - Pedigree
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
EDAT- 2000/08/10 11:00
MHDA- 2000/08/29 11:01
CRDT- 2000/08/10 11:00
PHST- 2000/08/10 11:00 [pubmed]
PHST- 2000/08/29 11:01 [medline]
PHST- 2000/08/10 11:00 [entrez]
AID - 10.1212/wnl.55.3.383 [doi]
PST - ppublish
SO  - Neurology. 2000 Aug 8;55(3):383-8. doi: 10.1212/wnl.55.3.383.

PMID- 10927802
OWN - NLM
STAT- MEDLINE
DCOM- 20000906
LR  - 20211203
IS  - 0003-9942 (Print)
IS  - 0003-9942 (Linking)
VI  - 57
IP  - 8
DP  - 2000 Aug
TI  - A patient with 2 different repeat expansion mutations.
PG  - 1199-203
AB  - BACKGROUND: Many inherited progressive encephalopathies have a poor outcome, and 
      some are caused by repeat expansion mutations. How would the presence of 2 
      different expansion mutations affect the phenotype? OBJECTIVE: To describe a 
      patient who has 2 distinct, rare genetic disorders: myotonic dystrophy (DM, OMIM 
      160900) and progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1, 
      OMIM 254800). Both conditions are caused by repeat expansion mutations. They 
      affect the central nervous system causing mental retardation, but also produce a 
      wide spectrum of disabilities in daily living. SETTING: Referral center. METHODS: 
      Clinical description with accompanying photographs, electroencephalography and 
      magnetic resonance imaging; DNA analysis of both of the mutations and chromosomal 
      analysis with prometaphase spreads. RESULTS: The patient had clinical 
      characteristics and findings of both myotonic dystrophy and progressive myoclonus 
      epilepsy of the Unverricht-Lundborg type. Electroencephalographic recordings over 
      a 3-year period showed typical findings for myoclonus epilepsy. The patient had 
      no gross anomalies in brain magnetic resonance imaging. She had a normal 
      karyotype, and both of the diagnoses were confirmed at the molecular level with 
      the direct detection of the mutations. CONCLUSIONS: Despite having 2 different 
      progressive inherited disorders affecting the central nervous system, the 
      patient, at age 28 years, showed only mild mental retardation with very slow 
      progression. However, clear deterioration in activities of daily living has taken 
      place during last 3 years. Arch Neurol. 2000;57:1199-1203
FAU - Nokelainen, P
AU  - Nokelainen P
AD  - Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 
      9DU, England. pnokelai@molbiol.ox.ac.uk
FAU - Heiskala, H
AU  - Heiskala H
FAU - Lehesjoki, A E
AU  - Lehesjoki AE
FAU - Kaski, M
AU  - Kaski M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arch Neurol
JT  - Archives of neurology
JID - 0372436
RN  - 0 (CSTB protein, human)
RN  - 0 (Cystatins)
RN  - 0 (DMPK protein, human)
RN  - 88844-95-5 (Cystatin B)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
CIN - Arch Neurol. 2000 Aug;57(8):1110-2. PMID: 10927789
CIN - Arch Neurol. 2001 Jun;58(6):1022. PMID: 11405822
MH  - Adult
MH  - Blotting, Southern
MH  - Cystatin B
MH  - Cystatins/genetics
MH  - DNA Mutational Analysis
MH  - Electromyography
MH  - Exons/genetics
MH  - Facies
MH  - Female
MH  - Humans
MH  - Intellectual Disability/*genetics
MH  - Magnetic Resonance Imaging
MH  - Myotonic Dystrophy/diagnosis/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Phenotype
MH  - Polymorphism, Genetic
MH  - Promoter Regions, Genetic/genetics
MH  - Protein Serine-Threonine Kinases/genetics
MH  - *Trinucleotide Repeat Expansion
MH  - Unverricht-Lundborg Syndrome/diagnosis/*genetics
EDAT- 2000/08/06 11:00
MHDA- 2000/09/09 11:01
CRDT- 2000/08/06 11:00
PHST- 2000/08/06 11:00 [pubmed]
PHST- 2000/09/09 11:01 [medline]
PHST- 2000/08/06 11:00 [entrez]
AID - nob8462 [pii]
AID - 10.1001/archneur.57.8.1199 [doi]
PST - ppublish
SO  - Arch Neurol. 2000 Aug;57(8):1199-203. doi: 10.1001/archneur.57.8.1199.

PMID- 10909850
OWN - NLM
STAT- MEDLINE
DCOM- 20001026
LR  - 20211203
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 8
IP  - 7
DP  - 2000 Jul
TI  - Myotonic dystrophy (DM) protein kinase levels in congenital and adult DM 
      patients.
PG  - 507-12
AB  - Myotonic dystrophy is caused by a (CTG)n trinucleotide repeat expansion located 
      in the 3' untranslated region of the myotonic dystrophy protein kinase gene 
      (DMPK). To date, the disease mechanism has proven elusive. The mutation would not 
      be expected to affect kinase function and yet the disease is inherited in a 
      dominant fashion. Mutant DMPK transcripts have been demonstrated to be retained 
      in affected cell nuclei which could reduce DMPK protein levels and cause disease 
      by haploinsufficiency. An alternate hypothesis is that the expansion confers a 
      toxic gain of function on the transcript. In previous studies, various 52-55 kDa 
      proteins have been detected using antisera targeted against DMPK and a decline of 
      two of these candidates in disease tissues was reported. Current information now 
      suggests that these proteins are not products of the myotonic dystrophy gene. We 
      have characterised an antiserum which has been confirmed to recognise authentic 
      71 and 80 kDa isoforms of DMPK. Determination of the kinase levels in disease 
      tissues with controls for patient age and tissue integrity demonstrates a modest 
      overexpression in adult patients. In tissues from severely affected congenital 
      patients only a slight decline is seen. This data argues against DMPK 
      haploinsufficiency as a disease mechanism.
FAU - Narang, M A
AU  - Narang MA
AD  - Soulange Gauthier Karsh Molecular Genetics Laboratory, Children's Hospital of 
      Eastern Ontario, Ottawa, Canada.
FAU - Waring, J D
AU  - Waring JD
FAU - Sabourin, L A
AU  - Sabourin LA
FAU - Korneluk, R G
AU  - Korneluk RG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Cells, Cultured
MH  - Female
MH  - Humans
MH  - Immunoblotting
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/cytology/enzymology
MH  - Myotonic Dystrophy/congenital/*enzymology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*metabolism
EDAT- 2000/07/26 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/07/26 11:00
PHST- 2000/07/26 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/07/26 11:00 [entrez]
AID - 10.1038/sj.ejhg.5200490 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2000 Jul;8(7):507-12. doi: 10.1038/sj.ejhg.5200490.

PMID- 10878662
OWN - NLM
STAT- MEDLINE
DCOM- 20001016
LR  - 20061115
IS  - 1018-4813 (Print)
IS  - 1018-4813 (Linking)
VI  - 8
IP  - 6
DP  - 2000 Jun
TI  - Complex patterns of male germline instability and somatic mosaicism in myotonic 
      dystrophy type 1.
PG  - 423-30
AB  - The genetic basis of myotonic dystrophy type 1 (DM1) is the expansion of a CTG 
      repeat in the 3' untranslated region of DM1PK. Once into the disease range, the 
      repeat becomes highly unstable and is biased toward expansion in both somatic and 
      germline tissues. Intergenerational differences usually reveal an increase in 
      allele length, concordant with the clinical anticipation characteristic of DM1, 
      but there have also been cases with intergenerational contractions of the repeat 
      length, accompanied by apparent anticipation. In order to gain a better 
      understanding of this intergenerational behaviour, we have obtained semen samples 
      from six DM males and used single molecule analyses to compare the allele 
      distributions present in their sperm and blood with those of their offspring. We 
      have confirmed that the male germline mutational pathway is distinct from that of 
      the soma, but the extent of variation is highly variable from one individual to 
      another and not obviously correlated with progenitor allele length. Nonetheless, 
      in all cases the alleles present in the father's sperm overlap with those 
      observed in their offspring. These data also provide further indications that the 
      interpretation of intergenerational transmissions by standard analyses is 
      frequently compromised by the masking of germline differences by age-dependent 
      somatic expansion in the parent.
FAU - Martorell, L
AU  - Martorell L
AD  - Servei de Genetica, Hospital de Sant Pau, Barcelona, Spain. genm@santpau.es
FAU - Monckton, D G
AU  - Monckton DG
FAU - Gamez, J
AU  - Gamez J
FAU - Baiget, M
AU  - Baiget M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Alleles
MH  - Anticipation, Genetic
MH  - Child
MH  - Humans
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - *Mosaicism
MH  - Myotonic Dystrophy/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - *Spermatozoa
MH  - Trinucleotide Repeat Expansion
EDAT- 2000/07/06 11:00
MHDA- 2000/10/21 11:01
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/10/21 11:01 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - 10.1038/sj.ejhg.5200478 [doi]
PST - ppublish
SO  - Eur J Hum Genet. 2000 Jun;8(6):423-30. doi: 10.1038/sj.ejhg.5200478.

PMID- 10802668
OWN - NLM
STAT- MEDLINE
DCOM- 20000612
LR  - 20071114
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 25
IP  - 1
DP  - 2000 May
TI  - Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts.
PG  - 110-4
AB  - Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by 
      skeletal muscle wasting, myotonia, cardiac arrhythmia, hyperinsulinaemia, mental 
      retardation and ocular cataracts. The genetic defect in DM is a CTG repeat 
      expansion located in the 3' untranslated region of DMPK and 5' of a 
      homeodomain-encoding gene, SIX5 (formerly DMAHP; refs 2-5). There are three 
      mechanisms by which CTG expansion can result in DM. First, repeat expansion may 
      alter the processing or transport of the mutant DMPK mRNA and consequently reduce 
      DMPK levels. Second, CTG expansion may establish a region of heterochromatin 3' 
      of the repeat sequence and decrease SIX5 transcription. Third, toxic effects of 
      the repeat expansion may be intrinsic to the repeated elements at the level of 
      DNA or RNA (refs 10,11). Previous studies have demonstrated that a dose-dependent 
      loss of Dm15 (the mouse DMPK homologue) in mice produces a partial DM phenotype 
      characterized by decreased development of skeletal muscle force and cardiac 
      conduction disorders. To test the role of Six5 loss in DM, we have analysed a 
      strain of mice in which Six5 was deleted. Our results demonstrate that the rate 
      and severity of cataract formation is inversely related to Six5 dosage and is 
      temporally progressive. Six5+/- and Six5-/- mice show increased steady-state 
      levels of the Na+/K+-ATPase alpha-1 subunit and decreased Dm15 mRNA levels. Thus, 
      altered ion homeostasis within the lens may contribute to cataract formation. As 
      ocular cataracts are a characteristic feature of DM, these results demonstrate 
      that decreased SIX5 transcription is important in the aetiology of DM. Our data 
      support the hypothesis that DM is a contiguous gene syndrome associated with the 
      partial loss of both DMPK and SIX5.
FAU - Sarkar, P S
AU  - Sarkar PS
AD  - Institute for Genetic Medicine, Keck School of Medicine, University of Southern 
      California, Los Angeles, California, USA.
FAU - Appukuttan, B
AU  - Appukuttan B
FAU - Han, J
AU  - Han J
FAU - Ito, Y
AU  - Ito Y
FAU - Ai, C
AU  - Ai C
FAU - Tsai, W
AU  - Tsai W
FAU - Chai, Y
AU  - Chai Y
FAU - Stout, J T
AU  - Stout JT
FAU - Reddy, S
AU  - Reddy S
LA  - eng
GR  - EYO3040/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Six5 protein, mouse)
SB  - IM
MH  - Animals
MH  - Cataract/*etiology/*genetics
MH  - Chromosome Mapping
MH  - Homeodomain Proteins/*genetics/*metabolism
MH  - Loss of Heterozygosity/*genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Restriction Mapping
EDAT- 2000/05/10 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/05/10 09:00
PHST- 2000/05/10 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/05/10 09:00 [entrez]
AID - 10.1038/75500 [doi]
PST - ppublish
SO  - Nat Genet. 2000 May;25(1):110-4. doi: 10.1038/75500.

PMID- 10802667
OWN - NLM
STAT- MEDLINE
DCOM- 20000612
LR  - 20211203
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 25
IP  - 1
DP  - 2000 May
TI  - Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy.
PG  - 105-9
AB  - Expansion of a CTG trinucleotide repeat in the 3' UTR of the gene DMPK at the DM1 
      locus on chromosome 19 causes myotonic dystrophy, a dominantly inherited disease 
      characterized by skeletal muscle dystrophy and myotonia, cataracts and cardiac 
      conduction defects. Targeted deletion of Dm15, the mouse orthologue of human 
      DMPK, produced mice with a mild myopathy and cardiac conduction abnormalities, 
      but without other features of myotonic dystrophy, such as myotonia and cataracts. 
      We, and others, have demonstrated that repeat expansion decreases expression of 
      the adjacent gene SIX5 (refs 7,8), which encodes a homeodomain transcription 
      factor. To determine whether SIX5 deficiency contributes to the myotonic 
      dystrophy phenotype, we disrupted mouse Six5 by replacing the first exon with a 
      beta-galactosidase reporter. Six5-mutant mice showed reporter expression in 
      multiple tissues, including the developing lens. Homozygous mutant mice had no 
      apparent abnormalities of skeletal muscle function, but developed lenticular 
      opacities at a higher rate than controls. Our results suggest that SIX5 
      deficiency contributes to the cataract phenotype in myotonic dystrophy, and that 
      myotonic dystrophy represents a multigenic disorder.
FAU - Klesert, T R
AU  - Klesert TR
AD  - Program in Developmental Biology and Divisions of Human Biology, Fred Hutchinson 
      Cancer Research Center, Seattle, Washington, USA.
FAU - Cho, D H
AU  - Cho DH
FAU - Clark, J I
AU  - Clark JI
FAU - Maylie, J
AU  - Maylie J
FAU - Adelman, J
AU  - Adelman J
FAU - Snider, L
AU  - Snider L
FAU - Yuen, E C
AU  - Yuen EC
FAU - Soriano, P
AU  - Soriano P
FAU - Tapscott, S J
AU  - Tapscott SJ
LA  - eng
GR  - R01 EY004542/EY/NEI NIH HHS/United States
GR  - AR45203/AR/NIAMS NIH HHS/United States
GR  - EY04542/EY/NEI NIH HHS/United States
GR  - HD 24875/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Six5 protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Animals
MH  - Cataract/enzymology/*etiology/*genetics/pathology
MH  - Exons/genetics
MH  - Gene Targeting
MH  - Homeodomain Proteins/*genetics/*metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 2000/05/10 09:00
MHDA- 2000/06/17 09:00
CRDT- 2000/05/10 09:00
PHST- 2000/05/10 09:00 [pubmed]
PHST- 2000/06/17 09:00 [medline]
PHST- 2000/05/10 09:00 [entrez]
AID - 10.1038/75490 [doi]
PST - ppublish
SO  - Nat Genet. 2000 May;25(1):105-9. doi: 10.1038/75490.

PMID- 10797405
OWN - NLM
STAT- MEDLINE
DCOM- 20000519
LR  - 20220330
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 23
IP  - 5
DP  - 2000 May
TI  - CTG triplet repeat expansion in a laryngeal carcinoma from a patient with 
      myotonic dystrophy.
PG  - 804-6
AB  - A 66-year-old Japanese man with myotonic dystrophy (DM) underwent total 
      laryngectomy for laryngeal carcinoma. The size of the expanded DNA fragment (EF) 
      from the leukocytes and normal laryngeal tissues of this patient was only 
      slightly longer than that in normal subjects. EF, however, was markedly longer in 
      the laryngeal carcinoma. These findings support the hypothesis that elongation of 
      the CTG repeat in the DM kinase gene occurs during acquired cell proliferation.
CI  - Copyright 2000 John Wiley & Sons, Inc.
FAU - Osanai, R
AU  - Osanai R
AD  - Department of Otolaryngology, Saitama Medical Center, Saitama Medical School, 
      1981 Kamoda-Tsujido, Kawagoe, Saitama 350-8550, Japan. oryuichi@saitama-med.ac.jp
FAU - Kinoshita, M
AU  - Kinoshita M
FAU - Hirose, K
AU  - Hirose K
FAU - Homma, T
AU  - Homma T
FAU - Kawabata, I
AU  - Kawabata I
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Aged
MH  - Cell Division
MH  - Humans
MH  - Laryngeal Neoplasms/*complications/*genetics/surgery
MH  - Leukocytes/chemistry
MH  - Male
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Trinucleotide Repeat Expansion
EDAT- 2000/05/08 09:00
MHDA- 2000/06/08 09:00
CRDT- 2000/05/08 09:00
PHST- 2000/05/08 09:00 [pubmed]
PHST- 2000/06/08 09:00 [medline]
PHST- 2000/05/08 09:00 [entrez]
AID - 10.1002/(SICI)1097-4598(200005)23:5<804::AID-MUS19>3.0.CO;2-E [pii]
AID - 10.1002/(sici)1097-4598(200005)23:5<804::aid-mus19>3.0.co;2-e [doi]
PST - ppublish
SO  - Muscle Nerve. 2000 May;23(5):804-6. doi: 
      10.1002/(sici)1097-4598(200005)23:5<804::aid-mus19>3.0.co;2-e.

PMID- 10767343
OWN - NLM
STAT- MEDLINE
DCOM- 20000623
LR  - 20240104
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 9
IP  - 8
DP  - 2000 May 1
TI  - Transgenic mice carrying large human genomic sequences with expanded CTG repeat 
      mimic closely the DM CTG repeat intergenerational and somatic instability.
PG  - 1185-94
AB  - Myotonic dystrophy (DM) is caused by a CTG repeat expansion in the 3'UTR of the 
      DM protein kinase (DMPK) gene. A very high level of instability is observed 
      through successive generations and the size of the repeat is generally correlated 
      with the severity of the disease and with age at onset. Furthermore, tissues from 
      DM patients exhibit somatic mosaicism that increases with age. We generated 
      transgenic mice carrying large human genomic sequences with 20, 55 or >300 CTG, 
      cloned from patients from the same affected DM family. Using large human flanking 
      sequences and a large amplification, we demonstrate that the intergenerational 
      CTG repeat instability is reproduced in mice, with a strong bias towards 
      expansions and with the same sex- and size-dependent characteristics as in 
      humans. Moreover, a high level of instability, increasing with age, can be 
      observed in tissues and in sperm. Although we did not observe dramatic expansions 
      (or 'big jumps' over several hundred CTG repeats) as in congenital forms of DM, 
      our model carrying >300 CTG is the first to show instability so close to the 
      human DM situation. Our three models carrying different sizes of CTG repeat 
      provide insight on the different factors modulating the CTG repeat instability.
FAU - Seznec, H
AU  - Seznec H
AD  - INSERM UR383, Hopital Necker-Enfants Malades, Universite Rene Descartes Paris V, 
      Paris, France.
FAU - Lia-Baldini, A S
AU  - Lia-Baldini AS
FAU - Duros, C
AU  - Duros C
FAU - Fouquet, C
AU  - Fouquet C
FAU - Lacroix, C
AU  - Lacroix C
FAU - Hofmann-Radvanyi, H
AU  - Hofmann-Radvanyi H
FAU - Junien, C
AU  - Junien C
FAU - Gourdon, G
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (3' Untranslated Regions)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Recombinant Proteins)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - 3' Untranslated Regions/genetics
MH  - Animals
MH  - Cloning, Molecular
MH  - Female
MH  - Gene Library
MH  - Genomic Imprinting
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Recombinant Proteins/biosynthesis
MH  - Spermatozoa/physiology
MH  - *Trinucleotide Repeats
EDAT- 2000/04/18 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/04/18 09:00
PHST- 2000/04/18 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/04/18 09:00 [entrez]
AID - ddd127 [pii]
AID - 10.1093/hmg/9.8.1185 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2000 May 1;9(8):1185-94. doi: 10.1093/hmg/9.8.1185.

PMID- 10701856
OWN - NLM
STAT- MEDLINE
DCOM- 20000327
LR  - 20190905
IS  - 0197-3851 (Print)
IS  - 0197-3851 (Linking)
VI  - 20
IP  - 1
DP  - 2000 Jan
TI  - Rapid detection of expansions by PCR and non-radioactive hybridization: 
      application for prenatal diagnosis of myotonic dystrophy.
PG  - 66-9
AB  - The mutation specific for myotonic dystrophy (DM) is an unstable expanded CTG 
      repeat located in the 3'-untranslated region of the myotonin protein kinase gene. 
      Expansion of the CTG repeat shows a positive correlation with the severity of the 
      disease and increases in successive generations of DM patients. Children with the 
      congenital form of DM show the most severe phenotype and have large expansions, 
      usually > 1000 repeats. For pregnant women with DM, prenatal diagnosis of DM may 
      be offered. To reduce the time between chorionic villus sampling or amniocentesis 
      and final results of DNA analysis in these cases, a fast and efficient method has 
      been developed. This method combines direct PCR analyses for normal alleles with 
      a nested PCR system followed by non-radioactive hybridization with a 
      single-stranded probe.
FAU - Zuhlke, C
AU  - Zuhlke C
AD  - Institut fur Humangenetik, Lubeck, Germany. zuehlke@medinf.mu-luebeck.de
FAU - Atici, J
AU  - Atici J
FAU - Martorell, L
AU  - Martorell L
FAU - Gembruch, U
AU  - Gembruch U
FAU - Kohl, M
AU  - Kohl M
FAU - Gopel, W
AU  - Gopel W
FAU - Schwinger, E
AU  - Schwinger E
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Prenat Diagn
JT  - Prenatal diagnosis
JID - 8106540
SB  - IM
MH  - Adult
MH  - Amniocentesis
MH  - Chorionic Villi Sampling
MH  - DNA Mutational Analysis
MH  - Female
MH  - Humans
MH  - Mutation
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - *Nucleic Acid Hybridization
MH  - Polymerase Chain Reaction
MH  - Pregnancy
MH  - *Prenatal Diagnosis
MH  - Repetitive Sequences, Nucleic Acid
EDAT- 2000/03/04 09:00
MHDA- 2000/04/01 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/04/01 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - 10.1002/(SICI)1097-0223(200001)20:1<66::AID-PD745>3.0.CO;2-H [pii]
AID - 10.1002/(sici)1097-0223(200001)20:1<66::aid-pd745>3.0.co;2-h [doi]
PST - ppublish
SO  - Prenat Diagn. 2000 Jan;20(1):66-9. doi: 
      10.1002/(sici)1097-0223(200001)20:1<66::aid-pd745>3.0.co;2-h.

PMID- 10699184
OWN - NLM
STAT- MEDLINE
DCOM- 20000414
LR  - 20240104
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 9
IP  - 4
DP  - 2000 Mar 1
TI  - Constitutive and regulated modes of splicing produce six major myotonic dystrophy 
      protein kinase (DMPK) isoforms with distinct properties.
PG  - 605-16
AB  - Myotonic dystrophy (DM) is the most prevalent inherited neuromuscular disease in 
      adults. The genetic defect is a CTG triplet repeat expansion in the 
      3'-untranslated region of the myotonic dystrophy protein kinase ( DMPK ) gene, 
      consisting of 15 exons. Using a transgenic DMPK-overexpressor mouse model, we 
      demonstrate here that the endogenous mouse DMPK gene and the human DMPK transgene 
      produce six major alternatively spliced mRNAs which have almost identical cell 
      type-dependent distribution frequencies and expression patterns. Use of a cryptic 
      5' splice site in exon 8, which results in absence or presence of 15 nucleotides 
      specifying a VSGGG peptide motif, and/or use of a cryptic 3' splice site in exon 
      14, which leads to a frameshift in the mRNA reading frame, occur as independent 
      stochastic events in all tissues examined. In contrast, the excision of exons 
      13/14 that causes a frameshift and creates a C-terminally truncated protein is 
      clearly cell type dependent and occurs predominantly in smooth muscle. We 
      generated all six full-length mouse cDNAs that result from combinations of these 
      three major splicing events and show that their transfection into cells in 
      culture leads to production of four different approximately 74 kDa full-length 
      (heart-, skeletal muscle- or brain-specific) and two C-terminally truncated 
      approximately 68 kDa (smooth muscle-specific) isoforms. Information on DMPK mRNA 
      and protein isoform expression patterns will be useful for recognizing 
      differential effects of (CTG)(n)expansion in DM manifestation.
FAU - Groenen, P J
AU  - Groenen PJ
AD  - Department of Cell Biology, Medical Faculty, University of Nijmegen, PO Box 9101, 
      6500 HB Nijmegen, The Netherlands.
FAU - Wansink, D G
AU  - Wansink DG
FAU - Coerwinkel, M
AU  - Coerwinkel M
FAU - van den Broek, W
AU  - van den Broek W
FAU - Jansen, G
AU  - Jansen G
FAU - Wieringa, B
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (DNA, Complementary)
RN  - 0 (Isoenzymes)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - *Alternative Splicing
MH  - Animals
MH  - COS Cells
MH  - DNA, Complementary/metabolism
MH  - Exons
MH  - Humans
MH  - Isoenzymes/genetics/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Processing, Post-Translational
MH  - Protein Serine-Threonine Kinases/*genetics/metabolism
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transgenes
EDAT- 2000/03/04 09:00
MHDA- 2000/04/25 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/04/25 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - ddd055 [pii]
AID - 10.1093/hmg/9.4.605 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2000 Mar 1;9(4):605-16. doi: 10.1093/hmg/9.4.605.

PMID- 10668800
OWN - NLM
STAT- MEDLINE
DCOM- 20000229
LR  - 20190607
IS  - 1355-8382 (Print)
IS  - 1469-9001 (Electronic)
IS  - 1355-8382 (Linking)
VI  - 6
IP  - 1
DP  - 2000 Jan
TI  - Expanded CUG repeat RNAs form hairpins that activate the double-stranded 
      RNA-dependent protein kinase PKR.
PG  - 79-87
AB  - Myotonic dystrophy is caused by an expanded CTG repeat in the 3' untranslated 
      region of the DM protein kinase (DMPK) gene. The expanded repeat triggers the 
      nuclear retention of mutant DMPK transcripts, but the resulting underexpression 
      of DMPK probably does not fully account for the severe phenotype. One proposed 
      disease mechanism is that nuclear accumulation of expanded CUG repeats may 
      interfere with nuclear function. Here we show by thermal melting and nuclease 
      digestion studies that CUG repeats form highly stable hairpins. Furthermore, CUG 
      repeats bind to the dsRNA-binding domain of PKR, the dsRNA-activated protein 
      kinase. The threshold for binding to PKR is approximately 15 CUG repeats, and the 
      affinity increases with longer repeat lengths. Finally, CUG repeats that are 
      pathologically expanded can activate PKR in vitro. These results raise the 
      possibility that the disease mechanism could be, in part, a gain of function by 
      mutant DMPK transcripts that involves sequestration or activation of dsRNA 
      binding proteins.
FAU - Tian, B
AU  - Tian B
AD  - Department of Biochemistry and Molecular Biology, New Jersey Medical School, 
      University of Medicine and Dentistry of New Jersey, Newark 17103, USA.
FAU - White, R J
AU  - White RJ
FAU - Xia, T
AU  - Xia T
FAU - Welle, S
AU  - Welle S
FAU - Turner, D H
AU  - Turner DH
FAU - Mathews, M B
AU  - Mathews MB
FAU - Thornton, C A
AU  - Thornton CA
LA  - eng
GR  - AI34552/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - RNA
JT  - RNA (New York, N.Y.)
JID - 9509184
RN  - 0 (RNA, Double-Stranded)
RN  - EC 2.7.11.1 (eIF-2 Kinase)
RN  - EC 3.1.- (Endoribonucleases)
RN  - EC 3.1.26.3 (Ribonuclease III)
SB  - IM
MH  - Base Pairing
MH  - Endoribonucleases/metabolism
MH  - Enzyme Activation
MH  - Nucleic Acid Conformation
MH  - Protein Binding
MH  - RNA, Double-Stranded/analysis/*metabolism
MH  - Ribonuclease III
MH  - *Trinucleotide Repeat Expansion
MH  - eIF-2 Kinase/*metabolism
PMC - PMC1369895
EDAT- 2000/02/11 09:00
MHDA- 2000/03/04 09:00
PMCR- 2000/01/01
CRDT- 2000/02/11 09:00
PHST- 2000/02/11 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/02/11 09:00 [entrez]
PHST- 2000/01/01 00:00 [pmc-release]
AID - 10.1017/s1355838200991544 [doi]
PST - ppublish
SO  - RNA. 2000 Jan;6(1):79-87. doi: 10.1017/s1355838200991544.

PMID- 10656235
OWN - NLM
STAT- MEDLINE
DCOM- 20000216
LR  - 20190831
IS  - 0742-3071 (Print)
IS  - 0742-3071 (Linking)
VI  - 16
IP  - 12
DP  - 1999 Dec
TI  - Length rather than a specific allele of dinucleotide repeat in the 5' upstream 
      region of the aldose reductase gene is associated with diabetic retinopathy.
PG  - 1044-7
AB  - AIMS: To assess the possible contribution of a genetic factor to diabetic 
      retinopathy. METHODS: (CA)n repeat length was investigated in the 5' upstream 
      region of the gene coding for aldose reductase (AR), which is a key enzyme of the 
      polyol pathway and plays a role in hyperglycaemia-induced tissue damage, in 
      Japanese patients with Type 2 DM. RESULTS: The dinucleotide repeat length was 
      significantly associated with proliferative diabetic retinopathy (PDR) (P= 0.029, 
      Mann-Whitney U-test); i.e. shorter alleles were more prevalent in the PDR group 
      than in the control group. CONCLUSIONS: (CA)n repeat length, rather than a 
      specific allele, in the 5' upstream region of the AR gene is associated with 
      diabetic retinopathy. These data suggest that the AR locus plays a role in 
      genetic susceptibility to diabetic retinopathy and that dinucleotide repeats in 
      genomic DNA may be related to disease predisposition.
FAU - Fujisawa, T
AU  - Fujisawa T
AD  - Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan.
FAU - Ikegami, H
AU  - Ikegami H
FAU - Kawaguchi, Y
AU  - Kawaguchi Y
FAU - Yamato, E
AU  - Yamato E
FAU - Nakagawa, Y
AU  - Nakagawa Y
FAU - Shen, G Q
AU  - Shen GQ
FAU - Fukuda, M
AU  - Fukuda M
FAU - Ogihara, T
AU  - Ogihara T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - EC 1.1.1.21 (Aldehyde Reductase)
SB  - IM
MH  - Aged
MH  - Aldehyde Reductase/*genetics
MH  - *Alleles
MH  - Diabetic Retinopathy/*genetics
MH  - *Dinucleotide Repeats
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2000/02/03 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/02/03 09:00
PHST- 2000/02/03 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/02/03 09:00 [entrez]
AID - 10.1046/j.1464-5491.1999.00192.x [doi]
PST - ppublish
SO  - Diabet Med. 1999 Dec;16(12):1044-7. doi: 10.1046/j.1464-5491.1999.00192.x.

PMID- 10655554
OWN - NLM
STAT- MEDLINE
DCOM- 20000504
LR  - 20190513
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 9
IP  - 3
DP  - 2000 Feb 12
TI  - Dramatic, expansion-biased, age-dependent, tissue-specific somatic mosaicism in a 
      transgenic mouse model of triplet repeat instability.
PG  - 439-45
AB  - Myotonic dystrophy type 1 (DM1) is one of a growing number of inherited human 
      diseases whose molecular basis has been implicated as the expansion of a 
      trinucleotide DNA repeat. Expanded disease-associated alleles of >50 CTG repeats 
      are unstable in both the germline and soma. Expansion of the unstable alleles 
      over time and variation of the level of mutation between the somatic tissues of 
      an individual are thought to account at least partially for the tissue 
      specificity and progressive nature of the symptoms. We previously generated a 
      number of transgenic mouse lines containing a large expanded CTG repeat tract 
      that replicated a number of the features of unstable DNA in humans, including 
      frequent sex-specific changes in allele length during intergenerational 
      transmission. Small length change mutations were apparent in the somatic tissues 
      of young mice in all of the lines generated, but the gross instability observed 
      in human DM1 patients was not replicated. We now show that in one of the lines, 
      Dmt -D, spectacular, expansion-biased, tissue-specific instability is observed in 
      older mice. The highest levels of instability were detected in kidney with gains 
      of >500 repeats, representing a tripling of allele length, in some cells. 
      Mosaicism accumulated in an age-dependent manner, but the tissue specificity did 
      not obviously correlate with cell turnover. Such gross somatic mosaicism was not 
      observed in three other lines examined, further emphasizing a role for flanking 
      DNA in modulating repeat stability.
FAU - Fortune, M T
AU  - Fortune MT
AD  - Division of Molecular Genetics, Institute for Biomedical and Life Sciences, 
      University of Glasgow, Anderson College, 56 Dumbarton Road, Glasgow G11 6NU, UK.
FAU - Vassilopoulos, C
AU  - Vassilopoulos C
FAU - Coolbaugh, M I
AU  - Coolbaugh MI
FAU - Siciliano, M J
AU  - Siciliano MJ
FAU - Monckton, D G
AU  - Monckton DG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Brain/metabolism
MH  - Female
MH  - Genetic Variation
MH  - Humans
MH  - Kidney/metabolism
MH  - Lung/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Mosaicism
MH  - Myotonic Dystrophy/*genetics/metabolism
MH  - Organ Specificity
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion
EDAT- 2000/02/03 09:00
MHDA- 2000/05/08 09:00
CRDT- 2000/02/03 09:00
PHST- 2000/02/03 09:00 [pubmed]
PHST- 2000/05/08 09:00 [medline]
PHST- 2000/02/03 09:00 [entrez]
AID - ddd044 [pii]
AID - 10.1093/hmg/9.3.439 [doi]
PST - ppublish
SO  - Hum Mol Genet. 2000 Feb 12;9(3):439-45. doi: 10.1093/hmg/9.3.439.

PMID- 10573472
OWN - NLM
STAT- MEDLINE
DCOM- 19991209
LR  - 20170214
IS  - 0883-0738 (Print)
IS  - 0883-0738 (Linking)
VI  - 14
IP  - 7
DP  - 1999 Jul
TI  - Expression of the myotonic dystrophy locus-associated homeodomain protein in 
      congenital myotonic dystrophy.
PG  - 471-3
AB  - DM locus-associated homeodomain protein (DMAHP), a newly recognized homeodomain 
      protein, is a candidate flanking gene and expressed in various tissues. We 
      examined the expression of the DMAHP in tissues from a congenital myotonic 
      dystrophy patient in comparison to that of control tissues by using 
      semiquantitative reverse transcriptase-polymerase chain reaction. Reduced 
      expression of DMAHP was observed in tissues from the patient with congenital 
      myotonic dystrophy. This finding supports that reduced expression of DMAHP is 
      related to the CTG repeat expansion.
FAU - Tachi, N
AU  - Tachi N
AD  - School of Health Sciences, Sapporo Medical University School of Medicine, Japan. 
      tati@shs.sapmed.ac.jp
FAU - Ohya, K
AU  - Ohya K
FAU - Chiba, S
AU  - Chiba S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
RN  - 0 (Homeodomain Proteins)
SB  - IM
MH  - Female
MH  - Gene Expression/*genetics
MH  - Gene Expression Regulation, Developmental/*genetics
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Infant, Newborn
MH  - Liver/metabolism
MH  - Muscles/metabolism
MH  - Myotonic Dystrophy/*genetics/metabolism/pathology
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 1999/11/26 00:00
MHDA- 1999/11/26 00:01
CRDT- 1999/11/26 00:00
PHST- 1999/11/26 00:00 [pubmed]
PHST- 1999/11/26 00:01 [medline]
PHST- 1999/11/26 00:00 [entrez]
AID - 10.1177/088307389901400713 [doi]
PST - ppublish
SO  - J Child Neurol. 1999 Jul;14(7):471-3. doi: 10.1177/088307389901400713.

PMID- 10480373
OWN - NLM
STAT- MEDLINE
DCOM- 19990923
LR  - 20211203
IS  - 0340-6717 (Print)
IS  - 0340-6717 (Linking)
VI  - 105
IP  - 1-2
DP  - 1999 Jul-Aug
TI  - CTG repeats distribution and Alu insertion polymorphism at myotonic dystrophy 
      (DM) gene in Amhara and Oromo populations of Ethiopia.
PG  - 165-7
AB  - Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disease, highly 
      variable and multisystemic, which is caused by the expansion of a CTG repeat 
      located in the 3' untranslated region of the DMPK gene. Normal alleles show a 
      copy number of 5-37 repeats on normal chromosomes, amplified to 50-3000 copies on 
      DM chromosomes. The trinucleotide repeat shows a trimodal allele distribution in 
      the majority of the examined population. The first class includes alleles 
      carrying (CTG)5, the second class, alleles in the range 7-18 repeats, and the 
      third class, alleles (CTG) > or =19. The frequency of this third class is 
      directly related to the prevalence of DM in different populations, suggesting 
      that normal large-sized alleles predispose toward DM. We studied CTG repeat 
      allele distribution and Alu insertion and/or deletion polymorphism at the 
      myotonic dystrophy locus in two major Ethiopian populations, the Amhara and 
      Oromo. CTG allele distribution and haplotype analysis on a total of 224 normal 
      chromosomes showed significant differences between the two ethnic groups. These 
      differences have a bearing on the out-of-Africa hypothesis for the origin of the 
      DM mutation. In addition, (CTG) > or =19 were exclusively detected in the Amhara 
      population, confirming the predisposing role of these alleles compared with the 
      DM expansion-mutation.
FAU - Gennarelli, M
AU  - Gennarelli M
AD  - Department of Biopathology and Diagnostic Imaging, Tor Vergata University of Rome 
      and C.S.S.-Mendel Institute, Italy.
FAU - Pavoni, M
AU  - Pavoni M
FAU - Cruciani, F
AU  - Cruciani F
FAU - De Stefano, G
AU  - De Stefano G
FAU - Dallapiccola, B
AU  - Dallapiccola B
FAU - Novelli, G
AU  - Novelli G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Alu Elements/*genetics
MH  - Ethiopia
MH  - Haplotypes
MH  - Humans
MH  - Jews
MH  - Myotonic Dystrophy/ethnology/*genetics
MH  - Myotonin-Protein Kinase
MH  - *Polymorphism, Genetic
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Trinucleotide Repeats
EDAT- 1999/09/10 00:00
MHDA- 1999/09/10 00:01
CRDT- 1999/09/10 00:00
PHST- 1999/09/10 00:00 [pubmed]
PHST- 1999/09/10 00:01 [medline]
PHST- 1999/09/10 00:00 [entrez]
AID - 10.1007/s004399900091 [doi]
PST - ppublish
SO  - Hum Genet. 1999 Jul-Aug;105(1-2):165-7. doi: 10.1007/s004399900091.

PMID- 10454725
OWN - NLM
STAT- MEDLINE
DCOM- 19990923
LR  - 20220330
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 22
IP  - 9
DP  - 1999 Sep
TI  - Elongation of (CTG)n repeats in myotonic dystrophy protein kinase gene in tumors 
      associated with myotonic dystrophy patients.
PG  - 1271-4
AB  - Length of (CTG)n triplet repeats in myotonic dystrophy protein kinase gene (DMPK) 
      was estimated in tumors, normal tissues of the same organs, muscles, and 
      leukocytes from three myotonic dystrophy (DM) patients and a non-DM patient. 
      Using cDNA 25 as a probe, a Southern blot analysis of EcoRI- and BglI-digested 
      DNA from these tissues demonstrated the longest expansion of the repeats in the 
      tumors of DM patients. In all tissues from a non-DM patient, the repeat length 
      was confirmed to be stable by PCR analysis. Our data suggest that expanded (CTG)n 
      repeat in tumor tissues may have increased the instability. This study emphasizes 
      the importance of a long-term prospective study on the incidence of tumors in DM 
      to clarify the pathological interrelation between the two entities.
CI  - Copyright 1999 John Wiley & Sons, Inc.
FAU - Jinnai, K
AU  - Jinnai K
AD  - Department of Neurology, National Sanatorium Hyogo-Chuo Hospital, 1314, Ohara, 
      Sanda 669-1592, Japan.
FAU - Sugio, T
AU  - Sugio T
FAU - Mitani, M
AU  - Mitani M
FAU - Hashimoto, K
AU  - Hashimoto K
FAU - Takahashi, K
AU  - Takahashi K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.1.21.- (Deoxyribonuclease EcoRI)
SB  - IM
MH  - Adenocarcinoma/complications/enzymology/*genetics
MH  - Colonic Neoplasms/complications/enzymology/*genetics
MH  - DNA/chemistry/metabolism
MH  - Deoxyribonuclease EcoRI/metabolism
MH  - Electrophoresis, Gel, Pulsed-Field
MH  - Humans
MH  - Insulinoma/complications/enzymology/*genetics
MH  - Leukocytes/enzymology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/enzymology
MH  - Myotonic Dystrophy/*complications
MH  - Myotonin-Protein Kinase
MH  - Pancreatic Neoplasms/complications/enzymology/*genetics
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Stomach Neoplasms/complications/enzymology/*genetics
EDAT- 1999/08/24 00:00
MHDA- 1999/08/24 00:01
CRDT- 1999/08/24 00:00
PHST- 1999/08/24 00:00 [pubmed]
PHST- 1999/08/24 00:01 [medline]
PHST- 1999/08/24 00:00 [entrez]
AID - 10.1002/(SICI)1097-4598(199909)22:9<1271::AID-MUS16>3.0.CO;2-D [pii]
AID - 10.1002/(sici)1097-4598(199909)22:9<1271::aid-mus16>3.0.co;2-d [doi]
PST - ppublish
SO  - Muscle Nerve. 1999 Sep;22(9):1271-4. doi: 
      10.1002/(sici)1097-4598(199909)22:9<1271::aid-mus16>3.0.co;2-d.

PMID- 10435210
OWN - NLM
STAT- MEDLINE
DCOM- 19991229
LR  - 20220129
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 46
IP  - 3
DP  - 1999 Aug 1
TI  - Cognitive impairment and (CTG)n expansion in myotonic dystrophy patients.
PG  - 425-31
AB  - BACKGROUND: Myotonic dystrophy (DM) is a genetic multisystemic disease with 
      muscular, endocrine, ocular, cardiac and cognitive impairment. The molecular 
      basis of the disease has been identified in an unstable base triplet (CTG)n 
      repeat located in the 3' untranslated region of the miotonin protein-kinase 
      (MT-PK) gene on the long arm of chromosome 19. Cognitive impairment could be a 
      direct expression of this genetic alteration at the central nervous system (CNS) 
      level rather than a consequence of the neuromuscular impairment. To explore this 
      hypothesis, we tested a group of genetically diagnosed, adult onset DM, of their 
      nonaffected relatives (NAR), of patients with spinal muscle atrophy (SMA), and of 
      normal controls using the Wechsler Adult Intelligence Scale (WAIS). METHODS: 
      Seventeen adult-onset DM patients, 9 NAR, 10 SMA patients and 20 unrelated normal 
      controls (NC) were studied. Clinical, neuromuscular and neuropsychiatric 
      evaluation, which included WAIS and the Schedule for Affective Disorders and 
      Schizophrenia (SADS), were performed on the four groups. DM, NAR and NC were also 
      assessed by a neurophysiological (P300) evaluation. A DNA analysis was performed 
      in DM and in NAR to measure presence and magnitude of CTG expansion. RESULTS: We 
      found a statistically significant difference between verbal (p < .0003), 
      nonverbal (p < .0001) and total (p < .0001) IQ of DM patients compared to IQs of 
      NAR, SMA and NC. Seven out of 11 WAIS subtests were significantly and 
      consistently lower in DM patients compared to SMA and/or NC. In DM patients there 
      was a statistically significant negative correlation between nonverbal (r = -.68; 
      p < .002) and total (r = .59; p < .01) IQ and (CTG)n. Patients with DM had a 
      significantly lower P300 amplitude compared to NAR and NC. CONCLUSIONS: Our study 
      indicates that in DM there is a mild but significant cognitive impairment which 
      correlates with the degree of CTG expansion and it is not dependent on the 
      neuromuscular impairment; however further studies with larger groups of patients 
      and controls are suggested to confirm our results, due to the small sample size 
      and to a possible effect of educational level in our patients.
FAU - Perini, G I
AU  - Perini GI
AD  - Department of Neurological and Psychiatric Sciences, University of Padova, Italy.
FAU - Menegazzo, E
AU  - Menegazzo E
FAU - Ermani, M
AU  - Ermani M
FAU - Zara, M
AU  - Zara M
FAU - Gemma, A
AU  - Gemma A
FAU - Ferruzza, E
AU  - Ferruzza E
FAU - Gennarelli, M
AU  - Gennarelli M
FAU - Angelini, C
AU  - Angelini C
LA  - eng
GR  - C.54/TI_/Telethon/Italy
PT  - Journal Article
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biopsy
MH  - Blotting, Southern
MH  - Cognition Disorders/*complications/*diagnosis
MH  - Electrophoresis, Agar Gel
MH  - Event-Related Potentials, P300/physiology
MH  - Evoked Potentials, Auditory/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology
MH  - Myotonic Dystrophy/*complications/*genetics
MH  - Polymerase Chain Reaction/methods
MH  - Severity of Illness Index
MH  - Trinucleotide Repeat Expansion/*genetics
MH  - Wechsler Scales
EDAT- 1999/08/06 00:00
MHDA- 1999/08/06 00:01
CRDT- 1999/08/06 00:00
PHST- 1999/08/06 00:00 [pubmed]
PHST- 1999/08/06 00:01 [medline]
PHST- 1999/08/06 00:00 [entrez]
AID - S0006-3223(99)00016-5 [pii]
AID - 10.1016/s0006-3223(99)00016-5 [doi]
PST - ppublish
SO  - Biol Psychiatry. 1999 Aug 1;46(3):425-31. doi: 10.1016/s0006-3223(99)00016-5.

PMID- 10414599
OWN - NLM
STAT- MEDLINE
DCOM- 19991119
LR  - 20191114
IS  - 0887-8013 (Print)
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Linking)
VI  - 13
IP  - 4
DP  - 1999
TI  - Application of FTA sample collection and DNA purification system on the 
      determination of CTG trinucleotide repeat size by PCR-based Southern blotting.
PG  - 188-93
AB  - Myotonic dystrophy (DM) is caused by a CTG trinucleotide expansion mutation at 
      exon 15 of the myotonic dystrophy protein kinase gene. The clinical severity of 
      this disease correlates with the length of the CTG trinucleotide repeats. 
      Determination of the CTG repeat length has been primarily relied on by Southern 
      blot analysis of restriction enzyme-digested genomic DNA. The development of 
      PCR-based Southern blotting methodology provides a much more sensitive and 
      simpler protocol for DM diagnosis. However, the quality of the template and the 
      high (G+C) ratio of the amplified region hamper the use of PCR on the diagnosis 
      of DM. A modified PCR protocol to amplify different lengths of CTG repeat region 
      using various concentrations of 7deaza-dGTP has been reported (1). Here we 
      describe a procedure including sample collection, DNA purification, and PCR 
      analysis of CTG repeat length without using 7-deaza-dGTP. This protocol is very 
      sensitive and convenient because only a small number of nucleate cells are needed 
      for detection of CTG expansion. Therefore, it could be very useful in clinical 
      and prenatal diagnosis as well as in prevalence study of DM.
FAU - Hsiao, K M
AU  - Hsiao KM
AD  - Department of Life Sciences, Chung Shan Medical and Dental College, Taichung, 
      Taiwan.
FAU - Lin, H M
AU  - Lin HM
FAU - Pan, H
AU  - Pan H
FAU - Li, T C
AU  - Li TC
FAU - Chen, S S
AU  - Chen SS
FAU - Jou, S B
AU  - Jou SB
FAU - Chiu, Y L
AU  - Chiu YL
FAU - Wu, M F
AU  - Wu MF
FAU - Lin, C C
AU  - Lin CC
FAU - Li, S Y
AU  - Li SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Oligonucleotides)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Blood Specimen Collection
MH  - Blotting, Southern
MH  - Cell Line
MH  - DNA/*chemistry/isolation & purification
MH  - Humans
MH  - *Oligonucleotides
MH  - Polymerase Chain Reaction
MH  - Reagent Kits, Diagnostic
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Sensitivity and Specificity
PMC - PMC6807929
EDAT- 1999/07/22 10:00
MHDA- 2000/06/20 09:00
PMCR- 1999/06/22
CRDT- 1999/07/22 10:00
PHST- 1999/07/22 10:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/07/22 10:00 [entrez]
PHST- 1999/06/22 00:00 [pmc-release]
AID - 10.1002/(SICI)1098-2825(1999)13:4<188::AID-JCLA8>3.0.CO;2-G [pii]
AID - JCLA8 [pii]
AID - 10.1002/(sici)1098-2825(1999)13:4<188::aid-jcla8>3.0.co;2-g [doi]
PST - ppublish
SO  - J Clin Lab Anal. 1999;13(4):188-93. doi: 
      10.1002/(sici)1098-2825(1999)13:4<188::aid-jcla8>3.0.co;2-g.

PMID- 10332037
OWN - NLM
STAT- MEDLINE
DCOM- 19990708
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 8
IP  - 6
DP  - 1999 Jun
TI  - Simultaneous analysis of expression of the three myotonic dystrophy locus genes 
      in adult skeletal muscle samples: the CTG expansion correlates inversely with 
      DMPK and 59 expression levels, but not DMAHP levels.
PG  - 1053-60
AB  - The causative mutation in the majority of cases of myotonic dystrophy has been 
      shown to be the expansion of a CTG trinucleotide repeat, but the mechanism(s) by 
      which this repeat leads to the very complex symptomatology in this disorder 
      remains controversial. We have developed a highly sensitive and quantifiable 
      assay, based on competitive RT-PCR, to test the hypothesis that the expansion 
      disrupts the expression of the genes in its immediate vicinity, DMPK, 59 and 
      DMAHP. In order to avoid cell culture-induced artifacts we performed these 
      experiments using adult skeletal muscle biopsy samples and analysed total 
      cytoplasmic poly(A)+mRNA levels for each gene simultaneously, as this is more 
      physiologically relevant than allele-specific levels. There was considerable 
      overlap between the expression levels of the three genes in myotonic dystrophy 
      patient samples and samples from control individuals. However, in the myotonic 
      dystrophy samples we detected a strong inverse correlation between the repeat 
      size and the levels of expression of DMPK and 59. This is the first report of a 
      possible effect of the CTG expansion on gene 59. Our results indicate that whilst 
      a simple dosage model of gene expression in the presence of the mutation is 
      unlikely to be sufficient in itself to explain the complex molecular pathology in 
      this disease, the repeat expansion may be a significant modifier of the 
      expression of these two genes.
FAU - Eriksson, M
AU  - Eriksson M
AD  - Department of Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
FAU - Ansved, T
AU  - Ansved T
FAU - Edstrom, L
AU  - Edstrom L
FAU - Anvret, M
AU  - Anvret M
FAU - Carey, N
AU  - Carey N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA, Complementary)
RN  - 0 (Dystrophin-Associated Proteins)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (SIX5 protein, human)
RN  - 0 (syntrophin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Biopsy
MH  - Cytoskeletal Proteins/genetics
MH  - DNA, Complementary/genetics
MH  - Data Interpretation, Statistical
MH  - Dystrophin-Associated Proteins
MH  - Female
MH  - Gene Expression Regulation
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Male
MH  - Membrane Proteins/genetics
MH  - Middle Aged
MH  - Muscle, Skeletal/*metabolism/pathology
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 1999/05/20 00:00
MHDA- 1999/05/20 00:01
CRDT- 1999/05/20 00:00
PHST- 1999/05/20 00:00 [pubmed]
PHST- 1999/05/20 00:01 [medline]
PHST- 1999/05/20 00:00 [entrez]
AID - ddc120 [pii]
AID - 10.1093/hmg/8.6.1053 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1999 Jun;8(6):1053-60. doi: 10.1093/hmg/8.6.1053.

PMID- 10332033
OWN - NLM
STAT- MEDLINE
DCOM- 19990708
LR  - 20220129
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 8
IP  - 6
DP  - 1999 Jun
TI  - Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on 
      allele-specific DMAHP/SIX5 expression.
PG  - 1017-23
AB  - Myotonic dystrophy (DM), the most common inherited muscle disorder, is caused by 
      a CTG expansion in the 3"-untranslated region of a protein kinase gene ( DMPK ). 
      The complex and variable phenotype is most likely caused by a complex molecular 
      pathogenesis, including deficiency of the DMPK protein, a trans -dominant 
      misregulation of RNA homeostasis and haploinsufficiency of a neighboring homeobox 
      gene [DM locus-associated homeodomain protein (DMAHP )]. Here, we study the 
      allele-specific transcriptional activity of the DMAHP/SIX5 gene in DM patient 
      tissues. Using a quantitative fluorescent RT-PCR assay, we tested allele-specific 
      accumulation of DMAHP/SIX5 transcripts in both total and poly(A)+pools. In muscle 
      biopsies, we found that transcript reductions of DMAHP/SIX5 alleles in cis with 
      CTG expansions correlated with the extent of expansion. A patient with 
      approximately 90 CTG repeats in muscle DNA (normal n < 37) showed a 20% reduction 
      of allele-specific transcript levels, while four other DM patients with larger 
      expansions showed 80% reductions. The effects of the CTG expansions on DMAHP 
      transcription were tissue specific: autopsy tissues from a patient with 1500 
      repeats showed 80% reductions in muscle and liver; however, RNA from other 
      tissues (lung, aorta, heart conduction tissue, cerebellum) showed 0-20% 
      reductions. Our results suggest that the effect of the CTG repeat on the 
      DMAHP/SIX5 promoter is variable and tissue-specific. Our data are consistent with 
      abnormalities of DMAHP/SIX5 probably having a more prominent role in disease 
      pathogenesis in muscle, liver and brain, but being less important in other 
      tissues.
FAU - Korade-Mirnics, Z
AU  - Korade-Mirnics Z
AD  - Department of Molecular Genetics and Biochemistry, University of Pittsburgh, 
      Pittsburgh, PA, USA,
FAU - Tarleton, J
AU  - Tarleton J
FAU - Servidei, S
AU  - Servidei S
FAU - Casey, R R
AU  - Casey RR
FAU - Gennarelli, M
AU  - Gennarelli M
FAU - Pegoraro, E
AU  - Pegoraro E
FAU - Angelini, C
AU  - Angelini C
FAU - Hoffman, E P
AU  - Hoffman EP
LA  - eng
GR  - 1061/TI_/Telethon/Italy
GR  - C.41/TI_/Telethon/Italy
GR  - P60-AR44811/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (SIX5 protein, human)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Autopsy
MH  - Biopsy
MH  - Child
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Regulation
MH  - Genotype
MH  - Homeodomain Proteins/genetics
MH  - Humans
MH  - Middle Aged
MH  - Muscles/metabolism/pathology
MH  - Myotonic Dystrophy/*genetics/pathology
MH  - RNA, Messenger/genetics/metabolism
MH  - Tissue Distribution
MH  - Transcription, Genetic
MH  - Trinucleotide Repeat Expansion/genetics
EDAT- 1999/05/20 00:00
MHDA- 1999/05/20 00:01
CRDT- 1999/05/20 00:00
PHST- 1999/05/20 00:00 [pubmed]
PHST- 1999/05/20 00:01 [medline]
PHST- 1999/05/20 00:00 [entrez]
AID - ddc112 [pii]
AID - 10.1093/hmg/8.6.1017 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1999 Jun;8(6):1017-23. doi: 10.1093/hmg/8.6.1017.

PMID- 10210916
OWN - NLM
STAT- MEDLINE
DCOM- 20000626
LR  - 20191103
IS  - 1351-5101 (Print)
IS  - 1351-5101 (Linking)
VI  - 6
IP  - 3
DP  - 1999 May
TI  - CTG-repeat length in distal and proximal leg muscles of symptomatic and 
      non-symptomatic patients with myotonic dystrophy: relation to muscle strength and 
      degree of histopathological abnormalities.
PG  - 341-6
AB  - Myotonic dystrophy (DM) is an autosomal dominant, multisystemic disorder with a 
      variable phenotypic expression including muscle weakness and myotonia. The muscle 
      wasting is most marked in distal limbs and in facial and neck muscles, although 
      proximal limb muscles become affected as the disease progresses. The 
      CTG-trinucleotide-repeat expansion associated with myotonic dystrophy is usually 
      larger in muscle tissue than in leukocytes. It is unclear whether the repeat 
      length itself bears any relation to the differences in the degree of weakness and 
      atrophy between different muscles. We therefore analysed CTG-repeat lengths in 
      blood and in proximal (m. vastus lateralis) and distal (m. tibialis anterior) 
      muscles of patients with DM (n = 4) and non-symptomatic carriers of the mutant DM 
      allele (n = 2) using conventional Southern blot hybridization. Muscle strength 
      and histopathological abnormalities were evaluated for each muscle. In patients 
      with clinical symptoms, the degree of paresis and morphological abnormalities was 
      markedly more pronounced in m. tibialis anterior than in m. vastus lateralis. In 
      these individuals, the CTG-repeat length was larger in muscles than in 
      leukocytes, whereas in the two non-symptomatic carriers no difference could be 
      detected. Furthermore, there was no clear difference in the repeat length between 
      the two muscles in any of the patients. In conclusion, the selective muscular 
      weakness and atrophy in DM do not seem to be related to differences in CTG-repeat 
      length between different muscles.
CI  - Copyright 1999 Lippincott Williams & Wilkins
FAU - Hedberg, B
AU  - Hedberg B
AD  - Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
FAU - Anvret, M
AU  - Anvret M
FAU - Ansved, T
AU  - Ansved T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
SB  - IM
MH  - Adult
MH  - Biopsy
MH  - Female
MH  - Humans
MH  - Leg/*pathology
MH  - Male
MH  - Muscle, Skeletal/*pathology
MH  - Myotonic Dystrophy/*genetics/*pathology
MH  - Trinucleotide Repeats
EDAT- 1999/04/22 02:04
MHDA- 2000/07/06 11:00
CRDT- 1999/04/22 02:04
PHST- 1999/04/22 02:04 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 1999/04/22 02:04 [entrez]
AID - NE060314 [pii]
AID - 10.1046/j.1468-1331.1999.630341.x [doi]
PST - ppublish
SO  - Eur J Neurol. 1999 May;6(3):341-6. doi: 10.1046/j.1468-1331.1999.630341.x.

PMID- 10192387
OWN - NLM
STAT- MEDLINE
DCOM- 19990426
LR  - 20220318
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 21
IP  - 4
DP  - 1999 Apr
TI  - An untranslated CTG expansion causes a novel form of spinocerebellar ataxia 
      (SCA8).
PG  - 379-84
AB  - Myotonic dystrophy (DM) is the only disease reported to be caused by a CTG 
      expansion. We now report that a non-coding CTG expansion causes a novel form of 
      spinocerebellar ataxia (SCA8). This expansion, located on chromosome 13q21, was 
      isolated directly from the genomic DNA of an ataxia patient by RAPID cloning. 
      SCA8 patients have expansions similar in size (107-127 CTG repeats) to those 
      found among adult-onset DM patients. SCA8 is the first example of a dominant SCA 
      not caused by a CAG expansion translated as a polyglutamine tract.
FAU - Koob, M D
AU  - Koob MD
AD  - Department of Neurology, Institute of Human Genetics, University of Minnesota, 
      Minneapolis 55455, USA. koobx001@gold.tc.umn.edu
FAU - Moseley, M L
AU  - Moseley ML
FAU - Schut, L J
AU  - Schut LJ
FAU - Benzow, K A
AU  - Benzow KA
FAU - Bird, T D
AU  - Bird TD
FAU - Day, J W
AU  - Day JW
FAU - Ranum, L P
AU  - Ranum LP
LA  - eng
SI  - GENBANK/AF126748
SI  - GENBANK/AF126749
GR  - P01 NS33718/NS/NINDS NIH HHS/United States
GR  - R01 NS36282/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (Untranslated Regions)
SB  - IM
CIN - Nat Genet. 2000 Mar;24(3):213; author reply 215. PMID: 10700167
CIN - Nat Genet. 2000 Mar;24(3):214-5. PMID: 10700168
MH  - Alleles
MH  - Female
MH  - Genes, Dominant
MH  - Humans
MH  - Male
MH  - Molecular Sequence Data
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - Random Amplified Polymorphic DNA Technique
MH  - Spinocerebellar Degenerations/*genetics
MH  - Transcription, Genetic
MH  - *Trinucleotide Repeats
MH  - *Untranslated Regions
EDAT- 1999/04/07 02:01
MHDA- 2001/03/23 10:01
CRDT- 1999/04/07 02:01
PHST- 1999/04/07 02:01 [pubmed]
PHST- 2001/03/23 10:01 [medline]
PHST- 1999/04/07 02:01 [entrez]
AID - 10.1038/7710 [doi]
PST - ppublish
SO  - Nat Genet. 1999 Apr;21(4):379-84. doi: 10.1038/7710.

PMID- 10189221
OWN - NLM
STAT- MEDLINE
DCOM- 19990401
LR  - 20211203
IS  - 1059-7794 (Print)
IS  - 1059-7794 (Linking)
VI  - 13
IP  - 1
DP  - 1999
TI  - Expansion of CTG repeat in myotonin protein kinase gene on Alu(ins)-HinfI-I 
      background in a myotonic dystrophy patient from India. Mutations in brief no. 
      210. Online.
PG  - 84
AB  - To determine the founder of Indian myotonic dystrophy mutation, we have studied 
      the expansion of CTG repeats in myotonin protein kinase gene and two intragenic 
      linked loci Alu(ins) / Alu(del) and G/T intron 9 HinfI polymorphism in ten 
      unrelated DM patients from eastern India. Out of these ten patients, 
      reconstruction of haplotype was possible for five patients unambiguously. In the 
      other five cases, haplotype for the normal allele was assumed to be the most 
      common haplotype found in normal individuals from Indian populations. Such 
      analysis showed that in nine cases, the expansion of CTG repeats took place on 
      Alu(ins)-HinfI-2 background indicating common founder with other DM mutation 
      published. However, in one case we observed a different haplotype 
      [Alu(ins)-HinfI-1] which could be a new mutation or due to admixture.
FAU - Basu, P
AU  - Basu P
AD  - Crystallography and Molecular Biology Division Saha Institute of Nuclear Physics, 
      1/AF, Bidhan Nagar, Calcutta-700 064, India.
FAU - Gangopadhaya, P K
AU  - Gangopadhaya PK
FAU - Murkherjee, S C
AU  - Murkherjee SC
FAU - Sinha, K K
AU  - Sinha KK
FAU - Bhattacharyya, N P
AU  - Bhattacharyya NP
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 3.1.21.4 (Deoxyribonucleases, Type II Site-Specific)
RN  - EC 3.1.21.4 (GANTC-specific type II deoxyribonucleases)
SB  - IM
MH  - Deoxyribonucleases, Type II Site-Specific/genetics
MH  - Humans
MH  - India
MH  - Introns/genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Trinucleotide Repeat Expansion/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 1999/04/03 03:16
MHDA- 2000/06/22 10:00
CRDT- 1999/04/03 03:16
PHST- 1999/04/03 03:16 [pubmed]
PHST- 2000/06/22 10:00 [medline]
PHST- 1999/04/03 03:16 [entrez]
AID - 10.1002/(SICI)1098-1004(1999)13:1<84::AID-HUMU14>3.0.CO;2-X [pii]
AID - 10.1002/(SICI)1098-1004(1999)13:1<84::AID-HUMU15>3.0.CO;2-U [doi]
PST - ppublish
SO  - Hum Mutat. 1999;13(1):84. doi: 
      10.1002/(SICI)1098-1004(1999)13:1<84::AID-HUMU15>3.0.CO;2-U.

PMID- 10063831
OWN - NLM
STAT- MEDLINE
DCOM- 19990507
LR  - 20191024
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 9
IP  - 1
DP  - 1999 Jan
TI  - Clinical and genetic characteristics of a five-generation family with a novel 
      form of myotonic dystrophy (DM2).
PG  - 19-27
AB  - We report the clinical and genetic characteristics of a five-generation family 
      (MN1) with an unusual form of myotonic dystrophy (DM). Affected individuals have 
      clinical features that are similar to DM including myotonia, distal weakness, 
      frontal balding, polychromatic cataracts, infertility and cardiac arrhythmias. 
      Genetic analyses reveal that affected individuals do not have the CTG expansion 
      associated with DM, nor is the disease locus linked to the DM region of 
      chromosome 19. We have also excluded the MN1 disease locus from the chromosomal 
      regions containing the genes for the muscle sodium (alpha- and beta-subunits) and 
      chloride channels, both of which are involved in other myotonic disorders. We 
      have recently mapped the disease locus (DM2) in this family to a 10 cM region of 
      chromosome 3q [Ranum LPW, Rasmussen PF, Benzow KA, Koob MD, Day JW. Nat Genet 
      1998;19:196-198]. The genetically distinct form of myotonic dystrophy in the MN1 
      kindred shares some of the clinical features of previously reported families with 
      proximal myotonic myopathy (PROMM). The size of the MN1 family (25 affected 
      individuals) makes it a unique resource for both clinical and genetic studies. 
      This second form of myotonic dystrophy may help resolve the confusion that 
      remains about how the CTG repeat expansion in the 3' untranslated portion of the 
      myotonin protein kinase gene causes the multisystem involvement of DM.
FAU - Day, J W
AU  - Day JW
AD  - Department of Neurology, University of Minnesota, Minneapolis 55455-0323, USA. 
      johnday@tc.umn.edu
FAU - Roelofs, R
AU  - Roelofs R
FAU - Leroy, B
AU  - Leroy B
FAU - Pech, I
AU  - Pech I
FAU - Benzow, K
AU  - Benzow K
FAU - Ranum, L P
AU  - Ranum LP
LA  - eng
GR  - R01 NS35870/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (Ion Channels)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Arrhythmias, Cardiac/physiopathology
MH  - Chromosome Mapping
MH  - Chromosomes, Human, Pair 3/genetics
MH  - Chromosomes, Human, Pair 9/genetics
MH  - DNA/analysis/genetics
MH  - Electromyography
MH  - Endocrine Glands/physiopathology
MH  - Female
MH  - Genetic Heterogeneity
MH  - Humans
MH  - Ion Channels/genetics/metabolism
MH  - Lens, Crystalline/pathology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology
MH  - Myotonic Dystrophy/*genetics/pathology/*physiopathology
MH  - Pedigree
EDAT- 1999/03/04 00:00
MHDA- 1999/03/04 00:01
CRDT- 1999/03/04 00:00
PHST- 1999/03/04 00:00 [pubmed]
PHST- 1999/03/04 00:01 [medline]
PHST- 1999/03/04 00:00 [entrez]
AID - S0960-8966(98)00094-7 [pii]
AID - 10.1016/s0960-8966(98)00094-7 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 1999 Jan;9(1):19-27. doi: 10.1016/s0960-8966(98)00094-7.

PMID- 9950368
OWN - NLM
STAT- MEDLINE
DCOM- 19990421
LR  - 20211203
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 36
IP  - 1
DP  - 1999 Jan
TI  - Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age 
      at onset is significant only for patients with small expansions.
PG  - 59-61
AB  - Myotonic dystrophy (DM) was the first of a group of diseases to be identified for 
      which the genetic basis is the expansion of a triplet repeat. Myotonic dystrophy 
      also exhibits anticipation, in which the disease worsens through successive 
      generations. These two features have led many groups to analyse whether a 
      significant negative correlation between triplet repeat length and severity of 
      disease exists. However, the recent molecular finding that two distinct subsets 
      of classically affected DM patients exist, those who export expansion derived 
      DMPK RNA and those who do not, led us to question whether combining data from 
      these two sets of patients is statistically valid. We found that although 
      patients with small expansions showed a significant correlation between age at 
      onset and triplet repeat length, those with larger expansions did not. The 
      theoretical triplet repeat size, which separated the two groups, was also 
      deduced.
FAU - Hamshere, M G
AU  - Hamshere MG
AD  - Department of Genetics, Queen's Medical Centre, University of Nottingham, UK.
FAU - Harley, H
AU  - Harley H
FAU - Harper, P
AU  - Harper P
FAU - Brook, J D
AU  - Brook JD
FAU - Brookfield, J F
AU  - Brookfield JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Age of Onset
MH  - Aged
MH  - Humans
MH  - Myotonic Dystrophy/blood/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/blood/genetics
MH  - Trinucleotide Repeats/*genetics
PMC - PMC1762955
EDAT- 1999/02/09 00:00
MHDA- 1999/02/09 00:01
PMCR- 2002/01/01
CRDT- 1999/02/09 00:00
PHST- 1999/02/09 00:00 [pubmed]
PHST- 1999/02/09 00:01 [medline]
PHST- 1999/02/09 00:00 [entrez]
PHST- 2002/01/01 00:00 [pmc-release]
PST - ppublish
SO  - J Med Genet. 1999 Jan;36(1):59-61.

PMID- 9887331
OWN - NLM
STAT- MEDLINE
DCOM- 19990318
LR  - 20190512
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 8
IP  - 1
DP  - 1999 Jan
TI  - Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded 
      in myotonic dystrophy.
PG  - 53-60
AB  - Myotonic dystrophy (DM) is a neuromuscular disorder associated with CTG triplet 
      repeat expansion in the myotonin protein kinase gene ( DMPK ). We previously 
      proposed a hypothesis suggesting that the expanded CUG repeats sequester specific 
      RNA-binding proteins and that such a sequestration results in abnormal RNA 
      processing of several RNAs containing CUG repeats in multiple tissues affected in 
      patients with DM. One of the members of the CUG-binding proteins, CUG-BP, has 
      been identified previously. Here we describe the second member of this family, 
      elav -type ribonucleoprotein (ETR-3), which is highly expressed in heart and is 
      able to interact with CUG repeats. Screening of a mouse liver cDNA library with a 
      CUG-BP probe identified two mETR-3 cDNAs. Two additional cDNAs from mouse heart 
      were amplified by RT-PCR. These cDNAs differ by several insertions/deletions and 
      might be generated via alternative splicing. Mouse ETR-3 has a mol. wt of 50 kDa 
      and displays a high level of homology to CUG-BP protein. The organization of the 
      RNA-binding domains (RBDs) within the ETR-3 molecule is similar to one within 
      CUG-BP. A study of mETR-3 RNA-binding activity showed that the mETR-3 binds to 
      (CUG)8repeats. Sequence analysis of mETR-3 indicates the presence of several CUG 
      repeats within the mETR-3 mRNA. Both CUG-BP and mETR-3 bind to mETR-3 mRNA via 
      CUG repeats, suggesting the possible involvement of CUG-BP-like proteins in the 
      regulation of mETR-3 processing. Analysis of the tissue distribution of ETR-3 
      showed that in human cells, ETR-3 mRNA is highly expressed in heart, but is 
      undetectable in other tissues examined. Our results suggest the existence of a 
      family of proteins that bind to CUG repeats and might be affected in DM by 
      expansion of CUG repeats.
FAU - Lu, X
AU  - Lu X
AD  - Departments of Medicine, Section of Cardiology and Pathology, Baylor College of 
      Medicine, One Baylor Plaza, Houston, TX 77030, USA.
FAU - Timchenko, N A
AU  - Timchenko NA
FAU - Timchenko, L T
AU  - Timchenko LT
LA  - eng
SI  - GENBANK/Y18298
GR  - AR44387/AR/NIAMS NIH HHS/United States
GR  - HL54313-02/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (CELF Proteins)
RN  - 0 (CELF2 protein, human)
RN  - 0 (DNA Primers)
RN  - 0 (DNA, Complementary)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 63231-63-0 (RNA)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Binding Sites/genetics
MH  - CELF Proteins
MH  - DNA Primers/genetics
MH  - DNA, Complementary/genetics
MH  - HeLa Cells
MH  - Humans
MH  - In Vitro Techniques
MH  - Mice
MH  - Molecular Sequence Data
MH  - Myocardium/metabolism
MH  - Myotonic Dystrophy/*genetics/*metabolism
MH  - Nerve Tissue Proteins
MH  - RNA/*genetics/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - *Trinucleotide Repeat Expansion
EDAT- 1999/01/15 00:00
MHDA- 1999/01/15 00:01
CRDT- 1999/01/15 00:00
PHST- 1999/01/15 00:00 [pubmed]
PHST- 1999/01/15 00:01 [medline]
PHST- 1999/01/15 00:00 [entrez]
AID - ddc012 [pii]
AID - 10.1093/hmg/8.1.53 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1999 Jan;8(1):53-60. doi: 10.1093/hmg/8.1.53.

PMID- 9858828
OWN - NLM
STAT- MEDLINE
DCOM- 19990201
LR  - 20211203
IS  - 0301-0171 (Print)
IS  - 0301-0171 (Linking)
VI  - 82
IP  - 3-4
DP  - 1998
TI  - Fluorescence in situ hybridization analysis of the replication properties of the 
      myotonic dystrophy protein kinase (DMPK) gene region.
PG  - 247-50
AB  - Myotonic dystrophy (DM) is caused by an expansion of a CTG repeat sequence in the 
      3' noncoding region of a protein kinase gene (DMPK) at 19q13.3. We used in situ 
      hybridization to analyse the replication timing of the genomic region containing 
      DMPK in fibroblasts and myoblasts from controls and myotonic dystrophy patients. 
      In this method the relative proportion of singlet to doublet hybridization 
      signals is used to infer the relative time of replication of specific loci or 
      regions. Our results show that in cells from normal individuals approximately 65% 
      of signals appear as doublets, indicating early replication. In DM patients with 
      a number of CTG repeats ranging from about 600-1800 we observed a significant 
      increase of singlet-doublets compared to the background level. These results 
      suggest the existence of replication alternations and/or structural differences 
      between the normal and mutant alleles induced by the presence of the DM mutation.
FAU - Rajcan-Separovic, E
AU  - Rajcan-Separovic E
AD  - British Columbia's Children's Hospital, Vancouver, BC (Canada). 
      eseparovic@wog.childhosp.bc.ca
FAU - Barcelo, J M
AU  - Barcelo JM
FAU - Korneluk, R G
AU  - Korneluk RG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Cytogenet Cell Genet
JT  - Cytogenetics and cell genetics
JID - 0367735
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Cells, Cultured
MH  - Cosmids
MH  - DNA Mutational Analysis
MH  - *DNA Replication
MH  - Fibroblasts/cytology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Muscle Fibers, Skeletal/cytology
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Skin/cytology
MH  - *Trinucleotide Repeats
EDAT- 1998/12/22 03:02
MHDA- 2000/08/16 11:00
CRDT- 1998/12/22 03:02
PHST- 1998/12/22 03:02 [pubmed]
PHST- 2000/08/16 11:00 [medline]
PHST- 1998/12/22 03:02 [entrez]
AID - ccg82247 [pii]
AID - 10.1159/000015111 [doi]
PST - ppublish
SO  - Cytogenet Cell Genet. 1998;82(3-4):247-50. doi: 10.1159/000015111.

PMID- 9856556
OWN - NLM
STAT- MEDLINE
DCOM- 19990217
LR  - 20041117
IS  - 0148-7299 (Print)
IS  - 0148-7299 (Linking)
VI  - 80
IP  - 4
DP  - 1998 Dec 4
TI  - Different patterns of obstetric complications in myotonic dystrophy in relation 
      to the disease status of the fetus.
PG  - 314-21
AB  - The obstetric histories of 26 women with myotonic dystrophy (DM), who had a total 
      of 67 gestations, were reviewed retrospectively comparing gestations with 
      affected (DM-fetuses) and unaffected fetuses (UA-fetuses). Second, the influence 
      of gestation on the disease course and the personal attitude towards family 
      planning in DM was assessed. Miscarriages and terminations occurred in 11 
      pregnancies. Of the 56 infants carried to term, 29 had or most likely had 
      inherited the gene for DM from their affected mothers at the time of 
      investigation; 18 (61%) in this series were affected by the congenital form of 
      DM. Perinatal loss rate was 11% and associated with congenital DM. The rate of 
      obstetric complications was significantly increased in all women. However, 
      preterm labor was a major problem in gestations with DM-fetuses (55 vs. 20%), as 
      was polyhydramnios (21% vs. none). While forceps deliveries or vacuum extractions 
      were required in 21% of deliveries with DM-fetuses and only 5% of UA-fetuses, the 
      frequency of Cesarean sections was similar in both groups (24 and 25%). Obstetric 
      problems were inversely correlated with age at onset of maternal DM, while no 
      effect of age at delivery or birth order on gestational outcome was seen. DNA 
      analysis confirmed the diagnosis in 19 patients by the presence of enlarged CTG 
      repeats (EcoRI-expansions) on chromosome 19. Of the 17 patients whose CTG repeat 
      length was known, 59% were classified as E2 (corresponding to 500-1000 repeats), 
      24% as E1 (<500 repeats), while larger expansions (E3; 1000-1500 repeats, or E4; 
      >1500 repeats) were seen in three patients (17%). Obstetric complications or 
      congenitally affected children occurred in all maternal phenotypes and CTG repeat 
      classes. Eight (31%) patients experienced a worsening of symptoms that was 
      temporary, weight related in three cases, and persistent in five. With the 
      exception of three patients, most new mothers were able to care for their 
      families. To conclude, pregnant women with DM need constant obstetric monitoring 
      and should be advised to deliver in centres with perinatal facilities.
FAU - Rudnik-Schoneborn, S
AU  - Rudnik-Schoneborn S
AD  - Institute for Human Genetics, University of Bonn, Germany. 
      rudnik@humgen.uni.bonn.de
FAU - Nicholson, G A
AU  - Nicholson GA
FAU - Morgan, G
AU  - Morgan G
FAU - Rohrig, D
AU  - Rohrig D
FAU - Zerres, K
AU  - Zerres K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Med Genet
JT  - American journal of medical genetics
JID - 7708900
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Female
MH  - Fetal Death/etiology
MH  - Fetal Diseases/etiology/genetics
MH  - Fetus/pathology
MH  - Humans
MH  - Maternal Age
MH  - Myotonic Dystrophy/*complications/genetics/pathology
MH  - Pregnancy
MH  - Pregnancy Complications/pathology/*physiopathology
MH  - Retrospective Studies
EDAT- 1998/12/18 03:03
MHDA- 2000/06/20 09:00
CRDT- 1998/12/18 03:03
PHST- 1998/12/18 03:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/12/18 03:03 [entrez]
AID - 10.1002/(SICI)1096-8628(19981204)80:4<314::AID-AJMG3>3.0.CO;2-I [pii]
PST - ppublish
SO  - Am J Med Genet. 1998 Dec 4;80(4):314-21.

PMID- 9776468
OWN - NLM
STAT- MEDLINE
DCOM- 19981230
LR  - 20211203
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 245
IP  - 10
DP  - 1998 Oct
TI  - Saccadic slowing in myotonic dystrophy and CTG repeat expansion.
PG  - 674-80
AB  - Recent studies have shown that the severity of the several clinical symptoms of 
      myotonic dystrophy (DM) is closely related to the size of a CTG triplet repeat in 
      the gene encoding myotonin protein kinase. Although neurotological findings, 
      including saccadic slowing in patients with DM, have been reported, the 
      relationship between these neurotological findings and elongation of the CTG 
      triplet repeat has not been discussed to our knowledge. We made a case-control 
      study that compared the saccadic velocity in 13 patients with DM and in 13 
      controls matched for age and sex. We also examined the correlation between the 
      saccadic velocity in DM patients and the size of the expanded DNA fragment (EF) 
      obtained by Southern blot analysis with EcoRI or BglI. We found: (1) The primary 
      eye position was normal in 9 of 12 patients. Divergent strabismus was present in 
      3 patients. (2) The range of ocular movement was normal in 2 patients, nearly 
      normal in 5 and minimally limited in the other 5. (3) Only 1 patient had lateral 
      gaze nystagmus, which was fine and transient. (4) The horizontal saccades were 
      essentially normometric in 11 of the 13 patients, slightly hypometric in 1 and 
      obviously hypometric in 1. These last 2 patients had the second longest and 
      longest EF sizes. The vertical saccades were essentially normometric in 8 of 12 
      patients, hypermetric in 3, and hypometric in the 1 with the longest EF size. (5) 
      The saccadic velocity in the DM patients was significantly lower than that in the 
      controls in the horizontal or vertical direction, the difference being more 
      prominent in the horizontal direction. (6) The correlation coefficients between 
      horizontal saccadic velocity and EF size, 0.801 (EcoRI) and 0.756 (BglI), had a 
      strong negative correlation (P < 0.01 for both EcoRI and BglI). No statistically 
      significant correlation was found between vertical saccadic velocity (upward and 
      downward) and EF sizes. Although it was difficult to determine whether saccadic 
      slowing was caused by central oculomotor system involvement or extraocular muscle 
      atrophy, the absence of gaze-evoked nystagmus in almost all of the patients 
      favours the latter. Our study shows that neurotological examinations that include 
      a saccadic velocity test are very useful for detecting subtle eye movement 
      abnormalities in DM and for quantitatively evaluating the clinical severity of 
      DM.
FAU - Osanai, R
AU  - Osanai R
AD  - Department of Otolaryngology, Saitama Medical Centre, Saitama Medical School, 
      Kawagoe, Japan.
FAU - Kinoshita, M
AU  - Kinoshita M
FAU - Hirose, K
AU  - Hirose K
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Attention/physiology
MH  - Case-Control Studies
MH  - Female
MH  - Genes, Dominant
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/genetics/*physiopathology
MH  - Myotonin-Protein Kinase
MH  - Nystagmus, Physiologic/physiology
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - Reaction Time/*physiology
MH  - Saccades/*physiology
MH  - *Trinucleotide Repeats
EDAT- 1998/10/17 00:00
MHDA- 1998/10/17 00:01
CRDT- 1998/10/17 00:00
PHST- 1998/10/17 00:00 [pubmed]
PHST- 1998/10/17 00:01 [medline]
PHST- 1998/10/17 00:00 [entrez]
AID - 10.1007/s004150050266 [doi]
PST - ppublish
SO  - J Neurol. 1998 Oct;245(10):674-80. doi: 10.1007/s004150050266.

PMID- 9668171
OWN - NLM
STAT- MEDLINE
DCOM- 19980909
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 7
IP  - 8
DP  - 1998 Aug
TI  - Somatic instability of the CTG repeat in mice transgenic for the myotonic 
      dystrophy region is age dependent but not correlated to the relative intertissue 
      transcription levels and proliferative capacities.
PG  - 1285-91
AB  - A (CTG)nexpansion in the 3'-untranslated region (UTR) of the DM protein kinase 
      gene ( DMPK ) is responsible for causing myotonic dystrophy (DM). Major 
      instability, with very large expansions between generations and high levels of 
      somatic mosaicism, is observed in patients. There is a good correlation between 
      repeat size (at least in leucocytes), clinical severity and age of onset. The 
      trinucleotide repeat instability mechanisms involved in DM and other human 
      genetic diseases are unknown. We studied somatic instability by measuring the CTG 
      repeat length at several ages in various tissues of transgenic mice carrying a 
      (CTG)55expansion surrounded by 45 kb of the human DM region, using small-pool 
      PCR. These mice have been shown to reproduce the intergenerational and somatic 
      instability of the 55 CTG repeat suggesting that surrounding sequences and the 
      chromatin environment are involved in instability mechanisms. As observed in some 
      of the tissues of DM patients, there is a tendency for repeat length and somatic 
      mosaicism to increase with the age of the mouse. Furthermore, we observed no 
      correlation between the somatic mutation rate and tissue proliferation capacity. 
      The somatic mutation rates in different tissues were also not correlated to the 
      relative inter-tissue difference in transcriptional levels of the three genes 
      (DMAHP , DMPK and 59) surrounding the repeat.
FAU - Lia, A S
AU  - Lia AS
AD  - INSERM UR383, Hopital Necker-Enfants Malades, clinique Maurice Lamy, 149-161 rue 
      de Sevres, 75743 Paris, Cedex 15, France.
FAU - Seznec, H
AU  - Seznec H
FAU - Hofmann-Radvanyi, H
AU  - Hofmann-Radvanyi H
FAU - Radvanyi, F
AU  - Radvanyi F
FAU - Duros, C
AU  - Duros C
FAU - Saquet, C
AU  - Saquet C
FAU - Blanche, M
AU  - Blanche M
FAU - Junien, C
AU  - Junien C
FAU - Gourdon, G
AU  - Gourdon G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Cell Division
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Muscle, Skeletal/pathology/physiopathology
MH  - Myotonic Dystrophy/*genetics/*pathology/*physiopathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - *Transcription, Genetic
EDAT- 1998/07/21 00:00
MHDA- 1998/07/21 00:01
CRDT- 1998/07/21 00:00
PHST- 1998/07/21 00:00 [pubmed]
PHST- 1998/07/21 00:01 [medline]
PHST- 1998/07/21 00:00 [entrez]
AID - ddb155 [pii]
AID - 10.1093/hmg/7.8.1285 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1998 Aug;7(8):1285-91. doi: 10.1093/hmg/7.8.1285.

PMID- 9649014
OWN - NLM
STAT- MEDLINE
DCOM- 19980902
LR  - 20190817
IS  - 0192-0790 (Print)
IS  - 0192-0790 (Linking)
VI  - 26
IP  - 4
DP  - 1998 Jun
TI  - Abnormal liver test results in myotonic dystrophy.
PG  - 292-5
AB  - Myotonic dystrophy (DM) is an autosomal dominant multisystem disorder. Little 
      evidence suggests the existence of liver damage in a small number of patients. We 
      have prospectively evaluated liver and gallbladder function in 53 patients with 
      DM in relation to clinical and genetic parameters. None of the patients had an 
      enlarged liver, signs of cirrhosis, or portal hypertension. All were free of 
      medication, and none were pregnant or had a history of alcohol abuse. In 35 (66%) 
      patients, serum activity of at least one of six liver enzymes assayed was 
      abnormal. An elevated level of alkaline phosphatase was found in 50.9%, of 
      gamma-glutamyltransferase in 52.8%, of 5' nucleotidase in 43.4%, of serum 
      aspartate aminotransferase in 35.8%, of serum alanine aminotransferase in 33.9%, 
      and of lactate dehydrogenase in 37.7%. Liver function test results did not 
      correlate with severity of muscle weakness, disease duration, or serum levels of 
      creatine kinase, glucose, or lipids. Motility of gallbladder and abdominal 
      ultrasonography were normal. Cytosine-thymidine-guanine repeat expansion by 
      southern blot did not correlate with liver enzyme abnormalities. We conclude that 
      elevation of liver enzymes is frequent in DM and should be included as an 
      additional laboratory finding of the disease.
FAU - Achiron, A
AU  - Achiron A
AD  - Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel.
FAU - Barak, Y
AU  - Barak Y
FAU - Magal, N
AU  - Magal N
FAU - Shohat, M
AU  - Shohat M
FAU - Cohen, M
AU  - Cohen M
FAU - Barar, R
AU  - Barar R
FAU - Gadoth, N
AU  - Gadoth N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
SB  - IM
MH  - Blotting, Southern
MH  - *Clinical Enzyme Tests
MH  - Female
MH  - Gallbladder Emptying
MH  - Humans
MH  - Liver/*enzymology
MH  - Liver Function Tests
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis/genetics/physiopathology
MH  - Prospective Studies
MH  - Trinucleotide Repeats
EDAT- 1998/07/02 00:00
MHDA- 1998/07/02 00:01
CRDT- 1998/07/02 00:00
PHST- 1998/07/02 00:00 [pubmed]
PHST- 1998/07/02 00:01 [medline]
PHST- 1998/07/02 00:00 [entrez]
AID - 10.1097/00004836-199806000-00016 [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 1998 Jun;26(4):292-5. doi: 
      10.1097/00004836-199806000-00016.

PMID- 9617710
OWN - NLM
STAT- MEDLINE
DCOM- 19980827
LR  - 20190831
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 245
IP  - 5
DP  - 1998 May
TI  - A new non-radioactive method for the screening and prenatal diagnosis of myotonic 
      dystrophy patients.
PG  - 289-93
AB  - Myotonic dystrophy (DM) is an autosomal dominant neuromuscular disease with an 
      estimated incidence of 1 in 8000 and is the most common form of muscular 
      dystrophy affecting adults. An unstable, untranslated part of the myotonic 
      dystrophy protein kinase gene on the long arm of chromosome 19, composed of CTG 
      repeats, is a genetic marker for DM. We have developed a fast non-radioactive 
      polymerase chain reaction (PCR) procedure to detect the (CTG)n repeat expansion 
      in DM patients and their relatives. Genomic DNA extracted from peripheral blood 
      lymphocytes was amplified by PCR using specific primers to flank the region 
      containing the triplets. To improve the amplification of this CG-rich region, 
      either 10% glycerol or rTth DNA polymerase XL (extra long) was added to the 
      reaction mixture, allowing amplification of huge expansions otherwise not 
      polymerized by PCR. The PCR products were Southern blotted and the expansion 
      revealed using a fluorescein-labelled (CTG)10 probe. We compared our results with 
      those obtained in 24 patients and relatives using genomic digestion followed by 
      radioactive Southern blot; in all cases the results overlapped. The same 
      technique was used for prenatal diagnosis in pregnant DM mothers. We conclude 
      that this new method is reliable for the genetic testing of DM patients.
FAU - Brugnoni, R
AU  - Brugnoni R
AD  - Divisione Malattie Neuromuscolari, Istituto Nazionale Neurologico C. Besta, 
      Milan, Italy.
FAU - Morandi, L
AU  - Morandi L
FAU - Brambati, B
AU  - Brambati B
FAU - Briscioli, V
AU  - Briscioli V
FAU - Cornelio, F
AU  - Cornelio F
FAU - Mantegazza, R
AU  - Mantegazza R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - TPY09G7XIR (Fluorescein)
SB  - IM
MH  - Adult
MH  - Blotting, Southern
MH  - Female
MH  - Fluorescein
MH  - Genome, Human
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - Myotonic Dystrophy/*diagnosis
MH  - Pedigree
MH  - Predictive Value of Tests
MH  - Pregnancy
MH  - *Prenatal Diagnosis
MH  - *Trinucleotide Repeats
EDAT- 1998/06/09 00:00
MHDA- 1998/06/09 00:01
CRDT- 1998/06/09 00:00
PHST- 1998/06/09 00:00 [pubmed]
PHST- 1998/06/09 00:01 [medline]
PHST- 1998/06/09 00:00 [entrez]
AID - 10.1007/s004150050220 [doi]
PST - ppublish
SO  - J Neurol. 1998 May;245(5):289-93. doi: 10.1007/s004150050220.

PMID- 9604547
OWN - NLM
STAT- MEDLINE
DCOM- 19980611
LR  - 20211203
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 107
DP  - 1998 Apr
TI  - Correlation of clinical profile of myotonic dystrophy with CTG repeats in the 
      myotonin protein kinase gene.
PG  - 187-96
AB  - The molecular genetic analyses (PCR and Southern hybridization) of Indian 
      patients with myotonic dystrophy (DM) were carried out to determine the degree of 
      repeat expansion and an attempt was made to correlate the repeat number with 
      disease severity. A scoring system based on the salient clinical features was 
      devised to objectively assess the disease severity. The repeat expansion was seen 
      in 11 of 12 patients examined and showed an inverse correlation with the age of 
      onset confirming the phenomenon of anticipation. This was further established in 
      the two pedigrees studied, clearly demonstrating both clinical and genetic 
      anticipation. The clinical severity score, however, did not correlate well with 
      the repeat number. Nonetheless, such molecular genetic analyses may have immense 
      value as a screening procedure to identify premutations as well as in prenatal 
      diagnoses.
FAU - Gourie-Devi, M
AU  - Gourie-Devi M
AD  - Department of Neurology, National Institute of Mental Health & Neuro Sciences 
      (Deemed University), Bangalore.
FAU - Chaudhuri, J R
AU  - Chaudhuri JR
FAU - Vasanth, A
AU  - Vasanth A
FAU - Saleem, Q
AU  - Saleem Q
FAU - Mutsuddi, M
AU  - Mutsuddi M
FAU - Gopinath, M
AU  - Gopinath M
FAU - Sarkar, P S
AU  - Sarkar PS
FAU - Brahmachari, S K
AU  - Brahmachari SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1998/05/30 00:00
MHDA- 1998/05/30 00:01
CRDT- 1998/05/30 00:00
PHST- 1998/05/30 00:00 [pubmed]
PHST- 1998/05/30 00:01 [medline]
PHST- 1998/05/30 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1998 Apr;107:187-96.

PMID- 9585397
OWN - NLM
STAT- MEDLINE
DCOM- 19980608
LR  - 20061115
IS  - 0742-3071 (Print)
IS  - 0742-3071 (Linking)
VI  - 15
IP  - 4
DP  - 1998 Apr
TI  - Polymorphisms of platelet glycoproteins in relation to macrovascular disease in 
      type 2 diabetes mellitus.
PG  - 315-9
AB  - We set out to determine the genotype distributions of the PI(A) polymorphism of 
      platelet glycoprotein IIIa, the HPA-3 polymorphism of platelet glycoprotein IIb, 
      and the variable number tandem repeat (VNTR) polymorphism of platelet 
      glycoprotein Ib in subjects with Type 2 diabetes mellitus (Type 2 DM) with (n = 
      125) and without (n = 90) a clinical history of macrovascular disease. In 215 
      white European subjects with Type 2 DM, presence of coronary artery disease was 
      determined as a clinical history of angina, myocardial infarction (MI), coronary 
      angioplasty or coronary artery by-pass grafting. Presence of peripheral vascular 
      disease was defined as a clinical history of intermittent claudication with 
      confirmatory vascular ultrasound or angiography, intermittent claudication with 
      undetectable foot pulses and no history of arthralgia or surgery for leg 
      ischaemia, confirmed by reference to medical case notes. Polymorphisms were 
      detected by polymerase chain reaction amplification of DNA. There was no 
      difference in the genotype distributions of subjects with and without 
      macrovascular disease. In subjects with a first MI before the age of 60 years (n 
      = 26), there was a 38% incidence of PI(A2) compared to 29% in subjects free from 
      clinically evident macrovascular disease, but this difference did not reach 
      statistical significance. This study does not support the hypothesis that 
      polymorphisms of platelet glycoproteins, in particular the PI(A) polymorphism of 
      platelet glycoprotein IIIa, play an important role in the pathogenesis of 
      macrovascular disease in subjects with Type 2 DM.
FAU - Carter, A M
AU  - Carter AM
AD  - Unit of Molecular Vascular Medicine, Research School of Medicine, University of 
      Leeds, Leeds General Infirmary, UK.
FAU - Mansfield, M W
AU  - Mansfield MW
FAU - Grant, P J
AU  - Grant PJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Platelet Glycoprotein GPIb-IX Complex)
SB  - IM
MH  - Coronary Disease/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Diabetic Angiopathies/*blood
MH  - Genotype
MH  - Humans
MH  - Middle Aged
MH  - Minisatellite Repeats
MH  - Peripheral Vascular Diseases/blood
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*genetics
MH  - Platelet Glycoprotein GPIb-IX Complex/*genetics
MH  - *Polymorphism, Genetic
EDAT- 1998/05/19 00:00
MHDA- 1998/05/19 00:01
CRDT- 1998/05/19 00:00
PHST- 1998/05/19 00:00 [pubmed]
PHST- 1998/05/19 00:01 [medline]
PHST- 1998/05/19 00:00 [entrez]
AID - 10.1002/(SICI)1096-9136(199804)15:4<315::AID-DIA590>3.0.CO;2-A [doi]
PST - ppublish
SO  - Diabet Med. 1998 Apr;15(4):315-9. doi: 
      10.1002/(SICI)1096-9136(199804)15:4<315::AID-DIA590>3.0.CO;2-A.

PMID- 9565989
OWN - NLM
STAT- MEDLINE
DCOM- 19980608
LR  - 20191024
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 8
IP  - 1
DP  - 1998 Feb
TI  - Impaired cerebral glucose metabolism in myotonic dystrophy: a triplet-size 
      dependent phenomenon.
PG  - 39-45
AB  - Myotonic dystrophy (DM) is caused by an expansion of a CTG triplet repeat 
      sequence in the 3'-noncoding region of a protein kinase gene, yet the mechanism 
      by which the triplet repeat expansion causes disease remains unknown. Impaired 
      glucose penetration into brain tissues has been described in DM patients and is a 
      phenomenon that remains unexplained. The present study shows that altered brain 
      glucose metabolism is triplet repeat dependent. We studied brain glucose 
      metabolism (CMRGlu, mumol/100 g/min) by the use of positron emission tomography 
      and 18F-fluoro-2-deoxy-D-glucose in 11 ambulatory non-obese DM patients and in 11 
      age and sex matched healthy subjects. All subjects underwent a glucose tolerance 
      test with plasma insulin determinations. The expansion of CTG triplet repeats was 
      analyzed in patients with the probe cDNA25 after EcoRI digestion. As compared to 
      controls, in DM patients, the CMRGlu was significantly decreased (26.26 +/- 5.05 
      vs. 33.43 +/- 2.18, mumol/100 g/min, P = 0.004), and after oral glucose loading, 
      plasma insulin levels were significantly higher and plasma glucose levels 
      remained unchanged (respectively, F = 11.21, P = 0.004 and F = 0.20, P = 0.66). 
      Subsequently, the glucose/insulin ratio was significantly lower in DM patients (F 
      = 6.25, P = 0.02). The length of the expansion of the CTG repeats correlated 
      negatively with the CMRGlu (r2 = 0.63, P = 0.003) and positively with the area 
      under the curve for insulin changes over time after oral glucose (r2 = 0.49, P = 
      0.016). We conclude that, in DM patients, the brain metabolism of glucose is 
      impaired in a repeat dependent manner.
FAU - Annane, D
AU  - Annane D
AD  - Service Hospitalier Frederic Joliot, Departement de Recherche Medicale, 
      Commissariat a L'Energie Atomique, Orsay, France.
FAU - Fiorelli, M
AU  - Fiorelli M
FAU - Mazoyer, B
AU  - Mazoyer B
FAU - Pappata, S
AU  - Pappata S
FAU - Eymard, B
AU  - Eymard B
FAU - Radvanyi, H
AU  - Radvanyi H
FAU - Junien, C
AU  - Junien C
FAU - Fardeau, M
AU  - Fardeau M
FAU - Merlet, P
AU  - Merlet P
FAU - Gajdos, P
AU  - Gajdos P
FAU - Syrota, A
AU  - Syrota A
FAU - Sansom, Y
AU  - Sansom Y
FAU - Duboc, D
AU  - Duboc D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.- (Protein Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Activities of Daily Living
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - Brain/diagnostic imaging/*metabolism
MH  - Female
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Glucose/*metabolism
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/*metabolism/physiopathology
MH  - Protein Kinases/genetics
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Reference Values
MH  - Tomography, Emission-Computed
MH  - *Trinucleotide Repeats
EDAT- 1998/05/05 00:00
MHDA- 1998/05/05 00:01
CRDT- 1998/05/05 00:00
PHST- 1998/05/05 00:00 [pubmed]
PHST- 1998/05/05 00:01 [medline]
PHST- 1998/05/05 00:00 [entrez]
AID - S0960896697001442 [pii]
AID - 10.1016/s0960-8966(97)00144-2 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 1998 Feb;8(1):39-45. doi: 10.1016/s0960-8966(97)00144-2.

PMID- 9550357
OWN - NLM
STAT- MEDLINE
DCOM- 19980521
LR  - 20190816
IS  - 0009-9163 (Print)
IS  - 0009-9163 (Linking)
VI  - 53
IP  - 1
DP  - 1998 Jan
TI  - Genotype-phenotype correlation in myotonic dystrophy.
PG  - 20-6
AB  - Myotonic dystrophy (DM) is caused by a mutation in the length of a trinucleotide 
      (CTG) repeat in the 3' untranslated region of the myotonin protein kinase gene 
      located on chromosome 19q13.3. The normal gene has between 5 and 36 CTG 
      trinucleotide repeats, whereas minimally affected individuals have 50 copies and 
      severely affected DM-patients have several thousands of such repeats. Since no 
      information on a genotype phenotype correlation in Austrian DM-patients is 
      available, we examined a small group of these patients for the unstable 
      trinucleotide repeat. Molecular analysis was used to clarify equivocal clinical 
      diagnoses and confirm clinical findings. We studied eight DM-families, a total of 
      57 individuals, of whom 18 were diagnosed with a trinucleotide repeat expansion. 
      Twenty-six unrelated individuals served as a control. Clinical assessment was 
      based on the muscular disability rating scale (MDRS) and a sum of symptoms score 
      (SSS). There was a significant correlation between the clinical scores (MDRS: 
      Spearman r = 0.51; p = 0.029: SSS: Spearman r = 0.538; p = 0.0259) used and the 
      size of the amplification of the trinucleotide repeat. The largest expansion 
      found in our group of patients was 6 kb. Furthermore, we observed both expansion 
      and contraction of the enlarged fragment during transmission from one generation 
      to the next.
FAU - Gharehbaghi-Schnell, E B
AU  - Gharehbaghi-Schnell EB
AD  - Department of Vascular Biology and Thrombosis Research, Faculty of Medicine, 
      University of Vienna, Austria.
FAU - Finsterer, J
AU  - Finsterer J
FAU - Korschineck, I
AU  - Korschineck I
FAU - Mamoli, B
AU  - Mamoli B
FAU - Binder, B R
AU  - Binder BR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Clin Genet
JT  - Clinical genetics
JID - 0253664
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Phenotype
MH  - Trinucleotide Repeats
EDAT- 1998/04/29 00:00
MHDA- 1998/04/29 00:01
CRDT- 1998/04/29 00:00
PHST- 1998/04/29 00:00 [pubmed]
PHST- 1998/04/29 00:01 [medline]
PHST- 1998/04/29 00:00 [entrez]
AID - 10.1034/j.1399-0004.1998.531530105.x [doi]
PST - ppublish
SO  - Clin Genet. 1998 Jan;53(1):20-6. doi: 10.1034/j.1399-0004.1998.531530105.x.

PMID- 9537423
OWN - NLM
STAT- MEDLINE
DCOM- 19980423
LR  - 20211203
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 18
IP  - 4
DP  - 1998 Apr
TI  - Ribozyme-mediated trans-splicing of a trinucleotide repeat.
PG  - 378-81
AB  - Trinucleotide repeat expansions (TREs) are a recently described class of 
      mutations characterized by a change in the size of the genomic fragment due to 
      amplification of the repeated unit. A number of diseases have been attributed to 
      TRE, including Huntington disease and myotonic dystrophy (DM), but attempts at 
      genetic therapy have yet to prove successful. A potential therapeutic approach 
      would be to repair the expanded repeat using the trans-splicing ability of group 
      I intron ribozymes. We have used DM as a model to test this hypothesis. A group I 
      intron ribozyme (DMPK-RZ1) was designed to modify the TRE at the 3' end of the 
      human myotonic dystrophy protein kinase (DMPK) transcripts. DMPK-RZ1 was shown to 
      ligate a small DMPK mRNA fragment, contained within the ribozyme, to a simple 
      DMPK-target RNA in vitro. It also modified a larger target transcript, leading to 
      replacement of twelve repeats with five repeats, both in vitro and in mammalian 
      cells. Finally, this ribozyme successfully replaced the 3' end of endogenous DMPK 
      mRNA in fibroblasts with a different 3' region. Ribozyme-mediated RNA repair may 
      thus form a novel therapeutic strategy for diseases associated with repeat 
      expansions.
FAU - Phylactou, L A
AU  - Phylactou LA
AD  - Department of Human Anatomy, Oxford University, United Kingdom. 
      leonidas.phylactou@anat.ox.ac.uk
FAU - Darrah, C
AU  - Darrah C
FAU - Wood, M J
AU  - Wood MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Catalytic)
RN  - 0 (RNA, Messenger)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Cell Line
MH  - Humans
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA/analysis/genetics
MH  - RNA Splicing/*drug effects
MH  - RNA, Catalytic/metabolism/*pharmacology
MH  - RNA, Messenger/analysis/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 1998/04/16 00:00
MHDA- 1998/04/16 00:01
CRDT- 1998/04/16 00:00
PHST- 1998/04/16 00:00 [pubmed]
PHST- 1998/04/16 00:01 [medline]
PHST- 1998/04/16 00:00 [entrez]
AID - 10.1038/ng0498-378 [doi]
PST - ppublish
SO  - Nat Genet. 1998 Apr;18(4):378-81. doi: 10.1038/ng0498-378.

PMID- 9503753
OWN - NLM
STAT- MEDLINE
DCOM- 19980422
LR  - 20041117
IS  - 0030-1876 (Print)
IS  - 0030-1876 (Linking)
VI  - 91
IP  - 1
DP  - 1998 Jan-Feb
TI  - Clinical expression of myotonic dystrophy: the predictive role of DNA diagnosis.
PG  - 7-10
AB  - Myotonic dystrophy (DM), the most common muscular dystrophy of adult life, 
      presents with a variety of clinical and genetic challenges to all involved; 
      patients, their families, and clinicians. The clinical picture is extremely 
      variable and may range from mild adult onset myotonia to severe congenital 
      hypotonia associated with respiratory distress. An infant born to a mother with 
      DM had remarkable hypotonia, expressionless face, respiratory difficulties, and 
      club feet. Direct molecular genetic testing of the newborn and the mother showed 
      trinucleotide repeat expansion mutations. Genetic counseling issues as well as 
      the value of prenatal diagnosis are presented.
FAU - Can, B
AU  - Can B
AD  - Chapman Institute of Medical Genetics, Tulsa, Oklahoma 74135, USA.
FAU - Schaefer, F V
AU  - Schaefer FV
FAU - Malik, S
AU  - Malik S
FAU - Floyd, M
AU  - Floyd M
FAU - Say, B
AU  - Say B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Okla State Med Assoc
JT  - The Journal of the Oklahoma State Medical Association
JID - 7503043
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - DNA/*genetics
MH  - Female
MH  - Genetic Counseling
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - *Polymerase Chain Reaction
MH  - Pregnancy
MH  - Prenatal Diagnosis
MH  - Trinucleotide Repeats/genetics
EDAT- 1998/03/21 00:00
MHDA- 1998/03/21 00:01
CRDT- 1998/03/21 00:00
PHST- 1998/03/21 00:00 [pubmed]
PHST- 1998/03/21 00:01 [medline]
PHST- 1998/03/21 00:00 [entrez]
PST - ppublish
SO  - J Okla State Med Assoc. 1998 Jan-Feb;91(1):7-10.

PMID- 9425239
OWN - NLM
STAT- MEDLINE
DCOM- 19980317
LR  - 20190512
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 7
IP  - 2
DP  - 1998 Feb
TI  - Progression of somatic CTG repeat length heterogeneity in the blood cells of 
      myotonic dystrophy patients.
PG  - 307-12
AB  - The genetic basis of myotonic dystrophy (DM) is the expansion of an unstable CTG 
      repeat in the 34 UTR of the DM protein kinase gene on chromosome 19. One of the 
      principal features of the DM mutation is an extraordinarily high level of somatic 
      mosaicism, due to an extremely high degree of somatic instability both within and 
      between different tissues. This instability appears to be biased towards further 
      expansion and continuous throughout the life of an individual, features that 
      could be associated with the progressive nature of the disease. Although 
      increasing measured allele size between patients clearly correlates with an 
      increased severity of symptoms and an earlier age of onset, this correlation is 
      not precise and measured allele length cannot be used as an accurate predictor of 
      age of onset. In order to further characterize the dynamics of DM CTG repeat 
      somatic instability, we have studied repeat length changes over time in 111 
      myotonic dystrophy patients with varying clinical severity and CTG repeat size 
      over time intervals of 1-7 years. We have found a direct progression of the size 
      heterogeneity over time related to initial CTG repeat size and the time interval 
      and always biased towards further expansion. Attempts to mathematically model the 
      dynamics have proved only partially successful suggesting that individual 
      specific genetic and/or environmental factors also play a role in somatic 
      mosaicism.
FAU - Martorell, L
AU  - Martorell L
AD  - Unitat de Genetica Molecular and Institut de Recerca, Hospital de Sant Pau, Pare 
      Claret 167, 08025 Barcelona, Spain.
FAU - Monckton, D G
AU  - Monckton DG
FAU - Gamez, J
AU  - Gamez J
FAU - Johnson, K J
AU  - Johnson KJ
FAU - Gich, I
AU  - Gich I
FAU - Lopez de Munain, A
AU  - Lopez de Munain A
FAU - Baiget, M
AU  - Baiget M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Alleles
MH  - Child
MH  - Chromosomes, Human, Pair 19/*genetics
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant, Newborn
MH  - Leukocytes/*chemistry
MH  - *Mosaicism
MH  - Myotonic Dystrophy/blood/epidemiology/*genetics
MH  - Organ Specificity
MH  - Polymerase Chain Reaction
MH  - Time Factors
MH  - *Trinucleotide Repeats
EDAT- 1998/03/21 00:00
MHDA- 1998/03/21 00:01
CRDT- 1998/03/21 00:00
PHST- 1998/03/21 00:00 [pubmed]
PHST- 1998/03/21 00:01 [medline]
PHST- 1998/03/21 00:00 [entrez]
AID - ddb033 [pii]
AID - 10.1093/hmg/7.2.307 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1998 Feb;7(2):307-12. doi: 10.1093/hmg/7.2.307.

PMID- 9402536
OWN - NLM
STAT- MEDLINE
DCOM- 19980129
LR  - 20190831
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 244
IP  - 10
DP  - 1997 Oct
TI  - Abnormal calcium metabolism in myotonic dystrophy as shown by the 
      Ellsworth-Howard test and its relation to CTG triplet repeat length.
PG  - 613-22
AB  - Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by 
      peculiar clinical features. Its molecular basis is the unstable expansion of a 
      CTG triplet repeat in the gene encoding myotonin protein kinase (Mt-PK), the 
      nucleotide sequence of which has extensive homology to the cyclic AMP 
      (cAMP)-dependent protein kinase gene. Extensive efforts have been made to clarify 
      the signal transduction pathway in which the responsible gene operates, but 
      confirming evidence has yet to be obtained. Because some symptoms in DM are 
      similar to those in hypoparathyroidism, we divided 24 DM patients into two groups 
      on the basis of their serum calcium levels; Group 1, those with normocalcemia (11 
      patients), and group 2, those with hypocalcemia (13 patients). The highly 
      sensitive parathyroid hormone (HS-PTH) plasma levels in group 1 were within 
      normal limits, whereas those in group 2 were abnormally high. Laboratory findings 
      for the group 2 patients resembled those for pseudohypoparathyroidism (PHP), 
      whereas those for group 1 patients were normal. The Ellsworth-Howard (EH) test 
      was used to determine which type of PHP the group 2 patients belonged to. Both 
      the phosphaturic (delta P) and urinary cAMP (UcAMP) responses were estimated. The 
      delta P responses in group 2 were significantly lower than those in group 1, but 
      their UcAMP responses did not differ. This is evidence that group 2 patients had 
      PHP type II, whereas group 1 patients were normal. We also investigated whether 
      the disease severity differed between the groups. Cataracts, ectopic 
      calcifications, and ossifications, which are associated with PHP, were more 
      frequent in group 2. In addition, the mean IQ in that group was significantly 
      lower. Clinically, the group 2 signs agreed well with those of PHP, whereas for 
      group 1 there was only a slight similarity. These results are additional evidence 
      that the patients in group 2 have abnormal calcium metabolism, the abnormality 
      being in the postadenylate cyclase-cAMP pathway in the renal tubular cells. The 
      degree of (CTG)n expansion, the so-called expanded DNA fragment (EF) size, was 
      determined by standard Southern blot analysis. The allelic EF sizes in both 
      groups were greater than in the healthy controls. Moreover, those in group 2 were 
      significantly longer than those in group 1. We therefore investigated whether EF 
      size is correlated with the serum calcium and plasma PTH levels, the delta P 
      responses in the EH test, and IQ. All these items were significantly correlated 
      with EF size. Our findings show that the expanded DNA fragment size in DM is 
      correlated with the degree of abnormal calcium metabolism.
FAU - Kinoshita, M
AU  - Kinoshita M
AD  - Fourth Department of Internal Medicine, Saitama Medical Center, Saitama Medical 
      School, Japan.
FAU - Komori, T
AU  - Komori T
FAU - Ohtake, T
AU  - Ohtake T
FAU - Takahashi, R
AU  - Takahashi R
FAU - Nagasawa, R
AU  - Nagasawa R
FAU - Hirose, K
AU  - Hirose K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - E0399OZS9N (Cyclic AMP)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Calcium/*metabolism
MH  - Cyclic AMP/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*metabolism
MH  - Pseudohypoparathyroidism/diagnosis/*metabolism
MH  - *Trinucleotide Repeats
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - 10.1007/s004150050155 [doi]
PST - ppublish
SO  - J Neurol. 1997 Oct;244(10):613-22. doi: 10.1007/s004150050155.

PMID- 9401353
OWN - NLM
STAT- MEDLINE
DCOM- 19980115
LR  - 20191024
IS  - 0025-5564 (Print)
IS  - 0025-5564 (Linking)
VI  - 147
IP  - 1
DP  - 1998 Jan 1
TI  - Dynamic balance of segregation distortion and selection maintains normal allele 
      sizes at the myotonic dystrophy locus.
PG  - 93-112
AB  - Myotonic dystrophy (DM), an autosomal dominant neurological disorder, is caused 
      by CTG-repeat expansions at the DMPK locus, with affected individuals having > or 
      = 50 repeats of this trinucleotide. Reduced reproductive fitness of affected 
      individuals and decreased viability of congenital DM have been noted. Expanded 
      CTG-repeat alleles are highly unstable, predominantly yielding even higher repeat 
      sizes. Preferential transmission of longer alleles from heterozygous mothers 
      within the normal size range of alleles also is observed. In view of these 
      observations, it is worth examining how DM has been maintained in human 
      populations for hundreds of generations. We present an analysis of the dynamic 
      properties of a model of joint effects of segregation distortion and selection 
      (intensity of which increases with allele sizes of an individual's genotype). Our 
      mathematical formulation and numerical analyses demonstrate that a weak 
      segregation distortion during female meiosis, together with selection of 
      comparable intensity (within the normal allele size range), can maintain an 
      equilibrium distribution of allele frequencies. Genetic drift, acting in 
      conjunction with the occasional contraction of alleles by mutation, can 
      contribute to the balance of segregation distortion and mutation, in the sense 
      that even weaker selection can explain the observed allele frequencies. The model 
      is applied to CTG-repeat size distributions at the DMPK locus, observed in normal 
      individuals from world populations.
FAU - Polanski, A
AU  - Polanski A
AD  - School of Public Health, University of Texas at Houston, USA.
FAU - Chakraborty, R
AU  - Chakraborty R
FAU - Kimmel, M
AU  - Kimmel M
FAU - Deka, R
AU  - Deka R
LA  - eng
GR  - GM41399/GM/NIGMS NIH HHS/United States
GR  - GM45861/GM/NIGMS NIH HHS/United States
GR  - GM58545/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Math Biosci
JT  - Mathematical biosciences
JID - 0103146
SB  - IM
MH  - Alleles
MH  - Evolution, Molecular
MH  - Female
MH  - Humans
MH  - Male
MH  - Mathematics
MH  - Minisatellite Repeats
MH  - Models, Genetic
MH  - Myotonic Dystrophy/*genetics
MH  - Selection, Genetic
MH  - Trinucleotide Repeats/genetics
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - S0025556497000825 [pii]
AID - 10.1016/s0025-5564(97)00082-5 [doi]
PST - ppublish
SO  - Math Biosci. 1998 Jan 1;147(1):93-112. doi: 10.1016/s0025-5564(97)00082-5.

PMID- 9371827
OWN - NLM
STAT- MEDLINE
DCOM- 19980108
LR  - 20211203
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 94
IP  - 24
DP  - 1997 Nov 25
TI  - Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat 
      RNA-binding protein in patients with myotonic dystrophy and in myotonin protein 
      kinase knockout mice.
PG  - 13221-6
AB  - Myotonic dystrophy (DM) is associated with expansion of CTG repeats in the 
      3'-untranslated region of the myotonin protein kinase (DMPK) gene. The molecular 
      mechanism whereby expansion of the (CUG)n repeats in the 3'-untranslated region 
      of DMPK gene induces DM is unknown. We previously isolated a protein with 
      specific binding to CUG repeat sequences (CUG-BP/hNab50) that possibly plays a 
      role in mRNA processing and/or transport. Here we present evidence that the 
      phosphorylation status and intracellular distribution of the RNA CUG-binding 
      protein, identical to hNab50 protein (CUG-BP/hNab50), are altered in homozygous 
      DM patient and that CUG-BP/hNab50 is a substrate for DMPK both in vivo and in 
      vitro. Data from two biological systems with reduced levels of DMPK, homozygous 
      DM patient and DMPK knockout mice, show that DMPK regulates both phosphorylation 
      and intracellular localization of the CUG-BP/hNab50 protein. Decreased levels of 
      DMPK observed in DM patients and DMPK knockout mice led to the elevation of the 
      hypophosphorylated form of CUG-BP/hNab50. Nuclear concentration of the 
      hypophosphorylated CUG-BP/hNab50 isoform is increased in DMPK knockout mice and 
      in homozygous DM patient. DMPK also interacts with and phosphorylates 
      CUG-BP/hNab50 protein in vitro. DMPK-mediated phosphorylation of CUG-BP/hNab50 
      results in dramatic reduction of the CUG-BP2, hypophosphorylated isoform, 
      accumulation of which was observed in the nuclei of DMPK knockout mice. These 
      data suggest a feedback mechanism whereby decreased levels of DMPK could alter 
      phosphorylation status of CUG-BP/hNab50, thus facilitating nuclear localization 
      of CUG-BP/hNab50. Our results suggest that DM pathophysiology could be, in part, 
      a result of sequestration of CUG-BP/hNab50 and, in part, of lowered DMPK levels, 
      which, in turn, affect processing and transport of specific subclass of mRNAs.
FAU - Roberts, R
AU  - Roberts R
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Timchenko, N A
AU  - Timchenko NA
FAU - Miller, J W
AU  - Miller JW
FAU - Reddy, S
AU  - Reddy S
FAU - Caskey, C T
AU  - Caskey CT
FAU - Swanson, M S
AU  - Swanson MS
FAU - Timchenko, L T
AU  - Timchenko LT
LA  - eng
GR  - 1 R01 AR10D44387-01/AR/NIAMS NIH HHS/United States
GR  - HL543-13/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleoproteins)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - CELF1 Protein
MH  - Homozygote
MH  - Humans
MH  - Mice
MH  - Mice, Knockout
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Phosphorylation
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - RNA-Binding Proteins/genetics/*metabolism
MH  - Ribonucleoproteins/*metabolism
MH  - *Trinucleotide Repeats
PMC - PMC24290
EDAT- 1997/12/16 00:00
MHDA- 1997/12/16 00:01
PMCR- 1998/05/25
CRDT- 1997/12/16 00:00
PHST- 1997/12/16 00:00 [pubmed]
PHST- 1997/12/16 00:01 [medline]
PHST- 1997/12/16 00:00 [entrez]
PHST- 1998/05/25 00:00 [pmc-release]
AID - 3136 [pii]
AID - 10.1073/pnas.94.24.13221 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13221-6. doi: 
      10.1073/pnas.94.24.13221.

PMID- 9391889
OWN - NLM
STAT- MEDLINE
DCOM- 19980130
LR  - 20190503
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 34
IP  - 11
DP  - 1997 Nov
TI  - Paternal transmission of congenital myotonic dystrophy.
PG  - 930-3
AB  - We report a rare case of paternally transmitted congenital myotonic dystrophy 
      (DM). The proband is a 23 year old, mentally retarded male who suffers severe 
      muscular weakness. He presented with respiratory and feeding difficulties at 
      birth. His two sibs suffer from childhood onset DM. Their late father had the 
      adult type of DM, with onset around 30 years. Only six other cases of paternal 
      transmission of congenital DM have been reported recently. We review the sex 
      related effects on transmission of congenital DM. Decreased fertility of males 
      with adult onset DM and contraction of the repeat upon male transmission 
      contribute to the almost absent occurrence of paternal transmission of congenital 
      DM. Also the fathers of the reported congenitally affected children showed, on 
      average, shorter CTG repeat lengths and hence less severe clinical symptoms than 
      the mothers of children with congenital DM. We conclude that paternal 
      transmission of congenital DM is rare and preferentially occurs with onset of DM 
      past 30 years in the father.
FAU - de Die-Smulders, C E
AU  - de Die-Smulders CE
AD  - Department of Clinical Genetics, Maastricht University, The Netherlands.
FAU - Smeets, H J
AU  - Smeets HJ
FAU - Loots, W
AU  - Loots W
FAU - Anten, H B
AU  - Anten HB
FAU - Mirandolle, J F
AU  - Mirandolle JF
FAU - Geraedts, J P
AU  - Geraedts JP
FAU - Howeler, C J
AU  - Howeler CJ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - DNA/analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscle Weakness/congenital/genetics
MH  - Myotonic Dystrophy/congenital/*genetics
MH  - Pedigree
MH  - Trinucleotide Repeats
PMC - PMC1051123
EDAT- 1997/12/10 00:00
MHDA- 1997/12/10 00:01
PMCR- 1997/11/01
CRDT- 1997/12/10 00:00
PHST- 1997/12/10 00:00 [pubmed]
PHST- 1997/12/10 00:01 [medline]
PHST- 1997/12/10 00:00 [entrez]
PHST- 1997/11/01 00:00 [pmc-release]
AID - 10.1136/jmg.34.11.930 [doi]
PST - ppublish
SO  - J Med Genet. 1997 Nov;34(11):930-3. doi: 10.1136/jmg.34.11.930.

PMID- 9294109
OWN - NLM
STAT- MEDLINE
DCOM- 19971208
LR  - 20211203
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 100
IP  - 6
DP  - 1997 Sep 15
TI  - Myotonic dystrophy protein kinase is involved in the modulation of the Ca2+ 
      homeostasis in skeletal muscle cells.
PG  - 1440-7
AB  - Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is 
      caused by (CTG)n-repeat expansion in a gene encoding a protein kinase (DM protein 
      kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis. To 
      obtain clues to the normal biological role of DMPK in cellular ion homeostasis, 
      we have compared the resting [Ca2+]i, the amplitude and shape of 
      depolarization-induced Ca2+ transients, and the content of ATP-driven ion pumps 
      in cultured skeletal muscle cells of wild-type and DMPK[-/-] knockout mice. In 
      vitro-differentiated DMPK[-/-] myotubes exhibit a higher resting [Ca2+]i than do 
      wild-type myotubes because of an altered open probability of voltage-dependent 
      l-type Ca2+ and Na+ channels. The mutant myotubes exhibit smaller and slower Ca2+ 
      responses upon triggering by acetylcholine or high external K+. In addition, we 
      observed that these Ca2+ transients partially result from an influx of 
      extracellular Ca2+ through the l-type Ca2+ channel. Neither the content nor the 
      activity of Na+/K+ ATPase and sarcoplasmic reticulum Ca2+-ATPase are affected by 
      DMPK absence. In conclusion, our data suggest that DMPK is involved in modulating 
      the initial events of excitation-contraction coupling in skeletal muscle.
FAU - Benders, A A
AU  - Benders AA
AD  - Department of Biochemistry, University of Nijmegen, P.O. Box 9101, 6500 HB 
      Nijmegen, The Netherlands.
FAU - Groenen, P J
AU  - Groenen PJ
FAU - Oerlemans, F T
AU  - Oerlemans FT
FAU - Veerkamp, J H
AU  - Veerkamp JH
FAU - Wieringa, B
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Calcium Channels)
RN  - 0 (DMPK protein, mouse)
RN  - 15662-33-6 (Ryanodine)
RN  - 4368-28-9 (Tetrodotoxin)
RN  - 660YQ98I10 (Potassium Chloride)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 7.2.2.10 (Calcium-Transporting ATPases)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
RN  - I9ZF7L6G2L (Nifedipine)
RN  - N9YNS0M02X (Acetylcholine)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Acetylcholine/pharmacology
MH  - Animals
MH  - Calcium/*metabolism
MH  - Calcium Channels/drug effects/physiology
MH  - Calcium-Transporting ATPases/metabolism
MH  - Cells, Cultured
MH  - Homeostasis
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Muscle, Skeletal/drug effects/*metabolism
MH  - Myotonic Dystrophy/*metabolism
MH  - Myotonin-Protein Kinase
MH  - Nifedipine/pharmacology
MH  - Potassium Chloride/pharmacology
MH  - Protein Serine-Threonine Kinases/deficiency/*physiology
MH  - Ryanodine/pharmacology
MH  - Sarcoplasmic Reticulum/enzymology
MH  - Sodium-Potassium-Exchanging ATPase/metabolism
MH  - Tetrodotoxin/pharmacology
PMC - PMC508322
EDAT- 1997/09/18 00:00
MHDA- 1997/09/18 00:01
PMCR- 1997/09/15
CRDT- 1997/09/18 00:00
PHST- 1997/09/18 00:00 [pubmed]
PHST- 1997/09/18 00:01 [medline]
PHST- 1997/09/18 00:00 [entrez]
PHST- 1997/09/15 00:00 [pmc-release]
AID - 10.1172/JCI119664 [doi]
PST - ppublish
SO  - J Clin Invest. 1997 Sep 15;100(6):1440-7. doi: 10.1172/JCI119664.

PMID- 9241283
OWN - NLM
STAT- MEDLINE
DCOM- 19970828
LR  - 20240104
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 16
IP  - 4
DP  - 1997 Aug
TI  - Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking 
      DMAHP gene.
PG  - 407-9
AB  - Myotonic dystrophy, or dystrophia myotonica (DM), is a highly variable 
      multisystem disease in which the classic adult-onset form displays progressive 
      muscle wasting, cataracts, heart block, gonadal atrophy, insulin resistance and 
      neuropsychiatric impairment. Its genetic basis is an expansion of CTG 
      trinucleotide repeats in the DMPK protein kinase gene. Among the triplet repeat 
      expansion disorders, DM is distinguished by the extended length of the repeat 
      tract (5-13 kb in postmortem tissue) and its location in the 3' untranslated 
      region of the gene that contains it. The pathophysiological mechanism for 
      multisystem degeneration in DM is not understood. In contrast to the profound 
      muscle wasting that characterizes advanced DM, only minor histopathological 
      abnormalities have occurred in DMPK knockout mice or in mice that overexpress a 
      human DMPK transgene, making it unlikely that changes in DMPK activity provide a 
      unitary explanation for the disease. A DNAse hypersensitive site that maps 0.7 kb 
      downstream (centromeric) from the CTG repeats is eliminated on DM chromosomes. 
      This finding indicates that the repeat expansion may alter the adjacent chromatin 
      structure and raises the possibility that it may also affect the expression of 
      flanking genes. An interesting candidate flanking gene is DMAHP, a recently 
      discovered homeodomain-encoding gene. We show here that DMAHP expression in 
      myoblasts, muscle and myocardium is reduced by the DM mutation is cis, and the 
      magnitude of this effect depends on the extent of CTG repeat expansion. These 
      observations support the hypothesis that DMAHP participates in the 
      pathophysiology of DM.
FAU - Thornton, C A
AU  - Thornton CA
AD  - Department of Neurology, School of Medicine and Dentistry, University of 
      Rochester, NY 14642, USA.
FAU - Wymer, J P
AU  - Wymer JP
FAU - Simmons, Z
AU  - Simmons Z
FAU - McClain, C
AU  - McClain C
FAU - Moxley, R T 3rd
AU  - Moxley RT 3rd
LA  - eng
SI  - GENBANK/X57127
SI  - GENBANK/X84813
GR  - NS01558/NS/NINDS NIH HHS/United States
GR  - P60AG10463/AG/NIA NIH HHS/United States
GR  - RR00044/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (DNA Primers)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (SIX5 protein, human)
RN  - 0 (Six5 protein, mouse)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - DNA Primers
MH  - Exons
MH  - *Gene Expression Regulation
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Mice
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Polymorphism, Genetic
MH  - RNA, Messenger
MH  - *Trinucleotide Repeats
EDAT- 1997/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1038/ng0897-407 [doi]
PST - ppublish
SO  - Nat Genet. 1997 Aug;16(4):407-9. doi: 10.1038/ng0897-407.

PMID- 9241282
OWN - NLM
STAT- MEDLINE
DCOM- 19970828
LR  - 20240104
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 16
IP  - 4
DP  - 1997 Aug
TI  - Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression 
      of DMAHP.
PG  - 402-6
AB  - Myotonic dystrophy, or dystrophia myotonica (DM), is an autosomal dominant 
      multisystem disorder caused by the expansion of a CTG trinucleotide repeat in the 
      3' untranslated region of the DMPK protein kinase gene on chromosome 19q13.3 
      (refs 1-3). Although the DM mutation was identified more than five years ago, the 
      pathogenic mechanisms underlying this most prevalent form of hereditary adult 
      neuromuscular disease remain elusive. Previous work from our laboratory 
      demonstrated that a DNase l-hypersensitive site located adjacent to the repeats 
      on the wild-type allele is eliminated by repeat expansion, indicating that large 
      CTG-repeat arrays may be associated with a local chromatin environment that 
      represses gene expression. Here we report that the hypersensitive site contains 
      an enhancer element that regulates transcription of the adjacent DMAHP homeobox 
      gene. Analysis of DMAHP expression in the cells of DM patients with loss of the 
      hypersensitive site revealed a two- to fourfold reduction in steady-state DMAHP 
      transcript levels relative to wild-type controls. Allele-specific analysis of 
      DMAHP expression showed that steady-state transcript levels from the expanded 
      allele were greatly reduced in comparison to those from the wild-type allele. 
      Together, these results demonstrate that CTG-repeat expansions can suppress local 
      gene expression and implicate DMAHP in DM pathogenesis.
FAU - Klesert, T R
AU  - Klesert TR
AD  - Division of Molecular Medicine, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington 98104, USA.
FAU - Otten, A D
AU  - Otten AD
FAU - Bird, T D
AU  - Bird TD
FAU - Tapscott, S J
AU  - Tapscott SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (SIX5 protein, human)
RN  - 0 (Six5 protein, mouse)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Base Sequence
MH  - Cell Line
MH  - Chromosome Mapping
MH  - *Gene Expression Regulation
MH  - Homeodomain Proteins/*genetics
MH  - Humans
MH  - Mice
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - *Trinucleotide Repeats
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1038/ng0897-402 [doi]
PST - ppublish
SO  - Nat Genet. 1997 Aug;16(4):402-6. doi: 10.1038/ng0897-402.

PMID- 9207101
OWN - NLM
STAT- MEDLINE
DCOM- 19970805
LR  - 20230331
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 94
IP  - 14
DP  - 1997 Jul 8
TI  - Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic 
      dystrophy protein kinase transcripts results in nuclear retention of transcripts.
PG  - 7388-93
AB  - Expansion of a CTG trinucleotide repeat in the 3' untranslated region (UTR) of 
      DMPK, the gene encoding myotonic dystrophy protein kinase, induces the dominantly 
      inherited neuromuscular disorder myotonic dystrophy (DM). Transcripts containing 
      the expanded trinucleotide are abundant in differentiated cultured myoblasts, and 
      they are spliced and polyadenylylated normally. However, mutant transcripts never 
      reach the cytoplasm in these nonmitotic cells; instead, they form stable clusters 
      that are tightly linked to the nuclear matrix, which can prevent effective 
      biochemical purification of these transcripts. In DM patients, reduced DMPK 
      protein levels, consequent to nuclear retention of mutant transcripts, are 
      probably a cause of disease development. Formation of nuclear foci is a novel 
      mechanism for preventing transcript export and effecting a loss of gene function.
FAU - Davis, B M
AU  - Davis BM
AD  - Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 
      02139, USA. bdavis@mit.edu
FAU - McCurrach, M E
AU  - McCurrach ME
FAU - Taneja, K L
AU  - Taneja KL
FAU - Singer, R H
AU  - Singer RH
FAU - Housman, D E
AU  - Housman DE
LA  - eng
GR  - 5R37-CA 17575-16/CA/NCI NIH HHS/United States
GR  - GM54577-13/GM/NIGMS NIH HHS/United States
GR  - P01-HL41484/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Cell Line
MH  - Humans
MH  - Mutation
MH  - Myotonic Dystrophy/genetics
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Transcription, Genetic
MH  - *Trinucleotide Repeats
PMC - PMC23831
EDAT- 1997/07/08 00:00
MHDA- 1997/07/08 00:01
PMCR- 1998/01/08
CRDT- 1997/07/08 00:00
PHST- 1997/07/08 00:00 [pubmed]
PHST- 1997/07/08 00:01 [medline]
PHST- 1997/07/08 00:00 [entrez]
PHST- 1998/01/08 00:00 [pmc-release]
AID - 1356 [pii]
AID - 10.1073/pnas.94.14.7388 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7388-93. doi: 
      10.1073/pnas.94.14.7388.

PMID- 9120013
OWN - NLM
STAT- MEDLINE
DCOM- 19970424
LR  - 20220129
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 99
IP  - 7
DP  - 1997 Apr 1
TI  - RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin 
      receptor RNA and protein consistent with abnormal insulin resistance.
PG  - 1691-8
AB  - Myotonic dystrophy is a dominantly inherited clinically variable multisystemic 
      disorder, and has been found to be caused by heterozygosity for a trinucleotide 
      repeat expansion mutation in the 3' untranslated region of a protein kinase gene 
      (DM kinase). The mechanisms by which the expanded repeat in DNA results in a 
      dominant biochemical defect and the varied clinical phenotype, is not known. We 
      have recently proposed a model where disease pathogenesis may occur at the RNA 
      level in myotonic dystrophy: the mutant DM kinase RNA with the expansion mutation 
      may disrupt cellular RNA metabolism in some general manner, as evidenced by 
      defects in RNA processing of the normal DM kinase gene in heterozygous patients 
      (dominant negative RNA mutation). Here we further test this hypothesis by 
      measuring RNA metabolism of other genes in patient muscle biopsies (nine adult 
      onset myotonic dystrophy patients, two congenital muscular dystrophy patients, 
      four normal controls, and four myopathic controls). We focused on the insulin 
      receptor gene because of the documented insulin resistance of DM patients. We 
      show that there is a significant decrease in insulin receptor RNA in both total 
      RNA and RNA polyA+ pools relative to normal and myopathic control muscles (P < 
      0.002), measured relative to both dystrophin RNA and muscle sodium channel RNA. 
      We also show reductions in insulin receptor protein. Our results reinforce the 
      concept of a generalized RNA metabolism defect in myotonic dystrophy, and offer a 
      possible molecular mechanism for the increased insulin resistance observed in 
      many myotonic dystrophy patients.
FAU - Morrone, A
AU  - Morrone A
AD  - Department of Molecular Genetics and Biochemistry, University of Pittsburgh 
      School of Medicine, Pennsylvania 15261, USA.
FAU - Pegoraro, E
AU  - Pegoraro E
FAU - Angelini, C
AU  - Angelini C
FAU - Zammarchi, E
AU  - Zammarchi E
FAU - Marconi, G
AU  - Marconi G
FAU - Hoffman, E P
AU  - Hoffman EP
LA  - eng
GR  - C.19/TI_/Telethon/Italy
GR  - NS34193/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (DMPK protein, human)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Humans
MH  - Infant
MH  - *Insulin Resistance
MH  - Middle Aged
MH  - Muscles/*metabolism
MH  - Myotonic Dystrophy/*metabolism
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/genetics
MH  - RNA/analysis/*metabolism
MH  - Receptor, Insulin/analysis/*genetics
PMC - PMC507989
EDAT- 1997/04/01 00:00
MHDA- 1997/04/01 00:01
PMCR- 1997/04/01
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 1997/04/01 00:01 [medline]
PHST- 1997/04/01 00:00 [entrez]
PHST- 1997/04/01 00:00 [pmc-release]
AID - 10.1172/JCI119332 [doi]
PST - ppublish
SO  - J Clin Invest. 1997 Apr 1;99(7):1691-8. doi: 10.1172/JCI119332.

PMID- 9183996
OWN - NLM
STAT- MEDLINE
DCOM- 19970717
LR  - 20081121
IS  - 0916-8478 (Print)
IS  - 0916-8478 (Linking)
VI  - 42
IP  - 1
DP  - 1997 Mar
TI  - Detection of the CTG repeat expansion in congenital myotonic dystrophy.
PG  - 169-80
AB  - Myotonic dystrophy (DM) is caused by an abnormal expansion of an unstable CTG 
      trinucleotide repeat in the 3' untranslated region of mRNA encoding a putative 
      serine/threonine protein kinase. We analyzed 59 patients with DM (28 congenital 
      DM families: 27 families with maternal transmission and 1 paternal transmission) 
      and 27 normal control subjects to evaluate their CTG repeat size between DM 
      patients and the normal controls, and to search for a correlation between the 
      clinical characteristics of congenital DM (CDM) and CTG repeat expansions. 
      Analysis was on the basis of the Southern blot and polymerase chain reaction 
      (PCR) methods, and by direct sequencing of PCR amplified CTG repeats. Analysis of 
      intergenerational differences in the CTG repeat size for mother-child pairs 
      showed a positive correlation (y = 1.0384x + 1265.2, r2 = 0.311). In addition to 
      the strong parental bias, this group showed genetic anticipation. There was a 
      significant correlation of the CTG repeat expansion with disease severity. The 
      largest CTG repeat expansion (2,293 CTG repeats) on average belonged to the 
      severe CDM group, and the smallest (129 CTG repeats) to the subclinical DM group. 
      The mutant allele of an asymptomatic father in the paternally transmitted 
      pedigree revealed 75 CTG repeats, demonstrating that he was a DM protomutation 
      carrier.
FAU - Ohya, K
AU  - Ohya K
AD  - Department of Pediatrics, Sapporo Medical University School of Medicine, Japan.
FAU - Tachi, N
AU  - Tachi N
FAU - Sato, T
AU  - Sato T
FAU - Kon, S
AU  - Kon S
FAU - Kikuchi, K
AU  - Kikuchi K
FAU - Chiba, S
AU  - Chiba S
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Jpn J Hum Genet
JT  - The Japanese journal of human genetics
JID - 9213239
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Blotting, Southern
MH  - Child
MH  - Child, Preschool
MH  - *DNA/chemistry
MH  - Family Health
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical
MH  - Male
MH  - Myotonic Dystrophy/*congenital/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - Trinucleotide Repeats/*genetics
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1007/BF02766919 [doi]
PST - ppublish
SO  - Jpn J Hum Genet. 1997 Mar;42(1):169-80. doi: 10.1007/BF02766919.

PMID- 9132495
OWN - NLM
STAT- MEDLINE
DCOM- 19970430
LR  - 20220330
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 34
IP  - 3
DP  - 1997 Mar
TI  - Mild myotonic dystrophy is associated with memory impairment in the context of 
      normal general intelligence.
PG  - 229-33
AB  - Previous investigations of cognitive function in myotonic dystrophy (DM) 
      suggested that DM subjects have impairment of general intelligence and severe 
      defects in executive function. These studies had to neglect patients with mild 
      clinical disease, since they were generally performed before the availability of 
      DNA testing for DM. We have investigated a group of milder DM cases (defined both 
      by their degree of disability and CTG expansion size) and have not found any 
      defect in general intelligence using the National Adult Reading Test, Standard 
      Progressive Matrices, and Mini-Mental State examination. Three executive function 
      tests were used. The cognitive estimates test and the Wisconsin Card Sorting Test 
      showed tendencies towards impairment, which were of borderline significance, but 
      the verbal fluency task was performed normally. However, in the face of normal 
      general intelligence, mild DM subjects as a group show impairment of memory 
      function. This suggests that memory function may be more sensitive to small CTG 
      repeat expansions than general intelligence.
FAU - Rubinsztein, J S
AU  - Rubinsztein JS
AD  - Section of Developmental Psychiatry, University of Cambridge, UK.
FAU - Rubinsztein, D C
AU  - Rubinsztein DC
FAU - McKenna, P J
AU  - McKenna PJ
FAU - Goodburn, S
AU  - Goodburn S
FAU - Holland, A J
AU  - Holland AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cognition
MH  - Humans
MH  - *Intelligence
MH  - *Memory
MH  - Middle Aged
MH  - Myotonic Dystrophy/genetics/*psychology
MH  - Trinucleotide Repeats/genetics
PMC - PMC1050898
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
PMCR- 1997/03/01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
PHST- 1997/03/01 00:00 [pmc-release]
AID - 10.1136/jmg.34.3.229 [doi]
PST - ppublish
SO  - J Med Genet. 1997 Mar;34(3):229-33. doi: 10.1136/jmg.34.3.229.

PMID- 9020848
OWN - NLM
STAT- MEDLINE
DCOM- 19970310
LR  - 20061115
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 15
IP  - 2
DP  - 1997 Feb
TI  - Hypermutable myotonic dystrophy CTG repeats in transgenic mice.
PG  - 193-6
AB  - Myotonic dystrophy (DM) is one of a growing number of inherited human disorders 
      associated with the expansion of triplet repeat DNA sequences. Expanded alleles 
      are highly unstable in both the germline and soma, accounting in large part for 
      the unusual genetics of this disorder, its phenotypic variability and probably, 
      the progressive nature of the symptoms. However, the molecular mechanisms and the 
      genetic factors modulating repeat stability in DM and the other human disorders 
      associated with expanded repeats are not well understood. To provide a model 
      system in which the turnover of triplet repeats could be studied throughout 
      mammalian development, we have generated five transgenic mouse lines 
      incorporating expanded CTG/CAG arrays derived from the human DM locus. Transgene 
      analysis has revealed germline hypermutability, including expansions, deletions 
      and parent-of-origin effects, somatic and early embryonic instability and 
      segregation distortion. Mutational differences between lines and sexes 
      demonstrate that stability, as in humans, is modulated by as yet unidentified cis 
      and trans acting genetic elements.
FAU - Monckton, D G
AU  - Monckton DG
AD  - Division of Molecular Genetics, Anderson College, University of Glasgow, 
      Scotland, UK. dmonck@molgen.gla.ac.uk
FAU - Coolbaugh, M I
AU  - Coolbaugh MI
FAU - Ashizawa, K T
AU  - Ashizawa KT
FAU - Siciliano, M J
AU  - Siciliano MJ
FAU - Caskey, C T
AU  - Caskey CT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
SB  - IM
CIN - Nat Genet. 1997 Feb;15(2):119-20. PMID: 9020832
MH  - Animals
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Mosaicism
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Polymerase Chain Reaction
MH  - Transgenes/*genetics
MH  - *Trinucleotide Repeats
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1038/ng0297-193 [doi]
PST - ppublish
SO  - Nat Genet. 1997 Feb;15(2):193-6. doi: 10.1038/ng0297-193.

PMID- 8957513
OWN - NLM
STAT- MEDLINE
DCOM- 19970312
LR  - 20061115
IS  - 0148-7299 (Print)
IS  - 0148-7299 (Linking)
VI  - 66
IP  - 1
DP  - 1996 Dec 2
TI  - Inability to induce fragile sites at CTG repeats in congenital myotonic 
      dystrophy.
PG  - 60-3
AB  - Myotonic dystrophy (DM) is a trinucleotide repeat syndrome which can contain 50 
      to over 2,000 CTG repeats in affected individuals, but does not express a fragile 
      site. Although one prior study [Jalal et al., Am J Med Genet 46:441-443, 1993] 
      did not find evidence of fragility at 19q13.3 in six individuals affected with DM 
      using induction protocols for folate sensitive fragile sites, other chemicals may 
      induce fragile site expression at this site. In an attempt to induce fragile 
      sites at 19q13.3, blood cultures from four congenital DM cases and four control 
      individuals treated with fluorodeoxyuridine (folate-sensitive rare fragile 
      sites), bromodeoxyurdine (rare and common fragile sites), aphidicolin (common 
      fragile sites), and 5-azacytidine (common fragile sites) were harvested using 
      routine cytogenetic technique. Slides were solid stained and 100 cells were 
      examined for fragile site expression, particularly on F group chromosomes. The 
      latter were photographed prior to destaining and G-banded to verify chromosome 
      and band location of breakage. No culture conditions induced a fragile site at 
      band 19q13.3 at > 1% expression in patients with congenital DM. Our results 
      suggest that CTG repeats, even when present in > 1,000 copies, may behave 
      differently from other large expansions which are associated with fragile sites. 
      The CTG repeats in DM are not associated with a methylated CpG island, as are 
      folate-sensitive fragile sites, which most likely plays a role in the expression 
      of fragile sites at the trinucleotide repetitive site.
FAU - Wenger, S L
AU  - Wenger SL
AD  - Department of Pediatrics, University of Pittsburgh, Children's Hospital of 
      Pittsburgh, Pennsylvania 15213-2583, USA.
FAU - Giangreco, C A
AU  - Giangreco CA
FAU - Tarleton, J
AU  - Tarleton J
FAU - Wessel, H B
AU  - Wessel HB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet
JT  - American journal of medical genetics
JID - 7708900
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Blotting, Southern
MH  - Cells, Cultured
MH  - Chromosome Banding
MH  - Chromosome Fragile Sites
MH  - *Chromosome Fragility
MH  - Chromosomes, Human, Pair 19
MH  - DNA/genetics
MH  - Humans
MH  - Myotonic Dystrophy/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1996/12/02 00:00
MHDA- 2000/06/20 09:00
CRDT- 1996/12/02 00:00
PHST- 1996/12/02 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1996/12/02 00:00 [entrez]
AID - 10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O [pii]
AID - 10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O [doi]
PST - ppublish
SO  - Am J Med Genet. 1996 Dec 2;66(1):60-3. doi: 
      10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O.

PMID- 8948631
OWN - NLM
STAT- MEDLINE
DCOM- 19970117
LR  - 20190501
IS  - 0305-1048 (Print)
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Linking)
VI  - 24
IP  - 22
DP  - 1996 Nov 15
TI  - Identification of a (CUG)n triplet repeat RNA-binding protein and its expression 
      in myotonic dystrophy.
PG  - 4407-14
AB  - Myotonic dystrophy (DM) is an autosomal dominant neuromuscular disease that is 
      associated with a (CTG)n repeat expansion in the 3'-untranslated region of the 
      myotonin protein kinase (Mt-PK) gene. This study reports the isolation and 
      characterization of a (CUG)n triplet repeat pre-mRNA/mRNA binding protein that 
      may play an important role in DM pathogenesis. Two HeLa cell proteins, CUG-BP1 
      and CUG-BP2, have been purified based upon their ability to bind specifically to 
      (CUG)8 oligonucleotides in vitro. While CUG-BP1 is the major (CUG)8-binding 
      activity in normal cells, nuclear CUG-BP2 binding activity increases in DM cells. 
      Both CUG-BP1 and CUG-BP2 have been identified as isoforms of a novel 
      heterogeneous nuclear ribonucleoprotein (hnRNP), hNab50. The CUG-BP/hNab50 
      protein is localized predominantly in the nucleus and is associated with 
      polyadenylated RNAs in vivo. In vitro RNA-binding/photocrosslinking studies 
      demonstrate that CUG-BP/hNab50 binds to RNAs containing the Mt-PK 3'-UTR. We 
      propose that the (CUG)n repeat region in Mt-PK mRNA is a binding site for 
      CUG-BP/hNab50 in vivo, and triplet repeat expansion leads to sequestration of 
      this hnRNP on mutant Mt-PK transcripts.
FAU - Timchenko, L T
AU  - Timchenko LT
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
FAU - Miller, J W
AU  - Miller JW
FAU - Timchenko, N A
AU  - Timchenko NA
FAU - DeVore, D R
AU  - DeVore DR
FAU - Datar, K V
AU  - Datar KV
FAU - Lin, L
AU  - Lin L
FAU - Roberts, R
AU  - Roberts R
FAU - Caskey, C T
AU  - Caskey CT
FAU - Swanson, M S
AU  - Swanson MS
LA  - eng
SI  - GENBANK/U63289
GR  - GM46272/GM/NIGMS NIH HHS/United States
GR  - HL54313-01/HL/NHLBI NIH HHS/United States
GR  - T32-HL07706/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
RN  - 0 (CELF1 Protein)
RN  - 0 (CELF1 protein, human)
RN  - 0 (Heterogeneous-Nuclear Ribonucleoproteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribonucleoproteins)
SB  - IM
MH  - Amino Acid Sequence
MH  - CELF1 Protein
MH  - HeLa Cells
MH  - Heterogeneous-Nuclear Ribonucleoproteins
MH  - Humans
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Neoplasm Proteins/metabolism
MH  - RNA Precursors/chemistry/isolation & purification/metabolism
MH  - RNA-Binding Proteins/*chemistry/genetics
MH  - Ribonucleoproteins/*chemistry/genetics/metabolism
MH  - *Trinucleotide Repeats
PMC - PMC146274
EDAT- 1996/11/15 00:00
MHDA- 1996/11/15 00:01
PMCR- 1996/11/15
CRDT- 1996/11/15 00:00
PHST- 1996/11/15 00:00 [pubmed]
PHST- 1996/11/15 00:01 [medline]
PHST- 1996/11/15 00:00 [entrez]
PHST- 1996/11/15 00:00 [pmc-release]
AID - 6e0437 [pii]
AID - 10.1093/nar/24.22.4407 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 1996 Nov 15;24(22):4407-14. doi: 10.1093/nar/24.22.4407.

PMID- 8923947
OWN - NLM
STAT- MEDLINE
DCOM- 19970221
LR  - 20220129
IS  - 0148-7299 (Print)
IS  - 0148-7299 (Linking)
VI  - 65
IP  - 4
DP  - 1996 Nov 11
TI  - Prediction of myotonic dystrophy clinical severity based on the number of 
      intragenic [CTG]n trinucleotide repeats.
PG  - 342-7
AB  - We carried out a genotype-phenotype correlation study, based on clinical findings 
      in 465 patients with myotonic dystrophy (DM), in order to assess [CTG] repeat 
      number as a predictive test of disease severity. Our analysis showed that the DM 
      subtypes defined by strict clinical criteria fall into three different classes 
      with a log-normal distribution. This distribution is useful in predicting the 
      probability of specific DM phenotypes based on triplet [CTG] number. This study 
      demonstrates that measurement of triplet expansions in patients' lymphocyte DNA 
      is highly valuable and accurate for prognostic assessment.
FAU - Gennarelli, M
AU  - Gennarelli M
AD  - Cattedra di Genetica Umana, Universita Tor Vergata, Rome, Italy.
FAU - Novelli, G
AU  - Novelli G
FAU - Andreasi Bassi, F
AU  - Andreasi Bassi F
FAU - Martorell, L
AU  - Martorell L
FAU - Cornet, M
AU  - Cornet M
FAU - Menegazzo, E
AU  - Menegazzo E
FAU - Mostacciuolo, M L
AU  - Mostacciuolo ML
FAU - Martinez, J M
AU  - Martinez JM
FAU - Angelini, C
AU  - Angelini C
FAU - Pizzuti, A
AU  - Pizzuti A
FAU - Baiget, M
AU  - Baiget M
FAU - Dallapiccola, B
AU  - Dallapiccola B
LA  - eng
GR  - 511/TI_/Telethon/Italy
GR  - C.19/TI_/Telethon/Italy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Med Genet
JT  - American journal of medical genetics
JID - 7708900
SB  - IM
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics/*physiopathology
MH  - Predictive Value of Tests
MH  - *Trinucleotide Repeats
EDAT- 1996/11/11 00:00
MHDA- 2000/06/20 09:00
CRDT- 1996/11/11 00:00
PHST- 1996/11/11 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1996/11/11 00:00 [entrez]
AID - 10.1002/(SICI)1096-8628(19961111)65:4<342::AID-AJMG18>3.0.CO;2-U [pii]
AID - 10.1002/(SICI)1096-8628(19961111)65:4<342::AID-AJMG18>3.0.CO;2-U [doi]
PST - ppublish
SO  - Am J Med Genet. 1996 Nov 11;65(4):342-7. doi: 
      10.1002/(SICI)1096-8628(19961111)65:4<342::AID-AJMG18>3.0.CO;2-U.

PMID- 8923304
OWN - NLM
STAT- MEDLINE
DCOM- 19970318
LR  - 20211203
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 243
IP  - 10
DP  - 1996 Oct
TI  - Myotonic dystrophy phenotype without expansion of (CTG)n repeat: an entity 
      distinct from proximal myotonic myopathy (PROMM)?
PG  - 715-21
AB  - Myotonic dystrophy (DM) is associated with an expansion of an unstable (CTG)n 
      repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene on 
      chromosome 19q13.3. We studied six patients from two families who showed no 
      expansions of the repeat, in spite of their clinical diagnosis of DM. These 
      patients had multi-systemic manifestations that were distinguishable from those 
      seen in other myotonic disorders, including proximal myotonic myopathy (PROMM). 
      In one additional family, two symptomatic members showed no expanded (CTG)n 
      repeats, while their affected relatives had the expanded repeats. DM haplotype 
      analysis failed to exclude the DMPK locus as a possible site of mutation in each 
      family; however, DMPK mRNA levels were normal. We conclude that a mutation(s) 
      other than the expanded (CTG)n repeat can cause the DM phenotype. The mutation(s) 
      in these families remain(s) to be mapped and characterized.
FAU - Abbruzzese, C
AU  - Abbruzzese C
AD  - San Camillo Hospital, Rome, Italy.
FAU - Krahe, R
AU  - Krahe R
FAU - Liguori, M
AU  - Liguori M
FAU - Tessarolo, D
AU  - Tessarolo D
FAU - Siciliano, M J
AU  - Siciliano MJ
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - Giacanelli, M
AU  - Giacanelli M
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Chromosomes, Human, Pair 19
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Protein Serine-Threonine Kinases/*genetics
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1007/BF00873977 [doi]
PST - ppublish
SO  - J Neurol. 1996 Oct;243(10):715-21. doi: 10.1007/BF00873977.

PMID- 8912317
OWN - NLM
STAT- MEDLINE
DCOM- 19970319
LR  - 20190822
IS  - 0028-3940 (Print)
IS  - 0028-3940 (Linking)
VI  - 38
IP  - 7
DP  - 1996 Oct
TI  - The clinical and genetic correlates of MRI findings in myotonic dystrophy.
PG  - 629-35
AB  - Amplification of an unstable CTG trinucleotide repeat sequence in a protein 
      kinase gene on chromosome 19 has recently been recognised as the molecular basis 
      of myotonic dystrophy (DM), a multi-system disorder with a wide spectrum of 
      muscular and extramuscular manifestations. The CTG expansion of 40 patients was 
      assessed by direct genotype analysis of the white blood cell DNA and correlated 
      with MRI of the brain and muscles, and with functional clinical data. Cerebral 
      pathology on MRI consisted of diffuse atrophy (68%), subcortical white matter 
      lesions (65%), wide Virchow-Robin spaces (38%) and thickening of the skull (35%). 
      Cerebral atrophy and extent of white matter disease correlated significantly with 
      mental retardation, duration of disease and CTG fragment amplification. MRI of 
      the muscular system showed fatty degeneration of different degrees in 
      neighbouring muscles causing a mosaic pattern of the thigh in 38% and the calf in 
      44%. Muscular changes on MRI were strongly correlated with muscular impairment 
      but less strongly with CTG expansion. Changes on MRI reflect the stage of 
      development of tissue pathology in DM, modified by defect of the DM gene. 
      Pathology on MRI is strongly correlated with functional deficits.
FAU - Bachmann, G
AU  - Bachmann G
AD  - Department of Radiology, Justus Liebig University, Giessen, Germany.
FAU - Damian, M S
AU  - Damian MS
FAU - Koch, M
AU  - Koch M
FAU - Schilling, G
AU  - Schilling G
FAU - Fach, B
AU  - Fach B
FAU - Stoppler, S
AU  - Stoppler S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Neuroradiology
JT  - Neuroradiology
JID - 1302751
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Brain/pathology
MH  - Child
MH  - Child, Preschool
MH  - Chromosomes, Human, Pair 19
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/pathology
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - Pedigree
MH  - Prospective Studies
MH  - Protein Kinases/genetics
MH  - Trinucleotide Repeats/genetics
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1007/s002340050322 [doi]
PST - ppublish
SO  - Neuroradiology. 1996 Oct;38(7):629-35. doi: 10.1007/s002340050322.

PMID- 8812415
OWN - NLM
STAT- MEDLINE
DCOM- 19970212
LR  - 20211203
IS  - 0888-7543 (Print)
IS  - 0888-7543 (Linking)
VI  - 36
IP  - 1
DP  - 1996 Aug 15
TI  - Instability of the expanded (CTG)n repeats in the myotonin protein kinase gene in 
      cultured lymphoblastoid cell lines from patients with myotonic dystrophy.
PG  - 47-53
AB  - The mutation associated with myotonic dystrophy (DM) is the expansion of an 
      unstable trinucleotide repeat, (CTG)n, in the 3'-untranslated region of the 
      myotonin protein kinase gene. Although expanded repeats show both germline and 
      somatic instability, the mechanisms of the instability are poorly understood. To 
      establish a model system in which somatic instability of the DM repeat could be 
      studied in more detail, we established lymphoblastoid cell lines (LBCL) from DM 
      patients. Analysis of the DNA from DM LBCL using Southern blotting showed that 
      the (CTG)n repeats were apparently stable up to 29 passages in culture. To study 
      infrequent repeat size mutations that are undetectable due to the size 
      heterogeneity, we established LBCL of single-cell origins by cloning using 
      multiple steps of limiting dilution. After expansion to approximately 10(6) cells 
      (equivalent to approximately 20 cell cycles), the DNAs of these cell lines were 
      analyzed by the small pool PCR technique using primers flanking the (CTG)n repeat 
      region. Two types of mutations of the expanded (CTG)n repeat alleles were 
      detected: (1) frequent mutations that show small changes of the (CTG)n repeat 
      size, resulting in alleles in a normal distribution around the progenitor allele, 
      and (2) relatively rare mutations with large changes of the (CTG)n repeat size, 
      with a bias toward contraction. The former may represent the mechanism 
      responsible for the somatic heterogeneity of the (CTG)n repeat size observed in 
      blood cells of DM patients. This in vitro experimental system will be useful for 
      further studies on mechanisms involved in the regulation of the somatic stability 
      of the (CTG)n repeats in DM.
FAU - Ashizawa, T
AU  - Ashizawa T
AD  - Department of Neurology, Baylor College of Medicine, Houston, Texas, 77030, USA.
FAU - Monckton, D G
AU  - Monckton DG
FAU - Vaishnav, S
AU  - Vaishnav S
FAU - Patel, B J
AU  - Patel BJ
FAU - Voskova, A
AU  - Voskova A
FAU - Caskey, C T
AU  - Caskey CT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genomics
JT  - Genomics
JID - 8800135
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Cell Line
MH  - Clone Cells
MH  - DNA/analysis/metabolism
MH  - Humans
MH  - *Lymphocytes
MH  - Mutation/*genetics
MH  - Myotonic Dystrophy/*genetics/immunology
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction/methods
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - Trinucleotide Repeats/*genetics
EDAT- 1996/08/15 00:00
MHDA- 1996/08/15 00:01
CRDT- 1996/08/15 00:00
PHST- 1996/08/15 00:00 [pubmed]
PHST- 1996/08/15 00:01 [medline]
PHST- 1996/08/15 00:00 [entrez]
AID - S0888-7543(96)90424-3 [pii]
AID - 10.1006/geno.1996.0424 [doi]
PST - ppublish
SO  - Genomics. 1996 Aug 15;36(1):47-53. doi: 10.1006/geno.1996.0424.

PMID- 8698331
OWN - NLM
STAT- MEDLINE
DCOM- 19960905
LR  - 20190722
IS  - 0340-6717 (Print)
IS  - 0340-6717 (Linking)
VI  - 98
IP  - 2
DP  - 1996 Aug
TI  - Stability of triplet repeats of myotonic dystrophy and fragile X loci in human 
      mutator mismatch repair cell lines.
PG  - 151-7
AB  - At least nine human genetic diseases, including myotonic dystrophy (DM) and 
      fragile X syndrome have been associated with the expansion of CTG or CGG 
      trinucleotide repeats within the disease loci. Little is known about the 
      molecular mechanisms or the genetic control of the expansion of triplet repeats. 
      Mutations in human mismatch repair genes are associated with the increased 
      polymorphism of many microsatellites, including dinucleotide repeats. The effect 
      of mutations in two mismatch repair genes on the size of trinucleotide repeats in 
      the DM and FRAXA loci has been analyzed. PCR and Southern analysis of the triplet 
      repeat regions of the DM and fragile X mental retardation (FRAXA) loci in cell 
      lines HTC116 and LoVo, which contain mutations in both alleles of the hMLH1 and 
      hMSH2 genes, respectively, indicated that the size of the endogenous (CTG)n and 
      (CGG)n tracts fall within the range observed in the normal population. This 
      suggests that mutations in hMLH1 or hMSH2 do not result in the instability of CTG 
      or CGG tracts to the levels observed in individuals with myotonic dystrophy or 
      fragile X syndrome.
FAU - Kramer, P R
AU  - Kramer PR
AD  - Department of Biochemistry and Biophysics, Texas A & M University, Houston 
      77030-3303, USA.
FAU - Pearson, C E
AU  - Pearson CE
FAU - Sinden, R R
AU  - Sinden RR
LA  - eng
GR  - ES 05652/ES/NIEHS NIH HHS/United States
GR  - GM 52982/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
SB  - IM
MH  - Base Sequence
MH  - Cell Line
MH  - DNA Repair/*genetics
MH  - Female
MH  - Fragile X Syndrome/*genetics
MH  - Humans
MH  - Male
MH  - Minisatellite Repeats
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - *Trinucleotide Repeats
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1007/s004390050179 [doi]
PST - ppublish
SO  - Hum Genet. 1996 Aug;98(2):151-7. doi: 10.1007/s004390050179.

PMID- 8698328
OWN - NLM
STAT- MEDLINE
DCOM- 19960905
LR  - 20190722
IS  - 0340-6717 (Print)
IS  - 0340-6717 (Linking)
VI  - 98
IP  - 2
DP  - 1996 Aug
TI  - Small increase in triplet repeat length of cerebellum from patients with myotonic 
      dystrophy.
PG  - 138-40
AB  - Myotonic dystrophy (DM) is genetically characterized by abnormal expansion of an 
      unstable CTG trinucleotide repeat, located in the 3'-untranslated region of mRNA 
      encoding the family of serine-threonine protein kinases. DNA extracted from 
      various organs of patients with DM was analyzed by the Southern blotting method. 
      We identified differently expanded bands in DNAs from various tissues from 
      patients with DM. In studying the length of the CTG repeat in different regions 
      of the brain, we found a noticeably small increase in repeat length in the 
      cerebellum compared with other tissues. While this phenomenon has been reported 
      in other triplet repeat diseases such as Huntington disease, spinocerebellar 
      ataxia type 1, and dentatorubral-pallidoluysian atrophy, we are the first to 
      describe it in DM. Although the mechanism of expansion of the triplet repeat 
      remains to be defined, the tissue-dependent somatic mosaicism suggests that its 
      occurrence may depend on the differentiated state of each tissue.
FAU - Ishii, S
AU  - Ishii S
AD  - Department of Inherited Metabolic Diseases, National Center of Neurology and 
      Psychiatry, Tokyo, Japan.
FAU - Nishio, T
AU  - Nishio T
FAU - Sunohara, N
AU  - Sunohara N
FAU - Yoshihara, T
AU  - Yoshihara T
FAU - Takemura, K
AU  - Takemura K
FAU - Hikiji, K
AU  - Hikiji K
FAU - Tsujino, S
AU  - Tsujino S
FAU - Sakuragawa, N
AU  - Sakuragawa N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Cerebellum/*metabolism
MH  - DNA/genetics/isolation & purification
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Minisatellite Repeats
MH  - Myotonic Dystrophy/*genetics
MH  - *Trinucleotide Repeats
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1007/s004390050176 [doi]
PST - ppublish
SO  - Hum Genet. 1996 Aug;98(2):138-40. doi: 10.1007/s004390050176.

PMID- 8673131
OWN - NLM
STAT- MEDLINE
DCOM- 19960812
LR  - 20211203
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 13
IP  - 3
DP  - 1996 Jul
TI  - Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in 
      mice.
PG  - 316-24
AB  - Myotonic dystrophy (DM) is commonly associated with CTG repeat expansions within 
      the gene for DM-protein kinase (DMPK). The effect of altered expression levels of 
      DMPK, which is ubiquitously expressed in all muscle cell lineages during 
      development, was examined by disrupting the endogenous Dmpk gene and 
      overexpressing a normal human DMPK transgene in mice. Nullizygous (-/-) mice 
      showed only inconsistent and minor size changes in head and neck muscle fibres at 
      older age, animals with the highest DMPK transgene expression showed hypertrophic 
      cardiomyopathy and enhanced neonatal mortality. However, both models lack other 
      frequent DM symptoms including the fibre-type dependent atrophy, myotonia, 
      cataract and male-infertility. These results strengthen the contention that 
      simple loss- or gain-of-expression of DMPK is not the only crucial requirement 
      for development of the disease.
FAU - Jansen, G
AU  - Jansen G
AD  - Department of Cell Biology and Histology, Medical Faculty, University of 
      Nijmegen, The Netherlands.
FAU - Groenen, P J
AU  - Groenen PJ
FAU - Bachner, D
AU  - Bachner D
FAU - Jap, P H
AU  - Jap PH
FAU - Coerwinkel, M
AU  - Coerwinkel M
FAU - Oerlemans, F
AU  - Oerlemans F
FAU - van den Broek, W
AU  - van den Broek W
FAU - Gohlsch, B
AU  - Gohlsch B
FAU - Pette, D
AU  - Pette D
FAU - Plomp, J J
AU  - Plomp JJ
FAU - Molenaar, P C
AU  - Molenaar PC
FAU - Nederhoff, M G
AU  - Nederhoff MG
FAU - van Echteld, C J
AU  - van Echteld CJ
FAU - Dekker, M
AU  - Dekker M
FAU - Berns, A
AU  - Berns A
FAU - Hameister, H
AU  - Hameister H
FAU - Wieringa, B
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
CIN - Nat Genet. 1996 Jul;13(3):259-60. PMID: 8673118
MH  - Animals
MH  - Base Sequence
MH  - Cardiomegaly/genetics/*pathology
MH  - Gene Expression Regulation, Developmental
MH  - Homozygote
MH  - Humans
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Molecular Sequence Data
MH  - Muscle Fibers, Skeletal/pathology
MH  - Mutation
MH  - Myotonic Dystrophy/*enzymology/genetics/pathology
MH  - Myotonin-Protein Kinase
MH  - Protein Serine-Threonine Kinases/*biosynthesis/deficiency/genetics
MH  - RNA, Messenger/analysis
MH  - Tissue Distribution
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
AID - 10.1038/ng0796-316 [doi]
PST - ppublish
SO  - Nat Genet. 1996 Jul;13(3):316-24. doi: 10.1038/ng0796-316.

PMID- 8659513
OWN - NLM
STAT- MEDLINE
DCOM- 19960801
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 59
IP  - 1
DP  - 1996 Jul
TI  - Segregation distortion of the CTG repeats at the myotonic dystrophy locus.
PG  - 109-18
AB  - Myotonic dystrophy (DM), an autosomal dominant neuromuscular disease, is caused 
      by a CTG-repeat expansion, with affected individuals having > or = 50 repeats of 
      this trinucleotide, at the DMPK locus of human chromosome 19q13.3. Severely 
      affected individuals die early in life; the milder form of this disease reduces 
      reproductive ability. Alleles in the normal range of CTG repeats are not as 
      unstable as the (CTG)(> or = 50) alleles. In the DM families, anticipation and 
      parental bias of allelic expansions have been noted. However, data on mechanism 
      of maintenance of DM in populations are conflicting. We present a 
      maximum-likelihood model for examining segregation distortion of CTG-repeat 
      alleles in normal families. Analyzing 726 meiotic events in 95 nuclear families 
      from the CEPH panel pedigrees, we find evidence of preferential transmission of 
      larger alleles (of size < or = 29 repeats) from females (the probability of 
      transmission of larger alleles is .565 +/- 0.03, different from .5 at P 
      approximately equal .028). There is no evidence of segregation distortion during 
      male meiosis. We propose a hypothesis that preferential transmission of larger 
      CTG-repeat alleles during female meiosis can compensate for mutational 
      contraction of repeats within the normal allelic size range, and reduced 
      viability and fertility of affected individuals. Thus, the pool of premutant 
      alleles at the DM locus can be maintained in populations, which can subsequently 
      mutate to the full mutation status to give rise to DM.
FAU - Chakraborty, R
AU  - Chakraborty R
AD  - Human Genetics Center, University of Texas Houston Health Science Center, Houston 
      77225, USA.
FAU - Stivers, D N
AU  - Stivers DN
FAU - Deka, R
AU  - Deka R
FAU - Yu, L M
AU  - Yu LM
FAU - Shriver, M D
AU  - Shriver MD
FAU - Ferrell, R E
AU  - Ferrell RE
LA  - eng
GR  - GM41399/GM/NIGMS NIH HHS/United States
GR  - GM45861/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
SB  - IM
MH  - Alleles
MH  - Base Sequence
MH  - Chromosomes, Human, Pair 19/genetics
MH  - Female
MH  - Gene Frequency
MH  - Genes, Dominant
MH  - Genotype
MH  - Humans
MH  - Likelihood Functions
MH  - Male
MH  - Meiosis/genetics
MH  - *Minisatellite Repeats
MH  - Models, Genetic
MH  - Myotonic Dystrophy/*genetics
MH  - Pedigree
MH  - Reference Values
MH  - Sex Characteristics
MH  - *Trinucleotide Repeats
PMC - PMC1915088
EDAT- 1996/07/01 00:00
MHDA- 1996/07/01 00:01
PMCR- 1997/01/01
CRDT- 1996/07/01 00:00
PHST- 1996/07/01 00:00 [pubmed]
PHST- 1996/07/01 00:01 [medline]
PHST- 1996/07/01 00:00 [entrez]
PHST- 1997/01/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1996 Jul;59(1):109-18.

PMID- 8784809
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20211203
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 6
IP  - 3
DP  - 1996 May
TI  - Reduction of serum IgG level and peripheral T-cell counts are correlated with CTG 
      repeat lengths in myotonic dystrophy patients.
PG  - 203-10
AB  - Myotonic dystrophy (DM) is an autosomal dominant multisystem disorder associated 
      with expansion of the CTG repeat within the 3' non-coding region of the myotonin 
      protein kinase (MT-PK) gene. CTG repeat length has been shown to correlate with 
      the clinical category and age at onset of the disease. The relationship between 
      CTG repeat length and immunological parameters were analyzed in this study. We 
      determined CTG repeat length in 14 DM patients and 15 normal controls using 
      Southern and PCR analyses, and then correlated their CTG repeat lengths with 
      their serum immunoglobulin (IgG, IgA, IgM) levels and the number of peripheral 
      white blood cells, including lymphocyte subsets. In DM patients, increasing CTG 
      repeat lengths correlated significantly with decreasing serum IgG levels, 
      decreasing total lymphocyte counts, and decreasing CD2+, CD3+, and CD4+ cell 
      counts. Immunological parameters were also influenced by the expansion of CTG 
      repeat in DM patients.
FAU - Nakamura, A
AU  - Nakamura A
AD  - Department of Neuromuscular Research, National Institute of Neuroscience, 
      National Center of Neurology and Psychiatry, Tokyo, Japan.
FAU - Kojo, T
AU  - Kojo T
FAU - Arahata, K
AU  - Arahata K
FAU - Takeda, S
AU  - Takeda S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 0 (Antigens, CD)
RN  - 0 (DMPK protein, human)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD/blood
MH  - Base Sequence
MH  - Female
MH  - Humans
MH  - Immunoglobulin A/blood
MH  - Immunoglobulin G/*blood
MH  - Immunoglobulin M/blood
MH  - Lymphocyte Count
MH  - Lymphocyte Subsets/immunology
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/blood/*genetics/immunology
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - Reference Values
MH  - Regression Analysis
MH  - Restriction Mapping
MH  - T-Lymphocytes/*immunology
MH  - *Trinucleotide Repeats
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 0960896696000107 [pii]
AID - 10.1016/0960-8966(96)00010-7 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 1996 May;6(3):203-10. doi: 10.1016/0960-8966(96)00010-7.

PMID- 8784800
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20191024
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 6
IP  - 3
DP  - 1996 May
TI  - A family with an unusual myotonic and myopathic phenotype and no CTG expansion 
      (proximal myotonic myopathy syndrome): a challenge for future molecular studies.
PG  - 143-50
AB  - Myotonic dystrophy (DM) is a well-defined autosomal dominant disorder 
      characterized by myotonia, muscle weakness, cardiac conduction defects, 
      cataracts, and endocrine abnormalities. Recently a newly recognized disorder, 
      similar to but distinct from DM, has been observed with multisystem findings 
      including intermittent myotonia, proximal myopathy, and occasional cardiac 
      conduction disturbances. This disorder has been called proximal myotonic myopathy 
      (PROMM). No history of anticipation is present and there is no linkage to the 
      gene locus for DM or to the loci for the muscle sodium or chloride channels. This 
      report describes a family with a normal size of the CTG trinucleotide repeat 
      expansion of the DM gene in which affected individuals have myotonia 
      (intermittent, exacerbated by cold), bilateral cataracts, mild hypogonadism and 
      mild temporal atrophy. Affected individuals also have proximal muscle weakness, 
      facial involvement, nonspecific abnormalities on muscle biopsy, normal cardiac 
      conduction, and no glucose intolerance. The absence of trinucleotide repeat 
      expansion in the DM gene is consistent with this family being affected by a 
      disorder distinct from DM, possibly a form of PROMM.
FAU - Meola, G
AU  - Meola G
AD  - Department of Neurology, University of Milan, San Donato Hospital, Italy.
FAU - Sansone, V
AU  - Sansone V
FAU - Radice, S
AU  - Radice S
FAU - Skradski, S
AU  - Skradski S
FAU - Ptacek, L
AU  - Ptacek L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Cataract
MH  - Female
MH  - Genetic Linkage
MH  - Humans
MH  - Hypogonadism
MH  - Male
MH  - Middle Aged
MH  - Myotonia/*genetics/physiopathology
MH  - Neuromuscular Diseases/*genetics/physiopathology
MH  - Phenotype
MH  - Syndrome
MH  - *Trinucleotide Repeats
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 0960896695000402 [pii]
AID - 10.1016/0960-8966(95)00040-2 [doi]
PST - ppublish
SO  - Neuromuscul Disord. 1996 May;6(3):143-50. doi: 10.1016/0960-8966(95)00040-2.

PMID- 8664297
OWN - NLM
STAT- MEDLINE
DCOM- 19960806
LR  - 20071114
IS  - 0006-2960 (Print)
IS  - 0006-2960 (Linking)
VI  - 35
IP  - 15
DP  - 1996 Apr 16
TI  - Alternative structures in duplex DNA formed within the trinucleotide repeats of 
      the myotonic dystrophy and fragile X loci.
PG  - 5041-53
AB  - Most models proposed to explain the disease-associated expansion of (CTG)n.(CAG)n 
      and (CGG)n.(CCG)n trinucleotide repeats include the formation of slipped strand 
      DNA structures during replication; however, physical evidence for these 
      alternative DNA secondary structures has not been reported. Using cloned 
      fragments from the myotonic dystrophy (DM) and fragile X syndrome (FRAXA) loci 
      containing normal, premutation, and full mutation lengths of repeats, we report 
      the formation of novel alternative DNA secondary structures that map within the 
      repeat tracts during reannealing of complementary strands, containing equal 
      lengths of repeats, into linear duplex DNA molecules. Linear duplex DNA molecules 
      containing these alternative DNA secondary structures are characterized by 
      reduced electrophoretic mobilities in polyacrylamide gels. These alternative 
      secondary structures are stable at physiological ionic strengths and to 
      temperatures up to at least 55 degrees C. Following reduplexing, the CAG strand 
      of the (CTG)n.(CAG)n repeats is preferentially sensitive to mung bean nuclease, 
      suggesting the presence of single-stranded DNA in the alternative DNA structure. 
      For (CTG)17, which is a repeat length found in normal individuals, less than 3% 
      of the DNA molecules formed alternative DNA structures upon reduplexing. DNA 
      molecules containing (CTG)50 or (CTG)255, which represent premutation and full 
      mutation lengths of triplet repeats, respectively, formed a heterogeneous 
      population of alternative DNA structures in >50% of DNA molecules. The complexity 
      of the structures formed increased with the length of the triplet repeat. The 
      relationship between repeat length and the propensity of formation and complexity 
      of the novel structures correlates with the effect of repeat length on genetic 
      instability in human diseases. These are the first results consistent with the 
      existence of slipped strand DNA structures. The potential involvement of these 
      structures, which we term S-DNA, in the gentic instability of triplet repeats is 
      discussed.
FAU - Pearson, C E
AU  - Pearson CE
AD  - Center for Genome Research, Institute for Bioscience and Technology in the Texas 
      Medical Center, Houston 77030-3303, USA.
FAU - Sinden, R R
AU  - Sinden RR
LA  - eng
GR  - GM52982/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Biochemistry
JT  - Biochemistry
JID - 0370623
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Base Sequence
MH  - DNA/*genetics
MH  - Fragile X Syndrome/*genetics
MH  - Humans
MH  - Models, Genetic
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - *Nucleic Acid Conformation
MH  - Restriction Mapping
MH  - *Trinucleotide Repeats
EDAT- 1996/04/16 00:00
MHDA- 1996/04/16 00:01
CRDT- 1996/04/16 00:00
PHST- 1996/04/16 00:00 [pubmed]
PHST- 1996/04/16 00:01 [medline]
PHST- 1996/04/16 00:00 [entrez]
AID - bi9601013 [pii]
AID - 10.1021/bi9601013 [doi]
PST - ppublish
SO  - Biochemistry. 1996 Apr 16;35(15):5041-53. doi: 10.1021/bi9601013.

PMID- 8929960
OWN - NLM
STAT- MEDLINE
DCOM- 19970512
LR  - 20190503
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 33
IP  - 2
DP  - 1996 Feb
TI  - CTG repeat length in muscle from patients affected with myotonic dystrophy (DM).
PG  - 173
FAU - Zatz, M
AU  - Zatz M
FAU - Passos-Bueno, M R
AU  - Passos-Bueno MR
FAU - Cerqueira, A
AU  - Cerqueira A
FAU - Vainzof, M
AU  - Vainzof M
LA  - eng
PT  - Comment
PT  - Comparative Study
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
SB  - IM
CON - J Med Genet. 1995 Aug;32(8):593-6. PMID: 7473648
MH  - Adult
MH  - Age Factors
MH  - Age of Onset
MH  - Child
MH  - DNA Mutational Analysis
MH  - Humans
MH  - Infant
MH  - Lymphocytes/chemistry
MH  - Muscle, Skeletal/*chemistry
MH  - Myotonic Dystrophy/epidemiology/*genetics
MH  - Organ Specificity
MH  - *Trinucleotide Repeats
PMC - PMC1051854
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
PMCR- 1996/02/01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PHST- 1996/02/01 00:00 [pmc-release]
AID - 10.1136/jmg.33.2.173-a [doi]
PST - ppublish
SO  - J Med Genet. 1996 Feb;33(2):173. doi: 10.1136/jmg.33.2.173-a.

PMID- 8563757
OWN - NLM
STAT- MEDLINE
DCOM- 19960305
LR  - 20131121
IS  - 1061-4036 (Print)
IS  - 1061-4036 (Linking)
VI  - 12
IP  - 2
DP  - 1996 Feb
TI  - Chromosomal localization of long trinucleotide repeats in the human genome by 
      fluorescence in situ hybridization.
PG  - 183-5
AB  - Trinucleotide microsatellites are widespread in the human and other mammalian 
      genomes. Expansions of unstable trinucleotide repeats have been associated so far 
      with a number of different genetic diseases including fragile X, myotonic 
      dystrophy (DM) and Huntington disease. While ten possible trinucleotides can 
      occur at the DNA level, only CTG and CCG repeats are involved in the disorders 
      described so far. However, the repeat expansion detection (RED) technique has 
      identified additional large repeats of ATG, CCT, CTT, and TGG of potentially 
      pathological significance in the human genome. We now show that conclusive 
      information about the chromosomal localization of long trinucleotide repeats can 
      be achieved in a relatively short time using fluorescence in situ hybridization 
      (FISH) with biotin-labelled trinucleotide polymers. Large CTG expansions (> 1 kb) 
      in DM and an unstable (CTG)306 repeat in a patient with schizophrenia were 
      detected by eye through the microscope without electronic enhancement. Digital 
      imaging was used to analyse the chromosomal distribution of long CCA and AGG 
      repeats. Our results suggest that long trinucleotide repeats occur in the normal 
      human genome and that the size of individual repeat loci may be polymorphic.
FAU - Haaf, T
AU  - Haaf T
AD  - Max-Planck-Institute of Molecular Genetics, Berlin, Germany.
FAU - Sirugo, G
AU  - Sirugo G
FAU - Kidd, K K
AU  - Kidd KK
FAU - Ward, D C
AU  - Ward DC
LA  - eng
GR  - MH-30929/MH/NIMH NIH HHS/United States
GR  - MH-39239/MH/NIMH NIH HHS/United States
GR  - MH-50390/MH/NIMH NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
RN  - 0 (DNA Probes)
RN  - 6SO6U10H04 (Biotin)
SB  - IM
MH  - Base Sequence
MH  - Biotin
MH  - Chromosome Mapping/*methods
MH  - DNA Probes
MH  - Genome
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Molecular Sequence Data
MH  - Schizophrenia, Paranoid/genetics
MH  - Trinucleotide Repeats/*genetics
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1038/ng0296-183 [doi]
PST - ppublish
SO  - Nat Genet. 1996 Feb;12(2):183-5. doi: 10.1038/ng0296-183.

PMID- 8905394
OWN - NLM
STAT- MEDLINE
DCOM- 19970129
LR  - 20190116
IS  - 0741-0395 (Print)
IS  - 0741-0395 (Linking)
VI  - 13
IP  - 5
DP  - 1996
TI  - Frequency of intergenerational contractions of the CTG repeats in myotonic 
      dystrophy.
PG  - 483-7
AB  - Myotonic dystrophy (MD), an autosomal dominant multisystemic disorder with a high 
      phenotypic variability, is the most common muscular dystrophy in adult life. The 
      mutation underlying DM has been characterized as an expanded CTG trinucleotide 
      repeat sequence in the 3 untranslated region of a protein kinase gene on 
      chromosome 19q13.2-13.3. We have analyzed the presence of CTG intergenerational 
      variations on transmission in parent-child pairs affected with DM. The series 
      includes 90% of all living affected descendants (symptomatic or asymptomatic) 
      from a given myotonic dystrophy (DM) patient. A contraction of the CTG repeat 
      size was observed in ten parent-child pairs (14.1%) and remained unchanged in 
      five (7%) pairs. The number of CTG repeats decreased in 2/30 maternal 
      transmissions (6.7%) and in 8/41 paternal transmissions (19.5%). We found 14 
      asymptomatic individuals carrying the CTG expansion among the offspring. In six 
      of them, a contraction of the CTG repeat was observed, and in all six cases, the 
      DM allele was paternally transmitted. Since nearly all the asymptomatic family 
      members of DM patients were analyzed in this series, the observed percentage of 
      contractions can be considered more realistic, even though the number of 
      parent-child pairs is small.
FAU - Lopez de Munain, A
AU  - Lopez de Munain A
AD  - Department of Neurology, Hospital Ntra.Sra de Aranzazu, San Sebastian, Basque 
      Country, Spain.
FAU - Cobo, A M
AU  - Cobo AM
FAU - Saenz, A
AU  - Saenz A
FAU - Blanco, A
AU  - Blanco A
FAU - Poza, J J
AU  - Poza JJ
FAU - Martorell, L
AU  - Martorell L
FAU - Marti-Masso, J F
AU  - Marti-Masso JF
FAU - Baiget, M
AU  - Baiget M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Genet Epidemiol
JT  - Genetic epidemiology
JID - 8411723
SB  - IM
MH  - Adult
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/epidemiology/*genetics
MH  - *Trinucleotide Repeats
EDAT- 1996/01/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1002/(SICI)1098-2272(1996)13:5<483::AID-GEPI4>3.0.CO;2-3 [pii]
AID - 10.1002/(SICI)1098-2272(1996)13:5<483::AID-GEPI4>3.0.CO;2-3 [doi]
PST - ppublish
SO  - Genet Epidemiol. 1996;13(5):483-7. doi: 
      10.1002/(SICI)1098-2272(1996)13:5<483::AID-GEPI4>3.0.CO;2-3.

PMID- 8595416
OWN - NLM
STAT- MEDLINE
DCOM- 19960418
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 4
IP  - 10
DP  - 1995 Oct
TI  - A novel homeodomain-encoding gene is associated with a large CpG island 
      interrupted by the myotonic dystrophy unstable (CTG)n repeat.
PG  - 1919-25
AB  - Myotonic dystrophy (DM) is associated with a (CTG)n trinucleotide repeat 
      expansion in the 3'-untranslated region of a protein kinase-encoding gene, DMPK, 
      which maps to chromosome 19q13.3. Characterisation of the expression of this gene 
      in patient tissues has thus far generated conflicting data on alterations in the 
      steady state levels of DMPK mRNA, and on the final DMPK protein levels in the 
      presence of the expansion. The DM region of chromosome 19 is gene rich, and it is 
      possible that the repeat expansion may lead to dysfunction of a number of 
      transcription units in the vicinity, perhaps as a consequence of chromatin 
      disruption. We have searched for genes associated with a CpG island at the 3' end 
      of DMPK. Sequencing of this region shows that the island extends over 3.5 kb and 
      is interrupted by the (CTG)n repeat. Comparison of genomic sequences downstream 
      (centromeric) of the repeat in human and mouse identified regions of significant 
      homology. These correspond to exons of a gene predicted to encode a homeodomain 
      protein. RT-PCR analysis shows that this gene, which we have called DM 
      locus-associated homeodomain protein (DMAHP), is expressed in a number of human 
      tissues, including skeletal muscle, heart and brain.
FAU - Boucher, C A
AU  - Boucher CA
AD  - Department of Anatomy, Charing Cross and Westminster Medical School, London, UK.
FAU - King, S K
AU  - King SK
FAU - Carey, N
AU  - Carey N
FAU - Krahe, R
AU  - Krahe R
FAU - Winchester, C L
AU  - Winchester CL
FAU - Rahman, S
AU  - Rahman S
FAU - Creavin, T
AU  - Creavin T
FAU - Meghji, P
AU  - Meghji P
FAU - Bailey, M E
AU  - Bailey ME
FAU - Chartier, F L
AU  - Chartier FL
AU  - et al.
LA  - eng
SI  - GENBANK/X84813
SI  - GENBANK/X84814
GR  - Wellcome Trust/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 0 (DMPK protein, mouse)
RN  - 0 (Dinucleoside Phosphates)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (SIX5 protein, human)
RN  - 0 (Six5 protein, mouse)
RN  - 2382-65-2 (cytidylyl-3'-5'-guanosine)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - Brain/metabolism
MH  - Centromere
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 19
MH  - Cloning, Molecular
MH  - *Dinucleoside Phosphates
MH  - Exons
MH  - Gene Expression
MH  - Gene Library
MH  - *Genes, Homeobox
MH  - Homeodomain Proteins/biosynthesis/*genetics
MH  - Humans
MH  - Mice
MH  - Molecular Sequence Data
MH  - Muscle, Skeletal/metabolism
MH  - Myocardium/metabolism
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Organ Specificity
MH  - Polymerase Chain Reaction
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Sequence Homology, Amino Acid
MH  - Sequence Homology, Nucleic Acid
MH  - Transcription, Genetic
EDAT- 1995/10/01 00:00
MHDA- 1995/10/01 00:01
CRDT- 1995/10/01 00:00
PHST- 1995/10/01 00:00 [pubmed]
PHST- 1995/10/01 00:01 [medline]
PHST- 1995/10/01 00:00 [entrez]
AID - 10.1093/hmg/4.10.1919 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1995 Oct;4(10):1919-25. doi: 10.1093/hmg/4.10.1919.

PMID- 7473648
OWN - NLM
STAT- MEDLINE
DCOM- 19951207
LR  - 20190503
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 32
IP  - 8
DP  - 1995 Aug
TI  - Comparison of CTG repeat length expansion and clinical progression of myotonic 
      dystrophy over a five year period.
PG  - 593-6
AB  - Myotonic dystrophy (DM) is associated with an underlying CTG trinucleotide repeat 
      expansion at a locus on chromosome 19q13.3. We have determined the repeat length 
      in 23 DM patients with varying clinical severity of symptoms and various sizes of 
      repeat amplification. We confirm that as in previous studies there is no strong 
      correlation between repeat length and clinical symptoms but find that the repeat 
      length in peripheral blood cells of patients increases over a time span of five 
      years indicating continuing mitotic instability of the repeat throughout life. 
      Repeat length progression does not appear to be indicative of clinical 
      progression but age probably is. The degree of expansion correlates with the 
      initial repeat size and 50% of the patients with continuing expansions showed 
      clinical progression of their disease symptoms over the five year study period.
FAU - Martorell, L
AU  - Martorell L
AD  - Unitat de Genetica Molecular, Hospital de Sant Pau, Barcelona, Spain.
FAU - Martinez, J M
AU  - Martinez JM
FAU - Carey, N
AU  - Carey N
FAU - Johnson, K
AU  - Johnson K
FAU - Baiget, M
AU  - Baiget M
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 9007-49-2 (DNA)
SB  - IM
CIN - J Med Genet. 1996 Feb;33(2):173. PMID: 8929960
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Base Sequence
MH  - Child
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 19
MH  - DNA/blood/genetics/isolation & purification
MH  - Humans
MH  - Infant, Newborn
MH  - Middle Aged
MH  - Myotonic Dystrophy/classification/*genetics/physiopathology
MH  - Polymerase Chain Reaction
MH  - *Repetitive Sequences, Nucleic Acid
PMC - PMC1051631
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
PMCR- 1995/08/01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
PHST- 1995/08/01 00:00 [pmc-release]
AID - 10.1136/jmg.32.8.593 [doi]
PST - ppublish
SO  - J Med Genet. 1995 Aug;32(8):593-6. doi: 10.1136/jmg.32.8.593.

PMID- 7626046
OWN - NLM
STAT- MEDLINE
DCOM- 19950831
LR  - 20211203
IS  - 0006-291X (Print)
IS  - 0006-291X (Linking)
VI  - 212
IP  - 2
DP  - 1995 Jul 17
TI  - Direct detection of expanded (CAG/CTG) repeats in the myotonin-protein kinase 
      genes of myotonic dystrophy patients using a high-stringency hybridization 
      method.
PG  - 341-6
AB  - Recent discoveries of genes containing (CAG/CTG) repeats as the causative genes 
      for neuromuscular diseases suggest that trinucleotide repeat expansions are 
      associated with a number of other neurodegenerative diseases, particularly in 
      those showing genetic anticipation. In order to efficiently identify expanded 
      trinucleotide repeats, we have developed a novel method using a single-stranded 
      probe containing (CAG)55, which allows direct detection of expanded (CAG/CTG) 
      repeats in the myotonin-protein kinase (Mt-PK) genes of patients with myotonic 
      dystrophy without the need for any prior information of chromosomal localizations 
      of the disease genes. This method is expected to be useful for identifying novel 
      genes for diseases associated with expanded (CAG/CTG) repeats.
FAU - Sanpei, K
AU  - Sanpei K
AD  - Department of Neurology, Niigata University, Japan.
FAU - Igarashi, S
AU  - Igarashi S
FAU - Eguchi, I
AU  - Eguchi I
FAU - Takiyama, Y
AU  - Takiyama Y
FAU - Tanaka, H
AU  - Tanaka H
FAU - Tsuji, S
AU  - Tsuji S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA Probes)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Base Sequence
MH  - DNA/chemistry
MH  - DNA Probes
MH  - Humans
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*enzymology/genetics
MH  - Myotonin-Protein Kinase
MH  - *Nucleic Acid Hybridization
MH  - Polymerase Chain Reaction
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1995/07/17 00:00
MHDA- 1995/07/17 00:01
CRDT- 1995/07/17 00:00
PHST- 1995/07/17 00:00 [pubmed]
PHST- 1995/07/17 00:01 [medline]
PHST- 1995/07/17 00:00 [entrez]
AID - S0006-291X(85)71975-4 [pii]
AID - 10.1006/bbrc.1995.1975 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 1995 Jul 17;212(2):341-6. doi: 
      10.1006/bbrc.1995.1975.

PMID- 8528201
OWN - NLM
STAT- MEDLINE
DCOM- 19960126
LR  - 20190512
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 4
IP  - 7
DP  - 1995 Jul
TI  - Heterogeneity of DM kinase repeat expansion in different fetal tissues and 
      further expansion during cell proliferation in vitro: evidence for a casual 
      involvement of methyl-directed DNA mismatch repair in triplet repeat stability.
PG  - 1147-53
AB  - We have analysed the mitotic behaviour of expanded CTG repeats in somatic tissues 
      and cultured somatic cells from myotonic dystrophy (DM) fetuses using indirect 
      and direct methods. Heterogeneity of expansions between fetal tissues was 
      demonstrated in a 16 week old fetus whereas there was no evidence for such a 
      somatic heterogeneity in a 13 week old fetus. Dilution plating of cultured cells 
      from an adult patient and a fetus resulted in isolation of clones showing single 
      expanded restriction fragments when the donor showed a heterogeneous smear of 
      expansions or a single expanded fragment. During proliferation in vitro to 45 
      doublings, DM cells experienced highly synchronous further repeat expansion which 
      first became evident at approximately 15 cell generations and reached a plateau 
      of maximum expansion at approximately 200 days. When mathematically expressed as 
      a function of culture time the dynamics of expansion of restriction fragments 
      followed a sigmoid curve. This unstable behaviour of CTG repeat expansions in DM 
      was compared to the mitotically stable patterns of full mutation in fragile X 
      fetal tissues and led to the hypothesis that methylation of CpGs within the 
      repeat sequence is a stabilizing factor of largely expanded CGG and GCC repeats 
      allowing for efficient methyl-directed strand-specific DNA mismatch repair.
FAU - Wohrle, D
AU  - Wohrle D
AD  - Abteilung Medizinische Genetik, Universitat Ulm, Germany.
FAU - Kennerknecht, I
AU  - Kennerknecht I
FAU - Wolf, M
AU  - Wolf M
FAU - Enders, H
AU  - Enders H
FAU - Schwemmle, S
AU  - Schwemmle S
FAU - Steinbach, P
AU  - Steinbach P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
SB  - IM
MH  - Adult
MH  - Cell Division
MH  - Cells, Cultured
MH  - *DNA Repair
MH  - Embryonic and Fetal Development
MH  - Female
MH  - *Fetus/cytology
MH  - Humans
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Skin/cytology
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - 10.1093/hmg/4.7.1147 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1995 Jul;4(7):1147-53. doi: 10.1093/hmg/4.7.1147.

PMID- 7590731
OWN - NLM
STAT- MEDLINE
DCOM- 19951204
LR  - 20211203
IS  - 0888-7543 (Print)
IS  - 0888-7543 (Linking)
VI  - 28
IP  - 1
DP  - 1995 Jul 1
TI  - Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription 
      and processing.
PG  - 1-14
AB  - The myotonic dystrophy (DM) mutation has been identified as an unstable, expanded 
      (CTG)n repeat in the 3' untranslated region of a gene designated DM protein 
      kinase (DMPK). Both decreased and increased levels of mutant DMPK mRNA as well as 
      decreased levels of protein have been variously reported and invoked to explain 
      disparate molecular bases of this dominantly inherited disease. Most recently, 
      increased nucleosome binding to such expanded repeats has been interpreted as 
      support for transcriptional repression. A quantitative allele-specific RT-PCR 
      procedure was developed and applied to a spectrum of patient tissue samples and 
      cell lines. Equal levels of unprocessed pre-mRNA were produced by the wildtype 
      (+) and disease (DM) alleles in skeletal muscle and cell lines of heterozygous DM 
      patients. Thus, any increased nucleosome binding had no effect at the level of 
      transcriptional initiation and transcription of the mutant DMPK locus. In 
      contrast, processed mRNA levels from the DM allele were reduced relative to 
      the+allele as the size of the expansion increased. The unstable repeat, 
      therefore, impairs post-transcriptional processing of DM allele transcripts. This 
      phenomenon has profound effects on overall DMPK locus steady-state transcript 
      levels in cells missing a wildtype allele and does not appear to be mediated by 
      imprinting, decreased mRNA stability, generation of aberrant splice forms, or 
      absence of polyadenylation of the mutant allele.
FAU - Krahe, R
AU  - Krahe R
AD  - Program in Genetics, Graduate School of Biomedical Sciences, University of Texas 
      Health Sciences Center at Houston 77030, USA.
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - Abbruzzese, C
AU  - Abbruzzese C
FAU - Roeder, E
AU  - Roeder E
FAU - Carango, P
AU  - Carango P
FAU - Giacanelli, M
AU  - Giacanelli M
FAU - Funanage, V L
AU  - Funanage VL
FAU - Siciliano, M J
AU  - Siciliano MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genomics
JT  - Genomics
JID - 8800135
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Animals
MH  - Base Sequence
MH  - CHO Cells
MH  - Child
MH  - Child, Preschool
MH  - *Chromosomes, Human, Pair 19
MH  - Cricetinae
MH  - Female
MH  - Fibroblasts/enzymology
MH  - Humans
MH  - Hybrid Cells
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Polymorphism, Genetic
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/genetics
MH  - Repetitive Sequences, Nucleic Acid
MH  - *Transcription, Genetic
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - S0888-7543(85)71099-3 [pii]
AID - 10.1006/geno.1995.1099 [doi]
PST - ppublish
SO  - Genomics. 1995 Jul 1;28(1):1-14. doi: 10.1006/geno.1995.1099.

PMID- 7561966
OWN - NLM
STAT- MEDLINE
DCOM- 19951113
LR  - 20220129
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 242
IP  - 6
DP  - 1995 Jun
TI  - Postzygotic instability of the myotonic dystrophy p[AGC] in repeat supported by 
      larger expansions in muscle and reduced amplifications in sperm.
PG  - 379-83
AB  - We have analysed the [AGC] expansion in leucocytes, muscle and sperm from 17 
      individuals affected by myotonic dystrophy (DM). Skeletal muscle showed a larger 
      repeat number than leucocytes in the same patient. A similar degree of expansion 
      was detected in differently affected muscles of a single patient. The germline 
      mutation (< or = 350 repeats) was expanded in somatic cells of the progeny in all 
      patients examined. Our results provide evidence of an early postzygotic 
      instability of the [AGC] repeat in DM.
FAU - Massari, A
AU  - Massari A
AD  - Department of Public Health and Cell Biology, Tor Vergata University, Rome, 
      Italy.
FAU - Gennarelli, M
AU  - Gennarelli M
FAU - Menegazzo, E
AU  - Menegazzo E
FAU - Pizzuti, A
AU  - Pizzuti A
FAU - Silani, V
AU  - Silani V
FAU - Mastrogiacomo, I
AU  - Mastrogiacomo I
FAU - Pagani, E
AU  - Pagani E
FAU - Angelini, C
AU  - Angelini C
FAU - Scarlato, G
AU  - Scarlato G
FAU - Novelli, G
AU  - Novelli G
AU  - et al.
LA  - eng
GR  - 511/TI_/Telethon/Italy
GR  - C.10/TI_/Telethon/Italy
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Leukocytes/*physiology
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*physiology
MH  - Myotonic Dystrophy/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Spermatozoa/*physiology
MH  - Zygote/*physiology
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.1007/BF00868393 [doi]
PST - ppublish
SO  - J Neurol. 1995 Jun;242(6):379-83. doi: 10.1007/BF00868393.

PMID- 7726160
OWN - NLM
STAT- MEDLINE
DCOM- 19950524
LR  - 20221207
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 56
IP  - 5
DP  - 1995 May
TI  - De novo myotonic dystrophy mutation in a Nigerian kindred.
PG  - 1067-74
AB  - An expansion of an unstable (CTG)n trinucleotide repeat in the 3' UTR of a gene 
      encoding a putative serine/threonine protein kinase (DMPK) on human chromosome 
      19q13.3 has been shown to be specific for the myotonic dystrophy (DM) disease 
      phenotype. In addition, a single haplotype composed of nine alleles within and 
      flanking DMPK over a physical distance of 30 kb has been shown to be in complete 
      linkage disequilibrium with DM. This has led to two hypotheses: (1) 
      predisposition for (CTG)n instability results from a founder effect that occurred 
      only once or a few times in human evolution; and (2) elements within the disease 
      haplotype may predispose the (CTG)n repeat to instability. A detailed haplotype 
      analysis of the DM region was conducted on a Nigerian (Yoruba) DM family, the 
      only indigenous sub-Saharan DM case reported to date. Each affected member of 
      this family had an expanded (CTG)n repeat in one of his or her DMPK alleles. 
      However, unlike all other DM populations studied thus far, disassociation of the 
      (CTG)n repeat expansion from other alleles of the putative predisposing haplotype 
      was found. We conclude that the expanded (CTG)n repeat in this family is the 
      result of an independent mutational event. Consequently, the origin of DM is 
      unlikely to be a single mutational event, and the hypothesis that a single 
      ancestral haplotype predisposes to repeat expansion is not compelling.
FAU - Krahe, R
AU  - Krahe R
AD  - Program in Genetics, Graduate School of Biomedical Sciences, University of Texas 
      Health Science Center at Houston, USA.
FAU - Eckhart, M
AU  - Eckhart M
FAU - Ogunniyi, A O
AU  - Ogunniyi AO
FAU - Osuntokun, B O
AU  - Osuntokun BO
FAU - Siciliano, M J
AU  - Siciliano MJ
FAU - Ashizawa, T
AU  - Ashizawa T
LA  - eng
PT  - Case Reports
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
GS  - DMPK
MH  - Adult
MH  - Aged
MH  - Base Sequence
MH  - Black People/*genetics
MH  - Blotting, Southern
MH  - Female
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Molecular Sequence Data
MH  - *Mutation
MH  - Myotonic Dystrophy/enzymology/epidemiology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Nigeria/epidemiology
MH  - Pedigree
MH  - Polymorphism, Restriction Fragment Length
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Repetitive Sequences, Nucleic Acid/genetics
MH  - White People/genetics
PMC - PMC1801445
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
PMCR- 1995/11/01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PHST- 1995/11/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1995 May;56(5):1067-74.

PMID- 7896884
OWN - NLM
STAT- MEDLINE
DCOM- 19950424
LR  - 20211203
IS  - 0021-9525 (Print)
IS  - 1540-8140 (Electronic)
IS  - 0021-9525 (Linking)
VI  - 128
IP  - 6
DP  - 1995 Mar
TI  - Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells 
      and tissues.
PG  - 995-1002
AB  - We have analyzed the intracellular localization of transcripts from the myotonin 
      protein kinase (Mt-PK) gene in fibroblasts and muscle biopsies from myotonic 
      dystrophy patients and normal controls. In affected individuals, a trinucleotide 
      expansion in the gene results in the phenotype, the severity of which is 
      proportional to the repeat length. A fluorochrome-conjugated probe (10 repeats of 
      CAG) hybridized specifically to this expanded repeat. Mt-PK transcripts 
      containing CTG repeat expansions were detected in the nucleus as bright foci in 
      DM patient fibroblasts and muscle biopsies, but not from normal individuals. 
      These foci represented transcripts from the Mt-PK gene since they simultaneously 
      hybridized to fluorochrome-conjugated probes to the 5'-end of the Mt-PK mRNA. A 
      single oligonucleotide probe to the repeat and the sense strand each conjugated 
      to different fluorochromes revealed the gene and the transcripts simultaneously, 
      and indicated that these focal concentrations (up to 13 per nucleus) represented 
      predominately posttranscriptional RNA since only a single focus contained both 
      the DNA and the RNA. This concentration of nuclear transcripts was diagnostic of 
      the affected state, and may represent aberrant processing of the RNA.
FAU - Taneja, K L
AU  - Taneja KL
AD  - Department of Cell Biology, University of Massachusetts Medical Center, Worcester 
      01655.
FAU - McCurrach, M
AU  - McCurrach M
FAU - Schalling, M
AU  - Schalling M
FAU - Housman, D
AU  - Housman D
FAU - Singer, R H
AU  - Singer RH
LA  - eng
SI  - GENBANK/L00727
GR  - HD 18066/HD/NICHD NIH HHS/United States
GR  - HG00299/HG/NHGRI NIH HHS/United States
GR  - HL 41484/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Cell Biol
JT  - The Journal of cell biology
JID - 0375356
RN  - 0 (DMPK protein, human)
RN  - 0 (DNA, Complementary)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Base Sequence
MH  - Cells, Cultured
MH  - DNA, Complementary
MH  - Female
MH  - Fibroblasts/enzymology
MH  - Humans
MH  - In Situ Hybridization
MH  - Molecular Sequence Data
MH  - Muscles/enzymology
MH  - Myotonic Dystrophy/*enzymology/pathology
MH  - Myotonin-Protein Kinase
MH  - Prognosis
MH  - Protein Kinases/*analysis/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - RNA, Messenger/*analysis
MH  - Repetitive Sequences, Nucleic Acid
MH  - Skin/enzymology
PMC - PMC2120416
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
PMCR- 1995/09/02
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
PHST- 1995/09/02 00:00 [pmc-release]
AID - 95204543 [pii]
AID - 10.1083/jcb.128.6.995 [doi]
PST - ppublish
SO  - J Cell Biol. 1995 Mar;128(6):995-1002. doi: 10.1083/jcb.128.6.995.

PMID- 7795594
OWN - NLM
STAT- MEDLINE
DCOM- 19950803
LR  - 20211203
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 4
IP  - 3
DP  - 1995 Mar
TI  - Analysis of the CTG repeat in skeletal muscle of young and adult myotonic 
      dystrophy patients: when does the expansion occur?
PG  - 401-6
AB  - The purpose of this investigation was to analyze the CTG expansion in muscle as 
      compared to lymphocytes DNA in a sample of selected myotonic dystrophy (DM) 
      patients of different ages and degrees of clinical severity, ranging from severe 
      congenital to minimally affected. Results from the present study showed that the 
      size of the CTG repeat was markedly larger in skeletal muscle than in lymphocytes 
      in all DM patients. In contrast to lymphocytes, no significant correlation was 
      found between the size of the CTG expansion in muscle and age at onset. In 
      addition, large expansions were observed in muscle from all adult symptomatic 
      patients independently of the presence of muscle weakness, which raises the 
      question of the value of analyzing CTG expansions in muscle for predicting the 
      severity of the phenotype. Differences between the size of the CTG expansions in 
      muscle as compared to lymphocytes were smaller in affected children suggesting an 
      apparent tendency to increase with aging and reaching a plateau in adulthood.
FAU - Zatz, M
AU  - Zatz M
AD  - Departamento de Biologia, Faculdade de Medicina, Universidad de Sao Paulo, 
      Brazil.
FAU - Passos-Bueno, M R
AU  - Passos-Bueno MR
FAU - Cerqueira, A
AU  - Cerqueira A
FAU - Marie, S K
AU  - Marie SK
FAU - Vainzof, M
AU  - Vainzof M
FAU - Pavanello, R C
AU  - Pavanello RC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DMPK protein, human)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Blotting, Southern
MH  - Child
MH  - Child, Preschool
MH  - DNA/*analysis
MH  - Female
MH  - Genetic Heterogeneity
MH  - Humans
MH  - Lymphocytes/chemistry
MH  - Male
MH  - Middle Aged
MH  - Muscle, Skeletal/*chemistry
MH  - Myotonic Dystrophy/*genetics/physiopathology
MH  - Myotonin-Protein Kinase
MH  - Polymorphism, Restriction Fragment Length
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 10.1093/hmg/4.3.401 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1995 Mar;4(3):401-6. doi: 10.1093/hmg/4.3.401.

PMID- 7767095
OWN - NLM
STAT- MEDLINE
DCOM- 19950706
LR  - 20220129
IS  - 0960-8966 (Print)
IS  - 0960-8966 (Linking)
VI  - 5
IP  - 2
DP  - 1995 Mar
TI  - Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 
      repeats.
PG  - 157-9
AB  - A myotonic dystrophy (DM) family is described in which discordant DM phenotypes 
      were found in the children of two affected sisters with similar CTG expansion and 
      clinical manifestations. In this family, congenital as well as early severe 
      childhood and later childhood onset DM coexist. This observation strengthens the 
      limited ability of lymphocytes CTG repeat number analysis in predicting 
      genotype-phenotype correlations in DM patients.
FAU - Novelli, G
AU  - Novelli G
AD  - Institute of Medical Genetics, Catholic University of Rome, Italy.
FAU - Gennarelli, M
AU  - Gennarelli M
FAU - Menegazzo, E
AU  - Menegazzo E
FAU - Angelini, C
AU  - Angelini C
FAU - Dallapiccola, B
AU  - Dallapiccola B
LA  - eng
GR  - 511/TI_/Telethon/Italy
GR  - C.19/TI_/Telethon/Italy
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Base Sequence
MH  - Child, Preschool
MH  - DNA/*analysis
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Molecular Sequence Data
MH  - Mutation/genetics
MH  - Myotonic Dystrophy/*genetics
MH  - Pedigree
MH  - Phenotype
MH  - Repetitive Sequences, Nucleic Acid/*genetics
EDAT- 1995/03/01 00:00
MHDA- 1995/03/01 00:01
CRDT- 1995/03/01 00:00
PHST- 1995/03/01 00:00 [pubmed]
PHST- 1995/03/01 00:01 [medline]
PHST- 1995/03/01 00:00 [entrez]
AID - 096089669400044A [pii]
AID - 10.1016/0960-8966(94)00044-a [doi]
PST - ppublish
SO  - Neuromuscul Disord. 1995 Mar;5(2):157-9. doi: 10.1016/0960-8966(94)00044-a.

PMID- 7825567
OWN - NLM
STAT- MEDLINE
DCOM- 19950213
LR  - 20211203
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 56
IP  - 1
DP  - 1995 Jan
TI  - Normal variation at the myotonic dystrophy locus in global human populations.
PG  - 123-30
AB  - Myotonic dystrophy (DM) is a dominant neuromuscular disease that results from an 
      unstable CTG-repeat expansion in the 3' UTR of the myotonin kinase gene at 
      19q13.3. This repeat is normally polymorphic with a trimodal distribution 
      reflecting 5-, 11-17-, and 19-30-repeat-length alleles. An absolute association 
      between expanded CTG alleles and the 1-kb insertion allele of an intragenic 
      polymorphism in Caucasians has led to the proposal that the 5-repeat allele gives 
      rise to alleles of 19-30 repeats, from which expanded alleles are derived, a 
      transition not involving the 11-17-repeat alleles. A survey of eight global 
      populations confirms the stability of the 11-17-repeat alleles but shows 
      disociation between the 1-kb insertion polymorphism and both the 5- and 
      19-30-repeat-length alleles. These data indicate more than one ancestral allele 
      from which expanded alleles are derived and suggest that widely variable 
      population frequencies of DM may reflect distinct frequencies of such predisposed 
      alleles.
FAU - Zerylnick, C
AU  - Zerylnick C
AD  - Howard Hughes Medical Institute, Emory University School of Medicine, Atlanta, GA 
      30322.
FAU - Torroni, A
AU  - Torroni A
FAU - Sherman, S L
AU  - Sherman SL
FAU - Warren, S T
AU  - Warren ST
LA  - eng
GR  - GM08490/GM/NIGMS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (DMPK protein, human)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Base Sequence
MH  - Genetic Variation
MH  - Humans
MH  - *Minisatellite Repeats
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Myotonin-Protein Kinase
MH  - Polymerase Chain Reaction
MH  - Protein Kinases/*genetics
MH  - *Protein Serine-Threonine Kinases
MH  - Racial Groups/genetics
MH  - Reference Values
PMC - PMC1801327
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
PMCR- 1995/07/01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PHST- 1995/07/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1995 Jan;56(1):123-30.

PMID- 7813083
OWN - NLM
STAT- MEDLINE
DCOM- 19950209
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 41
IP  - 1
DP  - 1995 Jan
TI  - A molecular protocol for diagnosing myotonic dystrophy.
PG  - 69-72
AB  - Myotonic dystrophy (DM) is an autosomal dominant genetic disease caused by an 
      unstable CTG repeat sequence in the 3' untranslated region of the myotonin 
      protein kinase gene. The CTG repeat is present 5-30 times in the normal 
      population, whereas DM patients have CTG expansions of 50 to several thousand 
      repeats. The age of onset of the disorder and the severity of the phenotype is 
      roughly correlated with the size of the CTG expansion. We developed a molecular 
      protocol for the diagnosis of DM based on an initial polymerase chain reaction 
      screen to detect normal-sized alleles and small expansions, followed by an 
      improved Southern protocol to detect larger expansions.
FAU - Guida, M
AU  - Guida M
AD  - Department of Pathology, Ohio State University, Columbus 43210.
FAU - Marger, R S
AU  - Marger RS
FAU - Papp, A C
AU  - Papp AC
FAU - Snyder, P J
AU  - Snyder PJ
FAU - Sedra, M S
AU  - Sedra MS
FAU - Kissel, J T
AU  - Kissel JT
FAU - Mendell, J R
AU  - Mendell JR
FAU - Prior, T W
AU  - Prior TW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (DNA Probes)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Base Sequence
MH  - Blotting, Southern
MH  - DNA Probes
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Pedigree
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Repetitive Sequences, Nucleic Acid
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Chem. 1995 Jan;41(1):69-72.

PMID- 7711720
OWN - NLM
STAT- MEDLINE
DCOM- 19950516
LR  - 20240104
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 4
IP  - 1
DP  - 1995 Jan
TI  - Somatic mosaicism, germline expansions, germline reversions and intergenerational 
      reductions in myotonic dystrophy males: small pool PCR analyses.
PG  - 1-8
AB  - In order to characterize the dynamics of CTG repeat instability in somatic and 
      germline tissue from myotonic dystrophy (DM) males we have used small pool 
      polymerase chain reaction (PCR) in a detailed quantitative analysis of repeat 
      length variation. We demonstrate that the heterogeneous smear of CTG repeats 
      observed in DM patients using standard analyses is comprised of multiple 
      unresolved bands that may be dissected into discrete length alleles derived from 
      single cells using single molecule PCR techniques. Analysis of somatic tissues 
      demonstrates a bias toward increasing allele length and a lower boundary below 
      which variant alleles are rare, consistent with a highly directional expansion 
      pathway in the soma. Two sperm samples show extensive variation and a size 
      increase bias, concordant with the phenomenon of anticipation. In addition, sperm 
      analysis shows that large contractions, including reversions into the normal size 
      range, are restricted to the germline. Detailed analysis of intergenerational 
      'reductions' paternally transmitted to two offspring suggests that some apparent 
      reductions may be artifacts of somatic expansion in the parent. Our data indicate 
      that in addition to germline variation, substantial somatic expansion can also 
      contribute to the intergenerational differences usually observed in DM.
FAU - Monckton, D G
AU  - Monckton DG
AD  - Department of Molecular and Human Genetics, Baylor College of Medicine, Texas 
      Medical Center, Houston, TX 77030, USA.
FAU - Wong, L J
AU  - Wong LJ
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - Caskey, C T
AU  - Caskey CT
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA Primers)
SB  - IM
MH  - Adult
MH  - Base Sequence
MH  - Child
MH  - DNA Primers
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Male
MH  - Molecular Sequence Data
MH  - *Mosaicism
MH  - Muscles/metabolism
MH  - Myotonic Dystrophy/blood/*genetics
MH  - Polymerase Chain Reaction
MH  - Spermatozoa/metabolism
EDAT- 1995/01/01 00:00
MHDA- 1995/01/01 00:01
CRDT- 1995/01/01 00:00
PHST- 1995/01/01 00:00 [pubmed]
PHST- 1995/01/01 00:01 [medline]
PHST- 1995/01/01 00:00 [entrez]
AID - 10.1093/hmg/4.1.1 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1995 Jan;4(1):1-8. doi: 10.1093/hmg/4.1.1.

PMID- 7874122
OWN - NLM
STAT- MEDLINE
DCOM- 19950404
LR  - 20061115
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 3
IP  - 11
DP  - 1994 Nov
TI  - Myotonic dystrophy CTG repeats and the associated insertion/deletion polymorphism 
      in human and primate populations.
PG  - 2031-5
AB  - Myotonic dystrophy (DM) is associated with abnormal expansions of the CTG repeats 
      in the 3' untranslated region of its gene. Previous studies in individuals of 
      European origin demonstrated strong linkage disequilibrium between different CTG 
      repeat length alleles and an Alu element insertion/deletion polymorphism in 
      intron 8 of the DM gene: CTG11-13 chromosomes were almost exclusively associated 
      with the deletion allele, while chromosomes with five or 19-30 repeats or disease 
      chromosomes were only found on the insertion allele. One of the models suggested 
      by these results proposed that the triplet repeats on insertion-associated 
      chromosomes were particularly prone to mutation. Studies of other triplet repeat 
      disorders have suggested that arrays of perfect repeats are more prone to 
      instability than those that are interrupted. We have examined the evolution of 
      this locus by typing a variety of primates and samples drawn from several 
      different human populations for both CTG repeat length and the insertion/deletion 
      polymorphism. DM gene sequences from different primates revealed inter- and 
      intraspecies variability in the number of CTG repeats. Human chromosomes with 
      five repeats or 11-13 repeats (the two major modes of the human CTG repeat 
      distributions) showed no evidence of preferential stabilization of these repeat 
      sizes by imperfect sequences. The insertion and deletion allele frequencies 
      showed large interpopulation variation and the degree of association between 
      these alleles and various CTG repeat lengths is not nearly as complete as was 
      previously supposed. We have found deletion alleles carrying long normal (> 19) 
      CTG repeats and insertion alleles associated with CTG11 - 13 in two african 
      populations.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Rubinsztein, D C
AU  - Rubinsztein DC
AD  - East Anglian Regional Genetics Service Molecular Genetics Laboratory, Cambridge, 
      UK.
FAU - Leggo, J
AU  - Leggo J
FAU - Amos, W
AU  - Amos W
FAU - Barton, D E
AU  - Barton DE
FAU - Ferguson-Smith, M A
AU  - Ferguson-Smith MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA Transposable Elements)
SB  - IM
GS  - DM
MH  - Animals
MH  - Base Sequence
MH  - *DNA Transposable Elements
MH  - Humans
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*genetics
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Primates/genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Sequence Deletion/*genetics
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
PST - ppublish
SO  - Hum Mol Genet. 1994 Nov;3(11):2031-5.

PMID- 8058147
OWN - NLM
STAT- MEDLINE
DCOM- 19940912
LR  - 20190514
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 44
IP  - 8
DP  - 1994 Aug
TI  - Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle 
      weakness, and cataracts.
PG  - 1448-52
AB  - We describe three families with a dominantly inherited disorder. Affected 
      individuals have myotonia, proximal muscle weakness, and cataracts. There was no 
      abnormal CTG repeat expansion of the myotonic dystrophy (DM) gene in DNA from 
      blood and muscle. The structure of the three families permitted linkage analysis, 
      and there is no linkage to the gene loci for DM or to the loci for the muscle 
      chloride channel disorders or muscle sodium channel disorders. The collection of 
      symptoms in these three families seems to represent a new disorder.
FAU - Ricker, K
AU  - Ricker K
AD  - Department of Neurology, University of Wurzburg, Germany.
FAU - Koch, M C
AU  - Koch MC
FAU - Lehmann-Horn, F
AU  - Lehmann-Horn F
FAU - Pongratz, D
AU  - Pongratz D
FAU - Otto, M
AU  - Otto M
FAU - Heine, R
AU  - Heine R
FAU - Moxley, R T 3rd
AU  - Moxley RT 3rd
LA  - eng
GR  - AG 10463-02/AG/NIA NIH HHS/United States
GR  - NIANS RO1 AR38894/AR/NIAMS NIH HHS/United States
GR  - NINDS RO1 NS22099/NS/NINDS NIH HHS/United States
GR  - etc.
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cataract/complications/*genetics
MH  - DNA/analysis
MH  - Electromyography
MH  - Female
MH  - Genetic Linkage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/complications/*genetics/physiopathology
MH  - Myotonia/complications/*genetics
MH  - Pedigree
EDAT- 1994/08/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
AID - 10.1212/wnl.44.8.1448 [doi]
PST - ppublish
SO  - Neurology. 1994 Aug;44(8):1448-52. doi: 10.1212/wnl.44.8.1448.

PMID- 8128954
OWN - NLM
STAT- MEDLINE
DCOM- 19940413
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 54
IP  - 4
DP  - 1994 Apr
TI  - Gonosomal mosaicism in myotonic dystrophy patients: involvement of mitotic events 
      in (CTG)n repeat variation and selection against extreme expansion in sperm.
PG  - 575-85
AB  - Myotonic dystrophy (DM) is caused by abnormal expansion of a polymorphic (CTG)n 
      repeat, located in the DM protein kinase gene. We determined the (CTG)n repeat 
      lengths in a broad range of tissue DNAs from patients with mild, classical, or 
      congenital manifestation of DM. Differences in the repeat length were seen in 
      somatic tissues from single DM individuals and twins. Repeats appeared to expand 
      to a similar extent in tissues originating from the same embryonal origin. In 
      most male patients carrying intermediate- or small-sized expansions in blood, the 
      repeat lengths covered a markedly wider range in sperm. In contrast, male 
      patients with large allele expansions in blood (> 700 CTGs) had similar or 
      smaller repeats in sperm, when detectable. Sperm alleles with > 1,000 CTGs were 
      not seen. We conclude that DM patients can be considered gonosomal mosaics, i.e., 
      combined somatic and germ-line tissue mosaics. Most remarkably, we observed 
      multiple cases where the length distributions of intermediate- or small-sized 
      alleles in fathers' sperm were significantly different from that in their 
      offspring's blood. Our combined findings indicate that intergenerational length 
      changes in the unstable CTG repeat are most likely to occur during early 
      embryonic mitotic divisions in both somatic and germ-line tissue formation. Both 
      the initial CTG length, the overall number of cell divisions involved in tissue 
      formation, and perhaps a specific selection process in spermatogenesis may 
      influence the dynamics of this process. A model explaining mitotic instability 
      and sex-dependent segregation phenomena in DM manifestation is discussed.
FAU - Jansen, G
AU  - Jansen G
AD  - Department of Cell Biology and Histology, Faculty of Medical Sciences, University 
      of Nijmegen, The Netherlands.
FAU - Willems, P
AU  - Willems P
FAU - Coerwinkel, M
AU  - Coerwinkel M
FAU - Nillesen, W
AU  - Nillesen W
FAU - Smeets, H
AU  - Smeets H
FAU - Vits, L
AU  - Vits L
FAU - Howeler, C
AU  - Howeler C
FAU - Brunner, H
AU  - Brunner H
FAU - Wieringa, B
AU  - Wieringa B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (Codon)
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Blotting, Southern
MH  - Codon
MH  - DNA Mutational Analysis
MH  - Female
MH  - Gene Expression Regulation, Enzymologic
MH  - Genetic Variation
MH  - Genotype
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Meiosis
MH  - Mitosis
MH  - Models, Genetic
MH  - *Mosaicism
MH  - Myotonic Dystrophy/*genetics
MH  - Organ Specificity
MH  - Pedigree
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Protein Kinases/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Selection, Genetic
MH  - Spermatozoa
PMC - PMC1918095
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
PMCR- 1994/10/01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
PHST- 1994/10/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1994 Apr;54(4):575-85.

PMID- 8279459
OWN - NLM
STAT- MEDLINE
DCOM- 19940204
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 54
IP  - 1
DP  - 1994 Jan
TI  - The 1.5-Mb region spanning the myotonic dystrophy locus shows uniform 
      recombination frequency.
PG  - 104-13
AB  - The myotonic dystrophy (DM) mutation has been identified as a heritable unstable 
      CTG trinucleotide repeat sequence. The intergenerational amplification of this 
      sequence is an example of a new class of dynamic mutations responsible for human 
      genetic diseases. To ascertain whether recombination activity influences, or is 
      affected by, the presence of this unique sequence, a comprehensive study of the 
      physical and genetic mapping data for the 1.5-Mb region of human chromosome 
      19q13.3, which contains the DM locus, was conducted. The recombination rate for 
      this region was examined by correlating genetic distance to physical distance for 
      six selected marker loci. The following markers span the DM region: 19qCEN-p 
      alpha 1.4 (D19S37)-APOC2-CKM-pE0.8 (D19S115)-pGB2.6 (DM)-p134c (D19S51)-19qTER. 
      Initial linear regression analysis of these two parameters failed to reveal a 
      significant linear correlation (coefficient of determination, r2 = .19), 
      suggesting nonuniform rates of recombination. However, the presence of a 
      recombination hot spot was believed to be unlikely, as the marker-to-marker pairs 
      that showed the greatest deviation in recombination frequency were not restricted 
      to a specific region of the 1.5 Mb studied and had relatively broad confidence 
      intervals, as reflected by low LOD values. A second linear regression analysis 
      using only marker intervals with high LOD scores (Zmax > 22) showed linear 
      correlation (r2 = .68) for the entire 1.5-Mb region. This analysis indicated a 
      relatively uniform recombination frequency in the 1.5-Mb region spanning the DM 
      locus. Furthermore, the recombinations observed were neither under- nor 
      overrepresented on DM chromosomes. Consequently, recombination activity is 
      unlikely to influence, or be affected by, the presence of the DM mutation.
FAU - Shutler, G G
AU  - Shutler GG
AD  - Molecular Genetics Laboratory, Children's Hospital of Eastern Ontario, Ottawa, 
      Canada.
FAU - MacKenzie, A E
AU  - MacKenzie AE
FAU - Korneluk, R G
AU  - Korneluk RG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
RN  - 0 (DNA Probes)
RN  - 0 (Genetic Markers)
SB  - IM
GS  - APOC2
GS  - CKM
GS  - DM
MH  - *Chromosomes, Human, Pair 19
MH  - DNA Probes
MH  - Female
MH  - Genetic Linkage
MH  - Genetic Markers
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*genetics
MH  - *Recombination, Genetic
MH  - Restriction Mapping
PMC - PMC1918079
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
PMCR- 1994/07/01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PHST- 1994/07/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1994 Jan;54(1):104-13.

PMID- 8151634
OWN - NLM
STAT- MEDLINE
DCOM- 19940510
LR  - 20190503
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 31
IP  - 1
DP  - 1994 Jan
TI  - French myotonic dystrophy families show expansion of a CTG repeat in complete 
      linkage disequilibrium with an intragenic 1 kb insertion.
PG  - 33-6
AB  - The molecular basis of myotonic dystrophy (DM) has been characterised. All DM 
      mutations characterised to date appear as an unstable elongation of a fragment 
      containing a tandem repeat of a CTG motif, which can be visualised in both EcoRI 
      and BamHI digests. It has been shown that the fragment is polymorphic in the 
      normal population. Another 1 kb insertion/deletion polymorphism located near the 
      unstable CTG repeat region has been identified. The 1 kb insertion allele is 
      present in all DM patients. These different polymorphic systems can be 
      distinguished using cDNA25 and BamHI, because this enzyme cuts between the site 
      of the 1 kb insertion and the CTG repeat. We thus haplotyped DM patients from 72 
      French families and clearly showed that all chromosomes (100%) with the DM 
      mutation carried the 1 kb insertion as well. In addition to this association, we 
      detected significant linkage disequilibrium between the DM locus and D19S63 for 
      which allelic frequencies were different from other European populations. Our 
      results in the French DM population are thus in agreement with the hypothesis 
      that the CTG expansion occurred on one or a few ancestral chromosomes carrying 
      the large 1 kb insertion allele.
FAU - Lavedan, C
AU  - Lavedan C
AD  - INSERM U73, Chateau de Longchamp, Bois de Boulogne, Paris, France.
FAU - Hofmann-Radvanyi, H
AU  - Hofmann-Radvanyi H
FAU - Boileau, C
AU  - Boileau C
FAU - Bonaiti-Pellie, C
AU  - Bonaiti-Pellie C
FAU - Savoy, D
AU  - Savoy D
FAU - Shelbourne, P
AU  - Shelbourne P
FAU - Duros, C
AU  - Duros C
FAU - Rabes, J P
AU  - Rabes JP
FAU - Dehaupas, I
AU  - Dehaupas I
FAU - Luce, S
AU  - Luce S
AU  - et al.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 0 (DNA Probes)
SB  - IM
MH  - Alleles
MH  - *Chromosome Aberrations
MH  - DNA Probes
MH  - Gene Frequency
MH  - Haplotypes
MH  - Humans
MH  - *Linkage Disequilibrium
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - *Repetitive Sequences, Nucleic Acid
MH  - Restriction Mapping
PMC - PMC1049595
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
PMCR- 1994/01/01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PHST- 1994/01/01 00:00 [pmc-release]
AID - 10.1136/jmg.31.1.33 [doi]
PST - ppublish
SO  - J Med Genet. 1994 Jan;31(1):33-6. doi: 10.1136/jmg.31.1.33.

PMID- 8288237
OWN - NLM
STAT- MEDLINE
DCOM- 19940222
LR  - 20211203
IS  - 0888-7543 (Print)
IS  - 0888-7543 (Linking)
VI  - 18
IP  - 2
DP  - 1993 Nov
TI  - Absence of myotonic dystrophy protein kinase (DMPK) mRNA as a result of a triplet 
      repeat expansion in myotonic dystrophy.
PG  - 340-8
AB  - Myotonic dystrophy is an autosomally dominant inherited disease in which 
      system-wide abnormalities are caused by a triplet repeat expansion within the 3' 
      untranslated region of the myotonic dystrophy protein kinase (DMPK) gene. To 
      determine the effect an expanded repeat region has on DMPK expression, we have 
      separated the chromosome 19 homologues from a 36-year-old woman with myotonic 
      dystrophy into different cell lines by way of somatic cell hybridization. Hybrid 
      DM9101 contains the normal DMPK allele (13 repeats), whereas hybrid DM1115 
      harbors the mutant allele (approximately 133 repeats). Reverse 
      transcription/polymerase chain reaction (RT/PCR) amplification of coding 
      sequences from the DMPK gene has shown both reduced levels of primary DMPK 
      transcripts and impaired processing of these transcripts in hybrid cell line 
      DM1115. These findings suggest that the presence of a large number of repeats in 
      the 3' untranslated region of the DMPK gene reduces both the synthesis and the 
      processing of DMPK mRNA, resulting in undetectable levels of processed DMPK mRNA 
      from the mutant allele.
FAU - Carango, P
AU  - Carango P
AD  - Medical Cell Biology Department, Alfred I. duPont Institute, Wilmington, Delaware 
      19899.
FAU - Noble, J E
AU  - Noble JE
FAU - Marks, H G
AU  - Marks HG
FAU - Funanage, V L
AU  - Funanage VL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genomics
JT  - Genomics
JID - 8800135
RN  - 0 (DMPK protein, human)
RN  - 0 (RNA, Messenger)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.1 (Myotonin-Protein Kinase)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
GS  - DMPK
MH  - Adult
MH  - Alleles
MH  - Animals
MH  - Base Sequence
MH  - CHO Cells
MH  - Cells, Cultured
MH  - Chromosomes, Human, Pair 19
MH  - Cricetinae
MH  - DNA
MH  - Female
MH  - Humans
MH  - Hybrid Cells
MH  - Introns
MH  - Male
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/enzymology/*genetics
MH  - Myotonin-Protein Kinase
MH  - Pedigree
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - RNA, Messenger/*metabolism
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
AID - S0888-7543(83)71474-6 [pii]
AID - 10.1006/geno.1993.1474 [doi]
PST - ppublish
SO  - Genomics. 1993 Nov;18(2):340-8. doi: 10.1006/geno.1993.1474.

PMID- 8213829
OWN - NLM
STAT- MEDLINE
DCOM- 19931119
LR  - 20200824
IS  - 0002-9297 (Print)
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 53
IP  - 5
DP  - 1993 Nov
TI  - Influence of sex of the transmitting parent as well as of parental allele size on 
      the CTG expansion in myotonic dystrophy (DM).
PG  - 1016-23
AB  - In patients with myotonic dystrophy (DM), the severity of clinical signs is 
      correlated with the length of a (CTG)n trinucleotide repeat sequence. This 
      sequence tends to expand in subsequent generations. In order to examine the 
      kinetics of this process and, in particular, the influence of the mutant-allele 
      size and the sex of the transmitting parent, we have studied (CTG)n repeat 
      lengths in the offspring of 38 healthy carriers with small mutations (less than 
      100 CTG trinucleotides, mean length [CTG]67). In these studies, we found a weakly 
      positive correlation between the size of the mutation in the carrier parents and 
      that in their offspring. Furthermore, we observed that, in the offspring of male 
      transmitters, repeat lengths exceeding 100 CTG trinucleotides were much more 
      frequent than in the offspring of carrier females (48 [92%] of 52 vs. 7 [44%] of 
      16, P = .0002). Similarly, in genealogical studies performed in 38 Dutch DM 
      kindreds, an excess of nonmanifesting male transmitters was noted, which was most 
      conspicuous in the generation immediately preceding that with phenotypic 
      expression of DM. Thus, two separate lines of evidence suggest that the sex of 
      the transmitting parent is an important factor that determines DM allele size in 
      the offspring. On the basis of our data, we estimate that when both parents are 
      asymptomatic, the odds are approximately 2:1 that the father carries the DM 
      mutation. Because expansion of the CTG repeat is more rapid with male 
      transmission, negative selection during spermatogenesis may be required to 
      explain the exclusive maternal inheritance of severe congenital onset DM.
FAU - Brunner, H G
AU  - Brunner HG
AD  - Department of Human Genetics, University Hospital, Nijmegen, The Netherlands.
FAU - Bruggenwirth, H T
AU  - Bruggenwirth HT
FAU - Nillesen, W
AU  - Nillesen W
FAU - Jansen, G
AU  - Jansen G
FAU - Hamel, B C
AU  - Hamel BC
FAU - Hoppe, R L
AU  - Hoppe RL
FAU - de Die, C E
AU  - de Die CE
FAU - Howeler, C J
AU  - Howeler CJ
FAU - van Oost, B A
AU  - van Oost BA
FAU - Wieringa, B
AU  - Wieringa B
AU  - et al.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Female
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
MH  - Parents
MH  - Pedigree
MH  - Phenotype
MH  - *Repetitive Sequences, Nucleic Acid
MH  - *Sex Characteristics
PMC - PMC1682295
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
PMCR- 1994/05/01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PHST- 1994/05/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Hum Genet. 1993 Nov;53(5):1016-23.

PMID- 8242066
OWN - NLM
STAT- MEDLINE
DCOM- 19931230
LR  - 20190512
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 2
IP  - 9
DP  - 1993 Sep
TI  - Fragile X syndrome unstable element, p(CCG)n, and other simple tandem repeat 
      sequences are binding sites for specific nuclear proteins.
PG  - 1429-35
AB  - The trinucleotide repeat sequences which become unstable in fragile X syndrome 
      and myotonic dystrophy are located in the untranslated regions of their 
      respective genes, FMR1 and DM1. This implies that a functional constraint other 
      than coding capacity maintains the presence of the repeats. In the case of 
      fragile X syndrome, sequences adjacent to the repeat are methylated in affected 
      individuals and the FMR1 gene is transcriptionally inactive. We demonstrate that 
      the fragile X p(CCG)n repeat itself is methylated in vivo and that methylation of 
      this repeat is able to inhibit in vitro binding of a novel, specific nuclear 
      p(CCG)n binding protein (CCG-BP1)--one of at least 10 distinct simple tandem 
      repeat sequence binding proteins (STR-BPs). We describe additional, apparently 
      distinct, binding activities both for the methylated form of the p(CCG)n repeat 
      and for each of the single strands of the repeat.
FAU - Richards, R I
AU  - Richards RI
AD  - Department of Cytogenetics and Molecular Genetics, Women's and Children's 
      Hospital, Adelaide, SA, Australia.
FAU - Holman, K
AU  - Holman K
FAU - Yu, S
AU  - Yu S
FAU - Sutherland, G R
AU  - Sutherland GR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oligodeoxyribonucleotides)
SB  - IM
MH  - Base Sequence
MH  - Binding Sites
MH  - DNA-Binding Proteins/*metabolism
MH  - Fragile X Syndrome/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Methylation
MH  - Molecular Sequence Data
MH  - Nuclear Proteins/*metabolism
MH  - Oligodeoxyribonucleotides/chemistry/*genetics/metabolism
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1993/09/01 00:00
MHDA- 1993/09/01 00:01
CRDT- 1993/09/01 00:00
PHST- 1993/09/01 00:00 [pubmed]
PHST- 1993/09/01 00:01 [medline]
PHST- 1993/09/01 00:00 [entrez]
AID - 10.1093/hmg/2.9.1429 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1993 Sep;2(9):1429-35. doi: 10.1093/hmg/2.9.1429.

PMID- 8370146
OWN - NLM
STAT- MEDLINE
DCOM- 19931014
LR  - 20190816
IS  - 0009-9163 (Print)
IS  - 0009-9163 (Linking)
VI  - 43
IP  - 6
DP  - 1993 Jun
TI  - Direct molecular diagnosis of myotonic dystrophy.
PG  - 276-85
AB  - Myotonic dystrophy (DM) arises from an unstable trinucleotide (CTGn) repeat 
      sequence within the DM locus at 19q13.3. Twenty-three myotonic dystrophy families 
      containing 205 persons with no symptoms, minimal manifestations, classic DM or 
      congenital DM were investigated to validate the application of the pM10M6 probe 
      to direct molecular diagnosis. Affected family members had been diagnosed 
      clinically and the unaffected family members had been assigned carrier 
      probabilities close to either zero or 100%, using closely linked flanking 
      markers. Southern analysis identified all 89 DM gene carriers as having 
      expansions of the unstable element. PstI detected all small expansions of the 
      repeat sequence as easily seen discrete bands; but large expansions were usually 
      seen as diffuse smears, sometimes difficult to distinguish from lane background. 
      EcoRI concentrated these diffuse smears, associated with somatic instability, 
      into discrete bands which were easy to detect; but it did not resolve the smaller 
      expansions present in 9 (10%) of the DM carriers. It is essential that PstI and 
      EcoRI gels are run in parallel to detect all DM gene carriers. The extent of 
      expansion of CTG correlated with age of onset and disease severity. Biopsies of 
      various fetal tissues from two terminated pregnancies confirmed the diagnosis 
      obtained by CVS and revealed no heterogeneity between tissues at this 
      developmental stage. Further expansion occurred during the culture of CVS cells, 
      indicating that direct prenatal diagnosis needs to be carried out on CVS tissue 
      rather than on cultured cells. The intergenerational change of the repeat 
      sequence from DM parent to DM offspring showed a significant parental sex 
      difference for those parents with large expansions. Contraction of the unstable 
      element was observed in the three males carrying the largest expansions and could 
      explain why congenital DM is exclusively of maternal origin.
FAU - Hecht, B K
AU  - Hecht BK
AD  - Department of Cytogenetics and Molecular Genetics, Women's and Children's 
      Hospital, North Adelaide, Australia.
FAU - Donnelly, A
AU  - Donnelly A
FAU - Gedeon, A K
AU  - Gedeon AK
FAU - Byard, R W
AU  - Byard RW
FAU - Haan, E A
AU  - Haan EA
FAU - Mulley, J C
AU  - Mulley JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Clin Genet
JT  - Clinical genetics
JID - 0253664
SB  - IM
MH  - Female
MH  - Genetic Linkage
MH  - Genotype
MH  - Heterozygote
MH  - Humans
MH  - Male
MH  - Myotonic Dystrophy/*diagnosis/genetics
MH  - Pedigree
MH  - Phenotype
MH  - Polymerase Chain Reaction
MH  - Prenatal Diagnosis/methods
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1111/j.1399-0004.1993.tb03819.x [doi]
PST - ppublish
SO  - Clin Genet. 1993 Jun;43(6):276-85. doi: 10.1111/j.1399-0004.1993.tb03819.x.

PMID- 8357018
OWN - NLM
STAT- MEDLINE
DCOM- 19930923
LR  - 20061115
IS  - 0148-7299 (Print)
IS  - 0148-7299 (Linking)
VI  - 46
IP  - 4
DP  - 1993 Jun 1
TI  - Absence of chromosome fragility at 19q13.3 in patients with myotonic dystrophy.
PG  - 441-3
AB  - Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by a 
      trinucleotide (AGC) amplification at 19q13.3. The degree of trinucleotide 
      amplification may increase in successive generations and generally correlates 
      with severity of the disorder. Because amplification of a trinucleotide repeat is 
      also associated with the observation of a fra(X)(q27.3) in the fragile X 
      syndrome, we investigated whether chromosome fragility at 19q13.3 might be 
      inducible in patients with DM. Using 3 different culture stress systems (medium 
      199, RPMI 1640 with excess TdR, and RPMI 1640 with FudR) and high resolution 
      chromosome analyses, we studied 6 individuals with DM and 5 unaffected relatives 
      representing two unrelated families. Molecular studies were done on two of the 
      most affected patients and showed AGC repeat sequences of 970 and 1,260 at 
      19q13.3. The normal range of AGC repeat is 5 to 30. We found no indication of 
      fragility at 19q13.3 in any of these individuals.
FAU - Jalal, S M
AU  - Jalal SM
AD  - Department of Medical Genetics, Mayo Clinic.
FAU - Lindor, N M
AU  - Lindor NM
FAU - Michels, V V
AU  - Michels VV
FAU - Buckley, D D
AU  - Buckley DD
FAU - Hoppe, D A
AU  - Hoppe DA
FAU - Sarkar, G
AU  - Sarkar G
FAU - Dewald, G W
AU  - Dewald GW
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Med Genet
JT  - American journal of medical genetics
JID - 7708900
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Chromosome Fragility
MH  - *Chromosomes, Human, Pair 19
MH  - Fragile X Syndrome/*genetics
MH  - Humans
MH  - Infant
MH  - Karyotyping
MH  - Middle Aged
MH  - Myotonic Dystrophy/*genetics
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1002/ajmg.1320460419 [doi]
PST - ppublish
SO  - Am J Med Genet. 1993 Jun 1;46(4):441-3. doi: 10.1002/ajmg.1320460419.

PMID- 8353490
OWN - NLM
STAT- MEDLINE
DCOM- 19930921
LR  - 20190512
IS  - 0964-6906 (Print)
IS  - 0964-6906 (Linking)
VI  - 2
IP  - 6
DP  - 1993 Jun
TI  - Molecular diagnosis of homozygous myotonic dystrophy in two asymptomatic sisters.
PG  - 711-5
AB  - The genetic defect underlying myotonic dystrophy (DM) has been identified as the 
      expansion of an unstable trinucleotide repeat sequence, and this discovery has 
      led to new approaches to diagnosis and genetic counselling in families with the 
      disorder. We report the genetic analysis of a consanguineous DM family in which 
      two asymptomatic sisters had been shown to be homozygous for the 'at risk' 
      haplotype. PCR analysis of the region spanning the trinucleotide expansion 
      demonstrated that both sisters possessed two alleles with repeat sizes normally 
      seen in minimally affected patients. Extensive clinical examination failed to 
      demonstrate any of the symptoms of DM in these women. The implications of this 
      finding, both for understanding the disease mechanism, and for genetic 
      counselling in such situations are discussed.
FAU - Cobo, A
AU  - Cobo A
AD  - Unitat de Genetica Molecular, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain.
FAU - Martinez, J M
AU  - Martinez JM
FAU - Martorell, L
AU  - Martorell L
FAU - Baiget, M
AU  - Baiget M
FAU - Johnson, K
AU  - Johnson K
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
RN  - 0 (DNA Probes)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Blotting, Southern
MH  - Consanguinity
MH  - DNA Probes
MH  - Electromyography
MH  - Female
MH  - Haplotypes/genetics
MH  - Homozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myotonic Dystrophy/congenital/*diagnosis/genetics/pathology
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1993/06/01 00:00
MHDA- 1993/06/01 00:01
CRDT- 1993/06/01 00:00
PHST- 1993/06/01 00:00 [pubmed]
PHST- 1993/06/01 00:01 [medline]
PHST- 1993/06/01 00:00 [entrez]
AID - 10.1093/hmg/2.6.711 [doi]
PST - ppublish
SO  - Hum Mol Genet. 1993 Jun;2(6):711-5. doi: 10.1093/hmg/2.6.711.

PMID- 8485915
OWN - NLM
STAT- MEDLINE
DCOM- 19930608
LR  - 20190512
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 92
IP  - 2
DP  - 1993 May
TI  - Gamma delta lymphocytes in endocrine autoimmunity: evidence of expansion in 
      Graves' disease but not in type 1 diabetes.
PG  - 288-95
AB  - Endocrine autoimmune disorders are mediated by T cell-dependent responses to 
      organ-specific antigens, but the mechanisms initiating the process remain 
      unknown. Lymphocytes which use the gamma delta heterodimer as T cell receptor 
      (TCR) for antigen constitute a distinct subset of T cells whose function remains 
      elusive. In order to investigate their possible involvement in endocrine 
      autoimmunity we have determined the proportion of gamma delta T cells in the 
      peripheral blood of 23 patients with type 1 (insulin-dependent) diabetes mellitus 
      (type-1 DM) and 30 patients with autoimmune thyrotoxicosis (Graves' disease). T 
      lymphocyte TCR expression was assessed by fluorescence-activated flow cytometry 
      on peripheral blood mononuclear cells using MoAbs UCHT1 (CD3), TCR delta 1 (gamma 
      delta TCR), WT31 and beta F1 (alpha beta TCR) and both the percentage of T cells 
      expressing gamma delta and the ratio gamma delta/alpha beta were calculated. In 
      the diabetic patients gamma delta cells were not significantly different from the 
      control group (7.7 +/- 54% versus 8.0 +/- 5.5% of T cells, P NS). There was no 
      relation between the proportion of gamma delta lymphocytes and the presence of 
      islet cell antibodies (ICA) in the sera. The Graves' patients showed a tendency 
      towards a higher proportion of gamma delta T lymphocytes than the controls (gamma 
      delta/alpha beta ratios: 0.095 +/- 0.047 versus 0.063 +/- 0.022, P = 0.03). In 14 
      Graves' patients the number of gamma delta were measured in paired samples of 
      peripheral and intrathyroidal lymphocytes, demonstrating an expansion of gamma 
      delta within the thyroid glands (0.21 +/- 0.3 versus 0.095 +/- 0.047, P = 0.032). 
      Immunohistochemical studies showed that gamma delta cells were scattered among 
      the predominant alpha beta lymphocytes infiltrating the thyroid gland and that 
      they account for 10% of intraepithelial lymphocytes. No relation was found 
      between the increase of gamma delta lymphocytes and any clinical features.
FAU - Roura-Mir, I C
AU  - Roura-Mir IC
AD  - Immunology Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
FAU - Alcalde, L
AU  - Alcalde L
FAU - Vargas, F
AU  - Vargas F
FAU - Tolosa, E
AU  - Tolosa E
FAU - Obiols, G
AU  - Obiols G
FAU - Foz, M
AU  - Foz M
FAU - Jaraquemada, D
AU  - Jaraquemada D
FAU - Pujol-Borrell, R
AU  - Pujol-Borrell R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Autoimmune Diseases/*immunology
MH  - Child
MH  - Diabetes Mellitus, Type 1/*immunology
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Graves Disease/*immunology
MH  - Humans
MH  - Immunophenotyping
MH  - Male
MH  - Middle Aged
MH  - Receptors, Antigen, T-Cell, gamma-delta/*immunology
MH  - T-Lymphocyte Subsets/*immunology
MH  - Thyroid Gland/immunology
PMC - PMC1554822
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
PMCR- 1994/05/01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PHST- 1994/05/01 00:00 [pmc-release]
AID - 10.1111/j.1365-2249.1993.tb03394.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 1993 May;92(2):288-95. doi: 10.1111/j.1365-2249.1993.tb03394.x.

PMID- 1453426
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20190503
IS  - 0022-2593 (Print)
IS  - 1468-6244 (Electronic)
IS  - 0022-2593 (Linking)
VI  - 29
IP  - 11
DP  - 1992 Nov
TI  - Presymptomatic diagnosis of myotonic dystrophy.
PG  - 780-4
AB  - The discovery of an expanded (CTG)n repeat sequence in myotonic dystrophy (DM) 
      has greatly improved our ability to detect DM gene carriers who have few or none 
      of the classical signs of this disorder. We report here our experience with two 
      such groups of gene carriers. We used a PCR based protocol that should be 
      especially sensitive to small increases in CTG triplet number which might escape 
      detection by conventional Southern blot analysis. Our analyses show that on 100 
      non-DM chromosomes the number of CTG triplets ranged from five to 37. We then 
      studied 17 obligate gene carriers aged 55 years and over who showed no muscle 
      weakness. All of the gene carriers in this group showed a relatively small 
      increase in the number of CTG triplets (52 to 90 CTG triplets) with limited 
      somatic mosaicism. We subsequently studied 11 subjects (aged 19 to 36 years) who 
      had previously been identified as gene carriers by genetic linkage studies, but 
      who lacked diagnostic signs. In this prospectively studied group, nine subjects 
      showed an expanded allele, confirming the earlier prediction from linked genetic 
      markers. The other two subjects had only two normal alleles and no expanded 
      allele. Revision of the clinical data casts doubt on the original diagnosis of DM 
      in their families. Preferential amplification of the normal non-expanded allele 
      was noted in three asymptomatic gene carriers in this study (as well as in two of 
      their clinically affected relatives). We caution that, at least in our hands, the 
      DM mutation can be confidently excluded by this PCR based method only if both 
      normal alleles have been identified.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Brunner, H G
AU  - Brunner HG
AD  - Department of Human Genetics, University Hospital, Nijmegen, The Netherlands.
FAU - Nillesen, W
AU  - Nillesen W
FAU - van Oost, B A
AU  - van Oost BA
FAU - Jansen, G
AU  - Jansen G
FAU - Wieringa, B
AU  - Wieringa B
FAU - Ropers, H H
AU  - Ropers HH
FAU - Smeets, H J
AU  - Smeets HJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Med Genet
JT  - Journal of medical genetics
JID - 2985087R
RN  - 9007-49-2 (DNA)
SB  - IM
GS  - DM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Base Sequence
MH  - DNA/genetics
MH  - DNA Mutational Analysis
MH  - Female
MH  - Gene Amplification
MH  - Genetic Carrier Screening
MH  - Genetic Linkage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Myotonic Dystrophy/*diagnosis/*genetics
MH  - Pedigree
MH  - Polymerase Chain Reaction
MH  - Repetitive Sequences, Nucleic Acid
PMC - PMC1016170
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
PMCR- 1992/11/01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
PHST- 1992/11/01 00:00 [pmc-release]
AID - 10.1136/jmg.29.11.780 [doi]
PST - ppublish
SO  - J Med Genet. 1992 Nov;29(11):780-4. doi: 10.1136/jmg.29.11.780.

PMID- 1546326
OWN - NLM
STAT- MEDLINE
DCOM- 19920413
LR  - 20220409
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 255
IP  - 5049
DP  - 1992 Mar 6
TI  - An unstable triplet repeat in a gene related to myotonic muscular dystrophy.
PG  - 1256-8
AB  - Synthetic oligonucleotides containing GC-rich triplet sequences were used in a 
      scanning strategy to identify unstable genetic sequences at the myotonic 
      dystrophy (DM) locus. A highly polymorphic GCT repeat was identified and found to 
      be unstable, with an increased number of repeats occurring in DM patients. In the 
      case of severe congenital DM, the paternal triplet allele was inherited unaltered 
      while the maternal, DM-associated allele was unstable. These studies suggest that 
      the mutational mechanism leading to DM is triplet amplification, similar to that 
      occurring in the fragile X syndrome. The triplet repeat sequence is within a gene 
      (to be referred to as myotonin-protein kinase), which has a sequence similar to 
      protein kinases.
FAU - Fu, Y H
AU  - Fu YH
AD  - Institute for Molecular Genetics, Baylor College of Medicine, Houston, TX 77030.
FAU - Pizzuti, A
AU  - Pizzuti A
FAU - Fenwick, R G Jr
AU  - Fenwick RG Jr
FAU - King, J
AU  - King J
FAU - Rajnarayan, S
AU  - Rajnarayan S
FAU - Dunne, P W
AU  - Dunne PW
FAU - Dubel, J
AU  - Dubel J
FAU - Nasser, G A
AU  - Nasser GA
FAU - Ashizawa, T
AU  - Ashizawa T
FAU - de Jong, P
AU  - de Jong P
AU  - et al.
LA  - eng
SI  - GENBANK/M87312
GR  - 5-M01-RR00350/RR/NCRR NIH HHS/United States
GR  - P30-HG00210/HG/NHGRI NIH HHS/United States
GR  - P50HL42267-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Amino Acid Sequence
MH  - Base Sequence
MH  - Chromosomes, Human, Pair 19
MH  - Cloning, Molecular
MH  - DNA/chemistry
MH  - Humans
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Myotonic Dystrophy/*genetics
MH  - Nucleic Acid Hybridization
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - *Repetitive Sequences, Nucleic Acid
EDAT- 1992/03/16 19:15
MHDA- 2001/03/28 10:01
CRDT- 1992/03/16 19:15
PHST- 1992/03/16 19:15 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1992/03/16 19:15 [entrez]
AID - 10.1126/science.1546326 [doi]
PST - ppublish
SO  - Science. 1992 Mar 6;255(5049):1256-8. doi: 10.1126/science.1546326.

PMID- 2670588
OWN - NLM
STAT- MEDLINE
DCOM- 19891012
LR  - 20190510
IS  - 0141-5387 (Print)
IS  - 0141-5387 (Linking)
VI  - 11
IP  - 2
DP  - 1989 May
TI  - Stability of magnetic versus mechanical palatal expansion.
PG  - 107-15
AB  - Spatial stability following palatal expansion (PE) treatment was studied 
      longitudinally on 8 Macaca fascicularis monkeys. The sample was divided into 
      short-term and long-term groups. The four subjects in each group received: (1) an 
      indirect screw (IS) PE appliance (F = 2035 g), (2) an indirect magnetic (IM) PE 
      appliance (F = 258 g and 360 g), (3) a direct magnetic (DM) PE appliance (F = 258 
      g and 360 g) and (4) a sham appliance. The terms direct and indirect describe 
      force transmission directly, via pinning to the palatal shelves or indirectly, 
      via abutment teeth. Active treatment in the long-term group was followed by a 4 
      month retention phase and a 2 month relapse phase. The implant study indicated 
      the transverse stability to be greatest in the skeletally borne appliance. 
      Correspondingly, intercanine distance relapse was 53 per cent and 23 per cent for 
      the IS and DM subjects, respectively. Intermolar expansion was significantly more 
      stable than intercanine expansion due to selective activity of the 
      circum-maxillary sutures (transverse suture) and root configuration. Sagittal 
      advancement and vertical superior translation, which are controlled by selective 
      activity of the premaxillary suture, were particularly apparent in the magnetic 
      appliances with a low force PE regimen. Clinical implications suggest that the 
      use of a low force PE regimen can be of substantial benefit in young skeletal 
      Class III patients with transverse maxillary deficiency.
FAU - Vardimon, A D
AU  - Vardimon AD
FAU - Graber, T M
AU  - Graber TM
FAU - Voss, L R
AU  - Voss LR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Orthod
JT  - European journal of orthodontics
JID - 7909010
SB  - IM
MH  - Animals
MH  - Macaca fascicularis
MH  - *Magnetics
MH  - Maxilla/anatomy & histology
MH  - *Orthodontic Appliances
MH  - Palatal Expansion Technique/*instrumentation
MH  - Palate/*anatomy & histology
MH  - Tooth Migration
EDAT- 1989/05/01 00:00
MHDA- 1989/05/01 00:01
CRDT- 1989/05/01 00:00
PHST- 1989/05/01 00:00 [pubmed]
PHST- 1989/05/01 00:01 [medline]
PHST- 1989/05/01 00:00 [entrez]
AID - 10.1093/oxfordjournals.ejo.a035971 [doi]
PST - ppublish
SO  - Eur J Orthod. 1989 May;11(2):107-15. doi: 10.1093/oxfordjournals.ejo.a035971.
